<SEC-DOCUMENT>0001599298-22-000147.txt : 20221221
<SEC-HEADER>0001599298-22-000147.hdr.sgml : 20221221
<ACCEPTANCE-DATETIME>20221221162010
ACCESSION NUMBER:		0001599298-22-000147
CONFORMED SUBMISSION TYPE:	10-K/A
PUBLIC DOCUMENT COUNT:		99
CONFORMED PERIOD OF REPORT:	20211231
FILED AS OF DATE:		20221221
DATE AS OF CHANGE:		20221221

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Summit Therapeutics Inc.
		CENTRAL INDEX KEY:			0001599298
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36866
		FILM NUMBER:		221478672

	BUSINESS ADDRESS:	
		STREET 1:		2882 SAND HILL ROAD
		STREET 2:		SUITE 106
		CITY:			MENLO PARK
		STATE:			CA
		ZIP:			94025
		BUSINESS PHONE:		617-514-7149

	MAIL ADDRESS:	
		STREET 1:		2882 SAND HILL ROAD
		STREET 2:		SUITE 106
		CITY:			MENLO PARK
		STATE:			CA
		ZIP:			94025

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Summit Therapeutics plc
		DATE OF NAME CHANGE:	20150219

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Summit Corp plc
		DATE OF NAME CHANGE:	20140205
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K/A
<SEQUENCE>1
<FILENAME>smmt-20211231.htm
<DESCRIPTION>10-K/A
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:48b41a33-da2b-4a8c-a794-72fce890713a,g:e36a0d9c-9c90-432d-82bf-4f94771c92ff,d:2eecdebedec64091994df5b7a96baab7--><html xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:smmt="http://www.summitplc.com/20211231" xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>smmt-20211231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN180L2ZyYWc6YTEwMzU4ZmQ1MzY0NDA2ZGFlMzU5YTI3MDRjOGIyZGEvdGFibGU6NTRmYWNmZWNjMGZjNDFmYWJiYWViMjM3N2M1NGU2ZmEvdGFibGVyYW5nZTo1NGZhY2ZlY2MwZmM0MWZhYmJhZWIyMzc3YzU0ZTZmYV8xLTEtMS0xLTEwOTg3Ng_30607081-7552-444c-893f-c948b4099d1f">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN180L2ZyYWc6YTEwMzU4ZmQ1MzY0NDA2ZGFlMzU5YTI3MDRjOGIyZGEvdGFibGU6NTRmYWNmZWNjMGZjNDFmYWJiYWViMjM3N2M1NGU2ZmEvdGFibGVyYW5nZTo1NGZhY2ZlY2MwZmM0MWZhYmJhZWIyMzc3YzU0ZTZmYV8yLTEtMS0xLTEwOTg3Ng_ce484099-05e4-4a45-9ec1-c36756327d3d">0001599298</ix:nonNumeric><ix:nonNumeric contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN180L2ZyYWc6YTEwMzU4ZmQ1MzY0NDA2ZGFlMzU5YTI3MDRjOGIyZGEvdGFibGU6NTRmYWNmZWNjMGZjNDFmYWJiYWViMjM3N2M1NGU2ZmEvdGFibGVyYW5nZTo1NGZhY2ZlY2MwZmM0MWZhYmJhZWIyMzc3YzU0ZTZmYV8zLTEtMS0xLTEwOTg3Ng_621c73dd-c1a9-4bfe-8a00-8735dc7cd8fb">2021</ix:nonNumeric><ix:nonNumeric contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN180L2ZyYWc6YTEwMzU4ZmQ1MzY0NDA2ZGFlMzU5YTI3MDRjOGIyZGEvdGFibGU6NTRmYWNmZWNjMGZjNDFmYWJiYWViMjM3N2M1NGU2ZmEvdGFibGVyYW5nZTo1NGZhY2ZlY2MwZmM0MWZhYmJhZWIyMzc3YzU0ZTZmYV80LTEtMS0xLTEwOTg3Ng_a7f5d95f-72cb-4a47-9be9-ae6a2ee681ad">FY</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="i9c7f9a766f914e7e955ad7e8a52dfc77_D20200918-20200918" decimals="INF" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMjQvZnJhZzo0ZTkyYWRlZGI3NWM0MmU2ODBhZmUzNzA2MWE0ODE2ZS90ZXh0cmVnaW9uOjRlOTJhZGVkYjc1YzQyZTY4MGFmZTM3MDYxYTQ4MTZlXzM1_e64910e8-7cb4-4718-8b58-eac6f58b9fbb">0.2</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i9c7f9a766f914e7e955ad7e8a52dfc77_D20200918-20200918" decimals="INF" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNzgvZnJhZzo2NWI0NmRiMWE3ZGE0OThhOTYwOTczMTg4NzhiYmNmYy90ZXh0cmVnaW9uOjY1YjQ2ZGIxYTdkYTQ5OGE5NjA5NzMxODg3OGJiY2ZjXzM1_97c55676-6a11-4bea-9370-d9bc4fb0c5b3">0.2</ix:nonFraction><ix:nonNumeric contextRef="ibedda2e6e02c4c85ad25b6fda3de4f3e_D20210101-20211231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODEvZnJhZzoyOTEzNTMwMjlmMjQ0ZTQ0ODgzNDE5NTEzYjBhODA3Ny90ZXh0cmVnaW9uOjI5MTM1MzAyOWYyNDRlNDQ4ODM0MTk1MTNiMGE4MDc3XzQ4MzA_52cfade8-6eaf-42ea-82a4-09b084b53c45">P3Y</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="smmt-20211231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia595af4209c94a0e84bcc1c89fef3796_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="idbfc95cd82ac4443bb9c319767213cfa_I20220310"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7372be6dc06143b5adbb4d2e83a596c5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="iadaf16e26a374273b81a7480b2aef461_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i23c022f251aa4a7bb86fd5562b7cf66a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i18956f3671924995bc8672c2e4f9774d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i10704a1cbc944be6935b29991fb87b7b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i50b9889462124695acb12b854dfc61e9_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie925211651134cc095c13ead145a9987_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie1c2f38f4911489ea019b962d6783b5d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id7966e0fd0224c4492484acc988b5ec7_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c007ce1c0eb4469a7130cee973d7baf_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i24918d03620c4ecaafa37fa8e2ca91b8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5c014f26be2f47f291a3aa91605b4237_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie706c5ed539d4ef3bd0c02c4a4ba65e9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7658aae35c1342aa8a4d460d73d54645_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic6b97fcd6da249ba8b8f4ae9d4f4b37d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2e2dff6c233a4cdbb090a82ca47e7ffc_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8d878058c8ed44bfb3e3c57c92407be4_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i598a27caa8a04c3d8039576d04308448_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i24c2e29db794467488a44f9569dc30e2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie363771b412541ff94d08b8f29d0252e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iebb70cd5cf5e4946b99f20b6f84c6333_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8194e85afada4be48c4dc89d2b7c2a07_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idb475943c8884e52b4a61d6e77d4d205_D20210512-20210512"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">smmt:RightsOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-12</xbrli:startDate><xbrli:endDate>2021-05-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i28fe3cc419e94f789497abebbcb3acff_I20210512"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">smmt:RightsOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-05-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9e4481b351c140ec829740b8f3c87fca_I20210511"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-05-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i9d8f0174c08f45cab10ea87b88a0b06d_I20210420"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">smmt:SecondPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idf7a081c7b9c4705a95c5f2ab53d19bb_D20220310-20220310"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">smmt:A2022NoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-10</xbrli:startDate><xbrli:endDate>2022-03-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id74d06c0cec74c7fa7641c591943da88_I20220310"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">smmt:A2022NoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9c7f9a766f914e7e955ad7e8a52dfc77_D20200918-20200918"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-18</xbrli:startDate><xbrli:endDate>2020-09-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if7798276e33b48af81058807002f7542_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">smmt:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib9e53bf038884fe1aebddae6ccd2c196_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">smmt:LaboratoryEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i942ccb9196bb4d0ab10e4c87af4250a2_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">smmt:OfficeAndTechnologyEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia8b911ed586c4e1bbdda461a2557aff7_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">smmt:OfficeAndTechnologyEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i593cfc00ba154e79a513606849b36e61_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if0549c486ffc4be2b6a75373c950243b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i32242c0ff70343c9adfcc11c6595a70f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>smmt:segment</xbrli:measure></xbrli:unit><xbrli:unit id="country"><xbrli:measure>smmt:country</xbrli:measure></xbrli:unit><xbrli:context id="i435477ccebf0489e8e94db10eb60db56_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if02b5108070a44ba843c22e648997315_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4d900fb56eda43068b75b033c9bfc547_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i71dfd1e7be4e496b90e176a973683625_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5429ceb33a414445be9322f8f9c293e3_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i05760767313140efb7f8f84e9096f9f3_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie0717192d4d74cfd912383af07cab29d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9367ade534d1492b81f243c12898e81d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i04c6be661f884e9f9fcec7b8a98ba02f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:LatinAmericaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie7b7d8e874e541099d3260b499ccef94_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:LatinAmericaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib314f5dd5ac24f47a60b0925a50a5081_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">smmt:EuroFarmaLaboratoriosSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if1c80590b2284b5092629628c5efb266_I20200229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">smmt:EuroFarmaLaboratoriosSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-02-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7d9fb711621141cd9ebefb15542db56a_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">smmt:EuroFarmaLaboratoriosSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5f7778418eab4524a04524ce76786f35_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">smmt:EuroFarmaLaboratoriosSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="milestone"><xbrli:measure>smmt:milestone</xbrli:measure></xbrli:unit><xbrli:context id="i7179bafa598f42ebb6c974d6b860624e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">smmt:EuroFarmaLaboratoriosSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i75af2dac1e474913ae259011f0e40ece_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">smmt:EuroFarmaLaboratoriosSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia4d86426c389449ebc2c7f1874dbc3fc_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">smmt:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab792aa058af48aba2d03719d4253bde_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">smmt:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4ef399140bb14718b545a1aaa04203df_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">smmt:OtherGrantFundingCounterpartiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i52c373554f2f40b4a54d0ff856b68cf6_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">smmt:OtherGrantFundingCounterpartiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5189024af3e3465a96e4c5c1204cfc1d_D20170901-20170930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">smmt:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-09-01</xbrli:startDate><xbrli:endDate>2017-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6080657079b74ddc92d888ef28f1a49a_D20170901-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">smmt:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-09-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ice72e22d8b604c7a9047363b98c2c5e0_D20210501-20210531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">smmt:CombatingAntibioticResistantBacteriaBiopharmaceuticalAcceleratorProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2021-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i31a55aa85c704fa1b0bf71fb5d66f073_D20210501-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">smmt:CombatingAntibioticResistantBacteriaBiopharmaceuticalAcceleratorProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iba2a2e6aa4554084aa69ed9ef72c2590_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">smmt:CombatingAntibioticResistantBacteriaBiopharmaceuticalAcceleratorProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3f5f274eec6e4854a5687bcb5cfc91d9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2ed068ac829e484093c122d76b8f373f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0ef15edbb3914ab3807ad48ae9426591_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i16643be7aeaf41edbc627f4639147976_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7e1be0d5904743408b0b38cc3f4a584c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i532f6b25e45149648f05717f44c7c477_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib1c1be44b3ba438881338233be927f12_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i17a5a82d4e56446b9587e3a8aad49a1b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5c71c63c2a0d454aa48a55ab0a0ec4ee_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1dba735cd51b4bd9acdace9e3eb39523_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i473628003f11481a823723bf532a0274_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5bc912ce09754534905d49a8cb511c7a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2fa48e55eff24bda9a7ebf8b065a3657_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="reporting_unit"><xbrli:measure>smmt:reporting_unit</xbrli:measure></xbrli:unit><xbrli:context id="i3b2b674d2a6f48e7af3dcc03537946c3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">smmt:UtrophinProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2491765d7faa4157a0b9a7f08084dcb2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">smmt:DiscuvaPlatformMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i558da201e4864ba0a1ff4a54d2b3b599_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">smmt:OptionOverNonFinancialAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i93b60cd7d5744711a30a544473f93063_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">smmt:OtherPatentsAndLicensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaf53a1912d5743a186cd8a0986d0a4c9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">smmt:UtrophinProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id2256d9dc5d54775a80518270c92d9cf_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">smmt:DiscuvaPlatformMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i74db8c4615a64aabac7a997f0967a92d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">smmt:OptionOverNonFinancialAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8ae4247d97144e01bf0a9c9b8cfd0111_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">smmt:OtherPatentsAndLicensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i137b9502c9084c29a43d474c1b31e151_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">smmt:OptionOverNonFinancialAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia3f12147410f43d28d06362b9dba4771_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">smmt:DiscuvaPlatformMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if6f9b4ae5c0b4a59bd0bbd8975258bb6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">smmt:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if02dcbd0b04f40f08ccd958c30a79c08_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">smmt:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic09e2474bf014397be8c508d9cbef4b5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">smmt:FurnitureAndFixturesOfficeEquipmentAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i30c79b436c2d47d98676b1f9a2231cdc_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">smmt:FurnitureAndFixturesOfficeEquipmentAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib30be684902148cdbfad1b6e48d5528d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2abb02e0508e40e5b35f04d561b326de_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i24a6a1407c6849eda580568b0680d532_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">smmt:MenloParkCaliforniaUSAndSawstonUKMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="contract"><xbrli:measure>smmt:contract</xbrli:measure></xbrli:unit><xbrli:context id="id630c360daad499f94b27cc39c3a0633_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">smmt:OxfordshireUKMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i065a06364b944635a5fea7a0548c3c71_I20200917"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-09-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib1b2bbd9c2ea4c81affedf30cb5ad225_I20200918"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-09-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6a505b52efdc43a7821a6b7cc66b172e_D20201106-20201106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-06</xbrli:startDate><xbrli:endDate>2020-11-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1cda89fc1bbb4c82a3c7a93284736d74_I20201106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-11-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ief39eb2f075b4eb78fa3e4ffac9e4610_D20191224-20191224"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-24</xbrli:startDate><xbrli:endDate>2019-12-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5b2fdb6bad994e6eb9c9380cb3807cd6_I20191224"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id3dfe8aa6a324f739c2caa516220e112_I20191224"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">smmt:ConsultingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib29a1c5799524e1987c045aee67b6831_D20191224-20191224"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">smmt:ConsultingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-24</xbrli:startDate><xbrli:endDate>2019-12-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia5f83af41ad746ffb1aa249c3a0f7238_D20200630-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">smmt:ConsultingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-30</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i829bd35e2a01482f995c5247b3243ee1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">smmt:ConsultingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if894fc66857243cf91a1a3e3a656bd4f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id2eec56c2a084d07bd27c69c542c646e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i52879ea7de8d4f93bf2933bde91a0538_I20200921"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">smmt:A2020StockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i77c56146a814495db85257a588d28851_D20200921-20200921"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">smmt:A2020StockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-21</xbrli:startDate><xbrli:endDate>2020-09-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia36692a70694499e8458216f476de0aa_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">smmt:A2020StockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9b560a9af3b441468dab3205aa4e621c_I20200819"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2e4f636d5f284aaa971b49db94dc48d6_D20200819-20200819"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-19</xbrli:startDate><xbrli:endDate>2020-08-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8a26223d9fc34901b9c170239c1296e3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia19b35b6945f47e0b9f50e24473f7b3f_D20210802-20210802"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-02</xbrli:startDate><xbrli:endDate>2021-08-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iabc12254dbae479c95e96111f5913844_D20220301-20220301"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-01</xbrli:startDate><xbrli:endDate>2022-03-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i75d2f909ade34437b24a7cd383ffa673_D20200819-20200819"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-19</xbrli:startDate><xbrli:endDate>2020-08-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibedda2e6e02c4c85ad25b6fda3de4f3e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8083f97ada2d4b42b9fe0c6f07ec03d4_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i444320f038034b09878835272c70885a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i269ac82e7b7e4434933ca3c53f23e541_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifb5f434783cc4b4c9ef2fe9ae4041cd4_D20210924-20210924"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-24</xbrli:startDate><xbrli:endDate>2021-09-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf72cce8ac64497daeaefb6469475537_D20210924-20210924"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-24</xbrli:startDate><xbrli:endDate>2021-09-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="employee"><xbrli:measure>smmt:employee</xbrli:measure></xbrli:unit><xbrli:context id="ib788877f138c4513a611e7bbf11174b9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifb40b671dcdb4ef29c0a6c97d77ebb15_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i151cdfd1b29442d4840888fb00f8949d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4d5f6c2289bf42c8a42f632397ea769e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i395ac2e436db41e1b784ce9a6a63fdfd_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1b7a43e1795f40b497c444b01b9f6b53_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">smmt:ConsultantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia09aa906eefb458f9f484f59eac63b0f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">us-gaap:InvestorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie40533d6881a4b8e84e00ba2095c6a46_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9692194cdd1947979995cb545a07d30f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1b50b0a3bb8f405dafa9635ba05d5e1a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id19f5fb0cc5346e48e222529f4a6e420_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7be0acfd60d747fbba039b448bffe68f_I20191224"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4f6915c5f2074c63ae73f25be0258821_I20191224"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">smmt:FormerChiefExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7f56091566944d9bb672ff557a22aff4_I20201106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-11-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibc0f44cee68945c1910a87557a1bdd5d_I20201106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:BeneficialOwnerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-11-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2a2d5cacc14249f0a5bbe8fcc0619c62_D20191224-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">smmt:ConsultingAgreementConsultancyFeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-24</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib8d80178d3e743bd88db3e643c215cb4_D20191224-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">smmt:ConsultancyAgreementWarrantVestingExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-24</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0346f51cbc1549bc97088b050e2cd48e_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:BeneficialOwnerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">smmt:AssignmentAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i093a476c99524d7c821d17ca295cc4d5_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">smmt:AssignmentAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4a8e4bc29f1645008a3ae3a8a5bb7985_D20210324-20210324"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">smmt:InitialPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-24</xbrli:startDate><xbrli:endDate>2021-03-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ad778717801435f8f8ca0b3e18b51e9_I20210324"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">smmt:InitialPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i325d85a3830d40bba514256f5133edfa_D20210324-20210324"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">smmt:InitialPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:UsTreasuryUstInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-24</xbrli:startDate><xbrli:endDate>2021-03-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i09dcbb2d540d490da156db0310d0ba16_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">smmt:InitialPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idb48cdbb6adf4bcf9f8d62840ec9c140_I20210326"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:context id="i581d5e9999fd48be88afa99a5a463cea_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5c623b14e066454399e945948de2ad12_D20210420-20210420"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">smmt:SecondPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-20</xbrli:startDate><xbrli:endDate>2021-04-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6f7965621e7641dba292d1568adf65f8_D20210420-20210420"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">smmt:SecondPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:UsTreasuryUstInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-20</xbrli:startDate><xbrli:endDate>2021-04-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie3fb42912674490dbad67b4354fdb2ee_D20210512-20210512"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">smmt:RightsOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-12</xbrli:startDate><xbrli:endDate>2021-05-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c16f78153794bfc9c3b372a28a98377_D20210512-20210512"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefOperatingOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">smmt:RightsOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-12</xbrli:startDate><xbrli:endDate>2021-05-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8148167fc4184c02abb40835e22beac6_I20210512"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefOperatingOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">smmt:RightsOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-05-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i11be25b5a09d46a5851abb451892b99c_I20210512"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">smmt:RightsOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-05-12</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i2eecdebedec64091994df5b7a96baab7_1"></div><div style="min-height:45pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">UNITED STATES SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">_____________________________</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xL2ZyYWc6MDM2ZTQxNmM1MThlNDc4YjgwMzhiOTA2MzE2OTQ1NGQvdGV4dHJlZ2lvbjowMzZlNDE2YzUxOGU0NzhiODAzOGI5MDYzMTY5NDU0ZF8zNDcx_a4d119ce-7817-41b6-93ac-97ae222b7637">10-K/A</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Amendment No. 1</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">_____________________________</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Mark One)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" name="dei:DocumentAnnualReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xL2ZyYWc6MDM2ZTQxNmM1MThlNDc4YjgwMzhiOTA2MzE2OTQ1NGQvdGV4dHJlZ2lvbjowMzZlNDE2YzUxOGU0NzhiODAzOGI5MDYzMTY5NDU0ZF8zNDcy_32fb0159-9407-4a78-a6be-6170988d4a5c">&#9746;</ix:nonNumeric>&#160;&#160;&#160;&#160;ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For the fiscal year ended <ix:nonNumeric contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xL2ZyYWc6MDM2ZTQxNmM1MThlNDc4YjgwMzhiOTA2MzE2OTQ1NGQvdGV4dHJlZ2lvbjowMzZlNDE2YzUxOGU0NzhiODAzOGI5MDYzMTY5NDU0ZF8yNzQ_ef4584c3-7879-4458-81d2-02bd9191d917"><ix:nonNumeric contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xL2ZyYWc6MDM2ZTQxNmM1MThlNDc4YjgwMzhiOTA2MzE2OTQ1NGQvdGV4dHJlZ2lvbjowMzZlNDE2YzUxOGU0NzhiODAzOGI5MDYzMTY5NDU0ZF8yNzQ_5fc38dde-19f9-4b0d-b4d4-ffcc2c176b09">December 31</ix:nonNumeric>, 2021</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">or</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xL2ZyYWc6MDM2ZTQxNmM1MThlNDc4YjgwMzhiOTA2MzE2OTQ1NGQvdGV4dHJlZ2lvbjowMzZlNDE2YzUxOGU0NzhiODAzOGI5MDYzMTY5NDU0ZF8zNDc0_191ceceb-9913-48ee-a7ae-0efba04ba2da">&#9744;</ix:nonNumeric>&#160;&#160;&#160;&#160;TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For the transition period from                      to                     </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Commission file number: <ix:nonNumeric contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xL2ZyYWc6MDM2ZTQxNmM1MThlNDc4YjgwMzhiOTA2MzE2OTQ1NGQvdGV4dHJlZ2lvbjowMzZlNDE2YzUxOGU0NzhiODAzOGI5MDYzMTY5NDU0ZF8zNDc1_f76d3680-2d4a-42dc-b188-918ce8c0b720">001-36866</ix:nonNumeric></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:46.637%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xL2ZyYWc6MDM2ZTQxNmM1MThlNDc4YjgwMzhiOTA2MzE2OTQ1NGQvdGV4dHJlZ2lvbjowMzZlNDE2YzUxOGU0NzhiODAzOGI5MDYzMTY5NDU0ZF8zNDYz_208b9510-1378-46b9-afb7-5d213c7db9c4">Summit Therapeutics Inc.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Exact Name of Registrant as Specified in its Charter)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:46.637%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.602%"><tr><td style="width:1.0%"></td><td style="width:20.669%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.298%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.661%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.972%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xL2ZyYWc6MDM2ZTQxNmM1MThlNDc4YjgwMzhiOTA2MzE2OTQ1NGQvdGFibGU6NTU3NjA0NWFiYTc3NDI1MDlkYTU2NzNkYjVhNjc4MzAvdGFibGVyYW5nZTo1NTc2MDQ1YWJhNzc0MjUwOWRhNTY3M2RiNWE2NzgzMF8wLTAtMS0xLTEwOTg3Ng_f00df743-f0a4-43c7-81d9-776784a7520e">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xL2ZyYWc6MDM2ZTQxNmM1MThlNDc4YjgwMzhiOTA2MzE2OTQ1NGQvdGFibGU6NTU3NjA0NWFiYTc3NDI1MDlkYTU2NzNkYjVhNjc4MzAvdGFibGVyYW5nZTo1NTc2MDQ1YWJhNzc0MjUwOWRhNTY3M2RiNWE2NzgzMF8wLTMtMS0xLTEwOTg3Ng_8c718507-d2e3-42cd-b3cf-685a55485230">37-1979717</ix:nonNumeric></span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(State or Other Jurisdiction of Incorporation or Organization)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(I.R.S. Employer Identification No.)</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xL2ZyYWc6MDM2ZTQxNmM1MThlNDc4YjgwMzhiOTA2MzE2OTQ1NGQvdGFibGU6NTU3NjA0NWFiYTc3NDI1MDlkYTU2NzNkYjVhNjc4MzAvdGFibGVyYW5nZTo1NTc2MDQ1YWJhNzc0MjUwOWRhNTY3M2RiNWE2NzgzMF8zLTAtMS0xLTEwOTg3Ng_9a547bd2-5a79-469a-ac87-5a6c42b83e3a">One Broadway, 14th Floor</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xL2ZyYWc6MDM2ZTQxNmM1MThlNDc4YjgwMzhiOTA2MzE2OTQ1NGQvdGFibGU6NTU3NjA0NWFiYTc3NDI1MDlkYTU2NzNkYjVhNjc4MzAvdGFibGVyYW5nZTo1NTc2MDQ1YWJhNzc0MjUwOWRhNTY3M2RiNWE2NzgzMF80LTAtMS0xLTEwOTg3Ng_8e313f15-e450-4c60-b8ab-891a41987b78">Cambridge,</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xL2ZyYWc6MDM2ZTQxNmM1MThlNDc4YjgwMzhiOTA2MzE2OTQ1NGQvdGFibGU6NTU3NjA0NWFiYTc3NDI1MDlkYTU2NzNkYjVhNjc4MzAvdGFibGVyYW5nZTo1NTc2MDQ1YWJhNzc0MjUwOWRhNTY3M2RiNWE2NzgzMF80LTEtMS0xLTEwOTg3Ng_fc1f5abb-99e6-437c-8419-c3814fe2aa91">MA</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xL2ZyYWc6MDM2ZTQxNmM1MThlNDc4YjgwMzhiOTA2MzE2OTQ1NGQvdGFibGU6NTU3NjA0NWFiYTc3NDI1MDlkYTU2NzNkYjVhNjc4MzAvdGFibGVyYW5nZTo1NTc2MDQ1YWJhNzc0MjUwOWRhNTY3M2RiNWE2NzgzMF80LTMtMS0xLTEwOTg3Ng_a8cb30a5-ee51-4e51-81fd-0a46a3bccd6c">02142</ix:nonNumeric></span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Address of Principal Executive Offices)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Zip Code)</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xL2ZyYWc6MDM2ZTQxNmM1MThlNDc4YjgwMzhiOTA2MzE2OTQ1NGQvdGV4dHJlZ2lvbjowMzZlNDE2YzUxOGU0NzhiODAzOGI5MDYzMTY5NDU0ZF8zNDY5_0c2025bb-5bb0-4917-9db4-a464906f3d01">617</ix:nonNumeric>) <ix:nonNumeric contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xL2ZyYWc6MDM2ZTQxNmM1MThlNDc4YjgwMzhiOTA2MzE2OTQ1NGQvdGV4dHJlZ2lvbjowMzZlNDE2YzUxOGU0NzhiODAzOGI5MDYzMTY5NDU0ZF8zNDY2_83517f9f-5f2f-4cbc-91bc-2ca2cd02e41c">514-7149</ix:nonNumeric></span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Registrant&#8217;s Telephone Number, Including Area Code)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:83.625%"><tr><td style="width:1.0%"></td><td style="width:34.039%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.172%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.489%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xL2ZyYWc6MDM2ZTQxNmM1MThlNDc4YjgwMzhiOTA2MzE2OTQ1NGQvdGFibGU6OTBiYjc0NWRlZTg0NGU1NDljMGZhZjA1ODMzZDRiNTMvdGFibGVyYW5nZTo5MGJiNzQ1ZGVlODQ0ZTU0OWMwZmFmMDU4MzNkNGI1M18xLTAtMS0xLTEwOTg3Ng_034e8dcf-755c-4a52-b2ed-ad599f54a057">Common Stock, par value $0.01 per share</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xL2ZyYWc6MDM2ZTQxNmM1MThlNDc4YjgwMzhiOTA2MzE2OTQ1NGQvdGFibGU6OTBiYjc0NWRlZTg0NGU1NDljMGZhZjA1ODMzZDRiNTMvdGFibGVyYW5nZTo5MGJiNzQ1ZGVlODQ0ZTU0OWMwZmFmMDU4MzNkNGI1M18xLTEtMS0xLTEwOTg3Ng_33187bbf-b7b7-4d79-99b5-668098135bf3">SMMT</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xL2ZyYWc6MDM2ZTQxNmM1MThlNDc4YjgwMzhiOTA2MzE2OTQ1NGQvdGFibGU6OTBiYjc0NWRlZTg0NGU1NDljMGZhZjA1ODMzZDRiNTMvdGFibGVyYW5nZTo5MGJiNzQ1ZGVlODQ0ZTU0OWMwZmFmMDU4MzNkNGI1M18xLTItMS0xLTEwOTg3Ng_f83c062f-65ae-4959-a520-694e0dadc229">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Securities registered pursuant to Section 12(g) of the Act: None</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.    Yes &#9744;    <ix:nonNumeric contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" name="dei:EntityWellKnownSeasonedIssuer" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xL2ZyYWc6MDM2ZTQxNmM1MThlNDc4YjgwMzhiOTA2MzE2OTQ1NGQvdGV4dHJlZ2lvbjowMzZlNDE2YzUxOGU0NzhiODAzOGI5MDYzMTY5NDU0ZF8zNDY0_ed38e6e4-0073-48b1-8712-2bdd5a8b8e18">No</ix:nonNumeric>  &#9746;</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.   Yes  &#9744;    <ix:nonNumeric contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" name="dei:EntityVoluntaryFilers" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xL2ZyYWc6MDM2ZTQxNmM1MThlNDc4YjgwMzhiOTA2MzE2OTQ1NGQvdGV4dHJlZ2lvbjowMzZlNDE2YzUxOGU0NzhiODAzOGI5MDYzMTY5NDU0ZF8zNDYw_dc9fcce2-ab10-42a3-8391-4f730db6b4ea">No</ix:nonNumeric>  &#9746;</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    <ix:nonNumeric contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xL2ZyYWc6MDM2ZTQxNmM1MThlNDc4YjgwMzhiOTA2MzE2OTQ1NGQvdGV4dHJlZ2lvbjowMzZlNDE2YzUxOGU0NzhiODAzOGI5MDYzMTY5NDU0ZF8zNDY3_f3c0d23f-74d2-4bcf-8d1c-4e397cadd0f5">Yes</ix:nonNumeric> &#9746;    No &#9744;</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted posted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    <ix:nonNumeric contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xL2ZyYWc6MDM2ZTQxNmM1MThlNDc4YjgwMzhiOTA2MzE2OTQ1NGQvdGV4dHJlZ2lvbjowMzZlNDE2YzUxOGU0NzhiODAzOGI5MDYzMTY5NDU0ZF8zNDYx_3e44e276-0cca-439b-88c7-b243732dc177">Yes</ix:nonNumeric>  &#9746;    No  &#9744;</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.929%"><tr><td style="width:1.0%"></td><td style="width:18.658%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:51.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.675%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.728%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Large accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xL2ZyYWc6MDM2ZTQxNmM1MThlNDc4YjgwMzhiOTA2MzE2OTQ1NGQvdGFibGU6ZTMxY2NkMDRmMTQxNDQ5ZDllZGQ0MzQzOTI3NDQ1YjUvdGFibGVyYW5nZTplMzFjY2QwNGYxNDE0NDlkOWVkZDQzNDM5Mjc0NDViNV8xLTAtMS0xLTEwOTg3Ng_f1cb7a0d-d7d9-40b0-a64b-b34a2e70f9b3">Non-accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xL2ZyYWc6MDM2ZTQxNmM1MThlNDc4YjgwMzhiOTA2MzE2OTQ1NGQvdGFibGU6ZTMxY2NkMDRmMTQxNDQ5ZDllZGQ0MzQzOTI3NDQ1YjUvdGFibGVyYW5nZTplMzFjY2QwNGYxNDE0NDlkOWVkZDQzNDM5Mjc0NDViNV8xLTMtMS0xLTEwOTg3Ng_3a6cda06-926d-4510-9644-1f97a6f3e916">&#9746;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xL2ZyYWc6MDM2ZTQxNmM1MThlNDc4YjgwMzhiOTA2MzE2OTQ1NGQvdGFibGU6ZTMxY2NkMDRmMTQxNDQ5ZDllZGQ0MzQzOTI3NDQ1YjUvdGFibGVyYW5nZTplMzFjY2QwNGYxNDE0NDlkOWVkZDQzNDM5Mjc0NDViNV8yLTMtMS0xLTEwOTg3Ng_1084739a-041a-47b1-9324-9b3ec916a771">&#9744;</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:3pt;margin-top:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   </span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.  <ix:nonNumeric contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" name="dei:IcfrAuditorAttestationFlag" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xL2ZyYWc6MDM2ZTQxNmM1MThlNDc4YjgwMzhiOTA2MzE2OTQ1NGQvdGV4dHJlZ2lvbjowMzZlNDE2YzUxOGU0NzhiODAzOGI5MDYzMTY5NDU0ZF8zNDcw_f6e7877b-5333-4406-8493-5951e6e5325e">&#9744;</ix:nonNumeric></span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes     No  <ix:nonNumeric contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" name="dei:EntityShellCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xL2ZyYWc6MDM2ZTQxNmM1MThlNDc4YjgwMzhiOTA2MzE2OTQ1NGQvdGV4dHJlZ2lvbjowMzZlNDE2YzUxOGU0NzhiODAzOGI5MDYzMTY5NDU0ZF8zNDc2_0347906d-3a92-4e27-9b96-e61003db648b">&#9746;</ix:nonNumeric></span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The aggregate market value of the voting common stock held by non-affiliates based on the closing stock price on June 30, 2021, was $<ix:nonFraction unitRef="usd" contextRef="ia595af4209c94a0e84bcc1c89fef3796_I20210630" decimals="-5" name="dei:EntityPublicFloat" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xL2ZyYWc6MDM2ZTQxNmM1MThlNDc4YjgwMzhiOTA2MzE2OTQ1NGQvdGV4dHJlZ2lvbjowMzZlNDE2YzUxOGU0NzhiODAzOGI5MDYzMTY5NDU0ZF8yOTQ5_a75bc2a3-2ddc-49ed-8ad9-735f8c59edc0">186.0</ix:nonFraction>&#160;million. For purposes of this computation only, all executive officers and directors have been deemed affiliates.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The number of outstanding shares of the registrant&#8217;s common stock, par value $0.01 per share, as of March 10, 2022 was <ix:nonFraction unitRef="shares" contextRef="idbfc95cd82ac4443bb9c319767213cfa_I20220310" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xL2ZyYWc6MDM2ZTQxNmM1MThlNDc4YjgwMzhiOTA2MzE2OTQ1NGQvdGV4dHJlZ2lvbjowMzZlNDE2YzUxOGU0NzhiODAzOGI5MDYzMTY5NDU0ZF8zMTc3_d3526d05-12d5-4f52-866b-9bb766b4b7d4">98,122,356</ix:nonFraction>.</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">DOCUMENTS INCORPORATED BY REFERENCE</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xL2ZyYWc6MDM2ZTQxNmM1MThlNDc4YjgwMzhiOTA2MzE2OTQ1NGQvdGV4dHJlZ2lvbjowMzZlNDE2YzUxOGU0NzhiODAzOGI5MDYzMTY5NDU0ZF8zNDYy_9175c063-70f3-4c06-9efa-f6e0d0887b6d" escape="true">Portions of the registrant&#8217;s definitive Proxy Statement to be filed with the Securities and Exchange Commission within 120 days after registrant&#8217;s fiscal year ended December 31, 2021 are incorporated by reference into Part III of this report.</ix:nonNumeric></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">EXPLANATORY NOTE</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">This amendment on Form 10-K/A amends our Annual Report on Form 10-K for the year ended December 31, 2021 to correct the date on the predecessor auditor opinion for the year ended December 31, 2020 from March 17, 2022 to March 31, 2021 and to correct the tenure statement on such report from 2020 to 2021. Except for these corrections, no other changes have been made to the Company's Annual Report on Form 10-K for the fiscal year ending December 31, 2021.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">In addition, the Company is including in this Amendment No. 1 currently dated certifications from (i) its Chairman and Chief Executive Officer, (ii) Executive Director, Co- Chief Executive Officer and President, (iii) Principal Financial Officer, and (iv) Chief Executive Officer, Co-Chief Executive Officer and Chief Financial Officer, as required by Sections 302 and 906 of the Sarbanes-Oxley Act of 2002 as Exhibits 31.1, 31.2, 31.3, and 32.1, respectively, and currently dated consents from the independent registered public accounting firms as Exhibits 23.1 and 23.2.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Except as expressly set forth above, this Amendment No. 1 speaks as of the original filing date of the Form 10-K, and does not reflect events that may have occurred subsequent to that date, nor does it modify or update in any way disclosure made in the original Form 10-K.</span></div><div style="text-indent:72pt"><span><br/></span></div><div id="i2eecdebedec64091994df5b7a96baab7_7"></div><div style="text-align:right"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:78.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.719%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i2eecdebedec64091994df5b7a96baab7_31">PART II</a></span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;8.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2eecdebedec64091994df5b7a96baab7_46">Financial Statements and Supplementary Data</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2eecdebedec64091994df5b7a96baab7_46">1</a></span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i2eecdebedec64091994df5b7a96baab7_79">PART IV</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;15.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2eecdebedec64091994df5b7a96baab7_82">Exhibits, Financial Statement Schedules</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2eecdebedec64091994df5b7a96baab7_82">1</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2eecdebedec64091994df5b7a96baab7_91">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2eecdebedec64091994df5b7a96baab7_91">7</a></span></div></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii</span></div></div></div><div id="i2eecdebedec64091994df5b7a96baab7_31"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:24pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II</span></div><div style="text-align:center"><span><br/></span></div><div id="i2eecdebedec64091994df5b7a96baab7_46"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;8. Financial Statements and Supplementary Data</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financial statements required to be filed pursuant to this Item 8 are included to this Report. An index of those financial statements is found in Item 15. </span></div><div><span><br/></span></div><div id="i2eecdebedec64091994df5b7a96baab7_79"></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART IV</span></div><div id="i2eecdebedec64091994df5b7a96baab7_82"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;15. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exhibits, Financial Statement Schedules</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.982%"><tr><td style="width:1.0%"></td><td style="width:25.770%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.770%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.160%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(1)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Financial Statements</span></div></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As part of this Report, the consolidated financial statements are listed in the accompanying index to financial statements on page </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i2eecdebedec64091994df5b7a96baab7_94">8</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">.</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:55.409%"><tr><td style="width:1.0%"></td><td style="width:19.744%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.744%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:57.212%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(2)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Financial Statement Schedules</span></div></td></tr></table></div><div style="text-indent:32.05pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">All financial statement schedules have been omitted because they are not applicable, not required, or the information required is shown in the consolidated financial statements or the notes thereto.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><div id="i2eecdebedec64091994df5b7a96baab7_85"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div><span><br/></span></div><div style="-sec-extract:summary"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.982%"><tr><td style="width:1.0%"></td><td style="width:25.770%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.770%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.160%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(3)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Exhibits</span></div></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The exhibits filed as part of this Report are listed below.</span></div><div><span><br/></span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.222%"><tr><td style="width:1.0%"></td><td style="width:8.674%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.551%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.375%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Exhibit&#160;No.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1599298/000119312520199664/d78408dex991.htm">Scheme of Arrangement, dated September 18, 2020 (incorporated by reference to Exhibit 99.1 to the Company&#8217;s Report on Form 6-K (File No. 001-36866), filed with the Securities and Exchange Commission on July 27, 2020)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1599298/000119312520248702/d76627dex31.htm">Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K (File No. 001-36866), filed with the Securities and Exchange Commission on September 18, 2020</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">)</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1599298/000119312520248702/d76627dex32.htm">Amended and Restated Bylaws (incorporated by reference to Exhibit 3.2 to the Company&#8217;s Current Report on Form 8-K (File No. 001-36866), filed with the Securities and Exchange Commission on September 18, 2020)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1599298/000119312519005734/d683406dex21.htm">Registration Rights Agreement, dated January 9, 2019, by and among Summit Therapeutics plc and Robert W. Duggan (incorporated by reference to Exhibit 2.1 to the Company&#8217;s Report on Form 6-K (File No. 001-36866), filed with the Securities and Exchange Commission on January 10, 2019)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1599298/000159929820000039/smmt-20200929.htm#i5f970bbb3fbc499788e0a3a1c28008bd_2832">Form of Specimen Stock Certificate (incorporated by reference to Exhibit 4.2 to the Company's Current Report on Form 8-K (File No. 001-36866), filed with the Securities and Exchange Commission on September 29, 2020)</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1599298/000119312520248702/d76627dex42.htm">Form of Consultant Warrant (incorporated by reference to Exhibit 4.2 to the Company&#8217;s Current Report on Form 8-K (File No. 001-36866), filed with the Securities and Exchange Commission on September 18, 2020)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1599298/000119312520248702/d76627dex41.htm">Form of Investor Warrant (incorporated by reference to Exhibit 4.1 to the Company&#8217;s Current Report on Form 8-K (File No. 001-36866), filed with the Securities and Exchange Commission on September 18, 2020)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1599298/000159929820000039/smmt-20200929.htm#i5f970bbb3fbc499788e0a3a1c28008bd_2771">Description of Securities Registered Under Section 12 of the Exchange Act (incorporated by reference to the description of securities contained in the Company's Current Report on Form 8-K (File No. 001-36866), filed with the Securities and Exchange Commission on September 18, 2020)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1599298/000092189520002819/ex103to8k12566007_11052020.htm">Registration Rights Agreement, dated November 6, 2020, by and among Summit Therapeutics Inc., Polar Capital Funds plc - Biotechnology Fund and the Mahkam Zanganeh Revocable Trust (incorporated by reference to Exhibit 10.3 to the Company's Current Report on Form 8-K (File No. 001-36866), filed with the Securities and Exchange Commission on November 6, 2020)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001599298/000119380521000519/ex41to8k12566001_04162021.htm">Form of Subscription Rights Certificate (incorporated by reference to Exhibit 4.1 to the Company&#8217;s Current Report on Form 8-K (File No. 001-36866), filed with the Securities and Exchange Commission on April 21, 2021)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1599298/000119312515070214/d822352dex103.htm">Translation Award Funding Agreement, entered into as of October 19, 2012, by and between the Wellcome Trust Limited and Summit Therapeutics plc (incorporated by reference to Exhibit 10.3 to the Company&#8217;s Registration Statement on Form F-1 (File No. 333-201807), as amended, filed with the Securities and Exchange Commission on February 27, 2015)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1599298/000119312515056561/d822352dex1010.htm">Service Agreement, effective as of January 14, 2015, by and between Cambridge Innovation Center and Summit Therapeutics Inc. (incorporated by reference to Exhibit 10.10 to the Company&#8217;s Registration Statement on Form F-1 (File No. 333-201807), as amended, filed with the Securities and Exchange Commission on February 20, 2015)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1599298/000159929820000005/sum-ex43_20191231x20f.htm">2005 Enterprise Management Incentive Scheme </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1599298/000159929820000005/sum-ex43_20191231x20f.htm">(incorporated by reference to Exhibit 4.3 to the Company&#8217;s Transition Report on 20-F (File No. 333-36866), as amended, filed with the Securities and Exchange Commission on April 30, 2020)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1599298/000119312516587491/d185299dex422.htm">2016 Long Term Incentive Plan (incorporated by reference to Exhibit 4.22 to the Company&#8217;s Annual Report on Form 20-F (File No. 001-36866), filed with the Securities and Exchange Commission on May 12, 2016)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1599298/000119312517104086/d365559dex423.htm">License and Collaboration Agreement, dated October 3, 2016, by and between Summit (Oxford) Ltd. and Sarepta Therapeutics, Inc. (incorporated by reference to Exhibit 4.23 to the Company&#8217;s Annual Report on Form 20-F (File No. 001-36866), filed with the Securities and Exchange Commission on March 30, 2017)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.222%"><tr><td style="width:1.0%"></td><td style="width:8.674%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.551%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.375%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Exhibit&#160;No.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1599298/000119312517104086/d365559dex425.htm">Lease, dated February 17, 2017, by and among MEPC Milton Park No. 1 Limited, MEPC Milton Park No. 2 Limited and Summit Therapeutics plc (incorporated by reference to Exhibit 4.25 to the Company&#8217;s Annual Report on Form 20-F (File No. 001-36866), filed with the Securities and Exchange Commission on March 30, 2017)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1599298/000162828018004229/sum-ex426_20180131x20f.htm">Agreement, dated September 5, 2017, by and between Summit (Oxford) Limited and the U.S. Department of Health and Human Services Biomedical Advanced Research and Development Authority&#160;(BARDA) (incorporated by reference to Exhibit 4.26 to the Company&#8217;s Annual Report on Form 20-F (File No. 001-36866), filed with the Securities and Exchange Commission on April 13, 2018)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1599298/000159929819000008/sum-ex413_20190131x20f.htm">Amendment of Solicitation/Modification of Contract (0001), dated June 19, 2018, to Agreement, dated September 5, 2017, by and between Summit (Oxford) Limited and the U.S. Department of Health and Human Services Biomedical Advanced Research and Development Authority&#160;(BARDA) </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1599298/000159929819000008/sum-ex413_20190131x20f.htm">(incorporated by reference to Exhibit 4.13 to the Company&#8217;s Transition Report on 20-F (File No. 333-36866) filed with the Securities and Exchange Commission on March 29, 2019)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.9+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1599298/000159929819000008/sum-ex414_20190131x20f.htm">Amendment of Solicitation/Modification of Contract (0002), dated August 14, 2018, to Agreement, dated September 5, 2017, by and between Summit (Oxford) Limited and the U.S. Department of Health and Human Services Biomedical Advanced Research and Development Authority&#160;(BARDA) </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1599298/000159929819000008/sum-ex414_20190131x20f.htm">(incorporated by reference to Exhibit 4.14 to the Company&#8217;s Transition Report on 20-F(File No. 333-36866) filed with the Securities and Exchange Commission on March 29, 2019)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.10+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1599298/000159929819000008/sum-ex415_20190131x20f.htm">Amendment of Solicitation/Modification of Contract (0003), dated February 14, 2019, to Agreement, dated September 5, 2017, by and between Summit (Oxford) Limited and the U.S. Department of Health and Human Services Biomedical Advanced Research and Development Authority&#160;(BARDA) </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1599298/000159929819000008/sum-ex415_20190131x20f.htm">(incorporated by reference to Exhibit 4.15 to the Company&#8217;s Transition Report on 20-F (File No. 333-36866), filed with the Securities and Exchange Commission on March 29, 2019)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.11&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1599298/000162828018004229/sum-ex427_20180131x20f.htm">License and Commercialization Agreement, dated December 18, 2017, by and between Summit (Oxford) Ltd. and Eurofarma Laborat&#243;rios S.A. (incorporated by reference to Exhibit 4.27 to the Company&#8217;s Annual Report on Form 20-F (File No. 001-36866), filed with the Securities and Exchange Commission on April 13, 2018)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.12&#8224;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1599298/000162828018004229/sum-ex428_20180131x20f.htm">Share Purchase Agreement, dated December 23, 2017, by and among Summit Therapeutics plc and the shareholders of Discuva Limited (incorporated by reference to Exhibit 4.28 to the Company&#8217;s Annual Report on Form 20-F (File No. 001-36866), filed with the Securities and Exchange Commission on April 13, 2018)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.13&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1599298/000162828018004229/sum-ex429_20180131x20f.htm">Transfer Incentive Agreement, dated December 23, 2017, by and among Discuva Limited and certain of its managers (incorporated by reference to Exhibit 4.29 to the Company&#8217;s Annual Report on Form 20-F (File No. 001-36866), filed with the Securities and Exchange Commission on April 13, 2018)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.14</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1599298/000162828018004229/sum-ex431_20180131x20f.htm">Lease, dated December 22, 2017, by and between Merrifield Centre Ltd and Discuva Limited (incorporated by reference to Exhibit 4.31 to the Company&#8217;s Annual Report on Form 20-F (File No. 001-36866), filed with the Securities and Exchange Commission on April 13, 2018)</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.15&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1599298/000162828018004229/sum-ex432_20180131x20f.htm">Equity and Revenue Sharing Agreement, dated October 16, 2017, by and between Summit (Oxford) Limited and the Wellcome Trust Limited (incorporated by reference to Exhibit 4.32 to the Company&#8217;s Annual Report on Form 20-F (File No. 001-36866), filed with the Securities and Exchange Commission on April 13, 2018)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.16</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1599298/000162828018004229/sum-ex433_20180131x20f.htm">Form of Non-Executive Director Restricted Stock Unit (RSU) Agreement (incorporated by reference to Exhibit 4.33 to the Company&#8217;s Annual Report on Form 20-F (File No. 001-36866), filed with the Securities and Exchange Commission on April 13, 2018)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.17</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1599298/000119312518350442/d639714dex101.htm">Securities Purchase Agreement, dated December 14, 2018, by and among Summit Therapeutics plc and Robert W. Duggan (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Report on Form 6-K (File No. 001-36866), filed with the Securities and Exchange Commission on December 17, 2018)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.18+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1599298/000159929820000005/sum-ex424_20190131x20f1.htm">Amendment of Solicitation/Modification of Contract (0004), dated June 17, 2019, to Agreement, dated September 5, 2017, by and between Summit (Oxford) Limited and the U.S. Department of Health and Human Services Biomedical Advanced Research and Development Authority&#160;(BARDA) </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1599298/000159929820000005/sum-ex424_20190131x20f1.htm">(incorporated by reference to Exhibit 4.24 to the Company&#8217;s Transition Report on 20-f (File No. 333-36866) filed with the Securities and Exchange Commission on April 30, 2020)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.222%"><tr><td style="width:1.0%"></td><td style="width:8.674%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.551%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.375%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Exhibit&#160;No.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.19</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1599298/000119312519307884/d824147dex41.htm">Securities Purchase Agreement, dated December 6, 2019, by and among Summit Therapeutics plc and Robert W. Duggan (incorporated by reference to Exhibit 4.1 to the Company&#8217;s Report on Form 6-K (File No. 001-36866), filed with the Securities and Exchange Commission on December 6, 2019)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.20</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1599298/000119312519307884/d824147dex42.htm">Placing Agreement, December 6, 2019, by and between Summit Therapeutics plc and Nplus1 Singer Advisory LLP (incorporated by reference to Exhibit 4.2 to the Company&#8217;s Report on Form 6-K (File No. 001-36866), filed with the Securities and Exchange Commission on December 6, 2019)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.21</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1599298/000119312519307884/d824147dex44.htm">Consulting Agreement, dated December 6, 2019, by and between Summit Therapeutics plc and Maky Zanganeh &amp; Associates, Inc. (incorporated by reference to Exhibit 4.4 to the Company's Report on Form 6-K (File No. 001-36866), filed with the Securities and Exchange Commission on December 6, 2019)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.22</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1599298/000119312518350442/d639714dex102.htm">Relationship Agreement, dated December 14, 2018, by and among Summit Therapeutics plc, Robert W. Duggan and Cairn Financial Advisers LLP (incorporated by reference to Exhibit 10.2 to the Company&#8217;s Report on Form 6-K (File No. 001-36866), filed with the Securities and Exchange Commission on December 17, 2018)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.23</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1599298/000119312519307884/d824147dex43.htm">Deed of Termination, dated December 6, 2019, by and among Summit Therapeutics plc, Robert Duggan and Cairn Financial Advisers LLP (incorporated by reference to Exhibit 4.3 to the Company&#8217;s Report on Form 6-K (File No. 001-36866), filed with the Securities and Exchange Commission on December 6, 2019)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.24+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1599298/000159929820000005/sumex436_20191231-20f.htm">Amendment of Solicitation/Modification of Contract (0005), dated January 21, 2020, to Agreement, dated September 5, 2017, by and between Summit (Oxford) Limited and the U.S. Department of Health and Human Services Biomedical Advanced Research and Development Authority&#160;(BARDA) </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1599298/000159929820000005/sumex436_20191231-20f.htm">(incorporated by reference to Exhibit 4.36 to the Company&#8217;s Transition Report on 20-F (File No. 333-36866)  filed with the Securities and Exchange Commission on April 30, 2020)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.25</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1599298/000119380520001233/ex101to8k12566001_10052020.htm">Securities Purchase Agreement, dated October 2, 2020, by and between Summit Therapeutics Inc. and Robert W. Duggan (incorporated by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K (File No. 001-36866) filed with the Securities and Exchange Commission on October 5, 2020)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.26</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1599298/000092189520002819/ex101to8k12566007_11052020.htm">Securities Purchase Agreement, dated November 6, 2020, by and between Summit Therapeutics Inc. and Polar Capital Fund plc - Biotechnology Fund (incorporated by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K (File No. 001-36866) filed with the Securities and Exchange Commission on November 6, 2020)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.27</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1599298/000092189520002819/ex102to8k12566007_11052020.htm">Securities Purchase Agreement, dated November 6, 2020, by and between Summit Therapeutics Inc. and Mahkam Zanganeh Revocable Trust (incorporated by reference to Exhibit 10.2 to the Company's Current Report on Form 8-K (File No. 001-36866) filed with the Securities and Exchange Commission on November 6, 2020)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.28#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1599298/000119312520248702/d76627dex101.htm">Form of Indemnification Agreement between Summit Therapeutics Inc. and each of its Executive Officers and Directors (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K (File No. 001-36866), filed with the Securities and Exchange Commission on September 18, 2020)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.29#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1599298/000159929820000039/smmt-20200929.htm#i5f970bbb3fbc499788e0a3a1c28008bd_3229">Offer of Employment, dated May 21, 2020, by and between Summit Therapeutics Inc. and Michael Donaldson (incorporated by reference to Exhibit 10.25 to the Company's Current Report on Form 8-K (File No. 001-36866), filed with the Securities and Exchange Commission on September 29, 2020)</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.30#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1599298/000159929820000039/smmt-20200929.htm#i5f970bbb3fbc499788e0a3a1c28008bd_3237">Contract of Employment, dated May 29, 2020, by and between Summit Therapeutics Inc. and Ventzislav Stefanov (incorporated by reference to Exhibit 10.26 to the Company's Current Report on Form 8-K (File No. 001-36866), filed with the Securities and Exchange Commission on September 29, 2020)</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.31#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1599298/000119312520248702/d76627dex102.htm">2020 Stock Incentive Plan (incorporated by reference to Exhibit 10.2 to the Company&#8217;s Current Report on Form 8-K (File No. 001-36866), filed with the Securities and Exchange Commission on September 18, 2020)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.32#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1599298/000159929820000039/smmt-20200929.htm#i5f970bbb3fbc499788e0a3a1c28008bd_2807">Form of Option Award under 2020 Stock Incentive Plan (incorporated by reference to Exhibit 10.28 to the Company's Current Report on Form 8-K (File No. 001-36866), filed with the Securities and Exchange Commission on September 29, 2020)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.33#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1599298/000159929820000039/smmt-20200929.htm#i5f970bbb3fbc499788e0a3a1c28008bd_2812">Form of Restricted Stock Unit Agreement under 2020 Stock Incentive Plan (incorporated by reference to Exhibit 10.29 to the Company's Current Report on Form 8-K (File No. 001-36866), filed with the Securities and Exchange Commission on September 29, 2020)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.34#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1599298/000119312520248702/d76627dex103.htm">2020 Employee Stock Purchase Plan (incorporated by reference to Exhibit 10.3 to the Company&#8217;s Current Report on Form 8-K (File No. 001-36866), filed with the Securities and Exchange Commission on September 18, 2020)</a></span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.222%"><tr><td style="width:1.0%"></td><td style="width:8.674%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.551%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.375%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Exhibit&#160;No.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.35</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001599298/000159929821000011/sum-ex1035_20201231x10k.htm">Contract of Employment, dated November 22, 2020, by and between Summit Therapeutics Inc. and Mahkam Zanganeh (incorporated by reference to Exhibit 10.35 to the Company's Annual Report on Form 10-K (File No. 001-36866), filed with the Securities and Exchange Commission on March 31, 2021)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.36</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001599298/000159929821000011/sum-ex1036_20201231x10k.htm">Sublease Agreement, dated March 26, 2021, by and between Maky Zanganeh &amp; Associates Inc. and Summit Therapeutics Sub Inc. (incorporated by reference to Exhibit 10.36 to the Company's Annual Report on Form 10-K (File No. 001-36866), filed with the Securities and Exchange Commission on March 31, 2021)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.37</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001599298/000092189521001523/ex101to8k12566003_05282021.htm">Exit Agreement, dated May 28, 2021, by and between Summit Therapeutics Inc. and Michael Donaldson (incorporated by reference to Exhibit 10.3 to the Company&#8217;s Current Report on Form 8-K (File No. 001-36866), filed with the Securities and Exchange Commission on May 28, 2021)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.38</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001599298/000159929822000022/summit-notepurchaseagreeme.htm">Note Purchase Agreement, dated March 10, 2022, by and between Summit Therapeutics Inc. and Robert W. Duggan (incorporated by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K (File. No. 001-36866), filed with the Securities and Exchange Commission on March 11, 2022)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.39</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001599298/000159929822000022/summit-promissorynote4867x.htm">Promissory Note, dated March 10, 2022, in the name of Robert W. Duggan (incorporated by reference to Exhibit 10.2 to the Company's Current Report on Form 8-K (File. No. 001-36866), filed with the Securities and Exchange Commission on March 11, 2022)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001599298/000092189521001494/ex161to8k12566001_05252021.htm">Letter from PwC to the Securities and Exchange Commission, dated May 26, 2021 (incorporated by reference to Exhibit 16.1 to the Company&#8217;s Current Report on Form 8-K (File No. 001-36866), filed with the Securities and Exchange Commission on May 26, 2021)</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1599298/000159929822000032/sum-ex211_20211231xxsubsid.htm">List of Significant Subsidiaries</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1599298/000159929822000032/sum-ex211_20211231xxsubsid.htm"> (</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1599298/000159929822000032/sum-ex211_20211231xxsubsid.htm">incorporated by reference to Exhibit 21.1 to the Company&#8217;s Annual Report on Form 10-K (File No. 001-36866), filed with the Securities and Exchange Commission on March 17, 2022</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1599298/000159929822000032/sum-ex211_20211231xxsubsid.htm">)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="sum-ex231_20211231x10xkaxu.htm">Consent of PricewaterhouseCoopers LLP, a Delaware limited liability partnership</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.2*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="sum-ex232_20211231x10xkaxu.htm">Consent of PricewaterhouseCoopers LLP, a United Kingdom entity</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="sum-ex311_20211231x10xka.htm">Certification of </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="sum-ex311_20211231x10xka.htm">Cha</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="sum-ex311_20211231x10xka.htm">irman and </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="sum-ex311_20211231x10xka.htm">Chief Executive Office</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="sum-ex311_20211231x10xka.htm">r, </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="sum-ex311_20211231x10xka.htm">Robert</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="sum-ex311_20211231x10xka.htm"> W. Duggan,</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="sum-ex311_20211231x10xka.htm"> pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to &#167;302 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="sum-ex312_20211231x10xka.htm">Certification of Executive Director, Co-Chief Executive Officer, and President, Dr. Maky Zanganeh, pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to &#167;302 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.3*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="sum-ex313_20211231x10xka.htm">Certification of Principal Financial Officer</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="sum-ex313_20211231x10xka.htm">, Ankur Dhingra,</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="sum-ex313_20211231x10xka.htm"> pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to &#167;302 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="sum-ex321_20211231x10xka.htm">Certification</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="sum-ex321_20211231x10xka.htm"> of Co-Chief Executive Officers and Chief Financial Officer</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="sum-ex321_20211231x10xka.htm"> pursuant to 18 U.S.C. &#167;1350, as adopted pursuant to &#167;906 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema Document</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Label Linkbase Document</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed herewith.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Confidential treatment has been granted as to certain portions of the exhibit. Confidential materials omitted and filed separately with the Securities and Exchange Commission.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certain portions of this exhibit have been omitted because they are not material and would likely cause competitive harm to the registrant if disclosed. </span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.222%"><tr><td style="width:1.0%"></td><td style="width:8.674%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.551%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.375%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Exhibit&#160;No.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The schedules and exhibits have been omitted. A copy of any omitted schedule or exhibit will be furnished to the Securities and Exchange Commission upon request. </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indicates management contract or compensatory plan or arrangement.</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div id="i2eecdebedec64091994df5b7a96baab7_91"></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="text-align:center"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-align:right;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:65.497%"><tr><td style="width:1.0%"></td><td style="width:18.766%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.141%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:74.793%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">SUMMIT THERAPEUTICS INC.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Ankur Dhingra</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name:<br/>Title:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ankur Dhingra<br/>Chief Financial Officer<br/>(Principal Financial Officer)</span></td></tr></table></div><div style="margin-top:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date: December 21,  2022</span></div><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><div id="i2eecdebedec64091994df5b7a96baab7_94"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.818%"><tr><td style="width:1.0%"></td><td style="width:88.848%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.952%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Summit Therapeutics Inc.</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Page</span></td></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Index to the Financial Statements</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i2eecdebedec64091994df5b7a96baab7_100">Report of Independent Registered Public Accounting Firm</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> (PCAOB ID <ix:nonNumeric contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" name="dei:AuditorFirmId" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN185NC9mcmFnOjgyMThiNzlmMDQ4ZjRiNDk5N2ViMzA3YzkwMWFkYmE5L3RhYmxlOjBkNDBhNTkzZTZiYTQxNjU4NWE1NjMyNjNjNjFmNzNiL3RhYmxlcmFuZ2U6MGQ0MGE1OTNlNmJhNDE2NTg1YTU2MzI2M2M2MWY3M2JfMy0wLTEtMS0xMDk4NzYvdGV4dHJlZ2lvbjpkMWI4NTBlMTNhMmE0NTFiYmQ1NGFmMDU4YzEwY2FjNV83MA_e14966fb-a997-4ba4-986b-ea9e31a3d51d">238</ix:nonNumeric>)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2eecdebedec64091994df5b7a96baab7_100">9</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i2eecdebedec64091994df5b7a96baab7_103">Report of Independent Registered Public Accounting Firm</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> (PCAOB ID <ix:nonNumeric contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231" name="dei:AuditorFirmId" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN185NC9mcmFnOjgyMThiNzlmMDQ4ZjRiNDk5N2ViMzA3YzkwMWFkYmE5L3RhYmxlOjBkNDBhNTkzZTZiYTQxNjU4NWE1NjMyNjNjNjFmNzNiL3RhYmxlcmFuZ2U6MGQ0MGE1OTNlNmJhNDE2NTg1YTU2MzI2M2M2MWY3M2JfNC0wLTEtMS0xMDk4NzYvdGV4dHJlZ2lvbjo3NDZjZDIwMDc1MmI0NmI0ODc1NWY1M2U0NjA4MmUyN183MA_45db54c2-1ae5-4299-bc47-f1ea6c328ec3">876</ix:nonNumeric>)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2eecdebedec64091994df5b7a96baab7_103">11</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i2eecdebedec64091994df5b7a96baab7_106">Consolidated Balance Sheets</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2eecdebedec64091994df5b7a96baab7_106">12</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i2eecdebedec64091994df5b7a96baab7_109">Consolidated Statements of Operations and Comprehensive Loss</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2eecdebedec64091994df5b7a96baab7_109">13</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i2eecdebedec64091994df5b7a96baab7_112">Consolidated Statements of Stockholders' Equity</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2eecdebedec64091994df5b7a96baab7_112">14</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i2eecdebedec64091994df5b7a96baab7_115">Consolidated Statements of Cash Flows</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2eecdebedec64091994df5b7a96baab7_115">15</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i2eecdebedec64091994df5b7a96baab7_118">Notes to the Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2eecdebedec64091994df5b7a96baab7_118">16</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><div id="i2eecdebedec64091994df5b7a96baab7_100"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Report of Independent Registered Public Accounting Firm</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">To the Board of Directors and Stockholders of Summit Therapeutics Inc.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Opinion on the Financial Statements</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We have audited the accompanying consolidated balance sheet of Summit Therapeutics Inc. and its subsidiaries (the &#8220;Company&#8221;) as of December 31, 2021, and the related consolidated statements of operations and comprehensive loss, of stockholders&#8217; equity and of cash flows for the year then ended, including the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2021 and the results of its operations and its cash flows for the year then ended in conformity with accounting principles generally accepted in the United States of America.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Basis for Opinion</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">These consolidated financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s consolidated financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We conducted our audit of these consolidated financial statements in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audit we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our audit included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audit provides a reasonable basis for our opinion.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Emphasis of Matter</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As discussed in Note 3 to the consolidated financial statements, the Company will require additional financing to fund its ongoing operations. Management&#8217;s evaluation of the events and conditions and management&#8217;s plans to mitigate this matter is also described in Note 3.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Critical Audit Matters</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The critical audit matter communicated below is a matter arising from the current period audit of the consolidated financial statements that was communicated or required to be communicated to the audit committee and that (i) relates to accounts or disclosures that are material to the consolidated financial statements and (ii) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%">Accrued and Prepaid Research and Development Costs</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">As described in Notes 4 and 14 to the consolidated financial statements, included within prepaid expenses as of December 31, 2021 is $6.1 million of prepayments relating to research and development expenditures. Included within accrued liabilities as of December 31, 2021 is $5.2 million relating to research and development expenditures.  The Company records accruals for estimated ongoing research and development costs or prepaid expenses where the payments made exceed the estimated costs.</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:107%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">These amounts are determined by management based on the estimated costs to complete each study or activity, the estimation of the current stage of completion and the invoices received, as well as predetermined milestones which are not reflective of the current stage of development for prepaid expenses. However, prepaid expenses decrease, and accrued liabilities increase as the activities progress, and if actual costs incurred exceed the prepaid expense, an accrual will be recorded for the liability. The key sensitivity is the estimated current stage of completion of each study or activity, which is based on information received from the supplier and management&#8217;s operational knowledge of the work completed under those contracts.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The principal considerations for our determination that performing procedures relating to accrued and prepaid research and development costs is a critical audit matter are the significant judgment by management when determining the estimated research and development costs, which in turn led to significant auditor judgment, subjectivity, and effort in performing procedures and evaluating audit evidence related to estimated current stage of completion of each study or activity. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the consolidated financial statements. These procedures included, among others, (i) evaluating management&#8217;s process on a sample basis for determining the current stage of completion of each study or activity; (ii) reading a sample of research and development contracts; (iii) evaluating the reasonableness of progress towards completion for a sample of research and development activities and the associated incurred cost based on invoices, external confirmations or other information received from the supplier; and (iv) testing the completeness and accuracy of the underlying data including total costs included within contracts and actual billed amounts for a sample of contracts.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">/s/ <ix:nonNumeric contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" name="dei:AuditorName" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDAvZnJhZzozNTZlMmU4ZmI0ZjY0YjExODE4Y2EwNDM1MzYzZTc0Zi90ZXh0cmVnaW9uOjM1NmUyZThmYjRmNjRiMTE4MThjYTA0MzUzNjNlNzRmXzY1NzE_e45a4107-b82a-4aa2-a69e-d892ab5b6f90">PricewaterhouseCoopers LLP</ix:nonNumeric> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:nonNumeric contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" name="dei:AuditorLocation" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDAvZnJhZzozNTZlMmU4ZmI0ZjY0YjExODE4Y2EwNDM1MzYzZTc0Zi90ZXh0cmVnaW9uOjM1NmUyZThmYjRmNjRiMTE4MThjYTA0MzUzNjNlNzRmXzY1NzM_e8151122-817d-43ee-a2f1-59fe8bb2ae49">Boston, Massachusetts</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">March 17, 2022</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We have served as the Company&#8217;s auditor since 2021.</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div id="i2eecdebedec64091994df5b7a96baab7_103"></div><div style="margin-top:12pt"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="padding-left:18pt;padding-right:18pt;text-align:center"><span><br/></span></div><div style="padding-left:18pt;padding-right:18pt;text-align:center;text-indent:-28.35pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Report of Independent Registered Public Accounting Firm</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-28.35pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">To the Board of Directors and Stockholders of Summit Therapeutics Inc. </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-28.35pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Opinion on Financial Statements</span></div><div style="padding-left:36pt;text-indent:-28.35pt"><span><br/></span></div><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We have audited the consolidated balance sheet of Summit Therapeutics Inc. and its subsidiaries (the &#8220;Company&#8221;) as of December 31, 2020, and the related Consolidated Statements of Operations and Comprehensive Loss, of Stockholders' Equity and of Cash Flows for the year ended December 31, 2020 including the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2020, and the results of its operations and its cash flows for the year ended December 31, 2020 in conformity with accounting principles generally accepted in the United States of America.    </span></div><div style="padding-left:36pt;text-indent:-28.35pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-28.35pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Basis for Opinion </span></div><div><span><br/></span></div><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">These consolidated financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company&#8217;s consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.  </span></div><div><span><br/></span></div><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We conducted our audit of these consolidated financial statements in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud.</span></div><div><span><br/></span></div><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our audit included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audit provides a reasonable basis for our opinion.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">   /s/ <ix:nonNumeric contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231" name="dei:AuditorName" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDMvZnJhZzozMmY1YzhhMzIyOWI0NWM3YWUzNWI3NjM3YTM3OGQwZC90ZXh0cmVnaW9uOjMyZjVjOGEzMjI5YjQ1YzdhZTM1Yjc2MzdhMzc4ZDBkXzI1NjA_853b3a5b-9bae-4fcf-ae0d-393da2858a50">PricewaterhouseCoopers LLP</ix:nonNumeric></span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-28.35pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:nonNumeric contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231" name="dei:AuditorLocation" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDMvZnJhZzozMmY1YzhhMzIyOWI0NWM3YWUzNWI3NjM3YTM3OGQwZC90ZXh0cmVnaW9uOjMyZjVjOGEzMjI5YjQ1YzdhZTM1Yjc2MzdhMzc4ZDBkXzI1NjI_fe4602c3-ca91-40ac-84bd-8f31eef8eaca">Reading, United Kingdom</ix:nonNumeric></span></div><div style="padding-left:36pt;text-indent:-28.35pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">March 31, 2021</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">   We served as the Company's auditor from 2013 to 2021.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><div id="i2eecdebedec64091994df5b7a96baab7_106"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summit Therapeutics Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Balance Sheets </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:59.222%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.974%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.469%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.471%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Cash</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231" decimals="-3" name="us-gaap:Cash" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDYvZnJhZzo1YTdkMDVlZTNkN2I0MmQ0OTk4NmY3ZmY3M2I1NzA1OS90YWJsZTpiMGQxMjA2OGI5ZGQ0MDNjYTBkYzdmNTI5ZTNjYWU4OS90YWJsZXJhbmdlOmIwZDEyMDY4YjlkZDQwM2NhMGRjN2Y1MjllM2NhZTg5XzMtMy0xLTEtMTA5ODc2_e39415ce-2099-42aa-97e8-8b5568e549c7">71,791</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7372be6dc06143b5adbb4d2e83a596c5_I20201231" decimals="-3" name="us-gaap:Cash" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDYvZnJhZzo1YTdkMDVlZTNkN2I0MmQ0OTk4NmY3ZmY3M2I1NzA1OS90YWJsZTpiMGQxMjA2OGI5ZGQ0MDNjYTBkYzdmNTI5ZTNjYWU4OS90YWJsZXJhbmdlOmIwZDEyMDY4YjlkZDQwM2NhMGRjN2Y1MjllM2NhZTg5XzMtNS0xLTEtMTA5ODc2_e25b9a2c-88a0-4526-ab9c-98fb37fc4e91">66,417</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Accounts receivable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDYvZnJhZzo1YTdkMDVlZTNkN2I0MmQ0OTk4NmY3ZmY3M2I1NzA1OS90YWJsZTpiMGQxMjA2OGI5ZGQ0MDNjYTBkYzdmNTI5ZTNjYWU4OS90YWJsZXJhbmdlOmIwZDEyMDY4YjlkZDQwM2NhMGRjN2Y1MjllM2NhZTg5XzQtMy0xLTEtMTA5ODc2_17cb26e4-49a0-494b-b534-ed0de537cdd5">1,464</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7372be6dc06143b5adbb4d2e83a596c5_I20201231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDYvZnJhZzo1YTdkMDVlZTNkN2I0MmQ0OTk4NmY3ZmY3M2I1NzA1OS90YWJsZTpiMGQxMjA2OGI5ZGQ0MDNjYTBkYzdmNTI5ZTNjYWU4OS90YWJsZXJhbmdlOmIwZDEyMDY4YjlkZDQwM2NhMGRjN2Y1MjllM2NhZTg5XzQtNS0xLTEtMTA5ODc2_7c7100da-8b21-4160-8d6c-7baaad8bca6b">331</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Prepaid expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231" decimals="-3" name="us-gaap:PrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDYvZnJhZzo1YTdkMDVlZTNkN2I0MmQ0OTk4NmY3ZmY3M2I1NzA1OS90YWJsZTpiMGQxMjA2OGI5ZGQ0MDNjYTBkYzdmNTI5ZTNjYWU4OS90YWJsZXJhbmdlOmIwZDEyMDY4YjlkZDQwM2NhMGRjN2Y1MjllM2NhZTg5XzUtMy0xLTEtMTA5ODc2_763a842b-e719-4917-993b-12007250ec0c">7,161</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7372be6dc06143b5adbb4d2e83a596c5_I20201231" decimals="-3" name="us-gaap:PrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDYvZnJhZzo1YTdkMDVlZTNkN2I0MmQ0OTk4NmY3ZmY3M2I1NzA1OS90YWJsZTpiMGQxMjA2OGI5ZGQ0MDNjYTBkYzdmNTI5ZTNjYWU4OS90YWJsZXJhbmdlOmIwZDEyMDY4YjlkZDQwM2NhMGRjN2Y1MjllM2NhZTg5XzUtNS0xLTEtMTA5ODc2_20374a73-4843-4356-80ca-241e77d58813">9,547</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231" decimals="-3" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDYvZnJhZzo1YTdkMDVlZTNkN2I0MmQ0OTk4NmY3ZmY3M2I1NzA1OS90YWJsZTpiMGQxMjA2OGI5ZGQ0MDNjYTBkYzdmNTI5ZTNjYWU4OS90YWJsZXJhbmdlOmIwZDEyMDY4YjlkZDQwM2NhMGRjN2Y1MjllM2NhZTg5XzYtMy0xLTEtMTA5ODc2_24b33c69-3618-49da-9979-568a8f9d4272">1,201</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7372be6dc06143b5adbb4d2e83a596c5_I20201231" decimals="-3" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDYvZnJhZzo1YTdkMDVlZTNkN2I0MmQ0OTk4NmY3ZmY3M2I1NzA1OS90YWJsZTpiMGQxMjA2OGI5ZGQ0MDNjYTBkYzdmNTI5ZTNjYWU4OS90YWJsZXJhbmdlOmIwZDEyMDY4YjlkZDQwM2NhMGRjN2Y1MjllM2NhZTg5XzYtNS0xLTEtMTA5ODc2_638ac02e-aeb2-4d39-96aa-7af21e968a31">1,523</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Research and development tax credit receivable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231" decimals="-3" name="smmt:ResearchAndDevelopmentTaxCreditReceivableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDYvZnJhZzo1YTdkMDVlZTNkN2I0MmQ0OTk4NmY3ZmY3M2I1NzA1OS90YWJsZTpiMGQxMjA2OGI5ZGQ0MDNjYTBkYzdmNTI5ZTNjYWU4OS90YWJsZXJhbmdlOmIwZDEyMDY4YjlkZDQwM2NhMGRjN2Y1MjllM2NhZTg5XzctMy0xLTEtMTA5ODc2_178335a4-d188-4bf4-a3b2-eb80c6638bcf">15,695</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7372be6dc06143b5adbb4d2e83a596c5_I20201231" decimals="-3" name="smmt:ResearchAndDevelopmentTaxCreditReceivableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDYvZnJhZzo1YTdkMDVlZTNkN2I0MmQ0OTk4NmY3ZmY3M2I1NzA1OS90YWJsZTpiMGQxMjA2OGI5ZGQ0MDNjYTBkYzdmNTI5ZTNjYWU4OS90YWJsZXJhbmdlOmIwZDEyMDY4YjlkZDQwM2NhMGRjN2Y1MjllM2NhZTg5XzctNS0xLTEtMTA5ODc2_2abd5492-25f3-4ec4-bf86-545c153ff749">9,856</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDYvZnJhZzo1YTdkMDVlZTNkN2I0MmQ0OTk4NmY3ZmY3M2I1NzA1OS90YWJsZTpiMGQxMjA2OGI5ZGQ0MDNjYTBkYzdmNTI5ZTNjYWU4OS90YWJsZXJhbmdlOmIwZDEyMDY4YjlkZDQwM2NhMGRjN2Y1MjllM2NhZTg5XzgtMy0xLTEtMTA5ODc2_4e9fc19b-6294-412c-88e6-ac24daf2f8df">97,312</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7372be6dc06143b5adbb4d2e83a596c5_I20201231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDYvZnJhZzo1YTdkMDVlZTNkN2I0MmQ0OTk4NmY3ZmY3M2I1NzA1OS90YWJsZTpiMGQxMjA2OGI5ZGQ0MDNjYTBkYzdmNTI5ZTNjYWU4OS90YWJsZXJhbmdlOmIwZDEyMDY4YjlkZDQwM2NhMGRjN2Y1MjllM2NhZTg5XzgtNS0xLTEtMTA5ODc2_fe77732f-13ee-4b40-97bc-a57e53b458f1">87,674</ix:nonFraction></span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Property and equipment, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDYvZnJhZzo1YTdkMDVlZTNkN2I0MmQ0OTk4NmY3ZmY3M2I1NzA1OS90YWJsZTpiMGQxMjA2OGI5ZGQ0MDNjYTBkYzdmNTI5ZTNjYWU4OS90YWJsZXJhbmdlOmIwZDEyMDY4YjlkZDQwM2NhMGRjN2Y1MjllM2NhZTg5XzExLTMtMS0xLTEwOTg3Ng_0b7a2c82-8dd2-4b4a-80ed-67dbc7dddee6">694</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7372be6dc06143b5adbb4d2e83a596c5_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDYvZnJhZzo1YTdkMDVlZTNkN2I0MmQ0OTk4NmY3ZmY3M2I1NzA1OS90YWJsZTpiMGQxMjA2OGI5ZGQ0MDNjYTBkYzdmNTI5ZTNjYWU4OS90YWJsZXJhbmdlOmIwZDEyMDY4YjlkZDQwM2NhMGRjN2Y1MjllM2NhZTg5XzExLTUtMS0xLTEwOTg3Ng_25472d5b-dd51-4e13-a613-254a92463fb2">725</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Right-of-use assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDYvZnJhZzo1YTdkMDVlZTNkN2I0MmQ0OTk4NmY3ZmY3M2I1NzA1OS90YWJsZTpiMGQxMjA2OGI5ZGQ0MDNjYTBkYzdmNTI5ZTNjYWU4OS90YWJsZXJhbmdlOmIwZDEyMDY4YjlkZDQwM2NhMGRjN2Y1MjllM2NhZTg5XzEyLTMtMS0xLTEwOTg3Ng_c9210cdf-c834-4d7f-827d-17eeb5ab74c1">2,790</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7372be6dc06143b5adbb4d2e83a596c5_I20201231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDYvZnJhZzo1YTdkMDVlZTNkN2I0MmQ0OTk4NmY3ZmY3M2I1NzA1OS90YWJsZTpiMGQxMjA2OGI5ZGQ0MDNjYTBkYzdmNTI5ZTNjYWU4OS90YWJsZXJhbmdlOmIwZDEyMDY4YjlkZDQwM2NhMGRjN2Y1MjllM2NhZTg5XzEyLTUtMS0xLTEwOTg3Ng_3172ad14-fd44-4e57-a8cd-54bd9500f70d">554</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Goodwill</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDYvZnJhZzo1YTdkMDVlZTNkN2I0MmQ0OTk4NmY3ZmY3M2I1NzA1OS90YWJsZTpiMGQxMjA2OGI5ZGQ0MDNjYTBkYzdmNTI5ZTNjYWU4OS90YWJsZXJhbmdlOmIwZDEyMDY4YjlkZDQwM2NhMGRjN2Y1MjllM2NhZTg5XzEzLTMtMS0xLTEwOTg3Ng_f723ffeb-ae51-4328-a14e-7bd35e2af855">2,009</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7372be6dc06143b5adbb4d2e83a596c5_I20201231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDYvZnJhZzo1YTdkMDVlZTNkN2I0MmQ0OTk4NmY3ZmY3M2I1NzA1OS90YWJsZTpiMGQxMjA2OGI5ZGQ0MDNjYTBkYzdmNTI5ZTNjYWU4OS90YWJsZXJhbmdlOmIwZDEyMDY4YjlkZDQwM2NhMGRjN2Y1MjllM2NhZTg5XzEzLTUtMS0xLTEwOTg3Ng_28806585-7c73-405b-96e5-cf4c2a544243">2,030</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Intangible assets, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDYvZnJhZzo1YTdkMDVlZTNkN2I0MmQ0OTk4NmY3ZmY3M2I1NzA1OS90YWJsZTpiMGQxMjA2OGI5ZGQ0MDNjYTBkYzdmNTI5ZTNjYWU4OS90YWJsZXJhbmdlOmIwZDEyMDY4YjlkZDQwM2NhMGRjN2Y1MjllM2NhZTg5XzE0LTMtMS0xLTEwOTg3Ng_ad517425-c3da-4c8d-9aaa-f7f801715297">10,399</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7372be6dc06143b5adbb4d2e83a596c5_I20201231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDYvZnJhZzo1YTdkMDVlZTNkN2I0MmQ0OTk4NmY3ZmY3M2I1NzA1OS90YWJsZTpiMGQxMjA2OGI5ZGQ0MDNjYTBkYzdmNTI5ZTNjYWU4OS90YWJsZXJhbmdlOmIwZDEyMDY4YjlkZDQwM2NhMGRjN2Y1MjllM2NhZTg5XzE0LTUtMS0xLTEwOTg3Ng_7aeb6ede-4ca6-43f0-809e-372f4eb6c201">11,515</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Other assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDYvZnJhZzo1YTdkMDVlZTNkN2I0MmQ0OTk4NmY3ZmY3M2I1NzA1OS90YWJsZTpiMGQxMjA2OGI5ZGQ0MDNjYTBkYzdmNTI5ZTNjYWU4OS90YWJsZXJhbmdlOmIwZDEyMDY4YjlkZDQwM2NhMGRjN2Y1MjllM2NhZTg5XzE1LTMtMS0xLTEwOTg3Ng_f8adcc98-bf38-4105-9218-4a62c61a2a79">170</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7372be6dc06143b5adbb4d2e83a596c5_I20201231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDYvZnJhZzo1YTdkMDVlZTNkN2I0MmQ0OTk4NmY3ZmY3M2I1NzA1OS90YWJsZTpiMGQxMjA2OGI5ZGQ0MDNjYTBkYzdmNTI5ZTNjYWU4OS90YWJsZXJhbmdlOmIwZDEyMDY4YjlkZDQwM2NhMGRjN2Y1MjllM2NhZTg5XzE1LTUtMS0xLTEwOTg3Ng_e4685005-8df1-4100-a303-44f4b387b12a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDYvZnJhZzo1YTdkMDVlZTNkN2I0MmQ0OTk4NmY3ZmY3M2I1NzA1OS90YWJsZTpiMGQxMjA2OGI5ZGQ0MDNjYTBkYzdmNTI5ZTNjYWU4OS90YWJsZXJhbmdlOmIwZDEyMDY4YjlkZDQwM2NhMGRjN2Y1MjllM2NhZTg5XzE2LTMtMS0xLTEwOTg3Ng_80a02674-532a-4ba7-8592-7c71413531d9">113,374</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7372be6dc06143b5adbb4d2e83a596c5_I20201231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDYvZnJhZzo1YTdkMDVlZTNkN2I0MmQ0OTk4NmY3ZmY3M2I1NzA1OS90YWJsZTpiMGQxMjA2OGI5ZGQ0MDNjYTBkYzdmNTI5ZTNjYWU4OS90YWJsZXJhbmdlOmIwZDEyMDY4YjlkZDQwM2NhMGRjN2Y1MjllM2NhZTg5XzE2LTUtMS0xLTEwOTg3Ng_b63d9859-fbb0-4a37-a9bb-b7a1348a996f">102,498</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities and stockholders' equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Accounts payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDYvZnJhZzo1YTdkMDVlZTNkN2I0MmQ0OTk4NmY3ZmY3M2I1NzA1OS90YWJsZTpiMGQxMjA2OGI5ZGQ0MDNjYTBkYzdmNTI5ZTNjYWU4OS90YWJsZXJhbmdlOmIwZDEyMDY4YjlkZDQwM2NhMGRjN2Y1MjllM2NhZTg5XzIwLTMtMS0xLTEwOTg3Ng_ba70b040-32e2-490c-aba8-2ffa3354da79">4,374</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7372be6dc06143b5adbb4d2e83a596c5_I20201231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDYvZnJhZzo1YTdkMDVlZTNkN2I0MmQ0OTk4NmY3ZmY3M2I1NzA1OS90YWJsZTpiMGQxMjA2OGI5ZGQ0MDNjYTBkYzdmNTI5ZTNjYWU4OS90YWJsZXJhbmdlOmIwZDEyMDY4YjlkZDQwM2NhMGRjN2Y1MjllM2NhZTg5XzIwLTUtMS0xLTEwOTg3Ng_86356982-7833-4ce6-8146-0528ef399101">6,140</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Accrued liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDYvZnJhZzo1YTdkMDVlZTNkN2I0MmQ0OTk4NmY3ZmY3M2I1NzA1OS90YWJsZTpiMGQxMjA2OGI5ZGQ0MDNjYTBkYzdmNTI5ZTNjYWU4OS90YWJsZXJhbmdlOmIwZDEyMDY4YjlkZDQwM2NhMGRjN2Y1MjllM2NhZTg5XzIxLTMtMS0xLTEwOTg3Ng_1448ccb3-c87d-45e4-bac4-7bcf8b1df85d">7,197</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7372be6dc06143b5adbb4d2e83a596c5_I20201231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDYvZnJhZzo1YTdkMDVlZTNkN2I0MmQ0OTk4NmY3ZmY3M2I1NzA1OS90YWJsZTpiMGQxMjA2OGI5ZGQ0MDNjYTBkYzdmNTI5ZTNjYWU4OS90YWJsZXJhbmdlOmIwZDEyMDY4YjlkZDQwM2NhMGRjN2Y1MjllM2NhZTg5XzIxLTUtMS0xLTEwOTg3Ng_115c729b-408f-4669-8861-842496de24c8">3,278</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Accrued compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDYvZnJhZzo1YTdkMDVlZTNkN2I0MmQ0OTk4NmY3ZmY3M2I1NzA1OS90YWJsZTpiMGQxMjA2OGI5ZGQ0MDNjYTBkYzdmNTI5ZTNjYWU4OS90YWJsZXJhbmdlOmIwZDEyMDY4YjlkZDQwM2NhMGRjN2Y1MjllM2NhZTg5XzIyLTMtMS0xLTEwOTg3Ng_49ef0698-0a5d-44a3-98b3-b86e8ac63e38">4,125</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7372be6dc06143b5adbb4d2e83a596c5_I20201231" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDYvZnJhZzo1YTdkMDVlZTNkN2I0MmQ0OTk4NmY3ZmY3M2I1NzA1OS90YWJsZTpiMGQxMjA2OGI5ZGQ0MDNjYTBkYzdmNTI5ZTNjYWU4OS90YWJsZXJhbmdlOmIwZDEyMDY4YjlkZDQwM2NhMGRjN2Y1MjllM2NhZTg5XzIyLTUtMS0xLTEwOTg3Ng_efad5597-e540-48dc-97e3-978ab3ce11e1">983</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDYvZnJhZzo1YTdkMDVlZTNkN2I0MmQ0OTk4NmY3ZmY3M2I1NzA1OS90YWJsZTpiMGQxMjA2OGI5ZGQ0MDNjYTBkYzdmNTI5ZTNjYWU4OS90YWJsZXJhbmdlOmIwZDEyMDY4YjlkZDQwM2NhMGRjN2Y1MjllM2NhZTg5XzIzLTMtMS0xLTEwOTg3Ng_48732084-fc55-4c5e-a268-df464938c282">1,091</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7372be6dc06143b5adbb4d2e83a596c5_I20201231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDYvZnJhZzo1YTdkMDVlZTNkN2I0MmQ0OTk4NmY3ZmY3M2I1NzA1OS90YWJsZTpiMGQxMjA2OGI5ZGQ0MDNjYTBkYzdmNTI5ZTNjYWU4OS90YWJsZXJhbmdlOmIwZDEyMDY4YjlkZDQwM2NhMGRjN2Y1MjllM2NhZTg5XzIzLTUtMS0xLTEwOTg3Ng_0f0d7e12-d0df-45eb-b82d-12fb9cede5ed">390</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Deferred revenue and other income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDYvZnJhZzo1YTdkMDVlZTNkN2I0MmQ0OTk4NmY3ZmY3M2I1NzA1OS90YWJsZTpiMGQxMjA2OGI5ZGQ0MDNjYTBkYzdmNTI5ZTNjYWU4OS90YWJsZXJhbmdlOmIwZDEyMDY4YjlkZDQwM2NhMGRjN2Y1MjllM2NhZTg5XzI0LTMtMS0xLTEwOTg3Ng_5d2d7a14-928d-4319-a677-d3df02d65aba">7,939</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7372be6dc06143b5adbb4d2e83a596c5_I20201231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDYvZnJhZzo1YTdkMDVlZTNkN2I0MmQ0OTk4NmY3ZmY3M2I1NzA1OS90YWJsZTpiMGQxMjA2OGI5ZGQ0MDNjYTBkYzdmNTI5ZTNjYWU4OS90YWJsZXJhbmdlOmIwZDEyMDY4YjlkZDQwM2NhMGRjN2Y1MjllM2NhZTg5XzI0LTUtMS0xLTEwOTg3Ng_26078134-7d42-4a3c-9aff-6d73c958519f">8,370</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDYvZnJhZzo1YTdkMDVlZTNkN2I0MmQ0OTk4NmY3ZmY3M2I1NzA1OS90YWJsZTpiMGQxMjA2OGI5ZGQ0MDNjYTBkYzdmNTI5ZTNjYWU4OS90YWJsZXJhbmdlOmIwZDEyMDY4YjlkZDQwM2NhMGRjN2Y1MjllM2NhZTg5XzI1LTMtMS0xLTEwOTg3Ng_d7e96388-2076-479f-8f90-80c48b16cf94">897</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7372be6dc06143b5adbb4d2e83a596c5_I20201231" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDYvZnJhZzo1YTdkMDVlZTNkN2I0MmQ0OTk4NmY3ZmY3M2I1NzA1OS90YWJsZTpiMGQxMjA2OGI5ZGQ0MDNjYTBkYzdmNTI5ZTNjYWU4OS90YWJsZXJhbmdlOmIwZDEyMDY4YjlkZDQwM2NhMGRjN2Y1MjllM2NhZTg5XzI1LTUtMS0xLTEwOTg3Ng_5e4c3e2a-82aa-4898-a66f-d8cb4dc3f3e2">729</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDYvZnJhZzo1YTdkMDVlZTNkN2I0MmQ0OTk4NmY3ZmY3M2I1NzA1OS90YWJsZTpiMGQxMjA2OGI5ZGQ0MDNjYTBkYzdmNTI5ZTNjYWU4OS90YWJsZXJhbmdlOmIwZDEyMDY4YjlkZDQwM2NhMGRjN2Y1MjllM2NhZTg5XzI2LTMtMS0xLTEwOTg3Ng_d49a41ae-25b2-42e0-81f0-908736eee7d3">25,623</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7372be6dc06143b5adbb4d2e83a596c5_I20201231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDYvZnJhZzo1YTdkMDVlZTNkN2I0MmQ0OTk4NmY3ZmY3M2I1NzA1OS90YWJsZTpiMGQxMjA2OGI5ZGQ0MDNjYTBkYzdmNTI5ZTNjYWU4OS90YWJsZXJhbmdlOmIwZDEyMDY4YjlkZDQwM2NhMGRjN2Y1MjllM2NhZTg5XzI2LTUtMS0xLTEwOTg3Ng_66c15a87-063d-482c-b0e0-995bb075a1c4">19,890</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Lease liabilities, net of current portion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDYvZnJhZzo1YTdkMDVlZTNkN2I0MmQ0OTk4NmY3ZmY3M2I1NzA1OS90YWJsZTpiMGQxMjA2OGI5ZGQ0MDNjYTBkYzdmNTI5ZTNjYWU4OS90YWJsZXJhbmdlOmIwZDEyMDY4YjlkZDQwM2NhMGRjN2Y1MjllM2NhZTg5XzI5LTMtMS0xLTEwOTg3Ng_8649eedb-4c4b-40bf-bc18-9b6aad17772b">1,691</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7372be6dc06143b5adbb4d2e83a596c5_I20201231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDYvZnJhZzo1YTdkMDVlZTNkN2I0MmQ0OTk4NmY3ZmY3M2I1NzA1OS90YWJsZTpiMGQxMjA2OGI5ZGQ0MDNjYTBkYzdmNTI5ZTNjYWU4OS90YWJsZXJhbmdlOmIwZDEyMDY4YjlkZDQwM2NhMGRjN2Y1MjllM2NhZTg5XzI5LTUtMS0xLTEwOTg3Ng_c6a1efcc-2d33-4b48-9f15-087b9fe5ffdd">75</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Deferred revenue and other income, net of current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDYvZnJhZzo1YTdkMDVlZTNkN2I0MmQ0OTk4NmY3ZmY3M2I1NzA1OS90YWJsZTpiMGQxMjA2OGI5ZGQ0MDNjYTBkYzdmNTI5ZTNjYWU4OS90YWJsZXJhbmdlOmIwZDEyMDY4YjlkZDQwM2NhMGRjN2Y1MjllM2NhZTg5XzMwLTMtMS0xLTEwOTg3Ng_47ea3fde-511b-4553-9765-83771f967507">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7372be6dc06143b5adbb4d2e83a596c5_I20201231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDYvZnJhZzo1YTdkMDVlZTNkN2I0MmQ0OTk4NmY3ZmY3M2I1NzA1OS90YWJsZTpiMGQxMjA2OGI5ZGQ0MDNjYTBkYzdmNTI5ZTNjYWU4OS90YWJsZXJhbmdlOmIwZDEyMDY4YjlkZDQwM2NhMGRjN2Y1MjllM2NhZTg5XzMwLTUtMS0xLTEwOTg3Ng_fffb6c70-1098-4365-a303-3691b07db4e3">569</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Other non-current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDYvZnJhZzo1YTdkMDVlZTNkN2I0MmQ0OTk4NmY3ZmY3M2I1NzA1OS90YWJsZTpiMGQxMjA2OGI5ZGQ0MDNjYTBkYzdmNTI5ZTNjYWU4OS90YWJsZXJhbmdlOmIwZDEyMDY4YjlkZDQwM2NhMGRjN2Y1MjllM2NhZTg5XzMxLTMtMS0xLTEwOTg3Ng_607138a2-461d-4a59-9ed9-12670cf7bafb">2,776</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7372be6dc06143b5adbb4d2e83a596c5_I20201231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDYvZnJhZzo1YTdkMDVlZTNkN2I0MmQ0OTk4NmY3ZmY3M2I1NzA1OS90YWJsZTpiMGQxMjA2OGI5ZGQ0MDNjYTBkYzdmNTI5ZTNjYWU4OS90YWJsZXJhbmdlOmIwZDEyMDY4YjlkZDQwM2NhMGRjN2Y1MjllM2NhZTg5XzMxLTUtMS0xLTEwOTg3Ng_51f635c9-a293-4d77-b86c-1570a8115cbc">2,511</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDYvZnJhZzo1YTdkMDVlZTNkN2I0MmQ0OTk4NmY3ZmY3M2I1NzA1OS90YWJsZTpiMGQxMjA2OGI5ZGQ0MDNjYTBkYzdmNTI5ZTNjYWU4OS90YWJsZXJhbmdlOmIwZDEyMDY4YjlkZDQwM2NhMGRjN2Y1MjllM2NhZTg5XzMyLTMtMS0xLTEwOTg3Ng_ed9835f8-e3c5-4f4a-89a3-4a3f750bda03">30,090</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7372be6dc06143b5adbb4d2e83a596c5_I20201231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDYvZnJhZzo1YTdkMDVlZTNkN2I0MmQ0OTk4NmY3ZmY3M2I1NzA1OS90YWJsZTpiMGQxMjA2OGI5ZGQ0MDNjYTBkYzdmNTI5ZTNjYWU4OS90YWJsZXJhbmdlOmIwZDEyMDY4YjlkZDQwM2NhMGRjN2Y1MjllM2NhZTg5XzMyLTUtMS0xLTEwOTg3Ng_83705ac1-c983-4fe4-a769-caeccbcee25e">23,045</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies (Note 19)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDYvZnJhZzo1YTdkMDVlZTNkN2I0MmQ0OTk4NmY3ZmY3M2I1NzA1OS90YWJsZTpiMGQxMjA2OGI5ZGQ0MDNjYTBkYzdmNTI5ZTNjYWU4OS90YWJsZXJhbmdlOmIwZDEyMDY4YjlkZDQwM2NhMGRjN2Y1MjllM2NhZTg5XzMzLTMtMS0xLTEwOTg3Ng_c2fafc5f-07f6-42a1-9f9e-f17d6899e600"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i7372be6dc06143b5adbb4d2e83a596c5_I20201231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDYvZnJhZzo1YTdkMDVlZTNkN2I0MmQ0OTk4NmY3ZmY3M2I1NzA1OS90YWJsZTpiMGQxMjA2OGI5ZGQ0MDNjYTBkYzdmNTI5ZTNjYWU4OS90YWJsZXJhbmdlOmIwZDEyMDY4YjlkZDQwM2NhMGRjN2Y1MjllM2NhZTg5XzMzLTUtMS0xLTEwOTg3Ng_cd934701-2f4a-4a9c-817f-226f9e807371"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders' equity:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;&#160;Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i7372be6dc06143b5adbb4d2e83a596c5_I20201231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDYvZnJhZzo1YTdkMDVlZTNkN2I0MmQ0OTk4NmY3ZmY3M2I1NzA1OS90YWJsZTpiMGQxMjA2OGI5ZGQ0MDNjYTBkYzdmNTI5ZTNjYWU4OS90YWJsZXJhbmdlOmIwZDEyMDY4YjlkZDQwM2NhMGRjN2Y1MjllM2NhZTg5XzM1LTAtMS0xLTEwOTg3Ni90ZXh0cmVnaW9uOmQyMWRiYzI5YWYwMTQ5ODM4ZTg4ZDEwMjVkYjQ2YTFhXzI0_3df8af3d-a501-4905-b7b4-41b50cc241a5"><ix:nonFraction unitRef="usdPerShare" contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDYvZnJhZzo1YTdkMDVlZTNkN2I0MmQ0OTk4NmY3ZmY3M2I1NzA1OS90YWJsZTpiMGQxMjA2OGI5ZGQ0MDNjYTBkYzdmNTI5ZTNjYWU4OS90YWJsZXJhbmdlOmIwZDEyMDY4YjlkZDQwM2NhMGRjN2Y1MjllM2NhZTg5XzM1LTAtMS0xLTEwOTg3Ni90ZXh0cmVnaW9uOmQyMWRiYzI5YWYwMTQ5ODM4ZTg4ZDEwMjVkYjQ2YTFhXzI0_be5d77a0-70cc-4119-b653-9e1b49e251e3">0.01</ix:nonFraction></ix:nonFraction> par value: <ix:nonFraction unitRef="shares" contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDYvZnJhZzo1YTdkMDVlZTNkN2I0MmQ0OTk4NmY3ZmY3M2I1NzA1OS90YWJsZTpiMGQxMjA2OGI5ZGQ0MDNjYTBkYzdmNTI5ZTNjYWU4OS90YWJsZXJhbmdlOmIwZDEyMDY4YjlkZDQwM2NhMGRjN2Y1MjllM2NhZTg5XzM1LTAtMS0xLTEwOTg3Ni90ZXh0cmVnaW9uOmQyMWRiYzI5YWYwMTQ5ODM4ZTg4ZDEwMjVkYjQ2YTFhXzM4_386f565c-dc29-4d94-84c8-ba24902938c7"><ix:nonFraction unitRef="shares" contextRef="i7372be6dc06143b5adbb4d2e83a596c5_I20201231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDYvZnJhZzo1YTdkMDVlZTNkN2I0MmQ0OTk4NmY3ZmY3M2I1NzA1OS90YWJsZTpiMGQxMjA2OGI5ZGQ0MDNjYTBkYzdmNTI5ZTNjYWU4OS90YWJsZXJhbmdlOmIwZDEyMDY4YjlkZDQwM2NhMGRjN2Y1MjllM2NhZTg5XzM1LTAtMS0xLTEwOTg3Ni90ZXh0cmVnaW9uOmQyMWRiYzI5YWYwMTQ5ODM4ZTg4ZDEwMjVkYjQ2YTFhXzM4_b848b6e9-51cb-4b2e-8629-af1b429f43af">250,000,000</ix:nonFraction></ix:nonFraction> shares authorized;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;&#160;<ix:nonFraction unitRef="shares" contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDYvZnJhZzo1YTdkMDVlZTNkN2I0MmQ0OTk4NmY3ZmY3M2I1NzA1OS90YWJsZTpiMGQxMjA2OGI5ZGQ0MDNjYTBkYzdmNTI5ZTNjYWU4OS90YWJsZXJhbmdlOmIwZDEyMDY4YjlkZDQwM2NhMGRjN2Y1MjllM2NhZTg5XzM1LTAtMS0xLTEwOTg3Ni90ZXh0cmVnaW9uOmQyMWRiYzI5YWYwMTQ5ODM4ZTg4ZDEwMjVkYjQ2YTFhXzY1_446dbb0c-a348-4d2d-9da7-2b616ee6ccab"><ix:nonFraction unitRef="shares" contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDYvZnJhZzo1YTdkMDVlZTNkN2I0MmQ0OTk4NmY3ZmY3M2I1NzA1OS90YWJsZTpiMGQxMjA2OGI5ZGQ0MDNjYTBkYzdmNTI5ZTNjYWU4OS90YWJsZXJhbmdlOmIwZDEyMDY4YjlkZDQwM2NhMGRjN2Y1MjllM2NhZTg5XzM1LTAtMS0xLTEwOTg3Ni90ZXh0cmVnaW9uOmQyMWRiYzI5YWYwMTQ5ODM4ZTg4ZDEwMjVkYjQ2YTFhXzY1_729f29d2-0ec7-4dd0-9083-c2970e1e1053">98,039,540</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i7372be6dc06143b5adbb4d2e83a596c5_I20201231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDYvZnJhZzo1YTdkMDVlZTNkN2I0MmQ0OTk4NmY3ZmY3M2I1NzA1OS90YWJsZTpiMGQxMjA2OGI5ZGQ0MDNjYTBkYzdmNTI5ZTNjYWU4OS90YWJsZXJhbmdlOmIwZDEyMDY4YjlkZDQwM2NhMGRjN2Y1MjllM2NhZTg5XzM1LTAtMS0xLTEwOTg3Ni90ZXh0cmVnaW9uOmQyMWRiYzI5YWYwMTQ5ODM4ZTg4ZDEwMjVkYjQ2YTFhXzcy_17bae385-5dcc-4096-9810-56b4c11a7846"><ix:nonFraction unitRef="shares" contextRef="i7372be6dc06143b5adbb4d2e83a596c5_I20201231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDYvZnJhZzo1YTdkMDVlZTNkN2I0MmQ0OTk4NmY3ZmY3M2I1NzA1OS90YWJsZTpiMGQxMjA2OGI5ZGQ0MDNjYTBkYzdmNTI5ZTNjYWU4OS90YWJsZXJhbmdlOmIwZDEyMDY4YjlkZDQwM2NhMGRjN2Y1MjllM2NhZTg5XzM1LTAtMS0xLTEwOTg3Ni90ZXh0cmVnaW9uOmQyMWRiYzI5YWYwMTQ5ODM4ZTg4ZDEwMjVkYjQ2YTFhXzcy_a4cf7e2d-dbac-42d8-becf-b48c460b76d3">82,575,064</ix:nonFraction></ix:nonFraction> shares issued and outstanding at</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;&#160;December 31, 2021 and 2020, respectively</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDYvZnJhZzo1YTdkMDVlZTNkN2I0MmQ0OTk4NmY3ZmY3M2I1NzA1OS90YWJsZTpiMGQxMjA2OGI5ZGQ0MDNjYTBkYzdmNTI5ZTNjYWU4OS90YWJsZXJhbmdlOmIwZDEyMDY4YjlkZDQwM2NhMGRjN2Y1MjllM2NhZTg5XzM1LTMtMS0xLTEwOTg3Ng_eb9f0fd7-4e1e-4e1d-8715-b62d0adbe509">980</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7372be6dc06143b5adbb4d2e83a596c5_I20201231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDYvZnJhZzo1YTdkMDVlZTNkN2I0MmQ0OTk4NmY3ZmY3M2I1NzA1OS90YWJsZTpiMGQxMjA2OGI5ZGQ0MDNjYTBkYzdmNTI5ZTNjYWU4OS90YWJsZXJhbmdlOmIwZDEyMDY4YjlkZDQwM2NhMGRjN2Y1MjllM2NhZTg5XzM1LTUtMS0xLTEwOTg3Ng_bedc54c8-ef7b-4070-b042-b5e5cfd3725c">826</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Additional paid-in capital</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDYvZnJhZzo1YTdkMDVlZTNkN2I0MmQ0OTk4NmY3ZmY3M2I1NzA1OS90YWJsZTpiMGQxMjA2OGI5ZGQ0MDNjYTBkYzdmNTI5ZTNjYWU4OS90YWJsZXJhbmdlOmIwZDEyMDY4YjlkZDQwM2NhMGRjN2Y1MjllM2NhZTg5XzM2LTMtMS0xLTEwOTg3Ng_bdd5b736-7c34-4eff-b450-f49b0f33b639">384,049</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7372be6dc06143b5adbb4d2e83a596c5_I20201231" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDYvZnJhZzo1YTdkMDVlZTNkN2I0MmQ0OTk4NmY3ZmY3M2I1NzA1OS90YWJsZTpiMGQxMjA2OGI5ZGQ0MDNjYTBkYzdmNTI5ZTNjYWU4OS90YWJsZXJhbmdlOmIwZDEyMDY4YjlkZDQwM2NhMGRjN2Y1MjllM2NhZTg5XzM2LTUtMS0xLTEwOTg3Ng_3188365d-9018-4854-935d-a575bf999d9b">293,367</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Accumulated other comprehensive loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDYvZnJhZzo1YTdkMDVlZTNkN2I0MmQ0OTk4NmY3ZmY3M2I1NzA1OS90YWJsZTpiMGQxMjA2OGI5ZGQ0MDNjYTBkYzdmNTI5ZTNjYWU4OS90YWJsZXJhbmdlOmIwZDEyMDY4YjlkZDQwM2NhMGRjN2Y1MjllM2NhZTg5XzM3LTMtMS0xLTEwOTg3Ng_0752be94-0dfd-4976-a641-9bf8b872a754">2,197</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7372be6dc06143b5adbb4d2e83a596c5_I20201231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDYvZnJhZzo1YTdkMDVlZTNkN2I0MmQ0OTk4NmY3ZmY3M2I1NzA1OS90YWJsZTpiMGQxMjA2OGI5ZGQ0MDNjYTBkYzdmNTI5ZTNjYWU4OS90YWJsZXJhbmdlOmIwZDEyMDY4YjlkZDQwM2NhMGRjN2Y1MjllM2NhZTg5XzM3LTUtMS0xLTEwOTg3Ng_f61d18f7-a7b8-4142-81d0-3d8adb626a3e">3,794</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Accumulated deficit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDYvZnJhZzo1YTdkMDVlZTNkN2I0MmQ0OTk4NmY3ZmY3M2I1NzA1OS90YWJsZTpiMGQxMjA2OGI5ZGQ0MDNjYTBkYzdmNTI5ZTNjYWU4OS90YWJsZXJhbmdlOmIwZDEyMDY4YjlkZDQwM2NhMGRjN2Y1MjllM2NhZTg5XzM4LTMtMS0xLTEwOTg3Ng_733de346-d22d-4676-a382-f62e1775b020">299,548</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7372be6dc06143b5adbb4d2e83a596c5_I20201231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDYvZnJhZzo1YTdkMDVlZTNkN2I0MmQ0OTk4NmY3ZmY3M2I1NzA1OS90YWJsZTpiMGQxMjA2OGI5ZGQ0MDNjYTBkYzdmNTI5ZTNjYWU4OS90YWJsZXJhbmdlOmIwZDEyMDY4YjlkZDQwM2NhMGRjN2Y1MjllM2NhZTg5XzM4LTUtMS0xLTEwOTg3Ng_3e13fed3-17a4-43c9-86a4-46de01a97c27">210,946</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders' equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDYvZnJhZzo1YTdkMDVlZTNkN2I0MmQ0OTk4NmY3ZmY3M2I1NzA1OS90YWJsZTpiMGQxMjA2OGI5ZGQ0MDNjYTBkYzdmNTI5ZTNjYWU4OS90YWJsZXJhbmdlOmIwZDEyMDY4YjlkZDQwM2NhMGRjN2Y1MjllM2NhZTg5XzM5LTMtMS0xLTEwOTg3Ng_12ca1fdb-e14a-442f-8cdd-00d645b2d350">83,284</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7372be6dc06143b5adbb4d2e83a596c5_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDYvZnJhZzo1YTdkMDVlZTNkN2I0MmQ0OTk4NmY3ZmY3M2I1NzA1OS90YWJsZTpiMGQxMjA2OGI5ZGQ0MDNjYTBkYzdmNTI5ZTNjYWU4OS90YWJsZXJhbmdlOmIwZDEyMDY4YjlkZDQwM2NhMGRjN2Y1MjllM2NhZTg5XzM5LTUtMS0xLTEwOTg3Ng_2e25c5a6-d92d-4cc0-8ec1-4ef7d5004c35">79,453</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders' equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDYvZnJhZzo1YTdkMDVlZTNkN2I0MmQ0OTk4NmY3ZmY3M2I1NzA1OS90YWJsZTpiMGQxMjA2OGI5ZGQ0MDNjYTBkYzdmNTI5ZTNjYWU4OS90YWJsZXJhbmdlOmIwZDEyMDY4YjlkZDQwM2NhMGRjN2Y1MjllM2NhZTg5XzQwLTMtMS0xLTEwOTg3Ng_14210816-b203-4aec-a7a5-3deb34e936a1">113,374</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7372be6dc06143b5adbb4d2e83a596c5_I20201231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDYvZnJhZzo1YTdkMDVlZTNkN2I0MmQ0OTk4NmY3ZmY3M2I1NzA1OS90YWJsZTpiMGQxMjA2OGI5ZGQ0MDNjYTBkYzdmNTI5ZTNjYWU4OS90YWJsZXJhbmdlOmIwZDEyMDY4YjlkZDQwM2NhMGRjN2Y1MjllM2NhZTg5XzQwLTUtMS0xLTEwOTg3Ng_22f5f88d-b182-40b5-a7d9-262acb5f511b">102,498</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:324pt;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of the consolidated financial statements</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><div id="i2eecdebedec64091994df5b7a96baab7_109"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summit Therapeutics Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Operations and Comprehensive Loss </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.467%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDkvZnJhZzpmY2YyZjBkNTU4YTE0MTUzOTZlNThlZWRjNDI1ZGUyNC90YWJsZTpiZGUxYmRjNTFiY2Y0NTJjOTdlNzEzNGM2ZWZkMTA1ZS90YWJsZXJhbmdlOmJkZTFiZGM1MWJjZjQ1MmM5N2U3MTM0YzZlZmQxMDVlXzEtMi0xLTEtMTA5ODc2_443b5b2a-dbfe-491a-8e09-2438a6c77734">1,809</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDkvZnJhZzpmY2YyZjBkNTU4YTE0MTUzOTZlNThlZWRjNDI1ZGUyNC90YWJsZTpiZGUxYmRjNTFiY2Y0NTJjOTdlNzEzNGM2ZWZkMTA1ZS90YWJsZXJhbmdlOmJkZTFiZGM1MWJjZjQ1MmM5N2U3MTM0YzZlZmQxMDVlXzEtNC0xLTEtMTA5ODc2_5676c1aa-cbad-4255-8e5b-ae20d38c45de">860</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDkvZnJhZzpmY2YyZjBkNTU4YTE0MTUzOTZlNThlZWRjNDI1ZGUyNC90YWJsZTpiZGUxYmRjNTFiY2Y0NTJjOTdlNzEzNGM2ZWZkMTA1ZS90YWJsZXJhbmdlOmJkZTFiZGM1MWJjZjQ1MmM5N2U3MTM0YzZlZmQxMDVlXzMtMi0xLTEtMTA5ODc2_31ccee25-466f-43b5-ace9-246cfc02e981">85,352</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDkvZnJhZzpmY2YyZjBkNTU4YTE0MTUzOTZlNThlZWRjNDI1ZGUyNC90YWJsZTpiZGUxYmRjNTFiY2Y0NTJjOTdlNzEzNGM2ZWZkMTA1ZS90YWJsZXJhbmdlOmJkZTFiZGM1MWJjZjQ1MmM5N2U3MTM0YzZlZmQxMDVlXzMtNC0xLTEtMTA5ODc2_82f6bb7b-b5c4-4a05-8dd2-079231f7c79d">53,274</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;General and administrative</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDkvZnJhZzpmY2YyZjBkNTU4YTE0MTUzOTZlNThlZWRjNDI1ZGUyNC90YWJsZTpiZGUxYmRjNTFiY2Y0NTJjOTdlNzEzNGM2ZWZkMTA1ZS90YWJsZXJhbmdlOmJkZTFiZGM1MWJjZjQ1MmM5N2U3MTM0YzZlZmQxMDVlXzQtMi0xLTEtMTA5ODc2_f7c823f8-50df-4d23-a623-f91ddd797c20">23,611</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDkvZnJhZzpmY2YyZjBkNTU4YTE0MTUzOTZlNThlZWRjNDI1ZGUyNC90YWJsZTpiZGUxYmRjNTFiY2Y0NTJjOTdlNzEzNGM2ZWZkMTA1ZS90YWJsZXJhbmdlOmJkZTFiZGM1MWJjZjQ1MmM5N2U3MTM0YzZlZmQxMDVlXzQtNC0xLTEtMTA5ODc2_267374cd-7cd3-4c41-b226-194e676b74cc">19,232</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Impairment of intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" decimals="-3" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDkvZnJhZzpmY2YyZjBkNTU4YTE0MTUzOTZlNThlZWRjNDI1ZGUyNC90YWJsZTpiZGUxYmRjNTFiY2Y0NTJjOTdlNzEzNGM2ZWZkMTA1ZS90YWJsZXJhbmdlOmJkZTFiZGM1MWJjZjQ1MmM5N2U3MTM0YzZlZmQxMDVlXzUtMi0xLTEtMTA5ODc2_b8c7e1b6-eca6-4534-94ca-274c3c85214b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231" decimals="-3" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDkvZnJhZzpmY2YyZjBkNTU4YTE0MTUzOTZlNThlZWRjNDI1ZGUyNC90YWJsZTpiZGUxYmRjNTFiY2Y0NTJjOTdlNzEzNGM2ZWZkMTA1ZS90YWJsZXJhbmdlOmJkZTFiZGM1MWJjZjQ1MmM5N2U3MTM0YzZlZmQxMDVlXzUtNC0xLTEtMTA5ODc2_52f0717f-ca6a-4763-b1e7-f33a5238503c">859</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDkvZnJhZzpmY2YyZjBkNTU4YTE0MTUzOTZlNThlZWRjNDI1ZGUyNC90YWJsZTpiZGUxYmRjNTFiY2Y0NTJjOTdlNzEzNGM2ZWZkMTA1ZS90YWJsZXJhbmdlOmJkZTFiZGM1MWJjZjQ1MmM5N2U3MTM0YzZlZmQxMDVlXzYtMi0xLTEtMTA5ODc2_a22f452c-39a5-4e1b-8727-67b0d05708c7">108,963</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDkvZnJhZzpmY2YyZjBkNTU4YTE0MTUzOTZlNThlZWRjNDI1ZGUyNC90YWJsZTpiZGUxYmRjNTFiY2Y0NTJjOTdlNzEzNGM2ZWZkMTA1ZS90YWJsZXJhbmdlOmJkZTFiZGM1MWJjZjQ1MmM5N2U3MTM0YzZlZmQxMDVlXzYtNC0xLTEtMTA5ODc2_b9416ce6-b653-4f66-ab0e-f393e06c3329">73,365</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" decimals="-3" name="us-gaap:OtherOperatingIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDkvZnJhZzpmY2YyZjBkNTU4YTE0MTUzOTZlNThlZWRjNDI1ZGUyNC90YWJsZTpiZGUxYmRjNTFiY2Y0NTJjOTdlNzEzNGM2ZWZkMTA1ZS90YWJsZXJhbmdlOmJkZTFiZGM1MWJjZjQ1MmM5N2U3MTM0YzZlZmQxMDVlXzctMi0xLTEtMTA5ODc2_3a122e80-6e0e-4c21-8942-c9dfd8380d93">20,968</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231" decimals="-3" name="us-gaap:OtherOperatingIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDkvZnJhZzpmY2YyZjBkNTU4YTE0MTUzOTZlNThlZWRjNDI1ZGUyNC90YWJsZTpiZGUxYmRjNTFiY2Y0NTJjOTdlNzEzNGM2ZWZkMTA1ZS90YWJsZXJhbmdlOmJkZTFiZGM1MWJjZjQ1MmM5N2U3MTM0YzZlZmQxMDVlXzctNC0xLTEtMTA5ODc2_74dd19d4-92bc-4fa0-9cb8-1a00a8c4c368">19,312</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDkvZnJhZzpmY2YyZjBkNTU4YTE0MTUzOTZlNThlZWRjNDI1ZGUyNC90YWJsZTpiZGUxYmRjNTFiY2Y0NTJjOTdlNzEzNGM2ZWZkMTA1ZS90YWJsZXJhbmdlOmJkZTFiZGM1MWJjZjQ1MmM5N2U3MTM0YzZlZmQxMDVlXzgtMi0xLTEtMTA5ODc2_d3ecf1ed-327d-404b-bcfc-c61c51644ef9">86,186</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDkvZnJhZzpmY2YyZjBkNTU4YTE0MTUzOTZlNThlZWRjNDI1ZGUyNC90YWJsZTpiZGUxYmRjNTFiY2Y0NTJjOTdlNzEzNGM2ZWZkMTA1ZS90YWJsZXJhbmdlOmJkZTFiZGM1MWJjZjQ1MmM5N2U3MTM0YzZlZmQxMDVlXzgtNC0xLTEtMTA5ODc2_83bca872-42fc-43c6-9f30-9ad38ea5a16a">53,193</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (expense) income, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDkvZnJhZzpmY2YyZjBkNTU4YTE0MTUzOTZlNThlZWRjNDI1ZGUyNC90YWJsZTpiZGUxYmRjNTFiY2Y0NTJjOTdlNzEzNGM2ZWZkMTA1ZS90YWJsZXJhbmdlOmJkZTFiZGM1MWJjZjQ1MmM5N2U3MTM0YzZlZmQxMDVlXzktMi0xLTEtMTA5ODc2_70547a5e-38c3-4916-a7aa-3a4bce4bf9a9">2,416</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDkvZnJhZzpmY2YyZjBkNTU4YTE0MTUzOTZlNThlZWRjNDI1ZGUyNC90YWJsZTpiZGUxYmRjNTFiY2Y0NTJjOTdlNzEzNGM2ZWZkMTA1ZS90YWJsZXJhbmdlOmJkZTFiZGM1MWJjZjQ1MmM5N2U3MTM0YzZlZmQxMDVlXzktNC0xLTEtMTA5ODc2_ef63f252-c9ba-48fa-8eb1-463b014c6154">283</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDkvZnJhZzpmY2YyZjBkNTU4YTE0MTUzOTZlNThlZWRjNDI1ZGUyNC90YWJsZTpiZGUxYmRjNTFiY2Y0NTJjOTdlNzEzNGM2ZWZkMTA1ZS90YWJsZXJhbmdlOmJkZTFiZGM1MWJjZjQ1MmM5N2U3MTM0YzZlZmQxMDVlXzEwLTItMS0xLTEwOTg3Ng_47e21dae-f06e-4c7b-a315-6e516ed446db">88,602</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDkvZnJhZzpmY2YyZjBkNTU4YTE0MTUzOTZlNThlZWRjNDI1ZGUyNC90YWJsZTpiZGUxYmRjNTFiY2Y0NTJjOTdlNzEzNGM2ZWZkMTA1ZS90YWJsZXJhbmdlOmJkZTFiZGM1MWJjZjQ1MmM5N2U3MTM0YzZlZmQxMDVlXzEwLTQtMS0xLTEwOTg3Ng_fdf5cdff-7992-4800-99b8-99438c4293b7">52,910</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDkvZnJhZzpmY2YyZjBkNTU4YTE0MTUzOTZlNThlZWRjNDI1ZGUyNC90YWJsZTpiZGUxYmRjNTFiY2Y0NTJjOTdlNzEzNGM2ZWZkMTA1ZS90YWJsZXJhbmdlOmJkZTFiZGM1MWJjZjQ1MmM5N2U3MTM0YzZlZmQxMDVlXzExLTItMS0xLTEwOTg3Ng_c5c9e777-d1ac-44f2-b6c1-25862022981b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDkvZnJhZzpmY2YyZjBkNTU4YTE0MTUzOTZlNThlZWRjNDI1ZGUyNC90YWJsZTpiZGUxYmRjNTFiY2Y0NTJjOTdlNzEzNGM2ZWZkMTA1ZS90YWJsZXJhbmdlOmJkZTFiZGM1MWJjZjQ1MmM5N2U3MTM0YzZlZmQxMDVlXzExLTQtMS0xLTEwOTg3Ng_5635446a-eb50-453b-89c9-eb84a220fe78">213</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDkvZnJhZzpmY2YyZjBkNTU4YTE0MTUzOTZlNThlZWRjNDI1ZGUyNC90YWJsZTpiZGUxYmRjNTFiY2Y0NTJjOTdlNzEzNGM2ZWZkMTA1ZS90YWJsZXJhbmdlOmJkZTFiZGM1MWJjZjQ1MmM5N2U3MTM0YzZlZmQxMDVlXzEyLTItMS0xLTEwOTg3Ng_c6d517a6-f913-440e-bb13-35cc46253cf7">88,602</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDkvZnJhZzpmY2YyZjBkNTU4YTE0MTUzOTZlNThlZWRjNDI1ZGUyNC90YWJsZTpiZGUxYmRjNTFiY2Y0NTJjOTdlNzEzNGM2ZWZkMTA1ZS90YWJsZXJhbmdlOmJkZTFiZGM1MWJjZjQ1MmM5N2U3MTM0YzZlZmQxMDVlXzEyLTQtMS0xLTEwOTg3Ng_6d25d829-8234-48ab-8a1b-3f918e72c1a0">52,697</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Basic and diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDkvZnJhZzpmY2YyZjBkNTU4YTE0MTUzOTZlNThlZWRjNDI1ZGUyNC90YWJsZTpiZGUxYmRjNTFiY2Y0NTJjOTdlNzEzNGM2ZWZkMTA1ZS90YWJsZXJhbmdlOmJkZTFiZGM1MWJjZjQ1MmM5N2U3MTM0YzZlZmQxMDVlXzE0LTItMS0xLTEwOTg3Ng_b4846293-5dbe-42ec-982f-e5d9f99f0bec"><ix:nonFraction unitRef="usdPerShare" contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDkvZnJhZzpmY2YyZjBkNTU4YTE0MTUzOTZlNThlZWRjNDI1ZGUyNC90YWJsZTpiZGUxYmRjNTFiY2Y0NTJjOTdlNzEzNGM2ZWZkMTA1ZS90YWJsZXJhbmdlOmJkZTFiZGM1MWJjZjQ1MmM5N2U3MTM0YzZlZmQxMDVlXzE0LTItMS0xLTEwOTg3Ng_cc6400be-9b3f-4caf-8a08-e93f00cd78af">0.96</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDkvZnJhZzpmY2YyZjBkNTU4YTE0MTUzOTZlNThlZWRjNDI1ZGUyNC90YWJsZTpiZGUxYmRjNTFiY2Y0NTJjOTdlNzEzNGM2ZWZkMTA1ZS90YWJsZXJhbmdlOmJkZTFiZGM1MWJjZjQ1MmM5N2U3MTM0YzZlZmQxMDVlXzE0LTQtMS0xLTEwOTg3Ng_6dbf18f3-1876-4387-815c-6123d233e7d5"><ix:nonFraction unitRef="usdPerShare" contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDkvZnJhZzpmY2YyZjBkNTU4YTE0MTUzOTZlNThlZWRjNDI1ZGUyNC90YWJsZTpiZGUxYmRjNTFiY2Y0NTJjOTdlNzEzNGM2ZWZkMTA1ZS90YWJsZXJhbmdlOmJkZTFiZGM1MWJjZjQ1MmM5N2U3MTM0YzZlZmQxMDVlXzE0LTQtMS0xLTEwOTg3Ng_b0011b5b-1fe1-40c0-8d2f-5c37180af633">0.76</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Basic and diluted</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDkvZnJhZzpmY2YyZjBkNTU4YTE0MTUzOTZlNThlZWRjNDI1ZGUyNC90YWJsZTpiZGUxYmRjNTFiY2Y0NTJjOTdlNzEzNGM2ZWZkMTA1ZS90YWJsZXJhbmdlOmJkZTFiZGM1MWJjZjQ1MmM5N2U3MTM0YzZlZmQxMDVlXzE2LTItMS0xLTEwOTg3Ng_6402986e-3b39-462a-9700-9ff90fef8c2c"><ix:nonFraction unitRef="shares" contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDkvZnJhZzpmY2YyZjBkNTU4YTE0MTUzOTZlNThlZWRjNDI1ZGUyNC90YWJsZTpiZGUxYmRjNTFiY2Y0NTJjOTdlNzEzNGM2ZWZkMTA1ZS90YWJsZXJhbmdlOmJkZTFiZGM1MWJjZjQ1MmM5N2U3MTM0YzZlZmQxMDVlXzE2LTItMS0xLTEwOTg3Ng_aa289f65-b634-441d-86d4-c6b1a2d9b77c">92,239,306</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDkvZnJhZzpmY2YyZjBkNTU4YTE0MTUzOTZlNThlZWRjNDI1ZGUyNC90YWJsZTpiZGUxYmRjNTFiY2Y0NTJjOTdlNzEzNGM2ZWZkMTA1ZS90YWJsZXJhbmdlOmJkZTFiZGM1MWJjZjQ1MmM5N2U3MTM0YzZlZmQxMDVlXzE2LTQtMS0xLTEwOTg3Ng_a1d05e4b-39e5-4f6e-8e57-aa93a4512bd6"><ix:nonFraction unitRef="shares" contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDkvZnJhZzpmY2YyZjBkNTU4YTE0MTUzOTZlNThlZWRjNDI1ZGUyNC90YWJsZTpiZGUxYmRjNTFiY2Y0NTJjOTdlNzEzNGM2ZWZkMTA1ZS90YWJsZXJhbmdlOmJkZTFiZGM1MWJjZjQ1MmM5N2U3MTM0YzZlZmQxMDVlXzE2LTQtMS0xLTEwOTg3Ng_eaf3e880-5146-4433-8ec5-f170cccfc765">69,524,148</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive (loss) income:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Foreign currency translation adjustments </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDkvZnJhZzpmY2YyZjBkNTU4YTE0MTUzOTZlNThlZWRjNDI1ZGUyNC90YWJsZTpiZGUxYmRjNTFiY2Y0NTJjOTdlNzEzNGM2ZWZkMTA1ZS90YWJsZXJhbmdlOmJkZTFiZGM1MWJjZjQ1MmM5N2U3MTM0YzZlZmQxMDVlXzE4LTItMS0xLTEwOTg3Ng_58cb0982-038f-429c-8795-cb8182113130">1,597</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDkvZnJhZzpmY2YyZjBkNTU4YTE0MTUzOTZlNThlZWRjNDI1ZGUyNC90YWJsZTpiZGUxYmRjNTFiY2Y0NTJjOTdlNzEzNGM2ZWZkMTA1ZS90YWJsZXJhbmdlOmJkZTFiZGM1MWJjZjQ1MmM5N2U3MTM0YzZlZmQxMDVlXzE4LTQtMS0xLTEwOTg3Ng_9c7c8ef4-43de-4af3-8576-c534ec7c7319">970</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDkvZnJhZzpmY2YyZjBkNTU4YTE0MTUzOTZlNThlZWRjNDI1ZGUyNC90YWJsZTpiZGUxYmRjNTFiY2Y0NTJjOTdlNzEzNGM2ZWZkMTA1ZS90YWJsZXJhbmdlOmJkZTFiZGM1MWJjZjQ1MmM5N2U3MTM0YzZlZmQxMDVlXzE5LTItMS0xLTEwOTg3Ng_52da3729-e60c-4d06-a947-4eafd6372412">87,005</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDkvZnJhZzpmY2YyZjBkNTU4YTE0MTUzOTZlNThlZWRjNDI1ZGUyNC90YWJsZTpiZGUxYmRjNTFiY2Y0NTJjOTdlNzEzNGM2ZWZkMTA1ZS90YWJsZXJhbmdlOmJkZTFiZGM1MWJjZjQ1MmM5N2U3MTM0YzZlZmQxMDVlXzE5LTQtMS0xLTEwOTg3Ng_6dc80d47-f986-441e-ac08-8178d65fd3dc">51,727</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of the consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><div id="i2eecdebedec64091994df5b7a96baab7_112"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summit Therapeutics Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Stockholders' Equity </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share data)</span></div><div><span><br/></span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.132%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.461%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.952%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.461%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.497%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.461%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.159%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.461%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.656%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.461%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.407%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.461%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.531%"></td><td style="width:0.1%"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Additional Paid-In Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Accumulated Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Stockholders' Equity</span></td></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iadaf16e26a374273b81a7480b2aef461_I20191231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTIvZnJhZzo0OTkyMzA4MmJmYzM0OTBkOGE0ZGI5NzkyZGY4Nzc3Yy90YWJsZTpkZmQwZGQ0ZjU2NGY0ZDNlYjdhNDAyYjk5OTJlMWNhNi90YWJsZXJhbmdlOmRmZDBkZDRmNTY0ZjRkM2ViN2E0MDJiOTk5MmUxY2E2XzItMi0xLTEtMTA5ODc2_fcbf844f-c345-4450-8312-4e9e5878da6e">67,178,054</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iadaf16e26a374273b81a7480b2aef461_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTIvZnJhZzo0OTkyMzA4MmJmYzM0OTBkOGE0ZGI5NzkyZGY4Nzc3Yy90YWJsZTpkZmQwZGQ0ZjU2NGY0ZDNlYjdhNDAyYjk5OTJlMWNhNi90YWJsZXJhbmdlOmRmZDBkZDRmNTY0ZjRkM2ViN2E0MDJiOTk5MmUxY2E2XzItNC0xLTEtMTA5ODc2_6f424f76-2556-4637-9572-bede90481c6f">672</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23c022f251aa4a7bb86fd5562b7cf66a_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTIvZnJhZzo0OTkyMzA4MmJmYzM0OTBkOGE0ZGI5NzkyZGY4Nzc3Yy90YWJsZTpkZmQwZGQ0ZjU2NGY0ZDNlYjdhNDAyYjk5OTJlMWNhNi90YWJsZXJhbmdlOmRmZDBkZDRmNTY0ZjRkM2ViN2E0MDJiOTk5MmUxY2E2XzItNi0xLTEtMTA5ODc2_e0cb4835-9854-4ae4-99aa-837d4b3055c0">241,204</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i18956f3671924995bc8672c2e4f9774d_I20191231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTIvZnJhZzo0OTkyMzA4MmJmYzM0OTBkOGE0ZGI5NzkyZGY4Nzc3Yy90YWJsZTpkZmQwZGQ0ZjU2NGY0ZDNlYjdhNDAyYjk5OTJlMWNhNi90YWJsZXJhbmdlOmRmZDBkZDRmNTY0ZjRkM2ViN2E0MDJiOTk5MmUxY2E2XzItOC0xLTEtMTA5ODc2_6f864ef5-bd03-404a-a90b-2a825312bab7">4,764</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i10704a1cbc944be6935b29991fb87b7b_I20191231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTIvZnJhZzo0OTkyMzA4MmJmYzM0OTBkOGE0ZGI5NzkyZGY4Nzc3Yy90YWJsZTpkZmQwZGQ0ZjU2NGY0ZDNlYjdhNDAyYjk5OTJlMWNhNi90YWJsZXJhbmdlOmRmZDBkZDRmNTY0ZjRkM2ViN2E0MDJiOTk5MmUxY2E2XzItMTAtMS0xLTEwOTg3Ng_7b8c8b17-968a-4924-83c6-f9468d2989f8">158,249</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50b9889462124695acb12b854dfc61e9_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTIvZnJhZzo0OTkyMzA4MmJmYzM0OTBkOGE0ZGI5NzkyZGY4Nzc3Yy90YWJsZTpkZmQwZGQ0ZjU2NGY0ZDNlYjdhNDAyYjk5OTJlMWNhNi90YWJsZXJhbmdlOmRmZDBkZDRmNTY0ZjRkM2ViN2E0MDJiOTk5MmUxY2E2XzItMTItMS0xLTEwOTg3Ng_2d5d0f84-2c34-48a3-bf74-926e30b6d0d3">78,863</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private placement of common stock, net of offering costs of $<ix:nonFraction unitRef="usd" contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTIvZnJhZzo0OTkyMzA4MmJmYzM0OTBkOGE0ZGI5NzkyZGY4Nzc3Yy90YWJsZTpkZmQwZGQ0ZjU2NGY0ZDNlYjdhNDAyYjk5OTJlMWNhNi90YWJsZXJhbmdlOmRmZDBkZDRmNTY0ZjRkM2ViN2E0MDJiOTk5MmUxY2E2XzMtMC0xLTEtMTA5ODc2L3RleHRyZWdpb246ZTI5YmFkM2MzNDRiNGE4N2FlYTI3NDFmYmU0YWEwYzZfNjQ_66bf4143-b1bb-4d2c-91e0-18d79a3e55b2">48</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie925211651134cc095c13ead145a9987_D20200101-20201231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTIvZnJhZzo0OTkyMzA4MmJmYzM0OTBkOGE0ZGI5NzkyZGY4Nzc3Yy90YWJsZTpkZmQwZGQ0ZjU2NGY0ZDNlYjdhNDAyYjk5OTJlMWNhNi90YWJsZXJhbmdlOmRmZDBkZDRmNTY0ZjRkM2ViN2E0MDJiOTk5MmUxY2E2XzMtMi0xLTEtMTA5ODc2_81d832ce-b0c7-4f23-90b8-882be2182953">14,970,060</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie925211651134cc095c13ead145a9987_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTIvZnJhZzo0OTkyMzA4MmJmYzM0OTBkOGE0ZGI5NzkyZGY4Nzc3Yy90YWJsZTpkZmQwZGQ0ZjU2NGY0ZDNlYjdhNDAyYjk5OTJlMWNhNi90YWJsZXJhbmdlOmRmZDBkZDRmNTY0ZjRkM2ViN2E0MDJiOTk5MmUxY2E2XzMtNC0xLTEtMTA5ODc2_0fe749a8-742d-46b3-96e2-aaeb05cd8d22">150</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1c2f38f4911489ea019b962d6783b5d_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTIvZnJhZzo0OTkyMzA4MmJmYzM0OTBkOGE0ZGI5NzkyZGY4Nzc3Yy90YWJsZTpkZmQwZGQ0ZjU2NGY0ZDNlYjdhNDAyYjk5OTJlMWNhNi90YWJsZXJhbmdlOmRmZDBkZDRmNTY0ZjRkM2ViN2E0MDJiOTk5MmUxY2E2XzMtNi0xLTEtMTA5ODc2_5798cd39-69b8-4091-b0ff-bcea433b5a4d">49,802</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTIvZnJhZzo0OTkyMzA4MmJmYzM0OTBkOGE0ZGI5NzkyZGY4Nzc3Yy90YWJsZTpkZmQwZGQ0ZjU2NGY0ZDNlYjdhNDAyYjk5OTJlMWNhNi90YWJsZXJhbmdlOmRmZDBkZDRmNTY0ZjRkM2ViN2E0MDJiOTk5MmUxY2E2XzMtMTItMS0xLTEwOTg3Ng_ab6dfb67-aecc-4db7-97e9-a5202fc05523">49,952</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fractional shares issued from reverse stock split</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie925211651134cc095c13ead145a9987_D20200101-20201231" decimals="INF" name="smmt:FractionalStockIssuedDuringPeriodSharesReverseStockSplit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTIvZnJhZzo0OTkyMzA4MmJmYzM0OTBkOGE0ZGI5NzkyZGY4Nzc3Yy90YWJsZTpkZmQwZGQ0ZjU2NGY0ZDNlYjdhNDAyYjk5OTJlMWNhNi90YWJsZXJhbmdlOmRmZDBkZDRmNTY0ZjRkM2ViN2E0MDJiOTk5MmUxY2E2XzQtMi0xLTEtMTA5ODc2_8109deaa-781d-4ea8-b70d-9cc98e6d0e1b">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance on common stock from exercise of share options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie925211651134cc095c13ead145a9987_D20200101-20201231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTIvZnJhZzo0OTkyMzA4MmJmYzM0OTBkOGE0ZGI5NzkyZGY4Nzc3Yy90YWJsZTpkZmQwZGQ0ZjU2NGY0ZDNlYjdhNDAyYjk5OTJlMWNhNi90YWJsZXJhbmdlOmRmZDBkZDRmNTY0ZjRkM2ViN2E0MDJiOTk5MmUxY2E2XzUtMi0xLTEtMTA5ODc2_fad550cc-0011-43d7-a9e6-fa000d8c0151">426,947</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie925211651134cc095c13ead145a9987_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTIvZnJhZzo0OTkyMzA4MmJmYzM0OTBkOGE0ZGI5NzkyZGY4Nzc3Yy90YWJsZTpkZmQwZGQ0ZjU2NGY0ZDNlYjdhNDAyYjk5OTJlMWNhNi90YWJsZXJhbmdlOmRmZDBkZDRmNTY0ZjRkM2ViN2E0MDJiOTk5MmUxY2E2XzUtNC0xLTEtMTA5ODc2_a2cf3e8d-02e4-4c96-80a3-6504f53c6a2d">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1c2f38f4911489ea019b962d6783b5d_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTIvZnJhZzo0OTkyMzA4MmJmYzM0OTBkOGE0ZGI5NzkyZGY4Nzc3Yy90YWJsZTpkZmQwZGQ0ZjU2NGY0ZDNlYjdhNDAyYjk5OTJlMWNhNi90YWJsZXJhbmdlOmRmZDBkZDRmNTY0ZjRkM2ViN2E0MDJiOTk5MmUxY2E2XzUtNi0xLTEtMTA5ODc2_b58eb507-d45f-471e-a90a-7f28c43b5310">595</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTIvZnJhZzo0OTkyMzA4MmJmYzM0OTBkOGE0ZGI5NzkyZGY4Nzc3Yy90YWJsZTpkZmQwZGQ0ZjU2NGY0ZDNlYjdhNDAyYjk5OTJlMWNhNi90YWJsZXJhbmdlOmRmZDBkZDRmNTY0ZjRkM2ViN2E0MDJiOTk5MmUxY2E2XzUtMTItMS0xLTEwOTg3Ng_ac219dc9-e0d1-4a41-a5e8-6190f24d6277">599</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1c2f38f4911489ea019b962d6783b5d_D20200101-20201231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTIvZnJhZzo0OTkyMzA4MmJmYzM0OTBkOGE0ZGI5NzkyZGY4Nzc3Yy90YWJsZTpkZmQwZGQ0ZjU2NGY0ZDNlYjdhNDAyYjk5OTJlMWNhNi90YWJsZXJhbmdlOmRmZDBkZDRmNTY0ZjRkM2ViN2E0MDJiOTk5MmUxY2E2XzYtNi0xLTEtMTA5ODc2_6edaae12-d269-4025-91c5-d8503fbf6481">1,766</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTIvZnJhZzo0OTkyMzA4MmJmYzM0OTBkOGE0ZGI5NzkyZGY4Nzc3Yy90YWJsZTpkZmQwZGQ0ZjU2NGY0ZDNlYjdhNDAyYjk5OTJlMWNhNi90YWJsZXJhbmdlOmRmZDBkZDRmNTY0ZjRkM2ViN2E0MDJiOTk5MmUxY2E2XzYtMTItMS0xLTEwOTg3Ng_be284c03-1686-416d-bae5-52ab672a4413">1,766</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7966e0fd0224c4492484acc988b5ec7_D20200101-20201231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTIvZnJhZzo0OTkyMzA4MmJmYzM0OTBkOGE0ZGI5NzkyZGY4Nzc3Yy90YWJsZTpkZmQwZGQ0ZjU2NGY0ZDNlYjdhNDAyYjk5OTJlMWNhNi90YWJsZXJhbmdlOmRmZDBkZDRmNTY0ZjRkM2ViN2E0MDJiOTk5MmUxY2E2XzctOC0xLTEtMTA5ODc2_130a5711-b275-46d2-bece-bbfe99063511">970</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTIvZnJhZzo0OTkyMzA4MmJmYzM0OTBkOGE0ZGI5NzkyZGY4Nzc3Yy90YWJsZTpkZmQwZGQ0ZjU2NGY0ZDNlYjdhNDAyYjk5OTJlMWNhNi90YWJsZXJhbmdlOmRmZDBkZDRmNTY0ZjRkM2ViN2E0MDJiOTk5MmUxY2E2XzctMTItMS0xLTEwOTg3Ng_c44594fa-1482-4cbc-83e8-502866ab0940">970</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c007ce1c0eb4469a7130cee973d7baf_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTIvZnJhZzo0OTkyMzA4MmJmYzM0OTBkOGE0ZGI5NzkyZGY4Nzc3Yy90YWJsZTpkZmQwZGQ0ZjU2NGY0ZDNlYjdhNDAyYjk5OTJlMWNhNi90YWJsZXJhbmdlOmRmZDBkZDRmNTY0ZjRkM2ViN2E0MDJiOTk5MmUxY2E2XzgtMTAtMS0xLTEwOTg3Ng_39f4336d-dd81-4ab2-8c9a-7bc181848292">52,697</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTIvZnJhZzo0OTkyMzA4MmJmYzM0OTBkOGE0ZGI5NzkyZGY4Nzc3Yy90YWJsZTpkZmQwZGQ0ZjU2NGY0ZDNlYjdhNDAyYjk5OTJlMWNhNi90YWJsZXJhbmdlOmRmZDBkZDRmNTY0ZjRkM2ViN2E0MDJiOTk5MmUxY2E2XzgtMTItMS0xLTEwOTg3Ng_85c70f21-af3c-4909-8b06-1fade14bb097">52,697</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i24918d03620c4ecaafa37fa8e2ca91b8_I20201231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTIvZnJhZzo0OTkyMzA4MmJmYzM0OTBkOGE0ZGI5NzkyZGY4Nzc3Yy90YWJsZTpkZmQwZGQ0ZjU2NGY0ZDNlYjdhNDAyYjk5OTJlMWNhNi90YWJsZXJhbmdlOmRmZDBkZDRmNTY0ZjRkM2ViN2E0MDJiOTk5MmUxY2E2XzktMi0xLTEtMTA5ODc2_b43d2e01-7c39-40d0-91a0-71905440f6b7">82,575,064</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24918d03620c4ecaafa37fa8e2ca91b8_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTIvZnJhZzo0OTkyMzA4MmJmYzM0OTBkOGE0ZGI5NzkyZGY4Nzc3Yy90YWJsZTpkZmQwZGQ0ZjU2NGY0ZDNlYjdhNDAyYjk5OTJlMWNhNi90YWJsZXJhbmdlOmRmZDBkZDRmNTY0ZjRkM2ViN2E0MDJiOTk5MmUxY2E2XzktNC0xLTEtMTA5ODc2_4bb83d9f-ea1d-465b-afc7-2155958f0f60">826</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c014f26be2f47f291a3aa91605b4237_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTIvZnJhZzo0OTkyMzA4MmJmYzM0OTBkOGE0ZGI5NzkyZGY4Nzc3Yy90YWJsZTpkZmQwZGQ0ZjU2NGY0ZDNlYjdhNDAyYjk5OTJlMWNhNi90YWJsZXJhbmdlOmRmZDBkZDRmNTY0ZjRkM2ViN2E0MDJiOTk5MmUxY2E2XzktNi0xLTEtMTA5ODc2_708e6c74-e137-40a2-aaf9-9badd34d27cc">293,367</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie706c5ed539d4ef3bd0c02c4a4ba65e9_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTIvZnJhZzo0OTkyMzA4MmJmYzM0OTBkOGE0ZGI5NzkyZGY4Nzc3Yy90YWJsZTpkZmQwZGQ0ZjU2NGY0ZDNlYjdhNDAyYjk5OTJlMWNhNi90YWJsZXJhbmdlOmRmZDBkZDRmNTY0ZjRkM2ViN2E0MDJiOTk5MmUxY2E2XzktOC0xLTEtMTA5ODc2_983041c6-d767-481f-b4cb-98c592dd8ae7">3,794</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7658aae35c1342aa8a4d460d73d54645_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTIvZnJhZzo0OTkyMzA4MmJmYzM0OTBkOGE0ZGI5NzkyZGY4Nzc3Yy90YWJsZTpkZmQwZGQ0ZjU2NGY0ZDNlYjdhNDAyYjk5OTJlMWNhNi90YWJsZXJhbmdlOmRmZDBkZDRmNTY0ZjRkM2ViN2E0MDJiOTk5MmUxY2E2XzktMTAtMS0xLTEwOTg3Ng_66d3a3df-7620-456e-8c69-c239df4fade0">210,946</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7372be6dc06143b5adbb4d2e83a596c5_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTIvZnJhZzo0OTkyMzA4MmJmYzM0OTBkOGE0ZGI5NzkyZGY4Nzc3Yy90YWJsZTpkZmQwZGQ0ZjU2NGY0ZDNlYjdhNDAyYjk5OTJlMWNhNi90YWJsZXJhbmdlOmRmZDBkZDRmNTY0ZjRkM2ViN2E0MDJiOTk5MmUxY2E2XzktMTItMS0xLTEwOTg3Ng_02fe97d3-ab28-4dd9-adf7-5e96f459e970">79,453</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rights offering of common stock, net of offering costs of $<ix:nonFraction unitRef="usd" contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTIvZnJhZzo0OTkyMzA4MmJmYzM0OTBkOGE0ZGI5NzkyZGY4Nzc3Yy90YWJsZTpkZmQwZGQ0ZjU2NGY0ZDNlYjdhNDAyYjk5OTJlMWNhNi90YWJsZXJhbmdlOmRmZDBkZDRmNTY0ZjRkM2ViN2E0MDJiOTk5MmUxY2E2XzEwLTAtMS0xLTEwOTg3Ni90ZXh0cmVnaW9uOjViM2FmZjk2Y2FlMjQ4OGI4MGM4NjMyZDVmMWIyNWE3XzYy_c0aeef7f-d2b3-49bc-8990-ec96faf507ae">159</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic6b97fcd6da249ba8b8f4ae9d4f4b37d_D20210101-20211231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTIvZnJhZzo0OTkyMzA4MmJmYzM0OTBkOGE0ZGI5NzkyZGY4Nzc3Yy90YWJsZTpkZmQwZGQ0ZjU2NGY0ZDNlYjdhNDAyYjk5OTJlMWNhNi90YWJsZXJhbmdlOmRmZDBkZDRmNTY0ZjRkM2ViN2E0MDJiOTk5MmUxY2E2XzEwLTItMS0xLTEwOTg3Ng_420249bb-d6c6-43d5-9753-f41b7d4b1ba6">14,312,976</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6b97fcd6da249ba8b8f4ae9d4f4b37d_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTIvZnJhZzo0OTkyMzA4MmJmYzM0OTBkOGE0ZGI5NzkyZGY4Nzc3Yy90YWJsZTpkZmQwZGQ0ZjU2NGY0ZDNlYjdhNDAyYjk5OTJlMWNhNi90YWJsZXJhbmdlOmRmZDBkZDRmNTY0ZjRkM2ViN2E0MDJiOTk5MmUxY2E2XzEwLTQtMS0xLTEwOTg3Ng_4bb746f4-6ae1-46ca-a741-8f4a9b8dfa67">143</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e2dff6c233a4cdbb090a82ca47e7ffc_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTIvZnJhZzo0OTkyMzA4MmJmYzM0OTBkOGE0ZGI5NzkyZGY4Nzc3Yy90YWJsZTpkZmQwZGQ0ZjU2NGY0ZDNlYjdhNDAyYjk5OTJlMWNhNi90YWJsZXJhbmdlOmRmZDBkZDRmNTY0ZjRkM2ViN2E0MDJiOTk5MmUxY2E2XzEwLTYtMS0xLTEwOTg3Ng_2a6d9fe5-d865-45f4-b99b-0323dac064fc">74,698</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTIvZnJhZzo0OTkyMzA4MmJmYzM0OTBkOGE0ZGI5NzkyZGY4Nzc3Yy90YWJsZTpkZmQwZGQ0ZjU2NGY0ZDNlYjdhNDAyYjk5OTJlMWNhNi90YWJsZXJhbmdlOmRmZDBkZDRmNTY0ZjRkM2ViN2E0MDJiOTk5MmUxY2E2XzEwLTEyLTEtMS0xMDk4NzY_323d2e2d-fc64-4add-9a97-05622a4dcf8e">74,841</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock from exercise of stock options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic6b97fcd6da249ba8b8f4ae9d4f4b37d_D20210101-20211231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTIvZnJhZzo0OTkyMzA4MmJmYzM0OTBkOGE0ZGI5NzkyZGY4Nzc3Yy90YWJsZTpkZmQwZGQ0ZjU2NGY0ZDNlYjdhNDAyYjk5OTJlMWNhNi90YWJsZXJhbmdlOmRmZDBkZDRmNTY0ZjRkM2ViN2E0MDJiOTk5MmUxY2E2XzExLTItMS0xLTEwOTg3Ng_b840f1e2-4ca9-46c4-b71c-262050709f11">1,151,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6b97fcd6da249ba8b8f4ae9d4f4b37d_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTIvZnJhZzo0OTkyMzA4MmJmYzM0OTBkOGE0ZGI5NzkyZGY4Nzc3Yy90YWJsZTpkZmQwZGQ0ZjU2NGY0ZDNlYjdhNDAyYjk5OTJlMWNhNi90YWJsZXJhbmdlOmRmZDBkZDRmNTY0ZjRkM2ViN2E0MDJiOTk5MmUxY2E2XzExLTQtMS0xLTEwOTg3Ng_6a952512-f2e8-4391-88a7-22264d30b7c3">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e2dff6c233a4cdbb090a82ca47e7ffc_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTIvZnJhZzo0OTkyMzA4MmJmYzM0OTBkOGE0ZGI5NzkyZGY4Nzc3Yy90YWJsZTpkZmQwZGQ0ZjU2NGY0ZDNlYjdhNDAyYjk5OTJlMWNhNi90YWJsZXJhbmdlOmRmZDBkZDRmNTY0ZjRkM2ViN2E0MDJiOTk5MmUxY2E2XzExLTYtMS0xLTEwOTg3Ng_338a18e0-5323-4696-83ae-1a866889bfca">3,077</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTIvZnJhZzo0OTkyMzA4MmJmYzM0OTBkOGE0ZGI5NzkyZGY4Nzc3Yy90YWJsZTpkZmQwZGQ0ZjU2NGY0ZDNlYjdhNDAyYjk5OTJlMWNhNi90YWJsZXJhbmdlOmRmZDBkZDRmNTY0ZjRkM2ViN2E0MDJiOTk5MmUxY2E2XzExLTEyLTEtMS0xMDk4NzY_b3ca41ef-bffe-4cba-b5f5-b12d0432fb7b">3,088</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e2dff6c233a4cdbb090a82ca47e7ffc_D20210101-20211231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTIvZnJhZzo0OTkyMzA4MmJmYzM0OTBkOGE0ZGI5NzkyZGY4Nzc3Yy90YWJsZTpkZmQwZGQ0ZjU2NGY0ZDNlYjdhNDAyYjk5OTJlMWNhNi90YWJsZXJhbmdlOmRmZDBkZDRmNTY0ZjRkM2ViN2E0MDJiOTk5MmUxY2E2XzEyLTYtMS0xLTEwOTg3Ng_837a8f92-b0c8-4433-ba3b-1305d9a5bbf0">12,804</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTIvZnJhZzo0OTkyMzA4MmJmYzM0OTBkOGE0ZGI5NzkyZGY4Nzc3Yy90YWJsZTpkZmQwZGQ0ZjU2NGY0ZDNlYjdhNDAyYjk5OTJlMWNhNi90YWJsZXJhbmdlOmRmZDBkZDRmNTY0ZjRkM2ViN2E0MDJiOTk5MmUxY2E2XzEyLTEyLTEtMS0xMDk4NzY_4e1be24d-5939-4171-b1ea-6720fb93bc7d">12,804</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Imputed interest expense on promissory note payable to a related party</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e2dff6c233a4cdbb090a82ca47e7ffc_D20210101-20211231" decimals="-3" name="smmt:AdjustmentsToAdditionalPaidInCapitalImputedInterestExpenseRelatedParty" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTIvZnJhZzo0OTkyMzA4MmJmYzM0OTBkOGE0ZGI5NzkyZGY4Nzc3Yy90YWJsZTpkZmQwZGQ0ZjU2NGY0ZDNlYjdhNDAyYjk5OTJlMWNhNi90YWJsZXJhbmdlOmRmZDBkZDRmNTY0ZjRkM2ViN2E0MDJiOTk5MmUxY2E2XzEzLTYtMS0xLTEwOTg3Ng_30f3fbbe-bb38-4822-8528-d264147d8f40">103</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" decimals="-3" name="smmt:AdjustmentsToAdditionalPaidInCapitalImputedInterestExpenseRelatedParty" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTIvZnJhZzo0OTkyMzA4MmJmYzM0OTBkOGE0ZGI5NzkyZGY4Nzc3Yy90YWJsZTpkZmQwZGQ0ZjU2NGY0ZDNlYjdhNDAyYjk5OTJlMWNhNi90YWJsZXJhbmdlOmRmZDBkZDRmNTY0ZjRkM2ViN2E0MDJiOTk5MmUxY2E2XzEzLTEyLTEtMS0xMDk4NzY_b83ebc3f-7a0b-40d8-973a-bdff3e9a68e0">103</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d878058c8ed44bfb3e3c57c92407be4_D20210101-20211231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTIvZnJhZzo0OTkyMzA4MmJmYzM0OTBkOGE0ZGI5NzkyZGY4Nzc3Yy90YWJsZTpkZmQwZGQ0ZjU2NGY0ZDNlYjdhNDAyYjk5OTJlMWNhNi90YWJsZXJhbmdlOmRmZDBkZDRmNTY0ZjRkM2ViN2E0MDJiOTk5MmUxY2E2XzE0LTgtMS0xLTEwOTg3Ng_322207aa-c73f-4ef5-888d-36639824f658">1,597</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTIvZnJhZzo0OTkyMzA4MmJmYzM0OTBkOGE0ZGI5NzkyZGY4Nzc3Yy90YWJsZTpkZmQwZGQ0ZjU2NGY0ZDNlYjdhNDAyYjk5OTJlMWNhNi90YWJsZXJhbmdlOmRmZDBkZDRmNTY0ZjRkM2ViN2E0MDJiOTk5MmUxY2E2XzE0LTEyLTEtMS0xMDk4NzY_d8d49ea5-edec-4333-98e8-978dfd3496bd">1,597</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i598a27caa8a04c3d8039576d04308448_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTIvZnJhZzo0OTkyMzA4MmJmYzM0OTBkOGE0ZGI5NzkyZGY4Nzc3Yy90YWJsZTpkZmQwZGQ0ZjU2NGY0ZDNlYjdhNDAyYjk5OTJlMWNhNi90YWJsZXJhbmdlOmRmZDBkZDRmNTY0ZjRkM2ViN2E0MDJiOTk5MmUxY2E2XzE1LTEwLTEtMS0xMDk4NzY_9561aa10-9e6f-489a-9d8d-57b953d8da54">88,602</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTIvZnJhZzo0OTkyMzA4MmJmYzM0OTBkOGE0ZGI5NzkyZGY4Nzc3Yy90YWJsZTpkZmQwZGQ0ZjU2NGY0ZDNlYjdhNDAyYjk5OTJlMWNhNi90YWJsZXJhbmdlOmRmZDBkZDRmNTY0ZjRkM2ViN2E0MDJiOTk5MmUxY2E2XzE1LTEyLTEtMS0xMDk4NzY_06174e45-63a0-4fb2-91b8-e81c157cda05">88,602</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i24c2e29db794467488a44f9569dc30e2_I20211231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTIvZnJhZzo0OTkyMzA4MmJmYzM0OTBkOGE0ZGI5NzkyZGY4Nzc3Yy90YWJsZTpkZmQwZGQ0ZjU2NGY0ZDNlYjdhNDAyYjk5OTJlMWNhNi90YWJsZXJhbmdlOmRmZDBkZDRmNTY0ZjRkM2ViN2E0MDJiOTk5MmUxY2E2XzE2LTItMS0xLTEwOTg3Ng_8444d37f-7b96-4362-84a0-d8938a1c962a">98,039,540</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24c2e29db794467488a44f9569dc30e2_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTIvZnJhZzo0OTkyMzA4MmJmYzM0OTBkOGE0ZGI5NzkyZGY4Nzc3Yy90YWJsZTpkZmQwZGQ0ZjU2NGY0ZDNlYjdhNDAyYjk5OTJlMWNhNi90YWJsZXJhbmdlOmRmZDBkZDRmNTY0ZjRkM2ViN2E0MDJiOTk5MmUxY2E2XzE2LTQtMS0xLTEwOTg3Ng_6b9b0576-a9fe-4fdc-bf95-cfda208b4404">980</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie363771b412541ff94d08b8f29d0252e_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTIvZnJhZzo0OTkyMzA4MmJmYzM0OTBkOGE0ZGI5NzkyZGY4Nzc3Yy90YWJsZTpkZmQwZGQ0ZjU2NGY0ZDNlYjdhNDAyYjk5OTJlMWNhNi90YWJsZXJhbmdlOmRmZDBkZDRmNTY0ZjRkM2ViN2E0MDJiOTk5MmUxY2E2XzE2LTYtMS0xLTEwOTg3Ng_96ae96e5-5b48-4ddd-b503-6e0474267ec9">384,049</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iebb70cd5cf5e4946b99f20b6f84c6333_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTIvZnJhZzo0OTkyMzA4MmJmYzM0OTBkOGE0ZGI5NzkyZGY4Nzc3Yy90YWJsZTpkZmQwZGQ0ZjU2NGY0ZDNlYjdhNDAyYjk5OTJlMWNhNi90YWJsZXJhbmdlOmRmZDBkZDRmNTY0ZjRkM2ViN2E0MDJiOTk5MmUxY2E2XzE2LTgtMS0xLTEwOTg3Ng_5b107d80-a8f7-4b05-bec7-6bf193e04d89">2,197</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8194e85afada4be48c4dc89d2b7c2a07_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTIvZnJhZzo0OTkyMzA4MmJmYzM0OTBkOGE0ZGI5NzkyZGY4Nzc3Yy90YWJsZTpkZmQwZGQ0ZjU2NGY0ZDNlYjdhNDAyYjk5OTJlMWNhNi90YWJsZXJhbmdlOmRmZDBkZDRmNTY0ZjRkM2ViN2E0MDJiOTk5MmUxY2E2XzE2LTEwLTEtMS0xMDk4NzY_a725d4da-75eb-471b-8c94-7cac9d4e2498">299,548</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTIvZnJhZzo0OTkyMzA4MmJmYzM0OTBkOGE0ZGI5NzkyZGY4Nzc3Yy90YWJsZTpkZmQwZGQ0ZjU2NGY0ZDNlYjdhNDAyYjk5OTJlMWNhNi90YWJsZXJhbmdlOmRmZDBkZDRmNTY0ZjRkM2ViN2E0MDJiOTk5MmUxY2E2XzE2LTEyLTEtMS0xMDk4NzY_b805d759-94e5-48a8-8734-aa6fa54cf43a">83,284</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of the consolidated financial statements. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><div id="i2eecdebedec64091994df5b7a96baab7_115"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Summit Therapeutics Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Cash Flows </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.022%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTUvZnJhZzo5NTczOWI5ZjE4OWU0YzEzOWRkZmZjZjI5YTBhN2U1Mi90YWJsZTo5MGNmYzZiNTUwYzQ0MmZkOTY5Nzc3YzEwZjAyZmZlMy90YWJsZXJhbmdlOjkwY2ZjNmI1NTBjNDQyZmQ5Njk3NzdjMTBmMDJmZmUzXzItMi0xLTEtMTA5ODc2_57d3c479-5fc3-42fb-81ef-193764142a81">88,602</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTUvZnJhZzo5NTczOWI5ZjE4OWU0YzEzOWRkZmZjZjI5YTBhN2U1Mi90YWJsZTo5MGNmYzZiNTUwYzQ0MmZkOTY5Nzc3YzEwZjAyZmZlMy90YWJsZXJhbmdlOjkwY2ZjNmI1NTBjNDQyZmQ5Njk3NzdjMTBmMDJmZmUzXzItNC0xLTEtMTA5ODc2_660ccf47-c21b-4f65-936c-4c7619967a93">52,697</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Gain on remeasurement of liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" decimals="-3" name="smmt:GainLossOnRemeasurementOfLiabilitiesOperatingAndNonoperating" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTUvZnJhZzo5NTczOWI5ZjE4OWU0YzEzOWRkZmZjZjI5YTBhN2U1Mi90YWJsZTo5MGNmYzZiNTUwYzQ0MmZkOTY5Nzc3YzEwZjAyZmZlMy90YWJsZXJhbmdlOjkwY2ZjNmI1NTBjNDQyZmQ5Njk3NzdjMTBmMDJmZmUzXzQtMi0xLTEtMTA5ODc2_b3775eac-ccff-4a4b-8262-f99a1687a754">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231" decimals="-3" name="smmt:GainLossOnRemeasurementOfLiabilitiesOperatingAndNonoperating" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTUvZnJhZzo5NTczOWI5ZjE4OWU0YzEzOWRkZmZjZjI5YTBhN2U1Mi90YWJsZTo5MGNmYzZiNTUwYzQ0MmZkOTY5Nzc3YzEwZjAyZmZlMy90YWJsZXJhbmdlOjkwY2ZjNmI1NTBjNDQyZmQ5Njk3NzdjMTBmMDJmZmUzXzQtNC0xLTEtMTA5ODc2_d913191f-2fa4-4876-bcc4-fe26bfe06d0a">480</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Gain on recognition of contingent consideration payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTUvZnJhZzo5NTczOWI5ZjE4OWU0YzEzOWRkZmZjZjI5YTBhN2U1Mi90YWJsZTo5MGNmYzZiNTUwYzQ0MmZkOTY5Nzc3YzEwZjAyZmZlMy90YWJsZXJhbmdlOjkwY2ZjNmI1NTBjNDQyZmQ5Njk3NzdjMTBmMDJmZmUzXzUtMi0xLTEtMTA5ODc2_3d71bc55-296e-42b2-8419-2591d6512abe">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTUvZnJhZzo5NTczOWI5ZjE4OWU0YzEzOWRkZmZjZjI5YTBhN2U1Mi90YWJsZTo5MGNmYzZiNTUwYzQ0MmZkOTY5Nzc3YzEwZjAyZmZlMy90YWJsZXJhbmdlOjkwY2ZjNmI1NTBjNDQyZmQ5Njk3NzdjMTBmMDJmZmUzXzUtNC0xLTEtMTA5ODc2_679a6f5c-ef3d-4eb3-8545-5381b6174d50">102</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Non-cash interest expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" decimals="-3" name="smmt:InterestExpenseIncomeNoncash" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTUvZnJhZzo5NTczOWI5ZjE4OWU0YzEzOWRkZmZjZjI5YTBhN2U1Mi90YWJsZTo5MGNmYzZiNTUwYzQ0MmZkOTY5Nzc3YzEwZjAyZmZlMy90YWJsZXJhbmdlOjkwY2ZjNmI1NTBjNDQyZmQ5Njk3NzdjMTBmMDJmZmUzXzYtMi0xLTEtMTA5ODc2_3714fd64-b4bd-48c3-8f6f-a688768b78f5">196</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231" decimals="-3" name="smmt:InterestExpenseIncomeNoncash" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTUvZnJhZzo5NTczOWI5ZjE4OWU0YzEzOWRkZmZjZjI5YTBhN2U1Mi90YWJsZTo5MGNmYzZiNTUwYzQ0MmZkOTY5Nzc3YzEwZjAyZmZlMy90YWJsZXJhbmdlOjkwY2ZjNmI1NTBjNDQyZmQ5Njk3NzdjMTBmMDJmZmUzXzYtNC0xLTEtMTA5ODc2_a0c5f136-2f51-4f45-859f-b553c766e406">255</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Unrealized foreign exchange loss (gain)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossUnrealized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTUvZnJhZzo5NTczOWI5ZjE4OWU0YzEzOWRkZmZjZjI5YTBhN2U1Mi90YWJsZTo5MGNmYzZiNTUwYzQ0MmZkOTY5Nzc3YzEwZjAyZmZlMy90YWJsZXJhbmdlOjkwY2ZjNmI1NTBjNDQyZmQ5Njk3NzdjMTBmMDJmZmUzXzctMi0xLTEtMTA5ODc2_b18d36f9-5bdb-4e44-b8b5-cd729b0dcb9f">326</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231" decimals="-3" name="us-gaap:ForeignCurrencyTransactionGainLossUnrealized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTUvZnJhZzo5NTczOWI5ZjE4OWU0YzEzOWRkZmZjZjI5YTBhN2U1Mi90YWJsZTo5MGNmYzZiNTUwYzQ0MmZkOTY5Nzc3YzEwZjAyZmZlMy90YWJsZXJhbmdlOjkwY2ZjNmI1NTBjNDQyZmQ5Njk3NzdjMTBmMDJmZmUzXzctNC0xLTEtMTA5ODc2_12e3a42e-619e-40f7-8bf3-d5a5ad690c83">278</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Amortization of operating right-of-use assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTUvZnJhZzo5NTczOWI5ZjE4OWU0YzEzOWRkZmZjZjI5YTBhN2U1Mi90YWJsZTo5MGNmYzZiNTUwYzQ0MmZkOTY5Nzc3YzEwZjAyZmZlMy90YWJsZXJhbmdlOjkwY2ZjNmI1NTBjNDQyZmQ5Njk3NzdjMTBmMDJmZmUzXzgtMi0xLTEtMTA5ODc2_264e7287-dd34-4460-afcd-110fb1108ffe">1,108</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTUvZnJhZzo5NTczOWI5ZjE4OWU0YzEzOWRkZmZjZjI5YTBhN2U1Mi90YWJsZTo5MGNmYzZiNTUwYzQ0MmZkOTY5Nzc3YzEwZjAyZmZlMy90YWJsZXJhbmdlOjkwY2ZjNmI1NTBjNDQyZmQ5Njk3NzdjMTBmMDJmZmUzXzgtNC0xLTEtMTA5ODc2_49c1a328-4f6b-43f7-b941-d54774471710">451</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Depreciation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" decimals="-3" name="us-gaap:Depreciation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTUvZnJhZzo5NTczOWI5ZjE4OWU0YzEzOWRkZmZjZjI5YTBhN2U1Mi90YWJsZTo5MGNmYzZiNTUwYzQ0MmZkOTY5Nzc3YzEwZjAyZmZlMy90YWJsZXJhbmdlOjkwY2ZjNmI1NTBjNDQyZmQ5Njk3NzdjMTBmMDJmZmUzXzktMi0xLTEtMTA5ODc2_b8d7075a-f619-4cb5-bda4-b126117fa97b">330</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231" decimals="-3" name="us-gaap:Depreciation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTUvZnJhZzo5NTczOWI5ZjE4OWU0YzEzOWRkZmZjZjI5YTBhN2U1Mi90YWJsZTo5MGNmYzZiNTUwYzQ0MmZkOTY5Nzc3YzEwZjAyZmZlMy90YWJsZXJhbmdlOjkwY2ZjNmI1NTBjNDQyZmQ5Njk3NzdjMTBmMDJmZmUzXzktNC0xLTEtMTA5ODc2_dda88ffb-cca8-4369-820e-6c804804ffed">302</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Amortization of intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTUvZnJhZzo5NTczOWI5ZjE4OWU0YzEzOWRkZmZjZjI5YTBhN2U1Mi90YWJsZTo5MGNmYzZiNTUwYzQ0MmZkOTY5Nzc3YzEwZjAyZmZlMy90YWJsZXJhbmdlOjkwY2ZjNmI1NTBjNDQyZmQ5Njk3NzdjMTBmMDJmZmUzXzEwLTItMS0xLTEwOTg3Ng_d9eb92cb-3cc8-478b-8eb9-ff9f77d5b56e">1,017</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTUvZnJhZzo5NTczOWI5ZjE4OWU0YzEzOWRkZmZjZjI5YTBhN2U1Mi90YWJsZTo5MGNmYzZiNTUwYzQ0MmZkOTY5Nzc3YzEwZjAyZmZlMy90YWJsZXJhbmdlOjkwY2ZjNmI1NTBjNDQyZmQ5Njk3NzdjMTBmMDJmZmUzXzEwLTQtMS0xLTEwOTg3Ng_be1ab8b7-079c-41c7-aa0c-4d28fcb570ab">1,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Impairment of intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" decimals="-3" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTUvZnJhZzo5NTczOWI5ZjE4OWU0YzEzOWRkZmZjZjI5YTBhN2U1Mi90YWJsZTo5MGNmYzZiNTUwYzQ0MmZkOTY5Nzc3YzEwZjAyZmZlMy90YWJsZXJhbmdlOjkwY2ZjNmI1NTBjNDQyZmQ5Njk3NzdjMTBmMDJmZmUzXzExLTItMS0xLTEwOTg3Ng_cfb74a62-e37c-4f88-bc3e-d554adc026b6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231" decimals="-3" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTUvZnJhZzo5NTczOWI5ZjE4OWU0YzEzOWRkZmZjZjI5YTBhN2U1Mi90YWJsZTo5MGNmYzZiNTUwYzQ0MmZkOTY5Nzc3YzEwZjAyZmZlMy90YWJsZXJhbmdlOjkwY2ZjNmI1NTBjNDQyZmQ5Njk3NzdjMTBmMDJmZmUzXzExLTQtMS0xLTEwOTg3Ng_ec452f72-de08-4566-9b9b-e3ab38333eee">859</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Stock-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTUvZnJhZzo5NTczOWI5ZjE4OWU0YzEzOWRkZmZjZjI5YTBhN2U1Mi90YWJsZTo5MGNmYzZiNTUwYzQ0MmZkOTY5Nzc3YzEwZjAyZmZlMy90YWJsZXJhbmdlOjkwY2ZjNmI1NTBjNDQyZmQ5Njk3NzdjMTBmMDJmZmUzXzEyLTItMS0xLTEwOTg3Ng_ec74bd86-3d8c-45ae-80a0-a611e3a81f90">12,804</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTUvZnJhZzo5NTczOWI5ZjE4OWU0YzEzOWRkZmZjZjI5YTBhN2U1Mi90YWJsZTo5MGNmYzZiNTUwYzQ0MmZkOTY5Nzc3YzEwZjAyZmZlMy90YWJsZXJhbmdlOjkwY2ZjNmI1NTBjNDQyZmQ5Njk3NzdjMTBmMDJmZmUzXzEyLTQtMS0xLTEwOTg3Ng_af44d036-6444-4672-b62d-86454aca90b4">1,766</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Other adjustments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherNoncashIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTUvZnJhZzo5NTczOWI5ZjE4OWU0YzEzOWRkZmZjZjI5YTBhN2U1Mi90YWJsZTo5MGNmYzZiNTUwYzQ0MmZkOTY5Nzc3YzEwZjAyZmZlMy90YWJsZXJhbmdlOjkwY2ZjNmI1NTBjNDQyZmQ5Njk3NzdjMTBmMDJmZmUzXzEzLTItMS0xLTEwOTg3Ng_8c0986d4-3d6a-4c05-9cc1-cfedf5e67ea7">301</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231" decimals="-3" name="us-gaap:OtherNoncashIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTUvZnJhZzo5NTczOWI5ZjE4OWU0YzEzOWRkZmZjZjI5YTBhN2U1Mi90YWJsZTo5MGNmYzZiNTUwYzQ0MmZkOTY5Nzc3YzEwZjAyZmZlMy90YWJsZXJhbmdlOjkwY2ZjNmI1NTBjNDQyZmQ5Njk3NzdjMTBmMDJmZmUzXzEzLTQtMS0xLTEwOTg3Ng_278de36b-1e8e-4aee-9ddd-b4197ece6eda">56</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Accounts receivable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTUvZnJhZzo5NTczOWI5ZjE4OWU0YzEzOWRkZmZjZjI5YTBhN2U1Mi90YWJsZTo5MGNmYzZiNTUwYzQ0MmZkOTY5Nzc3YzEwZjAyZmZlMy90YWJsZXJhbmdlOjkwY2ZjNmI1NTBjNDQyZmQ5Njk3NzdjMTBmMDJmZmUzXzE1LTItMS0xLTEwOTg3Ng_33e1ef75-c837-4653-bebc-ff0511486cfc">1,138</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTUvZnJhZzo5NTczOWI5ZjE4OWU0YzEzOWRkZmZjZjI5YTBhN2U1Mi90YWJsZTo5MGNmYzZiNTUwYzQ0MmZkOTY5Nzc3YzEwZjAyZmZlMy90YWJsZXJhbmdlOjkwY2ZjNmI1NTBjNDQyZmQ5Njk3NzdjMTBmMDJmZmUzXzE1LTQtMS0xLTEwOTg3Ng_2ffcc590-834e-4310-b0b2-782a10b58a69">212</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Prepaid expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTUvZnJhZzo5NTczOWI5ZjE4OWU0YzEzOWRkZmZjZjI5YTBhN2U1Mi90YWJsZTo5MGNmYzZiNTUwYzQ0MmZkOTY5Nzc3YzEwZjAyZmZlMy90YWJsZXJhbmdlOjkwY2ZjNmI1NTBjNDQyZmQ5Njk3NzdjMTBmMDJmZmUzXzE2LTItMS0xLTEwOTg3Ng_17832d1b-ae0d-4162-96c8-85d03c903832">2,345</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTUvZnJhZzo5NTczOWI5ZjE4OWU0YzEzOWRkZmZjZjI5YTBhN2U1Mi90YWJsZTo5MGNmYzZiNTUwYzQ0MmZkOTY5Nzc3YzEwZjAyZmZlMy90YWJsZXJhbmdlOjkwY2ZjNmI1NTBjNDQyZmQ5Njk3NzdjMTBmMDJmZmUzXzE2LTQtMS0xLTEwOTg3Ng_bd3a4d9a-83d5-47c4-9f93-339179d2e0c9">447</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Other current and long-term assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTUvZnJhZzo5NTczOWI5ZjE4OWU0YzEzOWRkZmZjZjI5YTBhN2U1Mi90YWJsZTo5MGNmYzZiNTUwYzQ0MmZkOTY5Nzc3YzEwZjAyZmZlMy90YWJsZXJhbmdlOjkwY2ZjNmI1NTBjNDQyZmQ5Njk3NzdjMTBmMDJmZmUzXzE3LTItMS0xLTEwOTg3Ng_118666e4-5d60-4120-8f4c-710a59b8bcdd">104</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTUvZnJhZzo5NTczOWI5ZjE4OWU0YzEzOWRkZmZjZjI5YTBhN2U1Mi90YWJsZTo5MGNmYzZiNTUwYzQ0MmZkOTY5Nzc3YzEwZjAyZmZlMy90YWJsZXJhbmdlOjkwY2ZjNmI1NTBjNDQyZmQ5Njk3NzdjMTBmMDJmZmUzXzE3LTQtMS0xLTEwOTg3Ng_f8f3c2da-b520-4a7e-9179-1fb1ab21c4cf">24</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Research and development tax credit receivable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" decimals="-3" name="smmt:IncreaseDecreaseInResearchAndDevelopmentTaxCreditReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTUvZnJhZzo5NTczOWI5ZjE4OWU0YzEzOWRkZmZjZjI5YTBhN2U1Mi90YWJsZTo5MGNmYzZiNTUwYzQ0MmZkOTY5Nzc3YzEwZjAyZmZlMy90YWJsZXJhbmdlOjkwY2ZjNmI1NTBjNDQyZmQ5Njk3NzdjMTBmMDJmZmUzXzE4LTItMS0xLTEwOTg3Ng_d633c702-8f1b-4a07-8547-c39a69c46c63">6,015</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231" decimals="-3" name="smmt:IncreaseDecreaseInResearchAndDevelopmentTaxCreditReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTUvZnJhZzo5NTczOWI5ZjE4OWU0YzEzOWRkZmZjZjI5YTBhN2U1Mi90YWJsZTo5MGNmYzZiNTUwYzQ0MmZkOTY5Nzc3YzEwZjAyZmZlMy90YWJsZXJhbmdlOjkwY2ZjNmI1NTBjNDQyZmQ5Njk3NzdjMTBmMDJmZmUzXzE4LTQtMS0xLTEwOTg3Ng_402d2dcc-2e86-4cf4-827f-7fbc691c876d">4,381</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Deferred revenue and other income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTUvZnJhZzo5NTczOWI5ZjE4OWU0YzEzOWRkZmZjZjI5YTBhN2U1Mi90YWJsZTo5MGNmYzZiNTUwYzQ0MmZkOTY5Nzc3YzEwZjAyZmZlMy90YWJsZXJhbmdlOjkwY2ZjNmI1NTBjNDQyZmQ5Njk3NzdjMTBmMDJmZmUzXzE5LTItMS0xLTEwOTg3Ng_7ec6998b-4171-4651-9e6e-ad36e13c6312">813</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTUvZnJhZzo5NTczOWI5ZjE4OWU0YzEzOWRkZmZjZjI5YTBhN2U1Mi90YWJsZTo5MGNmYzZiNTUwYzQ0MmZkOTY5Nzc3YzEwZjAyZmZlMy90YWJsZXJhbmdlOjkwY2ZjNmI1NTBjNDQyZmQ5Njk3NzdjMTBmMDJmZmUzXzE5LTQtMS0xLTEwOTg3Ng_601506c0-d94e-4ebc-b485-14ee1c4e36bb">5,372</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Accounts payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTUvZnJhZzo5NTczOWI5ZjE4OWU0YzEzOWRkZmZjZjI5YTBhN2U1Mi90YWJsZTo5MGNmYzZiNTUwYzQ0MmZkOTY5Nzc3YzEwZjAyZmZlMy90YWJsZXJhbmdlOjkwY2ZjNmI1NTBjNDQyZmQ5Njk3NzdjMTBmMDJmZmUzXzIwLTItMS0xLTEwOTg3Ng_14f83613-3e10-4918-b3af-aaa805d2a38f">1,711</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTUvZnJhZzo5NTczOWI5ZjE4OWU0YzEzOWRkZmZjZjI5YTBhN2U1Mi90YWJsZTo5MGNmYzZiNTUwYzQ0MmZkOTY5Nzc3YzEwZjAyZmZlMy90YWJsZXJhbmdlOjkwY2ZjNmI1NTBjNDQyZmQ5Njk3NzdjMTBmMDJmZmUzXzIwLTQtMS0xLTEwOTg3Ng_259211ba-eb6e-4a6b-8413-ba8e04a2dd85">1,642</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Accrued liabilities and accrued compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" decimals="-3" name="smmt:IncreaseDecreaseInAccruedLiabilitiesAndEmployeeRelatedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTUvZnJhZzo5NTczOWI5ZjE4OWU0YzEzOWRkZmZjZjI5YTBhN2U1Mi90YWJsZTo5MGNmYzZiNTUwYzQ0MmZkOTY5Nzc3YzEwZjAyZmZlMy90YWJsZXJhbmdlOjkwY2ZjNmI1NTBjNDQyZmQ5Njk3NzdjMTBmMDJmZmUzXzIxLTItMS0xLTEwOTg3Ng_d45c76b5-ecbb-4e5f-b8dd-dce79ee5f188">8,229</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231" decimals="-3" sign="-" name="smmt:IncreaseDecreaseInAccruedLiabilitiesAndEmployeeRelatedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTUvZnJhZzo5NTczOWI5ZjE4OWU0YzEzOWRkZmZjZjI5YTBhN2U1Mi90YWJsZTo5MGNmYzZiNTUwYzQ0MmZkOTY5Nzc3YzEwZjAyZmZlMy90YWJsZXJhbmdlOjkwY2ZjNmI1NTBjNDQyZmQ5Njk3NzdjMTBmMDJmZmUzXzIxLTQtMS0xLTEwOTg3Ng_28055448-5ff3-47ae-a8ab-1ec723e4fa7b">1,296</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTUvZnJhZzo5NTczOWI5ZjE4OWU0YzEzOWRkZmZjZjI5YTBhN2U1Mi90YWJsZTo5MGNmYzZiNTUwYzQ0MmZkOTY5Nzc3YzEwZjAyZmZlMy90YWJsZXJhbmdlOjkwY2ZjNmI1NTBjNDQyZmQ5Njk3NzdjMTBmMDJmZmUzXzIyLTItMS0xLTEwOTg3Ng_9b3ea128-7877-4be2-b575-32f51a91a79c">1,068</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTUvZnJhZzo5NTczOWI5ZjE4OWU0YzEzOWRkZmZjZjI5YTBhN2U1Mi90YWJsZTo5MGNmYzZiNTUwYzQ0MmZkOTY5Nzc3YzEwZjAyZmZlMy90YWJsZXJhbmdlOjkwY2ZjNmI1NTBjNDQyZmQ5Njk3NzdjMTBmMDJmZmUzXzIyLTQtMS0xLTEwOTg3Ng_dbc7a4e5-ee73-44cf-b242-2ffa2415ca4c">459</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTUvZnJhZzo5NTczOWI5ZjE4OWU0YzEzOWRkZmZjZjI5YTBhN2U1Mi90YWJsZTo5MGNmYzZiNTUwYzQ0MmZkOTY5Nzc3YzEwZjAyZmZlMy90YWJsZXJhbmdlOjkwY2ZjNmI1NTBjNDQyZmQ5Njk3NzdjMTBmMDJmZmUzXzIzLTItMS0xLTEwOTg3Ng_07129531-2fe9-443f-a750-4df3af75eba3">72,587</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTUvZnJhZzo5NTczOWI5ZjE4OWU0YzEzOWRkZmZjZjI5YTBhN2U1Mi90YWJsZTo5MGNmYzZiNTUwYzQ0MmZkOTY5Nzc3YzEwZjAyZmZlMy90YWJsZXJhbmdlOjkwY2ZjNmI1NTBjNDQyZmQ5Njk3NzdjMTBmMDJmZmUzXzIzLTQtMS0xLTEwOTg3Ng_d51745d3-5316-4981-a202-17e01d296971">48,111</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows used in investing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Purchase of property and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTUvZnJhZzo5NTczOWI5ZjE4OWU0YzEzOWRkZmZjZjI5YTBhN2U1Mi90YWJsZTo5MGNmYzZiNTUwYzQ0MmZkOTY5Nzc3YzEwZjAyZmZlMy90YWJsZXJhbmdlOjkwY2ZjNmI1NTBjNDQyZmQ5Njk3NzdjMTBmMDJmZmUzXzI2LTItMS0xLTEwOTg3Ng_d5849cff-aa10-4529-8cc6-b7c59a0a7050">306</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTUvZnJhZzo5NTczOWI5ZjE4OWU0YzEzOWRkZmZjZjI5YTBhN2U1Mi90YWJsZTo5MGNmYzZiNTUwYzQ0MmZkOTY5Nzc3YzEwZjAyZmZlMy90YWJsZXJhbmdlOjkwY2ZjNmI1NTBjNDQyZmQ5Njk3NzdjMTBmMDJmZmUzXzI2LTQtMS0xLTEwOTg3Ng_f79d4767-b59e-48ae-8310-e3f11bd962cc">421</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTUvZnJhZzo5NTczOWI5ZjE4OWU0YzEzOWRkZmZjZjI5YTBhN2U1Mi90YWJsZTo5MGNmYzZiNTUwYzQ0MmZkOTY5Nzc3YzEwZjAyZmZlMy90YWJsZXJhbmdlOjkwY2ZjNmI1NTBjNDQyZmQ5Njk3NzdjMTBmMDJmZmUzXzI3LTItMS0xLTEwOTg3Ng_12dda3a3-5da8-48e8-8f8d-9b768e459479">306</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTUvZnJhZzo5NTczOWI5ZjE4OWU0YzEzOWRkZmZjZjI5YTBhN2U1Mi90YWJsZTo5MGNmYzZiNTUwYzQ0MmZkOTY5Nzc3YzEwZjAyZmZlMy90YWJsZXJhbmdlOjkwY2ZjNmI1NTBjNDQyZmQ5Njk3NzdjMTBmMDJmZmUzXzI3LTQtMS0xLTEwOTg3Ng_faacd838-c0ce-478d-b4c0-20af0de56401">421</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows provided by financing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Proceeds from the issuance of common stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTUvZnJhZzo5NTczOWI5ZjE4OWU0YzEzOWRkZmZjZjI5YTBhN2U1Mi90YWJsZTo5MGNmYzZiNTUwYzQ0MmZkOTY5Nzc3YzEwZjAyZmZlMy90YWJsZXJhbmdlOjkwY2ZjNmI1NTBjNDQyZmQ5Njk3NzdjMTBmMDJmZmUzXzMwLTItMS0xLTEwOTg3Ng_75e24988-d3dd-4749-a369-acab81cd2e6a">75,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTUvZnJhZzo5NTczOWI5ZjE4OWU0YzEzOWRkZmZjZjI5YTBhN2U1Mi90YWJsZTo5MGNmYzZiNTUwYzQ0MmZkOTY5Nzc3YzEwZjAyZmZlMy90YWJsZXJhbmdlOjkwY2ZjNmI1NTBjNDQyZmQ5Njk3NzdjMTBmMDJmZmUzXzMwLTQtMS0xLTEwOTg3Ng_44466fe7-72ce-4f86-a3f7-2c336c24cc76">50,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Transaction costs from the issuance of common stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTUvZnJhZzo5NTczOWI5ZjE4OWU0YzEzOWRkZmZjZjI5YTBhN2U1Mi90YWJsZTo5MGNmYzZiNTUwYzQ0MmZkOTY5Nzc3YzEwZjAyZmZlMy90YWJsZXJhbmdlOjkwY2ZjNmI1NTBjNDQyZmQ5Njk3NzdjMTBmMDJmZmUzXzMxLTItMS0xLTEwOTg3Ng_ab43ce45-7cc7-4f91-9645-413a6bc1797b">118</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTUvZnJhZzo5NTczOWI5ZjE4OWU0YzEzOWRkZmZjZjI5YTBhN2U1Mi90YWJsZTo5MGNmYzZiNTUwYzQ0MmZkOTY5Nzc3YzEwZjAyZmZlMy90YWJsZXJhbmdlOjkwY2ZjNmI1NTBjNDQyZmQ5Njk3NzdjMTBmMDJmZmUzXzMxLTQtMS0xLTEwOTg3Ng_84d5e1ce-1d6f-498a-bdd7-0064dabdca58">48</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Proceeds from related party promissory notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromRelatedPartyDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTUvZnJhZzo5NTczOWI5ZjE4OWU0YzEzOWRkZmZjZjI5YTBhN2U1Mi90YWJsZTo5MGNmYzZiNTUwYzQ0MmZkOTY5Nzc3YzEwZjAyZmZlMy90YWJsZXJhbmdlOjkwY2ZjNmI1NTBjNDQyZmQ5Njk3NzdjMTBmMDJmZmUzXzMyLTItMS0xLTEwOTg3Ng_248cecbf-31a5-4ee6-ba17-99eb78db4e15">110,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromRelatedPartyDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTUvZnJhZzo5NTczOWI5ZjE4OWU0YzEzOWRkZmZjZjI5YTBhN2U1Mi90YWJsZTo5MGNmYzZiNTUwYzQ0MmZkOTY5Nzc3YzEwZjAyZmZlMy90YWJsZXJhbmdlOjkwY2ZjNmI1NTBjNDQyZmQ5Njk3NzdjMTBmMDJmZmUzXzMyLTQtMS0xLTEwOTg3Ng_b9b615df-299e-431f-80f2-61e8414c1d33">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Re-payment of related party promissory notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" decimals="-3" name="us-gaap:RepaymentsOfRelatedPartyDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTUvZnJhZzo5NTczOWI5ZjE4OWU0YzEzOWRkZmZjZjI5YTBhN2U1Mi90YWJsZTo5MGNmYzZiNTUwYzQ0MmZkOTY5Nzc3YzEwZjAyZmZlMy90YWJsZXJhbmdlOjkwY2ZjNmI1NTBjNDQyZmQ5Njk3NzdjMTBmMDJmZmUzXzMzLTItMS0xLTEwOTg3Ng_8d954248-5438-4c99-a207-3b01335e3483">110,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231" decimals="-3" name="us-gaap:RepaymentsOfRelatedPartyDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTUvZnJhZzo5NTczOWI5ZjE4OWU0YzEzOWRkZmZjZjI5YTBhN2U1Mi90YWJsZTo5MGNmYzZiNTUwYzQ0MmZkOTY5Nzc3YzEwZjAyZmZlMy90YWJsZXJhbmdlOjkwY2ZjNmI1NTBjNDQyZmQ5Njk3NzdjMTBmMDJmZmUzXzMzLTQtMS0xLTEwOTg3Ng_27c29feb-c9b4-4687-9638-c50614db232d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Payments of related party promissory notes issuance costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsOfDebtIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTUvZnJhZzo5NTczOWI5ZjE4OWU0YzEzOWRkZmZjZjI5YTBhN2U1Mi90YWJsZTo5MGNmYzZiNTUwYzQ0MmZkOTY5Nzc3YzEwZjAyZmZlMy90YWJsZXJhbmdlOjkwY2ZjNmI1NTBjNDQyZmQ5Njk3NzdjMTBmMDJmZmUzXzM0LTItMS0xLTEwOTg3Ng_ecdb1f8f-06a8-49a9-b942-04461a49b8d9">54</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsOfDebtIssuanceCosts" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTUvZnJhZzo5NTczOWI5ZjE4OWU0YzEzOWRkZmZjZjI5YTBhN2U1Mi90YWJsZTo5MGNmYzZiNTUwYzQ0MmZkOTY5Nzc3YzEwZjAyZmZlMy90YWJsZXJhbmdlOjkwY2ZjNmI1NTBjNDQyZmQ5Njk3NzdjMTBmMDJmZmUzXzM0LTQtMS0xLTEwOTg3Ng_ea94c09c-c781-427c-ae00-c562785eea39">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Proceeds from exercise of share options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTUvZnJhZzo5NTczOWI5ZjE4OWU0YzEzOWRkZmZjZjI5YTBhN2U1Mi90YWJsZTo5MGNmYzZiNTUwYzQ0MmZkOTY5Nzc3YzEwZjAyZmZlMy90YWJsZXJhbmdlOjkwY2ZjNmI1NTBjNDQyZmQ5Njk3NzdjMTBmMDJmZmUzXzM1LTItMS0xLTEwOTg3Ng_cea877f1-cf41-4889-8371-dc7c681b72f4">3,088</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTUvZnJhZzo5NTczOWI5ZjE4OWU0YzEzOWRkZmZjZjI5YTBhN2U1Mi90YWJsZTo5MGNmYzZiNTUwYzQ0MmZkOTY5Nzc3YzEwZjAyZmZlMy90YWJsZXJhbmdlOjkwY2ZjNmI1NTBjNDQyZmQ5Njk3NzdjMTBmMDJmZmUzXzM1LTQtMS0xLTEwOTg3Ng_0cac9bd6-1528-4983-9ced-db2d533dfd81">599</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTUvZnJhZzo5NTczOWI5ZjE4OWU0YzEzOWRkZmZjZjI5YTBhN2U1Mi90YWJsZTo5MGNmYzZiNTUwYzQ0MmZkOTY5Nzc3YzEwZjAyZmZlMy90YWJsZXJhbmdlOjkwY2ZjNmI1NTBjNDQyZmQ5Njk3NzdjMTBmMDJmZmUzXzM2LTItMS0xLTEwOTg3Ng_d157a823-4f47-42d1-8dcb-258f6dda4213">77,916</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTUvZnJhZzo5NTczOWI5ZjE4OWU0YzEzOWRkZmZjZjI5YTBhN2U1Mi90YWJsZTo5MGNmYzZiNTUwYzQ0MmZkOTY5Nzc3YzEwZjAyZmZlMy90YWJsZXJhbmdlOjkwY2ZjNmI1NTBjNDQyZmQ5Njk3NzdjMTBmMDJmZmUzXzM2LTQtMS0xLTEwOTg3Ng_7465e840-4534-4b08-a3a8-f228e57500d9">50,551</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange rates on cash</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" decimals="-3" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTUvZnJhZzo5NTczOWI5ZjE4OWU0YzEzOWRkZmZjZjI5YTBhN2U1Mi90YWJsZTo5MGNmYzZiNTUwYzQ0MmZkOTY5Nzc3YzEwZjAyZmZlMy90YWJsZXJhbmdlOjkwY2ZjNmI1NTBjNDQyZmQ5Njk3NzdjMTBmMDJmZmUzXzM3LTItMS0xLTEwOTg3Ng_cf6dc34f-812c-472e-bc1a-c2786979a82f">351</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231" decimals="-3" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTUvZnJhZzo5NTczOWI5ZjE4OWU0YzEzOWRkZmZjZjI5YTBhN2U1Mi90YWJsZTo5MGNmYzZiNTUwYzQ0MmZkOTY5Nzc3YzEwZjAyZmZlMy90YWJsZXJhbmdlOjkwY2ZjNmI1NTBjNDQyZmQ5Njk3NzdjMTBmMDJmZmUzXzM3LTQtMS0xLTEwOTg3Ng_9a03c60e-2588-43ff-abf0-dcaf6ae2b785">556</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase in cash</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTUvZnJhZzo5NTczOWI5ZjE4OWU0YzEzOWRkZmZjZjI5YTBhN2U1Mi90YWJsZTo5MGNmYzZiNTUwYzQ0MmZkOTY5Nzc3YzEwZjAyZmZlMy90YWJsZXJhbmdlOjkwY2ZjNmI1NTBjNDQyZmQ5Njk3NzdjMTBmMDJmZmUzXzM4LTItMS0xLTEwOTg3Ng_843a7258-5a20-41c5-9a2a-60d6a2f3ed1d">5,374</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTUvZnJhZzo5NTczOWI5ZjE4OWU0YzEzOWRkZmZjZjI5YTBhN2U1Mi90YWJsZTo5MGNmYzZiNTUwYzQ0MmZkOTY5Nzc3YzEwZjAyZmZlMy90YWJsZXJhbmdlOjkwY2ZjNmI1NTBjNDQyZmQ5Njk3NzdjMTBmMDJmZmUzXzM4LTQtMS0xLTEwOTg3Ng_a40e95a3-4cae-4f80-b4ff-1a9542a921c4">2,575</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash at beginning of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7372be6dc06143b5adbb4d2e83a596c5_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTUvZnJhZzo5NTczOWI5ZjE4OWU0YzEzOWRkZmZjZjI5YTBhN2U1Mi90YWJsZTo5MGNmYzZiNTUwYzQ0MmZkOTY5Nzc3YzEwZjAyZmZlMy90YWJsZXJhbmdlOjkwY2ZjNmI1NTBjNDQyZmQ5Njk3NzdjMTBmMDJmZmUzXzM5LTItMS0xLTEwOTg3Ng_19dd9267-80e2-44f5-bebd-b1cea5d87ef4">66,417</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50b9889462124695acb12b854dfc61e9_I20191231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTUvZnJhZzo5NTczOWI5ZjE4OWU0YzEzOWRkZmZjZjI5YTBhN2U1Mi90YWJsZTo5MGNmYzZiNTUwYzQ0MmZkOTY5Nzc3YzEwZjAyZmZlMy90YWJsZXJhbmdlOjkwY2ZjNmI1NTBjNDQyZmQ5Njk3NzdjMTBmMDJmZmUzXzM5LTQtMS0xLTEwOTg3Ng_72c1bb64-e20a-48ad-9712-c79e1cacf597">63,842</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash at end of period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTUvZnJhZzo5NTczOWI5ZjE4OWU0YzEzOWRkZmZjZjI5YTBhN2U1Mi90YWJsZTo5MGNmYzZiNTUwYzQ0MmZkOTY5Nzc3YzEwZjAyZmZlMy90YWJsZXJhbmdlOjkwY2ZjNmI1NTBjNDQyZmQ5Njk3NzdjMTBmMDJmZmUzXzQwLTItMS0xLTEwOTg3Ng_70ca904f-5244-493b-ba4b-7d9e7d59f65c">71,791</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7372be6dc06143b5adbb4d2e83a596c5_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTUvZnJhZzo5NTczOWI5ZjE4OWU0YzEzOWRkZmZjZjI5YTBhN2U1Mi90YWJsZTo5MGNmYzZiNTUwYzQ0MmZkOTY5Nzc3YzEwZjAyZmZlMy90YWJsZXJhbmdlOjkwY2ZjNmI1NTBjNDQyZmQ5Njk3NzdjMTBmMDJmZmUzXzQwLTQtMS0xLTEwOTg3Ng_48fbd21b-baf0-42b8-8571-87e8be59ca91">66,417</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental Disclosure of Cash Flow Information</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for interest on related party promissory note</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" decimals="-3" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTUvZnJhZzo5NTczOWI5ZjE4OWU0YzEzOWRkZmZjZjI5YTBhN2U1Mi90YWJsZTo5MGNmYzZiNTUwYzQ0MmZkOTY5Nzc3YzEwZjAyZmZlMy90YWJsZXJhbmdlOjkwY2ZjNmI1NTBjNDQyZmQ5Njk3NzdjMTBmMDJmZmUzXzQyLTItMS0xLTEwOTg3Ng_7f1595e6-7a3b-45d4-8a5a-ec8244890f7f">85</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTUvZnJhZzo5NTczOWI5ZjE4OWU0YzEzOWRkZmZjZjI5YTBhN2U1Mi90YWJsZTo5MGNmYzZiNTUwYzQ0MmZkOTY5Nzc3YzEwZjAyZmZlMy90YWJsZXJhbmdlOjkwY2ZjNmI1NTBjNDQyZmQ5Njk3NzdjMTBmMDJmZmUzXzQyLTQtMS0xLTEwOTg3Ng_bce30055-c0f4-4c78-8031-da2b831d4308">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid (received) for income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTUvZnJhZzo5NTczOWI5ZjE4OWU0YzEzOWRkZmZjZjI5YTBhN2U1Mi90YWJsZTo5MGNmYzZiNTUwYzQ0MmZkOTY5Nzc3YzEwZjAyZmZlMy90YWJsZXJhbmdlOjkwY2ZjNmI1NTBjNDQyZmQ5Njk3NzdjMTBmMDJmZmUzXzQzLTItMS0xLTEwOTg3Ng_870e5dc1-6f3a-44c9-b5e6-380850123fdc">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeTaxesPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTUvZnJhZzo5NTczOWI5ZjE4OWU0YzEzOWRkZmZjZjI5YTBhN2U1Mi90YWJsZTo5MGNmYzZiNTUwYzQ0MmZkOTY5Nzc3YzEwZjAyZmZlMy90YWJsZXJhbmdlOjkwY2ZjNmI1NTBjNDQyZmQ5Njk3NzdjMTBmMDJmZmUzXzQzLTQtMS0xLTEwOTg3Ng_50eff367-5018-48f7-8877-538c2ab5b9cf">70</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transaction costs included in accrued expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" decimals="-3" name="smmt:StockIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTUvZnJhZzo5NTczOWI5ZjE4OWU0YzEzOWRkZmZjZjI5YTBhN2U1Mi90YWJsZTo5MGNmYzZiNTUwYzQ0MmZkOTY5Nzc3YzEwZjAyZmZlMy90YWJsZXJhbmdlOjkwY2ZjNmI1NTBjNDQyZmQ5Njk3NzdjMTBmMDJmZmUzXzQ0LTItMS0xLTEwOTg3Ng_c1e308ab-8b5c-4ab8-82de-94e14a1c5def">41</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231" decimals="-3" name="smmt:StockIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTUvZnJhZzo5NTczOWI5ZjE4OWU0YzEzOWRkZmZjZjI5YTBhN2U1Mi90YWJsZTo5MGNmYzZiNTUwYzQ0MmZkOTY5Nzc3YzEwZjAyZmZlMy90YWJsZXJhbmdlOjkwY2ZjNmI1NTBjNDQyZmQ5Njk3NzdjMTBmMDJmZmUzXzQ0LTQtMS0xLTEwOTg3Ng_2d36a595-0151-4fdd-9980-a2d6e7d1ac0e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leased assets obtained in exchange for operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTUvZnJhZzo5NTczOWI5ZjE4OWU0YzEzOWRkZmZjZjI5YTBhN2U1Mi90YWJsZTo5MGNmYzZiNTUwYzQ0MmZkOTY5Nzc3YzEwZjAyZmZlMy90YWJsZXJhbmdlOjkwY2ZjNmI1NTBjNDQyZmQ5Njk3NzdjMTBmMDJmZmUzXzQ1LTItMS0xLTEwOTg3Ng_7668c0cc-3478-4e5c-b396-c9fc793558db">3,389</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTUvZnJhZzo5NTczOWI5ZjE4OWU0YzEzOWRkZmZjZjI5YTBhN2U1Mi90YWJsZTo5MGNmYzZiNTUwYzQ0MmZkOTY5Nzc3YzEwZjAyZmZlMy90YWJsZXJhbmdlOjkwY2ZjNmI1NTBjNDQyZmQ5Njk3NzdjMTBmMDJmZmUzXzQ1LTQtMS0xLTEwOTg3Ng_618324da-bb5a-4bc0-b0ac-50c67be573d3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of the consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><div id="i2eecdebedec64091994df5b7a96baab7_118"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summit Therapeutics Inc. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements </span></div><div><span><br/></span></div><div id="i2eecdebedec64091994df5b7a96baab7_121"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1. <ix:nonNumeric contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" name="us-gaap:NatureOfOperations" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMjEvZnJhZzo2ZTZjZDQ3MTdjOWY0ZTZhOGI5Mzk2ZDNjYjgxOTM0Ni90ZXh0cmVnaW9uOjZlNmNkNDcxN2M5ZjRlNmE4YjkzOTZkM2NiODE5MzQ2XzY2Mjk_84ba96a4-d98d-4485-a053-4ff1f2c2d149" continuedAt="i8c941f361ad944c6852ae810d1c0d2b3" escape="true">Nature of Business and Operations and Recent Events</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i8c941f361ad944c6852ae810d1c0d2b3" continuedAt="i09adaac1b1444108917fad7fdfc12ffa"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Nature of Business and Operations</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company is a biopharmaceutical company focused on the discovery, development, and commercialization of patient-, physician-, caregiver- and societal-friendly medicinal therapies intended to improve quality of life, increase life expectancy, and resolve serious unmet needs. The Company's novel mechanism pipeline of product candidates is designed with the goal to become the patient-friendly, new-era standard-of-care medicines, and to work in harmony with the human microbiome. Currently, the Company's lead product candidate, ridinilazole, is a novel first-in-class drug that is engaged in a global Phase III clinical trial program. On December 20, 2021, the Company announced topline results for the Phase III Ri-CoDIFy study evaluating ridinilazole for treating patients suffering from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Clostridioides difficile </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">infection, also known as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">C. difficile </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">infection, or CDI. The Company's second product candidate, SMT-738, was announced in May 2021 for combating multidrug resistant infections, specifically Carbapenem-resistant Enterobacteriaceae (&#8220;CRE&#8221;) infections. SMT-738 is the first of a novel class of precision antibiotics that has entered into preclinical development. The Company intends to expand its portfolio by developing further new mechanism, new era product offerings that are designed to work in harmony with the human gut microbiome in the therapeutic areas of oncology and infectious diseases. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 18, 2020, Summit Therapeutics Inc. ("Summit"), a Delaware corporation, became the successor issuer to Summit Therapeutics plc, a public limited company incorporated under the laws of England and Wales with the Registrar of Companies of England and Wales, United Kingdom ("U.K."), for certain purposes under both the Securities Act of 1933, as amended, and the Securities Exchange Act of 1934, as amended, or the Exchange Act. Such succession occurred pursuant to a statutory scheme of arrangement under U.K. law pursuant to which all Summit Therapeutics plc outstanding ordinary shares were exchanged on a five-for-one basis for newly issued shares of Summit common stock and Summit became the holding company of Summit Therapeutics plc (the predecessor registrant and former holding company) and its subsidiaries (which is referred to as the "Redomiciliation Transaction"). Concurrently, Summit Therapeutics plc was converted into a private limited company under the laws of England and Wales and renamed Summit Therapeutics Limited. In addition, the warrants and stock options to purchase shares of Summit Therapeutics plc were canceled and replacement warrants and stock options to purchase common stock in Summit Therapeutics Inc. were issued. The scheme of arrangement was accounted for as an exchange of equity interests among entities under common control. All assets and liabilities of Summit Therapeutics plc were assumed by Summit, resulting in the retention of the historical basis of accounting as if they had always been combined for accounting purposes and the historical consolidated financial statements of Summit Therapeutics plc became the historical consolidated financial statements of Summit Therapeutics Inc. All share and per share data for periods prior to the Redomiciliation Transaction in the financial statements were retroactively reflected to be presented as shares of the Company's common stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231" decimals="2" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMjEvZnJhZzo2ZTZjZDQ3MTdjOWY0ZTZhOGI5Mzk2ZDNjYjgxOTM0Ni90ZXh0cmVnaW9uOjZlNmNkNDcxN2M5ZjRlNmE4YjkzOTZkM2NiODE5MzQ2XzM0MTY_52a38653-2c20-4ee8-80f9-ba6681bde813">0.01</ix:nonFraction> per share.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Recent Events</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 12, 2021, the Company closed its rights offering, which was fully subscribed. The Company received aggregate gross proceeds from the rights offering of $<ix:nonFraction unitRef="usd" contextRef="idb475943c8884e52b4a61d6e77d4d205_D20210512-20210512" decimals="-3" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMjEvZnJhZzo2ZTZjZDQ3MTdjOWY0ZTZhOGI5Mzk2ZDNjYjgxOTM0Ni90ZXh0cmVnaW9uOjZlNmNkNDcxN2M5ZjRlNmE4YjkzOTZkM2NiODE5MzQ2XzM2MDU_21b2490e-4593-4c9e-a054-0e2ce6249258">75,000</ix:nonFraction> from the sale of&#8239;<ix:nonFraction unitRef="shares" contextRef="idb475943c8884e52b4a61d6e77d4d205_D20210512-20210512" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMjEvZnJhZzo2ZTZjZDQ3MTdjOWY0ZTZhOGI5Mzk2ZDNjYjgxOTM0Ni90ZXh0cmVnaW9uOjZlNmNkNDcxN2M5ZjRlNmE4YjkzOTZkM2NiODE5MzQ2XzM2MjU_40b162d0-4b67-4140-8246-5c95c6ef6159">14,312,976</ix:nonFraction>&#8239;shares of its common stock at a price per share of $<ix:nonFraction unitRef="usdPerShare" contextRef="i28fe3cc419e94f789497abebbcb3acff_I20210512" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMjEvZnJhZzo2ZTZjZDQ3MTdjOWY0ZTZhOGI5Mzk2ZDNjYjgxOTM0Ni90ZXh0cmVnaW9uOjZlNmNkNDcxN2M5ZjRlNmE4YjkzOTZkM2NiODE5MzQ2XzM2Nzk_0ab45cce-777b-40f1-baf0-b2de03f6bdc0">5.24</ix:nonFraction>. Issuance costs associated with the rights offering were immaterial. In connection with the closing of the rights offering, a promissory note, dated April 20, 2021, was issued by the Company in favor of the Company's Chairman, Chief Executive Officer, and the beneficial owner of approximately <ix:nonFraction unitRef="number" contextRef="i9e4481b351c140ec829740b8f3c87fca_I20210511" decimals="2" name="smmt:RelatedPartyTransactionBeneficialOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMjEvZnJhZzo2ZTZjZDQ3MTdjOWY0ZTZhOGI5Mzk2ZDNjYjgxOTM0Ni90ZXh0cmVnaW9uOjZlNmNkNDcxN2M5ZjRlNmE4YjkzOTZkM2NiODE5MzQ2XzM5NzY_b7dc3a82-2292-4416-a463-77f364e614f8">70</ix:nonFraction>% of its outstanding common stock prior to this rights offering, Robert W. Duggan, in the principal amount of $<ix:nonFraction unitRef="usd" contextRef="i9d8f0174c08f45cab10ea87b88a0b06d_I20210420" decimals="-3" name="us-gaap:NotesPayableRelatedPartiesCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMjEvZnJhZzo2ZTZjZDQ3MTdjOWY0ZTZhOGI5Mzk2ZDNjYjgxOTM0Ni90ZXh0cmVnaW9uOjZlNmNkNDcxN2M5ZjRlNmE4YjkzOTZkM2NiODE5MzQ2XzQwODc_cd062013-e3ae-4b41-83a9-cc20f9f28bca">55,000</ix:nonFraction>,&#8239;matured and became due and the Company repaid all principal and accrued interest thereunder using a portion of the proceeds from the rights offering. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 11, 2021, based on a thorough review of the design and enrollment status of its two ongoing blinded Phase III Ri-CoDIFy trials, the Company announced that it combined its two blinded pivotal Phase III clinical trials evaluating ridinilazole versus vancomycin into a single study and presented this decision to the United States ("U.S.") Food and Drug Administration (the "FDA") as such. During September 2021, the Company received feedback from the FDA that the FDA did not agree with the change to the primary endpoint that the Company proposed and subsequently implemented in its ongoing Phase III Ri-CoDIFy studies when combining the trials.  </span></div></ix:continuation><div><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summit Therapeutics Inc. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div></div><ix:continuation id="i09adaac1b1444108917fad7fdfc12ffa"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 20, 2021, the Company announced topline results for the Phase III Ri-CoDIFy study evaluating ridinilazole, for the treatment of and Sustained Clinical Response (&#8220;SCR&#8221;), as defined below, for patients suffering from&#8239;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">C. difficile</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8239;infection ("</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">C. diff.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8239;infection" or "CDI"). The study showed that ridinilazole resulted in a numerically higher SCR rate than vancomycin, but did not meet the study&#8217;s primary endpoint for superiority. The pivotal Phase III clinical trial consisted of two Phase III clinical trials combined into a single study, designed to assess, as the primary endpoint, the superiority of ridinilazole compared to vancomycin in SCR, which is defined as clinical response of the treated episode of CDI and no recurrence of CDI through 30 days after the end of treatment. Additional endpoints included safety, tolerability, analyses of the gut microbiome and metabolome, in addition to quality of life and health economic outcome measures. We are in the process of evaluating the future path forward with respect to ridinilazole, including potential partnership opportunities.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 10, 2022, the Company&#8217;s Chief Executive Officer, Robert W. Duggan, entered into a Note Purchase Agreement (the &#8220;2022 Note&#8221;), pursuant to which he has loaned the Company $<ix:nonFraction unitRef="usd" contextRef="idf7a081c7b9c4705a95c5f2ab53d19bb_D20220310-20220310" decimals="-3" name="us-gaap:ProceedsFromRelatedPartyDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMjEvZnJhZzo2ZTZjZDQ3MTdjOWY0ZTZhOGI5Mzk2ZDNjYjgxOTM0Ni90ZXh0cmVnaW9uOjZlNmNkNDcxN2M5ZjRlNmE4YjkzOTZkM2NiODE5MzQ2XzYxODA_69138b23-a984-44ed-9f22-fd824b580d4b">25,000</ix:nonFraction> in exchange for the issuance by the Company of an unsecured promissory note in the amount of $<ix:nonFraction unitRef="usd" contextRef="id74d06c0cec74c7fa7641c591943da88_I20220310" decimals="-3" name="us-gaap:NotesPayableRelatedPartiesCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMjEvZnJhZzo2ZTZjZDQ3MTdjOWY0ZTZhOGI5Mzk2ZDNjYjgxOTM0Ni90ZXh0cmVnaW9uOjZlNmNkNDcxN2M5ZjRlNmE4YjkzOTZkM2NiODE5MzQ2XzYyNzY_8d5360bb-1df5-46b7-85b8-71efccc7c96f">25,000</ix:nonFraction>. The 2022 Note is to accrue interest at a rate per annum equal to the prime rate as reported in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Wall Street Journal</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which is <ix:nonFraction unitRef="number" contextRef="idf7a081c7b9c4705a95c5f2ab53d19bb_D20220310-20220310" decimals="INF" name="us-gaap:RelatedPartyTransactionRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMjEvZnJhZzo2ZTZjZDQ3MTdjOWY0ZTZhOGI5Mzk2ZDNjYjgxOTM0Ni90ZXh0cmVnaW9uOjZlNmNkNDcxN2M5ZjRlNmE4YjkzOTZkM2NiODE5MzQ2XzY0MDk_2d605ab6-a553-4e44-8921-654e4bceff98">3.25</ix:nonFraction>% as of the effective date. The 2022 Note becomes due upon the earlier of (i) the consummation of a registered public offering with net proceeds of no less than $<ix:nonFraction unitRef="usd" contextRef="idf7a081c7b9c4705a95c5f2ab53d19bb_D20220310-20220310" decimals="-3" name="smmt:NotesPayableRelatedPartiesMaturityTriggeringEventPublicOfferingProceedsThreshold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMjEvZnJhZzo2ZTZjZDQ3MTdjOWY0ZTZhOGI5Mzk2ZDNjYjgxOTM0Ni90ZXh0cmVnaW9uOjZlNmNkNDcxN2M5ZjRlNmE4YjkzOTZkM2NiODE5MzQ2XzY1NzE_9c9d674c-41f3-44fd-b07b-fa148e8b1101">25,000</ix:nonFraction> or (ii) <ix:nonNumeric contextRef="idf7a081c7b9c4705a95c5f2ab53d19bb_D20220310-20220310" name="smmt:NotesPayableRelatedPartiesMaximumTerm" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMjEvZnJhZzo2ZTZjZDQ3MTdjOWY0ZTZhOGI5Mzk2ZDNjYjgxOTM0Ni90ZXh0cmVnaW9uOjZlNmNkNDcxN2M5ZjRlNmE4YjkzOTZkM2NiODE5MzQ2XzY1ODI_65a644fe-f3b7-4ee6-9ad6-9675b5620b7a">18</ix:nonNumeric> months from the date of issuance of the 2022 Note.</span></div></ix:continuation><div><span><br/></span></div><div><span><br/></span></div><div id="i2eecdebedec64091994df5b7a96baab7_127"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2. <ix:nonNumeric contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" name="us-gaap:BasisOfAccounting" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMjcvZnJhZzpjY2ZhZTllM2U4YWE0YmQ4YTM1NTg2ODc4MmU3NDc5MS90ZXh0cmVnaW9uOmNjZmFlOWUzZThhYTRiZDhhMzU1ODY4NzgyZTc0NzkxXzE5NzM_085ad767-c2ad-4dba-b1e1-b2d010b4401d" continuedAt="id10071b17cfc430aa57e4ce750f1b1e4" escape="true">Basis of Presentation and Use of Estimates </ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="id10071b17cfc430aa57e4ce750f1b1e4"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMjcvZnJhZzpjY2ZhZTllM2U4YWE0YmQ4YTM1NTg2ODc4MmU3NDc5MS90ZXh0cmVnaW9uOmNjZmFlOWUzZThhYTRiZDhhMzU1ODY4NzgyZTc0NzkxXzE5NzQ_e27502bd-b6ad-4c3a-a7eb-c0545d829087" continuedAt="i72802ea1cc884a9d98f91b4f49a2d4f6" escape="true">The consolidated financial statements include the accounts of Summit Therapeutics Inc. and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.</ix:nonNumeric></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i72802ea1cc884a9d98f91b4f49a2d4f6">The consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States ("U.S. GAAP") and pursuant to the rules and regulations of the U.S. Securities and Exchange Commission.</ix:continuation> <ix:nonNumeric contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMjcvZnJhZzpjY2ZhZTllM2U4YWE0YmQ4YTM1NTg2ODc4MmU3NDc5MS90ZXh0cmVnaW9uOmNjZmFlOWUzZThhYTRiZDhhMzU1ODY4NzgyZTc0NzkxXzE5NzU_83217f43-11fb-4ffd-8d8e-8f727d773307" continuedAt="ia505bba658684e88a9ae6d9fa5362282" escape="true">The preparation of these financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. On an on-going basis, management evaluates its estimates and judgments, including those related to revenue recognition, accrued research and development expenses, stock-based compensation, intangible assets, goodwill, other long-lived assets and income taxes. Management bases its estimates and judgments on historical experience and on various other factors that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.</ix:nonNumeric></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The progression of the COVID-19 pandemic continues to evolve and its enduring impact on the Company's business remains uncertain. Management believes the estimates and assumptions underlying its financial statements are reasonable and supportable based on the information available as of December 31, 2021, however, the extent to which the COVID-19 pandemic impacts the Company's financial results beyond December 31, 2021 will depend on future developments that are highly uncertain and cannot be predicted at this time.</span></div></ix:continuation><div><span><br/></span></div><div id="i2eecdebedec64091994df5b7a96baab7_130"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. <ix:nonNumeric contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" name="smmt:LiquidityAndCapitalResourcesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMzAvZnJhZzo3YzQxNzNjZTE2NjI0YzlhOTQwMzc1NmU5NzUwZGYxZS90ZXh0cmVnaW9uOjdjNDE3M2NlMTY2MjRjOWE5NDAzNzU2ZTk3NTBkZjFlXzIxMzM_2fa0c652-5801-4674-a185-ed826b3029f3" continuedAt="i2d503b3b9788410fb3ce75d29e489b22" escape="true">Liquidity and Capital Resources</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i2d503b3b9788410fb3ce75d29e489b22" continuedAt="ib93f60820254401b99bcf6fb137ca7fb"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2021, the Company incurred a net loss of $<ix:nonFraction unitRef="usd" contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMzAvZnJhZzo3YzQxNzNjZTE2NjI0YzlhOTQwMzc1NmU5NzUwZGYxZS90ZXh0cmVnaW9uOjdjNDE3M2NlMTY2MjRjOWE5NDAzNzU2ZTk3NTBkZjFlXzc0_88817334-2a0a-4d14-8d95-01f45f5f32ac">88,602</ix:nonFraction> and cash flows used in operating activities was $<ix:nonFraction unitRef="usd" contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMzAvZnJhZzo3YzQxNzNjZTE2NjI0YzlhOTQwMzc1NmU5NzUwZGYxZS90ZXh0cmVnaW9uOjdjNDE3M2NlMTY2MjRjOWE5NDAzNzU2ZTk3NTBkZjFlXzEyNQ_d9cbbf0c-8109-435d-8583-f5d178f3bb39">72,587</ix:nonFraction>. As of December 31, 2021, the Company had an accumulated deficit of $<ix:nonFraction unitRef="usd" contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMzAvZnJhZzo3YzQxNzNjZTE2NjI0YzlhOTQwMzc1NmU5NzUwZGYxZS90ZXh0cmVnaW9uOjdjNDE3M2NlMTY2MjRjOWE5NDAzNzU2ZTk3NTBkZjFlXzE5Ng_f73ae28a-8f82-41fe-bce9-96e342bd3f65">299,548</ix:nonFraction>, cash of $<ix:nonFraction unitRef="usd" contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231" decimals="-3" name="us-gaap:Cash" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMzAvZnJhZzo3YzQxNzNjZTE2NjI0YzlhOTQwMzc1NmU5NzUwZGYxZS90ZXh0cmVnaW9uOjdjNDE3M2NlMTY2MjRjOWE5NDAzNzU2ZTk3NTBkZjFlXzIwOA_938f73fe-cc51-4467-b71f-865f0646e134">71,791</ix:nonFraction>, research and development tax credit receivable of $<ix:nonFraction unitRef="usd" contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231" decimals="-3" name="smmt:ResearchAndDevelopmentTaxCreditReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMzAvZnJhZzo3YzQxNzNjZTE2NjI0YzlhOTQwMzc1NmU5NzUwZGYxZS90ZXh0cmVnaW9uOjdjNDE3M2NlMTY2MjRjOWE5NDAzNzU2ZTk3NTBkZjFlXzI2Mg_49dd8d0d-b1e2-4e59-88a4-a9daf39356f2">15,695</ix:nonFraction> and accounts receivable of $<ix:nonFraction unitRef="usd" contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMzAvZnJhZzo3YzQxNzNjZTE2NjI0YzlhOTQwMzc1NmU5NzUwZGYxZS90ZXh0cmVnaW9uOjdjNDE3M2NlMTY2MjRjOWE5NDAzNzU2ZTk3NTBkZjFlXzI5Mg_f05d968b-a341-4acb-9e1d-b7c3441f5a7d">1,464</ix:nonFraction>. The Company expects to continue to generate operating losses for the foreseeable future. Until the Company can generate substantial revenue and achieve profitability, the Company will need to raise additional capital to fund its ongoing operations and capital needs.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the Company's current funding arrangements and financial resources as of December 31, 2021, and after considering proceeds received of $<ix:nonFraction unitRef="usd" contextRef="idf7a081c7b9c4705a95c5f2ab53d19bb_D20220310-20220310" decimals="-3" name="us-gaap:ProceedsFromRelatedPartyDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMzAvZnJhZzo3YzQxNzNjZTE2NjI0YzlhOTQwMzc1NmU5NzUwZGYxZS90ZXh0cmVnaW9uOjdjNDE3M2NlMTY2MjRjOWE5NDAzNzU2ZTk3NTBkZjFlXzcwNw_e99bb308-06bb-46ed-bdfa-baa9fb15ba75">25,000</ix:nonFraction> from the 2022 Note issued on March 10, 2022, the Company has the ability to fund its operating costs and working capital needs for more than twelve months from the date of issuance. In order to continue to fund the operations of the Company beyond this time period, management has developed plans, which primarily consist of raising additional capital through some combination of equity or debt financings, and/or potentially entering into new collaborations. There is no assurance, however, that additional financing will be available when needed or that management of the Company will be able to obtain financing on terms acceptable to the Company. If the Company is unable to obtain funding when required </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summit Therapeutics Inc. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div></div><ix:continuation id="ib93f60820254401b99bcf6fb137ca7fb"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the future, the Company could be required to delay, reduce, or eliminate research and development programs, product portfolio expansion, or future commercialization efforts, which could adversely affect its business prospects.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements are prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of the business. The consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classifications of liabilities that might result from the outcome of this uncertainty.</span></div></ix:continuation><div id="i2eecdebedec64091994df5b7a96baab7_133"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMzMvZnJhZzpiZjJiYmY2YmZlMGU0MzY4YjE5YjYxN2ExNDJjYTNmMi90ZXh0cmVnaW9uOmJmMmJiZjZiZmUwZTQzNjhiMTliNjE3YTE0MmNhM2YyXzM2MTY2_95019874-889b-4d86-97a6-feee28d1bbaa" continuedAt="i983384cb10664676ae9a641d5f06f1d0" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i983384cb10664676ae9a641d5f06f1d0" continuedAt="i19f57f2310b24f47ad093fbacf7c5c4d"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The significant accounting policies adopted by the Company in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMzMvZnJhZzpiZjJiYmY2YmZlMGU0MzY4YjE5YjYxN2ExNDJjYTNmMi90ZXh0cmVnaW9uOmJmMmJiZjZiZmUwZTQzNjhiMTliNjE3YTE0MmNhM2YyXzM2MTg0_6faf412c-6639-4412-9e9c-178c963f8a4b" continuedAt="i2a5e2ca918724510839e4dd38cf27c6d" escape="true">Principles of Consolidation </ix:nonNumeric></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i2a5e2ca918724510839e4dd38cf27c6d">The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) and pursuant to the rules and regulations of the U.S. Securities and Exchange Commission. The consolidated financial statements include the accounts of Summit Therapeutics Inc. and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.</ix:continuation> </span></div><div><span><br/></span></div><ix:continuation id="ia505bba658684e88a9ae6d9fa5362282"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires the use of estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</span></div></ix:continuation><div><span><br/></span></div><ix:nonNumeric contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMzMvZnJhZzpiZjJiYmY2YmZlMGU0MzY4YjE5YjYxN2ExNDJjYTNmMi90ZXh0cmVnaW9uOmJmMmJiZjZiZmUwZTQzNjhiMTliNjE3YTE0MmNhM2YyXzM2MTYy_c8362a5e-6e84-4873-94a2-73d69413ded0" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Foreign Currency Translation</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The financial statements of the Company&#8217;s subsidiaries with functional currencies other than the U.S. dollar are translated into U.S. dollars using period-end exchange rates for assets and liabilities, historical exchange rates for stockholders&#8217; equity and weighted average exchange rates for operating results. Translation gains and losses are included in accumulated other comprehensive (loss) income in shareholders&#8217; equity. Foreign currency transaction gains and losses are included in other (expense) income, net in the results of operations. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company recorded realized and unrealized foreign currency transaction (losses) gains of $(<ix:nonFraction unitRef="usd" contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMzMvZnJhZzpiZjJiYmY2YmZlMGU0MzY4YjE5YjYxN2ExNDJjYTNmMi90ZXh0cmVnaW9uOmJmMmJiZjZiZmUwZTQzNjhiMTliNjE3YTE0MmNhM2YyXzE3OTI_8b6063c6-c37c-40a1-8547-c2ea3121c5da">2,135</ix:nonFraction>) and $<ix:nonFraction unitRef="usd" contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231" decimals="-3" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMzMvZnJhZzpiZjJiYmY2YmZlMGU0MzY4YjE5YjYxN2ExNDJjYTNmMi90ZXh0cmVnaW9uOmJmMmJiZjZiZmUwZTQzNjhiMTliNjE3YTE0MmNhM2YyXzE3OTk_25987653-a9aa-460e-9c3b-ea982305372c">54</ix:nonFraction> for the years ended December 31, 2021 and 2020, respectively, which is included in other (expense) income in the statements of operations and comprehensive loss.</span></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMzMvZnJhZzpiZjJiYmY2YmZlMGU0MzY4YjE5YjYxN2ExNDJjYTNmMi90ZXh0cmVnaW9uOmJmMmJiZjZiZmUwZTQzNjhiMTliNjE3YTE0MmNhM2YyXzM2MTcw_88e22b51-892f-48a1-90a6-4bf11e86e6a2" continuedAt="i485373a3a68441f7a1600ba9e1e79d01" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:103%">Revenue Recognition </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for revenue using Accounting Standards Codification ("ASC") 606 ("ASC 606"). This standard applies to all contracts with customers, except for contracts that are within the scope of other standards.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company enters into out-licensing agreements within the scope of ASC 606 under which it licenses certain rights to its product candidates to third parties. Such agreements may include the transfer of intellectual property rights in the form of licenses, transfer of technological know-how, delivery of drug substances, research and development services, and participation on certain committees with the counterparty. Payments made by the customers may include one or more of the following: non-refundable, up-front license fees; development, regulatory, and commercial milestone payments; payments for manufacturing supply services the Company provides through its contract manufacturers; and royalties on net sales of licensed products if they are successfully approved and commercialized. Each of these payments may result in license, collaboration, or other revenue, except revenue from royalties on net sales of licensed products, which would be classified as royalty revenue.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining the appropriate amount of revenue to be recognized as the Company fulfills its obligations under each of its out-licensing agreements, the following steps are performed: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) </span></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summit Therapeutics Inc. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div></div><ix:continuation id="i19f57f2310b24f47ad093fbacf7c5c4d" continuedAt="i454938a569bd496b8893df4263cc5a62"><ix:continuation id="i485373a3a68441f7a1600ba9e1e79d01" continuedAt="i287560208a3443e988588a854f2c4c94"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations and assesses whether each promised good or service is distinct. Revenue is then recognized in respect of the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. As part of the accounting for these arrangements, the Company must use significant judgment to determine: (a) the performance obligations based on the determination under step (ii) above; (b) the transaction price under step (iii) above; and (c) the standalone selling price for each performance obligation identified in the contract for the allocation of transaction price in step (iv) above. The Company also uses judgment to determine whether milestone payments or other variable consideration, except for royalties and sales-based milestones, should be included in the transaction price, as described below. The transaction price is allocated to each performance obligation based on the relative standalone selling price of each performance obligation in the contract, and the Company recognizes revenue based on those amounts when, or as, the performance obligations under the contract are satisfied.</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Exclusive Licenses</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the license to the Company&#8217;s intellectual property is determined to be distinct from the other promises or performance obligations identified in the arrangement, the Company recognizes revenue from nonrefundable, upfront fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. In assessing whether a promise or performance obligation is distinct from the other promises, the Company considers factors such as the research, development, manufacturing and commercialization capabilities of the collaboration partner and the availability of the associated expertise in the general marketplace. In addition, the Company considers whether the collaboration partner can benefit from a promise for its intended purpose without the receipt of the remaining promises, whether the value of the promise is dependent on the unsatisfied promises, whether there are other vendors that could provide the remaining promises, and whether it is separately identifiable from the remaining promises. For licenses that are combined with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of progress and related revenue recognition. The measure of progress, and the resulting periods over which revenue should be recognized, are subject to estimates by management and may change over the course of the research, development and licensing arrangement. Such a change could have a material impact on the amount of revenue the Company records in future periods. Under the Company&#8217;s existing license and collaboration agreements, the Company has concluded that the transfer of control to the customer occurs over the time period that the research and development services are to be provided by the Company, and this output method is, in management&#8217;s judgment, the best measure of progress towards satisfying the performance obligation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Milestone Payments</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of each arrangement that includes potential research, development or regulatory milestone payments, the Company evaluates whether the milestones are considered likely to be met and estimates the amount to be considered for inclusion in the transaction price using the most-likely-amount method. If it is probable that a significant reversal in the amount of cumulative revenue recognized would not occur, the associated milestone payment value is included in the transaction price. For milestone payments due upon events that are not within the control of the Company or the licensee, such as regulatory approvals, the Company is not able to assert that it is likely that the regulatory approval will be granted and that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur until those approvals are received. In making this assessment, the Company evaluates factors such as the scientific, clinical, regulatory, commercial and other risks that must be overcome to achieve the particular milestone. There is considerable judgment involved in determining whether it is probable that a significant reversal in the amount of cumulative revenue recognized would not occur. At the end of each subsequent reporting period, the Company reevaluates the probability of achievement of all milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price of the arrangement. Any such adjustments are recorded on a cumulative catch-up basis, which would affect the amounts of revenue and earnings in the period of adjustment.</span></div><div><span><br/></span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalties</span></div></ix:continuation></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summit Therapeutics Inc. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div></div><ix:continuation id="i454938a569bd496b8893df4263cc5a62" continuedAt="ic2072c2604954a87ac1be016472bbd2a"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i287560208a3443e988588a854f2c4c94">For arrangements that include sales-based royalties, including milestone payments due upon first commercial sales or based on a level of sales, that are the result of a customer-vendor relationship and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) the occurrence of the related sales or (ii) the date upon which the performance obligation to which some or all of the royalty has been allocated has been satisfied or partially satisfied. To date, the Company has not recognized any royalty revenue from any of its licensing arrangements.</ix:continuation></span></div><div><span><br/></span></div><ix:nonNumeric contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" name="smmt:OtherOperatingIncomePolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMzMvZnJhZzpiZjJiYmY2YmZlMGU0MzY4YjE5YjYxN2ExNDJjYTNmMi90ZXh0cmVnaW9uOmJmMmJiZjZiZmUwZTQzNjhiMTliNjE3YTE0MmNhM2YyXzM2MTc3_ab6ca3d6-b7a6-437a-9540-2a369b20101f" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Operating Income</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company generates income from government contracts that reimburse the Company for certain allowable costs for funded projects. For contracts with government agencies where the funding arrangement is considered central to the Company&#8217;s ongoing operations, the Company classifies the recognized funding received as other operating income.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income from government grants is recognized as the qualifying expenses related to the contracts are incurred, provided that there is reasonable assurance of recoverability. If the government agency approves the project proposed by the Company, the government agency funds the project upon receipt of the support for the costs incurred up to the contract limit. Income recognized upon incurring qualifying expenses in advance of billing is recorded as accrued income, a component of other current assets, in the consolidated balance sheet.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Grant income is not recognized as deductions of research and development costs because the Company acts as the principal in conducting the research and development activities and these contracts are central to its ongoing operations. The funds received through these means are held as deferred income in the consolidated balance sheets and are released to the consolidated statement of operations and comprehensive loss as the underlying expenditure is incurred and to the extent the conditions of the grant are met. The related costs incurred by the Company are included in research and development expense in the Company&#8217;s consolidated statements of operations and comprehensive loss.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company benefits from two U.K. research and development ("R&amp;D") tax credit cash rebate regimes: Small and Medium Enterprise ("SME") Program and the Research and Development Expenditure Credit ("RDEC") Program. Each reporting period, management evaluates which tax relief programs the Company is expected to be eligible for and records as other operating income the portion of the expense that it expects to qualify under the programs, that it plans to submit a claim for, and it has reasonable assurance that the amount will ultimately be realized. Based on criteria established by HM Revenue and Customs (&#8220;HMRC&#8221;), management of the Company expects a proportion of expenditures being undertaken in relation to its pipeline research, clinical trials management and manufacturing development activities to be eligible for the research and development tax relief programs for the year ended December 31, 2021. Qualifying expenditures largely comprise of employment costs for research staff, consumables, a proportion of relevant, permitted sub-contract costs and certain internal overhead costs incurred as part of research projects for which the Company does not receive commercial or other funding income. Credits related to the SME and RDEC Programs are recorded as other operating income in the consolidated statements of operations and other comprehensive (loss)/income. Under both schemes, the Company receives cash rebate payments of up to <ix:nonFraction unitRef="number" contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" decimals="3" name="smmt:ResearchAndDevelopmentTaxCreditCashRebateMaximumPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMzMvZnJhZzpiZjJiYmY2YmZlMGU0MzY4YjE5YjYxN2ExNDJjYTNmMi90ZXh0cmVnaW9uOmJmMmJiZjZiZmUwZTQzNjhiMTliNjE3YTE0MmNhM2YyXzEyODU1_de3f0be9-693f-4e62-bee9-aa2de8f469b0">33.3</ix:nonFraction>% of eligible research and development expenditures and these payments are not dependent on the Company&#8217;s pre-tax net income levels. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company has qualified under the more favorable SME regime for the year ended December 31, 2020 and expects to qualify under the SME regime for the year ending December 31, 2021.</span></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMzMvZnJhZzpiZjJiYmY2YmZlMGU0MzY4YjE5YjYxN2ExNDJjYTNmMi90ZXh0cmVnaW9uOmJmMmJiZjZiZmUwZTQzNjhiMTliNjE3YTE0MmNhM2YyXzM2MTc4_6243f654-30a9-488c-998b-94f8262814d1" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Net Income Per Share</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Basic net loss per share is computed by dividing the net loss by the weighted-average number of common shares outstanding for the period. Diluted net loss per share is computed by dividing the diluted net loss by the weighted-average number of common shares outstanding for the period, including potentially dilutive common shares. The dilutive effect of share options and warrants are determined under the treasury stock method using the average market price for the period.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, the assumed proceeds under the treasury stock method include the average unrecognized compensation expense of stock options and warrants that are in-the-money.</span></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" name="us-gaap:BusinessCombinationsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMzMvZnJhZzpiZjJiYmY2YmZlMGU0MzY4YjE5YjYxN2ExNDJjYTNmMi90ZXh0cmVnaW9uOmJmMmJiZjZiZmUwZTQzNjhiMTliNjE3YTE0MmNhM2YyXzM2MTY3_62e61449-1972-4108-83dd-150ddc1e6293" continuedAt="ic6cf32d6a5ad48ef8d2eade913c6c61c" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Business Combinations </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Business combinations are accounted for under the acquisition method. Acquired assets and assumed liabilities are measured at their fair values at the acquisition date. The excess of the consideration transferred over the net fair value of assets acquired and liabilities assumed is recorded as goodwill. The accounting for an acquisition involves a considerable amount of judgement and estimation. Cost, income, market or a combination of approaches may be used to establish the fair value of consideration exchanged, assets acquired, and liabilities assumed, depending on the nature of those items.  The valuation approach is </span></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summit Therapeutics Inc. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div></div><ix:continuation id="ic2072c2604954a87ac1be016472bbd2a" continuedAt="i3271226721c74ade8fe0325597561ade"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ic6cf32d6a5ad48ef8d2eade913c6c61c" continuedAt="ibf0cba6c06a943fa9c0e7642ec24dd59">determined in accordance with generally accepted valuation methods. Key areas of estimation and judgment may include the selection of valuation approaches, cost of capital, market characteristics, cost structure, impacts of synergies, and estimates of terminal value, among other factors.</ix:continuation></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ibf0cba6c06a943fa9c0e7642ec24dd59">While the Company uses estimates and assumptions as part of the purchase price allocation process to estimate the value of assets acquired and liabilities assumed, estimates are inherently uncertain and subject to refinement. During the measurement period, which maybe up to one year from the acquisition date, the Company may record adjustments to the assets acquired and liabilities assumed, with a corresponding offset to goodwill, to the extent that adjustments are identified to the preliminary purchase price allocation. Upon conclusion of the measurement period, or final determination of the value of the assets acquired and liabilities assumed, whichever comes first, any subsequent adjustments are recorded to results of operations. Results of operations related to business combinations are included prospectively beginning with the date of acquisition and transaction costs related to business combinations are recorded within general and administrative expenses.</ix:continuation> </span></div><div><span><br/></span></div><ix:nonNumeric contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" name="us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMzMvZnJhZzpiZjJiYmY2YmZlMGU0MzY4YjE5YjYxN2ExNDJjYTNmMi90ZXh0cmVnaW9uOmJmMmJiZjZiZmUwZTQzNjhiMTliNjE3YTE0MmNhM2YyXzM2MTc5_80b2fc78-0736-410f-b4fb-72147d6601ef" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:102%">Goodwill</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill represents the excess of the consideration transferred over the fair value of net assets acquired. Goodwill is assigned to reporting units at the time of acquisition or when there is a change in the reporting structure and bases that allocation on which reporting units will benefit from the acquired assets and liabilities. Reporting units are defined as operating segments or one level below an operating segment, referred to as a component. The Company assesses goodwill for impairment on an annual basis or more frequently when events and circumstances occur indicating that the recorded goodwill may be impaired.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In performing the Company&#8217;s annual goodwill impairment test, the Company is permitted to first assess qualitative factors to determine whether it is more likely than not that the fair value of the Company&#8217;s reporting unit is less than its carrying amount, including goodwill. In performing the qualitative assessment, the Company considers certain events and circumstances specific to the reporting unit and to the entity as a whole, such as macroeconomic conditions, industry and market considerations, overall financial performance and cost factors when evaluating whether it is more likely than not that the fair value of the reporting unit is less than its carrying amount. The Company is also permitted to bypass the qualitative assessment and proceed directly to the quantitative test. If the Company chooses to undertake the qualitative assessment and concludes that it is more likely than not that the fair value of the reporting unit is less than its carrying amount, the Company would then proceed to the quantitative impairment test. In the quantitative assessment, the Company compares the fair value of the reporting unit to its carrying amount, which includes goodwill. If the fair value exceeds the carrying value, no impairment loss exists. If the fair value is less than the carrying amount, a goodwill impairment loss is measured and recorded.</span></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, the Company performed its annual impairment assessment of goodwill by performing a qualitative analysis for its single identified reporting unit for goodwill and determined that it is more likely than not that the fair value of the reporting unit exceeded its carrying amount. </span></div><div><span><br/></span></div><ix:nonNumeric contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" name="us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMzMvZnJhZzpiZjJiYmY2YmZlMGU0MzY4YjE5YjYxN2ExNDJjYTNmMi90ZXh0cmVnaW9uOmJmMmJiZjZiZmUwZTQzNjhiMTliNjE3YTE0MmNhM2YyXzM2MTcx_a0eee61b-bb03-4d28-8ab0-917e01c98178" continuedAt="i077dbb750d834d47b6d7906e5e3ca590" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Intangible Assets </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets include patents, licenses, an option over non-financial assets and a research and development discovery platform ("Discuva Platform").</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Patents, licenses, and the option over non-financial assets are initially recorded at fair value, assigned an estimated useful life, and amortized primarily on a straight-line basis over their estimated useful lives. The Company evaluates the recoverability of its intangible and long-lived assets whenever events and changes in circumstances indicate that the carrying amount of an asset may not be fully recoverable. If events and circumstances indicate that the carrying amount may not fully be recoverable, the Company will perform a qualitative assessment, and consider certain events and circumstances specific to the intangible asset and to the entity as a whole, such as macroeconomic conditions, industry and market considerations, overall financial performance and cost factors when evaluating whether it is more likely than not that the fair value of the intangible asset is less than its carrying amount. This periodic review may result in an adjustment of estimated depreciable lives or asset impairment. When indicators of impairment are present, the carrying values of the asset are evaluated in relation to their operating performance and future undiscounted cash flows of the underlying business. If the future undiscounted cash flows are less than their carrying value, impairment exists. The impairment is measured as the difference between the carrying value and the fair </span></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summit Therapeutics Inc. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div></div><ix:continuation id="i3271226721c74ade8fe0325597561ade" continuedAt="if77add5ef5b74981aa92e65f4756e353"><ix:continuation id="i077dbb750d834d47b6d7906e5e3ca590"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">value of the underlying asset. Fair values are based on estimates of market prices and assumptions concerning the amount and timing of estimated future cash flows and assumed discount rates, reflecting varying degrees of perceived risk.</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMzMvZnJhZzpiZjJiYmY2YmZlMGU0MzY4YjE5YjYxN2ExNDJjYTNmMi90ZXh0cmVnaW9uOmJmMmJiZjZiZmUwZTQzNjhiMTliNjE3YTE0MmNhM2YyXzM2MTcy_4f4e53ab-d9ac-482e-a57b-47729a7c94be" continuedAt="i7a52c0c9485e43a881f53ca92bb0b37e" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other intangible assets are amortized in equal installments over their estimated useful lives as follows: </span></div><div style="margin-bottom:9pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.057%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.455%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:55.188%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intangible Asset</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortization Period</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Option over non-financial assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Over the period of the relevant agreement</span></td></tr></table></div></ix:nonNumeric><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of intangible assets is included as part of the research and development expense line shown on the face of the consolidated statement of operations and comprehensive loss.</span></div></ix:continuation><div><span><br/></span></div><div><span><br/></span></div><ix:nonNumeric contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMzMvZnJhZzpiZjJiYmY2YmZlMGU0MzY4YjE5YjYxN2ExNDJjYTNmMi90ZXh0cmVnaW9uOmJmMmJiZjZiZmUwZTQzNjhiMTliNjE3YTE0MmNhM2YyXzM2MTcz_3caaa74e-7c14-47b1-a791-840ec4254fc0" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Property and Equipment </span></div><div style="margin-bottom:9pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are stated at cost less accumulated depreciation. Cost comprises the purchase price plus any incidental costs of acquisition and commissioning. </span></div><ix:nonNumeric contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMzMvZnJhZzpiZjJiYmY2YmZlMGU0MzY4YjE5YjYxN2ExNDJjYTNmMi90ZXh0cmVnaW9uOmJmMmJiZjZiZmUwZTQzNjhiMTliNjE3YTE0MmNhM2YyXzM2MTc0_357ea5d7-f85c-4abe-adff-7d67efb48b8b" continuedAt="ifaefce4b05034c5792df085947e97a3c" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation is calculated based on cost, less residual value, in equal annual installments over the estimated useful lives of the assets. The residual value, if not insignificant, is reassessed annually.</span></div><div style="margin-bottom:9pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.057%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:60.743%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Over the shorter of the asset's useful life or the remaining lease term</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if7798276e33b48af81058807002f7542_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMzMvZnJhZzpiZjJiYmY2YmZlMGU0MzY4YjE5YjYxN2ExNDJjYTNmMi90YWJsZTozNTJkODI1NTVlNDk0Y2YxYWExMGQ4ODk4MzdlNGJhMC90YWJsZXJhbmdlOjM1MmQ4MjU1NWU0OTRjZjFhYTEwZDg4OTgzN2U0YmEwXzEtMS0xLTEtMTA5ODc2L3RleHRyZWdpb246NDRmM2NiMTUyMDBhNGU2MjkyYWM5NzJmZDI4MDM1NGRfNA_f3ccf320-8a7f-435c-93d4-631d47dad96a">2</ix:nonNumeric>-<ix:nonNumeric contextRef="ib9e53bf038884fe1aebddae6ccd2c196_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMzMvZnJhZzpiZjJiYmY2YmZlMGU0MzY4YjE5YjYxN2ExNDJjYTNmMi90YWJsZTozNTJkODI1NTVlNDk0Y2YxYWExMGQ4ODk4MzdlNGJhMC90YWJsZXJhbmdlOjM1MmQ4MjU1NWU0OTRjZjFhYTEwZDg4OTgzN2U0YmEwXzEtMS0xLTEtMTA5ODc2L3RleHRyZWdpb246NDRmM2NiMTUyMDBhNGU2MjkyYWM5NzJmZDI4MDM1NGRfNw_8572383f-1cbf-443e-bac4-e062b4f92a22">10</ix:nonNumeric> years </span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office and IT equipment</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i942ccb9196bb4d0ab10e4c87af4250a2_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMzMvZnJhZzpiZjJiYmY2YmZlMGU0MzY4YjE5YjYxN2ExNDJjYTNmMi90YWJsZTozNTJkODI1NTVlNDk0Y2YxYWExMGQ4ODk4MzdlNGJhMC90YWJsZXJhbmdlOjM1MmQ4MjU1NWU0OTRjZjFhYTEwZDg4OTgzN2U0YmEwXzItMS0xLTEtMTA5ODc2L3RleHRyZWdpb246NWU5NWJkMTk3NDFlNDU5MGJiZjgyMWU4OGQwYTYzYzRfNA_088fc7c1-0d79-4966-9fa4-170a58a8978c">3</ix:nonNumeric>-<ix:nonNumeric contextRef="ia8b911ed586c4e1bbdda461a2557aff7_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMzMvZnJhZzpiZjJiYmY2YmZlMGU0MzY4YjE5YjYxN2ExNDJjYTNmMi90YWJsZTozNTJkODI1NTVlNDk0Y2YxYWExMGQ4ODk4MzdlNGJhMC90YWJsZXJhbmdlOjM1MmQ4MjU1NWU0OTRjZjFhYTEwZDg4OTgzN2U0YmEwXzItMS0xLTEtMTA5ODc2L3RleHRyZWdpb246NWU5NWJkMTk3NDFlNDU5MGJiZjgyMWU4OGQwYTYzYzRfNw_aacc7882-1794-41dc-90c0-c0a50bc6e135">5</ix:nonNumeric> years</span></div></td></tr></table></div></ix:nonNumeric><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation is recognized as part of the general and administrative and research and development expense lines shown on the face of the consolidated statement of operations and comprehensive loss depending on the nature of the underlying assets.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expenditures for repairs and maintenance are expensed as incurred. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation are removed from the accounts and any resulting gain or loss is included in loss from operations.</span></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" name="us-gaap:LesseeLeasesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMzMvZnJhZzpiZjJiYmY2YmZlMGU0MzY4YjE5YjYxN2ExNDJjYTNmMi90ZXh0cmVnaW9uOmJmMmJiZjZiZmUwZTQzNjhiMTliNjE3YTE0MmNhM2YyXzM2MTgx_d8f51c2b-5dd9-48c0-9c7b-b648de7582b0" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Leases</span></div><div><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has operating leases for real estate. The Company does not have any finance leases. Under Accounting Standards Codification 842, a contract is or contains a lease when the lessee has the right to control the use of an identified asset. The Company determines if an arrangement is a lease at inception of the contract, which is the date on which the terms of the contract are agreed to and the agreement creates enforceable rights and obligations. The lease term used to calculate the lease liability include options to extend or terminate the lease when it is reasonably certain that the option will be exercised.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the lease commencement date, the Company measures and recognizes a lease liability and a right-of-use asset in the financial statements. Lease liabilities are recognized based on the present value of the future lease payments over the lease term at commencement date. The right-of use asset is measured by taking the present value of future lease payments, plus any incremental direct costs incurred, less any lease incentives received. As most of the Company's leases do not provide an implicit rate, the Company uses an estimated incremental borrowing rate based on the lease term and the economic environment of the lease at the lease commencement date, which is then utilized to determine the present value of future lease payments. Lease expense for minimum lease payments are recognized on a straight-line basis over the lease term, with variable lease payments recognized in the periods in which they are incurred.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has existing lease agreements with lease and non-lease components, has elected to account for the lease and non-lease components as a single lease component, and has allocated all of the contract consideration to the lease component only. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leases with an initial lease term of 12 months or less are not recorded on the balance sheet. The Company recognizes lease expense for its short-term leases on a straight-line basis over the lease term.</span></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div style="margin-bottom:9pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summit Therapeutics Inc. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div></div><ix:continuation id="if77add5ef5b74981aa92e65f4756e353" continuedAt="i0f5560b2a3aa4f59bbd3632430a2fc52"><ix:nonNumeric contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMzMvZnJhZzpiZjJiYmY2YmZlMGU0MzY4YjE5YjYxN2ExNDJjYTNmMi90ZXh0cmVnaW9uOmJmMmJiZjZiZmUwZTQzNjhiMTliNjE3YTE0MmNhM2YyXzM2MTgy_d7eb361f-c197-41ef-8101-e1b8ab951178" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development Costs</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed as incurred. Research and development expenses consist of costs incurred to discover, research and develop product candidates, including personnel expenses, stock-based compensation expense, allocated facility-related and depreciation expenses, third-party license fees and external costs of outside vendors engaged to conduct preclinical and clinical development activities and clinical trials as well as to manufacture clinical trial materials. Non - refundable prepayments for goods or services that will be used or rendered for future research and development activities are recorded as prepaid expenses. Such amounts are recognized as an expense as the goods are delivered or the related services are performed, or until it is no longer expected that the goods will be delivered, or the services rendered. Milestone and other payments made to third-parties with respect to in-process research and development, in accordance with the Company&#8217;s license, acquisition and other similar agreements are expensed when determined to be probable and estimable.</span></div><div><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into various research and development contracts with other companies. These agreements are generally cancellable, and related payments are recorded as research and development expenses as incurred. The Company records accruals for estimated ongoing research and development costs or prepaid expenses where the payments made exceeds the estimated costs. When evaluating the adequacy of these balances, the Company analyzes progress of the studies, including the estimated costs to complete each study or activity, the estimation of the current stage of completion and the invoices received, as well as predetermined milestones which are not reflective of the current stage of development for prepaid expenses. Actual results could differ from the Company&#8217;s estimates. In all cases, the full cost of each study or activity is expensed by the time the final report or where applicable, product, has been received. The Company&#8217;s historical estimates have not been materially different from the actual costs.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMzMvZnJhZzpiZjJiYmY2YmZlMGU0MzY4YjE5YjYxN2ExNDJjYTNmMi90ZXh0cmVnaW9uOmJmMmJiZjZiZmUwZTQzNjhiMTliNjE3YTE0MmNhM2YyXzM2MTU5_1056f479-64e2-4605-95e1-ef02a9220015" continuedAt="idd4a86b32cda447d929b1828f99ad2d7" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock-Based Compensation </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures and recognizes compensation expense for all stock option and restricted stock unit awards based on the estimated fair value of the award on the grant date. The Company uses the Black-Scholes option pricing model to estimate the fair value of stock option awards. The fair value is recognized as expense, over the requisite service period, which is generally the vesting period of the respective award, on a straight-line basis for each separately vesting portion of the award when the only condition to vesting is continued service.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If vesting is subject to a market or performance condition, recognition is based on the derived service period of the award. Expense for awards with performance conditions is estimated and adjusted on a quarterly basis based upon the assessment of the probability that the performance condition will be met. Use of the Black-Scholes option-pricing model requires management to apply judgment under highly subjective assumptions.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These assumptions include:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Expected term&#8212;The expected term of stock options represents the weighted-average period the stock options are expected to be outstanding. The Company uses the simplified method for estimating the expected term as provided by the Securities and Exchange Commission. The simplified method calculates the expected term as the average of the time-to-vesting and the contractual life of the options.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Expected volatility&#8212;The expected volatility was calculated based on historical volatility of the Company's share price.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Risk-free interest rate&#8212;The risk-free rate assumption is based on the U.S. Treasury instruments, the terms of which were consistent with the expected term of the Company&#8217;s stock options.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Expected dividend&#8212;The expected dividend assumption is based on the Company&#8217;s history and expectation of dividend payouts. The Company has not paid and does not intend to pay dividends. </span></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="idd4a86b32cda447d929b1828f99ad2d7">The Company estimates expected forfeitures at the time of grant instead of accounting for forfeitures as they occur. Stock option and restricted stock unit awards have been granted at fair value to non-employees, in connection with research and consulting services provided to the Company, to non-employees in connection with corporate activities, and to employees, in connection with Stock Purchase and Restriction Agreements. Equity awards generally vest over terms of <ix:nonNumeric contextRef="i593cfc00ba154e79a513606849b36e61_D20210101-20211231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMzMvZnJhZzpiZjJiYmY2YmZlMGU0MzY4YjE5YjYxN2ExNDJjYTNmMi90ZXh0cmVnaW9uOmJmMmJiZjZiZmUwZTQzNjhiMTliNjE3YTE0MmNhM2YyXzI3NjYx_2165f72f-5840-49d6-afb8-a1d14972d6f7">3</ix:nonNumeric> or <ix:nonNumeric contextRef="if0549c486ffc4be2b6a75373c950243b_D20210101-20211231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMzMvZnJhZzpiZjJiYmY2YmZlMGU0MzY4YjE5YjYxN2ExNDJjYTNmMi90ZXh0cmVnaW9uOmJmMmJiZjZiZmUwZTQzNjhiMTliNjE3YTE0MmNhM2YyXzI3NjY3_cf8f38cc-3749-4c02-a869-890f098e8e91">4</ix:nonNumeric> years.</ix:continuation> </span></div></ix:continuation><div><span><br/></span></div><div style="margin-bottom:9pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summit Therapeutics Inc. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div></div><ix:continuation id="i0f5560b2a3aa4f59bbd3632430a2fc52" continuedAt="i5ced57758c4045238922ec6772c19966"><ix:nonNumeric contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" name="us-gaap:IncomeTaxPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMzMvZnJhZzpiZjJiYmY2YmZlMGU0MzY4YjE5YjYxN2ExNDJjYTNmMi90ZXh0cmVnaW9uOmJmMmJiZjZiZmUwZTQzNjhiMTliNjE3YTE0MmNhM2YyXzM2MTUy_9fb1299b-2ef3-4164-a447-57dd97395905" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes is determined using the asset and liability approach. Tax laws may require items to be included in tax filings at different times than the items are reflected in the financial statements. A current asset or liability is recognized for the estimated taxes receivable or payable for the current year. Deferred taxes represent the future tax consequences expected to occur when the reported amounts of assets and liabilities are recovered or paid. Deferred taxes are initially recognized at enacted tax rates in force at the time of initial recognition and are subsequently adjusted for any enacted changes in tax rates and tax laws. Subsequent changes to deferred taxes originally recognized in equity are recognized in income. Valuation allowances are recorded to reduce deferred tax assets when it is more likely than not that a tax benefit will not be realized. The Company has recorded a full valuation allowance against the deferred tax assets in excess of its deferred tax liabilities, as the deferred tax liability represents future reversals of existing taxable temporary differences. The Company records interest and penalties related to income tax matters as part of income tax expense.</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" name="us-gaap:ConcentrationRiskCreditRisk" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMzMvZnJhZzpiZjJiYmY2YmZlMGU0MzY4YjE5YjYxN2ExNDJjYTNmMi90ZXh0cmVnaW9uOmJmMmJiZjZiZmUwZTQzNjhiMTliNjE3YTE0MmNhM2YyXzM2MTg2_e5e2bc7a-9f2d-4a89-a8ac-7b6178b49f9e" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentration of Credit Risk and of Significant Supplier</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of short-term cash deposits and accounts and other receivables. The Company's cash is comprised of short-term cash deposits at a variety of financial institutions with strong credit ratings in amounts that may exceed federally insured limits and has not experienced any losses on such accounts. Cash balances maintained during the year have been principally held with reputable U.K.-based and U.S.-based banks. The Company does not believe it is exposed to any unusual credit risk beyond the normal credit risk associated with commercial banking relationships.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains deposits in accredited financial institutions in excess of federally insured limits. The Company deposits its cash in financial institutions that it believes have high credit quality and has not experienced any losses on such accounts and does not believe it is exposed to any unusual credit risk beyond the normal credit risk associated with commercial banking relationships.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The credit risk with respect to customers and funding bodies is limited as the Company has only a small number of these arrangements, including with Eurofarma, BARDA and CARB-X. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company relies, and expects to continue to rely, on a number of vendors to conduct its clinical trials and preclinical studies, manufacture drug product and supply clinical trial and preclinical study materials for its development programs. These programs could be adversely affected by a significant interruption in these services or the availability of materials.</span></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMzMvZnJhZzpiZjJiYmY2YmZlMGU0MzY4YjE5YjYxN2ExNDJjYTNmMi90ZXh0cmVnaW9uOmJmMmJiZjZiZmUwZTQzNjhiMTliNjE3YTE0MmNhM2YyXzM2MTY4_21c1a242-f097-4be6-8c03-a4aa9069772c" continuedAt="ib79f66b51d8b4a548a8719d3917194ba" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:103%">Fair Value Measurements</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with the provisions of fair value accounting, a fair value measurement assumes that the transaction to sell an asset or transfer a liability occurs in the principal market for the asset or liability or, in the absence of a principal market, the most advantageous market for the asset or liability and defines fair value based on the exit price model.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value measurement guidance establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The guidance describes three levels of inputs that may be used to measure fair value:</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 1</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Quoted prices in active markets for identical assets or liabilities as of the reporting date. Active markets are those in which transactions for the asset or liability occur in sufficient frequency and volume to provide pricing information on an ongoing basis.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 2</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 2 assets and liabilities include debt securities with quoted prices that are traded less </span></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summit Therapeutics Inc. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div></div><ix:continuation id="i5ced57758c4045238922ec6772c19966" continuedAt="ie903427e97bf48f08f28ad1711454983"><ix:continuation id="ib79f66b51d8b4a548a8719d3917194ba"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">frequently than exchange-traded instruments or securities or derivative contracts that are valued using a pricing model with inputs that are observable in the market or can be derived principally from or corroborated by observable market data.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 3</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Level 3 assets and liabilities include financial instruments whose value is determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant management judgment or estimation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, the Company categorizes such assets and liabilities based on the lowest level input that is significant to the fair value measurement in its entirety. The Company&#8217;s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the asset.</span></div></ix:continuation><div><span><br/></span></div><ix:nonNumeric contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" name="smmt:AssumedContingentLiabilitiesPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMzMvZnJhZzpiZjJiYmY2YmZlMGU0MzY4YjE5YjYxN2ExNDJjYTNmMi90ZXh0cmVnaW9uOmJmMmJiZjZiZmUwZTQzNjhiMTliNjE3YTE0MmNhM2YyXzM2MTUz_289d354c-b633-4bf3-859a-628a596a6d45" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Assumed Contingent Liabilities</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the acquisition of Discuva Limited in December 2017, the Company assumed certain contingent liabilities as certain employees, former employees and former directors of Discuva Limited are eligible for payments from Discuva Limited based on specified development and clinical milestones related to proprietary product candidates developed under the Discuva Platform. The timing of these potential payments is uncertain. The fair value of the assumed contingent liability was estimated using the expected value of the payments. The assumed contingent liabilities are subsequently measured at amortized cost using discounted cash flow models which calculate the risk adjusted net present values of estimated potential future cash flows of the payments. The assumed contingent liabilities are remeasured when there is a specific significant event that provides evidence of a significant change in the probability of successful development and clinical milestones being achieved. The models will be updated for changes in the probability of successful development and clinical milestones being achieved and other associated assumptions with the discount factor remaining unchanged within the model. A discount factor of <ix:nonFraction unitRef="number" contextRef="i32242c0ff70343c9adfcc11c6595a70f_I20211231" decimals="2" name="smmt:BusinessCombinationAssumedContingentLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMzMvZnJhZzpiZjJiYmY2YmZlMGU0MzY4YjE5YjYxN2ExNDJjYTNmMi90ZXh0cmVnaW9uOmJmMmJiZjZiZmUwZTQzNjhiMTliNjE3YTE0MmNhM2YyXzM0MzUz_6ebe878f-10c0-4901-af2e-03f1e5f97045">13</ix:nonFraction>% has been used to discount the contingent liabilities back to net present value. This discount factor has been calculated using appropriate measures and rates which could have been obtained in the period that the contingent liabilities were assumed. Accretion of the discount factor is recognized as part of operating expenses in the consolidated statements of operations and comprehensive loss.</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" name="smmt:WarrantsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMzMvZnJhZzpiZjJiYmY2YmZlMGU0MzY4YjE5YjYxN2ExNDJjYTNmMi90ZXh0cmVnaW9uOmJmMmJiZjZiZmUwZTQzNjhiMTliNjE3YTE0MmNhM2YyXzM2MTY1_18890b22-9e06-4745-b281-38cc1f6aa4ea" continuedAt="ic075d99519d14f9388da34c5bb0459c0" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Warrants</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrants issued by the Company are recognized and classified as equity when, upon exercise, the Company would issue a fixed amount of its own equity instruments (common stock) in exchange for a fixed amount of cash or another financial asset.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consideration received, net of incremental costs directly attributable to the issue of such new warrants, is shown in equity. Such warrants are not remeasured at fair value in subsequent reporting periods.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrants issued in which external services are received as consideration for equity instruments of the company should be measured at the fair value of the goods or services received. Only if the fair value of the services cannot be measured reliably would the fair value of the equity instruments granted be used. The fair value for the warrants is calculated using the Black-Scholes formula and recorded in the consolidated statement of operations and comprehensive loss</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on a straight-line basis over the period of the consulting services. If the services are terminated prior to the end of the consultancy agreement, the warrants cease vesting and any unvested portion of the warrants will lapse immediately.</span></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ie903427e97bf48f08f28ad1711454983"><ix:continuation id="ic075d99519d14f9388da34c5bb0459c0">The warrants in issue are classified within stockholders&#8217; equity as they are indexed to the Company's own shares of common stock and require settlement in its shares of common stocks with no provision for any cash settlement.</ix:continuation></ix:continuation> </span></div><div><span><br/></span></div><div style="margin-bottom:9pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summit Therapeutics Inc. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div></div><div style="margin-bottom:9pt"><span><br/></span></div><div id="i2eecdebedec64091994df5b7a96baab7_136"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" name="us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMzYvZnJhZzpiYmFlYzkxMGE1OWU0MzZhYjRiOWFlM2Y3Yjg1YjQzMS90ZXh0cmVnaW9uOmJiYWVjOTEwYTU5ZTQzNmFiNGI5YWUzZjdiODViNDMxXzM4MjQ_18a7157d-a1a4-4577-bed9-f6cccb6ba026" continuedAt="i2e5d60fcb9fb406698f158c71937ccc9" escape="true"><ix:nonNumeric contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMzYvZnJhZzpiYmFlYzkxMGE1OWU0MzZhYjRiOWFlM2Y3Yjg1YjQzMS90ZXh0cmVnaW9uOmJiYWVjOTEwYTU5ZTQzNmFiNGI5YWUzZjdiODViNDMxXzM4MjQ_b911246c-cfd7-4859-8cde-d843b89f8f9f" continuedAt="ib477af67b68e444f8412bb7e0386aafe" escape="true">Recently Issued or Adopted Accounting Pronouncements </ix:nonNumeric></ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i2e5d60fcb9fb406698f158c71937ccc9"><ix:continuation id="ib477af67b68e444f8412bb7e0386aafe"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2021-10, " Government Assistance (Topic 832)." This ASU increases the transparency of government assistance including the disclosure of (1) the types of assistance, (2) an entity's accounting for the assistance, and (3) the effect of the assistance on an entity's financial statements as diversity currently exists in the recognition, measurement, presentation and disclosure of government assistance received by business entities because of the lack of specific authoritative guidance in U.S. GAAP. This ASU is effective for annual periods, and interim periods within those fiscal years, beginning after December 15, 2021. Early application of this ASU is permitted. The Company applied the amendments of this ASU to its disclosures during the fourth quarter of 2021 and the application of this ASU did not have a material impact on its financial position, results of operations or cash flows.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, the FASB issued ASU No. 2021-08, "Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers." This ASU improves the accounting for acquired revenue contracts with customers in a business combination by addressing diversity in practice and inconsistency relating to: 1) recognition of an acquired contract liability and 2) payment terms and their effect on subsequent revenue recognized by the acquirer. The amendments in this ASU require acquiring entities to apply Topic 606 to recognize and measure contract assets and contract liabilities in a business combination, whereas current U.S. GAAP requires that the acquirer measure such assets and liabilities at fair value on the acquisition date. This ASU is effective for annual periods, and interim periods within those fiscal years, beginning after December 15, 2022. The Company will apply this ASU on a prospective basis for business combinations once this ASU is effective and at that time, will be able to determine the potential impact on its financial position, results of operations or cash flows.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, the FASB issued AS No. 2021-04, "Earnings Per Share (Topic 260), Debt - Modifications and Extinguishments (Subtopic 470-50), Compensation - Stock Compensation (Topic 718), and Derivatives and Hedging Contracts in Entity's Own Equity (Subtopic 815-40) - Issuer's Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options." This ASU provides clarification and reduces diversity in an issuer&#8217;s accounting for modifications or exchanges of freestanding equity-classified written call options (such as warrants) that remain equity classified after modification or exchange. This ASU is effective for annual periods, and interim periods within those fiscal years, beginning after December 15, 2021. The Company will apply this ASU on a prospective basis for any modifications or exchanges once this ASU is effective and at that time, will be able to determine the potential impact on its financial position, results of operations or cash flows.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU No. 2019-12, "Income Taxes (Topic 740)." This ASU simplifies the accounting for income taxes by removing certain exceptions to the general principles in Topic 740. The amendments also improve consistent application and simplify U.S. GAAP for other areas of Topic 740 by clarifying and amending existing guidance. This ASU is effective for annual periods, and interim periods within those fiscal years, beginning after December 15, 2020. The Company adopted this ASU during the first quarter of 2021 and the adoption of this ASU did not have a material impact on its financial position, results of operations or cash flows.</span></div></ix:continuation></ix:continuation><div><span><br/></span></div><div id="i2eecdebedec64091994df5b7a96baab7_139"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" name="us-gaap:SegmentReportingDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMzkvZnJhZzoyMDEzMmFlNjNjMzU0YTBmYjAzOWU4NTU2M2Q0NzkxZS90ZXh0cmVnaW9uOjIwMTMyYWU2M2MzNTRhMGZiMDM5ZTg1NTYzZDQ3OTFlXzEzNTc_bc53e38d-95f9-464c-8b6d-da8863d31767" continuedAt="if99dbe7fed8f4b1db01a10a8d0fe015f" escape="true">Segment Reporting </ix:nonNumeric></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="if99dbe7fed8f4b1db01a10a8d0fe015f" continuedAt="if5bd7fad48724dce8c68d16d771f4e7e">The Company's chief operating decision makers (the "CODM function"), which are the Company's Chief Executive Officer and Chief Operating Officer, utilize consolidated financial information to make decisions about allocating resources and assessing performance for the entire Company. The CODM function approves of key operating and strategic decisions, including key decisions in clinical development and clinical operating activities, entering into significant contracts, such as revenue contracts and collaboration agreements and approves the Company's consolidated operating budget. The CODM function views the Company's operations and manages its business as a single reportable operating segment. The Company's single operating segment covers the Company&#8217;s research and development activities, primarily comprising the CDI program and antibiotic pipeline research activities. As the Company operates in <ix:nonFraction unitRef="segment" contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMzkvZnJhZzoyMDEzMmFlNjNjMzU0YTBmYjAzOWU4NTU2M2Q0NzkxZS90ZXh0cmVnaW9uOjIwMTMyYWU2M2MzNTRhMGZiMDM5ZTg1NTYzZDQ3OTFlXzkyMg_1d1e2133-2dab-412d-bab5-e94f4dbae9aa">one</ix:nonFraction> operating segment, all required financial segment information can be found in the consolidated financial statements.</ix:continuation></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summit Therapeutics Inc. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div></div><ix:continuation id="if5bd7fad48724dce8c68d16d771f4e7e"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates in <ix:nonFraction unitRef="country" contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231" decimals="INF" name="us-gaap:NumberOfCountriesInWhichEntityOperates" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMzkvZnJhZzoyMDEzMmFlNjNjMzU0YTBmYjAzOWU4NTU2M2Q0NzkxZS90ZXh0cmVnaW9uOjIwMTMyYWU2M2MzNTRhMGZiMDM5ZTg1NTYzZDQ3OTFlXzEwNjg_dffffd85-20fe-4f27-8590-9570b1d6c626">two</ix:nonFraction> geographic regions: the U.K. and the U.S. <ix:nonNumeric contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" name="us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMzkvZnJhZzoyMDEzMmFlNjNjMzU0YTBmYjAzOWU4NTU2M2Q0NzkxZS90ZXh0cmVnaW9uOjIwMTMyYWU2M2MzNTRhMGZiMDM5ZTg1NTYzZDQ3OTFlXzEzNTY_3c170fd5-cb25-465c-a915-f690ff40d9bf" continuedAt="i3cb6e777c95845d49595ccd87b810d98" escape="true">The following table summarizes the Company's long-lived assets, which include the Company's property and equipment, net and right-of-use assets by geography: </ix:nonNumeric></span></div><div><span><br/></span></div><div><ix:continuation id="i3cb6e777c95845d49595ccd87b810d98"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.467%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i435477ccebf0489e8e94db10eb60db56_I20211231" decimals="-3" name="us-gaap:NoncurrentAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMzkvZnJhZzoyMDEzMmFlNjNjMzU0YTBmYjAzOWU4NTU2M2Q0NzkxZS90YWJsZToxNDkyNWRiNzdlNjA0NzhiYWFlNWZjMWQ5OTZhYjc4Ni90YWJsZXJhbmdlOjE0OTI1ZGI3N2U2MDQ3OGJhYWU1ZmMxZDk5NmFiNzg2XzEtMi0xLTEtMTA5ODc2_4ae45559-f76d-49d1-91dc-5825ff36a1b8">2,762</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if02b5108070a44ba843c22e648997315_I20201231" decimals="-3" name="us-gaap:NoncurrentAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMzkvZnJhZzoyMDEzMmFlNjNjMzU0YTBmYjAzOWU4NTU2M2Q0NzkxZS90YWJsZToxNDkyNWRiNzdlNjA0NzhiYWFlNWZjMWQ5OTZhYjc4Ni90YWJsZXJhbmdlOjE0OTI1ZGI3N2U2MDQ3OGJhYWU1ZmMxZDk5NmFiNzg2XzEtNC0xLTEtMTA5ODc2_24aa7f83-b936-4169-b0f9-d9b6596b7ab5">1,228</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d900fb56eda43068b75b033c9bfc547_I20211231" decimals="-3" name="us-gaap:NoncurrentAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMzkvZnJhZzoyMDEzMmFlNjNjMzU0YTBmYjAzOWU4NTU2M2Q0NzkxZS90YWJsZToxNDkyNWRiNzdlNjA0NzhiYWFlNWZjMWQ5OTZhYjc4Ni90YWJsZXJhbmdlOjE0OTI1ZGI3N2U2MDQ3OGJhYWU1ZmMxZDk5NmFiNzg2XzItMi0xLTEtMTA5ODc2_2bd5c0e7-ddd4-466a-bcd4-c655f32bb678">722</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71dfd1e7be4e496b90e176a973683625_I20201231" decimals="-3" name="us-gaap:NoncurrentAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMzkvZnJhZzoyMDEzMmFlNjNjMzU0YTBmYjAzOWU4NTU2M2Q0NzkxZS90YWJsZToxNDkyNWRiNzdlNjA0NzhiYWFlNWZjMWQ5OTZhYjc4Ni90YWJsZXJhbmdlOjE0OTI1ZGI3N2U2MDQ3OGJhYWU1ZmMxZDk5NmFiNzg2XzItNC0xLTEtMTA5ODc2_6c4420e4-31b6-4e03-b40d-77f92f5f59cb">51</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231" decimals="-3" name="us-gaap:NoncurrentAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMzkvZnJhZzoyMDEzMmFlNjNjMzU0YTBmYjAzOWU4NTU2M2Q0NzkxZS90YWJsZToxNDkyNWRiNzdlNjA0NzhiYWFlNWZjMWQ5OTZhYjc4Ni90YWJsZXJhbmdlOjE0OTI1ZGI3N2U2MDQ3OGJhYWU1ZmMxZDk5NmFiNzg2XzMtMi0xLTEtMTA5ODc2_7dd0b59b-27eb-4b26-81e6-e5218d515446">3,484</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7372be6dc06143b5adbb4d2e83a596c5_I20201231" decimals="-3" name="us-gaap:NoncurrentAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMzkvZnJhZzoyMDEzMmFlNjNjMzU0YTBmYjAzOWU4NTU2M2Q0NzkxZS90YWJsZToxNDkyNWRiNzdlNjA0NzhiYWFlNWZjMWQ5OTZhYjc4Ni90YWJsZXJhbmdlOjE0OTI1ZGI3N2U2MDQ3OGJhYWU1ZmMxZDk5NmFiNzg2XzMtNC0xLTEtMTA5ODc2_e487c324-9d09-4e87-9967-13870c65f497">1,279</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></ix:continuation></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For details of revenue from external customers by geography refer to Note 7.</span></div></ix:continuation><div><span><br/></span></div><div><span><br/></span></div><div id="i2eecdebedec64091994df5b7a96baab7_142"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNDIvZnJhZzphMjRjNmNhMGI0NDc0YWQ0YTZkNjYyNTU4ODdkY2M1MS90ZXh0cmVnaW9uOmEyNGM2Y2EwYjQ0NzRhZDRhNmQ2NjI1NTg4N2RjYzUxXzQzMDc_77334486-479c-48fd-8fbb-572d23ed79ff" continuedAt="i84025b32eb3d488b82c5a934fd3f62f5" escape="true">Revenue </ix:nonNumeric></span></div><ix:continuation id="i84025b32eb3d488b82c5a934fd3f62f5" continuedAt="i406605a6e90849a28d47c41a0b5d45a9"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><ix:nonNumeric contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" name="us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNDIvZnJhZzphMjRjNmNhMGI0NDc0YWQ0YTZkNjYyNTU4ODdkY2M1MS90ZXh0cmVnaW9uOmEyNGM2Y2EwYjQ0NzRhZDRhNmQ2NjI1NTg4N2RjYzUxXzQzMDA_6c616d0f-c391-4f5b-b2e6-8b83760340b1" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes revenue by category:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.467%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue by category:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licensing agreements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5429ceb33a414445be9322f8f9c293e3_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNDIvZnJhZzphMjRjNmNhMGI0NDc0YWQ0YTZkNjYyNTU4ODdkY2M1MS90YWJsZTowMzI2ZWQxODJiMzM0YjA4YjIyYzFjZDQyNjZmM2RhNi90YWJsZXJhbmdlOjAzMjZlZDE4MmIzMzRiMDhiMjJjMWNkNDI2NmYzZGE2XzItMi0xLTEtMTA5ODc2_f22cabf4-4e61-44b4-9b19-70e423d8f1a0">1,809</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05760767313140efb7f8f84e9096f9f3_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNDIvZnJhZzphMjRjNmNhMGI0NDc0YWQ0YTZkNjYyNTU4ODdkY2M1MS90YWJsZTowMzI2ZWQxODJiMzM0YjA4YjIyYzFjZDQyNjZmM2RhNi90YWJsZXJhbmdlOjAzMjZlZDE4MmIzMzRiMDhiMjJjMWNkNDI2NmYzZGE2XzItNC0xLTEtMTA5ODc2_0087eee6-e514-4cf8-bea7-75fe427693c2">860</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:3pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue recognized during the years ended December 31, 2021 and December 31, 2020 consists of amounts received from the Company's license and commercialization agreement with Eurofarma Laborat&#243;rios S.A. </span></div><div><span><br/></span></div><ix:nonNumeric contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" name="us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNDIvZnJhZzphMjRjNmNhMGI0NDc0YWQ0YTZkNjYyNTU4ODdkY2M1MS90ZXh0cmVnaW9uOmEyNGM2Y2EwYjQ0NzRhZDRhNmQ2NjI1NTg4N2RjYzUxXzQzMDE_ca09d485-2ea1-444a-af2e-fe3032d85e4b" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes revenue by geography:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.467%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue by geography:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0717192d4d74cfd912383af07cab29d_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNDIvZnJhZzphMjRjNmNhMGI0NDc0YWQ0YTZkNjYyNTU4ODdkY2M1MS90YWJsZTpkNDg5ZDZjZjAyYjY0NDc4OGYxMGJlZDY1NzhlOWNkZS90YWJsZXJhbmdlOmQ0ODlkNmNmMDJiNjQ0Nzg4ZjEwYmVkNjU3OGU5Y2RlXzItMi0xLTEtMTA5ODc2_e1418ccd-c79b-4961-b99b-017caff3fce5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9367ade534d1492b81f243c12898e81d_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNDIvZnJhZzphMjRjNmNhMGI0NDc0YWQ0YTZkNjYyNTU4ODdkY2M1MS90YWJsZTpkNDg5ZDZjZjAyYjY0NDc4OGYxMGJlZDY1NzhlOWNkZS90YWJsZXJhbmdlOmQ0ODlkNmNmMDJiNjQ0Nzg4ZjEwYmVkNjU3OGU5Y2RlXzItNC0xLTEtMTA5ODc2_3c407754-70e9-45f4-b51b-7833292af35d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Latin America</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04c6be661f884e9f9fcec7b8a98ba02f_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNDIvZnJhZzphMjRjNmNhMGI0NDc0YWQ0YTZkNjYyNTU4ODdkY2M1MS90YWJsZTpkNDg5ZDZjZjAyYjY0NDc4OGYxMGJlZDY1NzhlOWNkZS90YWJsZXJhbmdlOmQ0ODlkNmNmMDJiNjQ0Nzg4ZjEwYmVkNjU3OGU5Y2RlXzMtMi0xLTEtMTA5ODc2_374be918-0d44-4193-8019-7946a4033172">1,809</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7b7d8e874e541099d3260b499ccef94_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNDIvZnJhZzphMjRjNmNhMGI0NDc0YWQ0YTZkNjYyNTU4ODdkY2M1MS90YWJsZTpkNDg5ZDZjZjAyYjY0NDc4OGYxMGJlZDY1NzhlOWNkZS90YWJsZXJhbmdlOmQ0ODlkNmNmMDJiNjQ0Nzg4ZjEwYmVkNjU3OGU5Y2RlXzMtNC0xLTEtMTA5ODc2_a7e4c357-d408-4a4f-9fc1-630e9c5eeba8">860</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNDIvZnJhZzphMjRjNmNhMGI0NDc0YWQ0YTZkNjYyNTU4ODdkY2M1MS90YWJsZTpkNDg5ZDZjZjAyYjY0NDc4OGYxMGJlZDY1NzhlOWNkZS90YWJsZXJhbmdlOmQ0ODlkNmNmMDJiNjQ0Nzg4ZjEwYmVkNjU3OGU5Y2RlXzQtMi0xLTEtMTA5ODc2_651dbe07-8217-4db6-b4a3-a0bc2c6bfe9e">1,809</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNDIvZnJhZzphMjRjNmNhMGI0NDc0YWQ0YTZkNjYyNTU4ODdkY2M1MS90YWJsZTpkNDg5ZDZjZjAyYjY0NDc4OGYxMGJlZDY1NzhlOWNkZS90YWJsZXJhbmdlOmQ0ODlkNmNmMDJiNjQ0Nzg4ZjEwYmVkNjU3OGU5Y2RlXzQtNC0xLTEtMTA5ODc2_bee57716-5944-40a0-ac49-be32167e87d4">860</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The analysis of revenue by geography has been identified on the basis of the geographical location of each collaboration partner.</span></div></ix:continuation><div><span><br/></span></div><div><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summit Therapeutics Inc. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div></div><ix:continuation id="i406605a6e90849a28d47c41a0b5d45a9"><ix:nonNumeric contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" name="us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNDIvZnJhZzphMjRjNmNhMGI0NDc0YWQ0YTZkNjYyNTU4ODdkY2M1MS90ZXh0cmVnaW9uOmEyNGM2Y2EwYjQ0NzRhZDRhNmQ2NjI1NTg4N2RjYzUxXzQzMDQ_5aac7138-af6d-42f1-ab11-0cf00c760f28" continuedAt="i30b003c4e3d845fc8ea5aa2273d73770" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the deferred revenue relating to Eurofarma Laborat&#243;rios S.A. and deferred other income relating to BARDA (as defined in Note 8), respectively:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.836%"><tr><td style="width:1.0%"></td><td style="width:82.049%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.902%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.649%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning deferred revenue and other income, January 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7372be6dc06143b5adbb4d2e83a596c5_I20201231" decimals="-3" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNDIvZnJhZzphMjRjNmNhMGI0NDc0YWQ0YTZkNjYyNTU4ODdkY2M1MS90YWJsZTo0MWM3MWViODM2ZDM0ZTYxODRhOGI1ZmZhNzEzYmU3OC90YWJsZXJhbmdlOjQxYzcxZWI4MzZkMzRlNjE4NGE4YjVmZmE3MTNiZTc4XzEtMi0xLTEtMTA5ODc2_459435e0-7509-4279-b277-0e2ebb6fa780">8,939</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" decimals="-3" name="smmt:ContractWithCustomerLiabilityAdditions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNDIvZnJhZzphMjRjNmNhMGI0NDc0YWQ0YTZkNjYyNTU4ODdkY2M1MS90YWJsZTo0MWM3MWViODM2ZDM0ZTYxODRhOGI1ZmZhNzEzYmU3OC90YWJsZXJhbmdlOjQxYzcxZWI4MzZkMzRlNjE4NGE4YjVmZmE3MTNiZTc4XzItMi0xLTEtMTA5ODc2_46620ac5-d5ca-420e-ae09-9843346cb7fc">5,438</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amount of deferred revenue and other income recognized in the statement of operations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNDIvZnJhZzphMjRjNmNhMGI0NDc0YWQ0YTZkNjYyNTU4ODdkY2M1MS90YWJsZTo0MWM3MWViODM2ZDM0ZTYxODRhOGI1ZmZhNzEzYmU3OC90YWJsZXJhbmdlOjQxYzcxZWI4MzZkMzRlNjE4NGE4YjVmZmE3MTNiZTc4XzMtMi0xLTEtMTA5ODc2_23bea5b2-4297-499b-9aeb-c2ecfa36222c">6,438</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending deferred revenue and other income, December 31</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231" decimals="-3" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNDIvZnJhZzphMjRjNmNhMGI0NDc0YWQ0YTZkNjYyNTU4ODdkY2M1MS90YWJsZTo0MWM3MWViODM2ZDM0ZTYxODRhOGI1ZmZhNzEzYmU3OC90YWJsZXJhbmdlOjQxYzcxZWI4MzZkMzRlNjE4NGE4YjVmZmE3MTNiZTc4XzQtMi0xLTEtMTA5ODc2_2eeb3f11-4b40-4fb8-a6c4-2a2695a529ac">7,939</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">__________</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning deferred revenue and other income included $<ix:nonFraction unitRef="usd" contextRef="i7372be6dc06143b5adbb4d2e83a596c5_I20201231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNDIvZnJhZzphMjRjNmNhMGI0NDc0YWQ0YTZkNjYyNTU4ODdkY2M1MS90ZXh0cmVnaW9uOmEyNGM2Y2EwYjQ0NzRhZDRhNmQ2NjI1NTg4N2RjYzUxXzY5NQ_e8306b19-0163-41d3-b60f-09c7f4391f34">8,370</ix:nonFraction> of current deferred revenue and other income and $<ix:nonFraction unitRef="usd" contextRef="i7372be6dc06143b5adbb4d2e83a596c5_I20201231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNDIvZnJhZzphMjRjNmNhMGI0NDc0YWQ0YTZkNjYyNTU4ODdkY2M1MS90ZXh0cmVnaW9uOmEyNGM2Y2EwYjQ0NzRhZDRhNmQ2NjI1NTg4N2RjYzUxXzc0Nw_c22bcd34-800b-4236-9f60-77340ea021d8">569</ix:nonFraction> of long-term deferred revenue and other income.</span></div></ix:nonNumeric><div><ix:continuation id="i30b003c4e3d845fc8ea5aa2273d73770"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ending deferred revenue and other income is classified within current liabilities.</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 8 below for further details regarding other income recognized under the BARDA contract. </span></div><div><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Eurofarma Laborat&#243;rios S.A.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 21, 2017, Summit announced it had entered into an exclusive license and commercialization agreement with Eurofarma Laborat&#243;rios S.A. ("Eurofarma"), pursuant to which the Company granted Eurofarma the exclusive right to commercialize ridinilazole in specified countries in South America, Central America and the Caribbean. The Company has retained commercialization rights in the rest of the world. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the license and commercialization agreement with Eurofarma, the Company received an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="ib314f5dd5ac24f47a60b0925a50a5081_I20171231" decimals="-3" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNDIvZnJhZzphMjRjNmNhMGI0NDc0YWQ0YTZkNjYyNTU4ODdkY2M1MS90ZXh0cmVnaW9uOmEyNGM2Y2EwYjQ0NzRhZDRhNmQ2NjI1NTg4N2RjYzUxXzE1NTU_87902035-7aee-4b8d-af85-d7c3d619a2f3">2,500</ix:nonFraction> in December 2017. In February 2020, the Company reached the first enrollment milestone and earned $<ix:nonFraction unitRef="usd" contextRef="if1c80590b2284b5092629628c5efb266_I20200229" decimals="-3" name="smmt:ContractWithCustomerLiabilityEnrollmentMilestone" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNDIvZnJhZzphMjRjNmNhMGI0NDc0YWQ0YTZkNjYyNTU4ODdkY2M1MS90ZXh0cmVnaW9uOmEyNGM2Y2EwYjQ0NzRhZDRhNmQ2NjI1NTg4N2RjYzUxXzE2NTY_89aa892a-4412-4cf5-a2df-a50a738a9aa1">1,000</ix:nonFraction>. In September 2021, the Company reached the second enrollment milestone and earned $<ix:nonFraction unitRef="usd" contextRef="i7d9fb711621141cd9ebefb15542db56a_I20210930" decimals="-3" name="smmt:ContractWithCustomerLiabilityEnrollmentMilestone" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNDIvZnJhZzphMjRjNmNhMGI0NDc0YWQ0YTZkNjYyNTU4ODdkY2M1MS90ZXh0cmVnaW9uOmEyNGM2Y2EwYjQ0NzRhZDRhNmQ2NjI1NTg4N2RjYzUxXzE3NDI_c9749e43-4f57-48de-805d-71526990d3be">1,250</ix:nonFraction>. The terms of the contract have been assessed under ASC 606 and currently only the upfront payment and the first <ix:nonFraction unitRef="milestone" contextRef="i5f7778418eab4524a04524ce76786f35_D20210101-20211231" decimals="INF" name="smmt:RevenueInformationUsedToDetermineTransactionPriceNumberOfEnrollmentMilestones" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNDIvZnJhZzphMjRjNmNhMGI0NDc0YWQ0YTZkNjYyNTU4ODdkY2M1MS90ZXh0cmVnaW9uOmEyNGM2Y2EwYjQ0NzRhZDRhNmQ2NjI1NTg4N2RjYzUxXzE4NTg_68eb3def-075a-4181-988d-a8b81b4d3a10">two</ix:nonFraction> enrollment milestone payments are included in the transaction price. These payments were initially reported as deferred revenue in the balance sheet and are being recognized as revenue ratably over the performance period. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue recognized during the period ended December 31, 2021 was based on the transaction price that included the upfront payment and the first <ix:nonFraction unitRef="milestone" contextRef="i5f7778418eab4524a04524ce76786f35_D20210101-20211231" decimals="INF" name="smmt:RevenueInformationUsedToDetermineTransactionPriceNumberOfEnrollmentMilestones" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNDIvZnJhZzphMjRjNmNhMGI0NDc0YWQ0YTZkNjYyNTU4ODdkY2M1MS90ZXh0cmVnaW9uOmEyNGM2Y2EwYjQ0NzRhZDRhNmQ2NjI1NTg4N2RjYzUxXzIyMjk_1627216c-d911-4e18-b856-f1eeaa8aeb6b">two</ix:nonFraction> enrollment milestones earned in accordance with the Company's revenue recognition policy. Revenue recognized during the period ended December 31, 2020 was based on the transaction price that included the upfront payment and the first enrollment milestone earned in accordance with the Company's revenue recognition policy. The revenue is being recognized ratably over the performance period to reflect the transfer of control to the customer occurring over the time period that the research and development services are provided by the Company. This output method is, in management&#8217;s judgment, the best measure of progress towards satisfying the performance obligation. As of December 31, 2021 and 2020, the current contract liability relating to the Eurofarma contract was $<ix:nonFraction unitRef="usd" contextRef="i7179bafa598f42ebb6c974d6b860624e_I20211231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNDIvZnJhZzphMjRjNmNhMGI0NDc0YWQ0YTZkNjYyNTU4ODdkY2M1MS90ZXh0cmVnaW9uOmEyNGM2Y2EwYjQ0NzRhZDRhNmQ2NjI1NTg4N2RjYzUxXzMwMDY_fbc7cc1e-1905-4d0b-9b7b-88e3873a6b0d">756</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i75af2dac1e474913ae259011f0e40ece_I20201231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNDIvZnJhZzphMjRjNmNhMGI0NDc0YWQ0YTZkNjYyNTU4ODdkY2M1MS90ZXh0cmVnaW9uOmEyNGM2Y2EwYjQ0NzRhZDRhNmQ2NjI1NTg4N2RjYzUxXzMwMTM_8e28f2cc-5073-4098-aaf8-d46435adc34c">759</ix:nonFraction>, respectively, and was recorded in current deferred revenue in the consolidated balance sheet. As of December 31, 2021 and 2020, the non-current contract liability relating to the Eurofarma contract was $<ix:nonFraction unitRef="usd" contextRef="i7179bafa598f42ebb6c974d6b860624e_I20211231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNDIvZnJhZzphMjRjNmNhMGI0NDc0YWQ0YTZkNjYyNTU4ODdkY2M1MS90ZXh0cmVnaW9uOmEyNGM2Y2EwYjQ0NzRhZDRhNmQ2NjI1NTg4N2RjYzUxXzMyMTk_ab5208cf-f7d3-4c28-8af7-531825183e44">0</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i75af2dac1e474913ae259011f0e40ece_I20201231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNDIvZnJhZzphMjRjNmNhMGI0NDc0YWQ0YTZkNjYyNTU4ODdkY2M1MS90ZXh0cmVnaW9uOmEyNGM2Y2EwYjQ0NzRhZDRhNmQ2NjI1NTg4N2RjYzUxXzMyMjY_3fb207b1-07af-4b51-9dc7-8cfaf1113590">569</ix:nonFraction>, respectively, and was recorded in non-current deferred revenue and other income in the consolidated balance sheet.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Company will be entitled to receive an additional $<ix:nonFraction unitRef="usd" contextRef="i5f7778418eab4524a04524ce76786f35_D20210101-20211231" decimals="-3" name="smmt:RevenueFromContractWithCustomerDevelopmentMilestoneRevenueEntitledToReceive" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNDIvZnJhZzphMjRjNmNhMGI0NDc0YWQ0YTZkNjYyNTU4ODdkY2M1MS90ZXh0cmVnaW9uOmEyNGM2Y2EwYjQ0NzRhZDRhNmQ2NjI1NTg4N2RjYzUxXzM0MTM_5a63ddb1-ab6e-4fd5-8d2f-2e2418a3f6f3">1,500</ix:nonFraction> for various development milestones. The Company is also eligible to receive up to $<ix:nonFraction unitRef="usd" contextRef="i5f7778418eab4524a04524ce76786f35_D20210101-20211231" decimals="-3" name="smmt:RevenueFromContractWithCustomerDevelopmentCommercialAndSalesMilestoneCumulativeNetSalesTargetAchievementRevenueEntitledToReceive" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNDIvZnJhZzphMjRjNmNhMGI0NDc0YWQ0YTZkNjYyNTU4ODdkY2M1MS90ZXh0cmVnaW9uOmEyNGM2Y2EwYjQ0NzRhZDRhNmQ2NjI1NTg4N2RjYzUxXzM0OTg_54022898-5d86-457a-b564-d49fdad4f254">21,400</ix:nonFraction> in additional development, commercial and sales milestones when cumulative net sales equal or exceed $<ix:nonFraction unitRef="usd" contextRef="i5f7778418eab4524a04524ce76786f35_D20210101-20211231" decimals="-3" name="smmt:RevenueFromContractWithCustomerDevelopmentCommercialAndSalesMilestoneCumulativeNetSalesTargetThreshold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNDIvZnJhZzphMjRjNmNhMGI0NDc0YWQ0YTZkNjYyNTU4ODdkY2M1MS90ZXh0cmVnaW9uOmEyNGM2Y2EwYjQ0NzRhZDRhNmQ2NjI1NTg4N2RjYzUxXzM2MDI_bcd906b7-ddc9-4bd7-991f-ac61bf80b8d0">100,000</ix:nonFraction> in the Eurofarma licensed territory. Each subsequent achievement of an additional $<ix:nonFraction unitRef="usd" contextRef="i5f7778418eab4524a04524ce76786f35_D20210101-20211231" decimals="-3" name="smmt:RevenueFromContractWithCustomerDevelopmentCommercialAndSalesMilestoneIncrementalCumulativeNetSalesTargetThreshold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNDIvZnJhZzphMjRjNmNhMGI0NDc0YWQ0YTZkNjYyNTU4ODdkY2M1MS90ZXh0cmVnaW9uOmEyNGM2Y2EwYjQ0NzRhZDRhNmQ2NjI1NTg4N2RjYzUxXzM2ODc_1cbd4309-635f-42e7-9d77-73d2a22113a6">100,000</ix:nonFraction> in cumulative net sales will result in the Company receiving additional milestone payments, which, when combined with anticipated product supply transfer payments from Eurofarma paid to the Company in connection with a commercial supply agreement to be entered into between the two parties, will provide payments estimated to range from a mid-teens to high-teens percentage of cumulative net sales in the territories where we have granted Eurofarma commercialization rights. Upon achievement of these milestones, the Company will recognize the revenues in accordance with the Company's revenue policy.</span></div></ix:continuation><div><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summit Therapeutics Inc. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div></div><div><span><br/></span></div><div id="i2eecdebedec64091994df5b7a96baab7_145"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8. <ix:nonNumeric contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" name="us-gaap:OtherOperatingIncomeAndExpenseTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNDUvZnJhZzpjN2YzZWYwYjFjMjA0Njk2YWVhYjdjM2FmMjBhODcwYy90ZXh0cmVnaW9uOmM3ZjNlZjBiMWMyMDQ2OTZhZWFiN2MzYWYyMGE4NzBjXzQxMzc_14fe922c-bc30-4bbc-b5e1-6a9a03e20f2f" continuedAt="ie3d39364b3d1488bb8ee990565aaf871" escape="true">Other Operating Income </ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="ie3d39364b3d1488bb8ee990565aaf871" continuedAt="if45c3616833e4c80b94ba44b3cdf2577"><ix:nonNumeric contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" name="smmt:ScheduleOfOtherOperatingIncomeByComponentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNDUvZnJhZzpjN2YzZWYwYjFjMjA0Njk2YWVhYjdjM2FmMjBhODcwYy90ZXh0cmVnaW9uOmM3ZjNlZjBiMWMyMDQ2OTZhZWFiN2MzYWYyMGE4NzBjXzQxNDU_68b6d17b-aa1e-433b-881b-f4748c411f61" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the components of other operating income by category:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.467%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other operating income by category:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Funding income from BARDA (as defined below)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4d86426c389449ebc2c7f1874dbc3fc_D20210101-20211231" decimals="-3" name="smmt:GrantFundingArrangementIncomeEarned" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNDUvZnJhZzpjN2YzZWYwYjFjMjA0Njk2YWVhYjdjM2FmMjBhODcwYy90YWJsZTo3NzFjODJmYTg4NDg0ZDkzODc1ZmFlZGZmNmNmNmUzNy90YWJsZXJhbmdlOjc3MWM4MmZhODg0ODRkOTM4NzVmYWVkZmY2Y2Y2ZTM3XzItMi0xLTEtMTA5ODc2_75f8ccb5-6773-49cc-9669-d4ff7ef066de">4,604</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab792aa058af48aba2d03719d4253bde_D20200101-20201231" decimals="-3" name="smmt:GrantFundingArrangementIncomeEarned" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNDUvZnJhZzpjN2YzZWYwYjFjMjA0Njk2YWVhYjdjM2FmMjBhODcwYy90YWJsZTo3NzFjODJmYTg4NDg0ZDkzODc1ZmFlZGZmNmNmNmUzNy90YWJsZXJhbmdlOjc3MWM4MmZhODg0ODRkOTM4NzVmYWVkZmY2Y2Y2ZTM3XzItNC0xLTEtMTA5ODc2_d280a58c-28af-498b-88f8-f562d20961bd">9,472</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development tax credits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" decimals="-3" name="smmt:ResearchAndDevelopmentTaxCredit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNDUvZnJhZzpjN2YzZWYwYjFjMjA0Njk2YWVhYjdjM2FmMjBhODcwYy90YWJsZTo3NzFjODJmYTg4NDg0ZDkzODc1ZmFlZGZmNmNmNmUzNy90YWJsZXJhbmdlOjc3MWM4MmZhODg0ODRkOTM4NzVmYWVkZmY2Y2Y2ZTM3XzMtMi0xLTEtMTA5ODc2_a837e75e-ff74-4153-bc0d-a893b1740818">15,206</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231" decimals="-3" name="smmt:ResearchAndDevelopmentTaxCredit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNDUvZnJhZzpjN2YzZWYwYjFjMjA0Njk2YWVhYjdjM2FmMjBhODcwYy90YWJsZTo3NzFjODJmYTg4NDg0ZDkzODc1ZmFlZGZmNmNmNmUzNy90YWJsZXJhbmdlOjc3MWM4MmZhODg0ODRkOTM4NzVmYWVkZmY2Y2Y2ZTM3XzMtNC0xLTEtMTA5ODc2_1a331733-f9fd-49d4-808e-98a1d75c6920">9,363</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Grant income from CARB-X (as defined below)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ef399140bb14718b545a1aaa04203df_D20210101-20211231" decimals="-3" name="smmt:GrantFundingArrangementIncomeEarned" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNDUvZnJhZzpjN2YzZWYwYjFjMjA0Njk2YWVhYjdjM2FmMjBhODcwYy90YWJsZTo3NzFjODJmYTg4NDg0ZDkzODc1ZmFlZGZmNmNmNmUzNy90YWJsZXJhbmdlOjc3MWM4MmZhODg0ODRkOTM4NzVmYWVkZmY2Y2Y2ZTM3XzQtMi0xLTEtMTA5ODc2_075c7e88-2f9f-467a-96de-2c092819cc4d">1,158</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52c373554f2f40b4a54d0ff856b68cf6_D20200101-20201231" decimals="-3" name="smmt:GrantFundingArrangementIncomeEarned" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNDUvZnJhZzpjN2YzZWYwYjFjMjA0Njk2YWVhYjdjM2FmMjBhODcwYy90YWJsZTo3NzFjODJmYTg4NDg0ZDkzODc1ZmFlZGZmNmNmNmUzNy90YWJsZXJhbmdlOjc3MWM4MmZhODg0ODRkOTM4NzVmYWVkZmY2Y2Y2ZTM3XzQtNC0xLTEtMTA5ODc2_07fe46ff-a87c-40eb-8777-0be0ee2856b0">477</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" decimals="-3" name="us-gaap:OtherOperatingIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNDUvZnJhZzpjN2YzZWYwYjFjMjA0Njk2YWVhYjdjM2FmMjBhODcwYy90YWJsZTo3NzFjODJmYTg4NDg0ZDkzODc1ZmFlZGZmNmNmNmUzNy90YWJsZXJhbmdlOjc3MWM4MmZhODg0ODRkOTM4NzVmYWVkZmY2Y2Y2ZTM3XzUtMi0xLTEtMTA5ODc2_d41a7fa1-2918-4b33-84f0-c9e46ea1a5b2">20,968</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231" decimals="-3" name="us-gaap:OtherOperatingIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNDUvZnJhZzpjN2YzZWYwYjFjMjA0Njk2YWVhYjdjM2FmMjBhODcwYy90YWJsZTo3NzFjODJmYTg4NDg0ZDkzODc1ZmFlZGZmNmNmNmUzNy90YWJsZXJhbmdlOjc3MWM4MmZhODg0ODRkOTM4NzVmYWVkZmY2Y2Y2ZTM3XzUtNC0xLTEtMTA5ODc2_a50f548d-c65e-4129-9466-d8b6829086ef">19,312</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BARDA (as defined below)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2017, the Company was awarded a funding contract from the Biomedical Advanced Research and Development Authority ("BARDA"), part of the Office of the Assistant Secretary for Preparedness and Response at the United States Department of Health and Human Services, in support of the Company's Ri-CoDIFy clinical trials and clinical development of of ridinilazole.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The awarded contract was originally worth up to $<ix:nonFraction unitRef="usd" contextRef="i5189024af3e3465a96e4c5c1204cfc1d_D20170901-20170930" decimals="-3" name="smmt:GrantFundingArrangementMaximumFundingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNDUvZnJhZzpjN2YzZWYwYjFjMjA0Njk2YWVhYjdjM2FmMjBhODcwYy90ZXh0cmVnaW9uOmM3ZjNlZjBiMWMyMDQ2OTZhZWFiN2MzYWYyMGE4NzBjXzU1MA_f7620929-a1f3-4e4e-a906-ee38f4b8fe9a">62,000</ix:nonFraction>. In June 2019 and again in January 2020, BARDA increased the value of the contract such that it is now worth up to $<ix:nonFraction unitRef="usd" contextRef="ia4d86426c389449ebc2c7f1874dbc3fc_D20210101-20211231" decimals="-3" name="smmt:GrantFundingArrangementMaximumFundingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNDUvZnJhZzpjN2YzZWYwYjFjMjA0Njk2YWVhYjdjM2FmMjBhODcwYy90ZXh0cmVnaW9uOmM3ZjNlZjBiMWMyMDQ2OTZhZWFiN2MzYWYyMGE4NzBjXzY2OA_b63de970-732c-41da-8b13-a5d0a5efc121">72,500</ix:nonFraction> and brought the total amount of committed funding to $<ix:nonFraction unitRef="usd" contextRef="ia4d86426c389449ebc2c7f1874dbc3fc_D20210101-20211231" decimals="-3" name="smmt:GrantFundingArrangementCommittedFundingTotal" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNDUvZnJhZzpjN2YzZWYwYjFjMjA0Njk2YWVhYjdjM2FmMjBhODcwYy90ZXh0cmVnaW9uOmM3ZjNlZjBiMWMyMDQ2OTZhZWFiN2MzYWYyMGE4NzBjXzcyNA_bf359a12-a8a5-4e34-a3ce-9da5f85758fc">62,400</ix:nonFraction>. The remaining federal government funding is dependent on BARDA in its sole discretion exercising the final independent option work segment, upon the achievement by the Company of certain agreed-upon milestones for ridinilazole. As of December 31, 2021, an aggregate of $<ix:nonFraction unitRef="usd" contextRef="i6080657079b74ddc92d888ef28f1a49a_D20170901-20211231" decimals="-3" name="smmt:GrantFundingArrangementFundingReceived" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNDUvZnJhZzpjN2YzZWYwYjFjMjA0Njk2YWVhYjdjM2FmMjBhODcwYy90ZXh0cmVnaW9uOmM3ZjNlZjBiMWMyMDQ2OTZhZWFiN2MzYWYyMGE4NzBjXzk4Mg_6cade9de-65cc-4130-9089-9346063079e3">56,492</ix:nonFraction> of the total committed BARDA funding had been received and the Company has recognized $<ix:nonFraction unitRef="usd" contextRef="i6080657079b74ddc92d888ef28f1a49a_D20170901-20211231" decimals="-3" name="smmt:GrantFundingArrangementIncomeEarned" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNDUvZnJhZzpjN2YzZWYwYjFjMjA0Njk2YWVhYjdjM2FmMjBhODcwYy90ZXh0cmVnaW9uOmM3ZjNlZjBiMWMyMDQ2OTZhZWFiN2MzYWYyMGE4NzBjXzEwNzE_f2e85972-d1da-4ebd-933a-cc33261fb222">50,265</ix:nonFraction> of cumulative income since contract inception.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and development credits</span></div><div><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income from tax credits, consist of R&amp;D tax credits received in the U.K. The Company benefits from two U.K. research and development tax credit cash rebate regimes: Small and Medium Enterprise Program ("SME, Program") and the Research and Development Expenditure Credit Program ("RDEC Program"). Qualifying expenditures largely comprise of employment costs for research staff, consumables, a proportion of relevant, permitted sub-contract costs and certain internal overhead costs incurred as part of research projects for which the Company does not receive income. Tax credits related to the SME Program and RDEC Program are recorded as other operating income in the consolidated statements of operations and other comprehensive loss. Under both schemes, the Company receives cash payments that are not dependent on the Company&#8217;s pre-tax net income levels.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on criteria established by Her Majesty&#8217;s Revenue and Customs ("HMRC"), a portion of expenditures being carried out in relation to the Company's pipeline research and development, clinical trials management and third-party manufacturing development activities are eligible for the SME regime and the Company expects such elements of expenditure will also continue to be eligible for the SME regime for future periods.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">As of December 31, 2021 and 2020, the current research and development tax credit receivable was $<ix:nonFraction unitRef="usd" contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231" decimals="-3" name="smmt:ResearchAndDevelopmentTaxCreditReceivableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNDUvZnJhZzpjN2YzZWYwYjFjMjA0Njk2YWVhYjdjM2FmMjBhODcwYy90ZXh0cmVnaW9uOmM3ZjNlZjBiMWMyMDQ2OTZhZWFiN2MzYWYyMGE4NzBjXzI1MTk_a7595fc5-eb4c-4a07-8a6e-f60d9f01de88">15,695</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i7372be6dc06143b5adbb4d2e83a596c5_I20201231" decimals="-3" name="smmt:ResearchAndDevelopmentTaxCreditReceivableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNDUvZnJhZzpjN2YzZWYwYjFjMjA0Njk2YWVhYjdjM2FmMjBhODcwYy90ZXh0cmVnaW9uOmM3ZjNlZjBiMWMyMDQ2OTZhZWFiN2MzYWYyMGE4NzBjXzI1MjY_f7c2926a-383d-4515-af59-756255b8fa6a">9,856</ix:nonFraction>, respectively.</span></div></ix:continuation><div style="margin-bottom:6pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summit Therapeutics Inc. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div></div><ix:continuation id="if45c3616833e4c80b94ba44b3cdf2577"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CARB-X (as defined below)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, the Company announced the selection of a new preclinical candidate, SMT-738, from the DDS-04 series for development in the fight against multi-drug resistant infections, specifically Carbapenem-resistant Enterobacteriaceae ("CRE") infections. Simultaneously, the Company announced it had received an award from the Trustees of Boston University under the Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator program ("CARB-X") to progress this candidate through preclinical development and Phase Ia clinical trials. The award commits initial funding of up to $<ix:nonFraction unitRef="usd" contextRef="ice72e22d8b604c7a9047363b98c2c5e0_D20210501-20210531" decimals="-3" name="smmt:GrantFundingArrangementCommittedFundingBase" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNDUvZnJhZzpjN2YzZWYwYjFjMjA0Njk2YWVhYjdjM2FmMjBhODcwYy90ZXh0cmVnaW9uOmM3ZjNlZjBiMWMyMDQ2OTZhZWFiN2MzYWYyMGE4NzBjXzMxNjA_0f8e3893-7756-4e44-af85-19a57122ea68">4,100</ix:nonFraction>, with the possibility of up to another $<ix:nonFraction unitRef="usd" contextRef="ice72e22d8b604c7a9047363b98c2c5e0_D20210501-20210531" decimals="-3" name="smmt:GrantFundingArrangementMilestoneFundingIncrease" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNDUvZnJhZzpjN2YzZWYwYjFjMjA0Njk2YWVhYjdjM2FmMjBhODcwYy90ZXh0cmVnaW9uOmM3ZjNlZjBiMWMyMDQ2OTZhZWFiN2MzYWYyMGE4NzBjXzMyMDI_3a1f2962-dc16-484d-945d-f9532a80ee5d">3,700</ix:nonFraction> based on the achievement of future milestones. As of December 31, 2021, $<ix:nonFraction unitRef="usd" contextRef="i31a55aa85c704fa1b0bf71fb5d66f073_D20210501-20211231" decimals="-3" name="smmt:GrantFundingArrangementFundingReceived" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNDUvZnJhZzpjN2YzZWYwYjFjMjA0Njk2YWVhYjdjM2FmMjBhODcwYy90ZXh0cmVnaW9uOmM3ZjNlZjBiMWMyMDQ2OTZhZWFiN2MzYWYyMGE4NzBjXzMyNzc_906ca6d4-c9c0-42fa-b3a2-b98420ac0df6">485</ix:nonFraction> of grant funding from CARB-X has been received, $<ix:nonFraction unitRef="usd" contextRef="iba2a2e6aa4554084aa69ed9ef72c2590_I20211231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNDUvZnJhZzpjN2YzZWYwYjFjMjA0Njk2YWVhYjdjM2FmMjBhODcwYy90ZXh0cmVnaW9uOmM3ZjNlZjBiMWMyMDQ2OTZhZWFiN2MzYWYyMGE4NzBjXzMzMjg_8f22224e-2a4c-4a81-8e24-f0cbae5db993">96</ix:nonFraction> is in accounts receivable for amounts billed, $<ix:nonFraction unitRef="usd" contextRef="iba2a2e6aa4554084aa69ed9ef72c2590_I20211231" decimals="-3" name="us-gaap:ContractWithCustomerAssetNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNDUvZnJhZzpjN2YzZWYwYjFjMjA0Njk2YWVhYjdjM2FmMjBhODcwYy90ZXh0cmVnaW9uOmM3ZjNlZjBiMWMyMDQ2OTZhZWFiN2MzYWYyMGE4NzBjXzMzNzc_d1edddac-a152-40df-b8df-bdb1ec5b389a">574</ix:nonFraction> is in other current assets as a contract asset and the Company has recognized $<ix:nonFraction unitRef="usd" contextRef="i31a55aa85c704fa1b0bf71fb5d66f073_D20210501-20211231" decimals="-3" name="smmt:GrantFundingArrangementIncomeEarned" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNDUvZnJhZzpjN2YzZWYwYjFjMjA0Njk2YWVhYjdjM2FmMjBhODcwYy90ZXh0cmVnaW9uOmM3ZjNlZjBiMWMyMDQ2OTZhZWFiN2MzYWYyMGE4NzBjXzM0NTg_aae98854-5e1c-43de-a6ab-e777d2205e83">1,155</ix:nonFraction> of cumulative income since contract inception.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Grant income recognized during the year ended December 31, 2021 relates to SMT-738. Grant income recognized during the year ended December, 31, 2020 consists of income from a sub-award from CARB-X for the Company's antibiotic pipeline research and development activities specifically relating to the DDS-01 series of antibiotics, targeting Neisseria gonorrhoeae, or N. gonorrhoeae, using the Discuva Platform. In the fourth quarter of 2020, the Company decided not to advance the DDS-01 series and to cease work on the gonorrhoeae program, and as such, no further grant income has been received from CARB-X under this sub-award.</span></div></ix:continuation><div style="margin-bottom:9pt"><span><br/></span></div><div id="i2eecdebedec64091994df5b7a96baab7_148"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9. <ix:nonNumeric contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" name="us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNDgvZnJhZzpjMGU3YmJjMDJjODA0NzU3OTk1MGEzODhlY2NlZTc5ZC90ZXh0cmVnaW9uOmMwZTdiYmMwMmM4MDQ3NTc5OTUwYTM4OGVjY2VlNzlkXzUwOA_848c4856-fd3a-4aa5-a62f-512f1659b72e" continuedAt="if6e60ebad7884d92bbe17a4819c60132" escape="true">Other (Expense) Income</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="if6e60ebad7884d92bbe17a4819c60132" continuedAt="i11a82209962e45a0a3af3ce56de9be11"><ix:nonNumeric contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" name="us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNDgvZnJhZzpjMGU3YmJjMDJjODA0NzU3OTk1MGEzODhlY2NlZTc5ZC90ZXh0cmVnaW9uOmMwZTdiYmMwMmM4MDQ3NTc5OTUwYTM4OGVjY2VlNzlkXzUwOQ_01b05d08-2ef8-43f5-acd3-176017b044c0" continuedAt="idfbea6252c504e88a849972380f4c799" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the components of other (expense) income:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.467%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign currency (loss) gain</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNDgvZnJhZzpjMGU3YmJjMDJjODA0NzU3OTk1MGEzODhlY2NlZTc5ZC90YWJsZTo0MmRlY2U1OGUyMzI0NTJmOGJkZDg2OTczZGE3NDc2YS90YWJsZXJhbmdlOjQyZGVjZTU4ZTIzMjQ1MmY4YmRkODY5NzNkYTc0NzZhXzEtMi0xLTEtMTA5ODc2_a110f518-c035-4ba8-81bb-7708eff957b9">2,135</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231" decimals="-3" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNDgvZnJhZzpjMGU3YmJjMDJjODA0NzU3OTk1MGEzODhlY2NlZTc5ZC90YWJsZTo0MmRlY2U1OGUyMzI0NTJmOGJkZDg2OTczZGE3NDc2YS90YWJsZXJhbmdlOjQyZGVjZTU4ZTIzMjQ1MmY4YmRkODY5NzNkYTc0NzZhXzEtNC0xLTEtMTA5ODc2_6bdca8b1-ed18-4032-b690-fdd06d164410">54</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Remeasurement of liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" decimals="-3" name="smmt:GainLossOnRemeasurementOfLiabilitiesNonoperating" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNDgvZnJhZzpjMGU3YmJjMDJjODA0NzU3OTk1MGEzODhlY2NlZTc5ZC90YWJsZTo0MmRlY2U1OGUyMzI0NTJmOGJkZDg2OTczZGE3NDc2YS90YWJsZXJhbmdlOjQyZGVjZTU4ZTIzMjQ1MmY4YmRkODY5NzNkYTc0NzZhXzItMi0xLTEtMTA5ODc2_80cc77c4-a230-4180-aa0a-574228136247">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231" decimals="-3" name="smmt:GainLossOnRemeasurementOfLiabilitiesNonoperating" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNDgvZnJhZzpjMGU3YmJjMDJjODA0NzU3OTk1MGEzODhlY2NlZTc5ZC90YWJsZTo0MmRlY2U1OGUyMzI0NTJmOGJkZDg2OTczZGE3NDc2YS90YWJsZXJhbmdlOjQyZGVjZTU4ZTIzMjQ1MmY4YmRkODY5NzNkYTc0NzZhXzItNC0xLTEtMTA5ODc2_bb15ed2b-8e54-4651-8137-93008123c889">480</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" decimals="-3" name="us-gaap:InvestmentIncomeInterest" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNDgvZnJhZzpjMGU3YmJjMDJjODA0NzU3OTk1MGEzODhlY2NlZTc5ZC90YWJsZTo0MmRlY2U1OGUyMzI0NTJmOGJkZDg2OTczZGE3NDc2YS90YWJsZXJhbmdlOjQyZGVjZTU4ZTIzMjQ1MmY4YmRkODY5NzNkYTc0NzZhXzMtMi0xLTEtMTA5ODc2_28804ddf-7bfc-463b-87fd-c5f20a0650d4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNDgvZnJhZzpjMGU3YmJjMDJjODA0NzU3OTk1MGEzODhlY2NlZTc5ZC90YWJsZTo0MmRlY2U1OGUyMzI0NTJmOGJkZDg2OTczZGE3NDc2YS90YWJsZXJhbmdlOjQyZGVjZTU4ZTIzMjQ1MmY4YmRkODY5NzNkYTc0NzZhXzMtNC0xLTEtMTA5ODc2_97fe0e26-0800-4e8a-9037-0ed1d575890e">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNDgvZnJhZzpjMGU3YmJjMDJjODA0NzU3OTk1MGEzODhlY2NlZTc5ZC90YWJsZTo0MmRlY2U1OGUyMzI0NTJmOGJkZDg2OTczZGE3NDc2YS90YWJsZXJhbmdlOjQyZGVjZTU4ZTIzMjQ1MmY4YmRkODY5NzNkYTc0NzZhXzQtMi0xLTEtMTA5ODc2_faa07b7b-54fa-48f3-9641-c51f5702db09">281</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNDgvZnJhZzpjMGU3YmJjMDJjODA0NzU3OTk1MGEzODhlY2NlZTc5ZC90YWJsZTo0MmRlY2U1OGUyMzI0NTJmOGJkZDg2OTczZGE3NDc2YS90YWJsZXJhbmdlOjQyZGVjZTU4ZTIzMjQ1MmY4YmRkODY5NzNkYTc0NzZhXzQtNC0xLTEtMTA5ODc2_7d23a34c-aa6f-430e-842d-7d1630aa84c3">255</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNDgvZnJhZzpjMGU3YmJjMDJjODA0NzU3OTk1MGEzODhlY2NlZTc5ZC90YWJsZTo0MmRlY2U1OGUyMzI0NTJmOGJkZDg2OTczZGE3NDc2YS90YWJsZXJhbmdlOjQyZGVjZTU4ZTIzMjQ1MmY4YmRkODY5NzNkYTc0NzZhXzUtMi0xLTEtMTA5ODc2_ab32b29c-5198-492c-a4c6-65df1aa4ed2d">2,416</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNDgvZnJhZzpjMGU3YmJjMDJjODA0NzU3OTk1MGEzODhlY2NlZTc5ZC90YWJsZTo0MmRlY2U1OGUyMzI0NTJmOGJkZDg2OTczZGE3NDc2YS90YWJsZXJhbmdlOjQyZGVjZTU4ZTIzMjQ1MmY4YmRkODY5NzNkYTc0NzZhXzUtNC0xLTEtMTA5ODc2_f5e88453-4596-4bf0-8e1c-0720d52790d7">283</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_____________</span></div></ix:nonNumeric></ix:continuation><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"><ix:continuation id="i11a82209962e45a0a3af3ce56de9be11" continuedAt="icbf25db8b03f4b62abe516ff793b869e"><ix:continuation id="idfbea6252c504e88a849972380f4c799" continuedAt="i83c17d12b5814fb0862983055ca99d77">(1)</ix:continuation></ix:continuation></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="icbf25db8b03f4b62abe516ff793b869e"><ix:continuation id="i83c17d12b5814fb0862983055ca99d77"> Remeasurement of liabilities during the year ended December 31, 2020, relates to a revaluation of assumed contingent liabilities for potential payments to certain employees, former employees and former directors of Discuva Limited, based on specified development and clinical milestones related to proprietary product candidates developed under the Discuva Platform (see Note 16 for further details).</ix:continuation></ix:continuation> </span></div><div><span><br/></span></div><div id="i2eecdebedec64091994df5b7a96baab7_151"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10. <ix:nonNumeric contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTEvZnJhZzo2YTM0ODA1OTRlOGY0MDQ2YmU4NGM5MTBjNDUyOTkzMS90ZXh0cmVnaW9uOjZhMzQ4MDU5NGU4ZjQwNDZiZTg0YzkxMGM0NTI5OTMxXzEwMTU4_85d541ca-a2b9-405d-be0b-532419d15020" continuedAt="i9237c78fab214802ada8c49bfdcafa0f" escape="true">Income Tax&#160;</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i9237c78fab214802ada8c49bfdcafa0f" continuedAt="i30fe2c56d40a455c9188ddfaf4148a5a"><ix:nonNumeric contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTEvZnJhZzo2YTM0ODA1OTRlOGY0MDQ2YmU4NGM5MTBjNDUyOTkzMS90ZXh0cmVnaW9uOjZhMzQ4MDU5NGU4ZjQwNDZiZTg0YzkxMGM0NTI5OTMxXzEwMTYx_c1b8dc02-107c-4019-b85d-7b4604994f9e" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of the Company's loss before income taxes are as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.467%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United Kingdom</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTEvZnJhZzo2YTM0ODA1OTRlOGY0MDQ2YmU4NGM5MTBjNDUyOTkzMS90YWJsZTo1MmNjMzJlZjljMDc0NjdjYWRlM2I3MmI0YjZlZDA3Ny90YWJsZXJhbmdlOjUyY2MzMmVmOWMwNzQ2N2NhZGUzYjcyYjRiNmVkMDc3XzEtMi0xLTEtMTA5ODc2_5192a60c-4fe5-4bd3-a9a2-be2273ff6321">72,244</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTEvZnJhZzo2YTM0ODA1OTRlOGY0MDQ2YmU4NGM5MTBjNDUyOTkzMS90YWJsZTo1MmNjMzJlZjljMDc0NjdjYWRlM2I3MmI0YjZlZDA3Ny90YWJsZXJhbmdlOjUyY2MzMmVmOWMwNzQ2N2NhZGUzYjcyYjRiNmVkMDc3XzEtNC0xLTEtMTA5ODc2_171b2c73-8d9a-4496-85b8-62b660167a87">51,197</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTEvZnJhZzo2YTM0ODA1OTRlOGY0MDQ2YmU4NGM5MTBjNDUyOTkzMS90YWJsZTo1MmNjMzJlZjljMDc0NjdjYWRlM2I3MmI0YjZlZDA3Ny90YWJsZXJhbmdlOjUyY2MzMmVmOWMwNzQ2N2NhZGUzYjcyYjRiNmVkMDc3XzItMi0xLTEtMTA5ODc2_080744df-9857-41e2-9237-a2753d252ed9">16,358</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTEvZnJhZzo2YTM0ODA1OTRlOGY0MDQ2YmU4NGM5MTBjNDUyOTkzMS90YWJsZTo1MmNjMzJlZjljMDc0NjdjYWRlM2I3MmI0YjZlZDA3Ny90YWJsZXJhbmdlOjUyY2MzMmVmOWMwNzQ2N2NhZGUzYjcyYjRiNmVkMDc3XzItNC0xLTEtMTA5ODc2_11f6c76d-83a6-4ce8-925d-9bac987dd8cb">1,713</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTEvZnJhZzo2YTM0ODA1OTRlOGY0MDQ2YmU4NGM5MTBjNDUyOTkzMS90YWJsZTo1MmNjMzJlZjljMDc0NjdjYWRlM2I3MmI0YjZlZDA3Ny90YWJsZXJhbmdlOjUyY2MzMmVmOWMwNzQ2N2NhZGUzYjcyYjRiNmVkMDc3XzMtMi0xLTEtMTA5ODc2_77f7af6d-a09c-413d-9704-f46c45b9e4ea">88,602</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTEvZnJhZzo2YTM0ODA1OTRlOGY0MDQ2YmU4NGM5MTBjNDUyOTkzMS90YWJsZTo1MmNjMzJlZjljMDc0NjdjYWRlM2I3MmI0YjZlZDA3Ny90YWJsZXJhbmdlOjUyY2MzMmVmOWMwNzQ2N2NhZGUzYjcyYjRiNmVkMDc3XzMtNC0xLTEtMTA5ODc2_1650c169-0f6e-4d32-b817-d394cbe3ee06">52,910</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summit Therapeutics Inc. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div></div><ix:continuation id="i30fe2c56d40a455c9188ddfaf4148a5a" continuedAt="ieda16ed1933c48c4a596dafea6b46ac4"><ix:nonNumeric contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTEvZnJhZzo2YTM0ODA1OTRlOGY0MDQ2YmU4NGM5MTBjNDUyOTkzMS90ZXh0cmVnaW9uOjZhMzQ4MDU5NGU4ZjQwNDZiZTg0YzkxMGM0NTI5OTMxXzEwMTU3_7d719edc-b2bb-40d4-901b-27aa77361dba" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant components of the provision for income taxes are as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.198%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current income tax benefit:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Federal United States</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" decimals="-3" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTEvZnJhZzo2YTM0ODA1OTRlOGY0MDQ2YmU4NGM5MTBjNDUyOTkzMS90YWJsZTpmNWZiZWZhMWQ5ZDY0MTM3OTA3MWM5MTIyNjg1ZDgyYi90YWJsZXJhbmdlOmY1ZmJlZmExZDlkNjQxMzc5MDcxYzkxMjI2ODVkODJiXzMtMS0xLTEtMTA5ODc2_4688d01c-21c7-4bf7-8dbc-db370fdc359b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTEvZnJhZzo2YTM0ODA1OTRlOGY0MDQ2YmU4NGM5MTBjNDUyOTkzMS90YWJsZTpmNWZiZWZhMWQ5ZDY0MTM3OTA3MWM5MTIyNjg1ZDgyYi90YWJsZXJhbmdlOmY1ZmJlZmExZDlkNjQxMzc5MDcxYzkxMjI2ODVkODJiXzMtMy0xLTEtMTA5ODc2_4e52c4a7-17df-4264-85c8-41c79d7ad208">215</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State - United States</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTEvZnJhZzo2YTM0ODA1OTRlOGY0MDQ2YmU4NGM5MTBjNDUyOTkzMS90YWJsZTpmNWZiZWZhMWQ5ZDY0MTM3OTA3MWM5MTIyNjg1ZDgyYi90YWJsZXJhbmdlOmY1ZmJlZmExZDlkNjQxMzc5MDcxYzkxMjI2ODVkODJiXzQtMS0xLTEtMTA5ODc2_c04431a7-09d7-41f8-b3ad-d6714921d813">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTEvZnJhZzo2YTM0ODA1OTRlOGY0MDQ2YmU4NGM5MTBjNDUyOTkzMS90YWJsZTpmNWZiZWZhMWQ5ZDY0MTM3OTA3MWM5MTIyNjg1ZDgyYi90YWJsZXJhbmdlOmY1ZmJlZmExZDlkNjQxMzc5MDcxYzkxMjI2ODVkODJiXzQtMy0xLTEtMTA5ODc2_b10ca8a3-8130-4b67-8f28-90158f2bac64">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-United States</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" decimals="-3" name="us-gaap:CurrentForeignTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTEvZnJhZzo2YTM0ODA1OTRlOGY0MDQ2YmU4NGM5MTBjNDUyOTkzMS90YWJsZTpmNWZiZWZhMWQ5ZDY0MTM3OTA3MWM5MTIyNjg1ZDgyYi90YWJsZXJhbmdlOmY1ZmJlZmExZDlkNjQxMzc5MDcxYzkxMjI2ODVkODJiXzUtMS0xLTEtMTA5ODc2_a7d29453-1054-43f6-96e3-227eb2a9b013">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231" decimals="-3" name="us-gaap:CurrentForeignTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTEvZnJhZzo2YTM0ODA1OTRlOGY0MDQ2YmU4NGM5MTBjNDUyOTkzMS90YWJsZTpmNWZiZWZhMWQ5ZDY0MTM3OTA3MWM5MTIyNjg1ZDgyYi90YWJsZXJhbmdlOmY1ZmJlZmExZDlkNjQxMzc5MDcxYzkxMjI2ODVkODJiXzUtMy0xLTEtMTA5ODc2_4168ea92-c790-4050-aac6-7b755aa33088">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTEvZnJhZzo2YTM0ODA1OTRlOGY0MDQ2YmU4NGM5MTBjNDUyOTkzMS90YWJsZTpmNWZiZWZhMWQ5ZDY0MTM3OTA3MWM5MTIyNjg1ZDgyYi90YWJsZXJhbmdlOmY1ZmJlZmExZDlkNjQxMzc5MDcxYzkxMjI2ODVkODJiXzYtMS0xLTEtMTA5ODc2_165108c4-53b5-4685-997b-cf5a236e1726">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTEvZnJhZzo2YTM0ODA1OTRlOGY0MDQ2YmU4NGM5MTBjNDUyOTkzMS90YWJsZTpmNWZiZWZhMWQ5ZDY0MTM3OTA3MWM5MTIyNjg1ZDgyYi90YWJsZXJhbmdlOmY1ZmJlZmExZDlkNjQxMzc5MDcxYzkxMjI2ODVkODJiXzYtMy0xLTEtMTA5ODc2_745228c5-a028-4991-9e47-d3548c2f75b9">213</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Federal - United States</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" decimals="-3" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTEvZnJhZzo2YTM0ODA1OTRlOGY0MDQ2YmU4NGM5MTBjNDUyOTkzMS90YWJsZTpmNWZiZWZhMWQ5ZDY0MTM3OTA3MWM5MTIyNjg1ZDgyYi90YWJsZXJhbmdlOmY1ZmJlZmExZDlkNjQxMzc5MDcxYzkxMjI2ODVkODJiXzctMS0xLTEtMTA5ODc2_f2b8a960-293e-494c-97ae-2c994ccd6b7f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231" decimals="-3" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTEvZnJhZzo2YTM0ODA1OTRlOGY0MDQ2YmU4NGM5MTBjNDUyOTkzMS90YWJsZTpmNWZiZWZhMWQ5ZDY0MTM3OTA3MWM5MTIyNjg1ZDgyYi90YWJsZXJhbmdlOmY1ZmJlZmExZDlkNjQxMzc5MDcxYzkxMjI2ODVkODJiXzctMy0xLTEtMTA5ODc2_2196f330-423c-4044-89a3-d182e2c55536">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State - United States</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" decimals="-3" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTEvZnJhZzo2YTM0ODA1OTRlOGY0MDQ2YmU4NGM5MTBjNDUyOTkzMS90YWJsZTpmNWZiZWZhMWQ5ZDY0MTM3OTA3MWM5MTIyNjg1ZDgyYi90YWJsZXJhbmdlOmY1ZmJlZmExZDlkNjQxMzc5MDcxYzkxMjI2ODVkODJiXzgtMS0xLTEtMTA5ODc2_5ae1ba15-d70f-4d3d-9906-55c14ce31c00">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231" decimals="-3" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTEvZnJhZzo2YTM0ODA1OTRlOGY0MDQ2YmU4NGM5MTBjNDUyOTkzMS90YWJsZTpmNWZiZWZhMWQ5ZDY0MTM3OTA3MWM5MTIyNjg1ZDgyYi90YWJsZXJhbmdlOmY1ZmJlZmExZDlkNjQxMzc5MDcxYzkxMjI2ODVkODJiXzgtMy0xLTEtMTA5ODc2_b9adc3cb-582c-4a9b-aada-60902286c179">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-United States</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" decimals="-3" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTEvZnJhZzo2YTM0ODA1OTRlOGY0MDQ2YmU4NGM5MTBjNDUyOTkzMS90YWJsZTpmNWZiZWZhMWQ5ZDY0MTM3OTA3MWM5MTIyNjg1ZDgyYi90YWJsZXJhbmdlOmY1ZmJlZmExZDlkNjQxMzc5MDcxYzkxMjI2ODVkODJiXzktMS0xLTEtMTA5ODc2_a085cb0c-9fd8-4d72-ab29-00b0e35ccb47">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231" decimals="-3" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTEvZnJhZzo2YTM0ODA1OTRlOGY0MDQ2YmU4NGM5MTBjNDUyOTkzMS90YWJsZTpmNWZiZWZhMWQ5ZDY0MTM3OTA3MWM5MTIyNjg1ZDgyYi90YWJsZXJhbmdlOmY1ZmJlZmExZDlkNjQxMzc5MDcxYzkxMjI2ODVkODJiXzktMy0xLTEtMTA5ODc2_dd8f9cfb-b38c-4f68-a36e-46047c071542">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total deferred tax</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" decimals="-3" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTEvZnJhZzo2YTM0ODA1OTRlOGY0MDQ2YmU4NGM5MTBjNDUyOTkzMS90YWJsZTpmNWZiZWZhMWQ5ZDY0MTM3OTA3MWM5MTIyNjg1ZDgyYi90YWJsZXJhbmdlOmY1ZmJlZmExZDlkNjQxMzc5MDcxYzkxMjI2ODVkODJiXzEwLTEtMS0xLTEwOTg3Ng_fe928ab0-74e9-4b84-b73c-1b611819fd68">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231" decimals="-3" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTEvZnJhZzo2YTM0ODA1OTRlOGY0MDQ2YmU4NGM5MTBjNDUyOTkzMS90YWJsZTpmNWZiZWZhMWQ5ZDY0MTM3OTA3MWM5MTIyNjg1ZDgyYi90YWJsZXJhbmdlOmY1ZmJlZmExZDlkNjQxMzc5MDcxYzkxMjI2ODVkODJiXzEwLTMtMS0xLTEwOTg3Ng_bde62a75-e976-46d4-a9a3-7af7c723f6ed">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total income tax benefit</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTEvZnJhZzo2YTM0ODA1OTRlOGY0MDQ2YmU4NGM5MTBjNDUyOTkzMS90YWJsZTpmNWZiZWZhMWQ5ZDY0MTM3OTA3MWM5MTIyNjg1ZDgyYi90YWJsZXJhbmdlOmY1ZmJlZmExZDlkNjQxMzc5MDcxYzkxMjI2ODVkODJiXzExLTEtMS0xLTEwOTg3Ng_af3adde1-7f14-4f61-ae5c-ef8a57297bce">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTEvZnJhZzo2YTM0ODA1OTRlOGY0MDQ2YmU4NGM5MTBjNDUyOTkzMS90YWJsZTpmNWZiZWZhMWQ5ZDY0MTM3OTA3MWM5MTIyNjg1ZDgyYi90YWJsZXJhbmdlOmY1ZmJlZmExZDlkNjQxMzc5MDcxYzkxMjI2ODVkODJiXzExLTMtMS0xLTEwOTg3Ng_f3b1175c-d324-48d8-b278-485b70cccad1">213</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div></ix:nonNumeric><div style="padding-left:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Deferred taxes are recognized for temporary differences between the basis of assets and liabilities for financial statement and income tax purposes. </span></div><div><span><br/></span></div><ix:nonNumeric contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTEvZnJhZzo2YTM0ODA1OTRlOGY0MDQ2YmU4NGM5MTBjNDUyOTkzMS90ZXh0cmVnaW9uOjZhMzQ4MDU5NGU4ZjQwNDZiZTg0YzkxMGM0NTI5OTMxXzEwMTUy_d819ae58-9c42-4737-b89b-344a2a1afab2" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The major components of deferred tax assets and liabilities are as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.742%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.468%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net operating loss carryforward</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTEvZnJhZzo2YTM0ODA1OTRlOGY0MDQ2YmU4NGM5MTBjNDUyOTkzMS90YWJsZTphODczM2E0MzA3NDA0ZTUxYWUwMWQwNTdkNzVkMzMyZi90YWJsZXJhbmdlOmE4NzMzYTQzMDc0MDRlNTFhZTAxZDA1N2Q3NWQzMzJmXzItMS0xLTEtMTA5ODc2_70877aa0-baa3-4c84-a454-227c148be516">49,422</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7372be6dc06143b5adbb4d2e83a596c5_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTEvZnJhZzo2YTM0ODA1OTRlOGY0MDQ2YmU4NGM5MTBjNDUyOTkzMS90YWJsZTphODczM2E0MzA3NDA0ZTUxYWUwMWQwNTdkNzVkMzMyZi90YWJsZXJhbmdlOmE4NzMzYTQzMDc0MDRlNTFhZTAxZDA1N2Q3NWQzMzJmXzItMy0xLTEtMTA5ODc2_94d92173-db66-4e7f-8f04-70b1324a3169">29,831</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development credit carryforward</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTEvZnJhZzo2YTM0ODA1OTRlOGY0MDQ2YmU4NGM5MTBjNDUyOTkzMS90YWJsZTphODczM2E0MzA3NDA0ZTUxYWUwMWQwNTdkNzVkMzMyZi90YWJsZXJhbmdlOmE4NzMzYTQzMDc0MDRlNTFhZTAxZDA1N2Q3NWQzMzJmXzMtMS0xLTEtMTA5ODc2_1642e2db-bea6-4100-a271-a09a4e7aad83">941</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7372be6dc06143b5adbb4d2e83a596c5_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTEvZnJhZzo2YTM0ODA1OTRlOGY0MDQ2YmU4NGM5MTBjNDUyOTkzMS90YWJsZTphODczM2E0MzA3NDA0ZTUxYWUwMWQwNTdkNzVkMzMyZi90YWJsZXJhbmdlOmE4NzMzYTQzMDc0MDRlNTFhZTAxZDA1N2Q3NWQzMzJmXzMtMy0xLTEtMTA5ODc2_9a28ee87-a54d-4208-99b5-4839d9f2602e">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTEvZnJhZzo2YTM0ODA1OTRlOGY0MDQ2YmU4NGM5MTBjNDUyOTkzMS90YWJsZTphODczM2E0MzA3NDA0ZTUxYWUwMWQwNTdkNzVkMzMyZi90YWJsZXJhbmdlOmE4NzMzYTQzMDc0MDRlNTFhZTAxZDA1N2Q3NWQzMzJmXzQtMS0xLTEtMTA5ODc2_4fcd46d8-8a64-4a7c-8bd3-26105c92e59b">2,560</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7372be6dc06143b5adbb4d2e83a596c5_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTEvZnJhZzo2YTM0ODA1OTRlOGY0MDQ2YmU4NGM5MTBjNDUyOTkzMS90YWJsZTphODczM2E0MzA3NDA0ZTUxYWUwMWQwNTdkNzVkMzMyZi90YWJsZXJhbmdlOmE4NzMzYTQzMDc0MDRlNTFhZTAxZDA1N2Q3NWQzMzJmXzQtMy0xLTEtMTA5ODc2_39e806bc-e629-48db-bdd8-6e0418ff586f">1,167</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTEvZnJhZzo2YTM0ODA1OTRlOGY0MDQ2YmU4NGM5MTBjNDUyOTkzMS90YWJsZTphODczM2E0MzA3NDA0ZTUxYWUwMWQwNTdkNzVkMzMyZi90YWJsZXJhbmdlOmE4NzMzYTQzMDc0MDRlNTFhZTAxZDA1N2Q3NWQzMzJmXzUtMS0xLTEtMTA5ODc2_e13ec877-9715-47cc-8819-79775790ca1f">1,477</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7372be6dc06143b5adbb4d2e83a596c5_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTEvZnJhZzo2YTM0ODA1OTRlOGY0MDQ2YmU4NGM5MTBjNDUyOTkzMS90YWJsZTphODczM2E0MzA3NDA0ZTUxYWUwMWQwNTdkNzVkMzMyZi90YWJsZXJhbmdlOmE4NzMzYTQzMDc0MDRlNTFhZTAxZDA1N2Q3NWQzMzJmXzUtMy0xLTEtMTA5ODc2_a2966721-bb60-41a4-8213-dae2e6590f85">491</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTEvZnJhZzo2YTM0ODA1OTRlOGY0MDQ2YmU4NGM5MTBjNDUyOTkzMS90YWJsZTphODczM2E0MzA3NDA0ZTUxYWUwMWQwNTdkNzVkMzMyZi90YWJsZXJhbmdlOmE4NzMzYTQzMDc0MDRlNTFhZTAxZDA1N2Q3NWQzMzJmXzYtMS0xLTEtMTA5ODc2_80726099-01ce-469f-829b-c8fc8b61650b">54,400</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7372be6dc06143b5adbb4d2e83a596c5_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTEvZnJhZzo2YTM0ODA1OTRlOGY0MDQ2YmU4NGM5MTBjNDUyOTkzMS90YWJsZTphODczM2E0MzA3NDA0ZTUxYWUwMWQwNTdkNzVkMzMyZi90YWJsZXJhbmdlOmE4NzMzYTQzMDc0MDRlNTFhZTAxZDA1N2Q3NWQzMzJmXzYtMy0xLTEtMTA5ODc2_47f21dc7-a2ce-4b5a-80b8-f2075d67438c">31,489</ix:nonFraction></span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible asset</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTEvZnJhZzo2YTM0ODA1OTRlOGY0MDQ2YmU4NGM5MTBjNDUyOTkzMS90YWJsZTphODczM2E0MzA3NDA0ZTUxYWUwMWQwNTdkNzVkMzMyZi90YWJsZXJhbmdlOmE4NzMzYTQzMDc0MDRlNTFhZTAxZDA1N2Q3NWQzMzJmXzktMS0xLTEtMTA5ODc2_f21b19a5-3d18-494d-b6f3-b380f583e8cc">2,600</ix:nonFraction>)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7372be6dc06143b5adbb4d2e83a596c5_I20201231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTEvZnJhZzo2YTM0ODA1OTRlOGY0MDQ2YmU4NGM5MTBjNDUyOTkzMS90YWJsZTphODczM2E0MzA3NDA0ZTUxYWUwMWQwNTdkNzVkMzMyZi90YWJsZXJhbmdlOmE4NzMzYTQzMDc0MDRlNTFhZTAxZDA1N2Q3NWQzMzJmXzktMy0xLTEtMTA5ODc2_28ce5451-a465-4c18-aba8-2bde2fcc6821">2,189</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTEvZnJhZzo2YTM0ODA1OTRlOGY0MDQ2YmU4NGM5MTBjNDUyOTkzMS90YWJsZTphODczM2E0MzA3NDA0ZTUxYWUwMWQwNTdkNzVkMzMyZi90YWJsZXJhbmdlOmE4NzMzYTQzMDc0MDRlNTFhZTAxZDA1N2Q3NWQzMzJmXzEwLTEtMS0xLTEwOTg3Ng_67dde2cf-64f3-411b-be0b-0bfe1f6ae094">54</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7372be6dc06143b5adbb4d2e83a596c5_I20201231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTEvZnJhZzo2YTM0ODA1OTRlOGY0MDQ2YmU4NGM5MTBjNDUyOTkzMS90YWJsZTphODczM2E0MzA3NDA0ZTUxYWUwMWQwNTdkNzVkMzMyZi90YWJsZXJhbmdlOmE4NzMzYTQzMDc0MDRlNTFhZTAxZDA1N2Q3NWQzMzJmXzEwLTMtMS0xLTEwOTg3Ng_92471dbb-1cf6-417a-afcd-7a5023ed0474">71</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTEvZnJhZzo2YTM0ODA1OTRlOGY0MDQ2YmU4NGM5MTBjNDUyOTkzMS90YWJsZTphODczM2E0MzA3NDA0ZTUxYWUwMWQwNTdkNzVkMzMyZi90YWJsZXJhbmdlOmE4NzMzYTQzMDc0MDRlNTFhZTAxZDA1N2Q3NWQzMzJmXzExLTEtMS0xLTEwOTg3Ng_97583218-7219-42a5-be2d-0c3cb67e76c4">2,654</ix:nonFraction>)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7372be6dc06143b5adbb4d2e83a596c5_I20201231" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTEvZnJhZzo2YTM0ODA1OTRlOGY0MDQ2YmU4NGM5MTBjNDUyOTkzMS90YWJsZTphODczM2E0MzA3NDA0ZTUxYWUwMWQwNTdkNzVkMzMyZi90YWJsZXJhbmdlOmE4NzMzYTQzMDc0MDRlNTFhZTAxZDA1N2Q3NWQzMzJmXzExLTMtMS0xLTEwOTg3Ng_d0049604-17e5-4c2c-9dfe-97aa74183f1c">2,260</ix:nonFraction>)</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net deferred tax assets before valuation allowance </span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231" decimals="-3" name="smmt:DeferredTaxAssetsLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTEvZnJhZzo2YTM0ODA1OTRlOGY0MDQ2YmU4NGM5MTBjNDUyOTkzMS90YWJsZTphODczM2E0MzA3NDA0ZTUxYWUwMWQwNTdkNzVkMzMyZi90YWJsZXJhbmdlOmE4NzMzYTQzMDc0MDRlNTFhZTAxZDA1N2Q3NWQzMzJmXzEzLTEtMS0xLTEwOTg3Ng_760d6dfc-ac7b-4941-917b-d36e5ef4ce23">51,746</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7372be6dc06143b5adbb4d2e83a596c5_I20201231" decimals="-3" name="smmt:DeferredTaxAssetsLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTEvZnJhZzo2YTM0ODA1OTRlOGY0MDQ2YmU4NGM5MTBjNDUyOTkzMS90YWJsZTphODczM2E0MzA3NDA0ZTUxYWUwMWQwNTdkNzVkMzMyZi90YWJsZXJhbmdlOmE4NzMzYTQzMDc0MDRlNTFhZTAxZDA1N2Q3NWQzMzJmXzEzLTMtMS0xLTEwOTg3Ng_cef1fa15-c76c-46ad-bfa3-1ffc893bf7b6">29,229</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTEvZnJhZzo2YTM0ODA1OTRlOGY0MDQ2YmU4NGM5MTBjNDUyOTkzMS90YWJsZTphODczM2E0MzA3NDA0ZTUxYWUwMWQwNTdkNzVkMzMyZi90YWJsZXJhbmdlOmE4NzMzYTQzMDc0MDRlNTFhZTAxZDA1N2Q3NWQzMzJmXzE0LTEtMS0xLTEwOTg3Ng_0adca284-f73a-4e1f-94db-d29dd788a729">51,746</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7372be6dc06143b5adbb4d2e83a596c5_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTEvZnJhZzo2YTM0ODA1OTRlOGY0MDQ2YmU4NGM5MTBjNDUyOTkzMS90YWJsZTphODczM2E0MzA3NDA0ZTUxYWUwMWQwNTdkNzVkMzMyZi90YWJsZXJhbmdlOmE4NzMzYTQzMDc0MDRlNTFhZTAxZDA1N2Q3NWQzMzJmXzE0LTMtMS0xLTEwOTg3Ng_d79379f2-d91e-43c7-b5f8-b5ae2fe5878c">29,229</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax, net</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTEvZnJhZzo2YTM0ODA1OTRlOGY0MDQ2YmU4NGM5MTBjNDUyOTkzMS90YWJsZTphODczM2E0MzA3NDA0ZTUxYWUwMWQwNTdkNzVkMzMyZi90YWJsZXJhbmdlOmE4NzMzYTQzMDc0MDRlNTFhZTAxZDA1N2Q3NWQzMzJmXzE1LTEtMS0xLTEwOTg3Ng_1625534b-701d-4d02-b3ab-19b5aac1fc43">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7372be6dc06143b5adbb4d2e83a596c5_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTEvZnJhZzo2YTM0ODA1OTRlOGY0MDQ2YmU4NGM5MTBjNDUyOTkzMS90YWJsZTphODczM2E0MzA3NDA0ZTUxYWUwMWQwNTdkNzVkMzMyZi90YWJsZXJhbmdlOmE4NzMzYTQzMDc0MDRlNTFhZTAxZDA1N2Q3NWQzMzJmXzE1LTMtMS0xLTEwOTg3Ng_973d0d09-10a5-454a-9370-b45cc8294687">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December 31, 2021 and 2020, the Company recorded a deferred tax asset of $<ix:nonFraction unitRef="usd" contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTEvZnJhZzo2YTM0ODA1OTRlOGY0MDQ2YmU4NGM5MTBjNDUyOTkzMS90ZXh0cmVnaW9uOjZhMzQ4MDU5NGU4ZjQwNDZiZTg0YzkxMGM0NTI5OTMxXzQ5MQ_94fbc4db-ef13-4d74-ae78-66153d55292b">54.400</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i7372be6dc06143b5adbb4d2e83a596c5_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTEvZnJhZzo2YTM0ODA1OTRlOGY0MDQ2YmU4NGM5MTBjNDUyOTkzMS90ZXh0cmVnaW9uOjZhMzQ4MDU5NGU4ZjQwNDZiZTg0YzkxMGM0NTI5OTMxXzQ5OA_ced0cacc-4d55-410c-8240-5b3105e763a5">31,489</ix:nonFraction> respectively. The Company has evaluated the positive and negative evidence bearing upon its ability to realize its deferred tax assets, which are comprised primarily of net operating loss carryforwards and excess tax benefits related to stock-based compensation. Management has considered the Company&#8217;s history of cumulative net losses in the United States ("U.S.") and the United Kingdom ("U.K."), estimated future taxable income, as well as prudent and feasible tax planning strategies, and has concluded that it is more likely than not that the Company will not realize the benefits of its U.S. federal and state deferred tax assets and U.K. deferred tax assets. Accordingly, a full valuation allowance has been established against these net deferred tax assets as of December 31, 2021 and 2020, respectively. The Company reevaluates the positive and negative evidence at each </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summit Therapeutics Inc. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div></div><ix:continuation id="ieda16ed1933c48c4a596dafea6b46ac4" continuedAt="i1d7613e06f084957b7183c1c3ee58a2e"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reporting period. The Company&#8217;s valuation allowance increased during 2021 by $<ix:nonFraction unitRef="usd" contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" decimals="-3" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTEvZnJhZzo2YTM0ODA1OTRlOGY0MDQ2YmU4NGM5MTBjNDUyOTkzMS90ZXh0cmVnaW9uOjZhMzQ4MDU5NGU4ZjQwNDZiZTg0YzkxMGM0NTI5OTMxXzE0NTg_8eb0ef27-eec5-45aa-bbc9-102fd9805ffe">22,517</ix:nonFraction> primarily due to the generation of net operating loss and stock-based compensation. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021 and 2020, the Company had U.S. Federal net operating loss carryforwards of approximately $<ix:nonFraction unitRef="usd" contextRef="i3f5f274eec6e4854a5687bcb5cfc91d9_I20211231" decimals="-3" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTEvZnJhZzo2YTM0ODA1OTRlOGY0MDQ2YmU4NGM5MTBjNDUyOTkzMS90ZXh0cmVnaW9uOjZhMzQ4MDU5NGU4ZjQwNDZiZTg0YzkxMGM0NTI5OTMxXzE2NjA_9d6f746f-0de6-48f2-8887-b5a7385a76c8">1,034</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i2ed068ac829e484093c122d76b8f373f_I20201231" decimals="-3" name="us-gaap:OperatingLossCarryforwards" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTEvZnJhZzo2YTM0ODA1OTRlOGY0MDQ2YmU4NGM5MTBjNDUyOTkzMS90ZXh0cmVnaW9uOjZhMzQ4MDU5NGU4ZjQwNDZiZTg0YzkxMGM0NTI5OTMxXzE2Njc_9e0f4da7-e027-4988-9dda-17b0f7aaa22f">232</ix:nonFraction>, respectively, which may be available to offset future income tax liabilities. The 2017 Tax Cuts and Jobs Act (&#8220; TCJA&#8221;) will generally allow losses incurred after 2017 to be carried over indefinitely, but will generally limit the net operating loss deduction to the lesser of the net operating loss carryover or 80% of a corporation&#8217;s taxable income (subject to Section 382 of the Internal Revenue Code of 1986, as amended). In addition, the Company has approximately $<ix:nonFraction unitRef="usd" contextRef="i0ef15edbb3914ab3807ad48ae9426591_I20211231" decimals="-3" name="us-gaap:OperatingLossCarryforwards" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTEvZnJhZzo2YTM0ODA1OTRlOGY0MDQ2YmU4NGM5MTBjNDUyOTkzMS90ZXh0cmVnaW9uOjZhMzQ4MDU5NGU4ZjQwNDZiZTg0YzkxMGM0NTI5OTMxXzIxMzc_6514ba44-3fd3-4004-8d9b-a82707963ad7">165</ix:nonFraction> in U.S. State loss carryforwards which expire through various dates through 2040 and as of December 31, 2021, the Company had an estimated U.S. federal research and development tax credit carryforwards of $<ix:nonFraction unitRef="usd" contextRef="i16643be7aeaf41edbc627f4639147976_I20211231" decimals="-3" name="us-gaap:TaxCreditCarryforwardAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTEvZnJhZzo2YTM0ODA1OTRlOGY0MDQ2YmU4NGM5MTBjNDUyOTkzMS90ZXh0cmVnaW9uOjZhMzQ4MDU5NGU4ZjQwNDZiZTg0YzkxMGM0NTI5OTMxXzIzNDU_4a335bcd-ec85-487e-9817-e9ba4067d59f">941</ix:nonFraction> which may be available to offset future tax liabilities, and each begin to expire in 2033. The Company also had approximately $<ix:nonFraction unitRef="usd" contextRef="i7e1be0d5904743408b0b38cc3f4a584c_I20211231" decimals="-3" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTEvZnJhZzo2YTM0ODA1OTRlOGY0MDQ2YmU4NGM5MTBjNDUyOTkzMS90ZXh0cmVnaW9uOjZhMzQ4MDU5NGU4ZjQwNDZiZTg0YzkxMGM0NTI5OTMxXzI0NzQ_999e5c9d-e976-4831-b23a-a5f4b6cb5435">191,714</ix:nonFraction> in U.K. loss carryforwards available to use against future taxable profits on a year-by-year basis (a potential deferred tax asset of $<ix:nonFraction unitRef="usd" contextRef="i7e1be0d5904743408b0b38cc3f4a584c_I20211231" decimals="-3" name="smmt:PotentialDeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTEvZnJhZzo2YTM0ODA1OTRlOGY0MDQ2YmU4NGM5MTBjNDUyOTkzMS90ZXh0cmVnaW9uOjZhMzQ4MDU5NGU4ZjQwNDZiZTg0YzkxMGM0NTI5OTMxXzI2MTE_b3a96956-3c27-44f3-b3c9-2e48cf3eadde">47,929</ix:nonFraction>). To the extent that U.K. taxable profits exceed &#163;5,000 in each year, the loss available to utilize against profits in excess of &#163;5,000 will be restricted to 50%. The U.K. loss carryforwards do not lapse and therefore, the full amount will be relieved over time provided there are sufficient profits against which the losses can be utilized. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Utilization of the U.S. net operating loss carryforwards and research and development tax credit carryforwards may be subject to a substantial annual limitation under Section 382 of the Internal Revenue Code of 1986 due to ownership changes that have occurred previously or that could occur in the future. These ownership changes may limit the amount of carryforwards that can be utilized annually to offset future taxable income. In general, an ownership change, as defined by Section 382, results from transactions increasing the ownership of certain shareholders or public groups in the stock of a corporation by more than 50% over a three-year period. The Company has not completed a study to assess whether a change of ownership has occurred, or whether there have been multiple ownership changes since its formation. Any limitation may result in the loss of a portion of the net operating loss carryforwards or research and development tax credit carryforwards before utilization.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.K. tax losses are subject to additional restrictions where there is a change in ownership in the business and certain other conditions are met. An ownership change of a UK tax resident company would occur where (directly or indirectly) a single person acquires more than half of the ordinary share capital of a company, or two or more persons each acquire a holding of at least 5% of the ordinary share capital of a company and these holdings together amount to more than half the ordinary share capital of a company. Where a change in ownership has occurred, and within three years prior to that change in ownership and five years afterwards, there is a major change in the nature and conduct of trade of that company or the trade of that business becomes small or negligible, any losses carried forward will be extinguished from the point of the change in ownership. In addition, losses accrued subsequent to April 1, 2017 will be extinguished on a change of ownership when there is a major change in the nature or conduct of a company&#8217;s business, or where there is a major change in the scale of that business, or a company ceases to carry on a particular trade or business. The Company has not completed a study to assess whether a change of ownership has occurred since its formation, or whether there has been a major change in the Company's business that would restrict the U.K. tax losses. Any limitation may result in the loss of a portion of the net operating loss carryforwards before utilization.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2017 Tax Cuts and Jobs Act (&#8220;2017 Act&#8221;) created a requirement that US corporations include in income earnings of certain controlled foreign corporations (&#8220;CFC&#8221;) under the global intangible low taxed income (&#8220;GILTI&#8221;) regime. Pursuant to the FASB Staff Q&amp;A, Topic 740 No.5. Accounting for Global Intangible Low-taxed Income, the Company is allowed to make an accounting policy election to either recognize deferred taxes for temporary basis differences expected to reverse as GILTI in future years or to provide for the tax expense related to GILTI in the year the tax is incurred as period expense only. The Company has elected to account for GILTI in the year the tax is incurred and include the current tax impact of GILTI in the effective tax rate. Given the Company's loss position in the U.S. and the valuation allowance recorded against its U.S. net deferred tax assets, these provisions have not had a material impact on the Company's consolidated financial statements.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 27, 2020, the United States enacted the Coronavirus Aid, Relief, and Economic Security Act (&#8220;CARES Act&#8221;). The Cares Act includes provisions relating to refundable payroll tax credits, deferment of the employer portion of certain payroll taxes, net operating loss carryback periods, alternative minimum tax credit refunds, modifications to the net interest deduction limitations, and technical corrections to tax depreciation methods for qualified improvement property. The CARES Act also </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summit Therapeutics Inc. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div></div><ix:continuation id="i1d7613e06f084957b7183c1c3ee58a2e"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">established a Paycheck Protection Program whereby certain small businesses are eligible for a loan to fund payroll expenses, rent, and related costs.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considered the provisions under the CARES Act and elected not to take advantage of the provisions of the CARES Act as the effect of such provisions was not expected to have a material impact on the Company&#8217;s results of operations, cash flows, and consolidated financial statements.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2021, the U.K. Government announced that from April 1, 2023, the corporation tax rate would increase to 25%. This new law was enacted on June 10, 2021. The overall effect of the change was an increase in net deferred tax assets by $<ix:nonFraction unitRef="usd" contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" decimals="-3" name="smmt:DeferredTaxAssetsNetIncreaseDecreaseDueToChangeInEnactedTaxRateAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTEvZnJhZzo2YTM0ODA1OTRlOGY0MDQ2YmU4NGM5MTBjNDUyOTkzMS90ZXh0cmVnaW9uOjZhMzQ4MDU5NGU4ZjQwNDZiZTg0YzkxMGM0NTI5OTMxXzc2MTA_b335d93d-43a6-4f49-9e92-e905f7432340"><ix:nonFraction unitRef="usd" contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" decimals="-3" name="smmt:ValuationAllowanceDeferredTaxAssetIncreaseDecreaseDueToChangeInEnactedTaxRateAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTEvZnJhZzo2YTM0ODA1OTRlOGY0MDQ2YmU4NGM5MTBjNDUyOTkzMS90ZXh0cmVnaW9uOjZhMzQ4MDU5NGU4ZjQwNDZiZTg0YzkxMGM0NTI5OTMxXzc2MTA_e1a86698-f828-4be8-8fab-e4d7f76f1f77">9,311</ix:nonFraction></ix:nonFraction> and an increase in valuation allowance by an equal amount.</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTEvZnJhZzo2YTM0ODA1OTRlOGY0MDQ2YmU4NGM5MTBjNDUyOTkzMS90ZXh0cmVnaW9uOjZhMzQ4MDU5NGU4ZjQwNDZiZTg0YzkxMGM0NTI5OTMxXzEwMTUz_0ee13b8e-ee6c-448d-a8c6-cebed369525f" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the Company's effective tax rate to the U.S. federal statutory rate is as follows: </span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.467%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:83%">Year Ended December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:83%">Year Ended December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. federal income tax statutory rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTEvZnJhZzo2YTM0ODA1OTRlOGY0MDQ2YmU4NGM5MTBjNDUyOTkzMS90YWJsZTo0MzIxNTIyOWE5ODI0NzYxYjQzYmM2ZDMyMTU2N2Q1OC90YWJsZXJhbmdlOjQzMjE1MjI5YTk4MjQ3NjFiNDNiYzZkMzIxNTY3ZDU4XzEtMi0xLTEtMTA5ODc2_4f515988-5eeb-48c3-b2a3-58f30d2052a2">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTEvZnJhZzo2YTM0ODA1OTRlOGY0MDQ2YmU4NGM5MTBjNDUyOTkzMS90YWJsZTo0MzIxNTIyOWE5ODI0NzYxYjQzYmM2ZDMyMTU2N2Q1OC90YWJsZXJhbmdlOjQzMjE1MjI5YTk4MjQ3NjFiNDNiYzZkMzIxNTY3ZDU4XzEtNC0xLTEtMTA5ODc2_5ce381a9-f209-42e3-a482-bad10c3269e2">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTEvZnJhZzo2YTM0ODA1OTRlOGY0MDQ2YmU4NGM5MTBjNDUyOTkzMS90YWJsZTo0MzIxNTIyOWE5ODI0NzYxYjQzYmM2ZDMyMTU2N2Q1OC90YWJsZXJhbmdlOjQzMjE1MjI5YTk4MjQ3NjFiNDNiYzZkMzIxNTY3ZDU4XzItMi0xLTEtMTA5ODc2_c4bb3886-6f90-4185-b735-570300b83b58">10.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTEvZnJhZzo2YTM0ODA1OTRlOGY0MDQ2YmU4NGM5MTBjNDUyOTkzMS90YWJsZTo0MzIxNTIyOWE5ODI0NzYxYjQzYmM2ZDMyMTU2N2Q1OC90YWJsZXJhbmdlOjQzMjE1MjI5YTk4MjQ3NjFiNDNiYzZkMzIxNTY3ZDU4XzItNC0xLTEtMTA5ODc2_0f1a8019-90ba-408d-83c9-51e455251736">12.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-deductible expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTEvZnJhZzo2YTM0ODA1OTRlOGY0MDQ2YmU4NGM5MTBjNDUyOTkzMS90YWJsZTo0MzIxNTIyOWE5ODI0NzYxYjQzYmM2ZDMyMTU2N2Q1OC90YWJsZXJhbmdlOjQzMjE1MjI5YTk4MjQ3NjFiNDNiYzZkMzIxNTY3ZDU4XzMtMi0xLTEtMTA5ODc2_a924daa0-181c-4fea-af49-49c83c219af0">0.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTEvZnJhZzo2YTM0ODA1OTRlOGY0MDQ2YmU4NGM5MTBjNDUyOTkzMS90YWJsZTo0MzIxNTIyOWE5ODI0NzYxYjQzYmM2ZDMyMTU2N2Q1OC90YWJsZXJhbmdlOjQzMjE1MjI5YTk4MjQ3NjFiNDNiYzZkMzIxNTY3ZDU4XzMtNC0xLTEtMTA5ODc2_a744e56d-b79b-4bb5-a221-2cf5cea1a4e9">3.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Refundable research and development tax credit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" decimals="3" name="smmt:EffectiveIncomeTaxRateReconciliationTaxCreditRefundableResearchPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTEvZnJhZzo2YTM0ODA1OTRlOGY0MDQ2YmU4NGM5MTBjNDUyOTkzMS90YWJsZTo0MzIxNTIyOWE5ODI0NzYxYjQzYmM2ZDMyMTU2N2Q1OC90YWJsZXJhbmdlOjQzMjE1MjI5YTk4MjQ3NjFiNDNiYzZkMzIxNTY3ZDU4XzQtMi0xLTEtMTA5ODc2_0d9320e0-0d89-4d33-99a9-77696076a2ab">8.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231" decimals="3" name="smmt:EffectiveIncomeTaxRateReconciliationTaxCreditRefundableResearchPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTEvZnJhZzo2YTM0ODA1OTRlOGY0MDQ2YmU4NGM5MTBjNDUyOTkzMS90YWJsZTo0MzIxNTIyOWE5ODI0NzYxYjQzYmM2ZDMyMTU2N2Q1OC90YWJsZXJhbmdlOjQzMjE1MjI5YTk4MjQ3NjFiNDNiYzZkMzIxNTY3ZDU4XzQtNC0xLTEtMTA5ODc2_f5cacc22-ddce-4e7d-b928-73e083c48dbd">7.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effect of foreign operations taxed at various rates</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTEvZnJhZzo2YTM0ODA1OTRlOGY0MDQ2YmU4NGM5MTBjNDUyOTkzMS90YWJsZTo0MzIxNTIyOWE5ODI0NzYxYjQzYmM2ZDMyMTU2N2Q1OC90YWJsZXJhbmdlOjQzMjE1MjI5YTk4MjQ3NjFiNDNiYzZkMzIxNTY3ZDU4XzUtMi0xLTEtMTA5ODc2_1b1c6713-71bb-426c-891c-39e1960a4368">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTEvZnJhZzo2YTM0ODA1OTRlOGY0MDQ2YmU4NGM5MTBjNDUyOTkzMS90YWJsZTo0MzIxNTIyOWE5ODI0NzYxYjQzYmM2ZDMyMTU2N2Q1OC90YWJsZXJhbmdlOjQzMjE1MjI5YTk4MjQ3NjFiNDNiYzZkMzIxNTY3ZDU4XzUtNC0xLTEtMTA5ODc2_754dd1a7-af9b-438b-8384-35a0ae38a2ee">0.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTEvZnJhZzo2YTM0ODA1OTRlOGY0MDQ2YmU4NGM5MTBjNDUyOTkzMS90YWJsZTo0MzIxNTIyOWE5ODI0NzYxYjQzYmM2ZDMyMTU2N2Q1OC90YWJsZXJhbmdlOjQzMjE1MjI5YTk4MjQ3NjFiNDNiYzZkMzIxNTY3ZDU4XzYtMi0xLTEtMTA5ODc2_e50d523b-a30c-49c5-8eb0-923d254b5702">1.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTEvZnJhZzo2YTM0ODA1OTRlOGY0MDQ2YmU4NGM5MTBjNDUyOTkzMS90YWJsZTo0MzIxNTIyOWE5ODI0NzYxYjQzYmM2ZDMyMTU2N2Q1OC90YWJsZXJhbmdlOjQzMjE1MjI5YTk4MjQ3NjFiNDNiYzZkMzIxNTY3ZDU4XzYtNC0xLTEtMTA5ODc2_53b39403-f42e-4775-bb8c-3dad1ce6b4a5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTEvZnJhZzo2YTM0ODA1OTRlOGY0MDQ2YmU4NGM5MTBjNDUyOTkzMS90YWJsZTo0MzIxNTIyOWE5ODI0NzYxYjQzYmM2ZDMyMTU2N2Q1OC90YWJsZXJhbmdlOjQzMjE1MjI5YTk4MjQ3NjFiNDNiYzZkMzIxNTY3ZDU4XzctMi0xLTEtMTA5ODc2_3b63ac83-c757-4b67-a48a-030276beee96">0.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTEvZnJhZzo2YTM0ODA1OTRlOGY0MDQ2YmU4NGM5MTBjNDUyOTkzMS90YWJsZTo0MzIxNTIyOWE5ODI0NzYxYjQzYmM2ZDMyMTU2N2Q1OC90YWJsZXJhbmdlOjQzMjE1MjI5YTk4MjQ3NjFiNDNiYzZkMzIxNTY3ZDU4XzctNC0xLTEtMTA5ODc2_f5468689-6c18-48bc-8855-c67725cdb2af">1.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" decimals="4" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTEvZnJhZzo2YTM0ODA1OTRlOGY0MDQ2YmU4NGM5MTBjNDUyOTkzMS90YWJsZTo0MzIxNTIyOWE5ODI0NzYxYjQzYmM2ZDMyMTU2N2Q1OC90YWJsZXJhbmdlOjQzMjE1MjI5YTk4MjQ3NjFiNDNiYzZkMzIxNTY3ZDU4XzgtMi0xLTEtMTA5ODc2_4cb54cb3-b82a-40ca-a222-90da0529a9c7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231" decimals="4" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTEvZnJhZzo2YTM0ODA1OTRlOGY0MDQ2YmU4NGM5MTBjNDUyOTkzMS90YWJsZTo0MzIxNTIyOWE5ODI0NzYxYjQzYmM2ZDMyMTU2N2Q1OC90YWJsZXJhbmdlOjQzMjE1MjI5YTk4MjQ3NjFiNDNiYzZkMzIxNTY3ZDU4XzgtNC0xLTEtMTA5ODc2_8ea6caef-123b-4afa-b3d1-a9af0689e9d8">0.30</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.K., the Company is entitled to a research and development tax relief for small and medium-sized enterprises which allows the Company an enhanced deduction rate of 230% on qualifying research and development expenditure (the tax relief). If the Company incurs tax losses, it is entitled to surrender the lesser of unrelieved tax loss sustained and the tax relief. As the realization of the tax relief does not depend on generation of future taxable income or the Company's ongoing tax status or tax position, the Company does not consider the tax relief as an element of income tax accounting under ASC 740. For the year ended December 31, 2021 and 2020, the Company recognized research and development tax relief of $<ix:nonFraction unitRef="usd" contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" decimals="-3" name="smmt:ResearchAndDevelopmentTaxCredit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTEvZnJhZzo2YTM0ODA1OTRlOGY0MDQ2YmU4NGM5MTBjNDUyOTkzMS90ZXh0cmVnaW9uOjZhMzQ4MDU5NGU4ZjQwNDZiZTg0YzkxMGM0NTI5OTMxXzg1MDY_cfd49dc7-6ee9-4564-a78d-c730ee8f981e">15,206</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231" decimals="-3" name="smmt:ResearchAndDevelopmentTaxCredit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTEvZnJhZzo2YTM0ODA1OTRlOGY0MDQ2YmU4NGM5MTBjNDUyOTkzMS90ZXh0cmVnaW9uOjZhMzQ4MDU5NGU4ZjQwNDZiZTg0YzkxMGM0NTI5OTMxXzg1MTM_f14297fb-1720-4d64-a5d9-725f7d1de2c3">9,363</ix:nonFraction> respectively, which is included in other operating income in the consolidated statements of operations and other comprehensive loss.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is the intention of the Company to reinvest the earnings of its non-U.S. subsidiaries in those operations and not to repatriate the earnings to the U.S. Accordingly, the Company does not provide for deferred taxes on differences between financial reporting and tax basis in its investments in foreign subsidiaries as they are considered permanent in duration or are not expected to reverse in the foreseeable future.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not have any uncertain tax positions as of December 31, 2021. In the U.K., tax returns for the year ended December 31, 2020 remains subject to examination by HMRC. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S., the Company files income tax returns in various states. In the U.S., tax years from 2018 remain subject to examination by the U.S. Internal Revenue Service and state tax authorities. The Company is not currently under examination by the Internal Revenue Service or any other jurisdiction for years 2018 through present. To the extent the Company has tax attribute carryforwards, the tax years in which the attribute was generated may be adjusted upon examination by the Internal Revenue Service or state tax authorities to the extent utilized in a future period. The Company&#8217;s policy is to recognize interest and penalties related to uncertain tax positions as part of its income tax provision. As of December 31, 2021, and 2020, the Company has recorded <ix:nonFraction unitRef="usd" contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231" decimals="INF" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTEvZnJhZzo2YTM0ODA1OTRlOGY0MDQ2YmU4NGM5MTBjNDUyOTkzMS90ZXh0cmVnaW9uOjZhMzQ4MDU5NGU4ZjQwNDZiZTg0YzkxMGM0NTI5OTMxXzEwMDIy_3282deaf-f2b8-4963-83df-53bcc831a7cd"><ix:nonFraction unitRef="usd" contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231" decimals="INF" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTEvZnJhZzo2YTM0ODA1OTRlOGY0MDQ2YmU4NGM5MTBjNDUyOTkzMS90ZXh0cmVnaW9uOjZhMzQ4MDU5NGU4ZjQwNDZiZTg0YzkxMGM0NTI5OTMxXzEwMDIy_5fe085eb-2c87-487f-8bd3-bb65b61c99f1"><ix:nonFraction unitRef="usd" contextRef="i7372be6dc06143b5adbb4d2e83a596c5_I20201231" decimals="INF" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTEvZnJhZzo2YTM0ODA1OTRlOGY0MDQ2YmU4NGM5MTBjNDUyOTkzMS90ZXh0cmVnaW9uOjZhMzQ4MDU5NGU4ZjQwNDZiZTg0YzkxMGM0NTI5OTMxXzEwMDIy_8d62c34b-43c2-4d8c-835e-d72ac401d555"><ix:nonFraction unitRef="usd" contextRef="i7372be6dc06143b5adbb4d2e83a596c5_I20201231" decimals="INF" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTEvZnJhZzo2YTM0ODA1OTRlOGY0MDQ2YmU4NGM5MTBjNDUyOTkzMS90ZXh0cmVnaW9uOjZhMzQ4MDU5NGU4ZjQwNDZiZTg0YzkxMGM0NTI5OTMxXzEwMDIy_90da97d1-b09d-4066-b80c-120a0527da13">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> liability for unrecognized tax benefits, interest, or penalties related to federal, state or foreign income tax matters.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summit Therapeutics Inc. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div></div><div style="text-align:justify"><span><br/></span></div><div id="i2eecdebedec64091994df5b7a96baab7_154"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11. <ix:nonNumeric contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTQvZnJhZzo2MmEwNjgyZGU2YzA0MWRlYjhhNGViZTQwMmJmYzcwYy90ZXh0cmVnaW9uOjYyYTA2ODJkZTZjMDQxZGViOGE0ZWJlNDAyYmZjNzBjXzEyMjg_39bd72d3-1c4a-4c03-bc43-b4c29281699a" continuedAt="i57ed7f38967c42fa8a2cb08c5fa3c8ce" escape="true">Loss per Share </ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i57ed7f38967c42fa8a2cb08c5fa3c8ce"><ix:nonNumeric contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTQvZnJhZzo2MmEwNjgyZGU2YzA0MWRlYjhhNGViZTQwMmJmYzcwYy90ZXh0cmVnaW9uOjYyYTA2ODJkZTZjMDQxZGViOGE0ZWJlNDAyYmZjNzBjXzEyMjU_73c23543-90b5-4d06-9faf-104d9a8dbf83" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the computation of basic and diluted net loss per share: </span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.198%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTQvZnJhZzo2MmEwNjgyZGU2YzA0MWRlYjhhNGViZTQwMmJmYzcwYy90YWJsZToyYTg4Mzg1ZmNkY2E0ZjBmOWViZTJhYWM4YjhkM2IzMi90YWJsZXJhbmdlOjJhODgzODVmY2RjYTRmMGY5ZWJlMmFhYzhiOGQzYjMyXzEtMS0xLTEtMTA5ODc2_c62441af-91b8-44c7-8bc6-44d1bdcc08af">88,602</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTQvZnJhZzo2MmEwNjgyZGU2YzA0MWRlYjhhNGViZTQwMmJmYzcwYy90YWJsZToyYTg4Mzg1ZmNkY2E0ZjBmOWViZTJhYWM4YjhkM2IzMi90YWJsZXJhbmdlOjJhODgzODVmY2RjYTRmMGY5ZWJlMmFhYzhiOGQzYjMyXzEtMy0xLTEtMTA5ODc2_aac3188b-56f6-43e4-9122-e07018301c52">52,697</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic weighted average number of shares of common stock outstanding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTQvZnJhZzo2MmEwNjgyZGU2YzA0MWRlYjhhNGViZTQwMmJmYzcwYy90YWJsZToyYTg4Mzg1ZmNkY2E0ZjBmOWViZTJhYWM4YjhkM2IzMi90YWJsZXJhbmdlOjJhODgzODVmY2RjYTRmMGY5ZWJlMmFhYzhiOGQzYjMyXzMtMS0xLTEtMTA5ODc2_11e28f38-fc49-4035-a1da-dfe36efb13f2">92,239,306</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTQvZnJhZzo2MmEwNjgyZGU2YzA0MWRlYjhhNGViZTQwMmJmYzcwYy90YWJsZToyYTg4Mzg1ZmNkY2E0ZjBmOWViZTJhYWM4YjhkM2IzMi90YWJsZXJhbmdlOjJhODgzODVmY2RjYTRmMGY5ZWJlMmFhYzhiOGQzYjMyXzMtMy0xLTEtMTA5ODc2_712bb3df-b59f-4c79-ad61-a4c5b28abfd0">69,524,148</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted weighted average number of shares of common stock outstanding</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTQvZnJhZzo2MmEwNjgyZGU2YzA0MWRlYjhhNGViZTQwMmJmYzcwYy90YWJsZToyYTg4Mzg1ZmNkY2E0ZjBmOWViZTJhYWM4YjhkM2IzMi90YWJsZXJhbmdlOjJhODgzODVmY2RjYTRmMGY5ZWJlMmFhYzhiOGQzYjMyXzQtMS0xLTEtMTA5ODc2_0a949783-24bf-4ba6-8e6b-4d35979d4756">92,239,306</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTQvZnJhZzo2MmEwNjgyZGU2YzA0MWRlYjhhNGViZTQwMmJmYzcwYy90YWJsZToyYTg4Mzg1ZmNkY2E0ZjBmOWViZTJhYWM4YjhkM2IzMi90YWJsZXJhbmdlOjJhODgzODVmY2RjYTRmMGY5ZWJlMmFhYzhiOGQzYjMyXzQtMy0xLTEtMTA5ODc2_1b6c7afa-f20e-479a-874d-55067b87c8a8">69,524,148</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic net loss per share</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTQvZnJhZzo2MmEwNjgyZGU2YzA0MWRlYjhhNGViZTQwMmJmYzcwYy90YWJsZToyYTg4Mzg1ZmNkY2E0ZjBmOWViZTJhYWM4YjhkM2IzMi90YWJsZXJhbmdlOjJhODgzODVmY2RjYTRmMGY5ZWJlMmFhYzhiOGQzYjMyXzUtMS0xLTEtMTA5ODc2_8887d1c6-0c6e-4e8d-9d46-a4f2dd17c668">0.96</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTQvZnJhZzo2MmEwNjgyZGU2YzA0MWRlYjhhNGViZTQwMmJmYzcwYy90YWJsZToyYTg4Mzg1ZmNkY2E0ZjBmOWViZTJhYWM4YjhkM2IzMi90YWJsZXJhbmdlOjJhODgzODVmY2RjYTRmMGY5ZWJlMmFhYzhiOGQzYjMyXzUtMy0xLTEtMTA5ODc2_f29d5eea-7124-4593-9df3-5db91f66aae6">0.76</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted net loss per share</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTQvZnJhZzo2MmEwNjgyZGU2YzA0MWRlYjhhNGViZTQwMmJmYzcwYy90YWJsZToyYTg4Mzg1ZmNkY2E0ZjBmOWViZTJhYWM4YjhkM2IzMi90YWJsZXJhbmdlOjJhODgzODVmY2RjYTRmMGY5ZWJlMmFhYzhiOGQzYjMyXzYtMS0xLTEtMTA5ODc2_5275471e-b2dd-41e0-9001-3d2ffd22a5e9">0.96</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTQvZnJhZzo2MmEwNjgyZGU2YzA0MWRlYjhhNGViZTQwMmJmYzcwYy90YWJsZToyYTg4Mzg1ZmNkY2E0ZjBmOWViZTJhYWM4YjhkM2IzMi90YWJsZXJhbmdlOjJhODgzODVmY2RjYTRmMGY5ZWJlMmFhYzhiOGQzYjMyXzYtMy0xLTEtMTA5ODc2_920374f9-fd01-4654-8998-bab8af736629">0.76</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div></ix:nonNumeric><div style="margin-top:1pt"><span><br/></span></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is computed by dividing the net loss by the weighted-average number of common shares outstanding for the period. Diluted net loss per share is computed by dividing the diluted net loss by the weighted-average number of common shares outstanding for the period, including potentially dilutive common shares. The dilutive effect of share options and warrants are determined under the treasury stock method using the average market price for the period.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the assumed proceeds under the treasury stock method include the average unrecognized compensation expense of stock options and warrants that are in-the-money. Since the Company was in a loss position for all periods presented, basic net loss per share is the same as diluted net loss per share for all periods, as the inclusion of all potential common share equivalents outstanding would have been anti-dilutive. </span></div><div style="margin-top:1pt"><span><br/></span></div><ix:nonNumeric contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTQvZnJhZzo2MmEwNjgyZGU2YzA0MWRlYjhhNGViZTQwMmJmYzcwYy90ZXh0cmVnaW9uOjYyYTA2ODJkZTZjMDQxZGViOGE0ZWJlNDAyYmZjNzBjXzEyMzI_ca96030d-8850-4f86-aca1-60333de58333" escape="true"><div style="margin-top:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following potentially dilutive securities were excluded from the computation of the diluted net loss per share of common stock for the periods presented because their effect would have been anti-dilutive: </span></div><div style="margin-top:1pt"><span><br/></span></div><div style="margin-top:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.198%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.523%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i532f6b25e45149648f05717f44c7c477_D20210101-20211231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTQvZnJhZzo2MmEwNjgyZGU2YzA0MWRlYjhhNGViZTQwMmJmYzcwYy90YWJsZTphY2YzYjk4ZjQ3YWI0NDUxOTZmMTU4YTNjNWRmODhkMy90YWJsZXJhbmdlOmFjZjNiOThmNDdhYjQ0NTE5NmYxNThhM2M1ZGY4OGQzXzEtMi0xLTEtMTA5ODc2_2909199a-50e7-4e51-b8d3-28cf9984b7f4">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib1c1be44b3ba438881338233be927f12_D20200101-20201231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTQvZnJhZzo2MmEwNjgyZGU2YzA0MWRlYjhhNGViZTQwMmJmYzcwYy90YWJsZTphY2YzYjk4ZjQ3YWI0NDUxOTZmMTU4YTNjNWRmODhkMy90YWJsZXJhbmdlOmFjZjNiOThmNDdhYjQ0NTE5NmYxNThhM2M1ZGY4OGQzXzEtNC0xLTEtMTA5ODc2_c098d7ef-15d3-44b9-ba22-a91eaaf1b251">26,923</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase common stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i17a5a82d4e56446b9587e3a8aad49a1b_D20210101-20211231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTQvZnJhZzo2MmEwNjgyZGU2YzA0MWRlYjhhNGViZTQwMmJmYzcwYy90YWJsZTphY2YzYjk4ZjQ3YWI0NDUxOTZmMTU4YTNjNWRmODhkMy90YWJsZXJhbmdlOmFjZjNiOThmNDdhYjQ0NTE5NmYxNThhM2M1ZGY4OGQzXzItMi0xLTEtMTA5ODc2_6ea979e2-4b80-444b-a38f-082b0710fd12">13,797,556</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5c71c63c2a0d454aa48a55ab0a0ec4ee_D20200101-20201231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTQvZnJhZzo2MmEwNjgyZGU2YzA0MWRlYjhhNGViZTQwMmJmYzcwYy90YWJsZTphY2YzYjk4ZjQ3YWI0NDUxOTZmMTU4YTNjNWRmODhkMy90YWJsZXJhbmdlOmFjZjNiOThmNDdhYjQ0NTE5NmYxNThhM2M1ZGY4OGQzXzItNC0xLTEtMTA5ODc2_112b5578-e4dd-4f4b-a0a0-0e47b061d587">3,672,968</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1dba735cd51b4bd9acdace9e3eb39523_D20210101-20211231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTQvZnJhZzo2MmEwNjgyZGU2YzA0MWRlYjhhNGViZTQwMmJmYzcwYy90YWJsZTphY2YzYjk4ZjQ3YWI0NDUxOTZmMTU4YTNjNWRmODhkMy90YWJsZXJhbmdlOmFjZjNiOThmNDdhYjQ0NTE5NmYxNThhM2M1ZGY4OGQzXzMtMi0xLTEtMTA5ODc2_330b23bb-6c21-4b5d-bed0-24139903cc18">5,821,137</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i473628003f11481a823723bf532a0274_D20200101-20201231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTQvZnJhZzo2MmEwNjgyZGU2YzA0MWRlYjhhNGViZTQwMmJmYzcwYy90YWJsZTphY2YzYjk4ZjQ3YWI0NDUxOTZmMTU4YTNjNWRmODhkMy90YWJsZXJhbmdlOmFjZjNiOThmNDdhYjQ0NTE5NmYxNThhM2M1ZGY4OGQzXzMtNC0xLTEtMTA5ODc2_5ee60f5c-cb1b-4df7-8f77-7c20c017c050">5,821,137</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares expected to be purchased under employee stock purchase plan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5bc912ce09754534905d49a8cb511c7a_D20210101-20211231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTQvZnJhZzo2MmEwNjgyZGU2YzA0MWRlYjhhNGViZTQwMmJmYzcwYy90YWJsZTphY2YzYjk4ZjQ3YWI0NDUxOTZmMTU4YTNjNWRmODhkMy90YWJsZXJhbmdlOmFjZjNiOThmNDdhYjQ0NTE5NmYxNThhM2M1ZGY4OGQzXzQtMi0xLTEtMTA5ODc2_d901eea1-782d-4783-be38-059e6f89ebe8">202,045</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2fa48e55eff24bda9a7ebf8b065a3657_D20200101-20201231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTQvZnJhZzo2MmEwNjgyZGU2YzA0MWRlYjhhNGViZTQwMmJmYzcwYy90YWJsZTphY2YzYjk4ZjQ3YWI0NDUxOTZmMTU4YTNjNWRmODhkMy90YWJsZXJhbmdlOmFjZjNiOThmNDdhYjQ0NTE5NmYxNThhM2M1ZGY4OGQzXzQtNC0xLTEtMTA5ODc2_519be26f-3c00-4442-b04b-bb02f62f6ee3">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTQvZnJhZzo2MmEwNjgyZGU2YzA0MWRlYjhhNGViZTQwMmJmYzcwYy90YWJsZTphY2YzYjk4ZjQ3YWI0NDUxOTZmMTU4YTNjNWRmODhkMy90YWJsZXJhbmdlOmFjZjNiOThmNDdhYjQ0NTE5NmYxNThhM2M1ZGY4OGQzXzUtMi0xLTEtMTA5ODc2_aefe2d4f-406f-4eb4-b99d-dbd5b2fa3039">19,820,738</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTQvZnJhZzo2MmEwNjgyZGU2YzA0MWRlYjhhNGViZTQwMmJmYzcwYy90YWJsZTphY2YzYjk4ZjQ3YWI0NDUxOTZmMTU4YTNjNWRmODhkMy90YWJsZXJhbmdlOmFjZjNiOThmNDdhYjQ0NTE5NmYxNThhM2M1ZGY4OGQzXzUtNC0xLTEtMTA5ODc2_519c3fa0-6061-48be-81db-ee0607f3aefd">9,521,028</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:1pt"><span><br/></span></div><div><span><br/></span></div><div id="i2eecdebedec64091994df5b7a96baab7_157"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12. <ix:nonNumeric contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTcvZnJhZzowZjZiOTE0MzkyZTQ0NTQ3ODFiMDExOWE2OTQwM2I4ZS90ZXh0cmVnaW9uOjBmNmI5MTQzOTJlNDQ1NDc4MWIwMTE5YTY5NDAzYjhlXzI5MTg_072fcd96-7559-42e1-8b34-29ff44fef047" continuedAt="i5def1ef873974a4b8374acc5e08f9a30" escape="true">Goodwill and Intangible Assets</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i5def1ef873974a4b8374acc5e08f9a30" continuedAt="idf891d2a12104aea9dc0b403882bea07"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Goodwill</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill is measured as the excess of the cost of the acquisition over the sum of the amounts assigned to tangible and identifiable intangible assets acquired less liabilities assumed. The Company assigns assets acquired (including goodwill) and liabilities assumed to one or more reporting units as of the date of acquisition. Typically acquisitions related to a single reporting unit do not require the allocation of goodwill to multiple reporting units. If the products obtained in an acquisition are assigned to multiple reporting units, the goodwill is distributed to the respective reporting units as part of the purchase price allocation process.</span></div></ix:continuation><div><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summit Therapeutics Inc. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div></div><ix:continuation id="idf891d2a12104aea9dc0b403882bea07" continuedAt="i0a8db732200b4ada9877eeabf53772db"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill and purchased intangible assets are reviewed for impairment annually during the fourth quarter of each fiscal year and whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. The process of evaluating the potential impairment of goodwill and intangible assets requires significant judgment. The Company regularly monitors current business conditions and other factors including, but not limited to, adverse industry or economic trends and lower projections of profitability that may impact future operating results. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s annual evaluation for impairment of goodwill consists of <ix:nonFraction unitRef="reporting_unit" contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" decimals="INF" name="us-gaap:NumberOfReportingUnits" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTcvZnJhZzowZjZiOTE0MzkyZTQ0NTQ3ODFiMDExOWE2OTQwM2I4ZS90ZXh0cmVnaW9uOjBmNmI5MTQzOTJlNDQ1NDc4MWIwMTE5YTY5NDAzYjhlXzEzMzI_dd141b3a-d11e-4b7e-bab3-da5f06157d5e">one</ix:nonFraction> reporting unit. In accordance with the Company&#8217;s policy, the Company completed its annual evaluation for impairment in the fourth quarter of 2021 using the qualitative assessment. <ix:nonFraction unitRef="usd" contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" decimals="INF" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTcvZnJhZzowZjZiOTE0MzkyZTQ0NTQ3ODFiMDExOWE2OTQwM2I4ZS90ZXh0cmVnaW9uOjBmNmI5MTQzOTJlNDQ1NDc4MWIwMTE5YTY5NDAzYjhlXzE1MTU_54e0b9a5-3dfc-4e15-ab54-154c15e3154b">No</ix:nonFraction> impairment charge was recognized for the year ended December 31, 2021 and there have been <ix:nonFraction unitRef="usd" contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231" decimals="INF" name="us-gaap:GoodwillImpairedAccumulatedImpairmentLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTcvZnJhZzowZjZiOTE0MzkyZTQ0NTQ3ODFiMDExOWE2OTQwM2I4ZS90ZXh0cmVnaW9uOjBmNmI5MTQzOTJlNDQ1NDc4MWIwMTE5YTY5NDAzYjhlXzE2MDg_5b57d322-8027-46a0-86d2-21db17739935">no</ix:nonFraction> cumulative goodwill impairment charges recognized to date.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021 and 2020, goodwill was $<ix:nonFraction unitRef="usd" contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTcvZnJhZzowZjZiOTE0MzkyZTQ0NTQ3ODFiMDExOWE2OTQwM2I4ZS90ZXh0cmVnaW9uOjBmNmI5MTQzOTJlNDQ1NDc4MWIwMTE5YTY5NDAzYjhlXzE3MTg_f695310e-b76a-402c-b05d-9687665b9112">2,009</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i7372be6dc06143b5adbb4d2e83a596c5_I20201231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTcvZnJhZzowZjZiOTE0MzkyZTQ0NTQ3ODFiMDExOWE2OTQwM2I4ZS90ZXh0cmVnaW9uOjBmNmI5MTQzOTJlNDQ1NDc4MWIwMTE5YTY5NDAzYjhlXzE3MjU_a9d7818e-a6be-4f75-95e3-5538e20f4b8c">2,030</ix:nonFraction>, respectively and represents goodwill recognized from the acquisition of Discuva Limited in December of 2017. Changes year over year are the result of foreign currency movements. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Intangible Assets</span></div><ix:continuation id="i7a52c0c9485e43a881f53ca92bb0b37e"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Components of the Company's acquired intangible assets are comprised of the following:</span></div><div style="margin-top:6pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.836%"><tr><td style="width:1.0%"></td><td style="width:49.293%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.587%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.587%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.587%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.650%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated amortization and impairment charges</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Utrophin program acquired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b2b674d2a6f48e7af3dcc03537946c3_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTcvZnJhZzowZjZiOTE0MzkyZTQ0NTQ3ODFiMDExOWE2OTQwM2I4ZS90YWJsZTpkNzhjMzExOTM4OWY0NDdkYmNlMjNjZWQwNTA2MDdmYy90YWJsZXJhbmdlOmQ3OGMzMTE5Mzg5ZjQ0N2RiY2UyM2NlZDA1MDYwN2ZjXzItMi0xLTEtMTA5ODc2_b60ebda3-f66a-4028-9047-3b0e7d15b0da">4,487</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b2b674d2a6f48e7af3dcc03537946c3_I20211231" decimals="-3" name="smmt:FiniteLivedIntangibleAssetsAccumulatedAmortizationAndImpairment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTcvZnJhZzowZjZiOTE0MzkyZTQ0NTQ3ODFiMDExOWE2OTQwM2I4ZS90YWJsZTpkNzhjMzExOTM4OWY0NDdkYmNlMjNjZWQwNTA2MDdmYy90YWJsZXJhbmdlOmQ3OGMzMTE5Mzg5ZjQ0N2RiY2UyM2NlZDA1MDYwN2ZjXzItNC0xLTEtMTA5ODc2_6ce112bf-266a-4b00-900c-fd8282e60767">4,487</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b2b674d2a6f48e7af3dcc03537946c3_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTcvZnJhZzowZjZiOTE0MzkyZTQ0NTQ3ODFiMDExOWE2OTQwM2I4ZS90YWJsZTpkNzhjMzExOTM4OWY0NDdkYmNlMjNjZWQwNTA2MDdmYy90YWJsZXJhbmdlOmQ3OGMzMTE5Mzg5ZjQ0N2RiY2UyM2NlZDA1MDYwN2ZjXzItNi0xLTEtMTA5ODc2_18395e09-bd24-4c94-8d53-f98eb7a25f1f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Discuva platform acquired</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2491765d7faa4157a0b9a7f08084dcb2_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTcvZnJhZzowZjZiOTE0MzkyZTQ0NTQ3ODFiMDExOWE2OTQwM2I4ZS90YWJsZTpkNzhjMzExOTM4OWY0NDdkYmNlMjNjZWQwNTA2MDdmYy90YWJsZXJhbmdlOmQ3OGMzMTE5Mzg5ZjQ0N2RiY2UyM2NlZDA1MDYwN2ZjXzMtMi0xLTEtMTA5ODc2_bc030ceb-64e6-4cae-adf7-3415aa27e968">14,416</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2491765d7faa4157a0b9a7f08084dcb2_I20211231" decimals="-3" name="smmt:FiniteLivedIntangibleAssetsAccumulatedAmortizationAndImpairment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTcvZnJhZzowZjZiOTE0MzkyZTQ0NTQ3ODFiMDExOWE2OTQwM2I4ZS90YWJsZTpkNzhjMzExOTM4OWY0NDdkYmNlMjNjZWQwNTA2MDdmYy90YWJsZXJhbmdlOmQ3OGMzMTE5Mzg5ZjQ0N2RiY2UyM2NlZDA1MDYwN2ZjXzMtNC0xLTEtMTA5ODc2_e44ac196-565e-4a25-8e1a-281af807d48c">4,017</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2491765d7faa4157a0b9a7f08084dcb2_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTcvZnJhZzowZjZiOTE0MzkyZTQ0NTQ3ODFiMDExOWE2OTQwM2I4ZS90YWJsZTpkNzhjMzExOTM4OWY0NDdkYmNlMjNjZWQwNTA2MDdmYy90YWJsZXJhbmdlOmQ3OGMzMTE5Mzg5ZjQ0N2RiY2UyM2NlZDA1MDYwN2ZjXzMtNi0xLTEtMTA5ODc2_7fcf7a6e-ce12-4725-8196-65d2f8b207e6">10,399</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Option over non-financial asset</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i558da201e4864ba0a1ff4a54d2b3b599_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTcvZnJhZzowZjZiOTE0MzkyZTQ0NTQ3ODFiMDExOWE2OTQwM2I4ZS90YWJsZTpkNzhjMzExOTM4OWY0NDdkYmNlMjNjZWQwNTA2MDdmYy90YWJsZXJhbmdlOmQ3OGMzMTE5Mzg5ZjQ0N2RiY2UyM2NlZDA1MDYwN2ZjXzQtMi0xLTEtMTA5ODc2_0e9bd11f-661c-448c-9228-c0e7f2b81145">912</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i558da201e4864ba0a1ff4a54d2b3b599_I20211231" decimals="-3" name="smmt:FiniteLivedIntangibleAssetsAccumulatedAmortizationAndImpairment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTcvZnJhZzowZjZiOTE0MzkyZTQ0NTQ3ODFiMDExOWE2OTQwM2I4ZS90YWJsZTpkNzhjMzExOTM4OWY0NDdkYmNlMjNjZWQwNTA2MDdmYy90YWJsZXJhbmdlOmQ3OGMzMTE5Mzg5ZjQ0N2RiY2UyM2NlZDA1MDYwN2ZjXzQtNC0xLTEtMTA5ODc2_a4e764ad-ad70-41cb-8b1b-29f279fd8d92">912</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i558da201e4864ba0a1ff4a54d2b3b599_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTcvZnJhZzowZjZiOTE0MzkyZTQ0NTQ3ODFiMDExOWE2OTQwM2I4ZS90YWJsZTpkNzhjMzExOTM4OWY0NDdkYmNlMjNjZWQwNTA2MDdmYy90YWJsZXJhbmdlOmQ3OGMzMTE5Mzg5ZjQ0N2RiY2UyM2NlZDA1MDYwN2ZjXzQtNi0xLTEtMTA5ODc2_61c783fb-7c12-454c-9233-94402362ead7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other patents and licenses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93b60cd7d5744711a30a544473f93063_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTcvZnJhZzowZjZiOTE0MzkyZTQ0NTQ3ODFiMDExOWE2OTQwM2I4ZS90YWJsZTpkNzhjMzExOTM4OWY0NDdkYmNlMjNjZWQwNTA2MDdmYy90YWJsZXJhbmdlOmQ3OGMzMTE5Mzg5ZjQ0N2RiY2UyM2NlZDA1MDYwN2ZjXzUtMi0xLTEtMTA5ODc2_4a0f9a7d-a14b-48bd-b81d-ca00250a0b7c">148</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i93b60cd7d5744711a30a544473f93063_I20211231" decimals="-3" name="smmt:FiniteLivedIntangibleAssetsAccumulatedAmortizationAndImpairment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTcvZnJhZzowZjZiOTE0MzkyZTQ0NTQ3ODFiMDExOWE2OTQwM2I4ZS90YWJsZTpkNzhjMzExOTM4OWY0NDdkYmNlMjNjZWQwNTA2MDdmYy90YWJsZXJhbmdlOmQ3OGMzMTE5Mzg5ZjQ0N2RiY2UyM2NlZDA1MDYwN2ZjXzUtNC0xLTEtMTA5ODc2_f8e620cc-1c7c-4343-b0b8-c9cf5b4b695a">148</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93b60cd7d5744711a30a544473f93063_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTcvZnJhZzowZjZiOTE0MzkyZTQ0NTQ3ODFiMDExOWE2OTQwM2I4ZS90YWJsZTpkNzhjMzExOTM4OWY0NDdkYmNlMjNjZWQwNTA2MDdmYy90YWJsZXJhbmdlOmQ3OGMzMTE5Mzg5ZjQ0N2RiY2UyM2NlZDA1MDYwN2ZjXzUtNi0xLTEtMTA5ODc2_366fb1a7-ef05-47ab-a20f-5297bdd2d4a6">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTcvZnJhZzowZjZiOTE0MzkyZTQ0NTQ3ODFiMDExOWE2OTQwM2I4ZS90YWJsZTpkNzhjMzExOTM4OWY0NDdkYmNlMjNjZWQwNTA2MDdmYy90YWJsZXJhbmdlOmQ3OGMzMTE5Mzg5ZjQ0N2RiY2UyM2NlZDA1MDYwN2ZjXzYtMi0xLTEtMTA5ODc2_73317ac4-5a30-4504-9bbc-a21bf8c9ce37">19,963</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231" decimals="-3" name="smmt:FiniteLivedIntangibleAssetsAccumulatedAmortizationAndImpairment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTcvZnJhZzowZjZiOTE0MzkyZTQ0NTQ3ODFiMDExOWE2OTQwM2I4ZS90YWJsZTpkNzhjMzExOTM4OWY0NDdkYmNlMjNjZWQwNTA2MDdmYy90YWJsZXJhbmdlOmQ3OGMzMTE5Mzg5ZjQ0N2RiY2UyM2NlZDA1MDYwN2ZjXzYtNC0xLTEtMTA5ODc2_6a6e1e6d-d75b-4910-a5c9-5550f19e0b87">9,564</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTcvZnJhZzowZjZiOTE0MzkyZTQ0NTQ3ODFiMDExOWE2OTQwM2I4ZS90YWJsZTpkNzhjMzExOTM4OWY0NDdkYmNlMjNjZWQwNTA2MDdmYy90YWJsZXJhbmdlOmQ3OGMzMTE5Mzg5ZjQ0N2RiY2UyM2NlZDA1MDYwN2ZjXzYtNi0xLTEtMTA5ODc2_ddc1243f-6498-4015-8904-4a2ede72ff29">10,399</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.397%"><tr><td style="width:1.0%"></td><td style="width:49.532%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.591%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.564%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.591%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.564%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.591%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.567%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated amortization and impairment charges</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Utrophin program acquired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf53a1912d5743a186cd8a0986d0a4c9_I20201231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTcvZnJhZzowZjZiOTE0MzkyZTQ0NTQ3ODFiMDExOWE2OTQwM2I4ZS90YWJsZTo4YjQ5MDE2MTQ2YmU0Mzg5OTY3ZjMyODE2ZGUwZTFlNC90YWJsZXJhbmdlOjhiNDkwMTYxNDZiZTQzODk5NjdmMzI4MTZkZTBlMWU0XzItMi0xLTEtMTA5ODc2_b5520808-36c7-4f3d-879e-d2577e83d2ee">4,534</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaf53a1912d5743a186cd8a0986d0a4c9_I20201231" decimals="-3" name="smmt:FiniteLivedIntangibleAssetsAccumulatedAmortizationAndImpairment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTcvZnJhZzowZjZiOTE0MzkyZTQ0NTQ3ODFiMDExOWE2OTQwM2I4ZS90YWJsZTo4YjQ5MDE2MTQ2YmU0Mzg5OTY3ZjMyODE2ZGUwZTFlNC90YWJsZXJhbmdlOjhiNDkwMTYxNDZiZTQzODk5NjdmMzI4MTZkZTBlMWU0XzItNC0xLTEtMTA5ODc2_ae8a7219-bc30-424e-9dda-f3dd3626cf2b">4,534</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf53a1912d5743a186cd8a0986d0a4c9_I20201231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTcvZnJhZzowZjZiOTE0MzkyZTQ0NTQ3ODFiMDExOWE2OTQwM2I4ZS90YWJsZTo4YjQ5MDE2MTQ2YmU0Mzg5OTY3ZjMyODE2ZGUwZTFlNC90YWJsZXJhbmdlOjhiNDkwMTYxNDZiZTQzODk5NjdmMzI4MTZkZTBlMWU0XzItNi0xLTEtMTA5ODc2_7995522d-7048-4279-82a8-35e804b6d171">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Discuva platform acquired</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2256d9dc5d54775a80518270c92d9cf_I20201231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTcvZnJhZzowZjZiOTE0MzkyZTQ0NTQ3ODFiMDExOWE2OTQwM2I4ZS90YWJsZTo4YjQ5MDE2MTQ2YmU0Mzg5OTY3ZjMyODE2ZGUwZTFlNC90YWJsZXJhbmdlOjhiNDkwMTYxNDZiZTQzODk5NjdmMzI4MTZkZTBlMWU0XzMtMi0xLTEtMTA5ODc2_40ca5c5f-f1a3-4392-8049-540380a62864">14,565</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id2256d9dc5d54775a80518270c92d9cf_I20201231" decimals="-3" name="smmt:FiniteLivedIntangibleAssetsAccumulatedAmortizationAndImpairment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTcvZnJhZzowZjZiOTE0MzkyZTQ0NTQ3ODFiMDExOWE2OTQwM2I4ZS90YWJsZTo4YjQ5MDE2MTQ2YmU0Mzg5OTY3ZjMyODE2ZGUwZTFlNC90YWJsZXJhbmdlOjhiNDkwMTYxNDZiZTQzODk5NjdmMzI4MTZkZTBlMWU0XzMtNC0xLTEtMTA5ODc2_7fb96e3a-ec3a-4bd2-b80b-ed7cb7cb531f">3,050</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2256d9dc5d54775a80518270c92d9cf_I20201231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTcvZnJhZzowZjZiOTE0MzkyZTQ0NTQ3ODFiMDExOWE2OTQwM2I4ZS90YWJsZTo4YjQ5MDE2MTQ2YmU0Mzg5OTY3ZjMyODE2ZGUwZTFlNC90YWJsZXJhbmdlOjhiNDkwMTYxNDZiZTQzODk5NjdmMzI4MTZkZTBlMWU0XzMtNi0xLTEtMTA5ODc2_28884617-2274-4053-b9dd-53970cc7f25e">11,515</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Option over non-financial asset</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74db8c4615a64aabac7a997f0967a92d_I20201231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTcvZnJhZzowZjZiOTE0MzkyZTQ0NTQ3ODFiMDExOWE2OTQwM2I4ZS90YWJsZTo4YjQ5MDE2MTQ2YmU0Mzg5OTY3ZjMyODE2ZGUwZTFlNC90YWJsZXJhbmdlOjhiNDkwMTYxNDZiZTQzODk5NjdmMzI4MTZkZTBlMWU0XzQtMi0xLTEtMTA5ODc2_aa18f209-3af7-4dc9-ac4e-81358024d33e">921</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i74db8c4615a64aabac7a997f0967a92d_I20201231" decimals="-3" name="smmt:FiniteLivedIntangibleAssetsAccumulatedAmortizationAndImpairment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTcvZnJhZzowZjZiOTE0MzkyZTQ0NTQ3ODFiMDExOWE2OTQwM2I4ZS90YWJsZTo4YjQ5MDE2MTQ2YmU0Mzg5OTY3ZjMyODE2ZGUwZTFlNC90YWJsZXJhbmdlOjhiNDkwMTYxNDZiZTQzODk5NjdmMzI4MTZkZTBlMWU0XzQtNC0xLTEtMTA5ODc2_3f2ccf86-bba4-4238-b070-a1ba1b62949e">921</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74db8c4615a64aabac7a997f0967a92d_I20201231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTcvZnJhZzowZjZiOTE0MzkyZTQ0NTQ3ODFiMDExOWE2OTQwM2I4ZS90YWJsZTo4YjQ5MDE2MTQ2YmU0Mzg5OTY3ZjMyODE2ZGUwZTFlNC90YWJsZXJhbmdlOjhiNDkwMTYxNDZiZTQzODk5NjdmMzI4MTZkZTBlMWU0XzQtNi0xLTEtMTA5ODc2_caa52ee0-d146-4ad0-a547-f088281ae637">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other patents and licenses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ae4247d97144e01bf0a9c9b8cfd0111_I20201231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTcvZnJhZzowZjZiOTE0MzkyZTQ0NTQ3ODFiMDExOWE2OTQwM2I4ZS90YWJsZTo4YjQ5MDE2MTQ2YmU0Mzg5OTY3ZjMyODE2ZGUwZTFlNC90YWJsZXJhbmdlOjhiNDkwMTYxNDZiZTQzODk5NjdmMzI4MTZkZTBlMWU0XzUtMi0xLTEtMTA5ODc2_cdf1bff6-abe4-49fc-b663-02e49bd97f53">150</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8ae4247d97144e01bf0a9c9b8cfd0111_I20201231" decimals="-3" name="smmt:FiniteLivedIntangibleAssetsAccumulatedAmortizationAndImpairment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTcvZnJhZzowZjZiOTE0MzkyZTQ0NTQ3ODFiMDExOWE2OTQwM2I4ZS90YWJsZTo4YjQ5MDE2MTQ2YmU0Mzg5OTY3ZjMyODE2ZGUwZTFlNC90YWJsZXJhbmdlOjhiNDkwMTYxNDZiZTQzODk5NjdmMzI4MTZkZTBlMWU0XzUtNC0xLTEtMTA5ODc2_bd336abe-957f-4f66-821e-e7620be1ee1d">150</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ae4247d97144e01bf0a9c9b8cfd0111_I20201231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTcvZnJhZzowZjZiOTE0MzkyZTQ0NTQ3ODFiMDExOWE2OTQwM2I4ZS90YWJsZTo4YjQ5MDE2MTQ2YmU0Mzg5OTY3ZjMyODE2ZGUwZTFlNC90YWJsZXJhbmdlOjhiNDkwMTYxNDZiZTQzODk5NjdmMzI4MTZkZTBlMWU0XzUtNi0xLTEtMTA5ODc2_507799e2-6f40-4cae-9d27-667f73abd587">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7372be6dc06143b5adbb4d2e83a596c5_I20201231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTcvZnJhZzowZjZiOTE0MzkyZTQ0NTQ3ODFiMDExOWE2OTQwM2I4ZS90YWJsZTo4YjQ5MDE2MTQ2YmU0Mzg5OTY3ZjMyODE2ZGUwZTFlNC90YWJsZXJhbmdlOjhiNDkwMTYxNDZiZTQzODk5NjdmMzI4MTZkZTBlMWU0XzYtMi0xLTEtMTA5ODc2_8acd621d-fa87-49df-8b09-bf3f325eda1f">20,170</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7372be6dc06143b5adbb4d2e83a596c5_I20201231" decimals="-3" name="smmt:FiniteLivedIntangibleAssetsAccumulatedAmortizationAndImpairment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTcvZnJhZzowZjZiOTE0MzkyZTQ0NTQ3ODFiMDExOWE2OTQwM2I4ZS90YWJsZTo4YjQ5MDE2MTQ2YmU0Mzg5OTY3ZjMyODE2ZGUwZTFlNC90YWJsZXJhbmdlOjhiNDkwMTYxNDZiZTQzODk5NjdmMzI4MTZkZTBlMWU0XzYtNC0xLTEtMTA5ODc2_23854865-e20d-4832-a82c-b118318c28b4">8,655</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7372be6dc06143b5adbb4d2e83a596c5_I20201231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTcvZnJhZzowZjZiOTE0MzkyZTQ0NTQ3ODFiMDExOWE2OTQwM2I4ZS90YWJsZTo4YjQ5MDE2MTQ2YmU0Mzg5OTY3ZjMyODE2ZGUwZTFlNC90YWJsZXJhbmdlOjhiNDkwMTYxNDZiZTQzODk5NjdmMzI4MTZkZTBlMWU0XzYtNi0xLTEtMTA5ODc2_757960b1-a5b0-4266-9286-d81f5f5f3ebb">11,515</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the year ended December 31, 2020, management identified an impairment related to the option over non-financial asset pursuant to an Evaluation and Option Agreement with a collaboration partner. The partner is no longer conducting antibiotic candidate programs over which the Company had the option, management therefore determined that the fair value of the option to acquire the assignment of the proprietary rights for antibiotic candidates is $<ix:nonFraction unitRef="usd" contextRef="i74db8c4615a64aabac7a997f0967a92d_I20201231" decimals="INF" name="us-gaap:FiniteLivedIntangibleAssetsFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTcvZnJhZzowZjZiOTE0MzkyZTQ0NTQ3ODFiMDExOWE2OTQwM2I4ZS90ZXh0cmVnaW9uOjBmNmI5MTQzOTJlNDQ1NDc4MWIwMTE5YTY5NDAzYjhlXzI0NzY_adcf8964-e18b-438e-bcb7-76bb656ef399">0</ix:nonFraction>. Accordingly, the asset was written off in its entirety resulting in an impairment charge of $<ix:nonFraction unitRef="usd" contextRef="i137b9502c9084c29a43d474c1b31e151_D20200101-20201231" decimals="-3" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTcvZnJhZzowZjZiOTE0MzkyZTQ0NTQ3ODFiMDExOWE2OTQwM2I4ZS90ZXh0cmVnaW9uOjBmNmI5MTQzOTJlNDQ1NDc4MWIwMTE5YTY5NDAzYjhlXzI1NzI_7ff29c64-599d-4963-80b5-0f03612443a7">859</ix:nonFraction> recognized in operating expenses.</span></div></ix:continuation><div style="margin-top:6pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense was $<ix:nonFraction unitRef="usd" contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTcvZnJhZzowZjZiOTE0MzkyZTQ0NTQ3ODFiMDExOWE2OTQwM2I4ZS90ZXh0cmVnaW9uOjBmNmI5MTQzOTJlNDQ1NDc4MWIwMTE5YTY5NDAzYjhlXzI2MzU_8859662f-94ca-4dcb-a273-3cb79382a59a">1,017</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTcvZnJhZzowZjZiOTE0MzkyZTQ0NTQ3ODFiMDExOWE2OTQwM2I4ZS90ZXh0cmVnaW9uOjBmNmI5MTQzOTJlNDQ1NDc4MWIwMTE5YTY5NDAzYjhlXzI2NDI_a47cd5d9-b9c8-471e-879f-45e273b7fd2a">1,250</ix:nonFraction> for the years ended December 31, 2021 and 2020, respectively. The weighted-average remaining life at December 31, 2021 for our Discuva platform intangible asset was approximately <ix:nonNumeric contextRef="ia3f12147410f43d28d06362b9dba4771_D20210101-20211231" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTcvZnJhZzowZjZiOTE0MzkyZTQ0NTQ3ODFiMDExOWE2OTQwM2I4ZS90ZXh0cmVnaW9uOjBmNmI5MTQzOTJlNDQ1NDc4MWIwMTE5YTY5NDAzYjhlXzI4MDk_7cd480e3-def9-4647-ab06-ba63367beb2d">10.4</ix:nonNumeric> years. </span></div></ix:continuation><div><span><br/></span></div><div><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summit Therapeutics Inc. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div></div><ix:continuation id="i0a8db732200b4ada9877eeabf53772db"><ix:nonNumeric contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTcvZnJhZzowZjZiOTE0MzkyZTQ0NTQ3ODFiMDExOWE2OTQwM2I4ZS90ZXh0cmVnaW9uOjBmNmI5MTQzOTJlNDQ1NDc4MWIwMTE5YTY5NDAzYjhlXzI5MTY_73ecaeb9-d05d-4f0d-add6-38edafda05e5" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated net amortization expense related to acquired intangible assets for future years is:</span></div><div><span><br/></span></div><div style="padding-left:72pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:62.134%"><tr><td style="width:1.0%"></td><td style="width:74.194%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.430%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTcvZnJhZzowZjZiOTE0MzkyZTQ0NTQ3ODFiMDExOWE2OTQwM2I4ZS90YWJsZTpiZjYyMDU4NWIwMzU0NzM2ODVhMTkwMzhmOTM0M2ZkNS90YWJsZXJhbmdlOmJmNjIwNTg1YjAzNTQ3MzY4NWExOTAzOGY5MzQzZmQ1XzEtMi0xLTEtMTA5ODc2_9ba500f5-6853-4779-9748-13844de5849b">999</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTcvZnJhZzowZjZiOTE0MzkyZTQ0NTQ3ODFiMDExOWE2OTQwM2I4ZS90YWJsZTpiZjYyMDU4NWIwMzU0NzM2ODVhMTkwMzhmOTM0M2ZkNS90YWJsZXJhbmdlOmJmNjIwNTg1YjAzNTQ3MzY4NWExOTAzOGY5MzQzZmQ1XzItMi0xLTEtMTA5ODc2_db06c8aa-3e8d-4b1b-a54d-7ed98a25b0d2">999</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTcvZnJhZzowZjZiOTE0MzkyZTQ0NTQ3ODFiMDExOWE2OTQwM2I4ZS90YWJsZTpiZjYyMDU4NWIwMzU0NzM2ODVhMTkwMzhmOTM0M2ZkNS90YWJsZXJhbmdlOmJmNjIwNTg1YjAzNTQ3MzY4NWExOTAzOGY5MzQzZmQ1XzMtMi0xLTEtMTA5ODc2_bf94a537-3722-4214-9394-97e74d3b3186">999</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTcvZnJhZzowZjZiOTE0MzkyZTQ0NTQ3ODFiMDExOWE2OTQwM2I4ZS90YWJsZTpiZjYyMDU4NWIwMzU0NzM2ODVhMTkwMzhmOTM0M2ZkNS90YWJsZXJhbmdlOmJmNjIwNTg1YjAzNTQ3MzY4NWExOTAzOGY5MzQzZmQ1XzQtMi0xLTEtMTA5ODc2_c890100a-ef08-46a3-b15a-6eac74f1e563">999</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTcvZnJhZzowZjZiOTE0MzkyZTQ0NTQ3ODFiMDExOWE2OTQwM2I4ZS90YWJsZTpiZjYyMDU4NWIwMzU0NzM2ODVhMTkwMzhmOTM0M2ZkNS90YWJsZXJhbmdlOmJmNjIwNTg1YjAzNTQ3MzY4NWExOTAzOGY5MzQzZmQ1XzUtMi0xLTEtMTA5ODc2_44574bf2-09cd-4e9b-b7fd-93279b971fa5">999</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTcvZnJhZzowZjZiOTE0MzkyZTQ0NTQ3ODFiMDExOWE2OTQwM2I4ZS90YWJsZTpiZjYyMDU4NWIwMzU0NzM2ODVhMTkwMzhmOTM0M2ZkNS90YWJsZXJhbmdlOmJmNjIwNTg1YjAzNTQ3MzY4NWExOTAzOGY5MzQzZmQ1XzYtMi0xLTEtMTA5ODc2_a756fd78-c37c-4a61-972d-1626524af8b2">5,404</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div id="i2eecdebedec64091994df5b7a96baab7_160"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13. <ix:nonNumeric contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNjAvZnJhZzo4M2ZiOGEyNGZmNzQ0ZGFhYmM1ZDliYjdiZDFjODk5YS90ZXh0cmVnaW9uOjgzZmI4YTI0ZmY3NDRkYWFiYzVkOWJiN2JkMWM4OTlhXzE0OQ_a61cc376-bcd3-477e-b9a9-e66a32579ba4" continuedAt="i28e22e50fc4147c6b1f34e5da642ae75" escape="true">Property and Equipment </ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i28e22e50fc4147c6b1f34e5da642ae75"><ix:continuation id="ifaefce4b05034c5792df085947e97a3c"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consisted of the following:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.421%"><tr><td style="width:1.0%"></td><td style="width:58.367%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.774%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.582%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.777%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6f9b4ae5c0b4a59bd0bbd8975258bb6_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNjAvZnJhZzo4M2ZiOGEyNGZmNzQ0ZGFhYmM1ZDliYjdiZDFjODk5YS90YWJsZTo0MTZlNTIxZDhjOGY0Yzk4YjY3MmMxZThmNTY0N2QzMC90YWJsZXJhbmdlOjQxNmU1MjFkOGM4ZjRjOThiNjcyYzFlOGY1NjQ3ZDMwXzEtMS0xLTEtMTA5ODc2_35968cb6-75d7-4873-b93a-b12c4adb3330">2,626</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if02dcbd0b04f40f08ccd958c30a79c08_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNjAvZnJhZzo4M2ZiOGEyNGZmNzQ0ZGFhYmM1ZDliYjdiZDFjODk5YS90YWJsZTo0MTZlNTIxZDhjOGY0Yzk4YjY3MmMxZThmNTY0N2QzMC90YWJsZXJhbmdlOjQxNmU1MjFkOGM4ZjRjOThiNjcyYzFlOGY1NjQ3ZDMwXzEtMy0xLTEtMTA5ODc2_b8567bf1-7566-4f7f-ab1f-3fb48afd836c">759</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures, office equipment and software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic09e2474bf014397be8c508d9cbef4b5_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNjAvZnJhZzo4M2ZiOGEyNGZmNzQ0ZGFhYmM1ZDliYjdiZDFjODk5YS90YWJsZTo0MTZlNTIxZDhjOGY0Yzk4YjY3MmMxZThmNTY0N2QzMC90YWJsZXJhbmdlOjQxNmU1MjFkOGM4ZjRjOThiNjcyYzFlOGY1NjQ3ZDMwXzItMS0xLTEtMTA5ODc2_44dc6647-271c-4538-ac30-095fce0ee5b3">1,081</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30c79b436c2d47d98676b1f9a2231cdc_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNjAvZnJhZzo4M2ZiOGEyNGZmNzQ0ZGFhYmM1ZDliYjdiZDFjODk5YS90YWJsZTo0MTZlNTIxZDhjOGY0Yzk4YjY3MmMxZThmNTY0N2QzMC90YWJsZXJhbmdlOjQxNmU1MjFkOGM4ZjRjOThiNjcyYzFlOGY1NjQ3ZDMwXzItMy0xLTEtMTA5ODc2_1adf60f9-78f0-4f35-a997-4ef0a916595f">804</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib30be684902148cdbfad1b6e48d5528d_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNjAvZnJhZzo4M2ZiOGEyNGZmNzQ0ZGFhYmM1ZDliYjdiZDFjODk5YS90YWJsZTo0MTZlNTIxZDhjOGY0Yzk4YjY3MmMxZThmNTY0N2QzMC90YWJsZXJhbmdlOjQxNmU1MjFkOGM4ZjRjOThiNjcyYzFlOGY1NjQ3ZDMwXzMtMS0xLTEtMTA5ODc2_b5002bd8-7fc2-49e4-828a-ff8a8b51ca62">364</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2abb02e0508e40e5b35f04d561b326de_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNjAvZnJhZzo4M2ZiOGEyNGZmNzQ0ZGFhYmM1ZDliYjdiZDFjODk5YS90YWJsZTo0MTZlNTIxZDhjOGY0Yzk4YjY3MmMxZThmNTY0N2QzMC90YWJsZXJhbmdlOjQxNmU1MjFkOGM4ZjRjOThiNjcyYzFlOGY1NjQ3ZDMwXzMtMy0xLTEtMTA5ODc2_c6db1928-eb27-4d70-82f5-fa28d06760a5">291</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, gross</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNjAvZnJhZzo4M2ZiOGEyNGZmNzQ0ZGFhYmM1ZDliYjdiZDFjODk5YS90YWJsZTo0MTZlNTIxZDhjOGY0Yzk4YjY3MmMxZThmNTY0N2QzMC90YWJsZXJhbmdlOjQxNmU1MjFkOGM4ZjRjOThiNjcyYzFlOGY1NjQ3ZDMwXzQtMS0xLTEtMTA5ODc2_5217a9a6-61dc-4bd9-b0b6-d915634a4660">4,071</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7372be6dc06143b5adbb4d2e83a596c5_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNjAvZnJhZzo4M2ZiOGEyNGZmNzQ0ZGFhYmM1ZDliYjdiZDFjODk5YS90YWJsZTo0MTZlNTIxZDhjOGY0Yzk4YjY3MmMxZThmNTY0N2QzMC90YWJsZXJhbmdlOjQxNmU1MjFkOGM4ZjRjOThiNjcyYzFlOGY1NjQ3ZDMwXzQtMy0xLTEtMTA5ODc2_1b48677b-cbe2-4699-bac8-1ffb67b475fe">1,854</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNjAvZnJhZzo4M2ZiOGEyNGZmNzQ0ZGFhYmM1ZDliYjdiZDFjODk5YS90YWJsZTo0MTZlNTIxZDhjOGY0Yzk4YjY3MmMxZThmNTY0N2QzMC90YWJsZXJhbmdlOjQxNmU1MjFkOGM4ZjRjOThiNjcyYzFlOGY1NjQ3ZDMwXzUtMS0xLTEtMTA5ODc2_ccbe8bf0-925d-44e3-a98b-c9aead351b37">3,377</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7372be6dc06143b5adbb4d2e83a596c5_I20201231" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNjAvZnJhZzo4M2ZiOGEyNGZmNzQ0ZGFhYmM1ZDliYjdiZDFjODk5YS90YWJsZTo0MTZlNTIxZDhjOGY0Yzk4YjY3MmMxZThmNTY0N2QzMC90YWJsZXJhbmdlOjQxNmU1MjFkOGM4ZjRjOThiNjcyYzFlOGY1NjQ3ZDMwXzUtMy0xLTEtMTA5ODc2_4d964636-632c-422e-8fe1-c09108dcd67b">1,129</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNjAvZnJhZzo4M2ZiOGEyNGZmNzQ0ZGFhYmM1ZDliYjdiZDFjODk5YS90YWJsZTo0MTZlNTIxZDhjOGY0Yzk4YjY3MmMxZThmNTY0N2QzMC90YWJsZXJhbmdlOjQxNmU1MjFkOGM4ZjRjOThiNjcyYzFlOGY1NjQ3ZDMwXzYtMS0xLTEtMTA5ODc2_ad567480-94c4-4477-af1d-fa9e3e653bbf">694</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7372be6dc06143b5adbb4d2e83a596c5_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNjAvZnJhZzo4M2ZiOGEyNGZmNzQ0ZGFhYmM1ZDliYjdiZDFjODk5YS90YWJsZTo0MTZlNTIxZDhjOGY0Yzk4YjY3MmMxZThmNTY0N2QzMC90YWJsZXJhbmdlOjQxNmU1MjFkOGM4ZjRjOThiNjcyYzFlOGY1NjQ3ZDMwXzYtMy0xLTEtMTA5ODc2_a7366a60-2cdd-485f-97fc-8c5ecad4228e">725</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="margin-top:1pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense for the years ended December 31, 2021 and 2020 was $<ix:nonFraction unitRef="usd" contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" decimals="-3" name="us-gaap:Depreciation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNjAvZnJhZzo4M2ZiOGEyNGZmNzQ0ZGFhYmM1ZDliYjdiZDFjODk5YS90ZXh0cmVnaW9uOjgzZmI4YTI0ZmY3NDRkYWFiYzVkOWJiN2JkMWM4OTlhXzEyNQ_2c7a2177-5974-48c4-827f-485c99bf3afa">330</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231" decimals="-3" name="us-gaap:Depreciation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNjAvZnJhZzo4M2ZiOGEyNGZmNzQ0ZGFhYmM1ZDliYjdiZDFjODk5YS90ZXh0cmVnaW9uOjgzZmI4YTI0ZmY3NDRkYWFiYzVkOWJiN2JkMWM4OTlhXzEzMg_afb51573-8639-4af8-80af-e7dd717fc1b9">302</ix:nonFraction>, respectively.</span></div></ix:continuation><div style="margin-top:6pt"><span><br/></span></div><div id="i2eecdebedec64091994df5b7a96baab7_163"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">14. <ix:nonNumeric contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" name="us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNjMvZnJhZzo4YTQyOWYzNDA1NWU0N2U3YWM3OTI4MTJkZjVlZWM4Ni90ZXh0cmVnaW9uOjhhNDI5ZjM0MDU1ZTQ3ZTdhYzc5MjgxMmRmNWVlYzg2XzEwMTc_d385a493-287a-4ed3-8042-65f7b85cb07b" continuedAt="i56a63e537b1045b9b776cb245e2508d8" escape="true">Research and Development Prepaid Expenses and Accrued Liabilities </ix:nonNumeric></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i56a63e537b1045b9b776cb245e2508d8" continuedAt="i0954f87b0ad64b60826c32b3d20c75e7">Included within prepaid expenses at December 31, 2021 and 2020 is $<ix:nonFraction unitRef="usd" contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231" decimals="-3" name="smmt:ResearchAndDevelopmentPrepaidExpensesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNjMvZnJhZzo4YTQyOWYzNDA1NWU0N2U3YWM3OTI4MTJkZjVlZWM4Ni90ZXh0cmVnaW9uOjhhNDI5ZjM0MDU1ZTQ3ZTdhYzc5MjgxMmRmNWVlYzg2XzY1_e8d2ab82-b10d-49fc-8df8-711ad34bdde7">6,138</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i7372be6dc06143b5adbb4d2e83a596c5_I20201231" decimals="-3" name="smmt:ResearchAndDevelopmentPrepaidExpensesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNjMvZnJhZzo4YTQyOWYzNDA1NWU0N2U3YWM3OTI4MTJkZjVlZWM4Ni90ZXh0cmVnaW9uOjhhNDI5ZjM0MDU1ZTQ3ZTdhYzc5MjgxMmRmNWVlYzg2Xzcy_a6241e28-858b-43d8-835c-a0181b4954dc">8,490</ix:nonFraction>, respectively, of prepayments relating to research and development expenditures. Included within accrued liabilities at December 31, 2021 and 2020 is $<ix:nonFraction unitRef="usd" contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231" decimals="-3" name="smmt:AccruedResearchAndDevelopmentCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNjMvZnJhZzo4YTQyOWYzNDA1NWU0N2U3YWM3OTI4MTJkZjVlZWM4Ni90ZXh0cmVnaW9uOjhhNDI5ZjM0MDU1ZTQ3ZTdhYzc5MjgxMmRmNWVlYzg2XzIxMA_c7752680-411e-4ff3-9dc9-69ae6cd113a3">5,226</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i7372be6dc06143b5adbb4d2e83a596c5_I20201231" decimals="-3" name="smmt:AccruedResearchAndDevelopmentCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNjMvZnJhZzo4YTQyOWYzNDA1NWU0N2U3YWM3OTI4MTJkZjVlZWM4Ni90ZXh0cmVnaW9uOjhhNDI5ZjM0MDU1ZTQ3ZTdhYzc5MjgxMmRmNWVlYzg2XzIxNw_d97cbc5b-6df5-4167-817b-af53cc0b20ec">1,502</ix:nonFraction>, respectively, relating to research and development expenditures.</ix:continuation></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i0954f87b0ad64b60826c32b3d20c75e7">These amounts are determined based on the estimated costs to complete each study or activity, the estimation of the current stage of completion and the invoices received, as well as predetermined milestones which are not reflective of the current stage of development for prepaid expenses. However, prepaid expenses decrease and accrued liabilities increase as the activities progress, and if actual costs incurred exceed the prepaid expense, an accrual will be recorded for the liability. The key sensitivity is the estimated current stage of completion of each study or activity, which is based on information received from the supplier and the Company's operational knowledge of the work completed under those contracts.</ix:continuation> </span></div><div style="margin-bottom:6pt"><span><br/></span></div><div id="i2eecdebedec64091994df5b7a96baab7_169"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">15. <ix:nonNumeric contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNjkvZnJhZzpkOWU4MTg1NDQyMmM0OWNlYWJjNjJkZmEzY2VmYzM5My90ZXh0cmVnaW9uOmQ5ZTgxODU0NDIyYzQ5Y2VhYmM2MmRmYTNjZWZjMzkzXzEyMDQ_03cb57bd-011a-46f3-b02f-6490cbb35541" continuedAt="i1e17ee0fcd984266a7410dd5be1a230f" escape="true">Leases</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i1e17ee0fcd984266a7410dd5be1a230f" continuedAt="ibad5198544d548ae8635eb9bc1e385ac"> </ix:continuation></span></div><div><span><br/></span></div><ix:continuation id="ibad5198544d548ae8635eb9bc1e385ac" continuedAt="i55509e356d214359b59e37c665aba4b3"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">The Company has operating leases for real estate. The Company does not have any finance leases. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">During the year ended December 31, 2021, the Company recorded $<ix:nonFraction unitRef="usd" contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNjkvZnJhZzpkOWU4MTg1NDQyMmM0OWNlYWJjNjJkZmEzY2VmYzM5My90ZXh0cmVnaW9uOmQ5ZTgxODU0NDIyYzQ5Y2VhYmM2MmRmYTNjZWZjMzkzXzE3NA_923c4cda-f273-41b1-b781-b029585f70d5">3,389</ix:nonFraction> of additional right-of-use assets of which $<ix:nonFraction unitRef="usd" contextRef="i24a6a1407c6849eda580568b0680d532_D20210101-20211231" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNjkvZnJhZzpkOWU4MTg1NDQyMmM0OWNlYWJjNjJkZmEzY2VmYzM5My90ZXh0cmVnaW9uOmQ5ZTgxODU0NDIyYzQ5Y2VhYmM2MmRmYTNjZWZjMzkzXzIyMA_bc90cdf0-7aaa-4a52-b883-282763938365">2,359</ix:nonFraction> related to <ix:nonFraction unitRef="contract" contextRef="i24a6a1407c6849eda580568b0680d532_D20210101-20211231" decimals="INF" name="smmt:LesseeOperatingLeaseNumberOfContracts" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNjkvZnJhZzpkOWU4MTg1NDQyMmM0OWNlYWJjNjJkZmEzY2VmYzM5My90ZXh0cmVnaW9uOmQ5ZTgxODU0NDIyYzQ5Y2VhYmM2MmRmYTNjZWZjMzkzXzIzNA_a18e5802-5d44-4e46-847d-1f43a00b97c8">two</ix:nonFraction> new leases that commenced during the period for its Menlo Park, California, U.S. and Sawston, U.K. locations and $<ix:nonFraction unitRef="usd" contextRef="id630c360daad499f94b27cc39c3a0633_D20210101-20211231" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNjkvZnJhZzpkOWU4MTg1NDQyMmM0OWNlYWJjNjJkZmEzY2VmYzM5My90ZXh0cmVnaW9uOmQ5ZTgxODU0NDIyYzQ5Y2VhYmM2MmRmYTNjZWZjMzkzXzM1MA_77ad9b82-3886-43e2-9022-4ad4c05cacf7">1,030</ix:nonFraction> which related to <ix:nonFraction unitRef="contract" contextRef="id630c360daad499f94b27cc39c3a0633_D20210101-20211231" decimals="INF" name="smmt:LesseeOperatingLeaseNumberOfContracts" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNjkvZnJhZzpkOWU4MTg1NDQyMmM0OWNlYWJjNjJkZmEzY2VmYzM5My90ZXh0cmVnaW9uOmQ5ZTgxODU0NDIyYzQ5Y2VhYmM2MmRmYTNjZWZjMzkzXzM3MA_c4c7dde2-3a12-499b-97c2-8af419a534c7">one</ix:nonFraction> lease that was extended during the period for its Oxfordshire, U.K location.</span></div><div style="margin-bottom:3pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value of the right-of-use assets as of December 31, 2021 and 2020 is $<ix:nonFraction unitRef="usd" contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNjkvZnJhZzpkOWU4MTg1NDQyMmM0OWNlYWJjNjJkZmEzY2VmYzM5My90ZXh0cmVnaW9uOmQ5ZTgxODU0NDIyYzQ5Y2VhYmM2MmRmYTNjZWZjMzkzXzUxOA_c9210cdf-c834-4d7f-827d-17eeb5ab74c1">2,790</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i7372be6dc06143b5adbb4d2e83a596c5_I20201231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNjkvZnJhZzpkOWU4MTg1NDQyMmM0OWNlYWJjNjJkZmEzY2VmYzM5My90ZXh0cmVnaW9uOmQ5ZTgxODU0NDIyYzQ5Y2VhYmM2MmRmYTNjZWZjMzkzXzUyNQ_42b5e1e6-2d34-4c1e-856e-87b81af24944">554</ix:nonFraction>, respectively.</span></div></ix:continuation><div><span><br/></span></div><div><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summit Therapeutics Inc. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div></div><ix:continuation id="i55509e356d214359b59e37c665aba4b3" continuedAt="i4074269831384d158a55bd82bef08667"><ix:nonNumeric contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" name="us-gaap:LeaseCostTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNjkvZnJhZzpkOWU4MTg1NDQyMmM0OWNlYWJjNjJkZmEzY2VmYzM5My90ZXh0cmVnaW9uOmQ5ZTgxODU0NDIyYzQ5Y2VhYmM2MmRmYTNjZWZjMzkzXzEyMDI_e51a556c-23a8-4297-ada5-beadaed19c27" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The elements of lease expense were as follows:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.467%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lease Cost:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Fixed lease costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" decimals="-3" name="us-gaap:OperatingLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNjkvZnJhZzpkOWU4MTg1NDQyMmM0OWNlYWJjNjJkZmEzY2VmYzM5My90YWJsZTo3MWZiMWJiM2FlZmM0ZTNlODQyY2RhOTRhNDFiZTU5OS90YWJsZXJhbmdlOjcxZmIxYmIzYWVmYzRlM2U4NDJjZGE5NGE0MWJlNTk5XzUtMi0xLTEtMTA5ODc2_056d72c3-bfdd-48ef-804a-11e0efdcbaab">785</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231" decimals="-3" name="us-gaap:OperatingLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNjkvZnJhZzpkOWU4MTg1NDQyMmM0OWNlYWJjNjJkZmEzY2VmYzM5My90YWJsZTo3MWZiMWJiM2FlZmM0ZTNlODQyY2RhOTRhNDFiZTU5OS90YWJsZXJhbmdlOjcxZmIxYmIzYWVmYzRlM2U4NDJjZGE5NGE0MWJlNTk5XzUtNC0xLTEtMTA5ODc2_68c17c8a-d379-4625-ac40-2e60784763b4">478</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Variable lease costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" decimals="-3" name="us-gaap:VariableLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNjkvZnJhZzpkOWU4MTg1NDQyMmM0OWNlYWJjNjJkZmEzY2VmYzM5My90YWJsZTo3MWZiMWJiM2FlZmM0ZTNlODQyY2RhOTRhNDFiZTU5OS90YWJsZXJhbmdlOjcxZmIxYmIzYWVmYzRlM2U4NDJjZGE5NGE0MWJlNTk5XzYtMi0xLTEtMTA5ODc2_e65d3c44-1a7e-4f45-b85b-38bdea9efa0f">164</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231" decimals="-3" name="us-gaap:VariableLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNjkvZnJhZzpkOWU4MTg1NDQyMmM0OWNlYWJjNjJkZmEzY2VmYzM5My90YWJsZTo3MWZiMWJiM2FlZmM0ZTNlODQyY2RhOTRhNDFiZTU5OS90YWJsZXJhbmdlOjcxZmIxYmIzYWVmYzRlM2U4NDJjZGE5NGE0MWJlNTk5XzYtNC0xLTEtMTA5ODc2_d99859cf-45ab-485f-bdf6-379313fdb088">171</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Short-term lease</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" decimals="-3" name="us-gaap:ShortTermLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNjkvZnJhZzpkOWU4MTg1NDQyMmM0OWNlYWJjNjJkZmEzY2VmYzM5My90YWJsZTo3MWZiMWJiM2FlZmM0ZTNlODQyY2RhOTRhNDFiZTU5OS90YWJsZXJhbmdlOjcxZmIxYmIzYWVmYzRlM2U4NDJjZGE5NGE0MWJlNTk5XzctMi0xLTEtMTA5ODc2_9e544de5-a6e2-4635-aa57-bfe9a27d7418">278</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231" decimals="-3" name="us-gaap:ShortTermLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNjkvZnJhZzpkOWU4MTg1NDQyMmM0OWNlYWJjNjJkZmEzY2VmYzM5My90YWJsZTo3MWZiMWJiM2FlZmM0ZTNlODQyY2RhOTRhNDFiZTU5OS90YWJsZXJhbmdlOjcxZmIxYmIzYWVmYzRlM2U4NDJjZGE5NGE0MWJlNTk5XzctNC0xLTEtMTA5ODc2_ae800722-ce64-472e-b005-950b2396c539">272</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total lease cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNjkvZnJhZzpkOWU4MTg1NDQyMmM0OWNlYWJjNjJkZmEzY2VmYzM5My90YWJsZTo3MWZiMWJiM2FlZmM0ZTNlODQyY2RhOTRhNDFiZTU5OS90YWJsZXJhbmdlOjcxZmIxYmIzYWVmYzRlM2U4NDJjZGE5NGE0MWJlNTk5XzgtMi0xLTEtMTA5ODc2_9434c790-8d84-45ed-ac4d-1581920a5904">1,227</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231" decimals="-3" name="us-gaap:LeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNjkvZnJhZzpkOWU4MTg1NDQyMmM0OWNlYWJjNjJkZmEzY2VmYzM5My90YWJsZTo3MWZiMWJiM2FlZmM0ZTNlODQyY2RhOTRhNDFiZTU5OS90YWJsZXJhbmdlOjcxZmIxYmIzYWVmYzRlM2U4NDJjZGE5NGE0MWJlNTk5XzgtNC0xLTEtMTA5ODc2_3e3a8a00-4047-4123-95e3-cdad28a9adba">921</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average discount rate and the weighted average remaining lease term were <ix:nonFraction unitRef="number" contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNjkvZnJhZzpkOWU4MTg1NDQyMmM0OWNlYWJjNjJkZmEzY2VmYzM5My90ZXh0cmVnaW9uOmQ5ZTgxODU0NDIyYzQ5Y2VhYmM2MmRmYTNjZWZjMzkzXzY4Mg_c76f36ab-10fa-4fbf-a72e-b5bd2509aa4f">2.5</ix:nonFraction>% and <ix:nonNumeric contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNjkvZnJhZzpkOWU4MTg1NDQyMmM0OWNlYWJjNjJkZmEzY2VmYzM5My90ZXh0cmVnaW9uOmQ5ZTgxODU0NDIyYzQ5Y2VhYmM2MmRmYTNjZWZjMzkzXzY4OQ_8afce575-bd0b-43f3-bc54-908c866ba958">3.9</ix:nonNumeric> years, respectively, as of December 31, 2021. The weighted average discount rate and the weighted average remaining lease term were <ix:nonFraction unitRef="number" contextRef="i7372be6dc06143b5adbb4d2e83a596c5_I20201231" decimals="4" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNjkvZnJhZzpkOWU4MTg1NDQyMmM0OWNlYWJjNjJkZmEzY2VmYzM5My90ZXh0cmVnaW9uOmQ5ZTgxODU0NDIyYzQ5Y2VhYmM2MmRmYTNjZWZjMzkzXzgyNA_e6e18b9d-b41b-490e-b7e2-e4c2cafc3eb9">3.75</ix:nonFraction>% and <ix:nonNumeric contextRef="i7372be6dc06143b5adbb4d2e83a596c5_I20201231" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNjkvZnJhZzpkOWU4MTg1NDQyMmM0OWNlYWJjNjJkZmEzY2VmYzM5My90ZXh0cmVnaW9uOmQ5ZTgxODU0NDIyYzQ5Y2VhYmM2MmRmYTNjZWZjMzkzXzgzMQ_4ea9e2f6-b7ef-4d71-a01c-5dd5138849d6">1.1</ix:nonNumeric> years, respectively, as of December 31, 2020.</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNjkvZnJhZzpkOWU4MTg1NDQyMmM0OWNlYWJjNjJkZmEzY2VmYzM5My90ZXh0cmVnaW9uOmQ5ZTgxODU0NDIyYzQ5Y2VhYmM2MmRmYTNjZWZjMzkzXzExOTk_adb5cb5f-43a1-4fbe-bf68-0553995354c1" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future lease payments under non-cancelable leases as of December 31, 2021 are detailed as follows:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:67.397%"><tr><td style="width:1.0%"></td><td style="width:75.255%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.318%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.941%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.886%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 5.5pt 2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year Ending December 31,</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amount</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 5.5pt 2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNjkvZnJhZzpkOWU4MTg1NDQyMmM0OWNlYWJjNjJkZmEzY2VmYzM5My90YWJsZTo4OTY4MTVjMjc4MjQ0OWJmOTk4NWYxOWEzMTc5MzE1ZC90YWJsZXJhbmdlOjg5NjgxNWMyNzgyNDQ5YmY5OTg1ZjE5YTMxNzkzMTVkXzEtMi0xLTEtMTA5ODc2_a02d4e7d-9223-494f-bfa6-e22bce55db8c">1,037</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 5.5pt 2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNjkvZnJhZzpkOWU4MTg1NDQyMmM0OWNlYWJjNjJkZmEzY2VmYzM5My90YWJsZTo4OTY4MTVjMjc4MjQ0OWJmOTk4NWYxOWEzMTc5MzE1ZC90YWJsZXJhbmdlOjg5NjgxNWMyNzgyNDQ5YmY5OTg1ZjE5YTMxNzkzMTVkXzItMi0xLTEtMTA5ODc2_32f2b696-26c3-4c51-abc4-f9edf406268d">509</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNjkvZnJhZzpkOWU4MTg1NDQyMmM0OWNlYWJjNjJkZmEzY2VmYzM5My90YWJsZTo4OTY4MTVjMjc4MjQ0OWJmOTk4NWYxOWEzMTc5MzE1ZC90YWJsZXJhbmdlOjg5NjgxNWMyNzgyNDQ5YmY5OTg1ZjE5YTMxNzkzMTVkXzMtMi0xLTEtMTA5ODc2_933f326e-e0a5-4b2a-9da6-f98f0a0c6e98">508</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNjkvZnJhZzpkOWU4MTg1NDQyMmM0OWNlYWJjNjJkZmEzY2VmYzM5My90YWJsZTo4OTY4MTVjMjc4MjQ0OWJmOTk4NWYxOWEzMTc5MzE1ZC90YWJsZXJhbmdlOjg5NjgxNWMyNzgyNDQ5YmY5OTg1ZjE5YTMxNzkzMTVkXzQtMi0xLTEtMTA5ODc2_9486bbd7-dd54-415e-84cc-7f2c651ac45a">508</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNjkvZnJhZzpkOWU4MTg1NDQyMmM0OWNlYWJjNjJkZmEzY2VmYzM5My90YWJsZTo4OTY4MTVjMjc4MjQ0OWJmOTk4NWYxOWEzMTc5MzE1ZC90YWJsZXJhbmdlOjg5NjgxNWMyNzgyNDQ5YmY5OTg1ZjE5YTMxNzkzMTVkXzUtMi0xLTEtMTA5ODc2_0d4f46ea-6feb-4dbe-b090-b947d9da90bd">386</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNjkvZnJhZzpkOWU4MTg1NDQyMmM0OWNlYWJjNjJkZmEzY2VmYzM5My90YWJsZTo4OTY4MTVjMjc4MjQ0OWJmOTk4NWYxOWEzMTc5MzE1ZC90YWJsZXJhbmdlOjg5NjgxNWMyNzgyNDQ5YmY5OTg1ZjE5YTMxNzkzMTVkXzYtMi0xLTEtMTA5ODc2_4816bef0-9b12-4288-b09a-2131e8ecd76e">2,948</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 5.5pt 2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNjkvZnJhZzpkOWU4MTg1NDQyMmM0OWNlYWJjNjJkZmEzY2VmYzM5My90YWJsZTo4OTY4MTVjMjc4MjQ0OWJmOTk4NWYxOWEzMTc5MzE1ZC90YWJsZXJhbmdlOjg5NjgxNWMyNzgyNDQ5YmY5OTg1ZjE5YTMxNzkzMTVkXzctMi0xLTEtMTA5ODc2_015f357d-5dfa-4080-b24a-7b53a0b29f69">166</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNjkvZnJhZzpkOWU4MTg1NDQyMmM0OWNlYWJjNjJkZmEzY2VmYzM5My90YWJsZTo4OTY4MTVjMjc4MjQ0OWJmOTk4NWYxOWEzMTc5MzE1ZC90YWJsZXJhbmdlOjg5NjgxNWMyNzgyNDQ5YmY5OTg1ZjE5YTMxNzkzMTVkXzgtMi0xLTEtMTA5ODc2_847d2fe8-16fa-4a9d-a039-72b05eab4f7d">2,782</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liabilities balance sheet presentation:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 5.5pt 2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNjkvZnJhZzpkOWU4MTg1NDQyMmM0OWNlYWJjNjJkZmEzY2VmYzM5My90YWJsZTo4OTY4MTVjMjc4MjQ0OWJmOTk4NWYxOWEzMTc5MzE1ZC90YWJsZXJhbmdlOjg5NjgxNWMyNzgyNDQ5YmY5OTg1ZjE5YTMxNzkzMTVkXzExLTItMS0xLTEwOTg3Ng_a2f53f07-34e6-4576-a9e7-f0e8bd90e48a">1,091</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 5.5pt 2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNjkvZnJhZzpkOWU4MTg1NDQyMmM0OWNlYWJjNjJkZmEzY2VmYzM5My90YWJsZTo4OTY4MTVjMjc4MjQ0OWJmOTk4NWYxOWEzMTc5MzE1ZC90YWJsZXJhbmdlOjg5NjgxNWMyNzgyNDQ5YmY5OTg1ZjE5YTMxNzkzMTVkXzEyLTItMS0xLTEwOTg3Ng_79d67e8b-d951-4e60-a842-8acd4604099e">1,691</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNjkvZnJhZzpkOWU4MTg1NDQyMmM0OWNlYWJjNjJkZmEzY2VmYzM5My90YWJsZTo4OTY4MTVjMjc4MjQ0OWJmOTk4NWYxOWEzMTc5MzE1ZC90YWJsZXJhbmdlOjg5NjgxNWMyNzgyNDQ5YmY5OTg1ZjE5YTMxNzkzMTVkXzEzLTItMS0xLTEwOTg3Ng_9a0d1053-f32d-4cc8-82b8-a0a53d9aca84">2,782</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i4074269831384d158a55bd82bef08667">Amounts presented above do not include payments related to the Company's Cambridge, Massachusetts, United States office where the lease term is month to month and therefore was not capitalized on the balance sheet.</ix:continuation> </span></div><div><span><br/></span></div><div id="i2eecdebedec64091994df5b7a96baab7_172"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">16. <ix:nonNumeric contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" name="us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureNoncurrentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNzIvZnJhZzoyOWQxMWFmZDkwOTY0ZDY5OGQxYzdlMzVmNDllMTAwZS90ZXh0cmVnaW9uOjI5ZDExYWZkOTA5NjRkNjk4ZDFjN2UzNWY0OWUxMDBlXzExMzc_003a6c68-3107-4ae0-aafe-cde8e6e24557" continuedAt="i32336c8f40ec4d67bc5ddadfa441b29d" escape="true">Other Non-Current Liabilities</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i32336c8f40ec4d67bc5ddadfa441b29d"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included within other non-current liabilities at December 31, 2021 and 2020 is $<ix:nonFraction unitRef="usd" contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231" decimals="-3" name="smmt:BusinessCombinationAssumedContingentLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNzIvZnJhZzoyOWQxMWFmZDkwOTY0ZDY5OGQxYzdlMzVmNDllMTAwZS90ZXh0cmVnaW9uOjI5ZDExYWZkOTA5NjRkNjk4ZDFjN2UzNWY0OWUxMDBlXzc3_88ca9ea0-6477-4d22-b501-8a4a8cdd9158">2,531</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i7372be6dc06143b5adbb4d2e83a596c5_I20201231" decimals="-3" name="smmt:BusinessCombinationAssumedContingentLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNzIvZnJhZzoyOWQxMWFmZDkwOTY0ZDY5OGQxYzdlMzVmNDllMTAwZS90ZXh0cmVnaW9uOjI5ZDExYWZkOTA5NjRkNjk4ZDFjN2UzNWY0OWUxMDBlXzg0_ac0cf1a3-9165-4dc4-8ec0-02dc99ffc501">2,263</ix:nonFraction>, respectively, relating to assumed contingent liabilities. As part of the acquisition of Discuva Limited in December 2017, the Company assumed certain contingent liabilities as certain employees, former employees and former directors of Discuva Limited are eligible for payments from Discuva Limited based on specified development and clinical milestones related to proprietary product candidates developed under the Discuva Platform. The timing of these potential payments is uncertain.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contingent liability was remeasured in the third quarter of 2020 to reflect a change in the timing of expected payments following the Company's decision not to advance the DDS-01 series of antibiotics and to cease work on the gonorrhoeae program. The gain on the remeasurement of the liability recognized during the year ended December 31, 2020 of $<ix:nonFraction unitRef="usd" contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231" decimals="-3" name="smmt:GainLossOnRemeasurementOfLiabilitiesNonoperating" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNzIvZnJhZzoyOWQxMWFmZDkwOTY0ZDY5OGQxYzdlMzVmNDllMTAwZS90ZXh0cmVnaW9uOjI5ZDExYWZkOTA5NjRkNjk4ZDFjN2UzNWY0OWUxMDBlXzkyOA_033b3624-2850-45e0-97ba-57635f1f8757">480</ix:nonFraction> is included within other (expense) income in the consolidated statements of operations and comprehensive loss. There were <ix:nonFraction unitRef="usd" contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" decimals="INF" name="smmt:GainLossOnRemeasurementOfLiabilitiesNonoperating" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNzIvZnJhZzoyOWQxMWFmZDkwOTY0ZDY5OGQxYzdlMzVmNDllMTAwZS90ZXh0cmVnaW9uOjI5ZDExYWZkOTA5NjRkNjk4ZDFjN2UzNWY0OWUxMDBlXzEwNTM_374d54d7-b83c-495f-aa43-428f8a366899">no</ix:nonFraction> remeasurement losses or gains recognized during the year ended December 31, 2021.</span></div></ix:continuation><div><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><div id="i2eecdebedec64091994df5b7a96baab7_175"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summit Therapeutics Inc. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">17. <ix:nonNumeric contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNzUvZnJhZzozNzYxNzMxNjEyYWM0MmY0OGUwMWRkOTgzNjdkMzgzZi90ZXh0cmVnaW9uOjM3NjE3MzE2MTJhYzQyZjQ4ZTAxZGQ5ODM2N2QzODNmXzQxMzY_cbbd47bc-7759-42ef-9ab7-7ac344abd173" continuedAt="i063f8bb17d6e422eb87879909f7def62" escape="true">Stockholders' Equity </ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i063f8bb17d6e422eb87879909f7def62" continuedAt="i9282f5dd2a8f47db95198d2a4b2eeaa9"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Reverse Stock Split</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In conjunction with the Company&#8217;s Redomiciliation Transaction in (as defined in Note </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), the Company acquired all of the outstanding ordinary shares of Summit Therapeutics plc on the basis of one share of the Company&#8217;s common stock for every 5 ordinary shares outstanding, which had the effect of a 1-for-5 reverse stock split. On the effective date of the Redomiciliation, the number of outstanding shares was reduced from <ix:nonFraction unitRef="shares" contextRef="i065a06364b944635a5fea7a0548c3c71_I20200917" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNzUvZnJhZzozNzYxNzMxNjEyYWM0MmY0OGUwMWRkOTgzNjdkMzgzZi90ZXh0cmVnaW9uOjM3NjE3MzE2MTJhYzQyZjQ4ZTAxZGQ5ODM2N2QzODNmXzQ2MA_46ff636b-db5a-4c83-8757-6c821ec6753b">336,159,511</ix:nonFraction> to <ix:nonFraction unitRef="shares" contextRef="ib1b2bbd9c2ea4c81affedf30cb5ad225_I20200918" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNzUvZnJhZzozNzYxNzMxNjEyYWM0MmY0OGUwMWRkOTgzNjdkMzgzZi90ZXh0cmVnaW9uOjM3NjE3MzE2MTJhYzQyZjQ4ZTAxZGQ5ODM2N2QzODNmXzQ2Ng_77a213aa-2383-4c4c-80be-733d4a08abd0">67,231,903</ix:nonFraction>. All share and per share amounts in these consolidated financial statements and related notes for periods prior to the Redomiciliation Transaction have been retroactively adjusted to reflect the effect of the exchange ratio.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Common Stock</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On May 12, 2021, the Company closed its rights offering, which was fully subscribed and received aggregate gross proceeds of $<ix:nonFraction unitRef="usd" contextRef="idb475943c8884e52b4a61d6e77d4d205_D20210512-20210512" decimals="-3" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNzUvZnJhZzozNzYxNzMxNjEyYWM0MmY0OGUwMWRkOTgzNjdkMzgzZi90ZXh0cmVnaW9uOjM3NjE3MzE2MTJhYzQyZjQ4ZTAxZGQ5ODM2N2QzODNmXzgzNA_06ce20b8-9870-4e3c-9580-ca432e47e08e">75,000</ix:nonFraction> from the sale of <ix:nonFraction unitRef="shares" contextRef="idb475943c8884e52b4a61d6e77d4d205_D20210512-20210512" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNzUvZnJhZzozNzYxNzMxNjEyYWM0MmY0OGUwMWRkOTgzNjdkMzgzZi90ZXh0cmVnaW9uOjM3NjE3MzE2MTJhYzQyZjQ4ZTAxZGQ5ODM2N2QzODNmXzg1NA_18067419-14aa-404e-89c1-7efdc0db8f32">14,312,976</ix:nonFraction> shares of common stock to existing investors at a price per share of $<ix:nonFraction unitRef="usdPerShare" contextRef="i28fe3cc419e94f789497abebbcb3acff_I20210512" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNzUvZnJhZzozNzYxNzMxNjEyYWM0MmY0OGUwMWRkOTgzNjdkMzgzZi90ZXh0cmVnaW9uOjM3NjE3MzE2MTJhYzQyZjQ4ZTAxZGQ5ODM2N2QzODNmXzkyNg_024ff66a-3811-4eeb-af24-2f3cdca30a68">5.24</ix:nonFraction>. Offering costs of $<ix:nonFraction unitRef="usd" contextRef="idb475943c8884e52b4a61d6e77d4d205_D20210512-20210512" decimals="-3" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNzUvZnJhZzozNzYxNzMxNjEyYWM0MmY0OGUwMWRkOTgzNjdkMzgzZi90ZXh0cmVnaW9uOjM3NjE3MzE2MTJhYzQyZjQ4ZTAxZGQ5ODM2N2QzODNmXzk0OA_30f895c1-78de-4826-bb90-82d418f75800">159</ix:nonFraction> were incurred. In connection with the closing of the rights offering, the Second Note (see Note 20) matured and became due and the Company repaid all principal and accrued interest thereunder using a portion of the proceeds from the rights offering.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 6, 2020 the Company completed a private placement of its common stock and received gross proceeds of $<ix:nonFraction unitRef="usd" contextRef="i6a505b52efdc43a7821a6b7cc66b172e_D20201106-20201106" decimals="-3" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNzUvZnJhZzozNzYxNzMxNjEyYWM0MmY0OGUwMWRkOTgzNjdkMzgzZi90ZXh0cmVnaW9uOjM3NjE3MzE2MTJhYzQyZjQ4ZTAxZGQ5ODM2N2QzODNmXzEzMTU_bf71a633-45e4-4a7a-9d85-f7346e8d4a48">50,000</ix:nonFraction> from the issuance and sale of <ix:nonFraction unitRef="shares" contextRef="i6a505b52efdc43a7821a6b7cc66b172e_D20201106-20201106" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNzUvZnJhZzozNzYxNzMxNjEyYWM0MmY0OGUwMWRkOTgzNjdkMzgzZi90ZXh0cmVnaW9uOjM3NjE3MzE2MTJhYzQyZjQ4ZTAxZGQ5ODM2N2QzODNmXzEzNDg_2eb360d5-03ca-469f-b88d-42cc6b2c8b9c">14,970,060</ix:nonFraction> shares of common stock to Mr. Robert W. Duggan and two other existing shareholders of the Company at a price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i1cda89fc1bbb4c82a3c7a93284736d74_I20201106" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNzUvZnJhZzozNzYxNzMxNjEyYWM0MmY0OGUwMWRkOTgzNjdkMzgzZi90ZXh0cmVnaW9uOjM3NjE3MzE2MTJhYzQyZjQ4ZTAxZGQ5ODM2N2QzODNmXzE0NjM_5954e1cb-1c15-4f55-9282-24a7e1441939">3.34</ix:nonFraction> per share. Offering costs of $<ix:nonFraction unitRef="usd" contextRef="i6a505b52efdc43a7821a6b7cc66b172e_D20201106-20201106" decimals="-3" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNzUvZnJhZzozNzYxNzMxNjEyYWM0MmY0OGUwMWRkOTgzNjdkMzgzZi90ZXh0cmVnaW9uOjM3NjE3MzE2MTJhYzQyZjQ4ZTAxZGQ5ODM2N2QzODNmXzE0OTU_5c32777c-6f40-4785-848f-08f4667aaf7f">48</ix:nonFraction> were incurred.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 24, 2019, the Company completed a private placement of its common stock, and received aggregate gross proceeds of $<ix:nonFraction unitRef="usd" contextRef="ief39eb2f075b4eb78fa3e4ffac9e4610_D20191224-20191224" decimals="-3" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNzUvZnJhZzozNzYxNzMxNjEyYWM0MmY0OGUwMWRkOTgzNjdkMzgzZi90ZXh0cmVnaW9uOjM3NjE3MzE2MTJhYzQyZjQ4ZTAxZGQ5ODM2N2QzODNmXzE2NDA_b1f9d420-c3d5-4172-9e2f-5abb35361fd5">50,000</ix:nonFraction> from the issuance and sale of <ix:nonFraction unitRef="shares" contextRef="ief39eb2f075b4eb78fa3e4ffac9e4610_D20191224-20191224" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNzUvZnJhZzozNzYxNzMxNjEyYWM0MmY0OGUwMWRkOTgzNjdkMzgzZi90ZXh0cmVnaW9uOjM3NjE3MzE2MTJhYzQyZjQ4ZTAxZGQ5ODM2N2QzODNmXzE2NzM_7181986f-d964-42ac-afaa-0bb970fb2a67">35,075,690</ix:nonFraction> shares of common stock to existing investors at a price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i5b2fdb6bad994e6eb9c9380cb3807cd6_I20191224" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNzUvZnJhZzozNzYxNzMxNjEyYWM0MmY0OGUwMWRkOTgzNjdkMzgzZi90ZXh0cmVnaW9uOjM3NjE3MzE2MTJhYzQyZjQ4ZTAxZGQ5ODM2N2QzODNmXzE3MzU_8f7e67ba-5ec8-4abc-9b80-7b153dedfe78">1.43</ix:nonFraction> per share. Offering costs of $<ix:nonFraction unitRef="usd" contextRef="ief39eb2f075b4eb78fa3e4ffac9e4610_D20191224-20191224" decimals="-3" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNzUvZnJhZzozNzYxNzMxNjEyYWM0MmY0OGUwMWRkOTgzNjdkMzgzZi90ZXh0cmVnaW9uOjM3NjE3MzE2MTJhYzQyZjQ4ZTAxZGQ5ODM2N2QzODNmXzE3Njc_bacc7150-55d8-4b22-a301-870d3a833faa">912</ix:nonFraction> were incurred. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Warrants</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the private placement on December 24, 2019, the participating investors were granted warrants with the right to subscribe for <ix:nonFraction unitRef="shares" contextRef="i5b2fdb6bad994e6eb9c9380cb3807cd6_I20191224" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNzUvZnJhZzozNzYxNzMxNjEyYWM0MmY0OGUwMWRkOTgzNjdkMzgzZi90ZXh0cmVnaW9uOjM3NjE3MzE2MTJhYzQyZjQ4ZTAxZGQ5ODM2N2QzODNmXzE5MzQ_cfe82858-09b0-4d05-b510-adb275b637bf">5,261,350</ix:nonFraction> shares of common stock at an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i5b2fdb6bad994e6eb9c9380cb3807cd6_I20191224" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNzUvZnJhZzozNzYxNzMxNjEyYWM0MmY0OGUwMWRkOTgzNjdkMzgzZi90ZXh0cmVnaW9uOjM3NjE3MzE2MTJhYzQyZjQ4ZTAxZGQ5ODM2N2QzODNmXzE5ODQ_a5e5013a-65fb-4878-ac1e-81e9c3d9b4bd">1.58</ix:nonFraction>, exercisable any time in the period commencing on the date falling six months following December 24, 2019 and ending on the tenth anniversary of admission. Each warrant entitles the warrant holder to subscribe in cash for <ix:nonFraction unitRef="shares" contextRef="i5b2fdb6bad994e6eb9c9380cb3807cd6_I20191224" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNzUvZnJhZzozNzYxNzMxNjEyYWM0MmY0OGUwMWRkOTgzNjdkMzgzZi90ZXh0cmVnaW9uOjM3NjE3MzE2MTJhYzQyZjQ4ZTAxZGQ5ODM2N2QzODNmXzIyMDk_f93dc0a9-ee12-445b-9d2c-94e782a88e38">one</ix:nonFraction> share. Shares of common stock allotted pursuant to the exercise of the warrant will rank in full for all dividends and other distributions with a record date after the exercise date with the shares of common stock in issue at that date. The Company has the option to require the warrant holder to exercise some or all of the outstanding warrants after the third anniversary date if the ten-day volume weighted average price of the shares of common stock as reported on Nasdaq represents a premium of at least <ix:nonFraction unitRef="number" contextRef="ief39eb2f075b4eb78fa3e4ffac9e4610_D20191224-20191224" decimals="INF" name="smmt:ClassOfWarrantOrRightMinimumTenDayVolumeWeightedAverageCommonStockPriceToWarrantExercisePricePremiumPercentage" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNzUvZnJhZzozNzYxNzMxNjEyYWM0MmY0OGUwMWRkOTgzNjdkMzgzZi90ZXh0cmVnaW9uOjM3NjE3MzE2MTJhYzQyZjQ4ZTAxZGQ5ODM2N2QzODNmXzI3MjE_5196f866-b63b-443a-8eb8-8aa99058f086">50</ix:nonFraction> percent to the exercise price. The warrants are classified within stockholders&#8217; equity as they are indexed to the Company's shares of common stock and require settlement in its shares of common stock with no provision for any cash settlement.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also, as part of the private placement on December 24, 2019, certain consultants were granted warrants with the right to subscribe for <ix:nonFraction unitRef="shares" contextRef="id3dfe8aa6a324f739c2caa516220e112_I20191224" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNzUvZnJhZzozNzYxNzMxNjEyYWM0MmY0OGUwMWRkOTgzNjdkMzgzZi90ZXh0cmVnaW9uOjM3NjE3MzE2MTJhYzQyZjQ4ZTAxZGQ5ODM2N2QzODNmXzMwOTQ_a63b383b-53fb-4c55-aaf5-30da51ee4e3d">3,358,732</ix:nonFraction> shares of common stock in exchange for certain services. The warrants have an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="id3dfe8aa6a324f739c2caa516220e112_I20191224" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNzUvZnJhZzozNzYxNzMxNjEyYWM0MmY0OGUwMWRkOTgzNjdkMzgzZi90ZXh0cmVnaW9uOjM3NjE3MzE2MTJhYzQyZjQ4ZTAxZGQ5ODM2N2QzODNmXzMxOTM_193b6c45-fc31-4f72-a1c5-37de9008de99">1.44</ix:nonFraction> and vest quarterly over <ix:nonNumeric contextRef="ib29a1c5799524e1987c045aee67b6831_D20191224-20191224" name="smmt:ClassOfWarrantOrRightQuarterlyVestingPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNzUvZnJhZzozNzYxNzMxNjEyYWM0MmY0OGUwMWRkOTgzNjdkMzgzZi90ZXh0cmVnaW9uOjM3NjE3MzE2MTJhYzQyZjQ4ZTAxZGQ5ODM2N2QzODNmXzMyMjA_834cc01d-c325-4ba4-998f-28e457c1f22b">three years</ix:nonNumeric>. If the consulting agreement terminated prior to <ix:nonNumeric contextRef="ib29a1c5799524e1987c045aee67b6831_D20191224-20191224" name="smmt:ClassOfWarrantOrRightQuarterlyVestingPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNzUvZnJhZzozNzYxNzMxNjEyYWM0MmY0OGUwMWRkOTgzNjdkMzgzZi90ZXh0cmVnaW9uOjM3NjE3MzE2MTJhYzQyZjQ4ZTAxZGQ5ODM2N2QzODNmXzMyNzI_69813705-cc1a-4817-9fa1-62e2be553a22">three years</ix:nonNumeric> after the date of the grant, all unvested warrants will be deemed cancelled. On June 30, 2020, the consulting agreement was terminated and <ix:nonFraction unitRef="shares" contextRef="ia5f83af41ad746ffb1aa249c3a0f7238_D20200630-20200630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNzUvZnJhZzozNzYxNzMxNjEyYWM0MmY0OGUwMWRkOTgzNjdkMzgzZi90ZXh0cmVnaW9uOjM3NjE3MzE2MTJhYzQyZjQ4ZTAxZGQ5ODM2N2QzODNmXzM0MTQ_cb95cd2e-5418-42d9-9119-e3852b1c50c1">2,798,945</ix:nonFraction> warrants cancelled immediately. The remaining <ix:nonFraction unitRef="shares" contextRef="i829bd35e2a01482f995c5247b3243ee1_I20211231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNzUvZnJhZzozNzYxNzMxNjEyYWM0MmY0OGUwMWRkOTgzNjdkMzgzZi90ZXh0cmVnaW9uOjM3NjE3MzE2MTJhYzQyZjQ4ZTAxZGQ5ODM2N2QzODNmXzM0NjM_c03e0305-b61d-47f2-b26d-377106afba0c">559,787</ix:nonFraction> of outstanding warrants are held by Dr. Maky Zanganeh and Dr. Elaine Stracker (see Note 20).</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrants granted over shares of common stock to consultants in exchange of certain services are similar to stock-based compensation (see Note 18). The Company had <ix:nonFraction unitRef="shares" contextRef="i7372be6dc06143b5adbb4d2e83a596c5_I20201231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNzUvZnJhZzozNzYxNzMxNjEyYWM0MmY0OGUwMWRkOTgzNjdkMzgzZi90ZXh0cmVnaW9uOjM3NjE3MzE2MTJhYzQyZjQ4ZTAxZGQ5ODM2N2QzODNmXzM3MjI_00046ca4-b99b-4787-a915-76855e47f7e6"><ix:nonFraction unitRef="shares" contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNzUvZnJhZzozNzYxNzMxNjEyYWM0MmY0OGUwMWRkOTgzNjdkMzgzZi90ZXh0cmVnaW9uOjM3NjE3MzE2MTJhYzQyZjQ4ZTAxZGQ5ODM2N2QzODNmXzM3MjI_10eca2dd-9266-410b-b328-626b759abe19">5,821,137</ix:nonFraction></ix:nonFraction> total warrants outstanding as of December 31, 2021 and 2020, respectively, and an intrinsic value of $<ix:nonFraction unitRef="usd" contextRef="if894fc66857243cf91a1a3e3a656bd4f_I20211231" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNzUvZnJhZzozNzYxNzMxNjEyYWM0MmY0OGUwMWRkOTgzNjdkMzgzZi90ZXh0cmVnaW9uOjM3NjE3MzE2MTJhYzQyZjQ4ZTAxZGQ5ODM2N2QzODNmXzM4MTE_4101f5ad-fe10-42c4-beca-b6cdece02476">6,559</ix:nonFraction> as of December 31, 2021 and $<ix:nonFraction unitRef="usd" contextRef="id2eec56c2a084d07bd27c69c542c646e_I20201231" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNzUvZnJhZzozNzYxNzMxNjEyYWM0MmY0OGUwMWRkOTgzNjdkMzgzZi90ZXh0cmVnaW9uOjM3NjE3MzE2MTJhYzQyZjQ4ZTAxZGQ5ODM2N2QzODNmXzM4NDI_51a42272-2563-43f1-b145-cdc363b27971">18,260</ix:nonFraction> as of December 31, 2020.</span></div></ix:continuation><div><span><br/></span></div><div style="margin-bottom:6pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summit Therapeutics Inc. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><ix:continuation id="i9282f5dd2a8f47db95198d2a4b2eeaa9" continuedAt="i5692f054acf5461baea6247f4615ff93">Dividends</ix:continuation></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i5692f054acf5461baea6247f4615ff93">The Company has never declared or paid cash dividends on its shares of common stock or on Summit Therapeutics plc's ordinary shares. The Company currently intends to retain all of its future earnings to fund the development and expansion of its business.</ix:continuation> </span></div><div id="i2eecdebedec64091994df5b7a96baab7_181"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18. <ix:nonNumeric contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODEvZnJhZzoyOTEzNTMwMjlmMjQ0ZTQ0ODgzNDE5NTEzYjBhODA3Ny90ZXh0cmVnaW9uOjI5MTM1MzAyOWYyNDRlNDQ4ODM0MTk1MTNiMGE4MDc3XzkwMzQ_e1ca2730-e181-4f8d-a7f7-ea794a131ccf" continuedAt="ia583f7580d5b4e8cad13e55cac77131a" escape="true">Stock-Based Compensation </ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="ia583f7580d5b4e8cad13e55cac77131a" continuedAt="i9f5f8bfeab3f4bd087160e05983e2c88"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2016 Long Term Incentive Plan</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, in conjunction with the Redomiciliation, the 2016 Long Term Incentive Plan, (the "2016 Plan") and the Company's outstanding restricted stock units ("RSUs") were assumed and adopted by Summit Therapeutics Inc., and all awards were exchanged with replacement awards issued. Subsequent to the Redomiciliation, no additional grants will be made under the 2016 Plan and any outstanding awards under the 2016 Plan and RSUs will continue with their original terms. The Company concluded that the adoption of the 2016 Plan and RSUs and issuance of replacement awards was a modification but with no change in the material rights and preferences and therefore, no recorded change in the fair value of each respective award is needed.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2020 Stock Award Plan</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, the Company&#8217;s Board of Directors approved the 2020 Stock Incentive Plan (the &#8220;2020 Plan&#8221;), which became effective on September 21, 2020. The 2020 plan provides for the grant of incentive stock options, nonqualified stock options, stock appreciation rights, restricted stock, restricted stock units and other stock-based awards. Upon the effectiveness of the 2020 Plan, the Company ceased granting awards under its 2016 Plan.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A total of <ix:nonFraction unitRef="shares" contextRef="i52879ea7de8d4f93bf2933bde91a0538_I20200921" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODEvZnJhZzoyOTEzNTMwMjlmMjQ0ZTQ0ODgzNDE5NTEzYjBhODA3Ny90ZXh0cmVnaW9uOjI5MTM1MzAyOWYyNDRlNDQ4ODM0MTk1MTNiMGE4MDc3XzEyNjg_e4cdb3a2-dc62-49d5-ae00-a549652f05b6">8,000,000</ix:nonFraction> shares of common stock were initially reserved for issuance under the 2020 Plan. Additionally, up to <ix:nonFraction unitRef="shares" contextRef="i52879ea7de8d4f93bf2933bde91a0538_I20200921" decimals="INF" name="smmt:CommonStockAndRestrictedStockUnitsAdditionalCapitalSharesAllowableForForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODEvZnJhZzoyOTEzNTMwMjlmMjQ0ZTQ0ODgzNDE5NTEzYjBhODA3Ny90ZXh0cmVnaW9uOjI5MTM1MzAyOWYyNDRlNDQ4ODM0MTk1MTNiMGE4MDc3XzEzNzI_b94c7a3b-01ed-4c26-831b-b06322491fe2">5,000,000</ix:nonFraction> shares of common stock, including RSUs can be added to the 2020 Plan for future issuance from options that expire, lapse unexercised or are terminated from the 2016 Plan or any other predecessor plans. The number of shares of common stock that may be issued under the 2020 Plan will automatically increase on each January 1, beginning in 2021 and continuing for each fiscal year until, and including, the fiscal year ending December 31, 2030, equal to the lesser of (i) <ix:nonFraction unitRef="shares" contextRef="i52879ea7de8d4f93bf2933bde91a0538_I20200921" decimals="INF" name="smmt:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODEvZnJhZzoyOTEzNTMwMjlmMjQ0ZTQ0ODgzNDE5NTEzYjBhODA3Ny90ZXh0cmVnaW9uOjI5MTM1MzAyOWYyNDRlNDQ4ODM0MTk1MTNiMGE4MDc3XzE4NDU_6bed9d8d-3767-4ff6-9202-a92e71669114">6,400,000</ix:nonFraction> shares of common stock, (ii) <ix:nonFraction unitRef="number" contextRef="i77c56146a814495db85257a588d28851_D20200921-20200921" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODEvZnJhZzoyOTEzNTMwMjlmMjQ0ZTQ0ODgzNDE5NTEzYjBhODA3Ny90ZXh0cmVnaW9uOjI5MTM1MzAyOWYyNDRlNDQ4ODM0MTk1MTNiMGE4MDc3XzE4Nzc_6edb38ac-f227-4c11-805c-72b135945568">4</ix:nonFraction>% of the common shares outstanding on the final day of the immediately preceding calendar year and (iii) an amount as determined by the Company&#8217;s Board of Directors. As of December 31, 2021, there are <ix:nonFraction unitRef="shares" contextRef="ia36692a70694499e8458216f476de0aa_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODEvZnJhZzoyOTEzNTMwMjlmMjQ0ZTQ0ODgzNDE5NTEzYjBhODA3Ny90ZXh0cmVnaW9uOjI5MTM1MzAyOWYyNDRlNDQ4ODM0MTk1MTNiMGE4MDc3XzIwNzk_09987d98-6ab8-474e-99bb-c057bcef71ef">2,293,700</ix:nonFraction> shares available to be issued under the 2020 Plan.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2020 Employee Stock Purchase Plan</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2020 Employee Stock Purchase Plan (the "2020 ESPP") was adopted by the Board of Directors and approved by the Company's shareholders on July 17, 2020 and approved by the predecessor company shareholders on August 19, 2020. The 2020 ESPP initially authorized the issuance of up to <ix:nonFraction unitRef="shares" contextRef="i9b560a9af3b441468dab3205aa4e621c_I20200819" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODEvZnJhZzoyOTEzNTMwMjlmMjQ0ZTQ0ODgzNDE5NTEzYjBhODA3Ny90ZXh0cmVnaW9uOjI5MTM1MzAyOWYyNDRlNDQ4ODM0MTk1MTNiMGE4MDc3XzI0NTM_ad048000-4361-411b-8ff9-8656a5b6e0fc">1,000,000</ix:nonFraction> shares of  common stock to participating employees. The number of common shares that may be issued under the 2020 ESPP automatically increases on each fiscal year commencing January 1, 2021 and continuing for each fiscal year until, and including the fiscal year commencing on, January 1, 2030 equal to the least of (i) <ix:nonFraction unitRef="shares" contextRef="i9b560a9af3b441468dab3205aa4e621c_I20200819" decimals="INF" name="smmt:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODEvZnJhZzoyOTEzNTMwMjlmMjQ0ZTQ0ODgzNDE5NTEzYjBhODA3Ny90ZXh0cmVnaW9uOjI5MTM1MzAyOWYyNDRlNDQ4ODM0MTk1MTNiMGE4MDc3XzI3NzY_c6b4e171-c490-47f2-8845-06e6c1683b54">1,600,000</ix:nonFraction> shares of common stock, (ii) <ix:nonFraction unitRef="number" contextRef="i2e4f636d5f284aaa971b49db94dc48d6_D20200819-20200819" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODEvZnJhZzoyOTEzNTMwMjlmMjQ0ZTQ0ODgzNDE5NTEzYjBhODA3Ny90ZXh0cmVnaW9uOjI5MTM1MzAyOWYyNDRlNDQ4ODM0MTk1MTNiMGE4MDc3XzI4MDg_ff15f894-b934-493f-8ffb-a318b1df0553">1</ix:nonFraction>% of the common shares outstanding on such date and  (iii) an amount as determined by the Company&#8217;s Board of Directors. As of December 31, 2021, there were <ix:nonFraction unitRef="shares" contextRef="i8a26223d9fc34901b9c170239c1296e3_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODEvZnJhZzoyOTEzNTMwMjlmMjQ0ZTQ0ODgzNDE5NTEzYjBhODA3Ny90ZXh0cmVnaW9uOjI5MTM1MzAyOWYyNDRlNDQ4ODM0MTk1MTNiMGE4MDc3XzI5NjU_c0dd2897-b36e-427b-83bb-942b5e149299">1,825,750</ix:nonFraction> shares available to be issued under the 2020 ESPP.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The first offering period of the 2020 ESPP plan consists of <ix:nonNumeric contextRef="ia19b35b6945f47e0b9f50e24473f7b3f_D20210802-20210802" name="smmt:ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODEvZnJhZzoyOTEzNTMwMjlmMjQ0ZTQ0ODgzNDE5NTEzYjBhODA3Ny90ZXh0cmVnaW9uOjI5MTM1MzAyOWYyNDRlNDQ4ODM0MTk1MTNiMGE4MDc3XzMwODA_3821a27c-8a32-4702-9918-92790f013811">seven months</ix:nonNumeric>, commenced on August 2, 2021 and will terminate on February 28, 2022. Offering periods thereafter will be <ix:nonNumeric contextRef="iabc12254dbae479c95e96111f5913844_D20220301-20220301" name="smmt:ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveOfferingPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODEvZnJhZzoyOTEzNTMwMjlmMjQ0ZTQ0ODgzNDE5NTEzYjBhODA3Ny90ZXh0cmVnaW9uOjI5MTM1MzAyOWYyNDRlNDQ4ODM0MTk1MTNiMGE4MDc3XzMxODk_3bca6773-ace9-4ef0-b737-c6f9fb8d37ec">six months</ix:nonNumeric> in duration and will commence immediately proceeding the end of the previous offering period, unless otherwise determined by the Board of Directors or Compensation Committee. The next offering period commenced on March 1, 2022. Under the 2020 ESPP, eligible employees can purchase shares of common stock through payroll deductions of up to <ix:nonFraction unitRef="number" contextRef="i9b560a9af3b441468dab3205aa4e621c_I20200819" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODEvZnJhZzoyOTEzNTMwMjlmMjQ0ZTQ0ODgzNDE5NTEzYjBhODA3Ny90ZXh0cmVnaW9uOjI5MTM1MzAyOWYyNDRlNDQ4ODM0MTk1MTNiMGE4MDc3XzM1MzI_9dcac0cc-77f2-438e-9dba-77ee7dee3883">15</ix:nonFraction>% of their compensation received during the plan period or such shorter period during which deductions from payroll are made, up to a defined maximum amount. The option price is determined based on the lesser of the closing price of common stock on (i) the first business day of the plan period or (ii) the exercise date, or shall be based solely on the closing price of the common stock on the exercise date; provided that such option price shall be at least <ix:nonFraction unitRef="number" contextRef="i75d2f909ade34437b24a7cd383ffa673_D20200819-20200819" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODEvZnJhZzoyOTEzNTMwMjlmMjQ0ZTQ0ODgzNDE5NTEzYjBhODA3Ny90ZXh0cmVnaW9uOjI5MTM1MzAyOWYyNDRlNDQ4ODM0MTk1MTNiMGE4MDc3XzM5OTM_674c9b49-2cb8-4ba1-82c6-a98cf6469f93">85</ix:nonFraction>% of the applicable closing price. In the absence of a determination by the Board of Directors or the Compensation Committee, the </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summit Therapeutics Inc. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div></div><ix:continuation id="i9f5f8bfeab3f4bd087160e05983e2c88" continuedAt="i67e6cf33394d4d72835b867ceb39003f"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">option price is <ix:nonFraction unitRef="number" contextRef="i2e4f636d5f284aaa971b49db94dc48d6_D20200819-20200819" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODEvZnJhZzoyOTEzNTMwMjlmMjQ0ZTQ0ODgzNDE5NTEzYjBhODA3Ny90ZXh0cmVnaW9uOjI5MTM1MzAyOWYyNDRlNDQ4ODM0MTk1MTNiMGE4MDc3XzQxNDA_84b704f6-c696-46cc-83dd-1860d19046d7">85</ix:nonFraction>% of the lesser of the closing price of the common stock on (i) the first business day of the plan period or (ii) the exercise date. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The closing price is the (a) the closing price (for the primary trading session) on the Nasdaq Global Select Market or (b) the average of the closing bid and asked prices in the over-the-counter-market, whichever is applicable, as published in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Wall Street Journal</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or another source selected by the Board or the Committee. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock Option Valuation</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates the fair value of stock options granted to employees and directors using the Black-Scholes valuation model. Stock options granted under the 2016 and 2020 Plans generally vest over <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODEvZnJhZzoyOTEzNTMwMjlmMjQ0ZTQ0ODgzNDE5NTEzYjBhODA3Ny90ZXh0cmVnaW9uOjI5MTM1MzAyOWYyNDRlNDQ4ODM0MTk1MTNiMGE4MDc3XzQ4MzA_52cfade8-6eaf-42ea-82a4-09b084b53c45">three</span> or <ix:nonNumeric contextRef="i8083f97ada2d4b42b9fe0c6f07ec03d4_D20210101-20211231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODEvZnJhZzoyOTEzNTMwMjlmMjQ0ZTQ0ODgzNDE5NTEzYjBhODA3Ny90ZXh0cmVnaW9uOjI5MTM1MzAyOWYyNDRlNDQ4ODM0MTk1MTNiMGE4MDc3XzQ4MzY_48de70a2-2fe3-4612-ac40-3ead2b8647a0">four years</ix:nonNumeric> and expire after <ix:nonNumeric contextRef="i444320f038034b09878835272c70885a_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODEvZnJhZzoyOTEzNTMwMjlmMjQ0ZTQ0ODgzNDE5NTEzYjBhODA3Ny90ZXh0cmVnaW9uOjI5MTM1MzAyOWYyNDRlNDQ4ODM0MTk1MTNiMGE4MDc3XzQ4NTY_75b4a867-661d-4a1c-9309-24e414c9503d">ten years</ix:nonNumeric>. This valuation methodology utilizes several key assumptions as highlighted below.</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODEvZnJhZzoyOTEzNTMwMjlmMjQ0ZTQ0ODgzNDE5NTEzYjBhODA3Ny90ZXh0cmVnaW9uOjI5MTM1MzAyOWYyNDRlNDQ4ODM0MTk1MTNiMGE4MDc3XzkwNDY_7b23bb7b-cac7-4860-bc67-47e2918a7d3c" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The assumptions used in the Company's valuation are summarized as follows, presented on a weighted average basis: </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">       </span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.649%"><tr><td style="width:1.0%"></td><td style="width:62.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.663%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.171%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.663%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.173%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:103%">Year Ended December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:103%">Year Ended December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i444320f038034b09878835272c70885a_D20210101-20211231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODEvZnJhZzoyOTEzNTMwMjlmMjQ0ZTQ0ODgzNDE5NTEzYjBhODA3Ny90YWJsZTozYjY5MDQyOTQyMTY0NTQwYjU2YTQ4OWZiZTNlOWY0Yi90YWJsZXJhbmdlOjNiNjkwNDI5NDIxNjQ1NDBiNTZhNDg5ZmJlM2U5ZjRiXzEtMi0xLTEtMTA5ODc2_c4ee37f9-b215-4e4c-a3c6-8ac40d24062e">1.05</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i269ac82e7b7e4434933ca3c53f23e541_D20200101-20201231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODEvZnJhZzoyOTEzNTMwMjlmMjQ0ZTQ0ODgzNDE5NTEzYjBhODA3Ny90YWJsZTozYjY5MDQyOTQyMTY0NTQwYjU2YTQ4OWZiZTNlOWY0Yi90YWJsZXJhbmdlOjNiNjkwNDI5NDIxNjQ1NDBiNTZhNDg5ZmJlM2U5ZjRiXzEtNC0xLTEtMTA5ODc2_a3dde256-e67a-4c99-9c1e-d604b27777c1">0.29</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i444320f038034b09878835272c70885a_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODEvZnJhZzoyOTEzNTMwMjlmMjQ0ZTQ0ODgzNDE5NTEzYjBhODA3Ny90YWJsZTozYjY5MDQyOTQyMTY0NTQwYjU2YTQ4OWZiZTNlOWY0Yi90YWJsZXJhbmdlOjNiNjkwNDI5NDIxNjQ1NDBiNTZhNDg5ZmJlM2U5ZjRiXzItMi0xLTEtMTA5ODc2_723477d7-dfd7-45a5-b9f5-7dd83b2a971a">5.7</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i269ac82e7b7e4434933ca3c53f23e541_D20200101-20201231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODEvZnJhZzoyOTEzNTMwMjlmMjQ0ZTQ0ODgzNDE5NTEzYjBhODA3Ny90YWJsZTozYjY5MDQyOTQyMTY0NTQwYjU2YTQ4OWZiZTNlOWY0Yi90YWJsZXJhbmdlOjNiNjkwNDI5NDIxNjQ1NDBiNTZhNDg5ZmJlM2U5ZjRiXzItNC0xLTEtMTA5ODc2_a767cfc3-45b8-4bfa-ab78-751929eda7fe">5.9</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i444320f038034b09878835272c70885a_D20210101-20211231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODEvZnJhZzoyOTEzNTMwMjlmMjQ0ZTQ0ODgzNDE5NTEzYjBhODA3Ny90YWJsZTozYjY5MDQyOTQyMTY0NTQwYjU2YTQ4OWZiZTNlOWY0Yi90YWJsZXJhbmdlOjNiNjkwNDI5NDIxNjQ1NDBiNTZhNDg5ZmJlM2U5ZjRiXzMtMi0xLTEtMTA5ODc2_f9e1c330-535f-4a77-8ea8-ee7572ddea81">74.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i269ac82e7b7e4434933ca3c53f23e541_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODEvZnJhZzoyOTEzNTMwMjlmMjQ0ZTQ0ODgzNDE5NTEzYjBhODA3Ny90YWJsZTozYjY5MDQyOTQyMTY0NTQwYjU2YTQ4OWZiZTNlOWY0Yi90YWJsZXJhbmdlOjNiNjkwNDI5NDIxNjQ1NDBiNTZhNDg5ZmJlM2U5ZjRiXzMtNC0xLTEtMTA5ODc2_10192c5d-5842-4821-8221-b5d9b251d11e">71.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected annual dividends per share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i444320f038034b09878835272c70885a_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODEvZnJhZzoyOTEzNTMwMjlmMjQ0ZTQ0ODgzNDE5NTEzYjBhODA3Ny90YWJsZTozYjY5MDQyOTQyMTY0NTQwYjU2YTQ4OWZiZTNlOWY0Yi90YWJsZXJhbmdlOjNiNjkwNDI5NDIxNjQ1NDBiNTZhNDg5ZmJlM2U5ZjRiXzQtMi0xLTEtMTA5ODc2_523d5bca-361e-4add-895a-2378b37d4487">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i269ac82e7b7e4434933ca3c53f23e541_D20200101-20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODEvZnJhZzoyOTEzNTMwMjlmMjQ0ZTQ0ODgzNDE5NTEzYjBhODA3Ny90YWJsZTozYjY5MDQyOTQyMTY0NTQwYjU2YTQ4OWZiZTNlOWY0Yi90YWJsZXJhbmdlOjNiNjkwNDI5NDIxNjQ1NDBiNTZhNDg5ZmJlM2U5ZjRiXzQtNC0xLTEtMTA5ODc2_a94cd817-f9ad-4ce1-a24a-5c6ea0b04d18">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><ix:nonNumeric contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODEvZnJhZzoyOTEzNTMwMjlmMjQ0ZTQ0ODgzNDE5NTEzYjBhODA3Ny90ZXh0cmVnaW9uOjI5MTM1MzAyOWYyNDRlNDQ4ODM0MTk1MTNiMGE4MDc3XzkwMzU_9f89bbf0-7b0b-4837-b277-34b6e1b03606" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">The following table summarizes the Company's stock option activity for the year ended December 31, 2021:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:103%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">&#160;&#160;&#160;&#160;</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.490%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.087%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of share options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted average exercise price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted average remaining contractual term</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate intrinsic value </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7372be6dc06143b5adbb4d2e83a596c5_I20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODEvZnJhZzoyOTEzNTMwMjlmMjQ0ZTQ0ODgzNDE5NTEzYjBhODA3Ny90YWJsZTo4ZGEzNGJjMTYwOWY0MmI3OTk4MzgyZDZmZDg3YzA0Mi90YWJsZXJhbmdlOjhkYTM0YmMxNjA5ZjQyYjc5OTgzODJkNmZkODdjMDQyXzEtMi0xLTEtMTA5ODc2_10688f4a-e4e4-4a73-a6dd-605b466ef228">3,672,968</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7372be6dc06143b5adbb4d2e83a596c5_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODEvZnJhZzoyOTEzNTMwMjlmMjQ0ZTQ0ODgzNDE5NTEzYjBhODA3Ny90YWJsZTo4ZGEzNGJjMTYwOWY0MmI3OTk4MzgyZDZmZDg3YzA0Mi90YWJsZXJhbmdlOjhkYTM0YmMxNjA5ZjQyYjc5OTgzODJkNmZkODdjMDQyXzEtNC0xLTEtMTA5ODc2_ee7edcd5-ce10-4a86-aa3d-1ad03f7232f0">2.90</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODEvZnJhZzoyOTEzNTMwMjlmMjQ0ZTQ0ODgzNDE5NTEzYjBhODA3Ny90YWJsZTo4ZGEzNGJjMTYwOWY0MmI3OTk4MzgyZDZmZDg3YzA0Mi90YWJsZXJhbmdlOjhkYTM0YmMxNjA5ZjQyYjc5OTgzODJkNmZkODdjMDQyXzEtNi0xLTEtMTA5ODc2_473d35b6-6876-4ab5-85a6-d5b242e57dff">8.9</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7372be6dc06143b5adbb4d2e83a596c5_I20201231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODEvZnJhZzoyOTEzNTMwMjlmMjQ0ZTQ0ODgzNDE5NTEzYjBhODA3Ny90YWJsZTo4ZGEzNGJjMTYwOWY0MmI3OTk4MzgyZDZmZDg3YzA0Mi90YWJsZXJhbmdlOjhkYTM0YmMxNjA5ZjQyYjc5OTgzODJkNmZkODdjMDQyXzEtOC0xLTEtMTA5ODc2_5435025c-bc07-47b4-a508-0bca9b10fd70">6,641</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Granted</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODEvZnJhZzoyOTEzNTMwMjlmMjQ0ZTQ0ODgzNDE5NTEzYjBhODA3Ny90YWJsZTo4ZGEzNGJjMTYwOWY0MmI3OTk4MzgyZDZmZDg3YzA0Mi90YWJsZXJhbmdlOjhkYTM0YmMxNjA5ZjQyYjc5OTgzODJkNmZkODdjMDQyXzItMi0xLTEtMTA5ODc2_cc4cc897-f5a8-4b32-852f-8ac01d0548c8">13,262,016</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODEvZnJhZzoyOTEzNTMwMjlmMjQ0ZTQ0ODgzNDE5NTEzYjBhODA3Ny90YWJsZTo4ZGEzNGJjMTYwOWY0MmI3OTk4MzgyZDZmZDg3YzA0Mi90YWJsZXJhbmdlOjhkYTM0YmMxNjA5ZjQyYjc5OTgzODJkNmZkODdjMDQyXzItNC0xLTEtMTA5ODc2_0853aa77-ba51-4651-af5a-4c0179457b47">5.76</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Forfeited</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODEvZnJhZzoyOTEzNTMwMjlmMjQ0ZTQ0ODgzNDE5NTEzYjBhODA3Ny90YWJsZTo4ZGEzNGJjMTYwOWY0MmI3OTk4MzgyZDZmZDg3YzA0Mi90YWJsZXJhbmdlOjhkYTM0YmMxNjA5ZjQyYjc5OTgzODJkNmZkODdjMDQyXzMtMi0xLTEtMTA5ODc2_db842fa6-7e8e-4c53-8887-cfd0c7aeca86">2,012,851</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODEvZnJhZzoyOTEzNTMwMjlmMjQ0ZTQ0ODgzNDE5NTEzYjBhODA3Ny90YWJsZTo4ZGEzNGJjMTYwOWY0MmI3OTk4MzgyZDZmZDg3YzA0Mi90YWJsZXJhbmdlOjhkYTM0YmMxNjA5ZjQyYjc5OTgzODJkNmZkODdjMDQyXzMtNC0xLTEtMTA5ODc2_358047b7-7bd3-4e13-97af-18b6b5cfb2af">3.61</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Exercised</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODEvZnJhZzoyOTEzNTMwMjlmMjQ0ZTQ0ODgzNDE5NTEzYjBhODA3Ny90YWJsZTo4ZGEzNGJjMTYwOWY0MmI3OTk4MzgyZDZmZDg3YzA0Mi90YWJsZXJhbmdlOjhkYTM0YmMxNjA5ZjQyYjc5OTgzODJkNmZkODdjMDQyXzQtMi0xLTEtMTA5ODc2_0fbff85e-7d90-4694-9366-23ce0b29c450">1,124,577</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODEvZnJhZzoyOTEzNTMwMjlmMjQ0ZTQ0ODgzNDE5NTEzYjBhODA3Ny90YWJsZTo4ZGEzNGJjMTYwOWY0MmI3OTk4MzgyZDZmZDg3YzA0Mi90YWJsZXJhbmdlOjhkYTM0YmMxNjA5ZjQyYjc5OTgzODJkNmZkODdjMDQyXzQtNC0xLTEtMTA5ODc2_bd4a9156-e0ac-4857-a8ee-374989b88135">2.74</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December&#160;31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODEvZnJhZzoyOTEzNTMwMjlmMjQ0ZTQ0ODgzNDE5NTEzYjBhODA3Ny90YWJsZTo4ZGEzNGJjMTYwOWY0MmI3OTk4MzgyZDZmZDg3YzA0Mi90YWJsZXJhbmdlOjhkYTM0YmMxNjA5ZjQyYjc5OTgzODJkNmZkODdjMDQyXzUtMi0xLTEtMTA5ODc2_13e6ce5e-c4ae-4ab0-a3e0-f3b436418d9e">13,797,556</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODEvZnJhZzoyOTEzNTMwMjlmMjQ0ZTQ0ODgzNDE5NTEzYjBhODA3Ny90YWJsZTo4ZGEzNGJjMTYwOWY0MmI3OTk4MzgyZDZmZDg3YzA0Mi90YWJsZXJhbmdlOjhkYTM0YmMxNjA5ZjQyYjc5OTgzODJkNmZkODdjMDQyXzUtNC0xLTEtMTA5ODc2_f78cd295-718f-4d2a-8f3f-05009a6c2c9d">5.55</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODEvZnJhZzoyOTEzNTMwMjlmMjQ0ZTQ0ODgzNDE5NTEzYjBhODA3Ny90YWJsZTo4ZGEzNGJjMTYwOWY0MmI3OTk4MzgyZDZmZDg3YzA0Mi90YWJsZXJhbmdlOjhkYTM0YmMxNjA5ZjQyYjc5OTgzODJkNmZkODdjMDQyXzUtNi0xLTEtMTA5ODc2_87fb1c62-8398-411d-8e2b-b73bea3045a6">8.6</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODEvZnJhZzoyOTEzNTMwMjlmMjQ0ZTQ0ODgzNDE5NTEzYjBhODA3Ny90YWJsZTo4ZGEzNGJjMTYwOWY0MmI3OTk4MzgyZDZmZDg3YzA0Mi90YWJsZXJhbmdlOjhkYTM0YmMxNjA5ZjQyYjc5OTgzODJkNmZkODdjMDQyXzUtOC0xLTEtMTA5ODc2_fb8554c1-1239-4399-8b3d-27bb88bbc1c5">712</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2021 - vested and expected to vest</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODEvZnJhZzoyOTEzNTMwMjlmMjQ0ZTQ0ODgzNDE5NTEzYjBhODA3Ny90YWJsZTo4ZGEzNGJjMTYwOWY0MmI3OTk4MzgyZDZmZDg3YzA0Mi90YWJsZXJhbmdlOjhkYTM0YmMxNjA5ZjQyYjc5OTgzODJkNmZkODdjMDQyXzYtMi0xLTEtMTA5ODc2_a256f2a2-1172-4bb1-b2a5-592094822bd5">12,685,817</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODEvZnJhZzoyOTEzNTMwMjlmMjQ0ZTQ0ODgzNDE5NTEzYjBhODA3Ny90YWJsZTo4ZGEzNGJjMTYwOWY0MmI3OTk4MzgyZDZmZDg3YzA0Mi90YWJsZXJhbmdlOjhkYTM0YmMxNjA5ZjQyYjc5OTgzODJkNmZkODdjMDQyXzYtNC0xLTEtMTA5ODc2_6370ca72-edd8-4076-aa21-836685177121">5.51</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODEvZnJhZzoyOTEzNTMwMjlmMjQ0ZTQ0ODgzNDE5NTEzYjBhODA3Ny90YWJsZTo4ZGEzNGJjMTYwOWY0MmI3OTk4MzgyZDZmZDg3YzA0Mi90YWJsZXJhbmdlOjhkYTM0YmMxNjA5ZjQyYjc5OTgzODJkNmZkODdjMDQyXzYtNi0xLTEtMTA5ODc2_64dd6424-e4e8-4618-9c66-12ad0f13a7b1">8.6</ix:nonNumeric> years</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODEvZnJhZzoyOTEzNTMwMjlmMjQ0ZTQ0ODgzNDE5NTEzYjBhODA3Ny90YWJsZTo4ZGEzNGJjMTYwOWY0MmI3OTk4MzgyZDZmZDg3YzA0Mi90YWJsZXJhbmdlOjhkYTM0YmMxNjA5ZjQyYjc5OTgzODJkNmZkODdjMDQyXzYtOC0xLTEtMTA5ODc2_506a6f23-f66e-44bd-90f0-2fd215b3ba60">709</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODEvZnJhZzoyOTEzNTMwMjlmMjQ0ZTQ0ODgzNDE5NTEzYjBhODA3Ny90YWJsZTo4ZGEzNGJjMTYwOWY0MmI3OTk4MzgyZDZmZDg3YzA0Mi90YWJsZXJhbmdlOjhkYTM0YmMxNjA5ZjQyYjc5OTgzODJkNmZkODdjMDQyXzctMi0xLTEtMTA5ODc2_7651fc79-9a3f-4c8f-bf57-99f2545662e4">1,598,709</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODEvZnJhZzoyOTEzNTMwMjlmMjQ0ZTQ0ODgzNDE5NTEzYjBhODA3Ny90YWJsZTo4ZGEzNGJjMTYwOWY0MmI3OTk4MzgyZDZmZDg3YzA0Mi90YWJsZXJhbmdlOjhkYTM0YmMxNjA5ZjQyYjc5OTgzODJkNmZkODdjMDQyXzctNC0xLTEtMTA5ODc2_d993f6bc-3108-4217-a49d-6f019ce6c558">3.60</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODEvZnJhZzoyOTEzNTMwMjlmMjQ0ZTQ0ODgzNDE5NTEzYjBhODA3Ny90YWJsZTo4ZGEzNGJjMTYwOWY0MmI3OTk4MzgyZDZmZDg3YzA0Mi90YWJsZXJhbmdlOjhkYTM0YmMxNjA5ZjQyYjc5OTgzODJkNmZkODdjMDQyXzctNi0xLTEtMTA5ODc2_bfe92af8-fad1-4698-bd49-1ac7708d31f0">7.2</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODEvZnJhZzoyOTEzNTMwMjlmMjQ0ZTQ0ODgzNDE5NTEzYjBhODA3Ny90YWJsZTo4ZGEzNGJjMTYwOWY0MmI3OTk4MzgyZDZmZDg3YzA0Mi90YWJsZXJhbmdlOjhkYTM0YmMxNjA5ZjQyYjc5OTgzODJkNmZkODdjMDQyXzctOC0xLTEtMTA5ODc2_b586cac8-7bb3-4ab3-ae03-42aaaaa30478">406</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average grant-date fair value of stock options granted during the years ended December 31, 2021 and 2020 was $<ix:nonFraction unitRef="usdPerShare" contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODEvZnJhZzoyOTEzNTMwMjlmMjQ0ZTQ0ODgzNDE5NTEzYjBhODA3Ny90ZXh0cmVnaW9uOjI5MTM1MzAyOWYyNDRlNDQ4ODM0MTk1MTNiMGE4MDc3XzUyODg_9e623a1c-0a76-41e4-9c89-7a8cbfedb93c">3.50</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODEvZnJhZzoyOTEzNTMwMjlmMjQ0ZTQ0ODgzNDE5NTEzYjBhODA3Ny90ZXh0cmVnaW9uOjI5MTM1MzAyOWYyNDRlNDQ4ODM0MTk1MTNiMGE4MDc3XzUyOTU_6cbd8c43-0238-49c5-b174-e4c8a6c364ff">2.20</ix:nonFraction>, per share, respectively. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate intrinsic value of stock options exercised during the years ended December 31, 2021 and December 31, 2020  was $<ix:nonFraction unitRef="usd" contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODEvZnJhZzoyOTEzNTMwMjlmMjQ0ZTQ0ODgzNDE5NTEzYjBhODA3Ny90ZXh0cmVnaW9uOjI5MTM1MzAyOWYyNDRlNDQ4ODM0MTk1MTNiMGE4MDc3XzU0NTE_3e937d94-73c0-46d3-991b-d2c313b878af">3,744</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODEvZnJhZzoyOTEzNTMwMjlmMjQ0ZTQ0ODgzNDE5NTEzYjBhODA3Ny90ZXh0cmVnaW9uOjI5MTM1MzAyOWYyNDRlNDQ4ODM0MTk1MTNiMGE4MDc3XzU0NTg_cc84982b-91e1-4719-b744-d9bb4915da23">857</ix:nonFraction>, respectively. The aggregate intrinsic value of stock options is calculated as the difference between the exercise price of the stock options and the fair value of the Company&#8217;s common stock for those stock options that had exercise prices lower than the fair value of the Company&#8217;s common stock.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, total unrecognized compensation cost related to unvested stock option grants was approximately $<ix:nonFraction unitRef="usd" contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODEvZnJhZzoyOTEzNTMwMjlmMjQ0ZTQ0ODgzNDE5NTEzYjBhODA3Ny90ZXh0cmVnaW9uOjI5MTM1MzAyOWYyNDRlNDQ4ODM0MTk1MTNiMGE4MDc3XzU4Nzk_45213412-05b9-4bdd-9f1a-dd3a9303ba66">27,905</ix:nonFraction>. This amount is expected to be recognized over a weighted average period of approximately <ix:nonNumeric contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODEvZnJhZzoyOTEzNTMwMjlmMjQ0ZTQ0ODgzNDE5NTEzYjBhODA3Ny90ZXh0cmVnaW9uOjI5MTM1MzAyOWYyNDRlNDQ4ODM0MTk1MTNiMGE4MDc3XzU5NzI_d8dfb2fe-5eb8-4305-a329-dce78482aed2">2.2</ix:nonNumeric> years.</span></div></ix:continuation><div><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summit Therapeutics Inc. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div></div><ix:continuation id="i67e6cf33394d4d72835b867ceb39003f" continuedAt="i89fd5e9d000f480ea88c534773061314"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In September 2021, the Compensation Committee of the Board of Directors approved a modification to the Company's outstanding performance-based stock option awards for active employees which removed the performance-based vesting criteria from these awards. Following this modification, the option awards are subject only to previously existing time-based vesting conditions. The Company accounted for this change as a modification in accordance with the requirements of Accounting Standards Codification Topic 718. As a result, <ix:nonFraction unitRef="shares" contextRef="ifb5f434783cc4b4c9ef2fe9ae4041cd4_D20210924-20210924" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODEvZnJhZzoyOTEzNTMwMjlmMjQ0ZTQ0ODgzNDE5NTEzYjBhODA3Ny90ZXh0cmVnaW9uOjI5MTM1MzAyOWYyNDRlNDQ4ODM0MTk1MTNiMGE4MDc3XzY1MDQ_52e83237-1ed7-42bb-94c4-982351ff7ac9">9,250,000</ix:nonFraction> options, related to <ix:nonFraction unitRef="employee" contextRef="ibf72cce8ac64497daeaefb6469475537_D20210924-20210924" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODEvZnJhZzoyOTEzNTMwMjlmMjQ0ZTQ0ODgzNDE5NTEzYjBhODA3Ny90ZXh0cmVnaW9uOjI5MTM1MzAyOWYyNDRlNDQ4ODM0MTk1MTNiMGE4MDc3XzY1Mjc_0997904f-8cb9-4637-acd5-d6413845fd05">twenty-five</ix:nonFraction> employees, that were previously authorized that had not achieved a grant date became granted on September 24, 2021 relating to the modification.  The Company will recognize the newly assessed measurement date fair value of the awards as compensation expense over the remaining vesting period. The incremental compensation expense related to the modification for the year ended December 31, 2021 was $<ix:nonFraction unitRef="usd" contextRef="i444320f038034b09878835272c70885a_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODEvZnJhZzoyOTEzNTMwMjlmMjQ0ZTQ0ODgzNDE5NTEzYjBhODA3Ny90ZXh0cmVnaW9uOjI5MTM1MzAyOWYyNDRlNDQ4ODM0MTk1MTNiMGE4MDc3XzY5Mjk_7f0a7b6f-2952-49ef-a783-a78f8a2b736b">4,872</ix:nonFraction>. The stock option activity above incorporates the modified awards. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restricted Stock Units</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's outstanding restricted stock units ("RSUs") consist of nominal-cost options which were granted to non-executive directors. <ix:nonNumeric contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODEvZnJhZzoyOTEzNTMwMjlmMjQ0ZTQ0ODgzNDE5NTEzYjBhODA3Ny90ZXh0cmVnaW9uOjI5MTM1MzAyOWYyNDRlNDQ4ODM0MTk1MTNiMGE4MDc3XzkwMzk_f4bc7aba-6f09-44b6-b19d-c36c54bab956" continuedAt="i3233c48870534c7082d932b630a5b39e" escape="true">The following table summarizes the activity relating to RSUs for the year ended December 31, 2021:</ix:nonNumeric></span></div><div style="margin-top:6pt"><ix:continuation id="i3233c48870534c7082d932b630a5b39e"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:73.830%"><tr><td style="width:1.0%"></td><td style="width:62.266%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.790%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.127%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.790%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.533%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.594%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Grant Date Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs - beginning of period</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib788877f138c4513a611e7bbf11174b9_I20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODEvZnJhZzoyOTEzNTMwMjlmMjQ0ZTQ0ODgzNDE5NTEzYjBhODA3Ny90YWJsZTo3NWQ1ZDk3YWY5NTA0ZTI4YmFlZDgzZDFiYzgyZmEwMS90YWJsZXJhbmdlOjc1ZDVkOTdhZjk1MDRlMjhiYWVkODNkMWJjODJmYTAxXzEtMy0xLTEtMTA5ODc2_b76e1892-08c8-429a-9e1f-049e16464c1a">26,923</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib788877f138c4513a611e7bbf11174b9_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODEvZnJhZzoyOTEzNTMwMjlmMjQ0ZTQ0ODgzNDE5NTEzYjBhODA3Ny90YWJsZTo3NWQ1ZDk3YWY5NTA0ZTI4YmFlZDgzZDFiYzgyZmEwMS90YWJsZXJhbmdlOjc1ZDVkOTdhZjk1MDRlMjhiYWVkODNkMWJjODJmYTAxXzEtNS0xLTEtMTA5ODc2_c0247dd9-97c3-408c-bf80-4d606cdf0585">1.60</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ifb40b671dcdb4ef29c0a6c97d77ebb15_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODEvZnJhZzoyOTEzNTMwMjlmMjQ0ZTQ0ODgzNDE5NTEzYjBhODA3Ny90YWJsZTo3NWQ1ZDk3YWY5NTA0ZTI4YmFlZDgzZDFiYzgyZmEwMS90YWJsZXJhbmdlOjc1ZDVkOTdhZjk1MDRlMjhiYWVkODNkMWJjODJmYTAxXzMtMy0xLTEtMTA5ODc2_67d27a98-ce91-42c3-b40a-e862eb65349d">26,923</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ifb40b671dcdb4ef29c0a6c97d77ebb15_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODEvZnJhZzoyOTEzNTMwMjlmMjQ0ZTQ0ODgzNDE5NTEzYjBhODA3Ny90YWJsZTo3NWQ1ZDk3YWY5NTA0ZTI4YmFlZDgzZDFiYzgyZmEwMS90YWJsZXJhbmdlOjc1ZDVkOTdhZjk1MDRlMjhiYWVkODNkMWJjODJmYTAxXzMtNS0xLTEtMTA5ODc2_76847b97-dabe-43a0-9ef5-6e0bacfd00f3">1.60</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs - end of period</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i151cdfd1b29442d4840888fb00f8949d_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODEvZnJhZzoyOTEzNTMwMjlmMjQ0ZTQ0ODgzNDE5NTEzYjBhODA3Ny90YWJsZTo3NWQ1ZDk3YWY5NTA0ZTI4YmFlZDgzZDFiYzgyZmEwMS90YWJsZXJhbmdlOjc1ZDVkOTdhZjk1MDRlMjhiYWVkODNkMWJjODJmYTAxXzQtMy0xLTEtMTA5ODc2_79ed6b7e-85b2-4867-a933-0dbe81087190">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i151cdfd1b29442d4840888fb00f8949d_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODEvZnJhZzoyOTEzNTMwMjlmMjQ0ZTQ0ODgzNDE5NTEzYjBhODA3Ny90YWJsZTo3NWQ1ZDk3YWY5NTA0ZTI4YmFlZDgzZDFiYzgyZmEwMS90YWJsZXJhbmdlOjc1ZDVkOTdhZjk1MDRlMjhiYWVkODNkMWJjODJmYTAxXzQtNS0xLTEtMTA5ODc2_11de9290-7e33-4196-b150-5b11c59b62f4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></ix:continuation></div><div style="margin-top:1pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate intrinsic value of restricted stock units vested during the years ended December 31, 2021 and December 31, 2020 was $<ix:nonFraction unitRef="usd" contextRef="i4d5f6c2289bf42c8a42f632397ea769e_D20200101-20201231" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODEvZnJhZzoyOTEzNTMwMjlmMjQ0ZTQ0ODgzNDE5NTEzYjBhODA3Ny90ZXh0cmVnaW9uOjI5MTM1MzAyOWYyNDRlNDQ4ODM0MTk1MTNiMGE4MDc3XzczNzg_7289d800-7785-45af-8482-42da29e5a8e4"><ix:nonFraction unitRef="usd" contextRef="ifb40b671dcdb4ef29c0a6c97d77ebb15_D20210101-20211231" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODEvZnJhZzoyOTEzNTMwMjlmMjQ0ZTQ0ODgzNDE5NTEzYjBhODA3Ny90ZXh0cmVnaW9uOjI5MTM1MzAyOWYyNDRlNDQ4ODM0MTk1MTNiMGE4MDc3XzczNzg_c6e2731d-1ea2-41c7-a63e-88186953e349">125</ix:nonFraction></ix:nonFraction>, respectively.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Warrants</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The fair value of warrants is estimated on the date of grant using the Black-Scholes valuation methodology. Expected volatilities are based on historical share price performance, weighted to exclude periods of unusually high volatility. The Company assumed the warrants to be exercised immediately on vesting. The risk-free rate is equal to the prevailing U.K. Gilts rate at grant date that most closely matches the expected term of the grant, as the warrants were issued prior to the Redomiciliation. Expected dividend yield is <ix:nonFraction unitRef="number" contextRef="i395ac2e436db41e1b784ce9a6a63fdfd_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODEvZnJhZzoyOTEzNTMwMjlmMjQ0ZTQ0ODgzNDE5NTEzYjBhODA3Ny90ZXh0cmVnaW9uOjI5MTM1MzAyOWYyNDRlNDQ4ODM0MTk1MTNiMGE4MDc3Xzc5MzY_f6d842d2-d4f7-419a-8b41-0f51ed01f0e9">zero</ix:nonFraction>, and consistent with the Board of Directors&#8217; view that the Company&#8217;s business model is to generate value through capital growth rather than the payment of dividends.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Each warrant entitles the warrant holder to subscribe in cash for <ix:nonFraction unitRef="shares" contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODEvZnJhZzoyOTEzNTMwMjlmMjQ0ZTQ0ODgzNDE5NTEzYjBhODA3Ny90ZXh0cmVnaW9uOjI5MTM1MzAyOWYyNDRlNDQ4ODM0MTk1MTNiMGE4MDc3XzgxNzI_fef33167-a59d-4070-915e-44ae3223c2ea">one</ix:nonFraction> share. Shares of common stock allotted pursuant to the exercise of the warrant will rank in full for all dividends and other distributions with a record date after the exercise date with the shares of common stock in issue at that date.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, <ix:nonFraction unitRef="shares" contextRef="if894fc66857243cf91a1a3e3a656bd4f_I20211231" decimals="INF" name="smmt:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODEvZnJhZzoyOTEzNTMwMjlmMjQ0ZTQ0ODgzNDE5NTEzYjBhODA3Ny90ZXh0cmVnaW9uOjI5MTM1MzAyOWYyNDRlNDQ4ODM0MTk1MTNiMGE4MDc3Xzg0MjI_439aec4b-3b2e-4e6e-907e-ad1f67996ff5">5,821,137</ix:nonFraction> warrants were granted, of which <ix:nonFraction unitRef="shares" contextRef="i1b7a43e1795f40b497c444b01b9f6b53_I20211231" decimals="INF" name="smmt:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODEvZnJhZzoyOTEzNTMwMjlmMjQ0ZTQ0ODgzNDE5NTEzYjBhODA3Ny90ZXh0cmVnaW9uOjI5MTM1MzAyOWYyNDRlNDQ4ODM0MTk1MTNiMGE4MDc3Xzg0NTc_f182ee6a-5e70-40ce-a17e-8a5f86e3be5b">559,787</ix:nonFraction> warrants were granted to consultants and <ix:nonFraction unitRef="shares" contextRef="ia09aa906eefb458f9f484f59eac63b0f_I20211231" decimals="INF" name="smmt:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODEvZnJhZzoyOTEzNTMwMjlmMjQ0ZTQ0ODgzNDE5NTEzYjBhODA3Ny90ZXh0cmVnaW9uOjI5MTM1MzAyOWYyNDRlNDQ4ODM0MTk1MTNiMGE4MDc3Xzg1MDE_f4251425-f205-4e14-b119-869f4df6545d">5,261,350</ix:nonFraction> warrants were granted to investors (refer to Note 20 for further details). All warrants are considered vested at December 31, 2021, have a weighted-average exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="if894fc66857243cf91a1a3e3a656bd4f_I20211231" decimals="2" name="smmt:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODEvZnJhZzoyOTEzNTMwMjlmMjQ0ZTQ0ODgzNDE5NTEzYjBhODA3Ny90ZXh0cmVnaW9uOjI5MTM1MzAyOWYyNDRlNDQ4ODM0MTk1MTNiMGE4MDc3Xzg2Nzg_0cd2028f-72d9-440a-9c6a-c869fe58ff1c">1.56</ix:nonFraction>, an aggregate intrinsic value of $<ix:nonFraction unitRef="usd" contextRef="i395ac2e436db41e1b784ce9a6a63fdfd_D20210101-20211231" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODEvZnJhZzoyOTEzNTMwMjlmMjQ0ZTQ0ODgzNDE5NTEzYjBhODA3Ny90ZXh0cmVnaW9uOjI5MTM1MzAyOWYyNDRlNDQ4ODM0MTk1MTNiMGE4MDc3Xzg3MTQ_3a69fc6d-c76f-4897-a1ae-20955e6a1ec6">6,559</ix:nonFraction>, and a weighted average remaining contractual life of <ix:nonNumeric contextRef="i395ac2e436db41e1b784ce9a6a63fdfd_D20210101-20211231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODEvZnJhZzoyOTEzNTMwMjlmMjQ0ZTQ0ODgzNDE5NTEzYjBhODA3Ny90ZXh0cmVnaW9uOjI5MTM1MzAyOWYyNDRlNDQ4ODM0MTk1MTNiMGE4MDc3Xzg3NzE_9c471d75-4638-4424-b8e3-530e3480cd03">4.0</ix:nonNumeric> years.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2021, there was <ix:nonFraction unitRef="usd" contextRef="if894fc66857243cf91a1a3e3a656bd4f_I20211231" decimals="INF" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODEvZnJhZzoyOTEzNTMwMjlmMjQ0ZTQ0ODgzNDE5NTEzYjBhODA3Ny90ZXh0cmVnaW9uOjI5MTM1MzAyOWYyNDRlNDQ4ODM0MTk1MTNiMGE4MDc3Xzg3OTI_7be580cc-dd08-40b9-a6f3-c552b02598a5">no</ix:nonFraction> unrecognized compensation expense related to warrants. </span></div></ix:continuation><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summit Therapeutics Inc. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div></div><ix:continuation id="i89fd5e9d000f480ea88c534773061314"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><ix:nonNumeric contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODEvZnJhZzoyOTEzNTMwMjlmMjQ0ZTQ0ODgzNDE5NTEzYjBhODA3Ny90ZXh0cmVnaW9uOjI5MTM1MzAyOWYyNDRlNDQ4ODM0MTk1MTNiMGE4MDc3XzkwNDM_545e38a6-629c-47cb-9682-58e43be0d0f9" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock&#8209;based compensation expense related to stock options is recorded within the consolidated statements of operations and comprehensive loss as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.485%"><tr><td style="width:1.0%"></td><td style="width:59.277%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.743%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.767%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.743%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.770%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:103%">Year Ended December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:103%">Year Ended December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">Research and development</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie40533d6881a4b8e84e00ba2095c6a46_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODEvZnJhZzoyOTEzNTMwMjlmMjQ0ZTQ0ODgzNDE5NTEzYjBhODA3Ny90YWJsZToyMGIxZDY4YjNkNDg0OGNlYTI4ZjdkM2I4MzRiNDhlNC90YWJsZXJhbmdlOjIwYjFkNjhiM2Q0ODQ4Y2VhMjhmN2QzYjgzNGI0OGU0XzEtMi0xLTEtMTA5ODc2_c5408058-41bb-4b43-85e3-e126c6029df1">5,909</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9692194cdd1947979995cb545a07d30f_D20200101-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODEvZnJhZzoyOTEzNTMwMjlmMjQ0ZTQ0ODgzNDE5NTEzYjBhODA3Ny90YWJsZToyMGIxZDY4YjNkNDg0OGNlYTI4ZjdkM2I4MzRiNDhlNC90YWJsZXJhbmdlOjIwYjFkNjhiM2Q0ODQ4Y2VhMjhmN2QzYjgzNGI0OGU0XzEtNC0xLTEtMTA5ODc2_295bb603-a230-4e2a-a9b8-a87b35461e8b">749</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">General and administrative</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b50b0a3bb8f405dafa9635ba05d5e1a_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODEvZnJhZzoyOTEzNTMwMjlmMjQ0ZTQ0ODgzNDE5NTEzYjBhODA3Ny90YWJsZToyMGIxZDY4YjNkNDg0OGNlYTI4ZjdkM2I4MzRiNDhlNC90YWJsZXJhbmdlOjIwYjFkNjhiM2Q0ODQ4Y2VhMjhmN2QzYjgzNGI0OGU0XzItMi0xLTEtMTA5ODc2_a338e36c-8aa0-4fe0-8ed1-79cd454eaad1">6,895</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%"><ix:nonFraction unitRef="usd" contextRef="id19f5fb0cc5346e48e222529f4a6e420_D20200101-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODEvZnJhZzoyOTEzNTMwMjlmMjQ0ZTQ0ODgzNDE5NTEzYjBhODA3Ny90YWJsZToyMGIxZDY4YjNkNDg0OGNlYTI4ZjdkM2I4MzRiNDhlNC90YWJsZXJhbmdlOjIwYjFkNjhiM2Q0ODQ4Y2VhMjhmN2QzYjgzNGI0OGU0XzItNC0xLTEtMTA5ODc2_4c2111fc-262e-4c0d-805f-68b2280a2e39">1,017</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">Total stock-based compensation</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODEvZnJhZzoyOTEzNTMwMjlmMjQ0ZTQ0ODgzNDE5NTEzYjBhODA3Ny90YWJsZToyMGIxZDY4YjNkNDg0OGNlYTI4ZjdkM2I4MzRiNDhlNC90YWJsZXJhbmdlOjIwYjFkNjhiM2Q0ODQ4Y2VhMjhmN2QzYjgzNGI0OGU0XzMtMi0xLTEtMTA5ODc2_ead88647-66e8-4f58-8482-e79df5e990cb">12,804</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODEvZnJhZzoyOTEzNTMwMjlmMjQ0ZTQ0ODgzNDE5NTEzYjBhODA3Ny90YWJsZToyMGIxZDY4YjNkNDg0OGNlYTI4ZjdkM2I4MzRiNDhlNC90YWJsZXJhbmdlOjIwYjFkNjhiM2Q0ODQ4Y2VhMjhmN2QzYjgzNGI0OGU0XzMtNC0xLTEtMTA5ODc2_1effc9fb-32e9-4b7f-b3ed-a3b431c5a01b">1,766</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div id="i2eecdebedec64091994df5b7a96baab7_184"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">19. <ix:nonNumeric contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODQvZnJhZzoxZmY5MTNiMmRmMjQ0NDQzYTQ4ZjMxMjhjZGFjNWM2OS90ZXh0cmVnaW9uOjFmZjkxM2IyZGYyNDQ0NDNhNDhmMzEyOGNkYWM1YzY5XzE0OTU_89c31c4d-7c0e-408b-9e36-670cfdf74aaf" continuedAt="ie699a2c0588c4c1ea2a26bad6cd61c4b" escape="true">Commitments and Contingencies </ix:nonNumeric></span></div><ix:continuation id="ie699a2c0588c4c1ea2a26bad6cd61c4b"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fixed asset purchase commitments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2021 and 2020, the Company had <ix:nonFraction unitRef="usd" contextRef="i7372be6dc06143b5adbb4d2e83a596c5_I20201231" decimals="INF" name="us-gaap:PurchaseObligation" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODQvZnJhZzoxZmY5MTNiMmRmMjQ0NDQzYTQ4ZjMxMjhjZGFjNWM2OS90ZXh0cmVnaW9uOjFmZjkxM2IyZGYyNDQ0NDNhNDhmMzEyOGNkYWM1YzY5Xzc2_14a61985-532a-457a-97a9-13cfb7ecfcc1"><ix:nonFraction unitRef="usd" contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231" decimals="INF" name="us-gaap:PurchaseObligation" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODQvZnJhZzoxZmY5MTNiMmRmMjQ0NDQzYTQ4ZjMxMjhjZGFjNWM2OS90ZXh0cmVnaW9uOjFmZjkxM2IyZGYyNDQ0NDNhNDhmMzEyOGNkYWM1YzY5Xzc2_a687a99e-7137-4208-ab5e-185084424144">no</ix:nonFraction></ix:nonFraction> capital commitments.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other commitments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into contracts in the normal course of business with various third parties for clinical trials, preclinical research studies and testing, manufacturing and other services and products for operating purposes. Most contracts provide for termination upon notice, and therefore are cancellable contracts. As of December 31, 2021, total contractual commitments are estimated to be approximately $<ix:nonFraction unitRef="usd" contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231" decimals="-3" name="us-gaap:OtherCommitment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODQvZnJhZzoxZmY5MTNiMmRmMjQ0NDQzYTQ4ZjMxMjhjZGFjNWM2OS90ZXh0cmVnaW9uOjFmZjkxM2IyZGYyNDQ0NDNhNDhmMzEyOGNkYWM1YzY5XzUxMg_a350bf70-8b44-4442-ad04-0fd89bdb69a1">17,046</ix:nonFraction> and the majority of these commitments are due within <ix:nonNumeric contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231" name="smmt:OtherCommitmentPeriodForWhichTheMajorityOfCommitmentsAreToBePaid" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODQvZnJhZzoxZmY5MTNiMmRmMjQ0NDQzYTQ4ZjMxMjhjZGFjNWM2OS90ZXh0cmVnaW9uOjFmZjkxM2IyZGYyNDQ0NDNhNDhmMzEyOGNkYWM1YzY5XzU2OA_da5f345a-e896-4e7f-8cd4-d0220ea22d98">one year</ix:nonNumeric>.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Indemnifications</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's certificate of incorporation provides that it will indemnify the directors and officers to the fullest extent permitted by Delaware law. In addition, the Company has entered into indemnification agreements with all of the directors and executive officers. These indemnification agreements may require the Company, among other things, to indemnify each such director or executive officer for some expenses, including attorneys&#8217; fees, judgments, fines, and settlement amounts incurred by him or her in any action or proceeding arising out of his or her service as one of the Company's directors or executive officers. The Company believes the fair value for these indemnification obligations is minimal. Accordingly, the Company has not recognized any liabilities relating to these obligations as of December 31, 2021.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Legal Proceedings</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is not currently subject to any material legal proceedings.</span></div></ix:continuation><div><span><br/></span></div><div id="i2eecdebedec64091994df5b7a96baab7_187"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">20. <ix:nonNumeric contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODcvZnJhZzplOWNhNGFmYWViZmI0NTMxYjI5ZWU4YTEwNjk3MDdjMS90ZXh0cmVnaW9uOmU5Y2E0YWZhZWJmYjQ1MzFiMjllZThhMTA2OTcwN2MxXzczNDk_4fd6702a-b0f6-41b9-ab63-3f8c15374123" continuedAt="i17ccc3ea14bb454788989b09ac78dbee" escape="true">Related Party Transactions </ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i17ccc3ea14bb454788989b09ac78dbee" continuedAt="i5ec1572604354a1798eeea46c7d0ddae"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&#160;6, 2019, the Company entered into a deed of termination of the relationship agreement with Mr. Robert W. Duggan and Cairn Financial Advisers LLP, a limited liability partnership incorporated in England and Wales with the Registrar of Companies of England and Wales, as the Company's nominated adviser. The relationship agreement regulated the Company&#8217;s relationship with Mr. Robert W. Duggan and limited Mr. Robert W. Duggan&#8217;s influence over the Company&#8217;s corporate actions and activities and the outcome of general matters pertaining to the Company. The deed of termination became effective on February 24, 2020, upon the cancellation of the admission of the ordinary shares on the Alternative Investment Market, a sub-market of the London Stock Exchanges.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">December 24, 2019 Private Placement</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 24, 2019, the Company completed a private placement of its common stock and received aggregate gross proceeds of $<ix:nonFraction unitRef="usd" contextRef="ief39eb2f075b4eb78fa3e4ffac9e4610_D20191224-20191224" decimals="-3" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODcvZnJhZzplOWNhNGFmYWViZmI0NTMxYjI5ZWU4YTEwNjk3MDdjMS90ZXh0cmVnaW9uOmU5Y2E0YWZhZWJmYjQ1MzFiMjllZThhMTA2OTcwN2MxXzk0Nw_02850f29-4c01-4230-99e7-c4d93f510759">50,000</ix:nonFraction> from the issuance and sale of <ix:nonFraction unitRef="shares" contextRef="ief39eb2f075b4eb78fa3e4ffac9e4610_D20191224-20191224" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODcvZnJhZzplOWNhNGFmYWViZmI0NTMxYjI5ZWU4YTEwNjk3MDdjMS90ZXh0cmVnaW9uOmU5Y2E0YWZhZWJmYjQ1MzFiMjllZThhMTA2OTcwN2MxXzk4MA_63473d1e-5fbd-49dd-9735-b4d39eff70e5">35,075,690</ix:nonFraction> shares of common stock at a price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i5b2fdb6bad994e6eb9c9380cb3807cd6_I20191224" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODcvZnJhZzplOWNhNGFmYWViZmI0NTMxYjI5ZWU4YTEwNjk3MDdjMS90ZXh0cmVnaW9uOmU5Y2E0YWZhZWJmYjQ1MzFiMjllZThhMTA2OTcwN2MxXzEwMjA_d8f220c7-969c-4091-939e-98d4338e7a68">1.43</ix:nonFraction> per share, of which <ix:nonFraction unitRef="shares" contextRef="i7be0acfd60d747fbba039b448bffe68f_I20191224" decimals="INF" name="us-gaap:CommonStockSharesSubscribedButUnissued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODcvZnJhZzplOWNhNGFmYWViZmI0NTMxYjI5ZWU4YTEwNjk3MDdjMS90ZXh0cmVnaW9uOmU5Y2E0YWZhZWJmYjQ1MzFiMjllZThhMTA2OTcwN2MxXzEwNDM_867df915-aacb-4d28-98c5-8f8077deb7c2">33,231,410</ix:nonFraction> shares of common stock were subscribed by Mr.&#160;Robert&#160;W. Duggan. Also, as part of the private placement, </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summit Therapeutics Inc. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div></div><ix:continuation id="i5ec1572604354a1798eeea46c7d0ddae" continuedAt="i1336acb8fdb548299657fe4784cda48b"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">participating investors were granted warrants with the right to subscribe for <ix:nonFraction unitRef="shares" contextRef="i5b2fdb6bad994e6eb9c9380cb3807cd6_I20191224" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODcvZnJhZzplOWNhNGFmYWViZmI0NTMxYjI5ZWU4YTEwNjk3MDdjMS90ZXh0cmVnaW9uOmU5Y2E0YWZhZWJmYjQ1MzFiMjllZThhMTA2OTcwN2MxXzEyMjg_cfe82858-09b0-4d05-b510-adb275b637bf">5,261,350</ix:nonFraction> shares of common stock at an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i5b2fdb6bad994e6eb9c9380cb3807cd6_I20191224" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODcvZnJhZzplOWNhNGFmYWViZmI0NTMxYjI5ZWU4YTEwNjk3MDdjMS90ZXh0cmVnaW9uOmU5Y2E0YWZhZWJmYjQ1MzFiMjllZThhMTA2OTcwN2MxXzEyNzg_a5e5013a-65fb-4878-ac1e-81e9c3d9b4bd">1.58</ix:nonFraction>, of which <ix:nonFraction unitRef="shares" contextRef="i7be0acfd60d747fbba039b448bffe68f_I20191224" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODcvZnJhZzplOWNhNGFmYWViZmI0NTMxYjI5ZWU4YTEwNjk3MDdjMS90ZXh0cmVnaW9uOmU5Y2E0YWZhZWJmYjQ1MzFiMjllZThhMTA2OTcwN2MxXzEyOTE_7836cc6c-6dad-4cb8-ac52-eb85689908d7">4,984,711</ix:nonFraction> were granted to Mr. Robert W. Duggan at an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i7be0acfd60d747fbba039b448bffe68f_I20191224" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODcvZnJhZzplOWNhNGFmYWViZmI0NTMxYjI5ZWU4YTEwNjk3MDdjMS90ZXh0cmVnaW9uOmU5Y2E0YWZhZWJmYjQ1MzFiMjllZThhMTA2OTcwN2MxXzEzNTU_0dcb4a3a-10db-4774-ac25-1ab29ed117d4">1.43</ix:nonFraction> per share for a subscription share plus a subscription warrant, pursuant to a securities purchase agreement he entered into with the Company.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In conjunction with the December 24, 2019 private placement, <ix:nonFraction unitRef="shares" contextRef="i4f6915c5f2074c63ae73f25be0258821_I20191224" decimals="INF" name="us-gaap:CommonStockSharesSubscribedButUnissued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODcvZnJhZzplOWNhNGFmYWViZmI0NTMxYjI5ZWU4YTEwNjk3MDdjMS90ZXh0cmVnaW9uOmU5Y2E0YWZhZWJmYjQ1MzFiMjllZThhMTA2OTcwN2MxXzE1NjI_05eb13fa-4423-40f3-a2f4-59270e722a22">90,495</ix:nonFraction> shares of common stock were subscribed by Mr.&#160;Glyn Edwards, the Company's former Chief Executive Officer. Also as part of this private placement, Mr. Glyn Edwards was granted warrants with the right to subscribe for <ix:nonFraction unitRef="shares" contextRef="i4f6915c5f2074c63ae73f25be0258821_I20191224" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODcvZnJhZzplOWNhNGFmYWViZmI0NTMxYjI5ZWU4YTEwNjk3MDdjMS90ZXh0cmVnaW9uOmU5Y2E0YWZhZWJmYjQ1MzFiMjllZThhMTA2OTcwN2MxXzE3ODE_9e63bbc1-385b-4b17-aa0f-bb28be12d240">13,574</ix:nonFraction> shares of common stock at an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i4f6915c5f2074c63ae73f25be0258821_I20191224" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODcvZnJhZzplOWNhNGFmYWViZmI0NTMxYjI5ZWU4YTEwNjk3MDdjMS90ZXh0cmVnaW9uOmU5Y2E0YWZhZWJmYjQ1MzFiMjllZThhMTA2OTcwN2MxXzE4MzE_355f75cd-6726-46cd-9fde-00993d1b957a">1.43</ix:nonFraction> per share for a subscription share plus a subscription warrant, pursuant to a securities purchase agreement he entered into with the Company. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">November 6, 2020 Private Placement</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 6, 2020 the Company completed a private placement of its common stock and received gross proceeds of $<ix:nonFraction unitRef="usd" contextRef="i6a505b52efdc43a7821a6b7cc66b172e_D20201106-20201106" decimals="-3" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODcvZnJhZzplOWNhNGFmYWViZmI0NTMxYjI5ZWU4YTEwNjk3MDdjMS90ZXh0cmVnaW9uOmU5Y2E0YWZhZWJmYjQ1MzFiMjllZThhMTA2OTcwN2MxXzIxMjc_bf71a633-45e4-4a7a-9d85-f7346e8d4a48">50,000</ix:nonFraction> from the issuance and sale of <ix:nonFraction unitRef="shares" contextRef="i6a505b52efdc43a7821a6b7cc66b172e_D20201106-20201106" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODcvZnJhZzplOWNhNGFmYWViZmI0NTMxYjI5ZWU4YTEwNjk3MDdjMS90ZXh0cmVnaW9uOmU5Y2E0YWZhZWJmYjQ1MzFiMjllZThhMTA2OTcwN2MxXzIxNjA_2eb360d5-03ca-469f-b88d-42cc6b2c8b9c">14,970,060</ix:nonFraction> shares of common stock at a price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i1cda89fc1bbb4c82a3c7a93284736d74_I20201106" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODcvZnJhZzplOWNhNGFmYWViZmI0NTMxYjI5ZWU4YTEwNjk3MDdjMS90ZXh0cmVnaW9uOmU5Y2E0YWZhZWJmYjQ1MzFiMjllZThhMTA2OTcwN2MxXzIyMDA_dfa93078-b64b-4dec-afb0-202ed3f3532d">3.34</ix:nonFraction> per share, of which <ix:nonFraction unitRef="shares" contextRef="i7f56091566944d9bb672ff557a22aff4_I20201106" decimals="INF" name="us-gaap:CommonStockSharesSubscribedButUnissued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODcvZnJhZzplOWNhNGFmYWViZmI0NTMxYjI5ZWU4YTEwNjk3MDdjMS90ZXh0cmVnaW9uOmU5Y2E0YWZhZWJmYjQ1MzFiMjllZThhMTA2OTcwN2MxXzIyMjM_d2271d13-4ac6-4837-8322-9f3c2338e767">14,071,856</ix:nonFraction> shares of common stock were subscribed by Mr. Robert W. Duggan.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In conjunction with the November 6, 2020 private placement, <ix:nonFraction unitRef="shares" contextRef="ibc0f44cee68945c1910a87557a1bdd5d_I20201106" decimals="INF" name="us-gaap:CommonStockSharesSubscribedButUnissued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODcvZnJhZzplOWNhNGFmYWViZmI0NTMxYjI5ZWU4YTEwNjk3MDdjMS90ZXh0cmVnaW9uOmU5Y2E0YWZhZWJmYjQ1MzFiMjllZThhMTA2OTcwN2MxXzIzNTE_ff65e520-b38d-4aa7-ad1b-4b910d95d5b3">149,701</ix:nonFraction> shares of common stock were subscribed by the Mahkam Zanganeh Revocable Trust. Dr. Maky Zanganeh was appointed to the Board of Directors on November 11, 2020 and became the Company's Chief Operations Officer on November 22, 2020. As trustee of the Mahkam Zanganeh Revocable Trust, Dr. Maky Zanganeh is deemed to beneficially own the securities of the Company held by the Mahkam Zanganeh Revocable Trust.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Consultancy Agreements</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, the Company had in place a consultancy agreement with Dr. Maky Zanganeh and Associates, Inc. (&#8220;MZA&#8221;) to provide support for clinical operation activities related to the global Phase III clinical program. Dr. Maky Zanganeh is the sole owner of MZA, and Dr. Elaine Stracker, who served for a period during fiscal year 2020 as a director of the Company and as the Company&#8217;s Interim Chief Operations Officer, was at the time the General Counsel and Senior Vice President for Corporate Development at MZA. The fees for such services under the consultancy agreement with MZA were $<ix:nonFraction unitRef="usd" contextRef="ib29a1c5799524e1987c045aee67b6831_D20191224-20191224" decimals="-3" name="smmt:RelatedPartyTransactionMonthlyExpensesFromTransactionsWithRelatedParty" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODcvZnJhZzplOWNhNGFmYWViZmI0NTMxYjI5ZWU4YTEwNjk3MDdjMS90ZXh0cmVnaW9uOmU5Y2E0YWZhZWJmYjQ1MzFiMjllZThhMTA2OTcwN2MxXzMzNjY_b28e09b8-e297-4d65-822d-bf5f25b689fc">75</ix:nonFraction> per month. In addition to such monthly fee, MZA was granted warrants over <ix:nonFraction unitRef="shares" contextRef="id3dfe8aa6a324f739c2caa516220e112_I20191224" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODcvZnJhZzplOWNhNGFmYWViZmI0NTMxYjI5ZWU4YTEwNjk3MDdjMS90ZXh0cmVnaW9uOmU5Y2E0YWZhZWJmYjQ1MzFiMjllZThhMTA2OTcwN2MxXzM0NDM_241bfaea-6ee6-4d97-8153-fb893d96ba48">3,358,732</ix:nonFraction> shares of common stock with an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="id3dfe8aa6a324f739c2caa516220e112_I20191224" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODcvZnJhZzplOWNhNGFmYWViZmI0NTMxYjI5ZWU4YTEwNjk3MDdjMS90ZXh0cmVnaW9uOmU5Y2E0YWZhZWJmYjQ1MzFiMjllZThhMTA2OTcwN2MxXzM0OTU_005d473f-73ce-412e-92bf-eb638c34376a">1.44</ix:nonFraction> per share, vesting on a quarterly basis over <ix:nonNumeric contextRef="ib29a1c5799524e1987c045aee67b6831_D20191224-20191224" name="smmt:ClassOfWarrantOrRightQuarterlyVestingPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODcvZnJhZzplOWNhNGFmYWViZmI0NTMxYjI5ZWU4YTEwNjk3MDdjMS90ZXh0cmVnaW9uOmU5Y2E0YWZhZWJmYjQ1MzFiMjllZThhMTA2OTcwN2MxXzM1NDM_5d6efe75-8a04-4a7a-9afe-c225620b66b1">three years</ix:nonNumeric> from the date of grant, subject to MZA&#8217;s provision of consultancy services to the Company during such period. During the period of MZA's engagement, $<ix:nonFraction unitRef="usd" contextRef="i2a2d5cacc14249f0a5bbe8fcc0619c62_D20191224-20200630" decimals="-3" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODcvZnJhZzplOWNhNGFmYWViZmI0NTMxYjI5ZWU4YTEwNjk3MDdjMS90ZXh0cmVnaW9uOmU5Y2E0YWZhZWJmYjQ1MzFiMjllZThhMTA2OTcwN2MxXzM2OTU_dc50d7a4-c847-46f6-8820-19d1db1148b4">470</ix:nonFraction> of consultancy fees were incurred by the Company and a warrant expense of $<ix:nonFraction unitRef="usd" contextRef="ib8d80178d3e743bd88db3e643c215cb4_D20191224-20200630" decimals="-3" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODcvZnJhZzplOWNhNGFmYWViZmI0NTMxYjI5ZWU4YTEwNjk3MDdjMS90ZXh0cmVnaW9uOmU5Y2E0YWZhZWJmYjQ1MzFiMjllZThhMTA2OTcwN2MxXzM3NzI_a6fd3a70-6d00-42ab-a4cb-90dcc5339ed6">512</ix:nonFraction> was recognized. The consultancy agreement with MZA was terminated by mutual agreement on June 30, 2020. The warrants granted to MZA were subsequently assigned to Dr. Maky Zanganeh and Dr. Elaine Stracker. Dr. Maky Zanganeh and Dr. Elaine Stracker have vested warrants to purchase <ix:nonFraction unitRef="shares" contextRef="i0346f51cbc1549bc97088b050e2cd48e_I20200630" decimals="INF" name="smmt:ClassOfWarrantOrRightVested" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODcvZnJhZzplOWNhNGFmYWViZmI0NTMxYjI5ZWU4YTEwNjk3MDdjMS90ZXh0cmVnaW9uOmU5Y2E0YWZhZWJmYjQ1MzFiMjllZThhMTA2OTcwN2MxXzQwNTU_109f83d6-9052-4a56-ab26-b05ade1ce473">489,815</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i093a476c99524d7c821d17ca295cc4d5_I20200630" decimals="INF" name="smmt:ClassOfWarrantOrRightVested" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODcvZnJhZzplOWNhNGFmYWViZmI0NTMxYjI5ZWU4YTEwNjk3MDdjMS90ZXh0cmVnaW9uOmU5Y2E0YWZhZWJmYjQ1MzFiMjllZThhMTA2OTcwN2MxXzQwNjI_052dfce1-4258-4317-ae05-e5647341339a">69,972</ix:nonFraction> shares of common stock, respectively, which can be exercised through June 30, 2025.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">March 24, 2021 Note Purchase Agreement</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 24, 2021, Mr. Robert W. Duggan, entered into a Note Purchase Agreement (the &#8220;Initial Purchase Agreement&#8221;) pursuant to which he has loaned the Company $<ix:nonFraction unitRef="usd" contextRef="i4a8e4bc29f1645008a3ae3a8a5bb7985_D20210324-20210324" decimals="-3" name="us-gaap:ProceedsFromRelatedPartyDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODcvZnJhZzplOWNhNGFmYWViZmI0NTMxYjI5ZWU4YTEwNjk3MDdjMS90ZXh0cmVnaW9uOmU5Y2E0YWZhZWJmYjQ1MzFiMjllZThhMTA2OTcwN2MxXzQzNDk_95bd9772-e3c9-4023-89c7-8f357d314041">55,000</ix:nonFraction> in exchange for the issuance by the Company of an unsecured promissory note (the &#8220;Initial Note&#8221;) in the amount of $<ix:nonFraction unitRef="usd" contextRef="i0ad778717801435f8f8ca0b3e18b51e9_I20210324" decimals="-3" name="us-gaap:NotesPayableRelatedPartiesCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODcvZnJhZzplOWNhNGFmYWViZmI0NTMxYjI5ZWU4YTEwNjk3MDdjMS90ZXh0cmVnaW9uOmU5Y2E0YWZhZWJmYjQ1MzFiMjllZThhMTA2OTcwN2MxXzQ0NjY_b169f710-79ce-4bbe-9705-0a1191fec903">55,000</ix:nonFraction>. The Initial Note was to accrue interest at a rate per annum equal to <ix:nonFraction unitRef="number" contextRef="i325d85a3830d40bba514256f5133edfa_D20210324-20210324" decimals="INF" name="smmt:RelatedPartyTransactionRateBasisSpreadOnVariableRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODcvZnJhZzplOWNhNGFmYWViZmI0NTMxYjI5ZWU4YTEwNjk3MDdjMS90ZXh0cmVnaW9uOmU5Y2E0YWZhZWJmYjQ1MzFiMjllZThhMTA2OTcwN2MxXzQ1Mzk_fbe2f727-4e7a-47a2-83b0-8714a8ac6771">150</ix:nonFraction>% of the applicable 10 Year U.S. Treasury rate, as adjusted monthly. The rate is initially estimated to be approximately <ix:nonFraction unitRef="number" contextRef="i4a8e4bc29f1645008a3ae3a8a5bb7985_D20210324-20210324" decimals="3" name="smmt:RelatedPartyTransactionExpectedRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODcvZnJhZzplOWNhNGFmYWViZmI0NTMxYjI5ZWU4YTEwNjk3MDdjMS90ZXh0cmVnaW9uOmU5Y2E0YWZhZWJmYjQ1MzFiMjllZThhMTA2OTcwN2MxXzQ2NjE_e9e8a075-5478-46f1-9694-895e9747ba1e">2.4</ix:nonFraction>%. The terms of the Initial Note were that it would mature and become due upon the earlier of (i) the consummation of a registered public offering with net proceeds of no less than $<ix:nonFraction unitRef="usd" contextRef="i4a8e4bc29f1645008a3ae3a8a5bb7985_D20210324-20210324" decimals="-3" name="smmt:NotesPayableRelatedPartiesMaturityTriggeringEventPublicOfferingProceedsThreshold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODcvZnJhZzplOWNhNGFmYWViZmI0NTMxYjI5ZWU4YTEwNjk3MDdjMS90ZXh0cmVnaW9uOmU5Y2E0YWZhZWJmYjQ1MzFiMjllZThhMTA2OTcwN2MxXzQ4NDM_83fbd8fe-7f0e-4534-8051-6e9facca3f8b">55,000</ix:nonFraction>, or (ii) <ix:nonNumeric contextRef="i4a8e4bc29f1645008a3ae3a8a5bb7985_D20210324-20210324" name="smmt:NotesPayableRelatedPartiesMaximumTerm" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODcvZnJhZzplOWNhNGFmYWViZmI0NTMxYjI5ZWU4YTEwNjk3MDdjMS90ZXh0cmVnaW9uOmU5Y2E0YWZhZWJmYjQ1MzFiMjllZThhMTA2OTcwN2MxXzQ4NTU_ab4d03dd-78e1-452f-9efe-8434313b886c">13</ix:nonNumeric> months from the date of issuance of the Initial Note. On April 20, 2021, the Company determined, with Mr. Duggan&#8217;s agreement, to rescind both the Initial Purchase Agreement and the Initial Note issued thereunder, and repaid the principal amount of the Initial Note in full, without interest or penalty, as such for the year ended December 31, 2021, the Company recognized imputed interest of $<ix:nonFraction unitRef="usd" contextRef="i09dcbb2d540d490da156db0310d0ba16_D20210101-20211231" decimals="-3" name="smmt:AdjustmentsToAdditionalPaidInCapitalImputedInterestExpenseRelatedParty" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODcvZnJhZzplOWNhNGFmYWViZmI0NTMxYjI5ZWU4YTEwNjk3MDdjMS90ZXh0cmVnaW9uOmU5Y2E0YWZhZWJmYjQ1MzFiMjllZThhMTA2OTcwN2MxXzUyNTA_b8e390f9-e5d5-4013-818e-20e812e322cf">103</ix:nonFraction> within additional paid in capital. For the year ended December 31, 2021, debt issuance costs recognized related to the Initial Note were immaterial.</span></div></ix:continuation><div><span><br/></span></div><div><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summit Therapeutics Inc. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div></div><ix:continuation id="i1336acb8fdb548299657fe4784cda48b"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">March 26, 2021 Sublease Agreement with Dr. Maky Zanganeh and Associates, Inc.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 26, 2021, the Company entered into a sublease with Dr. Maky Zanganeh and Associates, Inc. ("MZA") consisting of <ix:nonFraction unitRef="sqft" contextRef="idb48cdbb6adf4bcf9f8d62840ec9c140_I20210326" decimals="0" name="smmt:AreaOfPremisesSubleased" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODcvZnJhZzplOWNhNGFmYWViZmI0NTMxYjI5ZWU4YTEwNjk3MDdjMS90ZXh0cmVnaW9uOmU5Y2E0YWZhZWJmYjQ1MzFiMjllZThhMTA2OTcwN2MxXzU2MDQ_fdbe6c97-d7b8-414a-b32e-721af856336b">4,500</ix:nonFraction> square feet of office space at 2882 Sand Hill Road, Menlo Park, CA (the &#8220;Sublease&#8221;). Dr. Maky Zanganeh is the sole owner of MZA. The sublease runs until September 2022. The rent payable under the terms of the sublease is equivalent to the proportionate share of the rent payable by MZA to the third-party landlord, based on the square footage of office space sublet by the Company, and no mark-up has been applied. During the year ended December 31, 2021, payments of $<ix:nonFraction unitRef="usd" contextRef="i581d5e9999fd48be88afa99a5a463cea_D20210101-20211231" decimals="-3" name="smmt:RelatedPartyTransactionPaymentsToRelatedParty" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODcvZnJhZzplOWNhNGFmYWViZmI0NTMxYjI5ZWU4YTEwNjk3MDdjMS90ZXh0cmVnaW9uOmU5Y2E0YWZhZWJmYjQ1MzFiMjllZThhMTA2OTcwN2MxXzYwNzU_243cddf0-8e36-4d6f-98ec-30575153ad6c">556</ix:nonFraction>, were made pursuant to the sublease.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">April 20, 2021 Note Purchase Agreement</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 20, 2021, subsequent to the repayment of the Initial Note, Mr. Robert W. Duggan entered into a second Note Purchase Agreement (the &#8220;Second Purchase Agreement&#8221;) pursuant to which he loaned the Company $<ix:nonFraction unitRef="usd" contextRef="i5c623b14e066454399e945948de2ad12_D20210420-20210420" decimals="-3" name="us-gaap:ProceedsFromRelatedPartyDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODcvZnJhZzplOWNhNGFmYWViZmI0NTMxYjI5ZWU4YTEwNjk3MDdjMS90ZXh0cmVnaW9uOmU5Y2E0YWZhZWJmYjQ1MzFiMjllZThhMTA2OTcwN2MxXzYzNjU_f83d8385-8cf8-4366-b5c9-5d8795703904">55,000</ix:nonFraction> in exchange for the issuance by the Company of an unsecured promissory note (the &#8220;Second Note&#8221;) in the amount of $<ix:nonFraction unitRef="usd" contextRef="i9d8f0174c08f45cab10ea87b88a0b06d_I20210420" decimals="-3" name="us-gaap:NotesPayableRelatedPartiesCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODcvZnJhZzplOWNhNGFmYWViZmI0NTMxYjI5ZWU4YTEwNjk3MDdjMS90ZXh0cmVnaW9uOmU5Y2E0YWZhZWJmYjQ1MzFiMjllZThhMTA2OTcwN2MxXzY0ODE_6491d4aa-a5be-47e0-aba6-c72d0176797f">55,000</ix:nonFraction>. The Second Note accrued interest at a rate per annum equal to <ix:nonFraction unitRef="number" contextRef="i6f7965621e7641dba292d1568adf65f8_D20210420-20210420" decimals="INF" name="smmt:RelatedPartyTransactionRateBasisSpreadOnVariableRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODcvZnJhZzplOWNhNGFmYWViZmI0NTMxYjI5ZWU4YTEwNjk3MDdjMS90ZXh0cmVnaW9uOmU5Y2E0YWZhZWJmYjQ1MzFiMjllZThhMTA2OTcwN2MxXzY1NDc_fc925bac-61be-4911-8635-4e100322ba3f">150</ix:nonFraction>% of the applicable 10 Year US Treasury rate, as adjusted monthly (initially estimated to be approximately <ix:nonFraction unitRef="number" contextRef="i5c623b14e066454399e945948de2ad12_D20210420-20210420" decimals="3" name="smmt:RelatedPartyTransactionExpectedRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODcvZnJhZzplOWNhNGFmYWViZmI0NTMxYjI5ZWU4YTEwNjk3MDdjMS90ZXh0cmVnaW9uOmU5Y2E0YWZhZWJmYjQ1MzFiMjllZThhMTA2OTcwN2MxXzY2NTU_ccc9e01a-b2b7-4447-92c2-51058b35f3bf">2.4</ix:nonFraction>%). The Company was permitted to prepay any portion of the second note at its option without penalty.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">May 12, 2021 Rights Offering</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 12, 2021, the Company closed its rights offering, which was fully subscribed. Aggregate gross proceeds from the rights offering of $<ix:nonFraction unitRef="usd" contextRef="idb475943c8884e52b4a61d6e77d4d205_D20210512-20210512" decimals="-3" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODcvZnJhZzplOWNhNGFmYWViZmI0NTMxYjI5ZWU4YTEwNjk3MDdjMS90ZXh0cmVnaW9uOmU5Y2E0YWZhZWJmYjQ1MzFiMjllZThhMTA2OTcwN2MxXzY5Mjc_6f4da8ac-53e3-4606-99d8-77c7b6eed8c6">75,000</ix:nonFraction> from the sale of&#8239;<ix:nonFraction unitRef="shares" contextRef="idb475943c8884e52b4a61d6e77d4d205_D20210512-20210512" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODcvZnJhZzplOWNhNGFmYWViZmI0NTMxYjI5ZWU4YTEwNjk3MDdjMS90ZXh0cmVnaW9uOmU5Y2E0YWZhZWJmYjQ1MzFiMjllZThhMTA2OTcwN2MxXzY5NDc_ba3ff3b8-bb39-4505-98fd-74ffb2417155">14,312,976</ix:nonFraction>&#8239;shares of the Company's common stock, of which <ix:nonFraction unitRef="shares" contextRef="ie3fb42912674490dbad67b4354fdb2ee_D20210512-20210512" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODcvZnJhZzplOWNhNGFmYWViZmI0NTMxYjI5ZWU4YTEwNjk3MDdjMS90ZXh0cmVnaW9uOmU5Y2E0YWZhZWJmYjQ1MzFiMjllZThhMTA2OTcwN2MxXzY5OTc_415be3b8-63cc-4951-b7f3-706e24ede78c">11,365,921</ix:nonFraction> shares were purchased by Mr. Robert W. Duggan and <ix:nonFraction unitRef="shares" contextRef="i2c16f78153794bfc9c3b372a28a98377_D20210512-20210512" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODcvZnJhZzplOWNhNGFmYWViZmI0NTMxYjI5ZWU4YTEwNjk3MDdjMS90ZXh0cmVnaW9uOmU5Y2E0YWZhZWJmYjQ1MzFiMjllZThhMTA2OTcwN2MxXzcwNTA_50829544-31e4-4cd1-9a21-ef6480021656">389,977</ix:nonFraction> shares were purchased by Dr. Maky Zanganeh, at price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i8148167fc4184c02abb40835e22beac6_I20210512" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODcvZnJhZzplOWNhNGFmYWViZmI0NTMxYjI5ZWU4YTEwNjk3MDdjMS90ZXh0cmVnaW9uOmU5Y2E0YWZhZWJmYjQ1MzFiMjllZThhMTA2OTcwN2MxXzcxMDk_31dcb4cb-91c3-4042-a240-adc0a0e1ffe3"><ix:nonFraction unitRef="usdPerShare" contextRef="i11be25b5a09d46a5851abb451892b99c_I20210512" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODcvZnJhZzplOWNhNGFmYWViZmI0NTMxYjI5ZWU4YTEwNjk3MDdjMS90ZXh0cmVnaW9uOmU5Y2E0YWZhZWJmYjQ1MzFiMjllZThhMTA2OTcwN2MxXzcxMDk_9e263e41-279b-44c4-a6b7-f7f77aff4e36">5.24</ix:nonFraction></ix:nonFraction> per share. In connection with the closing of the rights offering, the Second Note, issued by the Company in favor of Mr. Robert W. Duggan, matured and became due and was repaid using a portion of the proceeds from the rights offering.</span></div></ix:continuation><div><span><br/></span></div><div><span><br/></span></div><div id="i2eecdebedec64091994df5b7a96baab7_190"></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">21. <ix:nonNumeric contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231" name="us-gaap:SubsequentEventsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xOTAvZnJhZzoyMzA5NDBmZjdjYTU0ZjlmYWMyYmZlZTQxNmM2N2E0Yy90ZXh0cmVnaW9uOjIzMDk0MGZmN2NhNTRmOWZhYzJiZmVlNDE2YzY3YTRjXzYwNA_6bb86354-8650-4430-9cc3-12dee5213ef1" continuedAt="i8551f347acf741558b823449b2d55869" escape="true">Subsequent Event</ix:nonNumeric></span></div><div><span><br/></span></div><div><ix:continuation id="i8551f347acf741558b823449b2d55869"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">On March 10, 2022, Mr. Robert W. Duggan, entered into a Note Purchase Agreement (the &#8220;2022 Note&#8221;), pursuant to which he has loaned the Company $<ix:nonFraction unitRef="usd" contextRef="idf7a081c7b9c4705a95c5f2ab53d19bb_D20220310-20220310" decimals="-3" name="us-gaap:ProceedsFromRelatedPartyDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xOTAvZnJhZzoyMzA5NDBmZjdjYTU0ZjlmYWMyYmZlZTQxNmM2N2E0Yy90ZXh0cmVnaW9uOjIzMDk0MGZmN2NhNTRmOWZhYzJiZmVlNDE2YzY3YTRjXzE1Nw_69138b23-a984-44ed-9f22-fd824b580d4b">25,000</ix:nonFraction> in exchange for the issuance by the Company of an unsecured promissory note in the amount of $<ix:nonFraction unitRef="usd" contextRef="id74d06c0cec74c7fa7641c591943da88_I20220310" decimals="-3" name="us-gaap:NotesPayableRelatedPartiesCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xOTAvZnJhZzoyMzA5NDBmZjdjYTU0ZjlmYWMyYmZlZTQxNmM2N2E0Yy90ZXh0cmVnaW9uOjIzMDk0MGZmN2NhNTRmOWZhYzJiZmVlNDE2YzY3YTRjXzI1Mw_8d5360bb-1df5-46b7-85b8-71efccc7c96f">25,000</ix:nonFraction>. The 2022 Note is to accrue interest at a rate per annum equal to the prime rate as reported in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%">Wall Street Journal</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">, which is <ix:nonFraction unitRef="number" contextRef="idf7a081c7b9c4705a95c5f2ab53d19bb_D20220310-20220310" decimals="INF" name="us-gaap:RelatedPartyTransactionRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xOTAvZnJhZzoyMzA5NDBmZjdjYTU0ZjlmYWMyYmZlZTQxNmM2N2E0Yy90ZXh0cmVnaW9uOjIzMDk0MGZmN2NhNTRmOWZhYzJiZmVlNDE2YzY3YTRjXzM4Ng_2d605ab6-a553-4e44-8921-654e4bceff98">3.25</ix:nonFraction>% as of the effective date. The 2022 Note becomes due upon the earlier of (i) the consummation of a registered public offering with net proceeds of no less than $<ix:nonFraction unitRef="usd" contextRef="idf7a081c7b9c4705a95c5f2ab53d19bb_D20220310-20220310" decimals="-3" name="smmt:NotesPayableRelatedPartiesMaturityTriggeringEventPublicOfferingProceedsThreshold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xOTAvZnJhZzoyMzA5NDBmZjdjYTU0ZjlmYWMyYmZlZTQxNmM2N2E0Yy90ZXh0cmVnaW9uOjIzMDk0MGZmN2NhNTRmOWZhYzJiZmVlNDE2YzY3YTRjXzU0OA_9c9d674c-41f3-44fd-b07b-fa148e8b1101">25,000</ix:nonFraction> or (ii) <ix:nonNumeric contextRef="idf7a081c7b9c4705a95c5f2ab53d19bb_D20220310-20220310" name="smmt:NotesPayableRelatedPartiesMaximumTerm" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xOTAvZnJhZzoyMzA5NDBmZjdjYTU0ZjlmYWMyYmZlZTQxNmM2N2E0Yy90ZXh0cmVnaW9uOjIzMDk0MGZmN2NhNTRmOWZhYzJiZmVlNDE2YzY3YTRjXzU1OQ_65a644fe-f3b7-4ee6-9ad6-9675b5620b7a">18</ix:nonNumeric> months from the date of issuance of the 2022 Note.</span></ix:continuation></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>2
<FILENAME>sum-ex231_20211231x10xkaxu.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ia0be3edb5a6c40b7bc29794c143169ed_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 23.1</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (Nos. 333-249316 and 333-251958) and Form S-8 (Nos. 333-249313, 333-238582, and 333-264163) of Summit Therapeutics Inc. of our report dated March 17, 2022 relating to the financial statements, which appears in this Form 10-K&#47;A.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; PricewaterhouseCoopers LLP</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Boston, MA</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 21, 2022</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.2
<SEQUENCE>3
<FILENAME>sum-ex232_20211231x10xkaxu.htm
<DESCRIPTION>EX-23.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i8ad7922a1ed94ca7a44f86b81c7d511a_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 23.2</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (No. 333-249316 and No. 333-251958) and Form S-8 (No. 333-249313, No. 333-238582 and No. 333-264163) of Summit Therapeutics Inc. of our report dated March 31, 2021 relating to the financial statements, which appears in this Form 10-K&#47;A.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; PricewaterhouseCoopers LLP</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reading, United Kingdom</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 21, 2022</font></div><div><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>sum-ex311_20211231x10xka.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i40e130f17ad147b9a6ebdac15d62a526_1"></div><div style="min-height:45.36pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Exhibit 31.1</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">PURSUANT TO RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">SARBANES-OXLEY ACT OF 2002</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">I, Robert W. Duggan, certify that&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:10.5pt">I have reviewed this Amendment No. 1 to the Annual Report on Form 10-K&#47;A of Summit Therapeutics Inc. (the &#8220;Company&#8221;)&#59;  </font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;  </font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Company as of, and for, the periods presented in this report&#59;  </font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:10.5pt">The Company&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Company and have&#58;</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:11.07pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:10.5pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:11.07pt">Evaluated the effectiveness of the Company&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:10.5pt">Disclosed in this report any change in the Company&#8217;s internal control over financial reporting that occurred during the Company's most recent fiscal quarter (the Company's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Company&#8217;s internal control over financial reporting&#59; and</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:10.5pt">The Company&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Company&#8217;s auditors and the audit committee of the Company&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:11.07pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Company&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:10.5pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the Company&#8217;s internal control over financial reporting.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Date&#58; December 21, 2022                                                                            </font></div><div style="height:45.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:45.36pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.071%"><tr><td style="width:1.0%"></td><td style="width:41.357%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.053%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.290%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="9" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="6" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Robert W. Duggan</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Robert W. Duggan</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chairman and Chief Executive Officer<br>(Principal Executive Officer) </font></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="height:45.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>sum-ex312_20211231x10xka.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ic5ca073e34df42f8bc9347ee1e5839cc_1"></div><div style="min-height:45.36pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Exhibit 31.2</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">PURSUANT TO RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">SARBANES-OXLEY ACT OF 2002</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">I, Dr. Maky Zanganeh, certify that&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:10.5pt">I have reviewed this Amendment No. 1 to the Annual Report on Form 10-K&#47;A of Summit Therapeutics Inc. (the &#8220;Company&#8221;)&#59;  </font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;  </font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Company as of, and for, the periods presented in this report&#59;  </font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:10.5pt">The Company&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Company and have&#58;</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:11.07pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:10.5pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:11.07pt">Evaluated the effectiveness of the Company&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:10.5pt">Disclosed in this report any change in the Company&#8217;s internal control over financial reporting that occurred during the Company's most recent fiscal quarter (the Company's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Company&#8217;s internal control over financial reporting&#59; and</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:10.5pt">The Company&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Company&#8217;s auditors and the audit committee of the Company&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:11.07pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Company&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:10.5pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the Company&#8217;s internal control over financial reporting.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Date&#58; December 21, 2022                                                                             </font></div><div style="height:45.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:45.36pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.144%"><tr><td style="width:1.0%"></td><td style="width:40.014%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.827%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.859%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="9" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="6" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Maky Zanganeh</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dr. Maky Zanganeh</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Director, Co-Chief Executive Officer, and President<br>(Principal Executive Officer) </font></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="height:45.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.3
<SEQUENCE>6
<FILENAME>sum-ex313_20211231x10xka.htm
<DESCRIPTION>EX-31.3
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="id25c1795767946069700874d6d143f0e_1"></div><div style="min-height:45.36pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Exhibit 31.3</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">PURSUANT TO RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">SARBANES-OXLEY ACT OF 2002</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">I, Ankur Dhingra, certify that&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:10.5pt">I have reviewed this Amendment No. 1 to the Annual Report on Form 10-K&#47;A of Summit Therapeutics Inc. (the &#8220;Company&#8221;)&#59;  </font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;  </font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Company as of, and for, the periods presented in this report&#59;  </font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:10.5pt">The Company&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Company and have&#58;</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:11.07pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:10.5pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:11.07pt">Evaluated the effectiveness of the Company&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:10.5pt">Disclosed in this report any change in the Company&#8217;s internal control over financial reporting that occurred during the Company's most recent fiscal quarter (the Company's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Company&#8217;s internal control over financial reporting&#59; and</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:10.5pt">The Company&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Company&#8217;s auditors and the audit committee of the Company&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:11.07pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Company&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:10.5pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the Company&#8217;s internal control over financial reporting.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Date&#58; December 21, 2022                                                                             </font></div><div style="height:45.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:45.36pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.144%"><tr><td style="width:1.0%"></td><td style="width:40.014%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.827%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.859%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="9" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="6" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Ankur Dhingra</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ankur Dhingra</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer<br>(Principal Financial Officer) </font></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="height:45.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>7
<FILENAME>sum-ex321_20211231x10xka.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ia07b3634bd0b4fbc8231d8e9d9291e2d_1"></div><div style="min-height:45.36pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Exhibit 32.1</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">CERTIFICATION OF</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div><font><br></font></div><div style="text-indent:24pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">In connection with Amendment No.1 to the Annual Report on Form 10-K&#47;A of Summit Therapeutics Inc. (the &#8220;Company&#8221;) for the year ended December 31, 2021, as filed with the U.S. Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), each of the undersigned officers hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of his or her knowledge&#58; </font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:9.67pt">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and </font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:9.67pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. </font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.937%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.775%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; December 21, 2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Robert W. Duggan</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Robert W. Duggan</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Chairman and Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Principal Executive Officer)</font></td></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; December 21, 2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Maky Zanganeh</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Dr. Maky Zanganeh</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Executive Director, Co-Chief Executive Officer, and President</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Principal Executive Officer)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; December 21, 2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Ankur Dhingra</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ankur Dhingra</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Principal Financial Officer)</font></td></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:45.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>smmt-20211231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:48b41a33-da2b-4a8c-a794-72fce890713a,g:e36a0d9c-9c90-432d-82bf-4f94771c92ff-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:smmt="http://www.summitplc.com/20211231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.summitplc.com/20211231">
  <xs:import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="smmt-20211231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="smmt-20211231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="smmt-20211231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="smmt-20211231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="DocumentandEntityInformation" roleURI="http://www.summitplc.com/role/DocumentandEntityInformation">
        <link:definition>0000001 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AuditInformation" roleURI="http://www.summitplc.com/role/AuditInformation">
        <link:definition>0000002 - Document - Audit Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://www.summitplc.com/role/ConsolidatedBalanceSheets">
        <link:definition>0000003 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.summitplc.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>0000004 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofOperationsandComprehensiveLoss" roleURI="http://www.summitplc.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss">
        <link:definition>0000005 - Statement - Consolidated Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofStockholdersEquity" roleURI="http://www.summitplc.com/role/ConsolidatedStatementsofStockholdersEquity">
        <link:definition>0000006 - Statement - Consolidated Statements of Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofStockholdersEquityDeficitParenthetical" roleURI="http://www.summitplc.com/role/ConsolidatedStatementsofStockholdersEquityDeficitParenthetical">
        <link:definition>0000007 - Statement - Consolidated Statements of Stockholders' Equity (Deficit) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlows" roleURI="http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows">
        <link:definition>0000008 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NatureofBusinessandOperationsandRecentEvents" roleURI="http://www.summitplc.com/role/NatureofBusinessandOperationsandRecentEvents">
        <link:definition>0000009 - Disclosure - Nature of Business and Operations and Recent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandUseofEstimates" roleURI="http://www.summitplc.com/role/BasisofPresentationandUseofEstimates">
        <link:definition>0000010 - Disclosure - Basis of Presentation and Use of Estimates</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LiquidityandCapitalResources" roleURI="http://www.summitplc.com/role/LiquidityandCapitalResources">
        <link:definition>0000011 - Disclosure - Liquidity and Capital Resources</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://www.summitplc.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>0000012 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RecentlyIssuedorAdoptedAccountingPronouncements" roleURI="http://www.summitplc.com/role/RecentlyIssuedorAdoptedAccountingPronouncements">
        <link:definition>0000013 - Disclosure - Recently Issued or Adopted Accounting Pronouncements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReporting" roleURI="http://www.summitplc.com/role/SegmentReporting">
        <link:definition>0000014 - Disclosure - Segment Reporting</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Revenue" roleURI="http://www.summitplc.com/role/Revenue">
        <link:definition>0000015 - Disclosure - Revenue</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherOperatingIncome" roleURI="http://www.summitplc.com/role/OtherOperatingIncome">
        <link:definition>0000016 - Disclosure - Other Operating Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherExpenseIncome" roleURI="http://www.summitplc.com/role/OtherExpenseIncome">
        <link:definition>0000017 - Disclosure - Other (Expense) Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTax" roleURI="http://www.summitplc.com/role/IncomeTax">
        <link:definition>0000018 - Disclosure - Income Tax</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LossperShare" roleURI="http://www.summitplc.com/role/LossperShare">
        <link:definition>0000019 - Disclosure - Loss per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssets" roleURI="http://www.summitplc.com/role/GoodwillandIntangibleAssets">
        <link:definition>0000020 - Disclosure - Goodwill and Intangible Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipment" roleURI="http://www.summitplc.com/role/PropertyandEquipment">
        <link:definition>0000021 - Disclosure - Property and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ResearchandDevelopmentPrepaidExpensesandAccruedLiabilities" roleURI="http://www.summitplc.com/role/ResearchandDevelopmentPrepaidExpensesandAccruedLiabilities">
        <link:definition>0000022 - Disclosure - Research and Development Prepaid Expenses and Accrued Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.summitplc.com/role/Leases">
        <link:definition>0000023 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherNonCurrentLiabilities" roleURI="http://www.summitplc.com/role/OtherNonCurrentLiabilities">
        <link:definition>0000024 - Disclosure - Other Non-Current Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://www.summitplc.com/role/StockholdersEquity">
        <link:definition>0000025 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensation" roleURI="http://www.summitplc.com/role/StockBasedCompensation">
        <link:definition>0000026 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.summitplc.com/role/CommitmentsandContingencies">
        <link:definition>0000027 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactions" roleURI="http://www.summitplc.com/role/RelatedPartyTransactions">
        <link:definition>0000028 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvent" roleURI="http://www.summitplc.com/role/SubsequentEvent">
        <link:definition>0000029 - Disclosure - Subsequent Event</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.summitplc.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>0000030 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesTables" roleURI="http://www.summitplc.com/role/SummaryofSignificantAccountingPoliciesTables">
        <link:definition>0000031 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingTables" roleURI="http://www.summitplc.com/role/SegmentReportingTables">
        <link:definition>0000032 - Disclosure - Segment Reporting (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueTables" roleURI="http://www.summitplc.com/role/RevenueTables">
        <link:definition>0000033 - Disclosure - Revenue (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherOperatingIncomeTables" roleURI="http://www.summitplc.com/role/OtherOperatingIncomeTables">
        <link:definition>0000034 - Disclosure - Other Operating Income (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherExpenseIncomeTables" roleURI="http://www.summitplc.com/role/OtherExpenseIncomeTables">
        <link:definition>0000035 - Disclosure - Other (Expense) Income (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxTables" roleURI="http://www.summitplc.com/role/IncomeTaxTables">
        <link:definition>0000036 - Disclosure - Income Tax (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LossperShareTables" roleURI="http://www.summitplc.com/role/LossperShareTables">
        <link:definition>0000037 - Disclosure - Loss per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsTables" roleURI="http://www.summitplc.com/role/GoodwillandIntangibleAssetsTables">
        <link:definition>0000038 - Disclosure - Goodwill and Intangible Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentTables" roleURI="http://www.summitplc.com/role/PropertyandEquipmentTables">
        <link:definition>0000039 - Disclosure - Property and Equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.summitplc.com/role/LeasesTables">
        <link:definition>0000040 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationTables" roleURI="http://www.summitplc.com/role/StockBasedCompensationTables">
        <link:definition>0000041 - Disclosure - Stock Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NatureofBusinessandOperationsandRecentEventsDetails" roleURI="http://www.summitplc.com/role/NatureofBusinessandOperationsandRecentEventsDetails">
        <link:definition>0000042 - Disclosure - Nature of Business and Operations and Recent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LiquidityandCapitalResourcesDetails" roleURI="http://www.summitplc.com/role/LiquidityandCapitalResourcesDetails">
        <link:definition>0000043 - Disclosure - Liquidity and Capital Resources (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesNarrativeDetails" roleURI="http://www.summitplc.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails">
        <link:definition>0000044 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPropertyandequipmentusefullivesDetails" roleURI="http://www.summitplc.com/role/SummaryofSignificantAccountingPoliciesPropertyandequipmentusefullivesDetails">
        <link:definition>0000045 - Disclosure - Summary of Significant Accounting Policies - Property and equipment useful lives (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingNarrativeDetails" roleURI="http://www.summitplc.com/role/SegmentReportingNarrativeDetails">
        <link:definition>0000046 - Disclosure - Segment Reporting - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingLonglivedassetsbygeographyDetails" roleURI="http://www.summitplc.com/role/SegmentReportingLonglivedassetsbygeographyDetails">
        <link:definition>0000047 - Disclosure - Segment Reporting - Long-lived assets by geography (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRevenuebycategoryDetails" roleURI="http://www.summitplc.com/role/RevenueRevenuebycategoryDetails">
        <link:definition>0000048 - Disclosure - Revenue - Revenue by category (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRevenuebygeographyDetails" roleURI="http://www.summitplc.com/role/RevenueRevenuebygeographyDetails">
        <link:definition>0000049 - Disclosure - Revenue - Revenue by geography (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueDeferredrevenueandotherincomeDetails" roleURI="http://www.summitplc.com/role/RevenueDeferredrevenueandotherincomeDetails">
        <link:definition>0000050 - Disclosure - Revenue - Deferred revenue and other income (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueNarrativeDetails" roleURI="http://www.summitplc.com/role/RevenueNarrativeDetails">
        <link:definition>0000051 - Disclosure - Revenue - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherOperatingIncomeOtheroperatingincomebycategoryDetails" roleURI="http://www.summitplc.com/role/OtherOperatingIncomeOtheroperatingincomebycategoryDetails">
        <link:definition>0000052 - Disclosure - Other Operating Income - Other operating income by category (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherOperatingIncomeNarrativeDetails" roleURI="http://www.summitplc.com/role/OtherOperatingIncomeNarrativeDetails">
        <link:definition>0000053 - Disclosure - Other Operating Income - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherExpenseIncomeDetails" roleURI="http://www.summitplc.com/role/OtherExpenseIncomeDetails">
        <link:definition>0000054 - Disclosure - Other (Expense) Income (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxComponentsoflossbeforeincometaxesDetails" roleURI="http://www.summitplc.com/role/IncomeTaxComponentsoflossbeforeincometaxesDetails">
        <link:definition>0000055 - Disclosure - Income Tax - Components of loss before income taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxSignificantcomponentsoftheprovisionforincometaxesDetails" roleURI="http://www.summitplc.com/role/IncomeTaxSignificantcomponentsoftheprovisionforincometaxesDetails">
        <link:definition>0000056 - Disclosure - Income Tax - Significant components of the provision for income taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxMajorcomponentsofdeferredtaxassetsandliabilitiesDetails" roleURI="http://www.summitplc.com/role/IncomeTaxMajorcomponentsofdeferredtaxassetsandliabilitiesDetails">
        <link:definition>0000057 - Disclosure - Income Tax - Major components of deferred tax assets and liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxNarrativeDetails" roleURI="http://www.summitplc.com/role/IncomeTaxNarrativeDetails">
        <link:definition>0000058 - Disclosure - Income Tax - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxReconciliationoftheeffectiveincometaxratetostatutoryrateDetails" roleURI="http://www.summitplc.com/role/IncomeTaxReconciliationoftheeffectiveincometaxratetostatutoryrateDetails">
        <link:definition>0000059 - Disclosure - Income Tax - Reconciliation of the effective income tax rate to statutory rate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LossperShareComputationofnetlosspershareDetails" roleURI="http://www.summitplc.com/role/LossperShareComputationofnetlosspershareDetails">
        <link:definition>0000060 - Disclosure - Loss per Share - Computation of net loss per share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LossperSharePotentiallydilutivesecuritiesexcludedfromthecomputationoflosspershareDetails" roleURI="http://www.summitplc.com/role/LossperSharePotentiallydilutivesecuritiesexcludedfromthecomputationoflosspershareDetails">
        <link:definition>0000061 - Disclosure - Loss per Share - Potentially dilutive securities excluded from the computation of loss per share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsNarrativeDetails" roleURI="http://www.summitplc.com/role/GoodwillandIntangibleAssetsNarrativeDetails">
        <link:definition>0000062 - Disclosure - Goodwill and Intangible Assets - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsScheduleofacquiredintangibleassetsDetails" roleURI="http://www.summitplc.com/role/GoodwillandIntangibleAssetsScheduleofacquiredintangibleassetsDetails">
        <link:definition>0000063 - Disclosure - Goodwill and Intangible Assets - Schedule of acquired intangible assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsEstimatedamortizationexpenseDetails" roleURI="http://www.summitplc.com/role/GoodwillandIntangibleAssetsEstimatedamortizationexpenseDetails">
        <link:definition>0000064 - Disclosure - Goodwill and Intangible Assets - Estimated amortization expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentComponentsofpropertyandequipmentDetails" roleURI="http://www.summitplc.com/role/PropertyandEquipmentComponentsofpropertyandequipmentDetails">
        <link:definition>0000065 - Disclosure - Property and Equipment - Components of property and equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentNarrativeDetails" roleURI="http://www.summitplc.com/role/PropertyandEquipmentNarrativeDetails">
        <link:definition>0000066 - Disclosure - Property and Equipment - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ResearchandDevelopmentPrepaidExpensesandAccruedLiabilitiesDetails" roleURI="http://www.summitplc.com/role/ResearchandDevelopmentPrepaidExpensesandAccruedLiabilitiesDetails">
        <link:definition>0000067 - Disclosure - Research and Development Prepaid Expenses and Accrued Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesNarrativeDetails" roleURI="http://www.summitplc.com/role/LeasesNarrativeDetails">
        <link:definition>0000068 - Disclosure - Leases - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesLeaseexpenseDetails" roleURI="http://www.summitplc.com/role/LeasesLeaseexpenseDetails">
        <link:definition>0000069 - Disclosure - Leases - Lease expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesFutureleasepaymentsDetails" roleURI="http://www.summitplc.com/role/LeasesFutureleasepaymentsDetails">
        <link:definition>0000070 - Disclosure - Leases - Future lease payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesFutureleasepaymentsDetails_1" roleURI="http://www.summitplc.com/role/LeasesFutureleasepaymentsDetails_1">
        <link:definition>0000070 - Disclosure - Leases - Future lease payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherNonCurrentLiabilitiesDetails" roleURI="http://www.summitplc.com/role/OtherNonCurrentLiabilitiesDetails">
        <link:definition>0000071 - Disclosure - Other Non-Current Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityDetails" roleURI="http://www.summitplc.com/role/StockholdersEquityDetails">
        <link:definition>0000072 - Disclosure - Stockholders' Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationNarrativeDetails" roleURI="http://www.summitplc.com/role/StockBasedCompensationNarrativeDetails">
        <link:definition>0000073 - Disclosure - Stock Based Compensation - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationWeightedaverageassumptionsusedforstockoptionawardsDetails" roleURI="http://www.summitplc.com/role/StockBasedCompensationWeightedaverageassumptionsusedforstockoptionawardsDetails">
        <link:definition>0000074 - Disclosure - Stock Based Compensation - Weighted-average assumptions used for stock option awards (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationStockoptionactivityDetails" roleURI="http://www.summitplc.com/role/StockBasedCompensationStockoptionactivityDetails">
        <link:definition>0000075 - Disclosure - Stock Based Compensation - Stock option activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationRSUactivityDetails" roleURI="http://www.summitplc.com/role/StockBasedCompensationRSUactivityDetails">
        <link:definition>0000076 - Disclosure - Stock-Based Compensation - RSU activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationSummaryofstockbasedcompensationexpenseDetails" roleURI="http://www.summitplc.com/role/StockBasedCompensationSummaryofstockbasedcompensationexpenseDetails">
        <link:definition>0000077 - Disclosure - Stock-Based Compensation - Summary of stock-based compensation expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesDetails" roleURI="http://www.summitplc.com/role/CommitmentsandContingenciesDetails">
        <link:definition>0000078 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactionsDetails" roleURI="http://www.summitplc.com/role/RelatedPartyTransactionsDetails">
        <link:definition>0000079 - Disclosure - Related Party Transactions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEventDetails" roleURI="http://www.summitplc.com/role/SubsequentEventDetails">
        <link:definition>0000080 - Disclosure - Subsequent Event (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="smmt_WarrantsPolicyPolicyTextBlock" abstract="false" name="WarrantsPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="smmt_DeferredTaxAssetsLiabilities" abstract="false" name="DeferredTaxAssetsLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="smmt_IncreaseDecreaseInResearchAndDevelopmentTaxCreditReceivable" abstract="false" name="IncreaseDecreaseInResearchAndDevelopmentTaxCreditReceivable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="smmt_NotesPayableRelatedPartiesMaturityTriggeringEventPublicOfferingProceedsThreshold" abstract="false" name="NotesPayableRelatedPartiesMaturityTriggeringEventPublicOfferingProceedsThreshold" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="smmt_AdjustmentsToAdditionalPaidInCapitalImputedInterestExpenseRelatedParty" abstract="false" name="AdjustmentsToAdditionalPaidInCapitalImputedInterestExpenseRelatedParty" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="smmt_DeferredTaxAssetsNetIncreaseDecreaseDueToChangeInEnactedTaxRateAmount" abstract="false" name="DeferredTaxAssetsNetIncreaseDecreaseDueToChangeInEnactedTaxRateAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="smmt_OtherPatentsAndLicensesMember" abstract="true" name="OtherPatentsAndLicensesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="smmt_ResearchAndDevelopmentTaxCreditCashRebateMaximumPercentage" abstract="false" name="ResearchAndDevelopmentTaxCreditCashRebateMaximumPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="smmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="smmt_ClassOfWarrantOrRightMinimumTenDayVolumeWeightedAverageCommonStockPriceToWarrantExercisePricePremiumPercentage" abstract="false" name="ClassOfWarrantOrRightMinimumTenDayVolumeWeightedAverageCommonStockPriceToWarrantExercisePricePremiumPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="smmt_SecondPurchaseAgreementMember" abstract="true" name="SecondPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="smmt_RevenueFromContractWithCustomerDevelopmentCommercialAndSalesMilestoneCumulativeNetSalesTargetAchievementRevenueEntitledToReceive" abstract="false" name="RevenueFromContractWithCustomerDevelopmentCommercialAndSalesMilestoneCumulativeNetSalesTargetAchievementRevenueEntitledToReceive" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="smmt_OtherOperatingIncomePolicyPolicyTextBlock" abstract="false" name="OtherOperatingIncomePolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="smmt_AssumedContingentLiabilitiesPolicyPolicyTextBlock" abstract="false" name="AssumedContingentLiabilitiesPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="smmt_GainLossOnRemeasurementOfLiabilitiesNonoperating" abstract="false" name="GainLossOnRemeasurementOfLiabilitiesNonoperating" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="smmt_A2022NoteMember" abstract="true" name="A2022NoteMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="smmt_FiniteLivedIntangibleAssetsAccumulatedAmortizationAndImpairment" abstract="false" name="FiniteLivedIntangibleAssetsAccumulatedAmortizationAndImpairment" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="smmt_MenloParkCaliforniaUSAndSawstonUKMember" abstract="true" name="MenloParkCaliforniaUSAndSawstonUKMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="smmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedOutstandingNumber" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedOutstandingNumber" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="smmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="smmt_ConsultancyAgreementWarrantVestingExpenseMember" abstract="true" name="ConsultancyAgreementWarrantVestingExpenseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="smmt_GrantFundingArrangementCommittedFundingTotal" abstract="false" name="GrantFundingArrangementCommittedFundingTotal" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="smmt_RelatedPartyTransactionPaymentsToRelatedParty" abstract="false" name="RelatedPartyTransactionPaymentsToRelatedParty" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="smmt_OfficeAndTechnologyEquipmentMember" abstract="true" name="OfficeAndTechnologyEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="smmt_ResearchAndDevelopmentTaxCredit" abstract="false" name="ResearchAndDevelopmentTaxCredit" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="smmt_InitialPurchaseAgreementMember" abstract="true" name="InitialPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="smmt_GrantFundingArrangementMilestoneFundingIncrease" abstract="false" name="GrantFundingArrangementMilestoneFundingIncrease" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="smmt_ConsultingAgreementMember" abstract="true" name="ConsultingAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="smmt_DiscuvaPlatformMember" abstract="true" name="DiscuvaPlatformMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="smmt_RightsOfferingMember" abstract="true" name="RightsOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="smmt_ResearchAndDevelopmentPrepaidExpensesCurrent" abstract="false" name="ResearchAndDevelopmentPrepaidExpensesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="smmt_ConsultingAgreementConsultancyFeesMember" abstract="true" name="ConsultingAgreementConsultancyFeesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="smmt_GrantFundingArrangementMaximumFundingValue" abstract="false" name="GrantFundingArrangementMaximumFundingValue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="smmt_RelatedPartyTransactionRateBasisSpreadOnVariableRate" abstract="false" name="RelatedPartyTransactionRateBasisSpreadOnVariableRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="smmt_StockIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" abstract="false" name="StockIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="smmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="smmt_EuroFarmaLaboratoriosSAMember" abstract="true" name="EuroFarmaLaboratoriosSAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="smmt_BusinessCombinationAssumedContingentLiabilityNoncurrent" abstract="false" name="BusinessCombinationAssumedContingentLiabilityNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="smmt_ScheduleOfOtherOperatingIncomeByComponentTableTextBlock" abstract="false" name="ScheduleOfOtherOperatingIncomeByComponentTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="smmt_ResearchAndDevelopmentTaxCreditReceivable" abstract="false" name="ResearchAndDevelopmentTaxCreditReceivable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="smmt_IncreaseDecreaseInAccruedLiabilitiesAndEmployeeRelatedLiabilities" abstract="false" name="IncreaseDecreaseInAccruedLiabilitiesAndEmployeeRelatedLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="smmt_LaboratoryEquipmentMember" abstract="true" name="LaboratoryEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="smmt_AuditInformationAbstract" abstract="true" name="AuditInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="smmt_ClassOfWarrantOrRightQuarterlyVestingPeriod" abstract="false" name="ClassOfWarrantOrRightQuarterlyVestingPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="smmt_OptionOverNonFinancialAssetsMember" abstract="true" name="OptionOverNonFinancialAssetsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="smmt_FormerChiefExecutiveOfficerMember" abstract="true" name="FormerChiefExecutiveOfficerMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="smmt_RevenueFromContractWithCustomerDevelopmentCommercialAndSalesMilestoneCumulativeNetSalesTargetThreshold" abstract="false" name="RevenueFromContractWithCustomerDevelopmentCommercialAndSalesMilestoneCumulativeNetSalesTargetThreshold" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="smmt_AreaOfPremisesSubleased" abstract="false" name="AreaOfPremisesSubleased" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:areaItemType"/>
  <xs:element id="smmt_RelatedPartyTransactionMonthlyExpensesFromTransactionsWithRelatedParty" abstract="false" name="RelatedPartyTransactionMonthlyExpensesFromTransactionsWithRelatedParty" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="smmt_ConsultantsMember" abstract="true" name="ConsultantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="smmt_CommonStockAndRestrictedStockUnitsAdditionalCapitalSharesAllowableForForFutureIssuance" abstract="false" name="CommonStockAndRestrictedStockUnitsAdditionalCapitalSharesAllowableForForFutureIssuance" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="smmt_GainLossOnRemeasurementOfLiabilitiesOperatingAndNonoperating" abstract="false" name="GainLossOnRemeasurementOfLiabilitiesOperatingAndNonoperating" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="smmt_GrantFundingArrangementFundingReceived" abstract="false" name="GrantFundingArrangementFundingReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="smmt_NotesPayableRelatedPartiesMaximumTerm" abstract="false" name="NotesPayableRelatedPartiesMaximumTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="smmt_IncomeStatementAndStatementOfComprehensiveIncomeAbstract" abstract="true" name="IncomeStatementAndStatementOfComprehensiveIncomeAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="smmt_InterestExpenseIncomeNoncash" abstract="false" name="InterestExpenseIncomeNoncash" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="smmt_OxfordshireUKMember" abstract="true" name="OxfordshireUKMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="smmt_OtherGrantFundingCounterpartiesMember" abstract="true" name="OtherGrantFundingCounterpartiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="smmt_RevenueFromContractWithCustomerDevelopmentMilestoneRevenueEntitledToReceive" abstract="false" name="RevenueFromContractWithCustomerDevelopmentMilestoneRevenueEntitledToReceive" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="smmt_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseDueToChangeInEnactedTaxRateAmount" abstract="false" name="ValuationAllowanceDeferredTaxAssetIncreaseDecreaseDueToChangeInEnactedTaxRateAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="smmt_ContractWithCustomerLiabilityEnrollmentMilestone" abstract="false" name="ContractWithCustomerLiabilityEnrollmentMilestone" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="smmt_AssignmentAgreementMember" abstract="true" name="AssignmentAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="smmt_ResearchAndDevelopmentTaxCreditReceivableCurrent" abstract="false" name="ResearchAndDevelopmentTaxCreditReceivableCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="smmt_RelatedPartyTransactionBeneficialOwnershipPercentage" abstract="false" name="RelatedPartyTransactionBeneficialOwnershipPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="smmt_GrantFundingArrangementIncomeEarned" abstract="false" name="GrantFundingArrangementIncomeEarned" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="smmt_RevenueInformationUsedToDetermineTransactionPriceNumberOfEnrollmentMilestones" abstract="false" name="RevenueInformationUsedToDetermineTransactionPriceNumberOfEnrollmentMilestones" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="smmt_RevenueFromContractWithCustomerDevelopmentCommercialAndSalesMilestoneIncrementalCumulativeNetSalesTargetThreshold" abstract="false" name="RevenueFromContractWithCustomerDevelopmentCommercialAndSalesMilestoneIncrementalCumulativeNetSalesTargetThreshold" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="smmt_FractionalStockIssuedDuringPeriodSharesReverseStockSplit" abstract="false" name="FractionalStockIssuedDuringPeriodSharesReverseStockSplit" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="smmt_ChangeInContractWithCustomerAssetAndLiabilityRollForward" abstract="true" name="ChangeInContractWithCustomerAssetAndLiabilityRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="smmt_CombatingAntibioticResistantBacteriaBiopharmaceuticalAcceleratorProgramMember" abstract="true" name="CombatingAntibioticResistantBacteriaBiopharmaceuticalAcceleratorProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="smmt_OtherCommitmentPeriodForWhichTheMajorityOfCommitmentsAreToBePaid" abstract="false" name="OtherCommitmentPeriodForWhichTheMajorityOfCommitmentsAreToBePaid" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="smmt_EffectiveIncomeTaxRateReconciliationTaxCreditRefundableResearchPercent" abstract="false" name="EffectiveIncomeTaxRateReconciliationTaxCreditRefundableResearchPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="smmt_LesseeOperatingLeaseNumberOfContracts" abstract="false" name="LesseeOperatingLeaseNumberOfContracts" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="smmt_FurnitureAndFixturesOfficeEquipmentAndSoftwareMember" abstract="true" name="FurnitureAndFixturesOfficeEquipmentAndSoftwareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="smmt_GrantFundingArrangementCommittedFundingBase" abstract="false" name="GrantFundingArrangementCommittedFundingBase" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="smmt_ClassOfWarrantOrRightVested" abstract="false" name="ClassOfWarrantOrRightVested" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="smmt_RelatedPartyTransactionExpectedRate" abstract="false" name="RelatedPartyTransactionExpectedRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="smmt_UtrophinProgramMember" abstract="true" name="UtrophinProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="smmt_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember" abstract="true" name="BiomedicalAdvancedResearchAndDevelopmentAuthorityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="smmt_LiquidityAndCapitalResourcesTextBlock" abstract="false" name="LiquidityAndCapitalResourcesTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="smmt_ContractWithCustomerLiabilityAdditions" abstract="false" name="ContractWithCustomerLiabilityAdditions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="smmt_PotentialDeferredTaxAssetsOperatingLossCarryforwards" abstract="false" name="PotentialDeferredTaxAssetsOperatingLossCarryforwards" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="smmt_A2020StockIncentivePlanMember" abstract="true" name="A2020StockIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="smmt_BusinessCombinationAssumedContingentLiabilityMeasurementInput" abstract="false" name="BusinessCombinationAssumedContingentLiabilityMeasurementInput" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:decimalItemType"/>
  <xs:element id="smmt_AccruedResearchAndDevelopmentCurrent" abstract="false" name="AccruedResearchAndDevelopmentCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="smmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveOfferingPeriod" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveOfferingPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>9
<FILENAME>smmt-20211231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:48b41a33-da2b-4a8c-a794-72fce890713a,g:e36a0d9c-9c90-432d-82bf-4f94771c92ff-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.summitplc.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="smmt-20211231.xsd#ConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.summitplc.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_0b3205db-3e57-49e6-afe0-bb822e2431b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_17d7fd82-585f-4bf0-ac3d-4bf3a741be96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_0b3205db-3e57-49e6-afe0-bb822e2431b1" xlink:to="loc_us-gaap_AccountsPayableCurrent_17d7fd82-585f-4bf0-ac3d-4bf3a741be96" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_226a8e4e-da9e-4b6d-a0d3-1604366f3d10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_0b3205db-3e57-49e6-afe0-bb822e2431b1" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_226a8e4e-da9e-4b6d-a0d3-1604366f3d10" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_36662db2-4d93-44b0-baa5-7fe83abd55d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_0b3205db-3e57-49e6-afe0-bb822e2431b1" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_36662db2-4d93-44b0-baa5-7fe83abd55d9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_6482ef08-e350-4aec-bb04-765bf69efb57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_0b3205db-3e57-49e6-afe0-bb822e2431b1" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_6482ef08-e350-4aec-bb04-765bf69efb57" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_be681f01-2dfe-4b7e-8dc6-a5c79a6dd163" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_0b3205db-3e57-49e6-afe0-bb822e2431b1" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_be681f01-2dfe-4b7e-8dc6-a5c79a6dd163" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_e822e3d1-09b7-4a31-b103-f3caac10d547" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_0b3205db-3e57-49e6-afe0-bb822e2431b1" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_e822e3d1-09b7-4a31-b103-f3caac10d547" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_8cf66ba3-54b9-474f-bdd6-752f300004f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_41a9e6c7-6b64-4d5f-981b-509239eb1561" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_8cf66ba3-54b9-474f-bdd6-752f300004f0" xlink:to="loc_us-gaap_CommonStockValue_41a9e6c7-6b64-4d5f-981b-509239eb1561" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_8a1042a9-d090-430a-a6a3-6a6e572c83c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_8cf66ba3-54b9-474f-bdd6-752f300004f0" xlink:to="loc_us-gaap_AdditionalPaidInCapital_8a1042a9-d090-430a-a6a3-6a6e572c83c3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_b28fdf8b-7815-4b95-8c52-40f40cd01a6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_8cf66ba3-54b9-474f-bdd6-752f300004f0" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_b28fdf8b-7815-4b95-8c52-40f40cd01a6a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_d26ba4bc-dcfe-42d6-b762-0b13e2a89782" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_8cf66ba3-54b9-474f-bdd6-752f300004f0" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_d26ba4bc-dcfe-42d6-b762-0b13e2a89782" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_b1923035-93e8-4847-8c0f-690d5dd30348" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_0e3b04df-30cf-47f2-9519-7479a1dfd2c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_b1923035-93e8-4847-8c0f-690d5dd30348" xlink:to="loc_us-gaap_AssetsCurrent_0e3b04df-30cf-47f2-9519-7479a1dfd2c6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_68c788cc-e0d0-442f-b159-d2274251bcb5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_b1923035-93e8-4847-8c0f-690d5dd30348" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_68c788cc-e0d0-442f-b159-d2274251bcb5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_cc7d665d-7310-49c8-894b-4799b76d47d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_b1923035-93e8-4847-8c0f-690d5dd30348" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_cc7d665d-7310-49c8-894b-4799b76d47d4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_f853232d-8eda-4d9b-9c26-79f4d0688912" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_b1923035-93e8-4847-8c0f-690d5dd30348" xlink:to="loc_us-gaap_Goodwill_f853232d-8eda-4d9b-9c26-79f4d0688912" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_8d1c5078-c8a0-4c8d-ba85-c5584ba982bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_b1923035-93e8-4847-8c0f-690d5dd30348" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_8d1c5078-c8a0-4c8d-ba85-c5584ba982bb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_912193a9-09a4-4159-818b-fed59157e287" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_b1923035-93e8-4847-8c0f-690d5dd30348" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_912193a9-09a4-4159-818b-fed59157e287" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_064a40e7-e947-48d1-a849-44bd6f695034" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_eb434a78-2dab-4903-879f-7bac5221441d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_064a40e7-e947-48d1-a849-44bd6f695034" xlink:to="loc_us-gaap_Liabilities_eb434a78-2dab-4903-879f-7bac5221441d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_d1bd1b7a-9534-435c-8ffd-13b7c9f53315" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_064a40e7-e947-48d1-a849-44bd6f695034" xlink:to="loc_us-gaap_CommitmentsAndContingencies_d1bd1b7a-9534-435c-8ffd-13b7c9f53315" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_39800b24-50c1-4bee-bd70-7d42b79a93ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_064a40e7-e947-48d1-a849-44bd6f695034" xlink:to="loc_us-gaap_StockholdersEquity_39800b24-50c1-4bee-bd70-7d42b79a93ba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_d40ab4ce-999f-4ff5-a830-5c8778712633" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Cash_b21018db-1606-4551-8de0-4c0e1a845305" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Cash"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d40ab4ce-999f-4ff5-a830-5c8778712633" xlink:to="loc_us-gaap_Cash_b21018db-1606-4551-8de0-4c0e1a845305" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_cee06f07-c87e-4a76-97f8-690b1e1c7020" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d40ab4ce-999f-4ff5-a830-5c8778712633" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_cee06f07-c87e-4a76-97f8-690b1e1c7020" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_2ebba649-3d28-496f-a470-b1dc538f4bc3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d40ab4ce-999f-4ff5-a830-5c8778712633" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_2ebba649-3d28-496f-a470-b1dc538f4bc3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_e9b46bc8-03bf-4c37-818c-5340c60f4b64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d40ab4ce-999f-4ff5-a830-5c8778712633" xlink:to="loc_us-gaap_OtherAssetsCurrent_e9b46bc8-03bf-4c37-818c-5340c60f4b64" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_ResearchAndDevelopmentTaxCreditReceivableCurrent_e72b1355-b0b2-4866-b768-39a37b96b489" xlink:href="smmt-20211231.xsd#smmt_ResearchAndDevelopmentTaxCreditReceivableCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d40ab4ce-999f-4ff5-a830-5c8778712633" xlink:to="loc_smmt_ResearchAndDevelopmentTaxCreditReceivableCurrent_e72b1355-b0b2-4866-b768-39a37b96b489" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_aa2bd56c-75c5-4f2d-ad9f-a121218bc363" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_0dd489d8-6c64-42e7-bd79-dc77394af90f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_aa2bd56c-75c5-4f2d-ad9f-a121218bc363" xlink:to="loc_us-gaap_LiabilitiesCurrent_0dd489d8-6c64-42e7-bd79-dc77394af90f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_a8229e1b-0c7d-4baa-9126-99493ddbdf1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_aa2bd56c-75c5-4f2d-ad9f-a121218bc363" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_a8229e1b-0c7d-4baa-9126-99493ddbdf1f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_fa61d0c1-bd98-4c39-b0c9-4199014c855a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_aa2bd56c-75c5-4f2d-ad9f-a121218bc363" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_fa61d0c1-bd98-4c39-b0c9-4199014c855a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_ecaae579-b854-49cf-92ec-60e1c8da1f34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_aa2bd56c-75c5-4f2d-ad9f-a121218bc363" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_ecaae579-b854-49cf-92ec-60e1c8da1f34" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="smmt-20211231.xsd#ConsolidatedStatementsofOperationsandComprehensiveLoss"/>
  <link:calculationLink xlink:role="http://www.summitplc.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_fd772f3a-40b3-45fb-96b1-9068dc204bf5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e375ec06-d6e6-489f-9e93-19e3dfe2e566" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_fd772f3a-40b3-45fb-96b1-9068dc204bf5" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e375ec06-d6e6-489f-9e93-19e3dfe2e566" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_f90dfce8-3eeb-4b49-962f-d1bb13a1c8a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_fd772f3a-40b3-45fb-96b1-9068dc204bf5" xlink:to="loc_us-gaap_OperatingExpenses_f90dfce8-3eeb-4b49-962f-d1bb13a1c8a4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncome_beba60dc-cc96-4cc5-a657-52b76d3b7ff6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherOperatingIncome"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_fd772f3a-40b3-45fb-96b1-9068dc204bf5" xlink:to="loc_us-gaap_OtherOperatingIncome_beba60dc-cc96-4cc5-a657-52b76d3b7ff6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_259a7f4d-e17c-4d85-8600-680697ee148c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_58f9d76a-13bb-4f51-8262-b2553770c874" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_259a7f4d-e17c-4d85-8600-680697ee148c" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_58f9d76a-13bb-4f51-8262-b2553770c874" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_f6078fa6-1b13-4186-a8e9-ed5977e3ec04" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_259a7f4d-e17c-4d85-8600-680697ee148c" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_f6078fa6-1b13-4186-a8e9-ed5977e3ec04" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_25063b0e-98a3-4c23-a7d6-735afc8d5413" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_9d94e44c-35db-47de-b137-95fa87d3c5b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_25063b0e-98a3-4c23-a7d6-735afc8d5413" xlink:to="loc_us-gaap_NetIncomeLoss_9d94e44c-35db-47de-b137-95fa87d3c5b5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_316e6239-edc5-4b70-b1ea-87e72d0f1fc7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_25063b0e-98a3-4c23-a7d6-735afc8d5413" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_316e6239-edc5-4b70-b1ea-87e72d0f1fc7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_73e71ce9-1820-45b6-a677-62c08f3df8bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_e7be16ac-6475-4093-b812-1e77610718b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_73e71ce9-1820-45b6-a677-62c08f3df8bb" xlink:to="loc_us-gaap_OperatingIncomeLoss_e7be16ac-6475-4093-b812-1e77610718b1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_88eb8797-279c-4384-9e08-9140879de841" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_73e71ce9-1820-45b6-a677-62c08f3df8bb" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_88eb8797-279c-4384-9e08-9140879de841" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_63b43eb7-bbe6-4818-a787-3f9401724d39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_81f48943-2f84-436b-9a8f-43649dd7419c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_63b43eb7-bbe6-4818-a787-3f9401724d39" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_81f48943-2f84-436b-9a8f-43649dd7419c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_041168ca-6718-4c6a-98b1-956d8d34bce2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_63b43eb7-bbe6-4818-a787-3f9401724d39" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_041168ca-6718-4c6a-98b1-956d8d34bce2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_c22783e3-e41a-4acd-8834-d27953932aa8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_63b43eb7-bbe6-4818-a787-3f9401724d39" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_c22783e3-e41a-4acd-8834-d27953932aa8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="smmt-20211231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7e2a9fd7-b361-4629-8a55-2c9a396ecbcc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_e8963f1b-addf-4509-af5a-07ab91f07063" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7e2a9fd7-b361-4629-8a55-2c9a396ecbcc" xlink:to="loc_us-gaap_NetIncomeLoss_e8963f1b-addf-4509-af5a-07ab91f07063" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_GainLossOnRemeasurementOfLiabilitiesOperatingAndNonoperating_0ab1b81c-4288-4467-99d5-06e165d03170" xlink:href="smmt-20211231.xsd#smmt_GainLossOnRemeasurementOfLiabilitiesOperatingAndNonoperating"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7e2a9fd7-b361-4629-8a55-2c9a396ecbcc" xlink:to="loc_smmt_GainLossOnRemeasurementOfLiabilitiesOperatingAndNonoperating_0ab1b81c-4288-4467-99d5-06e165d03170" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_4a313308-c020-4af3-a74c-de146f20838e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7e2a9fd7-b361-4629-8a55-2c9a396ecbcc" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_4a313308-c020-4af3-a74c-de146f20838e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_InterestExpenseIncomeNoncash_23e245d2-fc23-4760-9e83-412db4aa8bd3" xlink:href="smmt-20211231.xsd#smmt_InterestExpenseIncomeNoncash"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7e2a9fd7-b361-4629-8a55-2c9a396ecbcc" xlink:to="loc_smmt_InterestExpenseIncomeNoncash_23e245d2-fc23-4760-9e83-412db4aa8bd3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_7cbb3f05-0eb7-4e55-b110-a3b5d090c363" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7e2a9fd7-b361-4629-8a55-2c9a396ecbcc" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_7cbb3f05-0eb7-4e55-b110-a3b5d090c363" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_198a98d5-ab7f-42a1-9328-083ca36e9713" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7e2a9fd7-b361-4629-8a55-2c9a396ecbcc" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_198a98d5-ab7f-42a1-9328-083ca36e9713" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_57251f8d-10a6-4f21-ba54-ee22b1b5ab97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7e2a9fd7-b361-4629-8a55-2c9a396ecbcc" xlink:to="loc_us-gaap_Depreciation_57251f8d-10a6-4f21-ba54-ee22b1b5ab97" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_eb2e2267-86ae-4b00-ba9f-be01c3220e5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7e2a9fd7-b361-4629-8a55-2c9a396ecbcc" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_eb2e2267-86ae-4b00-ba9f-be01c3220e5c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_45450b99-4e46-4ee5-84e5-291d71fcbb5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7e2a9fd7-b361-4629-8a55-2c9a396ecbcc" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_45450b99-4e46-4ee5-84e5-291d71fcbb5a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_a84bfe89-9ef6-4994-b4be-496d9a6d1d0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7e2a9fd7-b361-4629-8a55-2c9a396ecbcc" xlink:to="loc_us-gaap_ShareBasedCompensation_a84bfe89-9ef6-4994-b4be-496d9a6d1d0a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_032016fe-aba9-45aa-9f06-783e0eccb855" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7e2a9fd7-b361-4629-8a55-2c9a396ecbcc" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_032016fe-aba9-45aa-9f06-783e0eccb855" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_6e5ecec0-464b-4d51-8401-ac3baed78fea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7e2a9fd7-b361-4629-8a55-2c9a396ecbcc" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_6e5ecec0-464b-4d51-8401-ac3baed78fea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_81e3fde3-4323-400a-971d-1418c3082496" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7e2a9fd7-b361-4629-8a55-2c9a396ecbcc" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_81e3fde3-4323-400a-971d-1418c3082496" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_1b3de9a6-fca2-4e63-9b01-c1fba6ab24a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:calculationArc order="14" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7e2a9fd7-b361-4629-8a55-2c9a396ecbcc" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_1b3de9a6-fca2-4e63-9b01-c1fba6ab24a4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_IncreaseDecreaseInResearchAndDevelopmentTaxCreditReceivable_8c6d28c2-87e5-4949-8231-ba0a3ed05d1b" xlink:href="smmt-20211231.xsd#smmt_IncreaseDecreaseInResearchAndDevelopmentTaxCreditReceivable"/>
    <link:calculationArc order="15" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7e2a9fd7-b361-4629-8a55-2c9a396ecbcc" xlink:to="loc_smmt_IncreaseDecreaseInResearchAndDevelopmentTaxCreditReceivable_8c6d28c2-87e5-4949-8231-ba0a3ed05d1b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_add13c21-511b-4f66-bd53-b419bec149a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="16" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7e2a9fd7-b361-4629-8a55-2c9a396ecbcc" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_add13c21-511b-4f66-bd53-b419bec149a8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_40a1005d-8199-42be-87c7-91d7fc0cc94d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="17" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7e2a9fd7-b361-4629-8a55-2c9a396ecbcc" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_40a1005d-8199-42be-87c7-91d7fc0cc94d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_IncreaseDecreaseInAccruedLiabilitiesAndEmployeeRelatedLiabilities_8c580bf5-c2e5-40e2-a248-8c258e4508e2" xlink:href="smmt-20211231.xsd#smmt_IncreaseDecreaseInAccruedLiabilitiesAndEmployeeRelatedLiabilities"/>
    <link:calculationArc order="18" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7e2a9fd7-b361-4629-8a55-2c9a396ecbcc" xlink:to="loc_smmt_IncreaseDecreaseInAccruedLiabilitiesAndEmployeeRelatedLiabilities_8c580bf5-c2e5-40e2-a248-8c258e4508e2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_c585f7a5-77ad-40f7-a0de-0d38e7102f5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:calculationArc order="19" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7e2a9fd7-b361-4629-8a55-2c9a396ecbcc" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_c585f7a5-77ad-40f7-a0de-0d38e7102f5c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_38e6086e-2a47-44a7-b76a-50fe6bbd1424" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1cbe598a-d6a2-4017-9fb9-7449a16f9b60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_38e6086e-2a47-44a7-b76a-50fe6bbd1424" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1cbe598a-d6a2-4017-9fb9-7449a16f9b60" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_55152660-a5ba-4916-aeb8-1414a8a50a27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_7e7776aa-c30d-4379-a921-0b1e9aecd67f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_55152660-a5ba-4916-aeb8-1414a8a50a27" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_7e7776aa-c30d-4379-a921-0b1e9aecd67f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_a7b282ff-576d-4d7a-ab9b-44a735e97c62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_55152660-a5ba-4916-aeb8-1414a8a50a27" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_a7b282ff-576d-4d7a-ab9b-44a735e97c62" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRelatedPartyDebt_fb68ef9d-b1a1-4765-9cf6-29bc0984d5cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromRelatedPartyDebt"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_55152660-a5ba-4916-aeb8-1414a8a50a27" xlink:to="loc_us-gaap_ProceedsFromRelatedPartyDebt_fb68ef9d-b1a1-4765-9cf6-29bc0984d5cd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfRelatedPartyDebt_e0e9e969-a249-4f11-a869-8dc5176f9ec7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfRelatedPartyDebt"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_55152660-a5ba-4916-aeb8-1414a8a50a27" xlink:to="loc_us-gaap_RepaymentsOfRelatedPartyDebt_e0e9e969-a249-4f11-a869-8dc5176f9ec7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_bc40cc56-2aca-47fc-a44b-2b457dd8e7dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_55152660-a5ba-4916-aeb8-1414a8a50a27" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_bc40cc56-2aca-47fc-a44b-2b457dd8e7dd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_eb8127c4-ea4c-45a1-8b8d-493cd7150b80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_55152660-a5ba-4916-aeb8-1414a8a50a27" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_eb8127c4-ea4c-45a1-8b8d-493cd7150b80" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_7480792a-96c0-4a30-932f-e419318ddad9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_958f3713-9af6-43ee-8527-8da27fe37eb3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_7480792a-96c0-4a30-932f-e419318ddad9" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_958f3713-9af6-43ee-8527-8da27fe37eb3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0cb7e2d9-12b5-4322-bbe0-ec5fc748dc61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_7480792a-96c0-4a30-932f-e419318ddad9" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0cb7e2d9-12b5-4322-bbe0-ec5fc748dc61" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f240dc15-dbb8-4a84-92f9-fc462d05ebe9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_7480792a-96c0-4a30-932f-e419318ddad9" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f240dc15-dbb8-4a84-92f9-fc462d05ebe9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_401bc8e1-089c-4327-a277-7ec1ba438599" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_7480792a-96c0-4a30-932f-e419318ddad9" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_401bc8e1-089c-4327-a277-7ec1ba438599" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/OtherOperatingIncomeOtheroperatingincomebycategoryDetails" xlink:type="simple" xlink:href="smmt-20211231.xsd#OtherOperatingIncomeOtheroperatingincomebycategoryDetails"/>
  <link:calculationLink xlink:role="http://www.summitplc.com/role/OtherOperatingIncomeOtheroperatingincomebycategoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncome_a0e6ee2b-e4a9-4b6c-abc3-1a7eb00eaf48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherOperatingIncome"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_GrantFundingArrangementIncomeEarned_c80ebb10-75ac-43bd-a675-9b643f60dd08" xlink:href="smmt-20211231.xsd#smmt_GrantFundingArrangementIncomeEarned"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherOperatingIncome_a0e6ee2b-e4a9-4b6c-abc3-1a7eb00eaf48" xlink:to="loc_smmt_GrantFundingArrangementIncomeEarned_c80ebb10-75ac-43bd-a675-9b643f60dd08" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_ResearchAndDevelopmentTaxCredit_c321dc1b-6fcd-4c29-8957-348330181824" xlink:href="smmt-20211231.xsd#smmt_ResearchAndDevelopmentTaxCredit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherOperatingIncome_a0e6ee2b-e4a9-4b6c-abc3-1a7eb00eaf48" xlink:to="loc_smmt_ResearchAndDevelopmentTaxCredit_c321dc1b-6fcd-4c29-8957-348330181824" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/OtherExpenseIncomeDetails" xlink:type="simple" xlink:href="smmt-20211231.xsd#OtherExpenseIncomeDetails"/>
  <link:calculationLink xlink:role="http://www.summitplc.com/role/OtherExpenseIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_00664c5a-f5dd-4181-9970-53255f1058cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_768cf4f9-3ccc-44f0-a8cb-19428ab5e5ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_00664c5a-f5dd-4181-9970-53255f1058cc" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_768cf4f9-3ccc-44f0-a8cb-19428ab5e5ca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_GainLossOnRemeasurementOfLiabilitiesNonoperating_02c613cc-ef90-455c-89a3-6b8cd8aff15b" xlink:href="smmt-20211231.xsd#smmt_GainLossOnRemeasurementOfLiabilitiesNonoperating"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_00664c5a-f5dd-4181-9970-53255f1058cc" xlink:to="loc_smmt_GainLossOnRemeasurementOfLiabilitiesNonoperating_02c613cc-ef90-455c-89a3-6b8cd8aff15b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_e2bb58da-6ceb-44d4-9435-63a1601744e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_00664c5a-f5dd-4181-9970-53255f1058cc" xlink:to="loc_us-gaap_InvestmentIncomeInterest_e2bb58da-6ceb-44d4-9435-63a1601744e3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_ee1b0991-74c7-477f-a72b-b14c57cfaad2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_00664c5a-f5dd-4181-9970-53255f1058cc" xlink:to="loc_us-gaap_InterestExpense_ee1b0991-74c7-477f-a72b-b14c57cfaad2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/IncomeTaxComponentsoflossbeforeincometaxesDetails" xlink:type="simple" xlink:href="smmt-20211231.xsd#IncomeTaxComponentsoflossbeforeincometaxesDetails"/>
  <link:calculationLink xlink:role="http://www.summitplc.com/role/IncomeTaxComponentsoflossbeforeincometaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1efb4cc9-0b28-46ae-96cf-553dc53e951d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_6bac1930-69c0-4673-bba7-699b7430b680" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1efb4cc9-0b28-46ae-96cf-553dc53e951d" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_6bac1930-69c0-4673-bba7-699b7430b680" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_1f49d8d7-bd55-4b7d-af2d-52935ba2f230" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1efb4cc9-0b28-46ae-96cf-553dc53e951d" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_1f49d8d7-bd55-4b7d-af2d-52935ba2f230" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/IncomeTaxSignificantcomponentsoftheprovisionforincometaxesDetails" xlink:type="simple" xlink:href="smmt-20211231.xsd#IncomeTaxSignificantcomponentsoftheprovisionforincometaxesDetails"/>
  <link:calculationLink xlink:role="http://www.summitplc.com/role/IncomeTaxSignificantcomponentsoftheprovisionforincometaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_d2e073d1-41b3-41cc-83e7-9524f66139db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_e7b75392-6fba-4a0e-a47b-c0dea2901919" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_d2e073d1-41b3-41cc-83e7-9524f66139db" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_e7b75392-6fba-4a0e-a47b-c0dea2901919" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_db1f28ac-0e5a-4b7a-88bc-5d814990d435" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_d2e073d1-41b3-41cc-83e7-9524f66139db" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_db1f28ac-0e5a-4b7a-88bc-5d814990d435" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_f34b1337-bc64-419a-a695-4960cc315d40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_12b6e0f8-11fb-421c-9d44-043d552623ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_f34b1337-bc64-419a-a695-4960cc315d40" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_12b6e0f8-11fb-421c-9d44-043d552623ee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_18faa415-2cc9-497f-b6e0-489e4d26f855" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_f34b1337-bc64-419a-a695-4960cc315d40" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_18faa415-2cc9-497f-b6e0-489e4d26f855" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_41958556-5c39-4a0d-9da6-7f58a14ac3d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_f34b1337-bc64-419a-a695-4960cc315d40" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_41958556-5c39-4a0d-9da6-7f58a14ac3d1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_acfdc116-e694-4e5f-99b0-d87debe5de05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_a2708380-2c50-40ec-b694-82957b8f1c8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_acfdc116-e694-4e5f-99b0-d87debe5de05" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_a2708380-2c50-40ec-b694-82957b8f1c8e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_d639a3f8-b013-43b4-8071-a17033ed90e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_acfdc116-e694-4e5f-99b0-d87debe5de05" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_d639a3f8-b013-43b4-8071-a17033ed90e4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_92ca3cd7-9915-484d-aa4f-b46fb3528f82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_acfdc116-e694-4e5f-99b0-d87debe5de05" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_92ca3cd7-9915-484d-aa4f-b46fb3528f82" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/IncomeTaxMajorcomponentsofdeferredtaxassetsandliabilitiesDetails" xlink:type="simple" xlink:href="smmt-20211231.xsd#IncomeTaxMajorcomponentsofdeferredtaxassetsandliabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.summitplc.com/role/IncomeTaxMajorcomponentsofdeferredtaxassetsandliabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_3ecd646f-e31e-4449-8fea-d8f8cbe98420" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_b541996f-9731-40c0-a9da-b846ccc4d803" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_3ecd646f-e31e-4449-8fea-d8f8cbe98420" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_b541996f-9731-40c0-a9da-b846ccc4d803" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_8810c156-ffb6-4ee8-8c5c-c7d9f0996124" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_3ecd646f-e31e-4449-8fea-d8f8cbe98420" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_8810c156-ffb6-4ee8-8c5c-c7d9f0996124" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_1850c30f-339e-4baf-a2ba-6ed712c56d53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_3ecd646f-e31e-4449-8fea-d8f8cbe98420" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_1850c30f-339e-4baf-a2ba-6ed712c56d53" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_5ca6efa8-95c4-4d0b-b13d-b1802d29e43b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_3ecd646f-e31e-4449-8fea-d8f8cbe98420" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_5ca6efa8-95c4-4d0b-b13d-b1802d29e43b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_DeferredTaxAssetsLiabilities_c2d764cf-1164-460c-8fea-5f669946fb8b" xlink:href="smmt-20211231.xsd#smmt_DeferredTaxAssetsLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_a4f2b3d4-dd5b-4234-9959-2c2e56c28363" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_smmt_DeferredTaxAssetsLiabilities_c2d764cf-1164-460c-8fea-5f669946fb8b" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_a4f2b3d4-dd5b-4234-9959-2c2e56c28363" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_2da47198-c166-4157-825b-147c6cc3dbeb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_smmt_DeferredTaxAssetsLiabilities_c2d764cf-1164-460c-8fea-5f669946fb8b" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_2da47198-c166-4157-825b-147c6cc3dbeb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_5dafbfb2-caac-4bee-863f-67c167293491" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_8a2925da-ce10-492f-a619-a09e6f5c3822" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_5dafbfb2-caac-4bee-863f-67c167293491" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_8a2925da-ce10-492f-a619-a09e6f5c3822" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_5d43823e-0abe-4c80-9094-d546b40fd63c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_5dafbfb2-caac-4bee-863f-67c167293491" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_5d43823e-0abe-4c80-9094-d546b40fd63c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_d0ec1d46-200a-4f51-a6fb-3e5fac3a3496" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_DeferredTaxAssetsLiabilities_7d006825-20a3-4fca-b207-c28c2bbf7734" xlink:href="smmt-20211231.xsd#smmt_DeferredTaxAssetsLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_d0ec1d46-200a-4f51-a6fb-3e5fac3a3496" xlink:to="loc_smmt_DeferredTaxAssetsLiabilities_7d006825-20a3-4fca-b207-c28c2bbf7734" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_7e951717-51ce-469b-a865-12777d5bd9a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_d0ec1d46-200a-4f51-a6fb-3e5fac3a3496" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_7e951717-51ce-469b-a865-12777d5bd9a5" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/IncomeTaxReconciliationoftheeffectiveincometaxratetostatutoryrateDetails" xlink:type="simple" xlink:href="smmt-20211231.xsd#IncomeTaxReconciliationoftheeffectiveincometaxratetostatutoryrateDetails"/>
  <link:calculationLink xlink:role="http://www.summitplc.com/role/IncomeTaxReconciliationoftheeffectiveincometaxratetostatutoryrateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_bfc94040-a5f3-4ebd-8788-b917f44c639f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_49d020f3-6e00-48b9-8741-65712098eeea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_bfc94040-a5f3-4ebd-8788-b917f44c639f" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_49d020f3-6e00-48b9-8741-65712098eeea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_25b3c082-2594-4d6f-b45e-24294a059bd2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_bfc94040-a5f3-4ebd-8788-b917f44c639f" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_25b3c082-2594-4d6f-b45e-24294a059bd2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_516ee1f3-6d51-4637-a546-3045bf36619b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_bfc94040-a5f3-4ebd-8788-b917f44c639f" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_516ee1f3-6d51-4637-a546-3045bf36619b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_EffectiveIncomeTaxRateReconciliationTaxCreditRefundableResearchPercent_a234f78f-7489-48b9-b0b4-f437462f1868" xlink:href="smmt-20211231.xsd#smmt_EffectiveIncomeTaxRateReconciliationTaxCreditRefundableResearchPercent"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_bfc94040-a5f3-4ebd-8788-b917f44c639f" xlink:to="loc_smmt_EffectiveIncomeTaxRateReconciliationTaxCreditRefundableResearchPercent_a234f78f-7489-48b9-b0b4-f437462f1868" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_2334d4c1-7fbe-42ba-b7e2-03b42d555117" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_bfc94040-a5f3-4ebd-8788-b917f44c639f" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_2334d4c1-7fbe-42ba-b7e2-03b42d555117" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_94484f21-9e0c-4ef8-881c-a6526bf5c2fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_bfc94040-a5f3-4ebd-8788-b917f44c639f" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_94484f21-9e0c-4ef8-881c-a6526bf5c2fd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_94679e07-a944-4eee-b66e-88f1291d21b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_bfc94040-a5f3-4ebd-8788-b917f44c639f" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_94679e07-a944-4eee-b66e-88f1291d21b2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/GoodwillandIntangibleAssetsScheduleofacquiredintangibleassetsDetails" xlink:type="simple" xlink:href="smmt-20211231.xsd#GoodwillandIntangibleAssetsScheduleofacquiredintangibleassetsDetails"/>
  <link:calculationLink xlink:role="http://www.summitplc.com/role/GoodwillandIntangibleAssetsScheduleofacquiredintangibleassetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_b9cd4c70-f3d9-4767-8701-56b2b920f9b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_ce747761-009d-4ac3-961c-d5108db6a43f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_b9cd4c70-f3d9-4767-8701-56b2b920f9b5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_ce747761-009d-4ac3-961c-d5108db6a43f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_FiniteLivedIntangibleAssetsAccumulatedAmortizationAndImpairment_7bc2a5e0-706c-4f87-b8b8-0438df3e1df5" xlink:href="smmt-20211231.xsd#smmt_FiniteLivedIntangibleAssetsAccumulatedAmortizationAndImpairment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_b9cd4c70-f3d9-4767-8701-56b2b920f9b5" xlink:to="loc_smmt_FiniteLivedIntangibleAssetsAccumulatedAmortizationAndImpairment_7bc2a5e0-706c-4f87-b8b8-0438df3e1df5" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/PropertyandEquipmentComponentsofpropertyandequipmentDetails" xlink:type="simple" xlink:href="smmt-20211231.xsd#PropertyandEquipmentComponentsofpropertyandequipmentDetails"/>
  <link:calculationLink xlink:role="http://www.summitplc.com/role/PropertyandEquipmentComponentsofpropertyandequipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_2db62557-31cc-4ca5-bfb3-3abdc22c8068" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_341b06d8-7dc1-4bb6-b033-3232b415abd4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_2db62557-31cc-4ca5-bfb3-3abdc22c8068" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_341b06d8-7dc1-4bb6-b033-3232b415abd4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_d2b19e9d-55db-4706-aba6-4b35b69deda9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_2db62557-31cc-4ca5-bfb3-3abdc22c8068" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_d2b19e9d-55db-4706-aba6-4b35b69deda9" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/LeasesLeaseexpenseDetails" xlink:type="simple" xlink:href="smmt-20211231.xsd#LeasesLeaseexpenseDetails"/>
  <link:calculationLink xlink:role="http://www.summitplc.com/role/LeasesLeaseexpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_8d11c3cd-a91b-4d3e-86e7-e32f3c8522a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_c7f7d28f-0e51-4621-889a-65150a363d48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_8d11c3cd-a91b-4d3e-86e7-e32f3c8522a3" xlink:to="loc_us-gaap_OperatingLeaseCost_c7f7d28f-0e51-4621-889a-65150a363d48" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_d5c869de-6900-4cd4-98e2-22076399e75c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableLeaseCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_8d11c3cd-a91b-4d3e-86e7-e32f3c8522a3" xlink:to="loc_us-gaap_VariableLeaseCost_d5c869de-6900-4cd4-98e2-22076399e75c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost_57d989b0-6422-4948-b0b4-7fd30686528e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_8d11c3cd-a91b-4d3e-86e7-e32f3c8522a3" xlink:to="loc_us-gaap_ShortTermLeaseCost_57d989b0-6422-4948-b0b4-7fd30686528e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/LeasesFutureleasepaymentsDetails" xlink:type="simple" xlink:href="smmt-20211231.xsd#LeasesFutureleasepaymentsDetails"/>
  <link:calculationLink xlink:role="http://www.summitplc.com/role/LeasesFutureleasepaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3d07adbf-fa96-4b2f-9999-4731befc32a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_99d786fa-5ee9-47f2-a8cd-0c6ac8025f72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3d07adbf-fa96-4b2f-9999-4731befc32a1" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_99d786fa-5ee9-47f2-a8cd-0c6ac8025f72" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_d8aedafc-7faf-4808-a905-f51cbc413990" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3d07adbf-fa96-4b2f-9999-4731befc32a1" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_d8aedafc-7faf-4808-a905-f51cbc413990" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_b208f771-e404-414a-9dd9-e1ef2e46019d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3d07adbf-fa96-4b2f-9999-4731befc32a1" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_b208f771-e404-414a-9dd9-e1ef2e46019d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_12e2e084-3cc4-4281-a083-6fd7db620661" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3d07adbf-fa96-4b2f-9999-4731befc32a1" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_12e2e084-3cc4-4281-a083-6fd7db620661" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_7307939a-ba74-42f8-97a9-165b476997b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3d07adbf-fa96-4b2f-9999-4731befc32a1" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_7307939a-ba74-42f8-97a9-165b476997b7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_915b3c73-4568-4645-b5a9-67652ab1af6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_c37a335a-67c2-4252-bbeb-84816860698b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_915b3c73-4568-4645-b5a9-67652ab1af6f" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_c37a335a-67c2-4252-bbeb-84816860698b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_962539c0-cceb-4d94-a6c1-36b9125419bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_915b3c73-4568-4645-b5a9-67652ab1af6f" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_962539c0-cceb-4d94-a6c1-36b9125419bb" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/LeasesFutureleasepaymentsDetails_1" xlink:type="simple" xlink:href="smmt-20211231.xsd#LeasesFutureleasepaymentsDetails_1"/>
  <link:calculationLink xlink:role="http://www.summitplc.com/role/LeasesFutureleasepaymentsDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e5a03225-d412-41b2-bf05-311769c0ddd3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_573cc3d9-ed01-4931-8581-008d41e56b44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e5a03225-d412-41b2-bf05-311769c0ddd3" xlink:to="loc_us-gaap_OperatingLeaseLiability_573cc3d9-ed01-4931-8581-008d41e56b44" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_430dfc15-a947-4261-b21f-d060f15f2118" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e5a03225-d412-41b2-bf05-311769c0ddd3" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_430dfc15-a947-4261-b21f-d060f15f2118" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>10
<FILENAME>smmt-20211231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:48b41a33-da2b-4a8c-a794-72fce890713a,g:e36a0d9c-9c90-432d-82bf-4f94771c92ff-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.summitplc.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="smmt-20211231.xsd#ConsolidatedStatementsofStockholdersEquity"/>
  <link:definitionLink xlink:role="http://www.summitplc.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="extended" id="i794dcb97821f4c3e9cff32c48beee0d0_ConsolidatedStatementsofStockholdersEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_d037ceb0-9b42-4fb3-8f65-f73dd419a534" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c3ef8ec7-8034-4c69-9c26-e5defe7b987e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d037ceb0-9b42-4fb3-8f65-f73dd419a534" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c3ef8ec7-8034-4c69-9c26-e5defe7b987e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_5473f8e4-e4c2-4955-961d-d1f3ef5c5b13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c3ef8ec7-8034-4c69-9c26-e5defe7b987e" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_5473f8e4-e4c2-4955-961d-d1f3ef5c5b13" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_f170b925-669e-4785-9959-9efe9a37b320" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c3ef8ec7-8034-4c69-9c26-e5defe7b987e" xlink:to="loc_us-gaap_StockholdersEquity_f170b925-669e-4785-9959-9efe9a37b320" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_ab25ac23-0c0e-415a-ab4a-aefeedfe2004" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c3ef8ec7-8034-4c69-9c26-e5defe7b987e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_ab25ac23-0c0e-415a-ab4a-aefeedfe2004" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_8274d8a2-6037-4e6f-84e4-f733ed49b997" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c3ef8ec7-8034-4c69-9c26-e5defe7b987e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_8274d8a2-6037-4e6f-84e4-f733ed49b997" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_FractionalStockIssuedDuringPeriodSharesReverseStockSplit_798a470d-4ae0-4ff0-8dda-ae012e1b2c73" xlink:href="smmt-20211231.xsd#smmt_FractionalStockIssuedDuringPeriodSharesReverseStockSplit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c3ef8ec7-8034-4c69-9c26-e5defe7b987e" xlink:to="loc_smmt_FractionalStockIssuedDuringPeriodSharesReverseStockSplit_798a470d-4ae0-4ff0-8dda-ae012e1b2c73" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_bc07bcdd-4852-4c71-a434-4595fcddd2a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c3ef8ec7-8034-4c69-9c26-e5defe7b987e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_bc07bcdd-4852-4c71-a434-4595fcddd2a7" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_82bea756-9af6-492c-bf3d-0f3ee329ed18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c3ef8ec7-8034-4c69-9c26-e5defe7b987e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_82bea756-9af6-492c-bf3d-0f3ee329ed18" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_7e4d315c-7e1a-40ca-81fe-d8d618d7cba4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c3ef8ec7-8034-4c69-9c26-e5defe7b987e" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_7e4d315c-7e1a-40ca-81fe-d8d618d7cba4" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_AdjustmentsToAdditionalPaidInCapitalImputedInterestExpenseRelatedParty_0ebb4e5f-64a8-4d23-8d48-52af792c6c35" xlink:href="smmt-20211231.xsd#smmt_AdjustmentsToAdditionalPaidInCapitalImputedInterestExpenseRelatedParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c3ef8ec7-8034-4c69-9c26-e5defe7b987e" xlink:to="loc_smmt_AdjustmentsToAdditionalPaidInCapitalImputedInterestExpenseRelatedParty_0ebb4e5f-64a8-4d23-8d48-52af792c6c35" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_b9473929-e05e-4857-a1f4-ca89fd9fe6bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c3ef8ec7-8034-4c69-9c26-e5defe7b987e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_b9473929-e05e-4857-a1f4-ca89fd9fe6bd" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_a1d45717-5c45-4665-a29a-463d4c7f938b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c3ef8ec7-8034-4c69-9c26-e5defe7b987e" xlink:to="loc_us-gaap_NetIncomeLoss_a1d45717-5c45-4665-a29a-463d4c7f938b" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_718dfd29-8099-488b-a473-1cde2a374f2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_04d64a2f-994a-411d-bec0-fecf23cb0e57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_8c625735-4c98-4353-8868-d314d9f94e5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_d037ceb0-9b42-4fb3-8f65-f73dd419a534" xlink:to="loc_us-gaap_StatementTable_8c625735-4c98-4353-8868-d314d9f94e5c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_a8b9a028-64ed-464e-9136-f43876b23d29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_8c625735-4c98-4353-8868-d314d9f94e5c" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_a8b9a028-64ed-464e-9136-f43876b23d29" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_a8b9a028-64ed-464e-9136-f43876b23d29_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_a8b9a028-64ed-464e-9136-f43876b23d29" xlink:to="loc_us-gaap_EquityComponentDomain_a8b9a028-64ed-464e-9136-f43876b23d29_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_a3459ff1-8d2e-4ab8-a34a-9ce281d3674b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_a8b9a028-64ed-464e-9136-f43876b23d29" xlink:to="loc_us-gaap_EquityComponentDomain_a3459ff1-8d2e-4ab8-a34a-9ce281d3674b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_84df9d53-28d1-46a7-8896-7b797d38ad58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_a3459ff1-8d2e-4ab8-a34a-9ce281d3674b" xlink:to="loc_us-gaap_CommonStockMember_84df9d53-28d1-46a7-8896-7b797d38ad58" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_6a4adbe8-442b-4592-a014-29763d51dc6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_a3459ff1-8d2e-4ab8-a34a-9ce281d3674b" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_6a4adbe8-442b-4592-a014-29763d51dc6a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_9adb2bd2-696e-4ad2-bcc8-625ca0c7df58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_a3459ff1-8d2e-4ab8-a34a-9ce281d3674b" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_9adb2bd2-696e-4ad2-bcc8-625ca0c7df58" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_42b14159-acdf-4b1c-9038-f3df7e7684c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_a3459ff1-8d2e-4ab8-a34a-9ce281d3674b" xlink:to="loc_us-gaap_RetainedEarningsMember_42b14159-acdf-4b1c-9038-f3df7e7684c2" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/NatureofBusinessandOperationsandRecentEventsDetails" xlink:type="simple" xlink:href="smmt-20211231.xsd#NatureofBusinessandOperationsandRecentEventsDetails"/>
  <link:definitionLink xlink:role="http://www.summitplc.com/role/NatureofBusinessandOperationsandRecentEventsDetails" xlink:type="extended" id="i6d21d60af02244be9848fd7f78edbce1_NatureofBusinessandOperationsandRecentEventsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_a19d53d8-0364-410b-82b4-332a25731e6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_5f600688-0841-45fe-bc3c-135717965458" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_a19d53d8-0364-410b-82b4-332a25731e6d" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_5f600688-0841-45fe-bc3c-135717965458" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_a6e03bb1-28f6-4fb8-ad30-a3dc00ea48b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_a19d53d8-0364-410b-82b4-332a25731e6d" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_a6e03bb1-28f6-4fb8-ad30-a3dc00ea48b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_ef46ebd5-7354-4b91-9df2-b1709251866e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_a19d53d8-0364-410b-82b4-332a25731e6d" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_ef46ebd5-7354-4b91-9df2-b1709251866e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_1b577cfd-cf7c-430a-97a3-1dd0afa9aebc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_a19d53d8-0364-410b-82b4-332a25731e6d" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_1b577cfd-cf7c-430a-97a3-1dd0afa9aebc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_ecec4aa1-a310-47e9-aaeb-21624303dd51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_a19d53d8-0364-410b-82b4-332a25731e6d" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_ecec4aa1-a310-47e9-aaeb-21624303dd51" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_RelatedPartyTransactionBeneficialOwnershipPercentage_559d0c5b-09d6-4398-a609-d56085eb4b65" xlink:href="smmt-20211231.xsd#smmt_RelatedPartyTransactionBeneficialOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_a19d53d8-0364-410b-82b4-332a25731e6d" xlink:to="loc_smmt_RelatedPartyTransactionBeneficialOwnershipPercentage_559d0c5b-09d6-4398-a609-d56085eb4b65" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent_e0592246-c56b-4d10-bcb8-7bc4fd327fc4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_a19d53d8-0364-410b-82b4-332a25731e6d" xlink:to="loc_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent_e0592246-c56b-4d10-bcb8-7bc4fd327fc4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRelatedPartyDebt_70818bdf-aa13-44f7-8aac-802ad17eb855" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromRelatedPartyDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_a19d53d8-0364-410b-82b4-332a25731e6d" xlink:to="loc_us-gaap_ProceedsFromRelatedPartyDebt_70818bdf-aa13-44f7-8aac-802ad17eb855" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionRate_afe35a7a-7d4e-456d-9815-90624741e518" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_a19d53d8-0364-410b-82b4-332a25731e6d" xlink:to="loc_us-gaap_RelatedPartyTransactionRate_afe35a7a-7d4e-456d-9815-90624741e518" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_NotesPayableRelatedPartiesMaturityTriggeringEventPublicOfferingProceedsThreshold_bc771f8a-3868-4ae3-a07e-ee134b1f248c" xlink:href="smmt-20211231.xsd#smmt_NotesPayableRelatedPartiesMaturityTriggeringEventPublicOfferingProceedsThreshold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_a19d53d8-0364-410b-82b4-332a25731e6d" xlink:to="loc_smmt_NotesPayableRelatedPartiesMaturityTriggeringEventPublicOfferingProceedsThreshold_bc771f8a-3868-4ae3-a07e-ee134b1f248c" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_NotesPayableRelatedPartiesMaximumTerm_fd1f207c-65f4-4c60-84c8-7a352923c0c1" xlink:href="smmt-20211231.xsd#smmt_NotesPayableRelatedPartiesMaximumTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_a19d53d8-0364-410b-82b4-332a25731e6d" xlink:to="loc_smmt_NotesPayableRelatedPartiesMaximumTerm_fd1f207c-65f4-4c60-84c8-7a352923c0c1" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_499b19b6-bd53-41e4-bb6c-5291e2e60b97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_a19d53d8-0364-410b-82b4-332a25731e6d" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_499b19b6-bd53-41e4-bb6c-5291e2e60b97" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_0593c8ff-be48-4c90-bed3-447091252ce5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_499b19b6-bd53-41e4-bb6c-5291e2e60b97" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_0593c8ff-be48-4c90-bed3-447091252ce5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0593c8ff-be48-4c90-bed3-447091252ce5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_0593c8ff-be48-4c90-bed3-447091252ce5" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0593c8ff-be48-4c90-bed3-447091252ce5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_a58f851f-dd74-418b-b8e2-32826fcae036" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_0593c8ff-be48-4c90-bed3-447091252ce5" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_a58f851f-dd74-418b-b8e2-32826fcae036" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_RightsOfferingMember_1a82e02e-f39e-4928-89c2-080544876677" xlink:href="smmt-20211231.xsd#smmt_RightsOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_a58f851f-dd74-418b-b8e2-32826fcae036" xlink:to="loc_smmt_RightsOfferingMember_1a82e02e-f39e-4928-89c2-080544876677" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_546f1ebf-9641-4251-b3ec-2b51e389d76a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_499b19b6-bd53-41e4-bb6c-5291e2e60b97" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_546f1ebf-9641-4251-b3ec-2b51e389d76a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_546f1ebf-9641-4251-b3ec-2b51e389d76a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_546f1ebf-9641-4251-b3ec-2b51e389d76a" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_546f1ebf-9641-4251-b3ec-2b51e389d76a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_2426effc-a0b3-472d-9769-be7d93c52ae0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_546f1ebf-9641-4251-b3ec-2b51e389d76a" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_2426effc-a0b3-472d-9769-be7d93c52ae0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_SecondPurchaseAgreementMember_a3633067-cc79-4113-87a7-9dc4d1bd4fe8" xlink:href="smmt-20211231.xsd#smmt_SecondPurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_2426effc-a0b3-472d-9769-be7d93c52ae0" xlink:to="loc_smmt_SecondPurchaseAgreementMember_a3633067-cc79-4113-87a7-9dc4d1bd4fe8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_A2022NoteMember_ee90b209-d6a9-4659-a5a5-76043500c414" xlink:href="smmt-20211231.xsd#smmt_A2022NoteMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_2426effc-a0b3-472d-9769-be7d93c52ae0" xlink:to="loc_smmt_A2022NoteMember_ee90b209-d6a9-4659-a5a5-76043500c414" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_df66f908-63ac-409f-9dfa-0772e5aad9c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_499b19b6-bd53-41e4-bb6c-5291e2e60b97" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_df66f908-63ac-409f-9dfa-0772e5aad9c6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_df66f908-63ac-409f-9dfa-0772e5aad9c6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_df66f908-63ac-409f-9dfa-0772e5aad9c6" xlink:to="loc_us-gaap_RelatedPartyDomain_df66f908-63ac-409f-9dfa-0772e5aad9c6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_7e0312a4-f57c-4f70-a469-29463358b89d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_df66f908-63ac-409f-9dfa-0772e5aad9c6" xlink:to="loc_us-gaap_RelatedPartyDomain_7e0312a4-f57c-4f70-a469-29463358b89d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ChiefExecutiveOfficerMember_3473558b-4ca2-4a98-9b08-f70043c6be8b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ChiefExecutiveOfficerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_7e0312a4-f57c-4f70-a469-29463358b89d" xlink:to="loc_srt_ChiefExecutiveOfficerMember_3473558b-4ca2-4a98-9b08-f70043c6be8b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_fb34298d-9f70-4218-a224-bd15824221cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_499b19b6-bd53-41e4-bb6c-5291e2e60b97" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_fb34298d-9f70-4218-a224-bd15824221cc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_fb34298d-9f70-4218-a224-bd15824221cc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_fb34298d-9f70-4218-a224-bd15824221cc" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_fb34298d-9f70-4218-a224-bd15824221cc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_fcd3209f-35ea-4714-a745-71ef2ee31204" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_fb34298d-9f70-4218-a224-bd15824221cc" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_fcd3209f-35ea-4714-a745-71ef2ee31204" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_429a912a-d698-4c04-bab0-3bc8431e77c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_fcd3209f-35ea-4714-a745-71ef2ee31204" xlink:to="loc_us-gaap_SubsequentEventMember_429a912a-d698-4c04-bab0-3bc8431e77c8" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/LiquidityandCapitalResourcesDetails" xlink:type="simple" xlink:href="smmt-20211231.xsd#LiquidityandCapitalResourcesDetails"/>
  <link:definitionLink xlink:role="http://www.summitplc.com/role/LiquidityandCapitalResourcesDetails" xlink:type="extended" id="i7dc0c72338c148778354202da38645ba_LiquidityandCapitalResourcesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_2a9d13ca-b97f-431b-bb49-7c92e956d1fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRelatedPartyDebt_f93a32fb-5eac-45da-9881-b68819e99875" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromRelatedPartyDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_2a9d13ca-b97f-431b-bb49-7c92e956d1fa" xlink:to="loc_us-gaap_ProceedsFromRelatedPartyDebt_f93a32fb-5eac-45da-9881-b68819e99875" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_74680219-c464-4638-9377-01a0f8545305" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_2a9d13ca-b97f-431b-bb49-7c92e956d1fa" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_74680219-c464-4638-9377-01a0f8545305" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_b0803301-2066-4b26-a3ae-23c9e46806bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_74680219-c464-4638-9377-01a0f8545305" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_b0803301-2066-4b26-a3ae-23c9e46806bf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_b0803301-2066-4b26-a3ae-23c9e46806bf_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_b0803301-2066-4b26-a3ae-23c9e46806bf" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_b0803301-2066-4b26-a3ae-23c9e46806bf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_f238d662-0061-443b-8740-aec3bdb6bce6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_b0803301-2066-4b26-a3ae-23c9e46806bf" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_f238d662-0061-443b-8740-aec3bdb6bce6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_A2022NoteMember_42899ccb-90a9-4ff4-8cd2-5be07e9ced8d" xlink:href="smmt-20211231.xsd#smmt_A2022NoteMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_f238d662-0061-443b-8740-aec3bdb6bce6" xlink:to="loc_smmt_A2022NoteMember_42899ccb-90a9-4ff4-8cd2-5be07e9ced8d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_dc6b65b0-4552-4ea6-904e-283bf0580683" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_74680219-c464-4638-9377-01a0f8545305" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_dc6b65b0-4552-4ea6-904e-283bf0580683" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_dc6b65b0-4552-4ea6-904e-283bf0580683_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_dc6b65b0-4552-4ea6-904e-283bf0580683" xlink:to="loc_us-gaap_RelatedPartyDomain_dc6b65b0-4552-4ea6-904e-283bf0580683_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_4af9c18b-efa1-4ecc-a7d0-3b7d5912f5d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_dc6b65b0-4552-4ea6-904e-283bf0580683" xlink:to="loc_us-gaap_RelatedPartyDomain_4af9c18b-efa1-4ecc-a7d0-3b7d5912f5d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ChiefExecutiveOfficerMember_c8dba188-13a5-4f38-97e8-079bc22e32eb" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ChiefExecutiveOfficerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_4af9c18b-efa1-4ecc-a7d0-3b7d5912f5d3" xlink:to="loc_srt_ChiefExecutiveOfficerMember_c8dba188-13a5-4f38-97e8-079bc22e32eb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_cba5967d-8efe-40ca-8051-e6f3fb5fe2dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_74680219-c464-4638-9377-01a0f8545305" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_cba5967d-8efe-40ca-8051-e6f3fb5fe2dd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_cba5967d-8efe-40ca-8051-e6f3fb5fe2dd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_cba5967d-8efe-40ca-8051-e6f3fb5fe2dd" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_cba5967d-8efe-40ca-8051-e6f3fb5fe2dd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_02d3adae-6090-4426-979c-7e5b0d66e84b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_cba5967d-8efe-40ca-8051-e6f3fb5fe2dd" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_02d3adae-6090-4426-979c-7e5b0d66e84b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_6066d61c-d418-4c32-9ee3-91ca9198a3ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_02d3adae-6090-4426-979c-7e5b0d66e84b" xlink:to="loc_us-gaap_SubsequentEventMember_6066d61c-d418-4c32-9ee3-91ca9198a3ee" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="smmt-20211231.xsd#SummaryofSignificantAccountingPoliciesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.summitplc.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended" id="i6385908339bc448e9737090e27a7c49a_SummaryofSignificantAccountingPoliciesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_acfacd03-ca85-41b1-9afb-d439e058714e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_20fa7913-37fe-43a2-bce6-e8e74864c550" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_acfacd03-ca85-41b1-9afb-d439e058714e" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_20fa7913-37fe-43a2-bce6-e8e74864c550" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_ResearchAndDevelopmentTaxCreditCashRebateMaximumPercentage_5f99395b-3c4d-4582-8be7-bddc54998d70" xlink:href="smmt-20211231.xsd#smmt_ResearchAndDevelopmentTaxCreditCashRebateMaximumPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_acfacd03-ca85-41b1-9afb-d439e058714e" xlink:to="loc_smmt_ResearchAndDevelopmentTaxCreditCashRebateMaximumPercentage_5f99395b-3c4d-4582-8be7-bddc54998d70" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_8f80bd93-e2cd-4c3c-b7b1-302cca0875c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_acfacd03-ca85-41b1-9afb-d439e058714e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_8f80bd93-e2cd-4c3c-b7b1-302cca0875c5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_BusinessCombinationAssumedContingentLiabilityMeasurementInput_db5f797f-7081-43f1-88ab-857e8fcf08cd" xlink:href="smmt-20211231.xsd#smmt_BusinessCombinationAssumedContingentLiabilityMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_acfacd03-ca85-41b1-9afb-d439e058714e" xlink:to="loc_smmt_BusinessCombinationAssumedContingentLiabilityMeasurementInput_db5f797f-7081-43f1-88ab-857e8fcf08cd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2189b7a3-d6f9-4908-974a-543ff6f2f2fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_acfacd03-ca85-41b1-9afb-d439e058714e" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2189b7a3-d6f9-4908-974a-543ff6f2f2fc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_e843f075-20b7-40d8-be07-2b5885ac45ed" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2189b7a3-d6f9-4908-974a-543ff6f2f2fc" xlink:to="loc_srt_RangeAxis_e843f075-20b7-40d8-be07-2b5885ac45ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e843f075-20b7-40d8-be07-2b5885ac45ed_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_e843f075-20b7-40d8-be07-2b5885ac45ed" xlink:to="loc_srt_RangeMember_e843f075-20b7-40d8-be07-2b5885ac45ed_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_030a93b9-e80f-4a4a-bd23-b551eb91d940" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_e843f075-20b7-40d8-be07-2b5885ac45ed" xlink:to="loc_srt_RangeMember_030a93b9-e80f-4a4a-bd23-b551eb91d940" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_b4326abe-720d-466c-b99a-f2bc89735c92" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_030a93b9-e80f-4a4a-bd23-b551eb91d940" xlink:to="loc_srt_MinimumMember_b4326abe-720d-466c-b99a-f2bc89735c92" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_d60ed27e-a312-4d1d-8fb8-7cd2b0065565" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_030a93b9-e80f-4a4a-bd23-b551eb91d940" xlink:to="loc_srt_MaximumMember_d60ed27e-a312-4d1d-8fb8-7cd2b0065565" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_3f7a30b2-c15e-427e-857c-4142186594e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2189b7a3-d6f9-4908-974a-543ff6f2f2fc" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_3f7a30b2-c15e-427e-857c-4142186594e1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_3f7a30b2-c15e-427e-857c-4142186594e1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_3f7a30b2-c15e-427e-857c-4142186594e1" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_3f7a30b2-c15e-427e-857c-4142186594e1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_505ee730-76b4-4652-8634-9982fe9f95c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_3f7a30b2-c15e-427e-857c-4142186594e1" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_505ee730-76b4-4652-8634-9982fe9f95c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_cb5ea6b3-090e-4bd4-89a0-4d29c2af22d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_505ee730-76b4-4652-8634-9982fe9f95c7" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_cb5ea6b3-090e-4bd4-89a0-4d29c2af22d4" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/SummaryofSignificantAccountingPoliciesPropertyandequipmentusefullivesDetails" xlink:type="simple" xlink:href="smmt-20211231.xsd#SummaryofSignificantAccountingPoliciesPropertyandequipmentusefullivesDetails"/>
  <link:definitionLink xlink:role="http://www.summitplc.com/role/SummaryofSignificantAccountingPoliciesPropertyandequipmentusefullivesDetails" xlink:type="extended" id="i3f16e5490cb043af8ccb64bff24657f1_SummaryofSignificantAccountingPoliciesPropertyandequipmentusefullivesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_04bba521-b333-434b-93a5-0220aa3af0e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_703043ee-b1ed-4ab4-811e-a64ff7127654" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_04bba521-b333-434b-93a5-0220aa3af0e2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_703043ee-b1ed-4ab4-811e-a64ff7127654" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_62d419a9-8fb3-4e77-ac62-c9f43063931d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_04bba521-b333-434b-93a5-0220aa3af0e2" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_62d419a9-8fb3-4e77-ac62-c9f43063931d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_acb98dd0-a36f-4526-a627-a11c38065b13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_62d419a9-8fb3-4e77-ac62-c9f43063931d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_acb98dd0-a36f-4526-a627-a11c38065b13" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_acb98dd0-a36f-4526-a627-a11c38065b13_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_acb98dd0-a36f-4526-a627-a11c38065b13" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_acb98dd0-a36f-4526-a627-a11c38065b13_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_34c7d36c-66a9-413e-85f6-dff1bb7d723a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_acb98dd0-a36f-4526-a627-a11c38065b13" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_34c7d36c-66a9-413e-85f6-dff1bb7d723a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_LaboratoryEquipmentMember_2f2f026c-05fc-45da-a6dd-182d581b16a9" xlink:href="smmt-20211231.xsd#smmt_LaboratoryEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_34c7d36c-66a9-413e-85f6-dff1bb7d723a" xlink:to="loc_smmt_LaboratoryEquipmentMember_2f2f026c-05fc-45da-a6dd-182d581b16a9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_OfficeAndTechnologyEquipmentMember_dc111dbd-2d29-49b8-ab2b-109395dadff4" xlink:href="smmt-20211231.xsd#smmt_OfficeAndTechnologyEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_34c7d36c-66a9-413e-85f6-dff1bb7d723a" xlink:to="loc_smmt_OfficeAndTechnologyEquipmentMember_dc111dbd-2d29-49b8-ab2b-109395dadff4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_f68ca565-3745-42a6-82b9-2488dd1a1d15" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_62d419a9-8fb3-4e77-ac62-c9f43063931d" xlink:to="loc_srt_RangeAxis_f68ca565-3745-42a6-82b9-2488dd1a1d15" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f68ca565-3745-42a6-82b9-2488dd1a1d15_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_f68ca565-3745-42a6-82b9-2488dd1a1d15" xlink:to="loc_srt_RangeMember_f68ca565-3745-42a6-82b9-2488dd1a1d15_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_08733390-5909-4f9d-a38e-f211e4d47497" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_f68ca565-3745-42a6-82b9-2488dd1a1d15" xlink:to="loc_srt_RangeMember_08733390-5909-4f9d-a38e-f211e4d47497" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_36554a00-e13d-454f-9258-3a50a227015b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_08733390-5909-4f9d-a38e-f211e4d47497" xlink:to="loc_srt_MinimumMember_36554a00-e13d-454f-9258-3a50a227015b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_f32d7f75-4bae-4b42-95c3-2b8a64875e46" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_08733390-5909-4f9d-a38e-f211e4d47497" xlink:to="loc_srt_MaximumMember_f32d7f75-4bae-4b42-95c3-2b8a64875e46" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/SegmentReportingLonglivedassetsbygeographyDetails" xlink:type="simple" xlink:href="smmt-20211231.xsd#SegmentReportingLonglivedassetsbygeographyDetails"/>
  <link:definitionLink xlink:role="http://www.summitplc.com/role/SegmentReportingLonglivedassetsbygeographyDetails" xlink:type="extended" id="i1f03d0b4da114528ace7770afb027905_SegmentReportingLonglivedassetsbygeographyDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_f0d80925-6856-438a-b7f9-4d4f2de66217" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncurrentAssets_a37381d2-2627-4f39-9a8c-31fe69b7ea92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncurrentAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_f0d80925-6856-438a-b7f9-4d4f2de66217" xlink:to="loc_us-gaap_NoncurrentAssets_a37381d2-2627-4f39-9a8c-31fe69b7ea92" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_d8db32e3-e2a4-470f-8254-6e4b3265134c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_f0d80925-6856-438a-b7f9-4d4f2de66217" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_d8db32e3-e2a4-470f-8254-6e4b3265134c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_d4151792-da4e-47af-849e-93a22e3c17ac" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_d8db32e3-e2a4-470f-8254-6e4b3265134c" xlink:to="loc_srt_StatementGeographicalAxis_d4151792-da4e-47af-849e-93a22e3c17ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_d4151792-da4e-47af-849e-93a22e3c17ac_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_d4151792-da4e-47af-849e-93a22e3c17ac" xlink:to="loc_srt_SegmentGeographicalDomain_d4151792-da4e-47af-849e-93a22e3c17ac_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_9070a4eb-e9ce-47a3-8e05-ccb18b807e0c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_d4151792-da4e-47af-849e-93a22e3c17ac" xlink:to="loc_srt_SegmentGeographicalDomain_9070a4eb-e9ce-47a3-8e05-ccb18b807e0c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_GB_c81d308f-98c8-408c-be47-77ecfbfd5862" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_GB"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_9070a4eb-e9ce-47a3-8e05-ccb18b807e0c" xlink:to="loc_country_GB_c81d308f-98c8-408c-be47-77ecfbfd5862" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_a7a07d79-9cd5-4073-b1cd-d803088233ef" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_9070a4eb-e9ce-47a3-8e05-ccb18b807e0c" xlink:to="loc_country_US_a7a07d79-9cd5-4073-b1cd-d803088233ef" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/RevenueRevenuebycategoryDetails" xlink:type="simple" xlink:href="smmt-20211231.xsd#RevenueRevenuebycategoryDetails"/>
  <link:definitionLink xlink:role="http://www.summitplc.com/role/RevenueRevenuebycategoryDetails" xlink:type="extended" id="i00f27a6c5f6b491abb272415ebd06bf3_RevenueRevenuebycategoryDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_44b41e2c-e254-4e39-8e38-f56708cd33db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c1ca3db7-a64e-42b8-b2fa-228c56edaa1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_44b41e2c-e254-4e39-8e38-f56708cd33db" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c1ca3db7-a64e-42b8-b2fa-228c56edaa1b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_53856599-8759-479e-92a9-088763b73b91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_44b41e2c-e254-4e39-8e38-f56708cd33db" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_53856599-8759-479e-92a9-088763b73b91" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_e9543403-b444-4191-a2ca-b25300dc0e6f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_53856599-8759-479e-92a9-088763b73b91" xlink:to="loc_srt_ProductOrServiceAxis_e9543403-b444-4191-a2ca-b25300dc0e6f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_e9543403-b444-4191-a2ca-b25300dc0e6f_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_e9543403-b444-4191-a2ca-b25300dc0e6f" xlink:to="loc_srt_ProductsAndServicesDomain_e9543403-b444-4191-a2ca-b25300dc0e6f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_d81ff820-30a7-44f6-92b1-bd910a6521e4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_e9543403-b444-4191-a2ca-b25300dc0e6f" xlink:to="loc_srt_ProductsAndServicesDomain_d81ff820-30a7-44f6-92b1-bd910a6521e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseAndServiceMember_a9bf1629-f22f-4a28-bdd4-a52f2285bb7f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseAndServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d81ff820-30a7-44f6-92b1-bd910a6521e4" xlink:to="loc_us-gaap_LicenseAndServiceMember_a9bf1629-f22f-4a28-bdd4-a52f2285bb7f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/RevenueRevenuebygeographyDetails" xlink:type="simple" xlink:href="smmt-20211231.xsd#RevenueRevenuebygeographyDetails"/>
  <link:definitionLink xlink:role="http://www.summitplc.com/role/RevenueRevenuebygeographyDetails" xlink:type="extended" id="i063835a7602b4d9a865bea518a94269f_RevenueRevenuebygeographyDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_3cdcba64-7f36-4fb2-963e-7b7dd9c339cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3636c5ce-f52b-4286-a99a-66c41ba4ef32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_3cdcba64-7f36-4fb2-963e-7b7dd9c339cb" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3636c5ce-f52b-4286-a99a-66c41ba4ef32" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_7095cd49-b09e-4c3c-a4c5-ad23d52bd596" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_3cdcba64-7f36-4fb2-963e-7b7dd9c339cb" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_7095cd49-b09e-4c3c-a4c5-ad23d52bd596" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_caad8edb-8f67-43dd-8f52-872f67d65edf" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_7095cd49-b09e-4c3c-a4c5-ad23d52bd596" xlink:to="loc_srt_StatementGeographicalAxis_caad8edb-8f67-43dd-8f52-872f67d65edf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_caad8edb-8f67-43dd-8f52-872f67d65edf_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_caad8edb-8f67-43dd-8f52-872f67d65edf" xlink:to="loc_srt_SegmentGeographicalDomain_caad8edb-8f67-43dd-8f52-872f67d65edf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_e78fcfb2-a390-47ce-8523-c8c9e14ba389" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_caad8edb-8f67-43dd-8f52-872f67d65edf" xlink:to="loc_srt_SegmentGeographicalDomain_e78fcfb2-a390-47ce-8523-c8c9e14ba389" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_1167b063-84d8-4f48-8acf-8b49166f3fe7" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_e78fcfb2-a390-47ce-8523-c8c9e14ba389" xlink:to="loc_country_US_1167b063-84d8-4f48-8acf-8b49166f3fe7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LatinAmericaMember_1a7147ba-70a9-453e-8247-5493f504a0f1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LatinAmericaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_e78fcfb2-a390-47ce-8523-c8c9e14ba389" xlink:to="loc_srt_LatinAmericaMember_1a7147ba-70a9-453e-8247-5493f504a0f1" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/RevenueNarrativeDetails" xlink:type="simple" xlink:href="smmt-20211231.xsd#RevenueNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.summitplc.com/role/RevenueNarrativeDetails" xlink:type="extended" id="i6db5750b00224899a501d4ebcb841242_RevenueNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_ef50a437-120a-4010-bb51-6cd1bc37b684" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_bddcbdf5-3fa9-46d7-9a35-f028dd277219" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_ef50a437-120a-4010-bb51-6cd1bc37b684" xlink:to="loc_us-gaap_ContractWithCustomerLiability_bddcbdf5-3fa9-46d7-9a35-f028dd277219" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_ContractWithCustomerLiabilityEnrollmentMilestone_3c808cdb-c646-492d-b0a3-e40180f07e14" xlink:href="smmt-20211231.xsd#smmt_ContractWithCustomerLiabilityEnrollmentMilestone"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_ef50a437-120a-4010-bb51-6cd1bc37b684" xlink:to="loc_smmt_ContractWithCustomerLiabilityEnrollmentMilestone_3c808cdb-c646-492d-b0a3-e40180f07e14" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_RevenueInformationUsedToDetermineTransactionPriceNumberOfEnrollmentMilestones_7097cd2f-d31a-4e4a-b65a-8891ef59eb3b" xlink:href="smmt-20211231.xsd#smmt_RevenueInformationUsedToDetermineTransactionPriceNumberOfEnrollmentMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_ef50a437-120a-4010-bb51-6cd1bc37b684" xlink:to="loc_smmt_RevenueInformationUsedToDetermineTransactionPriceNumberOfEnrollmentMilestones_7097cd2f-d31a-4e4a-b65a-8891ef59eb3b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_e8db30dd-860e-4840-a233-8765ed93a355" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_ef50a437-120a-4010-bb51-6cd1bc37b684" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_e8db30dd-860e-4840-a233-8765ed93a355" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_19387ddc-84af-4fd1-b7b9-4306a892a539" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_ef50a437-120a-4010-bb51-6cd1bc37b684" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_19387ddc-84af-4fd1-b7b9-4306a892a539" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_RevenueFromContractWithCustomerDevelopmentMilestoneRevenueEntitledToReceive_e92089e3-295e-431a-936f-d7bbc82086fd" xlink:href="smmt-20211231.xsd#smmt_RevenueFromContractWithCustomerDevelopmentMilestoneRevenueEntitledToReceive"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_ef50a437-120a-4010-bb51-6cd1bc37b684" xlink:to="loc_smmt_RevenueFromContractWithCustomerDevelopmentMilestoneRevenueEntitledToReceive_e92089e3-295e-431a-936f-d7bbc82086fd" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_RevenueFromContractWithCustomerDevelopmentCommercialAndSalesMilestoneCumulativeNetSalesTargetAchievementRevenueEntitledToReceive_97d567e0-4c52-4c13-9ccc-80b2a2562b74" xlink:href="smmt-20211231.xsd#smmt_RevenueFromContractWithCustomerDevelopmentCommercialAndSalesMilestoneCumulativeNetSalesTargetAchievementRevenueEntitledToReceive"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_ef50a437-120a-4010-bb51-6cd1bc37b684" xlink:to="loc_smmt_RevenueFromContractWithCustomerDevelopmentCommercialAndSalesMilestoneCumulativeNetSalesTargetAchievementRevenueEntitledToReceive_97d567e0-4c52-4c13-9ccc-80b2a2562b74" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_RevenueFromContractWithCustomerDevelopmentCommercialAndSalesMilestoneCumulativeNetSalesTargetThreshold_56408b6f-2d35-48d5-9285-83f7431506ff" xlink:href="smmt-20211231.xsd#smmt_RevenueFromContractWithCustomerDevelopmentCommercialAndSalesMilestoneCumulativeNetSalesTargetThreshold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_ef50a437-120a-4010-bb51-6cd1bc37b684" xlink:to="loc_smmt_RevenueFromContractWithCustomerDevelopmentCommercialAndSalesMilestoneCumulativeNetSalesTargetThreshold_56408b6f-2d35-48d5-9285-83f7431506ff" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_RevenueFromContractWithCustomerDevelopmentCommercialAndSalesMilestoneIncrementalCumulativeNetSalesTargetThreshold_2b5980b1-3975-4968-8520-a9b60adc344c" xlink:href="smmt-20211231.xsd#smmt_RevenueFromContractWithCustomerDevelopmentCommercialAndSalesMilestoneIncrementalCumulativeNetSalesTargetThreshold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_ef50a437-120a-4010-bb51-6cd1bc37b684" xlink:to="loc_smmt_RevenueFromContractWithCustomerDevelopmentCommercialAndSalesMilestoneIncrementalCumulativeNetSalesTargetThreshold_2b5980b1-3975-4968-8520-a9b60adc344c" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_25a8dfa8-34ba-4a61-872a-8ca948135f6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_ef50a437-120a-4010-bb51-6cd1bc37b684" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_25a8dfa8-34ba-4a61-872a-8ca948135f6b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_48d757ea-280d-4916-b9cd-3b29a536abdf" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_25a8dfa8-34ba-4a61-872a-8ca948135f6b" xlink:to="loc_srt_ProductOrServiceAxis_48d757ea-280d-4916-b9cd-3b29a536abdf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_48d757ea-280d-4916-b9cd-3b29a536abdf_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_48d757ea-280d-4916-b9cd-3b29a536abdf" xlink:to="loc_srt_ProductsAndServicesDomain_48d757ea-280d-4916-b9cd-3b29a536abdf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_e7f60d4b-a14f-40b0-bf97-cd1771c215a2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_48d757ea-280d-4916-b9cd-3b29a536abdf" xlink:to="loc_srt_ProductsAndServicesDomain_e7f60d4b-a14f-40b0-bf97-cd1771c215a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseAndServiceMember_57ffa544-515d-4e5b-8e63-c18960673c65" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseAndServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e7f60d4b-a14f-40b0-bf97-cd1771c215a2" xlink:to="loc_us-gaap_LicenseAndServiceMember_57ffa544-515d-4e5b-8e63-c18960673c65" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_8ba917a2-c65e-4a7a-86bf-410d4c08b103" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_25a8dfa8-34ba-4a61-872a-8ca948135f6b" xlink:to="loc_srt_CounterpartyNameAxis_8ba917a2-c65e-4a7a-86bf-410d4c08b103" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8ba917a2-c65e-4a7a-86bf-410d4c08b103_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_8ba917a2-c65e-4a7a-86bf-410d4c08b103" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8ba917a2-c65e-4a7a-86bf-410d4c08b103_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f6337819-bb91-4ccf-b51d-3af254e915f7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_8ba917a2-c65e-4a7a-86bf-410d4c08b103" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f6337819-bb91-4ccf-b51d-3af254e915f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_EuroFarmaLaboratoriosSAMember_aed8c949-864e-4a35-904b-9115148085e1" xlink:href="smmt-20211231.xsd#smmt_EuroFarmaLaboratoriosSAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f6337819-bb91-4ccf-b51d-3af254e915f7" xlink:to="loc_smmt_EuroFarmaLaboratoriosSAMember_aed8c949-864e-4a35-904b-9115148085e1" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/OtherOperatingIncomeOtheroperatingincomebycategoryDetails" xlink:type="simple" xlink:href="smmt-20211231.xsd#OtherOperatingIncomeOtheroperatingincomebycategoryDetails"/>
  <link:definitionLink xlink:role="http://www.summitplc.com/role/OtherOperatingIncomeOtheroperatingincomebycategoryDetails" xlink:type="extended" id="i7418380015694f4488d403ed4ba7e047_OtherOperatingIncomeOtheroperatingincomebycategoryDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_c66c0622-f42c-430f-91e4-e6ed8931d732" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_GrantFundingArrangementIncomeEarned_05b298f9-b5e9-404d-ab72-ebeb10126142" xlink:href="smmt-20211231.xsd#smmt_GrantFundingArrangementIncomeEarned"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_c66c0622-f42c-430f-91e4-e6ed8931d732" xlink:to="loc_smmt_GrantFundingArrangementIncomeEarned_05b298f9-b5e9-404d-ab72-ebeb10126142" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_ResearchAndDevelopmentTaxCredit_6103b85b-7c00-4589-903d-25f48d8bcb9b" xlink:href="smmt-20211231.xsd#smmt_ResearchAndDevelopmentTaxCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_c66c0622-f42c-430f-91e4-e6ed8931d732" xlink:to="loc_smmt_ResearchAndDevelopmentTaxCredit_6103b85b-7c00-4589-903d-25f48d8bcb9b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncome_da91ea9f-9399-472d-9b87-a485f70dc0d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherOperatingIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_c66c0622-f42c-430f-91e4-e6ed8931d732" xlink:to="loc_us-gaap_OtherOperatingIncome_da91ea9f-9399-472d-9b87-a485f70dc0d8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_cd801eaa-f566-4021-b2ed-05c6d47ddfbc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_c66c0622-f42c-430f-91e4-e6ed8931d732" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_cd801eaa-f566-4021-b2ed-05c6d47ddfbc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_1b901553-49e3-40e2-88b5-61505474f503" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_cd801eaa-f566-4021-b2ed-05c6d47ddfbc" xlink:to="loc_srt_CounterpartyNameAxis_1b901553-49e3-40e2-88b5-61505474f503" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1b901553-49e3-40e2-88b5-61505474f503_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_1b901553-49e3-40e2-88b5-61505474f503" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1b901553-49e3-40e2-88b5-61505474f503_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5a96757b-e697-4933-b847-0dc326d89214" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_1b901553-49e3-40e2-88b5-61505474f503" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5a96757b-e697-4933-b847-0dc326d89214" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember_9e0f8662-d73b-40e4-be76-d0910bcd0e3f" xlink:href="smmt-20211231.xsd#smmt_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5a96757b-e697-4933-b847-0dc326d89214" xlink:to="loc_smmt_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember_9e0f8662-d73b-40e4-be76-d0910bcd0e3f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_OtherGrantFundingCounterpartiesMember_71e2fdd5-125f-4166-8272-baf5a2390691" xlink:href="smmt-20211231.xsd#smmt_OtherGrantFundingCounterpartiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5a96757b-e697-4933-b847-0dc326d89214" xlink:to="loc_smmt_OtherGrantFundingCounterpartiesMember_71e2fdd5-125f-4166-8272-baf5a2390691" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/OtherOperatingIncomeNarrativeDetails" xlink:type="simple" xlink:href="smmt-20211231.xsd#OtherOperatingIncomeNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.summitplc.com/role/OtherOperatingIncomeNarrativeDetails" xlink:type="extended" id="id7e6e334cf1a4fb480e74a98d096c3c3_OtherOperatingIncomeNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b3dc4173-f2b7-4db4-ac99-b7d57b6705a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_GrantFundingArrangementMaximumFundingValue_e7392828-38bb-4a78-b4a1-9c422a715c96" xlink:href="smmt-20211231.xsd#smmt_GrantFundingArrangementMaximumFundingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b3dc4173-f2b7-4db4-ac99-b7d57b6705a1" xlink:to="loc_smmt_GrantFundingArrangementMaximumFundingValue_e7392828-38bb-4a78-b4a1-9c422a715c96" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_GrantFundingArrangementCommittedFundingTotal_48570c2d-d356-443c-afb2-6898ef85e178" xlink:href="smmt-20211231.xsd#smmt_GrantFundingArrangementCommittedFundingTotal"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b3dc4173-f2b7-4db4-ac99-b7d57b6705a1" xlink:to="loc_smmt_GrantFundingArrangementCommittedFundingTotal_48570c2d-d356-443c-afb2-6898ef85e178" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_GrantFundingArrangementFundingReceived_6c7c8674-09a2-4890-b412-f8952b2c8375" xlink:href="smmt-20211231.xsd#smmt_GrantFundingArrangementFundingReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b3dc4173-f2b7-4db4-ac99-b7d57b6705a1" xlink:to="loc_smmt_GrantFundingArrangementFundingReceived_6c7c8674-09a2-4890-b412-f8952b2c8375" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_GrantFundingArrangementIncomeEarned_70d06518-7ff0-49f7-bed6-fdaf9181e776" xlink:href="smmt-20211231.xsd#smmt_GrantFundingArrangementIncomeEarned"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b3dc4173-f2b7-4db4-ac99-b7d57b6705a1" xlink:to="loc_smmt_GrantFundingArrangementIncomeEarned_70d06518-7ff0-49f7-bed6-fdaf9181e776" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_ResearchAndDevelopmentTaxCreditReceivableCurrent_7f1a5a23-23ae-46f1-8c83-4390d1b8edfd" xlink:href="smmt-20211231.xsd#smmt_ResearchAndDevelopmentTaxCreditReceivableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b3dc4173-f2b7-4db4-ac99-b7d57b6705a1" xlink:to="loc_smmt_ResearchAndDevelopmentTaxCreditReceivableCurrent_7f1a5a23-23ae-46f1-8c83-4390d1b8edfd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_GrantFundingArrangementCommittedFundingBase_e8d75d57-e1f9-4d8a-a8e3-61028cd8a656" xlink:href="smmt-20211231.xsd#smmt_GrantFundingArrangementCommittedFundingBase"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b3dc4173-f2b7-4db4-ac99-b7d57b6705a1" xlink:to="loc_smmt_GrantFundingArrangementCommittedFundingBase_e8d75d57-e1f9-4d8a-a8e3-61028cd8a656" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_GrantFundingArrangementMilestoneFundingIncrease_c3471076-e564-4d33-808f-158b01bbfbb6" xlink:href="smmt-20211231.xsd#smmt_GrantFundingArrangementMilestoneFundingIncrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b3dc4173-f2b7-4db4-ac99-b7d57b6705a1" xlink:to="loc_smmt_GrantFundingArrangementMilestoneFundingIncrease_c3471076-e564-4d33-808f-158b01bbfbb6" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_8947342f-3900-4a6f-93fa-62cd6dfb177a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b3dc4173-f2b7-4db4-ac99-b7d57b6705a1" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_8947342f-3900-4a6f-93fa-62cd6dfb177a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_d3bba4a8-cbbb-4378-9c8c-781fa4160adf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b3dc4173-f2b7-4db4-ac99-b7d57b6705a1" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_d3bba4a8-cbbb-4378-9c8c-781fa4160adf" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_1e62b921-f1ea-44be-9279-6d039c9e6dbf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b3dc4173-f2b7-4db4-ac99-b7d57b6705a1" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_1e62b921-f1ea-44be-9279-6d039c9e6dbf" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_48fb424b-76f5-41a7-8894-45fbb7cb804e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_1e62b921-f1ea-44be-9279-6d039c9e6dbf" xlink:to="loc_srt_CounterpartyNameAxis_48fb424b-76f5-41a7-8894-45fbb7cb804e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_48fb424b-76f5-41a7-8894-45fbb7cb804e_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_48fb424b-76f5-41a7-8894-45fbb7cb804e" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_48fb424b-76f5-41a7-8894-45fbb7cb804e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c13afa86-580e-467f-ad8c-ac5defbd167a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_48fb424b-76f5-41a7-8894-45fbb7cb804e" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c13afa86-580e-467f-ad8c-ac5defbd167a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember_b50c73a1-12f0-43a4-ab0b-e873c085dac9" xlink:href="smmt-20211231.xsd#smmt_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c13afa86-580e-467f-ad8c-ac5defbd167a" xlink:to="loc_smmt_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember_b50c73a1-12f0-43a4-ab0b-e873c085dac9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_CombatingAntibioticResistantBacteriaBiopharmaceuticalAcceleratorProgramMember_0914d1d1-f543-41c3-8ebc-c9d2e0384ba8" xlink:href="smmt-20211231.xsd#smmt_CombatingAntibioticResistantBacteriaBiopharmaceuticalAcceleratorProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c13afa86-580e-467f-ad8c-ac5defbd167a" xlink:to="loc_smmt_CombatingAntibioticResistantBacteriaBiopharmaceuticalAcceleratorProgramMember_0914d1d1-f543-41c3-8ebc-c9d2e0384ba8" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/IncomeTaxNarrativeDetails" xlink:type="simple" xlink:href="smmt-20211231.xsd#IncomeTaxNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.summitplc.com/role/IncomeTaxNarrativeDetails" xlink:type="extended" id="i95085de65a29407fbf22d84cec11721f_IncomeTaxNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_33fd2f18-203d-4570-b0e9-d7ca1bc44a0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_ca328266-9f46-4d8d-b507-5ce533ce9fd1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_33fd2f18-203d-4570-b0e9-d7ca1bc44a0a" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_ca328266-9f46-4d8d-b507-5ce533ce9fd1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_1b45de03-f5be-4aae-b4b5-d1bb7e26f26f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_33fd2f18-203d-4570-b0e9-d7ca1bc44a0a" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_1b45de03-f5be-4aae-b4b5-d1bb7e26f26f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_98f53169-b8f8-4ecd-9920-c25db85f2f52" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_33fd2f18-203d-4570-b0e9-d7ca1bc44a0a" xlink:to="loc_us-gaap_OperatingLossCarryforwards_98f53169-b8f8-4ecd-9920-c25db85f2f52" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_d2c33d27-023f-4336-9102-c59eb18d4f97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_33fd2f18-203d-4570-b0e9-d7ca1bc44a0a" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_d2c33d27-023f-4336-9102-c59eb18d4f97" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_PotentialDeferredTaxAssetsOperatingLossCarryforwards_e256edbe-cf23-4bfd-b3ac-85a3da2fc934" xlink:href="smmt-20211231.xsd#smmt_PotentialDeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_33fd2f18-203d-4570-b0e9-d7ca1bc44a0a" xlink:to="loc_smmt_PotentialDeferredTaxAssetsOperatingLossCarryforwards_e256edbe-cf23-4bfd-b3ac-85a3da2fc934" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_DeferredTaxAssetsNetIncreaseDecreaseDueToChangeInEnactedTaxRateAmount_aba626bc-7ddd-49bd-aad0-cd8668483890" xlink:href="smmt-20211231.xsd#smmt_DeferredTaxAssetsNetIncreaseDecreaseDueToChangeInEnactedTaxRateAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_33fd2f18-203d-4570-b0e9-d7ca1bc44a0a" xlink:to="loc_smmt_DeferredTaxAssetsNetIncreaseDecreaseDueToChangeInEnactedTaxRateAmount_aba626bc-7ddd-49bd-aad0-cd8668483890" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseDueToChangeInEnactedTaxRateAmount_38abb5ef-a6b8-4f03-9e3a-7541bf16ace7" xlink:href="smmt-20211231.xsd#smmt_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseDueToChangeInEnactedTaxRateAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_33fd2f18-203d-4570-b0e9-d7ca1bc44a0a" xlink:to="loc_smmt_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseDueToChangeInEnactedTaxRateAmount_38abb5ef-a6b8-4f03-9e3a-7541bf16ace7" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_ResearchAndDevelopmentTaxCredit_dcffde83-027d-411d-9024-d84e38a824ce" xlink:href="smmt-20211231.xsd#smmt_ResearchAndDevelopmentTaxCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_33fd2f18-203d-4570-b0e9-d7ca1bc44a0a" xlink:to="loc_smmt_ResearchAndDevelopmentTaxCredit_dcffde83-027d-411d-9024-d84e38a824ce" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_e4af86f5-8937-4545-a90b-22f4a20d888b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_33fd2f18-203d-4570-b0e9-d7ca1bc44a0a" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_e4af86f5-8937-4545-a90b-22f4a20d888b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_4ee8098d-8ab4-41d7-91c6-50e2eeccad0c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_33fd2f18-203d-4570-b0e9-d7ca1bc44a0a" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_4ee8098d-8ab4-41d7-91c6-50e2eeccad0c" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_e9249b80-950d-4f6a-9a51-9d727f92cb0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_33fd2f18-203d-4570-b0e9-d7ca1bc44a0a" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_e9249b80-950d-4f6a-9a51-9d727f92cb0e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_52d794fa-fde5-455d-9755-2ba5b56cd942" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_e9249b80-950d-4f6a-9a51-9d727f92cb0e" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_52d794fa-fde5-455d-9755-2ba5b56cd942" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_52d794fa-fde5-455d-9755-2ba5b56cd942_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_52d794fa-fde5-455d-9755-2ba5b56cd942" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_52d794fa-fde5-455d-9755-2ba5b56cd942_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_cc96f34e-6891-47bf-bdc8-cf23bf82fa90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_52d794fa-fde5-455d-9755-2ba5b56cd942" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_cc96f34e-6891-47bf-bdc8-cf23bf82fa90" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_28066727-0428-426f-b0ef-8ad361b6675f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_cc96f34e-6891-47bf-bdc8-cf23bf82fa90" xlink:to="loc_us-gaap_DomesticCountryMember_28066727-0428-426f-b0ef-8ad361b6675f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_414d556b-30db-4574-b393-6ab86aa4eebd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_cc96f34e-6891-47bf-bdc8-cf23bf82fa90" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_414d556b-30db-4574-b393-6ab86aa4eebd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_72e1130f-774a-4bf6-906e-dd7e5777dea1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_cc96f34e-6891-47bf-bdc8-cf23bf82fa90" xlink:to="loc_us-gaap_ForeignCountryMember_72e1130f-774a-4bf6-906e-dd7e5777dea1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_3dba8c24-6a6f-4d09-988e-e12c53055f8c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_e9249b80-950d-4f6a-9a51-9d727f92cb0e" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_3dba8c24-6a6f-4d09-988e-e12c53055f8c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_3dba8c24-6a6f-4d09-988e-e12c53055f8c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_3dba8c24-6a6f-4d09-988e-e12c53055f8c" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_3dba8c24-6a6f-4d09-988e-e12c53055f8c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_4fb50104-8e07-440e-9be3-4efb482da587" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_3dba8c24-6a6f-4d09-988e-e12c53055f8c" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_4fb50104-8e07-440e-9be3-4efb482da587" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember_6fa42df9-e48e-47f4-8ec9-2ffc30af4e11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_4fb50104-8e07-440e-9be3-4efb482da587" xlink:to="loc_us-gaap_ResearchMember_6fa42df9-e48e-47f4-8ec9-2ffc30af4e11" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/LossperSharePotentiallydilutivesecuritiesexcludedfromthecomputationoflosspershareDetails" xlink:type="simple" xlink:href="smmt-20211231.xsd#LossperSharePotentiallydilutivesecuritiesexcludedfromthecomputationoflosspershareDetails"/>
  <link:definitionLink xlink:role="http://www.summitplc.com/role/LossperSharePotentiallydilutivesecuritiesexcludedfromthecomputationoflosspershareDetails" xlink:type="extended" id="iff7ded99b44f451399853eb86ac06d20_LossperSharePotentiallydilutivesecuritiesexcludedfromthecomputationoflosspershareDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_9b246491-6475-4957-9d9c-2387a9f969af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_7ffac96f-5410-492a-8668-83bf69419a57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_9b246491-6475-4957-9d9c-2387a9f969af" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_7ffac96f-5410-492a-8668-83bf69419a57" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_668e6a68-2860-4402-b8b3-7f0feaebf3e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_9b246491-6475-4957-9d9c-2387a9f969af" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_668e6a68-2860-4402-b8b3-7f0feaebf3e2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_cbf4fa57-a4dc-43d3-a25a-7405a09ef240" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_668e6a68-2860-4402-b8b3-7f0feaebf3e2" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_cbf4fa57-a4dc-43d3-a25a-7405a09ef240" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_cbf4fa57-a4dc-43d3-a25a-7405a09ef240_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_cbf4fa57-a4dc-43d3-a25a-7405a09ef240" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_cbf4fa57-a4dc-43d3-a25a-7405a09ef240_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_42a0a4df-a3e7-4b40-88bb-a059d0245e5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_cbf4fa57-a4dc-43d3-a25a-7405a09ef240" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_42a0a4df-a3e7-4b40-88bb-a059d0245e5b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_3a9fee4b-be1c-4515-b465-a6f063387fc8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_42a0a4df-a3e7-4b40-88bb-a059d0245e5b" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_3a9fee4b-be1c-4515-b465-a6f063387fc8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_895332c5-fc5c-4726-aa4c-80899eb2ab00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_42a0a4df-a3e7-4b40-88bb-a059d0245e5b" xlink:to="loc_us-gaap_EmployeeStockOptionMember_895332c5-fc5c-4726-aa4c-80899eb2ab00" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_8f297a5c-b78d-4369-85f0-d0fed3902cd9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_42a0a4df-a3e7-4b40-88bb-a059d0245e5b" xlink:to="loc_us-gaap_WarrantMember_8f297a5c-b78d-4369-85f0-d0fed3902cd9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_1f0e36cb-1970-4fd7-871f-155d1a12e1db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_42a0a4df-a3e7-4b40-88bb-a059d0245e5b" xlink:to="loc_us-gaap_EmployeeStockMember_1f0e36cb-1970-4fd7-871f-155d1a12e1db" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/GoodwillandIntangibleAssetsNarrativeDetails" xlink:type="simple" xlink:href="smmt-20211231.xsd#GoodwillandIntangibleAssetsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.summitplc.com/role/GoodwillandIntangibleAssetsNarrativeDetails" xlink:type="extended" id="i639d1791c72a4607b4cc98baec365ffb_GoodwillandIntangibleAssetsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_712f0483-e3ec-4c83-981e-28873ccb96fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_682391ab-e7c2-429a-865a-fcad77bf99ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_712f0483-e3ec-4c83-981e-28873ccb96fe" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_682391ab-e7c2-429a-865a-fcad77bf99ed" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_c1a4f05e-05db-4de6-ab6b-0c66c4a2bf31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_712f0483-e3ec-4c83-981e-28873ccb96fe" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_c1a4f05e-05db-4de6-ab6b-0c66c4a2bf31" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_29b56d00-f668-45af-a7c1-93a7c65d007b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_c1a4f05e-05db-4de6-ab6b-0c66c4a2bf31" xlink:to="loc_srt_ProductOrServiceAxis_29b56d00-f668-45af-a7c1-93a7c65d007b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_29b56d00-f668-45af-a7c1-93a7c65d007b_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_29b56d00-f668-45af-a7c1-93a7c65d007b" xlink:to="loc_srt_ProductsAndServicesDomain_29b56d00-f668-45af-a7c1-93a7c65d007b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_fef61f72-44c0-4003-8548-2e75687b9315" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_29b56d00-f668-45af-a7c1-93a7c65d007b" xlink:to="loc_srt_ProductsAndServicesDomain_fef61f72-44c0-4003-8548-2e75687b9315" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_DiscuvaPlatformMember_b616da61-ec88-454e-b694-a227e3e3a88e" xlink:href="smmt-20211231.xsd#smmt_DiscuvaPlatformMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_fef61f72-44c0-4003-8548-2e75687b9315" xlink:to="loc_smmt_DiscuvaPlatformMember_b616da61-ec88-454e-b694-a227e3e3a88e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_8833aedf-09b2-477a-b0b7-1c1b4ac5001b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_c1a4f05e-05db-4de6-ab6b-0c66c4a2bf31" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_8833aedf-09b2-477a-b0b7-1c1b4ac5001b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8833aedf-09b2-477a-b0b7-1c1b4ac5001b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_8833aedf-09b2-477a-b0b7-1c1b4ac5001b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8833aedf-09b2-477a-b0b7-1c1b4ac5001b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a9def4ab-f459-41c4-8a59-5a0a018776fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_8833aedf-09b2-477a-b0b7-1c1b4ac5001b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a9def4ab-f459-41c4-8a59-5a0a018776fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_b7a8a47c-bb15-4f01-b56a-c13087061cc4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a9def4ab-f459-41c4-8a59-5a0a018776fc" xlink:to="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_b7a8a47c-bb15-4f01-b56a-c13087061cc4" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/GoodwillandIntangibleAssetsScheduleofacquiredintangibleassetsDetails" xlink:type="simple" xlink:href="smmt-20211231.xsd#GoodwillandIntangibleAssetsScheduleofacquiredintangibleassetsDetails"/>
  <link:definitionLink xlink:role="http://www.summitplc.com/role/GoodwillandIntangibleAssetsScheduleofacquiredintangibleassetsDetails" xlink:type="extended" id="i988145ae15aa4242a8f11bf87fd5944c_GoodwillandIntangibleAssetsScheduleofacquiredintangibleassetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_c59d6473-4a8d-4210-b89f-2fcedb2db59d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_07895332-219c-486b-9e20-8e26edfa654e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_c59d6473-4a8d-4210-b89f-2fcedb2db59d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_07895332-219c-486b-9e20-8e26edfa654e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_FiniteLivedIntangibleAssetsAccumulatedAmortizationAndImpairment_db364a44-559c-4ace-9337-45870c1424a5" xlink:href="smmt-20211231.xsd#smmt_FiniteLivedIntangibleAssetsAccumulatedAmortizationAndImpairment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_c59d6473-4a8d-4210-b89f-2fcedb2db59d" xlink:to="loc_smmt_FiniteLivedIntangibleAssetsAccumulatedAmortizationAndImpairment_db364a44-559c-4ace-9337-45870c1424a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_9162791f-0eaa-4c7b-8218-5b5e0e086d50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_c59d6473-4a8d-4210-b89f-2fcedb2db59d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_9162791f-0eaa-4c7b-8218-5b5e0e086d50" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure_fc4369be-b4d2-4ca5-93b7-690c85e781c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_c59d6473-4a8d-4210-b89f-2fcedb2db59d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure_fc4369be-b4d2-4ca5-93b7-690c85e781c1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_c35ce0ff-a986-4aad-9710-0fafb95e19e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_c59d6473-4a8d-4210-b89f-2fcedb2db59d" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_c35ce0ff-a986-4aad-9710-0fafb95e19e0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_dfa12cfc-81f8-4c2b-9bc8-49c81d5378a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_c59d6473-4a8d-4210-b89f-2fcedb2db59d" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_dfa12cfc-81f8-4c2b-9bc8-49c81d5378a7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_0099f0b7-da99-4425-a8df-a0e4e901890f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_dfa12cfc-81f8-4c2b-9bc8-49c81d5378a7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_0099f0b7-da99-4425-a8df-a0e4e901890f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0099f0b7-da99-4425-a8df-a0e4e901890f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_0099f0b7-da99-4425-a8df-a0e4e901890f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0099f0b7-da99-4425-a8df-a0e4e901890f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_42e1afaf-c5a6-4f8a-9736-d0f4c0426e01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_0099f0b7-da99-4425-a8df-a0e4e901890f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_42e1afaf-c5a6-4f8a-9736-d0f4c0426e01" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_f3307257-cdc7-4f64-92dc-a35bd3873d66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_42e1afaf-c5a6-4f8a-9736-d0f4c0426e01" xlink:to="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_f3307257-cdc7-4f64-92dc-a35bd3873d66" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_OptionOverNonFinancialAssetsMember_efa1c6c4-fcf7-4c8b-9097-b2f0b29fb638" xlink:href="smmt-20211231.xsd#smmt_OptionOverNonFinancialAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_42e1afaf-c5a6-4f8a-9736-d0f4c0426e01" xlink:to="loc_smmt_OptionOverNonFinancialAssetsMember_efa1c6c4-fcf7-4c8b-9097-b2f0b29fb638" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_OtherPatentsAndLicensesMember_7016a85d-eaa7-41c9-a546-d1c8c4376c9d" xlink:href="smmt-20211231.xsd#smmt_OtherPatentsAndLicensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_42e1afaf-c5a6-4f8a-9736-d0f4c0426e01" xlink:to="loc_smmt_OtherPatentsAndLicensesMember_7016a85d-eaa7-41c9-a546-d1c8c4376c9d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_0a777259-2863-4940-8b88-3c3f302d7dbc" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_dfa12cfc-81f8-4c2b-9bc8-49c81d5378a7" xlink:to="loc_srt_ProductOrServiceAxis_0a777259-2863-4940-8b88-3c3f302d7dbc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_0a777259-2863-4940-8b88-3c3f302d7dbc_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_0a777259-2863-4940-8b88-3c3f302d7dbc" xlink:to="loc_srt_ProductsAndServicesDomain_0a777259-2863-4940-8b88-3c3f302d7dbc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_229fc7e6-37b5-40a1-a7f5-76a5057bfe2a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_0a777259-2863-4940-8b88-3c3f302d7dbc" xlink:to="loc_srt_ProductsAndServicesDomain_229fc7e6-37b5-40a1-a7f5-76a5057bfe2a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_UtrophinProgramMember_81395b1d-858e-40ce-9b1b-94b4891b97b4" xlink:href="smmt-20211231.xsd#smmt_UtrophinProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_229fc7e6-37b5-40a1-a7f5-76a5057bfe2a" xlink:to="loc_smmt_UtrophinProgramMember_81395b1d-858e-40ce-9b1b-94b4891b97b4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_DiscuvaPlatformMember_f6dda7d1-32ca-4f2c-8c80-d5aeaa469864" xlink:href="smmt-20211231.xsd#smmt_DiscuvaPlatformMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_229fc7e6-37b5-40a1-a7f5-76a5057bfe2a" xlink:to="loc_smmt_DiscuvaPlatformMember_f6dda7d1-32ca-4f2c-8c80-d5aeaa469864" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/PropertyandEquipmentComponentsofpropertyandequipmentDetails" xlink:type="simple" xlink:href="smmt-20211231.xsd#PropertyandEquipmentComponentsofpropertyandequipmentDetails"/>
  <link:definitionLink xlink:role="http://www.summitplc.com/role/PropertyandEquipmentComponentsofpropertyandequipmentDetails" xlink:type="extended" id="i4e74004610584915ab205cb769776adb_PropertyandEquipmentComponentsofpropertyandequipmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a34c8241-fec5-4c0d-b670-2858f5aa6156" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_ddf19cdb-de22-4342-b38f-35f484d25e6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a34c8241-fec5-4c0d-b670-2858f5aa6156" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_ddf19cdb-de22-4342-b38f-35f484d25e6e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_4985569f-c475-4063-bb0d-2e5489c3e488" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a34c8241-fec5-4c0d-b670-2858f5aa6156" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_4985569f-c475-4063-bb0d-2e5489c3e488" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_9c6334c3-8cdd-4d78-92fa-b1ccdbe42f8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a34c8241-fec5-4c0d-b670-2858f5aa6156" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_9c6334c3-8cdd-4d78-92fa-b1ccdbe42f8d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_e48ddecb-8226-4d38-83c6-df717ae1b5af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a34c8241-fec5-4c0d-b670-2858f5aa6156" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_e48ddecb-8226-4d38-83c6-df717ae1b5af" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a42f1d9e-172b-4b78-810e-287b6285e878" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_e48ddecb-8226-4d38-83c6-df717ae1b5af" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a42f1d9e-172b-4b78-810e-287b6285e878" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a42f1d9e-172b-4b78-810e-287b6285e878_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a42f1d9e-172b-4b78-810e-287b6285e878" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a42f1d9e-172b-4b78-810e-287b6285e878_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0e8d6e2b-20dc-49f9-8d21-b79eceee6656" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a42f1d9e-172b-4b78-810e-287b6285e878" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0e8d6e2b-20dc-49f9-8d21-b79eceee6656" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_LaboratoryEquipmentMember_663317a1-82ea-4f48-9a7a-b6d22c5849ce" xlink:href="smmt-20211231.xsd#smmt_LaboratoryEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0e8d6e2b-20dc-49f9-8d21-b79eceee6656" xlink:to="loc_smmt_LaboratoryEquipmentMember_663317a1-82ea-4f48-9a7a-b6d22c5849ce" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_FurnitureAndFixturesOfficeEquipmentAndSoftwareMember_4197deaa-4138-4d16-a18e-2cf36b841ef6" xlink:href="smmt-20211231.xsd#smmt_FurnitureAndFixturesOfficeEquipmentAndSoftwareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0e8d6e2b-20dc-49f9-8d21-b79eceee6656" xlink:to="loc_smmt_FurnitureAndFixturesOfficeEquipmentAndSoftwareMember_4197deaa-4138-4d16-a18e-2cf36b841ef6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_5dc828d2-8de8-4145-9033-c6923686c8aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0e8d6e2b-20dc-49f9-8d21-b79eceee6656" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_5dc828d2-8de8-4145-9033-c6923686c8aa" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="smmt-20211231.xsd#LeasesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.summitplc.com/role/LeasesNarrativeDetails" xlink:type="extended" id="if4adbbba339b41189bb526f3517cab7d_LeasesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_448a9a3d-8da6-4b6a-a841-1fe8fe09792f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_15950824-4969-44d8-9e11-acc78f5147a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_448a9a3d-8da6-4b6a-a841-1fe8fe09792f" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_15950824-4969-44d8-9e11-acc78f5147a9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_LesseeOperatingLeaseNumberOfContracts_37e7c256-dcb5-49e0-98aa-d5979c78ddd4" xlink:href="smmt-20211231.xsd#smmt_LesseeOperatingLeaseNumberOfContracts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_448a9a3d-8da6-4b6a-a841-1fe8fe09792f" xlink:to="loc_smmt_LesseeOperatingLeaseNumberOfContracts_37e7c256-dcb5-49e0-98aa-d5979c78ddd4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_7abd8d31-5d5e-4b90-8b65-6c8a219510c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_448a9a3d-8da6-4b6a-a841-1fe8fe09792f" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_7abd8d31-5d5e-4b90-8b65-6c8a219510c2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_e15ee108-6e57-486b-b302-c56800222113" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_448a9a3d-8da6-4b6a-a841-1fe8fe09792f" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_e15ee108-6e57-486b-b302-c56800222113" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_cb292f8c-396f-4e2f-b456-b98f8ada3718" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_448a9a3d-8da6-4b6a-a841-1fe8fe09792f" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_cb292f8c-396f-4e2f-b456-b98f8ada3718" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_74163a57-8b3b-42e8-bed2-b14e070ef306" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_448a9a3d-8da6-4b6a-a841-1fe8fe09792f" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_74163a57-8b3b-42e8-bed2-b14e070ef306" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_6869ea32-4f3c-4d8e-9cc6-065c808a0137" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_74163a57-8b3b-42e8-bed2-b14e070ef306" xlink:to="loc_srt_StatementGeographicalAxis_6869ea32-4f3c-4d8e-9cc6-065c808a0137" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_6869ea32-4f3c-4d8e-9cc6-065c808a0137_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_6869ea32-4f3c-4d8e-9cc6-065c808a0137" xlink:to="loc_srt_SegmentGeographicalDomain_6869ea32-4f3c-4d8e-9cc6-065c808a0137_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_48b0b9d6-cb91-4787-9ef2-b414695e7b5b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_6869ea32-4f3c-4d8e-9cc6-065c808a0137" xlink:to="loc_srt_SegmentGeographicalDomain_48b0b9d6-cb91-4787-9ef2-b414695e7b5b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_MenloParkCaliforniaUSAndSawstonUKMember_0479553d-ea8d-4bc7-98eb-2ebd541c78dc" xlink:href="smmt-20211231.xsd#smmt_MenloParkCaliforniaUSAndSawstonUKMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_48b0b9d6-cb91-4787-9ef2-b414695e7b5b" xlink:to="loc_smmt_MenloParkCaliforniaUSAndSawstonUKMember_0479553d-ea8d-4bc7-98eb-2ebd541c78dc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_OxfordshireUKMember_7d3a6915-e742-4004-855e-9e5ba0626ebe" xlink:href="smmt-20211231.xsd#smmt_OxfordshireUKMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_48b0b9d6-cb91-4787-9ef2-b414695e7b5b" xlink:to="loc_smmt_OxfordshireUKMember_7d3a6915-e742-4004-855e-9e5ba0626ebe" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/StockholdersEquityDetails" xlink:type="simple" xlink:href="smmt-20211231.xsd#StockholdersEquityDetails"/>
  <link:definitionLink xlink:role="http://www.summitplc.com/role/StockholdersEquityDetails" xlink:type="extended" id="i43b23073a0b3482fa932eb549420f7ee_StockholdersEquityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_b2bb58a8-9617-4479-b7b2-b00ea425c944" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_ea5aabe2-4b2a-480f-94d7-441c1fa419c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_b2bb58a8-9617-4479-b7b2-b00ea425c944" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_ea5aabe2-4b2a-480f-94d7-441c1fa419c6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_898e5e61-0fb6-4922-8d40-52aefb9a8073" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_b2bb58a8-9617-4479-b7b2-b00ea425c944" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_898e5e61-0fb6-4922-8d40-52aefb9a8073" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_1470542f-1e1d-45d3-a060-487408ed2017" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_b2bb58a8-9617-4479-b7b2-b00ea425c944" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_1470542f-1e1d-45d3-a060-487408ed2017" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_4664c100-3b0e-424c-9d4e-9b3684266ae2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_b2bb58a8-9617-4479-b7b2-b00ea425c944" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_4664c100-3b0e-424c-9d4e-9b3684266ae2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_60ef6ab6-2c9b-4f55-9c05-7c7cb3bf3f08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_b2bb58a8-9617-4479-b7b2-b00ea425c944" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_60ef6ab6-2c9b-4f55-9c05-7c7cb3bf3f08" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_cb7ce135-9c15-4b26-9f9d-d3663f054acf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_b2bb58a8-9617-4479-b7b2-b00ea425c944" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_cb7ce135-9c15-4b26-9f9d-d3663f054acf" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_18006427-34e2-453d-820c-a9217897078b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_b2bb58a8-9617-4479-b7b2-b00ea425c944" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_18006427-34e2-453d-820c-a9217897078b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_7c8a6823-2ded-4f0a-8e1e-9ca6428768e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_b2bb58a8-9617-4479-b7b2-b00ea425c944" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_7c8a6823-2ded-4f0a-8e1e-9ca6428768e3" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_90bbbf76-b0bd-4192-975d-6a34686d33b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_b2bb58a8-9617-4479-b7b2-b00ea425c944" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_90bbbf76-b0bd-4192-975d-6a34686d33b0" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_ClassOfWarrantOrRightMinimumTenDayVolumeWeightedAverageCommonStockPriceToWarrantExercisePricePremiumPercentage_52ec798e-f4c3-4e6e-8cb1-93f62dc70ff9" xlink:href="smmt-20211231.xsd#smmt_ClassOfWarrantOrRightMinimumTenDayVolumeWeightedAverageCommonStockPriceToWarrantExercisePricePremiumPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_b2bb58a8-9617-4479-b7b2-b00ea425c944" xlink:to="loc_smmt_ClassOfWarrantOrRightMinimumTenDayVolumeWeightedAverageCommonStockPriceToWarrantExercisePricePremiumPercentage_52ec798e-f4c3-4e6e-8cb1-93f62dc70ff9" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_ClassOfWarrantOrRightQuarterlyVestingPeriod_5cbf04ca-3b02-4b81-a14c-cfb27d668ace" xlink:href="smmt-20211231.xsd#smmt_ClassOfWarrantOrRightQuarterlyVestingPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_b2bb58a8-9617-4479-b7b2-b00ea425c944" xlink:to="loc_smmt_ClassOfWarrantOrRightQuarterlyVestingPeriod_5cbf04ca-3b02-4b81-a14c-cfb27d668ace" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_568d7ac9-4875-40c1-a622-f9276db8ac39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_b2bb58a8-9617-4479-b7b2-b00ea425c944" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_568d7ac9-4875-40c1-a622-f9276db8ac39" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_27960af4-ec56-43d0-b333-d60121d3aef1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_b2bb58a8-9617-4479-b7b2-b00ea425c944" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_27960af4-ec56-43d0-b333-d60121d3aef1" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_5880e2dd-266f-4fcb-82c1-c67b0643cab9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_b2bb58a8-9617-4479-b7b2-b00ea425c944" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_5880e2dd-266f-4fcb-82c1-c67b0643cab9" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_4d49cbff-e189-4c9e-8629-73de74d75757" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_b2bb58a8-9617-4479-b7b2-b00ea425c944" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_4d49cbff-e189-4c9e-8629-73de74d75757" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_e5d2d787-1932-414c-b5a9-b41b329429ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_4d49cbff-e189-4c9e-8629-73de74d75757" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_e5d2d787-1932-414c-b5a9-b41b329429ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e5d2d787-1932-414c-b5a9-b41b329429ca_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_e5d2d787-1932-414c-b5a9-b41b329429ca" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e5d2d787-1932-414c-b5a9-b41b329429ca_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b1a05735-7aa3-4647-8b01-c0884ec841a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_e5d2d787-1932-414c-b5a9-b41b329429ca" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b1a05735-7aa3-4647-8b01-c0884ec841a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_RightsOfferingMember_c5871940-15c1-49e8-bffe-d7b3dca1a24f" xlink:href="smmt-20211231.xsd#smmt_RightsOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b1a05735-7aa3-4647-8b01-c0884ec841a3" xlink:to="loc_smmt_RightsOfferingMember_c5871940-15c1-49e8-bffe-d7b3dca1a24f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_68e58b8e-fbe1-4e17-aee5-8b7d9832d0cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrivatePlacementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b1a05735-7aa3-4647-8b01-c0884ec841a3" xlink:to="loc_us-gaap_PrivatePlacementMember_68e58b8e-fbe1-4e17-aee5-8b7d9832d0cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_a5bcee8d-efdc-4655-ad40-af403e500214" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_4d49cbff-e189-4c9e-8629-73de74d75757" xlink:to="loc_us-gaap_AwardTypeAxis_a5bcee8d-efdc-4655-ad40-af403e500214" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a5bcee8d-efdc-4655-ad40-af403e500214_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_a5bcee8d-efdc-4655-ad40-af403e500214" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a5bcee8d-efdc-4655-ad40-af403e500214_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_be45cdb5-7bae-46b8-b868-b3964a3e2031" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_a5bcee8d-efdc-4655-ad40-af403e500214" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_be45cdb5-7bae-46b8-b868-b3964a3e2031" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_28d8cea8-97f2-4404-8b27-a9bc547201d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_be45cdb5-7bae-46b8-b868-b3964a3e2031" xlink:to="loc_us-gaap_WarrantMember_28d8cea8-97f2-4404-8b27-a9bc547201d7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_4c07b657-c45c-474f-b920-9fe0c5345dff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_4d49cbff-e189-4c9e-8629-73de74d75757" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_4c07b657-c45c-474f-b920-9fe0c5345dff" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_4c07b657-c45c-474f-b920-9fe0c5345dff_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_4c07b657-c45c-474f-b920-9fe0c5345dff" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_4c07b657-c45c-474f-b920-9fe0c5345dff_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_bf0fb0c2-5987-4de6-aecd-b80835fa6517" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_4c07b657-c45c-474f-b920-9fe0c5345dff" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_bf0fb0c2-5987-4de6-aecd-b80835fa6517" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_ConsultingAgreementMember_350af51e-a81e-4515-bb5e-aa6d82f9905a" xlink:href="smmt-20211231.xsd#smmt_ConsultingAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_bf0fb0c2-5987-4de6-aecd-b80835fa6517" xlink:to="loc_smmt_ConsultingAgreementMember_350af51e-a81e-4515-bb5e-aa6d82f9905a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1693a73c-052b-4259-a227-ce4a25cbc975" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_4d49cbff-e189-4c9e-8629-73de74d75757" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1693a73c-052b-4259-a227-ce4a25cbc975" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_1693a73c-052b-4259-a227-ce4a25cbc975_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1693a73c-052b-4259-a227-ce4a25cbc975" xlink:to="loc_us-gaap_RelatedPartyDomain_1693a73c-052b-4259-a227-ce4a25cbc975_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_18597935-c809-4896-a00e-400445ca7efa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1693a73c-052b-4259-a227-ce4a25cbc975" xlink:to="loc_us-gaap_RelatedPartyDomain_18597935-c809-4896-a00e-400445ca7efa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_cc925dcd-6301-4804-8101-764effb76416" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_AffiliatedEntityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_18597935-c809-4896-a00e-400445ca7efa" xlink:to="loc_srt_AffiliatedEntityMember_cc925dcd-6301-4804-8101-764effb76416" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/StockBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="smmt-20211231.xsd#StockBasedCompensationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.summitplc.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended" id="id78cc2781bf943849aeb634d7ebf5d53_StockBasedCompensationNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_07e961e3-7bc8-4c3b-8c87-c335bea5c7b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_e680ded0-9c77-4c33-8f6b-850dadeffaca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_07e961e3-7bc8-4c3b-8c87-c335bea5c7b4" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_e680ded0-9c77-4c33-8f6b-850dadeffaca" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_CommonStockAndRestrictedStockUnitsAdditionalCapitalSharesAllowableForForFutureIssuance_180d57ce-138c-49fa-b07f-1dbb3805f245" xlink:href="smmt-20211231.xsd#smmt_CommonStockAndRestrictedStockUnitsAdditionalCapitalSharesAllowableForForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_07e961e3-7bc8-4c3b-8c87-c335bea5c7b4" xlink:to="loc_smmt_CommonStockAndRestrictedStockUnitsAdditionalCapitalSharesAllowableForForFutureIssuance_180d57ce-138c-49fa-b07f-1dbb3805f245" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan_2a1d6189-99bd-4e6f-8b22-dea14221b290" xlink:href="smmt-20211231.xsd#smmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_07e961e3-7bc8-4c3b-8c87-c335bea5c7b4" xlink:to="loc_smmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan_2a1d6189-99bd-4e6f-8b22-dea14221b290" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_1056e672-ecc6-4103-892b-8fe0d44ee5d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_07e961e3-7bc8-4c3b-8c87-c335bea5c7b4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_1056e672-ecc6-4103-892b-8fe0d44ee5d1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_0981a89d-dcc2-494a-b8d0-79ee087b1888" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_07e961e3-7bc8-4c3b-8c87-c335bea5c7b4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_0981a89d-dcc2-494a-b8d0-79ee087b1888" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_562b93a7-fd65-4023-a058-7059aec418a0" xlink:href="smmt-20211231.xsd#smmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_07e961e3-7bc8-4c3b-8c87-c335bea5c7b4" xlink:to="loc_smmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_562b93a7-fd65-4023-a058-7059aec418a0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveOfferingPeriod_b587ec1f-b8e5-4cd0-9263-c8762eeb882f" xlink:href="smmt-20211231.xsd#smmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveOfferingPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_07e961e3-7bc8-4c3b-8c87-c335bea5c7b4" xlink:to="loc_smmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveOfferingPeriod_b587ec1f-b8e5-4cd0-9263-c8762eeb882f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_51c0d190-8861-4163-97eb-3cb48026b9d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_07e961e3-7bc8-4c3b-8c87-c335bea5c7b4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_51c0d190-8861-4163-97eb-3cb48026b9d4" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_3b1bf665-e134-459c-872e-877ef4fbf589" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_07e961e3-7bc8-4c3b-8c87-c335bea5c7b4" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_3b1bf665-e134-459c-872e-877ef4fbf589" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_2efabdcd-3f7f-4f79-97d6-91b8ac96cf4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_07e961e3-7bc8-4c3b-8c87-c335bea5c7b4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_2efabdcd-3f7f-4f79-97d6-91b8ac96cf4f" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_c4f8a202-4f25-4b6c-97fc-a02cf8def629" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_07e961e3-7bc8-4c3b-8c87-c335bea5c7b4" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_c4f8a202-4f25-4b6c-97fc-a02cf8def629" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_9ccb2c1b-687e-42b4-9113-7e129d09cb72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_07e961e3-7bc8-4c3b-8c87-c335bea5c7b4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_9ccb2c1b-687e-42b4-9113-7e129d09cb72" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_1e4fa8e6-5c14-4abd-9551-2048ca6c3dcf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_07e961e3-7bc8-4c3b-8c87-c335bea5c7b4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_1e4fa8e6-5c14-4abd-9551-2048ca6c3dcf" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_1637090f-88ac-4d6e-9a01-b02e96f88157" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_07e961e3-7bc8-4c3b-8c87-c335bea5c7b4" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_1637090f-88ac-4d6e-9a01-b02e96f88157" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_8b431b62-9294-4d97-b70f-e5ee509f8327" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_07e961e3-7bc8-4c3b-8c87-c335bea5c7b4" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_8b431b62-9294-4d97-b70f-e5ee509f8327" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_0d602b75-8273-45d9-8fc9-1582a415c2d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_07e961e3-7bc8-4c3b-8c87-c335bea5c7b4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_0d602b75-8273-45d9-8fc9-1582a415c2d6" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected_95ad83f2-f590-4cf9-bc50-5b8309e1c368" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_07e961e3-7bc8-4c3b-8c87-c335bea5c7b4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected_95ad83f2-f590-4cf9-bc50-5b8309e1c368" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_6f61506b-a54f-4ec8-b456-b1e3732411d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_07e961e3-7bc8-4c3b-8c87-c335bea5c7b4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_6f61506b-a54f-4ec8-b456-b1e3732411d3" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_c4d24b02-ece2-46f5-9f4f-a78b4d3837d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_07e961e3-7bc8-4c3b-8c87-c335bea5c7b4" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_c4d24b02-ece2-46f5-9f4f-a78b4d3837d1" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_3b88ef33-a05c-46f2-85ad-5bcd4f35bc31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_07e961e3-7bc8-4c3b-8c87-c335bea5c7b4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_3b88ef33-a05c-46f2-85ad-5bcd4f35bc31" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_f4935bfc-380b-424c-90db-04e5fd7038a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_07e961e3-7bc8-4c3b-8c87-c335bea5c7b4" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_f4935bfc-380b-424c-90db-04e5fd7038a6" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedOutstandingNumber_cbf67ed7-0845-4631-a3c1-27072d1721c4" xlink:href="smmt-20211231.xsd#smmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_07e961e3-7bc8-4c3b-8c87-c335bea5c7b4" xlink:to="loc_smmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedOutstandingNumber_cbf67ed7-0845-4631-a3c1-27072d1721c4" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_ed881739-9384-410c-a14f-8766c3820eb4" xlink:href="smmt-20211231.xsd#smmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_07e961e3-7bc8-4c3b-8c87-c335bea5c7b4" xlink:to="loc_smmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_ed881739-9384-410c-a14f-8766c3820eb4" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_197f009a-63f7-4da0-90ff-d55ef5a70e66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_07e961e3-7bc8-4c3b-8c87-c335bea5c7b4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_197f009a-63f7-4da0-90ff-d55ef5a70e66" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_a0c1885e-b33a-4194-b521-ddd10a883265" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_07e961e3-7bc8-4c3b-8c87-c335bea5c7b4" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_a0c1885e-b33a-4194-b521-ddd10a883265" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ca3c0340-04d6-4801-a239-59df9f7bb607" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_07e961e3-7bc8-4c3b-8c87-c335bea5c7b4" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ca3c0340-04d6-4801-a239-59df9f7bb607" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_37de71cc-6e0a-487b-8f48-9a823e2c2f5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ca3c0340-04d6-4801-a239-59df9f7bb607" xlink:to="loc_us-gaap_PlanNameAxis_37de71cc-6e0a-487b-8f48-9a823e2c2f5a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_37de71cc-6e0a-487b-8f48-9a823e2c2f5a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_37de71cc-6e0a-487b-8f48-9a823e2c2f5a" xlink:to="loc_us-gaap_PlanNameDomain_37de71cc-6e0a-487b-8f48-9a823e2c2f5a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_369b5b9f-06ae-442d-ad6e-4d8d3ed3d515" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_37de71cc-6e0a-487b-8f48-9a823e2c2f5a" xlink:to="loc_us-gaap_PlanNameDomain_369b5b9f-06ae-442d-ad6e-4d8d3ed3d515" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_A2020StockIncentivePlanMember_2fe6745a-79f5-4144-944e-3efc4d785ae7" xlink:href="smmt-20211231.xsd#smmt_A2020StockIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_369b5b9f-06ae-442d-ad6e-4d8d3ed3d515" xlink:to="loc_smmt_A2020StockIncentivePlanMember_2fe6745a-79f5-4144-944e-3efc4d785ae7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_97fcd349-c593-43fe-8ff5-dc5c896c73b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ca3c0340-04d6-4801-a239-59df9f7bb607" xlink:to="loc_us-gaap_AwardTypeAxis_97fcd349-c593-43fe-8ff5-dc5c896c73b4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_97fcd349-c593-43fe-8ff5-dc5c896c73b4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_97fcd349-c593-43fe-8ff5-dc5c896c73b4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_97fcd349-c593-43fe-8ff5-dc5c896c73b4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_06744694-f37f-47f5-b491-f0bc09b9386f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_97fcd349-c593-43fe-8ff5-dc5c896c73b4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_06744694-f37f-47f5-b491-f0bc09b9386f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_166a675c-19dc-4260-906c-7740bdf02dde" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_06744694-f37f-47f5-b491-f0bc09b9386f" xlink:to="loc_us-gaap_EmployeeStockMember_166a675c-19dc-4260-906c-7740bdf02dde" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_fd65d798-b8c3-474e-a4f9-2285356d3bc5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_06744694-f37f-47f5-b491-f0bc09b9386f" xlink:to="loc_us-gaap_EmployeeStockOptionMember_fd65d798-b8c3-474e-a4f9-2285356d3bc5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_6b3bc862-d13f-4fc2-b7ef-1208f32eb6f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_06744694-f37f-47f5-b491-f0bc09b9386f" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_6b3bc862-d13f-4fc2-b7ef-1208f32eb6f2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_07c06326-8de2-4458-8e7c-2c6e75ee59a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_06744694-f37f-47f5-b491-f0bc09b9386f" xlink:to="loc_us-gaap_WarrantMember_07c06326-8de2-4458-8e7c-2c6e75ee59a7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_07e5a718-232a-4279-aa25-ba246898aa11" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ca3c0340-04d6-4801-a239-59df9f7bb607" xlink:to="loc_srt_RangeAxis_07e5a718-232a-4279-aa25-ba246898aa11" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_07e5a718-232a-4279-aa25-ba246898aa11_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_07e5a718-232a-4279-aa25-ba246898aa11" xlink:to="loc_srt_RangeMember_07e5a718-232a-4279-aa25-ba246898aa11_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_89c98fbe-88d9-4389-9193-117b8346a3de" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_07e5a718-232a-4279-aa25-ba246898aa11" xlink:to="loc_srt_RangeMember_89c98fbe-88d9-4389-9193-117b8346a3de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_bf32466f-b683-4829-9f17-42a244c2b406" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_89c98fbe-88d9-4389-9193-117b8346a3de" xlink:to="loc_srt_MinimumMember_bf32466f-b683-4829-9f17-42a244c2b406" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_9e0a093c-21e4-4f26-9dd1-9a9b32b201ef" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_89c98fbe-88d9-4389-9193-117b8346a3de" xlink:to="loc_srt_MaximumMember_9e0a093c-21e4-4f26-9dd1-9a9b32b201ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_ab45da86-99ed-48f8-86c9-eb87cdb2af6e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ca3c0340-04d6-4801-a239-59df9f7bb607" xlink:to="loc_srt_StatementScenarioAxis_ab45da86-99ed-48f8-86c9-eb87cdb2af6e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_ab45da86-99ed-48f8-86c9-eb87cdb2af6e_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_ab45da86-99ed-48f8-86c9-eb87cdb2af6e" xlink:to="loc_srt_ScenarioUnspecifiedDomain_ab45da86-99ed-48f8-86c9-eb87cdb2af6e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_75e9d088-4b55-405d-84df-365d3f98b4b2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_ab45da86-99ed-48f8-86c9-eb87cdb2af6e" xlink:to="loc_srt_ScenarioUnspecifiedDomain_75e9d088-4b55-405d-84df-365d3f98b4b2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_17c6fbc6-5f23-4f24-ae78-590c18a88325" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_75e9d088-4b55-405d-84df-365d3f98b4b2" xlink:to="loc_srt_ScenarioForecastMember_17c6fbc6-5f23-4f24-ae78-590c18a88325" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_5dd094d1-14ac-4737-936b-8db3db51fcf0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ca3c0340-04d6-4801-a239-59df9f7bb607" xlink:to="loc_srt_TitleOfIndividualAxis_5dd094d1-14ac-4737-936b-8db3db51fcf0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_5dd094d1-14ac-4737-936b-8db3db51fcf0_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_5dd094d1-14ac-4737-936b-8db3db51fcf0" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_5dd094d1-14ac-4737-936b-8db3db51fcf0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_51e6da6d-efc2-40a3-b75a-9d93ca9a56ff" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_5dd094d1-14ac-4737-936b-8db3db51fcf0" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_51e6da6d-efc2-40a3-b75a-9d93ca9a56ff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_ConsultantsMember_d8f2b192-1163-4b13-8db2-962296f6f527" xlink:href="smmt-20211231.xsd#smmt_ConsultantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_51e6da6d-efc2-40a3-b75a-9d93ca9a56ff" xlink:to="loc_smmt_ConsultantsMember_d8f2b192-1163-4b13-8db2-962296f6f527" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestorMember_58860790-d15e-43ec-88c3-e7855a783e19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_51e6da6d-efc2-40a3-b75a-9d93ca9a56ff" xlink:to="loc_us-gaap_InvestorMember_58860790-d15e-43ec-88c3-e7855a783e19" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/StockBasedCompensationWeightedaverageassumptionsusedforstockoptionawardsDetails" xlink:type="simple" xlink:href="smmt-20211231.xsd#StockBasedCompensationWeightedaverageassumptionsusedforstockoptionawardsDetails"/>
  <link:definitionLink xlink:role="http://www.summitplc.com/role/StockBasedCompensationWeightedaverageassumptionsusedforstockoptionawardsDetails" xlink:type="extended" id="i69185d05c3a14d96a6b8e22d8d7b0260_StockBasedCompensationWeightedaverageassumptionsusedforstockoptionawardsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b4fae576-0f1b-4230-9c33-f2c05a55f86d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_bc4b1625-bca1-433f-8301-a2b7315394ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b4fae576-0f1b-4230-9c33-f2c05a55f86d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_bc4b1625-bca1-433f-8301-a2b7315394ca" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_31d28dfd-6f5b-41bb-ab54-4df21e729528" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b4fae576-0f1b-4230-9c33-f2c05a55f86d" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_31d28dfd-6f5b-41bb-ab54-4df21e729528" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_e7b2b3da-7c3c-44ac-946f-a32c00d91675" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b4fae576-0f1b-4230-9c33-f2c05a55f86d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_e7b2b3da-7c3c-44ac-946f-a32c00d91675" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_8d1028ff-c6f5-45a5-afe9-cd8f072a1aa0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b4fae576-0f1b-4230-9c33-f2c05a55f86d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_8d1028ff-c6f5-45a5-afe9-cd8f072a1aa0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1effb91d-36c7-4867-b16f-990d640ff219" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b4fae576-0f1b-4230-9c33-f2c05a55f86d" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1effb91d-36c7-4867-b16f-990d640ff219" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_620138ca-ba51-4d22-b2a9-b877c547b370" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1effb91d-36c7-4867-b16f-990d640ff219" xlink:to="loc_us-gaap_AwardTypeAxis_620138ca-ba51-4d22-b2a9-b877c547b370" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_620138ca-ba51-4d22-b2a9-b877c547b370_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_620138ca-ba51-4d22-b2a9-b877c547b370" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_620138ca-ba51-4d22-b2a9-b877c547b370_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e4ec2a98-d3f7-4f9e-9cab-a680b56d1201" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_620138ca-ba51-4d22-b2a9-b877c547b370" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e4ec2a98-d3f7-4f9e-9cab-a680b56d1201" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_01bf89d8-e22d-49d7-8e3d-64be64a964fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e4ec2a98-d3f7-4f9e-9cab-a680b56d1201" xlink:to="loc_us-gaap_EmployeeStockOptionMember_01bf89d8-e22d-49d7-8e3d-64be64a964fa" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/StockBasedCompensationRSUactivityDetails" xlink:type="simple" xlink:href="smmt-20211231.xsd#StockBasedCompensationRSUactivityDetails"/>
  <link:definitionLink xlink:role="http://www.summitplc.com/role/StockBasedCompensationRSUactivityDetails" xlink:type="extended" id="i61b29b7c5fd44c8da4e021b47f50d6be_StockBasedCompensationRSUactivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c378b180-282e-4341-b37e-34332d62f3c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b21fa1c9-2039-435e-88fd-bc54efa65fba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c378b180-282e-4341-b37e-34332d62f3c1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b21fa1c9-2039-435e-88fd-bc54efa65fba" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_611b2226-6b1b-4386-b0a0-ed5079e28bb8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b21fa1c9-2039-435e-88fd-bc54efa65fba" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_611b2226-6b1b-4386-b0a0-ed5079e28bb8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_024ede9b-ba46-454c-b807-95940cbe7f3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b21fa1c9-2039-435e-88fd-bc54efa65fba" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_024ede9b-ba46-454c-b807-95940cbe7f3d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3010ebc1-935b-499a-9eff-4907caf7db43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_adf6f765-cd61-461f-8d8e-5213e11e17b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c378b180-282e-4341-b37e-34332d62f3c1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_adf6f765-cd61-461f-8d8e-5213e11e17b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6d0038ab-d3e4-41ad-8078-704f1c6e2c61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_adf6f765-cd61-461f-8d8e-5213e11e17b4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6d0038ab-d3e4-41ad-8078-704f1c6e2c61" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_14de5ea8-e65c-4099-af01-92515b74bb0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_adf6f765-cd61-461f-8d8e-5213e11e17b4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_14de5ea8-e65c-4099-af01-92515b74bb0e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_bf860d17-1e49-421c-9c15-fd0059dc4dbb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_550701a7-2f96-4319-910a-327ed1bbddd4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c378b180-282e-4341-b37e-34332d62f3c1" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_550701a7-2f96-4319-910a-327ed1bbddd4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_7261d68b-c545-41a1-a03f-3c42a1876a4c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_550701a7-2f96-4319-910a-327ed1bbddd4" xlink:to="loc_us-gaap_AwardTypeAxis_7261d68b-c545-41a1-a03f-3c42a1876a4c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7261d68b-c545-41a1-a03f-3c42a1876a4c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_7261d68b-c545-41a1-a03f-3c42a1876a4c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7261d68b-c545-41a1-a03f-3c42a1876a4c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_41f0a547-68fb-4383-9e94-72238d8110ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_7261d68b-c545-41a1-a03f-3c42a1876a4c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_41f0a547-68fb-4383-9e94-72238d8110ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_ee54d227-035c-4dfb-8f92-4a091ca0640c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_41f0a547-68fb-4383-9e94-72238d8110ae" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_ee54d227-035c-4dfb-8f92-4a091ca0640c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/StockBasedCompensationSummaryofstockbasedcompensationexpenseDetails" xlink:type="simple" xlink:href="smmt-20211231.xsd#StockBasedCompensationSummaryofstockbasedcompensationexpenseDetails"/>
  <link:definitionLink xlink:role="http://www.summitplc.com/role/StockBasedCompensationSummaryofstockbasedcompensationexpenseDetails" xlink:type="extended" id="i619cde114eea4354ac32a393fbd13f03_StockBasedCompensationSummaryofstockbasedcompensationexpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_8902b500-5bc5-4e98-8860-09e7a7f90b80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_18ae6917-777e-4202-9927-81e38b01794e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_8902b500-5bc5-4e98-8860-09e7a7f90b80" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_18ae6917-777e-4202-9927-81e38b01794e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_9c5d14f1-b803-430e-9d4c-69bb48fc9994" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_8902b500-5bc5-4e98-8860-09e7a7f90b80" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_9c5d14f1-b803-430e-9d4c-69bb48fc9994" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_42766e23-601d-46a9-a5db-cae9e823e6e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_9c5d14f1-b803-430e-9d4c-69bb48fc9994" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_42766e23-601d-46a9-a5db-cae9e823e6e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_42766e23-601d-46a9-a5db-cae9e823e6e3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_42766e23-601d-46a9-a5db-cae9e823e6e3" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_42766e23-601d-46a9-a5db-cae9e823e6e3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_a15588cd-7d86-4ab1-8ad9-2ee49915aab5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_42766e23-601d-46a9-a5db-cae9e823e6e3" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_a15588cd-7d86-4ab1-8ad9-2ee49915aab5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_d296e750-0100-4bfc-858b-9c0931ba6d98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_a15588cd-7d86-4ab1-8ad9-2ee49915aab5" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_d296e750-0100-4bfc-858b-9c0931ba6d98" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_64e6354c-2146-4b0b-ae06-3a4876260287" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_a15588cd-7d86-4ab1-8ad9-2ee49915aab5" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_64e6354c-2146-4b0b-ae06-3a4876260287" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/RelatedPartyTransactionsDetails" xlink:type="simple" xlink:href="smmt-20211231.xsd#RelatedPartyTransactionsDetails"/>
  <link:definitionLink xlink:role="http://www.summitplc.com/role/RelatedPartyTransactionsDetails" xlink:type="extended" id="ie0f67cbcf9d7434ebf6abf94da36c338_RelatedPartyTransactionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_17361ca9-a9ae-4e49-b603-f7e6f6f338e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_c2d9743c-ba29-420a-9b0b-23fb24782101" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_17361ca9-a9ae-4e49-b603-f7e6f6f338e4" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_c2d9743c-ba29-420a-9b0b-23fb24782101" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_a3385a4a-667a-44cf-9e63-6dbf6634ad9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_17361ca9-a9ae-4e49-b603-f7e6f6f338e4" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_a3385a4a-667a-44cf-9e63-6dbf6634ad9e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_87c94785-3d07-40b4-abd8-a3f266c3a8d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_17361ca9-a9ae-4e49-b603-f7e6f6f338e4" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_87c94785-3d07-40b4-abd8-a3f266c3a8d3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesSubscribedButUnissued_070cdc13-ac33-496b-b501-12f4dea72e48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesSubscribedButUnissued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_17361ca9-a9ae-4e49-b603-f7e6f6f338e4" xlink:to="loc_us-gaap_CommonStockSharesSubscribedButUnissued_070cdc13-ac33-496b-b501-12f4dea72e48" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_9416264c-1316-438b-ba2c-28cee48d64fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_17361ca9-a9ae-4e49-b603-f7e6f6f338e4" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_9416264c-1316-438b-ba2c-28cee48d64fe" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_54748d10-55ee-4fa9-b906-4ceed216ea26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_17361ca9-a9ae-4e49-b603-f7e6f6f338e4" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_54748d10-55ee-4fa9-b906-4ceed216ea26" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_RelatedPartyTransactionMonthlyExpensesFromTransactionsWithRelatedParty_188d81ab-a320-4ab7-80a9-0003d3ac0dec" xlink:href="smmt-20211231.xsd#smmt_RelatedPartyTransactionMonthlyExpensesFromTransactionsWithRelatedParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_17361ca9-a9ae-4e49-b603-f7e6f6f338e4" xlink:to="loc_smmt_RelatedPartyTransactionMonthlyExpensesFromTransactionsWithRelatedParty_188d81ab-a320-4ab7-80a9-0003d3ac0dec" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_ClassOfWarrantOrRightQuarterlyVestingPeriod_d7a3e900-3b67-4933-928c-66e5cb3554ee" xlink:href="smmt-20211231.xsd#smmt_ClassOfWarrantOrRightQuarterlyVestingPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_17361ca9-a9ae-4e49-b603-f7e6f6f338e4" xlink:to="loc_smmt_ClassOfWarrantOrRightQuarterlyVestingPeriod_d7a3e900-3b67-4933-928c-66e5cb3554ee" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_bf2644b6-b596-41fb-8c8f-463b1de99681" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_17361ca9-a9ae-4e49-b603-f7e6f6f338e4" xlink:to="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_bf2644b6-b596-41fb-8c8f-463b1de99681" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_ClassOfWarrantOrRightVested_98b05499-e57b-442f-9f37-57ef2a693f17" xlink:href="smmt-20211231.xsd#smmt_ClassOfWarrantOrRightVested"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_17361ca9-a9ae-4e49-b603-f7e6f6f338e4" xlink:to="loc_smmt_ClassOfWarrantOrRightVested_98b05499-e57b-442f-9f37-57ef2a693f17" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRelatedPartyDebt_3e5fb594-1906-4ca0-b7c8-ba7b5a2898b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromRelatedPartyDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_17361ca9-a9ae-4e49-b603-f7e6f6f338e4" xlink:to="loc_us-gaap_ProceedsFromRelatedPartyDebt_3e5fb594-1906-4ca0-b7c8-ba7b5a2898b9" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent_f9bbf4a5-cbb0-45de-896e-75c04d0e1cee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_17361ca9-a9ae-4e49-b603-f7e6f6f338e4" xlink:to="loc_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent_f9bbf4a5-cbb0-45de-896e-75c04d0e1cee" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_RelatedPartyTransactionRateBasisSpreadOnVariableRate_106374fb-bc62-44d6-bcee-6df3f37ca736" xlink:href="smmt-20211231.xsd#smmt_RelatedPartyTransactionRateBasisSpreadOnVariableRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_17361ca9-a9ae-4e49-b603-f7e6f6f338e4" xlink:to="loc_smmt_RelatedPartyTransactionRateBasisSpreadOnVariableRate_106374fb-bc62-44d6-bcee-6df3f37ca736" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_RelatedPartyTransactionExpectedRate_005df35b-358e-485f-9081-a7634834c718" xlink:href="smmt-20211231.xsd#smmt_RelatedPartyTransactionExpectedRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_17361ca9-a9ae-4e49-b603-f7e6f6f338e4" xlink:to="loc_smmt_RelatedPartyTransactionExpectedRate_005df35b-358e-485f-9081-a7634834c718" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_NotesPayableRelatedPartiesMaturityTriggeringEventPublicOfferingProceedsThreshold_75e26553-19e8-47cf-8cf3-907b18f1a3ec" xlink:href="smmt-20211231.xsd#smmt_NotesPayableRelatedPartiesMaturityTriggeringEventPublicOfferingProceedsThreshold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_17361ca9-a9ae-4e49-b603-f7e6f6f338e4" xlink:to="loc_smmt_NotesPayableRelatedPartiesMaturityTriggeringEventPublicOfferingProceedsThreshold_75e26553-19e8-47cf-8cf3-907b18f1a3ec" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_NotesPayableRelatedPartiesMaximumTerm_cf98edd8-6200-44e8-a647-a13998ce46d4" xlink:href="smmt-20211231.xsd#smmt_NotesPayableRelatedPartiesMaximumTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_17361ca9-a9ae-4e49-b603-f7e6f6f338e4" xlink:to="loc_smmt_NotesPayableRelatedPartiesMaximumTerm_cf98edd8-6200-44e8-a647-a13998ce46d4" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_AdjustmentsToAdditionalPaidInCapitalImputedInterestExpenseRelatedParty_eb84b7bd-a2a0-48ef-be06-670e003a0ee8" xlink:href="smmt-20211231.xsd#smmt_AdjustmentsToAdditionalPaidInCapitalImputedInterestExpenseRelatedParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_17361ca9-a9ae-4e49-b603-f7e6f6f338e4" xlink:to="loc_smmt_AdjustmentsToAdditionalPaidInCapitalImputedInterestExpenseRelatedParty_eb84b7bd-a2a0-48ef-be06-670e003a0ee8" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_AreaOfPremisesSubleased_4f70e848-3757-4bc3-8b6a-101bb45fcc4a" xlink:href="smmt-20211231.xsd#smmt_AreaOfPremisesSubleased"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_17361ca9-a9ae-4e49-b603-f7e6f6f338e4" xlink:to="loc_smmt_AreaOfPremisesSubleased_4f70e848-3757-4bc3-8b6a-101bb45fcc4a" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_RelatedPartyTransactionPaymentsToRelatedParty_333412a3-c06b-43bd-98d3-4678b8327654" xlink:href="smmt-20211231.xsd#smmt_RelatedPartyTransactionPaymentsToRelatedParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_17361ca9-a9ae-4e49-b603-f7e6f6f338e4" xlink:to="loc_smmt_RelatedPartyTransactionPaymentsToRelatedParty_333412a3-c06b-43bd-98d3-4678b8327654" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_732a1398-5ec3-4b9e-b0f4-ad98085ddf89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_17361ca9-a9ae-4e49-b603-f7e6f6f338e4" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_732a1398-5ec3-4b9e-b0f4-ad98085ddf89" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_34c3bfc5-a231-4f53-ac3a-8442cf736dd3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_732a1398-5ec3-4b9e-b0f4-ad98085ddf89" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_34c3bfc5-a231-4f53-ac3a-8442cf736dd3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_34c3bfc5-a231-4f53-ac3a-8442cf736dd3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_34c3bfc5-a231-4f53-ac3a-8442cf736dd3" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_34c3bfc5-a231-4f53-ac3a-8442cf736dd3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7903c1f4-6613-4df9-9b03-bfb297f55baa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_34c3bfc5-a231-4f53-ac3a-8442cf736dd3" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7903c1f4-6613-4df9-9b03-bfb297f55baa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_ca0983a0-b953-4537-af7e-22a94ac41472" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrivatePlacementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7903c1f4-6613-4df9-9b03-bfb297f55baa" xlink:to="loc_us-gaap_PrivatePlacementMember_ca0983a0-b953-4537-af7e-22a94ac41472" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_RightsOfferingMember_99954662-568d-46c3-9faa-501d88a4f408" xlink:href="smmt-20211231.xsd#smmt_RightsOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7903c1f4-6613-4df9-9b03-bfb297f55baa" xlink:to="loc_smmt_RightsOfferingMember_99954662-568d-46c3-9faa-501d88a4f408" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_01387f60-2a47-43aa-bf5f-658acf1f879c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_732a1398-5ec3-4b9e-b0f4-ad98085ddf89" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_01387f60-2a47-43aa-bf5f-658acf1f879c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_01387f60-2a47-43aa-bf5f-658acf1f879c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_01387f60-2a47-43aa-bf5f-658acf1f879c" xlink:to="loc_us-gaap_RelatedPartyDomain_01387f60-2a47-43aa-bf5f-658acf1f879c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_2b44be5b-6b20-40c3-8f6e-e0eb9a6797c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_01387f60-2a47-43aa-bf5f-658acf1f879c" xlink:to="loc_us-gaap_RelatedPartyDomain_2b44be5b-6b20-40c3-8f6e-e0eb9a6797c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ChiefExecutiveOfficerMember_a9785bb4-be56-4e58-95b5-20d2ae34a557" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ChiefExecutiveOfficerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_2b44be5b-6b20-40c3-8f6e-e0eb9a6797c6" xlink:to="loc_srt_ChiefExecutiveOfficerMember_a9785bb4-be56-4e58-95b5-20d2ae34a557" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_FormerChiefExecutiveOfficerMember_f4335f13-f3d1-4deb-b8ee-0f7653d01d61" xlink:href="smmt-20211231.xsd#smmt_FormerChiefExecutiveOfficerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_2b44be5b-6b20-40c3-8f6e-e0eb9a6797c6" xlink:to="loc_smmt_FormerChiefExecutiveOfficerMember_f4335f13-f3d1-4deb-b8ee-0f7653d01d61" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BeneficialOwnerMember_0706eccb-be81-460c-8104-9ac8ad61f0f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BeneficialOwnerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_2b44be5b-6b20-40c3-8f6e-e0eb9a6797c6" xlink:to="loc_us-gaap_BeneficialOwnerMember_0706eccb-be81-460c-8104-9ac8ad61f0f0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_102dd46b-7e23-4689-b702-f181c6947e85" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_AffiliatedEntityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_2b44be5b-6b20-40c3-8f6e-e0eb9a6797c6" xlink:to="loc_srt_AffiliatedEntityMember_102dd46b-7e23-4689-b702-f181c6947e85" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_c03e7ad7-123e-4f10-99e2-0b4a513decf4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_DirectorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_2b44be5b-6b20-40c3-8f6e-e0eb9a6797c6" xlink:to="loc_srt_DirectorMember_c03e7ad7-123e-4f10-99e2-0b4a513decf4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ChiefOperatingOfficerMember_bf799675-5ae7-42fd-9d67-5dbee62802f8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ChiefOperatingOfficerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_2b44be5b-6b20-40c3-8f6e-e0eb9a6797c6" xlink:to="loc_srt_ChiefOperatingOfficerMember_bf799675-5ae7-42fd-9d67-5dbee62802f8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_91aea077-772b-43b2-a042-a14a4de40b3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_732a1398-5ec3-4b9e-b0f4-ad98085ddf89" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_91aea077-772b-43b2-a042-a14a4de40b3d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_91aea077-772b-43b2-a042-a14a4de40b3d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_91aea077-772b-43b2-a042-a14a4de40b3d" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_91aea077-772b-43b2-a042-a14a4de40b3d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_e4c0ed1b-aa12-453b-801e-27b2f1e3de46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_91aea077-772b-43b2-a042-a14a4de40b3d" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_e4c0ed1b-aa12-453b-801e-27b2f1e3de46" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_ConsultingAgreementMember_a0aea3e9-1c7e-4377-8a74-319f90643782" xlink:href="smmt-20211231.xsd#smmt_ConsultingAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_e4c0ed1b-aa12-453b-801e-27b2f1e3de46" xlink:to="loc_smmt_ConsultingAgreementMember_a0aea3e9-1c7e-4377-8a74-319f90643782" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_ConsultingAgreementConsultancyFeesMember_127e709c-c59f-480e-8fab-b0263727f6d3" xlink:href="smmt-20211231.xsd#smmt_ConsultingAgreementConsultancyFeesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_smmt_ConsultingAgreementMember_a0aea3e9-1c7e-4377-8a74-319f90643782" xlink:to="loc_smmt_ConsultingAgreementConsultancyFeesMember_127e709c-c59f-480e-8fab-b0263727f6d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_ConsultancyAgreementWarrantVestingExpenseMember_dd4ac51b-8a80-42f9-96f5-004e6285c1fa" xlink:href="smmt-20211231.xsd#smmt_ConsultancyAgreementWarrantVestingExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_smmt_ConsultingAgreementMember_a0aea3e9-1c7e-4377-8a74-319f90643782" xlink:to="loc_smmt_ConsultancyAgreementWarrantVestingExpenseMember_dd4ac51b-8a80-42f9-96f5-004e6285c1fa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_AssignmentAgreementMember_7c0fc460-be2c-45f2-a0c3-79d4e2d3d706" xlink:href="smmt-20211231.xsd#smmt_AssignmentAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_e4c0ed1b-aa12-453b-801e-27b2f1e3de46" xlink:to="loc_smmt_AssignmentAgreementMember_7c0fc460-be2c-45f2-a0c3-79d4e2d3d706" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_InitialPurchaseAgreementMember_1ca5737f-e287-49b8-9690-e878f76beee4" xlink:href="smmt-20211231.xsd#smmt_InitialPurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_e4c0ed1b-aa12-453b-801e-27b2f1e3de46" xlink:to="loc_smmt_InitialPurchaseAgreementMember_1ca5737f-e287-49b8-9690-e878f76beee4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_SecondPurchaseAgreementMember_ff77e39d-1341-4328-b3f7-75cdc0d9f1be" xlink:href="smmt-20211231.xsd#smmt_SecondPurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_e4c0ed1b-aa12-453b-801e-27b2f1e3de46" xlink:to="loc_smmt_SecondPurchaseAgreementMember_ff77e39d-1341-4328-b3f7-75cdc0d9f1be" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_32fe9279-04d0-4158-94af-5508af4f9138" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_732a1398-5ec3-4b9e-b0f4-ad98085ddf89" xlink:to="loc_us-gaap_VariableRateAxis_32fe9279-04d0-4158-94af-5508af4f9138" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_32fe9279-04d0-4158-94af-5508af4f9138_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_32fe9279-04d0-4158-94af-5508af4f9138" xlink:to="loc_us-gaap_VariableRateDomain_32fe9279-04d0-4158-94af-5508af4f9138_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_509bb3d3-d0e1-4df6-94e8-1d3ef232a2ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_32fe9279-04d0-4158-94af-5508af4f9138" xlink:to="loc_us-gaap_VariableRateDomain_509bb3d3-d0e1-4df6-94e8-1d3ef232a2ce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UsTreasuryUstInterestRateMember_7ecf80f3-c1f1-49bc-b3e6-2c67c30a3b3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UsTreasuryUstInterestRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_509bb3d3-d0e1-4df6-94e8-1d3ef232a2ce" xlink:to="loc_us-gaap_UsTreasuryUstInterestRateMember_7ecf80f3-c1f1-49bc-b3e6-2c67c30a3b3d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_02ad80a7-b2ab-4c46-96d1-ac96e2c1da86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_732a1398-5ec3-4b9e-b0f4-ad98085ddf89" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_02ad80a7-b2ab-4c46-96d1-ac96e2c1da86" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_02ad80a7-b2ab-4c46-96d1-ac96e2c1da86_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_02ad80a7-b2ab-4c46-96d1-ac96e2c1da86" xlink:to="loc_us-gaap_EquityComponentDomain_02ad80a7-b2ab-4c46-96d1-ac96e2c1da86_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_1d356b41-ca5d-455c-b535-75df74d2793c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_02ad80a7-b2ab-4c46-96d1-ac96e2c1da86" xlink:to="loc_us-gaap_EquityComponentDomain_1d356b41-ca5d-455c-b535-75df74d2793c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_7792200d-cfb9-47cc-ab9a-6af81c6a9a72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1d356b41-ca5d-455c-b535-75df74d2793c" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_7792200d-cfb9-47cc-ab9a-6af81c6a9a72" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/SubsequentEventDetails" xlink:type="simple" xlink:href="smmt-20211231.xsd#SubsequentEventDetails"/>
  <link:definitionLink xlink:role="http://www.summitplc.com/role/SubsequentEventDetails" xlink:type="extended" id="if07d7ae469ab405788dc65be488fd043_SubsequentEventDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_5019fb33-54b1-42c1-8589-c7ea7d128cd9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRelatedPartyDebt_72f4d9df-bdcb-448d-877d-36852ecb91d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromRelatedPartyDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_5019fb33-54b1-42c1-8589-c7ea7d128cd9" xlink:to="loc_us-gaap_ProceedsFromRelatedPartyDebt_72f4d9df-bdcb-448d-877d-36852ecb91d5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent_73b248c1-4a75-40aa-8c0f-241b7a92d9de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_5019fb33-54b1-42c1-8589-c7ea7d128cd9" xlink:to="loc_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent_73b248c1-4a75-40aa-8c0f-241b7a92d9de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionRate_9498739b-2ae6-4808-92db-7424b5ff61d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_5019fb33-54b1-42c1-8589-c7ea7d128cd9" xlink:to="loc_us-gaap_RelatedPartyTransactionRate_9498739b-2ae6-4808-92db-7424b5ff61d9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_NotesPayableRelatedPartiesMaturityTriggeringEventPublicOfferingProceedsThreshold_e0ba6657-b48b-4b02-a857-70d0cc4a0646" xlink:href="smmt-20211231.xsd#smmt_NotesPayableRelatedPartiesMaturityTriggeringEventPublicOfferingProceedsThreshold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_5019fb33-54b1-42c1-8589-c7ea7d128cd9" xlink:to="loc_smmt_NotesPayableRelatedPartiesMaturityTriggeringEventPublicOfferingProceedsThreshold_e0ba6657-b48b-4b02-a857-70d0cc4a0646" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_NotesPayableRelatedPartiesMaximumTerm_22d9d6ab-7a29-4352-a90a-bccb5838b298" xlink:href="smmt-20211231.xsd#smmt_NotesPayableRelatedPartiesMaximumTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_5019fb33-54b1-42c1-8589-c7ea7d128cd9" xlink:to="loc_smmt_NotesPayableRelatedPartiesMaximumTerm_22d9d6ab-7a29-4352-a90a-bccb5838b298" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_2a5b3dca-1257-4414-bac9-b484f16b1be2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_5019fb33-54b1-42c1-8589-c7ea7d128cd9" xlink:to="loc_us-gaap_SubsequentEventTable_2a5b3dca-1257-4414-bac9-b484f16b1be2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_f7dca983-70f2-4da4-8d2a-728ae933d919" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_2a5b3dca-1257-4414-bac9-b484f16b1be2" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_f7dca983-70f2-4da4-8d2a-728ae933d919" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_f7dca983-70f2-4da4-8d2a-728ae933d919_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_f7dca983-70f2-4da4-8d2a-728ae933d919" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_f7dca983-70f2-4da4-8d2a-728ae933d919_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_a6f146bb-4a2a-4500-86d5-7ec88e971fc3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_f7dca983-70f2-4da4-8d2a-728ae933d919" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_a6f146bb-4a2a-4500-86d5-7ec88e971fc3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_c9242a59-e2ec-47e1-840c-acd29e25d003" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_a6f146bb-4a2a-4500-86d5-7ec88e971fc3" xlink:to="loc_us-gaap_SubsequentEventMember_c9242a59-e2ec-47e1-840c-acd29e25d003" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_ff4bec4b-4c4a-416a-b97f-a87a60ab0cbd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_2a5b3dca-1257-4414-bac9-b484f16b1be2" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_ff4bec4b-4c4a-416a-b97f-a87a60ab0cbd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_ff4bec4b-4c4a-416a-b97f-a87a60ab0cbd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_ff4bec4b-4c4a-416a-b97f-a87a60ab0cbd" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_ff4bec4b-4c4a-416a-b97f-a87a60ab0cbd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_76f232a9-1cda-4f78-ba56-c7941367f73f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_ff4bec4b-4c4a-416a-b97f-a87a60ab0cbd" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_76f232a9-1cda-4f78-ba56-c7941367f73f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_A2022NoteMember_47c3b068-82d2-4b5b-8818-a619707cd8da" xlink:href="smmt-20211231.xsd#smmt_A2022NoteMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_76f232a9-1cda-4f78-ba56-c7941367f73f" xlink:to="loc_smmt_A2022NoteMember_47c3b068-82d2-4b5b-8818-a619707cd8da" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_31e15617-bf6b-4eaf-b849-882cd3e5b827" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_2a5b3dca-1257-4414-bac9-b484f16b1be2" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_31e15617-bf6b-4eaf-b849-882cd3e5b827" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_31e15617-bf6b-4eaf-b849-882cd3e5b827_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_31e15617-bf6b-4eaf-b849-882cd3e5b827" xlink:to="loc_us-gaap_RelatedPartyDomain_31e15617-bf6b-4eaf-b849-882cd3e5b827_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_f091a2cf-09ec-46ab-9ef1-1a2741897f08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_31e15617-bf6b-4eaf-b849-882cd3e5b827" xlink:to="loc_us-gaap_RelatedPartyDomain_f091a2cf-09ec-46ab-9ef1-1a2741897f08" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ChiefExecutiveOfficerMember_121942b6-fbbb-41f6-9b3a-562a0c3f02bf" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ChiefExecutiveOfficerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_f091a2cf-09ec-46ab-9ef1-1a2741897f08" xlink:to="loc_srt_ChiefExecutiveOfficerMember_121942b6-fbbb-41f6-9b3a-562a0c3f02bf" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>smmt-20211231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:48b41a33-da2b-4a8c-a794-72fce890713a,g:e36a0d9c-9c90-432d-82bf-4f94771c92ff-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_405f2fa8-a0d2-4c0a-91df-04355736b1ca_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Disclosure of Cash Flow Information</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_e2b2239a-1eb9-4767-9478-bb4b46168d44_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. federal income tax statutory rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_e6b33f99-48fc-4727-9d55-c52b6d292c6c_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_9ddc2bdc-d5a9-486d-b5cd-735b68c3f7e3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_d360b566-4cf2-45a9-9d1a-ee884bf3f96c_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State - United States</link:label>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_545ede85-a13c-425e-ae00-f540c1dd9ae2_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_5c2cb3e3-e276-48d7-af27-bb31865beb68_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_4900a37b-6206-40c0-a9e3-5383b88a7566_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_f4023dff-261a-4049-8bff-6c7d8df09482_negatedLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_e7182b24-21b5-43cc-a380-2463baec3f9a_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_7d5e3f2d-d29f-4416-b4b2-12fea5596637_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_00dede85-f7ed-4dca-8923-3bd7b71d597d_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss carryforward</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_29979723-8135-4e33-8580-dbf2fdf5195e_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_8648c59e-d7ab-4885-b4f7-286ccae2bac1_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_4a03ff75-443e-4766-b433-e68446ce44dc_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_195624b9-8fce-4b00-8a7f-b26f58651fc4_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_984a391f-26bf-4e02-8f7e-e5c4fbbc192d_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_MenloParkCaliforniaUSAndSawstonUKMember_e5cff316-3564-485b-827c-a7676a692672_terseLabel_en-US" xlink:label="lab_smmt_MenloParkCaliforniaUSAndSawstonUKMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Menlo Park, California, U.S. and Sawston, UK</link:label>
    <link:label id="lab_smmt_MenloParkCaliforniaUSAndSawstonUKMember_label_en-US" xlink:label="lab_smmt_MenloParkCaliforniaUSAndSawstonUKMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Menlo Park, California, US and Sawston, UK [Member]</link:label>
    <link:label id="lab_smmt_MenloParkCaliforniaUSAndSawstonUKMember_documentation_en-US" xlink:label="lab_smmt_MenloParkCaliforniaUSAndSawstonUKMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Menlo Park, California, US and Sawston, UK</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_MenloParkCaliforniaUSAndSawstonUKMember" xlink:href="smmt-20211231.xsd#smmt_MenloParkCaliforniaUSAndSawstonUKMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_MenloParkCaliforniaUSAndSawstonUKMember" xlink:to="lab_smmt_MenloParkCaliforniaUSAndSawstonUKMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_7f3c4d8c-1d85-486f-8639-9d8b4c146275_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of deferred revenue and other income</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:to="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_ea7c7077-d06d-4aa7-8291-bb15c605d824_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of intangible assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_63935fb6-d3b4-46b3-9b3d-20cd4c459cc9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_ce495280-3ff5-4ab1-9116-74cb5942a835_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining lease term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_85c1ccb9-9680-4d4c-b065-4cfd117a3c10_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Translation</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_69a7caa4-3f46-45ec-9355-1ad8fb4e9974_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_42d4360a-135c-4928-967d-2e84f9603454_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_RevenueFromContractWithCustomerDevelopmentCommercialAndSalesMilestoneCumulativeNetSalesTargetThreshold_40e4bd51-d3ab-4c04-a03f-a8a57a7fa7b2_terseLabel_en-US" xlink:label="lab_smmt_RevenueFromContractWithCustomerDevelopmentCommercialAndSalesMilestoneCumulativeNetSalesTargetThreshold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative net sales target threshold</link:label>
    <link:label id="lab_smmt_RevenueFromContractWithCustomerDevelopmentCommercialAndSalesMilestoneCumulativeNetSalesTargetThreshold_label_en-US" xlink:label="lab_smmt_RevenueFromContractWithCustomerDevelopmentCommercialAndSalesMilestoneCumulativeNetSalesTargetThreshold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Contract With Customer, Development, Commercial And Sales Milestone, Cumulative Net Sales Target Threshold</link:label>
    <link:label id="lab_smmt_RevenueFromContractWithCustomerDevelopmentCommercialAndSalesMilestoneCumulativeNetSalesTargetThreshold_documentation_en-US" xlink:label="lab_smmt_RevenueFromContractWithCustomerDevelopmentCommercialAndSalesMilestoneCumulativeNetSalesTargetThreshold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Contract With Customer, Development, Commercial And Sales Milestone, Cumulative Net Sales Target Threshold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_RevenueFromContractWithCustomerDevelopmentCommercialAndSalesMilestoneCumulativeNetSalesTargetThreshold" xlink:href="smmt-20211231.xsd#smmt_RevenueFromContractWithCustomerDevelopmentCommercialAndSalesMilestoneCumulativeNetSalesTargetThreshold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_RevenueFromContractWithCustomerDevelopmentCommercialAndSalesMilestoneCumulativeNetSalesTargetThreshold" xlink:to="lab_smmt_RevenueFromContractWithCustomerDevelopmentCommercialAndSalesMilestoneCumulativeNetSalesTargetThreshold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_abd541b2-62b1-4c0d-9df1-48e7e685c56c_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_2af8a548-75bf-433a-a24e-ceff4e956657_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected annual dividends per share</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_2b097fc6-9b1f-46c8-89c5-a2b035033a83_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares available for grant (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_ef431183-ef95-4e26-9833-6a93ad490720_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_28f67723-2937-4ded-915c-72e34a462382_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_e05d3a0f-c176-47c1-9d9b-df902199e64d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of other (expense) income</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Other Nonoperating Income (Expense) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_79858920-a227-4732-8106-1a9f8c2a129a_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_1aef1288-5231-4fea-be5d-85b63dc39ea5_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expenses from related party transactions</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Expenses from Transactions with Related Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:to="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_3ab130a6-9c9b-4df4-b65e-a524eff1f191_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible asset</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_fbf85f61-8186-4f3d-8c1e-deb9b6cf8c37_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value, options exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_96918402-f81c-4348-904f-b46f9f91111d_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_83bbddd7-de93-4ac0-87e9-ed0261237820_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_4c5ed0e5-4f42-4440-b861-6c74b1504adc_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_1855fedd-a800-45fd-9d8a-9f9fdcce58c4_verboseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization expense</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_15d2d1bd-a671-49c3-88f1-601b8873be76_terseLabel_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining useful life</link:label>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_label_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Finite-lived Intangible Assets, Weighted Average Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:to="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_AssignmentAgreementMember_6085dfb7-66aa-4795-b1de-917b6baf4d6b_terseLabel_en-US" xlink:label="lab_smmt_AssignmentAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assignment Agreement</link:label>
    <link:label id="lab_smmt_AssignmentAgreementMember_label_en-US" xlink:label="lab_smmt_AssignmentAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assignment Agreement [Member]</link:label>
    <link:label id="lab_smmt_AssignmentAgreementMember_documentation_en-US" xlink:label="lab_smmt_AssignmentAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assignment Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_AssignmentAgreementMember" xlink:href="smmt-20211231.xsd#smmt_AssignmentAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_AssignmentAgreementMember" xlink:to="lab_smmt_AssignmentAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableLeaseCost_6a1f549a-6f32-454d-a590-556c12768968_terseLabel_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable lease costs</link:label>
    <link:label id="lab_us-gaap_VariableLeaseCost_label_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableLeaseCost" xlink:to="lab_us-gaap_VariableLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_7e161c8b-89ba-4f0d-8509-d81c4ebe8b27_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax, net</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_80b7f037-9a9c-4195-8673-69be88206629_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average discount rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_766ce454-5525-4991-aeb6-bc52617fe088_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potentially dilutive securities excluded from the computation of diluted loss per share</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_297aab2d-6ffa-4dd3-b4e6-82115cb3c93b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of deferred revenue and other income recognized in the statement of operations</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_f9870eca-3570-4ece-a750-78928ac50714_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_eb94a9c4-65b4-48dd-8149-31409f84a492_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrivatePlacementMember_abc2c0a8-3769-45f1-b705-8cff9dc7fd26_terseLabel_en-US" xlink:label="lab_us-gaap_PrivatePlacementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Private placement</link:label>
    <link:label id="lab_us-gaap_PrivatePlacementMember_label_en-US" xlink:label="lab_us-gaap_PrivatePlacementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Private Placement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrivatePlacementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrivatePlacementMember" xlink:to="lab_us-gaap_PrivatePlacementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_fe26d88e-6a32-4408-8c8d-82629f1f4099_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reverse stock split ratio</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note, Stock Split, Conversion Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_12750566-47c1-4cc6-8c86-b992d6a725f2_terseLabel_en-US" xlink:label="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customer [Line Items]</link:label>
    <link:label id="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_label_en-US" xlink:label="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customer [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:to="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_ResearchAndDevelopmentTaxCreditReceivableCurrent_2a65bec8-88d1-4499-b284-3c5b0855bec3_terseLabel_en-US" xlink:label="lab_smmt_ResearchAndDevelopmentTaxCreditReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development tax credit receivable</link:label>
    <link:label id="lab_smmt_ResearchAndDevelopmentTaxCreditReceivableCurrent_2cdf00ef-8812-4ac9-995c-50788c27dc63_verboseLabel_en-US" xlink:label="lab_smmt_ResearchAndDevelopmentTaxCreditReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current research and development tax credit receivable</link:label>
    <link:label id="lab_smmt_ResearchAndDevelopmentTaxCreditReceivableCurrent_label_en-US" xlink:label="lab_smmt_ResearchAndDevelopmentTaxCreditReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Tax Credit Receivable, Current</link:label>
    <link:label id="lab_smmt_ResearchAndDevelopmentTaxCreditReceivableCurrent_documentation_en-US" xlink:label="lab_smmt_ResearchAndDevelopmentTaxCreditReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Tax Credit Receivable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_ResearchAndDevelopmentTaxCreditReceivableCurrent" xlink:href="smmt-20211231.xsd#smmt_ResearchAndDevelopmentTaxCreditReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_ResearchAndDevelopmentTaxCreditReceivableCurrent" xlink:to="lab_smmt_ResearchAndDevelopmentTaxCreditReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_08321238-0724-40a0-a4ff-e7cd41e97de5_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_label_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_96d00687-1ca6-4a3a-953c-7f00675d7099_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c63bc591-5bf8-4e6b-ae67-e98e113e5cc8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_294724c2-b62f-4f2a-a1a0-7fb58a616a7d_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_026cd234-1de2-4d3b-a230-ef22a867202c_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_55c40096-d5c2-4c40-a9dc-83edf80bef56_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock option activity, additional disclosures</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_FormerChiefExecutiveOfficerMember_9775b586-c539-4dbf-8b4a-0e4e8e20b088_terseLabel_en-US" xlink:label="lab_smmt_FormerChiefExecutiveOfficerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Former Chief Executive Officer</link:label>
    <link:label id="lab_smmt_FormerChiefExecutiveOfficerMember_label_en-US" xlink:label="lab_smmt_FormerChiefExecutiveOfficerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Former Chief Executive Officer [Member]</link:label>
    <link:label id="lab_smmt_FormerChiefExecutiveOfficerMember_documentation_en-US" xlink:label="lab_smmt_FormerChiefExecutiveOfficerMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Former Chief Executive Officer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_FormerChiefExecutiveOfficerMember" xlink:href="smmt-20211231.xsd#smmt_FormerChiefExecutiveOfficerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_FormerChiefExecutiveOfficerMember" xlink:to="lab_smmt_FormerChiefExecutiveOfficerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_bc7ba1fd-54e2-424c-9e1a-c07918c56812_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of share options, exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_b94fa940-64be-4efb-8648-f3b17bd2a8f2_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative goodwill impairment charges</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impaired, Accumulated Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_15b34e59-9728-4b82-936a-375cf4508d8c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Income Tax [Line Items]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_98c84276-8c34-45b9-8288-af792fe8d947_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price, vested and expected to vest (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_FurnitureAndFixturesOfficeEquipmentAndSoftwareMember_31b72672-0bc4-4d12-88df-8a9df6e8521d_terseLabel_en-US" xlink:label="lab_smmt_FurnitureAndFixturesOfficeEquipmentAndSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and fixtures, office equipment and software</link:label>
    <link:label id="lab_smmt_FurnitureAndFixturesOfficeEquipmentAndSoftwareMember_label_en-US" xlink:label="lab_smmt_FurnitureAndFixturesOfficeEquipmentAndSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and Fixtures, Office Equipment and Software [Member]</link:label>
    <link:label id="lab_smmt_FurnitureAndFixturesOfficeEquipmentAndSoftwareMember_documentation_en-US" xlink:label="lab_smmt_FurnitureAndFixturesOfficeEquipmentAndSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and Fixtures, Office Equipment and Software</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_FurnitureAndFixturesOfficeEquipmentAndSoftwareMember" xlink:href="smmt-20211231.xsd#smmt_FurnitureAndFixturesOfficeEquipmentAndSoftwareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_FurnitureAndFixturesOfficeEquipmentAndSoftwareMember" xlink:to="lab_smmt_FurnitureAndFixturesOfficeEquipmentAndSoftwareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_d6c6b722-9fcb-463d-8e26-a92be0d8f416_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_4a1faf37-96ee-4b73-be73-5c0ae762f0d7_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_OptionOverNonFinancialAssetsMember_7909dcc9-c81b-45b4-9bdf-d78671894701_terseLabel_en-US" xlink:label="lab_smmt_OptionOverNonFinancialAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option over non-financial asset</link:label>
    <link:label id="lab_smmt_OptionOverNonFinancialAssetsMember_label_en-US" xlink:label="lab_smmt_OptionOverNonFinancialAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option Over Non-Financial Assets [Member]</link:label>
    <link:label id="lab_smmt_OptionOverNonFinancialAssetsMember_documentation_en-US" xlink:label="lab_smmt_OptionOverNonFinancialAssetsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option Over Non-Financial Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_OptionOverNonFinancialAssetsMember" xlink:href="smmt-20211231.xsd#smmt_OptionOverNonFinancialAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_OptionOverNonFinancialAssetsMember" xlink:to="lab_smmt_OptionOverNonFinancialAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_GrantFundingArrangementMilestoneFundingIncrease_e59a1dcf-b138-4736-a678-9ec15710fd9f_terseLabel_en-US" xlink:label="lab_smmt_GrantFundingArrangementMilestoneFundingIncrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funding increase based on achievement of future milestones</link:label>
    <link:label id="lab_smmt_GrantFundingArrangementMilestoneFundingIncrease_label_en-US" xlink:label="lab_smmt_GrantFundingArrangementMilestoneFundingIncrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant Funding Arrangement, Milestone, Funding Increase</link:label>
    <link:label id="lab_smmt_GrantFundingArrangementMilestoneFundingIncrease_documentation_en-US" xlink:label="lab_smmt_GrantFundingArrangementMilestoneFundingIncrease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant Funding Arrangement, Milestone, Funding Increase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_GrantFundingArrangementMilestoneFundingIncrease" xlink:href="smmt-20211231.xsd#smmt_GrantFundingArrangementMilestoneFundingIncrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_GrantFundingArrangementMilestoneFundingIncrease" xlink:to="lab_smmt_GrantFundingArrangementMilestoneFundingIncrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8968d329-2d31-43f2-88d6-9eaa13ee4601_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0b97c50c-0143-4913-ade9-0b1f0211acc0_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_54c95001-62b6-4503-b843-36f4bee9668d_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromRelatedPartyDebt_645a976e-3c0b-4c24-9f40-55fe698e56ac_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromRelatedPartyDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from related party promissory notes</link:label>
    <link:label id="lab_us-gaap_ProceedsFromRelatedPartyDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromRelatedPartyDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Related Party Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRelatedPartyDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromRelatedPartyDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromRelatedPartyDebt" xlink:to="lab_us-gaap_ProceedsFromRelatedPartyDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_6c17cadd-7aaf-4248-8662-cd3b5740e880_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Noncurrent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_c095efc5-15d5-4f81-a0c8-a5cdf467d2b8_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_4e1b8e79-c712-4aa1-9d1d-233e6899c85d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_502f1713-6aca-45f8-be55-974df04e8db6_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_ClassOfWarrantOrRightVested_4b57de7b-8060-4af2-b622-74c00555feac_terseLabel_en-US" xlink:label="lab_smmt_ClassOfWarrantOrRightVested" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants vested (in shares)</link:label>
    <link:label id="lab_smmt_ClassOfWarrantOrRightVested_label_en-US" xlink:label="lab_smmt_ClassOfWarrantOrRightVested" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Vested</link:label>
    <link:label id="lab_smmt_ClassOfWarrantOrRightVested_documentation_en-US" xlink:label="lab_smmt_ClassOfWarrantOrRightVested" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Vested</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_ClassOfWarrantOrRightVested" xlink:href="smmt-20211231.xsd#smmt_ClassOfWarrantOrRightVested"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_ClassOfWarrantOrRightVested" xlink:to="lab_smmt_ClassOfWarrantOrRightVested" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock_08bb4ea7-ad09-4b80-b4b1-25af072b3889_terseLabel_en-US" xlink:label="lab_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of long-lived assets by geography</link:label>
    <link:label id="lab_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-lived Assets by Geographic Areas [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" xlink:to="lab_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_d1a938f5-3897-462d-90d5-bfe7c36f47ab_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_RelatedPartyTransactionExpectedRate_e4bc073b-346d-4c71-a561-a00837b47c8c_terseLabel_en-US" xlink:label="lab_smmt_RelatedPartyTransactionExpectedRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes payable, estimated interest rate</link:label>
    <link:label id="lab_smmt_RelatedPartyTransactionExpectedRate_label_en-US" xlink:label="lab_smmt_RelatedPartyTransactionExpectedRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Expected Rate</link:label>
    <link:label id="lab_smmt_RelatedPartyTransactionExpectedRate_documentation_en-US" xlink:label="lab_smmt_RelatedPartyTransactionExpectedRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Expected Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_RelatedPartyTransactionExpectedRate" xlink:href="smmt-20211231.xsd#smmt_RelatedPartyTransactionExpectedRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_RelatedPartyTransactionExpectedRate" xlink:to="lab_smmt_RelatedPartyTransactionExpectedRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_4bc7722d-c478-4cfb-bfcc-762ed91ba83f_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leased assets obtained in exchange for operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_c86c476b-45ab-443b-936a-34aa17c9137a_verboseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional right-of-use assets recorded</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_b27a191d-6ff4-4848-ad63-3199469a2a76_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Major components of deferred tax assets and liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_InterestExpenseIncomeNoncash_87ac47e0-2d4d-4dc6-b798-4e090750e19d_terseLabel_en-US" xlink:label="lab_smmt_InterestExpenseIncomeNoncash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash interest expense</link:label>
    <link:label id="lab_smmt_InterestExpenseIncomeNoncash_label_en-US" xlink:label="lab_smmt_InterestExpenseIncomeNoncash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense (Income), Noncash</link:label>
    <link:label id="lab_smmt_InterestExpenseIncomeNoncash_documentation_en-US" xlink:label="lab_smmt_InterestExpenseIncomeNoncash" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense (Income), Noncash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_InterestExpenseIncomeNoncash" xlink:href="smmt-20211231.xsd#smmt_InterestExpenseIncomeNoncash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_InterestExpenseIncomeNoncash" xlink:to="lab_smmt_InterestExpenseIncomeNoncash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_957eb3c0-af4d-457c-b83d-573bec16ae5a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum common stock purchase allowable as a percentage of compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_1c73fb2d-e5a8-4a38-b121-f2238745b429_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_cdd27c2e-ad06-4425-a1d1-550d2871c84e_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_77b0d6f6-9917-47d9-8930-649b040f6c90_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Prepaid Expenses and Accrued Liabilities</link:label>
    <link:label id="lab_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research, Development, and Computer Software Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:to="lab_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_ad321e59-4c5a-4aa5-a823-30c5c910f2a1_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_08ade3a0-b8f6-46f4-92ea-24dca32f163e_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_582fd1ad-ce54-4063-ac39-d12887c09451_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_44592b68-daf1-46b1-9c49-ffdb8bba3084_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic net loss per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_9561c19b-51f6-43e5-8afd-158ff7cfff12_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_0bed9da3-946a-4c94-93ff-665191269275_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_28eaf48e-3203-4791-8bce-bde95c394391_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_f7d46f0d-7195-430a-93c8-6b1383db976c_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_22017f48-0977-4c9a-95da-46eeac323a3a_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_EffectiveIncomeTaxRateReconciliationTaxCreditRefundableResearchPercent_07cf51a3-184a-4dd1-9094-93ee108a801a_negatedLabel_en-US" xlink:label="lab_smmt_EffectiveIncomeTaxRateReconciliationTaxCreditRefundableResearchPercent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Refundable research and development tax credit</link:label>
    <link:label id="lab_smmt_EffectiveIncomeTaxRateReconciliationTaxCreditRefundableResearchPercent_label_en-US" xlink:label="lab_smmt_EffectiveIncomeTaxRateReconciliationTaxCreditRefundableResearchPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit Refundable, Research, Percent</link:label>
    <link:label id="lab_smmt_EffectiveIncomeTaxRateReconciliationTaxCreditRefundableResearchPercent_documentation_en-US" xlink:label="lab_smmt_EffectiveIncomeTaxRateReconciliationTaxCreditRefundableResearchPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit Refundable, Research, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_EffectiveIncomeTaxRateReconciliationTaxCreditRefundableResearchPercent" xlink:href="smmt-20211231.xsd#smmt_EffectiveIncomeTaxRateReconciliationTaxCreditRefundableResearchPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_EffectiveIncomeTaxRateReconciliationTaxCreditRefundableResearchPercent" xlink:to="lab_smmt_EffectiveIncomeTaxRateReconciliationTaxCreditRefundableResearchPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_f617a286-74d5-408b-a8af-f6b72c047eeb_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseCurrent" xlink:to="lab_us-gaap_PrepaidExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f9f95527-02d6-49e2-add8-2ae3008ce093_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_FractionalStockIssuedDuringPeriodSharesReverseStockSplit_24ed159d-f6f2-467d-bd44-55f5e4845172_terseLabel_en-US" xlink:label="lab_smmt_FractionalStockIssuedDuringPeriodSharesReverseStockSplit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fractional shares issued from reverse stock split</link:label>
    <link:label id="lab_smmt_FractionalStockIssuedDuringPeriodSharesReverseStockSplit_label_en-US" xlink:label="lab_smmt_FractionalStockIssuedDuringPeriodSharesReverseStockSplit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fractional Stock Issued During Period, Shares, Reverse Stock Split</link:label>
    <link:label id="lab_smmt_FractionalStockIssuedDuringPeriodSharesReverseStockSplit_documentation_en-US" xlink:label="lab_smmt_FractionalStockIssuedDuringPeriodSharesReverseStockSplit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fractional Stock Issued During Period, Shares, Reverse Stock Split</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_FractionalStockIssuedDuringPeriodSharesReverseStockSplit" xlink:href="smmt-20211231.xsd#smmt_FractionalStockIssuedDuringPeriodSharesReverseStockSplit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_FractionalStockIssuedDuringPeriodSharesReverseStockSplit" xlink:to="lab_smmt_FractionalStockIssuedDuringPeriodSharesReverseStockSplit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestorMember_a763c5d4-870d-450f-ae1e-c0e2a2cc77a8_terseLabel_en-US" xlink:label="lab_us-gaap_InvestorMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investor</link:label>
    <link:label id="lab_us-gaap_InvestorMember_label_en-US" xlink:label="lab_us-gaap_InvestorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investor [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestorMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestorMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestorMember" xlink:to="lab_us-gaap_InvestorMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UsTreasuryUstInterestRateMember_ed1a9caa-913a-4658-a930-03951889aff0_terseLabel_en-US" xlink:label="lab_us-gaap_UsTreasuryUstInterestRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">10 year US Treasury rate</link:label>
    <link:label id="lab_us-gaap_UsTreasuryUstInterestRateMember_label_en-US" xlink:label="lab_us-gaap_UsTreasuryUstInterestRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury (UST) Interest Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UsTreasuryUstInterestRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UsTreasuryUstInterestRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UsTreasuryUstInterestRateMember" xlink:to="lab_us-gaap_UsTreasuryUstInterestRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_WarrantsPolicyPolicyTextBlock_7a7ccdb0-a1b0-4211-807a-2b0c46a003ce_terseLabel_en-US" xlink:label="lab_smmt_WarrantsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants</link:label>
    <link:label id="lab_smmt_WarrantsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_smmt_WarrantsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Policy [Policy Text Block]</link:label>
    <link:label id="lab_smmt_WarrantsPolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_smmt_WarrantsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Policy</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_WarrantsPolicyPolicyTextBlock" xlink:href="smmt-20211231.xsd#smmt_WarrantsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_WarrantsPolicyPolicyTextBlock" xlink:to="lab_smmt_WarrantsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_4362026c-7201-4b8a-b787-6c2b000b963f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other adjustments</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_5bb7489d-b6ae-4843-a883-b797503b6f50_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_66ee0b8f-e8a6-4bf1-a369-e8e17e148afc_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Costs</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_bd576bf1-6f99-4161-847e-310d359cc728_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_dca0c4af-f97b-4b79-ba33-cb491d1946a9_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5cb7c7af-2b5d-4b5d-b8b9-883f53d87832_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows used in investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_0fa50aec-6275-4088-a521-ac33d6e464c1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized foreign exchange loss (gain)</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), Unrealized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_ClassOfWarrantOrRightMinimumTenDayVolumeWeightedAverageCommonStockPriceToWarrantExercisePricePremiumPercentage_ebe642c2-35d7-435f-8aaa-1af86efb394d_terseLabel_en-US" xlink:label="lab_smmt_ClassOfWarrantOrRightMinimumTenDayVolumeWeightedAverageCommonStockPriceToWarrantExercisePricePremiumPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum volume weighted average common stock price to warrant exercise price, premium, percentage</link:label>
    <link:label id="lab_smmt_ClassOfWarrantOrRightMinimumTenDayVolumeWeightedAverageCommonStockPriceToWarrantExercisePricePremiumPercentage_label_en-US" xlink:label="lab_smmt_ClassOfWarrantOrRightMinimumTenDayVolumeWeightedAverageCommonStockPriceToWarrantExercisePricePremiumPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Minimum Ten Day Volume Weighted Average Common Stock Price to Warrant Exercise Price, Premium, Percentage</link:label>
    <link:label id="lab_smmt_ClassOfWarrantOrRightMinimumTenDayVolumeWeightedAverageCommonStockPriceToWarrantExercisePricePremiumPercentage_documentation_en-US" xlink:label="lab_smmt_ClassOfWarrantOrRightMinimumTenDayVolumeWeightedAverageCommonStockPriceToWarrantExercisePricePremiumPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Minimum Ten Day Volume Weighted Average Common Stock Price to Warrant Exercise Price, Premium, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_ClassOfWarrantOrRightMinimumTenDayVolumeWeightedAverageCommonStockPriceToWarrantExercisePricePremiumPercentage" xlink:href="smmt-20211231.xsd#smmt_ClassOfWarrantOrRightMinimumTenDayVolumeWeightedAverageCommonStockPriceToWarrantExercisePricePremiumPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_ClassOfWarrantOrRightMinimumTenDayVolumeWeightedAverageCommonStockPriceToWarrantExercisePricePremiumPercentage" xlink:to="lab_smmt_ClassOfWarrantOrRightMinimumTenDayVolumeWeightedAverageCommonStockPriceToWarrantExercisePricePremiumPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_7eb86a63-1c6b-41da-b1e1-0556f077c878_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill impairment charge</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_AuditInformationAbstract_label_en-US" xlink:label="lab_smmt_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit Information [Abstract]</link:label>
    <link:label id="lab_smmt_AuditInformationAbstract_documentation_en-US" xlink:label="lab_smmt_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_AuditInformationAbstract" xlink:href="smmt-20211231.xsd#smmt_AuditInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_AuditInformationAbstract" xlink:to="lab_smmt_AuditInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_65644c24-c764-4fb7-a4a7-f29cf01e2854_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionRate_e914990b-3c47-48e6-8de2-b19450f9c5de_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionRate_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionRate" xlink:to="lab_us-gaap_RelatedPartyTransactionRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_7ea46907-4933-4049-a941-9f278c6cceef_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_9ee82f1f-c51e-4f9b-8da8-99edd7730cca_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_abfd9531-8292-4e3d-aa68-c32857c95cb4_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected_2ff7374d-59ee-4810-8c7e-53732726fb24_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of employees affected by modification</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Plan Modification, Number of Grantees Affected</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_OtherOperatingIncomePolicyPolicyTextBlock_3e4bc6d8-8727-48ce-aebd-77174e43e1b4_terseLabel_en-US" xlink:label="lab_smmt_OtherOperatingIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Operating Income</link:label>
    <link:label id="lab_smmt_OtherOperatingIncomePolicyPolicyTextBlock_label_en-US" xlink:label="lab_smmt_OtherOperatingIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Operating Income, Policy [Policy Text Block]</link:label>
    <link:label id="lab_smmt_OtherOperatingIncomePolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_smmt_OtherOperatingIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Operating Income, Policy</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_OtherOperatingIncomePolicyPolicyTextBlock" xlink:href="smmt-20211231.xsd#smmt_OtherOperatingIncomePolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_OtherOperatingIncomePolicyPolicyTextBlock" xlink:to="lab_smmt_OtherOperatingIncomePolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure_8a13ee5f-8a3e-45d9-8c04-1ca14cf96309_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of option over non-financial asset</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived Intangible Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIncomeAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_0a3d0b96-ff7e-4900-ab2e-599025946e0c_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue and other income</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_a2add420-4cd2-4b1f-933c-cc9f851d167a_netLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current deferred revenue and other income</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_c4674ac9-9ce8-4f0b-ae59-986aac96dbc8_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current contract liability</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementScenarioAxis_cde81ea6-fe02-432f-b7b8-2fa56cf4267d_terseLabel_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:label id="lab_srt_StatementScenarioAxis_label_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_95e2e853-3cf0-4178-ae66-6a4819ad7cd9_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_bfe0b2af-208a-4ce0-9ab3-5b67d7988d9a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_db6c8051-7250-4d33-8b60-36ced46cf2b9_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_e0af7634-3133-423e-b7fa-4b66f8ade608_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_54db9d0d-b6f4-4366-8759-44e39ef00bdd_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and stockholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_09cce88e-7d67-4b02-95fb-c6e6faac2361_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_d38e7be0-05e1-4902-967b-a9f625f02127_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_37e3bcc9-a6d5-4791-8c1c-7325e0048d0f_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureNoncurrentTextBlock_34bdf7a2-0b84-49fc-bb48-b21ee3bbbdb1_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureNoncurrentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Non-Current Liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureNoncurrentTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureNoncurrentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Noncurrent [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureNoncurrentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureNoncurrentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureNoncurrentTextBlock" xlink:to="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureNoncurrentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_33839940-1672-44ca-8201-b0d093faa4a5_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_687529a2-a4da-4270-822e-79341dc7cb92_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingChangesAndErrorCorrectionsAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Changes and Error Corrections [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingChangesAndErrorCorrectionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:to="lab_us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_6fd40541-d4ac-43c8-9686-6561d3cb52c9_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance on common stock from exercise of share options</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_EuroFarmaLaboratoriosSAMember_b1310e21-1aa4-41c3-b480-6164b46977d8_terseLabel_en-US" xlink:label="lab_smmt_EuroFarmaLaboratoriosSAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EuroFarma</link:label>
    <link:label id="lab_smmt_EuroFarmaLaboratoriosSAMember_label_en-US" xlink:label="lab_smmt_EuroFarmaLaboratoriosSAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EuroFarma Laboratorios S.A. [Member]</link:label>
    <link:label id="lab_smmt_EuroFarmaLaboratoriosSAMember_documentation_en-US" xlink:label="lab_smmt_EuroFarmaLaboratoriosSAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EuroFarma Laboratorios S.A.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_EuroFarmaLaboratoriosSAMember" xlink:href="smmt-20211231.xsd#smmt_EuroFarmaLaboratoriosSAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_EuroFarmaLaboratoriosSAMember" xlink:to="lab_smmt_EuroFarmaLaboratoriosSAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_6672840b-81cb-4684-a297-efc5c8d61010_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_b7b2cee6-9785-4562-98a9-5916c70bb247_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on recognition of contingent consideration payable</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_AffiliatedEntityMember_a1e20b89-96bb-442b-b6fa-e4804c6a6bf4_terseLabel_en-US" xlink:label="lab_srt_AffiliatedEntityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliated entity</link:label>
    <link:label id="lab_srt_AffiliatedEntityMember_label_en-US" xlink:label="lab_srt_AffiliatedEntityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliated Entity [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_AffiliatedEntityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_AffiliatedEntityMember" xlink:to="lab_srt_AffiliatedEntityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_eaf76cf4-df18-4f33-b2d7-52a4d08aae71_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c29cf596-63d9-4ce5-8c06-9f17bc185ee7_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rates on cash</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_c0f87031-03c6-41a3-b0a7-cbf2332c0686_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenues from External Customers and Long-Lived Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenues from External Customers and Long-Lived Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:to="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveOfferingPeriod_9cad53e8-bde3-4bf9-9ee2-529b2291f6d5_terseLabel_en-US" xlink:label="lab_smmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveOfferingPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consecutive offering period</link:label>
    <link:label id="lab_smmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveOfferingPeriod_label_en-US" xlink:label="lab_smmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveOfferingPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-based Payment Award, Consecutive Offering Period</link:label>
    <link:label id="lab_smmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveOfferingPeriod_documentation_en-US" xlink:label="lab_smmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveOfferingPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-based Payment Award, Consecutive Offering Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveOfferingPeriod" xlink:href="smmt-20211231.xsd#smmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveOfferingPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveOfferingPeriod" xlink:to="lab_smmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveOfferingPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_0126362f-d93d-4b78-9ced-94450e1ec6dc_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_bf978cac-4133-4b55-8ee6-f3d0eaa488bb_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_752e4ec7-d938-46bc-bb42-9b9b944671c5_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_d5f52239-d421-40ec-b067-39b68f529ee3_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax asset</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_fbeeef65-d171-4c63-9a78-f5fe787dd71e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_66c5433f-793b-46e7-b5e6-9d87d7028c0f_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherOperatingIncomeAndExpenseTextBlock_07eb3902-6efa-4916-a796-d9e772c6a0df_terseLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeAndExpenseTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Operating Income</link:label>
    <link:label id="lab_us-gaap_OtherOperatingIncomeAndExpenseTextBlock_label_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeAndExpenseTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Operating Income and Expense [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeAndExpenseTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherOperatingIncomeAndExpenseTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOperatingIncomeAndExpenseTextBlock" xlink:to="lab_us-gaap_OtherOperatingIncomeAndExpenseTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_bf78250d-9e0d-439a-994e-5cae17ff7c5b_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_RevenueFromContractWithCustomerDevelopmentCommercialAndSalesMilestoneIncrementalCumulativeNetSalesTargetThreshold_92e270c3-9247-4e5a-a0f4-b8d0f24a396a_terseLabel_en-US" xlink:label="lab_smmt_RevenueFromContractWithCustomerDevelopmentCommercialAndSalesMilestoneIncrementalCumulativeNetSalesTargetThreshold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental cumulative net sales target threshold</link:label>
    <link:label id="lab_smmt_RevenueFromContractWithCustomerDevelopmentCommercialAndSalesMilestoneIncrementalCumulativeNetSalesTargetThreshold_label_en-US" xlink:label="lab_smmt_RevenueFromContractWithCustomerDevelopmentCommercialAndSalesMilestoneIncrementalCumulativeNetSalesTargetThreshold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Contract With Customer, Development, Commercial And Sales Milestone, Incremental Cumulative Net Sales Target Threshold</link:label>
    <link:label id="lab_smmt_RevenueFromContractWithCustomerDevelopmentCommercialAndSalesMilestoneIncrementalCumulativeNetSalesTargetThreshold_documentation_en-US" xlink:label="lab_smmt_RevenueFromContractWithCustomerDevelopmentCommercialAndSalesMilestoneIncrementalCumulativeNetSalesTargetThreshold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Contract With Customer, Development, Commercial And Sales Milestone, Incremental Cumulative Net Sales Target Threshold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_RevenueFromContractWithCustomerDevelopmentCommercialAndSalesMilestoneIncrementalCumulativeNetSalesTargetThreshold" xlink:href="smmt-20211231.xsd#smmt_RevenueFromContractWithCustomerDevelopmentCommercialAndSalesMilestoneIncrementalCumulativeNetSalesTargetThreshold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_RevenueFromContractWithCustomerDevelopmentCommercialAndSalesMilestoneIncrementalCumulativeNetSalesTargetThreshold" xlink:to="lab_smmt_RevenueFromContractWithCustomerDevelopmentCommercialAndSalesMilestoneIncrementalCumulativeNetSalesTargetThreshold" xlink:type="arc" order="1"/>
    <link:label id="lab_country_GB_c71e98c3-3b92-43cc-82eb-914378726ad3_terseLabel_en-US" xlink:label="lab_country_GB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United Kingdom</link:label>
    <link:label id="lab_country_GB_label_en-US" xlink:label="lab_country_GB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED KINGDOM</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_GB" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_GB"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_GB" xlink:to="lab_country_GB" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_693ca988-e04e-49ca-9f8a-aefb4f3f7514_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_b73d3063-3b17-4806-b570-83135bfa5e4d_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Private placement/Rights offering of common stock, net of offering costs</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_285d33a7-29b3-487f-80a9-7508ffdbe085_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_StockIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_9f7ca989-ff3a-4a7a-9cac-8c8d769fe13f_terseLabel_en-US" xlink:label="lab_smmt_StockIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction costs included in accrued expenses</link:label>
    <link:label id="lab_smmt_StockIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_label_en-US" xlink:label="lab_smmt_StockIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issuance Costs Incurred During Noncash or Partial Noncash Transaction</link:label>
    <link:label id="lab_smmt_StockIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_documentation_en-US" xlink:label="lab_smmt_StockIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issuance Costs Incurred During Noncash or Partial Noncash Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_StockIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:href="smmt-20211231.xsd#smmt_StockIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_StockIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:to="lab_smmt_StockIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_7d883539-93ed-4a7f-bc04-62ed11d479d2_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_58575219-f9fa-47d3-98b1-6062e5477ca5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price, exercisable (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_be2e88dc-e7f3-4b47-bede-91d5152464b4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant components of the provision for income taxes</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_a4137172-68f8-479e-bc9d-4a899619196b_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_1c62f78e-b0db-4f5d-95df-d6a0e138bce6_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_3c3a6a60-d29d-4292-9149-599f2b88321a_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for interest and penalties</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_0962ab0c-5a11-4dfd-aec9-731af92d25f6_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining contractual term, options outstanding</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_e44c83fb-0e7d-4c00-a311-8c51e65b6b7d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction costs from the issuance of common stock</link:label>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_199f1323-00e1-4e98-bc9d-7f2bd74e0c9b_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Offering costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_23b2884c-3492-44ce-8411-5eb4b33d2e16_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Private placement/Rights offering of common stock, net of offering costs (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_b53f3bb9-4a31-4614-9896-aca0de3a73a0_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_52d71821-6280-4e97-8247-2115636a54a6_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal United States</link:label>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Federal Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_8a6b4c95-1b82-462f-849d-dfe9b31eb3f3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of revenue by category</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Products and Services [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:to="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_9760d597-bba5-4209-b45a-600c8c870eef_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_e0efe12a-a995-4a94-bb9e-a2c9654a93bd_verboseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency transaction (losses) gains</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_c4839d21-2173-48c2-be39-c0f3b5f1810f_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency (loss) gain</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_5019efad-4003-4aa7-8e9d-b2706dc44e6d_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.01 par value: 250,000,000 shares authorized; 98,039,540 and 82,575,064 shares issued and outstanding at December 31, 2021 and 2020, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_0940bd33-2079-4d00-a0e8-f9494a3299a7_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_86fe1542-dc5c-4852-bbfe-beaee7de4972_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (expense) income, net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_6bf0fca6-7ddb-4168-a3fb-4b54e1b82021_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (expense) income, net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_b78cac6e-4a79-4b37-afe7-425a4caa11d9_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation expense for options, period of recognition</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_e1f74f4e-6796-43e9-a330-c5150270987f_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_be4013b4-329a-46da-a3c8-df04579b895b_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_fa47ca40-a938-4b4f-8257-c1640803f3b7_verboseLabel_en-US" xlink:label="lab_smmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price (in dollars per share)</link:label>
    <link:label id="lab_smmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_smmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement By Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Weighted Average Exercise Price</link:label>
    <link:label id="lab_smmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_documentation_en-US" xlink:label="lab_smmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement By Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:href="smmt-20211231.xsd#smmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:to="lab_smmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_d437a211-24d0-49e4-9c39-8a541733b877_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_acbed462-4fe6-448a-8d34-6ee58be0b3fd_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies (Note 19)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTable_6b88f935-278d-4f97-b712-8e94a695a1f3_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_GrantFundingArrangementIncomeEarned_5b08120b-8b58-46b6-b75e-d55aae0d0e45_terseLabel_en-US" xlink:label="lab_smmt_GrantFundingArrangementIncomeEarned" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funding/Grant income</link:label>
    <link:label id="lab_smmt_GrantFundingArrangementIncomeEarned_label_en-US" xlink:label="lab_smmt_GrantFundingArrangementIncomeEarned" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant Funding Arrangement, Income Earned</link:label>
    <link:label id="lab_smmt_GrantFundingArrangementIncomeEarned_documentation_en-US" xlink:label="lab_smmt_GrantFundingArrangementIncomeEarned" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant Funding Arrangement, Income Earned</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_GrantFundingArrangementIncomeEarned" xlink:href="smmt-20211231.xsd#smmt_GrantFundingArrangementIncomeEarned"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_GrantFundingArrangementIncomeEarned" xlink:to="lab_smmt_GrantFundingArrangementIncomeEarned" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_43c3005e-2dbf-464e-8920-b4b25cd2768a_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_dc8feeec-a7fc-4efe-8316-9d729e46931c_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_ef5e93ef-8058-499b-ad8f-85c797a35937_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_IncreaseDecreaseInResearchAndDevelopmentTaxCreditReceivable_26248f1a-14fa-4c50-9c27-b21112267be7_negatedTerseLabel_en-US" xlink:label="lab_smmt_IncreaseDecreaseInResearchAndDevelopmentTaxCreditReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development tax credit receivable</link:label>
    <link:label id="lab_smmt_IncreaseDecreaseInResearchAndDevelopmentTaxCreditReceivable_label_en-US" xlink:label="lab_smmt_IncreaseDecreaseInResearchAndDevelopmentTaxCreditReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Research And Development Tax Credit Receivable</link:label>
    <link:label id="lab_smmt_IncreaseDecreaseInResearchAndDevelopmentTaxCreditReceivable_documentation_en-US" xlink:label="lab_smmt_IncreaseDecreaseInResearchAndDevelopmentTaxCreditReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Research And Development Tax Credit Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_IncreaseDecreaseInResearchAndDevelopmentTaxCreditReceivable" xlink:href="smmt-20211231.xsd#smmt_IncreaseDecreaseInResearchAndDevelopmentTaxCreditReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_IncreaseDecreaseInResearchAndDevelopmentTaxCreditReceivable" xlink:to="lab_smmt_IncreaseDecreaseInResearchAndDevelopmentTaxCreditReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_4d32a11d-d614-42f2-89d1-45aa598a938f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of related party promissory notes issuance costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_0b697ba9-0b8c-4479-b36b-fef1e3e7b96d_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock_278ded65-fa59-4e5c-a802-777a1ecc0228_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (Expense) Income</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income and Expense [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock" xlink:to="lab_us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_f2fb44bc-6f4f-48c0-b136-2ca5e652ffe3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of weighted-average assumptions used for stock option awards</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_RelatedPartyTransactionMonthlyExpensesFromTransactionsWithRelatedParty_f2053998-2c1b-44bf-a2fd-a728818ce233_terseLabel_en-US" xlink:label="lab_smmt_RelatedPartyTransactionMonthlyExpensesFromTransactionsWithRelatedParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Monthly expense from related party</link:label>
    <link:label id="lab_smmt_RelatedPartyTransactionMonthlyExpensesFromTransactionsWithRelatedParty_label_en-US" xlink:label="lab_smmt_RelatedPartyTransactionMonthlyExpensesFromTransactionsWithRelatedParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Monthly Expenses From Transactions With Related Party</link:label>
    <link:label id="lab_smmt_RelatedPartyTransactionMonthlyExpensesFromTransactionsWithRelatedParty_documentation_en-US" xlink:label="lab_smmt_RelatedPartyTransactionMonthlyExpensesFromTransactionsWithRelatedParty" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Monthly Expenses From Transactions With Related Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_RelatedPartyTransactionMonthlyExpensesFromTransactionsWithRelatedParty" xlink:href="smmt-20211231.xsd#smmt_RelatedPartyTransactionMonthlyExpensesFromTransactionsWithRelatedParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_RelatedPartyTransactionMonthlyExpensesFromTransactionsWithRelatedParty" xlink:to="lab_smmt_RelatedPartyTransactionMonthlyExpensesFromTransactionsWithRelatedParty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_1cf2cdec-5499-4cb0-a9a9-159e814290aa_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_GrantFundingArrangementCommittedFundingTotal_d46ffd8e-af5f-4244-8c70-d4c50c836492_terseLabel_en-US" xlink:label="lab_smmt_GrantFundingArrangementCommittedFundingTotal" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total committed funding</link:label>
    <link:label id="lab_smmt_GrantFundingArrangementCommittedFundingTotal_label_en-US" xlink:label="lab_smmt_GrantFundingArrangementCommittedFundingTotal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant Funding Arrangement, Committed Funding, Total</link:label>
    <link:label id="lab_smmt_GrantFundingArrangementCommittedFundingTotal_documentation_en-US" xlink:label="lab_smmt_GrantFundingArrangementCommittedFundingTotal" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant Funding Arrangement, Committed Funding, Total</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_GrantFundingArrangementCommittedFundingTotal" xlink:href="smmt-20211231.xsd#smmt_GrantFundingArrangementCommittedFundingTotal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_GrantFundingArrangementCommittedFundingTotal" xlink:to="lab_smmt_GrantFundingArrangementCommittedFundingTotal" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_8d7cea16-897d-4931-8c6a-4eb2d6ec35a7_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-United States</link:label>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Foreign Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorName_1c9049a0-fc2c-4d81-bfd7-382539d5c506_terseLabel_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:label id="lab_dei_AuditorName_label_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName" xlink:to="lab_dei_AuditorName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_590bcb38-4f0d-4cf9-9b34-978cb6d888a6_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues from External Customers and Long-Lived Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues from External Customers and Long-Lived Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_ac099511-7947-4ac9-b1ad-62d01078d872_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of revenue by geography</link:label>
    <link:label id="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Geographic Areas [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:to="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_LiquidityAndCapitalResourcesTextBlock_23d682a8-3d63-4c53-8c0c-44deaf703870_terseLabel_en-US" xlink:label="lab_smmt_LiquidityAndCapitalResourcesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liquidity and Capital Resources</link:label>
    <link:label id="lab_smmt_LiquidityAndCapitalResourcesTextBlock_label_en-US" xlink:label="lab_smmt_LiquidityAndCapitalResourcesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liquidity and Capital Resources [Text Block]</link:label>
    <link:label id="lab_smmt_LiquidityAndCapitalResourcesTextBlock_documentation_en-US" xlink:label="lab_smmt_LiquidityAndCapitalResourcesTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liquidity and Capital Resources</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_LiquidityAndCapitalResourcesTextBlock" xlink:href="smmt-20211231.xsd#smmt_LiquidityAndCapitalResourcesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_LiquidityAndCapitalResourcesTextBlock" xlink:to="lab_smmt_LiquidityAndCapitalResourcesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_FiniteLivedIntangibleAssetsAccumulatedAmortizationAndImpairment_116c8c3f-4615-42a9-903c-6bb296bb6d16_negatedTerseLabel_en-US" xlink:label="lab_smmt_FiniteLivedIntangibleAssetsAccumulatedAmortizationAndImpairment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated amortization and impairment charges</link:label>
    <link:label id="lab_smmt_FiniteLivedIntangibleAssetsAccumulatedAmortizationAndImpairment_label_en-US" xlink:label="lab_smmt_FiniteLivedIntangibleAssetsAccumulatedAmortizationAndImpairment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization And Impairment</link:label>
    <link:label id="lab_smmt_FiniteLivedIntangibleAssetsAccumulatedAmortizationAndImpairment_documentation_en-US" xlink:label="lab_smmt_FiniteLivedIntangibleAssetsAccumulatedAmortizationAndImpairment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization And Impairment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_FiniteLivedIntangibleAssetsAccumulatedAmortizationAndImpairment" xlink:href="smmt-20211231.xsd#smmt_FiniteLivedIntangibleAssetsAccumulatedAmortizationAndImpairment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_FiniteLivedIntangibleAssetsAccumulatedAmortizationAndImpairment" xlink:to="lab_smmt_FiniteLivedIntangibleAssetsAccumulatedAmortizationAndImpairment" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_PotentialDeferredTaxAssetsOperatingLossCarryforwards_6d9fa2b6-c34c-4dce-bfcc-4fbbe88c8753_terseLabel_en-US" xlink:label="lab_smmt_PotentialDeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential deferred tax asset</link:label>
    <link:label id="lab_smmt_PotentialDeferredTaxAssetsOperatingLossCarryforwards_label_en-US" xlink:label="lab_smmt_PotentialDeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:label id="lab_smmt_PotentialDeferredTaxAssetsOperatingLossCarryforwards_documentation_en-US" xlink:label="lab_smmt_PotentialDeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_PotentialDeferredTaxAssetsOperatingLossCarryforwards" xlink:href="smmt-20211231.xsd#smmt_PotentialDeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_PotentialDeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_smmt_PotentialDeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_7e3b8fc8-06c7-418b-be60-3e04041befa5_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_e5a31474-ecb6-4dd8-9244-daa2902b9d19_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_b4fb98e8-86db-4f60-9c95-2531110d7624_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_label_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_d97353ae-44aa-4f62-b35b-9c0bb0143d5a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_6921054d-b3b5-4da4-92ef-dadd1cecbbfb_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration received on sale of stock</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Cash_e3da28e9-7901-42a3-bd06-62047a43d880_terseLabel_en-US" xlink:label="lab_us-gaap_Cash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash</link:label>
    <link:label id="lab_us-gaap_Cash_label_en-US" xlink:label="lab_us-gaap_Cash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Cash" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Cash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Cash" xlink:to="lab_us-gaap_Cash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_730bb3be-65ba-4510-b1fd-5a4d0f36aea5_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_f4b0a125-6e0a-4ec5-b433-a3d509cde203_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_39418fe4-4356-4805-8453-389b73adb121_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock based compensation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_CombatingAntibioticResistantBacteriaBiopharmaceuticalAcceleratorProgramMember_5cce66b5-babc-4788-bb7f-617df152a929_terseLabel_en-US" xlink:label="lab_smmt_CombatingAntibioticResistantBacteriaBiopharmaceuticalAcceleratorProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CARB-X</link:label>
    <link:label id="lab_smmt_CombatingAntibioticResistantBacteriaBiopharmaceuticalAcceleratorProgramMember_label_en-US" xlink:label="lab_smmt_CombatingAntibioticResistantBacteriaBiopharmaceuticalAcceleratorProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator Program [Member]</link:label>
    <link:label id="lab_smmt_CombatingAntibioticResistantBacteriaBiopharmaceuticalAcceleratorProgramMember_documentation_en-US" xlink:label="lab_smmt_CombatingAntibioticResistantBacteriaBiopharmaceuticalAcceleratorProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_CombatingAntibioticResistantBacteriaBiopharmaceuticalAcceleratorProgramMember" xlink:href="smmt-20211231.xsd#smmt_CombatingAntibioticResistantBacteriaBiopharmaceuticalAcceleratorProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_CombatingAntibioticResistantBacteriaBiopharmaceuticalAcceleratorProgramMember" xlink:to="lab_smmt_CombatingAntibioticResistantBacteriaBiopharmaceuticalAcceleratorProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_ContractWithCustomerLiabilityAdditions_b1de4979-98ec-4964-8b8c-fdcce6226a76_terseLabel_en-US" xlink:label="lab_smmt_ContractWithCustomerLiabilityAdditions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions</link:label>
    <link:label id="lab_smmt_ContractWithCustomerLiabilityAdditions_label_en-US" xlink:label="lab_smmt_ContractWithCustomerLiabilityAdditions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Additions</link:label>
    <link:label id="lab_smmt_ContractWithCustomerLiabilityAdditions_documentation_en-US" xlink:label="lab_smmt_ContractWithCustomerLiabilityAdditions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Additions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_ContractWithCustomerLiabilityAdditions" xlink:href="smmt-20211231.xsd#smmt_ContractWithCustomerLiabilityAdditions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_ContractWithCustomerLiabilityAdditions" xlink:to="lab_smmt_ContractWithCustomerLiabilityAdditions" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_RightsOfferingMember_b5b84439-146a-46f1-a019-8f797432dd42_terseLabel_en-US" xlink:label="lab_smmt_RightsOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rights Offering</link:label>
    <link:label id="lab_smmt_RightsOfferingMember_label_en-US" xlink:label="lab_smmt_RightsOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rights Offering [Member]</link:label>
    <link:label id="lab_smmt_RightsOfferingMember_documentation_en-US" xlink:label="lab_smmt_RightsOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rights Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_RightsOfferingMember" xlink:href="smmt-20211231.xsd#smmt_RightsOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_RightsOfferingMember" xlink:to="lab_smmt_RightsOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_32c1ee93-5c50-4f61-9a22-dc840dcf50d9_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of common stock shares into which each warrant converts (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_UtrophinProgramMember_a40747f1-f9a4-49f9-bd51-28f6718acffb_terseLabel_en-US" xlink:label="lab_smmt_UtrophinProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Utrophin program</link:label>
    <link:label id="lab_smmt_UtrophinProgramMember_label_en-US" xlink:label="lab_smmt_UtrophinProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Utrophin Program [Member]</link:label>
    <link:label id="lab_smmt_UtrophinProgramMember_documentation_en-US" xlink:label="lab_smmt_UtrophinProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Utrophin Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_UtrophinProgramMember" xlink:href="smmt-20211231.xsd#smmt_UtrophinProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_UtrophinProgramMember" xlink:to="lab_smmt_UtrophinProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_781ff1cf-d2cb-430f-9df7-171518f93af7_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current income tax benefit:</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_43ee8d31-10bb-4d84-806c-2fc0cddeecae_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options to purchase common stock</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_ed7c207b-289c-4ae3-ad99-2d606abe12ba_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_RevenueFromContractWithCustomerDevelopmentCommercialAndSalesMilestoneCumulativeNetSalesTargetAchievementRevenueEntitledToReceive_5377ec83-4463-44d7-b409-9d7a4f2f4276_terseLabel_en-US" xlink:label="lab_smmt_RevenueFromContractWithCustomerDevelopmentCommercialAndSalesMilestoneCumulativeNetSalesTargetAchievementRevenueEntitledToReceive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue entitled to receive upon achieving cumulative net sales targets</link:label>
    <link:label id="lab_smmt_RevenueFromContractWithCustomerDevelopmentCommercialAndSalesMilestoneCumulativeNetSalesTargetAchievementRevenueEntitledToReceive_label_en-US" xlink:label="lab_smmt_RevenueFromContractWithCustomerDevelopmentCommercialAndSalesMilestoneCumulativeNetSalesTargetAchievementRevenueEntitledToReceive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Contract With Customer, Development, Commercial And Sales Milestone, Cumulative Net Sales Target Achievement, Revenue Entitled To Receive</link:label>
    <link:label id="lab_smmt_RevenueFromContractWithCustomerDevelopmentCommercialAndSalesMilestoneCumulativeNetSalesTargetAchievementRevenueEntitledToReceive_documentation_en-US" xlink:label="lab_smmt_RevenueFromContractWithCustomerDevelopmentCommercialAndSalesMilestoneCumulativeNetSalesTargetAchievementRevenueEntitledToReceive" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Contract With Customer, Development, Commercial And Sales Milestone, Cumulative Net Sales Target Achievement, Revenue Entitled To Receive</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_RevenueFromContractWithCustomerDevelopmentCommercialAndSalesMilestoneCumulativeNetSalesTargetAchievementRevenueEntitledToReceive" xlink:href="smmt-20211231.xsd#smmt_RevenueFromContractWithCustomerDevelopmentCommercialAndSalesMilestoneCumulativeNetSalesTargetAchievementRevenueEntitledToReceive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_RevenueFromContractWithCustomerDevelopmentCommercialAndSalesMilestoneCumulativeNetSalesTargetAchievementRevenueEntitledToReceive" xlink:to="lab_smmt_RevenueFromContractWithCustomerDevelopmentCommercialAndSalesMilestoneCumulativeNetSalesTargetAchievementRevenueEntitledToReceive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidExpense_2e0af206-a416-429e-9cfb-ffeb7f1cec83_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidExpense_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_GainLossOnRemeasurementOfLiabilitiesOperatingAndNonoperating_189b6389-771b-464c-9871-a080e6b613aa_negatedTerseLabel_en-US" xlink:label="lab_smmt_GainLossOnRemeasurementOfLiabilitiesOperatingAndNonoperating" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on remeasurement of liabilities</link:label>
    <link:label id="lab_smmt_GainLossOnRemeasurementOfLiabilitiesOperatingAndNonoperating_label_en-US" xlink:label="lab_smmt_GainLossOnRemeasurementOfLiabilitiesOperatingAndNonoperating" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) On Remeasurement Of Liabilities, Operating And Nonoperating</link:label>
    <link:label id="lab_smmt_GainLossOnRemeasurementOfLiabilitiesOperatingAndNonoperating_documentation_en-US" xlink:label="lab_smmt_GainLossOnRemeasurementOfLiabilitiesOperatingAndNonoperating" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) On Remeasurement Of Liabilities, Operating And Nonoperating</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_GainLossOnRemeasurementOfLiabilitiesOperatingAndNonoperating" xlink:href="smmt-20211231.xsd#smmt_GainLossOnRemeasurementOfLiabilitiesOperatingAndNonoperating"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_GainLossOnRemeasurementOfLiabilitiesOperatingAndNonoperating" xlink:to="lab_smmt_GainLossOnRemeasurementOfLiabilitiesOperatingAndNonoperating" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_833c73cb-c070-477b-9ec6-db8e22491917_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Offering cots</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_b0d6df5a-73d5-420a-9028-dfeb08f1dec7_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_ba841130-ae27-45f4-9fc3-43466a4ad243_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_28d284b8-e4ba-4295-9310-abdcb4bc9d1f_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Income Tax [Table]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:to="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_91495fcf-f2b1-4081-8b14-e83789489d2d_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_0f0f16ea-0f60-45bc-903b-a1a9fbef7f8f_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateAxis_05738c3a-c9e2-487c-bc8d-93ef1e71893d_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis" xlink:to="lab_us-gaap_VariableRateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_af96bfb3-0395-4dbb-87f8-4ad9539177a2_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United Kingdom</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Foreign</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_878c6fe8-a12c-4f84-ac95-5720297fb72d_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_a0be962b-73cd-4017-9597-a0904d6b2558_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating loss</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesSubscribedButUnissued_e6882ce8-7ef3-423f-8715-c586442bb48b_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesSubscribedButUnissued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares of common stock subscribed (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesSubscribedButUnissued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesSubscribedButUnissued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Subscribed but Unissued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesSubscribedButUnissued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesSubscribedButUnissued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesSubscribedButUnissued" xlink:to="lab_us-gaap_CommonStockSharesSubscribedButUnissued" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_GrantFundingArrangementCommittedFundingBase_e6153785-ecbc-4cfd-9366-34c2cedd77fe_terseLabel_en-US" xlink:label="lab_smmt_GrantFundingArrangementCommittedFundingBase" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Committed funding base</link:label>
    <link:label id="lab_smmt_GrantFundingArrangementCommittedFundingBase_label_en-US" xlink:label="lab_smmt_GrantFundingArrangementCommittedFundingBase" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant Funding Arrangement, Committed Funding, Base</link:label>
    <link:label id="lab_smmt_GrantFundingArrangementCommittedFundingBase_documentation_en-US" xlink:label="lab_smmt_GrantFundingArrangementCommittedFundingBase" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant Funding Arrangement, Committed Funding, Base</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_GrantFundingArrangementCommittedFundingBase" xlink:href="smmt-20211231.xsd#smmt_GrantFundingArrangementCommittedFundingBase"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_GrantFundingArrangementCommittedFundingBase" xlink:to="lab_smmt_GrantFundingArrangementCommittedFundingBase" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_f0519ca5-d969-4838-8ec6-092d811d768b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_b41825a2-c58e-48e0-8796-f6272b8f082c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_97b735e3-c3ae-4f1f-878f-9b67fab0d8e0_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_AdjustmentsToAdditionalPaidInCapitalImputedInterestExpenseRelatedParty_d81ba27d-aa24-45a6-add2-677f82373f57_terseLabel_en-US" xlink:label="lab_smmt_AdjustmentsToAdditionalPaidInCapitalImputedInterestExpenseRelatedParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Imputed interest expense on promissory note payable to a related party</link:label>
    <link:label id="lab_smmt_AdjustmentsToAdditionalPaidInCapitalImputedInterestExpenseRelatedParty_label_en-US" xlink:label="lab_smmt_AdjustmentsToAdditionalPaidInCapitalImputedInterestExpenseRelatedParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Imputed Interest Expense, Related Party</link:label>
    <link:label id="lab_smmt_AdjustmentsToAdditionalPaidInCapitalImputedInterestExpenseRelatedParty_documentation_en-US" xlink:label="lab_smmt_AdjustmentsToAdditionalPaidInCapitalImputedInterestExpenseRelatedParty" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Imputed Interest Expense, Related Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_AdjustmentsToAdditionalPaidInCapitalImputedInterestExpenseRelatedParty" xlink:href="smmt-20211231.xsd#smmt_AdjustmentsToAdditionalPaidInCapitalImputedInterestExpenseRelatedParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_AdjustmentsToAdditionalPaidInCapitalImputedInterestExpenseRelatedParty" xlink:to="lab_smmt_AdjustmentsToAdditionalPaidInCapitalImputedInterestExpenseRelatedParty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_28e7b02f-12dc-4a5b-b4d4-720d138af17c_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fc610337-7d2a-4bd7-8f3f-0510f7fe83a5_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_5f75ee45-161c-4f17-b274-1647f461c6b1_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_1bd9e7b2-023f-486b-8258-1f3153b12e58_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateDomain_d05631a1-afcf-4203-be00-c022659def39_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain" xlink:to="lab_us-gaap_VariableRateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_0858b73c-07f3-4a4e-b6cc-6b34a79336de_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_77b23fdc-c871-4ef5-b367-4fcf4d42dab2_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_Depreciation_cd00b3d3-5424-4fc8-8db2-085ac0262333_verboseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation expense</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_85190cb3-5bcc-4f66-bcdc-57f3e24c3a7a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants cancelled (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures and Expirations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_5d745854-b652-4cfe-bb13-a2c80cf31f47_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of RSU activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_7d6b7866-3e5f-4bd5-a734-027abeb19b22_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of common stock shares into which warrants may be converted (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_DeferredTaxAssetsLiabilities_a471f257-5d25-45cd-a30e-faacd7e74cb9_totalLabel_en-US" xlink:label="lab_smmt_DeferredTaxAssetsLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred tax assets before valuation allowance</link:label>
    <link:label id="lab_smmt_DeferredTaxAssetsLiabilities_label_en-US" xlink:label="lab_smmt_DeferredTaxAssetsLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets (Liabilities)</link:label>
    <link:label id="lab_smmt_DeferredTaxAssetsLiabilities_documentation_en-US" xlink:label="lab_smmt_DeferredTaxAssetsLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets (Liabilities)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_DeferredTaxAssetsLiabilities" xlink:href="smmt-20211231.xsd#smmt_DeferredTaxAssetsLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_DeferredTaxAssetsLiabilities" xlink:to="lab_smmt_DeferredTaxAssetsLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_7946006f-5d10-458b-88c7-7789f31f0a7d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_025dcea3-ef03-4e44-903c-5bc7b25dd5ff_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_c17cfb3b-998c-4e9f-b904-b434c896bdda_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_7194c0ac-29d5-48d2-b312-284dadb72776_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_BusinessCombinationAssumedContingentLiabilityNoncurrent_fa3b5b65-f227-47a3-a84c-6aa0ee45e745_terseLabel_en-US" xlink:label="lab_smmt_BusinessCombinationAssumedContingentLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assumed contingent liabilities, non-current</link:label>
    <link:label id="lab_smmt_BusinessCombinationAssumedContingentLiabilityNoncurrent_label_en-US" xlink:label="lab_smmt_BusinessCombinationAssumedContingentLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Assumed Contingent Liability, Noncurrent</link:label>
    <link:label id="lab_smmt_BusinessCombinationAssumedContingentLiabilityNoncurrent_documentation_en-US" xlink:label="lab_smmt_BusinessCombinationAssumedContingentLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Assumed Contingent Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_BusinessCombinationAssumedContingentLiabilityNoncurrent" xlink:href="smmt-20211231.xsd#smmt_BusinessCombinationAssumedContingentLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_BusinessCombinationAssumedContingentLiabilityNoncurrent" xlink:to="lab_smmt_BusinessCombinationAssumedContingentLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_d2ab770b-cf67-4598-a313-96d9eabae8f5_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_9124b987-0ecc-47ff-80fd-372390d1400e_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_8c3e794f-8f85-4b14-a1c1-7ac23587dd9b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9ab5f586-d552-4833-888e-230b12c11da4_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows provided by financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_cf44b320-0e4c-4233-aff0-2f495d30a5f8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value, options outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_93c9db3a-8dcd-45ce-ba9e-d670197e9214_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of future lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_35bfe66d-7000-4f03-8242-c103c4f9a708_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_77e91f40-e009-4656-b66e-39b81812ecb2_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_492ec7db-a333-40f4-9378-f2107c4c134f_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_015cea8b-8990-4b1b-93de-565d49a25b89_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_ResearchAndDevelopmentPrepaidExpensesCurrent_b996bb89-bf0e-472f-8cc0-236f22938cb5_terseLabel_en-US" xlink:label="lab_smmt_ResearchAndDevelopmentPrepaidExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid research and development expenditures</link:label>
    <link:label id="lab_smmt_ResearchAndDevelopmentPrepaidExpensesCurrent_label_en-US" xlink:label="lab_smmt_ResearchAndDevelopmentPrepaidExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Prepaid Expenses, Current</link:label>
    <link:label id="lab_smmt_ResearchAndDevelopmentPrepaidExpensesCurrent_documentation_en-US" xlink:label="lab_smmt_ResearchAndDevelopmentPrepaidExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Prepaid Expenses, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_ResearchAndDevelopmentPrepaidExpensesCurrent" xlink:href="smmt-20211231.xsd#smmt_ResearchAndDevelopmentPrepaidExpensesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_ResearchAndDevelopmentPrepaidExpensesCurrent" xlink:to="lab_smmt_ResearchAndDevelopmentPrepaidExpensesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_dee8a1f5-1e92-4c3d-a0d5-a3ef59131bcf_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_dd1b7081-3693-4086-87d9-344110fa5d1b_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_OtherGrantFundingCounterpartiesMember_b772d30b-f38c-4a87-8650-f9ed2871c9f4_terseLabel_en-US" xlink:label="lab_smmt_OtherGrantFundingCounterpartiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other grant funding counterparties</link:label>
    <link:label id="lab_smmt_OtherGrantFundingCounterpartiesMember_label_en-US" xlink:label="lab_smmt_OtherGrantFundingCounterpartiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Grant Funding Counterparties [Member]</link:label>
    <link:label id="lab_smmt_OtherGrantFundingCounterpartiesMember_documentation_en-US" xlink:label="lab_smmt_OtherGrantFundingCounterpartiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Grant Funding Counterparties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_OtherGrantFundingCounterpartiesMember" xlink:href="smmt-20211231.xsd#smmt_OtherGrantFundingCounterpartiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_OtherGrantFundingCounterpartiesMember" xlink:to="lab_smmt_OtherGrantFundingCounterpartiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_d7eff09d-4b3c-4dda-9813-f1b994e463d7_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_e3a07aca-a476-43ad-b7a1-1ac76f0f58f4_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value, exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_5d74266a-16e5-49f9-8429-8bad901eaa54_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_ResearchAndDevelopmentTaxCreditCashRebateMaximumPercentage_6dd79c8b-bec7-4a26-9d65-5892127c2f6b_terseLabel_en-US" xlink:label="lab_smmt_ResearchAndDevelopmentTaxCreditCashRebateMaximumPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development maximum cash rebate percentage</link:label>
    <link:label id="lab_smmt_ResearchAndDevelopmentTaxCreditCashRebateMaximumPercentage_label_en-US" xlink:label="lab_smmt_ResearchAndDevelopmentTaxCreditCashRebateMaximumPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Tax Credit, Cash Rebate Maximum, Percentage</link:label>
    <link:label id="lab_smmt_ResearchAndDevelopmentTaxCreditCashRebateMaximumPercentage_documentation_en-US" xlink:label="lab_smmt_ResearchAndDevelopmentTaxCreditCashRebateMaximumPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Tax Credit, Cash Rebate Maximum, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_ResearchAndDevelopmentTaxCreditCashRebateMaximumPercentage" xlink:href="smmt-20211231.xsd#smmt_ResearchAndDevelopmentTaxCreditCashRebateMaximumPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_ResearchAndDevelopmentTaxCreditCashRebateMaximumPercentage" xlink:to="lab_smmt_ResearchAndDevelopmentTaxCreditCashRebateMaximumPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_47517cec-6c62-4050-a339-6e30a97757c0_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, estimated useful Lives</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_OfficeAndTechnologyEquipmentMember_3efabd3d-44ae-4b27-aba7-881ad8b8120f_terseLabel_en-US" xlink:label="lab_smmt_OfficeAndTechnologyEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office and IT equipment</link:label>
    <link:label id="lab_smmt_OfficeAndTechnologyEquipmentMember_label_en-US" xlink:label="lab_smmt_OfficeAndTechnologyEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office And Technology Equipment [Member]</link:label>
    <link:label id="lab_smmt_OfficeAndTechnologyEquipmentMember_documentation_en-US" xlink:label="lab_smmt_OfficeAndTechnologyEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office And Technology Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_OfficeAndTechnologyEquipmentMember" xlink:href="smmt-20211231.xsd#smmt_OfficeAndTechnologyEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_OfficeAndTechnologyEquipmentMember" xlink:to="lab_smmt_OfficeAndTechnologyEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_9f63d318-49c7-40b8-b865-a9e93b81021d_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_ChangeInContractWithCustomerAssetAndLiabilityRollForward_9d037ea1-5676-4dec-86b6-c45470586552_terseLabel_en-US" xlink:label="lab_smmt_ChangeInContractWithCustomerAssetAndLiabilityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Contract with Customer, Asset and Liability [Roll Forward]</link:label>
    <link:label id="lab_smmt_ChangeInContractWithCustomerAssetAndLiabilityRollForward_label_en-US" xlink:label="lab_smmt_ChangeInContractWithCustomerAssetAndLiabilityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Contract with Customer, Asset and Liability [Roll Forward]</link:label>
    <link:label id="lab_smmt_ChangeInContractWithCustomerAssetAndLiabilityRollForward_documentation_en-US" xlink:label="lab_smmt_ChangeInContractWithCustomerAssetAndLiabilityRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Contract with Customer, Asset and Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_ChangeInContractWithCustomerAssetAndLiabilityRollForward" xlink:href="smmt-20211231.xsd#smmt_ChangeInContractWithCustomerAssetAndLiabilityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_ChangeInContractWithCustomerAssetAndLiabilityRollForward" xlink:to="lab_smmt_ChangeInContractWithCustomerAssetAndLiabilityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_2fa90ab3-0f14-4fd7-907b-492bc8340922_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration of Credit Risk and of Significant Supplier</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_6fcd13ca-6fc8-474f-b6ea-b58e59ca1e82_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities, net of current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_9c2719a2-979f-4269-a2c1-045102234477_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_e02ab567-b095-4570-a0a0-a2d6e2de40c4_totalLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_dca67477-a020-452d-9940-38e6086d850d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsNoncurrentAbstract_6f207ef3-56bb-42f2-8995-f22dabd62098_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Noncurrent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract" xlink:to="lab_us-gaap_AssetsNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_4b312afc-465a-4501-97d9-aa09d8554fd2_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_0a05a2bf-34d6-4829-9675-97ac44498553_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_f006588c-8eb8-47ba-87c2-f96bf6c13af2_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_7aeb9415-21a1-4d71-8434-8d21d30b4ab6_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_a2b380ef-51cd-4190-96f6-734efea469d8_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_e3b9f2fb-a1ed-41f9-9d96-54bef97c5a89_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_ResearchAndDevelopmentTaxCredit_2c8e9277-fe01-4380-9a13-fa8998acfac6_terseLabel_en-US" xlink:label="lab_smmt_ResearchAndDevelopmentTaxCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development tax credits</link:label>
    <link:label id="lab_smmt_ResearchAndDevelopmentTaxCredit_0fa02fd5-ca2e-4149-866e-826e58412e8c_verboseLabel_en-US" xlink:label="lab_smmt_ResearchAndDevelopmentTaxCredit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development tax relief</link:label>
    <link:label id="lab_smmt_ResearchAndDevelopmentTaxCredit_label_en-US" xlink:label="lab_smmt_ResearchAndDevelopmentTaxCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development, Tax Credit</link:label>
    <link:label id="lab_smmt_ResearchAndDevelopmentTaxCredit_documentation_en-US" xlink:label="lab_smmt_ResearchAndDevelopmentTaxCredit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development, Tax Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_ResearchAndDevelopmentTaxCredit" xlink:href="smmt-20211231.xsd#smmt_ResearchAndDevelopmentTaxCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_ResearchAndDevelopmentTaxCredit" xlink:to="lab_smmt_ResearchAndDevelopmentTaxCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_36955950-3127-4811-be39-5ad942d0a313_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_6df1c5da-b4f2-4b68-bad9-c512b24445d0_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_fed4f97f-3438-45d9-9e26-6cfbbe78a8ac_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_75b9f68d-0f43-474a-bd3d-8fdec333b3ba_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_NotesPayableRelatedPartiesMaximumTerm_13f3a8b3-6421-4fac-949c-7a1c14e876a6_terseLabel_en-US" xlink:label="lab_smmt_NotesPayableRelatedPartiesMaximumTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes payable, maximum term</link:label>
    <link:label id="lab_smmt_NotesPayableRelatedPartiesMaximumTerm_label_en-US" xlink:label="lab_smmt_NotesPayableRelatedPartiesMaximumTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable, Related Parties, Maximum Term</link:label>
    <link:label id="lab_smmt_NotesPayableRelatedPartiesMaximumTerm_documentation_en-US" xlink:label="lab_smmt_NotesPayableRelatedPartiesMaximumTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable, Related Parties, Maximum Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_NotesPayableRelatedPartiesMaximumTerm" xlink:href="smmt-20211231.xsd#smmt_NotesPayableRelatedPartiesMaximumTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_NotesPayableRelatedPartiesMaximumTerm" xlink:to="lab_smmt_NotesPayableRelatedPartiesMaximumTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfCountriesInWhichEntityOperates_85a80377-71be-496c-92c9-108989d94de6_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfCountriesInWhichEntityOperates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of geographic regions in which the Company operates</link:label>
    <link:label id="lab_us-gaap_NumberOfCountriesInWhichEntityOperates_label_en-US" xlink:label="lab_us-gaap_NumberOfCountriesInWhichEntityOperates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Countries in which Entity Operates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfCountriesInWhichEntityOperates" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfCountriesInWhichEntityOperates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfCountriesInWhichEntityOperates" xlink:to="lab_us-gaap_NumberOfCountriesInWhichEntityOperates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_338b9442-7749-4306-a814-9003b49471cb_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recently Issued or Adopted Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherOperatingIncome_3c51ee3b-bcd1-41b1-9c90-20c390ed7248_terseLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other operating income</link:label>
    <link:label id="lab_us-gaap_OtherOperatingIncome_617d6b7d-0368-4493-ace0-2cc694cf9341_totalLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingIncome" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other operating income</link:label>
    <link:label id="lab_us-gaap_OtherOperatingIncome_label_en-US" xlink:label="lab_us-gaap_OtherOperatingIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Operating Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherOperatingIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOperatingIncome" xlink:to="lab_us-gaap_OtherOperatingIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_334b4092-8a7c-49c8-b148-0634ec48e986_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from exercise of share options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_a160167b-3b77-4562-bb36-0b8d9a31fcba_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_d08136af-2286-4838-ae8b-a6b1b5758224_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_813313d8-08c7-4841-bd29-1665bac89ff5_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_531ae6f1-805a-4ad0-8530-2867f570ca77_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax benefit</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_12d0623f-7d57-43e8-95eb-9336ce0b697e_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total income tax benefit</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_RevenueFromContractWithCustomerDevelopmentMilestoneRevenueEntitledToReceive_51a7814c-15e7-4cdb-acb3-6250cd561317_terseLabel_en-US" xlink:label="lab_smmt_RevenueFromContractWithCustomerDevelopmentMilestoneRevenueEntitledToReceive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue entitled to receive upon various development milestones</link:label>
    <link:label id="lab_smmt_RevenueFromContractWithCustomerDevelopmentMilestoneRevenueEntitledToReceive_label_en-US" xlink:label="lab_smmt_RevenueFromContractWithCustomerDevelopmentMilestoneRevenueEntitledToReceive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Contract With Customer, Development Milestone, Revenue Entitled To Receive</link:label>
    <link:label id="lab_smmt_RevenueFromContractWithCustomerDevelopmentMilestoneRevenueEntitledToReceive_documentation_en-US" xlink:label="lab_smmt_RevenueFromContractWithCustomerDevelopmentMilestoneRevenueEntitledToReceive" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Contract With Customer, Development Milestone, Revenue Entitled To Receive</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_RevenueFromContractWithCustomerDevelopmentMilestoneRevenueEntitledToReceive" xlink:href="smmt-20211231.xsd#smmt_RevenueFromContractWithCustomerDevelopmentMilestoneRevenueEntitledToReceive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_RevenueFromContractWithCustomerDevelopmentMilestoneRevenueEntitledToReceive" xlink:to="lab_smmt_RevenueFromContractWithCustomerDevelopmentMilestoneRevenueEntitledToReceive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_3eb7f1df-325b-4e69-93a2-83268d5f1f0a_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_b4920b53-0131-4037-a4ed-dbbbb6ed841a_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_eb7e9694-80d9-49e0-944c-c0dd6f7635af_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_9340947e-3b02-4572-bbf3-ef30eb183160_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_0db8365e-759f-44c1-aad0-6399d007fab0_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_f802c148-189a-4aab-bab6-ca8919113a48_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_865305db-626b-45b5-892c-b8a79e0f793f_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_9db5e3c0-13fd-4cbc-bc8d-1920448a25d5_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_6707cb95-e334-4d00-b0f7-d5b85d38d179_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_c64db83d-0793-4af1-9041-a049dc6e1421_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_ResearchAndDevelopmentTaxCreditReceivable_ea507274-aed5-44cc-9a4b-c8f101c2a628_terseLabel_en-US" xlink:label="lab_smmt_ResearchAndDevelopmentTaxCreditReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development tax credit receivable</link:label>
    <link:label id="lab_smmt_ResearchAndDevelopmentTaxCreditReceivable_label_en-US" xlink:label="lab_smmt_ResearchAndDevelopmentTaxCreditReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Tax Credit Receivable</link:label>
    <link:label id="lab_smmt_ResearchAndDevelopmentTaxCreditReceivable_documentation_en-US" xlink:label="lab_smmt_ResearchAndDevelopmentTaxCreditReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Tax Credit Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_ResearchAndDevelopmentTaxCreditReceivable" xlink:href="smmt-20211231.xsd#smmt_ResearchAndDevelopmentTaxCreditReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_ResearchAndDevelopmentTaxCreditReceivable" xlink:to="lab_smmt_ResearchAndDevelopmentTaxCreditReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_a51b5ed9-87b6-4cfb-8526-52b47a833cf7_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average common shares outstanding:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding Reconciliation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BeneficialOwnerMember_6c4aa94c-f9b7-4d2e-a7da-01d21e70c5ea_terseLabel_en-US" xlink:label="lab_us-gaap_BeneficialOwnerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beneficial owner</link:label>
    <link:label id="lab_us-gaap_BeneficialOwnerMember_label_en-US" xlink:label="lab_us-gaap_BeneficialOwnerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beneficial Owner [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BeneficialOwnerMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BeneficialOwnerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BeneficialOwnerMember" xlink:to="lab_us-gaap_BeneficialOwnerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_b5745bae-f3bf-4a7e-86ff-d6dedf4a1d80_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_5e3d037d-5436-4271-a8d5-2fe48fe109f9_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal - United States</link:label>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_9ef61349-f26d-4758-87d7-0098e9da4da2_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_57dede72-7dc1-4faa-9b4e-fed4ab3a6555_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in valuation allowance</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ChiefOperatingOfficerMember_e51fca7d-86f5-4091-b458-7e612590f98f_terseLabel_en-US" xlink:label="lab_srt_ChiefOperatingOfficerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chief Operations Officer</link:label>
    <link:label id="lab_srt_ChiefOperatingOfficerMember_label_en-US" xlink:label="lab_srt_ChiefOperatingOfficerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chief Operating Officer [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ChiefOperatingOfficerMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ChiefOperatingOfficerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ChiefOperatingOfficerMember" xlink:to="lab_srt_ChiefOperatingOfficerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_557d05df-f815-4f16-970d-55da12a62c12_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation expense for options</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_4d7dbbd4-210d-417d-bb26-cb593f02caeb_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_29dd5399-f358-4a3f-bd10-c079f1bbfd75_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccounting_874f2b45-9769-4280-8b85-ed22777517f4_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccounting" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation and Use of Estimates</link:label>
    <link:label id="lab_us-gaap_BasisOfAccounting_label_en-US" xlink:label="lab_us-gaap_BasisOfAccounting" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccounting" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccounting"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccounting" xlink:to="lab_us-gaap_BasisOfAccounting" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_d3a688a9-c804-4af0-81d9-fe5935e8c63b_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_866b95ae-8219-4b61-8050-e397637d4f37_terseLabel_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference</link:label>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_label_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_6ebf319d-3705-43c5-80ed-36ce18d96913_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ChiefExecutiveOfficerMember_a58ffaf3-7830-4c18-8f49-0535f159e6c7_terseLabel_en-US" xlink:label="lab_srt_ChiefExecutiveOfficerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chief Executive Officer</link:label>
    <link:label id="lab_srt_ChiefExecutiveOfficerMember_label_en-US" xlink:label="lab_srt_ChiefExecutiveOfficerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chief Executive Officer [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ChiefExecutiveOfficerMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ChiefExecutiveOfficerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ChiefExecutiveOfficerMember" xlink:to="lab_srt_ChiefExecutiveOfficerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_5ba3c45f-feb5-4944-bb7c-99bd36567fc8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average grant date fair value of stock options granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_2adfc5f7-dfda-4c36-9a7e-df1d78f6cc03_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermLeaseCost_bb8ea77d-dfa6-4e15-b665-a3798c00e40b_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term lease</link:label>
    <link:label id="lab_us-gaap_ShortTermLeaseCost_label_en-US" xlink:label="lab_us-gaap_ShortTermLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermLeaseCost" xlink:to="lab_us-gaap_ShortTermLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_SecondPurchaseAgreementMember_635f380b-9988-4ea5-aa0e-4f660bd6516e_terseLabel_en-US" xlink:label="lab_smmt_SecondPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Second Purchase Agreement</link:label>
    <link:label id="lab_smmt_SecondPurchaseAgreementMember_label_en-US" xlink:label="lab_smmt_SecondPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Second Purchase Agreement [Member]</link:label>
    <link:label id="lab_smmt_SecondPurchaseAgreementMember_documentation_en-US" xlink:label="lab_smmt_SecondPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Second Purchase Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_SecondPurchaseAgreementMember" xlink:href="smmt-20211231.xsd#smmt_SecondPurchaseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_SecondPurchaseAgreementMember" xlink:to="lab_smmt_SecondPurchaseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_ff4a240a-c241-442c-a8c7-e0b1d67d0159_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_184a2698-dc55-4e98-9076-b516911692d6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_e57d726e-2702-4efa-b9f6-edc8989f8873_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental costs related to the modification</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Plan Modification, Incremental Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember_5136f32c-738c-45e0-8d13-49bfb839bc84_terseLabel_en-US" xlink:label="lab_smmt_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BARDA</link:label>
    <link:label id="lab_smmt_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember_label_en-US" xlink:label="lab_smmt_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Biomedical Advanced Research And Development Authority [Member]</link:label>
    <link:label id="lab_smmt_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember_documentation_en-US" xlink:label="lab_smmt_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Biomedical Advanced Research And Development Authority</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember" xlink:href="smmt-20211231.xsd#smmt_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember" xlink:to="lab_smmt_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_a383a647-cd56-46a9-b75f-8d85f13eadd2_terseLabel_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets:</link:label>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_label_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Deferred Tax Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_d83e38c9-9ccd-4b81-84bf-2d7095858af1_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_IncomeStatementAndStatementOfComprehensiveIncomeAbstract_3b08a9f1-7a79-455d-9af5-8646d76b1c4a_terseLabel_en-US" xlink:label="lab_smmt_IncomeStatementAndStatementOfComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement And Statement Of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_smmt_IncomeStatementAndStatementOfComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_smmt_IncomeStatementAndStatementOfComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement And Statement Of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_smmt_IncomeStatementAndStatementOfComprehensiveIncomeAbstract_documentation_en-US" xlink:label="lab_smmt_IncomeStatementAndStatementOfComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement And Statement Of Comprehensive Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_IncomeStatementAndStatementOfComprehensiveIncomeAbstract" xlink:href="smmt-20211231.xsd#smmt_IncomeStatementAndStatementOfComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_IncomeStatementAndStatementOfComprehensiveIncomeAbstract" xlink:to="lab_smmt_IncomeStatementAndStatementOfComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_26179a3b-0f2a-44bd-8396-b05dd612cff8_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue and other income</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_ConsultancyAgreementWarrantVestingExpenseMember_c66d9cc3-0dca-4e53-8501-2804071a8c13_terseLabel_en-US" xlink:label="lab_smmt_ConsultancyAgreementWarrantVestingExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant vesting expense</link:label>
    <link:label id="lab_smmt_ConsultancyAgreementWarrantVestingExpenseMember_label_en-US" xlink:label="lab_smmt_ConsultancyAgreementWarrantVestingExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consultancy Agreement, Warrant Vesting Expense [Member]</link:label>
    <link:label id="lab_smmt_ConsultancyAgreementWarrantVestingExpenseMember_documentation_en-US" xlink:label="lab_smmt_ConsultancyAgreementWarrantVestingExpenseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consultancy Agreement, Warrant Vesting Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_ConsultancyAgreementWarrantVestingExpenseMember" xlink:href="smmt-20211231.xsd#smmt_ConsultancyAgreementWarrantVestingExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_ConsultancyAgreementWarrantVestingExpenseMember" xlink:to="lab_smmt_ConsultancyAgreementWarrantVestingExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_c375666a-c992-4fe9-9fd6-8d13b3958daf_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Intangible Assets, Finite-lived</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Intangible Assets, Finite-lived</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_6ccc5cb9-9835-4342-b567-5deccf0c6b18_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitment_3e1b11e2-7670-4e12-ab21-45270b58c18d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual commitments</link:label>
    <link:label id="lab_us-gaap_OtherCommitment_label_en-US" xlink:label="lab_us-gaap_OtherCommitment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitment" xlink:to="lab_us-gaap_OtherCommitment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticCountryMember_4004fb26-3f4d-4a99-bc0d-cc740644181c_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Federal</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember" xlink:to="lab_us-gaap_DomesticCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_b6c9fe1e-f350-401c-a70c-fa3f4634845a_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in valuation allowance</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_6d8381e7-679a-4856-8846-6b36a8e8c90c_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_7e4f62f6-98d8-4835-8419-e8aa6c262947_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_cc4a8ac6-83b9-4773-b9e0-109b319acacc_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase price of common stock as a percentage of closing price</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_397fdfa1-235f-4c17-8b65-b2ab82a654b1_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss before income tax</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_259fee0f-b11b-4af0-aeab-2589f2828ccb_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_4351cc85-c4ad-409c-bbd6-954282ed9a1f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockLineItems_8c4fc345-03b5-470d-b7df-1619af192675_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_a1873c2a-8396-45df-b763-02a8967b4951_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue and other income, net of current portion</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_7aee2abb-bde0-4602-ae46-269f9e663baa_netLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term deferred revenue and other income</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_fbb54427-f09e-4f0a-90fb-4d2e542b387b_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current contract liability</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorLocation_5c4da614-01c8-446b-91d6-20aa6545f48c_terseLabel_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:label id="lab_dei_AuditorLocation_label_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation" xlink:to="lab_dei_AuditorLocation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_65f1b210-c4b4-4117-8337-bc82e4e2dda7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Products and Services [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Products and Services [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:to="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_790aeec2-2732-497b-8dec-2fe9525b11fb_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_15a71c0c-2a63-4b68-bab4-f8c76f3b0230_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options granted previously subject to performance-based vesting (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2506c5b8-73b2-4a9f-b792-4f5686dbf969_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_ec7be322-aabe-40cd-8cb5-cf6f25dd07ad_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of net loss per share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_7470782c-d666-493c-89eb-56eb00aa4dcf_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioForecastMember_a44766bf-0f41-4ddd-b5c5-709d960cf55f_terseLabel_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast</link:label>
    <link:label id="lab_srt_ScenarioForecastMember_label_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioForecastMember" xlink:to="lab_srt_ScenarioForecastMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_7612afb6-8d3a-4c40-a3ff-b5c599ced765_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_928d462d-5b41-4fce-963e-bdba97d46325_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_RevenueInformationUsedToDetermineTransactionPriceNumberOfEnrollmentMilestones_c4d3aa75-2e63-47df-8839-d848160de69c_terseLabel_en-US" xlink:label="lab_smmt_RevenueInformationUsedToDetermineTransactionPriceNumberOfEnrollmentMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of enrollment milestones included in transaction price</link:label>
    <link:label id="lab_smmt_RevenueInformationUsedToDetermineTransactionPriceNumberOfEnrollmentMilestones_label_en-US" xlink:label="lab_smmt_RevenueInformationUsedToDetermineTransactionPriceNumberOfEnrollmentMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Information Used to Determine Transaction Price, Number of Enrollment Milestones</link:label>
    <link:label id="lab_smmt_RevenueInformationUsedToDetermineTransactionPriceNumberOfEnrollmentMilestones_documentation_en-US" xlink:label="lab_smmt_RevenueInformationUsedToDetermineTransactionPriceNumberOfEnrollmentMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Information Used to Determine Transaction Price, Number of Enrollment Milestones</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_RevenueInformationUsedToDetermineTransactionPriceNumberOfEnrollmentMilestones" xlink:href="smmt-20211231.xsd#smmt_RevenueInformationUsedToDetermineTransactionPriceNumberOfEnrollmentMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_RevenueInformationUsedToDetermineTransactionPriceNumberOfEnrollmentMilestones" xlink:to="lab_smmt_RevenueInformationUsedToDetermineTransactionPriceNumberOfEnrollmentMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_c790b4b4-76a2-4d2b-9faf-a33980be9453_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from the issuance of common stock</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_9d6bb5c3-99a1-492e-843b-528600af0531_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_DirectorMember_8d4274a1-41c7-4526-aee5-4a72c4cec083_terseLabel_en-US" xlink:label="lab_srt_DirectorMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Director</link:label>
    <link:label id="lab_srt_DirectorMember_label_en-US" xlink:label="lab_srt_DirectorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Director [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_DirectorMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_DirectorMember" xlink:to="lab_srt_DirectorMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_8d27930f-9777-4c7d-8a82-130fd73f21ad_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_8f6eece7-cd61-40e6-af5a-13b8729c3f35_terseLabel_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities:</link:label>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Deferred Tax Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_ed8e2b77-6d6c-4d30-8bce-dc370a17c102_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_0542d89b-46a8-48bc-ab25-96dc45f1b888_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for interest on related party promissory note</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_61967468-4e0f-46d9-8932-a9f7d2261ce5_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualAxis_54bfb0e8-214c-42e4-932b-bc8e0b86a31f_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:label id="lab_srt_TitleOfIndividualAxis_label_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_ccab52ae-fad3-4753-bb79-a22a1beab375_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_49745716-148e-444c-a517-3441db95e814_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_43182b90-b81f-4c31-a188-aeda1105cec7_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_InitialPurchaseAgreementMember_3ca3afba-385f-49e6-baee-d10580a414a0_terseLabel_en-US" xlink:label="lab_smmt_InitialPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial Purchase Agreement</link:label>
    <link:label id="lab_smmt_InitialPurchaseAgreementMember_label_en-US" xlink:label="lab_smmt_InitialPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial Purchase Agreement [Member]</link:label>
    <link:label id="lab_smmt_InitialPurchaseAgreementMember_documentation_en-US" xlink:label="lab_smmt_InitialPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial Purchase Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_InitialPurchaseAgreementMember" xlink:href="smmt-20211231.xsd#smmt_InitialPurchaseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_InitialPurchaseAgreementMember" xlink:to="lab_smmt_InitialPurchaseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_815ea685-60c7-4b16-ade7-a3d082a032c5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_54b7ad17-ab93-408b-a92b-1ea3e380f57b_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_52a1f877-a3f6-466f-8829-d2d666073990_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_788f7a5b-8ae8-4417-9259-c3fbebe133d6_negatedLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_32f3860f-fde7-4846-86b8-0051477dd8ca_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax credit carryforward</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:to="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_AssumedContingentLiabilitiesPolicyPolicyTextBlock_762efa5b-4829-4fba-996b-c8c47f3713d5_terseLabel_en-US" xlink:label="lab_smmt_AssumedContingentLiabilitiesPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assumed Contingent Liabilities</link:label>
    <link:label id="lab_smmt_AssumedContingentLiabilitiesPolicyPolicyTextBlock_label_en-US" xlink:label="lab_smmt_AssumedContingentLiabilitiesPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assumed Contingent Liabilities, Policy [Policy Text Block]</link:label>
    <link:label id="lab_smmt_AssumedContingentLiabilitiesPolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_smmt_AssumedContingentLiabilitiesPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assumed Contingent Liabilities, Policy</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_AssumedContingentLiabilitiesPolicyPolicyTextBlock" xlink:href="smmt-20211231.xsd#smmt_AssumedContingentLiabilitiesPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_AssumedContingentLiabilitiesPolicyPolicyTextBlock" xlink:to="lab_smmt_AssumedContingentLiabilitiesPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_5f1c2cfc-20d8-4f7e-b624-b3a630b3e8d9_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of lease expense</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_221086f6-3fd3-44cd-98ab-54a9c7f740d5_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_eb2d9598-784a-483c-9af2-6ffcfb4ca463_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:to="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_dc2a3db1-eaa2-410a-8547-53dcf921fef0_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_OtherPatentsAndLicensesMember_4888853a-54c6-4c07-a659-673f986d55ef_terseLabel_en-US" xlink:label="lab_smmt_OtherPatentsAndLicensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other patents and licenses</link:label>
    <link:label id="lab_smmt_OtherPatentsAndLicensesMember_label_en-US" xlink:label="lab_smmt_OtherPatentsAndLicensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Patents and Licenses [Member]</link:label>
    <link:label id="lab_smmt_OtherPatentsAndLicensesMember_documentation_en-US" xlink:label="lab_smmt_OtherPatentsAndLicensesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Patents and Licenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_OtherPatentsAndLicensesMember" xlink:href="smmt-20211231.xsd#smmt_OtherPatentsAndLicensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_OtherPatentsAndLicensesMember" xlink:to="lab_smmt_OtherPatentsAndLicensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_e0a95812-a25c-40e1-98d3-d940ded81ca2_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-deductible expenses</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_20011bae-8c91-4aa6-81b5-db562a2a1f3d_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_7756a482-7880-4224-a35a-7520c9085d94_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic weighted average number of shares of common stock outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_061f3ab9-f475-4b4f-82e3-41e8a5216e4e_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_d717abbd-d398-4d74-9876-015630e6221b_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted net loss per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_8d541906-ace2-4b53-b9f0-c927e7a0a48f_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. State</link:label>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_label_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicenseAndServiceMember_c0333044-4908-402d-adfc-d4314aff1b83_terseLabel_en-US" xlink:label="lab_us-gaap_LicenseAndServiceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing agreements</link:label>
    <link:label id="lab_us-gaap_LicenseAndServiceMember_label_en-US" xlink:label="lab_us-gaap_LicenseAndServiceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License and Service [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseAndServiceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseAndServiceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicenseAndServiceMember" xlink:to="lab_us-gaap_LicenseAndServiceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_07e4a0ec-cc35-4d03-a88b-80144de239e6_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_72ac4e7f-06a0-4ab6-ab9b-b4df28f003d0_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of operating right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Amortization Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_3fe4d942-7fba-4e1f-b54c-8f12e40e0511_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid (received) for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaidNet" xlink:to="lab_us-gaap_IncomeTaxesPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_IncreaseDecreaseInAccruedLiabilitiesAndEmployeeRelatedLiabilities_d27b8fe3-8b6b-4aa4-b025-901d627bfb6c_terseLabel_en-US" xlink:label="lab_smmt_IncreaseDecreaseInAccruedLiabilitiesAndEmployeeRelatedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities and accrued compensation</link:label>
    <link:label id="lab_smmt_IncreaseDecreaseInAccruedLiabilitiesAndEmployeeRelatedLiabilities_label_en-US" xlink:label="lab_smmt_IncreaseDecreaseInAccruedLiabilitiesAndEmployeeRelatedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities and Employee-related Liabilities</link:label>
    <link:label id="lab_smmt_IncreaseDecreaseInAccruedLiabilitiesAndEmployeeRelatedLiabilities_documentation_en-US" xlink:label="lab_smmt_IncreaseDecreaseInAccruedLiabilitiesAndEmployeeRelatedLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities and Employee-related Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_IncreaseDecreaseInAccruedLiabilitiesAndEmployeeRelatedLiabilities" xlink:href="smmt-20211231.xsd#smmt_IncreaseDecreaseInAccruedLiabilitiesAndEmployeeRelatedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_IncreaseDecreaseInAccruedLiabilitiesAndEmployeeRelatedLiabilities" xlink:to="lab_smmt_IncreaseDecreaseInAccruedLiabilitiesAndEmployeeRelatedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_3993e778-7a33-4979-9b0f-897f0e857b90_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostAbstract_f3671413-c1e8-42b2-8a96-55034fe576e6_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Cost:</link:label>
    <link:label id="lab_us-gaap_LeaseCostAbstract_label_en-US" xlink:label="lab_us-gaap_LeaseCostAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostAbstract" xlink:to="lab_us-gaap_LeaseCostAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_697a1340-7936-48ee-a429-3331a42f201e_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_22a2880e-8ac6-46fe-be37-81f274f79ff1_periodStartLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning deferred revenue and other income</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_b5d447fd-e6cc-4c96-b8eb-6e47d6253435_periodEndLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending deferred revenue and other income</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_1097781c-9282-479d-968e-96c017aa62f3_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue, upfront payment</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_DiscuvaPlatformMember_0de011dc-f007-4b1b-8ad2-1e308490a11d_terseLabel_en-US" xlink:label="lab_smmt_DiscuvaPlatformMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discuva platform</link:label>
    <link:label id="lab_smmt_DiscuvaPlatformMember_label_en-US" xlink:label="lab_smmt_DiscuvaPlatformMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discuva Platform [Member]</link:label>
    <link:label id="lab_smmt_DiscuvaPlatformMember_documentation_en-US" xlink:label="lab_smmt_DiscuvaPlatformMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discuva Platform</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_DiscuvaPlatformMember" xlink:href="smmt-20211231.xsd#smmt_DiscuvaPlatformMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_DiscuvaPlatformMember" xlink:to="lab_smmt_DiscuvaPlatformMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_59e47a3f-6484-430e-bf23-fa69309ecdd8_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_49ee0ee5-cd58-4868-911e-1319b16b62bd_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive (loss) income:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_54d7857b-9be2-47c3-876d-27742ca87c47_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining contractual term</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_a3835508-7a07-40fb-90b4-d69a043ae319_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_440b064f-618d-4f90-9a15-55f69435e36d_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_OxfordshireUKMember_c5fe230b-4648-4c0c-b54c-53eb0e62b21c_terseLabel_en-US" xlink:label="lab_smmt_OxfordshireUKMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oxfordshire, UK</link:label>
    <link:label id="lab_smmt_OxfordshireUKMember_label_en-US" xlink:label="lab_smmt_OxfordshireUKMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oxfordshire, UK [Member]</link:label>
    <link:label id="lab_smmt_OxfordshireUKMember_documentation_en-US" xlink:label="lab_smmt_OxfordshireUKMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oxfordshire, UK</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_OxfordshireUKMember" xlink:href="smmt-20211231.xsd#smmt_OxfordshireUKMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_OxfordshireUKMember" xlink:to="lab_smmt_OxfordshireUKMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_7c3c58c8-3b4e-41ab-8deb-382dbd879614_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of the effective income tax rate to the statutory rate</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_c399b8ce-6dad-4fbb-9e79-04c4b922c84e_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_AreaOfPremisesSubleased_f47fd00d-c9c3-4c81-8101-5fdbe7b329f0_terseLabel_en-US" xlink:label="lab_smmt_AreaOfPremisesSubleased" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Area of premises subleased</link:label>
    <link:label id="lab_smmt_AreaOfPremisesSubleased_label_en-US" xlink:label="lab_smmt_AreaOfPremisesSubleased" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Area Of Premises Subleased</link:label>
    <link:label id="lab_smmt_AreaOfPremisesSubleased_documentation_en-US" xlink:label="lab_smmt_AreaOfPremisesSubleased" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Area Of Premises Subleased</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_AreaOfPremisesSubleased" xlink:href="smmt-20211231.xsd#smmt_AreaOfPremisesSubleased"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_AreaOfPremisesSubleased" xlink:to="lab_smmt_AreaOfPremisesSubleased" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_3c6d13d0-0c9c-4116-a628-1f85363861ed_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCountryMember_d13eab3e-a148-4ab1-9749-216562c064fa_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.K.</link:label>
    <link:label id="lab_us-gaap_ForeignCountryMember_label_en-US" xlink:label="lab_us-gaap_ForeignCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCountryMember" xlink:to="lab_us-gaap_ForeignCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_d7b37ac7-2bba-4e5c-beba-932cf734287d_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsPolicy" xlink:to="lab_us-gaap_BusinessCombinationsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_81392053-d0df-4e4b-83aa-173d49b55fc9_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_428c8a89-6b6a-4698-8567-55db6e50665f_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_0e8bbc88-04ca-477f-b82f-665c9184c2ff_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_c5a66e6c-3c07-45bd-aa72-73494e26185b_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_DeferredTaxAssetsNetIncreaseDecreaseDueToChangeInEnactedTaxRateAmount_994e3cd4-6979-4c4e-929c-d0c4fc9eeaba_terseLabel_en-US" xlink:label="lab_smmt_DeferredTaxAssetsNetIncreaseDecreaseDueToChangeInEnactedTaxRateAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in net deferred tax assets due to change in enacted tax rate</link:label>
    <link:label id="lab_smmt_DeferredTaxAssetsNetIncreaseDecreaseDueToChangeInEnactedTaxRateAmount_label_en-US" xlink:label="lab_smmt_DeferredTaxAssetsNetIncreaseDecreaseDueToChangeInEnactedTaxRateAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net, Increase (Decrease) Due To Change In Enacted Tax Rate, Amount</link:label>
    <link:label id="lab_smmt_DeferredTaxAssetsNetIncreaseDecreaseDueToChangeInEnactedTaxRateAmount_documentation_en-US" xlink:label="lab_smmt_DeferredTaxAssetsNetIncreaseDecreaseDueToChangeInEnactedTaxRateAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net, Increase (Decrease) Due To Change In Enacted Tax Rate, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_DeferredTaxAssetsNetIncreaseDecreaseDueToChangeInEnactedTaxRateAmount" xlink:href="smmt-20211231.xsd#smmt_DeferredTaxAssetsNetIncreaseDecreaseDueToChangeInEnactedTaxRateAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_DeferredTaxAssetsNetIncreaseDecreaseDueToChangeInEnactedTaxRateAmount" xlink:to="lab_smmt_DeferredTaxAssetsNetIncreaseDecreaseDueToChangeInEnactedTaxRateAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_5196ba18-2d0b-431e-bf82-01fb69827665_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComputerSoftwareIntangibleAssetMember_35efcecb-e188-4fbd-a75b-2131e47f06a1_terseLabel_en-US" xlink:label="lab_us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Software</link:label>
    <link:label id="lab_us-gaap_ComputerSoftwareIntangibleAssetMember_label_en-US" xlink:label="lab_us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Software, Intangible Asset [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:to="lab_us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_b308dcbf-feaa-48f1-8ff4-98e7ef87e081_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportingUnits_0ce73aec-20b2-4d3b-adc5-0d08ba44da2e_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportingUnits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of reporting units</link:label>
    <link:label id="lab_us-gaap_NumberOfReportingUnits_label_en-US" xlink:label="lab_us-gaap_NumberOfReportingUnits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Reporting Units</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportingUnits" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfReportingUnits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportingUnits" xlink:to="lab_us-gaap_NumberOfReportingUnits" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_373d56db-4f23-499c-8a97-115feaa6f06d_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_156f732c-f15f-4d36-bf14-690c6995ca15_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_69a6605b-e568-436f-9715-a2dc3d060c31_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of share options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_6ea3480c-b7fe-4c5c-ab47-ecd05005c374_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State - United States</link:label>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCost_7c76f3c3-9967-4e58-bf89-2e2d3d80298d_totalLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease cost</link:label>
    <link:label id="lab_us-gaap_LeaseCost_label_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_NotesPayableRelatedPartiesMaturityTriggeringEventPublicOfferingProceedsThreshold_afbdbce2-f8eb-4e7d-b993-ad60e69e50db_terseLabel_en-US" xlink:label="lab_smmt_NotesPayableRelatedPartiesMaturityTriggeringEventPublicOfferingProceedsThreshold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes payable, maturity triggering event, public offering proceeds threshold</link:label>
    <link:label id="lab_smmt_NotesPayableRelatedPartiesMaturityTriggeringEventPublicOfferingProceedsThreshold_label_en-US" xlink:label="lab_smmt_NotesPayableRelatedPartiesMaturityTriggeringEventPublicOfferingProceedsThreshold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable, Related Parties, Maturity Triggering Event, Public Offering Proceeds Threshold</link:label>
    <link:label id="lab_smmt_NotesPayableRelatedPartiesMaturityTriggeringEventPublicOfferingProceedsThreshold_documentation_en-US" xlink:label="lab_smmt_NotesPayableRelatedPartiesMaturityTriggeringEventPublicOfferingProceedsThreshold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable, Related Parties, Maturity Triggering Event, Public Offering Proceeds Threshold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_NotesPayableRelatedPartiesMaturityTriggeringEventPublicOfferingProceedsThreshold" xlink:href="smmt-20211231.xsd#smmt_NotesPayableRelatedPartiesMaturityTriggeringEventPublicOfferingProceedsThreshold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_NotesPayableRelatedPartiesMaturityTriggeringEventPublicOfferingProceedsThreshold" xlink:to="lab_smmt_NotesPayableRelatedPartiesMaturityTriggeringEventPublicOfferingProceedsThreshold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_70193b0a-acf7-47ac-b94c-9ef2ee9253a0_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of property and equipment useful lives</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_7b56c6d8-9a5d-4066-b6d0-fd936d997c39_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of property and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_aad0ff28-115d-43f6-9028-2c5efd92e7ce_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development credit carryforward</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Research</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_3b20c983-fedb-4f6b-a5a6-d5d714209b5e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_c68d3ce8-147c-48c5-a9ef-c95277e57a11_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_e8cd9703-2b54-4fcf-aed4-7c40545fb616_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_f41c0ca5-a0c3-45e1-841f-dfb83ada928e_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_f3912a8a-6cf8-4e63-b571-d04939de998b_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_38429686-4266-4b7d-829e-0f9f43e88937_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_GrantFundingArrangementFundingReceived_49e35149-b852-4f84-b4a0-1a376f8542b1_terseLabel_en-US" xlink:label="lab_smmt_GrantFundingArrangementFundingReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funding received</link:label>
    <link:label id="lab_smmt_GrantFundingArrangementFundingReceived_label_en-US" xlink:label="lab_smmt_GrantFundingArrangementFundingReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant Funding Arrangement, Funding Received</link:label>
    <link:label id="lab_smmt_GrantFundingArrangementFundingReceived_documentation_en-US" xlink:label="lab_smmt_GrantFundingArrangementFundingReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant Funding Arrangement, Funding Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_GrantFundingArrangementFundingReceived" xlink:href="smmt-20211231.xsd#smmt_GrantFundingArrangementFundingReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_GrantFundingArrangementFundingReceived" xlink:to="lab_smmt_GrantFundingArrangementFundingReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_d83b388f-6e3e-489a-9d50-2a5dab6c4616_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule estimated future amortization expense related to acquired intangible assets</link:label>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_673ad04b-4069-40e3-8969-cd089c9fb1e7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_ea6c20ff-3038-4bc8-8127-4cd218530594_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfRelatedPartyDebt_26dee827-e969-4d36-9557-a55266744308_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfRelatedPartyDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Re-payment of related party promissory notes</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfRelatedPartyDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfRelatedPartyDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Related Party Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfRelatedPartyDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfRelatedPartyDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfRelatedPartyDebt" xlink:to="lab_us-gaap_RepaymentsOfRelatedPartyDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_03d863eb-96c9-4566-9fd0-849e46042021_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_2951328f-0f1b-4394-806f-722a8bb4498d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_794838a0-f972-4d6c-aa3d-4086720d7a30_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustment</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_6182fdb5-db00-4654-89af-7165b42262e4_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain" xlink:to="lab_us-gaap_RelatedPartyTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_ScheduleOfOtherOperatingIncomeByComponentTableTextBlock_d3ceafac-9a0f-4e2b-b873-a9319176841c_terseLabel_en-US" xlink:label="lab_smmt_ScheduleOfOtherOperatingIncomeByComponentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of other operating income by category</link:label>
    <link:label id="lab_smmt_ScheduleOfOtherOperatingIncomeByComponentTableTextBlock_label_en-US" xlink:label="lab_smmt_ScheduleOfOtherOperatingIncomeByComponentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Other Operating Income, by Component [Table Text Block]</link:label>
    <link:label id="lab_smmt_ScheduleOfOtherOperatingIncomeByComponentTableTextBlock_documentation_en-US" xlink:label="lab_smmt_ScheduleOfOtherOperatingIncomeByComponentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Other Operating Income, by Component</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_ScheduleOfOtherOperatingIncomeByComponentTableTextBlock" xlink:href="smmt-20211231.xsd#smmt_ScheduleOfOtherOperatingIncomeByComponentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_ScheduleOfOtherOperatingIncomeByComponentTableTextBlock" xlink:to="lab_smmt_ScheduleOfOtherOperatingIncomeByComponentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesOther_50c3907b-9c83-4caf-b1fe-2ada3fb87c73_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesOther" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_25683992-e148-487a-b695-4e28627cd4b1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current and long-term assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1808a4d8-8ee9-4320-9ddc-0b7fdf274c52_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price of warrants (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_d166a875-ba60-46c7-b6b0-83161cdbc98c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of share options, vested and expected to vest (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityAbstract_ec51ef08-c178-4c35-be09-5736f6ed34d7_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating lease liabilities balance sheet presentation:</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_8a19d0ea-e4e8-44a4-9f0f-94312e03f526_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_b2e66f48-fa6b-4aec-9f52-0650e065e314_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantMember_f6abf945-4693-44ab-bc13-5d4e1d643ddf_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants</link:label>
    <link:label id="lab_us-gaap_WarrantMember_label_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_ead99fa0-e4bc-4a48-87c9-c5da8ab47411_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_d1c350e1-b274-4db7-8a76-5f37b7e5e2f8_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_2bd72bfa-0b98-49d5-bf80-edc603c04577_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining contractual term, exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchMember_0580a168-acd0-4bba-aac3-7bcc3e1f618f_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development tax credit carryforwards</link:label>
    <link:label id="lab_us-gaap_ResearchMember_label_en-US" xlink:label="lab_us-gaap_ResearchMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Tax Credit Carryforward [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchMember" xlink:to="lab_us-gaap_ResearchMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_39a20e34-fedc-428e-abb8-22639c1b928e_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_BusinessCombinationAssumedContingentLiabilityMeasurementInput_7a606247-d3eb-46ac-8829-862bafc02c8b_terseLabel_en-US" xlink:label="lab_smmt_BusinessCombinationAssumedContingentLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assumed contingent liability, measurement input</link:label>
    <link:label id="lab_smmt_BusinessCombinationAssumedContingentLiabilityMeasurementInput_label_en-US" xlink:label="lab_smmt_BusinessCombinationAssumedContingentLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Assumed Contingent Liability, Measurement Input</link:label>
    <link:label id="lab_smmt_BusinessCombinationAssumedContingentLiabilityMeasurementInput_documentation_en-US" xlink:label="lab_smmt_BusinessCombinationAssumedContingentLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Assumed Contingent Liability, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_BusinessCombinationAssumedContingentLiabilityMeasurementInput" xlink:href="smmt-20211231.xsd#smmt_BusinessCombinationAssumedContingentLiabilityMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_BusinessCombinationAssumedContingentLiabilityMeasurementInput" xlink:to="lab_smmt_BusinessCombinationAssumedContingentLiabilityMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract_8587403a-177e-48e2-a0d0-a02de4560ae4_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic and Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e3d1eef7-dfe7-4879-8ad8-7cb04c3bde4d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_c86a88e9-ea73-4e49-bac9-7bf7a2b5f60a_totalLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedOutstandingNumber_1d82f41d-5939-4827-9329-2cc792158420_terseLabel_en-US" xlink:label="lab_smmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding vested awards (in shares)</link:label>
    <link:label id="lab_smmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedOutstandingNumber_label_en-US" xlink:label="lab_smmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested, Outstanding, Number</link:label>
    <link:label id="lab_smmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedOutstandingNumber_documentation_en-US" xlink:label="lab_smmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedOutstandingNumber" xlink:href="smmt-20211231.xsd#smmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedOutstandingNumber" xlink:to="lab_smmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_ContractWithCustomerLiabilityEnrollmentMilestone_5edc60c9-c861-4985-a3cf-149e27ceb2d1_terseLabel_en-US" xlink:label="lab_smmt_ContractWithCustomerLiabilityEnrollmentMilestone" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue, enrollment milestone</link:label>
    <link:label id="lab_smmt_ContractWithCustomerLiabilityEnrollmentMilestone_label_en-US" xlink:label="lab_smmt_ContractWithCustomerLiabilityEnrollmentMilestone" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Liability, Enrollment Milestone</link:label>
    <link:label id="lab_smmt_ContractWithCustomerLiabilityEnrollmentMilestone_documentation_en-US" xlink:label="lab_smmt_ContractWithCustomerLiabilityEnrollmentMilestone" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Liability, Enrollment Milestone</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_ContractWithCustomerLiabilityEnrollmentMilestone" xlink:href="smmt-20211231.xsd#smmt_ContractWithCustomerLiabilityEnrollmentMilestone"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_ContractWithCustomerLiabilityEnrollmentMilestone" xlink:to="lab_smmt_ContractWithCustomerLiabilityEnrollmentMilestone" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_b1a6f1ce-77d0-4cf8-9477-34e0377654e5_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_6c6c4fff-9f56-43e4-b687-5e169c51cacb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of loss before income taxes</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNetCurrent_7a6d0f10-3bb7-41e7-bb72-26b8ca980e8b_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current contract asset</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNetCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Asset, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:to="lab_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_58425d24-f0b2-4e17-9cef-058bb60c256e_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c57cf89d-6e9c-48bd-9488-1b091fc203db_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_A2020StockIncentivePlanMember_de51f6ae-134f-48ba-b35b-d0d9c31ff20d_terseLabel_en-US" xlink:label="lab_smmt_A2020StockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Plan</link:label>
    <link:label id="lab_smmt_A2020StockIncentivePlanMember_label_en-US" xlink:label="lab_smmt_A2020StockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Stock Incentive Plan [Member]</link:label>
    <link:label id="lab_smmt_A2020StockIncentivePlanMember_documentation_en-US" xlink:label="lab_smmt_A2020StockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Stock Incentive Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_A2020StockIncentivePlanMember" xlink:href="smmt-20211231.xsd#smmt_A2020StockIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_A2020StockIncentivePlanMember" xlink:to="lab_smmt_A2020StockIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_a780b4d5-315e-4618-8ae0-70d5df673caf_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_ff32ec5a-2c2b-4f2c-b444-f5402c3cab85_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_a360a4bf-7556-4e21-a022-8ceb43a1b8a9_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_88c6ceca-29aa-4cc4-9e43-2e51c420971e_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_06c169b9-1a5b-4fa6-8653-5174629044f7_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Discount Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:to="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_b4fff91f-58d1-4039-ae66-6e4add9b2161_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_afda562a-099c-4110-8108-0f7c574755c4_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others [Line Items]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_1ddcf9df-e4b2-4345-a546-04e0d41ac187_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_1571db9b-5be2-4c15-b974-8c433036e8ff_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares initially reserve for future issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_96a3c109-e170-41de-a85c-55592326c85c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of acquired intangible assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_d412ded4-7e10-47d8-8fa6-73ca87b568c9_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_422303bd-a30f-457e-bf2f-fcb5f405fe51_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_bf1a974e-5649-47c5-8aff-3e55ec16d5b3_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_LesseeOperatingLeaseNumberOfContracts_cad4cb72-a60d-4916-92ee-bc31dffbc3ef_terseLabel_en-US" xlink:label="lab_smmt_LesseeOperatingLeaseNumberOfContracts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of leases</link:label>
    <link:label id="lab_smmt_LesseeOperatingLeaseNumberOfContracts_label_en-US" xlink:label="lab_smmt_LesseeOperatingLeaseNumberOfContracts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Number Of Contracts</link:label>
    <link:label id="lab_smmt_LesseeOperatingLeaseNumberOfContracts_documentation_en-US" xlink:label="lab_smmt_LesseeOperatingLeaseNumberOfContracts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Number Of Contracts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_LesseeOperatingLeaseNumberOfContracts" xlink:href="smmt-20211231.xsd#smmt_LesseeOperatingLeaseNumberOfContracts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_LesseeOperatingLeaseNumberOfContracts" xlink:to="lab_smmt_LesseeOperatingLeaseNumberOfContracts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_0ea2fced-3ce7-4ff1-8401-b4a2cc02756a_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_98c55f13-9bb8-49fb-a9f2-7abcfe610277_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance on common stock from exercise of share options (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_f76b0c2f-c385-4f32-a01e-b2b3dcc1d96b_negatedNetLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_f1c37a37-347c-491f-9ee8-bda1250a10ee_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_d54404e5-9295-458d-be74-98f19c8d1666_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_e8838409-3afe-4011-b2bc-ee1053878d3a_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted weighted average number of shares of common stock outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_565c238d-f266-4116-8770-47f16a2e2024_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Domestic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_RelatedPartyTransactionBeneficialOwnershipPercentage_79a74e65-0af6-466b-99f1-4bd42901c311_terseLabel_en-US" xlink:label="lab_smmt_RelatedPartyTransactionBeneficialOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beneficial ownership percentage</link:label>
    <link:label id="lab_smmt_RelatedPartyTransactionBeneficialOwnershipPercentage_label_en-US" xlink:label="lab_smmt_RelatedPartyTransactionBeneficialOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Beneficial Ownership Percentage</link:label>
    <link:label id="lab_smmt_RelatedPartyTransactionBeneficialOwnershipPercentage_documentation_en-US" xlink:label="lab_smmt_RelatedPartyTransactionBeneficialOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Ownership Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_RelatedPartyTransactionBeneficialOwnershipPercentage" xlink:href="smmt-20211231.xsd#smmt_RelatedPartyTransactionBeneficialOwnershipPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_RelatedPartyTransactionBeneficialOwnershipPercentage" xlink:to="lab_smmt_RelatedPartyTransactionBeneficialOwnershipPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_51d69bb2-2632-49f3-b400-97d44a893f32_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan_96e15175-67e7-454e-8920-789d74db5e93_terseLabel_en-US" xlink:label="lab_smmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of additional shares that can be added to the plan for future issuance (in shares)</link:label>
    <link:label id="lab_smmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan_label_en-US" xlink:label="lab_smmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Allowable Under The Plan</link:label>
    <link:label id="lab_smmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan_documentation_en-US" xlink:label="lab_smmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Allowable Under The Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan" xlink:href="smmt-20211231.xsd#smmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan" xlink:to="lab_smmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_ca072e35-450c-4149-ac14-f910e7e1d05c_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_f9622d48-210f-4186-8277-08fa4b39042f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of stock option activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseDueToChangeInEnactedTaxRateAmount_853389f9-bcaa-4a47-97a3-bbe9e00aac52_terseLabel_en-US" xlink:label="lab_smmt_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseDueToChangeInEnactedTaxRateAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in valuation allowance due to change in enacted tax rate</link:label>
    <link:label id="lab_smmt_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseDueToChangeInEnactedTaxRateAmount_label_en-US" xlink:label="lab_smmt_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseDueToChangeInEnactedTaxRateAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease) Due To Change In Enacted Tax Rate, Amount</link:label>
    <link:label id="lab_smmt_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseDueToChangeInEnactedTaxRateAmount_documentation_en-US" xlink:label="lab_smmt_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseDueToChangeInEnactedTaxRateAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease) Due To Change In Enacted Tax Rate, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseDueToChangeInEnactedTaxRateAmount" xlink:href="smmt-20211231.xsd#smmt_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseDueToChangeInEnactedTaxRateAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseDueToChangeInEnactedTaxRateAmount" xlink:to="lab_smmt_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseDueToChangeInEnactedTaxRateAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_df67df90-0363-4d38-ac23-14600254f205_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_e76c9077-3891-4dbd-89f1-2c3c28eed876_terseLabel_en-US" xlink:label="lab_smmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Offering period</link:label>
    <link:label id="lab_smmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_label_en-US" xlink:label="lab_smmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-based Payment Award, Offering Period</link:label>
    <link:label id="lab_smmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_documentation_en-US" xlink:label="lab_smmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-based Payment Award, Offering Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" xlink:href="smmt-20211231.xsd#smmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" xlink:to="lab_smmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_bbc53e62-ca6c-4bcd-b52d-9922c53d9d61_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_bd581908-7bb5-4b5d-9dee-11e71aa5d4b7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of potentially dilutive securities excluded from the computation of loss per share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_ConsultingAgreementConsultancyFeesMember_166a292d-af1f-48b5-b09a-a7d234e7b45c_terseLabel_en-US" xlink:label="lab_smmt_ConsultingAgreementConsultancyFeesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consultancy fees</link:label>
    <link:label id="lab_smmt_ConsultingAgreementConsultancyFeesMember_label_en-US" xlink:label="lab_smmt_ConsultingAgreementConsultancyFeesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consulting Agreement, Consultancy Fees [Member]</link:label>
    <link:label id="lab_smmt_ConsultingAgreementConsultancyFeesMember_documentation_en-US" xlink:label="lab_smmt_ConsultingAgreementConsultancyFeesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consulting Agreement, Consultancy Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_ConsultingAgreementConsultancyFeesMember" xlink:href="smmt-20211231.xsd#smmt_ConsultingAgreementConsultancyFeesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_ConsultingAgreementConsultancyFeesMember" xlink:to="lab_smmt_ConsultingAgreementConsultancyFeesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_ef0a3d9b-1dd7-4eab-a683-d0974fe33551_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_OtherCommitmentPeriodForWhichTheMajorityOfCommitmentsAreToBePaid_1523643c-b789-490d-86a7-0cf8689ea989_terseLabel_en-US" xlink:label="lab_smmt_OtherCommitmentPeriodForWhichTheMajorityOfCommitmentsAreToBePaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period for which the majority of contractual commitments are to be paid</link:label>
    <link:label id="lab_smmt_OtherCommitmentPeriodForWhichTheMajorityOfCommitmentsAreToBePaid_label_en-US" xlink:label="lab_smmt_OtherCommitmentPeriodForWhichTheMajorityOfCommitmentsAreToBePaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitment, Period for Which the Majority of Commitments are To Be Paid</link:label>
    <link:label id="lab_smmt_OtherCommitmentPeriodForWhichTheMajorityOfCommitmentsAreToBePaid_documentation_en-US" xlink:label="lab_smmt_OtherCommitmentPeriodForWhichTheMajorityOfCommitmentsAreToBePaid" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitment, Period for Which the Majority of Commitments are To Be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_OtherCommitmentPeriodForWhichTheMajorityOfCommitmentsAreToBePaid" xlink:href="smmt-20211231.xsd#smmt_OtherCommitmentPeriodForWhichTheMajorityOfCommitmentsAreToBePaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_OtherCommitmentPeriodForWhichTheMajorityOfCommitmentsAreToBePaid" xlink:to="lab_smmt_OtherCommitmentPeriodForWhichTheMajorityOfCommitmentsAreToBePaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorFirmId_2941ef0c-2f3a-453d-b40e-5a8ecd694fc5_terseLabel_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:label id="lab_dei_AuditorFirmId_label_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId" xlink:to="lab_dei_AuditorFirmId" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PurchaseObligation_b8421335-83c6-4149-92d5-66aef0d8155a_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital commitments</link:label>
    <link:label id="lab_us-gaap_PurchaseObligation_label_en-US" xlink:label="lab_us-gaap_PurchaseObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseObligation" xlink:to="lab_us-gaap_PurchaseObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8decff1e-29b4-4d12-8a56-4ff7d9b6f06c_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_e1d42113-d175-4000-8e7d-8fac5299dcb0_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_71ed11e3-b1b9-4b3d-a947-9e415feeba6b_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_68862a4c-f1bf-4326-9799-e9169b2a57a3_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_51aa1e06-ab25-431d-8410-35a3945a8455_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_LaboratoryEquipmentMember_25a82434-9615-46f3-9a91-1e192d5a3cfa_terseLabel_en-US" xlink:label="lab_smmt_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory equipment</link:label>
    <link:label id="lab_smmt_LaboratoryEquipmentMember_label_en-US" xlink:label="lab_smmt_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory Equipment [Member]</link:label>
    <link:label id="lab_smmt_LaboratoryEquipmentMember_documentation_en-US" xlink:label="lab_smmt_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_LaboratoryEquipmentMember" xlink:href="smmt-20211231.xsd#smmt_LaboratoryEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_LaboratoryEquipmentMember" xlink:to="lab_smmt_LaboratoryEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_ClassOfWarrantOrRightQuarterlyVestingPeriod_dbc91f7e-ba1d-477d-9a30-9ca485476713_terseLabel_en-US" xlink:label="lab_smmt_ClassOfWarrantOrRightQuarterlyVestingPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants quarterly vesting period</link:label>
    <link:label id="lab_smmt_ClassOfWarrantOrRightQuarterlyVestingPeriod_label_en-US" xlink:label="lab_smmt_ClassOfWarrantOrRightQuarterlyVestingPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Quarterly Vesting Period</link:label>
    <link:label id="lab_smmt_ClassOfWarrantOrRightQuarterlyVestingPeriod_documentation_en-US" xlink:label="lab_smmt_ClassOfWarrantOrRightQuarterlyVestingPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Quarterly Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_ClassOfWarrantOrRightQuarterlyVestingPeriod" xlink:href="smmt-20211231.xsd#smmt_ClassOfWarrantOrRightQuarterlyVestingPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_ClassOfWarrantOrRightQuarterlyVestingPeriod" xlink:to="lab_smmt_ClassOfWarrantOrRightQuarterlyVestingPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_50ece4eb-7dfe-4cea-8a06-8cc8c721b46d_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows used in operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_860639bf-d6ba-44e4-84c7-ce1f90dd04ec_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_102e42cc-b4ec-4370-aae9-ecd78eb052a9_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_db415938-aecc-4f18-9926-6e8c10cf0de3_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principles of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_4f8ed3a6-636d-4115-a1a9-2ad7ca3a9bea_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1537c61e-36ea-4c9d-bce5-31572a55950e_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_88256fb4-05b9-4bf0-a6ff-f79113397996_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockMember_a0de2777-7605-4046-ad83-63cdd033d14e_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares expected to be purchased under employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_a1c0e6c4-c0ce-43bd-9923-4eee4e3bba22_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ESPP</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember" xlink:to="lab_us-gaap_EmployeeStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_RelatedPartyTransactionRateBasisSpreadOnVariableRate_b30f8bca-0f37-4f66-9378-26b9bb82592d_terseLabel_en-US" xlink:label="lab_smmt_RelatedPartyTransactionRateBasisSpreadOnVariableRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes payable, basis spread on variable rate</link:label>
    <link:label id="lab_smmt_RelatedPartyTransactionRateBasisSpreadOnVariableRate_label_en-US" xlink:label="lab_smmt_RelatedPartyTransactionRateBasisSpreadOnVariableRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Rate, Basis Spread On Variable Rate</link:label>
    <link:label id="lab_smmt_RelatedPartyTransactionRateBasisSpreadOnVariableRate_documentation_en-US" xlink:label="lab_smmt_RelatedPartyTransactionRateBasisSpreadOnVariableRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Rate, Basis Spread On Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_RelatedPartyTransactionRateBasisSpreadOnVariableRate" xlink:href="smmt-20211231.xsd#smmt_RelatedPartyTransactionRateBasisSpreadOnVariableRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_RelatedPartyTransactionRateBasisSpreadOnVariableRate" xlink:to="lab_smmt_RelatedPartyTransactionRateBasisSpreadOnVariableRate" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_A2022NoteMember_fdde2f32-9aa9-4f88-b909-f1c8cc5addcf_terseLabel_en-US" xlink:label="lab_smmt_A2022NoteMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 Note</link:label>
    <link:label id="lab_smmt_A2022NoteMember_label_en-US" xlink:label="lab_smmt_A2022NoteMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 Note [Member]</link:label>
    <link:label id="lab_smmt_A2022NoteMember_documentation_en-US" xlink:label="lab_smmt_A2022NoteMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 Note</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_A2022NoteMember" xlink:href="smmt-20211231.xsd#smmt_A2022NoteMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_A2022NoteMember" xlink:to="lab_smmt_A2022NoteMember" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_AccruedResearchAndDevelopmentCurrent_406314bd-d69c-4214-887c-aaf1d82b2e65_terseLabel_en-US" xlink:label="lab_smmt_AccruedResearchAndDevelopmentCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued research and development expenditure</link:label>
    <link:label id="lab_smmt_AccruedResearchAndDevelopmentCurrent_label_en-US" xlink:label="lab_smmt_AccruedResearchAndDevelopmentCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Research And Development, Current</link:label>
    <link:label id="lab_smmt_AccruedResearchAndDevelopmentCurrent_documentation_en-US" xlink:label="lab_smmt_AccruedResearchAndDevelopmentCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Research And Development, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_AccruedResearchAndDevelopmentCurrent" xlink:href="smmt-20211231.xsd#smmt_AccruedResearchAndDevelopmentCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_AccruedResearchAndDevelopmentCurrent" xlink:to="lab_smmt_AccruedResearchAndDevelopmentCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_RelatedPartyTransactionPaymentsToRelatedParty_f4631a7b-2b3f-42a6-934c-0a5219ab5b4a_terseLabel_en-US" xlink:label="lab_smmt_RelatedPartyTransactionPaymentsToRelatedParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to related party</link:label>
    <link:label id="lab_smmt_RelatedPartyTransactionPaymentsToRelatedParty_label_en-US" xlink:label="lab_smmt_RelatedPartyTransactionPaymentsToRelatedParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Payments To Related Party</link:label>
    <link:label id="lab_smmt_RelatedPartyTransactionPaymentsToRelatedParty_documentation_en-US" xlink:label="lab_smmt_RelatedPartyTransactionPaymentsToRelatedParty" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Payments To Related Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_RelatedPartyTransactionPaymentsToRelatedParty" xlink:href="smmt-20211231.xsd#smmt_RelatedPartyTransactionPaymentsToRelatedParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_RelatedPartyTransactionPaymentsToRelatedParty" xlink:to="lab_smmt_RelatedPartyTransactionPaymentsToRelatedParty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_76a4f6cb-101d-4528-8c56-c9149defe779_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value, vested and expected to vest</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_2ed92cf5-8377-4cfd-910f-a4f3cacc805e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum percentage of outstanding shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LatinAmericaMember_0676f6e2-471e-4d41-8e4c-16b5eacbf4f8_terseLabel_en-US" xlink:label="lab_srt_LatinAmericaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Latin America</link:label>
    <link:label id="lab_srt_LatinAmericaMember_label_en-US" xlink:label="lab_srt_LatinAmericaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Latin America [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LatinAmericaMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LatinAmericaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LatinAmericaMember" xlink:to="lab_srt_LatinAmericaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_aedeb43d-d973-48e0-91c3-4bb0063adaaa_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_ConsultingAgreementMember_b5a95253-36b2-418b-93dc-25b5dc24a2ff_terseLabel_en-US" xlink:label="lab_smmt_ConsultingAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consulting Agreement</link:label>
    <link:label id="lab_smmt_ConsultingAgreementMember_label_en-US" xlink:label="lab_smmt_ConsultingAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consulting Agreement [Member]</link:label>
    <link:label id="lab_smmt_ConsultingAgreementMember_documentation_en-US" xlink:label="lab_smmt_ConsultingAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consulting Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_ConsultingAgreementMember" xlink:href="smmt-20211231.xsd#smmt_ConsultingAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_ConsultingAgreementMember" xlink:to="lab_smmt_ConsultingAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncurrentAssets_16b759e4-3aa7-4d2d-b7ee-adbee694b960_terseLabel_en-US" xlink:label="lab_us-gaap_NoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-lived assets</link:label>
    <link:label id="lab_us-gaap_NoncurrentAssets_label_en-US" xlink:label="lab_us-gaap_NoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncurrentAssets" xlink:to="lab_us-gaap_NoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_846c2231-3769-4910-b11b-3bc6afb6e05a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_832eab03-0134-43e8-87e2-967fd45ca3b0_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_GainLossOnRemeasurementOfLiabilitiesNonoperating_4e822da2-dcdc-4df2-91dd-fc9df1e1abff_terseLabel_en-US" xlink:label="lab_smmt_GainLossOnRemeasurementOfLiabilitiesNonoperating" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remeasurement of liabilities</link:label>
    <link:label id="lab_smmt_GainLossOnRemeasurementOfLiabilitiesNonoperating_3a29a696-06a4-46fb-b204-fc24fce45611_verboseLabel_en-US" xlink:label="lab_smmt_GainLossOnRemeasurementOfLiabilitiesNonoperating" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on remeasurement of contingent liability</link:label>
    <link:label id="lab_smmt_GainLossOnRemeasurementOfLiabilitiesNonoperating_label_en-US" xlink:label="lab_smmt_GainLossOnRemeasurementOfLiabilitiesNonoperating" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) On Remeasurement Of Liabilities, Nonoperating</link:label>
    <link:label id="lab_smmt_GainLossOnRemeasurementOfLiabilitiesNonoperating_documentation_en-US" xlink:label="lab_smmt_GainLossOnRemeasurementOfLiabilitiesNonoperating" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) On Remeasurement Of Liabilities, Nonoperating</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_GainLossOnRemeasurementOfLiabilitiesNonoperating" xlink:href="smmt-20211231.xsd#smmt_GainLossOnRemeasurementOfLiabilitiesNonoperating"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_GainLossOnRemeasurementOfLiabilitiesNonoperating" xlink:to="lab_smmt_GainLossOnRemeasurementOfLiabilitiesNonoperating" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_8484f881-961e-4d70-b7e9-699a23da1423_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recently Issued or Adopted Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_e599ae38-fc32-4302-858e-2600f5f03071_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_a3ab6776-00da-4f65-b133-30a8e68f66b5_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_f8afe418-0117-41d4-b83d-58973d449757_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_b02fea25-4f13-41c1-99a1-a28ae894e430_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_d39a2dbe-9c1e-4dde-8e19-560341e8c7db_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_45ee9f31-7c49-4a1d-a235-dfab4155d623_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_CommonStockAndRestrictedStockUnitsAdditionalCapitalSharesAllowableForForFutureIssuance_ad945def-3d6d-4db4-8cbe-0b0c8d3c9d4a_terseLabel_en-US" xlink:label="lab_smmt_CommonStockAndRestrictedStockUnitsAdditionalCapitalSharesAllowableForForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares that can be added to the plan (in shares)</link:label>
    <link:label id="lab_smmt_CommonStockAndRestrictedStockUnitsAdditionalCapitalSharesAllowableForForFutureIssuance_label_en-US" xlink:label="lab_smmt_CommonStockAndRestrictedStockUnitsAdditionalCapitalSharesAllowableForForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock and Restricted Stock Units, Additional Capital Shares Allowable For For Future Issuance</link:label>
    <link:label id="lab_smmt_CommonStockAndRestrictedStockUnitsAdditionalCapitalSharesAllowableForForFutureIssuance_documentation_en-US" xlink:label="lab_smmt_CommonStockAndRestrictedStockUnitsAdditionalCapitalSharesAllowableForForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock and Restricted Stock Units, Additional Capital Shares Allowable For For Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_CommonStockAndRestrictedStockUnitsAdditionalCapitalSharesAllowableForForFutureIssuance" xlink:href="smmt-20211231.xsd#smmt_CommonStockAndRestrictedStockUnitsAdditionalCapitalSharesAllowableForForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_CommonStockAndRestrictedStockUnitsAdditionalCapitalSharesAllowableForForFutureIssuance" xlink:to="lab_smmt_CommonStockAndRestrictedStockUnitsAdditionalCapitalSharesAllowableForForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_d1e36d5a-5d61-4cce-bbc6-591cf2c7df7c_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of foreign operations taxed at various rates</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_4179802e-a902-42fc-90f0-ea7077eee20f_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-United States</link:label>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Foreign Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_ConsultantsMember_09b57587-c642-4c58-a433-dee334dc14f7_terseLabel_en-US" xlink:label="lab_smmt_ConsultantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consultants</link:label>
    <link:label id="lab_smmt_ConsultantsMember_label_en-US" xlink:label="lab_smmt_ConsultantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consultants [Member]</link:label>
    <link:label id="lab_smmt_ConsultantsMember_documentation_en-US" xlink:label="lab_smmt_ConsultantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consultants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_ConsultantsMember" xlink:href="smmt-20211231.xsd#smmt_ConsultantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_ConsultantsMember" xlink:to="lab_smmt_ConsultantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_cb4c754a-2dce-482d-b7bf-ea80c4cd39b8_terseLabel_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_label_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NatureOfOperations_9f4b435e-7ca9-4faf-a60d-cd5a8c529e93_terseLabel_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nature of Business and Operations and Recent Events</link:label>
    <link:label id="lab_us-gaap_NatureOfOperations_label_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nature of Operations [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NatureOfOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NatureOfOperations" xlink:to="lab_us-gaap_NatureOfOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_002cdddc-3ef4-4378-ba26-364590d7ec16_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_GrantFundingArrangementMaximumFundingValue_edeeb092-7ff3-42e4-8f1a-7816183a071f_terseLabel_en-US" xlink:label="lab_smmt_GrantFundingArrangementMaximumFundingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum funding value</link:label>
    <link:label id="lab_smmt_GrantFundingArrangementMaximumFundingValue_label_en-US" xlink:label="lab_smmt_GrantFundingArrangementMaximumFundingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant Funding Arrangement, Maximum Funding Value</link:label>
    <link:label id="lab_smmt_GrantFundingArrangementMaximumFundingValue_documentation_en-US" xlink:label="lab_smmt_GrantFundingArrangementMaximumFundingValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant Funding Arrangement, Maximum Funding Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_GrantFundingArrangementMaximumFundingValue" xlink:href="smmt-20211231.xsd#smmt_GrantFundingArrangementMaximumFundingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_GrantFundingArrangementMaximumFundingValue" xlink:to="lab_smmt_GrantFundingArrangementMaximumFundingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent_cc65e3f6-8d04-4c26-9738-67e6a1204bfc_terseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes payable</link:label>
    <link:label id="lab_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable, Related Parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent" xlink:to="lab_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_431e8e6f-3a0e-444d-9f42-8c4662213981_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_354a7e10-c60b-49f2-9e54-9988dd41a174_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed lease costs</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_052bc866-a276-4d3d-a9e6-87b922965ea8_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_6ca81831-371a-4d67-b33a-930d2060008c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_a84ec372-52f7-4330-8f8d-4771cca13240_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_918136dc-966f-410d-925b-c2be78f67fa8_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining contractual term, vested and expected to vest</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>smmt-20211231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:48b41a33-da2b-4a8c-a794-72fce890713a,g:e36a0d9c-9c90-432d-82bf-4f94771c92ff-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.summitplc.com/role/DocumentandEntityInformation" xlink:type="simple" xlink:href="smmt-20211231.xsd#DocumentandEntityInformation"/>
  <link:presentationLink xlink:role="http://www.summitplc.com/role/DocumentandEntityInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_7c116d1f-87ca-45c5-bf72-ea782e9a6d69" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_6450324d-14ef-483d-90da-bc501b23cdaf" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7c116d1f-87ca-45c5-bf72-ea782e9a6d69" xlink:to="loc_dei_DocumentType_6450324d-14ef-483d-90da-bc501b23cdaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_2762ffc7-144c-4a56-bbbd-479e136c1e5e" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7c116d1f-87ca-45c5-bf72-ea782e9a6d69" xlink:to="loc_dei_DocumentAnnualReport_2762ffc7-144c-4a56-bbbd-479e136c1e5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_62248c20-b453-4484-9c3d-fc675f9ce8ff" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7c116d1f-87ca-45c5-bf72-ea782e9a6d69" xlink:to="loc_dei_DocumentPeriodEndDate_62248c20-b453-4484-9c3d-fc675f9ce8ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_54e964a7-a5f8-498f-872d-e6684fcd2751" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7c116d1f-87ca-45c5-bf72-ea782e9a6d69" xlink:to="loc_dei_CurrentFiscalYearEndDate_54e964a7-a5f8-498f-872d-e6684fcd2751" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_8720dee3-fc86-4572-89ee-5166c44a51c8" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7c116d1f-87ca-45c5-bf72-ea782e9a6d69" xlink:to="loc_dei_DocumentTransitionReport_8720dee3-fc86-4572-89ee-5166c44a51c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_6fc4ed14-17b7-4e84-9d94-13b28a0f9e29" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7c116d1f-87ca-45c5-bf72-ea782e9a6d69" xlink:to="loc_dei_EntityFileNumber_6fc4ed14-17b7-4e84-9d94-13b28a0f9e29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_01ee45a3-65b3-4ad5-89e1-38f09dc289f7" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7c116d1f-87ca-45c5-bf72-ea782e9a6d69" xlink:to="loc_dei_EntityRegistrantName_01ee45a3-65b3-4ad5-89e1-38f09dc289f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_0a6dfe8e-d3d8-4e0a-9dc5-dd9dbcf966c3" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7c116d1f-87ca-45c5-bf72-ea782e9a6d69" xlink:to="loc_dei_EntityIncorporationStateCountryCode_0a6dfe8e-d3d8-4e0a-9dc5-dd9dbcf966c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_35a081eb-bc8a-495c-b4fd-75933c67af3a" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7c116d1f-87ca-45c5-bf72-ea782e9a6d69" xlink:to="loc_dei_EntityTaxIdentificationNumber_35a081eb-bc8a-495c-b4fd-75933c67af3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_5c553e4b-7e52-4a1b-aa7d-3cd1f2fcd511" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7c116d1f-87ca-45c5-bf72-ea782e9a6d69" xlink:to="loc_dei_EntityAddressAddressLine1_5c553e4b-7e52-4a1b-aa7d-3cd1f2fcd511" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_d471ec1b-1f3b-43a6-a6f4-b3f23dce1718" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7c116d1f-87ca-45c5-bf72-ea782e9a6d69" xlink:to="loc_dei_EntityAddressCityOrTown_d471ec1b-1f3b-43a6-a6f4-b3f23dce1718" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_d260c78f-3f15-44b0-bd57-7f229950c49b" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7c116d1f-87ca-45c5-bf72-ea782e9a6d69" xlink:to="loc_dei_EntityAddressStateOrProvince_d260c78f-3f15-44b0-bd57-7f229950c49b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_65ba50ea-b6cb-4c90-9177-8f7c22071094" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7c116d1f-87ca-45c5-bf72-ea782e9a6d69" xlink:to="loc_dei_EntityAddressPostalZipCode_65ba50ea-b6cb-4c90-9177-8f7c22071094" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_301984e4-4f6e-467e-a7d3-68f2852a3fad" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7c116d1f-87ca-45c5-bf72-ea782e9a6d69" xlink:to="loc_dei_CityAreaCode_301984e4-4f6e-467e-a7d3-68f2852a3fad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_944ed88f-af01-4193-b094-1840a73a191c" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7c116d1f-87ca-45c5-bf72-ea782e9a6d69" xlink:to="loc_dei_LocalPhoneNumber_944ed88f-af01-4193-b094-1840a73a191c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_aad8a252-8706-456c-be28-903ff8c3d11e" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7c116d1f-87ca-45c5-bf72-ea782e9a6d69" xlink:to="loc_dei_Security12bTitle_aad8a252-8706-456c-be28-903ff8c3d11e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_3d1b55be-08e9-40a8-8e2c-3954f5b6899b" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7c116d1f-87ca-45c5-bf72-ea782e9a6d69" xlink:to="loc_dei_TradingSymbol_3d1b55be-08e9-40a8-8e2c-3954f5b6899b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_dc2d8497-6df1-4822-b2c0-31ca4c55d4e9" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7c116d1f-87ca-45c5-bf72-ea782e9a6d69" xlink:to="loc_dei_SecurityExchangeName_dc2d8497-6df1-4822-b2c0-31ca4c55d4e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_042ee654-c070-4c0c-a753-e1c1befc933f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7c116d1f-87ca-45c5-bf72-ea782e9a6d69" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_042ee654-c070-4c0c-a753-e1c1befc933f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_651bd64c-57a6-4560-a652-ab009843820c" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7c116d1f-87ca-45c5-bf72-ea782e9a6d69" xlink:to="loc_dei_EntityVoluntaryFilers_651bd64c-57a6-4560-a652-ab009843820c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_000e18fc-5d0c-4f87-8f8f-f6265cbd3572" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7c116d1f-87ca-45c5-bf72-ea782e9a6d69" xlink:to="loc_dei_EntityCurrentReportingStatus_000e18fc-5d0c-4f87-8f8f-f6265cbd3572" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_e2abd518-7f5e-40ac-a2ac-bdc5fdb0a77e" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7c116d1f-87ca-45c5-bf72-ea782e9a6d69" xlink:to="loc_dei_EntityInteractiveDataCurrent_e2abd518-7f5e-40ac-a2ac-bdc5fdb0a77e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_938dbffc-b042-433e-9cd2-423ef07a03f2" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7c116d1f-87ca-45c5-bf72-ea782e9a6d69" xlink:to="loc_dei_EntityFilerCategory_938dbffc-b042-433e-9cd2-423ef07a03f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_eb5957b2-031f-4df2-96bc-20490f8931f3" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7c116d1f-87ca-45c5-bf72-ea782e9a6d69" xlink:to="loc_dei_EntitySmallBusiness_eb5957b2-031f-4df2-96bc-20490f8931f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_8a335fed-4bc7-4fc0-8ef8-7f62a9c6f9da" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7c116d1f-87ca-45c5-bf72-ea782e9a6d69" xlink:to="loc_dei_EntityEmergingGrowthCompany_8a335fed-4bc7-4fc0-8ef8-7f62a9c6f9da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_05d74a46-3b98-453d-8dbc-2e1370977da9" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7c116d1f-87ca-45c5-bf72-ea782e9a6d69" xlink:to="loc_dei_IcfrAuditorAttestationFlag_05d74a46-3b98-453d-8dbc-2e1370977da9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_519544de-9e7c-452f-b204-ca514085d953" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7c116d1f-87ca-45c5-bf72-ea782e9a6d69" xlink:to="loc_dei_EntityShellCompany_519544de-9e7c-452f-b204-ca514085d953" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_cf6a7d20-56f5-4734-9aa9-5b703d70e615" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7c116d1f-87ca-45c5-bf72-ea782e9a6d69" xlink:to="loc_dei_EntityPublicFloat_cf6a7d20-56f5-4734-9aa9-5b703d70e615" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_bf7bb4f7-b16e-41e1-a8b6-dd9bdbe59d68" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7c116d1f-87ca-45c5-bf72-ea782e9a6d69" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_bf7bb4f7-b16e-41e1-a8b6-dd9bdbe59d68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_56444ea8-613c-42ca-b7f4-5fac0b447f67" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7c116d1f-87ca-45c5-bf72-ea782e9a6d69" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_56444ea8-613c-42ca-b7f4-5fac0b447f67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_82cd4c7e-235f-470e-b655-429ca60bbccb" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7c116d1f-87ca-45c5-bf72-ea782e9a6d69" xlink:to="loc_dei_AmendmentFlag_82cd4c7e-235f-470e-b655-429ca60bbccb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_9f513f7c-37ad-4a55-af01-7d06707779f4" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7c116d1f-87ca-45c5-bf72-ea782e9a6d69" xlink:to="loc_dei_EntityCentralIndexKey_9f513f7c-37ad-4a55-af01-7d06707779f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_2afbb4ce-d418-40f7-887d-03dadc7ab1db" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7c116d1f-87ca-45c5-bf72-ea782e9a6d69" xlink:to="loc_dei_DocumentFiscalYearFocus_2afbb4ce-d418-40f7-887d-03dadc7ab1db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_ed63adb3-becf-4592-b362-b42f7b080bad" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7c116d1f-87ca-45c5-bf72-ea782e9a6d69" xlink:to="loc_dei_DocumentFiscalPeriodFocus_ed63adb3-becf-4592-b362-b42f7b080bad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/AuditInformation" xlink:type="simple" xlink:href="smmt-20211231.xsd#AuditInformation"/>
  <link:presentationLink xlink:role="http://www.summitplc.com/role/AuditInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_smmt_AuditInformationAbstract_cd1d11a4-9113-4313-b286-9727ddc522ac" xlink:href="smmt-20211231.xsd#smmt_AuditInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId_b6a7dcc2-cdfa-427d-93fe-1635df02c4ea" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_smmt_AuditInformationAbstract_cd1d11a4-9113-4313-b286-9727ddc522ac" xlink:to="loc_dei_AuditorFirmId_b6a7dcc2-cdfa-427d-93fe-1635df02c4ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName_26044e97-72f9-4f45-8842-3b9c02cab3f5" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_smmt_AuditInformationAbstract_cd1d11a4-9113-4313-b286-9727ddc522ac" xlink:to="loc_dei_AuditorName_26044e97-72f9-4f45-8842-3b9c02cab3f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation_eee19423-dd3e-4a9d-9803-9050a9f3d1d8" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_smmt_AuditInformationAbstract_cd1d11a4-9113-4313-b286-9727ddc522ac" xlink:to="loc_dei_AuditorLocation_eee19423-dd3e-4a9d-9803-9050a9f3d1d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="smmt-20211231.xsd#ConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.summitplc.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_45a3d81b-9e2b-48cd-9df7-987d76f36f39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_ac4a3dc0-5453-438b-be38-0a50e1eeb588" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_45a3d81b-9e2b-48cd-9df7-987d76f36f39" xlink:to="loc_us-gaap_AssetsAbstract_ac4a3dc0-5453-438b-be38-0a50e1eeb588" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_eee3d04a-06e3-448d-ad03-0092d4d81d67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_ac4a3dc0-5453-438b-be38-0a50e1eeb588" xlink:to="loc_us-gaap_AssetsCurrentAbstract_eee3d04a-06e3-448d-ad03-0092d4d81d67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Cash_e668082d-a16c-4932-be9d-efe9dd4dba3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Cash"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_eee3d04a-06e3-448d-ad03-0092d4d81d67" xlink:to="loc_us-gaap_Cash_e668082d-a16c-4932-be9d-efe9dd4dba3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_1f0d67b8-fdec-4375-be15-f7ed83d705e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_eee3d04a-06e3-448d-ad03-0092d4d81d67" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_1f0d67b8-fdec-4375-be15-f7ed83d705e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_f477da99-01d7-42f1-b527-21b513757108" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_eee3d04a-06e3-448d-ad03-0092d4d81d67" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_f477da99-01d7-42f1-b527-21b513757108" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_a6ee528b-60d0-434c-ae20-27a19297291d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_eee3d04a-06e3-448d-ad03-0092d4d81d67" xlink:to="loc_us-gaap_OtherAssetsCurrent_a6ee528b-60d0-434c-ae20-27a19297291d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_ResearchAndDevelopmentTaxCreditReceivableCurrent_5f915349-61ad-4d68-bb12-54efcc2fc01f" xlink:href="smmt-20211231.xsd#smmt_ResearchAndDevelopmentTaxCreditReceivableCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_eee3d04a-06e3-448d-ad03-0092d4d81d67" xlink:to="loc_smmt_ResearchAndDevelopmentTaxCreditReceivableCurrent_5f915349-61ad-4d68-bb12-54efcc2fc01f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_ce2dfaaa-faeb-405e-91cc-37465c41f3e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_eee3d04a-06e3-448d-ad03-0092d4d81d67" xlink:to="loc_us-gaap_AssetsCurrent_ce2dfaaa-faeb-405e-91cc-37465c41f3e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrentAbstract_7e81ddd0-99fe-47f2-9c4a-fbdb53ded285" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_ac4a3dc0-5453-438b-be38-0a50e1eeb588" xlink:to="loc_us-gaap_AssetsNoncurrentAbstract_7e81ddd0-99fe-47f2-9c4a-fbdb53ded285" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_46964798-2b42-48c4-bf95-bd9867cf1bf0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_7e81ddd0-99fe-47f2-9c4a-fbdb53ded285" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_46964798-2b42-48c4-bf95-bd9867cf1bf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_e141a47a-c9ee-4dee-8f67-2ace3b73de31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_7e81ddd0-99fe-47f2-9c4a-fbdb53ded285" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_e141a47a-c9ee-4dee-8f67-2ace3b73de31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_face78a0-cd13-40ad-9046-3aecf61df657" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_7e81ddd0-99fe-47f2-9c4a-fbdb53ded285" xlink:to="loc_us-gaap_Goodwill_face78a0-cd13-40ad-9046-3aecf61df657" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_d7bf71e8-9a73-4efb-b4c6-5344c078d5ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_7e81ddd0-99fe-47f2-9c4a-fbdb53ded285" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_d7bf71e8-9a73-4efb-b4c6-5344c078d5ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_0b4ea316-b57d-4fc2-a873-d9f276b4ab59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_7e81ddd0-99fe-47f2-9c4a-fbdb53ded285" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_0b4ea316-b57d-4fc2-a873-d9f276b4ab59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_ba06de83-562f-401c-a98c-de56b81b4ce5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_ac4a3dc0-5453-438b-be38-0a50e1eeb588" xlink:to="loc_us-gaap_Assets_ba06de83-562f-401c-a98c-de56b81b4ce5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_87922384-8580-4520-8710-1f13273e7375" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_45a3d81b-9e2b-48cd-9df7-987d76f36f39" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_87922384-8580-4520-8710-1f13273e7375" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_e26d2cb8-c714-4eb9-82dc-77ce09df177b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_87922384-8580-4520-8710-1f13273e7375" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_e26d2cb8-c714-4eb9-82dc-77ce09df177b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_906bbad0-707e-4e9a-a5f5-50695e4772f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_e26d2cb8-c714-4eb9-82dc-77ce09df177b" xlink:to="loc_us-gaap_AccountsPayableCurrent_906bbad0-707e-4e9a-a5f5-50695e4772f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_9f26fc1e-e70a-4676-a7a1-b1d2e352fdb5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_e26d2cb8-c714-4eb9-82dc-77ce09df177b" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_9f26fc1e-e70a-4676-a7a1-b1d2e352fdb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_4e893faa-21f1-4783-9f24-6907fedd9c17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_e26d2cb8-c714-4eb9-82dc-77ce09df177b" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_4e893faa-21f1-4783-9f24-6907fedd9c17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_8218904a-33d9-4dab-9d4f-54b37747e5ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_e26d2cb8-c714-4eb9-82dc-77ce09df177b" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_8218904a-33d9-4dab-9d4f-54b37747e5ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_4c9a071a-e654-4591-868b-a7f69e982bac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_e26d2cb8-c714-4eb9-82dc-77ce09df177b" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_4c9a071a-e654-4591-868b-a7f69e982bac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_1fccd33e-81cf-40b6-bc5d-ef431352d76b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_e26d2cb8-c714-4eb9-82dc-77ce09df177b" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_1fccd33e-81cf-40b6-bc5d-ef431352d76b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_8debf32c-9ea5-44f7-b63c-057559686cd2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_e26d2cb8-c714-4eb9-82dc-77ce09df177b" xlink:to="loc_us-gaap_LiabilitiesCurrent_8debf32c-9ea5-44f7-b63c-057559686cd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_4169444a-7f7e-477c-bbc8-a29652857c69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_87922384-8580-4520-8710-1f13273e7375" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_4169444a-7f7e-477c-bbc8-a29652857c69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_d07eb618-382b-4050-bfa7-63258d0969f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_4169444a-7f7e-477c-bbc8-a29652857c69" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_d07eb618-382b-4050-bfa7-63258d0969f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_d568fe6d-b62b-492d-856d-6680fab55b94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_4169444a-7f7e-477c-bbc8-a29652857c69" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_d568fe6d-b62b-492d-856d-6680fab55b94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_684cd2ed-0e4d-49b3-8ef7-e549108177ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_4169444a-7f7e-477c-bbc8-a29652857c69" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_684cd2ed-0e4d-49b3-8ef7-e549108177ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_9db74303-ae23-47e8-b7fc-1b31ba0f4cb5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_87922384-8580-4520-8710-1f13273e7375" xlink:to="loc_us-gaap_Liabilities_9db74303-ae23-47e8-b7fc-1b31ba0f4cb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_4aab6776-8595-4254-b0b8-be190420921e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_87922384-8580-4520-8710-1f13273e7375" xlink:to="loc_us-gaap_CommitmentsAndContingencies_4aab6776-8595-4254-b0b8-be190420921e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_849186e1-572b-4478-87a4-5b641b93207d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_87922384-8580-4520-8710-1f13273e7375" xlink:to="loc_us-gaap_StockholdersEquityAbstract_849186e1-572b-4478-87a4-5b641b93207d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_0dbea190-9458-4073-bcd3-d73f65ddfa06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_849186e1-572b-4478-87a4-5b641b93207d" xlink:to="loc_us-gaap_CommonStockValue_0dbea190-9458-4073-bcd3-d73f65ddfa06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_b0af0f52-2220-487d-a615-d9bc6b259fc2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_849186e1-572b-4478-87a4-5b641b93207d" xlink:to="loc_us-gaap_AdditionalPaidInCapital_b0af0f52-2220-487d-a615-d9bc6b259fc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_459ca268-3e97-44cd-8c55-032854eefa93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_849186e1-572b-4478-87a4-5b641b93207d" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_459ca268-3e97-44cd-8c55-032854eefa93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_7ea2fd0c-dd2b-4560-b944-ba9b1fb31578" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_849186e1-572b-4478-87a4-5b641b93207d" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_7ea2fd0c-dd2b-4560-b944-ba9b1fb31578" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_1614f67f-0323-49d7-8f50-f44bf93accf8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_849186e1-572b-4478-87a4-5b641b93207d" xlink:to="loc_us-gaap_StockholdersEquity_1614f67f-0323-49d7-8f50-f44bf93accf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_47d1af34-23ba-4a71-b689-a5a2250c6de1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_87922384-8580-4520-8710-1f13273e7375" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_47d1af34-23ba-4a71-b689-a5a2250c6de1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="smmt-20211231.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.summitplc.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_e64d1315-4100-4457-84f0-4e59a59436ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_44c37167-ed36-4363-81a9-bea23d34075d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_e64d1315-4100-4457-84f0-4e59a59436ab" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_44c37167-ed36-4363-81a9-bea23d34075d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_ddf7a93b-828e-49df-9300-8860bb853b37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_e64d1315-4100-4457-84f0-4e59a59436ab" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_ddf7a93b-828e-49df-9300-8860bb853b37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_5d2e7e04-f725-4303-a89c-c86d5e1bbc82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_e64d1315-4100-4457-84f0-4e59a59436ab" xlink:to="loc_us-gaap_CommonStockSharesIssued_5d2e7e04-f725-4303-a89c-c86d5e1bbc82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_b34e9527-9ccd-47bf-953b-01db2578d713" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_e64d1315-4100-4457-84f0-4e59a59436ab" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_b34e9527-9ccd-47bf-953b-01db2578d713" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="smmt-20211231.xsd#ConsolidatedStatementsofOperationsandComprehensiveLoss"/>
  <link:presentationLink xlink:role="http://www.summitplc.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_smmt_IncomeStatementAndStatementOfComprehensiveIncomeAbstract_b81f6fb6-7155-4c6a-a852-eccd0c1c0092" xlink:href="smmt-20211231.xsd#smmt_IncomeStatementAndStatementOfComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_0a10f7a5-ced3-491c-a280-2dc67e40f6d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_smmt_IncomeStatementAndStatementOfComprehensiveIncomeAbstract_b81f6fb6-7155-4c6a-a852-eccd0c1c0092" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_0a10f7a5-ced3-491c-a280-2dc67e40f6d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_56787e08-4fb5-4943-b23b-73557ca267d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_smmt_IncomeStatementAndStatementOfComprehensiveIncomeAbstract_b81f6fb6-7155-4c6a-a852-eccd0c1c0092" xlink:to="loc_us-gaap_OperatingExpensesAbstract_56787e08-4fb5-4943-b23b-73557ca267d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_14eae4b6-23fa-495f-aea3-f8972c8c4ecb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_56787e08-4fb5-4943-b23b-73557ca267d6" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_14eae4b6-23fa-495f-aea3-f8972c8c4ecb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_b1d71458-ba03-4128-bf78-3ccc533b58e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_56787e08-4fb5-4943-b23b-73557ca267d6" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_b1d71458-ba03-4128-bf78-3ccc533b58e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_e8922220-59b2-4bdf-bfe5-6b641bd55242" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_56787e08-4fb5-4943-b23b-73557ca267d6" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_e8922220-59b2-4bdf-bfe5-6b641bd55242" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_b5277149-14f4-4072-a058-5dac9d252823" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_56787e08-4fb5-4943-b23b-73557ca267d6" xlink:to="loc_us-gaap_OperatingExpenses_b5277149-14f4-4072-a058-5dac9d252823" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncome_f30b7b08-e8be-4668-baac-488207baf26d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherOperatingIncome"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_smmt_IncomeStatementAndStatementOfComprehensiveIncomeAbstract_b81f6fb6-7155-4c6a-a852-eccd0c1c0092" xlink:to="loc_us-gaap_OtherOperatingIncome_f30b7b08-e8be-4668-baac-488207baf26d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_69c814eb-cf71-4be6-8f8f-b2df40708cd1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_smmt_IncomeStatementAndStatementOfComprehensiveIncomeAbstract_b81f6fb6-7155-4c6a-a852-eccd0c1c0092" xlink:to="loc_us-gaap_OperatingIncomeLoss_69c814eb-cf71-4be6-8f8f-b2df40708cd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_b38cdcf5-d5ab-49c2-86fd-f9419b45ca01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_smmt_IncomeStatementAndStatementOfComprehensiveIncomeAbstract_b81f6fb6-7155-4c6a-a852-eccd0c1c0092" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_b38cdcf5-d5ab-49c2-86fd-f9419b45ca01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_3fd6e43d-f4c3-445d-8ec1-c29bf5662639" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_smmt_IncomeStatementAndStatementOfComprehensiveIncomeAbstract_b81f6fb6-7155-4c6a-a852-eccd0c1c0092" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_3fd6e43d-f4c3-445d-8ec1-c29bf5662639" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_16a33e50-6cab-4d31-9067-f542005a8810" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_smmt_IncomeStatementAndStatementOfComprehensiveIncomeAbstract_b81f6fb6-7155-4c6a-a852-eccd0c1c0092" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_16a33e50-6cab-4d31-9067-f542005a8810" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_078c7f01-b7ef-4117-902d-7d294b404fa5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_smmt_IncomeStatementAndStatementOfComprehensiveIncomeAbstract_b81f6fb6-7155-4c6a-a852-eccd0c1c0092" xlink:to="loc_us-gaap_NetIncomeLoss_078c7f01-b7ef-4117-902d-7d294b404fa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_d59cb685-2c06-485c-a093-34b500c20975" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_smmt_IncomeStatementAndStatementOfComprehensiveIncomeAbstract_b81f6fb6-7155-4c6a-a852-eccd0c1c0092" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_d59cb685-2c06-485c-a093-34b500c20975" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_9ffc7a29-f857-49d1-9148-dfb06b288b46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_d59cb685-2c06-485c-a093-34b500c20975" xlink:to="loc_us-gaap_EarningsPerShareBasic_9ffc7a29-f857-49d1-9148-dfb06b288b46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_ff944f98-5540-4bff-a6f3-35b889c88d2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_d59cb685-2c06-485c-a093-34b500c20975" xlink:to="loc_us-gaap_EarningsPerShareDiluted_ff944f98-5540-4bff-a6f3-35b889c88d2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_bac67ab3-9e1f-4c6a-a7b2-e11a8fd42233" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_smmt_IncomeStatementAndStatementOfComprehensiveIncomeAbstract_b81f6fb6-7155-4c6a-a852-eccd0c1c0092" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_bac67ab3-9e1f-4c6a-a7b2-e11a8fd42233" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_219e5560-d0ed-45bf-8553-1742422b1c84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_bac67ab3-9e1f-4c6a-a7b2-e11a8fd42233" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_219e5560-d0ed-45bf-8553-1742422b1c84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_cbe103f3-f19c-456d-a7f5-7e91b58b945d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_bac67ab3-9e1f-4c6a-a7b2-e11a8fd42233" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_cbe103f3-f19c-456d-a7f5-7e91b58b945d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_c57859af-fd85-4f31-b507-968fb469d9df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_smmt_IncomeStatementAndStatementOfComprehensiveIncomeAbstract_b81f6fb6-7155-4c6a-a852-eccd0c1c0092" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_c57859af-fd85-4f31-b507-968fb469d9df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_78fe0b96-16f4-4580-aac1-18faf4165084" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_c57859af-fd85-4f31-b507-968fb469d9df" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_78fe0b96-16f4-4580-aac1-18faf4165084" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_12ed4034-3a92-4474-a5c9-ad94f7af1488" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_smmt_IncomeStatementAndStatementOfComprehensiveIncomeAbstract_b81f6fb6-7155-4c6a-a852-eccd0c1c0092" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_12ed4034-3a92-4474-a5c9-ad94f7af1488" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="smmt-20211231.xsd#ConsolidatedStatementsofStockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.summitplc.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_c5baaeee-a04c-4d0b-a25a-6dd9c441c2e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_8c625735-4c98-4353-8868-d314d9f94e5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_c5baaeee-a04c-4d0b-a25a-6dd9c441c2e6" xlink:to="loc_us-gaap_StatementTable_8c625735-4c98-4353-8868-d314d9f94e5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_a8b9a028-64ed-464e-9136-f43876b23d29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_8c625735-4c98-4353-8868-d314d9f94e5c" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_a8b9a028-64ed-464e-9136-f43876b23d29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_a3459ff1-8d2e-4ab8-a34a-9ce281d3674b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_a8b9a028-64ed-464e-9136-f43876b23d29" xlink:to="loc_us-gaap_EquityComponentDomain_a3459ff1-8d2e-4ab8-a34a-9ce281d3674b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_84df9d53-28d1-46a7-8896-7b797d38ad58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_a3459ff1-8d2e-4ab8-a34a-9ce281d3674b" xlink:to="loc_us-gaap_CommonStockMember_84df9d53-28d1-46a7-8896-7b797d38ad58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_6a4adbe8-442b-4592-a014-29763d51dc6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_a3459ff1-8d2e-4ab8-a34a-9ce281d3674b" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_6a4adbe8-442b-4592-a014-29763d51dc6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_9adb2bd2-696e-4ad2-bcc8-625ca0c7df58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_a3459ff1-8d2e-4ab8-a34a-9ce281d3674b" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_9adb2bd2-696e-4ad2-bcc8-625ca0c7df58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_42b14159-acdf-4b1c-9038-f3df7e7684c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_a3459ff1-8d2e-4ab8-a34a-9ce281d3674b" xlink:to="loc_us-gaap_RetainedEarningsMember_42b14159-acdf-4b1c-9038-f3df7e7684c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_d037ceb0-9b42-4fb3-8f65-f73dd419a534" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_8c625735-4c98-4353-8868-d314d9f94e5c" xlink:to="loc_us-gaap_StatementLineItems_d037ceb0-9b42-4fb3-8f65-f73dd419a534" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c3ef8ec7-8034-4c69-9c26-e5defe7b987e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d037ceb0-9b42-4fb3-8f65-f73dd419a534" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c3ef8ec7-8034-4c69-9c26-e5defe7b987e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_5473f8e4-e4c2-4955-961d-d1f3ef5c5b13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c3ef8ec7-8034-4c69-9c26-e5defe7b987e" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_5473f8e4-e4c2-4955-961d-d1f3ef5c5b13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_f170b925-669e-4785-9959-9efe9a37b320" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c3ef8ec7-8034-4c69-9c26-e5defe7b987e" xlink:to="loc_us-gaap_StockholdersEquity_f170b925-669e-4785-9959-9efe9a37b320" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_ab25ac23-0c0e-415a-ab4a-aefeedfe2004" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c3ef8ec7-8034-4c69-9c26-e5defe7b987e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_ab25ac23-0c0e-415a-ab4a-aefeedfe2004" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_8274d8a2-6037-4e6f-84e4-f733ed49b997" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c3ef8ec7-8034-4c69-9c26-e5defe7b987e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_8274d8a2-6037-4e6f-84e4-f733ed49b997" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_FractionalStockIssuedDuringPeriodSharesReverseStockSplit_798a470d-4ae0-4ff0-8dda-ae012e1b2c73" xlink:href="smmt-20211231.xsd#smmt_FractionalStockIssuedDuringPeriodSharesReverseStockSplit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c3ef8ec7-8034-4c69-9c26-e5defe7b987e" xlink:to="loc_smmt_FractionalStockIssuedDuringPeriodSharesReverseStockSplit_798a470d-4ae0-4ff0-8dda-ae012e1b2c73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_bc07bcdd-4852-4c71-a434-4595fcddd2a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c3ef8ec7-8034-4c69-9c26-e5defe7b987e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_bc07bcdd-4852-4c71-a434-4595fcddd2a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_82bea756-9af6-492c-bf3d-0f3ee329ed18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c3ef8ec7-8034-4c69-9c26-e5defe7b987e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_82bea756-9af6-492c-bf3d-0f3ee329ed18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_7e4d315c-7e1a-40ca-81fe-d8d618d7cba4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c3ef8ec7-8034-4c69-9c26-e5defe7b987e" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_7e4d315c-7e1a-40ca-81fe-d8d618d7cba4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_AdjustmentsToAdditionalPaidInCapitalImputedInterestExpenseRelatedParty_0ebb4e5f-64a8-4d23-8d48-52af792c6c35" xlink:href="smmt-20211231.xsd#smmt_AdjustmentsToAdditionalPaidInCapitalImputedInterestExpenseRelatedParty"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c3ef8ec7-8034-4c69-9c26-e5defe7b987e" xlink:to="loc_smmt_AdjustmentsToAdditionalPaidInCapitalImputedInterestExpenseRelatedParty_0ebb4e5f-64a8-4d23-8d48-52af792c6c35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_b9473929-e05e-4857-a1f4-ca89fd9fe6bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c3ef8ec7-8034-4c69-9c26-e5defe7b987e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_b9473929-e05e-4857-a1f4-ca89fd9fe6bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_a1d45717-5c45-4665-a29a-463d4c7f938b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c3ef8ec7-8034-4c69-9c26-e5defe7b987e" xlink:to="loc_us-gaap_NetIncomeLoss_a1d45717-5c45-4665-a29a-463d4c7f938b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_718dfd29-8099-488b-a473-1cde2a374f2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c3ef8ec7-8034-4c69-9c26-e5defe7b987e" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_718dfd29-8099-488b-a473-1cde2a374f2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_04d64a2f-994a-411d-bec0-fecf23cb0e57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c3ef8ec7-8034-4c69-9c26-e5defe7b987e" xlink:to="loc_us-gaap_StockholdersEquity_04d64a2f-994a-411d-bec0-fecf23cb0e57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/ConsolidatedStatementsofStockholdersEquityDeficitParenthetical" xlink:type="simple" xlink:href="smmt-20211231.xsd#ConsolidatedStatementsofStockholdersEquityDeficitParenthetical"/>
  <link:presentationLink xlink:role="http://www.summitplc.com/role/ConsolidatedStatementsofStockholdersEquityDeficitParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_677117d2-732c-46e9-8f95-d294de7e9097" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_bb960c4e-dab0-4c51-aa10-7fb5db2ca4f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_677117d2-732c-46e9-8f95-d294de7e9097" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_bb960c4e-dab0-4c51-aa10-7fb5db2ca4f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="smmt-20211231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_a098e014-3ddc-4f0f-b3c6-3df0ff85d2b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_9cd99a8e-63c4-49e8-b678-2533fedd59bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_a098e014-3ddc-4f0f-b3c6-3df0ff85d2b7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_9cd99a8e-63c4-49e8-b678-2533fedd59bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_d78680fa-c411-4b6e-a24d-11a774e97fbc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_9cd99a8e-63c4-49e8-b678-2533fedd59bf" xlink:to="loc_us-gaap_NetIncomeLoss_d78680fa-c411-4b6e-a24d-11a774e97fbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a7da0379-a69f-4bf5-90c8-5aad1b9b9239" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_9cd99a8e-63c4-49e8-b678-2533fedd59bf" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a7da0379-a69f-4bf5-90c8-5aad1b9b9239" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_GainLossOnRemeasurementOfLiabilitiesOperatingAndNonoperating_1d423922-9cda-4c38-b725-cd6218a6888e" xlink:href="smmt-20211231.xsd#smmt_GainLossOnRemeasurementOfLiabilitiesOperatingAndNonoperating"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a7da0379-a69f-4bf5-90c8-5aad1b9b9239" xlink:to="loc_smmt_GainLossOnRemeasurementOfLiabilitiesOperatingAndNonoperating_1d423922-9cda-4c38-b725-cd6218a6888e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_7edc4ce3-ef31-407d-b423-4c43c2b438f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a7da0379-a69f-4bf5-90c8-5aad1b9b9239" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_7edc4ce3-ef31-407d-b423-4c43c2b438f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_InterestExpenseIncomeNoncash_f707f1c7-f04d-416c-8d55-86dbd5e41d93" xlink:href="smmt-20211231.xsd#smmt_InterestExpenseIncomeNoncash"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a7da0379-a69f-4bf5-90c8-5aad1b9b9239" xlink:to="loc_smmt_InterestExpenseIncomeNoncash_f707f1c7-f04d-416c-8d55-86dbd5e41d93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_d1a14682-cca1-4a14-90c2-0fedcb9f1533" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a7da0379-a69f-4bf5-90c8-5aad1b9b9239" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_d1a14682-cca1-4a14-90c2-0fedcb9f1533" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_db379072-35eb-43aa-9471-4f70e4344f40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a7da0379-a69f-4bf5-90c8-5aad1b9b9239" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_db379072-35eb-43aa-9471-4f70e4344f40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_d47fd254-7746-44a8-b761-1c0745e7a909" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a7da0379-a69f-4bf5-90c8-5aad1b9b9239" xlink:to="loc_us-gaap_Depreciation_d47fd254-7746-44a8-b761-1c0745e7a909" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_9f388266-d3dc-4a62-9b39-a45cc8e7c4c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a7da0379-a69f-4bf5-90c8-5aad1b9b9239" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_9f388266-d3dc-4a62-9b39-a45cc8e7c4c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_bcbf6028-27ec-4d96-9170-6d5fa09f0502" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a7da0379-a69f-4bf5-90c8-5aad1b9b9239" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_bcbf6028-27ec-4d96-9170-6d5fa09f0502" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_15728aea-8b7f-476b-ac1d-940a1c94f004" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a7da0379-a69f-4bf5-90c8-5aad1b9b9239" xlink:to="loc_us-gaap_ShareBasedCompensation_15728aea-8b7f-476b-ac1d-940a1c94f004" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_e4a0eb1c-ebd3-45f6-9c78-0f649dea1371" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a7da0379-a69f-4bf5-90c8-5aad1b9b9239" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_e4a0eb1c-ebd3-45f6-9c78-0f649dea1371" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5a734c37-2ab7-4f0f-ba43-15f68f5c0760" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a7da0379-a69f-4bf5-90c8-5aad1b9b9239" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5a734c37-2ab7-4f0f-ba43-15f68f5c0760" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_7325b162-80a0-47f0-b8fc-e78b1c5a76d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5a734c37-2ab7-4f0f-ba43-15f68f5c0760" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_7325b162-80a0-47f0-b8fc-e78b1c5a76d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_f6bee5a0-885c-4a20-931c-2800eaf10af9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5a734c37-2ab7-4f0f-ba43-15f68f5c0760" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_f6bee5a0-885c-4a20-931c-2800eaf10af9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_046f033e-32e7-4576-b7d1-ec6c91a05391" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5a734c37-2ab7-4f0f-ba43-15f68f5c0760" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_046f033e-32e7-4576-b7d1-ec6c91a05391" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_IncreaseDecreaseInResearchAndDevelopmentTaxCreditReceivable_22d750d2-5fd9-4e77-b25c-e92fde86037f" xlink:href="smmt-20211231.xsd#smmt_IncreaseDecreaseInResearchAndDevelopmentTaxCreditReceivable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5a734c37-2ab7-4f0f-ba43-15f68f5c0760" xlink:to="loc_smmt_IncreaseDecreaseInResearchAndDevelopmentTaxCreditReceivable_22d750d2-5fd9-4e77-b25c-e92fde86037f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_f7a4f740-7d45-4b1d-adfb-ea8f308ee1d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5a734c37-2ab7-4f0f-ba43-15f68f5c0760" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_f7a4f740-7d45-4b1d-adfb-ea8f308ee1d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_14a1c4d4-899f-4664-be70-125b7e2ba539" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5a734c37-2ab7-4f0f-ba43-15f68f5c0760" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_14a1c4d4-899f-4664-be70-125b7e2ba539" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_IncreaseDecreaseInAccruedLiabilitiesAndEmployeeRelatedLiabilities_61a7ff52-0ea0-4b81-9b68-67b9eccc59fc" xlink:href="smmt-20211231.xsd#smmt_IncreaseDecreaseInAccruedLiabilitiesAndEmployeeRelatedLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5a734c37-2ab7-4f0f-ba43-15f68f5c0760" xlink:to="loc_smmt_IncreaseDecreaseInAccruedLiabilitiesAndEmployeeRelatedLiabilities_61a7ff52-0ea0-4b81-9b68-67b9eccc59fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_5b6db40c-e55c-4ea3-b399-47ed4ad1834d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5a734c37-2ab7-4f0f-ba43-15f68f5c0760" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_5b6db40c-e55c-4ea3-b399-47ed4ad1834d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b8221390-b0a4-49a5-862b-89c710ce5931" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_9cd99a8e-63c4-49e8-b678-2533fedd59bf" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b8221390-b0a4-49a5-862b-89c710ce5931" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_e4dff551-4376-4f2a-b5f1-0ca508e489cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_a098e014-3ddc-4f0f-b3c6-3df0ff85d2b7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_e4dff551-4376-4f2a-b5f1-0ca508e489cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2435f6e2-636b-45ab-b68c-1e3f653f00e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_e4dff551-4376-4f2a-b5f1-0ca508e489cf" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2435f6e2-636b-45ab-b68c-1e3f653f00e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_bd826664-898f-4be6-bdea-e354500ff6fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_e4dff551-4376-4f2a-b5f1-0ca508e489cf" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_bd826664-898f-4be6-bdea-e354500ff6fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_ddb2f321-815b-4eca-b8e4-db81bf84920a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_a098e014-3ddc-4f0f-b3c6-3df0ff85d2b7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_ddb2f321-815b-4eca-b8e4-db81bf84920a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_01776b2c-66bd-45f0-a673-6c02d4942bf7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_ddb2f321-815b-4eca-b8e4-db81bf84920a" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_01776b2c-66bd-45f0-a673-6c02d4942bf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_61fbf454-9b30-4329-a544-4c4853990cb8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_ddb2f321-815b-4eca-b8e4-db81bf84920a" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_61fbf454-9b30-4329-a544-4c4853990cb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRelatedPartyDebt_0dcfd02d-386b-4210-894b-50302bb32f71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromRelatedPartyDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_ddb2f321-815b-4eca-b8e4-db81bf84920a" xlink:to="loc_us-gaap_ProceedsFromRelatedPartyDebt_0dcfd02d-386b-4210-894b-50302bb32f71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfRelatedPartyDebt_d727c731-5eb4-4ba9-9624-ba90e8d40d24" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfRelatedPartyDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_ddb2f321-815b-4eca-b8e4-db81bf84920a" xlink:to="loc_us-gaap_RepaymentsOfRelatedPartyDebt_d727c731-5eb4-4ba9-9624-ba90e8d40d24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_762ec728-70d5-44be-8e38-40b99880a378" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_ddb2f321-815b-4eca-b8e4-db81bf84920a" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_762ec728-70d5-44be-8e38-40b99880a378" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_9d532d86-3955-430e-bb39-0a08e976c795" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_ddb2f321-815b-4eca-b8e4-db81bf84920a" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_9d532d86-3955-430e-bb39-0a08e976c795" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_e3c4d236-fc94-4d48-a37b-099d70375376" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_ddb2f321-815b-4eca-b8e4-db81bf84920a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_e3c4d236-fc94-4d48-a37b-099d70375376" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9f451cf0-83de-4837-9460-972e4c51e58a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_a098e014-3ddc-4f0f-b3c6-3df0ff85d2b7" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9f451cf0-83de-4837-9460-972e4c51e58a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_a66eee3f-8232-43fc-a3ac-7c047998c3fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_a098e014-3ddc-4f0f-b3c6-3df0ff85d2b7" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_a66eee3f-8232-43fc-a3ac-7c047998c3fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_13beab36-b1df-4727-832d-8db16a1a8083" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_a098e014-3ddc-4f0f-b3c6-3df0ff85d2b7" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_13beab36-b1df-4727-832d-8db16a1a8083" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_107be522-4969-47f5-8d95-e15393594bf2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_a098e014-3ddc-4f0f-b3c6-3df0ff85d2b7" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_107be522-4969-47f5-8d95-e15393594bf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_abf6d990-1a33-4f3d-b52e-8b4a97a12ea8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_a098e014-3ddc-4f0f-b3c6-3df0ff85d2b7" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_abf6d990-1a33-4f3d-b52e-8b4a97a12ea8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_27931153-776f-4d53-9705-a25730d7bcd4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_abf6d990-1a33-4f3d-b52e-8b4a97a12ea8" xlink:to="loc_us-gaap_InterestPaidNet_27931153-776f-4d53-9705-a25730d7bcd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_0f0d6224-7d2d-4c9d-a384-6454efb05e65" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_abf6d990-1a33-4f3d-b52e-8b4a97a12ea8" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_0f0d6224-7d2d-4c9d-a384-6454efb05e65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_StockIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_b315347c-413e-4dbd-9cad-a797962698cc" xlink:href="smmt-20211231.xsd#smmt_StockIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_abf6d990-1a33-4f3d-b52e-8b4a97a12ea8" xlink:to="loc_smmt_StockIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_b315347c-413e-4dbd-9cad-a797962698cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_4cff3dae-1663-4cfe-85c3-1d490d3c6666" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_abf6d990-1a33-4f3d-b52e-8b4a97a12ea8" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_4cff3dae-1663-4cfe-85c3-1d490d3c6666" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/NatureofBusinessandOperationsandRecentEvents" xlink:type="simple" xlink:href="smmt-20211231.xsd#NatureofBusinessandOperationsandRecentEvents"/>
  <link:presentationLink xlink:role="http://www.summitplc.com/role/NatureofBusinessandOperationsandRecentEvents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2edc372e-7aaa-44b2-bc4d-03cc099e61d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations_a4cee233-25c1-426a-83f0-461c8777d3fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NatureOfOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2edc372e-7aaa-44b2-bc4d-03cc099e61d4" xlink:to="loc_us-gaap_NatureOfOperations_a4cee233-25c1-426a-83f0-461c8777d3fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/BasisofPresentationandUseofEstimates" xlink:type="simple" xlink:href="smmt-20211231.xsd#BasisofPresentationandUseofEstimates"/>
  <link:presentationLink xlink:role="http://www.summitplc.com/role/BasisofPresentationandUseofEstimates" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6c94ce9a-946f-4dae-a578-2b36e0080670" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccounting_e0a4a17d-58ed-4213-8a48-ec9263c3bcbe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccounting"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6c94ce9a-946f-4dae-a578-2b36e0080670" xlink:to="loc_us-gaap_BasisOfAccounting_e0a4a17d-58ed-4213-8a48-ec9263c3bcbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/LiquidityandCapitalResources" xlink:type="simple" xlink:href="smmt-20211231.xsd#LiquidityandCapitalResources"/>
  <link:presentationLink xlink:role="http://www.summitplc.com/role/LiquidityandCapitalResources" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_23507255-0c02-4389-85b8-6ca8156dea1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_LiquidityAndCapitalResourcesTextBlock_30d8ba0c-cd57-4cbf-83e1-6c346601662f" xlink:href="smmt-20211231.xsd#smmt_LiquidityAndCapitalResourcesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_23507255-0c02-4389-85b8-6ca8156dea1c" xlink:to="loc_smmt_LiquidityAndCapitalResourcesTextBlock_30d8ba0c-cd57-4cbf-83e1-6c346601662f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="smmt-20211231.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.summitplc.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_e280b7c8-2cd7-4c6b-8d66-16ec8a5a22ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_a12c6fd1-eebb-4919-96fc-d3739f92c5ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e280b7c8-2cd7-4c6b-8d66-16ec8a5a22ba" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_a12c6fd1-eebb-4919-96fc-d3739f92c5ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/RecentlyIssuedorAdoptedAccountingPronouncements" xlink:type="simple" xlink:href="smmt-20211231.xsd#RecentlyIssuedorAdoptedAccountingPronouncements"/>
  <link:presentationLink xlink:role="http://www.summitplc.com/role/RecentlyIssuedorAdoptedAccountingPronouncements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingChangesAndErrorCorrectionsAbstract_76eab484-6109-44c3-9e4c-081c0a90c760" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingChangesAndErrorCorrectionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_a2503c28-440b-4c17-9d6e-f5493a4cf326" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingChangesAndErrorCorrectionsAbstract_76eab484-6109-44c3-9e4c-081c0a90c760" xlink:to="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_a2503c28-440b-4c17-9d6e-f5493a4cf326" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/SegmentReporting" xlink:type="simple" xlink:href="smmt-20211231.xsd#SegmentReporting"/>
  <link:presentationLink xlink:role="http://www.summitplc.com/role/SegmentReporting" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_0916bab3-b0fa-4c81-8510-a9312b3426f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_f97bfd46-9ee5-491b-aaef-1b14dff4aa22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_0916bab3-b0fa-4c81-8510-a9312b3426f6" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_f97bfd46-9ee5-491b-aaef-1b14dff4aa22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/Revenue" xlink:type="simple" xlink:href="smmt-20211231.xsd#Revenue"/>
  <link:presentationLink xlink:role="http://www.summitplc.com/role/Revenue" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_d7e5ce6c-bfcc-4c62-9fbd-cd4da4721973" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_6abf35b0-087d-4afb-a780-e1af1633d716" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_d7e5ce6c-bfcc-4c62-9fbd-cd4da4721973" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_6abf35b0-087d-4afb-a780-e1af1633d716" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/OtherOperatingIncome" xlink:type="simple" xlink:href="smmt-20211231.xsd#OtherOperatingIncome"/>
  <link:presentationLink xlink:role="http://www.summitplc.com/role/OtherOperatingIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_4ae19777-fd75-48ed-89f1-900ff6158fe3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeAndExpenseTextBlock_f2cde3f5-f1eb-442e-8180-996c37b09734" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherOperatingIncomeAndExpenseTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_4ae19777-fd75-48ed-89f1-900ff6158fe3" xlink:to="loc_us-gaap_OtherOperatingIncomeAndExpenseTextBlock_f2cde3f5-f1eb-442e-8180-996c37b09734" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/OtherExpenseIncome" xlink:type="simple" xlink:href="smmt-20211231.xsd#OtherExpenseIncome"/>
  <link:presentationLink xlink:role="http://www.summitplc.com/role/OtherExpenseIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_afe4fd84-33d5-47ef-8a01-32431e3c6604" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock_1efd4b35-11c2-456f-972c-7505b06eee6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_afe4fd84-33d5-47ef-8a01-32431e3c6604" xlink:to="loc_us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock_1efd4b35-11c2-456f-972c-7505b06eee6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/IncomeTax" xlink:type="simple" xlink:href="smmt-20211231.xsd#IncomeTax"/>
  <link:presentationLink xlink:role="http://www.summitplc.com/role/IncomeTax" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_dc7dd41a-a729-4448-a2a8-0dc8eaeb350b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_e6f1e524-bc08-4832-9839-e331daab52a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_dc7dd41a-a729-4448-a2a8-0dc8eaeb350b" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_e6f1e524-bc08-4832-9839-e331daab52a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/LossperShare" xlink:type="simple" xlink:href="smmt-20211231.xsd#LossperShare"/>
  <link:presentationLink xlink:role="http://www.summitplc.com/role/LossperShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_e9be6d8e-62ca-4c93-9391-e1e3d4b252a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_ad032dd4-2dbe-4011-8461-943310fd2e45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_e9be6d8e-62ca-4c93-9391-e1e3d4b252a7" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_ad032dd4-2dbe-4011-8461-943310fd2e45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/GoodwillandIntangibleAssets" xlink:type="simple" xlink:href="smmt-20211231.xsd#GoodwillandIntangibleAssets"/>
  <link:presentationLink xlink:role="http://www.summitplc.com/role/GoodwillandIntangibleAssets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_3c8c0f2b-5b32-4fba-9a31-4be0d29bf1e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_2fc5cdbb-002f-4bbd-bdd5-70bdadc5e52f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_3c8c0f2b-5b32-4fba-9a31-4be0d29bf1e0" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_2fc5cdbb-002f-4bbd-bdd5-70bdadc5e52f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/PropertyandEquipment" xlink:type="simple" xlink:href="smmt-20211231.xsd#PropertyandEquipment"/>
  <link:presentationLink xlink:role="http://www.summitplc.com/role/PropertyandEquipment" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_64be4f2f-f224-4f0f-8c3d-232c3f9fa818" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_56ba20fe-fb1c-4d9c-8244-f8cd3afe288f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_64be4f2f-f224-4f0f-8c3d-232c3f9fa818" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_56ba20fe-fb1c-4d9c-8244-f8cd3afe288f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/ResearchandDevelopmentPrepaidExpensesandAccruedLiabilities" xlink:type="simple" xlink:href="smmt-20211231.xsd#ResearchandDevelopmentPrepaidExpensesandAccruedLiabilities"/>
  <link:presentationLink xlink:role="http://www.summitplc.com/role/ResearchandDevelopmentPrepaidExpensesandAccruedLiabilities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_b3f8be5b-32a4-48b3-bebc-e136f8bd1c09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_08c8cf54-12ce-4101-8466-cb33211f9dd3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_b3f8be5b-32a4-48b3-bebc-e136f8bd1c09" xlink:to="loc_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_08c8cf54-12ce-4101-8466-cb33211f9dd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/Leases" xlink:type="simple" xlink:href="smmt-20211231.xsd#Leases"/>
  <link:presentationLink xlink:role="http://www.summitplc.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_559c5c07-a980-41c3-9d78-f8dd59516939" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_5d6e98f1-c9f0-4b08-8122-08384a3d5b16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_559c5c07-a980-41c3-9d78-f8dd59516939" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_5d6e98f1-c9f0-4b08-8122-08384a3d5b16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/OtherNonCurrentLiabilities" xlink:type="simple" xlink:href="smmt-20211231.xsd#OtherNonCurrentLiabilities"/>
  <link:presentationLink xlink:role="http://www.summitplc.com/role/OtherNonCurrentLiabilities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_0efb0de0-5c24-4bb3-9a37-565568c03be5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureNoncurrentTextBlock_a7dc87bb-a4d9-4781-87d6-9e79a387e7a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureNoncurrentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_0efb0de0-5c24-4bb3-9a37-565568c03be5" xlink:to="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureNoncurrentTextBlock_a7dc87bb-a4d9-4781-87d6-9e79a387e7a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/StockholdersEquity" xlink:type="simple" xlink:href="smmt-20211231.xsd#StockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.summitplc.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_e5f2f2e7-4cf9-43c7-8cd5-eb5ab9b11b2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1f4f9676-7b71-4f67-82fd-ab69c030853b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_e5f2f2e7-4cf9-43c7-8cd5-eb5ab9b11b2f" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1f4f9676-7b71-4f67-82fd-ab69c030853b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="smmt-20211231.xsd#StockBasedCompensation"/>
  <link:presentationLink xlink:role="http://www.summitplc.com/role/StockBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3ca50eea-38d2-4013-acb4-7ac27c04bc5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_83273b14-f083-419d-8f73-c4a1357df113" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3ca50eea-38d2-4013-acb4-7ac27c04bc5b" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_83273b14-f083-419d-8f73-c4a1357df113" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="smmt-20211231.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.summitplc.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_40959886-1b2b-4ae1-a0ce-98d6df1fd04d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_56bad454-0e5f-4bb5-b34e-8a0cf2bb1c92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_40959886-1b2b-4ae1-a0ce-98d6df1fd04d" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_56bad454-0e5f-4bb5-b34e-8a0cf2bb1c92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/RelatedPartyTransactions" xlink:type="simple" xlink:href="smmt-20211231.xsd#RelatedPartyTransactions"/>
  <link:presentationLink xlink:role="http://www.summitplc.com/role/RelatedPartyTransactions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_130b733f-0c6c-4395-85e4-6b9e0472a212" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_f2941476-68c4-4116-ba52-27b25611025a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_130b733f-0c6c-4395-85e4-6b9e0472a212" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_f2941476-68c4-4116-ba52-27b25611025a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/SubsequentEvent" xlink:type="simple" xlink:href="smmt-20211231.xsd#SubsequentEvent"/>
  <link:presentationLink xlink:role="http://www.summitplc.com/role/SubsequentEvent" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_cf6310bd-89e6-453e-ac4b-3a7f6cdadab3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_ae2addf5-26fc-4d3b-8390-4ce45ec69a01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_cf6310bd-89e6-453e-ac4b-3a7f6cdadab3" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_ae2addf5-26fc-4d3b-8390-4ce45ec69a01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="smmt-20211231.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.summitplc.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_1d55edcf-6857-4f9a-9742-692ba98ce4b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_6ca72ed7-a87f-435a-a8eb-2a08046f16b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1d55edcf-6857-4f9a-9742-692ba98ce4b4" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_6ca72ed7-a87f-435a-a8eb-2a08046f16b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_b8907562-ff2b-4ad0-8f21-dfcde12d72d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1d55edcf-6857-4f9a-9742-692ba98ce4b4" xlink:to="loc_us-gaap_UseOfEstimates_b8907562-ff2b-4ad0-8f21-dfcde12d72d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_d70284e9-f5bb-4924-8c36-db091f26c50b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1d55edcf-6857-4f9a-9742-692ba98ce4b4" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_d70284e9-f5bb-4924-8c36-db091f26c50b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_9639e9d1-1020-4513-99d7-52a9b9be1ba9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1d55edcf-6857-4f9a-9742-692ba98ce4b4" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_9639e9d1-1020-4513-99d7-52a9b9be1ba9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_14ce6469-1f19-4285-b8cb-90e3052e260d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1d55edcf-6857-4f9a-9742-692ba98ce4b4" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_14ce6469-1f19-4285-b8cb-90e3052e260d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_OtherOperatingIncomePolicyPolicyTextBlock_cbba5295-bdfc-4e95-a2ca-d91c45f4de92" xlink:href="smmt-20211231.xsd#smmt_OtherOperatingIncomePolicyPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1d55edcf-6857-4f9a-9742-692ba98ce4b4" xlink:to="loc_smmt_OtherOperatingIncomePolicyPolicyTextBlock_cbba5295-bdfc-4e95-a2ca-d91c45f4de92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_87a7fa5f-95b9-4cf3-8eb8-05606706eff5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1d55edcf-6857-4f9a-9742-692ba98ce4b4" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_87a7fa5f-95b9-4cf3-8eb8-05606706eff5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy_0fa5c10d-6e32-488f-8565-874e31f7f4d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1d55edcf-6857-4f9a-9742-692ba98ce4b4" xlink:to="loc_us-gaap_BusinessCombinationsPolicy_0fa5c10d-6e32-488f-8565-874e31f7f4d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_7de27392-dc04-458c-96a9-fdc3804fe794" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1d55edcf-6857-4f9a-9742-692ba98ce4b4" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_7de27392-dc04-458c-96a9-fdc3804fe794" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_dc34bfc2-fbb4-47d0-80e0-3f3e2e51cf6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1d55edcf-6857-4f9a-9742-692ba98ce4b4" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_dc34bfc2-fbb4-47d0-80e0-3f3e2e51cf6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_fc24755f-dda2-4114-a05c-6b43ae00d3ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1d55edcf-6857-4f9a-9742-692ba98ce4b4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_fc24755f-dda2-4114-a05c-6b43ae00d3ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_90f031bf-40b5-4bc8-888a-e3a240041aed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1d55edcf-6857-4f9a-9742-692ba98ce4b4" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_90f031bf-40b5-4bc8-888a-e3a240041aed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_40bfb0bd-7827-46db-9655-ab72d19b4cfa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1d55edcf-6857-4f9a-9742-692ba98ce4b4" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_40bfb0bd-7827-46db-9655-ab72d19b4cfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_6966d528-c509-4a03-ab7f-7d1cbf195a79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1d55edcf-6857-4f9a-9742-692ba98ce4b4" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_6966d528-c509-4a03-ab7f-7d1cbf195a79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_6bbc6530-26f1-4504-8802-b606dc3e8d48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1d55edcf-6857-4f9a-9742-692ba98ce4b4" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_6bbc6530-26f1-4504-8802-b606dc3e8d48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_010a2bcd-e525-467a-8dac-c33c62202616" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1d55edcf-6857-4f9a-9742-692ba98ce4b4" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_010a2bcd-e525-467a-8dac-c33c62202616" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_9d0101ea-158d-4145-879e-50b4b83b3970" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1d55edcf-6857-4f9a-9742-692ba98ce4b4" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_9d0101ea-158d-4145-879e-50b4b83b3970" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_AssumedContingentLiabilitiesPolicyPolicyTextBlock_666a50f8-6e8a-42d1-8f65-a8c91ca993ed" xlink:href="smmt-20211231.xsd#smmt_AssumedContingentLiabilitiesPolicyPolicyTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1d55edcf-6857-4f9a-9742-692ba98ce4b4" xlink:to="loc_smmt_AssumedContingentLiabilitiesPolicyPolicyTextBlock_666a50f8-6e8a-42d1-8f65-a8c91ca993ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_WarrantsPolicyPolicyTextBlock_b06f8c8c-d098-475d-bdf3-2fd61dd2aa8f" xlink:href="smmt-20211231.xsd#smmt_WarrantsPolicyPolicyTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1d55edcf-6857-4f9a-9742-692ba98ce4b4" xlink:to="loc_smmt_WarrantsPolicyPolicyTextBlock_b06f8c8c-d098-475d-bdf3-2fd61dd2aa8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_4b71b6ba-3e80-47cf-b67b-721966f73f52" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1d55edcf-6857-4f9a-9742-692ba98ce4b4" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_4b71b6ba-3e80-47cf-b67b-721966f73f52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="smmt-20211231.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://www.summitplc.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_753830ea-f963-459d-902e-b8be017531c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_f41a423b-7d14-4119-9f18-43ffd8f7ad99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_753830ea-f963-459d-902e-b8be017531c1" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_f41a423b-7d14-4119-9f18-43ffd8f7ad99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_39f7014c-05a6-4366-8192-14242d29c196" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_753830ea-f963-459d-902e-b8be017531c1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_39f7014c-05a6-4366-8192-14242d29c196" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/SegmentReportingTables" xlink:type="simple" xlink:href="smmt-20211231.xsd#SegmentReportingTables"/>
  <link:presentationLink xlink:role="http://www.summitplc.com/role/SegmentReportingTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_a7b2438e-801f-451a-9cd5-e55ee8a2c3a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock_b71ac8d3-52c5-4fd3-9fe0-79d2a7f7026b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_a7b2438e-801f-451a-9cd5-e55ee8a2c3a6" xlink:to="loc_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock_b71ac8d3-52c5-4fd3-9fe0-79d2a7f7026b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/RevenueTables" xlink:type="simple" xlink:href="smmt-20211231.xsd#RevenueTables"/>
  <link:presentationLink xlink:role="http://www.summitplc.com/role/RevenueTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_d02c33a6-031d-43fe-af0b-78af66ca34da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_dc269852-501c-41c8-9ac9-ebc1c5a7989a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_d02c33a6-031d-43fe-af0b-78af66ca34da" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_dc269852-501c-41c8-9ac9-ebc1c5a7989a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_0a66d742-3589-4771-926d-7890321a8281" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_d02c33a6-031d-43fe-af0b-78af66ca34da" xlink:to="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_0a66d742-3589-4771-926d-7890321a8281" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_a2058bd4-2474-418a-85ac-b9e126d1baf2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_d02c33a6-031d-43fe-af0b-78af66ca34da" xlink:to="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_a2058bd4-2474-418a-85ac-b9e126d1baf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/OtherOperatingIncomeTables" xlink:type="simple" xlink:href="smmt-20211231.xsd#OtherOperatingIncomeTables"/>
  <link:presentationLink xlink:role="http://www.summitplc.com/role/OtherOperatingIncomeTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_6883ecaa-0d7b-4e04-ad53-8f1f79d388d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_ScheduleOfOtherOperatingIncomeByComponentTableTextBlock_da22d7c5-e169-4c23-935a-9db30e0f4493" xlink:href="smmt-20211231.xsd#smmt_ScheduleOfOtherOperatingIncomeByComponentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_6883ecaa-0d7b-4e04-ad53-8f1f79d388d8" xlink:to="loc_smmt_ScheduleOfOtherOperatingIncomeByComponentTableTextBlock_da22d7c5-e169-4c23-935a-9db30e0f4493" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/OtherExpenseIncomeTables" xlink:type="simple" xlink:href="smmt-20211231.xsd#OtherExpenseIncomeTables"/>
  <link:presentationLink xlink:role="http://www.summitplc.com/role/OtherExpenseIncomeTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_bffb2f33-17a6-46f6-994d-98b070d2e51d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_1cc132a4-e08a-4ee6-b074-4d9653ca63d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_bffb2f33-17a6-46f6-994d-98b070d2e51d" xlink:to="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_1cc132a4-e08a-4ee6-b074-4d9653ca63d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/IncomeTaxTables" xlink:type="simple" xlink:href="smmt-20211231.xsd#IncomeTaxTables"/>
  <link:presentationLink xlink:role="http://www.summitplc.com/role/IncomeTaxTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_7d041338-e307-4a9c-8915-4975f801a3ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_611091b1-d141-4188-9b28-41c9355ce2b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_7d041338-e307-4a9c-8915-4975f801a3ad" xlink:to="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_611091b1-d141-4188-9b28-41c9355ce2b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_19c55a54-74f9-4681-841e-4ceb5223542e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_7d041338-e307-4a9c-8915-4975f801a3ad" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_19c55a54-74f9-4681-841e-4ceb5223542e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_7435f5cc-7890-4e37-b12b-f9bd0224bb02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_7d041338-e307-4a9c-8915-4975f801a3ad" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_7435f5cc-7890-4e37-b12b-f9bd0224bb02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_fb6d184f-3814-4b00-999e-4baf6542ac95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_7d041338-e307-4a9c-8915-4975f801a3ad" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_fb6d184f-3814-4b00-999e-4baf6542ac95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/LossperShareTables" xlink:type="simple" xlink:href="smmt-20211231.xsd#LossperShareTables"/>
  <link:presentationLink xlink:role="http://www.summitplc.com/role/LossperShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_0cb63497-3301-487c-915f-917461437fbb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_7b643f4c-3085-4828-b3a1-fd2dcd2dafb8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0cb63497-3301-487c-915f-917461437fbb" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_7b643f4c-3085-4828-b3a1-fd2dcd2dafb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_4fd3689d-a1ce-438b-b7f1-9e43b248a840" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0cb63497-3301-487c-915f-917461437fbb" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_4fd3689d-a1ce-438b-b7f1-9e43b248a840" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/GoodwillandIntangibleAssetsTables" xlink:type="simple" xlink:href="smmt-20211231.xsd#GoodwillandIntangibleAssetsTables"/>
  <link:presentationLink xlink:role="http://www.summitplc.com/role/GoodwillandIntangibleAssetsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b13fa4eb-5e69-4931-ba25-866456f7ba99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_b0018acc-1c75-4e4a-8cb7-0e507cc14c7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b13fa4eb-5e69-4931-ba25-866456f7ba99" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_b0018acc-1c75-4e4a-8cb7-0e507cc14c7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_97077e44-2aab-4d3b-bfd9-a6acb5ca2a50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b13fa4eb-5e69-4931-ba25-866456f7ba99" xlink:to="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_97077e44-2aab-4d3b-bfd9-a6acb5ca2a50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/PropertyandEquipmentTables" xlink:type="simple" xlink:href="smmt-20211231.xsd#PropertyandEquipmentTables"/>
  <link:presentationLink xlink:role="http://www.summitplc.com/role/PropertyandEquipmentTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_db49ea86-54e3-457e-8591-b066335b46fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_adadf3ad-6abe-44c4-b3a1-0b36b476d5b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_db49ea86-54e3-457e-8591-b066335b46fe" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_adadf3ad-6abe-44c4-b3a1-0b36b476d5b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/LeasesTables" xlink:type="simple" xlink:href="smmt-20211231.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://www.summitplc.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_d8d527f8-6649-4cb5-b7d5-55be22f099ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_dec058dd-1ce6-416d-9656-cf2a679ec69e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d8d527f8-6649-4cb5-b7d5-55be22f099ef" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_dec058dd-1ce6-416d-9656-cf2a679ec69e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_4c3c19d8-53e4-419b-8a28-c879d88a5090" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d8d527f8-6649-4cb5-b7d5-55be22f099ef" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_4c3c19d8-53e4-419b-8a28-c879d88a5090" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="smmt-20211231.xsd#StockBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://www.summitplc.com/role/StockBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7e1e4848-a8ee-4d3a-9a81-464c5c384166" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_115ce75b-4593-4571-9dfa-9b743cf06aff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7e1e4848-a8ee-4d3a-9a81-464c5c384166" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_115ce75b-4593-4571-9dfa-9b743cf06aff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_b9ebe0f2-ce20-422b-a8a6-e7cbb9d9170b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7e1e4848-a8ee-4d3a-9a81-464c5c384166" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_b9ebe0f2-ce20-422b-a8a6-e7cbb9d9170b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_0a18ea20-4776-4d9f-bfc6-f48dd0e6491f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7e1e4848-a8ee-4d3a-9a81-464c5c384166" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_0a18ea20-4776-4d9f-bfc6-f48dd0e6491f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_c8a95fb5-ea67-40cf-a4fd-26474b6f174e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7e1e4848-a8ee-4d3a-9a81-464c5c384166" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_c8a95fb5-ea67-40cf-a4fd-26474b6f174e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/NatureofBusinessandOperationsandRecentEventsDetails" xlink:type="simple" xlink:href="smmt-20211231.xsd#NatureofBusinessandOperationsandRecentEventsDetails"/>
  <link:presentationLink xlink:role="http://www.summitplc.com/role/NatureofBusinessandOperationsandRecentEventsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0db18e0f-6c60-4394-8fdd-928cd5af051c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_499b19b6-bd53-41e4-bb6c-5291e2e60b97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0db18e0f-6c60-4394-8fdd-928cd5af051c" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_499b19b6-bd53-41e4-bb6c-5291e2e60b97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_0593c8ff-be48-4c90-bed3-447091252ce5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_499b19b6-bd53-41e4-bb6c-5291e2e60b97" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_0593c8ff-be48-4c90-bed3-447091252ce5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_a58f851f-dd74-418b-b8e2-32826fcae036" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_0593c8ff-be48-4c90-bed3-447091252ce5" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_a58f851f-dd74-418b-b8e2-32826fcae036" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_RightsOfferingMember_1a82e02e-f39e-4928-89c2-080544876677" xlink:href="smmt-20211231.xsd#smmt_RightsOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_a58f851f-dd74-418b-b8e2-32826fcae036" xlink:to="loc_smmt_RightsOfferingMember_1a82e02e-f39e-4928-89c2-080544876677" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_546f1ebf-9641-4251-b3ec-2b51e389d76a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_499b19b6-bd53-41e4-bb6c-5291e2e60b97" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_546f1ebf-9641-4251-b3ec-2b51e389d76a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_2426effc-a0b3-472d-9769-be7d93c52ae0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_546f1ebf-9641-4251-b3ec-2b51e389d76a" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_2426effc-a0b3-472d-9769-be7d93c52ae0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_SecondPurchaseAgreementMember_a3633067-cc79-4113-87a7-9dc4d1bd4fe8" xlink:href="smmt-20211231.xsd#smmt_SecondPurchaseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_2426effc-a0b3-472d-9769-be7d93c52ae0" xlink:to="loc_smmt_SecondPurchaseAgreementMember_a3633067-cc79-4113-87a7-9dc4d1bd4fe8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_A2022NoteMember_ee90b209-d6a9-4659-a5a5-76043500c414" xlink:href="smmt-20211231.xsd#smmt_A2022NoteMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_2426effc-a0b3-472d-9769-be7d93c52ae0" xlink:to="loc_smmt_A2022NoteMember_ee90b209-d6a9-4659-a5a5-76043500c414" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_df66f908-63ac-409f-9dfa-0772e5aad9c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_499b19b6-bd53-41e4-bb6c-5291e2e60b97" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_df66f908-63ac-409f-9dfa-0772e5aad9c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_7e0312a4-f57c-4f70-a469-29463358b89d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_df66f908-63ac-409f-9dfa-0772e5aad9c6" xlink:to="loc_us-gaap_RelatedPartyDomain_7e0312a4-f57c-4f70-a469-29463358b89d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ChiefExecutiveOfficerMember_3473558b-4ca2-4a98-9b08-f70043c6be8b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ChiefExecutiveOfficerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_7e0312a4-f57c-4f70-a469-29463358b89d" xlink:to="loc_srt_ChiefExecutiveOfficerMember_3473558b-4ca2-4a98-9b08-f70043c6be8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_fb34298d-9f70-4218-a224-bd15824221cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_499b19b6-bd53-41e4-bb6c-5291e2e60b97" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_fb34298d-9f70-4218-a224-bd15824221cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_fcd3209f-35ea-4714-a745-71ef2ee31204" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_fb34298d-9f70-4218-a224-bd15824221cc" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_fcd3209f-35ea-4714-a745-71ef2ee31204" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_429a912a-d698-4c04-bab0-3bc8431e77c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_fcd3209f-35ea-4714-a745-71ef2ee31204" xlink:to="loc_us-gaap_SubsequentEventMember_429a912a-d698-4c04-bab0-3bc8431e77c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_a19d53d8-0364-410b-82b4-332a25731e6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_499b19b6-bd53-41e4-bb6c-5291e2e60b97" xlink:to="loc_us-gaap_SubsidiarySaleOfStockLineItems_a19d53d8-0364-410b-82b4-332a25731e6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_5f600688-0841-45fe-bc3c-135717965458" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_a19d53d8-0364-410b-82b4-332a25731e6d" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_5f600688-0841-45fe-bc3c-135717965458" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_a6e03bb1-28f6-4fb8-ad30-a3dc00ea48b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_a19d53d8-0364-410b-82b4-332a25731e6d" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_a6e03bb1-28f6-4fb8-ad30-a3dc00ea48b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_ef46ebd5-7354-4b91-9df2-b1709251866e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_a19d53d8-0364-410b-82b4-332a25731e6d" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_ef46ebd5-7354-4b91-9df2-b1709251866e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_1b577cfd-cf7c-430a-97a3-1dd0afa9aebc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_a19d53d8-0364-410b-82b4-332a25731e6d" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_1b577cfd-cf7c-430a-97a3-1dd0afa9aebc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_ecec4aa1-a310-47e9-aaeb-21624303dd51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_a19d53d8-0364-410b-82b4-332a25731e6d" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_ecec4aa1-a310-47e9-aaeb-21624303dd51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_RelatedPartyTransactionBeneficialOwnershipPercentage_559d0c5b-09d6-4398-a609-d56085eb4b65" xlink:href="smmt-20211231.xsd#smmt_RelatedPartyTransactionBeneficialOwnershipPercentage"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_a19d53d8-0364-410b-82b4-332a25731e6d" xlink:to="loc_smmt_RelatedPartyTransactionBeneficialOwnershipPercentage_559d0c5b-09d6-4398-a609-d56085eb4b65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent_e0592246-c56b-4d10-bcb8-7bc4fd327fc4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_a19d53d8-0364-410b-82b4-332a25731e6d" xlink:to="loc_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent_e0592246-c56b-4d10-bcb8-7bc4fd327fc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRelatedPartyDebt_70818bdf-aa13-44f7-8aac-802ad17eb855" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromRelatedPartyDebt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_a19d53d8-0364-410b-82b4-332a25731e6d" xlink:to="loc_us-gaap_ProceedsFromRelatedPartyDebt_70818bdf-aa13-44f7-8aac-802ad17eb855" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionRate_afe35a7a-7d4e-456d-9815-90624741e518" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionRate"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_a19d53d8-0364-410b-82b4-332a25731e6d" xlink:to="loc_us-gaap_RelatedPartyTransactionRate_afe35a7a-7d4e-456d-9815-90624741e518" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_NotesPayableRelatedPartiesMaturityTriggeringEventPublicOfferingProceedsThreshold_bc771f8a-3868-4ae3-a07e-ee134b1f248c" xlink:href="smmt-20211231.xsd#smmt_NotesPayableRelatedPartiesMaturityTriggeringEventPublicOfferingProceedsThreshold"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_a19d53d8-0364-410b-82b4-332a25731e6d" xlink:to="loc_smmt_NotesPayableRelatedPartiesMaturityTriggeringEventPublicOfferingProceedsThreshold_bc771f8a-3868-4ae3-a07e-ee134b1f248c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_NotesPayableRelatedPartiesMaximumTerm_fd1f207c-65f4-4c60-84c8-7a352923c0c1" xlink:href="smmt-20211231.xsd#smmt_NotesPayableRelatedPartiesMaximumTerm"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_a19d53d8-0364-410b-82b4-332a25731e6d" xlink:to="loc_smmt_NotesPayableRelatedPartiesMaximumTerm_fd1f207c-65f4-4c60-84c8-7a352923c0c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/LiquidityandCapitalResourcesDetails" xlink:type="simple" xlink:href="smmt-20211231.xsd#LiquidityandCapitalResourcesDetails"/>
  <link:presentationLink xlink:role="http://www.summitplc.com/role/LiquidityandCapitalResourcesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_cd94aaac-3eb7-4d04-b3ff-c92963ac2255" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_b66b8ac2-1228-418c-95c8-2b51fe42f88b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_cd94aaac-3eb7-4d04-b3ff-c92963ac2255" xlink:to="loc_us-gaap_NetIncomeLoss_b66b8ac2-1228-418c-95c8-2b51fe42f88b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_16f354b1-8dab-465f-8d4d-dcd94b71e4a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_cd94aaac-3eb7-4d04-b3ff-c92963ac2255" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_16f354b1-8dab-465f-8d4d-dcd94b71e4a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_7326d1ea-6d15-4fdd-93ad-bf71f8a69801" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_cd94aaac-3eb7-4d04-b3ff-c92963ac2255" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_7326d1ea-6d15-4fdd-93ad-bf71f8a69801" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Cash_ffe1bfe6-18d1-42e1-b120-ab12bb7415de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Cash"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_cd94aaac-3eb7-4d04-b3ff-c92963ac2255" xlink:to="loc_us-gaap_Cash_ffe1bfe6-18d1-42e1-b120-ab12bb7415de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_ResearchAndDevelopmentTaxCreditReceivable_9518b948-e294-4461-8b37-61a205da6edd" xlink:href="smmt-20211231.xsd#smmt_ResearchAndDevelopmentTaxCreditReceivable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_cd94aaac-3eb7-4d04-b3ff-c92963ac2255" xlink:to="loc_smmt_ResearchAndDevelopmentTaxCreditReceivable_9518b948-e294-4461-8b37-61a205da6edd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_7a5177ed-62c8-42e7-acbc-15114bb9362b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_cd94aaac-3eb7-4d04-b3ff-c92963ac2255" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_7a5177ed-62c8-42e7-acbc-15114bb9362b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_74680219-c464-4638-9377-01a0f8545305" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_cd94aaac-3eb7-4d04-b3ff-c92963ac2255" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_74680219-c464-4638-9377-01a0f8545305" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_b0803301-2066-4b26-a3ae-23c9e46806bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_74680219-c464-4638-9377-01a0f8545305" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_b0803301-2066-4b26-a3ae-23c9e46806bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_f238d662-0061-443b-8740-aec3bdb6bce6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_b0803301-2066-4b26-a3ae-23c9e46806bf" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_f238d662-0061-443b-8740-aec3bdb6bce6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_A2022NoteMember_42899ccb-90a9-4ff4-8cd2-5be07e9ced8d" xlink:href="smmt-20211231.xsd#smmt_A2022NoteMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_f238d662-0061-443b-8740-aec3bdb6bce6" xlink:to="loc_smmt_A2022NoteMember_42899ccb-90a9-4ff4-8cd2-5be07e9ced8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_dc6b65b0-4552-4ea6-904e-283bf0580683" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_74680219-c464-4638-9377-01a0f8545305" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_dc6b65b0-4552-4ea6-904e-283bf0580683" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_4af9c18b-efa1-4ecc-a7d0-3b7d5912f5d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_dc6b65b0-4552-4ea6-904e-283bf0580683" xlink:to="loc_us-gaap_RelatedPartyDomain_4af9c18b-efa1-4ecc-a7d0-3b7d5912f5d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ChiefExecutiveOfficerMember_c8dba188-13a5-4f38-97e8-079bc22e32eb" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ChiefExecutiveOfficerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_4af9c18b-efa1-4ecc-a7d0-3b7d5912f5d3" xlink:to="loc_srt_ChiefExecutiveOfficerMember_c8dba188-13a5-4f38-97e8-079bc22e32eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_cba5967d-8efe-40ca-8051-e6f3fb5fe2dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_74680219-c464-4638-9377-01a0f8545305" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_cba5967d-8efe-40ca-8051-e6f3fb5fe2dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_02d3adae-6090-4426-979c-7e5b0d66e84b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_cba5967d-8efe-40ca-8051-e6f3fb5fe2dd" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_02d3adae-6090-4426-979c-7e5b0d66e84b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_6066d61c-d418-4c32-9ee3-91ca9198a3ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_02d3adae-6090-4426-979c-7e5b0d66e84b" xlink:to="loc_us-gaap_SubsequentEventMember_6066d61c-d418-4c32-9ee3-91ca9198a3ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_2a9d13ca-b97f-431b-bb49-7c92e956d1fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_74680219-c464-4638-9377-01a0f8545305" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_2a9d13ca-b97f-431b-bb49-7c92e956d1fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRelatedPartyDebt_f93a32fb-5eac-45da-9881-b68819e99875" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromRelatedPartyDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_2a9d13ca-b97f-431b-bb49-7c92e956d1fa" xlink:to="loc_us-gaap_ProceedsFromRelatedPartyDebt_f93a32fb-5eac-45da-9881-b68819e99875" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="smmt-20211231.xsd#SummaryofSignificantAccountingPoliciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.summitplc.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_1dae6a8e-72f4-4e6c-9533-cfa986b48e5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2189b7a3-d6f9-4908-974a-543ff6f2f2fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1dae6a8e-72f4-4e6c-9533-cfa986b48e5f" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2189b7a3-d6f9-4908-974a-543ff6f2f2fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_e843f075-20b7-40d8-be07-2b5885ac45ed" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2189b7a3-d6f9-4908-974a-543ff6f2f2fc" xlink:to="loc_srt_RangeAxis_e843f075-20b7-40d8-be07-2b5885ac45ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_030a93b9-e80f-4a4a-bd23-b551eb91d940" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_e843f075-20b7-40d8-be07-2b5885ac45ed" xlink:to="loc_srt_RangeMember_030a93b9-e80f-4a4a-bd23-b551eb91d940" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_b4326abe-720d-466c-b99a-f2bc89735c92" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_030a93b9-e80f-4a4a-bd23-b551eb91d940" xlink:to="loc_srt_MinimumMember_b4326abe-720d-466c-b99a-f2bc89735c92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_d60ed27e-a312-4d1d-8fb8-7cd2b0065565" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_030a93b9-e80f-4a4a-bd23-b551eb91d940" xlink:to="loc_srt_MaximumMember_d60ed27e-a312-4d1d-8fb8-7cd2b0065565" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_3f7a30b2-c15e-427e-857c-4142186594e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2189b7a3-d6f9-4908-974a-543ff6f2f2fc" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_3f7a30b2-c15e-427e-857c-4142186594e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_505ee730-76b4-4652-8634-9982fe9f95c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_3f7a30b2-c15e-427e-857c-4142186594e1" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_505ee730-76b4-4652-8634-9982fe9f95c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_cb5ea6b3-090e-4bd4-89a0-4d29c2af22d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_505ee730-76b4-4652-8634-9982fe9f95c7" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_cb5ea6b3-090e-4bd4-89a0-4d29c2af22d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_acfacd03-ca85-41b1-9afb-d439e058714e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2189b7a3-d6f9-4908-974a-543ff6f2f2fc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_acfacd03-ca85-41b1-9afb-d439e058714e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_20fa7913-37fe-43a2-bce6-e8e74864c550" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_acfacd03-ca85-41b1-9afb-d439e058714e" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_20fa7913-37fe-43a2-bce6-e8e74864c550" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_ResearchAndDevelopmentTaxCreditCashRebateMaximumPercentage_5f99395b-3c4d-4582-8be7-bddc54998d70" xlink:href="smmt-20211231.xsd#smmt_ResearchAndDevelopmentTaxCreditCashRebateMaximumPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_acfacd03-ca85-41b1-9afb-d439e058714e" xlink:to="loc_smmt_ResearchAndDevelopmentTaxCreditCashRebateMaximumPercentage_5f99395b-3c4d-4582-8be7-bddc54998d70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_8f80bd93-e2cd-4c3c-b7b1-302cca0875c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_acfacd03-ca85-41b1-9afb-d439e058714e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_8f80bd93-e2cd-4c3c-b7b1-302cca0875c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_BusinessCombinationAssumedContingentLiabilityMeasurementInput_db5f797f-7081-43f1-88ab-857e8fcf08cd" xlink:href="smmt-20211231.xsd#smmt_BusinessCombinationAssumedContingentLiabilityMeasurementInput"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_acfacd03-ca85-41b1-9afb-d439e058714e" xlink:to="loc_smmt_BusinessCombinationAssumedContingentLiabilityMeasurementInput_db5f797f-7081-43f1-88ab-857e8fcf08cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/SummaryofSignificantAccountingPoliciesPropertyandequipmentusefullivesDetails" xlink:type="simple" xlink:href="smmt-20211231.xsd#SummaryofSignificantAccountingPoliciesPropertyandequipmentusefullivesDetails"/>
  <link:presentationLink xlink:role="http://www.summitplc.com/role/SummaryofSignificantAccountingPoliciesPropertyandequipmentusefullivesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_d38eea0d-9a19-49e0-a140-b13595873947" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_62d419a9-8fb3-4e77-ac62-c9f43063931d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d38eea0d-9a19-49e0-a140-b13595873947" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_62d419a9-8fb3-4e77-ac62-c9f43063931d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_acb98dd0-a36f-4526-a627-a11c38065b13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_62d419a9-8fb3-4e77-ac62-c9f43063931d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_acb98dd0-a36f-4526-a627-a11c38065b13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_34c7d36c-66a9-413e-85f6-dff1bb7d723a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_acb98dd0-a36f-4526-a627-a11c38065b13" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_34c7d36c-66a9-413e-85f6-dff1bb7d723a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_LaboratoryEquipmentMember_2f2f026c-05fc-45da-a6dd-182d581b16a9" xlink:href="smmt-20211231.xsd#smmt_LaboratoryEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_34c7d36c-66a9-413e-85f6-dff1bb7d723a" xlink:to="loc_smmt_LaboratoryEquipmentMember_2f2f026c-05fc-45da-a6dd-182d581b16a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_OfficeAndTechnologyEquipmentMember_dc111dbd-2d29-49b8-ab2b-109395dadff4" xlink:href="smmt-20211231.xsd#smmt_OfficeAndTechnologyEquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_34c7d36c-66a9-413e-85f6-dff1bb7d723a" xlink:to="loc_smmt_OfficeAndTechnologyEquipmentMember_dc111dbd-2d29-49b8-ab2b-109395dadff4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_f68ca565-3745-42a6-82b9-2488dd1a1d15" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_62d419a9-8fb3-4e77-ac62-c9f43063931d" xlink:to="loc_srt_RangeAxis_f68ca565-3745-42a6-82b9-2488dd1a1d15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_08733390-5909-4f9d-a38e-f211e4d47497" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_f68ca565-3745-42a6-82b9-2488dd1a1d15" xlink:to="loc_srt_RangeMember_08733390-5909-4f9d-a38e-f211e4d47497" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_36554a00-e13d-454f-9258-3a50a227015b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_08733390-5909-4f9d-a38e-f211e4d47497" xlink:to="loc_srt_MinimumMember_36554a00-e13d-454f-9258-3a50a227015b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_f32d7f75-4bae-4b42-95c3-2b8a64875e46" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_08733390-5909-4f9d-a38e-f211e4d47497" xlink:to="loc_srt_MaximumMember_f32d7f75-4bae-4b42-95c3-2b8a64875e46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_04bba521-b333-434b-93a5-0220aa3af0e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_62d419a9-8fb3-4e77-ac62-c9f43063931d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_04bba521-b333-434b-93a5-0220aa3af0e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_703043ee-b1ed-4ab4-811e-a64ff7127654" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_04bba521-b333-434b-93a5-0220aa3af0e2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_703043ee-b1ed-4ab4-811e-a64ff7127654" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/SegmentReportingNarrativeDetails" xlink:type="simple" xlink:href="smmt-20211231.xsd#SegmentReportingNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.summitplc.com/role/SegmentReportingNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_9ac33c06-5d03-4aa9-8cce-70cbf25750ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_580157d0-9bc8-4fef-b3b3-129dc8873c0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_9ac33c06-5d03-4aa9-8cce-70cbf25750ad" xlink:to="loc_us-gaap_NumberOfOperatingSegments_580157d0-9bc8-4fef-b3b3-129dc8873c0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfCountriesInWhichEntityOperates_f355df6d-4564-48e3-bec5-51837622abb9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfCountriesInWhichEntityOperates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_9ac33c06-5d03-4aa9-8cce-70cbf25750ad" xlink:to="loc_us-gaap_NumberOfCountriesInWhichEntityOperates_f355df6d-4564-48e3-bec5-51837622abb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/SegmentReportingLonglivedassetsbygeographyDetails" xlink:type="simple" xlink:href="smmt-20211231.xsd#SegmentReportingLonglivedassetsbygeographyDetails"/>
  <link:presentationLink xlink:role="http://www.summitplc.com/role/SegmentReportingLonglivedassetsbygeographyDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_9fbe13ea-2edb-49b5-a92c-f2a5ec961426" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_d8db32e3-e2a4-470f-8254-6e4b3265134c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_9fbe13ea-2edb-49b5-a92c-f2a5ec961426" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_d8db32e3-e2a4-470f-8254-6e4b3265134c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_d4151792-da4e-47af-849e-93a22e3c17ac" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_d8db32e3-e2a4-470f-8254-6e4b3265134c" xlink:to="loc_srt_StatementGeographicalAxis_d4151792-da4e-47af-849e-93a22e3c17ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_9070a4eb-e9ce-47a3-8e05-ccb18b807e0c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_d4151792-da4e-47af-849e-93a22e3c17ac" xlink:to="loc_srt_SegmentGeographicalDomain_9070a4eb-e9ce-47a3-8e05-ccb18b807e0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_GB_c81d308f-98c8-408c-be47-77ecfbfd5862" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_GB"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_9070a4eb-e9ce-47a3-8e05-ccb18b807e0c" xlink:to="loc_country_GB_c81d308f-98c8-408c-be47-77ecfbfd5862" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_a7a07d79-9cd5-4073-b1cd-d803088233ef" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_9070a4eb-e9ce-47a3-8e05-ccb18b807e0c" xlink:to="loc_country_US_a7a07d79-9cd5-4073-b1cd-d803088233ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_f0d80925-6856-438a-b7f9-4d4f2de66217" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_d8db32e3-e2a4-470f-8254-6e4b3265134c" xlink:to="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_f0d80925-6856-438a-b7f9-4d4f2de66217" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncurrentAssets_a37381d2-2627-4f39-9a8c-31fe69b7ea92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncurrentAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_f0d80925-6856-438a-b7f9-4d4f2de66217" xlink:to="loc_us-gaap_NoncurrentAssets_a37381d2-2627-4f39-9a8c-31fe69b7ea92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/RevenueRevenuebycategoryDetails" xlink:type="simple" xlink:href="smmt-20211231.xsd#RevenueRevenuebycategoryDetails"/>
  <link:presentationLink xlink:role="http://www.summitplc.com/role/RevenueRevenuebycategoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_cefa2f99-3d6c-4946-ac5e-b50f6624d08b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_53856599-8759-479e-92a9-088763b73b91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_cefa2f99-3d6c-4946-ac5e-b50f6624d08b" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_53856599-8759-479e-92a9-088763b73b91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_e9543403-b444-4191-a2ca-b25300dc0e6f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_53856599-8759-479e-92a9-088763b73b91" xlink:to="loc_srt_ProductOrServiceAxis_e9543403-b444-4191-a2ca-b25300dc0e6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_d81ff820-30a7-44f6-92b1-bd910a6521e4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_e9543403-b444-4191-a2ca-b25300dc0e6f" xlink:to="loc_srt_ProductsAndServicesDomain_d81ff820-30a7-44f6-92b1-bd910a6521e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseAndServiceMember_a9bf1629-f22f-4a28-bdd4-a52f2285bb7f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseAndServiceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d81ff820-30a7-44f6-92b1-bd910a6521e4" xlink:to="loc_us-gaap_LicenseAndServiceMember_a9bf1629-f22f-4a28-bdd4-a52f2285bb7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_44b41e2c-e254-4e39-8e38-f56708cd33db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_53856599-8759-479e-92a9-088763b73b91" xlink:to="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_44b41e2c-e254-4e39-8e38-f56708cd33db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c1ca3db7-a64e-42b8-b2fa-228c56edaa1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_44b41e2c-e254-4e39-8e38-f56708cd33db" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c1ca3db7-a64e-42b8-b2fa-228c56edaa1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/RevenueRevenuebygeographyDetails" xlink:type="simple" xlink:href="smmt-20211231.xsd#RevenueRevenuebygeographyDetails"/>
  <link:presentationLink xlink:role="http://www.summitplc.com/role/RevenueRevenuebygeographyDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_1caa0b60-1276-4b77-bef1-a1ba84359fc9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_7095cd49-b09e-4c3c-a4c5-ad23d52bd596" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_1caa0b60-1276-4b77-bef1-a1ba84359fc9" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_7095cd49-b09e-4c3c-a4c5-ad23d52bd596" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_caad8edb-8f67-43dd-8f52-872f67d65edf" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_7095cd49-b09e-4c3c-a4c5-ad23d52bd596" xlink:to="loc_srt_StatementGeographicalAxis_caad8edb-8f67-43dd-8f52-872f67d65edf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_e78fcfb2-a390-47ce-8523-c8c9e14ba389" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_caad8edb-8f67-43dd-8f52-872f67d65edf" xlink:to="loc_srt_SegmentGeographicalDomain_e78fcfb2-a390-47ce-8523-c8c9e14ba389" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_1167b063-84d8-4f48-8acf-8b49166f3fe7" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_e78fcfb2-a390-47ce-8523-c8c9e14ba389" xlink:to="loc_country_US_1167b063-84d8-4f48-8acf-8b49166f3fe7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LatinAmericaMember_1a7147ba-70a9-453e-8247-5493f504a0f1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LatinAmericaMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_e78fcfb2-a390-47ce-8523-c8c9e14ba389" xlink:to="loc_srt_LatinAmericaMember_1a7147ba-70a9-453e-8247-5493f504a0f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_3cdcba64-7f36-4fb2-963e-7b7dd9c339cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_7095cd49-b09e-4c3c-a4c5-ad23d52bd596" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_3cdcba64-7f36-4fb2-963e-7b7dd9c339cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3636c5ce-f52b-4286-a99a-66c41ba4ef32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_3cdcba64-7f36-4fb2-963e-7b7dd9c339cb" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3636c5ce-f52b-4286-a99a-66c41ba4ef32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/RevenueDeferredrevenueandotherincomeDetails" xlink:type="simple" xlink:href="smmt-20211231.xsd#RevenueDeferredrevenueandotherincomeDetails"/>
  <link:presentationLink xlink:role="http://www.summitplc.com/role/RevenueDeferredrevenueandotherincomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_ef537bc8-a6a4-4dd5-a687-7b5af5a865bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_ChangeInContractWithCustomerAssetAndLiabilityRollForward_46eeef7a-66f7-41e9-a928-fba1c2f3aa03" xlink:href="smmt-20211231.xsd#smmt_ChangeInContractWithCustomerAssetAndLiabilityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_ef537bc8-a6a4-4dd5-a687-7b5af5a865bb" xlink:to="loc_smmt_ChangeInContractWithCustomerAssetAndLiabilityRollForward_46eeef7a-66f7-41e9-a928-fba1c2f3aa03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_3d1b8672-65ce-4ad2-ba5f-4c3d3c527dd3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_smmt_ChangeInContractWithCustomerAssetAndLiabilityRollForward_46eeef7a-66f7-41e9-a928-fba1c2f3aa03" xlink:to="loc_us-gaap_ContractWithCustomerLiability_3d1b8672-65ce-4ad2-ba5f-4c3d3c527dd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_ContractWithCustomerLiabilityAdditions_83948648-b91e-4be5-8f40-879324b303c8" xlink:href="smmt-20211231.xsd#smmt_ContractWithCustomerLiabilityAdditions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_smmt_ChangeInContractWithCustomerAssetAndLiabilityRollForward_46eeef7a-66f7-41e9-a928-fba1c2f3aa03" xlink:to="loc_smmt_ContractWithCustomerLiabilityAdditions_83948648-b91e-4be5-8f40-879324b303c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_1fd94db2-d22d-4f57-90ae-831dabc2ad5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_smmt_ChangeInContractWithCustomerAssetAndLiabilityRollForward_46eeef7a-66f7-41e9-a928-fba1c2f3aa03" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_1fd94db2-d22d-4f57-90ae-831dabc2ad5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_c74fae87-e1bf-496c-b75b-34b68b929ab3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_smmt_ChangeInContractWithCustomerAssetAndLiabilityRollForward_46eeef7a-66f7-41e9-a928-fba1c2f3aa03" xlink:to="loc_us-gaap_ContractWithCustomerLiability_c74fae87-e1bf-496c-b75b-34b68b929ab3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_7490e1b4-b65d-4dec-ae92-8691ae384687" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_ef537bc8-a6a4-4dd5-a687-7b5af5a865bb" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_7490e1b4-b65d-4dec-ae92-8691ae384687" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_6de1ca0c-3723-4e8a-a39d-a531a8c61620" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_ef537bc8-a6a4-4dd5-a687-7b5af5a865bb" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_6de1ca0c-3723-4e8a-a39d-a531a8c61620" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/RevenueNarrativeDetails" xlink:type="simple" xlink:href="smmt-20211231.xsd#RevenueNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.summitplc.com/role/RevenueNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_1456497e-e81b-4dd6-99ab-660c2b8fd834" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_25a8dfa8-34ba-4a61-872a-8ca948135f6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_1456497e-e81b-4dd6-99ab-660c2b8fd834" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_25a8dfa8-34ba-4a61-872a-8ca948135f6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_48d757ea-280d-4916-b9cd-3b29a536abdf" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_25a8dfa8-34ba-4a61-872a-8ca948135f6b" xlink:to="loc_srt_ProductOrServiceAxis_48d757ea-280d-4916-b9cd-3b29a536abdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_e7f60d4b-a14f-40b0-bf97-cd1771c215a2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_48d757ea-280d-4916-b9cd-3b29a536abdf" xlink:to="loc_srt_ProductsAndServicesDomain_e7f60d4b-a14f-40b0-bf97-cd1771c215a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseAndServiceMember_57ffa544-515d-4e5b-8e63-c18960673c65" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseAndServiceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e7f60d4b-a14f-40b0-bf97-cd1771c215a2" xlink:to="loc_us-gaap_LicenseAndServiceMember_57ffa544-515d-4e5b-8e63-c18960673c65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_8ba917a2-c65e-4a7a-86bf-410d4c08b103" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_25a8dfa8-34ba-4a61-872a-8ca948135f6b" xlink:to="loc_srt_CounterpartyNameAxis_8ba917a2-c65e-4a7a-86bf-410d4c08b103" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f6337819-bb91-4ccf-b51d-3af254e915f7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_8ba917a2-c65e-4a7a-86bf-410d4c08b103" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f6337819-bb91-4ccf-b51d-3af254e915f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_EuroFarmaLaboratoriosSAMember_aed8c949-864e-4a35-904b-9115148085e1" xlink:href="smmt-20211231.xsd#smmt_EuroFarmaLaboratoriosSAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f6337819-bb91-4ccf-b51d-3af254e915f7" xlink:to="loc_smmt_EuroFarmaLaboratoriosSAMember_aed8c949-864e-4a35-904b-9115148085e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_ef50a437-120a-4010-bb51-6cd1bc37b684" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_25a8dfa8-34ba-4a61-872a-8ca948135f6b" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_ef50a437-120a-4010-bb51-6cd1bc37b684" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_bddcbdf5-3fa9-46d7-9a35-f028dd277219" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_ef50a437-120a-4010-bb51-6cd1bc37b684" xlink:to="loc_us-gaap_ContractWithCustomerLiability_bddcbdf5-3fa9-46d7-9a35-f028dd277219" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_ContractWithCustomerLiabilityEnrollmentMilestone_3c808cdb-c646-492d-b0a3-e40180f07e14" xlink:href="smmt-20211231.xsd#smmt_ContractWithCustomerLiabilityEnrollmentMilestone"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_ef50a437-120a-4010-bb51-6cd1bc37b684" xlink:to="loc_smmt_ContractWithCustomerLiabilityEnrollmentMilestone_3c808cdb-c646-492d-b0a3-e40180f07e14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_RevenueInformationUsedToDetermineTransactionPriceNumberOfEnrollmentMilestones_7097cd2f-d31a-4e4a-b65a-8891ef59eb3b" xlink:href="smmt-20211231.xsd#smmt_RevenueInformationUsedToDetermineTransactionPriceNumberOfEnrollmentMilestones"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_ef50a437-120a-4010-bb51-6cd1bc37b684" xlink:to="loc_smmt_RevenueInformationUsedToDetermineTransactionPriceNumberOfEnrollmentMilestones_7097cd2f-d31a-4e4a-b65a-8891ef59eb3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_e8db30dd-860e-4840-a233-8765ed93a355" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_ef50a437-120a-4010-bb51-6cd1bc37b684" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_e8db30dd-860e-4840-a233-8765ed93a355" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_19387ddc-84af-4fd1-b7b9-4306a892a539" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_ef50a437-120a-4010-bb51-6cd1bc37b684" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_19387ddc-84af-4fd1-b7b9-4306a892a539" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_RevenueFromContractWithCustomerDevelopmentMilestoneRevenueEntitledToReceive_e92089e3-295e-431a-936f-d7bbc82086fd" xlink:href="smmt-20211231.xsd#smmt_RevenueFromContractWithCustomerDevelopmentMilestoneRevenueEntitledToReceive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_ef50a437-120a-4010-bb51-6cd1bc37b684" xlink:to="loc_smmt_RevenueFromContractWithCustomerDevelopmentMilestoneRevenueEntitledToReceive_e92089e3-295e-431a-936f-d7bbc82086fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_RevenueFromContractWithCustomerDevelopmentCommercialAndSalesMilestoneCumulativeNetSalesTargetAchievementRevenueEntitledToReceive_97d567e0-4c52-4c13-9ccc-80b2a2562b74" xlink:href="smmt-20211231.xsd#smmt_RevenueFromContractWithCustomerDevelopmentCommercialAndSalesMilestoneCumulativeNetSalesTargetAchievementRevenueEntitledToReceive"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_ef50a437-120a-4010-bb51-6cd1bc37b684" xlink:to="loc_smmt_RevenueFromContractWithCustomerDevelopmentCommercialAndSalesMilestoneCumulativeNetSalesTargetAchievementRevenueEntitledToReceive_97d567e0-4c52-4c13-9ccc-80b2a2562b74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_RevenueFromContractWithCustomerDevelopmentCommercialAndSalesMilestoneCumulativeNetSalesTargetThreshold_56408b6f-2d35-48d5-9285-83f7431506ff" xlink:href="smmt-20211231.xsd#smmt_RevenueFromContractWithCustomerDevelopmentCommercialAndSalesMilestoneCumulativeNetSalesTargetThreshold"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_ef50a437-120a-4010-bb51-6cd1bc37b684" xlink:to="loc_smmt_RevenueFromContractWithCustomerDevelopmentCommercialAndSalesMilestoneCumulativeNetSalesTargetThreshold_56408b6f-2d35-48d5-9285-83f7431506ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_RevenueFromContractWithCustomerDevelopmentCommercialAndSalesMilestoneIncrementalCumulativeNetSalesTargetThreshold_2b5980b1-3975-4968-8520-a9b60adc344c" xlink:href="smmt-20211231.xsd#smmt_RevenueFromContractWithCustomerDevelopmentCommercialAndSalesMilestoneIncrementalCumulativeNetSalesTargetThreshold"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_ef50a437-120a-4010-bb51-6cd1bc37b684" xlink:to="loc_smmt_RevenueFromContractWithCustomerDevelopmentCommercialAndSalesMilestoneIncrementalCumulativeNetSalesTargetThreshold_2b5980b1-3975-4968-8520-a9b60adc344c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/OtherOperatingIncomeOtheroperatingincomebycategoryDetails" xlink:type="simple" xlink:href="smmt-20211231.xsd#OtherOperatingIncomeOtheroperatingincomebycategoryDetails"/>
  <link:presentationLink xlink:role="http://www.summitplc.com/role/OtherOperatingIncomeOtheroperatingincomebycategoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_32dbe19c-e32d-4dca-859d-9ff2be27b750" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_cd801eaa-f566-4021-b2ed-05c6d47ddfbc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_32dbe19c-e32d-4dca-859d-9ff2be27b750" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_cd801eaa-f566-4021-b2ed-05c6d47ddfbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_1b901553-49e3-40e2-88b5-61505474f503" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_cd801eaa-f566-4021-b2ed-05c6d47ddfbc" xlink:to="loc_srt_CounterpartyNameAxis_1b901553-49e3-40e2-88b5-61505474f503" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5a96757b-e697-4933-b847-0dc326d89214" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_1b901553-49e3-40e2-88b5-61505474f503" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5a96757b-e697-4933-b847-0dc326d89214" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember_9e0f8662-d73b-40e4-be76-d0910bcd0e3f" xlink:href="smmt-20211231.xsd#smmt_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5a96757b-e697-4933-b847-0dc326d89214" xlink:to="loc_smmt_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember_9e0f8662-d73b-40e4-be76-d0910bcd0e3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_OtherGrantFundingCounterpartiesMember_71e2fdd5-125f-4166-8272-baf5a2390691" xlink:href="smmt-20211231.xsd#smmt_OtherGrantFundingCounterpartiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5a96757b-e697-4933-b847-0dc326d89214" xlink:to="loc_smmt_OtherGrantFundingCounterpartiesMember_71e2fdd5-125f-4166-8272-baf5a2390691" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_c66c0622-f42c-430f-91e4-e6ed8931d732" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_cd801eaa-f566-4021-b2ed-05c6d47ddfbc" xlink:to="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_c66c0622-f42c-430f-91e4-e6ed8931d732" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_GrantFundingArrangementIncomeEarned_05b298f9-b5e9-404d-ab72-ebeb10126142" xlink:href="smmt-20211231.xsd#smmt_GrantFundingArrangementIncomeEarned"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_c66c0622-f42c-430f-91e4-e6ed8931d732" xlink:to="loc_smmt_GrantFundingArrangementIncomeEarned_05b298f9-b5e9-404d-ab72-ebeb10126142" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_ResearchAndDevelopmentTaxCredit_6103b85b-7c00-4589-903d-25f48d8bcb9b" xlink:href="smmt-20211231.xsd#smmt_ResearchAndDevelopmentTaxCredit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_c66c0622-f42c-430f-91e4-e6ed8931d732" xlink:to="loc_smmt_ResearchAndDevelopmentTaxCredit_6103b85b-7c00-4589-903d-25f48d8bcb9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncome_da91ea9f-9399-472d-9b87-a485f70dc0d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherOperatingIncome"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_c66c0622-f42c-430f-91e4-e6ed8931d732" xlink:to="loc_us-gaap_OtherOperatingIncome_da91ea9f-9399-472d-9b87-a485f70dc0d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/OtherOperatingIncomeNarrativeDetails" xlink:type="simple" xlink:href="smmt-20211231.xsd#OtherOperatingIncomeNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.summitplc.com/role/OtherOperatingIncomeNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_bd9bf8be-9592-4209-b254-4cd709dc18ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_1e62b921-f1ea-44be-9279-6d039c9e6dbf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_bd9bf8be-9592-4209-b254-4cd709dc18ef" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_1e62b921-f1ea-44be-9279-6d039c9e6dbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_48fb424b-76f5-41a7-8894-45fbb7cb804e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_1e62b921-f1ea-44be-9279-6d039c9e6dbf" xlink:to="loc_srt_CounterpartyNameAxis_48fb424b-76f5-41a7-8894-45fbb7cb804e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c13afa86-580e-467f-ad8c-ac5defbd167a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_48fb424b-76f5-41a7-8894-45fbb7cb804e" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c13afa86-580e-467f-ad8c-ac5defbd167a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember_b50c73a1-12f0-43a4-ab0b-e873c085dac9" xlink:href="smmt-20211231.xsd#smmt_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c13afa86-580e-467f-ad8c-ac5defbd167a" xlink:to="loc_smmt_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember_b50c73a1-12f0-43a4-ab0b-e873c085dac9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_CombatingAntibioticResistantBacteriaBiopharmaceuticalAcceleratorProgramMember_0914d1d1-f543-41c3-8ebc-c9d2e0384ba8" xlink:href="smmt-20211231.xsd#smmt_CombatingAntibioticResistantBacteriaBiopharmaceuticalAcceleratorProgramMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c13afa86-580e-467f-ad8c-ac5defbd167a" xlink:to="loc_smmt_CombatingAntibioticResistantBacteriaBiopharmaceuticalAcceleratorProgramMember_0914d1d1-f543-41c3-8ebc-c9d2e0384ba8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b3dc4173-f2b7-4db4-ac99-b7d57b6705a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_1e62b921-f1ea-44be-9279-6d039c9e6dbf" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b3dc4173-f2b7-4db4-ac99-b7d57b6705a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_GrantFundingArrangementMaximumFundingValue_e7392828-38bb-4a78-b4a1-9c422a715c96" xlink:href="smmt-20211231.xsd#smmt_GrantFundingArrangementMaximumFundingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b3dc4173-f2b7-4db4-ac99-b7d57b6705a1" xlink:to="loc_smmt_GrantFundingArrangementMaximumFundingValue_e7392828-38bb-4a78-b4a1-9c422a715c96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_GrantFundingArrangementCommittedFundingTotal_48570c2d-d356-443c-afb2-6898ef85e178" xlink:href="smmt-20211231.xsd#smmt_GrantFundingArrangementCommittedFundingTotal"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b3dc4173-f2b7-4db4-ac99-b7d57b6705a1" xlink:to="loc_smmt_GrantFundingArrangementCommittedFundingTotal_48570c2d-d356-443c-afb2-6898ef85e178" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_GrantFundingArrangementFundingReceived_6c7c8674-09a2-4890-b412-f8952b2c8375" xlink:href="smmt-20211231.xsd#smmt_GrantFundingArrangementFundingReceived"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b3dc4173-f2b7-4db4-ac99-b7d57b6705a1" xlink:to="loc_smmt_GrantFundingArrangementFundingReceived_6c7c8674-09a2-4890-b412-f8952b2c8375" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_GrantFundingArrangementIncomeEarned_70d06518-7ff0-49f7-bed6-fdaf9181e776" xlink:href="smmt-20211231.xsd#smmt_GrantFundingArrangementIncomeEarned"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b3dc4173-f2b7-4db4-ac99-b7d57b6705a1" xlink:to="loc_smmt_GrantFundingArrangementIncomeEarned_70d06518-7ff0-49f7-bed6-fdaf9181e776" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_ResearchAndDevelopmentTaxCreditReceivableCurrent_7f1a5a23-23ae-46f1-8c83-4390d1b8edfd" xlink:href="smmt-20211231.xsd#smmt_ResearchAndDevelopmentTaxCreditReceivableCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b3dc4173-f2b7-4db4-ac99-b7d57b6705a1" xlink:to="loc_smmt_ResearchAndDevelopmentTaxCreditReceivableCurrent_7f1a5a23-23ae-46f1-8c83-4390d1b8edfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_GrantFundingArrangementCommittedFundingBase_e8d75d57-e1f9-4d8a-a8e3-61028cd8a656" xlink:href="smmt-20211231.xsd#smmt_GrantFundingArrangementCommittedFundingBase"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b3dc4173-f2b7-4db4-ac99-b7d57b6705a1" xlink:to="loc_smmt_GrantFundingArrangementCommittedFundingBase_e8d75d57-e1f9-4d8a-a8e3-61028cd8a656" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_GrantFundingArrangementMilestoneFundingIncrease_c3471076-e564-4d33-808f-158b01bbfbb6" xlink:href="smmt-20211231.xsd#smmt_GrantFundingArrangementMilestoneFundingIncrease"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b3dc4173-f2b7-4db4-ac99-b7d57b6705a1" xlink:to="loc_smmt_GrantFundingArrangementMilestoneFundingIncrease_c3471076-e564-4d33-808f-158b01bbfbb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_8947342f-3900-4a6f-93fa-62cd6dfb177a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b3dc4173-f2b7-4db4-ac99-b7d57b6705a1" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_8947342f-3900-4a6f-93fa-62cd6dfb177a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_d3bba4a8-cbbb-4378-9c8c-781fa4160adf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b3dc4173-f2b7-4db4-ac99-b7d57b6705a1" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_d3bba4a8-cbbb-4378-9c8c-781fa4160adf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/OtherExpenseIncomeDetails" xlink:type="simple" xlink:href="smmt-20211231.xsd#OtherExpenseIncomeDetails"/>
  <link:presentationLink xlink:role="http://www.summitplc.com/role/OtherExpenseIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_8ea4ceb7-0785-4ec5-889a-7a18e568f506" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_abbe0b95-c394-4990-9fb0-f42b08af3e7f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_8ea4ceb7-0785-4ec5-889a-7a18e568f506" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_abbe0b95-c394-4990-9fb0-f42b08af3e7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_GainLossOnRemeasurementOfLiabilitiesNonoperating_ffe6aaec-2e0c-4556-a185-153757b49304" xlink:href="smmt-20211231.xsd#smmt_GainLossOnRemeasurementOfLiabilitiesNonoperating"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_8ea4ceb7-0785-4ec5-889a-7a18e568f506" xlink:to="loc_smmt_GainLossOnRemeasurementOfLiabilitiesNonoperating_ffe6aaec-2e0c-4556-a185-153757b49304" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_4ea0e5d2-3d4f-4989-bfe0-f862a79e7a2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_8ea4ceb7-0785-4ec5-889a-7a18e568f506" xlink:to="loc_us-gaap_InvestmentIncomeInterest_4ea0e5d2-3d4f-4989-bfe0-f862a79e7a2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_e7bce5c1-bc2e-450e-a33d-f3849e810b09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_8ea4ceb7-0785-4ec5-889a-7a18e568f506" xlink:to="loc_us-gaap_InterestExpense_e7bce5c1-bc2e-450e-a33d-f3849e810b09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_a90224f4-3e9b-4c92-98cd-aad879b4a61d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_8ea4ceb7-0785-4ec5-889a-7a18e568f506" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_a90224f4-3e9b-4c92-98cd-aad879b4a61d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/IncomeTaxComponentsoflossbeforeincometaxesDetails" xlink:type="simple" xlink:href="smmt-20211231.xsd#IncomeTaxComponentsoflossbeforeincometaxesDetails"/>
  <link:presentationLink xlink:role="http://www.summitplc.com/role/IncomeTaxComponentsoflossbeforeincometaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_43e7e8bf-1073-4535-a24b-302e7023f7e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_425b8adb-8245-4e4f-90f0-14600168c175" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_43e7e8bf-1073-4535-a24b-302e7023f7e2" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_425b8adb-8245-4e4f-90f0-14600168c175" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_b98eca85-2200-4ea9-a58d-4ccdca7ed1a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_43e7e8bf-1073-4535-a24b-302e7023f7e2" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_b98eca85-2200-4ea9-a58d-4ccdca7ed1a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_fb5bf0fb-53a7-4a65-901d-aef6e5a77c3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_43e7e8bf-1073-4535-a24b-302e7023f7e2" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_fb5bf0fb-53a7-4a65-901d-aef6e5a77c3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/IncomeTaxSignificantcomponentsoftheprovisionforincometaxesDetails" xlink:type="simple" xlink:href="smmt-20211231.xsd#IncomeTaxSignificantcomponentsoftheprovisionforincometaxesDetails"/>
  <link:presentationLink xlink:role="http://www.summitplc.com/role/IncomeTaxSignificantcomponentsoftheprovisionforincometaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_7c645983-04e3-467c-85c0-b4491fe03f17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_419ea3de-4634-43eb-ad51-8560e32ed874" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_7c645983-04e3-467c-85c0-b4491fe03f17" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_419ea3de-4634-43eb-ad51-8560e32ed874" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_f8faed2c-2d28-4be9-973a-4d157f0702b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_419ea3de-4634-43eb-ad51-8560e32ed874" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_f8faed2c-2d28-4be9-973a-4d157f0702b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_5531f79b-688b-481b-85c8-45e2b6efedee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_419ea3de-4634-43eb-ad51-8560e32ed874" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_5531f79b-688b-481b-85c8-45e2b6efedee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_217b2baa-08a1-4d09-aaed-c6e5d9af965c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_419ea3de-4634-43eb-ad51-8560e32ed874" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_217b2baa-08a1-4d09-aaed-c6e5d9af965c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_a19ac0ca-71ee-4ded-a0b4-f95f3fa009a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_419ea3de-4634-43eb-ad51-8560e32ed874" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_a19ac0ca-71ee-4ded-a0b4-f95f3fa009a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_7c8ae832-270a-4823-bc48-db334dd4ae08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_7c645983-04e3-467c-85c0-b4491fe03f17" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_7c8ae832-270a-4823-bc48-db334dd4ae08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_968cd6d2-a979-4051-90c0-9899951eeb22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_7c645983-04e3-467c-85c0-b4491fe03f17" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_968cd6d2-a979-4051-90c0-9899951eeb22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_3bc596f5-4601-4410-8612-74ed7adde12c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_7c645983-04e3-467c-85c0-b4491fe03f17" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_3bc596f5-4601-4410-8612-74ed7adde12c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_eb843e0b-1dc9-442f-a467-b09a25fffd52" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_7c645983-04e3-467c-85c0-b4491fe03f17" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_eb843e0b-1dc9-442f-a467-b09a25fffd52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_57e3c162-696e-4990-8a2b-4f0759de1b1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_7c645983-04e3-467c-85c0-b4491fe03f17" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_57e3c162-696e-4990-8a2b-4f0759de1b1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/IncomeTaxMajorcomponentsofdeferredtaxassetsandliabilitiesDetails" xlink:type="simple" xlink:href="smmt-20211231.xsd#IncomeTaxMajorcomponentsofdeferredtaxassetsandliabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.summitplc.com/role/IncomeTaxMajorcomponentsofdeferredtaxassetsandliabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_657020f1-1c34-48a6-83d7-23dfb0008079" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_e3e51359-8e30-407c-9092-aba962fa4269" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_657020f1-1c34-48a6-83d7-23dfb0008079" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_e3e51359-8e30-407c-9092-aba962fa4269" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_de74b392-353f-40b8-8215-c0b3c5601c6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_e3e51359-8e30-407c-9092-aba962fa4269" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_de74b392-353f-40b8-8215-c0b3c5601c6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_7f90da66-6e77-469b-b1f7-d9048efd570b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_e3e51359-8e30-407c-9092-aba962fa4269" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_7f90da66-6e77-469b-b1f7-d9048efd570b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_6e364657-3ffe-43f6-bb97-ebd235ab0916" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_e3e51359-8e30-407c-9092-aba962fa4269" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_6e364657-3ffe-43f6-bb97-ebd235ab0916" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_41b144da-393a-4a9f-a463-2c3cc8f03166" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_e3e51359-8e30-407c-9092-aba962fa4269" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_41b144da-393a-4a9f-a463-2c3cc8f03166" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_c00b6aea-d341-44f3-b406-0255ec37e035" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_e3e51359-8e30-407c-9092-aba962fa4269" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_c00b6aea-d341-44f3-b406-0255ec37e035" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_582f59a0-7ed2-4395-b198-0ca9076416d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_657020f1-1c34-48a6-83d7-23dfb0008079" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_582f59a0-7ed2-4395-b198-0ca9076416d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_9066a038-69ae-4ead-8674-1f2985512152" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_582f59a0-7ed2-4395-b198-0ca9076416d7" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_9066a038-69ae-4ead-8674-1f2985512152" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_18d0f2ab-f667-4bbd-9e70-94a15ad770fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_582f59a0-7ed2-4395-b198-0ca9076416d7" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_18d0f2ab-f667-4bbd-9e70-94a15ad770fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_d45dacfd-be52-425c-811c-364a83733f74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_582f59a0-7ed2-4395-b198-0ca9076416d7" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_d45dacfd-be52-425c-811c-364a83733f74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_DeferredTaxAssetsLiabilities_f73d9683-77d3-44af-94ae-eaffd1c531f2" xlink:href="smmt-20211231.xsd#smmt_DeferredTaxAssetsLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_657020f1-1c34-48a6-83d7-23dfb0008079" xlink:to="loc_smmt_DeferredTaxAssetsLiabilities_f73d9683-77d3-44af-94ae-eaffd1c531f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_e83477f9-85b8-4335-b6b0-e12896117760" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_657020f1-1c34-48a6-83d7-23dfb0008079" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_e83477f9-85b8-4335-b6b0-e12896117760" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_12b166cc-b775-4a67-896b-a446c2acb0d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_657020f1-1c34-48a6-83d7-23dfb0008079" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_12b166cc-b775-4a67-896b-a446c2acb0d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/IncomeTaxNarrativeDetails" xlink:type="simple" xlink:href="smmt-20211231.xsd#IncomeTaxNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.summitplc.com/role/IncomeTaxNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_29380508-b0b4-4d27-8b5b-af204f1eff12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_e9249b80-950d-4f6a-9a51-9d727f92cb0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_29380508-b0b4-4d27-8b5b-af204f1eff12" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_e9249b80-950d-4f6a-9a51-9d727f92cb0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_52d794fa-fde5-455d-9755-2ba5b56cd942" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_e9249b80-950d-4f6a-9a51-9d727f92cb0e" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_52d794fa-fde5-455d-9755-2ba5b56cd942" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_cc96f34e-6891-47bf-bdc8-cf23bf82fa90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_52d794fa-fde5-455d-9755-2ba5b56cd942" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_cc96f34e-6891-47bf-bdc8-cf23bf82fa90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_28066727-0428-426f-b0ef-8ad361b6675f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_cc96f34e-6891-47bf-bdc8-cf23bf82fa90" xlink:to="loc_us-gaap_DomesticCountryMember_28066727-0428-426f-b0ef-8ad361b6675f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_414d556b-30db-4574-b393-6ab86aa4eebd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_cc96f34e-6891-47bf-bdc8-cf23bf82fa90" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_414d556b-30db-4574-b393-6ab86aa4eebd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_72e1130f-774a-4bf6-906e-dd7e5777dea1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCountryMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_cc96f34e-6891-47bf-bdc8-cf23bf82fa90" xlink:to="loc_us-gaap_ForeignCountryMember_72e1130f-774a-4bf6-906e-dd7e5777dea1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_3dba8c24-6a6f-4d09-988e-e12c53055f8c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_e9249b80-950d-4f6a-9a51-9d727f92cb0e" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_3dba8c24-6a6f-4d09-988e-e12c53055f8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_4fb50104-8e07-440e-9be3-4efb482da587" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_3dba8c24-6a6f-4d09-988e-e12c53055f8c" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_4fb50104-8e07-440e-9be3-4efb482da587" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember_6fa42df9-e48e-47f4-8ec9-2ffc30af4e11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_4fb50104-8e07-440e-9be3-4efb482da587" xlink:to="loc_us-gaap_ResearchMember_6fa42df9-e48e-47f4-8ec9-2ffc30af4e11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_33fd2f18-203d-4570-b0e9-d7ca1bc44a0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_e9249b80-950d-4f6a-9a51-9d727f92cb0e" xlink:to="loc_us-gaap_OperatingLossCarryforwardsLineItems_33fd2f18-203d-4570-b0e9-d7ca1bc44a0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_ca328266-9f46-4d8d-b507-5ce533ce9fd1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_33fd2f18-203d-4570-b0e9-d7ca1bc44a0a" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_ca328266-9f46-4d8d-b507-5ce533ce9fd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_1b45de03-f5be-4aae-b4b5-d1bb7e26f26f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_33fd2f18-203d-4570-b0e9-d7ca1bc44a0a" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_1b45de03-f5be-4aae-b4b5-d1bb7e26f26f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_98f53169-b8f8-4ecd-9920-c25db85f2f52" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_33fd2f18-203d-4570-b0e9-d7ca1bc44a0a" xlink:to="loc_us-gaap_OperatingLossCarryforwards_98f53169-b8f8-4ecd-9920-c25db85f2f52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_d2c33d27-023f-4336-9102-c59eb18d4f97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_33fd2f18-203d-4570-b0e9-d7ca1bc44a0a" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_d2c33d27-023f-4336-9102-c59eb18d4f97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_PotentialDeferredTaxAssetsOperatingLossCarryforwards_e256edbe-cf23-4bfd-b3ac-85a3da2fc934" xlink:href="smmt-20211231.xsd#smmt_PotentialDeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_33fd2f18-203d-4570-b0e9-d7ca1bc44a0a" xlink:to="loc_smmt_PotentialDeferredTaxAssetsOperatingLossCarryforwards_e256edbe-cf23-4bfd-b3ac-85a3da2fc934" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_DeferredTaxAssetsNetIncreaseDecreaseDueToChangeInEnactedTaxRateAmount_aba626bc-7ddd-49bd-aad0-cd8668483890" xlink:href="smmt-20211231.xsd#smmt_DeferredTaxAssetsNetIncreaseDecreaseDueToChangeInEnactedTaxRateAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_33fd2f18-203d-4570-b0e9-d7ca1bc44a0a" xlink:to="loc_smmt_DeferredTaxAssetsNetIncreaseDecreaseDueToChangeInEnactedTaxRateAmount_aba626bc-7ddd-49bd-aad0-cd8668483890" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseDueToChangeInEnactedTaxRateAmount_38abb5ef-a6b8-4f03-9e3a-7541bf16ace7" xlink:href="smmt-20211231.xsd#smmt_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseDueToChangeInEnactedTaxRateAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_33fd2f18-203d-4570-b0e9-d7ca1bc44a0a" xlink:to="loc_smmt_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseDueToChangeInEnactedTaxRateAmount_38abb5ef-a6b8-4f03-9e3a-7541bf16ace7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_ResearchAndDevelopmentTaxCredit_dcffde83-027d-411d-9024-d84e38a824ce" xlink:href="smmt-20211231.xsd#smmt_ResearchAndDevelopmentTaxCredit"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_33fd2f18-203d-4570-b0e9-d7ca1bc44a0a" xlink:to="loc_smmt_ResearchAndDevelopmentTaxCredit_dcffde83-027d-411d-9024-d84e38a824ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_e4af86f5-8937-4545-a90b-22f4a20d888b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_33fd2f18-203d-4570-b0e9-d7ca1bc44a0a" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_e4af86f5-8937-4545-a90b-22f4a20d888b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_4ee8098d-8ab4-41d7-91c6-50e2eeccad0c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_33fd2f18-203d-4570-b0e9-d7ca1bc44a0a" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_4ee8098d-8ab4-41d7-91c6-50e2eeccad0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/IncomeTaxReconciliationoftheeffectiveincometaxratetostatutoryrateDetails" xlink:type="simple" xlink:href="smmt-20211231.xsd#IncomeTaxReconciliationoftheeffectiveincometaxratetostatutoryrateDetails"/>
  <link:presentationLink xlink:role="http://www.summitplc.com/role/IncomeTaxReconciliationoftheeffectiveincometaxratetostatutoryrateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_cef387fb-8ee9-4dbc-9639-b504123c5636" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_6fc1be3b-3a9f-4ba2-bcd9-546a50db164a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_cef387fb-8ee9-4dbc-9639-b504123c5636" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_6fc1be3b-3a9f-4ba2-bcd9-546a50db164a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_3bfcdd90-803f-4bf1-90fe-4240f3f2e7f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_cef387fb-8ee9-4dbc-9639-b504123c5636" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_3bfcdd90-803f-4bf1-90fe-4240f3f2e7f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_f83646af-2c48-4a75-9dd4-e049e4130532" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_cef387fb-8ee9-4dbc-9639-b504123c5636" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_f83646af-2c48-4a75-9dd4-e049e4130532" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_EffectiveIncomeTaxRateReconciliationTaxCreditRefundableResearchPercent_2966fbad-8965-470b-aa17-e8a8f5be86c5" xlink:href="smmt-20211231.xsd#smmt_EffectiveIncomeTaxRateReconciliationTaxCreditRefundableResearchPercent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_cef387fb-8ee9-4dbc-9639-b504123c5636" xlink:to="loc_smmt_EffectiveIncomeTaxRateReconciliationTaxCreditRefundableResearchPercent_2966fbad-8965-470b-aa17-e8a8f5be86c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_7063f5b0-3c3d-4d5f-a507-a9d46e8bceca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_cef387fb-8ee9-4dbc-9639-b504123c5636" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_7063f5b0-3c3d-4d5f-a507-a9d46e8bceca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_689821ee-2270-4ab0-ae1b-4f4b755ff895" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_cef387fb-8ee9-4dbc-9639-b504123c5636" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_689821ee-2270-4ab0-ae1b-4f4b755ff895" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_081597d7-c2d4-4e5d-b698-dbd1ace8d6cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_cef387fb-8ee9-4dbc-9639-b504123c5636" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_081597d7-c2d4-4e5d-b698-dbd1ace8d6cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_979a0e29-4545-4707-9472-47ae8fa06c99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_cef387fb-8ee9-4dbc-9639-b504123c5636" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_979a0e29-4545-4707-9472-47ae8fa06c99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/LossperShareComputationofnetlosspershareDetails" xlink:type="simple" xlink:href="smmt-20211231.xsd#LossperShareComputationofnetlosspershareDetails"/>
  <link:presentationLink xlink:role="http://www.summitplc.com/role/LossperShareComputationofnetlosspershareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_423c8293-ebe0-41cc-876f-750176d2625c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_47916dde-d04a-4263-b526-7f73314fa33c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_423c8293-ebe0-41cc-876f-750176d2625c" xlink:to="loc_us-gaap_NetIncomeLoss_47916dde-d04a-4263-b526-7f73314fa33c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_80c3dd6d-1e4d-4bf0-9337-f07da9d0d9ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_423c8293-ebe0-41cc-876f-750176d2625c" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_80c3dd6d-1e4d-4bf0-9337-f07da9d0d9ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_dd993a5f-aa33-475e-940d-2b13facc950f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_423c8293-ebe0-41cc-876f-750176d2625c" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_dd993a5f-aa33-475e-940d-2b13facc950f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_9910281f-f40f-4c62-bd36-da68e78e0c02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_423c8293-ebe0-41cc-876f-750176d2625c" xlink:to="loc_us-gaap_EarningsPerShareBasic_9910281f-f40f-4c62-bd36-da68e78e0c02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_d4467be7-845e-4d07-9d9b-994d0400b935" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_423c8293-ebe0-41cc-876f-750176d2625c" xlink:to="loc_us-gaap_EarningsPerShareDiluted_d4467be7-845e-4d07-9d9b-994d0400b935" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/LossperSharePotentiallydilutivesecuritiesexcludedfromthecomputationoflosspershareDetails" xlink:type="simple" xlink:href="smmt-20211231.xsd#LossperSharePotentiallydilutivesecuritiesexcludedfromthecomputationoflosspershareDetails"/>
  <link:presentationLink xlink:role="http://www.summitplc.com/role/LossperSharePotentiallydilutivesecuritiesexcludedfromthecomputationoflosspershareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_64f40204-cd56-48e4-8336-2dba112d047f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_668e6a68-2860-4402-b8b3-7f0feaebf3e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_64f40204-cd56-48e4-8336-2dba112d047f" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_668e6a68-2860-4402-b8b3-7f0feaebf3e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_cbf4fa57-a4dc-43d3-a25a-7405a09ef240" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_668e6a68-2860-4402-b8b3-7f0feaebf3e2" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_cbf4fa57-a4dc-43d3-a25a-7405a09ef240" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_42a0a4df-a3e7-4b40-88bb-a059d0245e5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_cbf4fa57-a4dc-43d3-a25a-7405a09ef240" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_42a0a4df-a3e7-4b40-88bb-a059d0245e5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_3a9fee4b-be1c-4515-b465-a6f063387fc8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_42a0a4df-a3e7-4b40-88bb-a059d0245e5b" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_3a9fee4b-be1c-4515-b465-a6f063387fc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_895332c5-fc5c-4726-aa4c-80899eb2ab00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_42a0a4df-a3e7-4b40-88bb-a059d0245e5b" xlink:to="loc_us-gaap_EmployeeStockOptionMember_895332c5-fc5c-4726-aa4c-80899eb2ab00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_8f297a5c-b78d-4369-85f0-d0fed3902cd9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_42a0a4df-a3e7-4b40-88bb-a059d0245e5b" xlink:to="loc_us-gaap_WarrantMember_8f297a5c-b78d-4369-85f0-d0fed3902cd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_1f0e36cb-1970-4fd7-871f-155d1a12e1db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_42a0a4df-a3e7-4b40-88bb-a059d0245e5b" xlink:to="loc_us-gaap_EmployeeStockMember_1f0e36cb-1970-4fd7-871f-155d1a12e1db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_9b246491-6475-4957-9d9c-2387a9f969af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_668e6a68-2860-4402-b8b3-7f0feaebf3e2" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_9b246491-6475-4957-9d9c-2387a9f969af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_7ffac96f-5410-492a-8668-83bf69419a57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_9b246491-6475-4957-9d9c-2387a9f969af" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_7ffac96f-5410-492a-8668-83bf69419a57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/GoodwillandIntangibleAssetsNarrativeDetails" xlink:type="simple" xlink:href="smmt-20211231.xsd#GoodwillandIntangibleAssetsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.summitplc.com/role/GoodwillandIntangibleAssetsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_76bc75b0-8432-4d5a-9c49-b8336f8bda6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportingUnits_47374426-8f17-4680-8ac7-40d7e424a759" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfReportingUnits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_76bc75b0-8432-4d5a-9c49-b8336f8bda6b" xlink:to="loc_us-gaap_NumberOfReportingUnits_47374426-8f17-4680-8ac7-40d7e424a759" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_6623f006-7ce4-48d6-b908-4f57ba8b3340" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_76bc75b0-8432-4d5a-9c49-b8336f8bda6b" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_6623f006-7ce4-48d6-b908-4f57ba8b3340" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_b4c1336b-53f1-4e2e-ba9c-f7a5ecb46316" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_76bc75b0-8432-4d5a-9c49-b8336f8bda6b" xlink:to="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_b4c1336b-53f1-4e2e-ba9c-f7a5ecb46316" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_defdd74b-ac23-443f-ac3c-a9ed268fad12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_76bc75b0-8432-4d5a-9c49-b8336f8bda6b" xlink:to="loc_us-gaap_Goodwill_defdd74b-ac23-443f-ac3c-a9ed268fad12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_2e2dd36f-7724-4dc7-b442-7211b0e6441d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_76bc75b0-8432-4d5a-9c49-b8336f8bda6b" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_2e2dd36f-7724-4dc7-b442-7211b0e6441d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_c1a4f05e-05db-4de6-ab6b-0c66c4a2bf31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_76bc75b0-8432-4d5a-9c49-b8336f8bda6b" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_c1a4f05e-05db-4de6-ab6b-0c66c4a2bf31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_29b56d00-f668-45af-a7c1-93a7c65d007b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_c1a4f05e-05db-4de6-ab6b-0c66c4a2bf31" xlink:to="loc_srt_ProductOrServiceAxis_29b56d00-f668-45af-a7c1-93a7c65d007b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_fef61f72-44c0-4003-8548-2e75687b9315" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_29b56d00-f668-45af-a7c1-93a7c65d007b" xlink:to="loc_srt_ProductsAndServicesDomain_fef61f72-44c0-4003-8548-2e75687b9315" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_DiscuvaPlatformMember_b616da61-ec88-454e-b694-a227e3e3a88e" xlink:href="smmt-20211231.xsd#smmt_DiscuvaPlatformMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_fef61f72-44c0-4003-8548-2e75687b9315" xlink:to="loc_smmt_DiscuvaPlatformMember_b616da61-ec88-454e-b694-a227e3e3a88e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_8833aedf-09b2-477a-b0b7-1c1b4ac5001b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_c1a4f05e-05db-4de6-ab6b-0c66c4a2bf31" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_8833aedf-09b2-477a-b0b7-1c1b4ac5001b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a9def4ab-f459-41c4-8a59-5a0a018776fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_8833aedf-09b2-477a-b0b7-1c1b4ac5001b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a9def4ab-f459-41c4-8a59-5a0a018776fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_b7a8a47c-bb15-4f01-b56a-c13087061cc4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a9def4ab-f459-41c4-8a59-5a0a018776fc" xlink:to="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_b7a8a47c-bb15-4f01-b56a-c13087061cc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_712f0483-e3ec-4c83-981e-28873ccb96fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_c1a4f05e-05db-4de6-ab6b-0c66c4a2bf31" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_712f0483-e3ec-4c83-981e-28873ccb96fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_682391ab-e7c2-429a-865a-fcad77bf99ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_712f0483-e3ec-4c83-981e-28873ccb96fe" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_682391ab-e7c2-429a-865a-fcad77bf99ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/GoodwillandIntangibleAssetsScheduleofacquiredintangibleassetsDetails" xlink:type="simple" xlink:href="smmt-20211231.xsd#GoodwillandIntangibleAssetsScheduleofacquiredintangibleassetsDetails"/>
  <link:presentationLink xlink:role="http://www.summitplc.com/role/GoodwillandIntangibleAssetsScheduleofacquiredintangibleassetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_ac147022-69d2-4004-83e4-654af6a391bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_dfa12cfc-81f8-4c2b-9bc8-49c81d5378a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_ac147022-69d2-4004-83e4-654af6a391bd" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_dfa12cfc-81f8-4c2b-9bc8-49c81d5378a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_0099f0b7-da99-4425-a8df-a0e4e901890f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_dfa12cfc-81f8-4c2b-9bc8-49c81d5378a7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_0099f0b7-da99-4425-a8df-a0e4e901890f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_42e1afaf-c5a6-4f8a-9736-d0f4c0426e01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_0099f0b7-da99-4425-a8df-a0e4e901890f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_42e1afaf-c5a6-4f8a-9736-d0f4c0426e01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_f3307257-cdc7-4f64-92dc-a35bd3873d66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_42e1afaf-c5a6-4f8a-9736-d0f4c0426e01" xlink:to="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_f3307257-cdc7-4f64-92dc-a35bd3873d66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_OptionOverNonFinancialAssetsMember_efa1c6c4-fcf7-4c8b-9097-b2f0b29fb638" xlink:href="smmt-20211231.xsd#smmt_OptionOverNonFinancialAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_42e1afaf-c5a6-4f8a-9736-d0f4c0426e01" xlink:to="loc_smmt_OptionOverNonFinancialAssetsMember_efa1c6c4-fcf7-4c8b-9097-b2f0b29fb638" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_OtherPatentsAndLicensesMember_7016a85d-eaa7-41c9-a546-d1c8c4376c9d" xlink:href="smmt-20211231.xsd#smmt_OtherPatentsAndLicensesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_42e1afaf-c5a6-4f8a-9736-d0f4c0426e01" xlink:to="loc_smmt_OtherPatentsAndLicensesMember_7016a85d-eaa7-41c9-a546-d1c8c4376c9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_0a777259-2863-4940-8b88-3c3f302d7dbc" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_dfa12cfc-81f8-4c2b-9bc8-49c81d5378a7" xlink:to="loc_srt_ProductOrServiceAxis_0a777259-2863-4940-8b88-3c3f302d7dbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_229fc7e6-37b5-40a1-a7f5-76a5057bfe2a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_0a777259-2863-4940-8b88-3c3f302d7dbc" xlink:to="loc_srt_ProductsAndServicesDomain_229fc7e6-37b5-40a1-a7f5-76a5057bfe2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_UtrophinProgramMember_81395b1d-858e-40ce-9b1b-94b4891b97b4" xlink:href="smmt-20211231.xsd#smmt_UtrophinProgramMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_229fc7e6-37b5-40a1-a7f5-76a5057bfe2a" xlink:to="loc_smmt_UtrophinProgramMember_81395b1d-858e-40ce-9b1b-94b4891b97b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_DiscuvaPlatformMember_f6dda7d1-32ca-4f2c-8c80-d5aeaa469864" xlink:href="smmt-20211231.xsd#smmt_DiscuvaPlatformMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_229fc7e6-37b5-40a1-a7f5-76a5057bfe2a" xlink:to="loc_smmt_DiscuvaPlatformMember_f6dda7d1-32ca-4f2c-8c80-d5aeaa469864" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_c59d6473-4a8d-4210-b89f-2fcedb2db59d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_dfa12cfc-81f8-4c2b-9bc8-49c81d5378a7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_c59d6473-4a8d-4210-b89f-2fcedb2db59d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_07895332-219c-486b-9e20-8e26edfa654e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_c59d6473-4a8d-4210-b89f-2fcedb2db59d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_07895332-219c-486b-9e20-8e26edfa654e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_FiniteLivedIntangibleAssetsAccumulatedAmortizationAndImpairment_db364a44-559c-4ace-9337-45870c1424a5" xlink:href="smmt-20211231.xsd#smmt_FiniteLivedIntangibleAssetsAccumulatedAmortizationAndImpairment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_c59d6473-4a8d-4210-b89f-2fcedb2db59d" xlink:to="loc_smmt_FiniteLivedIntangibleAssetsAccumulatedAmortizationAndImpairment_db364a44-559c-4ace-9337-45870c1424a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_9162791f-0eaa-4c7b-8218-5b5e0e086d50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_c59d6473-4a8d-4210-b89f-2fcedb2db59d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_9162791f-0eaa-4c7b-8218-5b5e0e086d50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure_fc4369be-b4d2-4ca5-93b7-690c85e781c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_c59d6473-4a8d-4210-b89f-2fcedb2db59d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure_fc4369be-b4d2-4ca5-93b7-690c85e781c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_c35ce0ff-a986-4aad-9710-0fafb95e19e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_c59d6473-4a8d-4210-b89f-2fcedb2db59d" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_c35ce0ff-a986-4aad-9710-0fafb95e19e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/GoodwillandIntangibleAssetsEstimatedamortizationexpenseDetails" xlink:type="simple" xlink:href="smmt-20211231.xsd#GoodwillandIntangibleAssetsEstimatedamortizationexpenseDetails"/>
  <link:presentationLink xlink:role="http://www.summitplc.com/role/GoodwillandIntangibleAssetsEstimatedamortizationexpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_160732a6-f98e-4c18-8f85-51ea2fe3f8e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_6d8dbe6c-8e0f-4590-ada9-119098599b46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_160732a6-f98e-4c18-8f85-51ea2fe3f8e7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_6d8dbe6c-8e0f-4590-ada9-119098599b46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_a5592dae-59d1-4622-b3bb-b5be850b55c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_160732a6-f98e-4c18-8f85-51ea2fe3f8e7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_a5592dae-59d1-4622-b3bb-b5be850b55c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_7feaeb5d-da9c-417b-bb5a-427b74a74451" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_160732a6-f98e-4c18-8f85-51ea2fe3f8e7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_7feaeb5d-da9c-417b-bb5a-427b74a74451" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_a89374bd-1ebe-4c22-86d2-9e36d66a4e3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_160732a6-f98e-4c18-8f85-51ea2fe3f8e7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_a89374bd-1ebe-4c22-86d2-9e36d66a4e3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_a2985150-981e-4e8d-b5dc-f92aa1dbdf31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_160732a6-f98e-4c18-8f85-51ea2fe3f8e7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_a2985150-981e-4e8d-b5dc-f92aa1dbdf31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_5890a859-e5ae-491b-803e-8e60470e9107" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_160732a6-f98e-4c18-8f85-51ea2fe3f8e7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_5890a859-e5ae-491b-803e-8e60470e9107" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/PropertyandEquipmentComponentsofpropertyandequipmentDetails" xlink:type="simple" xlink:href="smmt-20211231.xsd#PropertyandEquipmentComponentsofpropertyandequipmentDetails"/>
  <link:presentationLink xlink:role="http://www.summitplc.com/role/PropertyandEquipmentComponentsofpropertyandequipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_d6503dd4-cb8a-468e-af01-d5d7f1ccac5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_e48ddecb-8226-4d38-83c6-df717ae1b5af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_d6503dd4-cb8a-468e-af01-d5d7f1ccac5c" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_e48ddecb-8226-4d38-83c6-df717ae1b5af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a42f1d9e-172b-4b78-810e-287b6285e878" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_e48ddecb-8226-4d38-83c6-df717ae1b5af" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a42f1d9e-172b-4b78-810e-287b6285e878" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0e8d6e2b-20dc-49f9-8d21-b79eceee6656" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a42f1d9e-172b-4b78-810e-287b6285e878" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0e8d6e2b-20dc-49f9-8d21-b79eceee6656" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_LaboratoryEquipmentMember_663317a1-82ea-4f48-9a7a-b6d22c5849ce" xlink:href="smmt-20211231.xsd#smmt_LaboratoryEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0e8d6e2b-20dc-49f9-8d21-b79eceee6656" xlink:to="loc_smmt_LaboratoryEquipmentMember_663317a1-82ea-4f48-9a7a-b6d22c5849ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_FurnitureAndFixturesOfficeEquipmentAndSoftwareMember_4197deaa-4138-4d16-a18e-2cf36b841ef6" xlink:href="smmt-20211231.xsd#smmt_FurnitureAndFixturesOfficeEquipmentAndSoftwareMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0e8d6e2b-20dc-49f9-8d21-b79eceee6656" xlink:to="loc_smmt_FurnitureAndFixturesOfficeEquipmentAndSoftwareMember_4197deaa-4138-4d16-a18e-2cf36b841ef6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_5dc828d2-8de8-4145-9033-c6923686c8aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0e8d6e2b-20dc-49f9-8d21-b79eceee6656" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_5dc828d2-8de8-4145-9033-c6923686c8aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a34c8241-fec5-4c0d-b670-2858f5aa6156" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_e48ddecb-8226-4d38-83c6-df717ae1b5af" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a34c8241-fec5-4c0d-b670-2858f5aa6156" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_ddf19cdb-de22-4342-b38f-35f484d25e6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a34c8241-fec5-4c0d-b670-2858f5aa6156" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_ddf19cdb-de22-4342-b38f-35f484d25e6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_4985569f-c475-4063-bb0d-2e5489c3e488" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a34c8241-fec5-4c0d-b670-2858f5aa6156" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_4985569f-c475-4063-bb0d-2e5489c3e488" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_9c6334c3-8cdd-4d78-92fa-b1ccdbe42f8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a34c8241-fec5-4c0d-b670-2858f5aa6156" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_9c6334c3-8cdd-4d78-92fa-b1ccdbe42f8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/PropertyandEquipmentNarrativeDetails" xlink:type="simple" xlink:href="smmt-20211231.xsd#PropertyandEquipmentNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.summitplc.com/role/PropertyandEquipmentNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_47a9c3be-b8b3-4084-b8d1-b4f997e63aa9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_b6f2159c-e382-4929-ac7d-32280bba777b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_47a9c3be-b8b3-4084-b8d1-b4f997e63aa9" xlink:to="loc_us-gaap_Depreciation_b6f2159c-e382-4929-ac7d-32280bba777b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/ResearchandDevelopmentPrepaidExpensesandAccruedLiabilitiesDetails" xlink:type="simple" xlink:href="smmt-20211231.xsd#ResearchandDevelopmentPrepaidExpensesandAccruedLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.summitplc.com/role/ResearchandDevelopmentPrepaidExpensesandAccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_d6582636-0264-481f-b2e2-24d7e8aafaea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_ResearchAndDevelopmentPrepaidExpensesCurrent_402bc27a-cb0c-422d-8a67-1722a6af3e96" xlink:href="smmt-20211231.xsd#smmt_ResearchAndDevelopmentPrepaidExpensesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_d6582636-0264-481f-b2e2-24d7e8aafaea" xlink:to="loc_smmt_ResearchAndDevelopmentPrepaidExpensesCurrent_402bc27a-cb0c-422d-8a67-1722a6af3e96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_AccruedResearchAndDevelopmentCurrent_7fbb7928-ef9f-4d91-a53e-1cbe202266d4" xlink:href="smmt-20211231.xsd#smmt_AccruedResearchAndDevelopmentCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_d6582636-0264-481f-b2e2-24d7e8aafaea" xlink:to="loc_smmt_AccruedResearchAndDevelopmentCurrent_7fbb7928-ef9f-4d91-a53e-1cbe202266d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="smmt-20211231.xsd#LeasesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.summitplc.com/role/LeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_7d9ef9c8-1278-4df8-9e55-6b760f4fa78e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_74163a57-8b3b-42e8-bed2-b14e070ef306" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_7d9ef9c8-1278-4df8-9e55-6b760f4fa78e" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_74163a57-8b3b-42e8-bed2-b14e070ef306" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_6869ea32-4f3c-4d8e-9cc6-065c808a0137" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_74163a57-8b3b-42e8-bed2-b14e070ef306" xlink:to="loc_srt_StatementGeographicalAxis_6869ea32-4f3c-4d8e-9cc6-065c808a0137" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_48b0b9d6-cb91-4787-9ef2-b414695e7b5b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_6869ea32-4f3c-4d8e-9cc6-065c808a0137" xlink:to="loc_srt_SegmentGeographicalDomain_48b0b9d6-cb91-4787-9ef2-b414695e7b5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_MenloParkCaliforniaUSAndSawstonUKMember_0479553d-ea8d-4bc7-98eb-2ebd541c78dc" xlink:href="smmt-20211231.xsd#smmt_MenloParkCaliforniaUSAndSawstonUKMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_48b0b9d6-cb91-4787-9ef2-b414695e7b5b" xlink:to="loc_smmt_MenloParkCaliforniaUSAndSawstonUKMember_0479553d-ea8d-4bc7-98eb-2ebd541c78dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_OxfordshireUKMember_7d3a6915-e742-4004-855e-9e5ba0626ebe" xlink:href="smmt-20211231.xsd#smmt_OxfordshireUKMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_48b0b9d6-cb91-4787-9ef2-b414695e7b5b" xlink:to="loc_smmt_OxfordshireUKMember_7d3a6915-e742-4004-855e-9e5ba0626ebe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_448a9a3d-8da6-4b6a-a841-1fe8fe09792f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_74163a57-8b3b-42e8-bed2-b14e070ef306" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_448a9a3d-8da6-4b6a-a841-1fe8fe09792f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_15950824-4969-44d8-9e11-acc78f5147a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_448a9a3d-8da6-4b6a-a841-1fe8fe09792f" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_15950824-4969-44d8-9e11-acc78f5147a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_LesseeOperatingLeaseNumberOfContracts_37e7c256-dcb5-49e0-98aa-d5979c78ddd4" xlink:href="smmt-20211231.xsd#smmt_LesseeOperatingLeaseNumberOfContracts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_448a9a3d-8da6-4b6a-a841-1fe8fe09792f" xlink:to="loc_smmt_LesseeOperatingLeaseNumberOfContracts_37e7c256-dcb5-49e0-98aa-d5979c78ddd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_7abd8d31-5d5e-4b90-8b65-6c8a219510c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_448a9a3d-8da6-4b6a-a841-1fe8fe09792f" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_7abd8d31-5d5e-4b90-8b65-6c8a219510c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_e15ee108-6e57-486b-b302-c56800222113" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_448a9a3d-8da6-4b6a-a841-1fe8fe09792f" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_e15ee108-6e57-486b-b302-c56800222113" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_cb292f8c-396f-4e2f-b456-b98f8ada3718" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_448a9a3d-8da6-4b6a-a841-1fe8fe09792f" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_cb292f8c-396f-4e2f-b456-b98f8ada3718" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/LeasesLeaseexpenseDetails" xlink:type="simple" xlink:href="smmt-20211231.xsd#LeasesLeaseexpenseDetails"/>
  <link:presentationLink xlink:role="http://www.summitplc.com/role/LeasesLeaseexpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_e85153f9-a883-409f-a2b4-39ab7e94e748" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostAbstract_d2a07a1a-dbfb-4ea4-885f-a2d80837bd0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_e85153f9-a883-409f-a2b4-39ab7e94e748" xlink:to="loc_us-gaap_LeaseCostAbstract_d2a07a1a-dbfb-4ea4-885f-a2d80837bd0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_5952084f-c2ab-44db-aea1-e461767c81e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_d2a07a1a-dbfb-4ea4-885f-a2d80837bd0e" xlink:to="loc_us-gaap_OperatingLeaseCost_5952084f-c2ab-44db-aea1-e461767c81e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_103bf37c-6e3e-4831-b95a-3f9b9c87555b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableLeaseCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_d2a07a1a-dbfb-4ea4-885f-a2d80837bd0e" xlink:to="loc_us-gaap_VariableLeaseCost_103bf37c-6e3e-4831-b95a-3f9b9c87555b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost_26bb8a61-ca79-48c3-a4ca-c298f8c1d7b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_d2a07a1a-dbfb-4ea4-885f-a2d80837bd0e" xlink:to="loc_us-gaap_ShortTermLeaseCost_26bb8a61-ca79-48c3-a4ca-c298f8c1d7b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_612d08dd-3563-47d5-ba9d-1ec8dfe19819" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_d2a07a1a-dbfb-4ea4-885f-a2d80837bd0e" xlink:to="loc_us-gaap_LeaseCost_612d08dd-3563-47d5-ba9d-1ec8dfe19819" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/LeasesFutureleasepaymentsDetails" xlink:type="simple" xlink:href="smmt-20211231.xsd#LeasesFutureleasepaymentsDetails"/>
  <link:presentationLink xlink:role="http://www.summitplc.com/role/LeasesFutureleasepaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_d57aeb01-fd9f-41de-97fc-8d42493a37a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_9137c415-bafe-427d-943a-36b8fe84e418" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d57aeb01-fd9f-41de-97fc-8d42493a37a5" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_9137c415-bafe-427d-943a-36b8fe84e418" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_56e4f514-48b7-4e0f-aaae-358f012edf78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d57aeb01-fd9f-41de-97fc-8d42493a37a5" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_56e4f514-48b7-4e0f-aaae-358f012edf78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_d130b3c9-8d34-40c1-a507-513a6a9b859d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d57aeb01-fd9f-41de-97fc-8d42493a37a5" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_d130b3c9-8d34-40c1-a507-513a6a9b859d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_64f8906a-d9eb-430b-80a8-98c37d3a3f1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d57aeb01-fd9f-41de-97fc-8d42493a37a5" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_64f8906a-d9eb-430b-80a8-98c37d3a3f1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_1df1cbf5-9ff2-40d6-9980-c66657ae31e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d57aeb01-fd9f-41de-97fc-8d42493a37a5" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_1df1cbf5-9ff2-40d6-9980-c66657ae31e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_183bcd36-2b0b-4ec4-a39c-9560aa1eedd4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d57aeb01-fd9f-41de-97fc-8d42493a37a5" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_183bcd36-2b0b-4ec4-a39c-9560aa1eedd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_c177671d-7354-4d4f-b53d-57dd608bd3ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d57aeb01-fd9f-41de-97fc-8d42493a37a5" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_c177671d-7354-4d4f-b53d-57dd608bd3ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_944f6076-13c9-46ce-a47d-bf819837eede" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d57aeb01-fd9f-41de-97fc-8d42493a37a5" xlink:to="loc_us-gaap_OperatingLeaseLiability_944f6076-13c9-46ce-a47d-bf819837eede" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityAbstract_9304b5a2-76cb-4e56-a25f-5879b87a511f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d57aeb01-fd9f-41de-97fc-8d42493a37a5" xlink:to="loc_us-gaap_OperatingLeaseLiabilityAbstract_9304b5a2-76cb-4e56-a25f-5879b87a511f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_96c0aeca-a3c7-47b4-bc22-1b7326009c16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilityAbstract_9304b5a2-76cb-4e56-a25f-5879b87a511f" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_96c0aeca-a3c7-47b4-bc22-1b7326009c16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_edde69b5-418d-4991-b2b4-0329af2e3b16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilityAbstract_9304b5a2-76cb-4e56-a25f-5879b87a511f" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_edde69b5-418d-4991-b2b4-0329af2e3b16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_dc52a72e-b7e4-4bbb-b575-3b586a40be72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilityAbstract_9304b5a2-76cb-4e56-a25f-5879b87a511f" xlink:to="loc_us-gaap_OperatingLeaseLiability_dc52a72e-b7e4-4bbb-b575-3b586a40be72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/LeasesFutureleasepaymentsDetails_1" xlink:type="simple" xlink:href="smmt-20211231.xsd#LeasesFutureleasepaymentsDetails_1"/>
  <link:presentationLink xlink:role="http://www.summitplc.com/role/LeasesFutureleasepaymentsDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.summitplc.com/role/OtherNonCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="smmt-20211231.xsd#OtherNonCurrentLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.summitplc.com/role/OtherNonCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_434d9dfb-fc04-447d-b3ed-e09b10b8e32b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_BusinessCombinationAssumedContingentLiabilityNoncurrent_ba63841d-076f-4b89-8a06-7b0a630c0f2e" xlink:href="smmt-20211231.xsd#smmt_BusinessCombinationAssumedContingentLiabilityNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_434d9dfb-fc04-447d-b3ed-e09b10b8e32b" xlink:to="loc_smmt_BusinessCombinationAssumedContingentLiabilityNoncurrent_ba63841d-076f-4b89-8a06-7b0a630c0f2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_GainLossOnRemeasurementOfLiabilitiesNonoperating_dab78fb2-52c2-420b-94d6-3e9a42d02539" xlink:href="smmt-20211231.xsd#smmt_GainLossOnRemeasurementOfLiabilitiesNonoperating"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_434d9dfb-fc04-447d-b3ed-e09b10b8e32b" xlink:to="loc_smmt_GainLossOnRemeasurementOfLiabilitiesNonoperating_dab78fb2-52c2-420b-94d6-3e9a42d02539" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/StockholdersEquityDetails" xlink:type="simple" xlink:href="smmt-20211231.xsd#StockholdersEquityDetails"/>
  <link:presentationLink xlink:role="http://www.summitplc.com/role/StockholdersEquityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_4d99c38e-951f-4e13-9832-59f65ec7c305" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_4d49cbff-e189-4c9e-8629-73de74d75757" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_4d99c38e-951f-4e13-9832-59f65ec7c305" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_4d49cbff-e189-4c9e-8629-73de74d75757" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_e5d2d787-1932-414c-b5a9-b41b329429ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_4d49cbff-e189-4c9e-8629-73de74d75757" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_e5d2d787-1932-414c-b5a9-b41b329429ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b1a05735-7aa3-4647-8b01-c0884ec841a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_e5d2d787-1932-414c-b5a9-b41b329429ca" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b1a05735-7aa3-4647-8b01-c0884ec841a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_RightsOfferingMember_c5871940-15c1-49e8-bffe-d7b3dca1a24f" xlink:href="smmt-20211231.xsd#smmt_RightsOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b1a05735-7aa3-4647-8b01-c0884ec841a3" xlink:to="loc_smmt_RightsOfferingMember_c5871940-15c1-49e8-bffe-d7b3dca1a24f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_68e58b8e-fbe1-4e17-aee5-8b7d9832d0cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrivatePlacementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b1a05735-7aa3-4647-8b01-c0884ec841a3" xlink:to="loc_us-gaap_PrivatePlacementMember_68e58b8e-fbe1-4e17-aee5-8b7d9832d0cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_a5bcee8d-efdc-4655-ad40-af403e500214" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_4d49cbff-e189-4c9e-8629-73de74d75757" xlink:to="loc_us-gaap_AwardTypeAxis_a5bcee8d-efdc-4655-ad40-af403e500214" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_be45cdb5-7bae-46b8-b868-b3964a3e2031" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_a5bcee8d-efdc-4655-ad40-af403e500214" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_be45cdb5-7bae-46b8-b868-b3964a3e2031" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_28d8cea8-97f2-4404-8b27-a9bc547201d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_be45cdb5-7bae-46b8-b868-b3964a3e2031" xlink:to="loc_us-gaap_WarrantMember_28d8cea8-97f2-4404-8b27-a9bc547201d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_4c07b657-c45c-474f-b920-9fe0c5345dff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_4d49cbff-e189-4c9e-8629-73de74d75757" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_4c07b657-c45c-474f-b920-9fe0c5345dff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_bf0fb0c2-5987-4de6-aecd-b80835fa6517" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_4c07b657-c45c-474f-b920-9fe0c5345dff" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_bf0fb0c2-5987-4de6-aecd-b80835fa6517" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_ConsultingAgreementMember_350af51e-a81e-4515-bb5e-aa6d82f9905a" xlink:href="smmt-20211231.xsd#smmt_ConsultingAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_bf0fb0c2-5987-4de6-aecd-b80835fa6517" xlink:to="loc_smmt_ConsultingAgreementMember_350af51e-a81e-4515-bb5e-aa6d82f9905a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1693a73c-052b-4259-a227-ce4a25cbc975" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_4d49cbff-e189-4c9e-8629-73de74d75757" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1693a73c-052b-4259-a227-ce4a25cbc975" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_18597935-c809-4896-a00e-400445ca7efa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1693a73c-052b-4259-a227-ce4a25cbc975" xlink:to="loc_us-gaap_RelatedPartyDomain_18597935-c809-4896-a00e-400445ca7efa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_cc925dcd-6301-4804-8101-764effb76416" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_AffiliatedEntityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_18597935-c809-4896-a00e-400445ca7efa" xlink:to="loc_srt_AffiliatedEntityMember_cc925dcd-6301-4804-8101-764effb76416" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_b2bb58a8-9617-4479-b7b2-b00ea425c944" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_4d49cbff-e189-4c9e-8629-73de74d75757" xlink:to="loc_us-gaap_SubsidiarySaleOfStockLineItems_b2bb58a8-9617-4479-b7b2-b00ea425c944" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_ea5aabe2-4b2a-480f-94d7-441c1fa419c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_b2bb58a8-9617-4479-b7b2-b00ea425c944" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_ea5aabe2-4b2a-480f-94d7-441c1fa419c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_898e5e61-0fb6-4922-8d40-52aefb9a8073" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_b2bb58a8-9617-4479-b7b2-b00ea425c944" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_898e5e61-0fb6-4922-8d40-52aefb9a8073" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_1470542f-1e1d-45d3-a060-487408ed2017" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_b2bb58a8-9617-4479-b7b2-b00ea425c944" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_1470542f-1e1d-45d3-a060-487408ed2017" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_4664c100-3b0e-424c-9d4e-9b3684266ae2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_b2bb58a8-9617-4479-b7b2-b00ea425c944" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_4664c100-3b0e-424c-9d4e-9b3684266ae2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_60ef6ab6-2c9b-4f55-9c05-7c7cb3bf3f08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_b2bb58a8-9617-4479-b7b2-b00ea425c944" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_60ef6ab6-2c9b-4f55-9c05-7c7cb3bf3f08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_cb7ce135-9c15-4b26-9f9d-d3663f054acf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_b2bb58a8-9617-4479-b7b2-b00ea425c944" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_cb7ce135-9c15-4b26-9f9d-d3663f054acf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_18006427-34e2-453d-820c-a9217897078b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_b2bb58a8-9617-4479-b7b2-b00ea425c944" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_18006427-34e2-453d-820c-a9217897078b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_7c8a6823-2ded-4f0a-8e1e-9ca6428768e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_b2bb58a8-9617-4479-b7b2-b00ea425c944" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_7c8a6823-2ded-4f0a-8e1e-9ca6428768e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_90bbbf76-b0bd-4192-975d-6a34686d33b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_b2bb58a8-9617-4479-b7b2-b00ea425c944" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_90bbbf76-b0bd-4192-975d-6a34686d33b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_ClassOfWarrantOrRightMinimumTenDayVolumeWeightedAverageCommonStockPriceToWarrantExercisePricePremiumPercentage_52ec798e-f4c3-4e6e-8cb1-93f62dc70ff9" xlink:href="smmt-20211231.xsd#smmt_ClassOfWarrantOrRightMinimumTenDayVolumeWeightedAverageCommonStockPriceToWarrantExercisePricePremiumPercentage"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_b2bb58a8-9617-4479-b7b2-b00ea425c944" xlink:to="loc_smmt_ClassOfWarrantOrRightMinimumTenDayVolumeWeightedAverageCommonStockPriceToWarrantExercisePricePremiumPercentage_52ec798e-f4c3-4e6e-8cb1-93f62dc70ff9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_ClassOfWarrantOrRightQuarterlyVestingPeriod_5cbf04ca-3b02-4b81-a14c-cfb27d668ace" xlink:href="smmt-20211231.xsd#smmt_ClassOfWarrantOrRightQuarterlyVestingPeriod"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_b2bb58a8-9617-4479-b7b2-b00ea425c944" xlink:to="loc_smmt_ClassOfWarrantOrRightQuarterlyVestingPeriod_5cbf04ca-3b02-4b81-a14c-cfb27d668ace" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_568d7ac9-4875-40c1-a622-f9276db8ac39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_b2bb58a8-9617-4479-b7b2-b00ea425c944" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_568d7ac9-4875-40c1-a622-f9276db8ac39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_27960af4-ec56-43d0-b333-d60121d3aef1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_b2bb58a8-9617-4479-b7b2-b00ea425c944" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_27960af4-ec56-43d0-b333-d60121d3aef1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_5880e2dd-266f-4fcb-82c1-c67b0643cab9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_b2bb58a8-9617-4479-b7b2-b00ea425c944" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_5880e2dd-266f-4fcb-82c1-c67b0643cab9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/StockBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="smmt-20211231.xsd#StockBasedCompensationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.summitplc.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1e97b5cb-f837-47f9-8b57-caafb0786f61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ca3c0340-04d6-4801-a239-59df9f7bb607" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1e97b5cb-f837-47f9-8b57-caafb0786f61" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ca3c0340-04d6-4801-a239-59df9f7bb607" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_37de71cc-6e0a-487b-8f48-9a823e2c2f5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ca3c0340-04d6-4801-a239-59df9f7bb607" xlink:to="loc_us-gaap_PlanNameAxis_37de71cc-6e0a-487b-8f48-9a823e2c2f5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_369b5b9f-06ae-442d-ad6e-4d8d3ed3d515" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_37de71cc-6e0a-487b-8f48-9a823e2c2f5a" xlink:to="loc_us-gaap_PlanNameDomain_369b5b9f-06ae-442d-ad6e-4d8d3ed3d515" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_A2020StockIncentivePlanMember_2fe6745a-79f5-4144-944e-3efc4d785ae7" xlink:href="smmt-20211231.xsd#smmt_A2020StockIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_369b5b9f-06ae-442d-ad6e-4d8d3ed3d515" xlink:to="loc_smmt_A2020StockIncentivePlanMember_2fe6745a-79f5-4144-944e-3efc4d785ae7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_97fcd349-c593-43fe-8ff5-dc5c896c73b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ca3c0340-04d6-4801-a239-59df9f7bb607" xlink:to="loc_us-gaap_AwardTypeAxis_97fcd349-c593-43fe-8ff5-dc5c896c73b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_06744694-f37f-47f5-b491-f0bc09b9386f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_97fcd349-c593-43fe-8ff5-dc5c896c73b4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_06744694-f37f-47f5-b491-f0bc09b9386f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_166a675c-19dc-4260-906c-7740bdf02dde" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_06744694-f37f-47f5-b491-f0bc09b9386f" xlink:to="loc_us-gaap_EmployeeStockMember_166a675c-19dc-4260-906c-7740bdf02dde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_fd65d798-b8c3-474e-a4f9-2285356d3bc5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_06744694-f37f-47f5-b491-f0bc09b9386f" xlink:to="loc_us-gaap_EmployeeStockOptionMember_fd65d798-b8c3-474e-a4f9-2285356d3bc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_6b3bc862-d13f-4fc2-b7ef-1208f32eb6f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_06744694-f37f-47f5-b491-f0bc09b9386f" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_6b3bc862-d13f-4fc2-b7ef-1208f32eb6f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_07c06326-8de2-4458-8e7c-2c6e75ee59a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_06744694-f37f-47f5-b491-f0bc09b9386f" xlink:to="loc_us-gaap_WarrantMember_07c06326-8de2-4458-8e7c-2c6e75ee59a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_07e5a718-232a-4279-aa25-ba246898aa11" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ca3c0340-04d6-4801-a239-59df9f7bb607" xlink:to="loc_srt_RangeAxis_07e5a718-232a-4279-aa25-ba246898aa11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_89c98fbe-88d9-4389-9193-117b8346a3de" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_07e5a718-232a-4279-aa25-ba246898aa11" xlink:to="loc_srt_RangeMember_89c98fbe-88d9-4389-9193-117b8346a3de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_bf32466f-b683-4829-9f17-42a244c2b406" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_89c98fbe-88d9-4389-9193-117b8346a3de" xlink:to="loc_srt_MinimumMember_bf32466f-b683-4829-9f17-42a244c2b406" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_9e0a093c-21e4-4f26-9dd1-9a9b32b201ef" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_89c98fbe-88d9-4389-9193-117b8346a3de" xlink:to="loc_srt_MaximumMember_9e0a093c-21e4-4f26-9dd1-9a9b32b201ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_ab45da86-99ed-48f8-86c9-eb87cdb2af6e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ca3c0340-04d6-4801-a239-59df9f7bb607" xlink:to="loc_srt_StatementScenarioAxis_ab45da86-99ed-48f8-86c9-eb87cdb2af6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_75e9d088-4b55-405d-84df-365d3f98b4b2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_ab45da86-99ed-48f8-86c9-eb87cdb2af6e" xlink:to="loc_srt_ScenarioUnspecifiedDomain_75e9d088-4b55-405d-84df-365d3f98b4b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_17c6fbc6-5f23-4f24-ae78-590c18a88325" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_75e9d088-4b55-405d-84df-365d3f98b4b2" xlink:to="loc_srt_ScenarioForecastMember_17c6fbc6-5f23-4f24-ae78-590c18a88325" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_5dd094d1-14ac-4737-936b-8db3db51fcf0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ca3c0340-04d6-4801-a239-59df9f7bb607" xlink:to="loc_srt_TitleOfIndividualAxis_5dd094d1-14ac-4737-936b-8db3db51fcf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_51e6da6d-efc2-40a3-b75a-9d93ca9a56ff" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_5dd094d1-14ac-4737-936b-8db3db51fcf0" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_51e6da6d-efc2-40a3-b75a-9d93ca9a56ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_ConsultantsMember_d8f2b192-1163-4b13-8db2-962296f6f527" xlink:href="smmt-20211231.xsd#smmt_ConsultantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_51e6da6d-efc2-40a3-b75a-9d93ca9a56ff" xlink:to="loc_smmt_ConsultantsMember_d8f2b192-1163-4b13-8db2-962296f6f527" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestorMember_58860790-d15e-43ec-88c3-e7855a783e19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestorMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_51e6da6d-efc2-40a3-b75a-9d93ca9a56ff" xlink:to="loc_us-gaap_InvestorMember_58860790-d15e-43ec-88c3-e7855a783e19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_07e961e3-7bc8-4c3b-8c87-c335bea5c7b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ca3c0340-04d6-4801-a239-59df9f7bb607" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_07e961e3-7bc8-4c3b-8c87-c335bea5c7b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_e680ded0-9c77-4c33-8f6b-850dadeffaca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_07e961e3-7bc8-4c3b-8c87-c335bea5c7b4" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_e680ded0-9c77-4c33-8f6b-850dadeffaca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_CommonStockAndRestrictedStockUnitsAdditionalCapitalSharesAllowableForForFutureIssuance_180d57ce-138c-49fa-b07f-1dbb3805f245" xlink:href="smmt-20211231.xsd#smmt_CommonStockAndRestrictedStockUnitsAdditionalCapitalSharesAllowableForForFutureIssuance"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_07e961e3-7bc8-4c3b-8c87-c335bea5c7b4" xlink:to="loc_smmt_CommonStockAndRestrictedStockUnitsAdditionalCapitalSharesAllowableForForFutureIssuance_180d57ce-138c-49fa-b07f-1dbb3805f245" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan_2a1d6189-99bd-4e6f-8b22-dea14221b290" xlink:href="smmt-20211231.xsd#smmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_07e961e3-7bc8-4c3b-8c87-c335bea5c7b4" xlink:to="loc_smmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan_2a1d6189-99bd-4e6f-8b22-dea14221b290" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_1056e672-ecc6-4103-892b-8fe0d44ee5d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_07e961e3-7bc8-4c3b-8c87-c335bea5c7b4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_1056e672-ecc6-4103-892b-8fe0d44ee5d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_0981a89d-dcc2-494a-b8d0-79ee087b1888" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_07e961e3-7bc8-4c3b-8c87-c335bea5c7b4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_0981a89d-dcc2-494a-b8d0-79ee087b1888" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_562b93a7-fd65-4023-a058-7059aec418a0" xlink:href="smmt-20211231.xsd#smmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_07e961e3-7bc8-4c3b-8c87-c335bea5c7b4" xlink:to="loc_smmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_562b93a7-fd65-4023-a058-7059aec418a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveOfferingPeriod_b587ec1f-b8e5-4cd0-9263-c8762eeb882f" xlink:href="smmt-20211231.xsd#smmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveOfferingPeriod"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_07e961e3-7bc8-4c3b-8c87-c335bea5c7b4" xlink:to="loc_smmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveOfferingPeriod_b587ec1f-b8e5-4cd0-9263-c8762eeb882f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_51c0d190-8861-4163-97eb-3cb48026b9d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_07e961e3-7bc8-4c3b-8c87-c335bea5c7b4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_51c0d190-8861-4163-97eb-3cb48026b9d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_3b1bf665-e134-459c-872e-877ef4fbf589" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_07e961e3-7bc8-4c3b-8c87-c335bea5c7b4" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_3b1bf665-e134-459c-872e-877ef4fbf589" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_2efabdcd-3f7f-4f79-97d6-91b8ac96cf4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_07e961e3-7bc8-4c3b-8c87-c335bea5c7b4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_2efabdcd-3f7f-4f79-97d6-91b8ac96cf4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_c4f8a202-4f25-4b6c-97fc-a02cf8def629" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_07e961e3-7bc8-4c3b-8c87-c335bea5c7b4" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_c4f8a202-4f25-4b6c-97fc-a02cf8def629" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_9ccb2c1b-687e-42b4-9113-7e129d09cb72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_07e961e3-7bc8-4c3b-8c87-c335bea5c7b4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_9ccb2c1b-687e-42b4-9113-7e129d09cb72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_1e4fa8e6-5c14-4abd-9551-2048ca6c3dcf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_07e961e3-7bc8-4c3b-8c87-c335bea5c7b4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_1e4fa8e6-5c14-4abd-9551-2048ca6c3dcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_1637090f-88ac-4d6e-9a01-b02e96f88157" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_07e961e3-7bc8-4c3b-8c87-c335bea5c7b4" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_1637090f-88ac-4d6e-9a01-b02e96f88157" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_8b431b62-9294-4d97-b70f-e5ee509f8327" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_07e961e3-7bc8-4c3b-8c87-c335bea5c7b4" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_8b431b62-9294-4d97-b70f-e5ee509f8327" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_0d602b75-8273-45d9-8fc9-1582a415c2d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_07e961e3-7bc8-4c3b-8c87-c335bea5c7b4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_0d602b75-8273-45d9-8fc9-1582a415c2d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected_95ad83f2-f590-4cf9-bc50-5b8309e1c368" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_07e961e3-7bc8-4c3b-8c87-c335bea5c7b4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected_95ad83f2-f590-4cf9-bc50-5b8309e1c368" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_6f61506b-a54f-4ec8-b456-b1e3732411d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_07e961e3-7bc8-4c3b-8c87-c335bea5c7b4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_6f61506b-a54f-4ec8-b456-b1e3732411d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_c4d24b02-ece2-46f5-9f4f-a78b4d3837d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_07e961e3-7bc8-4c3b-8c87-c335bea5c7b4" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_c4d24b02-ece2-46f5-9f4f-a78b4d3837d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_3b88ef33-a05c-46f2-85ad-5bcd4f35bc31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_07e961e3-7bc8-4c3b-8c87-c335bea5c7b4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_3b88ef33-a05c-46f2-85ad-5bcd4f35bc31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_f4935bfc-380b-424c-90db-04e5fd7038a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_07e961e3-7bc8-4c3b-8c87-c335bea5c7b4" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_f4935bfc-380b-424c-90db-04e5fd7038a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedOutstandingNumber_cbf67ed7-0845-4631-a3c1-27072d1721c4" xlink:href="smmt-20211231.xsd#smmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedOutstandingNumber"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_07e961e3-7bc8-4c3b-8c87-c335bea5c7b4" xlink:to="loc_smmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedOutstandingNumber_cbf67ed7-0845-4631-a3c1-27072d1721c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_ed881739-9384-410c-a14f-8766c3820eb4" xlink:href="smmt-20211231.xsd#smmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_07e961e3-7bc8-4c3b-8c87-c335bea5c7b4" xlink:to="loc_smmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_ed881739-9384-410c-a14f-8766c3820eb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_197f009a-63f7-4da0-90ff-d55ef5a70e66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_07e961e3-7bc8-4c3b-8c87-c335bea5c7b4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_197f009a-63f7-4da0-90ff-d55ef5a70e66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_a0c1885e-b33a-4194-b521-ddd10a883265" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_07e961e3-7bc8-4c3b-8c87-c335bea5c7b4" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_a0c1885e-b33a-4194-b521-ddd10a883265" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/StockBasedCompensationWeightedaverageassumptionsusedforstockoptionawardsDetails" xlink:type="simple" xlink:href="smmt-20211231.xsd#StockBasedCompensationWeightedaverageassumptionsusedforstockoptionawardsDetails"/>
  <link:presentationLink xlink:role="http://www.summitplc.com/role/StockBasedCompensationWeightedaverageassumptionsusedforstockoptionawardsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6d989707-ae68-4f96-aad5-41b78e0ea1d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1effb91d-36c7-4867-b16f-990d640ff219" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6d989707-ae68-4f96-aad5-41b78e0ea1d8" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1effb91d-36c7-4867-b16f-990d640ff219" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_620138ca-ba51-4d22-b2a9-b877c547b370" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1effb91d-36c7-4867-b16f-990d640ff219" xlink:to="loc_us-gaap_AwardTypeAxis_620138ca-ba51-4d22-b2a9-b877c547b370" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e4ec2a98-d3f7-4f9e-9cab-a680b56d1201" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_620138ca-ba51-4d22-b2a9-b877c547b370" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e4ec2a98-d3f7-4f9e-9cab-a680b56d1201" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_01bf89d8-e22d-49d7-8e3d-64be64a964fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e4ec2a98-d3f7-4f9e-9cab-a680b56d1201" xlink:to="loc_us-gaap_EmployeeStockOptionMember_01bf89d8-e22d-49d7-8e3d-64be64a964fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b4fae576-0f1b-4230-9c33-f2c05a55f86d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1effb91d-36c7-4867-b16f-990d640ff219" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b4fae576-0f1b-4230-9c33-f2c05a55f86d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_bc4b1625-bca1-433f-8301-a2b7315394ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b4fae576-0f1b-4230-9c33-f2c05a55f86d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_bc4b1625-bca1-433f-8301-a2b7315394ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_31d28dfd-6f5b-41bb-ab54-4df21e729528" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b4fae576-0f1b-4230-9c33-f2c05a55f86d" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_31d28dfd-6f5b-41bb-ab54-4df21e729528" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_e7b2b3da-7c3c-44ac-946f-a32c00d91675" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b4fae576-0f1b-4230-9c33-f2c05a55f86d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_e7b2b3da-7c3c-44ac-946f-a32c00d91675" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_8d1028ff-c6f5-45a5-afe9-cd8f072a1aa0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b4fae576-0f1b-4230-9c33-f2c05a55f86d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_8d1028ff-c6f5-45a5-afe9-cd8f072a1aa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/StockBasedCompensationStockoptionactivityDetails" xlink:type="simple" xlink:href="smmt-20211231.xsd#StockBasedCompensationStockoptionactivityDetails"/>
  <link:presentationLink xlink:role="http://www.summitplc.com/role/StockBasedCompensationStockoptionactivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d71166f4-c873-4f9a-a883-0de10c599e27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0cb1073a-301c-4079-86c6-d728e25b3239" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d71166f4-c873-4f9a-a883-0de10c599e27" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0cb1073a-301c-4079-86c6-d728e25b3239" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_e8282a1d-66a6-4459-a24d-a5742a7cd148" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0cb1073a-301c-4079-86c6-d728e25b3239" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_e8282a1d-66a6-4459-a24d-a5742a7cd148" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_403f3f6a-ec6a-490f-93c6-ed537f6aee70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0cb1073a-301c-4079-86c6-d728e25b3239" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_403f3f6a-ec6a-490f-93c6-ed537f6aee70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_3f821f0a-2e12-41a3-988e-6b657c6880c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0cb1073a-301c-4079-86c6-d728e25b3239" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_3f821f0a-2e12-41a3-988e-6b657c6880c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_02e5cd5d-f69f-4793-a027-89e2fb8d86a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0cb1073a-301c-4079-86c6-d728e25b3239" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_02e5cd5d-f69f-4793-a027-89e2fb8d86a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedNetLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_abc4f712-075d-4b4d-b622-8732d7cc2390" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0cb1073a-301c-4079-86c6-d728e25b3239" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_abc4f712-075d-4b4d-b622-8732d7cc2390" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_de4f5cc1-d45e-4d53-8680-f43815eabd1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d71166f4-c873-4f9a-a883-0de10c599e27" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_de4f5cc1-d45e-4d53-8680-f43815eabd1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_01ab9c28-273c-45fe-99ed-ca52ee2f2a61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_de4f5cc1-d45e-4d53-8680-f43815eabd1e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_01ab9c28-273c-45fe-99ed-ca52ee2f2a61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_62247059-dea5-4297-81f3-5fffc41a790d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_de4f5cc1-d45e-4d53-8680-f43815eabd1e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_62247059-dea5-4297-81f3-5fffc41a790d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_fc81897c-812b-4304-b568-2d342bf99423" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_de4f5cc1-d45e-4d53-8680-f43815eabd1e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_fc81897c-812b-4304-b568-2d342bf99423" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_db59dd8b-78d8-4eae-8da1-0461248f0d44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_de4f5cc1-d45e-4d53-8680-f43815eabd1e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_db59dd8b-78d8-4eae-8da1-0461248f0d44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_ea829e26-c2a7-432f-a90c-383021498852" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_de4f5cc1-d45e-4d53-8680-f43815eabd1e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_ea829e26-c2a7-432f-a90c-383021498852" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_9f187269-35e4-47bb-b599-28bc8e441ab8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d71166f4-c873-4f9a-a883-0de10c599e27" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_9f187269-35e4-47bb-b599-28bc8e441ab8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_aa11a856-4d66-4d7f-a9f7-749b75f205e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_9f187269-35e4-47bb-b599-28bc8e441ab8" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_aa11a856-4d66-4d7f-a9f7-749b75f205e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3e1a3b93-d430-4df8-a49b-7c2128732d52" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_9f187269-35e4-47bb-b599-28bc8e441ab8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3e1a3b93-d430-4df8-a49b-7c2128732d52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_e52b2b1a-9c71-4eb5-ac4e-788935eb7f14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_9f187269-35e4-47bb-b599-28bc8e441ab8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_e52b2b1a-9c71-4eb5-ac4e-788935eb7f14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_7fc30d2a-0e57-4074-a928-c931a834bc70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_9f187269-35e4-47bb-b599-28bc8e441ab8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_7fc30d2a-0e57-4074-a928-c931a834bc70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_737bcffb-1bb7-4dfe-bbcf-3182f96f8e0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_9f187269-35e4-47bb-b599-28bc8e441ab8" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_737bcffb-1bb7-4dfe-bbcf-3182f96f8e0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_b81fbc6d-115e-43a6-af8f-7c7917f60ba4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_9f187269-35e4-47bb-b599-28bc8e441ab8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_b81fbc6d-115e-43a6-af8f-7c7917f60ba4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_1ca5a620-4ba9-4feb-817c-e470c903d2a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_9f187269-35e4-47bb-b599-28bc8e441ab8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_1ca5a620-4ba9-4feb-817c-e470c903d2a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_0b13f0c1-105d-43ce-b969-74509a58c659" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_9f187269-35e4-47bb-b599-28bc8e441ab8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_0b13f0c1-105d-43ce-b969-74509a58c659" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_7b486446-ee7a-4530-9fed-e8be4d056d0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_9f187269-35e4-47bb-b599-28bc8e441ab8" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_7b486446-ee7a-4530-9fed-e8be4d056d0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_c488e46d-d008-4b21-b91f-3f853879313e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_9f187269-35e4-47bb-b599-28bc8e441ab8" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_c488e46d-d008-4b21-b91f-3f853879313e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/StockBasedCompensationRSUactivityDetails" xlink:type="simple" xlink:href="smmt-20211231.xsd#StockBasedCompensationRSUactivityDetails"/>
  <link:presentationLink xlink:role="http://www.summitplc.com/role/StockBasedCompensationRSUactivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_24496cb4-16d9-4773-b125-750d7818411f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_550701a7-2f96-4319-910a-327ed1bbddd4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_24496cb4-16d9-4773-b125-750d7818411f" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_550701a7-2f96-4319-910a-327ed1bbddd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_7261d68b-c545-41a1-a03f-3c42a1876a4c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_550701a7-2f96-4319-910a-327ed1bbddd4" xlink:to="loc_us-gaap_AwardTypeAxis_7261d68b-c545-41a1-a03f-3c42a1876a4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_41f0a547-68fb-4383-9e94-72238d8110ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_7261d68b-c545-41a1-a03f-3c42a1876a4c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_41f0a547-68fb-4383-9e94-72238d8110ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_ee54d227-035c-4dfb-8f92-4a091ca0640c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_41f0a547-68fb-4383-9e94-72238d8110ae" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_ee54d227-035c-4dfb-8f92-4a091ca0640c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c378b180-282e-4341-b37e-34332d62f3c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_550701a7-2f96-4319-910a-327ed1bbddd4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c378b180-282e-4341-b37e-34332d62f3c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b21fa1c9-2039-435e-88fd-bc54efa65fba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c378b180-282e-4341-b37e-34332d62f3c1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b21fa1c9-2039-435e-88fd-bc54efa65fba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_611b2226-6b1b-4386-b0a0-ed5079e28bb8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b21fa1c9-2039-435e-88fd-bc54efa65fba" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_611b2226-6b1b-4386-b0a0-ed5079e28bb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_024ede9b-ba46-454c-b807-95940cbe7f3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b21fa1c9-2039-435e-88fd-bc54efa65fba" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_024ede9b-ba46-454c-b807-95940cbe7f3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3010ebc1-935b-499a-9eff-4907caf7db43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b21fa1c9-2039-435e-88fd-bc54efa65fba" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3010ebc1-935b-499a-9eff-4907caf7db43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_adf6f765-cd61-461f-8d8e-5213e11e17b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c378b180-282e-4341-b37e-34332d62f3c1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_adf6f765-cd61-461f-8d8e-5213e11e17b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6d0038ab-d3e4-41ad-8078-704f1c6e2c61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_adf6f765-cd61-461f-8d8e-5213e11e17b4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6d0038ab-d3e4-41ad-8078-704f1c6e2c61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_14de5ea8-e65c-4099-af01-92515b74bb0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_adf6f765-cd61-461f-8d8e-5213e11e17b4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_14de5ea8-e65c-4099-af01-92515b74bb0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_bf860d17-1e49-421c-9c15-fd0059dc4dbb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_adf6f765-cd61-461f-8d8e-5213e11e17b4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_bf860d17-1e49-421c-9c15-fd0059dc4dbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/StockBasedCompensationSummaryofstockbasedcompensationexpenseDetails" xlink:type="simple" xlink:href="smmt-20211231.xsd#StockBasedCompensationSummaryofstockbasedcompensationexpenseDetails"/>
  <link:presentationLink xlink:role="http://www.summitplc.com/role/StockBasedCompensationSummaryofstockbasedcompensationexpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c2b88fd3-febc-448c-a226-2ff211d4b0e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_9c5d14f1-b803-430e-9d4c-69bb48fc9994" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c2b88fd3-febc-448c-a226-2ff211d4b0e4" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_9c5d14f1-b803-430e-9d4c-69bb48fc9994" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_42766e23-601d-46a9-a5db-cae9e823e6e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_9c5d14f1-b803-430e-9d4c-69bb48fc9994" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_42766e23-601d-46a9-a5db-cae9e823e6e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_a15588cd-7d86-4ab1-8ad9-2ee49915aab5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_42766e23-601d-46a9-a5db-cae9e823e6e3" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_a15588cd-7d86-4ab1-8ad9-2ee49915aab5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_d296e750-0100-4bfc-858b-9c0931ba6d98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_a15588cd-7d86-4ab1-8ad9-2ee49915aab5" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_d296e750-0100-4bfc-858b-9c0931ba6d98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_64e6354c-2146-4b0b-ae06-3a4876260287" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_a15588cd-7d86-4ab1-8ad9-2ee49915aab5" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_64e6354c-2146-4b0b-ae06-3a4876260287" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_8902b500-5bc5-4e98-8860-09e7a7f90b80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_9c5d14f1-b803-430e-9d4c-69bb48fc9994" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_8902b500-5bc5-4e98-8860-09e7a7f90b80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_18ae6917-777e-4202-9927-81e38b01794e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_8902b500-5bc5-4e98-8860-09e7a7f90b80" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_18ae6917-777e-4202-9927-81e38b01794e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/CommitmentsandContingenciesDetails" xlink:type="simple" xlink:href="smmt-20211231.xsd#CommitmentsandContingenciesDetails"/>
  <link:presentationLink xlink:role="http://www.summitplc.com/role/CommitmentsandContingenciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5174135f-c73c-44a9-ad2e-72913ee7019a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligation_47077cf4-b77a-44f7-b206-8f1b86aae03e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseObligation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5174135f-c73c-44a9-ad2e-72913ee7019a" xlink:to="loc_us-gaap_PurchaseObligation_47077cf4-b77a-44f7-b206-8f1b86aae03e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitment_0f32c06d-c696-42dd-b6a6-5442009ac110" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5174135f-c73c-44a9-ad2e-72913ee7019a" xlink:to="loc_us-gaap_OtherCommitment_0f32c06d-c696-42dd-b6a6-5442009ac110" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_OtherCommitmentPeriodForWhichTheMajorityOfCommitmentsAreToBePaid_8e86be42-7176-4045-9fb8-669518ae4edb" xlink:href="smmt-20211231.xsd#smmt_OtherCommitmentPeriodForWhichTheMajorityOfCommitmentsAreToBePaid"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5174135f-c73c-44a9-ad2e-72913ee7019a" xlink:to="loc_smmt_OtherCommitmentPeriodForWhichTheMajorityOfCommitmentsAreToBePaid_8e86be42-7176-4045-9fb8-669518ae4edb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/RelatedPartyTransactionsDetails" xlink:type="simple" xlink:href="smmt-20211231.xsd#RelatedPartyTransactionsDetails"/>
  <link:presentationLink xlink:role="http://www.summitplc.com/role/RelatedPartyTransactionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_b9a17bde-1a51-45f9-8309-0d18b79f9c02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_732a1398-5ec3-4b9e-b0f4-ad98085ddf89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_b9a17bde-1a51-45f9-8309-0d18b79f9c02" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_732a1398-5ec3-4b9e-b0f4-ad98085ddf89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_34c3bfc5-a231-4f53-ac3a-8442cf736dd3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_732a1398-5ec3-4b9e-b0f4-ad98085ddf89" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_34c3bfc5-a231-4f53-ac3a-8442cf736dd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7903c1f4-6613-4df9-9b03-bfb297f55baa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_34c3bfc5-a231-4f53-ac3a-8442cf736dd3" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7903c1f4-6613-4df9-9b03-bfb297f55baa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_ca0983a0-b953-4537-af7e-22a94ac41472" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrivatePlacementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7903c1f4-6613-4df9-9b03-bfb297f55baa" xlink:to="loc_us-gaap_PrivatePlacementMember_ca0983a0-b953-4537-af7e-22a94ac41472" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_RightsOfferingMember_99954662-568d-46c3-9faa-501d88a4f408" xlink:href="smmt-20211231.xsd#smmt_RightsOfferingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7903c1f4-6613-4df9-9b03-bfb297f55baa" xlink:to="loc_smmt_RightsOfferingMember_99954662-568d-46c3-9faa-501d88a4f408" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_01387f60-2a47-43aa-bf5f-658acf1f879c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_732a1398-5ec3-4b9e-b0f4-ad98085ddf89" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_01387f60-2a47-43aa-bf5f-658acf1f879c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_2b44be5b-6b20-40c3-8f6e-e0eb9a6797c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_01387f60-2a47-43aa-bf5f-658acf1f879c" xlink:to="loc_us-gaap_RelatedPartyDomain_2b44be5b-6b20-40c3-8f6e-e0eb9a6797c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ChiefExecutiveOfficerMember_a9785bb4-be56-4e58-95b5-20d2ae34a557" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ChiefExecutiveOfficerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_2b44be5b-6b20-40c3-8f6e-e0eb9a6797c6" xlink:to="loc_srt_ChiefExecutiveOfficerMember_a9785bb4-be56-4e58-95b5-20d2ae34a557" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_FormerChiefExecutiveOfficerMember_f4335f13-f3d1-4deb-b8ee-0f7653d01d61" xlink:href="smmt-20211231.xsd#smmt_FormerChiefExecutiveOfficerMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_2b44be5b-6b20-40c3-8f6e-e0eb9a6797c6" xlink:to="loc_smmt_FormerChiefExecutiveOfficerMember_f4335f13-f3d1-4deb-b8ee-0f7653d01d61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BeneficialOwnerMember_0706eccb-be81-460c-8104-9ac8ad61f0f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BeneficialOwnerMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_2b44be5b-6b20-40c3-8f6e-e0eb9a6797c6" xlink:to="loc_us-gaap_BeneficialOwnerMember_0706eccb-be81-460c-8104-9ac8ad61f0f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_102dd46b-7e23-4689-b702-f181c6947e85" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_AffiliatedEntityMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_2b44be5b-6b20-40c3-8f6e-e0eb9a6797c6" xlink:to="loc_srt_AffiliatedEntityMember_102dd46b-7e23-4689-b702-f181c6947e85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_c03e7ad7-123e-4f10-99e2-0b4a513decf4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_DirectorMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_2b44be5b-6b20-40c3-8f6e-e0eb9a6797c6" xlink:to="loc_srt_DirectorMember_c03e7ad7-123e-4f10-99e2-0b4a513decf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ChiefOperatingOfficerMember_bf799675-5ae7-42fd-9d67-5dbee62802f8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ChiefOperatingOfficerMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_2b44be5b-6b20-40c3-8f6e-e0eb9a6797c6" xlink:to="loc_srt_ChiefOperatingOfficerMember_bf799675-5ae7-42fd-9d67-5dbee62802f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_91aea077-772b-43b2-a042-a14a4de40b3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_732a1398-5ec3-4b9e-b0f4-ad98085ddf89" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_91aea077-772b-43b2-a042-a14a4de40b3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_e4c0ed1b-aa12-453b-801e-27b2f1e3de46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_91aea077-772b-43b2-a042-a14a4de40b3d" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_e4c0ed1b-aa12-453b-801e-27b2f1e3de46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_ConsultingAgreementMember_a0aea3e9-1c7e-4377-8a74-319f90643782" xlink:href="smmt-20211231.xsd#smmt_ConsultingAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_e4c0ed1b-aa12-453b-801e-27b2f1e3de46" xlink:to="loc_smmt_ConsultingAgreementMember_a0aea3e9-1c7e-4377-8a74-319f90643782" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_ConsultingAgreementConsultancyFeesMember_127e709c-c59f-480e-8fab-b0263727f6d3" xlink:href="smmt-20211231.xsd#smmt_ConsultingAgreementConsultancyFeesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_smmt_ConsultingAgreementMember_a0aea3e9-1c7e-4377-8a74-319f90643782" xlink:to="loc_smmt_ConsultingAgreementConsultancyFeesMember_127e709c-c59f-480e-8fab-b0263727f6d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_ConsultancyAgreementWarrantVestingExpenseMember_dd4ac51b-8a80-42f9-96f5-004e6285c1fa" xlink:href="smmt-20211231.xsd#smmt_ConsultancyAgreementWarrantVestingExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_smmt_ConsultingAgreementMember_a0aea3e9-1c7e-4377-8a74-319f90643782" xlink:to="loc_smmt_ConsultancyAgreementWarrantVestingExpenseMember_dd4ac51b-8a80-42f9-96f5-004e6285c1fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_AssignmentAgreementMember_7c0fc460-be2c-45f2-a0c3-79d4e2d3d706" xlink:href="smmt-20211231.xsd#smmt_AssignmentAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_e4c0ed1b-aa12-453b-801e-27b2f1e3de46" xlink:to="loc_smmt_AssignmentAgreementMember_7c0fc460-be2c-45f2-a0c3-79d4e2d3d706" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_InitialPurchaseAgreementMember_1ca5737f-e287-49b8-9690-e878f76beee4" xlink:href="smmt-20211231.xsd#smmt_InitialPurchaseAgreementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_e4c0ed1b-aa12-453b-801e-27b2f1e3de46" xlink:to="loc_smmt_InitialPurchaseAgreementMember_1ca5737f-e287-49b8-9690-e878f76beee4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_SecondPurchaseAgreementMember_ff77e39d-1341-4328-b3f7-75cdc0d9f1be" xlink:href="smmt-20211231.xsd#smmt_SecondPurchaseAgreementMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_e4c0ed1b-aa12-453b-801e-27b2f1e3de46" xlink:to="loc_smmt_SecondPurchaseAgreementMember_ff77e39d-1341-4328-b3f7-75cdc0d9f1be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_32fe9279-04d0-4158-94af-5508af4f9138" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_732a1398-5ec3-4b9e-b0f4-ad98085ddf89" xlink:to="loc_us-gaap_VariableRateAxis_32fe9279-04d0-4158-94af-5508af4f9138" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_509bb3d3-d0e1-4df6-94e8-1d3ef232a2ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_32fe9279-04d0-4158-94af-5508af4f9138" xlink:to="loc_us-gaap_VariableRateDomain_509bb3d3-d0e1-4df6-94e8-1d3ef232a2ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UsTreasuryUstInterestRateMember_7ecf80f3-c1f1-49bc-b3e6-2c67c30a3b3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UsTreasuryUstInterestRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_509bb3d3-d0e1-4df6-94e8-1d3ef232a2ce" xlink:to="loc_us-gaap_UsTreasuryUstInterestRateMember_7ecf80f3-c1f1-49bc-b3e6-2c67c30a3b3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_02ad80a7-b2ab-4c46-96d1-ac96e2c1da86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_732a1398-5ec3-4b9e-b0f4-ad98085ddf89" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_02ad80a7-b2ab-4c46-96d1-ac96e2c1da86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_1d356b41-ca5d-455c-b535-75df74d2793c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_02ad80a7-b2ab-4c46-96d1-ac96e2c1da86" xlink:to="loc_us-gaap_EquityComponentDomain_1d356b41-ca5d-455c-b535-75df74d2793c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_7792200d-cfb9-47cc-ab9a-6af81c6a9a72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1d356b41-ca5d-455c-b535-75df74d2793c" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_7792200d-cfb9-47cc-ab9a-6af81c6a9a72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_17361ca9-a9ae-4e49-b603-f7e6f6f338e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_732a1398-5ec3-4b9e-b0f4-ad98085ddf89" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_17361ca9-a9ae-4e49-b603-f7e6f6f338e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_c2d9743c-ba29-420a-9b0b-23fb24782101" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_17361ca9-a9ae-4e49-b603-f7e6f6f338e4" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_c2d9743c-ba29-420a-9b0b-23fb24782101" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_a3385a4a-667a-44cf-9e63-6dbf6634ad9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_17361ca9-a9ae-4e49-b603-f7e6f6f338e4" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_a3385a4a-667a-44cf-9e63-6dbf6634ad9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_87c94785-3d07-40b4-abd8-a3f266c3a8d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_17361ca9-a9ae-4e49-b603-f7e6f6f338e4" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_87c94785-3d07-40b4-abd8-a3f266c3a8d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesSubscribedButUnissued_070cdc13-ac33-496b-b501-12f4dea72e48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesSubscribedButUnissued"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_17361ca9-a9ae-4e49-b603-f7e6f6f338e4" xlink:to="loc_us-gaap_CommonStockSharesSubscribedButUnissued_070cdc13-ac33-496b-b501-12f4dea72e48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_9416264c-1316-438b-ba2c-28cee48d64fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_17361ca9-a9ae-4e49-b603-f7e6f6f338e4" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_9416264c-1316-438b-ba2c-28cee48d64fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_54748d10-55ee-4fa9-b906-4ceed216ea26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_17361ca9-a9ae-4e49-b603-f7e6f6f338e4" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_54748d10-55ee-4fa9-b906-4ceed216ea26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_RelatedPartyTransactionMonthlyExpensesFromTransactionsWithRelatedParty_188d81ab-a320-4ab7-80a9-0003d3ac0dec" xlink:href="smmt-20211231.xsd#smmt_RelatedPartyTransactionMonthlyExpensesFromTransactionsWithRelatedParty"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_17361ca9-a9ae-4e49-b603-f7e6f6f338e4" xlink:to="loc_smmt_RelatedPartyTransactionMonthlyExpensesFromTransactionsWithRelatedParty_188d81ab-a320-4ab7-80a9-0003d3ac0dec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_ClassOfWarrantOrRightQuarterlyVestingPeriod_d7a3e900-3b67-4933-928c-66e5cb3554ee" xlink:href="smmt-20211231.xsd#smmt_ClassOfWarrantOrRightQuarterlyVestingPeriod"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_17361ca9-a9ae-4e49-b603-f7e6f6f338e4" xlink:to="loc_smmt_ClassOfWarrantOrRightQuarterlyVestingPeriod_d7a3e900-3b67-4933-928c-66e5cb3554ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_bf2644b6-b596-41fb-8c8f-463b1de99681" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_17361ca9-a9ae-4e49-b603-f7e6f6f338e4" xlink:to="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_bf2644b6-b596-41fb-8c8f-463b1de99681" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_ClassOfWarrantOrRightVested_98b05499-e57b-442f-9f37-57ef2a693f17" xlink:href="smmt-20211231.xsd#smmt_ClassOfWarrantOrRightVested"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_17361ca9-a9ae-4e49-b603-f7e6f6f338e4" xlink:to="loc_smmt_ClassOfWarrantOrRightVested_98b05499-e57b-442f-9f37-57ef2a693f17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRelatedPartyDebt_3e5fb594-1906-4ca0-b7c8-ba7b5a2898b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromRelatedPartyDebt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_17361ca9-a9ae-4e49-b603-f7e6f6f338e4" xlink:to="loc_us-gaap_ProceedsFromRelatedPartyDebt_3e5fb594-1906-4ca0-b7c8-ba7b5a2898b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent_f9bbf4a5-cbb0-45de-896e-75c04d0e1cee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_17361ca9-a9ae-4e49-b603-f7e6f6f338e4" xlink:to="loc_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent_f9bbf4a5-cbb0-45de-896e-75c04d0e1cee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_RelatedPartyTransactionRateBasisSpreadOnVariableRate_106374fb-bc62-44d6-bcee-6df3f37ca736" xlink:href="smmt-20211231.xsd#smmt_RelatedPartyTransactionRateBasisSpreadOnVariableRate"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_17361ca9-a9ae-4e49-b603-f7e6f6f338e4" xlink:to="loc_smmt_RelatedPartyTransactionRateBasisSpreadOnVariableRate_106374fb-bc62-44d6-bcee-6df3f37ca736" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_RelatedPartyTransactionExpectedRate_005df35b-358e-485f-9081-a7634834c718" xlink:href="smmt-20211231.xsd#smmt_RelatedPartyTransactionExpectedRate"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_17361ca9-a9ae-4e49-b603-f7e6f6f338e4" xlink:to="loc_smmt_RelatedPartyTransactionExpectedRate_005df35b-358e-485f-9081-a7634834c718" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_NotesPayableRelatedPartiesMaturityTriggeringEventPublicOfferingProceedsThreshold_75e26553-19e8-47cf-8cf3-907b18f1a3ec" xlink:href="smmt-20211231.xsd#smmt_NotesPayableRelatedPartiesMaturityTriggeringEventPublicOfferingProceedsThreshold"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_17361ca9-a9ae-4e49-b603-f7e6f6f338e4" xlink:to="loc_smmt_NotesPayableRelatedPartiesMaturityTriggeringEventPublicOfferingProceedsThreshold_75e26553-19e8-47cf-8cf3-907b18f1a3ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_NotesPayableRelatedPartiesMaximumTerm_cf98edd8-6200-44e8-a647-a13998ce46d4" xlink:href="smmt-20211231.xsd#smmt_NotesPayableRelatedPartiesMaximumTerm"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_17361ca9-a9ae-4e49-b603-f7e6f6f338e4" xlink:to="loc_smmt_NotesPayableRelatedPartiesMaximumTerm_cf98edd8-6200-44e8-a647-a13998ce46d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_AdjustmentsToAdditionalPaidInCapitalImputedInterestExpenseRelatedParty_eb84b7bd-a2a0-48ef-be06-670e003a0ee8" xlink:href="smmt-20211231.xsd#smmt_AdjustmentsToAdditionalPaidInCapitalImputedInterestExpenseRelatedParty"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_17361ca9-a9ae-4e49-b603-f7e6f6f338e4" xlink:to="loc_smmt_AdjustmentsToAdditionalPaidInCapitalImputedInterestExpenseRelatedParty_eb84b7bd-a2a0-48ef-be06-670e003a0ee8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_AreaOfPremisesSubleased_4f70e848-3757-4bc3-8b6a-101bb45fcc4a" xlink:href="smmt-20211231.xsd#smmt_AreaOfPremisesSubleased"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_17361ca9-a9ae-4e49-b603-f7e6f6f338e4" xlink:to="loc_smmt_AreaOfPremisesSubleased_4f70e848-3757-4bc3-8b6a-101bb45fcc4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_RelatedPartyTransactionPaymentsToRelatedParty_333412a3-c06b-43bd-98d3-4678b8327654" xlink:href="smmt-20211231.xsd#smmt_RelatedPartyTransactionPaymentsToRelatedParty"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_17361ca9-a9ae-4e49-b603-f7e6f6f338e4" xlink:to="loc_smmt_RelatedPartyTransactionPaymentsToRelatedParty_333412a3-c06b-43bd-98d3-4678b8327654" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/SubsequentEventDetails" xlink:type="simple" xlink:href="smmt-20211231.xsd#SubsequentEventDetails"/>
  <link:presentationLink xlink:role="http://www.summitplc.com/role/SubsequentEventDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_db794362-1128-425a-a4c7-538a7583b74e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_2a5b3dca-1257-4414-bac9-b484f16b1be2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_db794362-1128-425a-a4c7-538a7583b74e" xlink:to="loc_us-gaap_SubsequentEventTable_2a5b3dca-1257-4414-bac9-b484f16b1be2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_f7dca983-70f2-4da4-8d2a-728ae933d919" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_2a5b3dca-1257-4414-bac9-b484f16b1be2" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_f7dca983-70f2-4da4-8d2a-728ae933d919" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_a6f146bb-4a2a-4500-86d5-7ec88e971fc3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_f7dca983-70f2-4da4-8d2a-728ae933d919" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_a6f146bb-4a2a-4500-86d5-7ec88e971fc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_c9242a59-e2ec-47e1-840c-acd29e25d003" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_a6f146bb-4a2a-4500-86d5-7ec88e971fc3" xlink:to="loc_us-gaap_SubsequentEventMember_c9242a59-e2ec-47e1-840c-acd29e25d003" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_ff4bec4b-4c4a-416a-b97f-a87a60ab0cbd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_2a5b3dca-1257-4414-bac9-b484f16b1be2" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_ff4bec4b-4c4a-416a-b97f-a87a60ab0cbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_76f232a9-1cda-4f78-ba56-c7941367f73f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_ff4bec4b-4c4a-416a-b97f-a87a60ab0cbd" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_76f232a9-1cda-4f78-ba56-c7941367f73f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_A2022NoteMember_47c3b068-82d2-4b5b-8818-a619707cd8da" xlink:href="smmt-20211231.xsd#smmt_A2022NoteMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_76f232a9-1cda-4f78-ba56-c7941367f73f" xlink:to="loc_smmt_A2022NoteMember_47c3b068-82d2-4b5b-8818-a619707cd8da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_31e15617-bf6b-4eaf-b849-882cd3e5b827" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_2a5b3dca-1257-4414-bac9-b484f16b1be2" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_31e15617-bf6b-4eaf-b849-882cd3e5b827" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_f091a2cf-09ec-46ab-9ef1-1a2741897f08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_31e15617-bf6b-4eaf-b849-882cd3e5b827" xlink:to="loc_us-gaap_RelatedPartyDomain_f091a2cf-09ec-46ab-9ef1-1a2741897f08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ChiefExecutiveOfficerMember_121942b6-fbbb-41f6-9b3a-562a0c3f02bf" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ChiefExecutiveOfficerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_f091a2cf-09ec-46ab-9ef1-1a2741897f08" xlink:to="loc_srt_ChiefExecutiveOfficerMember_121942b6-fbbb-41f6-9b3a-562a0c3f02bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_5019fb33-54b1-42c1-8589-c7ea7d128cd9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_2a5b3dca-1257-4414-bac9-b484f16b1be2" xlink:to="loc_us-gaap_SubsequentEventLineItems_5019fb33-54b1-42c1-8589-c7ea7d128cd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRelatedPartyDebt_72f4d9df-bdcb-448d-877d-36852ecb91d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromRelatedPartyDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_5019fb33-54b1-42c1-8589-c7ea7d128cd9" xlink:to="loc_us-gaap_ProceedsFromRelatedPartyDebt_72f4d9df-bdcb-448d-877d-36852ecb91d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent_73b248c1-4a75-40aa-8c0f-241b7a92d9de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_5019fb33-54b1-42c1-8589-c7ea7d128cd9" xlink:to="loc_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent_73b248c1-4a75-40aa-8c0f-241b7a92d9de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionRate_9498739b-2ae6-4808-92db-7424b5ff61d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_5019fb33-54b1-42c1-8589-c7ea7d128cd9" xlink:to="loc_us-gaap_RelatedPartyTransactionRate_9498739b-2ae6-4808-92db-7424b5ff61d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_NotesPayableRelatedPartiesMaturityTriggeringEventPublicOfferingProceedsThreshold_e0ba6657-b48b-4b02-a857-70d0cc4a0646" xlink:href="smmt-20211231.xsd#smmt_NotesPayableRelatedPartiesMaturityTriggeringEventPublicOfferingProceedsThreshold"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_5019fb33-54b1-42c1-8589-c7ea7d128cd9" xlink:to="loc_smmt_NotesPayableRelatedPartiesMaturityTriggeringEventPublicOfferingProceedsThreshold_e0ba6657-b48b-4b02-a857-70d0cc4a0646" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_NotesPayableRelatedPartiesMaximumTerm_22d9d6ab-7a29-4352-a90a-bccb5838b298" xlink:href="smmt-20211231.xsd#smmt_NotesPayableRelatedPartiesMaximumTerm"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_5019fb33-54b1-42c1-8589-c7ea7d128cd9" xlink:to="loc_smmt_NotesPayableRelatedPartiesMaximumTerm_22d9d6ab-7a29-4352-a90a-bccb5838b298" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140707893492256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Mar. 10, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K/A<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36866<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Summit Therapeutics Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">37-1979717<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">One Broadway, 14th Floor<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Cambridge,<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">514-7149<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.01 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">SMMT<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 186.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98,122,356<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text">Portions of the registrant&#8217;s definitive Proxy Statement to be filed with the Securities and Exchange Commission within 120 days after registrant&#8217;s fiscal year ended December 31, 2021 are incorporated by reference into Part III of this report.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001599298<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140707893264192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_AuditInformationAbstract', window );"><strong>Audit Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">238<span></span>
</td>
<td class="text">876<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">PricewaterhouseCoopers LLP<span></span>
</td>
<td class="text">PricewaterhouseCoopers LLP<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Boston, Massachusetts<span></span>
</td>
<td class="text">Reading, United Kingdom<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_AuditInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Audit Information [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_AuditInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140707892656144">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="nump">$ 71,791<span></span>
</td>
<td class="nump">$ 66,417<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">1,464<span></span>
</td>
<td class="nump">331<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">7,161<span></span>
</td>
<td class="nump">9,547<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">1,201<span></span>
</td>
<td class="nump">1,523<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_ResearchAndDevelopmentTaxCreditReceivableCurrent', window );">Research and development tax credit receivable</a></td>
<td class="nump">15,695<span></span>
</td>
<td class="nump">9,856<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">97,312<span></span>
</td>
<td class="nump">87,674<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>Non-current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">694<span></span>
</td>
<td class="nump">725<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="nump">2,790<span></span>
</td>
<td class="nump">554<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">2,009<span></span>
</td>
<td class="nump">2,030<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net</a></td>
<td class="nump">10,399<span></span>
</td>
<td class="nump">11,515<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">170<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">113,374<span></span>
</td>
<td class="nump">102,498<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">4,374<span></span>
</td>
<td class="nump">6,140<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">7,197<span></span>
</td>
<td class="nump">3,278<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation</a></td>
<td class="nump">4,125<span></span>
</td>
<td class="nump">983<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease liabilities</a></td>
<td class="nump">1,091<span></span>
</td>
<td class="nump">390<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue and other income</a></td>
<td class="nump">7,939<span></span>
</td>
<td class="nump">8,370<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">897<span></span>
</td>
<td class="nump">729<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">25,623<span></span>
</td>
<td class="nump">19,890<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Non-current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liabilities, net of current portion</a></td>
<td class="nump">1,691<span></span>
</td>
<td class="nump">75<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue and other income, net of current portion</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">569<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other non-current liabilities</a></td>
<td class="nump">2,776<span></span>
</td>
<td class="nump">2,511<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">30,090<span></span>
</td>
<td class="nump">23,045<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 19)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.01 par value: 250,000,000 shares authorized; 98,039,540 and 82,575,064 shares issued and outstanding at December 31, 2021 and 2020, respectively</a></td>
<td class="nump">980<span></span>
</td>
<td class="nump">826<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">384,049<span></span>
</td>
<td class="nump">293,367<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(2,197)<span></span>
</td>
<td class="num">(3,794)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(299,548)<span></span>
</td>
<td class="num">(210,946)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">83,284<span></span>
</td>
<td class="nump">79,453<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 113,374<span></span>
</td>
<td class="nump">$ 102,498<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_ResearchAndDevelopmentTaxCreditReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research And Development Tax Credit Receivable, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_ResearchAndDevelopmentTaxCreditReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631418-115840<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631419-115840<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6787-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123349782&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140707893411424">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock par value (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">250,000,000<span></span>
</td>
<td class="nump">250,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">98,039,540<span></span>
</td>
<td class="nump">82,575,064<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">98,039,540<span></span>
</td>
<td class="nump">82,575,064<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140707893621136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_IncomeStatementAndStatementOfComprehensiveIncomeAbstract', window );"><strong>Income Statement And Statement Of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 1,809<span></span>
</td>
<td class="nump">$ 860<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">85,352<span></span>
</td>
<td class="nump">53,274<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">23,611<span></span>
</td>
<td class="nump">19,232<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Impairment of intangible assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">859<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">108,963<span></span>
</td>
<td class="nump">73,365<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOperatingIncome', window );">Other operating income</a></td>
<td class="nump">20,968<span></span>
</td>
<td class="nump">19,312<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(86,186)<span></span>
</td>
<td class="num">(53,193)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other (expense) income, net</a></td>
<td class="num">(2,416)<span></span>
</td>
<td class="nump">283<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income tax</a></td>
<td class="num">(88,602)<span></span>
</td>
<td class="num">(52,910)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">213<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (88,602)<span></span>
</td>
<td class="num">$ (52,697)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract', window );"><strong>Net loss per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in dollars per share)</a></td>
<td class="num">$ (0.96)<span></span>
</td>
<td class="num">$ (0.76)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in dollars per share)</a></td>
<td class="num">$ (0.96)<span></span>
</td>
<td class="num">$ (0.76)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract', window );"><strong>Weighted average common shares outstanding:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
<td class="nump">92,239,306<span></span>
</td>
<td class="nump">69,524,148<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in shares)</a></td>
<td class="nump">92,239,306<span></span>
</td>
<td class="nump">69,524,148<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive (loss) income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustments</a></td>
<td class="nump">$ 1,597<span></span>
</td>
<td class="nump">$ 970<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (87,005)<span></span>
</td>
<td class="num">$ (51,727)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_IncomeStatementAndStatementOfComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income Statement And Statement Of Comprehensive Income</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_IncomeStatementAndStatementOfComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569643-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of other operating income, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140707892531296">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Loss</div></th>
<th class="th"><div>Total Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67,178,054<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2019</a></td>
<td class="nump">$ 78,863<span></span>
</td>
<td class="nump">$ 672<span></span>
</td>
<td class="nump">$ 241,204<span></span>
</td>
<td class="num">$ (4,764)<span></span>
</td>
<td class="num">$ (158,249)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Private placement/Rights offering of common stock, net of offering costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,970,060<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Private placement/Rights offering of common stock, net of offering costs</a></td>
<td class="nump">49,952<span></span>
</td>
<td class="nump">$ 150<span></span>
</td>
<td class="nump">49,802<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_FractionalStockIssuedDuringPeriodSharesReverseStockSplit', window );">Fractional shares issued from reverse stock split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance on common stock from exercise of share options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">426,947<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance on common stock from exercise of share options</a></td>
<td class="nump">599<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">595<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">1,766<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,766<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustment</a></td>
<td class="nump">970<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">970<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (52,697)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(52,697)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2020</a></td>
<td class="nump">82,575,064<span></span>
</td>
<td class="nump">82,575,064<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2020</a></td>
<td class="nump">$ 79,453<span></span>
</td>
<td class="nump">$ 826<span></span>
</td>
<td class="nump">293,367<span></span>
</td>
<td class="num">(3,794)<span></span>
</td>
<td class="num">(210,946)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Private placement/Rights offering of common stock, net of offering costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,312,976<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Private placement/Rights offering of common stock, net of offering costs</a></td>
<td class="nump">$ 74,841<span></span>
</td>
<td class="nump">$ 143<span></span>
</td>
<td class="nump">74,698<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance on common stock from exercise of share options (in shares)</a></td>
<td class="nump">1,124,577<span></span>
</td>
<td class="nump">1,151,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance on common stock from exercise of share options</a></td>
<td class="nump">$ 3,088<span></span>
</td>
<td class="nump">$ 11<span></span>
</td>
<td class="nump">3,077<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">12,804<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,804<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_AdjustmentsToAdditionalPaidInCapitalImputedInterestExpenseRelatedParty', window );">Imputed interest expense on promissory note payable to a related party</a></td>
<td class="nump">103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustment</a></td>
<td class="nump">1,597<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,597<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (88,602)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(88,602)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2021</a></td>
<td class="nump">98,039,540<span></span>
</td>
<td class="nump">98,039,540<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2021</a></td>
<td class="nump">$ 83,284<span></span>
</td>
<td class="nump">$ 980<span></span>
</td>
<td class="nump">$ 384,049<span></span>
</td>
<td class="num">$ (2,197)<span></span>
</td>
<td class="num">$ (299,548)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_AdjustmentsToAdditionalPaidInCapitalImputedInterestExpenseRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments to Additional Paid in Capital, Imputed Interest Expense, Related Party</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_AdjustmentsToAdditionalPaidInCapitalImputedInterestExpenseRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_FractionalStockIssuedDuringPeriodSharesReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fractional Stock Issued During Period, Shares, Reverse Stock Split</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_FractionalStockIssuedDuringPeriodSharesReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123468992&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569643-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140707895072976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity (Deficit) (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement of Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Offering cots</a></td>
<td class="nump">$ 159<span></span>
</td>
<td class="nump">$ 48<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140707892545776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (88,602)<span></span>
</td>
<td class="num">$ (52,697)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_GainLossOnRemeasurementOfLiabilitiesOperatingAndNonoperating', window );">Gain on remeasurement of liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(480)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Gain on recognition of contingent consideration payable</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(102)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_InterestExpenseIncomeNoncash', window );">Non-cash interest expense</a></td>
<td class="nump">196<span></span>
</td>
<td class="nump">255<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized', window );">Unrealized foreign exchange loss (gain)</a></td>
<td class="nump">326<span></span>
</td>
<td class="num">(278)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Amortization of operating right-of-use assets</a></td>
<td class="nump">1,108<span></span>
</td>
<td class="nump">451<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">330<span></span>
</td>
<td class="nump">302<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">1,017<span></span>
</td>
<td class="nump">1,250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Impairment of intangible assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">859<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">12,804<span></span>
</td>
<td class="nump">1,766<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other adjustments</a></td>
<td class="nump">301<span></span>
</td>
<td class="num">(56)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(1,138)<span></span>
</td>
<td class="nump">212<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses</a></td>
<td class="nump">2,345<span></span>
</td>
<td class="num">(447)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other current and long-term assets</a></td>
<td class="nump">104<span></span>
</td>
<td class="num">(24)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_IncreaseDecreaseInResearchAndDevelopmentTaxCreditReceivable', window );">Research and development tax credit receivable</a></td>
<td class="num">(6,015)<span></span>
</td>
<td class="num">(4,381)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue and other income</a></td>
<td class="num">(813)<span></span>
</td>
<td class="nump">5,372<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(1,711)<span></span>
</td>
<td class="nump">1,642<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_IncreaseDecreaseInAccruedLiabilitiesAndEmployeeRelatedLiabilities', window );">Accrued liabilities and accrued compensation</a></td>
<td class="nump">8,229<span></span>
</td>
<td class="num">(1,296)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="num">(1,068)<span></span>
</td>
<td class="num">(459)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(72,587)<span></span>
</td>
<td class="num">(48,111)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows used in investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(306)<span></span>
</td>
<td class="num">(421)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(306)<span></span>
</td>
<td class="num">(421)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows provided by financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the issuance of common stock</a></td>
<td class="nump">75,000<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Transaction costs from the issuance of common stock</a></td>
<td class="num">(118)<span></span>
</td>
<td class="num">(48)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromRelatedPartyDebt', window );">Proceeds from related party promissory notes</a></td>
<td class="nump">110,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfRelatedPartyDebt', window );">Re-payment of related party promissory notes</a></td>
<td class="num">(110,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Payments of related party promissory notes issuance costs</a></td>
<td class="num">(54)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of share options</a></td>
<td class="nump">3,088<span></span>
</td>
<td class="nump">599<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">77,916<span></span>
</td>
<td class="nump">50,551<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rates on cash</a></td>
<td class="nump">351<span></span>
</td>
<td class="nump">556<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Increase in cash</a></td>
<td class="nump">5,374<span></span>
</td>
<td class="nump">2,575<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash at beginning of period</a></td>
<td class="nump">66,417<span></span>
</td>
<td class="nump">63,842<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash at end of period</a></td>
<td class="nump">71,791<span></span>
</td>
<td class="nump">66,417<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental Disclosure of Cash Flow Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest on related party promissory note</a></td>
<td class="nump">85<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Cash paid (received) for income taxes</a></td>
<td class="nump">7<span></span>
</td>
<td class="num">(70)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_StockIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction', window );">Transaction costs included in accrued expenses</a></td>
<td class="nump">41<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Leased assets obtained in exchange for operating lease liabilities</a></td>
<td class="nump">$ 3,389<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_GainLossOnRemeasurementOfLiabilitiesOperatingAndNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain (Loss) On Remeasurement Of Liabilities, Operating And Nonoperating</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_GainLossOnRemeasurementOfLiabilitiesOperatingAndNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_IncreaseDecreaseInAccruedLiabilitiesAndEmployeeRelatedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) in Accrued Liabilities and Employee-related Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_IncreaseDecreaseInAccruedLiabilitiesAndEmployeeRelatedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_IncreaseDecreaseInResearchAndDevelopmentTaxCreditReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Research And Development Tax Credit Receivable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_IncreaseDecreaseInResearchAndDevelopmentTaxCreditReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_InterestExpenseIncomeNoncash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest Expense (Income), Noncash</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_InterestExpenseIncomeNoncash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_StockIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issuance Costs Incurred During Noncash or Partial Noncash Transaction</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_StockIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124440516&amp;loc=d3e30840-110895<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=125521441&amp;loc=d3e30690-110894<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossUnrealized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123371682&amp;loc=d3e55415-109406<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140707979546144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Business and Operations and Recent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Nature of Business and Operations and Recent Events</a></td>
<td class="text">Nature of Business and Operations and Recent Events<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Nature of Business and Operations</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company is a biopharmaceutical company focused on the discovery, development, and commercialization of patient-, physician-, caregiver- and societal-friendly medicinal therapies intended to improve quality of life, increase life expectancy, and resolve serious unmet needs. The Company's novel mechanism pipeline of product candidates is designed with the goal to become the patient-friendly, new-era standard-of-care medicines, and to work in harmony with the human microbiome. Currently, the Company's lead product candidate, ridinilazole, is a novel first-in-class drug that is engaged in a global Phase III clinical trial program. On December 20, 2021, the Company announced topline results for the Phase III Ri-CoDIFy study evaluating ridinilazole for treating patients suffering from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Clostridioides difficile </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">infection, also known as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">C. difficile </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">infection, or CDI. The Company's second product candidate, SMT-738, was announced in May 2021 for combating multidrug resistant infections, specifically Carbapenem-resistant Enterobacteriaceae (&#8220;CRE&#8221;) infections. SMT-738 is the first of a novel class of precision antibiotics that has entered into preclinical development. The Company intends to expand its portfolio by developing further new mechanism, new era product offerings that are designed to work in harmony with the human gut microbiome in the therapeutic areas of oncology and infectious diseases. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 18, 2020, Summit Therapeutics Inc. ("Summit"), a Delaware corporation, became the successor issuer to Summit Therapeutics plc, a public limited company incorporated under the laws of England and Wales with the Registrar of Companies of England and Wales, United Kingdom ("U.K."), for certain purposes under both the Securities Act of 1933, as amended, and the Securities Exchange Act of 1934, as amended, or the Exchange Act. Such succession occurred pursuant to a statutory scheme of arrangement under U.K. law pursuant to which all Summit Therapeutics plc outstanding ordinary shares were exchanged on a five-for-one basis for newly issued shares of Summit common stock and Summit became the holding company of Summit Therapeutics plc (the predecessor registrant and former holding company) and its subsidiaries (which is referred to as the "Redomiciliation Transaction"). Concurrently, Summit Therapeutics plc was converted into a private limited company under the laws of England and Wales and renamed Summit Therapeutics Limited. In addition, the warrants and stock options to purchase shares of Summit Therapeutics plc were canceled and replacement warrants and stock options to purchase common stock in Summit Therapeutics Inc. were issued. The scheme of arrangement was accounted for as an exchange of equity interests among entities under common control. All assets and liabilities of Summit Therapeutics plc were assumed by Summit, resulting in the retention of the historical basis of accounting as if they had always been combined for accounting purposes and the historical consolidated financial statements of Summit Therapeutics plc became the historical consolidated financial statements of Summit Therapeutics Inc. All share and per share data for periods prior to the Redomiciliation Transaction in the financial statements were retroactively reflected to be presented as shares of the Company's common stock, par value $0.01 per share.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Recent Events</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 12, 2021, the Company closed its rights offering, which was fully subscribed. The Company received aggregate gross proceeds from the rights offering of $75,000 from the sale of&#8239;14,312,976&#8239;shares of its common stock at a price per share of $5.24. Issuance costs associated with the rights offering were immaterial. In connection with the closing of the rights offering, a promissory note, dated April 20, 2021, was issued by the Company in favor of the Company's Chairman, Chief Executive Officer, and the beneficial owner of approximately 70% of its outstanding common stock prior to this rights offering, Robert W. Duggan, in the principal amount of $55,000,&#8239;matured and became due and the Company repaid all principal and accrued interest thereunder using a portion of the proceeds from the rights offering. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 11, 2021, based on a thorough review of the design and enrollment status of its two ongoing blinded Phase III Ri-CoDIFy trials, the Company announced that it combined its two blinded pivotal Phase III clinical trials evaluating ridinilazole versus vancomycin into a single study and presented this decision to the United States ("U.S.") Food and Drug Administration (the "FDA") as such. During September 2021, the Company received feedback from the FDA that the FDA did not agree with the change to the primary endpoint that the Company proposed and subsequently implemented in its ongoing Phase III Ri-CoDIFy studies when combining the trials.  </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 20, 2021, the Company announced topline results for the Phase III Ri-CoDIFy study evaluating ridinilazole, for the treatment of and Sustained Clinical Response (&#8220;SCR&#8221;), as defined below, for patients suffering from&#8239;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">C. difficile</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8239;infection ("</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">C. diff.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8239;infection" or "CDI"). The study showed that ridinilazole resulted in a numerically higher SCR rate than vancomycin, but did not meet the study&#8217;s primary endpoint for superiority. The pivotal Phase III clinical trial consisted of two Phase III clinical trials combined into a single study, designed to assess, as the primary endpoint, the superiority of ridinilazole compared to vancomycin in SCR, which is defined as clinical response of the treated episode of CDI and no recurrence of CDI through 30 days after the end of treatment. Additional endpoints included safety, tolerability, analyses of the gut microbiome and metabolome, in addition to quality of life and health economic outcome measures. We are in the process of evaluating the future path forward with respect to ridinilazole, including potential partnership opportunities.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 10, 2022, the Company&#8217;s Chief Executive Officer, Robert W. Duggan, entered into a Note Purchase Agreement (the &#8220;2022 Note&#8221;), pursuant to which he has loaned the Company $25,000 in exchange for the issuance by the Company of an unsecured promissory note in the amount of $25,000. The 2022 Note is to accrue interest at a rate per annum equal to the prime rate as reported in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Wall Street Journal</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which is 3.25% as of the effective date. The 2022 Note becomes due upon the earlier of (i) the consummation of a registered public offering with net proceeds of no less than $25,000 or (ii) 18 months from the date of issuance of the 2022 Note.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140707897772704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Use of Estimates<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccounting', window );">Basis of Presentation and Use of Estimates</a></td>
<td class="text">Basis of Presentation and Use of Estimates <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of Summit Therapeutics Inc. and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States ("U.S. GAAP") and pursuant to the rules and regulations of the U.S. Securities and Exchange Commission. The preparation of these financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. On an on-going basis, management evaluates its estimates and judgments, including those related to revenue recognition, accrued research and development expenses, stock-based compensation, intangible assets, goodwill, other long-lived assets and income taxes. Management bases its estimates and judgments on historical experience and on various other factors that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The progression of the COVID-19 pandemic continues to evolve and its enduring impact on the Company's business remains uncertain. Management believes the estimates and assumptions underlying its financial statements are reasonable and supportable based on the information available as of December 31, 2021, however, the extent to which the COVID-19 pandemic impacts the Company's financial results beyond December 31, 2021 will depend on future developments that are highly uncertain and cannot be predicted at this time.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccounting">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccounting</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140707895092304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liquidity and Capital Resources<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_LiquidityAndCapitalResourcesTextBlock', window );">Liquidity and Capital Resources</a></td>
<td class="text">Liquidity and Capital Resources<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2021, the Company incurred a net loss of $88,602 and cash flows used in operating activities was $72,587. As of December 31, 2021, the Company had an accumulated deficit of $299,548, cash of $71,791, research and development tax credit receivable of $15,695 and accounts receivable of $1,464. The Company expects to continue to generate operating losses for the foreseeable future. Until the Company can generate substantial revenue and achieve profitability, the Company will need to raise additional capital to fund its ongoing operations and capital needs.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the Company's current funding arrangements and financial resources as of December 31, 2021, and after considering proceeds received of $25,000 from the 2022 Note issued on March 10, 2022, the Company has the ability to fund its operating costs and working capital needs for more than twelve months from the date of issuance. In order to continue to fund the operations of the Company beyond this time period, management has developed plans, which primarily consist of raising additional capital through some combination of equity or debt financings, and/or potentially entering into new collaborations. There is no assurance, however, that additional financing will be available when needed or that management of the Company will be able to obtain financing on terms acceptable to the Company. If the Company is unable to obtain funding when required </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the future, the Company could be required to delay, reduce, or eliminate research and development programs, product portfolio expansion, or future commercialization efforts, which could adversely affect its business prospects.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements are prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of the business. The consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classifications of liabilities that might result from the outcome of this uncertainty.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_LiquidityAndCapitalResourcesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liquidity and Capital Resources</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_LiquidityAndCapitalResourcesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140707979611232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The significant accounting policies adopted by the Company in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Principles of Consolidation </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) and pursuant to the rules and regulations of the U.S. Securities and Exchange Commission. The consolidated financial statements include the accounts of Summit Therapeutics Inc. and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires the use of estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Foreign Currency Translation</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The financial statements of the Company&#8217;s subsidiaries with functional currencies other than the U.S. dollar are translated into U.S. dollars using period-end exchange rates for assets and liabilities, historical exchange rates for stockholders&#8217; equity and weighted average exchange rates for operating results. Translation gains and losses are included in accumulated other comprehensive (loss) income in shareholders&#8217; equity. Foreign currency transaction gains and losses are included in other (expense) income, net in the results of operations. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company recorded realized and unrealized foreign currency transaction (losses) gains of $(2,135) and $54 for the years ended December 31, 2021 and 2020, respectively, which is included in other (expense) income in the statements of operations and comprehensive loss.</span></div><div><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:103%">Revenue Recognition </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for revenue using Accounting Standards Codification ("ASC") 606 ("ASC 606"). This standard applies to all contracts with customers, except for contracts that are within the scope of other standards.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company enters into out-licensing agreements within the scope of ASC 606 under which it licenses certain rights to its product candidates to third parties. Such agreements may include the transfer of intellectual property rights in the form of licenses, transfer of technological know-how, delivery of drug substances, research and development services, and participation on certain committees with the counterparty. Payments made by the customers may include one or more of the following: non-refundable, up-front license fees; development, regulatory, and commercial milestone payments; payments for manufacturing supply services the Company provides through its contract manufacturers; and royalties on net sales of licensed products if they are successfully approved and commercialized. Each of these payments may result in license, collaboration, or other revenue, except revenue from royalties on net sales of licensed products, which would be classified as royalty revenue.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining the appropriate amount of revenue to be recognized as the Company fulfills its obligations under each of its out-licensing agreements, the following steps are performed: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations and assesses whether each promised good or service is distinct. Revenue is then recognized in respect of the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. As part of the accounting for these arrangements, the Company must use significant judgment to determine: (a) the performance obligations based on the determination under step (ii) above; (b) the transaction price under step (iii) above; and (c) the standalone selling price for each performance obligation identified in the contract for the allocation of transaction price in step (iv) above. The Company also uses judgment to determine whether milestone payments or other variable consideration, except for royalties and sales-based milestones, should be included in the transaction price, as described below. The transaction price is allocated to each performance obligation based on the relative standalone selling price of each performance obligation in the contract, and the Company recognizes revenue based on those amounts when, or as, the performance obligations under the contract are satisfied.</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Exclusive Licenses</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the license to the Company&#8217;s intellectual property is determined to be distinct from the other promises or performance obligations identified in the arrangement, the Company recognizes revenue from nonrefundable, upfront fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. In assessing whether a promise or performance obligation is distinct from the other promises, the Company considers factors such as the research, development, manufacturing and commercialization capabilities of the collaboration partner and the availability of the associated expertise in the general marketplace. In addition, the Company considers whether the collaboration partner can benefit from a promise for its intended purpose without the receipt of the remaining promises, whether the value of the promise is dependent on the unsatisfied promises, whether there are other vendors that could provide the remaining promises, and whether it is separately identifiable from the remaining promises. For licenses that are combined with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of progress and related revenue recognition. The measure of progress, and the resulting periods over which revenue should be recognized, are subject to estimates by management and may change over the course of the research, development and licensing arrangement. Such a change could have a material impact on the amount of revenue the Company records in future periods. Under the Company&#8217;s existing license and collaboration agreements, the Company has concluded that the transfer of control to the customer occurs over the time period that the research and development services are to be provided by the Company, and this output method is, in management&#8217;s judgment, the best measure of progress towards satisfying the performance obligation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Milestone Payments</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of each arrangement that includes potential research, development or regulatory milestone payments, the Company evaluates whether the milestones are considered likely to be met and estimates the amount to be considered for inclusion in the transaction price using the most-likely-amount method. If it is probable that a significant reversal in the amount of cumulative revenue recognized would not occur, the associated milestone payment value is included in the transaction price. For milestone payments due upon events that are not within the control of the Company or the licensee, such as regulatory approvals, the Company is not able to assert that it is likely that the regulatory approval will be granted and that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur until those approvals are received. In making this assessment, the Company evaluates factors such as the scientific, clinical, regulatory, commercial and other risks that must be overcome to achieve the particular milestone. There is considerable judgment involved in determining whether it is probable that a significant reversal in the amount of cumulative revenue recognized would not occur. At the end of each subsequent reporting period, the Company reevaluates the probability of achievement of all milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price of the arrangement. Any such adjustments are recorded on a cumulative catch-up basis, which would affect the amounts of revenue and earnings in the period of adjustment.</span></div><div><span><br/></span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalties</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For arrangements that include sales-based royalties, including milestone payments due upon first commercial sales or based on a level of sales, that are the result of a customer-vendor relationship and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) the occurrence of the related sales or (ii) the date upon which the performance obligation to which some or all of the royalty has been allocated has been satisfied or partially satisfied. To date, the Company has not recognized any royalty revenue from any of its licensing arrangements.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Operating Income</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company generates income from government contracts that reimburse the Company for certain allowable costs for funded projects. For contracts with government agencies where the funding arrangement is considered central to the Company&#8217;s ongoing operations, the Company classifies the recognized funding received as other operating income.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income from government grants is recognized as the qualifying expenses related to the contracts are incurred, provided that there is reasonable assurance of recoverability. If the government agency approves the project proposed by the Company, the government agency funds the project upon receipt of the support for the costs incurred up to the contract limit. Income recognized upon incurring qualifying expenses in advance of billing is recorded as accrued income, a component of other current assets, in the consolidated balance sheet.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Grant income is not recognized as deductions of research and development costs because the Company acts as the principal in conducting the research and development activities and these contracts are central to its ongoing operations. The funds received through these means are held as deferred income in the consolidated balance sheets and are released to the consolidated statement of operations and comprehensive loss as the underlying expenditure is incurred and to the extent the conditions of the grant are met. The related costs incurred by the Company are included in research and development expense in the Company&#8217;s consolidated statements of operations and comprehensive loss.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company benefits from two U.K. research and development ("R&amp;D") tax credit cash rebate regimes: Small and Medium Enterprise ("SME") Program and the Research and Development Expenditure Credit ("RDEC") Program. Each reporting period, management evaluates which tax relief programs the Company is expected to be eligible for and records as other operating income the portion of the expense that it expects to qualify under the programs, that it plans to submit a claim for, and it has reasonable assurance that the amount will ultimately be realized. Based on criteria established by HM Revenue and Customs (&#8220;HMRC&#8221;), management of the Company expects a proportion of expenditures being undertaken in relation to its pipeline research, clinical trials management and manufacturing development activities to be eligible for the research and development tax relief programs for the year ended December 31, 2021. Qualifying expenditures largely comprise of employment costs for research staff, consumables, a proportion of relevant, permitted sub-contract costs and certain internal overhead costs incurred as part of research projects for which the Company does not receive commercial or other funding income. Credits related to the SME and RDEC Programs are recorded as other operating income in the consolidated statements of operations and other comprehensive (loss)/income. Under both schemes, the Company receives cash rebate payments of up to 33.3% of eligible research and development expenditures and these payments are not dependent on the Company&#8217;s pre-tax net income levels. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company has qualified under the more favorable SME regime for the year ended December 31, 2020 and expects to qualify under the SME regime for the year ending December 31, 2021.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Net Income Per Share</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Basic net loss per share is computed by dividing the net loss by the weighted-average number of common shares outstanding for the period. Diluted net loss per share is computed by dividing the diluted net loss by the weighted-average number of common shares outstanding for the period, including potentially dilutive common shares. The dilutive effect of share options and warrants are determined under the treasury stock method using the average market price for the period.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, the assumed proceeds under the treasury stock method include the average unrecognized compensation expense of stock options and warrants that are in-the-money.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Business Combinations </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Business combinations are accounted for under the acquisition method. Acquired assets and assumed liabilities are measured at their fair values at the acquisition date. The excess of the consideration transferred over the net fair value of assets acquired and liabilities assumed is recorded as goodwill. The accounting for an acquisition involves a considerable amount of judgement and estimation. Cost, income, market or a combination of approaches may be used to establish the fair value of consideration exchanged, assets acquired, and liabilities assumed, depending on the nature of those items.  The valuation approach is </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">determined in accordance with generally accepted valuation methods. Key areas of estimation and judgment may include the selection of valuation approaches, cost of capital, market characteristics, cost structure, impacts of synergies, and estimates of terminal value, among other factors.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While the Company uses estimates and assumptions as part of the purchase price allocation process to estimate the value of assets acquired and liabilities assumed, estimates are inherently uncertain and subject to refinement. During the measurement period, which maybe up to one year from the acquisition date, the Company may record adjustments to the assets acquired and liabilities assumed, with a corresponding offset to goodwill, to the extent that adjustments are identified to the preliminary purchase price allocation. Upon conclusion of the measurement period, or final determination of the value of the assets acquired and liabilities assumed, whichever comes first, any subsequent adjustments are recorded to results of operations. Results of operations related to business combinations are included prospectively beginning with the date of acquisition and transaction costs related to business combinations are recorded within general and administrative expenses. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:102%">Goodwill</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill represents the excess of the consideration transferred over the fair value of net assets acquired. Goodwill is assigned to reporting units at the time of acquisition or when there is a change in the reporting structure and bases that allocation on which reporting units will benefit from the acquired assets and liabilities. Reporting units are defined as operating segments or one level below an operating segment, referred to as a component. The Company assesses goodwill for impairment on an annual basis or more frequently when events and circumstances occur indicating that the recorded goodwill may be impaired.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In performing the Company&#8217;s annual goodwill impairment test, the Company is permitted to first assess qualitative factors to determine whether it is more likely than not that the fair value of the Company&#8217;s reporting unit is less than its carrying amount, including goodwill. In performing the qualitative assessment, the Company considers certain events and circumstances specific to the reporting unit and to the entity as a whole, such as macroeconomic conditions, industry and market considerations, overall financial performance and cost factors when evaluating whether it is more likely than not that the fair value of the reporting unit is less than its carrying amount. The Company is also permitted to bypass the qualitative assessment and proceed directly to the quantitative test. If the Company chooses to undertake the qualitative assessment and concludes that it is more likely than not that the fair value of the reporting unit is less than its carrying amount, the Company would then proceed to the quantitative impairment test. In the quantitative assessment, the Company compares the fair value of the reporting unit to its carrying amount, which includes goodwill. If the fair value exceeds the carrying value, no impairment loss exists. If the fair value is less than the carrying amount, a goodwill impairment loss is measured and recorded.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, the Company performed its annual impairment assessment of goodwill by performing a qualitative analysis for its single identified reporting unit for goodwill and determined that it is more likely than not that the fair value of the reporting unit exceeded its carrying amount. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Intangible Assets </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets include patents, licenses, an option over non-financial assets and a research and development discovery platform ("Discuva Platform").</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Patents, licenses, and the option over non-financial assets are initially recorded at fair value, assigned an estimated useful life, and amortized primarily on a straight-line basis over their estimated useful lives. The Company evaluates the recoverability of its intangible and long-lived assets whenever events and changes in circumstances indicate that the carrying amount of an asset may not be fully recoverable. If events and circumstances indicate that the carrying amount may not fully be recoverable, the Company will perform a qualitative assessment, and consider certain events and circumstances specific to the intangible asset and to the entity as a whole, such as macroeconomic conditions, industry and market considerations, overall financial performance and cost factors when evaluating whether it is more likely than not that the fair value of the intangible asset is less than its carrying amount. This periodic review may result in an adjustment of estimated depreciable lives or asset impairment. When indicators of impairment are present, the carrying values of the asset are evaluated in relation to their operating performance and future undiscounted cash flows of the underlying business. If the future undiscounted cash flows are less than their carrying value, impairment exists. The impairment is measured as the difference between the carrying value and the fair </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">value of the underlying asset. Fair values are based on estimates of market prices and assumptions concerning the amount and timing of estimated future cash flows and assumed discount rates, reflecting varying degrees of perceived risk.</span></div><div><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other intangible assets are amortized in equal installments over their estimated useful lives as follows: </span></div><div style="margin-bottom:9pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.057%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.455%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:55.188%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intangible Asset</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortization Period</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Option over non-financial assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Over the period of the relevant agreement</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of intangible assets is included as part of the research and development expense line shown on the face of the consolidated statement of operations and comprehensive loss.</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Property and Equipment </span></div><div style="margin-bottom:9pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are stated at cost less accumulated depreciation. Cost comprises the purchase price plus any incidental costs of acquisition and commissioning. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation is calculated based on cost, less residual value, in equal annual installments over the estimated useful lives of the assets. The residual value, if not insignificant, is reassessed annually.</span></div><div style="margin-bottom:9pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.057%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:60.743%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Over the shorter of the asset's useful life or the remaining lease term</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2-10 years </span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office and IT equipment</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3-5 years</span></div></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation is recognized as part of the general and administrative and research and development expense lines shown on the face of the consolidated statement of operations and comprehensive loss depending on the nature of the underlying assets.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expenditures for repairs and maintenance are expensed as incurred. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation are removed from the accounts and any resulting gain or loss is included in loss from operations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Leases</span></div><div><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has operating leases for real estate. The Company does not have any finance leases. Under Accounting Standards Codification 842, a contract is or contains a lease when the lessee has the right to control the use of an identified asset. The Company determines if an arrangement is a lease at inception of the contract, which is the date on which the terms of the contract are agreed to and the agreement creates enforceable rights and obligations. The lease term used to calculate the lease liability include options to extend or terminate the lease when it is reasonably certain that the option will be exercised.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the lease commencement date, the Company measures and recognizes a lease liability and a right-of-use asset in the financial statements. Lease liabilities are recognized based on the present value of the future lease payments over the lease term at commencement date. The right-of use asset is measured by taking the present value of future lease payments, plus any incremental direct costs incurred, less any lease incentives received. As most of the Company's leases do not provide an implicit rate, the Company uses an estimated incremental borrowing rate based on the lease term and the economic environment of the lease at the lease commencement date, which is then utilized to determine the present value of future lease payments. Lease expense for minimum lease payments are recognized on a straight-line basis over the lease term, with variable lease payments recognized in the periods in which they are incurred.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has existing lease agreements with lease and non-lease components, has elected to account for the lease and non-lease components as a single lease component, and has allocated all of the contract consideration to the lease component only. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leases with an initial lease term of 12 months or less are not recorded on the balance sheet. The Company recognizes lease expense for its short-term leases on a straight-line basis over the lease term.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development Costs</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed as incurred. Research and development expenses consist of costs incurred to discover, research and develop product candidates, including personnel expenses, stock-based compensation expense, allocated facility-related and depreciation expenses, third-party license fees and external costs of outside vendors engaged to conduct preclinical and clinical development activities and clinical trials as well as to manufacture clinical trial materials. Non - refundable prepayments for goods or services that will be used or rendered for future research and development activities are recorded as prepaid expenses. Such amounts are recognized as an expense as the goods are delivered or the related services are performed, or until it is no longer expected that the goods will be delivered, or the services rendered. Milestone and other payments made to third-parties with respect to in-process research and development, in accordance with the Company&#8217;s license, acquisition and other similar agreements are expensed when determined to be probable and estimable.</span></div><div><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into various research and development contracts with other companies. These agreements are generally cancellable, and related payments are recorded as research and development expenses as incurred. The Company records accruals for estimated ongoing research and development costs or prepaid expenses where the payments made exceeds the estimated costs. When evaluating the adequacy of these balances, the Company analyzes progress of the studies, including the estimated costs to complete each study or activity, the estimation of the current stage of completion and the invoices received, as well as predetermined milestones which are not reflective of the current stage of development for prepaid expenses. Actual results could differ from the Company&#8217;s estimates. In all cases, the full cost of each study or activity is expensed by the time the final report or where applicable, product, has been received. The Company&#8217;s historical estimates have not been materially different from the actual costs.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock-Based Compensation </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures and recognizes compensation expense for all stock option and restricted stock unit awards based on the estimated fair value of the award on the grant date. The Company uses the Black-Scholes option pricing model to estimate the fair value of stock option awards. The fair value is recognized as expense, over the requisite service period, which is generally the vesting period of the respective award, on a straight-line basis for each separately vesting portion of the award when the only condition to vesting is continued service.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If vesting is subject to a market or performance condition, recognition is based on the derived service period of the award. Expense for awards with performance conditions is estimated and adjusted on a quarterly basis based upon the assessment of the probability that the performance condition will be met. Use of the Black-Scholes option-pricing model requires management to apply judgment under highly subjective assumptions.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These assumptions include:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Expected term&#8212;The expected term of stock options represents the weighted-average period the stock options are expected to be outstanding. The Company uses the simplified method for estimating the expected term as provided by the Securities and Exchange Commission. The simplified method calculates the expected term as the average of the time-to-vesting and the contractual life of the options.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Expected volatility&#8212;The expected volatility was calculated based on historical volatility of the Company's share price.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Risk-free interest rate&#8212;The risk-free rate assumption is based on the U.S. Treasury instruments, the terms of which were consistent with the expected term of the Company&#8217;s stock options.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Expected dividend&#8212;The expected dividend assumption is based on the Company&#8217;s history and expectation of dividend payouts. The Company has not paid and does not intend to pay dividends. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates expected forfeitures at the time of grant instead of accounting for forfeitures as they occur. Stock option and restricted stock unit awards have been granted at fair value to non-employees, in connection with research and consulting services provided to the Company, to non-employees in connection with corporate activities, and to employees, in connection with Stock Purchase and Restriction Agreements. Equity awards generally vest over terms of 3 or 4 years. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes is determined using the asset and liability approach. Tax laws may require items to be included in tax filings at different times than the items are reflected in the financial statements. A current asset or liability is recognized for the estimated taxes receivable or payable for the current year. Deferred taxes represent the future tax consequences expected to occur when the reported amounts of assets and liabilities are recovered or paid. Deferred taxes are initially recognized at enacted tax rates in force at the time of initial recognition and are subsequently adjusted for any enacted changes in tax rates and tax laws. Subsequent changes to deferred taxes originally recognized in equity are recognized in income. Valuation allowances are recorded to reduce deferred tax assets when it is more likely than not that a tax benefit will not be realized. The Company has recorded a full valuation allowance against the deferred tax assets in excess of its deferred tax liabilities, as the deferred tax liability represents future reversals of existing taxable temporary differences. The Company records interest and penalties related to income tax matters as part of income tax expense.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentration of Credit Risk and of Significant Supplier</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of short-term cash deposits and accounts and other receivables. The Company's cash is comprised of short-term cash deposits at a variety of financial institutions with strong credit ratings in amounts that may exceed federally insured limits and has not experienced any losses on such accounts. Cash balances maintained during the year have been principally held with reputable U.K.-based and U.S.-based banks. The Company does not believe it is exposed to any unusual credit risk beyond the normal credit risk associated with commercial banking relationships.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains deposits in accredited financial institutions in excess of federally insured limits. The Company deposits its cash in financial institutions that it believes have high credit quality and has not experienced any losses on such accounts and does not believe it is exposed to any unusual credit risk beyond the normal credit risk associated with commercial banking relationships.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The credit risk with respect to customers and funding bodies is limited as the Company has only a small number of these arrangements, including with Eurofarma, BARDA and CARB-X. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company relies, and expects to continue to rely, on a number of vendors to conduct its clinical trials and preclinical studies, manufacture drug product and supply clinical trial and preclinical study materials for its development programs. These programs could be adversely affected by a significant interruption in these services or the availability of materials.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:103%">Fair Value Measurements</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with the provisions of fair value accounting, a fair value measurement assumes that the transaction to sell an asset or transfer a liability occurs in the principal market for the asset or liability or, in the absence of a principal market, the most advantageous market for the asset or liability and defines fair value based on the exit price model.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value measurement guidance establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The guidance describes three levels of inputs that may be used to measure fair value:</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 1</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Quoted prices in active markets for identical assets or liabilities as of the reporting date. Active markets are those in which transactions for the asset or liability occur in sufficient frequency and volume to provide pricing information on an ongoing basis.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 2</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 2 assets and liabilities include debt securities with quoted prices that are traded less </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">frequently than exchange-traded instruments or securities or derivative contracts that are valued using a pricing model with inputs that are observable in the market or can be derived principally from or corroborated by observable market data.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 3</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Level 3 assets and liabilities include financial instruments whose value is determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant management judgment or estimation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, the Company categorizes such assets and liabilities based on the lowest level input that is significant to the fair value measurement in its entirety. The Company&#8217;s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the asset.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Assumed Contingent Liabilities</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the acquisition of Discuva Limited in December 2017, the Company assumed certain contingent liabilities as certain employees, former employees and former directors of Discuva Limited are eligible for payments from Discuva Limited based on specified development and clinical milestones related to proprietary product candidates developed under the Discuva Platform. The timing of these potential payments is uncertain. The fair value of the assumed contingent liability was estimated using the expected value of the payments. The assumed contingent liabilities are subsequently measured at amortized cost using discounted cash flow models which calculate the risk adjusted net present values of estimated potential future cash flows of the payments. The assumed contingent liabilities are remeasured when there is a specific significant event that provides evidence of a significant change in the probability of successful development and clinical milestones being achieved. The models will be updated for changes in the probability of successful development and clinical milestones being achieved and other associated assumptions with the discount factor remaining unchanged within the model. A discount factor of 13% has been used to discount the contingent liabilities back to net present value. This discount factor has been calculated using appropriate measures and rates which could have been obtained in the period that the contingent liabilities were assumed. Accretion of the discount factor is recognized as part of operating expenses in the consolidated statements of operations and comprehensive loss.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Warrants</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrants issued by the Company are recognized and classified as equity when, upon exercise, the Company would issue a fixed amount of its own equity instruments (common stock) in exchange for a fixed amount of cash or another financial asset.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consideration received, net of incremental costs directly attributable to the issue of such new warrants, is shown in equity. Such warrants are not remeasured at fair value in subsequent reporting periods.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrants issued in which external services are received as consideration for equity instruments of the company should be measured at the fair value of the goods or services received. Only if the fair value of the services cannot be measured reliably would the fair value of the equity instruments granted be used. The fair value for the warrants is calculated using the Black-Scholes formula and recorded in the consolidated statement of operations and comprehensive loss</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on a straight-line basis over the period of the consulting services. If the services are terminated prior to the end of the consultancy agreement, the warrants cease vesting and any unvested portion of the warrants will lapse immediately.</span></div>The warrants in issue are classified within stockholders&#8217; equity as they are indexed to the Company's own shares of common stock and require settlement in its shares of common stocks with no provision for any cash settlement.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140707899050736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Recently Issued or Adopted Accounting Pronouncements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingChangesAndErrorCorrectionsAbstract', window );"><strong>Accounting Changes and Error Corrections [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock', window );">Recently Issued or Adopted Accounting Pronouncements</a></td>
<td class="text">Recently Issued or Adopted Accounting Pronouncements <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2021-10, " Government Assistance (Topic 832)." This ASU increases the transparency of government assistance including the disclosure of (1) the types of assistance, (2) an entity's accounting for the assistance, and (3) the effect of the assistance on an entity's financial statements as diversity currently exists in the recognition, measurement, presentation and disclosure of government assistance received by business entities because of the lack of specific authoritative guidance in U.S. GAAP. This ASU is effective for annual periods, and interim periods within those fiscal years, beginning after December 15, 2021. Early application of this ASU is permitted. The Company applied the amendments of this ASU to its disclosures during the fourth quarter of 2021 and the application of this ASU did not have a material impact on its financial position, results of operations or cash flows.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, the FASB issued ASU No. 2021-08, "Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers." This ASU improves the accounting for acquired revenue contracts with customers in a business combination by addressing diversity in practice and inconsistency relating to: 1) recognition of an acquired contract liability and 2) payment terms and their effect on subsequent revenue recognized by the acquirer. The amendments in this ASU require acquiring entities to apply Topic 606 to recognize and measure contract assets and contract liabilities in a business combination, whereas current U.S. GAAP requires that the acquirer measure such assets and liabilities at fair value on the acquisition date. This ASU is effective for annual periods, and interim periods within those fiscal years, beginning after December 15, 2022. The Company will apply this ASU on a prospective basis for business combinations once this ASU is effective and at that time, will be able to determine the potential impact on its financial position, results of operations or cash flows.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, the FASB issued AS No. 2021-04, "Earnings Per Share (Topic 260), Debt - Modifications and Extinguishments (Subtopic 470-50), Compensation - Stock Compensation (Topic 718), and Derivatives and Hedging Contracts in Entity's Own Equity (Subtopic 815-40) - Issuer's Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options." This ASU provides clarification and reduces diversity in an issuer&#8217;s accounting for modifications or exchanges of freestanding equity-classified written call options (such as warrants) that remain equity classified after modification or exchange. This ASU is effective for annual periods, and interim periods within those fiscal years, beginning after December 15, 2021. The Company will apply this ASU on a prospective basis for any modifications or exchanges once this ASU is effective and at that time, will be able to determine the potential impact on its financial position, results of operations or cash flows.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU No. 2019-12, "Income Taxes (Topic 740)." This ASU simplifies the accounting for income taxes by removing certain exceptions to the general principles in Topic 740. The amendments also improve consistent application and simplify U.S. GAAP for other areas of Topic 740 by clarifying and amending existing guidance. This ASU is effective for annual periods, and interim periods within those fiscal years, beginning after December 15, 2020. The Company adopted this ASU during the first quarter of 2021 and the adoption of this ASU did not have a material impact on its financial position, results of operations or cash flows.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingChangesAndErrorCorrectionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingChangesAndErrorCorrectionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123338486&amp;loc=SL49131195-203048<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -URI http://asc.fasb.org/topic&amp;trid=2122394<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123338486&amp;loc=SL49131195-203048<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section S99<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=122038215&amp;loc=SL108384541-122693<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124402435&amp;loc=SL124402458-218513<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (i)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123338486&amp;loc=SL49131195-203048<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124402435&amp;loc=SL124402458-218513<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (j)<br> -URI http://asc.fasb.org/extlink&amp;oid=123338486&amp;loc=SL49131195-203048<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 11.M.Q2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038215&amp;loc=d3e31137-122693<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122150657&amp;loc=SL122150809-237846<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (c)<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140707898925936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Reporting</a></td>
<td class="text">Segment Reporting The Company's chief operating decision makers (the "CODM function"), which are the Company's Chief Executive Officer and Chief Operating Officer, utilize consolidated financial information to make decisions about allocating resources and assessing performance for the entire Company. The CODM function approves of key operating and strategic decisions, including key decisions in clinical development and clinical operating activities, entering into significant contracts, such as revenue contracts and collaboration agreements and approves the Company's consolidated operating budget. The CODM function views the Company's operations and manages its business as a single reportable operating segment. The Company's single operating segment covers the Company&#8217;s research and development activities, primarily comprising the CDI program and antibiotic pipeline research activities. As the Company operates in one operating segment, all required financial segment information can be found in the consolidated financial statements.<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates in two geographic regions: the U.K. and the U.S. The following table summarizes the Company's long-lived assets, which include the Company's property and equipment, net and right-of-use assets by geography: </span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.467%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,762&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,228&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">722&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,484&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,279&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For details of revenue from external customers by geography refer to Note 7.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 34<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8981-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8721-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8844-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8657-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8721-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -URI http://asc.fasb.org/topic&amp;trid=2134510<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140707899025408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenue</a></td>
<td class="text">Revenue <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes revenue by category:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.467%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue by category:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licensing agreements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,809&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">860&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><div style="margin-bottom:3pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue recognized during the years ended December 31, 2021 and December 31, 2020 consists of amounts received from the Company's license and commercialization agreement with Eurofarma Laborat&#243;rios S.A. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes revenue by geography:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.467%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue by geography:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Latin America</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,809&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">860&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,809&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">860&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The analysis of revenue by geography has been identified on the basis of the geographical location of each collaboration partner.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the deferred revenue relating to Eurofarma Laborat&#243;rios S.A. and deferred other income relating to BARDA (as defined in Note 8), respectively:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.836%"><tr><td style="width:1.0%"/><td style="width:82.049%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.902%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.649%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning deferred revenue and other income, January 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,939&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,438</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amount of deferred revenue and other income recognized in the statement of operations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,438)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending deferred revenue and other income, December 31</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,939&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">__________</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning deferred revenue and other income included $8,370 of current deferred revenue and other income and $569 of long-term deferred revenue and other income.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ending deferred revenue and other income is classified within current liabilities.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 8 below for further details regarding other income recognized under the BARDA contract. </span></div><div><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Eurofarma Laborat&#243;rios S.A.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 21, 2017, Summit announced it had entered into an exclusive license and commercialization agreement with Eurofarma Laborat&#243;rios S.A. ("Eurofarma"), pursuant to which the Company granted Eurofarma the exclusive right to commercialize ridinilazole in specified countries in South America, Central America and the Caribbean. The Company has retained commercialization rights in the rest of the world. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the license and commercialization agreement with Eurofarma, the Company received an upfront payment of $2,500 in December 2017. In February 2020, the Company reached the first enrollment milestone and earned $1,000. In September 2021, the Company reached the second enrollment milestone and earned $1,250. The terms of the contract have been assessed under ASC 606 and currently only the upfront payment and the first two enrollment milestone payments are included in the transaction price. These payments were initially reported as deferred revenue in the balance sheet and are being recognized as revenue ratably over the performance period. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue recognized during the period ended December 31, 2021 was based on the transaction price that included the upfront payment and the first two enrollment milestones earned in accordance with the Company's revenue recognition policy. Revenue recognized during the period ended December 31, 2020 was based on the transaction price that included the upfront payment and the first enrollment milestone earned in accordance with the Company's revenue recognition policy. The revenue is being recognized ratably over the performance period to reflect the transfer of control to the customer occurring over the time period that the research and development services are provided by the Company. This output method is, in management&#8217;s judgment, the best measure of progress towards satisfying the performance obligation. As of December 31, 2021 and 2020, the current contract liability relating to the Eurofarma contract was $756 and $759, respectively, and was recorded in current deferred revenue in the consolidated balance sheet. As of December 31, 2021 and 2020, the non-current contract liability relating to the Eurofarma contract was $0 and $569, respectively, and was recorded in non-current deferred revenue and other income in the consolidated balance sheet.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Company will be entitled to receive an additional $1,500 for various development milestones. The Company is also eligible to receive up to $21,400 in additional development, commercial and sales milestones when cumulative net sales equal or exceed $100,000 in the Eurofarma licensed territory. Each subsequent achievement of an additional $100,000 in cumulative net sales will result in the Company receiving additional milestone payments, which, when combined with anticipated product supply transfer payments from Eurofarma paid to the Company in connection with a commercial supply agreement to be entered into between the two parties, will provide payments estimated to range from a mid-teens to high-teens percentage of cumulative net sales in the territories where we have granted Eurofarma commercialization rights. Upon achievement of these milestones, the Company will recognize the revenues in accordance with the Company's revenue policy.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130551-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130556-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130550-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130558-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140707898940384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Operating Income<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other Income and Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeAndExpenseTextBlock', window );">Other Operating Income</a></td>
<td class="text">Other Operating Income <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the components of other operating income by category:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.467%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other operating income by category:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Funding income from BARDA (as defined below)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,604&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,472&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development tax credits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,206&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,363&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Grant income from CARB-X (as defined below)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,158&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">477&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,968&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,312&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BARDA (as defined below)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2017, the Company was awarded a funding contract from the Biomedical Advanced Research and Development Authority ("BARDA"), part of the Office of the Assistant Secretary for Preparedness and Response at the United States Department of Health and Human Services, in support of the Company's Ri-CoDIFy clinical trials and clinical development of of ridinilazole.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The awarded contract was originally worth up to $62,000. In June 2019 and again in January 2020, BARDA increased the value of the contract such that it is now worth up to $72,500 and brought the total amount of committed funding to $62,400. The remaining federal government funding is dependent on BARDA in its sole discretion exercising the final independent option work segment, upon the achievement by the Company of certain agreed-upon milestones for ridinilazole. As of December 31, 2021, an aggregate of $56,492 of the total committed BARDA funding had been received and the Company has recognized $50,265 of cumulative income since contract inception.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and development credits</span></div><div><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income from tax credits, consist of R&amp;D tax credits received in the U.K. The Company benefits from two U.K. research and development tax credit cash rebate regimes: Small and Medium Enterprise Program ("SME, Program") and the Research and Development Expenditure Credit Program ("RDEC Program"). Qualifying expenditures largely comprise of employment costs for research staff, consumables, a proportion of relevant, permitted sub-contract costs and certain internal overhead costs incurred as part of research projects for which the Company does not receive income. Tax credits related to the SME Program and RDEC Program are recorded as other operating income in the consolidated statements of operations and other comprehensive loss. Under both schemes, the Company receives cash payments that are not dependent on the Company&#8217;s pre-tax net income levels.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on criteria established by Her Majesty&#8217;s Revenue and Customs ("HMRC"), a portion of expenditures being carried out in relation to the Company's pipeline research and development, clinical trials management and third-party manufacturing development activities are eligible for the SME regime and the Company expects such elements of expenditure will also continue to be eligible for the SME regime for future periods.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">As of December 31, 2021 and 2020, the current research and development tax credit receivable was $15,695 and $9,856, respectively.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CARB-X (as defined below)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, the Company announced the selection of a new preclinical candidate, SMT-738, from the DDS-04 series for development in the fight against multi-drug resistant infections, specifically Carbapenem-resistant Enterobacteriaceae ("CRE") infections. Simultaneously, the Company announced it had received an award from the Trustees of Boston University under the Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator program ("CARB-X") to progress this candidate through preclinical development and Phase Ia clinical trials. The award commits initial funding of up to $4,100, with the possibility of up to another $3,700 based on the achievement of future milestones. As of December 31, 2021, $485 of grant funding from CARB-X has been received, $96 is in accounts receivable for amounts billed, $574 is in other current assets as a contract asset and the Company has recognized $1,155 of cumulative income since contract inception.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Grant income recognized during the year ended December 31, 2021 relates to SMT-738. Grant income recognized during the year ended December, 31, 2020 consists of income from a sub-award from CARB-X for the Company's antibiotic pipeline research and development activities specifically relating to the DDS-01 series of antibiotics, targeting Neisseria gonorrhoeae, or N. gonorrhoeae, using the Discuva Platform. In the fourth quarter of 2020, the Company decided not to advance the DDS-01 series and to cease work on the gonorrhoeae program, and as such, no further grant income has been received from CARB-X under this sub-award.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingIncomeAndExpenseTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other operating income and other operating expense items.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingIncomeAndExpenseTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140707895044560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other (Expense) Income<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other Income and Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock', window );">Other (Expense) Income</a></td>
<td class="text">Other (Expense) Income<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the components of other (expense) income:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.467%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign currency (loss) gain</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,135)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Remeasurement of liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">480&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(281)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(255)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,416)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">283&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_____________</span></div>(1) Remeasurement of liabilities during the year ended December 31, 2020, relates to a revaluation of assumed contingent liabilities for potential payments to certain employees, former employees and former directors of Discuva Limited, based on specified development and clinical milestones related to proprietary product candidates developed under the Discuva Platform (see Note 16 for further details).<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the components of non-operating income or non-operating expense, including, but not limited to, amounts earned from dividends, interest on securities, gain (loss) on securities sold, equity earnings of unconsolidated affiliates, gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140707895134272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Tax<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Tax</a></td>
<td class="text">Income Tax&#160;<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of the Company's loss before income taxes are as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.467%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United Kingdom</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(72,244)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(51,197)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,358)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,713)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(88,602)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52,910)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant components of the provision for income taxes are as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.198%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current income tax benefit:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Federal United States</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(215)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State - United States</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-United States</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(213)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Federal - United States</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State - United States</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-United States</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total deferred tax</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total income tax benefit</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(213)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div style="padding-left:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Deferred taxes are recognized for temporary differences between the basis of assets and liabilities for financial statement and income tax purposes. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The major components of deferred tax assets and liabilities are as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.742%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.467%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.468%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net operating loss carryforward</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,422&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,831&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development credit carryforward</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">941&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,560&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,167</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,477&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">491</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,400&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,489</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible asset</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,600)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,189)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(71)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,654)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,260)</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net deferred tax assets before valuation allowance </span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,746</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,229</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51,746)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29,229)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax, net</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December 31, 2021 and 2020, the Company recorded a deferred tax asset of $54.400 and $31,489 respectively. The Company has evaluated the positive and negative evidence bearing upon its ability to realize its deferred tax assets, which are comprised primarily of net operating loss carryforwards and excess tax benefits related to stock-based compensation. Management has considered the Company&#8217;s history of cumulative net losses in the United States ("U.S.") and the United Kingdom ("U.K."), estimated future taxable income, as well as prudent and feasible tax planning strategies, and has concluded that it is more likely than not that the Company will not realize the benefits of its U.S. federal and state deferred tax assets and U.K. deferred tax assets. Accordingly, a full valuation allowance has been established against these net deferred tax assets as of December 31, 2021 and 2020, respectively. The Company reevaluates the positive and negative evidence at each </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reporting period. The Company&#8217;s valuation allowance increased during 2021 by $22,517 primarily due to the generation of net operating loss and stock-based compensation. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021 and 2020, the Company had U.S. Federal net operating loss carryforwards of approximately $1,034 and $232, respectively, which may be available to offset future income tax liabilities. The 2017 Tax Cuts and Jobs Act (&#8220; TCJA&#8221;) will generally allow losses incurred after 2017 to be carried over indefinitely, but will generally limit the net operating loss deduction to the lesser of the net operating loss carryover or 80% of a corporation&#8217;s taxable income (subject to Section 382 of the Internal Revenue Code of 1986, as amended). In addition, the Company has approximately $165 in U.S. State loss carryforwards which expire through various dates through 2040 and as of December 31, 2021, the Company had an estimated U.S. federal research and development tax credit carryforwards of $941 which may be available to offset future tax liabilities, and each begin to expire in 2033. The Company also had approximately $191,714 in U.K. loss carryforwards available to use against future taxable profits on a year-by-year basis (a potential deferred tax asset of $47,929). To the extent that U.K. taxable profits exceed &#163;5,000 in each year, the loss available to utilize against profits in excess of &#163;5,000 will be restricted to 50%. The U.K. loss carryforwards do not lapse and therefore, the full amount will be relieved over time provided there are sufficient profits against which the losses can be utilized. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Utilization of the U.S. net operating loss carryforwards and research and development tax credit carryforwards may be subject to a substantial annual limitation under Section 382 of the Internal Revenue Code of 1986 due to ownership changes that have occurred previously or that could occur in the future. These ownership changes may limit the amount of carryforwards that can be utilized annually to offset future taxable income. In general, an ownership change, as defined by Section 382, results from transactions increasing the ownership of certain shareholders or public groups in the stock of a corporation by more than 50% over a three-year period. The Company has not completed a study to assess whether a change of ownership has occurred, or whether there have been multiple ownership changes since its formation. Any limitation may result in the loss of a portion of the net operating loss carryforwards or research and development tax credit carryforwards before utilization.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.K. tax losses are subject to additional restrictions where there is a change in ownership in the business and certain other conditions are met. An ownership change of a UK tax resident company would occur where (directly or indirectly) a single person acquires more than half of the ordinary share capital of a company, or two or more persons each acquire a holding of at least 5% of the ordinary share capital of a company and these holdings together amount to more than half the ordinary share capital of a company. Where a change in ownership has occurred, and within three years prior to that change in ownership and five years afterwards, there is a major change in the nature and conduct of trade of that company or the trade of that business becomes small or negligible, any losses carried forward will be extinguished from the point of the change in ownership. In addition, losses accrued subsequent to April 1, 2017 will be extinguished on a change of ownership when there is a major change in the nature or conduct of a company&#8217;s business, or where there is a major change in the scale of that business, or a company ceases to carry on a particular trade or business. The Company has not completed a study to assess whether a change of ownership has occurred since its formation, or whether there has been a major change in the Company's business that would restrict the U.K. tax losses. Any limitation may result in the loss of a portion of the net operating loss carryforwards before utilization.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2017 Tax Cuts and Jobs Act (&#8220;2017 Act&#8221;) created a requirement that US corporations include in income earnings of certain controlled foreign corporations (&#8220;CFC&#8221;) under the global intangible low taxed income (&#8220;GILTI&#8221;) regime. Pursuant to the FASB Staff Q&amp;A, Topic 740 No.5. Accounting for Global Intangible Low-taxed Income, the Company is allowed to make an accounting policy election to either recognize deferred taxes for temporary basis differences expected to reverse as GILTI in future years or to provide for the tax expense related to GILTI in the year the tax is incurred as period expense only. The Company has elected to account for GILTI in the year the tax is incurred and include the current tax impact of GILTI in the effective tax rate. Given the Company's loss position in the U.S. and the valuation allowance recorded against its U.S. net deferred tax assets, these provisions have not had a material impact on the Company's consolidated financial statements.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 27, 2020, the United States enacted the Coronavirus Aid, Relief, and Economic Security Act (&#8220;CARES Act&#8221;). The Cares Act includes provisions relating to refundable payroll tax credits, deferment of the employer portion of certain payroll taxes, net operating loss carryback periods, alternative minimum tax credit refunds, modifications to the net interest deduction limitations, and technical corrections to tax depreciation methods for qualified improvement property. The CARES Act also </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">established a Paycheck Protection Program whereby certain small businesses are eligible for a loan to fund payroll expenses, rent, and related costs.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considered the provisions under the CARES Act and elected not to take advantage of the provisions of the CARES Act as the effect of such provisions was not expected to have a material impact on the Company&#8217;s results of operations, cash flows, and consolidated financial statements.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2021, the U.K. Government announced that from April 1, 2023, the corporation tax rate would increase to 25%. This new law was enacted on June 10, 2021. The overall effect of the change was an increase in net deferred tax assets by $9,311 and an increase in valuation allowance by an equal amount.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the Company's effective tax rate to the U.S. federal statutory rate is as follows: </span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.467%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:83%">Year Ended December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:83%">Year Ended December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. federal income tax statutory rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-deductible expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Refundable research and development tax credit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effect of foreign operations taxed at various rates</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.30&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.K., the Company is entitled to a research and development tax relief for small and medium-sized enterprises which allows the Company an enhanced deduction rate of 230% on qualifying research and development expenditure (the tax relief). If the Company incurs tax losses, it is entitled to surrender the lesser of unrelieved tax loss sustained and the tax relief. As the realization of the tax relief does not depend on generation of future taxable income or the Company's ongoing tax status or tax position, the Company does not consider the tax relief as an element of income tax accounting under ASC 740. For the year ended December 31, 2021 and 2020, the Company recognized research and development tax relief of $15,206 and $9,363 respectively, which is included in other operating income in the consolidated statements of operations and other comprehensive loss.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is the intention of the Company to reinvest the earnings of its non-U.S. subsidiaries in those operations and not to repatriate the earnings to the U.S. Accordingly, the Company does not provide for deferred taxes on differences between financial reporting and tax basis in its investments in foreign subsidiaries as they are considered permanent in duration or are not expected to reverse in the foreseeable future.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not have any uncertain tax positions as of December 31, 2021. In the U.K., tax returns for the year ended December 31, 2020 remains subject to examination by HMRC. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S., the Company files income tax returns in various states. In the U.S., tax years from 2018 remain subject to examination by the U.S. Internal Revenue Service and state tax authorities. The Company is not currently under examination by the Internal Revenue Service or any other jurisdiction for years 2018 through present. To the extent the Company has tax attribute carryforwards, the tax years in which the attribute was generated may be adjusted upon examination by the Internal Revenue Service or state tax authorities to the extent utilized in a future period. The Company&#8217;s policy is to recognize interest and penalties related to uncertain tax positions as part of its income tax provision. As of December 31, 2021, and 2020, the Company has recorded no liability for unrecognized tax benefits, interest, or penalties related to federal, state or foreign income tax matters.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140707899050736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Loss per Share</a></td>
<td class="text">Loss per Share <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the computation of basic and diluted net loss per share: </span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.198%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(88,602)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52,697)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic weighted average number of shares of common stock outstanding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,239,306&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,524,148&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted weighted average number of shares of common stock outstanding</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,239,306&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,524,148&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic net loss per share</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.96)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.76)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted net loss per share</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.96)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.76)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><div style="margin-top:1pt"><span><br/></span></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is computed by dividing the net loss by the weighted-average number of common shares outstanding for the period. Diluted net loss per share is computed by dividing the diluted net loss by the weighted-average number of common shares outstanding for the period, including potentially dilutive common shares. The dilutive effect of share options and warrants are determined under the treasury stock method using the average market price for the period.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the assumed proceeds under the treasury stock method include the average unrecognized compensation expense of stock options and warrants that are in-the-money. Since the Company was in a loss position for all periods presented, basic net loss per share is the same as diluted net loss per share for all periods, as the inclusion of all potential common share equivalents outstanding would have been anti-dilutive. </span></div><div style="margin-top:1pt"><span><br/></span></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following potentially dilutive securities were excluded from the computation of the diluted net loss per share of common stock for the periods presented because their effect would have been anti-dilutive: </span></div><div style="margin-top:1pt"><span><br/></span></div><div style="margin-top:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.198%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.523%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,923</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase common stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,797,556</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,672,968</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,821,137</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,821,137</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares expected to be purchased under employee stock purchase plan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202,045</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,820,738</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,521,028</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140707895044560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Goodwill and Intangible Assets</a></td>
<td class="text">Goodwill and Intangible Assets<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Goodwill</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill is measured as the excess of the cost of the acquisition over the sum of the amounts assigned to tangible and identifiable intangible assets acquired less liabilities assumed. The Company assigns assets acquired (including goodwill) and liabilities assumed to one or more reporting units as of the date of acquisition. Typically acquisitions related to a single reporting unit do not require the allocation of goodwill to multiple reporting units. If the products obtained in an acquisition are assigned to multiple reporting units, the goodwill is distributed to the respective reporting units as part of the purchase price allocation process.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill and purchased intangible assets are reviewed for impairment annually during the fourth quarter of each fiscal year and whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. The process of evaluating the potential impairment of goodwill and intangible assets requires significant judgment. The Company regularly monitors current business conditions and other factors including, but not limited to, adverse industry or economic trends and lower projections of profitability that may impact future operating results. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s annual evaluation for impairment of goodwill consists of one reporting unit. In accordance with the Company&#8217;s policy, the Company completed its annual evaluation for impairment in the fourth quarter of 2021 using the qualitative assessment. No impairment charge was recognized for the year ended December 31, 2021 and there have been no cumulative goodwill impairment charges recognized to date.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021 and 2020, goodwill was $2,009 and $2,030, respectively and represents goodwill recognized from the acquisition of Discuva Limited in December of 2017. Changes year over year are the result of foreign currency movements. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Intangible Assets</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Components of the Company's acquired intangible assets are comprised of the following:</span></div><div style="margin-top:6pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.836%"><tr><td style="width:1.0%"/><td style="width:49.293%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.587%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.587%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.587%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.650%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated amortization and impairment charges</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Utrophin program acquired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,487&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,487)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Discuva platform acquired</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,416&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,017)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,399&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Option over non-financial asset</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">912&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(912)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other patents and licenses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(148)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,963&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,564)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,399&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.397%"><tr><td style="width:1.0%"/><td style="width:49.532%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.591%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.564%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.591%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.564%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.591%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.567%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated amortization and impairment charges</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Utrophin program acquired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,534&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,534)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Discuva platform acquired</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,565&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,050)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,515&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Option over non-financial asset</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">921&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(921)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other patents and licenses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(150)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,170&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,655)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,515&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the year ended December 31, 2020, management identified an impairment related to the option over non-financial asset pursuant to an Evaluation and Option Agreement with a collaboration partner. The partner is no longer conducting antibiotic candidate programs over which the Company had the option, management therefore determined that the fair value of the option to acquire the assignment of the proprietary rights for antibiotic candidates is $0. Accordingly, the asset was written off in its entirety resulting in an impairment charge of $859 recognized in operating expenses.</span></div><div style="margin-top:6pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense was $1,017 and $1,250 for the years ended December 31, 2021 and 2020, respectively. The weighted-average remaining life at December 31, 2021 for our Discuva platform intangible asset was approximately 10.4 years. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated net amortization expense related to acquired intangible assets for future years is:</span></div><div><span><br/></span></div><div style="padding-left:72pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:62.134%"><tr><td style="width:1.0%"/><td style="width:74.194%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.430%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">999&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">999&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">999&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">999&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">999&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,404&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140707898970832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment</a></td>
<td class="text">Property and Equipment <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consisted of the following:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.421%"><tr><td style="width:1.0%"/><td style="width:58.367%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.774%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.582%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.777%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,626&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">759&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures, office equipment and software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,081&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">804&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">364&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">291&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, gross</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,071&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,854&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,377&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,129&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">694&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">725&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:1pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense for the years ended December 31, 2021 and 2020 was $330 and $302, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140707898966016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Research and Development Prepaid Expenses and Accrued Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock', window );">Research and Development Prepaid Expenses and Accrued Liabilities</a></td>
<td class="text">Research and Development Prepaid Expenses and Accrued Liabilities Included within prepaid expenses at December 31, 2021 and 2020 is $6,138 and $8,490, respectively, of prepayments relating to research and development expenditures. Included within accrued liabilities at December 31, 2021 and 2020 is $5,226 and $1,502, respectively, relating to research and development expenditures.These amounts are determined based on the estimated costs to complete each study or activity, the estimation of the current stage of completion and the invoices received, as well as predetermined milestones which are not reflective of the current stage of development for prepaid expenses. However, prepaid expenses decrease and accrued liabilities increase as the activities progress, and if actual costs incurred exceed the prepaid expense, an accrual will be recorded for the liability. The key sensitivity is the estimated current stage of completion of each study or activity, which is based on information received from the supplier and the Company's operational knowledge of the work completed under those contracts.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 730<br> -URI http://asc.fasb.org/subtopic&amp;trid=2197926<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140707899080416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">The Company has operating leases for real estate. The Company does not have any finance leases. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">During the year ended December 31, 2021, the Company recorded $3,389 of additional right-of-use assets of which $2,359 related to two new leases that commenced during the period for its Menlo Park, California, U.S. and Sawston, U.K. locations and $1,030 which related to one lease that was extended during the period for its Oxfordshire, U.K location.</span></div><div style="margin-bottom:3pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value of the right-of-use assets as of December 31, 2021 and 2020 is $2,790 and $554, respectively.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The elements of lease expense were as follows:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.467%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lease Cost:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Fixed lease costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">785&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">478&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Variable lease costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Short-term lease</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">278</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">272</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total lease cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,227&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">921&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average discount rate and the weighted average remaining lease term were 2.5% and 3.9 years, respectively, as of December 31, 2021. The weighted average discount rate and the weighted average remaining lease term were 3.75% and 1.1 years, respectively, as of December 31, 2020.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future lease payments under non-cancelable leases as of December 31, 2021 are detailed as follows:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:67.397%"><tr><td style="width:1.0%"/><td style="width:75.255%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.318%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.941%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.886%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 5.5pt 2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year Ending December 31,</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amount</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 5.5pt 2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,037&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 5.5pt 2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">509&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">508&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">508&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">386&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,948&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 5.5pt 2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,782&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liabilities balance sheet presentation:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 5.5pt 2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,091&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 5.5pt 2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,691&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,782&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div>Amounts presented above do not include payments related to the Company's Cambridge, Massachusetts, United States office where the lease term is month to month and therefore was not capitalized on the balance sheet.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140707899087680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Non-Current Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureNoncurrentTextBlock', window );">Other Non-Current Liabilities</a></td>
<td class="text">Other Non-Current Liabilities<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included within other non-current liabilities at December 31, 2021 and 2020 is $2,531 and $2,263, respectively, relating to assumed contingent liabilities. As part of the acquisition of Discuva Limited in December 2017, the Company assumed certain contingent liabilities as certain employees, former employees and former directors of Discuva Limited are eligible for payments from Discuva Limited based on specified development and clinical milestones related to proprietary product candidates developed under the Discuva Platform. The timing of these potential payments is uncertain.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contingent liability was remeasured in the third quarter of 2020 to reflect a change in the timing of expected payments following the Company's decision not to advance the DDS-01 series of antibiotics and to cease work on the gonorrhoeae program. The gain on the remeasurement of the liability recognized during the year ended December 31, 2020 of $480 is included within other (expense) income in the consolidated statements of operations and comprehensive loss. There were no remeasurement losses or gains recognized during the year ended December 31, 2021.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureNoncurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as noncurrent at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureNoncurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140707899002560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text">Stockholders' Equity <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Reverse Stock Split</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In conjunction with the Company&#8217;s Redomiciliation Transaction in (as defined in Note </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), the Company acquired all of the outstanding ordinary shares of Summit Therapeutics plc on the basis of one share of the Company&#8217;s common stock for every 5 ordinary shares outstanding, which had the effect of a 1-for-5 reverse stock split. On the effective date of the Redomiciliation, the number of outstanding shares was reduced from 336,159,511 to 67,231,903. All share and per share amounts in these consolidated financial statements and related notes for periods prior to the Redomiciliation Transaction have been retroactively adjusted to reflect the effect of the exchange ratio.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Common Stock</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On May 12, 2021, the Company closed its rights offering, which was fully subscribed and received aggregate gross proceeds of $75,000 from the sale of 14,312,976 shares of common stock to existing investors at a price per share of $5.24. Offering costs of $159 were incurred. In connection with the closing of the rights offering, the Second Note (see Note 20) matured and became due and the Company repaid all principal and accrued interest thereunder using a portion of the proceeds from the rights offering.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 6, 2020 the Company completed a private placement of its common stock and received gross proceeds of $50,000 from the issuance and sale of 14,970,060 shares of common stock to Mr. Robert W. Duggan and two other existing shareholders of the Company at a price of $3.34 per share. Offering costs of $48 were incurred.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 24, 2019, the Company completed a private placement of its common stock, and received aggregate gross proceeds of $50,000 from the issuance and sale of 35,075,690 shares of common stock to existing investors at a price of $1.43 per share. Offering costs of $912 were incurred. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Warrants</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the private placement on December 24, 2019, the participating investors were granted warrants with the right to subscribe for 5,261,350 shares of common stock at an exercise price of $1.58, exercisable any time in the period commencing on the date falling six months following December 24, 2019 and ending on the tenth anniversary of admission. Each warrant entitles the warrant holder to subscribe in cash for one share. Shares of common stock allotted pursuant to the exercise of the warrant will rank in full for all dividends and other distributions with a record date after the exercise date with the shares of common stock in issue at that date. The Company has the option to require the warrant holder to exercise some or all of the outstanding warrants after the third anniversary date if the ten-day volume weighted average price of the shares of common stock as reported on Nasdaq represents a premium of at least 50 percent to the exercise price. The warrants are classified within stockholders&#8217; equity as they are indexed to the Company's shares of common stock and require settlement in its shares of common stock with no provision for any cash settlement.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also, as part of the private placement on December 24, 2019, certain consultants were granted warrants with the right to subscribe for 3,358,732 shares of common stock in exchange for certain services. The warrants have an exercise price of $1.44 and vest quarterly over three years. If the consulting agreement terminated prior to three years after the date of the grant, all unvested warrants will be deemed cancelled. On June 30, 2020, the consulting agreement was terminated and 2,798,945 warrants cancelled immediately. The remaining 559,787 of outstanding warrants are held by Dr. Maky Zanganeh and Dr. Elaine Stracker (see Note 20).</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrants granted over shares of common stock to consultants in exchange of certain services are similar to stock-based compensation (see Note 18). The Company had 5,821,137 total warrants outstanding as of December 31, 2021 and 2020, respectively, and an intrinsic value of $6,559 as of December 31, 2021 and $18,260 as of December 31, 2020.</span></div>DividendsThe Company has never declared or paid cash dividends on its shares of common stock or on Summit Therapeutics plc's ordinary shares. The Company currently intends to retain all of its future earnings to fund the development and expansion of its business.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140707898907056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text">Stock-Based Compensation <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2016 Long Term Incentive Plan</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, in conjunction with the Redomiciliation, the 2016 Long Term Incentive Plan, (the "2016 Plan") and the Company's outstanding restricted stock units ("RSUs") were assumed and adopted by Summit Therapeutics Inc., and all awards were exchanged with replacement awards issued. Subsequent to the Redomiciliation, no additional grants will be made under the 2016 Plan and any outstanding awards under the 2016 Plan and RSUs will continue with their original terms. The Company concluded that the adoption of the 2016 Plan and RSUs and issuance of replacement awards was a modification but with no change in the material rights and preferences and therefore, no recorded change in the fair value of each respective award is needed.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2020 Stock Award Plan</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, the Company&#8217;s Board of Directors approved the 2020 Stock Incentive Plan (the &#8220;2020 Plan&#8221;), which became effective on September 21, 2020. The 2020 plan provides for the grant of incentive stock options, nonqualified stock options, stock appreciation rights, restricted stock, restricted stock units and other stock-based awards. Upon the effectiveness of the 2020 Plan, the Company ceased granting awards under its 2016 Plan.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A total of 8,000,000 shares of common stock were initially reserved for issuance under the 2020 Plan. Additionally, up to 5,000,000 shares of common stock, including RSUs can be added to the 2020 Plan for future issuance from options that expire, lapse unexercised or are terminated from the 2016 Plan or any other predecessor plans. The number of shares of common stock that may be issued under the 2020 Plan will automatically increase on each January 1, beginning in 2021 and continuing for each fiscal year until, and including, the fiscal year ending December 31, 2030, equal to the lesser of (i) 6,400,000 shares of common stock, (ii) 4% of the common shares outstanding on the final day of the immediately preceding calendar year and (iii) an amount as determined by the Company&#8217;s Board of Directors. As of December 31, 2021, there are 2,293,700 shares available to be issued under the 2020 Plan.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2020 Employee Stock Purchase Plan</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2020 Employee Stock Purchase Plan (the "2020 ESPP") was adopted by the Board of Directors and approved by the Company's shareholders on July 17, 2020 and approved by the predecessor company shareholders on August 19, 2020. The 2020 ESPP initially authorized the issuance of up to 1,000,000 shares of  common stock to participating employees. The number of common shares that may be issued under the 2020 ESPP automatically increases on each fiscal year commencing January 1, 2021 and continuing for each fiscal year until, and including the fiscal year commencing on, January 1, 2030 equal to the least of (i) 1,600,000 shares of common stock, (ii) 1% of the common shares outstanding on such date and  (iii) an amount as determined by the Company&#8217;s Board of Directors. As of December 31, 2021, there were 1,825,750 shares available to be issued under the 2020 ESPP.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The first offering period of the 2020 ESPP plan consists of seven months, commenced on August 2, 2021 and will terminate on February 28, 2022. Offering periods thereafter will be six months in duration and will commence immediately proceeding the end of the previous offering period, unless otherwise determined by the Board of Directors or Compensation Committee. The next offering period commenced on March 1, 2022. Under the 2020 ESPP, eligible employees can purchase shares of common stock through payroll deductions of up to 15% of their compensation received during the plan period or such shorter period during which deductions from payroll are made, up to a defined maximum amount. The option price is determined based on the lesser of the closing price of common stock on (i) the first business day of the plan period or (ii) the exercise date, or shall be based solely on the closing price of the common stock on the exercise date; provided that such option price shall be at least 85% of the applicable closing price. In the absence of a determination by the Board of Directors or the Compensation Committee, the </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">option price is 85% of the lesser of the closing price of the common stock on (i) the first business day of the plan period or (ii) the exercise date. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The closing price is the (a) the closing price (for the primary trading session) on the Nasdaq Global Select Market or (b) the average of the closing bid and asked prices in the over-the-counter-market, whichever is applicable, as published in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Wall Street Journal</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or another source selected by the Board or the Committee. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock Option Valuation</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates the fair value of stock options granted to employees and directors using the Black-Scholes valuation model. Stock options granted under the 2016 and 2020 Plans generally vest over <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODEvZnJhZzoyOTEzNTMwMjlmMjQ0ZTQ0ODgzNDE5NTEzYjBhODA3Ny90ZXh0cmVnaW9uOjI5MTM1MzAyOWYyNDRlNDQ4ODM0MTk1MTNiMGE4MDc3XzQ4MzA_52cfade8-6eaf-42ea-82a4-09b084b53c45">three</span> or four years and expire after ten years. This valuation methodology utilizes several key assumptions as highlighted below.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The assumptions used in the Company's valuation are summarized as follows, presented on a weighted average basis: </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">       </span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.649%"><tr><td style="width:1.0%"/><td style="width:62.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.663%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.171%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.663%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.173%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:103%">Year Ended December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:103%">Year Ended December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.05&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.29&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.7</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.9</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected annual dividends per share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">The following table summarizes the Company's stock option activity for the year ended December 31, 2021:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:103%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">&#160;&#160;&#160;&#160;</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.490%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.087%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of share options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted average exercise price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted average remaining contractual term</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate intrinsic value </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,672,968&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.90&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.9 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,641&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Granted</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,262,016&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.76&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Forfeited</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,012,851)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.61&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Exercised</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,124,577)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.74&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December&#160;31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,797,556&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.6 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">712&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2021 - vested and expected to vest</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,685,817&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.51&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.6 years</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">709&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,598,709&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.2 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">406&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average grant-date fair value of stock options granted during the years ended December 31, 2021 and 2020 was $3.50 and $2.20, per share, respectively. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate intrinsic value of stock options exercised during the years ended December 31, 2021 and December 31, 2020  was $3,744 and $857, respectively. The aggregate intrinsic value of stock options is calculated as the difference between the exercise price of the stock options and the fair value of the Company&#8217;s common stock for those stock options that had exercise prices lower than the fair value of the Company&#8217;s common stock.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, total unrecognized compensation cost related to unvested stock option grants was approximately $27,905. This amount is expected to be recognized over a weighted average period of approximately 2.2 years.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In September 2021, the Compensation Committee of the Board of Directors approved a modification to the Company's outstanding performance-based stock option awards for active employees which removed the performance-based vesting criteria from these awards. Following this modification, the option awards are subject only to previously existing time-based vesting conditions. The Company accounted for this change as a modification in accordance with the requirements of Accounting Standards Codification Topic 718. As a result, 9,250,000 options, related to twenty-five employees, that were previously authorized that had not achieved a grant date became granted on September 24, 2021 relating to the modification.  The Company will recognize the newly assessed measurement date fair value of the awards as compensation expense over the remaining vesting period. The incremental compensation expense related to the modification for the year ended December 31, 2021 was $4,872. The stock option activity above incorporates the modified awards. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restricted Stock Units</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's outstanding restricted stock units ("RSUs") consist of nominal-cost options which were granted to non-executive directors. The following table summarizes the activity relating to RSUs for the year ended December 31, 2021:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:73.830%"><tr><td style="width:1.0%"/><td style="width:62.266%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.790%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.127%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.790%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.533%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.594%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Grant Date Fair Value</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs - beginning of period</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,923&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.60&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26,923)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.60&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs - end of period</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div style="margin-top:1pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate intrinsic value of restricted stock units vested during the years ended December 31, 2021 and December 31, 2020 was $125, respectively.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Warrants</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The fair value of warrants is estimated on the date of grant using the Black-Scholes valuation methodology. Expected volatilities are based on historical share price performance, weighted to exclude periods of unusually high volatility. The Company assumed the warrants to be exercised immediately on vesting. The risk-free rate is equal to the prevailing U.K. Gilts rate at grant date that most closely matches the expected term of the grant, as the warrants were issued prior to the Redomiciliation. Expected dividend yield is zero, and consistent with the Board of Directors&#8217; view that the Company&#8217;s business model is to generate value through capital growth rather than the payment of dividends.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Each warrant entitles the warrant holder to subscribe in cash for one share. Shares of common stock allotted pursuant to the exercise of the warrant will rank in full for all dividends and other distributions with a record date after the exercise date with the shares of common stock in issue at that date.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, 5,821,137 warrants were granted, of which 559,787 warrants were granted to consultants and 5,261,350 warrants were granted to investors (refer to Note 20 for further details). All warrants are considered vested at December 31, 2021, have a weighted-average exercise price of $1.56, an aggregate intrinsic value of $6,559, and a weighted average remaining contractual life of 4.0 years.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2021, there was no unrecognized compensation expense related to warrants. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock&#8209;based compensation expense related to stock options is recorded within the consolidated statements of operations and comprehensive loss as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.485%"><tr><td style="width:1.0%"/><td style="width:59.277%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.743%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.767%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.743%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.770%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:103%">Year Ended December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:103%">Year Ended December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">Research and development</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,909&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">749&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">General and administrative</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,895&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">1,017&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">Total stock-based compensation</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,804&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,766&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140707899038816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies <div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fixed asset purchase commitments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2021 and 2020, the Company had no capital commitments.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other commitments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into contracts in the normal course of business with various third parties for clinical trials, preclinical research studies and testing, manufacturing and other services and products for operating purposes. Most contracts provide for termination upon notice, and therefore are cancellable contracts. As of December 31, 2021, total contractual commitments are estimated to be approximately $17,046 and the majority of these commitments are due within one year.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Indemnifications</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's certificate of incorporation provides that it will indemnify the directors and officers to the fullest extent permitted by Delaware law. In addition, the Company has entered into indemnification agreements with all of the directors and executive officers. These indemnification agreements may require the Company, among other things, to indemnify each such director or executive officer for some expenses, including attorneys&#8217; fees, judgments, fines, and settlement amounts incurred by him or her in any action or proceeding arising out of his or her service as one of the Company's directors or executive officers. The Company believes the fair value for these indemnification obligations is minimal. Accordingly, the Company has not recognized any liabilities relating to these obligations as of December 31, 2021.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Legal Proceedings</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is not currently subject to any material legal proceedings.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140707899087680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text">Related Party Transactions <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&#160;6, 2019, the Company entered into a deed of termination of the relationship agreement with Mr. Robert W. Duggan and Cairn Financial Advisers LLP, a limited liability partnership incorporated in England and Wales with the Registrar of Companies of England and Wales, as the Company's nominated adviser. The relationship agreement regulated the Company&#8217;s relationship with Mr. Robert W. Duggan and limited Mr. Robert W. Duggan&#8217;s influence over the Company&#8217;s corporate actions and activities and the outcome of general matters pertaining to the Company. The deed of termination became effective on February 24, 2020, upon the cancellation of the admission of the ordinary shares on the Alternative Investment Market, a sub-market of the London Stock Exchanges.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">December 24, 2019 Private Placement</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 24, 2019, the Company completed a private placement of its common stock and received aggregate gross proceeds of $50,000 from the issuance and sale of 35,075,690 shares of common stock at a price of $1.43 per share, of which 33,231,410 shares of common stock were subscribed by Mr.&#160;Robert&#160;W. Duggan. Also, as part of the private placement, </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">participating investors were granted warrants with the right to subscribe for 5,261,350 shares of common stock at an exercise price of $1.58, of which 4,984,711 were granted to Mr. Robert W. Duggan at an exercise price of $1.43 per share for a subscription share plus a subscription warrant, pursuant to a securities purchase agreement he entered into with the Company.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In conjunction with the December 24, 2019 private placement, 90,495 shares of common stock were subscribed by Mr.&#160;Glyn Edwards, the Company's former Chief Executive Officer. Also as part of this private placement, Mr. Glyn Edwards was granted warrants with the right to subscribe for 13,574 shares of common stock at an exercise price of $1.43 per share for a subscription share plus a subscription warrant, pursuant to a securities purchase agreement he entered into with the Company. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">November 6, 2020 Private Placement</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 6, 2020 the Company completed a private placement of its common stock and received gross proceeds of $50,000 from the issuance and sale of 14,970,060 shares of common stock at a price of $3.34 per share, of which 14,071,856 shares of common stock were subscribed by Mr. Robert W. Duggan.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In conjunction with the November 6, 2020 private placement, 149,701 shares of common stock were subscribed by the Mahkam Zanganeh Revocable Trust. Dr. Maky Zanganeh was appointed to the Board of Directors on November 11, 2020 and became the Company's Chief Operations Officer on November 22, 2020. As trustee of the Mahkam Zanganeh Revocable Trust, Dr. Maky Zanganeh is deemed to beneficially own the securities of the Company held by the Mahkam Zanganeh Revocable Trust.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Consultancy Agreements</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, the Company had in place a consultancy agreement with Dr. Maky Zanganeh and Associates, Inc. (&#8220;MZA&#8221;) to provide support for clinical operation activities related to the global Phase III clinical program. Dr. Maky Zanganeh is the sole owner of MZA, and Dr. Elaine Stracker, who served for a period during fiscal year 2020 as a director of the Company and as the Company&#8217;s Interim Chief Operations Officer, was at the time the General Counsel and Senior Vice President for Corporate Development at MZA. The fees for such services under the consultancy agreement with MZA were $75 per month. In addition to such monthly fee, MZA was granted warrants over 3,358,732 shares of common stock with an exercise price of $1.44 per share, vesting on a quarterly basis over three years from the date of grant, subject to MZA&#8217;s provision of consultancy services to the Company during such period. During the period of MZA's engagement, $470 of consultancy fees were incurred by the Company and a warrant expense of $512 was recognized. The consultancy agreement with MZA was terminated by mutual agreement on June 30, 2020. The warrants granted to MZA were subsequently assigned to Dr. Maky Zanganeh and Dr. Elaine Stracker. Dr. Maky Zanganeh and Dr. Elaine Stracker have vested warrants to purchase 489,815 and 69,972 shares of common stock, respectively, which can be exercised through June 30, 2025.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">March 24, 2021 Note Purchase Agreement</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 24, 2021, Mr. Robert W. Duggan, entered into a Note Purchase Agreement (the &#8220;Initial Purchase Agreement&#8221;) pursuant to which he has loaned the Company $55,000 in exchange for the issuance by the Company of an unsecured promissory note (the &#8220;Initial Note&#8221;) in the amount of $55,000. The Initial Note was to accrue interest at a rate per annum equal to 150% of the applicable 10 Year U.S. Treasury rate, as adjusted monthly. The rate is initially estimated to be approximately 2.4%. The terms of the Initial Note were that it would mature and become due upon the earlier of (i) the consummation of a registered public offering with net proceeds of no less than $55,000, or (ii) 13 months from the date of issuance of the Initial Note. On April 20, 2021, the Company determined, with Mr. Duggan&#8217;s agreement, to rescind both the Initial Purchase Agreement and the Initial Note issued thereunder, and repaid the principal amount of the Initial Note in full, without interest or penalty, as such for the year ended December 31, 2021, the Company recognized imputed interest of $103 within additional paid in capital. For the year ended December 31, 2021, debt issuance costs recognized related to the Initial Note were immaterial.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">March 26, 2021 Sublease Agreement with Dr. Maky Zanganeh and Associates, Inc.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 26, 2021, the Company entered into a sublease with Dr. Maky Zanganeh and Associates, Inc. ("MZA") consisting of 4,500 square feet of office space at 2882 Sand Hill Road, Menlo Park, CA (the &#8220;Sublease&#8221;). Dr. Maky Zanganeh is the sole owner of MZA. The sublease runs until September 2022. The rent payable under the terms of the sublease is equivalent to the proportionate share of the rent payable by MZA to the third-party landlord, based on the square footage of office space sublet by the Company, and no mark-up has been applied. During the year ended December 31, 2021, payments of $556, were made pursuant to the sublease.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">April 20, 2021 Note Purchase Agreement</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 20, 2021, subsequent to the repayment of the Initial Note, Mr. Robert W. Duggan entered into a second Note Purchase Agreement (the &#8220;Second Purchase Agreement&#8221;) pursuant to which he loaned the Company $55,000 in exchange for the issuance by the Company of an unsecured promissory note (the &#8220;Second Note&#8221;) in the amount of $55,000. The Second Note accrued interest at a rate per annum equal to 150% of the applicable 10 Year US Treasury rate, as adjusted monthly (initially estimated to be approximately 2.4%). The Company was permitted to prepay any portion of the second note at its option without penalty.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">May 12, 2021 Rights Offering</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 12, 2021, the Company closed its rights offering, which was fully subscribed. Aggregate gross proceeds from the rights offering of $75,000 from the sale of&#8239;14,312,976&#8239;shares of the Company's common stock, of which 11,365,921 shares were purchased by Mr. Robert W. Duggan and 389,977 shares were purchased by Dr. Maky Zanganeh, at price of $5.24 per share. In connection with the closing of the rights offering, the Second Note, issued by the Company in favor of Mr. Robert W. Duggan, matured and became due and was repaid using a portion of the proceeds from the rights offering.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140707898975424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Event<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Event</a></td>
<td class="text">Subsequent Event<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">On March 10, 2022, Mr. Robert W. Duggan, entered into a Note Purchase Agreement (the &#8220;2022 Note&#8221;), pursuant to which he has loaned the Company $25,000 in exchange for the issuance by the Company of an unsecured promissory note in the amount of $25,000. The 2022 Note is to accrue interest at a rate per annum equal to the prime rate as reported in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%">Wall Street Journal</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">, which is 3.25% as of the effective date. The 2022 Note becomes due upon the earlier of (i) the consummation of a registered public offering with net proceeds of no less than $25,000 or (ii) 18 months from the date of issuance of the 2022 Note.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140707892740800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text">The consolidated financial statements include the accounts of Summit Therapeutics Inc. and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.The consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States ("U.S. GAAP") and pursuant to the rules and regulations of the U.S. Securities and Exchange Commission.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text">The preparation of these financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. On an on-going basis, management evaluates its estimates and judgments, including those related to revenue recognition, accrued research and development expenses, stock-based compensation, intangible assets, goodwill, other long-lived assets and income taxes. Management bases its estimates and judgments on historical experience and on various other factors that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires the use of estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text">Principles of Consolidation The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) and pursuant to the rules and regulations of the U.S. Securities and Exchange Commission. The consolidated financial statements include the accounts of Summit Therapeutics Inc. and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency Translation</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Foreign Currency Translation</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The financial statements of the Company&#8217;s subsidiaries with functional currencies other than the U.S. dollar are translated into U.S. dollars using period-end exchange rates for assets and liabilities, historical exchange rates for stockholders&#8217; equity and weighted average exchange rates for operating results. Translation gains and losses are included in accumulated other comprehensive (loss) income in shareholders&#8217; equity. Foreign currency transaction gains and losses are included in other (expense) income, net in the results of operations. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company recorded realized and unrealized foreign currency transaction (losses) gains of $(2,135) and $54 for the years ended December 31, 2021 and 2020, respectively, which is included in other (expense) income in the statements of operations and comprehensive loss.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:103%">Revenue Recognition </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for revenue using Accounting Standards Codification ("ASC") 606 ("ASC 606"). This standard applies to all contracts with customers, except for contracts that are within the scope of other standards.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company enters into out-licensing agreements within the scope of ASC 606 under which it licenses certain rights to its product candidates to third parties. Such agreements may include the transfer of intellectual property rights in the form of licenses, transfer of technological know-how, delivery of drug substances, research and development services, and participation on certain committees with the counterparty. Payments made by the customers may include one or more of the following: non-refundable, up-front license fees; development, regulatory, and commercial milestone payments; payments for manufacturing supply services the Company provides through its contract manufacturers; and royalties on net sales of licensed products if they are successfully approved and commercialized. Each of these payments may result in license, collaboration, or other revenue, except revenue from royalties on net sales of licensed products, which would be classified as royalty revenue.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining the appropriate amount of revenue to be recognized as the Company fulfills its obligations under each of its out-licensing agreements, the following steps are performed: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations and assesses whether each promised good or service is distinct. Revenue is then recognized in respect of the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. As part of the accounting for these arrangements, the Company must use significant judgment to determine: (a) the performance obligations based on the determination under step (ii) above; (b) the transaction price under step (iii) above; and (c) the standalone selling price for each performance obligation identified in the contract for the allocation of transaction price in step (iv) above. The Company also uses judgment to determine whether milestone payments or other variable consideration, except for royalties and sales-based milestones, should be included in the transaction price, as described below. The transaction price is allocated to each performance obligation based on the relative standalone selling price of each performance obligation in the contract, and the Company recognizes revenue based on those amounts when, or as, the performance obligations under the contract are satisfied.</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Exclusive Licenses</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the license to the Company&#8217;s intellectual property is determined to be distinct from the other promises or performance obligations identified in the arrangement, the Company recognizes revenue from nonrefundable, upfront fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. In assessing whether a promise or performance obligation is distinct from the other promises, the Company considers factors such as the research, development, manufacturing and commercialization capabilities of the collaboration partner and the availability of the associated expertise in the general marketplace. In addition, the Company considers whether the collaboration partner can benefit from a promise for its intended purpose without the receipt of the remaining promises, whether the value of the promise is dependent on the unsatisfied promises, whether there are other vendors that could provide the remaining promises, and whether it is separately identifiable from the remaining promises. For licenses that are combined with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of progress and related revenue recognition. The measure of progress, and the resulting periods over which revenue should be recognized, are subject to estimates by management and may change over the course of the research, development and licensing arrangement. Such a change could have a material impact on the amount of revenue the Company records in future periods. Under the Company&#8217;s existing license and collaboration agreements, the Company has concluded that the transfer of control to the customer occurs over the time period that the research and development services are to be provided by the Company, and this output method is, in management&#8217;s judgment, the best measure of progress towards satisfying the performance obligation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Milestone Payments</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of each arrangement that includes potential research, development or regulatory milestone payments, the Company evaluates whether the milestones are considered likely to be met and estimates the amount to be considered for inclusion in the transaction price using the most-likely-amount method. If it is probable that a significant reversal in the amount of cumulative revenue recognized would not occur, the associated milestone payment value is included in the transaction price. For milestone payments due upon events that are not within the control of the Company or the licensee, such as regulatory approvals, the Company is not able to assert that it is likely that the regulatory approval will be granted and that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur until those approvals are received. In making this assessment, the Company evaluates factors such as the scientific, clinical, regulatory, commercial and other risks that must be overcome to achieve the particular milestone. There is considerable judgment involved in determining whether it is probable that a significant reversal in the amount of cumulative revenue recognized would not occur. At the end of each subsequent reporting period, the Company reevaluates the probability of achievement of all milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price of the arrangement. Any such adjustments are recorded on a cumulative catch-up basis, which would affect the amounts of revenue and earnings in the period of adjustment.</span></div><div><span><br/></span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalties</span></div>For arrangements that include sales-based royalties, including milestone payments due upon first commercial sales or based on a level of sales, that are the result of a customer-vendor relationship and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) the occurrence of the related sales or (ii) the date upon which the performance obligation to which some or all of the royalty has been allocated has been satisfied or partially satisfied. To date, the Company has not recognized any royalty revenue from any of its licensing arrangements.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_OtherOperatingIncomePolicyPolicyTextBlock', window );">Other Operating Income</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Operating Income</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company generates income from government contracts that reimburse the Company for certain allowable costs for funded projects. For contracts with government agencies where the funding arrangement is considered central to the Company&#8217;s ongoing operations, the Company classifies the recognized funding received as other operating income.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income from government grants is recognized as the qualifying expenses related to the contracts are incurred, provided that there is reasonable assurance of recoverability. If the government agency approves the project proposed by the Company, the government agency funds the project upon receipt of the support for the costs incurred up to the contract limit. Income recognized upon incurring qualifying expenses in advance of billing is recorded as accrued income, a component of other current assets, in the consolidated balance sheet.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Grant income is not recognized as deductions of research and development costs because the Company acts as the principal in conducting the research and development activities and these contracts are central to its ongoing operations. The funds received through these means are held as deferred income in the consolidated balance sheets and are released to the consolidated statement of operations and comprehensive loss as the underlying expenditure is incurred and to the extent the conditions of the grant are met. The related costs incurred by the Company are included in research and development expense in the Company&#8217;s consolidated statements of operations and comprehensive loss.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company benefits from two U.K. research and development ("R&amp;D") tax credit cash rebate regimes: Small and Medium Enterprise ("SME") Program and the Research and Development Expenditure Credit ("RDEC") Program. Each reporting period, management evaluates which tax relief programs the Company is expected to be eligible for and records as other operating income the portion of the expense that it expects to qualify under the programs, that it plans to submit a claim for, and it has reasonable assurance that the amount will ultimately be realized. Based on criteria established by HM Revenue and Customs (&#8220;HMRC&#8221;), management of the Company expects a proportion of expenditures being undertaken in relation to its pipeline research, clinical trials management and manufacturing development activities to be eligible for the research and development tax relief programs for the year ended December 31, 2021. Qualifying expenditures largely comprise of employment costs for research staff, consumables, a proportion of relevant, permitted sub-contract costs and certain internal overhead costs incurred as part of research projects for which the Company does not receive commercial or other funding income. Credits related to the SME and RDEC Programs are recorded as other operating income in the consolidated statements of operations and other comprehensive (loss)/income. Under both schemes, the Company receives cash rebate payments of up to 33.3% of eligible research and development expenditures and these payments are not dependent on the Company&#8217;s pre-tax net income levels. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company has qualified under the more favorable SME regime for the year ended December 31, 2020 and expects to qualify under the SME regime for the year ending December 31, 2021.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Income Per Share</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Net Income Per Share</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Basic net loss per share is computed by dividing the net loss by the weighted-average number of common shares outstanding for the period. Diluted net loss per share is computed by dividing the diluted net loss by the weighted-average number of common shares outstanding for the period, including potentially dilutive common shares. The dilutive effect of share options and warrants are determined under the treasury stock method using the average market price for the period.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, the assumed proceeds under the treasury stock method include the average unrecognized compensation expense of stock options and warrants that are in-the-money.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationsPolicy', window );">Business Combinations</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Business Combinations </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Business combinations are accounted for under the acquisition method. Acquired assets and assumed liabilities are measured at their fair values at the acquisition date. The excess of the consideration transferred over the net fair value of assets acquired and liabilities assumed is recorded as goodwill. The accounting for an acquisition involves a considerable amount of judgement and estimation. Cost, income, market or a combination of approaches may be used to establish the fair value of consideration exchanged, assets acquired, and liabilities assumed, depending on the nature of those items.  The valuation approach is </span></div>determined in accordance with generally accepted valuation methods. Key areas of estimation and judgment may include the selection of valuation approaches, cost of capital, market characteristics, cost structure, impacts of synergies, and estimates of terminal value, among other factors.While the Company uses estimates and assumptions as part of the purchase price allocation process to estimate the value of assets acquired and liabilities assumed, estimates are inherently uncertain and subject to refinement. During the measurement period, which maybe up to one year from the acquisition date, the Company may record adjustments to the assets acquired and liabilities assumed, with a corresponding offset to goodwill, to the extent that adjustments are identified to the preliminary purchase price allocation. Upon conclusion of the measurement period, or final determination of the value of the assets acquired and liabilities assumed, whichever comes first, any subsequent adjustments are recorded to results of operations. Results of operations related to business combinations are included prospectively beginning with the date of acquisition and transaction costs related to business combinations are recorded within general and administrative expenses.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy', window );">Goodwill</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:102%">Goodwill</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill represents the excess of the consideration transferred over the fair value of net assets acquired. Goodwill is assigned to reporting units at the time of acquisition or when there is a change in the reporting structure and bases that allocation on which reporting units will benefit from the acquired assets and liabilities. Reporting units are defined as operating segments or one level below an operating segment, referred to as a component. The Company assesses goodwill for impairment on an annual basis or more frequently when events and circumstances occur indicating that the recorded goodwill may be impaired.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In performing the Company&#8217;s annual goodwill impairment test, the Company is permitted to first assess qualitative factors to determine whether it is more likely than not that the fair value of the Company&#8217;s reporting unit is less than its carrying amount, including goodwill. In performing the qualitative assessment, the Company considers certain events and circumstances specific to the reporting unit and to the entity as a whole, such as macroeconomic conditions, industry and market considerations, overall financial performance and cost factors when evaluating whether it is more likely than not that the fair value of the reporting unit is less than its carrying amount. The Company is also permitted to bypass the qualitative assessment and proceed directly to the quantitative test. If the Company chooses to undertake the qualitative assessment and concludes that it is more likely than not that the fair value of the reporting unit is less than its carrying amount, the Company would then proceed to the quantitative impairment test. In the quantitative assessment, the Company compares the fair value of the reporting unit to its carrying amount, which includes goodwill. If the fair value exceeds the carrying value, no impairment loss exists. If the fair value is less than the carrying amount, a goodwill impairment loss is measured and recorded.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy', window );">Intangible Assets</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Intangible Assets </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets include patents, licenses, an option over non-financial assets and a research and development discovery platform ("Discuva Platform").</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Patents, licenses, and the option over non-financial assets are initially recorded at fair value, assigned an estimated useful life, and amortized primarily on a straight-line basis over their estimated useful lives. The Company evaluates the recoverability of its intangible and long-lived assets whenever events and changes in circumstances indicate that the carrying amount of an asset may not be fully recoverable. If events and circumstances indicate that the carrying amount may not fully be recoverable, the Company will perform a qualitative assessment, and consider certain events and circumstances specific to the intangible asset and to the entity as a whole, such as macroeconomic conditions, industry and market considerations, overall financial performance and cost factors when evaluating whether it is more likely than not that the fair value of the intangible asset is less than its carrying amount. This periodic review may result in an adjustment of estimated depreciable lives or asset impairment. When indicators of impairment are present, the carrying values of the asset are evaluated in relation to their operating performance and future undiscounted cash flows of the underlying business. If the future undiscounted cash flows are less than their carrying value, impairment exists. The impairment is measured as the difference between the carrying value and the fair </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">value of the underlying asset. Fair values are based on estimates of market prices and assumptions concerning the amount and timing of estimated future cash flows and assumed discount rates, reflecting varying degrees of perceived risk.</span></div><div><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other intangible assets are amortized in equal installments over their estimated useful lives as follows: </span></div><div style="margin-bottom:9pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.057%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.455%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:55.188%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intangible Asset</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortization Period</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Option over non-financial assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Over the period of the relevant agreement</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of intangible assets is included as part of the research and development expense line shown on the face of the consolidated statement of operations and comprehensive loss.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Property and Equipment </span></div><div style="margin-bottom:9pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are stated at cost less accumulated depreciation. Cost comprises the purchase price plus any incidental costs of acquisition and commissioning. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation is calculated based on cost, less residual value, in equal annual installments over the estimated useful lives of the assets. The residual value, if not insignificant, is reassessed annually.</span></div><div style="margin-bottom:9pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.057%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:60.743%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Over the shorter of the asset's useful life or the remaining lease term</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2-10 years </span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office and IT equipment</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3-5 years</span></div></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation is recognized as part of the general and administrative and research and development expense lines shown on the face of the consolidated statement of operations and comprehensive loss depending on the nature of the underlying assets.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expenditures for repairs and maintenance are expensed as incurred. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation are removed from the accounts and any resulting gain or loss is included in loss from operations.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Leases</span></div><div><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has operating leases for real estate. The Company does not have any finance leases. Under Accounting Standards Codification 842, a contract is or contains a lease when the lessee has the right to control the use of an identified asset. The Company determines if an arrangement is a lease at inception of the contract, which is the date on which the terms of the contract are agreed to and the agreement creates enforceable rights and obligations. The lease term used to calculate the lease liability include options to extend or terminate the lease when it is reasonably certain that the option will be exercised.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the lease commencement date, the Company measures and recognizes a lease liability and a right-of-use asset in the financial statements. Lease liabilities are recognized based on the present value of the future lease payments over the lease term at commencement date. The right-of use asset is measured by taking the present value of future lease payments, plus any incremental direct costs incurred, less any lease incentives received. As most of the Company's leases do not provide an implicit rate, the Company uses an estimated incremental borrowing rate based on the lease term and the economic environment of the lease at the lease commencement date, which is then utilized to determine the present value of future lease payments. Lease expense for minimum lease payments are recognized on a straight-line basis over the lease term, with variable lease payments recognized in the periods in which they are incurred.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has existing lease agreements with lease and non-lease components, has elected to account for the lease and non-lease components as a single lease component, and has allocated all of the contract consideration to the lease component only. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leases with an initial lease term of 12 months or less are not recorded on the balance sheet. The Company recognizes lease expense for its short-term leases on a straight-line basis over the lease term.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development Costs</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed as incurred. Research and development expenses consist of costs incurred to discover, research and develop product candidates, including personnel expenses, stock-based compensation expense, allocated facility-related and depreciation expenses, third-party license fees and external costs of outside vendors engaged to conduct preclinical and clinical development activities and clinical trials as well as to manufacture clinical trial materials. Non - refundable prepayments for goods or services that will be used or rendered for future research and development activities are recorded as prepaid expenses. Such amounts are recognized as an expense as the goods are delivered or the related services are performed, or until it is no longer expected that the goods will be delivered, or the services rendered. Milestone and other payments made to third-parties with respect to in-process research and development, in accordance with the Company&#8217;s license, acquisition and other similar agreements are expensed when determined to be probable and estimable.</span></div><div><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into various research and development contracts with other companies. These agreements are generally cancellable, and related payments are recorded as research and development expenses as incurred. The Company records accruals for estimated ongoing research and development costs or prepaid expenses where the payments made exceeds the estimated costs. When evaluating the adequacy of these balances, the Company analyzes progress of the studies, including the estimated costs to complete each study or activity, the estimation of the current stage of completion and the invoices received, as well as predetermined milestones which are not reflective of the current stage of development for prepaid expenses. Actual results could differ from the Company&#8217;s estimates. In all cases, the full cost of each study or activity is expensed by the time the final report or where applicable, product, has been received. The Company&#8217;s historical estimates have not been materially different from the actual costs.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock-Based Compensation </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures and recognizes compensation expense for all stock option and restricted stock unit awards based on the estimated fair value of the award on the grant date. The Company uses the Black-Scholes option pricing model to estimate the fair value of stock option awards. The fair value is recognized as expense, over the requisite service period, which is generally the vesting period of the respective award, on a straight-line basis for each separately vesting portion of the award when the only condition to vesting is continued service.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If vesting is subject to a market or performance condition, recognition is based on the derived service period of the award. Expense for awards with performance conditions is estimated and adjusted on a quarterly basis based upon the assessment of the probability that the performance condition will be met. Use of the Black-Scholes option-pricing model requires management to apply judgment under highly subjective assumptions.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These assumptions include:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Expected term&#8212;The expected term of stock options represents the weighted-average period the stock options are expected to be outstanding. The Company uses the simplified method for estimating the expected term as provided by the Securities and Exchange Commission. The simplified method calculates the expected term as the average of the time-to-vesting and the contractual life of the options.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Expected volatility&#8212;The expected volatility was calculated based on historical volatility of the Company's share price.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Risk-free interest rate&#8212;The risk-free rate assumption is based on the U.S. Treasury instruments, the terms of which were consistent with the expected term of the Company&#8217;s stock options.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Expected dividend&#8212;The expected dividend assumption is based on the Company&#8217;s history and expectation of dividend payouts. The Company has not paid and does not intend to pay dividends. </span></div>The Company estimates expected forfeitures at the time of grant instead of accounting for forfeitures as they occur. Stock option and restricted stock unit awards have been granted at fair value to non-employees, in connection with research and consulting services provided to the Company, to non-employees in connection with corporate activities, and to employees, in connection with Stock Purchase and Restriction Agreements. Equity awards generally vest over terms of 3 or 4 years.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes is determined using the asset and liability approach. Tax laws may require items to be included in tax filings at different times than the items are reflected in the financial statements. A current asset or liability is recognized for the estimated taxes receivable or payable for the current year. Deferred taxes represent the future tax consequences expected to occur when the reported amounts of assets and liabilities are recovered or paid. Deferred taxes are initially recognized at enacted tax rates in force at the time of initial recognition and are subsequently adjusted for any enacted changes in tax rates and tax laws. Subsequent changes to deferred taxes originally recognized in equity are recognized in income. Valuation allowances are recorded to reduce deferred tax assets when it is more likely than not that a tax benefit will not be realized. The Company has recorded a full valuation allowance against the deferred tax assets in excess of its deferred tax liabilities, as the deferred tax liability represents future reversals of existing taxable temporary differences. The Company records interest and penalties related to income tax matters as part of income tax expense.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk and of Significant Supplier</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentration of Credit Risk and of Significant Supplier</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of short-term cash deposits and accounts and other receivables. The Company's cash is comprised of short-term cash deposits at a variety of financial institutions with strong credit ratings in amounts that may exceed federally insured limits and has not experienced any losses on such accounts. Cash balances maintained during the year have been principally held with reputable U.K.-based and U.S.-based banks. The Company does not believe it is exposed to any unusual credit risk beyond the normal credit risk associated with commercial banking relationships.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains deposits in accredited financial institutions in excess of federally insured limits. The Company deposits its cash in financial institutions that it believes have high credit quality and has not experienced any losses on such accounts and does not believe it is exposed to any unusual credit risk beyond the normal credit risk associated with commercial banking relationships.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The credit risk with respect to customers and funding bodies is limited as the Company has only a small number of these arrangements, including with Eurofarma, BARDA and CARB-X. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company relies, and expects to continue to rely, on a number of vendors to conduct its clinical trials and preclinical studies, manufacture drug product and supply clinical trial and preclinical study materials for its development programs. These programs could be adversely affected by a significant interruption in these services or the availability of materials.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Financial Value Measurements</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:103%">Fair Value Measurements</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with the provisions of fair value accounting, a fair value measurement assumes that the transaction to sell an asset or transfer a liability occurs in the principal market for the asset or liability or, in the absence of a principal market, the most advantageous market for the asset or liability and defines fair value based on the exit price model.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value measurement guidance establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The guidance describes three levels of inputs that may be used to measure fair value:</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 1</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Quoted prices in active markets for identical assets or liabilities as of the reporting date. Active markets are those in which transactions for the asset or liability occur in sufficient frequency and volume to provide pricing information on an ongoing basis.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 2</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 2 assets and liabilities include debt securities with quoted prices that are traded less </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">frequently than exchange-traded instruments or securities or derivative contracts that are valued using a pricing model with inputs that are observable in the market or can be derived principally from or corroborated by observable market data.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 3</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Level 3 assets and liabilities include financial instruments whose value is determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant management judgment or estimation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, the Company categorizes such assets and liabilities based on the lowest level input that is significant to the fair value measurement in its entirety. The Company&#8217;s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the asset.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_AssumedContingentLiabilitiesPolicyPolicyTextBlock', window );">Assumed Contingent Liabilities</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Assumed Contingent Liabilities</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the acquisition of Discuva Limited in December 2017, the Company assumed certain contingent liabilities as certain employees, former employees and former directors of Discuva Limited are eligible for payments from Discuva Limited based on specified development and clinical milestones related to proprietary product candidates developed under the Discuva Platform. The timing of these potential payments is uncertain. The fair value of the assumed contingent liability was estimated using the expected value of the payments. The assumed contingent liabilities are subsequently measured at amortized cost using discounted cash flow models which calculate the risk adjusted net present values of estimated potential future cash flows of the payments. The assumed contingent liabilities are remeasured when there is a specific significant event that provides evidence of a significant change in the probability of successful development and clinical milestones being achieved. The models will be updated for changes in the probability of successful development and clinical milestones being achieved and other associated assumptions with the discount factor remaining unchanged within the model. A discount factor of 13% has been used to discount the contingent liabilities back to net present value. This discount factor has been calculated using appropriate measures and rates which could have been obtained in the period that the contingent liabilities were assumed. Accretion of the discount factor is recognized as part of operating expenses in the consolidated statements of operations and comprehensive loss.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_WarrantsPolicyPolicyTextBlock', window );">Warrants</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Warrants</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrants issued by the Company are recognized and classified as equity when, upon exercise, the Company would issue a fixed amount of its own equity instruments (common stock) in exchange for a fixed amount of cash or another financial asset.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consideration received, net of incremental costs directly attributable to the issue of such new warrants, is shown in equity. Such warrants are not remeasured at fair value in subsequent reporting periods.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrants issued in which external services are received as consideration for equity instruments of the company should be measured at the fair value of the goods or services received. Only if the fair value of the services cannot be measured reliably would the fair value of the equity instruments granted be used. The fair value for the warrants is calculated using the Black-Scholes formula and recorded in the consolidated statement of operations and comprehensive loss</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on a straight-line basis over the period of the consulting services. If the services are terminated prior to the end of the consultancy agreement, the warrants cease vesting and any unvested portion of the warrants will lapse immediately.</span></div>The warrants in issue are classified within stockholders&#8217; equity as they are indexed to the Company's own shares of common stock and require settlement in its shares of common stocks with no provision for any cash settlement.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Issued or Adopted Accounting Pronouncements</a></td>
<td class="text">Recently Issued or Adopted Accounting Pronouncements <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2021-10, " Government Assistance (Topic 832)." This ASU increases the transparency of government assistance including the disclosure of (1) the types of assistance, (2) an entity's accounting for the assistance, and (3) the effect of the assistance on an entity's financial statements as diversity currently exists in the recognition, measurement, presentation and disclosure of government assistance received by business entities because of the lack of specific authoritative guidance in U.S. GAAP. This ASU is effective for annual periods, and interim periods within those fiscal years, beginning after December 15, 2021. Early application of this ASU is permitted. The Company applied the amendments of this ASU to its disclosures during the fourth quarter of 2021 and the application of this ASU did not have a material impact on its financial position, results of operations or cash flows.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, the FASB issued ASU No. 2021-08, "Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers." This ASU improves the accounting for acquired revenue contracts with customers in a business combination by addressing diversity in practice and inconsistency relating to: 1) recognition of an acquired contract liability and 2) payment terms and their effect on subsequent revenue recognized by the acquirer. The amendments in this ASU require acquiring entities to apply Topic 606 to recognize and measure contract assets and contract liabilities in a business combination, whereas current U.S. GAAP requires that the acquirer measure such assets and liabilities at fair value on the acquisition date. This ASU is effective for annual periods, and interim periods within those fiscal years, beginning after December 15, 2022. The Company will apply this ASU on a prospective basis for business combinations once this ASU is effective and at that time, will be able to determine the potential impact on its financial position, results of operations or cash flows.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, the FASB issued AS No. 2021-04, "Earnings Per Share (Topic 260), Debt - Modifications and Extinguishments (Subtopic 470-50), Compensation - Stock Compensation (Topic 718), and Derivatives and Hedging Contracts in Entity's Own Equity (Subtopic 815-40) - Issuer's Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options." This ASU provides clarification and reduces diversity in an issuer&#8217;s accounting for modifications or exchanges of freestanding equity-classified written call options (such as warrants) that remain equity classified after modification or exchange. This ASU is effective for annual periods, and interim periods within those fiscal years, beginning after December 15, 2021. The Company will apply this ASU on a prospective basis for any modifications or exchanges once this ASU is effective and at that time, will be able to determine the potential impact on its financial position, results of operations or cash flows.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU No. 2019-12, "Income Taxes (Topic 740)." This ASU simplifies the accounting for income taxes by removing certain exceptions to the general principles in Topic 740. The amendments also improve consistent application and simplify U.S. GAAP for other areas of Topic 740 by clarifying and amending existing guidance. This ASU is effective for annual periods, and interim periods within those fiscal years, beginning after December 15, 2020. The Company adopted this ASU during the first quarter of 2021 and the adoption of this ASU did not have a material impact on its financial position, results of operations or cash flows.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_AssumedContingentLiabilitiesPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Assumed Contingent Liabilities, Policy</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_AssumedContingentLiabilitiesPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_OtherOperatingIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Operating Income, Policy</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_OtherOperatingIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_WarrantsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants, Policy</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_WarrantsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (a)-(d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6909625&amp;loc=d3e227-128457<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123345438&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13279-108611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI http://asc.fasb.org/topic&amp;trid=2175825<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140707898904464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of acquired intangible assets</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other intangible assets are amortized in equal installments over their estimated useful lives as follows: </span></div><div style="margin-bottom:9pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.057%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.455%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:55.188%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intangible Asset</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortization Period</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Option over non-financial assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Over the period of the relevant agreement</span></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Components of the Company's acquired intangible assets are comprised of the following:</span></div><div style="margin-top:6pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.836%"><tr><td style="width:1.0%"/><td style="width:49.293%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.587%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.587%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.587%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.650%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated amortization and impairment charges</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Utrophin program acquired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,487&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,487)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Discuva platform acquired</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,416&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,017)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,399&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Option over non-financial asset</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">912&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(912)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other patents and licenses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(148)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,963&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,564)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,399&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.397%"><tr><td style="width:1.0%"/><td style="width:49.532%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.591%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.564%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.591%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.564%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.591%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.567%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated amortization and impairment charges</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Utrophin program acquired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,534&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,534)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Discuva platform acquired</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,565&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,050)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,515&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Option over non-financial asset</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">921&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(921)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other patents and licenses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(150)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,170&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,655)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,515&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the year ended December 31, 2020, management identified an impairment related to the option over non-financial asset pursuant to an Evaluation and Option Agreement with a collaboration partner. The partner is no longer conducting antibiotic candidate programs over which the Company had the option, management therefore determined that the fair value of the option to acquire the assignment of the proprietary rights for antibiotic candidates is $0. Accordingly, the asset was written off in its entirety resulting in an impairment charge of $859 recognized in operating expenses.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of property and equipment useful lives</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation is calculated based on cost, less residual value, in equal annual installments over the estimated useful lives of the assets. The residual value, if not insignificant, is reassessed annually.</span></div><div style="margin-bottom:9pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.057%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:60.743%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Over the shorter of the asset's useful life or the remaining lease term</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2-10 years </span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office and IT equipment</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3-5 years</span></div></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consisted of the following:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.421%"><tr><td style="width:1.0%"/><td style="width:58.367%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.774%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.582%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.777%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,626&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">759&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures, office equipment and software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,081&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">804&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">364&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">291&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, gross</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,071&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,854&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,377&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,129&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">694&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">725&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140707898985616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock', window );">Summary of long-lived assets by geography</a></td>
<td class="text">The following table summarizes the Company's long-lived assets, which include the Company's property and equipment, net and right-of-use assets by geography: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.467%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,762&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,228&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">722&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,484&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,279&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-lived assets, excluding financial instruments, long-term customer relationships of a financial institution, mortgage rights, deferred policy acquisition costs, and deferred tax assets, by geographic areas located in the entity's country of domicile and foreign countries in which the entity holds assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140707895093520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock', window );">Summary of revenue by category</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes revenue by category:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.467%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue by category:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licensing agreements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,809&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">860&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock', window );">Summary of revenue by geography</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes revenue by geography:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.467%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue by geography:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Latin America</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,809&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">860&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,809&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">860&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock', window );">Summary of deferred revenue and other income</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the deferred revenue relating to Eurofarma Laborat&#243;rios S.A. and deferred other income relating to BARDA (as defined in Note 8), respectively:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.836%"><tr><td style="width:1.0%"/><td style="width:82.049%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.902%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.649%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning deferred revenue and other income, January 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,939&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,438</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amount of deferred revenue and other income recognized in the statement of operations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,438)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending deferred revenue and other income, December 31</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,939&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">__________</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning deferred revenue and other income included $8,370 of current deferred revenue and other income and $569 of long-term deferred revenue and other income.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ending deferred revenue and other income is classified within current liabilities.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph a<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140707899038816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Operating Income (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other Income and Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_ScheduleOfOtherOperatingIncomeByComponentTableTextBlock', window );">Summary of other operating income by category</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the components of other operating income by category:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.467%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other operating income by category:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Funding income from BARDA (as defined below)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,604&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,472&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development tax credits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,206&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,363&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Grant income from CARB-X (as defined below)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,158&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">477&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,968&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,312&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_ScheduleOfOtherOperatingIncomeByComponentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of Other Operating Income, by Component</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_ScheduleOfOtherOperatingIncomeByComponentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140707898940384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other (Expense) Income (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other Income and Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock', window );">Schedule of other (expense) income</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the components of other (expense) income:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.467%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign currency (loss) gain</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,135)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Remeasurement of liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">480&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(281)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(255)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,416)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">283&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_____________</span></div>(1) Remeasurement of liabilities during the year ended December 31, 2020, relates to a revaluation of assumed contingent liabilities for potential payments to certain employees, former employees and former directors of Discuva Limited, based on specified development and clinical milestones related to proprietary product candidates developed under the Discuva Platform (see Note 16 for further details).<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140707892151824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Tax (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Components of loss before income taxes</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of the Company's loss before income taxes are as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.467%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United Kingdom</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(72,244)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(51,197)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,358)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,713)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(88,602)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52,910)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Significant components of the provision for income taxes</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant components of the provision for income taxes are as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.198%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current income tax benefit:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Federal United States</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(215)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State - United States</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-United States</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(213)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Federal - United States</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State - United States</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-United States</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total deferred tax</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total income tax benefit</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(213)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Major components of deferred tax assets and liabilities</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The major components of deferred tax assets and liabilities are as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.742%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.467%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.468%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net operating loss carryforward</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,422&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,831&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development credit carryforward</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">941&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,560&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,167</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,477&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">491</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,400&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,489</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible asset</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,600)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,189)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(71)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,654)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,260)</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net deferred tax assets before valuation allowance </span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,746</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,229</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51,746)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29,229)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax, net</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Reconciliation of the effective income tax rate to the statutory rate</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the Company's effective tax rate to the U.S. federal statutory rate is as follows: </span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.467%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:83%">Year Ended December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:83%">Year Ended December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. federal income tax statutory rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-deductible expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Refundable research and development tax credit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effect of foreign operations taxed at various rates</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.30&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140707891450720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of net loss per share</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the computation of basic and diluted net loss per share: </span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.198%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(88,602)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52,697)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic weighted average number of shares of common stock outstanding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,239,306&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,524,148&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted weighted average number of shares of common stock outstanding</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,239,306&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,524,148&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic net loss per share</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.96)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.76)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted net loss per share</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.96)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.76)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of potentially dilutive securities excluded from the computation of loss per share</a></td>
<td class="text"><div style="margin-top:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following potentially dilutive securities were excluded from the computation of the diluted net loss per share of common stock for the periods presented because their effect would have been anti-dilutive: </span></div><div style="margin-top:1pt"><span><br/></span></div><div style="margin-top:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.198%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.523%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,923</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase common stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,797,556</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,672,968</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,821,137</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,821,137</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares expected to be purchased under employee stock purchase plan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202,045</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,820,738</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,521,028</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140707893594400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of acquired intangible assets</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other intangible assets are amortized in equal installments over their estimated useful lives as follows: </span></div><div style="margin-bottom:9pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.057%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.455%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:55.188%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intangible Asset</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortization Period</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Option over non-financial assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Over the period of the relevant agreement</span></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Components of the Company's acquired intangible assets are comprised of the following:</span></div><div style="margin-top:6pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.836%"><tr><td style="width:1.0%"/><td style="width:49.293%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.587%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.587%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.587%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.650%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated amortization and impairment charges</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Utrophin program acquired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,487&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,487)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Discuva platform acquired</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,416&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,017)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,399&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Option over non-financial asset</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">912&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(912)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other patents and licenses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(148)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,963&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,564)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,399&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.397%"><tr><td style="width:1.0%"/><td style="width:49.532%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.591%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.564%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.591%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.564%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.591%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.567%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated amortization and impairment charges</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Utrophin program acquired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,534&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,534)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Discuva platform acquired</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,565&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,050)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,515&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Option over non-financial asset</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">921&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(921)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other patents and licenses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(150)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,170&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,655)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,515&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the year ended December 31, 2020, management identified an impairment related to the option over non-financial asset pursuant to an Evaluation and Option Agreement with a collaboration partner. The partner is no longer conducting antibiotic candidate programs over which the Company had the option, management therefore determined that the fair value of the option to acquire the assignment of the proprietary rights for antibiotic candidates is $0. Accordingly, the asset was written off in its entirety resulting in an impairment charge of $859 recognized in operating expenses.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule estimated future amortization expense related to acquired intangible assets</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated net amortization expense related to acquired intangible assets for future years is:</span></div><div><span><br/></span></div><div style="padding-left:72pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:62.134%"><tr><td style="width:1.0%"/><td style="width:74.194%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.430%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">999&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">999&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">999&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">999&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">999&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,404&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140707898907056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of property and equipment</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation is calculated based on cost, less residual value, in equal annual installments over the estimated useful lives of the assets. The residual value, if not insignificant, is reassessed annually.</span></div><div style="margin-bottom:9pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.057%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:60.743%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Over the shorter of the asset's useful life or the remaining lease term</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2-10 years </span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office and IT equipment</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3-5 years</span></div></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consisted of the following:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.421%"><tr><td style="width:1.0%"/><td style="width:58.367%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.774%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.582%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.777%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,626&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">759&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures, office equipment and software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,081&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">804&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">364&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">291&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, gross</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,071&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,854&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,377&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,129&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">694&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">725&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140707893404384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of lease expense</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The elements of lease expense were as follows:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.467%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lease Cost:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Fixed lease costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">785&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">478&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Variable lease costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Short-term lease</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">278</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">272</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total lease cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,227&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">921&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of future lease payments</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future lease payments under non-cancelable leases as of December 31, 2021 are detailed as follows:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:67.397%"><tr><td style="width:1.0%"/><td style="width:75.255%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.318%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.941%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.886%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 5.5pt 2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year Ending December 31,</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amount</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 5.5pt 2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,037&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 5.5pt 2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">509&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">508&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">508&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">386&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,948&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 5.5pt 2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,782&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liabilities balance sheet presentation:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 5.5pt 2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,091&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 5.5pt 2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,691&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,782&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140707893343472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of weighted-average assumptions used for stock option awards</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The assumptions used in the Company's valuation are summarized as follows, presented on a weighted average basis: </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">       </span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.649%"><tr><td style="width:1.0%"/><td style="width:62.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.663%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.171%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.663%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.173%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:103%">Year Ended December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:103%">Year Ended December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.05&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.29&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.7</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.9</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected annual dividends per share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of stock option activity</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">The following table summarizes the Company's stock option activity for the year ended December 31, 2021:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:103%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">&#160;&#160;&#160;&#160;</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.490%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.087%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of share options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted average exercise price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted average remaining contractual term</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate intrinsic value </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,672,968&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.90&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.9 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,641&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Granted</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,262,016&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.76&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Forfeited</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,012,851)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.61&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Exercised</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,124,577)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.74&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December&#160;31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,797,556&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.6 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">712&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2021 - vested and expected to vest</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,685,817&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.51&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.6 years</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">709&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,598,709&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.2 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">406&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Schedule of RSU activity</a></td>
<td class="text">The following table summarizes the activity relating to RSUs for the year ended December 31, 2021:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:73.830%"><tr><td style="width:1.0%"/><td style="width:62.266%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.790%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.127%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.790%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.533%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.594%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Grant Date Fair Value</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs - beginning of period</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,923&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.60&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26,923)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.60&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs - end of period</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of stock-based compensation expense</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock&#8209;based compensation expense related to stock options is recorded within the consolidated statements of operations and comprehensive loss as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.485%"><tr><td style="width:1.0%"/><td style="width:59.277%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.743%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.767%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.743%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.770%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:103%">Year Ended December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:103%">Year Ended December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">Research and development</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,909&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">749&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">General and administrative</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,895&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">1,017&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">Total stock-based compensation</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,804&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,766&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140707887742592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Business and Operations and Recent Events (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 10, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 12, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 20, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Sep. 18, 2020</div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th"><div>May 11, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Reverse stock split ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromRelatedPartyDebt', window );">Proceeds from related party promissory notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 110,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_ChiefExecutiveOfficerMember', window );">Chief Executive Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_RelatedPartyTransactionBeneficialOwnershipPercentage', window );">Beneficial ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=smmt_SecondPurchaseAgreementMember', window );">Second Purchase Agreement | Chief Executive Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent', window );">Notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromRelatedPartyDebt', window );">Proceeds from related party promissory notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=smmt_A2022NoteMember', window );">2022 Note | Chief Executive Officer | Subsequent event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent', window );">Notes payable</a></td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromRelatedPartyDebt', window );">Proceeds from related party promissory notes</a></td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionRate', window );">Interest rate</a></td>
<td class="nump">3.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_NotesPayableRelatedPartiesMaturityTriggeringEventPublicOfferingProceedsThreshold', window );">Notes payable, maturity triggering event, public offering proceeds threshold</a></td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_NotesPayableRelatedPartiesMaximumTerm', window );">Notes payable, maximum term</a></td>
<td class="text">18 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=smmt_RightsOfferingMember', window );">Rights Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Consideration received on sale of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares issued (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,312,976<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=smmt_RightsOfferingMember', window );">Rights Offering | Chief Executive Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares issued (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,365,921<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_NotesPayableRelatedPartiesMaturityTriggeringEventPublicOfferingProceedsThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Notes Payable, Related Parties, Maturity Triggering Event, Public Offering Proceeds Threshold</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_NotesPayableRelatedPartiesMaturityTriggeringEventPublicOfferingProceedsThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_NotesPayableRelatedPartiesMaximumTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Notes Payable, Related Parties, Maximum Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_NotesPayableRelatedPartiesMaximumTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_RelatedPartyTransactionBeneficialOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Related Party Transaction, Ownership Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_RelatedPartyTransactionBeneficialOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount for notes payable (written promise to pay), due to related parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Identify the stated interest rate per the agreement, for example, leasing and debt arrangements between related parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_ChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_ChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=smmt_SecondPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=smmt_SecondPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=smmt_A2022NoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=smmt_A2022NoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=smmt_RightsOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=smmt_RightsOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140707892254144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liquidity and Capital Resources (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 10, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 88,602<span></span>
</td>
<td class="nump">$ 52,697<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72,587<span></span>
</td>
<td class="nump">48,111<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">299,548<span></span>
</td>
<td class="nump">210,946<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71,791<span></span>
</td>
<td class="nump">66,417<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_ResearchAndDevelopmentTaxCreditReceivable', window );">Research and development tax credit receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,695<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,464<span></span>
</td>
<td class="nump">331<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromRelatedPartyDebt', window );">Proceeds from related party promissory notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 110,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=smmt_A2022NoteMember', window );">2022 Note | Chief Executive Officer | Subsequent event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromRelatedPartyDebt', window );">Proceeds from related party promissory notes</a></td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_ResearchAndDevelopmentTaxCreditReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research And Development Tax Credit Receivable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_ResearchAndDevelopmentTaxCreditReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631418-115840<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631419-115840<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=smmt_A2022NoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=smmt_A2022NoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_ChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_ChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140707892260144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Narrative (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign currency transaction (losses) gains</a></td>
<td class="num">$ (2,135)<span></span>
</td>
<td class="nump">$ 54<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_ResearchAndDevelopmentTaxCreditCashRebateMaximumPercentage', window );">Research and development maximum cash rebate percentage</a></td>
<td class="nump">33.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember', window );">Discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_BusinessCombinationAssumedContingentLiabilityMeasurementInput', window );">Assumed contingent liability, measurement input</a></td>
<td class="nump">0.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_BusinessCombinationAssumedContingentLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Assumed Contingent Liability, Measurement Input</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_BusinessCombinationAssumedContingentLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_ResearchAndDevelopmentTaxCreditCashRebateMaximumPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research And Development Tax Credit, Cash Rebate Maximum, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_ResearchAndDevelopmentTaxCreditCashRebateMaximumPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=125521441&amp;loc=d3e30690-110894<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123602790&amp;loc=d3e30226-110892<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=120253306&amp;loc=d3e28228-110885<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124440516&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140707887602800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Property and equipment useful lives (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=smmt_LaboratoryEquipmentMember', window );">Laboratory equipment | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, estimated useful Lives</a></td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=smmt_LaboratoryEquipmentMember', window );">Laboratory equipment | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, estimated useful Lives</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=smmt_OfficeAndTechnologyEquipmentMember', window );">Office and IT equipment | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, estimated useful Lives</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=smmt_OfficeAndTechnologyEquipmentMember', window );">Office and IT equipment | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, estimated useful Lives</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=smmt_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=smmt_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=smmt_OfficeAndTechnologyEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=smmt_OfficeAndTechnologyEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140707891726752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>segment </div>
<div>country</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfCountriesInWhichEntityOperates', window );">Number of geographic regions in which the Company operates | country</a></td>
<td class="nump">2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfCountriesInWhichEntityOperates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of countries in which the entity operates as of balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfCountriesInWhichEntityOperates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140707891758656">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Segment Reporting - Long-lived assets by geography (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-lived assets</a></td>
<td class="nump">$ 3,484<span></span>
</td>
<td class="nump">$ 1,279<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_GB', window );">United Kingdom</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-lived assets</a></td>
<td class="nump">2,762<span></span>
</td>
<td class="nump">1,228<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-lived assets</a></td>
<td class="nump">$ 722<span></span>
</td>
<td class="nump">$ 51<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_GB">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_GB</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140707888564000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue - Revenue by category (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 1,809<span></span>
</td>
<td class="nump">$ 860<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember', window );">Licensing agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 1,809<span></span>
</td>
<td class="nump">$ 860<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140707893666688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue - Revenue by geography (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 1,809<span></span>
</td>
<td class="nump">$ 860<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_LatinAmericaMember', window );">Latin America</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 1,809<span></span>
</td>
<td class="nump">$ 860<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_LatinAmericaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_LatinAmericaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140707887570816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue - Deferred revenue and other income (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_ChangeInContractWithCustomerAssetAndLiabilityRollForward', window );"><strong>Change in Contract with Customer, Asset and Liability [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Beginning deferred revenue and other income</a></td>
<td class="nump">$ 8,939<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_ContractWithCustomerLiabilityAdditions', window );">Additions</a></td>
<td class="nump">5,438<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Amount of deferred revenue and other income recognized in the statement of operations</a></td>
<td class="num">(6,438)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Ending deferred revenue and other income</a></td>
<td class="nump">7,939<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Current deferred revenue and other income</a></td>
<td class="nump">7,939<span></span>
</td>
<td class="nump">$ 8,370<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Long-term deferred revenue and other income</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 569<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_ChangeInContractWithCustomerAssetAndLiabilityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in Contract with Customer, Asset and Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_ChangeInContractWithCustomerAssetAndLiabilityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_ContractWithCustomerLiabilityAdditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract with Customer, Liability, Additions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_ContractWithCustomerLiabilityAdditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140707892558800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue - Narrative (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>milestone</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 29, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue, upfront payment</a></td>
<td class="nump">$ 7,939<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,939<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Current contract liability</a></td>
<td class="nump">7,939<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,370<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Non-current contract liability</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">569<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember', window );">Licensing agreements | EuroFarma</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue, upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_ContractWithCustomerLiabilityEnrollmentMilestone', window );">Deferred revenue, enrollment milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_RevenueInformationUsedToDetermineTransactionPriceNumberOfEnrollmentMilestones', window );">Number of enrollment milestones included in transaction price | milestone</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Current contract liability</a></td>
<td class="nump">$ 756<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">759<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Non-current contract liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 569<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_RevenueFromContractWithCustomerDevelopmentMilestoneRevenueEntitledToReceive', window );">Revenue entitled to receive upon various development milestones</a></td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_RevenueFromContractWithCustomerDevelopmentCommercialAndSalesMilestoneCumulativeNetSalesTargetAchievementRevenueEntitledToReceive', window );">Revenue entitled to receive upon achieving cumulative net sales targets</a></td>
<td class="nump">21,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_RevenueFromContractWithCustomerDevelopmentCommercialAndSalesMilestoneCumulativeNetSalesTargetThreshold', window );">Cumulative net sales target threshold</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_RevenueFromContractWithCustomerDevelopmentCommercialAndSalesMilestoneIncrementalCumulativeNetSalesTargetThreshold', window );">Incremental cumulative net sales target threshold</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_ContractWithCustomerLiabilityEnrollmentMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer, Liability, Enrollment Milestone</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_ContractWithCustomerLiabilityEnrollmentMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_RevenueFromContractWithCustomerDevelopmentCommercialAndSalesMilestoneCumulativeNetSalesTargetAchievementRevenueEntitledToReceive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue From Contract With Customer, Development, Commercial And Sales Milestone, Cumulative Net Sales Target Achievement, Revenue Entitled To Receive</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_RevenueFromContractWithCustomerDevelopmentCommercialAndSalesMilestoneCumulativeNetSalesTargetAchievementRevenueEntitledToReceive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_RevenueFromContractWithCustomerDevelopmentCommercialAndSalesMilestoneCumulativeNetSalesTargetThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue From Contract With Customer, Development, Commercial And Sales Milestone, Cumulative Net Sales Target Threshold</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_RevenueFromContractWithCustomerDevelopmentCommercialAndSalesMilestoneCumulativeNetSalesTargetThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_RevenueFromContractWithCustomerDevelopmentCommercialAndSalesMilestoneIncrementalCumulativeNetSalesTargetThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue From Contract With Customer, Development, Commercial And Sales Milestone, Incremental Cumulative Net Sales Target Threshold</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_RevenueFromContractWithCustomerDevelopmentCommercialAndSalesMilestoneIncrementalCumulativeNetSalesTargetThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_RevenueFromContractWithCustomerDevelopmentMilestoneRevenueEntitledToReceive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue From Contract With Customer, Development Milestone, Revenue Entitled To Receive</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_RevenueFromContractWithCustomerDevelopmentMilestoneRevenueEntitledToReceive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_RevenueInformationUsedToDetermineTransactionPriceNumberOfEnrollmentMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue, Information Used to Determine Transaction Price, Number of Enrollment Milestones</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_RevenueInformationUsedToDetermineTransactionPriceNumberOfEnrollmentMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=smmt_EuroFarmaLaboratoriosSAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=smmt_EuroFarmaLaboratoriosSAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140707893556688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Operating Income - Other operating income by category (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1">52 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_ResearchAndDevelopmentTaxCredit', window );">Research and development tax credits</a></td>
<td class="nump">$ 15,206<span></span>
</td>
<td class="nump">$ 9,363<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOperatingIncome', window );">Other operating income</a></td>
<td class="nump">20,968<span></span>
</td>
<td class="nump">19,312<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=smmt_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember', window );">BARDA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_GrantFundingArrangementIncomeEarned', window );">Funding/Grant income</a></td>
<td class="nump">4,604<span></span>
</td>
<td class="nump">9,472<span></span>
</td>
<td class="nump">$ 50,265<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=smmt_OtherGrantFundingCounterpartiesMember', window );">Other grant funding counterparties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_GrantFundingArrangementIncomeEarned', window );">Funding/Grant income</a></td>
<td class="nump">$ 1,158<span></span>
</td>
<td class="nump">$ 477<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_GrantFundingArrangementIncomeEarned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Grant Funding Arrangement, Income Earned</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_GrantFundingArrangementIncomeEarned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_ResearchAndDevelopmentTaxCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research And Development, Tax Credit</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_ResearchAndDevelopmentTaxCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of other operating income, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=smmt_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=smmt_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=smmt_OtherGrantFundingCounterpartiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=smmt_OtherGrantFundingCounterpartiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140707888575312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Operating Income - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">8 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1">52 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_ResearchAndDevelopmentTaxCreditReceivableCurrent', window );">Current research and development tax credit receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,695<span></span>
</td>
<td class="nump">$ 15,695<span></span>
</td>
<td class="nump">$ 9,856<span></span>
</td>
<td class="nump">$ 15,695<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,464<span></span>
</td>
<td class="nump">1,464<span></span>
</td>
<td class="nump">331<span></span>
</td>
<td class="nump">1,464<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=smmt_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember', window );">BARDA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_GrantFundingArrangementMaximumFundingValue', window );">Maximum funding value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 62,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_GrantFundingArrangementCommittedFundingTotal', window );">Total committed funding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_GrantFundingArrangementFundingReceived', window );">Funding received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,492<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_GrantFundingArrangementIncomeEarned', window );">Funding/Grant income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,604<span></span>
</td>
<td class="nump">$ 9,472<span></span>
</td>
<td class="nump">50,265<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=smmt_CombatingAntibioticResistantBacteriaBiopharmaceuticalAcceleratorProgramMember', window );">CARB-X</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_GrantFundingArrangementFundingReceived', window );">Funding received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">485<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_GrantFundingArrangementIncomeEarned', window );">Funding/Grant income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,155<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_GrantFundingArrangementCommittedFundingBase', window );">Committed funding base</a></td>
<td class="nump">$ 4,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_GrantFundingArrangementMilestoneFundingIncrease', window );">Funding increase based on achievement of future milestones</a></td>
<td class="nump">$ 3,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">96<span></span>
</td>
<td class="nump">96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">96<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrent', window );">Current contract asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 574<span></span>
</td>
<td class="nump">$ 574<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 574<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_GrantFundingArrangementCommittedFundingBase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Grant Funding Arrangement, Committed Funding, Base</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_GrantFundingArrangementCommittedFundingBase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_GrantFundingArrangementCommittedFundingTotal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Grant Funding Arrangement, Committed Funding, Total</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_GrantFundingArrangementCommittedFundingTotal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_GrantFundingArrangementFundingReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Grant Funding Arrangement, Funding Received</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_GrantFundingArrangementFundingReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_GrantFundingArrangementIncomeEarned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Grant Funding Arrangement, Income Earned</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_GrantFundingArrangementIncomeEarned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_GrantFundingArrangementMaximumFundingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Grant Funding Arrangement, Maximum Funding Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_GrantFundingArrangementMaximumFundingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_GrantFundingArrangementMilestoneFundingIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Grant Funding Arrangement, Milestone, Funding Increase</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_GrantFundingArrangementMilestoneFundingIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_ResearchAndDevelopmentTaxCreditReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research And Development Tax Credit Receivable, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_ResearchAndDevelopmentTaxCreditReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130533-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=smmt_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=smmt_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=smmt_CombatingAntibioticResistantBacteriaBiopharmaceuticalAcceleratorProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=smmt_CombatingAntibioticResistantBacteriaBiopharmaceuticalAcceleratorProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140707893651280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other (Expense) Income (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other Income and Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign currency (loss) gain</a></td>
<td class="num">$ (2,135,000)<span></span>
</td>
<td class="nump">$ 54,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_GainLossOnRemeasurementOfLiabilitiesNonoperating', window );">Remeasurement of liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">480,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(281,000)<span></span>
</td>
<td class="num">(255,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other (expense) income, net</a></td>
<td class="num">$ (2,416,000)<span></span>
</td>
<td class="nump">$ 283,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_GainLossOnRemeasurementOfLiabilitiesNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain (Loss) On Remeasurement Of Liabilities, Nonoperating</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_GainLossOnRemeasurementOfLiabilitiesNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=125521441&amp;loc=d3e30690-110894<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123602790&amp;loc=d3e30226-110892<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=120253306&amp;loc=d3e28228-110885<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124440516&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140707891748352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Tax - Components of loss before income taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">United Kingdom</a></td>
<td class="num">$ (72,244)<span></span>
</td>
<td class="num">$ (51,197)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">United States</a></td>
<td class="num">(16,358)<span></span>
</td>
<td class="num">(1,713)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income tax</a></td>
<td class="num">$ (88,602)<span></span>
</td>
<td class="num">$ (52,910)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140707888081600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Tax - Significant components of the provision for income taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current income tax benefit:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal United States</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (215)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State - United States</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">Non-United States</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(213)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal - United States</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State - United States</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit', window );">Non-United States</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total deferred tax</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total income tax benefit</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (213)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredForeignIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140707893342368">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Tax - Major components of deferred tax assets and liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforward</a></td>
<td class="nump">$ 49,422<span></span>
</td>
<td class="nump">$ 29,831<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development credit carryforward</a></td>
<td class="nump">941<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock based compensation</a></td>
<td class="nump">2,560<span></span>
</td>
<td class="nump">1,167<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">1,477<span></span>
</td>
<td class="nump">491<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">54,400<span></span>
</td>
<td class="nump">31,489<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets', window );">Intangible asset</a></td>
<td class="num">(2,600)<span></span>
</td>
<td class="num">(2,189)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesOther', window );">Other</a></td>
<td class="num">(54)<span></span>
</td>
<td class="num">(71)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="num">(2,654)<span></span>
</td>
<td class="num">(2,260)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_DeferredTaxAssetsLiabilities', window );">Net deferred tax assets before valuation allowance</a></td>
<td class="nump">51,746<span></span>
</td>
<td class="nump">29,229<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(51,746)<span></span>
</td>
<td class="num">(29,229)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Deferred tax, net</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_DeferredTaxAssetsLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets (Liabilities)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_DeferredTaxAssetsLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140707892545184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Tax - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Schedule Of Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Deferred tax asset</a></td>
<td class="nump">$ 54,400,000<span></span>
</td>
<td class="nump">$ 31,489,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Increase in valuation allowance</a></td>
<td class="nump">22,517,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_DeferredTaxAssetsNetIncreaseDecreaseDueToChangeInEnactedTaxRateAmount', window );">Increase in net deferred tax assets due to change in enacted tax rate</a></td>
<td class="nump">9,311,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseDueToChangeInEnactedTaxRateAmount', window );">Increase in valuation allowance due to change in enacted tax rate</a></td>
<td class="nump">9,311,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_ResearchAndDevelopmentTaxCredit', window );">Research and development tax relief</a></td>
<td class="nump">15,206,000<span></span>
</td>
<td class="nump">9,363,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Liability for unrecognized tax benefits</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Liability for interest and penalties</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember', window );">Research and development tax credit carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Schedule Of Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward</a></td>
<td class="nump">941,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">U.S. Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Schedule Of Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">1,034,000<span></span>
</td>
<td class="nump">$ 232,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">U.S. State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Schedule Of Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">165,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">U.K.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Schedule Of Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">191,714,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_PotentialDeferredTaxAssetsOperatingLossCarryforwards', window );">Potential deferred tax asset</a></td>
<td class="nump">$ 47,929,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_DeferredTaxAssetsNetIncreaseDecreaseDueToChangeInEnactedTaxRateAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Net, Increase (Decrease) Due To Change In Enacted Tax Rate, Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_DeferredTaxAssetsNetIncreaseDecreaseDueToChangeInEnactedTaxRateAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_PotentialDeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Potential Deferred Tax Assets, Operating Loss Carryforwards</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_PotentialDeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_ResearchAndDevelopmentTaxCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research And Development, Tax Credit</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_ResearchAndDevelopmentTaxCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseDueToChangeInEnactedTaxRateAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Valuation Allowance, Deferred Tax Asset, Increase (Decrease) Due To Change In Enacted Tax Rate, Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseDueToChangeInEnactedTaxRateAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140707892338496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Tax - Reconciliation of the effective income tax rate to statutory rate (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">U.S. federal income tax statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(10.50%)<span></span>
</td>
<td class="num">(12.10%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense', window );">Non-deductible expenses</a></td>
<td class="num">(0.40%)<span></span>
</td>
<td class="num">(3.90%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_EffectiveIncomeTaxRateReconciliationTaxCreditRefundableResearchPercent', window );">Refundable research and development tax credit</a></td>
<td class="num">(8.30%)<span></span>
</td>
<td class="num">(7.00%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Effect of foreign operations taxed at various rates</a></td>
<td class="nump">0.50%<span></span>
</td>
<td class="nump">0.90%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent', window );">Stock-based compensation</a></td>
<td class="num">(1.60%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other</a></td>
<td class="num">(0.70%)<span></span>
</td>
<td class="nump">1.40%<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.30%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_EffectiveIncomeTaxRateReconciliationTaxCreditRefundableResearchPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Tax Credit Refundable, Research, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_EffectiveIncomeTaxRateReconciliationTaxCreditRefundableResearchPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 740<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120384911&amp;loc=d3e23163-113944<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140707892737680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss per Share - Computation of net loss per share (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (88,602)<span></span>
</td>
<td class="num">$ (52,697)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic weighted average number of shares of common stock outstanding (in shares)</a></td>
<td class="nump">92,239,306<span></span>
</td>
<td class="nump">69,524,148<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted weighted average number of shares of common stock outstanding (in shares)</a></td>
<td class="nump">92,239,306<span></span>
</td>
<td class="nump">69,524,148<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net loss per share (in dollars per share)</a></td>
<td class="num">$ (0.96)<span></span>
</td>
<td class="num">$ (0.76)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net loss per share (in dollars per share)</a></td>
<td class="num">$ (0.96)<span></span>
</td>
<td class="num">$ (0.76)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140707888602864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss per Share - Potentially dilutive securities excluded from the computation of loss per share (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities excluded from the computation of diluted loss per share</a></td>
<td class="nump">19,820,738<span></span>
</td>
<td class="nump">9,521,028<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities excluded from the computation of diluted loss per share</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">26,923<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Options to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities excluded from the computation of diluted loss per share</a></td>
<td class="nump">13,797,556<span></span>
</td>
<td class="nump">3,672,968<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities excluded from the computation of diluted loss per share</a></td>
<td class="nump">5,821,137<span></span>
</td>
<td class="nump">5,821,137<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember', window );">Shares expected to be purchased under employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities excluded from the computation of diluted loss per share</a></td>
<td class="nump">202,045<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140707893556240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>reporting_unit</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportingUnits', window );">Number of reporting units | reporting_unit</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment charge</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss', window );">Cumulative goodwill impairment charges</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">2,009,000<span></span>
</td>
<td class="nump">$ 2,030,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense</a></td>
<td class="nump">$ 1,017,000<span></span>
</td>
<td class="nump">$ 1,250,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=smmt_DiscuvaPlatformMember', window );">Discuva platform | Software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted-average remaining useful life</a></td>
<td class="text">10 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairedAccumulatedImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportingUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of reporting units tested for impairment of goodwill. A reporting unit is an operating segment or one level below an operating segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportingUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=smmt_DiscuvaPlatformMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=smmt_DiscuvaPlatformMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140707891634064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Schedule of acquired intangible assets (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross</a></td>
<td class="nump">$ 20,170,000<span></span>
</td>
<td class="nump">$ 19,963,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_FiniteLivedIntangibleAssetsAccumulatedAmortizationAndImpairment', window );">Accumulated amortization and impairment charges</a></td>
<td class="num">(8,655,000)<span></span>
</td>
<td class="num">(9,564,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">11,515,000<span></span>
</td>
<td class="nump">10,399,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember', window );">Software | Utrophin program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross</a></td>
<td class="nump">4,534,000<span></span>
</td>
<td class="nump">4,487,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_FiniteLivedIntangibleAssetsAccumulatedAmortizationAndImpairment', window );">Accumulated amortization and impairment charges</a></td>
<td class="num">(4,534,000)<span></span>
</td>
<td class="num">(4,487,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember', window );">Software | Discuva platform</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross</a></td>
<td class="nump">14,565,000<span></span>
</td>
<td class="nump">14,416,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_FiniteLivedIntangibleAssetsAccumulatedAmortizationAndImpairment', window );">Accumulated amortization and impairment charges</a></td>
<td class="num">(3,050,000)<span></span>
</td>
<td class="num">(4,017,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">11,515,000<span></span>
</td>
<td class="nump">10,399,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=smmt_OptionOverNonFinancialAssetsMember', window );">Option over non-financial asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross</a></td>
<td class="nump">921,000<span></span>
</td>
<td class="nump">912,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_FiniteLivedIntangibleAssetsAccumulatedAmortizationAndImpairment', window );">Accumulated amortization and impairment charges</a></td>
<td class="num">(921,000)<span></span>
</td>
<td class="num">(912,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure', window );">Fair value of option over non-financial asset</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment of Intangible Assets, Finite-lived</a></td>
<td class="nump">859,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=smmt_OtherPatentsAndLicensesMember', window );">Other patents and licenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross</a></td>
<td class="nump">150,000<span></span>
</td>
<td class="nump">148,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_FiniteLivedIntangibleAssetsAccumulatedAmortizationAndImpairment', window );">Accumulated amortization and impairment charges</a></td>
<td class="num">(150,000)<span></span>
</td>
<td class="num">(148,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_FiniteLivedIntangibleAssetsAccumulatedAmortizationAndImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finite-Lived Intangible Assets, Accumulated Amortization And Impairment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_FiniteLivedIntangibleAssetsAccumulatedAmortizationAndImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of assets, excluding financial assets, that lack physical substance, having a limited useful life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsFinitelived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=smmt_UtrophinProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=smmt_UtrophinProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=smmt_DiscuvaPlatformMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=smmt_DiscuvaPlatformMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=smmt_OptionOverNonFinancialAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=smmt_OptionOverNonFinancialAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=smmt_OtherPatentsAndLicensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=smmt_OtherPatentsAndLicensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140707889380432">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Estimated amortization expense (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2022</a></td>
<td class="nump">$ 999<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2023</a></td>
<td class="nump">999<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2024</a></td>
<td class="nump">999<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2025</a></td>
<td class="nump">999<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2026</a></td>
<td class="nump">999<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive', window );">Thereafter</a></td>
<td class="nump">$ 5,404<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140707891631504">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment - Components of property and equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 4,071<span></span>
</td>
<td class="nump">$ 1,854<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation</a></td>
<td class="nump">3,377<span></span>
</td>
<td class="nump">1,129<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">694<span></span>
</td>
<td class="nump">725<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=smmt_LaboratoryEquipmentMember', window );">Laboratory equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">2,626<span></span>
</td>
<td class="nump">759<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=smmt_FurnitureAndFixturesOfficeEquipmentAndSoftwareMember', window );">Furniture and fixtures, office equipment and software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">1,081<span></span>
</td>
<td class="nump">804<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 364<span></span>
</td>
<td class="nump">$ 291<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=smmt_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=smmt_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=smmt_FurnitureAndFixturesOfficeEquipmentAndSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=smmt_FurnitureAndFixturesOfficeEquipmentAndSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140707894968816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 330<span></span>
</td>
<td class="nump">$ 302<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140707893364400">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Research and Development Prepaid Expenses and Accrued Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_ResearchAndDevelopmentPrepaidExpensesCurrent', window );">Prepaid research and development expenditures</a></td>
<td class="nump">$ 6,138<span></span>
</td>
<td class="nump">$ 8,490<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_AccruedResearchAndDevelopmentCurrent', window );">Accrued research and development expenditure</a></td>
<td class="nump">$ 5,226<span></span>
</td>
<td class="nump">$ 1,502<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_AccruedResearchAndDevelopmentCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Research And Development, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_AccruedResearchAndDevelopmentCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_ResearchAndDevelopmentPrepaidExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and Development Prepaid Expenses, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_ResearchAndDevelopmentPrepaidExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140707892547536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Narrative (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>contract</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Additional right-of-use assets recorded</a></td>
<td class="nump">$ 3,389<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="nump">$ 2,790<span></span>
</td>
<td class="nump">$ 554<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate</a></td>
<td class="nump">2.50%<span></span>
</td>
<td class="nump">3.75%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term</a></td>
<td class="text">3 years 10 months 24 days<span></span>
</td>
<td class="text">1 year 1 month 6 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=smmt_MenloParkCaliforniaUSAndSawstonUKMember', window );">Menlo Park, California, U.S. and Sawston, UK</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Additional right-of-use assets recorded</a></td>
<td class="nump">$ 2,359<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_LesseeOperatingLeaseNumberOfContracts', window );">Number of leases | contract</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=smmt_OxfordshireUKMember', window );">Oxfordshire, UK</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Additional right-of-use assets recorded</a></td>
<td class="nump">$ 1,030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_LesseeOperatingLeaseNumberOfContracts', window );">Number of leases | contract</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_LesseeOperatingLeaseNumberOfContracts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Number Of Contracts</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_LesseeOperatingLeaseNumberOfContracts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=smmt_MenloParkCaliforniaUSAndSawstonUKMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=smmt_MenloParkCaliforniaUSAndSawstonUKMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=smmt_OxfordshireUKMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=smmt_OxfordshireUKMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140707893587792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Lease expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Lease Cost:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Fixed lease costs</a></td>
<td class="nump">$ 785<span></span>
</td>
<td class="nump">$ 478<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease costs</a></td>
<td class="nump">164<span></span>
</td>
<td class="nump">171<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCost', window );">Short-term lease</a></td>
<td class="nump">278<span></span>
</td>
<td class="nump">272<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease cost</a></td>
<td class="nump">$ 1,227<span></span>
</td>
<td class="nump">$ 921<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease cost, excluding expense for lease with term of one month or less.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140707892535344">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Future lease payments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2022</a></td>
<td class="nump">$ 1,037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2023</a></td>
<td class="nump">509<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2024</a></td>
<td class="nump">508<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2025</a></td>
<td class="nump">508<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2026</a></td>
<td class="nump">386<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">2,948<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="nump">166<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">2,782<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityAbstract', window );"><strong>Total operating lease liabilities balance sheet presentation:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current lease liabilities</a></td>
<td class="nump">1,091<span></span>
</td>
<td class="nump">$ 390<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Non-current lease liabilities</a></td>
<td class="nump">1,691<span></span>
</td>
<td class="nump">$ 75<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">$ 2,782<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140707893364400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Non-Current Liabilities (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_BusinessCombinationAssumedContingentLiabilityNoncurrent', window );">Assumed contingent liabilities, non-current</a></td>
<td class="nump">$ 2,531,000<span></span>
</td>
<td class="nump">$ 2,263,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_GainLossOnRemeasurementOfLiabilitiesNonoperating', window );">Gain on remeasurement of contingent liability</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 480,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_BusinessCombinationAssumedContingentLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Assumed Contingent Liability, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_BusinessCombinationAssumedContingentLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_GainLossOnRemeasurementOfLiabilitiesNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain (Loss) On Remeasurement Of Liabilities, Nonoperating</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_GainLossOnRemeasurementOfLiabilitiesNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140707889115488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>May 12, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 06, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 18, 2020 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 24, 2019 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 17, 2020 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Reverse stock split ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67,231,903<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98,039,540<span></span>
</td>
<td class="nump">82,575,064<span></span>
</td>
<td class="nump">336,159,511<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Offering costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 118<span></span>
</td>
<td class="nump">$ 48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Number of common stock shares into which each warrant converts (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,821,137<span></span>
</td>
<td class="nump">5,821,137<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=smmt_ConsultingAgreementMember', window );">Consulting Agreement | Affiliated entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of common stock shares into which warrants may be converted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,358,732<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_ClassOfWarrantOrRightQuarterlyVestingPeriod', window );">Warrants quarterly vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_WarrantMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">Aggregate intrinsic value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,559<span></span>
</td>
<td class="nump">$ 18,260<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_WarrantMember', window );">Warrants | Consulting Agreement | Affiliated entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations', window );">Warrants cancelled (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,798,945<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">559,787<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=smmt_RightsOfferingMember', window );">Rights Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Consideration received on sale of stock | $</a></td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares issued (in shares)</a></td>
<td class="nump">14,312,976<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 5.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Offering costs | $</a></td>
<td class="nump">$ 159<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Consideration received on sale of stock | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,970,060<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,075,690<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Offering costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 912<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of common stock shares into which warrants may be converted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,261,350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.58<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Number of common stock shares into which each warrant converts (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_ClassOfWarrantOrRightMinimumTenDayVolumeWeightedAverageCommonStockPriceToWarrantExercisePricePremiumPercentage', window );">Minimum volume weighted average common stock price to warrant exercise price, premium, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_ClassOfWarrantOrRightMinimumTenDayVolumeWeightedAverageCommonStockPriceToWarrantExercisePricePremiumPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Minimum Ten Day Volume Weighted Average Common Stock Price to Warrant Exercise Price, Premium, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_ClassOfWarrantOrRightMinimumTenDayVolumeWeightedAverageCommonStockPriceToWarrantExercisePricePremiumPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_ClassOfWarrantOrRightQuarterlyVestingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Quarterly Vesting Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_ClassOfWarrantOrRightQuarterlyVestingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares under non-option equity instrument agreements that were either cancelled or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=smmt_ConsultingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=smmt_ConsultingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=smmt_RightsOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=smmt_RightsOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140707886772080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Based Compensation - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 01, 2022</div></th>
<th class="th">
<div>Sep. 24, 2021 </div>
<div>employee </div>
<div>shares</div>
</th>
<th class="th"><div>Aug. 02, 2021</div></th>
<th class="th">
<div>Sep. 21, 2020 </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 19, 2020 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value of stock options granted (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.50<span></span>
</td>
<td class="nump">$ 2.20<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Aggregate intrinsic value, options exercised | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,744,000<span></span>
</td>
<td class="nump">$ 857,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation expense for options | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,905,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation expense for options, period of recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock options granted previously subject to performance-based vesting (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,262,016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Number of common stock shares into which each warrant converts (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of shares initially reserve for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan', window );">Number of additional shares that can be added to the plan for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Maximum percentage of outstanding shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for grant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,825,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod', window );">Offering period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate', window );">Maximum common stock purchase allowable as a percentage of compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Purchase price of common stock as a percentage of closing price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">ESPP | Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveOfferingPeriod', window );">Consecutive offering period</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">ESPP | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Purchase price of common stock as a percentage of closing price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected', window );">Number of employees affected by modification | employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost', window );">Incremental costs related to the modification | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,872,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested', window );">Aggregate intrinsic value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125,000<span></span>
</td>
<td class="nump">$ 125,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_WarrantMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested', window );">Aggregate intrinsic value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,559,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedOutstandingNumber', window );">Outstanding vested awards (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,821,137<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Weighted average remaining contractual term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized compensation expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_WarrantMember', window );">Warrants | Consultants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedOutstandingNumber', window );">Outstanding vested awards (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">559,787<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_WarrantMember', window );">Warrants | Investor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedOutstandingNumber', window );">Outstanding vested awards (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,261,350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=smmt_A2020StockIncentivePlanMember', window );">2020 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of shares initially reserve for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_CommonStockAndRestrictedStockUnitsAdditionalCapitalSharesAllowableForForFutureIssuance', window );">Number of shares that can be added to the plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan', window );">Number of additional shares that can be added to the plan for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Maximum percentage of outstanding shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for grant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,293,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_CommonStockAndRestrictedStockUnitsAdditionalCapitalSharesAllowableForForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock and Restricted Stock Units, Additional Capital Shares Allowable For For Future Issuance</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_CommonStockAndRestrictedStockUnitsAdditionalCapitalSharesAllowableForForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveOfferingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-based Payment Award, Consecutive Offering Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveOfferingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested, Outstanding, Number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement By Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Weighted Average Exercise Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Allowable Under The Plan</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-based Payment Award, Offering Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>An excess of the fair value of the modified award over the fair value of the award immediately before the modification.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of grantees affected by modification of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of vested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=smmt_ConsultantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=smmt_ConsultantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=us-gaap_InvestorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=us-gaap_InvestorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=smmt_A2020StockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=smmt_A2020StockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140707897830288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Based Compensation - Weighted-average assumptions used for stock option awards (Details) - Stock options<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">1.05%<span></span>
</td>
<td class="nump">0.29%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">5 years 8 months 12 days<span></span>
</td>
<td class="text">5 years 10 months 24 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">74.50%<span></span>
</td>
<td class="nump">71.90%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected annual dividends per share</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Rate of weighted-average expected volatility for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140707891550624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Based Compensation - Stock option activity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 24, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of share options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Beginning balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,672,968<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">9,250,000<span></span>
</td>
<td class="nump">13,262,016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,012,851)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,124,577)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Ending balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,797,556<span></span>
</td>
<td class="nump">3,672,968<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted average exercise price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Beginning balance (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Ending balance (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.55<span></span>
</td>
<td class="nump">$ 2.90<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Stock option activity, additional disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual term, options outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years 7 months 6 days<span></span>
</td>
<td class="text">8 years 10 months 24 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value, options outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 712<span></span>
</td>
<td class="nump">$ 6,641<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number of share options, vested and expected to vest (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,685,817<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, vested and expected to vest (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual term, vested and expected to vest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Aggregate intrinsic value, vested and expected to vest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 709<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of share options, exercisable (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,598,709<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price, exercisable (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual term, exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate intrinsic value, exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 406<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140707894927632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - RSU activity (Details) - RSUs<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning balance (in shares) | shares</a></td>
<td class="nump">26,923<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares) | shares</a></td>
<td class="num">(26,923)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending balance (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Beginning balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 1.60<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share) | $ / shares</a></td>
<td class="nump">1.60<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Ending balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140707887603696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of stock-based compensation expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="nump">$ 12,804<span></span>
</td>
<td class="nump">$ 1,766<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="nump">5,909<span></span>
</td>
<td class="nump">749<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="nump">$ 6,895<span></span>
</td>
<td class="nump">$ 1,017<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140707892585056">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PurchaseObligation', window );">Capital commitments</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Contractual commitments</a></td>
<td class="nump">$ 17,046,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_OtherCommitmentPeriodForWhichTheMajorityOfCommitmentsAreToBePaid', window );">Period for which the majority of contractual commitments are to be paid</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_OtherCommitmentPeriodForWhichTheMajorityOfCommitmentsAreToBePaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Commitment, Period for Which the Majority of Commitments are To Be Paid</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_OtherCommitmentPeriodForWhichTheMajorityOfCommitmentsAreToBePaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140707885274416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>May 12, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 20, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 24, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 06, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 24, 2019 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 26, 2021 </div>
<div>ft&#178;</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromRelatedPartyDebt', window );">Proceeds from related party promissory notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 110,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_AdjustmentsToAdditionalPaidInCapitalImputedInterestExpenseRelatedParty', window );">Imputed interest expense on promissory note payable to a related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember', window );">Additional Paid-In Capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_AdjustmentsToAdditionalPaidInCapitalImputedInterestExpenseRelatedParty', window );">Imputed interest expense on promissory note payable to a related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_ChiefExecutiveOfficerMember', window );">Chief Executive Officer | Initial Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromRelatedPartyDebt', window );">Proceeds from related party promissory notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent', window );">Notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_RelatedPartyTransactionExpectedRate', window );">Notes payable, estimated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_NotesPayableRelatedPartiesMaturityTriggeringEventPublicOfferingProceedsThreshold', window );">Notes payable, maturity triggering event, public offering proceeds threshold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_NotesPayableRelatedPartiesMaximumTerm', window );">Notes payable, maximum term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">13 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_ChiefExecutiveOfficerMember', window );">Chief Executive Officer | Initial Purchase Agreement | Additional Paid-In Capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_AdjustmentsToAdditionalPaidInCapitalImputedInterestExpenseRelatedParty', window );">Imputed interest expense on promissory note payable to a related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_ChiefExecutiveOfficerMember', window );">Chief Executive Officer | Initial Purchase Agreement | 10 year US Treasury rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_RelatedPartyTransactionRateBasisSpreadOnVariableRate', window );">Notes payable, basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_ChiefExecutiveOfficerMember', window );">Chief Executive Officer | Second Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromRelatedPartyDebt', window );">Proceeds from related party promissory notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent', window );">Notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_RelatedPartyTransactionExpectedRate', window );">Notes payable, estimated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_ChiefExecutiveOfficerMember', window );">Chief Executive Officer | Second Purchase Agreement | 10 year US Treasury rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_RelatedPartyTransactionRateBasisSpreadOnVariableRate', window );">Notes payable, basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_BeneficialOwnerMember', window );">Beneficial owner | Assignment Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_ClassOfWarrantOrRightVested', window );">Warrants vested (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">489,815<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember', window );">Affiliated entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_AreaOfPremisesSubleased', window );">Area of premises subleased | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_RelatedPartyTransactionPaymentsToRelatedParty', window );">Payments to related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 556<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember', window );">Affiliated entity | Consulting Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of common stock shares into which warrants may be converted (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,358,732<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_RelatedPartyTransactionMonthlyExpensesFromTransactionsWithRelatedParty', window );">Monthly expense from related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_ClassOfWarrantOrRightQuarterlyVestingPeriod', window );">Warrants quarterly vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember', window );">Affiliated entity | Consultancy fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty', window );">Expenses from related party transactions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 470<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember', window );">Affiliated entity | Warrant vesting expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty', window );">Expenses from related party transactions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 512<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_DirectorMember', window );">Director | Assignment Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_ClassOfWarrantOrRightVested', window );">Warrants vested (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69,972<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Consideration received on sale of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares issued (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,970,060<span></span>
</td>
<td class="nump">35,075,690<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.34<span></span>
</td>
<td class="nump">$ 1.43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of common stock shares into which warrants may be converted (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,261,350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.58<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private placement | Chief Executive Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesSubscribedButUnissued', window );">Number of shares of common stock subscribed (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,071,856<span></span>
</td>
<td class="nump">33,231,410<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of common stock shares into which warrants may be converted (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,984,711<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private placement | Former Chief Executive Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesSubscribedButUnissued', window );">Number of shares of common stock subscribed (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90,495<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of common stock shares into which warrants may be converted (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,574<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private placement | Beneficial owner</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesSubscribedButUnissued', window );">Number of shares of common stock subscribed (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">149,701<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=smmt_RightsOfferingMember', window );">Rights Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Consideration received on sale of stock</a></td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares issued (in shares) | shares</a></td>
<td class="nump">14,312,976<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 5.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=smmt_RightsOfferingMember', window );">Rights Offering | Chief Executive Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares issued (in shares) | shares</a></td>
<td class="nump">11,365,921<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 5.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=smmt_RightsOfferingMember', window );">Rights Offering | Chief Operations Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares issued (in shares) | shares</a></td>
<td class="nump">389,977<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 5.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_AdjustmentsToAdditionalPaidInCapitalImputedInterestExpenseRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments to Additional Paid in Capital, Imputed Interest Expense, Related Party</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_AdjustmentsToAdditionalPaidInCapitalImputedInterestExpenseRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_AreaOfPremisesSubleased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area Of Premises Subleased</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_AreaOfPremisesSubleased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_ClassOfWarrantOrRightQuarterlyVestingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Quarterly Vesting Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_ClassOfWarrantOrRightQuarterlyVestingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_ClassOfWarrantOrRightVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Vested</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_ClassOfWarrantOrRightVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_NotesPayableRelatedPartiesMaturityTriggeringEventPublicOfferingProceedsThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Notes Payable, Related Parties, Maturity Triggering Event, Public Offering Proceeds Threshold</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_NotesPayableRelatedPartiesMaturityTriggeringEventPublicOfferingProceedsThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_NotesPayableRelatedPartiesMaximumTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Notes Payable, Related Parties, Maximum Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_NotesPayableRelatedPartiesMaximumTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_RelatedPartyTransactionExpectedRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Related Party Transaction, Expected Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_RelatedPartyTransactionExpectedRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_RelatedPartyTransactionMonthlyExpensesFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Related Party Transaction, Monthly Expenses From Transactions With Related Party</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_RelatedPartyTransactionMonthlyExpensesFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_RelatedPartyTransactionPaymentsToRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Related Party Transaction, Payments To Related Party</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_RelatedPartyTransactionPaymentsToRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_RelatedPartyTransactionRateBasisSpreadOnVariableRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Related Party Transaction, Rate, Basis Spread On Variable Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_RelatedPartyTransactionRateBasisSpreadOnVariableRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesSubscribedButUnissued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of common stock allocated to investors to buy shares of a new issue of common stock before they are offered to the public. When stock is sold on a subscription basis, the issuer does not initially receive the total proceeds. In general, the issuer does not issue the shares to the investor until it receives the entire proceeds.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesSubscribedButUnissued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount for notes payable (written promise to pay), due to related parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_ChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_ChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=smmt_InitialPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=smmt_InitialPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_UsTreasuryUstInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_UsTreasuryUstInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=smmt_SecondPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=smmt_SecondPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_BeneficialOwnerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_BeneficialOwnerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=smmt_AssignmentAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=smmt_AssignmentAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=smmt_ConsultingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=smmt_ConsultingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=smmt_ConsultingAgreementConsultancyFeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=smmt_ConsultingAgreementConsultancyFeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=smmt_ConsultancyAgreementWarrantVestingExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=smmt_ConsultancyAgreementWarrantVestingExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=smmt_FormerChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=smmt_FormerChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=smmt_RightsOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=smmt_RightsOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_ChiefOperatingOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_ChiefOperatingOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140707892550896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Event (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 10, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromRelatedPartyDebt', window );">Proceeds from related party promissory notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 110,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent event | 2022 Note | Chief Executive Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromRelatedPartyDebt', window );">Proceeds from related party promissory notes</a></td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent', window );">Notes payable</a></td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionRate', window );">Interest rate</a></td>
<td class="nump">3.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_NotesPayableRelatedPartiesMaturityTriggeringEventPublicOfferingProceedsThreshold', window );">Notes payable, maturity triggering event, public offering proceeds threshold</a></td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_NotesPayableRelatedPartiesMaximumTerm', window );">Notes payable, maximum term</a></td>
<td class="text">18 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_NotesPayableRelatedPartiesMaturityTriggeringEventPublicOfferingProceedsThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Notes Payable, Related Parties, Maturity Triggering Event, Public Offering Proceeds Threshold</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_NotesPayableRelatedPartiesMaturityTriggeringEventPublicOfferingProceedsThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_NotesPayableRelatedPartiesMaximumTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Notes Payable, Related Parties, Maximum Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_NotesPayableRelatedPartiesMaximumTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount for notes payable (written promise to pay), due to related parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Identify the stated interest rate per the agreement, for example, leasing and debt arrangements between related parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=smmt_A2022NoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=smmt_A2022NoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_ChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_ChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>smmt-20211231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2021"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:smmt="http://www.summitplc.com/20211231"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="smmt-20211231.xsd" xlink:type="simple"/>
    <context id="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia595af4209c94a0e84bcc1c89fef3796_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="idbfc95cd82ac4443bb9c319767213cfa_I20220310">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
        </entity>
        <period>
            <instant>2022-03-10</instant>
        </period>
    </context>
    <context id="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7372be6dc06143b5adbb4d2e83a596c5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iadaf16e26a374273b81a7480b2aef461_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i23c022f251aa4a7bb86fd5562b7cf66a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i18956f3671924995bc8672c2e4f9774d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i10704a1cbc944be6935b29991fb87b7b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i50b9889462124695acb12b854dfc61e9_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie925211651134cc095c13ead145a9987_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie1c2f38f4911489ea019b962d6783b5d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id7966e0fd0224c4492484acc988b5ec7_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0c007ce1c0eb4469a7130cee973d7baf_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i24918d03620c4ecaafa37fa8e2ca91b8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5c014f26be2f47f291a3aa91605b4237_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie706c5ed539d4ef3bd0c02c4a4ba65e9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7658aae35c1342aa8a4d460d73d54645_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic6b97fcd6da249ba8b8f4ae9d4f4b37d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i2e2dff6c233a4cdbb090a82ca47e7ffc_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8d878058c8ed44bfb3e3c57c92407be4_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i598a27caa8a04c3d8039576d04308448_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i24c2e29db794467488a44f9569dc30e2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie363771b412541ff94d08b8f29d0252e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iebb70cd5cf5e4946b99f20b6f84c6333_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8194e85afada4be48c4dc89d2b7c2a07_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idb475943c8884e52b4a61d6e77d4d205_D20210512-20210512">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">smmt:RightsOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-12</startDate>
            <endDate>2021-05-12</endDate>
        </period>
    </context>
    <context id="i28fe3cc419e94f789497abebbcb3acff_I20210512">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">smmt:RightsOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-12</instant>
        </period>
    </context>
    <context id="i9e4481b351c140ec829740b8f3c87fca_I20210511">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-11</instant>
        </period>
    </context>
    <context id="i9d8f0174c08f45cab10ea87b88a0b06d_I20210420">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">smmt:SecondPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-20</instant>
        </period>
    </context>
    <context id="idf7a081c7b9c4705a95c5f2ab53d19bb_D20220310-20220310">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">smmt:A2022NoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-10</startDate>
            <endDate>2022-03-10</endDate>
        </period>
    </context>
    <context id="id74d06c0cec74c7fa7641c591943da88_I20220310">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">smmt:A2022NoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-10</instant>
        </period>
    </context>
    <context id="i9c7f9a766f914e7e955ad7e8a52dfc77_D20200918-20200918">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
        </entity>
        <period>
            <startDate>2020-09-18</startDate>
            <endDate>2020-09-18</endDate>
        </period>
    </context>
    <context id="if7798276e33b48af81058807002f7542_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">smmt:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib9e53bf038884fe1aebddae6ccd2c196_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">smmt:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i942ccb9196bb4d0ab10e4c87af4250a2_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">smmt:OfficeAndTechnologyEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia8b911ed586c4e1bbdda461a2557aff7_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">smmt:OfficeAndTechnologyEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i593cfc00ba154e79a513606849b36e61_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if0549c486ffc4be2b6a75373c950243b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i32242c0ff70343c9adfcc11c6595a70f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i435477ccebf0489e8e94db10eb60db56_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if02b5108070a44ba843c22e648997315_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4d900fb56eda43068b75b033c9bfc547_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i71dfd1e7be4e496b90e176a973683625_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5429ceb33a414445be9322f8f9c293e3_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i05760767313140efb7f8f84e9096f9f3_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie0717192d4d74cfd912383af07cab29d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9367ade534d1492b81f243c12898e81d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i04c6be661f884e9f9fcec7b8a98ba02f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:LatinAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie7b7d8e874e541099d3260b499ccef94_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:LatinAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib314f5dd5ac24f47a60b0925a50a5081_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">smmt:EuroFarmaLaboratoriosSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="if1c80590b2284b5092629628c5efb266_I20200229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">smmt:EuroFarmaLaboratoriosSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-29</instant>
        </period>
    </context>
    <context id="i7d9fb711621141cd9ebefb15542db56a_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">smmt:EuroFarmaLaboratoriosSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i5f7778418eab4524a04524ce76786f35_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">smmt:EuroFarmaLaboratoriosSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7179bafa598f42ebb6c974d6b860624e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">smmt:EuroFarmaLaboratoriosSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i75af2dac1e474913ae259011f0e40ece_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">smmt:EuroFarmaLaboratoriosSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia4d86426c389449ebc2c7f1874dbc3fc_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">smmt:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iab792aa058af48aba2d03719d4253bde_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">smmt:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4ef399140bb14718b545a1aaa04203df_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">smmt:OtherGrantFundingCounterpartiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i52c373554f2f40b4a54d0ff856b68cf6_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">smmt:OtherGrantFundingCounterpartiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i5189024af3e3465a96e4c5c1204cfc1d_D20170901-20170930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">smmt:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-09-01</startDate>
            <endDate>2017-09-30</endDate>
        </period>
    </context>
    <context id="i6080657079b74ddc92d888ef28f1a49a_D20170901-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">smmt:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-09-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ice72e22d8b604c7a9047363b98c2c5e0_D20210501-20210531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">smmt:CombatingAntibioticResistantBacteriaBiopharmaceuticalAcceleratorProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="i31a55aa85c704fa1b0bf71fb5d66f073_D20210501-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">smmt:CombatingAntibioticResistantBacteriaBiopharmaceuticalAcceleratorProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iba2a2e6aa4554084aa69ed9ef72c2590_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">smmt:CombatingAntibioticResistantBacteriaBiopharmaceuticalAcceleratorProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3f5f274eec6e4854a5687bcb5cfc91d9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2ed068ac829e484093c122d76b8f373f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0ef15edbb3914ab3807ad48ae9426591_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i16643be7aeaf41edbc627f4639147976_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7e1be0d5904743408b0b38cc3f4a584c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i532f6b25e45149648f05717f44c7c477_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib1c1be44b3ba438881338233be927f12_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i17a5a82d4e56446b9587e3a8aad49a1b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5c71c63c2a0d454aa48a55ab0a0ec4ee_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1dba735cd51b4bd9acdace9e3eb39523_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i473628003f11481a823723bf532a0274_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i5bc912ce09754534905d49a8cb511c7a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i2fa48e55eff24bda9a7ebf8b065a3657_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3b2b674d2a6f48e7af3dcc03537946c3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">smmt:UtrophinProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2491765d7faa4157a0b9a7f08084dcb2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">smmt:DiscuvaPlatformMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i558da201e4864ba0a1ff4a54d2b3b599_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">smmt:OptionOverNonFinancialAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i93b60cd7d5744711a30a544473f93063_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">smmt:OtherPatentsAndLicensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iaf53a1912d5743a186cd8a0986d0a4c9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">smmt:UtrophinProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id2256d9dc5d54775a80518270c92d9cf_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">smmt:DiscuvaPlatformMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i74db8c4615a64aabac7a997f0967a92d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">smmt:OptionOverNonFinancialAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8ae4247d97144e01bf0a9c9b8cfd0111_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">smmt:OtherPatentsAndLicensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i137b9502c9084c29a43d474c1b31e151_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">smmt:OptionOverNonFinancialAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia3f12147410f43d28d06362b9dba4771_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">smmt:DiscuvaPlatformMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if6f9b4ae5c0b4a59bd0bbd8975258bb6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">smmt:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if02dcbd0b04f40f08ccd958c30a79c08_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">smmt:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic09e2474bf014397be8c508d9cbef4b5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">smmt:FurnitureAndFixturesOfficeEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i30c79b436c2d47d98676b1f9a2231cdc_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">smmt:FurnitureAndFixturesOfficeEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib30be684902148cdbfad1b6e48d5528d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2abb02e0508e40e5b35f04d561b326de_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i24a6a1407c6849eda580568b0680d532_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">smmt:MenloParkCaliforniaUSAndSawstonUKMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id630c360daad499f94b27cc39c3a0633_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">smmt:OxfordshireUKMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i065a06364b944635a5fea7a0548c3c71_I20200917">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
        </entity>
        <period>
            <instant>2020-09-17</instant>
        </period>
    </context>
    <context id="ib1b2bbd9c2ea4c81affedf30cb5ad225_I20200918">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
        </entity>
        <period>
            <instant>2020-09-18</instant>
        </period>
    </context>
    <context id="i6a505b52efdc43a7821a6b7cc66b172e_D20201106-20201106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-06</startDate>
            <endDate>2020-11-06</endDate>
        </period>
    </context>
    <context id="i1cda89fc1bbb4c82a3c7a93284736d74_I20201106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-06</instant>
        </period>
    </context>
    <context id="ief39eb2f075b4eb78fa3e4ffac9e4610_D20191224-20191224">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-24</startDate>
            <endDate>2019-12-24</endDate>
        </period>
    </context>
    <context id="i5b2fdb6bad994e6eb9c9380cb3807cd6_I20191224">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-24</instant>
        </period>
    </context>
    <context id="id3dfe8aa6a324f739c2caa516220e112_I20191224">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">smmt:ConsultingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-24</instant>
        </period>
    </context>
    <context id="ib29a1c5799524e1987c045aee67b6831_D20191224-20191224">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">smmt:ConsultingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-24</startDate>
            <endDate>2019-12-24</endDate>
        </period>
    </context>
    <context id="ia5f83af41ad746ffb1aa249c3a0f7238_D20200630-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">smmt:ConsultingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-30</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i829bd35e2a01482f995c5247b3243ee1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">smmt:ConsultingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if894fc66857243cf91a1a3e3a656bd4f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id2eec56c2a084d07bd27c69c542c646e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i52879ea7de8d4f93bf2933bde91a0538_I20200921">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">smmt:A2020StockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-21</instant>
        </period>
    </context>
    <context id="i77c56146a814495db85257a588d28851_D20200921-20200921">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">smmt:A2020StockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-21</startDate>
            <endDate>2020-09-21</endDate>
        </period>
    </context>
    <context id="ia36692a70694499e8458216f476de0aa_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">smmt:A2020StockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9b560a9af3b441468dab3205aa4e621c_I20200819">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-19</instant>
        </period>
    </context>
    <context id="i2e4f636d5f284aaa971b49db94dc48d6_D20200819-20200819">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-19</startDate>
            <endDate>2020-08-19</endDate>
        </period>
    </context>
    <context id="i8a26223d9fc34901b9c170239c1296e3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia19b35b6945f47e0b9f50e24473f7b3f_D20210802-20210802">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-02</startDate>
            <endDate>2021-08-02</endDate>
        </period>
    </context>
    <context id="iabc12254dbae479c95e96111f5913844_D20220301-20220301">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-01</startDate>
            <endDate>2022-03-01</endDate>
        </period>
    </context>
    <context id="i75d2f909ade34437b24a7cd383ffa673_D20200819-20200819">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-19</startDate>
            <endDate>2020-08-19</endDate>
        </period>
    </context>
    <context id="ibedda2e6e02c4c85ad25b6fda3de4f3e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8083f97ada2d4b42b9fe0c6f07ec03d4_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i444320f038034b09878835272c70885a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i269ac82e7b7e4434933ca3c53f23e541_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ifb5f434783cc4b4c9ef2fe9ae4041cd4_D20210924-20210924">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
        </entity>
        <period>
            <startDate>2021-09-24</startDate>
            <endDate>2021-09-24</endDate>
        </period>
    </context>
    <context id="ibf72cce8ac64497daeaefb6469475537_D20210924-20210924">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-24</startDate>
            <endDate>2021-09-24</endDate>
        </period>
    </context>
    <context id="ib788877f138c4513a611e7bbf11174b9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ifb40b671dcdb4ef29c0a6c97d77ebb15_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i151cdfd1b29442d4840888fb00f8949d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4d5f6c2289bf42c8a42f632397ea769e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i395ac2e436db41e1b784ce9a6a63fdfd_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i1b7a43e1795f40b497c444b01b9f6b53_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">smmt:ConsultantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia09aa906eefb458f9f484f59eac63b0f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie40533d6881a4b8e84e00ba2095c6a46_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9692194cdd1947979995cb545a07d30f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1b50b0a3bb8f405dafa9635ba05d5e1a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id19f5fb0cc5346e48e222529f4a6e420_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7be0acfd60d747fbba039b448bffe68f_I20191224">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-24</instant>
        </period>
    </context>
    <context id="i4f6915c5f2074c63ae73f25be0258821_I20191224">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">smmt:FormerChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-24</instant>
        </period>
    </context>
    <context id="i7f56091566944d9bb672ff557a22aff4_I20201106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-06</instant>
        </period>
    </context>
    <context id="ibc0f44cee68945c1910a87557a1bdd5d_I20201106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:BeneficialOwnerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-06</instant>
        </period>
    </context>
    <context id="i2a2d5cacc14249f0a5bbe8fcc0619c62_D20191224-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">smmt:ConsultingAgreementConsultancyFeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-24</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ib8d80178d3e743bd88db3e643c215cb4_D20191224-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">smmt:ConsultancyAgreementWarrantVestingExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-24</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i0346f51cbc1549bc97088b050e2cd48e_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">smmt:AssignmentAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:BeneficialOwnerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i093a476c99524d7c821d17ca295cc4d5_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">smmt:AssignmentAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i4a8e4bc29f1645008a3ae3a8a5bb7985_D20210324-20210324">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">smmt:InitialPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-24</startDate>
            <endDate>2021-03-24</endDate>
        </period>
    </context>
    <context id="i0ad778717801435f8f8ca0b3e18b51e9_I20210324">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">smmt:InitialPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-24</instant>
        </period>
    </context>
    <context id="i325d85a3830d40bba514256f5133edfa_D20210324-20210324">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">smmt:InitialPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:UsTreasuryUstInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-24</startDate>
            <endDate>2021-03-24</endDate>
        </period>
    </context>
    <context id="i09dcbb2d540d490da156db0310d0ba16_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">smmt:InitialPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="idb48cdbb6adf4bcf9f8d62840ec9c140_I20210326">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-26</instant>
        </period>
    </context>
    <context id="i581d5e9999fd48be88afa99a5a463cea_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5c623b14e066454399e945948de2ad12_D20210420-20210420">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">smmt:SecondPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-20</startDate>
            <endDate>2021-04-20</endDate>
        </period>
    </context>
    <context id="i6f7965621e7641dba292d1568adf65f8_D20210420-20210420">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">smmt:SecondPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:UsTreasuryUstInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-20</startDate>
            <endDate>2021-04-20</endDate>
        </period>
    </context>
    <context id="ie3fb42912674490dbad67b4354fdb2ee_D20210512-20210512">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">smmt:RightsOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-12</startDate>
            <endDate>2021-05-12</endDate>
        </period>
    </context>
    <context id="i2c16f78153794bfc9c3b372a28a98377_D20210512-20210512">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefOperatingOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">smmt:RightsOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-12</startDate>
            <endDate>2021-05-12</endDate>
        </period>
    </context>
    <context id="i8148167fc4184c02abb40835e22beac6_I20210512">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefOperatingOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">smmt:RightsOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-12</instant>
        </period>
    </context>
    <context id="i11be25b5a09d46a5851abb451892b99c_I20210512">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">smmt:RightsOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-12</instant>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="segment">
        <measure>smmt:segment</measure>
    </unit>
    <unit id="country">
        <measure>smmt:country</measure>
    </unit>
    <unit id="milestone">
        <measure>smmt:milestone</measure>
    </unit>
    <unit id="reporting_unit">
        <measure>smmt:reporting_unit</measure>
    </unit>
    <unit id="contract">
        <measure>smmt:contract</measure>
    </unit>
    <unit id="employee">
        <measure>smmt:employee</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN180L2ZyYWc6YTEwMzU4ZmQ1MzY0NDA2ZGFlMzU5YTI3MDRjOGIyZGEvdGFibGU6NTRmYWNmZWNjMGZjNDFmYWJiYWViMjM3N2M1NGU2ZmEvdGFibGVyYW5nZTo1NGZhY2ZlY2MwZmM0MWZhYmJhZWIyMzc3YzU0ZTZmYV8xLTEtMS0xLTEwOTg3Ng_30607081-7552-444c-893f-c948b4099d1f">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN180L2ZyYWc6YTEwMzU4ZmQ1MzY0NDA2ZGFlMzU5YTI3MDRjOGIyZGEvdGFibGU6NTRmYWNmZWNjMGZjNDFmYWJiYWViMjM3N2M1NGU2ZmEvdGFibGVyYW5nZTo1NGZhY2ZlY2MwZmM0MWZhYmJhZWIyMzc3YzU0ZTZmYV8yLTEtMS0xLTEwOTg3Ng_ce484099-05e4-4a45-9ec1-c36756327d3d">0001599298</dei:EntityCentralIndexKey>
    <dei:DocumentFiscalYearFocus
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN180L2ZyYWc6YTEwMzU4ZmQ1MzY0NDA2ZGFlMzU5YTI3MDRjOGIyZGEvdGFibGU6NTRmYWNmZWNjMGZjNDFmYWJiYWViMjM3N2M1NGU2ZmEvdGFibGVyYW5nZTo1NGZhY2ZlY2MwZmM0MWZhYmJhZWIyMzc3YzU0ZTZmYV8zLTEtMS0xLTEwOTg3Ng_621c73dd-c1a9-4bfe-8a00-8735dc7cd8fb">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN180L2ZyYWc6YTEwMzU4ZmQ1MzY0NDA2ZGFlMzU5YTI3MDRjOGIyZGEvdGFibGU6NTRmYWNmZWNjMGZjNDFmYWJiYWViMjM3N2M1NGU2ZmEvdGFibGVyYW5nZTo1NGZhY2ZlY2MwZmM0MWZhYmJhZWIyMzc3YzU0ZTZmYV80LTEtMS0xLTEwOTg3Ng_a7f5d95f-72cb-4a47-9be9-ae6a2ee681ad">FY</dei:DocumentFiscalPeriodFocus>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="i9c7f9a766f914e7e955ad7e8a52dfc77_D20200918-20200918"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMjQvZnJhZzo0ZTkyYWRlZGI3NWM0MmU2ODBhZmUzNzA2MWE0ODE2ZS90ZXh0cmVnaW9uOjRlOTJhZGVkYjc1YzQyZTY4MGFmZTM3MDYxYTQ4MTZlXzM1_e64910e8-7cb4-4718-8b58-eac6f58b9fbb"
      unitRef="number">0.2</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="i9c7f9a766f914e7e955ad7e8a52dfc77_D20200918-20200918"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNzgvZnJhZzo2NWI0NmRiMWE3ZGE0OThhOTYwOTczMTg4NzhiYmNmYy90ZXh0cmVnaW9uOjY1YjQ2ZGIxYTdkYTQ5OGE5NjA5NzMxODg3OGJiY2ZjXzM1_97c55676-6a11-4bea-9370-d9bc4fb0c5b3"
      unitRef="number">0.2</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="ibedda2e6e02c4c85ad25b6fda3de4f3e_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODEvZnJhZzoyOTEzNTMwMjlmMjQ0ZTQ0ODgzNDE5NTEzYjBhODA3Ny90ZXh0cmVnaW9uOjI5MTM1MzAyOWYyNDRlNDQ4ODM0MTk1MTNiMGE4MDc3XzQ4MzA_52cfade8-6eaf-42ea-82a4-09b084b53c45">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <dei:DocumentType
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xL2ZyYWc6MDM2ZTQxNmM1MThlNDc4YjgwMzhiOTA2MzE2OTQ1NGQvdGV4dHJlZ2lvbjowMzZlNDE2YzUxOGU0NzhiODAzOGI5MDYzMTY5NDU0ZF8zNDcx_a4d119ce-7817-41b6-93ac-97ae222b7637">10-K/A</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xL2ZyYWc6MDM2ZTQxNmM1MThlNDc4YjgwMzhiOTA2MzE2OTQ1NGQvdGV4dHJlZ2lvbjowMzZlNDE2YzUxOGU0NzhiODAzOGI5MDYzMTY5NDU0ZF8zNDcy_32fb0159-9407-4a78-a6be-6170988d4a5c">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xL2ZyYWc6MDM2ZTQxNmM1MThlNDc4YjgwMzhiOTA2MzE2OTQ1NGQvdGV4dHJlZ2lvbjowMzZlNDE2YzUxOGU0NzhiODAzOGI5MDYzMTY5NDU0ZF8yNzQ_ef4584c3-7879-4458-81d2-02bd9191d917">2021-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xL2ZyYWc6MDM2ZTQxNmM1MThlNDc4YjgwMzhiOTA2MzE2OTQ1NGQvdGV4dHJlZ2lvbjowMzZlNDE2YzUxOGU0NzhiODAzOGI5MDYzMTY5NDU0ZF8yNzQ_5fc38dde-19f9-4b0d-b4d4-ffcc2c176b09">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xL2ZyYWc6MDM2ZTQxNmM1MThlNDc4YjgwMzhiOTA2MzE2OTQ1NGQvdGV4dHJlZ2lvbjowMzZlNDE2YzUxOGU0NzhiODAzOGI5MDYzMTY5NDU0ZF8zNDc0_191ceceb-9913-48ee-a7ae-0efba04ba2da">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xL2ZyYWc6MDM2ZTQxNmM1MThlNDc4YjgwMzhiOTA2MzE2OTQ1NGQvdGV4dHJlZ2lvbjowMzZlNDE2YzUxOGU0NzhiODAzOGI5MDYzMTY5NDU0ZF8zNDc1_f76d3680-2d4a-42dc-b188-918ce8c0b720">001-36866</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xL2ZyYWc6MDM2ZTQxNmM1MThlNDc4YjgwMzhiOTA2MzE2OTQ1NGQvdGV4dHJlZ2lvbjowMzZlNDE2YzUxOGU0NzhiODAzOGI5MDYzMTY5NDU0ZF8zNDYz_208b9510-1378-46b9-afb7-5d213c7db9c4">Summit Therapeutics Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xL2ZyYWc6MDM2ZTQxNmM1MThlNDc4YjgwMzhiOTA2MzE2OTQ1NGQvdGFibGU6NTU3NjA0NWFiYTc3NDI1MDlkYTU2NzNkYjVhNjc4MzAvdGFibGVyYW5nZTo1NTc2MDQ1YWJhNzc0MjUwOWRhNTY3M2RiNWE2NzgzMF8wLTAtMS0xLTEwOTg3Ng_f00df743-f0a4-43c7-81d9-776784a7520e">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xL2ZyYWc6MDM2ZTQxNmM1MThlNDc4YjgwMzhiOTA2MzE2OTQ1NGQvdGFibGU6NTU3NjA0NWFiYTc3NDI1MDlkYTU2NzNkYjVhNjc4MzAvdGFibGVyYW5nZTo1NTc2MDQ1YWJhNzc0MjUwOWRhNTY3M2RiNWE2NzgzMF8wLTMtMS0xLTEwOTg3Ng_8c718507-d2e3-42cd-b3cf-685a55485230">37-1979717</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xL2ZyYWc6MDM2ZTQxNmM1MThlNDc4YjgwMzhiOTA2MzE2OTQ1NGQvdGFibGU6NTU3NjA0NWFiYTc3NDI1MDlkYTU2NzNkYjVhNjc4MzAvdGFibGVyYW5nZTo1NTc2MDQ1YWJhNzc0MjUwOWRhNTY3M2RiNWE2NzgzMF8zLTAtMS0xLTEwOTg3Ng_9a547bd2-5a79-469a-ac87-5a6c42b83e3a">One Broadway, 14th Floor</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xL2ZyYWc6MDM2ZTQxNmM1MThlNDc4YjgwMzhiOTA2MzE2OTQ1NGQvdGFibGU6NTU3NjA0NWFiYTc3NDI1MDlkYTU2NzNkYjVhNjc4MzAvdGFibGVyYW5nZTo1NTc2MDQ1YWJhNzc0MjUwOWRhNTY3M2RiNWE2NzgzMF80LTAtMS0xLTEwOTg3Ng_8e313f15-e450-4c60-b8ab-891a41987b78">Cambridge,</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xL2ZyYWc6MDM2ZTQxNmM1MThlNDc4YjgwMzhiOTA2MzE2OTQ1NGQvdGFibGU6NTU3NjA0NWFiYTc3NDI1MDlkYTU2NzNkYjVhNjc4MzAvdGFibGVyYW5nZTo1NTc2MDQ1YWJhNzc0MjUwOWRhNTY3M2RiNWE2NzgzMF80LTEtMS0xLTEwOTg3Ng_fc1f5abb-99e6-437c-8419-c3814fe2aa91">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xL2ZyYWc6MDM2ZTQxNmM1MThlNDc4YjgwMzhiOTA2MzE2OTQ1NGQvdGFibGU6NTU3NjA0NWFiYTc3NDI1MDlkYTU2NzNkYjVhNjc4MzAvdGFibGVyYW5nZTo1NTc2MDQ1YWJhNzc0MjUwOWRhNTY3M2RiNWE2NzgzMF80LTMtMS0xLTEwOTg3Ng_a8cb30a5-ee51-4e51-81fd-0a46a3bccd6c">02142</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xL2ZyYWc6MDM2ZTQxNmM1MThlNDc4YjgwMzhiOTA2MzE2OTQ1NGQvdGV4dHJlZ2lvbjowMzZlNDE2YzUxOGU0NzhiODAzOGI5MDYzMTY5NDU0ZF8zNDY5_0c2025bb-5bb0-4917-9db4-a464906f3d01">617</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xL2ZyYWc6MDM2ZTQxNmM1MThlNDc4YjgwMzhiOTA2MzE2OTQ1NGQvdGV4dHJlZ2lvbjowMzZlNDE2YzUxOGU0NzhiODAzOGI5MDYzMTY5NDU0ZF8zNDY2_83517f9f-5f2f-4cbc-91bc-2ca2cd02e41c">514-7149</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xL2ZyYWc6MDM2ZTQxNmM1MThlNDc4YjgwMzhiOTA2MzE2OTQ1NGQvdGFibGU6OTBiYjc0NWRlZTg0NGU1NDljMGZhZjA1ODMzZDRiNTMvdGFibGVyYW5nZTo5MGJiNzQ1ZGVlODQ0ZTU0OWMwZmFmMDU4MzNkNGI1M18xLTAtMS0xLTEwOTg3Ng_034e8dcf-755c-4a52-b2ed-ad599f54a057">Common Stock, par value $0.01 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xL2ZyYWc6MDM2ZTQxNmM1MThlNDc4YjgwMzhiOTA2MzE2OTQ1NGQvdGFibGU6OTBiYjc0NWRlZTg0NGU1NDljMGZhZjA1ODMzZDRiNTMvdGFibGVyYW5nZTo5MGJiNzQ1ZGVlODQ0ZTU0OWMwZmFmMDU4MzNkNGI1M18xLTEtMS0xLTEwOTg3Ng_33187bbf-b7b7-4d79-99b5-668098135bf3">SMMT</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xL2ZyYWc6MDM2ZTQxNmM1MThlNDc4YjgwMzhiOTA2MzE2OTQ1NGQvdGFibGU6OTBiYjc0NWRlZTg0NGU1NDljMGZhZjA1ODMzZDRiNTMvdGFibGVyYW5nZTo5MGJiNzQ1ZGVlODQ0ZTU0OWMwZmFmMDU4MzNkNGI1M18xLTItMS0xLTEwOTg3Ng_f83c062f-65ae-4959-a520-694e0dadc229">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xL2ZyYWc6MDM2ZTQxNmM1MThlNDc4YjgwMzhiOTA2MzE2OTQ1NGQvdGV4dHJlZ2lvbjowMzZlNDE2YzUxOGU0NzhiODAzOGI5MDYzMTY5NDU0ZF8zNDY0_ed38e6e4-0073-48b1-8712-2bdd5a8b8e18">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xL2ZyYWc6MDM2ZTQxNmM1MThlNDc4YjgwMzhiOTA2MzE2OTQ1NGQvdGV4dHJlZ2lvbjowMzZlNDE2YzUxOGU0NzhiODAzOGI5MDYzMTY5NDU0ZF8zNDYw_dc9fcce2-ab10-42a3-8391-4f730db6b4ea">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xL2ZyYWc6MDM2ZTQxNmM1MThlNDc4YjgwMzhiOTA2MzE2OTQ1NGQvdGV4dHJlZ2lvbjowMzZlNDE2YzUxOGU0NzhiODAzOGI5MDYzMTY5NDU0ZF8zNDY3_f3c0d23f-74d2-4bcf-8d1c-4e397cadd0f5">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xL2ZyYWc6MDM2ZTQxNmM1MThlNDc4YjgwMzhiOTA2MzE2OTQ1NGQvdGV4dHJlZ2lvbjowMzZlNDE2YzUxOGU0NzhiODAzOGI5MDYzMTY5NDU0ZF8zNDYx_3e44e276-0cca-439b-88c7-b243732dc177">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xL2ZyYWc6MDM2ZTQxNmM1MThlNDc4YjgwMzhiOTA2MzE2OTQ1NGQvdGFibGU6ZTMxY2NkMDRmMTQxNDQ5ZDllZGQ0MzQzOTI3NDQ1YjUvdGFibGVyYW5nZTplMzFjY2QwNGYxNDE0NDlkOWVkZDQzNDM5Mjc0NDViNV8xLTAtMS0xLTEwOTg3Ng_f1cb7a0d-d7d9-40b0-a64b-b34a2e70f9b3">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xL2ZyYWc6MDM2ZTQxNmM1MThlNDc4YjgwMzhiOTA2MzE2OTQ1NGQvdGFibGU6ZTMxY2NkMDRmMTQxNDQ5ZDllZGQ0MzQzOTI3NDQ1YjUvdGFibGVyYW5nZTplMzFjY2QwNGYxNDE0NDlkOWVkZDQzNDM5Mjc0NDViNV8xLTMtMS0xLTEwOTg3Ng_3a6cda06-926d-4510-9644-1f97a6f3e916">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xL2ZyYWc6MDM2ZTQxNmM1MThlNDc4YjgwMzhiOTA2MzE2OTQ1NGQvdGFibGU6ZTMxY2NkMDRmMTQxNDQ5ZDllZGQ0MzQzOTI3NDQ1YjUvdGFibGVyYW5nZTplMzFjY2QwNGYxNDE0NDlkOWVkZDQzNDM5Mjc0NDViNV8yLTMtMS0xLTEwOTg3Ng_1084739a-041a-47b1-9324-9b3ec916a771">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xL2ZyYWc6MDM2ZTQxNmM1MThlNDc4YjgwMzhiOTA2MzE2OTQ1NGQvdGV4dHJlZ2lvbjowMzZlNDE2YzUxOGU0NzhiODAzOGI5MDYzMTY5NDU0ZF8zNDcw_f6e7877b-5333-4406-8493-5951e6e5325e">false</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xL2ZyYWc6MDM2ZTQxNmM1MThlNDc4YjgwMzhiOTA2MzE2OTQ1NGQvdGV4dHJlZ2lvbjowMzZlNDE2YzUxOGU0NzhiODAzOGI5MDYzMTY5NDU0ZF8zNDc2_0347906d-3a92-4e27-9b96-e61003db648b">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="ia595af4209c94a0e84bcc1c89fef3796_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xL2ZyYWc6MDM2ZTQxNmM1MThlNDc4YjgwMzhiOTA2MzE2OTQ1NGQvdGV4dHJlZ2lvbjowMzZlNDE2YzUxOGU0NzhiODAzOGI5MDYzMTY5NDU0ZF8yOTQ5_a75bc2a3-2ddc-49ed-8ad9-735f8c59edc0"
      unitRef="usd">186000000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="idbfc95cd82ac4443bb9c319767213cfa_I20220310"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xL2ZyYWc6MDM2ZTQxNmM1MThlNDc4YjgwMzhiOTA2MzE2OTQ1NGQvdGV4dHJlZ2lvbjowMzZlNDE2YzUxOGU0NzhiODAzOGI5MDYzMTY5NDU0ZF8zMTc3_d3526d05-12d5-4f52-866b-9bb766b4b7d4"
      unitRef="shares">98122356</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xL2ZyYWc6MDM2ZTQxNmM1MThlNDc4YjgwMzhiOTA2MzE2OTQ1NGQvdGV4dHJlZ2lvbjowMzZlNDE2YzUxOGU0NzhiODAzOGI5MDYzMTY5NDU0ZF8zNDYy_9175c063-70f3-4c06-9efa-f6e0d0887b6d">Portions of the registrant&#x2019;s definitive Proxy Statement to be filed with the Securities and Exchange Commission within 120 days after registrant&#x2019;s fiscal year ended December 31, 2021 are incorporated by reference into Part III of this report.</dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:AuditorFirmId
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN185NC9mcmFnOjgyMThiNzlmMDQ4ZjRiNDk5N2ViMzA3YzkwMWFkYmE5L3RhYmxlOjBkNDBhNTkzZTZiYTQxNjU4NWE1NjMyNjNjNjFmNzNiL3RhYmxlcmFuZ2U6MGQ0MGE1OTNlNmJhNDE2NTg1YTU2MzI2M2M2MWY3M2JfMy0wLTEtMS0xMDk4NzYvdGV4dHJlZ2lvbjpkMWI4NTBlMTNhMmE0NTFiYmQ1NGFmMDU4YzEwY2FjNV83MA_e14966fb-a997-4ba4-986b-ea9e31a3d51d">238</dei:AuditorFirmId>
    <dei:AuditorFirmId
      contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN185NC9mcmFnOjgyMThiNzlmMDQ4ZjRiNDk5N2ViMzA3YzkwMWFkYmE5L3RhYmxlOjBkNDBhNTkzZTZiYTQxNjU4NWE1NjMyNjNjNjFmNzNiL3RhYmxlcmFuZ2U6MGQ0MGE1OTNlNmJhNDE2NTg1YTU2MzI2M2M2MWY3M2JfNC0wLTEtMS0xMDk4NzYvdGV4dHJlZ2lvbjo3NDZjZDIwMDc1MmI0NmI0ODc1NWY1M2U0NjA4MmUyN183MA_45db54c2-1ae5-4299-bc47-f1ea6c328ec3">876</dei:AuditorFirmId>
    <dei:AuditorName
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDAvZnJhZzozNTZlMmU4ZmI0ZjY0YjExODE4Y2EwNDM1MzYzZTc0Zi90ZXh0cmVnaW9uOjM1NmUyZThmYjRmNjRiMTE4MThjYTA0MzUzNjNlNzRmXzY1NzE_e45a4107-b82a-4aa2-a69e-d892ab5b6f90">PricewaterhouseCoopers LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDAvZnJhZzozNTZlMmU4ZmI0ZjY0YjExODE4Y2EwNDM1MzYzZTc0Zi90ZXh0cmVnaW9uOjM1NmUyZThmYjRmNjRiMTE4MThjYTA0MzUzNjNlNzRmXzY1NzM_e8151122-817d-43ee-a2f1-59fe8bb2ae49">Boston, Massachusetts</dei:AuditorLocation>
    <dei:AuditorName
      contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDMvZnJhZzozMmY1YzhhMzIyOWI0NWM3YWUzNWI3NjM3YTM3OGQwZC90ZXh0cmVnaW9uOjMyZjVjOGEzMjI5YjQ1YzdhZTM1Yjc2MzdhMzc4ZDBkXzI1NjA_853b3a5b-9bae-4fcf-ae0d-393da2858a50">PricewaterhouseCoopers LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDMvZnJhZzozMmY1YzhhMzIyOWI0NWM3YWUzNWI3NjM3YTM3OGQwZC90ZXh0cmVnaW9uOjMyZjVjOGEzMjI5YjQ1YzdhZTM1Yjc2MzdhMzc4ZDBkXzI1NjI_fe4602c3-ca91-40ac-84bd-8f31eef8eaca">Reading, United Kingdom</dei:AuditorLocation>
    <us-gaap:Cash
      contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDYvZnJhZzo1YTdkMDVlZTNkN2I0MmQ0OTk4NmY3ZmY3M2I1NzA1OS90YWJsZTpiMGQxMjA2OGI5ZGQ0MDNjYTBkYzdmNTI5ZTNjYWU4OS90YWJsZXJhbmdlOmIwZDEyMDY4YjlkZDQwM2NhMGRjN2Y1MjllM2NhZTg5XzMtMy0xLTEtMTA5ODc2_e39415ce-2099-42aa-97e8-8b5568e549c7"
      unitRef="usd">71791000</us-gaap:Cash>
    <us-gaap:Cash
      contextRef="i7372be6dc06143b5adbb4d2e83a596c5_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDYvZnJhZzo1YTdkMDVlZTNkN2I0MmQ0OTk4NmY3ZmY3M2I1NzA1OS90YWJsZTpiMGQxMjA2OGI5ZGQ0MDNjYTBkYzdmNTI5ZTNjYWU4OS90YWJsZXJhbmdlOmIwZDEyMDY4YjlkZDQwM2NhMGRjN2Y1MjllM2NhZTg5XzMtNS0xLTEtMTA5ODc2_e25b9a2c-88a0-4526-ab9c-98fb37fc4e91"
      unitRef="usd">66417000</us-gaap:Cash>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDYvZnJhZzo1YTdkMDVlZTNkN2I0MmQ0OTk4NmY3ZmY3M2I1NzA1OS90YWJsZTpiMGQxMjA2OGI5ZGQ0MDNjYTBkYzdmNTI5ZTNjYWU4OS90YWJsZXJhbmdlOmIwZDEyMDY4YjlkZDQwM2NhMGRjN2Y1MjllM2NhZTg5XzQtMy0xLTEtMTA5ODc2_17cb26e4-49a0-494b-b534-ed0de537cdd5"
      unitRef="usd">1464000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i7372be6dc06143b5adbb4d2e83a596c5_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDYvZnJhZzo1YTdkMDVlZTNkN2I0MmQ0OTk4NmY3ZmY3M2I1NzA1OS90YWJsZTpiMGQxMjA2OGI5ZGQ0MDNjYTBkYzdmNTI5ZTNjYWU4OS90YWJsZXJhbmdlOmIwZDEyMDY4YjlkZDQwM2NhMGRjN2Y1MjllM2NhZTg5XzQtNS0xLTEtMTA5ODc2_7c7100da-8b21-4160-8d6c-7baaad8bca6b"
      unitRef="usd">331000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDYvZnJhZzo1YTdkMDVlZTNkN2I0MmQ0OTk4NmY3ZmY3M2I1NzA1OS90YWJsZTpiMGQxMjA2OGI5ZGQ0MDNjYTBkYzdmNTI5ZTNjYWU4OS90YWJsZXJhbmdlOmIwZDEyMDY4YjlkZDQwM2NhMGRjN2Y1MjllM2NhZTg5XzUtMy0xLTEtMTA5ODc2_763a842b-e719-4917-993b-12007250ec0c"
      unitRef="usd">7161000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="i7372be6dc06143b5adbb4d2e83a596c5_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDYvZnJhZzo1YTdkMDVlZTNkN2I0MmQ0OTk4NmY3ZmY3M2I1NzA1OS90YWJsZTpiMGQxMjA2OGI5ZGQ0MDNjYTBkYzdmNTI5ZTNjYWU4OS90YWJsZXJhbmdlOmIwZDEyMDY4YjlkZDQwM2NhMGRjN2Y1MjllM2NhZTg5XzUtNS0xLTEtMTA5ODc2_20374a73-4843-4356-80ca-241e77d58813"
      unitRef="usd">9547000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDYvZnJhZzo1YTdkMDVlZTNkN2I0MmQ0OTk4NmY3ZmY3M2I1NzA1OS90YWJsZTpiMGQxMjA2OGI5ZGQ0MDNjYTBkYzdmNTI5ZTNjYWU4OS90YWJsZXJhbmdlOmIwZDEyMDY4YjlkZDQwM2NhMGRjN2Y1MjllM2NhZTg5XzYtMy0xLTEtMTA5ODc2_24b33c69-3618-49da-9979-568a8f9d4272"
      unitRef="usd">1201000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="i7372be6dc06143b5adbb4d2e83a596c5_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDYvZnJhZzo1YTdkMDVlZTNkN2I0MmQ0OTk4NmY3ZmY3M2I1NzA1OS90YWJsZTpiMGQxMjA2OGI5ZGQ0MDNjYTBkYzdmNTI5ZTNjYWU4OS90YWJsZXJhbmdlOmIwZDEyMDY4YjlkZDQwM2NhMGRjN2Y1MjllM2NhZTg5XzYtNS0xLTEtMTA5ODc2_638ac02e-aeb2-4d39-96aa-7af21e968a31"
      unitRef="usd">1523000</us-gaap:OtherAssetsCurrent>
    <smmt:ResearchAndDevelopmentTaxCreditReceivableCurrent
      contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDYvZnJhZzo1YTdkMDVlZTNkN2I0MmQ0OTk4NmY3ZmY3M2I1NzA1OS90YWJsZTpiMGQxMjA2OGI5ZGQ0MDNjYTBkYzdmNTI5ZTNjYWU4OS90YWJsZXJhbmdlOmIwZDEyMDY4YjlkZDQwM2NhMGRjN2Y1MjllM2NhZTg5XzctMy0xLTEtMTA5ODc2_178335a4-d188-4bf4-a3b2-eb80c6638bcf"
      unitRef="usd">15695000</smmt:ResearchAndDevelopmentTaxCreditReceivableCurrent>
    <smmt:ResearchAndDevelopmentTaxCreditReceivableCurrent
      contextRef="i7372be6dc06143b5adbb4d2e83a596c5_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDYvZnJhZzo1YTdkMDVlZTNkN2I0MmQ0OTk4NmY3ZmY3M2I1NzA1OS90YWJsZTpiMGQxMjA2OGI5ZGQ0MDNjYTBkYzdmNTI5ZTNjYWU4OS90YWJsZXJhbmdlOmIwZDEyMDY4YjlkZDQwM2NhMGRjN2Y1MjllM2NhZTg5XzctNS0xLTEtMTA5ODc2_2abd5492-25f3-4ec4-bf86-545c153ff749"
      unitRef="usd">9856000</smmt:ResearchAndDevelopmentTaxCreditReceivableCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDYvZnJhZzo1YTdkMDVlZTNkN2I0MmQ0OTk4NmY3ZmY3M2I1NzA1OS90YWJsZTpiMGQxMjA2OGI5ZGQ0MDNjYTBkYzdmNTI5ZTNjYWU4OS90YWJsZXJhbmdlOmIwZDEyMDY4YjlkZDQwM2NhMGRjN2Y1MjllM2NhZTg5XzgtMy0xLTEtMTA5ODc2_4e9fc19b-6294-412c-88e6-ac24daf2f8df"
      unitRef="usd">97312000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i7372be6dc06143b5adbb4d2e83a596c5_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDYvZnJhZzo1YTdkMDVlZTNkN2I0MmQ0OTk4NmY3ZmY3M2I1NzA1OS90YWJsZTpiMGQxMjA2OGI5ZGQ0MDNjYTBkYzdmNTI5ZTNjYWU4OS90YWJsZXJhbmdlOmIwZDEyMDY4YjlkZDQwM2NhMGRjN2Y1MjllM2NhZTg5XzgtNS0xLTEtMTA5ODc2_fe77732f-13ee-4b40-97bc-a57e53b458f1"
      unitRef="usd">87674000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDYvZnJhZzo1YTdkMDVlZTNkN2I0MmQ0OTk4NmY3ZmY3M2I1NzA1OS90YWJsZTpiMGQxMjA2OGI5ZGQ0MDNjYTBkYzdmNTI5ZTNjYWU4OS90YWJsZXJhbmdlOmIwZDEyMDY4YjlkZDQwM2NhMGRjN2Y1MjllM2NhZTg5XzExLTMtMS0xLTEwOTg3Ng_0b7a2c82-8dd2-4b4a-80ed-67dbc7dddee6"
      unitRef="usd">694000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i7372be6dc06143b5adbb4d2e83a596c5_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDYvZnJhZzo1YTdkMDVlZTNkN2I0MmQ0OTk4NmY3ZmY3M2I1NzA1OS90YWJsZTpiMGQxMjA2OGI5ZGQ0MDNjYTBkYzdmNTI5ZTNjYWU4OS90YWJsZXJhbmdlOmIwZDEyMDY4YjlkZDQwM2NhMGRjN2Y1MjllM2NhZTg5XzExLTUtMS0xLTEwOTg3Ng_25472d5b-dd51-4e13-a613-254a92463fb2"
      unitRef="usd">725000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDYvZnJhZzo1YTdkMDVlZTNkN2I0MmQ0OTk4NmY3ZmY3M2I1NzA1OS90YWJsZTpiMGQxMjA2OGI5ZGQ0MDNjYTBkYzdmNTI5ZTNjYWU4OS90YWJsZXJhbmdlOmIwZDEyMDY4YjlkZDQwM2NhMGRjN2Y1MjllM2NhZTg5XzEyLTMtMS0xLTEwOTg3Ng_c9210cdf-c834-4d7f-827d-17eeb5ab74c1"
      unitRef="usd">2790000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i7372be6dc06143b5adbb4d2e83a596c5_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDYvZnJhZzo1YTdkMDVlZTNkN2I0MmQ0OTk4NmY3ZmY3M2I1NzA1OS90YWJsZTpiMGQxMjA2OGI5ZGQ0MDNjYTBkYzdmNTI5ZTNjYWU4OS90YWJsZXJhbmdlOmIwZDEyMDY4YjlkZDQwM2NhMGRjN2Y1MjllM2NhZTg5XzEyLTUtMS0xLTEwOTg3Ng_3172ad14-fd44-4e57-a8cd-54bd9500f70d"
      unitRef="usd">554000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:Goodwill
      contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDYvZnJhZzo1YTdkMDVlZTNkN2I0MmQ0OTk4NmY3ZmY3M2I1NzA1OS90YWJsZTpiMGQxMjA2OGI5ZGQ0MDNjYTBkYzdmNTI5ZTNjYWU4OS90YWJsZXJhbmdlOmIwZDEyMDY4YjlkZDQwM2NhMGRjN2Y1MjllM2NhZTg5XzEzLTMtMS0xLTEwOTg3Ng_f723ffeb-ae51-4328-a14e-7bd35e2af855"
      unitRef="usd">2009000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i7372be6dc06143b5adbb4d2e83a596c5_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDYvZnJhZzo1YTdkMDVlZTNkN2I0MmQ0OTk4NmY3ZmY3M2I1NzA1OS90YWJsZTpiMGQxMjA2OGI5ZGQ0MDNjYTBkYzdmNTI5ZTNjYWU4OS90YWJsZXJhbmdlOmIwZDEyMDY4YjlkZDQwM2NhMGRjN2Y1MjllM2NhZTg5XzEzLTUtMS0xLTEwOTg3Ng_28806585-7c73-405b-96e5-cf4c2a544243"
      unitRef="usd">2030000</us-gaap:Goodwill>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDYvZnJhZzo1YTdkMDVlZTNkN2I0MmQ0OTk4NmY3ZmY3M2I1NzA1OS90YWJsZTpiMGQxMjA2OGI5ZGQ0MDNjYTBkYzdmNTI5ZTNjYWU4OS90YWJsZXJhbmdlOmIwZDEyMDY4YjlkZDQwM2NhMGRjN2Y1MjllM2NhZTg5XzE0LTMtMS0xLTEwOTg3Ng_ad517425-c3da-4c8d-9aaa-f7f801715297"
      unitRef="usd">10399000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i7372be6dc06143b5adbb4d2e83a596c5_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDYvZnJhZzo1YTdkMDVlZTNkN2I0MmQ0OTk4NmY3ZmY3M2I1NzA1OS90YWJsZTpiMGQxMjA2OGI5ZGQ0MDNjYTBkYzdmNTI5ZTNjYWU4OS90YWJsZXJhbmdlOmIwZDEyMDY4YjlkZDQwM2NhMGRjN2Y1MjllM2NhZTg5XzE0LTUtMS0xLTEwOTg3Ng_7aeb6ede-4ca6-43f0-809e-372f4eb6c201"
      unitRef="usd">11515000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDYvZnJhZzo1YTdkMDVlZTNkN2I0MmQ0OTk4NmY3ZmY3M2I1NzA1OS90YWJsZTpiMGQxMjA2OGI5ZGQ0MDNjYTBkYzdmNTI5ZTNjYWU4OS90YWJsZXJhbmdlOmIwZDEyMDY4YjlkZDQwM2NhMGRjN2Y1MjllM2NhZTg5XzE1LTMtMS0xLTEwOTg3Ng_f8adcc98-bf38-4105-9218-4a62c61a2a79"
      unitRef="usd">170000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i7372be6dc06143b5adbb4d2e83a596c5_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDYvZnJhZzo1YTdkMDVlZTNkN2I0MmQ0OTk4NmY3ZmY3M2I1NzA1OS90YWJsZTpiMGQxMjA2OGI5ZGQ0MDNjYTBkYzdmNTI5ZTNjYWU4OS90YWJsZXJhbmdlOmIwZDEyMDY4YjlkZDQwM2NhMGRjN2Y1MjllM2NhZTg5XzE1LTUtMS0xLTEwOTg3Ng_e4685005-8df1-4100-a303-44f4b387b12a"
      unitRef="usd">0</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDYvZnJhZzo1YTdkMDVlZTNkN2I0MmQ0OTk4NmY3ZmY3M2I1NzA1OS90YWJsZTpiMGQxMjA2OGI5ZGQ0MDNjYTBkYzdmNTI5ZTNjYWU4OS90YWJsZXJhbmdlOmIwZDEyMDY4YjlkZDQwM2NhMGRjN2Y1MjllM2NhZTg5XzE2LTMtMS0xLTEwOTg3Ng_80a02674-532a-4ba7-8592-7c71413531d9"
      unitRef="usd">113374000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i7372be6dc06143b5adbb4d2e83a596c5_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDYvZnJhZzo1YTdkMDVlZTNkN2I0MmQ0OTk4NmY3ZmY3M2I1NzA1OS90YWJsZTpiMGQxMjA2OGI5ZGQ0MDNjYTBkYzdmNTI5ZTNjYWU4OS90YWJsZXJhbmdlOmIwZDEyMDY4YjlkZDQwM2NhMGRjN2Y1MjllM2NhZTg5XzE2LTUtMS0xLTEwOTg3Ng_b63d9859-fbb0-4a37-a9bb-b7a1348a996f"
      unitRef="usd">102498000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDYvZnJhZzo1YTdkMDVlZTNkN2I0MmQ0OTk4NmY3ZmY3M2I1NzA1OS90YWJsZTpiMGQxMjA2OGI5ZGQ0MDNjYTBkYzdmNTI5ZTNjYWU4OS90YWJsZXJhbmdlOmIwZDEyMDY4YjlkZDQwM2NhMGRjN2Y1MjllM2NhZTg5XzIwLTMtMS0xLTEwOTg3Ng_ba70b040-32e2-490c-aba8-2ffa3354da79"
      unitRef="usd">4374000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i7372be6dc06143b5adbb4d2e83a596c5_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDYvZnJhZzo1YTdkMDVlZTNkN2I0MmQ0OTk4NmY3ZmY3M2I1NzA1OS90YWJsZTpiMGQxMjA2OGI5ZGQ0MDNjYTBkYzdmNTI5ZTNjYWU4OS90YWJsZXJhbmdlOmIwZDEyMDY4YjlkZDQwM2NhMGRjN2Y1MjllM2NhZTg5XzIwLTUtMS0xLTEwOTg3Ng_86356982-7833-4ce6-8146-0528ef399101"
      unitRef="usd">6140000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDYvZnJhZzo1YTdkMDVlZTNkN2I0MmQ0OTk4NmY3ZmY3M2I1NzA1OS90YWJsZTpiMGQxMjA2OGI5ZGQ0MDNjYTBkYzdmNTI5ZTNjYWU4OS90YWJsZXJhbmdlOmIwZDEyMDY4YjlkZDQwM2NhMGRjN2Y1MjllM2NhZTg5XzIxLTMtMS0xLTEwOTg3Ng_1448ccb3-c87d-45e4-bac4-7bcf8b1df85d"
      unitRef="usd">7197000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i7372be6dc06143b5adbb4d2e83a596c5_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDYvZnJhZzo1YTdkMDVlZTNkN2I0MmQ0OTk4NmY3ZmY3M2I1NzA1OS90YWJsZTpiMGQxMjA2OGI5ZGQ0MDNjYTBkYzdmNTI5ZTNjYWU4OS90YWJsZXJhbmdlOmIwZDEyMDY4YjlkZDQwM2NhMGRjN2Y1MjllM2NhZTg5XzIxLTUtMS0xLTEwOTg3Ng_115c729b-408f-4669-8861-842496de24c8"
      unitRef="usd">3278000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDYvZnJhZzo1YTdkMDVlZTNkN2I0MmQ0OTk4NmY3ZmY3M2I1NzA1OS90YWJsZTpiMGQxMjA2OGI5ZGQ0MDNjYTBkYzdmNTI5ZTNjYWU4OS90YWJsZXJhbmdlOmIwZDEyMDY4YjlkZDQwM2NhMGRjN2Y1MjllM2NhZTg5XzIyLTMtMS0xLTEwOTg3Ng_49ef0698-0a5d-44a3-98b3-b86e8ac63e38"
      unitRef="usd">4125000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i7372be6dc06143b5adbb4d2e83a596c5_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDYvZnJhZzo1YTdkMDVlZTNkN2I0MmQ0OTk4NmY3ZmY3M2I1NzA1OS90YWJsZTpiMGQxMjA2OGI5ZGQ0MDNjYTBkYzdmNTI5ZTNjYWU4OS90YWJsZXJhbmdlOmIwZDEyMDY4YjlkZDQwM2NhMGRjN2Y1MjllM2NhZTg5XzIyLTUtMS0xLTEwOTg3Ng_efad5597-e540-48dc-97e3-978ab3ce11e1"
      unitRef="usd">983000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDYvZnJhZzo1YTdkMDVlZTNkN2I0MmQ0OTk4NmY3ZmY3M2I1NzA1OS90YWJsZTpiMGQxMjA2OGI5ZGQ0MDNjYTBkYzdmNTI5ZTNjYWU4OS90YWJsZXJhbmdlOmIwZDEyMDY4YjlkZDQwM2NhMGRjN2Y1MjllM2NhZTg5XzIzLTMtMS0xLTEwOTg3Ng_48732084-fc55-4c5e-a268-df464938c282"
      unitRef="usd">1091000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i7372be6dc06143b5adbb4d2e83a596c5_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDYvZnJhZzo1YTdkMDVlZTNkN2I0MmQ0OTk4NmY3ZmY3M2I1NzA1OS90YWJsZTpiMGQxMjA2OGI5ZGQ0MDNjYTBkYzdmNTI5ZTNjYWU4OS90YWJsZXJhbmdlOmIwZDEyMDY4YjlkZDQwM2NhMGRjN2Y1MjllM2NhZTg5XzIzLTUtMS0xLTEwOTg3Ng_0f0d7e12-d0df-45eb-b82d-12fb9cede5ed"
      unitRef="usd">390000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDYvZnJhZzo1YTdkMDVlZTNkN2I0MmQ0OTk4NmY3ZmY3M2I1NzA1OS90YWJsZTpiMGQxMjA2OGI5ZGQ0MDNjYTBkYzdmNTI5ZTNjYWU4OS90YWJsZXJhbmdlOmIwZDEyMDY4YjlkZDQwM2NhMGRjN2Y1MjllM2NhZTg5XzI0LTMtMS0xLTEwOTg3Ng_5d2d7a14-928d-4319-a677-d3df02d65aba"
      unitRef="usd">7939000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i7372be6dc06143b5adbb4d2e83a596c5_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDYvZnJhZzo1YTdkMDVlZTNkN2I0MmQ0OTk4NmY3ZmY3M2I1NzA1OS90YWJsZTpiMGQxMjA2OGI5ZGQ0MDNjYTBkYzdmNTI5ZTNjYWU4OS90YWJsZXJhbmdlOmIwZDEyMDY4YjlkZDQwM2NhMGRjN2Y1MjllM2NhZTg5XzI0LTUtMS0xLTEwOTg3Ng_26078134-7d42-4a3c-9aff-6d73c958519f"
      unitRef="usd">8370000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDYvZnJhZzo1YTdkMDVlZTNkN2I0MmQ0OTk4NmY3ZmY3M2I1NzA1OS90YWJsZTpiMGQxMjA2OGI5ZGQ0MDNjYTBkYzdmNTI5ZTNjYWU4OS90YWJsZXJhbmdlOmIwZDEyMDY4YjlkZDQwM2NhMGRjN2Y1MjllM2NhZTg5XzI1LTMtMS0xLTEwOTg3Ng_d7e96388-2076-479f-8f90-80c48b16cf94"
      unitRef="usd">897000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i7372be6dc06143b5adbb4d2e83a596c5_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDYvZnJhZzo1YTdkMDVlZTNkN2I0MmQ0OTk4NmY3ZmY3M2I1NzA1OS90YWJsZTpiMGQxMjA2OGI5ZGQ0MDNjYTBkYzdmNTI5ZTNjYWU4OS90YWJsZXJhbmdlOmIwZDEyMDY4YjlkZDQwM2NhMGRjN2Y1MjllM2NhZTg5XzI1LTUtMS0xLTEwOTg3Ng_5e4c3e2a-82aa-4898-a66f-d8cb4dc3f3e2"
      unitRef="usd">729000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDYvZnJhZzo1YTdkMDVlZTNkN2I0MmQ0OTk4NmY3ZmY3M2I1NzA1OS90YWJsZTpiMGQxMjA2OGI5ZGQ0MDNjYTBkYzdmNTI5ZTNjYWU4OS90YWJsZXJhbmdlOmIwZDEyMDY4YjlkZDQwM2NhMGRjN2Y1MjllM2NhZTg5XzI2LTMtMS0xLTEwOTg3Ng_d49a41ae-25b2-42e0-81f0-908736eee7d3"
      unitRef="usd">25623000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i7372be6dc06143b5adbb4d2e83a596c5_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDYvZnJhZzo1YTdkMDVlZTNkN2I0MmQ0OTk4NmY3ZmY3M2I1NzA1OS90YWJsZTpiMGQxMjA2OGI5ZGQ0MDNjYTBkYzdmNTI5ZTNjYWU4OS90YWJsZXJhbmdlOmIwZDEyMDY4YjlkZDQwM2NhMGRjN2Y1MjllM2NhZTg5XzI2LTUtMS0xLTEwOTg3Ng_66c15a87-063d-482c-b0e0-995bb075a1c4"
      unitRef="usd">19890000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDYvZnJhZzo1YTdkMDVlZTNkN2I0MmQ0OTk4NmY3ZmY3M2I1NzA1OS90YWJsZTpiMGQxMjA2OGI5ZGQ0MDNjYTBkYzdmNTI5ZTNjYWU4OS90YWJsZXJhbmdlOmIwZDEyMDY4YjlkZDQwM2NhMGRjN2Y1MjllM2NhZTg5XzI5LTMtMS0xLTEwOTg3Ng_8649eedb-4c4b-40bf-bc18-9b6aad17772b"
      unitRef="usd">1691000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i7372be6dc06143b5adbb4d2e83a596c5_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDYvZnJhZzo1YTdkMDVlZTNkN2I0MmQ0OTk4NmY3ZmY3M2I1NzA1OS90YWJsZTpiMGQxMjA2OGI5ZGQ0MDNjYTBkYzdmNTI5ZTNjYWU4OS90YWJsZXJhbmdlOmIwZDEyMDY4YjlkZDQwM2NhMGRjN2Y1MjllM2NhZTg5XzI5LTUtMS0xLTEwOTg3Ng_c6a1efcc-2d33-4b48-9f15-087b9fe5ffdd"
      unitRef="usd">75000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDYvZnJhZzo1YTdkMDVlZTNkN2I0MmQ0OTk4NmY3ZmY3M2I1NzA1OS90YWJsZTpiMGQxMjA2OGI5ZGQ0MDNjYTBkYzdmNTI5ZTNjYWU4OS90YWJsZXJhbmdlOmIwZDEyMDY4YjlkZDQwM2NhMGRjN2Y1MjllM2NhZTg5XzMwLTMtMS0xLTEwOTg3Ng_47ea3fde-511b-4553-9765-83771f967507"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i7372be6dc06143b5adbb4d2e83a596c5_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDYvZnJhZzo1YTdkMDVlZTNkN2I0MmQ0OTk4NmY3ZmY3M2I1NzA1OS90YWJsZTpiMGQxMjA2OGI5ZGQ0MDNjYTBkYzdmNTI5ZTNjYWU4OS90YWJsZXJhbmdlOmIwZDEyMDY4YjlkZDQwM2NhMGRjN2Y1MjllM2NhZTg5XzMwLTUtMS0xLTEwOTg3Ng_fffb6c70-1098-4365-a303-3691b07db4e3"
      unitRef="usd">569000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDYvZnJhZzo1YTdkMDVlZTNkN2I0MmQ0OTk4NmY3ZmY3M2I1NzA1OS90YWJsZTpiMGQxMjA2OGI5ZGQ0MDNjYTBkYzdmNTI5ZTNjYWU4OS90YWJsZXJhbmdlOmIwZDEyMDY4YjlkZDQwM2NhMGRjN2Y1MjllM2NhZTg5XzMxLTMtMS0xLTEwOTg3Ng_607138a2-461d-4a59-9ed9-12670cf7bafb"
      unitRef="usd">2776000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i7372be6dc06143b5adbb4d2e83a596c5_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDYvZnJhZzo1YTdkMDVlZTNkN2I0MmQ0OTk4NmY3ZmY3M2I1NzA1OS90YWJsZTpiMGQxMjA2OGI5ZGQ0MDNjYTBkYzdmNTI5ZTNjYWU4OS90YWJsZXJhbmdlOmIwZDEyMDY4YjlkZDQwM2NhMGRjN2Y1MjllM2NhZTg5XzMxLTUtMS0xLTEwOTg3Ng_51f635c9-a293-4d77-b86c-1570a8115cbc"
      unitRef="usd">2511000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDYvZnJhZzo1YTdkMDVlZTNkN2I0MmQ0OTk4NmY3ZmY3M2I1NzA1OS90YWJsZTpiMGQxMjA2OGI5ZGQ0MDNjYTBkYzdmNTI5ZTNjYWU4OS90YWJsZXJhbmdlOmIwZDEyMDY4YjlkZDQwM2NhMGRjN2Y1MjllM2NhZTg5XzMyLTMtMS0xLTEwOTg3Ng_ed9835f8-e3c5-4f4a-89a3-4a3f750bda03"
      unitRef="usd">30090000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i7372be6dc06143b5adbb4d2e83a596c5_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDYvZnJhZzo1YTdkMDVlZTNkN2I0MmQ0OTk4NmY3ZmY3M2I1NzA1OS90YWJsZTpiMGQxMjA2OGI5ZGQ0MDNjYTBkYzdmNTI5ZTNjYWU4OS90YWJsZXJhbmdlOmIwZDEyMDY4YjlkZDQwM2NhMGRjN2Y1MjllM2NhZTg5XzMyLTUtMS0xLTEwOTg3Ng_83705ac1-c983-4fe4-a769-caeccbcee25e"
      unitRef="usd">23045000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDYvZnJhZzo1YTdkMDVlZTNkN2I0MmQ0OTk4NmY3ZmY3M2I1NzA1OS90YWJsZTpiMGQxMjA2OGI5ZGQ0MDNjYTBkYzdmNTI5ZTNjYWU4OS90YWJsZXJhbmdlOmIwZDEyMDY4YjlkZDQwM2NhMGRjN2Y1MjllM2NhZTg5XzMzLTMtMS0xLTEwOTg3Ng_c2fafc5f-07f6-42a1-9f9e-f17d6899e600"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i7372be6dc06143b5adbb4d2e83a596c5_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDYvZnJhZzo1YTdkMDVlZTNkN2I0MmQ0OTk4NmY3ZmY3M2I1NzA1OS90YWJsZTpiMGQxMjA2OGI5ZGQ0MDNjYTBkYzdmNTI5ZTNjYWU4OS90YWJsZXJhbmdlOmIwZDEyMDY4YjlkZDQwM2NhMGRjN2Y1MjllM2NhZTg5XzMzLTUtMS0xLTEwOTg3Ng_cd934701-2f4a-4a9c-817f-226f9e807371"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i7372be6dc06143b5adbb4d2e83a596c5_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDYvZnJhZzo1YTdkMDVlZTNkN2I0MmQ0OTk4NmY3ZmY3M2I1NzA1OS90YWJsZTpiMGQxMjA2OGI5ZGQ0MDNjYTBkYzdmNTI5ZTNjYWU4OS90YWJsZXJhbmdlOmIwZDEyMDY4YjlkZDQwM2NhMGRjN2Y1MjllM2NhZTg5XzM1LTAtMS0xLTEwOTg3Ni90ZXh0cmVnaW9uOmQyMWRiYzI5YWYwMTQ5ODM4ZTg4ZDEwMjVkYjQ2YTFhXzI0_3df8af3d-a501-4905-b7b4-41b50cc241a5"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDYvZnJhZzo1YTdkMDVlZTNkN2I0MmQ0OTk4NmY3ZmY3M2I1NzA1OS90YWJsZTpiMGQxMjA2OGI5ZGQ0MDNjYTBkYzdmNTI5ZTNjYWU4OS90YWJsZXJhbmdlOmIwZDEyMDY4YjlkZDQwM2NhMGRjN2Y1MjllM2NhZTg5XzM1LTAtMS0xLTEwOTg3Ni90ZXh0cmVnaW9uOmQyMWRiYzI5YWYwMTQ5ODM4ZTg4ZDEwMjVkYjQ2YTFhXzI0_be5d77a0-70cc-4119-b653-9e1b49e251e3"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDYvZnJhZzo1YTdkMDVlZTNkN2I0MmQ0OTk4NmY3ZmY3M2I1NzA1OS90YWJsZTpiMGQxMjA2OGI5ZGQ0MDNjYTBkYzdmNTI5ZTNjYWU4OS90YWJsZXJhbmdlOmIwZDEyMDY4YjlkZDQwM2NhMGRjN2Y1MjllM2NhZTg5XzM1LTAtMS0xLTEwOTg3Ni90ZXh0cmVnaW9uOmQyMWRiYzI5YWYwMTQ5ODM4ZTg4ZDEwMjVkYjQ2YTFhXzM4_386f565c-dc29-4d94-84c8-ba24902938c7"
      unitRef="shares">250000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i7372be6dc06143b5adbb4d2e83a596c5_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDYvZnJhZzo1YTdkMDVlZTNkN2I0MmQ0OTk4NmY3ZmY3M2I1NzA1OS90YWJsZTpiMGQxMjA2OGI5ZGQ0MDNjYTBkYzdmNTI5ZTNjYWU4OS90YWJsZXJhbmdlOmIwZDEyMDY4YjlkZDQwM2NhMGRjN2Y1MjllM2NhZTg5XzM1LTAtMS0xLTEwOTg3Ni90ZXh0cmVnaW9uOmQyMWRiYzI5YWYwMTQ5ODM4ZTg4ZDEwMjVkYjQ2YTFhXzM4_b848b6e9-51cb-4b2e-8629-af1b429f43af"
      unitRef="shares">250000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDYvZnJhZzo1YTdkMDVlZTNkN2I0MmQ0OTk4NmY3ZmY3M2I1NzA1OS90YWJsZTpiMGQxMjA2OGI5ZGQ0MDNjYTBkYzdmNTI5ZTNjYWU4OS90YWJsZXJhbmdlOmIwZDEyMDY4YjlkZDQwM2NhMGRjN2Y1MjllM2NhZTg5XzM1LTAtMS0xLTEwOTg3Ni90ZXh0cmVnaW9uOmQyMWRiYzI5YWYwMTQ5ODM4ZTg4ZDEwMjVkYjQ2YTFhXzY1_446dbb0c-a348-4d2d-9da7-2b616ee6ccab"
      unitRef="shares">98039540</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDYvZnJhZzo1YTdkMDVlZTNkN2I0MmQ0OTk4NmY3ZmY3M2I1NzA1OS90YWJsZTpiMGQxMjA2OGI5ZGQ0MDNjYTBkYzdmNTI5ZTNjYWU4OS90YWJsZXJhbmdlOmIwZDEyMDY4YjlkZDQwM2NhMGRjN2Y1MjllM2NhZTg5XzM1LTAtMS0xLTEwOTg3Ni90ZXh0cmVnaW9uOmQyMWRiYzI5YWYwMTQ5ODM4ZTg4ZDEwMjVkYjQ2YTFhXzY1_729f29d2-0ec7-4dd0-9083-c2970e1e1053"
      unitRef="shares">98039540</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i7372be6dc06143b5adbb4d2e83a596c5_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDYvZnJhZzo1YTdkMDVlZTNkN2I0MmQ0OTk4NmY3ZmY3M2I1NzA1OS90YWJsZTpiMGQxMjA2OGI5ZGQ0MDNjYTBkYzdmNTI5ZTNjYWU4OS90YWJsZXJhbmdlOmIwZDEyMDY4YjlkZDQwM2NhMGRjN2Y1MjllM2NhZTg5XzM1LTAtMS0xLTEwOTg3Ni90ZXh0cmVnaW9uOmQyMWRiYzI5YWYwMTQ5ODM4ZTg4ZDEwMjVkYjQ2YTFhXzcy_17bae385-5dcc-4096-9810-56b4c11a7846"
      unitRef="shares">82575064</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i7372be6dc06143b5adbb4d2e83a596c5_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDYvZnJhZzo1YTdkMDVlZTNkN2I0MmQ0OTk4NmY3ZmY3M2I1NzA1OS90YWJsZTpiMGQxMjA2OGI5ZGQ0MDNjYTBkYzdmNTI5ZTNjYWU4OS90YWJsZXJhbmdlOmIwZDEyMDY4YjlkZDQwM2NhMGRjN2Y1MjllM2NhZTg5XzM1LTAtMS0xLTEwOTg3Ni90ZXh0cmVnaW9uOmQyMWRiYzI5YWYwMTQ5ODM4ZTg4ZDEwMjVkYjQ2YTFhXzcy_a4cf7e2d-dbac-42d8-becf-b48c460b76d3"
      unitRef="shares">82575064</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDYvZnJhZzo1YTdkMDVlZTNkN2I0MmQ0OTk4NmY3ZmY3M2I1NzA1OS90YWJsZTpiMGQxMjA2OGI5ZGQ0MDNjYTBkYzdmNTI5ZTNjYWU4OS90YWJsZXJhbmdlOmIwZDEyMDY4YjlkZDQwM2NhMGRjN2Y1MjllM2NhZTg5XzM1LTMtMS0xLTEwOTg3Ng_eb9f0fd7-4e1e-4e1d-8715-b62d0adbe509"
      unitRef="usd">980000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i7372be6dc06143b5adbb4d2e83a596c5_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDYvZnJhZzo1YTdkMDVlZTNkN2I0MmQ0OTk4NmY3ZmY3M2I1NzA1OS90YWJsZTpiMGQxMjA2OGI5ZGQ0MDNjYTBkYzdmNTI5ZTNjYWU4OS90YWJsZXJhbmdlOmIwZDEyMDY4YjlkZDQwM2NhMGRjN2Y1MjllM2NhZTg5XzM1LTUtMS0xLTEwOTg3Ng_bedc54c8-ef7b-4070-b042-b5e5cfd3725c"
      unitRef="usd">826000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDYvZnJhZzo1YTdkMDVlZTNkN2I0MmQ0OTk4NmY3ZmY3M2I1NzA1OS90YWJsZTpiMGQxMjA2OGI5ZGQ0MDNjYTBkYzdmNTI5ZTNjYWU4OS90YWJsZXJhbmdlOmIwZDEyMDY4YjlkZDQwM2NhMGRjN2Y1MjllM2NhZTg5XzM2LTMtMS0xLTEwOTg3Ng_bdd5b736-7c34-4eff-b450-f49b0f33b639"
      unitRef="usd">384049000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i7372be6dc06143b5adbb4d2e83a596c5_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDYvZnJhZzo1YTdkMDVlZTNkN2I0MmQ0OTk4NmY3ZmY3M2I1NzA1OS90YWJsZTpiMGQxMjA2OGI5ZGQ0MDNjYTBkYzdmNTI5ZTNjYWU4OS90YWJsZXJhbmdlOmIwZDEyMDY4YjlkZDQwM2NhMGRjN2Y1MjllM2NhZTg5XzM2LTUtMS0xLTEwOTg3Ng_3188365d-9018-4854-935d-a575bf999d9b"
      unitRef="usd">293367000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDYvZnJhZzo1YTdkMDVlZTNkN2I0MmQ0OTk4NmY3ZmY3M2I1NzA1OS90YWJsZTpiMGQxMjA2OGI5ZGQ0MDNjYTBkYzdmNTI5ZTNjYWU4OS90YWJsZXJhbmdlOmIwZDEyMDY4YjlkZDQwM2NhMGRjN2Y1MjllM2NhZTg5XzM3LTMtMS0xLTEwOTg3Ng_0752be94-0dfd-4976-a641-9bf8b872a754"
      unitRef="usd">-2197000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i7372be6dc06143b5adbb4d2e83a596c5_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDYvZnJhZzo1YTdkMDVlZTNkN2I0MmQ0OTk4NmY3ZmY3M2I1NzA1OS90YWJsZTpiMGQxMjA2OGI5ZGQ0MDNjYTBkYzdmNTI5ZTNjYWU4OS90YWJsZXJhbmdlOmIwZDEyMDY4YjlkZDQwM2NhMGRjN2Y1MjllM2NhZTg5XzM3LTUtMS0xLTEwOTg3Ng_f61d18f7-a7b8-4142-81d0-3d8adb626a3e"
      unitRef="usd">-3794000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDYvZnJhZzo1YTdkMDVlZTNkN2I0MmQ0OTk4NmY3ZmY3M2I1NzA1OS90YWJsZTpiMGQxMjA2OGI5ZGQ0MDNjYTBkYzdmNTI5ZTNjYWU4OS90YWJsZXJhbmdlOmIwZDEyMDY4YjlkZDQwM2NhMGRjN2Y1MjllM2NhZTg5XzM4LTMtMS0xLTEwOTg3Ng_733de346-d22d-4676-a382-f62e1775b020"
      unitRef="usd">-299548000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i7372be6dc06143b5adbb4d2e83a596c5_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDYvZnJhZzo1YTdkMDVlZTNkN2I0MmQ0OTk4NmY3ZmY3M2I1NzA1OS90YWJsZTpiMGQxMjA2OGI5ZGQ0MDNjYTBkYzdmNTI5ZTNjYWU4OS90YWJsZXJhbmdlOmIwZDEyMDY4YjlkZDQwM2NhMGRjN2Y1MjllM2NhZTg5XzM4LTUtMS0xLTEwOTg3Ng_3e13fed3-17a4-43c9-86a4-46de01a97c27"
      unitRef="usd">-210946000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDYvZnJhZzo1YTdkMDVlZTNkN2I0MmQ0OTk4NmY3ZmY3M2I1NzA1OS90YWJsZTpiMGQxMjA2OGI5ZGQ0MDNjYTBkYzdmNTI5ZTNjYWU4OS90YWJsZXJhbmdlOmIwZDEyMDY4YjlkZDQwM2NhMGRjN2Y1MjllM2NhZTg5XzM5LTMtMS0xLTEwOTg3Ng_12ca1fdb-e14a-442f-8cdd-00d645b2d350"
      unitRef="usd">83284000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7372be6dc06143b5adbb4d2e83a596c5_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDYvZnJhZzo1YTdkMDVlZTNkN2I0MmQ0OTk4NmY3ZmY3M2I1NzA1OS90YWJsZTpiMGQxMjA2OGI5ZGQ0MDNjYTBkYzdmNTI5ZTNjYWU4OS90YWJsZXJhbmdlOmIwZDEyMDY4YjlkZDQwM2NhMGRjN2Y1MjllM2NhZTg5XzM5LTUtMS0xLTEwOTg3Ng_2e25c5a6-d92d-4cc0-8ec1-4ef7d5004c35"
      unitRef="usd">79453000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDYvZnJhZzo1YTdkMDVlZTNkN2I0MmQ0OTk4NmY3ZmY3M2I1NzA1OS90YWJsZTpiMGQxMjA2OGI5ZGQ0MDNjYTBkYzdmNTI5ZTNjYWU4OS90YWJsZXJhbmdlOmIwZDEyMDY4YjlkZDQwM2NhMGRjN2Y1MjllM2NhZTg5XzQwLTMtMS0xLTEwOTg3Ng_14210816-b203-4aec-a7a5-3deb34e936a1"
      unitRef="usd">113374000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i7372be6dc06143b5adbb4d2e83a596c5_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDYvZnJhZzo1YTdkMDVlZTNkN2I0MmQ0OTk4NmY3ZmY3M2I1NzA1OS90YWJsZTpiMGQxMjA2OGI5ZGQ0MDNjYTBkYzdmNTI5ZTNjYWU4OS90YWJsZXJhbmdlOmIwZDEyMDY4YjlkZDQwM2NhMGRjN2Y1MjllM2NhZTg5XzQwLTUtMS0xLTEwOTg3Ng_22f5f88d-b182-40b5-a7d9-262acb5f511b"
      unitRef="usd">102498000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDkvZnJhZzpmY2YyZjBkNTU4YTE0MTUzOTZlNThlZWRjNDI1ZGUyNC90YWJsZTpiZGUxYmRjNTFiY2Y0NTJjOTdlNzEzNGM2ZWZkMTA1ZS90YWJsZXJhbmdlOmJkZTFiZGM1MWJjZjQ1MmM5N2U3MTM0YzZlZmQxMDVlXzEtMi0xLTEtMTA5ODc2_443b5b2a-dbfe-491a-8e09-2438a6c77734"
      unitRef="usd">1809000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDkvZnJhZzpmY2YyZjBkNTU4YTE0MTUzOTZlNThlZWRjNDI1ZGUyNC90YWJsZTpiZGUxYmRjNTFiY2Y0NTJjOTdlNzEzNGM2ZWZkMTA1ZS90YWJsZXJhbmdlOmJkZTFiZGM1MWJjZjQ1MmM5N2U3MTM0YzZlZmQxMDVlXzEtNC0xLTEtMTA5ODc2_5676c1aa-cbad-4255-8e5b-ae20d38c45de"
      unitRef="usd">860000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDkvZnJhZzpmY2YyZjBkNTU4YTE0MTUzOTZlNThlZWRjNDI1ZGUyNC90YWJsZTpiZGUxYmRjNTFiY2Y0NTJjOTdlNzEzNGM2ZWZkMTA1ZS90YWJsZXJhbmdlOmJkZTFiZGM1MWJjZjQ1MmM5N2U3MTM0YzZlZmQxMDVlXzMtMi0xLTEtMTA5ODc2_31ccee25-466f-43b5-ace9-246cfc02e981"
      unitRef="usd">85352000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDkvZnJhZzpmY2YyZjBkNTU4YTE0MTUzOTZlNThlZWRjNDI1ZGUyNC90YWJsZTpiZGUxYmRjNTFiY2Y0NTJjOTdlNzEzNGM2ZWZkMTA1ZS90YWJsZXJhbmdlOmJkZTFiZGM1MWJjZjQ1MmM5N2U3MTM0YzZlZmQxMDVlXzMtNC0xLTEtMTA5ODc2_82f6bb7b-b5c4-4a05-8dd2-079231f7c79d"
      unitRef="usd">53274000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDkvZnJhZzpmY2YyZjBkNTU4YTE0MTUzOTZlNThlZWRjNDI1ZGUyNC90YWJsZTpiZGUxYmRjNTFiY2Y0NTJjOTdlNzEzNGM2ZWZkMTA1ZS90YWJsZXJhbmdlOmJkZTFiZGM1MWJjZjQ1MmM5N2U3MTM0YzZlZmQxMDVlXzQtMi0xLTEtMTA5ODc2_f7c823f8-50df-4d23-a623-f91ddd797c20"
      unitRef="usd">23611000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDkvZnJhZzpmY2YyZjBkNTU4YTE0MTUzOTZlNThlZWRjNDI1ZGUyNC90YWJsZTpiZGUxYmRjNTFiY2Y0NTJjOTdlNzEzNGM2ZWZkMTA1ZS90YWJsZXJhbmdlOmJkZTFiZGM1MWJjZjQ1MmM5N2U3MTM0YzZlZmQxMDVlXzQtNC0xLTEtMTA5ODc2_267374cd-7cd3-4c41-b226-194e676b74cc"
      unitRef="usd">19232000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDkvZnJhZzpmY2YyZjBkNTU4YTE0MTUzOTZlNThlZWRjNDI1ZGUyNC90YWJsZTpiZGUxYmRjNTFiY2Y0NTJjOTdlNzEzNGM2ZWZkMTA1ZS90YWJsZXJhbmdlOmJkZTFiZGM1MWJjZjQ1MmM5N2U3MTM0YzZlZmQxMDVlXzUtMi0xLTEtMTA5ODc2_b8c7e1b6-eca6-4534-94ca-274c3c85214b"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDkvZnJhZzpmY2YyZjBkNTU4YTE0MTUzOTZlNThlZWRjNDI1ZGUyNC90YWJsZTpiZGUxYmRjNTFiY2Y0NTJjOTdlNzEzNGM2ZWZkMTA1ZS90YWJsZXJhbmdlOmJkZTFiZGM1MWJjZjQ1MmM5N2U3MTM0YzZlZmQxMDVlXzUtNC0xLTEtMTA5ODc2_52f0717f-ca6a-4763-b1e7-f33a5238503c"
      unitRef="usd">859000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:OperatingExpenses
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDkvZnJhZzpmY2YyZjBkNTU4YTE0MTUzOTZlNThlZWRjNDI1ZGUyNC90YWJsZTpiZGUxYmRjNTFiY2Y0NTJjOTdlNzEzNGM2ZWZkMTA1ZS90YWJsZXJhbmdlOmJkZTFiZGM1MWJjZjQ1MmM5N2U3MTM0YzZlZmQxMDVlXzYtMi0xLTEtMTA5ODc2_a22f452c-39a5-4e1b-8727-67b0d05708c7"
      unitRef="usd">108963000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDkvZnJhZzpmY2YyZjBkNTU4YTE0MTUzOTZlNThlZWRjNDI1ZGUyNC90YWJsZTpiZGUxYmRjNTFiY2Y0NTJjOTdlNzEzNGM2ZWZkMTA1ZS90YWJsZXJhbmdlOmJkZTFiZGM1MWJjZjQ1MmM5N2U3MTM0YzZlZmQxMDVlXzYtNC0xLTEtMTA5ODc2_b9416ce6-b653-4f66-ab0e-f393e06c3329"
      unitRef="usd">73365000</us-gaap:OperatingExpenses>
    <us-gaap:OtherOperatingIncome
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDkvZnJhZzpmY2YyZjBkNTU4YTE0MTUzOTZlNThlZWRjNDI1ZGUyNC90YWJsZTpiZGUxYmRjNTFiY2Y0NTJjOTdlNzEzNGM2ZWZkMTA1ZS90YWJsZXJhbmdlOmJkZTFiZGM1MWJjZjQ1MmM5N2U3MTM0YzZlZmQxMDVlXzctMi0xLTEtMTA5ODc2_3a122e80-6e0e-4c21-8942-c9dfd8380d93"
      unitRef="usd">20968000</us-gaap:OtherOperatingIncome>
    <us-gaap:OtherOperatingIncome
      contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDkvZnJhZzpmY2YyZjBkNTU4YTE0MTUzOTZlNThlZWRjNDI1ZGUyNC90YWJsZTpiZGUxYmRjNTFiY2Y0NTJjOTdlNzEzNGM2ZWZkMTA1ZS90YWJsZXJhbmdlOmJkZTFiZGM1MWJjZjQ1MmM5N2U3MTM0YzZlZmQxMDVlXzctNC0xLTEtMTA5ODc2_74dd19d4-92bc-4fa0-9cb8-1a00a8c4c368"
      unitRef="usd">19312000</us-gaap:OtherOperatingIncome>
    <us-gaap:OperatingIncomeLoss
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDkvZnJhZzpmY2YyZjBkNTU4YTE0MTUzOTZlNThlZWRjNDI1ZGUyNC90YWJsZTpiZGUxYmRjNTFiY2Y0NTJjOTdlNzEzNGM2ZWZkMTA1ZS90YWJsZXJhbmdlOmJkZTFiZGM1MWJjZjQ1MmM5N2U3MTM0YzZlZmQxMDVlXzgtMi0xLTEtMTA5ODc2_d3ecf1ed-327d-404b-bcfc-c61c51644ef9"
      unitRef="usd">-86186000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDkvZnJhZzpmY2YyZjBkNTU4YTE0MTUzOTZlNThlZWRjNDI1ZGUyNC90YWJsZTpiZGUxYmRjNTFiY2Y0NTJjOTdlNzEzNGM2ZWZkMTA1ZS90YWJsZXJhbmdlOmJkZTFiZGM1MWJjZjQ1MmM5N2U3MTM0YzZlZmQxMDVlXzgtNC0xLTEtMTA5ODc2_83bca872-42fc-43c6-9f30-9ad38ea5a16a"
      unitRef="usd">-53193000</us-gaap:OperatingIncomeLoss>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDkvZnJhZzpmY2YyZjBkNTU4YTE0MTUzOTZlNThlZWRjNDI1ZGUyNC90YWJsZTpiZGUxYmRjNTFiY2Y0NTJjOTdlNzEzNGM2ZWZkMTA1ZS90YWJsZXJhbmdlOmJkZTFiZGM1MWJjZjQ1MmM5N2U3MTM0YzZlZmQxMDVlXzktMi0xLTEtMTA5ODc2_70547a5e-38c3-4916-a7aa-3a4bce4bf9a9"
      unitRef="usd">-2416000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDkvZnJhZzpmY2YyZjBkNTU4YTE0MTUzOTZlNThlZWRjNDI1ZGUyNC90YWJsZTpiZGUxYmRjNTFiY2Y0NTJjOTdlNzEzNGM2ZWZkMTA1ZS90YWJsZXJhbmdlOmJkZTFiZGM1MWJjZjQ1MmM5N2U3MTM0YzZlZmQxMDVlXzktNC0xLTEtMTA5ODc2_ef63f252-c9ba-48fa-8eb1-463b014c6154"
      unitRef="usd">283000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDkvZnJhZzpmY2YyZjBkNTU4YTE0MTUzOTZlNThlZWRjNDI1ZGUyNC90YWJsZTpiZGUxYmRjNTFiY2Y0NTJjOTdlNzEzNGM2ZWZkMTA1ZS90YWJsZXJhbmdlOmJkZTFiZGM1MWJjZjQ1MmM5N2U3MTM0YzZlZmQxMDVlXzEwLTItMS0xLTEwOTg3Ng_47e21dae-f06e-4c7b-a315-6e516ed446db"
      unitRef="usd">-88602000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDkvZnJhZzpmY2YyZjBkNTU4YTE0MTUzOTZlNThlZWRjNDI1ZGUyNC90YWJsZTpiZGUxYmRjNTFiY2Y0NTJjOTdlNzEzNGM2ZWZkMTA1ZS90YWJsZXJhbmdlOmJkZTFiZGM1MWJjZjQ1MmM5N2U3MTM0YzZlZmQxMDVlXzEwLTQtMS0xLTEwOTg3Ng_fdf5cdff-7992-4800-99b8-99438c4293b7"
      unitRef="usd">-52910000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDkvZnJhZzpmY2YyZjBkNTU4YTE0MTUzOTZlNThlZWRjNDI1ZGUyNC90YWJsZTpiZGUxYmRjNTFiY2Y0NTJjOTdlNzEzNGM2ZWZkMTA1ZS90YWJsZXJhbmdlOmJkZTFiZGM1MWJjZjQ1MmM5N2U3MTM0YzZlZmQxMDVlXzExLTItMS0xLTEwOTg3Ng_c5c9e777-d1ac-44f2-b6c1-25862022981b"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDkvZnJhZzpmY2YyZjBkNTU4YTE0MTUzOTZlNThlZWRjNDI1ZGUyNC90YWJsZTpiZGUxYmRjNTFiY2Y0NTJjOTdlNzEzNGM2ZWZkMTA1ZS90YWJsZXJhbmdlOmJkZTFiZGM1MWJjZjQ1MmM5N2U3MTM0YzZlZmQxMDVlXzExLTQtMS0xLTEwOTg3Ng_5635446a-eb50-453b-89c9-eb84a220fe78"
      unitRef="usd">-213000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDkvZnJhZzpmY2YyZjBkNTU4YTE0MTUzOTZlNThlZWRjNDI1ZGUyNC90YWJsZTpiZGUxYmRjNTFiY2Y0NTJjOTdlNzEzNGM2ZWZkMTA1ZS90YWJsZXJhbmdlOmJkZTFiZGM1MWJjZjQ1MmM5N2U3MTM0YzZlZmQxMDVlXzEyLTItMS0xLTEwOTg3Ng_c6d517a6-f913-440e-bb13-35cc46253cf7"
      unitRef="usd">-88602000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDkvZnJhZzpmY2YyZjBkNTU4YTE0MTUzOTZlNThlZWRjNDI1ZGUyNC90YWJsZTpiZGUxYmRjNTFiY2Y0NTJjOTdlNzEzNGM2ZWZkMTA1ZS90YWJsZXJhbmdlOmJkZTFiZGM1MWJjZjQ1MmM5N2U3MTM0YzZlZmQxMDVlXzEyLTQtMS0xLTEwOTg3Ng_6d25d829-8234-48ab-8a1b-3f918e72c1a0"
      unitRef="usd">-52697000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDkvZnJhZzpmY2YyZjBkNTU4YTE0MTUzOTZlNThlZWRjNDI1ZGUyNC90YWJsZTpiZGUxYmRjNTFiY2Y0NTJjOTdlNzEzNGM2ZWZkMTA1ZS90YWJsZXJhbmdlOmJkZTFiZGM1MWJjZjQ1MmM5N2U3MTM0YzZlZmQxMDVlXzE0LTItMS0xLTEwOTg3Ng_b4846293-5dbe-42ec-982f-e5d9f99f0bec"
      unitRef="usdPerShare">-0.96</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDkvZnJhZzpmY2YyZjBkNTU4YTE0MTUzOTZlNThlZWRjNDI1ZGUyNC90YWJsZTpiZGUxYmRjNTFiY2Y0NTJjOTdlNzEzNGM2ZWZkMTA1ZS90YWJsZXJhbmdlOmJkZTFiZGM1MWJjZjQ1MmM5N2U3MTM0YzZlZmQxMDVlXzE0LTItMS0xLTEwOTg3Ng_cc6400be-9b3f-4caf-8a08-e93f00cd78af"
      unitRef="usdPerShare">-0.96</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDkvZnJhZzpmY2YyZjBkNTU4YTE0MTUzOTZlNThlZWRjNDI1ZGUyNC90YWJsZTpiZGUxYmRjNTFiY2Y0NTJjOTdlNzEzNGM2ZWZkMTA1ZS90YWJsZXJhbmdlOmJkZTFiZGM1MWJjZjQ1MmM5N2U3MTM0YzZlZmQxMDVlXzE0LTQtMS0xLTEwOTg3Ng_6dbf18f3-1876-4387-815c-6123d233e7d5"
      unitRef="usdPerShare">-0.76</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDkvZnJhZzpmY2YyZjBkNTU4YTE0MTUzOTZlNThlZWRjNDI1ZGUyNC90YWJsZTpiZGUxYmRjNTFiY2Y0NTJjOTdlNzEzNGM2ZWZkMTA1ZS90YWJsZXJhbmdlOmJkZTFiZGM1MWJjZjQ1MmM5N2U3MTM0YzZlZmQxMDVlXzE0LTQtMS0xLTEwOTg3Ng_b0011b5b-1fe1-40c0-8d2f-5c37180af633"
      unitRef="usdPerShare">-0.76</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDkvZnJhZzpmY2YyZjBkNTU4YTE0MTUzOTZlNThlZWRjNDI1ZGUyNC90YWJsZTpiZGUxYmRjNTFiY2Y0NTJjOTdlNzEzNGM2ZWZkMTA1ZS90YWJsZXJhbmdlOmJkZTFiZGM1MWJjZjQ1MmM5N2U3MTM0YzZlZmQxMDVlXzE2LTItMS0xLTEwOTg3Ng_6402986e-3b39-462a-9700-9ff90fef8c2c"
      unitRef="shares">92239306</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDkvZnJhZzpmY2YyZjBkNTU4YTE0MTUzOTZlNThlZWRjNDI1ZGUyNC90YWJsZTpiZGUxYmRjNTFiY2Y0NTJjOTdlNzEzNGM2ZWZkMTA1ZS90YWJsZXJhbmdlOmJkZTFiZGM1MWJjZjQ1MmM5N2U3MTM0YzZlZmQxMDVlXzE2LTItMS0xLTEwOTg3Ng_aa289f65-b634-441d-86d4-c6b1a2d9b77c"
      unitRef="shares">92239306</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDkvZnJhZzpmY2YyZjBkNTU4YTE0MTUzOTZlNThlZWRjNDI1ZGUyNC90YWJsZTpiZGUxYmRjNTFiY2Y0NTJjOTdlNzEzNGM2ZWZkMTA1ZS90YWJsZXJhbmdlOmJkZTFiZGM1MWJjZjQ1MmM5N2U3MTM0YzZlZmQxMDVlXzE2LTQtMS0xLTEwOTg3Ng_a1d05e4b-39e5-4f6e-8e57-aa93a4512bd6"
      unitRef="shares">69524148</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDkvZnJhZzpmY2YyZjBkNTU4YTE0MTUzOTZlNThlZWRjNDI1ZGUyNC90YWJsZTpiZGUxYmRjNTFiY2Y0NTJjOTdlNzEzNGM2ZWZkMTA1ZS90YWJsZXJhbmdlOmJkZTFiZGM1MWJjZjQ1MmM5N2U3MTM0YzZlZmQxMDVlXzE2LTQtMS0xLTEwOTg3Ng_eaf3e880-5146-4433-8ec5-f170cccfc765"
      unitRef="shares">69524148</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDkvZnJhZzpmY2YyZjBkNTU4YTE0MTUzOTZlNThlZWRjNDI1ZGUyNC90YWJsZTpiZGUxYmRjNTFiY2Y0NTJjOTdlNzEzNGM2ZWZkMTA1ZS90YWJsZXJhbmdlOmJkZTFiZGM1MWJjZjQ1MmM5N2U3MTM0YzZlZmQxMDVlXzE4LTItMS0xLTEwOTg3Ng_58cb0982-038f-429c-8795-cb8182113130"
      unitRef="usd">1597000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDkvZnJhZzpmY2YyZjBkNTU4YTE0MTUzOTZlNThlZWRjNDI1ZGUyNC90YWJsZTpiZGUxYmRjNTFiY2Y0NTJjOTdlNzEzNGM2ZWZkMTA1ZS90YWJsZXJhbmdlOmJkZTFiZGM1MWJjZjQ1MmM5N2U3MTM0YzZlZmQxMDVlXzE4LTQtMS0xLTEwOTg3Ng_9c7c8ef4-43de-4af3-8576-c534ec7c7319"
      unitRef="usd">970000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDkvZnJhZzpmY2YyZjBkNTU4YTE0MTUzOTZlNThlZWRjNDI1ZGUyNC90YWJsZTpiZGUxYmRjNTFiY2Y0NTJjOTdlNzEzNGM2ZWZkMTA1ZS90YWJsZXJhbmdlOmJkZTFiZGM1MWJjZjQ1MmM5N2U3MTM0YzZlZmQxMDVlXzE5LTItMS0xLTEwOTg3Ng_52da3729-e60c-4d06-a947-4eafd6372412"
      unitRef="usd">-87005000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMDkvZnJhZzpmY2YyZjBkNTU4YTE0MTUzOTZlNThlZWRjNDI1ZGUyNC90YWJsZTpiZGUxYmRjNTFiY2Y0NTJjOTdlNzEzNGM2ZWZkMTA1ZS90YWJsZXJhbmdlOmJkZTFiZGM1MWJjZjQ1MmM5N2U3MTM0YzZlZmQxMDVlXzE5LTQtMS0xLTEwOTg3Ng_6dc80d47-f986-441e-ac08-8178d65fd3dc"
      unitRef="usd">-51727000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="iadaf16e26a374273b81a7480b2aef461_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTIvZnJhZzo0OTkyMzA4MmJmYzM0OTBkOGE0ZGI5NzkyZGY4Nzc3Yy90YWJsZTpkZmQwZGQ0ZjU2NGY0ZDNlYjdhNDAyYjk5OTJlMWNhNi90YWJsZXJhbmdlOmRmZDBkZDRmNTY0ZjRkM2ViN2E0MDJiOTk5MmUxY2E2XzItMi0xLTEtMTA5ODc2_fcbf844f-c345-4450-8312-4e9e5878da6e"
      unitRef="shares">67178054</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="iadaf16e26a374273b81a7480b2aef461_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTIvZnJhZzo0OTkyMzA4MmJmYzM0OTBkOGE0ZGI5NzkyZGY4Nzc3Yy90YWJsZTpkZmQwZGQ0ZjU2NGY0ZDNlYjdhNDAyYjk5OTJlMWNhNi90YWJsZXJhbmdlOmRmZDBkZDRmNTY0ZjRkM2ViN2E0MDJiOTk5MmUxY2E2XzItNC0xLTEtMTA5ODc2_6f424f76-2556-4637-9572-bede90481c6f"
      unitRef="usd">672000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i23c022f251aa4a7bb86fd5562b7cf66a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTIvZnJhZzo0OTkyMzA4MmJmYzM0OTBkOGE0ZGI5NzkyZGY4Nzc3Yy90YWJsZTpkZmQwZGQ0ZjU2NGY0ZDNlYjdhNDAyYjk5OTJlMWNhNi90YWJsZXJhbmdlOmRmZDBkZDRmNTY0ZjRkM2ViN2E0MDJiOTk5MmUxY2E2XzItNi0xLTEtMTA5ODc2_e0cb4835-9854-4ae4-99aa-837d4b3055c0"
      unitRef="usd">241204000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i18956f3671924995bc8672c2e4f9774d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTIvZnJhZzo0OTkyMzA4MmJmYzM0OTBkOGE0ZGI5NzkyZGY4Nzc3Yy90YWJsZTpkZmQwZGQ0ZjU2NGY0ZDNlYjdhNDAyYjk5OTJlMWNhNi90YWJsZXJhbmdlOmRmZDBkZDRmNTY0ZjRkM2ViN2E0MDJiOTk5MmUxY2E2XzItOC0xLTEtMTA5ODc2_6f864ef5-bd03-404a-a90b-2a825312bab7"
      unitRef="usd">-4764000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i10704a1cbc944be6935b29991fb87b7b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTIvZnJhZzo0OTkyMzA4MmJmYzM0OTBkOGE0ZGI5NzkyZGY4Nzc3Yy90YWJsZTpkZmQwZGQ0ZjU2NGY0ZDNlYjdhNDAyYjk5OTJlMWNhNi90YWJsZXJhbmdlOmRmZDBkZDRmNTY0ZjRkM2ViN2E0MDJiOTk5MmUxY2E2XzItMTAtMS0xLTEwOTg3Ng_7b8c8b17-968a-4924-83c6-f9468d2989f8"
      unitRef="usd">-158249000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i50b9889462124695acb12b854dfc61e9_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTIvZnJhZzo0OTkyMzA4MmJmYzM0OTBkOGE0ZGI5NzkyZGY4Nzc3Yy90YWJsZTpkZmQwZGQ0ZjU2NGY0ZDNlYjdhNDAyYjk5OTJlMWNhNi90YWJsZXJhbmdlOmRmZDBkZDRmNTY0ZjRkM2ViN2E0MDJiOTk5MmUxY2E2XzItMTItMS0xLTEwOTg3Ng_2d5d0f84-2c34-48a3-bf74-926e30b6d0d3"
      unitRef="usd">78863000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTIvZnJhZzo0OTkyMzA4MmJmYzM0OTBkOGE0ZGI5NzkyZGY4Nzc3Yy90YWJsZTpkZmQwZGQ0ZjU2NGY0ZDNlYjdhNDAyYjk5OTJlMWNhNi90YWJsZXJhbmdlOmRmZDBkZDRmNTY0ZjRkM2ViN2E0MDJiOTk5MmUxY2E2XzMtMC0xLTEtMTA5ODc2L3RleHRyZWdpb246ZTI5YmFkM2MzNDRiNGE4N2FlYTI3NDFmYmU0YWEwYzZfNjQ_66bf4143-b1bb-4d2c-91e0-18d79a3e55b2"
      unitRef="usd">48000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="ie925211651134cc095c13ead145a9987_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTIvZnJhZzo0OTkyMzA4MmJmYzM0OTBkOGE0ZGI5NzkyZGY4Nzc3Yy90YWJsZTpkZmQwZGQ0ZjU2NGY0ZDNlYjdhNDAyYjk5OTJlMWNhNi90YWJsZXJhbmdlOmRmZDBkZDRmNTY0ZjRkM2ViN2E0MDJiOTk5MmUxY2E2XzMtMi0xLTEtMTA5ODc2_81d832ce-b0c7-4f23-90b8-882be2182953"
      unitRef="shares">14970060</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ie925211651134cc095c13ead145a9987_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTIvZnJhZzo0OTkyMzA4MmJmYzM0OTBkOGE0ZGI5NzkyZGY4Nzc3Yy90YWJsZTpkZmQwZGQ0ZjU2NGY0ZDNlYjdhNDAyYjk5OTJlMWNhNi90YWJsZXJhbmdlOmRmZDBkZDRmNTY0ZjRkM2ViN2E0MDJiOTk5MmUxY2E2XzMtNC0xLTEtMTA5ODc2_0fe749a8-742d-46b3-96e2-aaeb05cd8d22"
      unitRef="usd">150000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ie1c2f38f4911489ea019b962d6783b5d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTIvZnJhZzo0OTkyMzA4MmJmYzM0OTBkOGE0ZGI5NzkyZGY4Nzc3Yy90YWJsZTpkZmQwZGQ0ZjU2NGY0ZDNlYjdhNDAyYjk5OTJlMWNhNi90YWJsZXJhbmdlOmRmZDBkZDRmNTY0ZjRkM2ViN2E0MDJiOTk5MmUxY2E2XzMtNi0xLTEtMTA5ODc2_5798cd39-69b8-4091-b0ff-bcea433b5a4d"
      unitRef="usd">49802000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTIvZnJhZzo0OTkyMzA4MmJmYzM0OTBkOGE0ZGI5NzkyZGY4Nzc3Yy90YWJsZTpkZmQwZGQ0ZjU2NGY0ZDNlYjdhNDAyYjk5OTJlMWNhNi90YWJsZXJhbmdlOmRmZDBkZDRmNTY0ZjRkM2ViN2E0MDJiOTk5MmUxY2E2XzMtMTItMS0xLTEwOTg3Ng_ab6dfb67-aecc-4db7-97e9-a5202fc05523"
      unitRef="usd">49952000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <smmt:FractionalStockIssuedDuringPeriodSharesReverseStockSplit
      contextRef="ie925211651134cc095c13ead145a9987_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTIvZnJhZzo0OTkyMzA4MmJmYzM0OTBkOGE0ZGI5NzkyZGY4Nzc3Yy90YWJsZTpkZmQwZGQ0ZjU2NGY0ZDNlYjdhNDAyYjk5OTJlMWNhNi90YWJsZXJhbmdlOmRmZDBkZDRmNTY0ZjRkM2ViN2E0MDJiOTk5MmUxY2E2XzQtMi0xLTEtMTA5ODc2_8109deaa-781d-4ea8-b70d-9cc98e6d0e1b"
      unitRef="shares">3</smmt:FractionalStockIssuedDuringPeriodSharesReverseStockSplit>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ie925211651134cc095c13ead145a9987_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTIvZnJhZzo0OTkyMzA4MmJmYzM0OTBkOGE0ZGI5NzkyZGY4Nzc3Yy90YWJsZTpkZmQwZGQ0ZjU2NGY0ZDNlYjdhNDAyYjk5OTJlMWNhNi90YWJsZXJhbmdlOmRmZDBkZDRmNTY0ZjRkM2ViN2E0MDJiOTk5MmUxY2E2XzUtMi0xLTEtMTA5ODc2_fad550cc-0011-43d7-a9e6-fa000d8c0151"
      unitRef="shares">426947</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ie925211651134cc095c13ead145a9987_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTIvZnJhZzo0OTkyMzA4MmJmYzM0OTBkOGE0ZGI5NzkyZGY4Nzc3Yy90YWJsZTpkZmQwZGQ0ZjU2NGY0ZDNlYjdhNDAyYjk5OTJlMWNhNi90YWJsZXJhbmdlOmRmZDBkZDRmNTY0ZjRkM2ViN2E0MDJiOTk5MmUxY2E2XzUtNC0xLTEtMTA5ODc2_a2cf3e8d-02e4-4c96-80a3-6504f53c6a2d"
      unitRef="usd">4000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ie1c2f38f4911489ea019b962d6783b5d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTIvZnJhZzo0OTkyMzA4MmJmYzM0OTBkOGE0ZGI5NzkyZGY4Nzc3Yy90YWJsZTpkZmQwZGQ0ZjU2NGY0ZDNlYjdhNDAyYjk5OTJlMWNhNi90YWJsZXJhbmdlOmRmZDBkZDRmNTY0ZjRkM2ViN2E0MDJiOTk5MmUxY2E2XzUtNi0xLTEtMTA5ODc2_b58eb507-d45f-471e-a90a-7f28c43b5310"
      unitRef="usd">595000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTIvZnJhZzo0OTkyMzA4MmJmYzM0OTBkOGE0ZGI5NzkyZGY4Nzc3Yy90YWJsZTpkZmQwZGQ0ZjU2NGY0ZDNlYjdhNDAyYjk5OTJlMWNhNi90YWJsZXJhbmdlOmRmZDBkZDRmNTY0ZjRkM2ViN2E0MDJiOTk5MmUxY2E2XzUtMTItMS0xLTEwOTg3Ng_ac219dc9-e0d1-4a41-a5e8-6190f24d6277"
      unitRef="usd">599000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ie1c2f38f4911489ea019b962d6783b5d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTIvZnJhZzo0OTkyMzA4MmJmYzM0OTBkOGE0ZGI5NzkyZGY4Nzc3Yy90YWJsZTpkZmQwZGQ0ZjU2NGY0ZDNlYjdhNDAyYjk5OTJlMWNhNi90YWJsZXJhbmdlOmRmZDBkZDRmNTY0ZjRkM2ViN2E0MDJiOTk5MmUxY2E2XzYtNi0xLTEtMTA5ODc2_6edaae12-d269-4025-91c5-d8503fbf6481"
      unitRef="usd">1766000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTIvZnJhZzo0OTkyMzA4MmJmYzM0OTBkOGE0ZGI5NzkyZGY4Nzc3Yy90YWJsZTpkZmQwZGQ0ZjU2NGY0ZDNlYjdhNDAyYjk5OTJlMWNhNi90YWJsZXJhbmdlOmRmZDBkZDRmNTY0ZjRkM2ViN2E0MDJiOTk5MmUxY2E2XzYtMTItMS0xLTEwOTg3Ng_be284c03-1686-416d-bae5-52ab672a4413"
      unitRef="usd">1766000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="id7966e0fd0224c4492484acc988b5ec7_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTIvZnJhZzo0OTkyMzA4MmJmYzM0OTBkOGE0ZGI5NzkyZGY4Nzc3Yy90YWJsZTpkZmQwZGQ0ZjU2NGY0ZDNlYjdhNDAyYjk5OTJlMWNhNi90YWJsZXJhbmdlOmRmZDBkZDRmNTY0ZjRkM2ViN2E0MDJiOTk5MmUxY2E2XzctOC0xLTEtMTA5ODc2_130a5711-b275-46d2-bece-bbfe99063511"
      unitRef="usd">970000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTIvZnJhZzo0OTkyMzA4MmJmYzM0OTBkOGE0ZGI5NzkyZGY4Nzc3Yy90YWJsZTpkZmQwZGQ0ZjU2NGY0ZDNlYjdhNDAyYjk5OTJlMWNhNi90YWJsZXJhbmdlOmRmZDBkZDRmNTY0ZjRkM2ViN2E0MDJiOTk5MmUxY2E2XzctMTItMS0xLTEwOTg3Ng_c44594fa-1482-4cbc-83e8-502866ab0940"
      unitRef="usd">970000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="i0c007ce1c0eb4469a7130cee973d7baf_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTIvZnJhZzo0OTkyMzA4MmJmYzM0OTBkOGE0ZGI5NzkyZGY4Nzc3Yy90YWJsZTpkZmQwZGQ0ZjU2NGY0ZDNlYjdhNDAyYjk5OTJlMWNhNi90YWJsZXJhbmdlOmRmZDBkZDRmNTY0ZjRkM2ViN2E0MDJiOTk5MmUxY2E2XzgtMTAtMS0xLTEwOTg3Ng_39f4336d-dd81-4ab2-8c9a-7bc181848292"
      unitRef="usd">-52697000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTIvZnJhZzo0OTkyMzA4MmJmYzM0OTBkOGE0ZGI5NzkyZGY4Nzc3Yy90YWJsZTpkZmQwZGQ0ZjU2NGY0ZDNlYjdhNDAyYjk5OTJlMWNhNi90YWJsZXJhbmdlOmRmZDBkZDRmNTY0ZjRkM2ViN2E0MDJiOTk5MmUxY2E2XzgtMTItMS0xLTEwOTg3Ng_85c70f21-af3c-4909-8b06-1fade14bb097"
      unitRef="usd">-52697000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i24918d03620c4ecaafa37fa8e2ca91b8_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTIvZnJhZzo0OTkyMzA4MmJmYzM0OTBkOGE0ZGI5NzkyZGY4Nzc3Yy90YWJsZTpkZmQwZGQ0ZjU2NGY0ZDNlYjdhNDAyYjk5OTJlMWNhNi90YWJsZXJhbmdlOmRmZDBkZDRmNTY0ZjRkM2ViN2E0MDJiOTk5MmUxY2E2XzktMi0xLTEtMTA5ODc2_b43d2e01-7c39-40d0-91a0-71905440f6b7"
      unitRef="shares">82575064</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i24918d03620c4ecaafa37fa8e2ca91b8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTIvZnJhZzo0OTkyMzA4MmJmYzM0OTBkOGE0ZGI5NzkyZGY4Nzc3Yy90YWJsZTpkZmQwZGQ0ZjU2NGY0ZDNlYjdhNDAyYjk5OTJlMWNhNi90YWJsZXJhbmdlOmRmZDBkZDRmNTY0ZjRkM2ViN2E0MDJiOTk5MmUxY2E2XzktNC0xLTEtMTA5ODc2_4bb83d9f-ea1d-465b-afc7-2155958f0f60"
      unitRef="usd">826000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5c014f26be2f47f291a3aa91605b4237_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTIvZnJhZzo0OTkyMzA4MmJmYzM0OTBkOGE0ZGI5NzkyZGY4Nzc3Yy90YWJsZTpkZmQwZGQ0ZjU2NGY0ZDNlYjdhNDAyYjk5OTJlMWNhNi90YWJsZXJhbmdlOmRmZDBkZDRmNTY0ZjRkM2ViN2E0MDJiOTk5MmUxY2E2XzktNi0xLTEtMTA5ODc2_708e6c74-e137-40a2-aaf9-9badd34d27cc"
      unitRef="usd">293367000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie706c5ed539d4ef3bd0c02c4a4ba65e9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTIvZnJhZzo0OTkyMzA4MmJmYzM0OTBkOGE0ZGI5NzkyZGY4Nzc3Yy90YWJsZTpkZmQwZGQ0ZjU2NGY0ZDNlYjdhNDAyYjk5OTJlMWNhNi90YWJsZXJhbmdlOmRmZDBkZDRmNTY0ZjRkM2ViN2E0MDJiOTk5MmUxY2E2XzktOC0xLTEtMTA5ODc2_983041c6-d767-481f-b4cb-98c592dd8ae7"
      unitRef="usd">-3794000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7658aae35c1342aa8a4d460d73d54645_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTIvZnJhZzo0OTkyMzA4MmJmYzM0OTBkOGE0ZGI5NzkyZGY4Nzc3Yy90YWJsZTpkZmQwZGQ0ZjU2NGY0ZDNlYjdhNDAyYjk5OTJlMWNhNi90YWJsZXJhbmdlOmRmZDBkZDRmNTY0ZjRkM2ViN2E0MDJiOTk5MmUxY2E2XzktMTAtMS0xLTEwOTg3Ng_66d3a3df-7620-456e-8c69-c239df4fade0"
      unitRef="usd">-210946000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7372be6dc06143b5adbb4d2e83a596c5_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTIvZnJhZzo0OTkyMzA4MmJmYzM0OTBkOGE0ZGI5NzkyZGY4Nzc3Yy90YWJsZTpkZmQwZGQ0ZjU2NGY0ZDNlYjdhNDAyYjk5OTJlMWNhNi90YWJsZXJhbmdlOmRmZDBkZDRmNTY0ZjRkM2ViN2E0MDJiOTk5MmUxY2E2XzktMTItMS0xLTEwOTg3Ng_02fe97d3-ab28-4dd9-adf7-5e96f459e970"
      unitRef="usd">79453000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTIvZnJhZzo0OTkyMzA4MmJmYzM0OTBkOGE0ZGI5NzkyZGY4Nzc3Yy90YWJsZTpkZmQwZGQ0ZjU2NGY0ZDNlYjdhNDAyYjk5OTJlMWNhNi90YWJsZXJhbmdlOmRmZDBkZDRmNTY0ZjRkM2ViN2E0MDJiOTk5MmUxY2E2XzEwLTAtMS0xLTEwOTg3Ni90ZXh0cmVnaW9uOjViM2FmZjk2Y2FlMjQ4OGI4MGM4NjMyZDVmMWIyNWE3XzYy_c0aeef7f-d2b3-49bc-8990-ec96faf507ae"
      unitRef="usd">159000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="ic6b97fcd6da249ba8b8f4ae9d4f4b37d_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTIvZnJhZzo0OTkyMzA4MmJmYzM0OTBkOGE0ZGI5NzkyZGY4Nzc3Yy90YWJsZTpkZmQwZGQ0ZjU2NGY0ZDNlYjdhNDAyYjk5OTJlMWNhNi90YWJsZXJhbmdlOmRmZDBkZDRmNTY0ZjRkM2ViN2E0MDJiOTk5MmUxY2E2XzEwLTItMS0xLTEwOTg3Ng_420249bb-d6c6-43d5-9753-f41b7d4b1ba6"
      unitRef="shares">14312976</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ic6b97fcd6da249ba8b8f4ae9d4f4b37d_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTIvZnJhZzo0OTkyMzA4MmJmYzM0OTBkOGE0ZGI5NzkyZGY4Nzc3Yy90YWJsZTpkZmQwZGQ0ZjU2NGY0ZDNlYjdhNDAyYjk5OTJlMWNhNi90YWJsZXJhbmdlOmRmZDBkZDRmNTY0ZjRkM2ViN2E0MDJiOTk5MmUxY2E2XzEwLTQtMS0xLTEwOTg3Ng_4bb746f4-6ae1-46ca-a741-8f4a9b8dfa67"
      unitRef="usd">143000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i2e2dff6c233a4cdbb090a82ca47e7ffc_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTIvZnJhZzo0OTkyMzA4MmJmYzM0OTBkOGE0ZGI5NzkyZGY4Nzc3Yy90YWJsZTpkZmQwZGQ0ZjU2NGY0ZDNlYjdhNDAyYjk5OTJlMWNhNi90YWJsZXJhbmdlOmRmZDBkZDRmNTY0ZjRkM2ViN2E0MDJiOTk5MmUxY2E2XzEwLTYtMS0xLTEwOTg3Ng_2a6d9fe5-d865-45f4-b99b-0323dac064fc"
      unitRef="usd">74698000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTIvZnJhZzo0OTkyMzA4MmJmYzM0OTBkOGE0ZGI5NzkyZGY4Nzc3Yy90YWJsZTpkZmQwZGQ0ZjU2NGY0ZDNlYjdhNDAyYjk5OTJlMWNhNi90YWJsZXJhbmdlOmRmZDBkZDRmNTY0ZjRkM2ViN2E0MDJiOTk5MmUxY2E2XzEwLTEyLTEtMS0xMDk4NzY_323d2e2d-fc64-4add-9a97-05622a4dcf8e"
      unitRef="usd">74841000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ic6b97fcd6da249ba8b8f4ae9d4f4b37d_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTIvZnJhZzo0OTkyMzA4MmJmYzM0OTBkOGE0ZGI5NzkyZGY4Nzc3Yy90YWJsZTpkZmQwZGQ0ZjU2NGY0ZDNlYjdhNDAyYjk5OTJlMWNhNi90YWJsZXJhbmdlOmRmZDBkZDRmNTY0ZjRkM2ViN2E0MDJiOTk5MmUxY2E2XzExLTItMS0xLTEwOTg3Ng_b840f1e2-4ca9-46c4-b71c-262050709f11"
      unitRef="shares">1151500</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ic6b97fcd6da249ba8b8f4ae9d4f4b37d_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTIvZnJhZzo0OTkyMzA4MmJmYzM0OTBkOGE0ZGI5NzkyZGY4Nzc3Yy90YWJsZTpkZmQwZGQ0ZjU2NGY0ZDNlYjdhNDAyYjk5OTJlMWNhNi90YWJsZXJhbmdlOmRmZDBkZDRmNTY0ZjRkM2ViN2E0MDJiOTk5MmUxY2E2XzExLTQtMS0xLTEwOTg3Ng_6a952512-f2e8-4391-88a7-22264d30b7c3"
      unitRef="usd">11000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i2e2dff6c233a4cdbb090a82ca47e7ffc_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTIvZnJhZzo0OTkyMzA4MmJmYzM0OTBkOGE0ZGI5NzkyZGY4Nzc3Yy90YWJsZTpkZmQwZGQ0ZjU2NGY0ZDNlYjdhNDAyYjk5OTJlMWNhNi90YWJsZXJhbmdlOmRmZDBkZDRmNTY0ZjRkM2ViN2E0MDJiOTk5MmUxY2E2XzExLTYtMS0xLTEwOTg3Ng_338a18e0-5323-4696-83ae-1a866889bfca"
      unitRef="usd">3077000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTIvZnJhZzo0OTkyMzA4MmJmYzM0OTBkOGE0ZGI5NzkyZGY4Nzc3Yy90YWJsZTpkZmQwZGQ0ZjU2NGY0ZDNlYjdhNDAyYjk5OTJlMWNhNi90YWJsZXJhbmdlOmRmZDBkZDRmNTY0ZjRkM2ViN2E0MDJiOTk5MmUxY2E2XzExLTEyLTEtMS0xMDk4NzY_b3ca41ef-bffe-4cba-b5f5-b12d0432fb7b"
      unitRef="usd">3088000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i2e2dff6c233a4cdbb090a82ca47e7ffc_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTIvZnJhZzo0OTkyMzA4MmJmYzM0OTBkOGE0ZGI5NzkyZGY4Nzc3Yy90YWJsZTpkZmQwZGQ0ZjU2NGY0ZDNlYjdhNDAyYjk5OTJlMWNhNi90YWJsZXJhbmdlOmRmZDBkZDRmNTY0ZjRkM2ViN2E0MDJiOTk5MmUxY2E2XzEyLTYtMS0xLTEwOTg3Ng_837a8f92-b0c8-4433-ba3b-1305d9a5bbf0"
      unitRef="usd">12804000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTIvZnJhZzo0OTkyMzA4MmJmYzM0OTBkOGE0ZGI5NzkyZGY4Nzc3Yy90YWJsZTpkZmQwZGQ0ZjU2NGY0ZDNlYjdhNDAyYjk5OTJlMWNhNi90YWJsZXJhbmdlOmRmZDBkZDRmNTY0ZjRkM2ViN2E0MDJiOTk5MmUxY2E2XzEyLTEyLTEtMS0xMDk4NzY_4e1be24d-5939-4171-b1ea-6720fb93bc7d"
      unitRef="usd">12804000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <smmt:AdjustmentsToAdditionalPaidInCapitalImputedInterestExpenseRelatedParty
      contextRef="i2e2dff6c233a4cdbb090a82ca47e7ffc_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTIvZnJhZzo0OTkyMzA4MmJmYzM0OTBkOGE0ZGI5NzkyZGY4Nzc3Yy90YWJsZTpkZmQwZGQ0ZjU2NGY0ZDNlYjdhNDAyYjk5OTJlMWNhNi90YWJsZXJhbmdlOmRmZDBkZDRmNTY0ZjRkM2ViN2E0MDJiOTk5MmUxY2E2XzEzLTYtMS0xLTEwOTg3Ng_30f3fbbe-bb38-4822-8528-d264147d8f40"
      unitRef="usd">103000</smmt:AdjustmentsToAdditionalPaidInCapitalImputedInterestExpenseRelatedParty>
    <smmt:AdjustmentsToAdditionalPaidInCapitalImputedInterestExpenseRelatedParty
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTIvZnJhZzo0OTkyMzA4MmJmYzM0OTBkOGE0ZGI5NzkyZGY4Nzc3Yy90YWJsZTpkZmQwZGQ0ZjU2NGY0ZDNlYjdhNDAyYjk5OTJlMWNhNi90YWJsZXJhbmdlOmRmZDBkZDRmNTY0ZjRkM2ViN2E0MDJiOTk5MmUxY2E2XzEzLTEyLTEtMS0xMDk4NzY_b83ebc3f-7a0b-40d8-973a-bdff3e9a68e0"
      unitRef="usd">103000</smmt:AdjustmentsToAdditionalPaidInCapitalImputedInterestExpenseRelatedParty>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i8d878058c8ed44bfb3e3c57c92407be4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTIvZnJhZzo0OTkyMzA4MmJmYzM0OTBkOGE0ZGI5NzkyZGY4Nzc3Yy90YWJsZTpkZmQwZGQ0ZjU2NGY0ZDNlYjdhNDAyYjk5OTJlMWNhNi90YWJsZXJhbmdlOmRmZDBkZDRmNTY0ZjRkM2ViN2E0MDJiOTk5MmUxY2E2XzE0LTgtMS0xLTEwOTg3Ng_322207aa-c73f-4ef5-888d-36639824f658"
      unitRef="usd">1597000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTIvZnJhZzo0OTkyMzA4MmJmYzM0OTBkOGE0ZGI5NzkyZGY4Nzc3Yy90YWJsZTpkZmQwZGQ0ZjU2NGY0ZDNlYjdhNDAyYjk5OTJlMWNhNi90YWJsZXJhbmdlOmRmZDBkZDRmNTY0ZjRkM2ViN2E0MDJiOTk5MmUxY2E2XzE0LTEyLTEtMS0xMDk4NzY_d8d49ea5-edec-4333-98e8-978dfd3496bd"
      unitRef="usd">1597000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="i598a27caa8a04c3d8039576d04308448_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTIvZnJhZzo0OTkyMzA4MmJmYzM0OTBkOGE0ZGI5NzkyZGY4Nzc3Yy90YWJsZTpkZmQwZGQ0ZjU2NGY0ZDNlYjdhNDAyYjk5OTJlMWNhNi90YWJsZXJhbmdlOmRmZDBkZDRmNTY0ZjRkM2ViN2E0MDJiOTk5MmUxY2E2XzE1LTEwLTEtMS0xMDk4NzY_9561aa10-9e6f-489a-9d8d-57b953d8da54"
      unitRef="usd">-88602000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTIvZnJhZzo0OTkyMzA4MmJmYzM0OTBkOGE0ZGI5NzkyZGY4Nzc3Yy90YWJsZTpkZmQwZGQ0ZjU2NGY0ZDNlYjdhNDAyYjk5OTJlMWNhNi90YWJsZXJhbmdlOmRmZDBkZDRmNTY0ZjRkM2ViN2E0MDJiOTk5MmUxY2E2XzE1LTEyLTEtMS0xMDk4NzY_06174e45-63a0-4fb2-91b8-e81c157cda05"
      unitRef="usd">-88602000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i24c2e29db794467488a44f9569dc30e2_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTIvZnJhZzo0OTkyMzA4MmJmYzM0OTBkOGE0ZGI5NzkyZGY4Nzc3Yy90YWJsZTpkZmQwZGQ0ZjU2NGY0ZDNlYjdhNDAyYjk5OTJlMWNhNi90YWJsZXJhbmdlOmRmZDBkZDRmNTY0ZjRkM2ViN2E0MDJiOTk5MmUxY2E2XzE2LTItMS0xLTEwOTg3Ng_8444d37f-7b96-4362-84a0-d8938a1c962a"
      unitRef="shares">98039540</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i24c2e29db794467488a44f9569dc30e2_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTIvZnJhZzo0OTkyMzA4MmJmYzM0OTBkOGE0ZGI5NzkyZGY4Nzc3Yy90YWJsZTpkZmQwZGQ0ZjU2NGY0ZDNlYjdhNDAyYjk5OTJlMWNhNi90YWJsZXJhbmdlOmRmZDBkZDRmNTY0ZjRkM2ViN2E0MDJiOTk5MmUxY2E2XzE2LTQtMS0xLTEwOTg3Ng_6b9b0576-a9fe-4fdc-bf95-cfda208b4404"
      unitRef="usd">980000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie363771b412541ff94d08b8f29d0252e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTIvZnJhZzo0OTkyMzA4MmJmYzM0OTBkOGE0ZGI5NzkyZGY4Nzc3Yy90YWJsZTpkZmQwZGQ0ZjU2NGY0ZDNlYjdhNDAyYjk5OTJlMWNhNi90YWJsZXJhbmdlOmRmZDBkZDRmNTY0ZjRkM2ViN2E0MDJiOTk5MmUxY2E2XzE2LTYtMS0xLTEwOTg3Ng_96ae96e5-5b48-4ddd-b503-6e0474267ec9"
      unitRef="usd">384049000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iebb70cd5cf5e4946b99f20b6f84c6333_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTIvZnJhZzo0OTkyMzA4MmJmYzM0OTBkOGE0ZGI5NzkyZGY4Nzc3Yy90YWJsZTpkZmQwZGQ0ZjU2NGY0ZDNlYjdhNDAyYjk5OTJlMWNhNi90YWJsZXJhbmdlOmRmZDBkZDRmNTY0ZjRkM2ViN2E0MDJiOTk5MmUxY2E2XzE2LTgtMS0xLTEwOTg3Ng_5b107d80-a8f7-4b05-bec7-6bf193e04d89"
      unitRef="usd">-2197000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8194e85afada4be48c4dc89d2b7c2a07_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTIvZnJhZzo0OTkyMzA4MmJmYzM0OTBkOGE0ZGI5NzkyZGY4Nzc3Yy90YWJsZTpkZmQwZGQ0ZjU2NGY0ZDNlYjdhNDAyYjk5OTJlMWNhNi90YWJsZXJhbmdlOmRmZDBkZDRmNTY0ZjRkM2ViN2E0MDJiOTk5MmUxY2E2XzE2LTEwLTEtMS0xMDk4NzY_a725d4da-75eb-471b-8c94-7cac9d4e2498"
      unitRef="usd">-299548000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTIvZnJhZzo0OTkyMzA4MmJmYzM0OTBkOGE0ZGI5NzkyZGY4Nzc3Yy90YWJsZTpkZmQwZGQ0ZjU2NGY0ZDNlYjdhNDAyYjk5OTJlMWNhNi90YWJsZXJhbmdlOmRmZDBkZDRmNTY0ZjRkM2ViN2E0MDJiOTk5MmUxY2E2XzE2LTEyLTEtMS0xMDk4NzY_b805d759-94e5-48a8-8734-aa6fa54cf43a"
      unitRef="usd">83284000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTUvZnJhZzo5NTczOWI5ZjE4OWU0YzEzOWRkZmZjZjI5YTBhN2U1Mi90YWJsZTo5MGNmYzZiNTUwYzQ0MmZkOTY5Nzc3YzEwZjAyZmZlMy90YWJsZXJhbmdlOjkwY2ZjNmI1NTBjNDQyZmQ5Njk3NzdjMTBmMDJmZmUzXzItMi0xLTEtMTA5ODc2_57d3c479-5fc3-42fb-81ef-193764142a81"
      unitRef="usd">-88602000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTUvZnJhZzo5NTczOWI5ZjE4OWU0YzEzOWRkZmZjZjI5YTBhN2U1Mi90YWJsZTo5MGNmYzZiNTUwYzQ0MmZkOTY5Nzc3YzEwZjAyZmZlMy90YWJsZXJhbmdlOjkwY2ZjNmI1NTBjNDQyZmQ5Njk3NzdjMTBmMDJmZmUzXzItNC0xLTEtMTA5ODc2_660ccf47-c21b-4f65-936c-4c7619967a93"
      unitRef="usd">-52697000</us-gaap:NetIncomeLoss>
    <smmt:GainLossOnRemeasurementOfLiabilitiesOperatingAndNonoperating
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTUvZnJhZzo5NTczOWI5ZjE4OWU0YzEzOWRkZmZjZjI5YTBhN2U1Mi90YWJsZTo5MGNmYzZiNTUwYzQ0MmZkOTY5Nzc3YzEwZjAyZmZlMy90YWJsZXJhbmdlOjkwY2ZjNmI1NTBjNDQyZmQ5Njk3NzdjMTBmMDJmZmUzXzQtMi0xLTEtMTA5ODc2_b3775eac-ccff-4a4b-8262-f99a1687a754"
      unitRef="usd">0</smmt:GainLossOnRemeasurementOfLiabilitiesOperatingAndNonoperating>
    <smmt:GainLossOnRemeasurementOfLiabilitiesOperatingAndNonoperating
      contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTUvZnJhZzo5NTczOWI5ZjE4OWU0YzEzOWRkZmZjZjI5YTBhN2U1Mi90YWJsZTo5MGNmYzZiNTUwYzQ0MmZkOTY5Nzc3YzEwZjAyZmZlMy90YWJsZXJhbmdlOjkwY2ZjNmI1NTBjNDQyZmQ5Njk3NzdjMTBmMDJmZmUzXzQtNC0xLTEtMTA5ODc2_d913191f-2fa4-4876-bcc4-fe26bfe06d0a"
      unitRef="usd">480000</smmt:GainLossOnRemeasurementOfLiabilitiesOperatingAndNonoperating>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTUvZnJhZzo5NTczOWI5ZjE4OWU0YzEzOWRkZmZjZjI5YTBhN2U1Mi90YWJsZTo5MGNmYzZiNTUwYzQ0MmZkOTY5Nzc3YzEwZjAyZmZlMy90YWJsZXJhbmdlOjkwY2ZjNmI1NTBjNDQyZmQ5Njk3NzdjMTBmMDJmZmUzXzUtMi0xLTEtMTA5ODc2_3d71bc55-296e-42b2-8419-2591d6512abe"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTUvZnJhZzo5NTczOWI5ZjE4OWU0YzEzOWRkZmZjZjI5YTBhN2U1Mi90YWJsZTo5MGNmYzZiNTUwYzQ0MmZkOTY5Nzc3YzEwZjAyZmZlMy90YWJsZXJhbmdlOjkwY2ZjNmI1NTBjNDQyZmQ5Njk3NzdjMTBmMDJmZmUzXzUtNC0xLTEtMTA5ODc2_679a6f5c-ef3d-4eb3-8545-5381b6174d50"
      unitRef="usd">-102000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <smmt:InterestExpenseIncomeNoncash
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTUvZnJhZzo5NTczOWI5ZjE4OWU0YzEzOWRkZmZjZjI5YTBhN2U1Mi90YWJsZTo5MGNmYzZiNTUwYzQ0MmZkOTY5Nzc3YzEwZjAyZmZlMy90YWJsZXJhbmdlOjkwY2ZjNmI1NTBjNDQyZmQ5Njk3NzdjMTBmMDJmZmUzXzYtMi0xLTEtMTA5ODc2_3714fd64-b4bd-48c3-8f6f-a688768b78f5"
      unitRef="usd">196000</smmt:InterestExpenseIncomeNoncash>
    <smmt:InterestExpenseIncomeNoncash
      contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTUvZnJhZzo5NTczOWI5ZjE4OWU0YzEzOWRkZmZjZjI5YTBhN2U1Mi90YWJsZTo5MGNmYzZiNTUwYzQ0MmZkOTY5Nzc3YzEwZjAyZmZlMy90YWJsZXJhbmdlOjkwY2ZjNmI1NTBjNDQyZmQ5Njk3NzdjMTBmMDJmZmUzXzYtNC0xLTEtMTA5ODc2_a0c5f136-2f51-4f45-859f-b553c766e406"
      unitRef="usd">255000</smmt:InterestExpenseIncomeNoncash>
    <us-gaap:ForeignCurrencyTransactionGainLossUnrealized
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTUvZnJhZzo5NTczOWI5ZjE4OWU0YzEzOWRkZmZjZjI5YTBhN2U1Mi90YWJsZTo5MGNmYzZiNTUwYzQ0MmZkOTY5Nzc3YzEwZjAyZmZlMy90YWJsZXJhbmdlOjkwY2ZjNmI1NTBjNDQyZmQ5Njk3NzdjMTBmMDJmZmUzXzctMi0xLTEtMTA5ODc2_b18d36f9-5bdb-4e44-b8b5-cd729b0dcb9f"
      unitRef="usd">-326000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
    <us-gaap:ForeignCurrencyTransactionGainLossUnrealized
      contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTUvZnJhZzo5NTczOWI5ZjE4OWU0YzEzOWRkZmZjZjI5YTBhN2U1Mi90YWJsZTo5MGNmYzZiNTUwYzQ0MmZkOTY5Nzc3YzEwZjAyZmZlMy90YWJsZXJhbmdlOjkwY2ZjNmI1NTBjNDQyZmQ5Njk3NzdjMTBmMDJmZmUzXzctNC0xLTEtMTA5ODc2_12e3a42e-619e-40f7-8bf3-d5a5ad690c83"
      unitRef="usd">278000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTUvZnJhZzo5NTczOWI5ZjE4OWU0YzEzOWRkZmZjZjI5YTBhN2U1Mi90YWJsZTo5MGNmYzZiNTUwYzQ0MmZkOTY5Nzc3YzEwZjAyZmZlMy90YWJsZXJhbmdlOjkwY2ZjNmI1NTBjNDQyZmQ5Njk3NzdjMTBmMDJmZmUzXzgtMi0xLTEtMTA5ODc2_264e7287-dd34-4460-afcd-110fb1108ffe"
      unitRef="usd">1108000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTUvZnJhZzo5NTczOWI5ZjE4OWU0YzEzOWRkZmZjZjI5YTBhN2U1Mi90YWJsZTo5MGNmYzZiNTUwYzQ0MmZkOTY5Nzc3YzEwZjAyZmZlMy90YWJsZXJhbmdlOjkwY2ZjNmI1NTBjNDQyZmQ5Njk3NzdjMTBmMDJmZmUzXzgtNC0xLTEtMTA5ODc2_49c1a328-4f6b-43f7-b941-d54774471710"
      unitRef="usd">451000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:Depreciation
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTUvZnJhZzo5NTczOWI5ZjE4OWU0YzEzOWRkZmZjZjI5YTBhN2U1Mi90YWJsZTo5MGNmYzZiNTUwYzQ0MmZkOTY5Nzc3YzEwZjAyZmZlMy90YWJsZXJhbmdlOjkwY2ZjNmI1NTBjNDQyZmQ5Njk3NzdjMTBmMDJmZmUzXzktMi0xLTEtMTA5ODc2_b8d7075a-f619-4cb5-bda4-b126117fa97b"
      unitRef="usd">330000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTUvZnJhZzo5NTczOWI5ZjE4OWU0YzEzOWRkZmZjZjI5YTBhN2U1Mi90YWJsZTo5MGNmYzZiNTUwYzQ0MmZkOTY5Nzc3YzEwZjAyZmZlMy90YWJsZXJhbmdlOjkwY2ZjNmI1NTBjNDQyZmQ5Njk3NzdjMTBmMDJmZmUzXzktNC0xLTEtMTA5ODc2_dda88ffb-cca8-4369-820e-6c804804ffed"
      unitRef="usd">302000</us-gaap:Depreciation>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTUvZnJhZzo5NTczOWI5ZjE4OWU0YzEzOWRkZmZjZjI5YTBhN2U1Mi90YWJsZTo5MGNmYzZiNTUwYzQ0MmZkOTY5Nzc3YzEwZjAyZmZlMy90YWJsZXJhbmdlOjkwY2ZjNmI1NTBjNDQyZmQ5Njk3NzdjMTBmMDJmZmUzXzEwLTItMS0xLTEwOTg3Ng_d9eb92cb-3cc8-478b-8eb9-ff9f77d5b56e"
      unitRef="usd">1017000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTUvZnJhZzo5NTczOWI5ZjE4OWU0YzEzOWRkZmZjZjI5YTBhN2U1Mi90YWJsZTo5MGNmYzZiNTUwYzQ0MmZkOTY5Nzc3YzEwZjAyZmZlMy90YWJsZXJhbmdlOjkwY2ZjNmI1NTBjNDQyZmQ5Njk3NzdjMTBmMDJmZmUzXzEwLTQtMS0xLTEwOTg3Ng_be1ab8b7-079c-41c7-aa0c-4d28fcb570ab"
      unitRef="usd">1250000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTUvZnJhZzo5NTczOWI5ZjE4OWU0YzEzOWRkZmZjZjI5YTBhN2U1Mi90YWJsZTo5MGNmYzZiNTUwYzQ0MmZkOTY5Nzc3YzEwZjAyZmZlMy90YWJsZXJhbmdlOjkwY2ZjNmI1NTBjNDQyZmQ5Njk3NzdjMTBmMDJmZmUzXzExLTItMS0xLTEwOTg3Ng_cfb74a62-e37c-4f88-bc3e-d554adc026b6"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTUvZnJhZzo5NTczOWI5ZjE4OWU0YzEzOWRkZmZjZjI5YTBhN2U1Mi90YWJsZTo5MGNmYzZiNTUwYzQ0MmZkOTY5Nzc3YzEwZjAyZmZlMy90YWJsZXJhbmdlOjkwY2ZjNmI1NTBjNDQyZmQ5Njk3NzdjMTBmMDJmZmUzXzExLTQtMS0xLTEwOTg3Ng_ec452f72-de08-4566-9b9b-e3ab38333eee"
      unitRef="usd">859000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ShareBasedCompensation
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTUvZnJhZzo5NTczOWI5ZjE4OWU0YzEzOWRkZmZjZjI5YTBhN2U1Mi90YWJsZTo5MGNmYzZiNTUwYzQ0MmZkOTY5Nzc3YzEwZjAyZmZlMy90YWJsZXJhbmdlOjkwY2ZjNmI1NTBjNDQyZmQ5Njk3NzdjMTBmMDJmZmUzXzEyLTItMS0xLTEwOTg3Ng_ec74bd86-3d8c-45ae-80a0-a611e3a81f90"
      unitRef="usd">12804000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTUvZnJhZzo5NTczOWI5ZjE4OWU0YzEzOWRkZmZjZjI5YTBhN2U1Mi90YWJsZTo5MGNmYzZiNTUwYzQ0MmZkOTY5Nzc3YzEwZjAyZmZlMy90YWJsZXJhbmdlOjkwY2ZjNmI1NTBjNDQyZmQ5Njk3NzdjMTBmMDJmZmUzXzEyLTQtMS0xLTEwOTg3Ng_af44d036-6444-4672-b62d-86454aca90b4"
      unitRef="usd">1766000</us-gaap:ShareBasedCompensation>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTUvZnJhZzo5NTczOWI5ZjE4OWU0YzEzOWRkZmZjZjI5YTBhN2U1Mi90YWJsZTo5MGNmYzZiNTUwYzQ0MmZkOTY5Nzc3YzEwZjAyZmZlMy90YWJsZXJhbmdlOjkwY2ZjNmI1NTBjNDQyZmQ5Njk3NzdjMTBmMDJmZmUzXzEzLTItMS0xLTEwOTg3Ng_8c0986d4-3d6a-4c05-9cc1-cfedf5e67ea7"
      unitRef="usd">-301000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTUvZnJhZzo5NTczOWI5ZjE4OWU0YzEzOWRkZmZjZjI5YTBhN2U1Mi90YWJsZTo5MGNmYzZiNTUwYzQ0MmZkOTY5Nzc3YzEwZjAyZmZlMy90YWJsZXJhbmdlOjkwY2ZjNmI1NTBjNDQyZmQ5Njk3NzdjMTBmMDJmZmUzXzEzLTQtMS0xLTEwOTg3Ng_278de36b-1e8e-4aee-9ddd-b4197ece6eda"
      unitRef="usd">56000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTUvZnJhZzo5NTczOWI5ZjE4OWU0YzEzOWRkZmZjZjI5YTBhN2U1Mi90YWJsZTo5MGNmYzZiNTUwYzQ0MmZkOTY5Nzc3YzEwZjAyZmZlMy90YWJsZXJhbmdlOjkwY2ZjNmI1NTBjNDQyZmQ5Njk3NzdjMTBmMDJmZmUzXzE1LTItMS0xLTEwOTg3Ng_33e1ef75-c837-4653-bebc-ff0511486cfc"
      unitRef="usd">1138000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTUvZnJhZzo5NTczOWI5ZjE4OWU0YzEzOWRkZmZjZjI5YTBhN2U1Mi90YWJsZTo5MGNmYzZiNTUwYzQ0MmZkOTY5Nzc3YzEwZjAyZmZlMy90YWJsZXJhbmdlOjkwY2ZjNmI1NTBjNDQyZmQ5Njk3NzdjMTBmMDJmZmUzXzE1LTQtMS0xLTEwOTg3Ng_2ffcc590-834e-4310-b0b2-782a10b58a69"
      unitRef="usd">-212000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTUvZnJhZzo5NTczOWI5ZjE4OWU0YzEzOWRkZmZjZjI5YTBhN2U1Mi90YWJsZTo5MGNmYzZiNTUwYzQ0MmZkOTY5Nzc3YzEwZjAyZmZlMy90YWJsZXJhbmdlOjkwY2ZjNmI1NTBjNDQyZmQ5Njk3NzdjMTBmMDJmZmUzXzE2LTItMS0xLTEwOTg3Ng_17832d1b-ae0d-4162-96c8-85d03c903832"
      unitRef="usd">-2345000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTUvZnJhZzo5NTczOWI5ZjE4OWU0YzEzOWRkZmZjZjI5YTBhN2U1Mi90YWJsZTo5MGNmYzZiNTUwYzQ0MmZkOTY5Nzc3YzEwZjAyZmZlMy90YWJsZXJhbmdlOjkwY2ZjNmI1NTBjNDQyZmQ5Njk3NzdjMTBmMDJmZmUzXzE2LTQtMS0xLTEwOTg3Ng_bd3a4d9a-83d5-47c4-9f93-339179d2e0c9"
      unitRef="usd">447000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTUvZnJhZzo5NTczOWI5ZjE4OWU0YzEzOWRkZmZjZjI5YTBhN2U1Mi90YWJsZTo5MGNmYzZiNTUwYzQ0MmZkOTY5Nzc3YzEwZjAyZmZlMy90YWJsZXJhbmdlOjkwY2ZjNmI1NTBjNDQyZmQ5Njk3NzdjMTBmMDJmZmUzXzE3LTItMS0xLTEwOTg3Ng_118666e4-5d60-4120-8f4c-710a59b8bcdd"
      unitRef="usd">-104000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTUvZnJhZzo5NTczOWI5ZjE4OWU0YzEzOWRkZmZjZjI5YTBhN2U1Mi90YWJsZTo5MGNmYzZiNTUwYzQ0MmZkOTY5Nzc3YzEwZjAyZmZlMy90YWJsZXJhbmdlOjkwY2ZjNmI1NTBjNDQyZmQ5Njk3NzdjMTBmMDJmZmUzXzE3LTQtMS0xLTEwOTg3Ng_f8f3c2da-b520-4a7e-9179-1fb1ab21c4cf"
      unitRef="usd">24000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <smmt:IncreaseDecreaseInResearchAndDevelopmentTaxCreditReceivable
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTUvZnJhZzo5NTczOWI5ZjE4OWU0YzEzOWRkZmZjZjI5YTBhN2U1Mi90YWJsZTo5MGNmYzZiNTUwYzQ0MmZkOTY5Nzc3YzEwZjAyZmZlMy90YWJsZXJhbmdlOjkwY2ZjNmI1NTBjNDQyZmQ5Njk3NzdjMTBmMDJmZmUzXzE4LTItMS0xLTEwOTg3Ng_d633c702-8f1b-4a07-8547-c39a69c46c63"
      unitRef="usd">6015000</smmt:IncreaseDecreaseInResearchAndDevelopmentTaxCreditReceivable>
    <smmt:IncreaseDecreaseInResearchAndDevelopmentTaxCreditReceivable
      contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTUvZnJhZzo5NTczOWI5ZjE4OWU0YzEzOWRkZmZjZjI5YTBhN2U1Mi90YWJsZTo5MGNmYzZiNTUwYzQ0MmZkOTY5Nzc3YzEwZjAyZmZlMy90YWJsZXJhbmdlOjkwY2ZjNmI1NTBjNDQyZmQ5Njk3NzdjMTBmMDJmZmUzXzE4LTQtMS0xLTEwOTg3Ng_402d2dcc-2e86-4cf4-827f-7fbc691c876d"
      unitRef="usd">4381000</smmt:IncreaseDecreaseInResearchAndDevelopmentTaxCreditReceivable>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTUvZnJhZzo5NTczOWI5ZjE4OWU0YzEzOWRkZmZjZjI5YTBhN2U1Mi90YWJsZTo5MGNmYzZiNTUwYzQ0MmZkOTY5Nzc3YzEwZjAyZmZlMy90YWJsZXJhbmdlOjkwY2ZjNmI1NTBjNDQyZmQ5Njk3NzdjMTBmMDJmZmUzXzE5LTItMS0xLTEwOTg3Ng_7ec6998b-4171-4651-9e6e-ad36e13c6312"
      unitRef="usd">-813000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTUvZnJhZzo5NTczOWI5ZjE4OWU0YzEzOWRkZmZjZjI5YTBhN2U1Mi90YWJsZTo5MGNmYzZiNTUwYzQ0MmZkOTY5Nzc3YzEwZjAyZmZlMy90YWJsZXJhbmdlOjkwY2ZjNmI1NTBjNDQyZmQ5Njk3NzdjMTBmMDJmZmUzXzE5LTQtMS0xLTEwOTg3Ng_601506c0-d94e-4ebc-b485-14ee1c4e36bb"
      unitRef="usd">5372000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTUvZnJhZzo5NTczOWI5ZjE4OWU0YzEzOWRkZmZjZjI5YTBhN2U1Mi90YWJsZTo5MGNmYzZiNTUwYzQ0MmZkOTY5Nzc3YzEwZjAyZmZlMy90YWJsZXJhbmdlOjkwY2ZjNmI1NTBjNDQyZmQ5Njk3NzdjMTBmMDJmZmUzXzIwLTItMS0xLTEwOTg3Ng_14f83613-3e10-4918-b3af-aaa805d2a38f"
      unitRef="usd">-1711000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTUvZnJhZzo5NTczOWI5ZjE4OWU0YzEzOWRkZmZjZjI5YTBhN2U1Mi90YWJsZTo5MGNmYzZiNTUwYzQ0MmZkOTY5Nzc3YzEwZjAyZmZlMy90YWJsZXJhbmdlOjkwY2ZjNmI1NTBjNDQyZmQ5Njk3NzdjMTBmMDJmZmUzXzIwLTQtMS0xLTEwOTg3Ng_259211ba-eb6e-4a6b-8413-ba8e04a2dd85"
      unitRef="usd">1642000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <smmt:IncreaseDecreaseInAccruedLiabilitiesAndEmployeeRelatedLiabilities
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTUvZnJhZzo5NTczOWI5ZjE4OWU0YzEzOWRkZmZjZjI5YTBhN2U1Mi90YWJsZTo5MGNmYzZiNTUwYzQ0MmZkOTY5Nzc3YzEwZjAyZmZlMy90YWJsZXJhbmdlOjkwY2ZjNmI1NTBjNDQyZmQ5Njk3NzdjMTBmMDJmZmUzXzIxLTItMS0xLTEwOTg3Ng_d45c76b5-ecbb-4e5f-b8dd-dce79ee5f188"
      unitRef="usd">8229000</smmt:IncreaseDecreaseInAccruedLiabilitiesAndEmployeeRelatedLiabilities>
    <smmt:IncreaseDecreaseInAccruedLiabilitiesAndEmployeeRelatedLiabilities
      contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTUvZnJhZzo5NTczOWI5ZjE4OWU0YzEzOWRkZmZjZjI5YTBhN2U1Mi90YWJsZTo5MGNmYzZiNTUwYzQ0MmZkOTY5Nzc3YzEwZjAyZmZlMy90YWJsZXJhbmdlOjkwY2ZjNmI1NTBjNDQyZmQ5Njk3NzdjMTBmMDJmZmUzXzIxLTQtMS0xLTEwOTg3Ng_28055448-5ff3-47ae-a8ab-1ec723e4fa7b"
      unitRef="usd">-1296000</smmt:IncreaseDecreaseInAccruedLiabilitiesAndEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTUvZnJhZzo5NTczOWI5ZjE4OWU0YzEzOWRkZmZjZjI5YTBhN2U1Mi90YWJsZTo5MGNmYzZiNTUwYzQ0MmZkOTY5Nzc3YzEwZjAyZmZlMy90YWJsZXJhbmdlOjkwY2ZjNmI1NTBjNDQyZmQ5Njk3NzdjMTBmMDJmZmUzXzIyLTItMS0xLTEwOTg3Ng_9b3ea128-7877-4be2-b575-32f51a91a79c"
      unitRef="usd">-1068000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTUvZnJhZzo5NTczOWI5ZjE4OWU0YzEzOWRkZmZjZjI5YTBhN2U1Mi90YWJsZTo5MGNmYzZiNTUwYzQ0MmZkOTY5Nzc3YzEwZjAyZmZlMy90YWJsZXJhbmdlOjkwY2ZjNmI1NTBjNDQyZmQ5Njk3NzdjMTBmMDJmZmUzXzIyLTQtMS0xLTEwOTg3Ng_dbc7a4e5-ee73-44cf-b242-2ffa2415ca4c"
      unitRef="usd">-459000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTUvZnJhZzo5NTczOWI5ZjE4OWU0YzEzOWRkZmZjZjI5YTBhN2U1Mi90YWJsZTo5MGNmYzZiNTUwYzQ0MmZkOTY5Nzc3YzEwZjAyZmZlMy90YWJsZXJhbmdlOjkwY2ZjNmI1NTBjNDQyZmQ5Njk3NzdjMTBmMDJmZmUzXzIzLTItMS0xLTEwOTg3Ng_07129531-2fe9-443f-a750-4df3af75eba3"
      unitRef="usd">-72587000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTUvZnJhZzo5NTczOWI5ZjE4OWU0YzEzOWRkZmZjZjI5YTBhN2U1Mi90YWJsZTo5MGNmYzZiNTUwYzQ0MmZkOTY5Nzc3YzEwZjAyZmZlMy90YWJsZXJhbmdlOjkwY2ZjNmI1NTBjNDQyZmQ5Njk3NzdjMTBmMDJmZmUzXzIzLTQtMS0xLTEwOTg3Ng_d51745d3-5316-4981-a202-17e01d296971"
      unitRef="usd">-48111000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTUvZnJhZzo5NTczOWI5ZjE4OWU0YzEzOWRkZmZjZjI5YTBhN2U1Mi90YWJsZTo5MGNmYzZiNTUwYzQ0MmZkOTY5Nzc3YzEwZjAyZmZlMy90YWJsZXJhbmdlOjkwY2ZjNmI1NTBjNDQyZmQ5Njk3NzdjMTBmMDJmZmUzXzI2LTItMS0xLTEwOTg3Ng_d5849cff-aa10-4529-8cc6-b7c59a0a7050"
      unitRef="usd">306000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTUvZnJhZzo5NTczOWI5ZjE4OWU0YzEzOWRkZmZjZjI5YTBhN2U1Mi90YWJsZTo5MGNmYzZiNTUwYzQ0MmZkOTY5Nzc3YzEwZjAyZmZlMy90YWJsZXJhbmdlOjkwY2ZjNmI1NTBjNDQyZmQ5Njk3NzdjMTBmMDJmZmUzXzI2LTQtMS0xLTEwOTg3Ng_f79d4767-b59e-48ae-8310-e3f11bd962cc"
      unitRef="usd">421000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTUvZnJhZzo5NTczOWI5ZjE4OWU0YzEzOWRkZmZjZjI5YTBhN2U1Mi90YWJsZTo5MGNmYzZiNTUwYzQ0MmZkOTY5Nzc3YzEwZjAyZmZlMy90YWJsZXJhbmdlOjkwY2ZjNmI1NTBjNDQyZmQ5Njk3NzdjMTBmMDJmZmUzXzI3LTItMS0xLTEwOTg3Ng_12dda3a3-5da8-48e8-8f8d-9b768e459479"
      unitRef="usd">-306000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTUvZnJhZzo5NTczOWI5ZjE4OWU0YzEzOWRkZmZjZjI5YTBhN2U1Mi90YWJsZTo5MGNmYzZiNTUwYzQ0MmZkOTY5Nzc3YzEwZjAyZmZlMy90YWJsZXJhbmdlOjkwY2ZjNmI1NTBjNDQyZmQ5Njk3NzdjMTBmMDJmZmUzXzI3LTQtMS0xLTEwOTg3Ng_faacd838-c0ce-478d-b4c0-20af0de56401"
      unitRef="usd">-421000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTUvZnJhZzo5NTczOWI5ZjE4OWU0YzEzOWRkZmZjZjI5YTBhN2U1Mi90YWJsZTo5MGNmYzZiNTUwYzQ0MmZkOTY5Nzc3YzEwZjAyZmZlMy90YWJsZXJhbmdlOjkwY2ZjNmI1NTBjNDQyZmQ5Njk3NzdjMTBmMDJmZmUzXzMwLTItMS0xLTEwOTg3Ng_75e24988-d3dd-4749-a369-acab81cd2e6a"
      unitRef="usd">75000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTUvZnJhZzo5NTczOWI5ZjE4OWU0YzEzOWRkZmZjZjI5YTBhN2U1Mi90YWJsZTo5MGNmYzZiNTUwYzQ0MmZkOTY5Nzc3YzEwZjAyZmZlMy90YWJsZXJhbmdlOjkwY2ZjNmI1NTBjNDQyZmQ5Njk3NzdjMTBmMDJmZmUzXzMwLTQtMS0xLTEwOTg3Ng_44466fe7-72ce-4f86-a3f7-2c336c24cc76"
      unitRef="usd">50000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTUvZnJhZzo5NTczOWI5ZjE4OWU0YzEzOWRkZmZjZjI5YTBhN2U1Mi90YWJsZTo5MGNmYzZiNTUwYzQ0MmZkOTY5Nzc3YzEwZjAyZmZlMy90YWJsZXJhbmdlOjkwY2ZjNmI1NTBjNDQyZmQ5Njk3NzdjMTBmMDJmZmUzXzMxLTItMS0xLTEwOTg3Ng_ab43ce45-7cc7-4f91-9645-413a6bc1797b"
      unitRef="usd">118000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTUvZnJhZzo5NTczOWI5ZjE4OWU0YzEzOWRkZmZjZjI5YTBhN2U1Mi90YWJsZTo5MGNmYzZiNTUwYzQ0MmZkOTY5Nzc3YzEwZjAyZmZlMy90YWJsZXJhbmdlOjkwY2ZjNmI1NTBjNDQyZmQ5Njk3NzdjMTBmMDJmZmUzXzMxLTQtMS0xLTEwOTg3Ng_84d5e1ce-1d6f-498a-bdd7-0064dabdca58"
      unitRef="usd">48000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ProceedsFromRelatedPartyDebt
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTUvZnJhZzo5NTczOWI5ZjE4OWU0YzEzOWRkZmZjZjI5YTBhN2U1Mi90YWJsZTo5MGNmYzZiNTUwYzQ0MmZkOTY5Nzc3YzEwZjAyZmZlMy90YWJsZXJhbmdlOjkwY2ZjNmI1NTBjNDQyZmQ5Njk3NzdjMTBmMDJmZmUzXzMyLTItMS0xLTEwOTg3Ng_248cecbf-31a5-4ee6-ba17-99eb78db4e15"
      unitRef="usd">110000000</us-gaap:ProceedsFromRelatedPartyDebt>
    <us-gaap:ProceedsFromRelatedPartyDebt
      contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTUvZnJhZzo5NTczOWI5ZjE4OWU0YzEzOWRkZmZjZjI5YTBhN2U1Mi90YWJsZTo5MGNmYzZiNTUwYzQ0MmZkOTY5Nzc3YzEwZjAyZmZlMy90YWJsZXJhbmdlOjkwY2ZjNmI1NTBjNDQyZmQ5Njk3NzdjMTBmMDJmZmUzXzMyLTQtMS0xLTEwOTg3Ng_b9b615df-299e-431f-80f2-61e8414c1d33"
      unitRef="usd">0</us-gaap:ProceedsFromRelatedPartyDebt>
    <us-gaap:RepaymentsOfRelatedPartyDebt
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTUvZnJhZzo5NTczOWI5ZjE4OWU0YzEzOWRkZmZjZjI5YTBhN2U1Mi90YWJsZTo5MGNmYzZiNTUwYzQ0MmZkOTY5Nzc3YzEwZjAyZmZlMy90YWJsZXJhbmdlOjkwY2ZjNmI1NTBjNDQyZmQ5Njk3NzdjMTBmMDJmZmUzXzMzLTItMS0xLTEwOTg3Ng_8d954248-5438-4c99-a207-3b01335e3483"
      unitRef="usd">110000000</us-gaap:RepaymentsOfRelatedPartyDebt>
    <us-gaap:RepaymentsOfRelatedPartyDebt
      contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTUvZnJhZzo5NTczOWI5ZjE4OWU0YzEzOWRkZmZjZjI5YTBhN2U1Mi90YWJsZTo5MGNmYzZiNTUwYzQ0MmZkOTY5Nzc3YzEwZjAyZmZlMy90YWJsZXJhbmdlOjkwY2ZjNmI1NTBjNDQyZmQ5Njk3NzdjMTBmMDJmZmUzXzMzLTQtMS0xLTEwOTg3Ng_27c29feb-c9b4-4687-9638-c50614db232d"
      unitRef="usd">0</us-gaap:RepaymentsOfRelatedPartyDebt>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTUvZnJhZzo5NTczOWI5ZjE4OWU0YzEzOWRkZmZjZjI5YTBhN2U1Mi90YWJsZTo5MGNmYzZiNTUwYzQ0MmZkOTY5Nzc3YzEwZjAyZmZlMy90YWJsZXJhbmdlOjkwY2ZjNmI1NTBjNDQyZmQ5Njk3NzdjMTBmMDJmZmUzXzM0LTItMS0xLTEwOTg3Ng_ecdb1f8f-06a8-49a9-b942-04461a49b8d9"
      unitRef="usd">54000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTUvZnJhZzo5NTczOWI5ZjE4OWU0YzEzOWRkZmZjZjI5YTBhN2U1Mi90YWJsZTo5MGNmYzZiNTUwYzQ0MmZkOTY5Nzc3YzEwZjAyZmZlMy90YWJsZXJhbmdlOjkwY2ZjNmI1NTBjNDQyZmQ5Njk3NzdjMTBmMDJmZmUzXzM0LTQtMS0xLTEwOTg3Ng_ea94c09c-c781-427c-ae00-c562785eea39"
      unitRef="usd">0</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTUvZnJhZzo5NTczOWI5ZjE4OWU0YzEzOWRkZmZjZjI5YTBhN2U1Mi90YWJsZTo5MGNmYzZiNTUwYzQ0MmZkOTY5Nzc3YzEwZjAyZmZlMy90YWJsZXJhbmdlOjkwY2ZjNmI1NTBjNDQyZmQ5Njk3NzdjMTBmMDJmZmUzXzM1LTItMS0xLTEwOTg3Ng_cea877f1-cf41-4889-8371-dc7c681b72f4"
      unitRef="usd">3088000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTUvZnJhZzo5NTczOWI5ZjE4OWU0YzEzOWRkZmZjZjI5YTBhN2U1Mi90YWJsZTo5MGNmYzZiNTUwYzQ0MmZkOTY5Nzc3YzEwZjAyZmZlMy90YWJsZXJhbmdlOjkwY2ZjNmI1NTBjNDQyZmQ5Njk3NzdjMTBmMDJmZmUzXzM1LTQtMS0xLTEwOTg3Ng_0cac9bd6-1528-4983-9ced-db2d533dfd81"
      unitRef="usd">599000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTUvZnJhZzo5NTczOWI5ZjE4OWU0YzEzOWRkZmZjZjI5YTBhN2U1Mi90YWJsZTo5MGNmYzZiNTUwYzQ0MmZkOTY5Nzc3YzEwZjAyZmZlMy90YWJsZXJhbmdlOjkwY2ZjNmI1NTBjNDQyZmQ5Njk3NzdjMTBmMDJmZmUzXzM2LTItMS0xLTEwOTg3Ng_d157a823-4f47-42d1-8dcb-258f6dda4213"
      unitRef="usd">77916000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTUvZnJhZzo5NTczOWI5ZjE4OWU0YzEzOWRkZmZjZjI5YTBhN2U1Mi90YWJsZTo5MGNmYzZiNTUwYzQ0MmZkOTY5Nzc3YzEwZjAyZmZlMy90YWJsZXJhbmdlOjkwY2ZjNmI1NTBjNDQyZmQ5Njk3NzdjMTBmMDJmZmUzXzM2LTQtMS0xLTEwOTg3Ng_7465e840-4534-4b08-a3a8-f228e57500d9"
      unitRef="usd">50551000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTUvZnJhZzo5NTczOWI5ZjE4OWU0YzEzOWRkZmZjZjI5YTBhN2U1Mi90YWJsZTo5MGNmYzZiNTUwYzQ0MmZkOTY5Nzc3YzEwZjAyZmZlMy90YWJsZXJhbmdlOjkwY2ZjNmI1NTBjNDQyZmQ5Njk3NzdjMTBmMDJmZmUzXzM3LTItMS0xLTEwOTg3Ng_cf6dc34f-812c-472e-bc1a-c2786979a82f"
      unitRef="usd">351000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTUvZnJhZzo5NTczOWI5ZjE4OWU0YzEzOWRkZmZjZjI5YTBhN2U1Mi90YWJsZTo5MGNmYzZiNTUwYzQ0MmZkOTY5Nzc3YzEwZjAyZmZlMy90YWJsZXJhbmdlOjkwY2ZjNmI1NTBjNDQyZmQ5Njk3NzdjMTBmMDJmZmUzXzM3LTQtMS0xLTEwOTg3Ng_9a03c60e-2588-43ff-abf0-dcaf6ae2b785"
      unitRef="usd">556000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTUvZnJhZzo5NTczOWI5ZjE4OWU0YzEzOWRkZmZjZjI5YTBhN2U1Mi90YWJsZTo5MGNmYzZiNTUwYzQ0MmZkOTY5Nzc3YzEwZjAyZmZlMy90YWJsZXJhbmdlOjkwY2ZjNmI1NTBjNDQyZmQ5Njk3NzdjMTBmMDJmZmUzXzM4LTItMS0xLTEwOTg3Ng_843a7258-5a20-41c5-9a2a-60d6a2f3ed1d"
      unitRef="usd">5374000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTUvZnJhZzo5NTczOWI5ZjE4OWU0YzEzOWRkZmZjZjI5YTBhN2U1Mi90YWJsZTo5MGNmYzZiNTUwYzQ0MmZkOTY5Nzc3YzEwZjAyZmZlMy90YWJsZXJhbmdlOjkwY2ZjNmI1NTBjNDQyZmQ5Njk3NzdjMTBmMDJmZmUzXzM4LTQtMS0xLTEwOTg3Ng_a40e95a3-4cae-4f80-b4ff-1a9542a921c4"
      unitRef="usd">2575000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i7372be6dc06143b5adbb4d2e83a596c5_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTUvZnJhZzo5NTczOWI5ZjE4OWU0YzEzOWRkZmZjZjI5YTBhN2U1Mi90YWJsZTo5MGNmYzZiNTUwYzQ0MmZkOTY5Nzc3YzEwZjAyZmZlMy90YWJsZXJhbmdlOjkwY2ZjNmI1NTBjNDQyZmQ5Njk3NzdjMTBmMDJmZmUzXzM5LTItMS0xLTEwOTg3Ng_19dd9267-80e2-44f5-bebd-b1cea5d87ef4"
      unitRef="usd">66417000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i50b9889462124695acb12b854dfc61e9_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTUvZnJhZzo5NTczOWI5ZjE4OWU0YzEzOWRkZmZjZjI5YTBhN2U1Mi90YWJsZTo5MGNmYzZiNTUwYzQ0MmZkOTY5Nzc3YzEwZjAyZmZlMy90YWJsZXJhbmdlOjkwY2ZjNmI1NTBjNDQyZmQ5Njk3NzdjMTBmMDJmZmUzXzM5LTQtMS0xLTEwOTg3Ng_72c1bb64-e20a-48ad-9712-c79e1cacf597"
      unitRef="usd">63842000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTUvZnJhZzo5NTczOWI5ZjE4OWU0YzEzOWRkZmZjZjI5YTBhN2U1Mi90YWJsZTo5MGNmYzZiNTUwYzQ0MmZkOTY5Nzc3YzEwZjAyZmZlMy90YWJsZXJhbmdlOjkwY2ZjNmI1NTBjNDQyZmQ5Njk3NzdjMTBmMDJmZmUzXzQwLTItMS0xLTEwOTg3Ng_70ca904f-5244-493b-ba4b-7d9e7d59f65c"
      unitRef="usd">71791000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i7372be6dc06143b5adbb4d2e83a596c5_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTUvZnJhZzo5NTczOWI5ZjE4OWU0YzEzOWRkZmZjZjI5YTBhN2U1Mi90YWJsZTo5MGNmYzZiNTUwYzQ0MmZkOTY5Nzc3YzEwZjAyZmZlMy90YWJsZXJhbmdlOjkwY2ZjNmI1NTBjNDQyZmQ5Njk3NzdjMTBmMDJmZmUzXzQwLTQtMS0xLTEwOTg3Ng_48fbd21b-baf0-42b8-8571-87e8be59ca91"
      unitRef="usd">66417000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTUvZnJhZzo5NTczOWI5ZjE4OWU0YzEzOWRkZmZjZjI5YTBhN2U1Mi90YWJsZTo5MGNmYzZiNTUwYzQ0MmZkOTY5Nzc3YzEwZjAyZmZlMy90YWJsZXJhbmdlOjkwY2ZjNmI1NTBjNDQyZmQ5Njk3NzdjMTBmMDJmZmUzXzQyLTItMS0xLTEwOTg3Ng_7f1595e6-7a3b-45d4-8a5a-ec8244890f7f"
      unitRef="usd">85000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTUvZnJhZzo5NTczOWI5ZjE4OWU0YzEzOWRkZmZjZjI5YTBhN2U1Mi90YWJsZTo5MGNmYzZiNTUwYzQ0MmZkOTY5Nzc3YzEwZjAyZmZlMy90YWJsZXJhbmdlOjkwY2ZjNmI1NTBjNDQyZmQ5Njk3NzdjMTBmMDJmZmUzXzQyLTQtMS0xLTEwOTg3Ng_bce30055-c0f4-4c78-8031-da2b831d4308"
      unitRef="usd">0</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTUvZnJhZzo5NTczOWI5ZjE4OWU0YzEzOWRkZmZjZjI5YTBhN2U1Mi90YWJsZTo5MGNmYzZiNTUwYzQ0MmZkOTY5Nzc3YzEwZjAyZmZlMy90YWJsZXJhbmdlOjkwY2ZjNmI1NTBjNDQyZmQ5Njk3NzdjMTBmMDJmZmUzXzQzLTItMS0xLTEwOTg3Ng_870e5dc1-6f3a-44c9-b5e6-380850123fdc"
      unitRef="usd">7000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTUvZnJhZzo5NTczOWI5ZjE4OWU0YzEzOWRkZmZjZjI5YTBhN2U1Mi90YWJsZTo5MGNmYzZiNTUwYzQ0MmZkOTY5Nzc3YzEwZjAyZmZlMy90YWJsZXJhbmdlOjkwY2ZjNmI1NTBjNDQyZmQ5Njk3NzdjMTBmMDJmZmUzXzQzLTQtMS0xLTEwOTg3Ng_50eff367-5018-48f7-8877-538c2ab5b9cf"
      unitRef="usd">-70000</us-gaap:IncomeTaxesPaidNet>
    <smmt:StockIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTUvZnJhZzo5NTczOWI5ZjE4OWU0YzEzOWRkZmZjZjI5YTBhN2U1Mi90YWJsZTo5MGNmYzZiNTUwYzQ0MmZkOTY5Nzc3YzEwZjAyZmZlMy90YWJsZXJhbmdlOjkwY2ZjNmI1NTBjNDQyZmQ5Njk3NzdjMTBmMDJmZmUzXzQ0LTItMS0xLTEwOTg3Ng_c1e308ab-8b5c-4ab8-82de-94e14a1c5def"
      unitRef="usd">41000</smmt:StockIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction>
    <smmt:StockIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
      contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTUvZnJhZzo5NTczOWI5ZjE4OWU0YzEzOWRkZmZjZjI5YTBhN2U1Mi90YWJsZTo5MGNmYzZiNTUwYzQ0MmZkOTY5Nzc3YzEwZjAyZmZlMy90YWJsZXJhbmdlOjkwY2ZjNmI1NTBjNDQyZmQ5Njk3NzdjMTBmMDJmZmUzXzQ0LTQtMS0xLTEwOTg3Ng_2d36a595-0151-4fdd-9980-a2d6e7d1ac0e"
      unitRef="usd">0</smmt:StockIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTUvZnJhZzo5NTczOWI5ZjE4OWU0YzEzOWRkZmZjZjI5YTBhN2U1Mi90YWJsZTo5MGNmYzZiNTUwYzQ0MmZkOTY5Nzc3YzEwZjAyZmZlMy90YWJsZXJhbmdlOjkwY2ZjNmI1NTBjNDQyZmQ5Njk3NzdjMTBmMDJmZmUzXzQ1LTItMS0xLTEwOTg3Ng_7668c0cc-3478-4e5c-b396-c9fc793558db"
      unitRef="usd">3389000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMTUvZnJhZzo5NTczOWI5ZjE4OWU0YzEzOWRkZmZjZjI5YTBhN2U1Mi90YWJsZTo5MGNmYzZiNTUwYzQ0MmZkOTY5Nzc3YzEwZjAyZmZlMy90YWJsZXJhbmdlOjkwY2ZjNmI1NTBjNDQyZmQ5Njk3NzdjMTBmMDJmZmUzXzQ1LTQtMS0xLTEwOTg3Ng_618324da-bb5a-4bc0-b0ac-50c67be573d3"
      unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:NatureOfOperations
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMjEvZnJhZzo2ZTZjZDQ3MTdjOWY0ZTZhOGI5Mzk2ZDNjYjgxOTM0Ni90ZXh0cmVnaW9uOjZlNmNkNDcxN2M5ZjRlNmE4YjkzOTZkM2NiODE5MzQ2XzY2Mjk_84ba96a4-d98d-4485-a053-4ff1f2c2d149">Nature of Business and Operations and Recent Events&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Nature of Business and Operations&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company is a biopharmaceutical company focused on the discovery, development, and commercialization of patient-, physician-, caregiver- and societal-friendly medicinal therapies intended to improve quality of life, increase life expectancy, and resolve serious unmet needs. The Company's novel mechanism pipeline of product candidates is designed with the goal to become the patient-friendly, new-era standard-of-care medicines, and to work in harmony with the human microbiome. Currently, the Company's lead product candidate, ridinilazole, is a novel first-in-class drug that is engaged in a global Phase III clinical trial program. On December 20, 2021, the Company announced topline results for the Phase III Ri-CoDIFy study evaluating ridinilazole for treating patients suffering from &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Clostridioides difficile &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;infection, also known as &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;C. difficile &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;infection, or CDI. The Company's second product candidate, SMT-738, was announced in May 2021 for combating multidrug resistant infections, specifically Carbapenem-resistant Enterobacteriaceae (&#x201c;CRE&#x201d;) infections. SMT-738 is the first of a novel class of precision antibiotics that has entered into preclinical development. The Company intends to expand its portfolio by developing further new mechanism, new era product offerings that are designed to work in harmony with the human gut microbiome in the therapeutic areas of oncology and infectious diseases. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 18, 2020, Summit Therapeutics Inc. ("Summit"), a Delaware corporation, became the successor issuer to Summit Therapeutics plc, a public limited company incorporated under the laws of England and Wales with the Registrar of Companies of England and Wales, United Kingdom ("U.K."), for certain purposes under both the Securities Act of 1933, as amended, and the Securities Exchange Act of 1934, as amended, or the Exchange Act. Such succession occurred pursuant to a statutory scheme of arrangement under U.K. law pursuant to which all Summit Therapeutics plc outstanding ordinary shares were exchanged on a five-for-one basis for newly issued shares of Summit common stock and Summit became the holding company of Summit Therapeutics plc (the predecessor registrant and former holding company) and its subsidiaries (which is referred to as the "Redomiciliation Transaction"). Concurrently, Summit Therapeutics plc was converted into a private limited company under the laws of England and Wales and renamed Summit Therapeutics Limited. In addition, the warrants and stock options to purchase shares of Summit Therapeutics plc were canceled and replacement warrants and stock options to purchase common stock in Summit Therapeutics Inc. were issued. The scheme of arrangement was accounted for as an exchange of equity interests among entities under common control. All assets and liabilities of Summit Therapeutics plc were assumed by Summit, resulting in the retention of the historical basis of accounting as if they had always been combined for accounting purposes and the historical consolidated financial statements of Summit Therapeutics plc became the historical consolidated financial statements of Summit Therapeutics Inc. All share and per share data for periods prior to the Redomiciliation Transaction in the financial statements were retroactively reflected to be presented as shares of the Company's common stock, par value $0.01 per share.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Recent Events&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 12, 2021, the Company closed its rights offering, which was fully subscribed. The Company received aggregate gross proceeds from the rights offering of $75,000 from the sale of&#x202f;14,312,976&#x202f;shares of its common stock at a price per share of $5.24. Issuance costs associated with the rights offering were immaterial. In connection with the closing of the rights offering, a promissory note, dated April 20, 2021, was issued by the Company in favor of the Company's Chairman, Chief Executive Officer, and the beneficial owner of approximately 70% of its outstanding common stock prior to this rights offering, Robert W. Duggan, in the principal amount of $55,000,&#x202f;matured and became due and the Company repaid all principal and accrued interest thereunder using a portion of the proceeds from the rights offering. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 11, 2021, based on a thorough review of the design and enrollment status of its two ongoing blinded Phase III Ri-CoDIFy trials, the Company announced that it combined its two blinded pivotal Phase III clinical trials evaluating ridinilazole versus vancomycin into a single study and presented this decision to the United States ("U.S.") Food and Drug Administration (the "FDA") as such. During September 2021, the Company received feedback from the FDA that the FDA did not agree with the change to the primary endpoint that the Company proposed and subsequently implemented in its ongoing Phase III Ri-CoDIFy studies when combining the trials.  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 20, 2021, the Company announced topline results for the Phase III Ri-CoDIFy study evaluating ridinilazole, for the treatment of and Sustained Clinical Response (&#x201c;SCR&#x201d;), as defined below, for patients suffering from&#x202f;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;C. difficile&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x202f;infection ("&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;C. diff.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x202f;infection" or "CDI"). The study showed that ridinilazole resulted in a numerically higher SCR rate than vancomycin, but did not meet the study&#x2019;s primary endpoint for superiority. The pivotal Phase III clinical trial consisted of two Phase III clinical trials combined into a single study, designed to assess, as the primary endpoint, the superiority of ridinilazole compared to vancomycin in SCR, which is defined as clinical response of the treated episode of CDI and no recurrence of CDI through 30 days after the end of treatment. Additional endpoints included safety, tolerability, analyses of the gut microbiome and metabolome, in addition to quality of life and health economic outcome measures. We are in the process of evaluating the future path forward with respect to ridinilazole, including potential partnership opportunities.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 10, 2022, the Company&#x2019;s Chief Executive Officer, Robert W. Duggan, entered into a Note Purchase Agreement (the &#x201c;2022 Note&#x201d;), pursuant to which he has loaned the Company $25,000 in exchange for the issuance by the Company of an unsecured promissory note in the amount of $25,000. The 2022 Note is to accrue interest at a rate per annum equal to the prime rate as reported in the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Wall Street Journal&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which is 3.25% as of the effective date. The 2022 Note becomes due upon the earlier of (i) the consummation of a registered public offering with net proceeds of no less than $25,000 or (ii) 18 months from the date of issuance of the 2022 Note.&lt;/span&gt;&lt;/div&gt;</us-gaap:NatureOfOperations>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMjEvZnJhZzo2ZTZjZDQ3MTdjOWY0ZTZhOGI5Mzk2ZDNjYjgxOTM0Ni90ZXh0cmVnaW9uOjZlNmNkNDcxN2M5ZjRlNmE4YjkzOTZkM2NiODE5MzQ2XzM0MTY_52a38653-2c20-4ee8-80f9-ba6681bde813"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="idb475943c8884e52b4a61d6e77d4d205_D20210512-20210512"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMjEvZnJhZzo2ZTZjZDQ3MTdjOWY0ZTZhOGI5Mzk2ZDNjYjgxOTM0Ni90ZXh0cmVnaW9uOjZlNmNkNDcxN2M5ZjRlNmE4YjkzOTZkM2NiODE5MzQ2XzM2MDU_21b2490e-4593-4c9e-a054-0e2ce6249258"
      unitRef="usd">75000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="idb475943c8884e52b4a61d6e77d4d205_D20210512-20210512"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMjEvZnJhZzo2ZTZjZDQ3MTdjOWY0ZTZhOGI5Mzk2ZDNjYjgxOTM0Ni90ZXh0cmVnaW9uOjZlNmNkNDcxN2M5ZjRlNmE4YjkzOTZkM2NiODE5MzQ2XzM2MjU_40b162d0-4b67-4140-8246-5c95c6ef6159"
      unitRef="shares">14312976</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i28fe3cc419e94f789497abebbcb3acff_I20210512"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMjEvZnJhZzo2ZTZjZDQ3MTdjOWY0ZTZhOGI5Mzk2ZDNjYjgxOTM0Ni90ZXh0cmVnaW9uOjZlNmNkNDcxN2M5ZjRlNmE4YjkzOTZkM2NiODE5MzQ2XzM2Nzk_0ab45cce-777b-40f1-baf0-b2de03f6bdc0"
      unitRef="usdPerShare">5.24</us-gaap:SaleOfStockPricePerShare>
    <smmt:RelatedPartyTransactionBeneficialOwnershipPercentage
      contextRef="i9e4481b351c140ec829740b8f3c87fca_I20210511"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMjEvZnJhZzo2ZTZjZDQ3MTdjOWY0ZTZhOGI5Mzk2ZDNjYjgxOTM0Ni90ZXh0cmVnaW9uOjZlNmNkNDcxN2M5ZjRlNmE4YjkzOTZkM2NiODE5MzQ2XzM5NzY_b7dc3a82-2292-4416-a463-77f364e614f8"
      unitRef="number">0.70</smmt:RelatedPartyTransactionBeneficialOwnershipPercentage>
    <us-gaap:NotesPayableRelatedPartiesCurrentAndNoncurrent
      contextRef="i9d8f0174c08f45cab10ea87b88a0b06d_I20210420"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMjEvZnJhZzo2ZTZjZDQ3MTdjOWY0ZTZhOGI5Mzk2ZDNjYjgxOTM0Ni90ZXh0cmVnaW9uOjZlNmNkNDcxN2M5ZjRlNmE4YjkzOTZkM2NiODE5MzQ2XzQwODc_cd062013-e3ae-4b41-83a9-cc20f9f28bca"
      unitRef="usd">55000000</us-gaap:NotesPayableRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:ProceedsFromRelatedPartyDebt
      contextRef="idf7a081c7b9c4705a95c5f2ab53d19bb_D20220310-20220310"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMjEvZnJhZzo2ZTZjZDQ3MTdjOWY0ZTZhOGI5Mzk2ZDNjYjgxOTM0Ni90ZXh0cmVnaW9uOjZlNmNkNDcxN2M5ZjRlNmE4YjkzOTZkM2NiODE5MzQ2XzYxODA_69138b23-a984-44ed-9f22-fd824b580d4b"
      unitRef="usd">25000000</us-gaap:ProceedsFromRelatedPartyDebt>
    <us-gaap:NotesPayableRelatedPartiesCurrentAndNoncurrent
      contextRef="id74d06c0cec74c7fa7641c591943da88_I20220310"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMjEvZnJhZzo2ZTZjZDQ3MTdjOWY0ZTZhOGI5Mzk2ZDNjYjgxOTM0Ni90ZXh0cmVnaW9uOjZlNmNkNDcxN2M5ZjRlNmE4YjkzOTZkM2NiODE5MzQ2XzYyNzY_8d5360bb-1df5-46b7-85b8-71efccc7c96f"
      unitRef="usd">25000000</us-gaap:NotesPayableRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:RelatedPartyTransactionRate
      contextRef="idf7a081c7b9c4705a95c5f2ab53d19bb_D20220310-20220310"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMjEvZnJhZzo2ZTZjZDQ3MTdjOWY0ZTZhOGI5Mzk2ZDNjYjgxOTM0Ni90ZXh0cmVnaW9uOjZlNmNkNDcxN2M5ZjRlNmE4YjkzOTZkM2NiODE5MzQ2XzY0MDk_2d605ab6-a553-4e44-8921-654e4bceff98"
      unitRef="number">0.0325</us-gaap:RelatedPartyTransactionRate>
    <smmt:NotesPayableRelatedPartiesMaturityTriggeringEventPublicOfferingProceedsThreshold
      contextRef="idf7a081c7b9c4705a95c5f2ab53d19bb_D20220310-20220310"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMjEvZnJhZzo2ZTZjZDQ3MTdjOWY0ZTZhOGI5Mzk2ZDNjYjgxOTM0Ni90ZXh0cmVnaW9uOjZlNmNkNDcxN2M5ZjRlNmE4YjkzOTZkM2NiODE5MzQ2XzY1NzE_9c9d674c-41f3-44fd-b07b-fa148e8b1101"
      unitRef="usd">25000000</smmt:NotesPayableRelatedPartiesMaturityTriggeringEventPublicOfferingProceedsThreshold>
    <smmt:NotesPayableRelatedPartiesMaximumTerm
      contextRef="idf7a081c7b9c4705a95c5f2ab53d19bb_D20220310-20220310"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMjEvZnJhZzo2ZTZjZDQ3MTdjOWY0ZTZhOGI5Mzk2ZDNjYjgxOTM0Ni90ZXh0cmVnaW9uOjZlNmNkNDcxN2M5ZjRlNmE4YjkzOTZkM2NiODE5MzQ2XzY1ODI_65a644fe-f3b7-4ee6-9ad6-9675b5620b7a">P18M</smmt:NotesPayableRelatedPartiesMaximumTerm>
    <us-gaap:BasisOfAccounting
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMjcvZnJhZzpjY2ZhZTllM2U4YWE0YmQ4YTM1NTg2ODc4MmU3NDc5MS90ZXh0cmVnaW9uOmNjZmFlOWUzZThhYTRiZDhhMzU1ODY4NzgyZTc0NzkxXzE5NzM_085ad767-c2ad-4dba-b1e1-b2d010b4401d">Basis of Presentation and Use of Estimates &lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements include the accounts of Summit Therapeutics Inc. and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States ("U.S. GAAP") and pursuant to the rules and regulations of the U.S. Securities and Exchange Commission. The preparation of these financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. On an on-going basis, management evaluates its estimates and judgments, including those related to revenue recognition, accrued research and development expenses, stock-based compensation, intangible assets, goodwill, other long-lived assets and income taxes. Management bases its estimates and judgments on historical experience and on various other factors that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The progression of the COVID-19 pandemic continues to evolve and its enduring impact on the Company's business remains uncertain. Management believes the estimates and assumptions underlying its financial statements are reasonable and supportable based on the information available as of December 31, 2021, however, the extent to which the COVID-19 pandemic impacts the Company's financial results beyond December 31, 2021 will depend on future developments that are highly uncertain and cannot be predicted at this time.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccounting>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMjcvZnJhZzpjY2ZhZTllM2U4YWE0YmQ4YTM1NTg2ODc4MmU3NDc5MS90ZXh0cmVnaW9uOmNjZmFlOWUzZThhYTRiZDhhMzU1ODY4NzgyZTc0NzkxXzE5NzQ_e27502bd-b6ad-4c3a-a7eb-c0545d829087">The consolidated financial statements include the accounts of Summit Therapeutics Inc. and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.The consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States ("U.S. GAAP") and pursuant to the rules and regulations of the U.S. Securities and Exchange Commission.</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMjcvZnJhZzpjY2ZhZTllM2U4YWE0YmQ4YTM1NTg2ODc4MmU3NDc5MS90ZXh0cmVnaW9uOmNjZmFlOWUzZThhYTRiZDhhMzU1ODY4NzgyZTc0NzkxXzE5NzU_83217f43-11fb-4ffd-8d8e-8f727d773307">The preparation of these financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. On an on-going basis, management evaluates its estimates and judgments, including those related to revenue recognition, accrued research and development expenses, stock-based compensation, intangible assets, goodwill, other long-lived assets and income taxes. Management bases its estimates and judgments on historical experience and on various other factors that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of the consolidated financial statements in conformity with U.S. GAAP requires the use of estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <smmt:LiquidityAndCapitalResourcesTextBlock
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMzAvZnJhZzo3YzQxNzNjZTE2NjI0YzlhOTQwMzc1NmU5NzUwZGYxZS90ZXh0cmVnaW9uOjdjNDE3M2NlMTY2MjRjOWE5NDAzNzU2ZTk3NTBkZjFlXzIxMzM_2fa0c652-5801-4674-a185-ed826b3029f3">Liquidity and Capital Resources&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December 31, 2021, the Company incurred a net loss of $88,602 and cash flows used in operating activities was $72,587. As of December 31, 2021, the Company had an accumulated deficit of $299,548, cash of $71,791, research and development tax credit receivable of $15,695 and accounts receivable of $1,464. The Company expects to continue to generate operating losses for the foreseeable future. Until the Company can generate substantial revenue and achieve profitability, the Company will need to raise additional capital to fund its ongoing operations and capital needs.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Based on the Company's current funding arrangements and financial resources as of December 31, 2021, and after considering proceeds received of $25,000 from the 2022 Note issued on March 10, 2022, the Company has the ability to fund its operating costs and working capital needs for more than twelve months from the date of issuance. In order to continue to fund the operations of the Company beyond this time period, management has developed plans, which primarily consist of raising additional capital through some combination of equity or debt financings, and/or potentially entering into new collaborations. There is no assurance, however, that additional financing will be available when needed or that management of the Company will be able to obtain financing on terms acceptable to the Company. If the Company is unable to obtain funding when required &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in the future, the Company could be required to delay, reduce, or eliminate research and development programs, product portfolio expansion, or future commercialization efforts, which could adversely affect its business prospects.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying consolidated financial statements are prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of the business. The consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classifications of liabilities that might result from the outcome of this uncertainty.&lt;/span&gt;&lt;/div&gt;</smmt:LiquidityAndCapitalResourcesTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMzAvZnJhZzo3YzQxNzNjZTE2NjI0YzlhOTQwMzc1NmU5NzUwZGYxZS90ZXh0cmVnaW9uOjdjNDE3M2NlMTY2MjRjOWE5NDAzNzU2ZTk3NTBkZjFlXzc0_88817334-2a0a-4d14-8d95-01f45f5f32ac"
      unitRef="usd">-88602000</us-gaap:NetIncomeLoss>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMzAvZnJhZzo3YzQxNzNjZTE2NjI0YzlhOTQwMzc1NmU5NzUwZGYxZS90ZXh0cmVnaW9uOjdjNDE3M2NlMTY2MjRjOWE5NDAzNzU2ZTk3NTBkZjFlXzEyNQ_d9cbbf0c-8109-435d-8583-f5d178f3bb39"
      unitRef="usd">-72587000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMzAvZnJhZzo3YzQxNzNjZTE2NjI0YzlhOTQwMzc1NmU5NzUwZGYxZS90ZXh0cmVnaW9uOjdjNDE3M2NlMTY2MjRjOWE5NDAzNzU2ZTk3NTBkZjFlXzE5Ng_f73ae28a-8f82-41fe-bce9-96e342bd3f65"
      unitRef="usd">-299548000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:Cash
      contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMzAvZnJhZzo3YzQxNzNjZTE2NjI0YzlhOTQwMzc1NmU5NzUwZGYxZS90ZXh0cmVnaW9uOjdjNDE3M2NlMTY2MjRjOWE5NDAzNzU2ZTk3NTBkZjFlXzIwOA_938f73fe-cc51-4467-b71f-865f0646e134"
      unitRef="usd">71791000</us-gaap:Cash>
    <smmt:ResearchAndDevelopmentTaxCreditReceivable
      contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMzAvZnJhZzo3YzQxNzNjZTE2NjI0YzlhOTQwMzc1NmU5NzUwZGYxZS90ZXh0cmVnaW9uOjdjNDE3M2NlMTY2MjRjOWE5NDAzNzU2ZTk3NTBkZjFlXzI2Mg_49dd8d0d-b1e2-4e59-88a4-a9daf39356f2"
      unitRef="usd">15695000</smmt:ResearchAndDevelopmentTaxCreditReceivable>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMzAvZnJhZzo3YzQxNzNjZTE2NjI0YzlhOTQwMzc1NmU5NzUwZGYxZS90ZXh0cmVnaW9uOjdjNDE3M2NlMTY2MjRjOWE5NDAzNzU2ZTk3NTBkZjFlXzI5Mg_f05d968b-a341-4acb-9e1d-b7c3441f5a7d"
      unitRef="usd">1464000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:ProceedsFromRelatedPartyDebt
      contextRef="idf7a081c7b9c4705a95c5f2ab53d19bb_D20220310-20220310"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMzAvZnJhZzo3YzQxNzNjZTE2NjI0YzlhOTQwMzc1NmU5NzUwZGYxZS90ZXh0cmVnaW9uOjdjNDE3M2NlMTY2MjRjOWE5NDAzNzU2ZTk3NTBkZjFlXzcwNw_e99bb308-06bb-46ed-bdfa-baa9fb15ba75"
      unitRef="usd">25000000</us-gaap:ProceedsFromRelatedPartyDebt>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMzMvZnJhZzpiZjJiYmY2YmZlMGU0MzY4YjE5YjYxN2ExNDJjYTNmMi90ZXh0cmVnaW9uOmJmMmJiZjZiZmUwZTQzNjhiMTliNjE3YTE0MmNhM2YyXzM2MTY2_95019874-889b-4d86-97a6-feee28d1bbaa">Summary of Significant Accounting Policies&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The significant accounting policies adopted by the Company in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Principles of Consolidation &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;) and pursuant to the rules and regulations of the U.S. Securities and Exchange Commission. The consolidated financial statements include the accounts of Summit Therapeutics Inc. and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of the consolidated financial statements in conformity with U.S. GAAP requires the use of estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Foreign Currency Translation&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The financial statements of the Company&#x2019;s subsidiaries with functional currencies other than the U.S. dollar are translated into U.S. dollars using period-end exchange rates for assets and liabilities, historical exchange rates for stockholders&#x2019; equity and weighted average exchange rates for operating results. Translation gains and losses are included in accumulated other comprehensive (loss) income in shareholders&#x2019; equity. Foreign currency transaction gains and losses are included in other (expense) income, net in the results of operations. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company recorded realized and unrealized foreign currency transaction (losses) gains of $(2,135) and $54 for the years ended December 31, 2021 and 2020, respectively, which is included in other (expense) income in the statements of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:103%"&gt;Revenue Recognition &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for revenue using Accounting Standards Codification ("ASC") 606 ("ASC 606"). This standard applies to all contracts with customers, except for contracts that are within the scope of other standards.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company enters into out-licensing agreements within the scope of ASC 606 under which it licenses certain rights to its product candidates to third parties. Such agreements may include the transfer of intellectual property rights in the form of licenses, transfer of technological know-how, delivery of drug substances, research and development services, and participation on certain committees with the counterparty. Payments made by the customers may include one or more of the following: non-refundable, up-front license fees; development, regulatory, and commercial milestone payments; payments for manufacturing supply services the Company provides through its contract manufacturers; and royalties on net sales of licensed products if they are successfully approved and commercialized. Each of these payments may result in license, collaboration, or other revenue, except revenue from royalties on net sales of licensed products, which would be classified as royalty revenue.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In determining the appropriate amount of revenue to be recognized as the Company fulfills its obligations under each of its out-licensing agreements, the following steps are performed: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations and assesses whether each promised good or service is distinct. Revenue is then recognized in respect of the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. As part of the accounting for these arrangements, the Company must use significant judgment to determine: (a) the performance obligations based on the determination under step (ii) above; (b) the transaction price under step (iii) above; and (c) the standalone selling price for each performance obligation identified in the contract for the allocation of transaction price in step (iv) above. The Company also uses judgment to determine whether milestone payments or other variable consideration, except for royalties and sales-based milestones, should be included in the transaction price, as described below. The transaction price is allocated to each performance obligation based on the relative standalone selling price of each performance obligation in the contract, and the Company recognizes revenue based on those amounts when, or as, the performance obligations under the contract are satisfied.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Exclusive Licenses&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If the license to the Company&#x2019;s intellectual property is determined to be distinct from the other promises or performance obligations identified in the arrangement, the Company recognizes revenue from nonrefundable, upfront fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. In assessing whether a promise or performance obligation is distinct from the other promises, the Company considers factors such as the research, development, manufacturing and commercialization capabilities of the collaboration partner and the availability of the associated expertise in the general marketplace. In addition, the Company considers whether the collaboration partner can benefit from a promise for its intended purpose without the receipt of the remaining promises, whether the value of the promise is dependent on the unsatisfied promises, whether there are other vendors that could provide the remaining promises, and whether it is separately identifiable from the remaining promises. For licenses that are combined with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of progress and related revenue recognition. The measure of progress, and the resulting periods over which revenue should be recognized, are subject to estimates by management and may change over the course of the research, development and licensing arrangement. Such a change could have a material impact on the amount of revenue the Company records in future periods. Under the Company&#x2019;s existing license and collaboration agreements, the Company has concluded that the transfer of control to the customer occurs over the time period that the research and development services are to be provided by the Company, and this output method is, in management&#x2019;s judgment, the best measure of progress towards satisfying the performance obligation.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Milestone Payments&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the inception of each arrangement that includes potential research, development or regulatory milestone payments, the Company evaluates whether the milestones are considered likely to be met and estimates the amount to be considered for inclusion in the transaction price using the most-likely-amount method. If it is probable that a significant reversal in the amount of cumulative revenue recognized would not occur, the associated milestone payment value is included in the transaction price. For milestone payments due upon events that are not within the control of the Company or the licensee, such as regulatory approvals, the Company is not able to assert that it is likely that the regulatory approval will be granted and that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur until those approvals are received. In making this assessment, the Company evaluates factors such as the scientific, clinical, regulatory, commercial and other risks that must be overcome to achieve the particular milestone. There is considerable judgment involved in determining whether it is probable that a significant reversal in the amount of cumulative revenue recognized would not occur. At the end of each subsequent reporting period, the Company reevaluates the probability of achievement of all milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price of the arrangement. Any such adjustments are recorded on a cumulative catch-up basis, which would affect the amounts of revenue and earnings in the period of adjustment.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Royalties&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For arrangements that include sales-based royalties, including milestone payments due upon first commercial sales or based on a level of sales, that are the result of a customer-vendor relationship and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) the occurrence of the related sales or (ii) the date upon which the performance obligation to which some or all of the royalty has been allocated has been satisfied or partially satisfied. To date, the Company has not recognized any royalty revenue from any of its licensing arrangements.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Other Operating Income&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company generates income from government contracts that reimburse the Company for certain allowable costs for funded projects. For contracts with government agencies where the funding arrangement is considered central to the Company&#x2019;s ongoing operations, the Company classifies the recognized funding received as other operating income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income from government grants is recognized as the qualifying expenses related to the contracts are incurred, provided that there is reasonable assurance of recoverability. If the government agency approves the project proposed by the Company, the government agency funds the project upon receipt of the support for the costs incurred up to the contract limit. Income recognized upon incurring qualifying expenses in advance of billing is recorded as accrued income, a component of other current assets, in the consolidated balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Grant income is not recognized as deductions of research and development costs because the Company acts as the principal in conducting the research and development activities and these contracts are central to its ongoing operations. The funds received through these means are held as deferred income in the consolidated balance sheets and are released to the consolidated statement of operations and comprehensive loss as the underlying expenditure is incurred and to the extent the conditions of the grant are met. The related costs incurred by the Company are included in research and development expense in the Company&#x2019;s consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company benefits from two U.K. research and development ("R&amp;amp;D") tax credit cash rebate regimes: Small and Medium Enterprise ("SME") Program and the Research and Development Expenditure Credit ("RDEC") Program. Each reporting period, management evaluates which tax relief programs the Company is expected to be eligible for and records as other operating income the portion of the expense that it expects to qualify under the programs, that it plans to submit a claim for, and it has reasonable assurance that the amount will ultimately be realized. Based on criteria established by HM Revenue and Customs (&#x201c;HMRC&#x201d;), management of the Company expects a proportion of expenditures being undertaken in relation to its pipeline research, clinical trials management and manufacturing development activities to be eligible for the research and development tax relief programs for the year ended December 31, 2021. Qualifying expenditures largely comprise of employment costs for research staff, consumables, a proportion of relevant, permitted sub-contract costs and certain internal overhead costs incurred as part of research projects for which the Company does not receive commercial or other funding income. Credits related to the SME and RDEC Programs are recorded as other operating income in the consolidated statements of operations and other comprehensive (loss)/income. Under both schemes, the Company receives cash rebate payments of up to 33.3% of eligible research and development expenditures and these payments are not dependent on the Company&#x2019;s pre-tax net income levels. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company has qualified under the more favorable SME regime for the year ended December 31, 2020 and expects to qualify under the SME regime for the year ending December 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Net Income Per Share&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Basic net loss per share is computed by dividing the net loss by the weighted-average number of common shares outstanding for the period. Diluted net loss per share is computed by dividing the diluted net loss by the weighted-average number of common shares outstanding for the period, including potentially dilutive common shares. The dilutive effect of share options and warrants are determined under the treasury stock method using the average market price for the period.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In addition, the assumed proceeds under the treasury stock method include the average unrecognized compensation expense of stock options and warrants that are in-the-money.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Business Combinations &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Business combinations are accounted for under the acquisition method. Acquired assets and assumed liabilities are measured at their fair values at the acquisition date. The excess of the consideration transferred over the net fair value of assets acquired and liabilities assumed is recorded as goodwill. The accounting for an acquisition involves a considerable amount of judgement and estimation. Cost, income, market or a combination of approaches may be used to establish the fair value of consideration exchanged, assets acquired, and liabilities assumed, depending on the nature of those items.  The valuation approach is &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;determined in accordance with generally accepted valuation methods. Key areas of estimation and judgment may include the selection of valuation approaches, cost of capital, market characteristics, cost structure, impacts of synergies, and estimates of terminal value, among other factors.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;While the Company uses estimates and assumptions as part of the purchase price allocation process to estimate the value of assets acquired and liabilities assumed, estimates are inherently uncertain and subject to refinement. During the measurement period, which maybe up to one year from the acquisition date, the Company may record adjustments to the assets acquired and liabilities assumed, with a corresponding offset to goodwill, to the extent that adjustments are identified to the preliminary purchase price allocation. Upon conclusion of the measurement period, or final determination of the value of the assets acquired and liabilities assumed, whichever comes first, any subsequent adjustments are recorded to results of operations. Results of operations related to business combinations are included prospectively beginning with the date of acquisition and transaction costs related to business combinations are recorded within general and administrative expenses. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:102%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill represents the excess of the consideration transferred over the fair value of net assets acquired. Goodwill is assigned to reporting units at the time of acquisition or when there is a change in the reporting structure and bases that allocation on which reporting units will benefit from the acquired assets and liabilities. Reporting units are defined as operating segments or one level below an operating segment, referred to as a component. The Company assesses goodwill for impairment on an annual basis or more frequently when events and circumstances occur indicating that the recorded goodwill may be impaired.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In performing the Company&#x2019;s annual goodwill impairment test, the Company is permitted to first assess qualitative factors to determine whether it is more likely than not that the fair value of the Company&#x2019;s reporting unit is less than its carrying amount, including goodwill. In performing the qualitative assessment, the Company considers certain events and circumstances specific to the reporting unit and to the entity as a whole, such as macroeconomic conditions, industry and market considerations, overall financial performance and cost factors when evaluating whether it is more likely than not that the fair value of the reporting unit is less than its carrying amount. The Company is also permitted to bypass the qualitative assessment and proceed directly to the quantitative test. If the Company chooses to undertake the qualitative assessment and concludes that it is more likely than not that the fair value of the reporting unit is less than its carrying amount, the Company would then proceed to the quantitative impairment test. In the quantitative assessment, the Company compares the fair value of the reporting unit to its carrying amount, which includes goodwill. If the fair value exceeds the carrying value, no impairment loss exists. If the fair value is less than the carrying amount, a goodwill impairment loss is measured and recorded.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2021, the Company performed its annual impairment assessment of goodwill by performing a qualitative analysis for its single identified reporting unit for goodwill and determined that it is more likely than not that the fair value of the reporting unit exceeded its carrying amount. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Intangible Assets &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets include patents, licenses, an option over non-financial assets and a research and development discovery platform ("Discuva Platform").&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Patents, licenses, and the option over non-financial assets are initially recorded at fair value, assigned an estimated useful life, and amortized primarily on a straight-line basis over their estimated useful lives. The Company evaluates the recoverability of its intangible and long-lived assets whenever events and changes in circumstances indicate that the carrying amount of an asset may not be fully recoverable. If events and circumstances indicate that the carrying amount may not fully be recoverable, the Company will perform a qualitative assessment, and consider certain events and circumstances specific to the intangible asset and to the entity as a whole, such as macroeconomic conditions, industry and market considerations, overall financial performance and cost factors when evaluating whether it is more likely than not that the fair value of the intangible asset is less than its carrying amount. This periodic review may result in an adjustment of estimated depreciable lives or asset impairment. When indicators of impairment are present, the carrying values of the asset are evaluated in relation to their operating performance and future undiscounted cash flows of the underlying business. If the future undiscounted cash flows are less than their carrying value, impairment exists. The impairment is measured as the difference between the carrying value and the fair &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;value of the underlying asset. Fair values are based on estimates of market prices and assumptions concerning the amount and timing of estimated future cash flows and assumed discount rates, reflecting varying degrees of perceived risk.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other intangible assets are amortized in equal installments over their estimated useful lives as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.057%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.455%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.188%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Intangible Asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortization Period&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Option over non-financial assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Over the period of the relevant agreement&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization of intangible assets is included as part of the research and development expense line shown on the face of the consolidated statement of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Property and Equipment &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment are stated at cost less accumulated depreciation. Cost comprises the purchase price plus any incidental costs of acquisition and commissioning. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation is calculated based on cost, less residual value, in equal annual installments over the estimated useful lives of the assets. The residual value, if not insignificant, is reassessed annually.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.057%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.743%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Over the shorter of the asset's useful life or the remaining lease term&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2-10 years &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Office and IT equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3-5 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation is recognized as part of the general and administrative and research and development expense lines shown on the face of the consolidated statement of operations and comprehensive loss depending on the nature of the underlying assets.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expenditures for repairs and maintenance are expensed as incurred. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation are removed from the accounts and any resulting gain or loss is included in loss from operations.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has operating leases for real estate. The Company does not have any finance leases. Under Accounting Standards Codification 842, a contract is or contains a lease when the lessee has the right to control the use of an identified asset. The Company determines if an arrangement is a lease at inception of the contract, which is the date on which the terms of the contract are agreed to and the agreement creates enforceable rights and obligations. The lease term used to calculate the lease liability include options to extend or terminate the lease when it is reasonably certain that the option will be exercised.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the lease commencement date, the Company measures and recognizes a lease liability and a right-of-use asset in the financial statements. Lease liabilities are recognized based on the present value of the future lease payments over the lease term at commencement date. The right-of use asset is measured by taking the present value of future lease payments, plus any incremental direct costs incurred, less any lease incentives received. As most of the Company's leases do not provide an implicit rate, the Company uses an estimated incremental borrowing rate based on the lease term and the economic environment of the lease at the lease commencement date, which is then utilized to determine the present value of future lease payments. Lease expense for minimum lease payments are recognized on a straight-line basis over the lease term, with variable lease payments recognized in the periods in which they are incurred.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has existing lease agreements with lease and non-lease components, has elected to account for the lease and non-lease components as a single lease component, and has allocated all of the contract consideration to the lease component only. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Leases with an initial lease term of 12 months or less are not recorded on the balance sheet. The Company recognizes lease expense for its short-term leases on a straight-line basis over the lease term.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Research and Development Costs&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development costs are expensed as incurred. Research and development expenses consist of costs incurred to discover, research and develop product candidates, including personnel expenses, stock-based compensation expense, allocated facility-related and depreciation expenses, third-party license fees and external costs of outside vendors engaged to conduct preclinical and clinical development activities and clinical trials as well as to manufacture clinical trial materials. Non - refundable prepayments for goods or services that will be used or rendered for future research and development activities are recorded as prepaid expenses. Such amounts are recognized as an expense as the goods are delivered or the related services are performed, or until it is no longer expected that the goods will be delivered, or the services rendered. Milestone and other payments made to third-parties with respect to in-process research and development, in accordance with the Company&#x2019;s license, acquisition and other similar agreements are expensed when determined to be probable and estimable.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has entered into various research and development contracts with other companies. These agreements are generally cancellable, and related payments are recorded as research and development expenses as incurred. The Company records accruals for estimated ongoing research and development costs or prepaid expenses where the payments made exceeds the estimated costs. When evaluating the adequacy of these balances, the Company analyzes progress of the studies, including the estimated costs to complete each study or activity, the estimation of the current stage of completion and the invoices received, as well as predetermined milestones which are not reflective of the current stage of development for prepaid expenses. Actual results could differ from the Company&#x2019;s estimates. In all cases, the full cost of each study or activity is expensed by the time the final report or where applicable, product, has been received. The Company&#x2019;s historical estimates have not been materially different from the actual costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Stock-Based Compensation &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company measures and recognizes compensation expense for all stock option and restricted stock unit awards based on the estimated fair value of the award on the grant date. The Company uses the Black-Scholes option pricing model to estimate the fair value of stock option awards. The fair value is recognized as expense, over the requisite service period, which is generally the vesting period of the respective award, on a straight-line basis for each separately vesting portion of the award when the only condition to vesting is continued service.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If vesting is subject to a market or performance condition, recognition is based on the derived service period of the award. Expense for awards with performance conditions is estimated and adjusted on a quarterly basis based upon the assessment of the probability that the performance condition will be met. Use of the Black-Scholes option-pricing model requires management to apply judgment under highly subjective assumptions.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These assumptions include:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Expected term&#x2014;The expected term of stock options represents the weighted-average period the stock options are expected to be outstanding. The Company uses the simplified method for estimating the expected term as provided by the Securities and Exchange Commission. The simplified method calculates the expected term as the average of the time-to-vesting and the contractual life of the options.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Expected volatility&#x2014;The expected volatility was calculated based on historical volatility of the Company's share price.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Risk-free interest rate&#x2014;The risk-free rate assumption is based on the U.S. Treasury instruments, the terms of which were consistent with the expected term of the Company&#x2019;s stock options.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Expected dividend&#x2014;The expected dividend assumption is based on the Company&#x2019;s history and expectation of dividend payouts. The Company has not paid and does not intend to pay dividends. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company estimates expected forfeitures at the time of grant instead of accounting for forfeitures as they occur. Stock option and restricted stock unit awards have been granted at fair value to non-employees, in connection with research and consulting services provided to the Company, to non-employees in connection with corporate activities, and to employees, in connection with Stock Purchase and Restriction Agreements. Equity awards generally vest over terms of 3 or 4 years. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The provision for income taxes is determined using the asset and liability approach. Tax laws may require items to be included in tax filings at different times than the items are reflected in the financial statements. A current asset or liability is recognized for the estimated taxes receivable or payable for the current year. Deferred taxes represent the future tax consequences expected to occur when the reported amounts of assets and liabilities are recovered or paid. Deferred taxes are initially recognized at enacted tax rates in force at the time of initial recognition and are subsequently adjusted for any enacted changes in tax rates and tax laws. Subsequent changes to deferred taxes originally recognized in equity are recognized in income. Valuation allowances are recorded to reduce deferred tax assets when it is more likely than not that a tax benefit will not be realized. The Company has recorded a full valuation allowance against the deferred tax assets in excess of its deferred tax liabilities, as the deferred tax liability represents future reversals of existing taxable temporary differences. The Company records interest and penalties related to income tax matters as part of income tax expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Concentration of Credit Risk and of Significant Supplier&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of short-term cash deposits and accounts and other receivables. The Company's cash is comprised of short-term cash deposits at a variety of financial institutions with strong credit ratings in amounts that may exceed federally insured limits and has not experienced any losses on such accounts. Cash balances maintained during the year have been principally held with reputable U.K.-based and U.S.-based banks. The Company does not believe it is exposed to any unusual credit risk beyond the normal credit risk associated with commercial banking relationships.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company maintains deposits in accredited financial institutions in excess of federally insured limits. The Company deposits its cash in financial institutions that it believes have high credit quality and has not experienced any losses on such accounts and does not believe it is exposed to any unusual credit risk beyond the normal credit risk associated with commercial banking relationships.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The credit risk with respect to customers and funding bodies is limited as the Company has only a small number of these arrangements, including with Eurofarma, BARDA and CARB-X. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company relies, and expects to continue to rely, on a number of vendors to conduct its clinical trials and preclinical studies, manufacture drug product and supply clinical trial and preclinical study materials for its development programs. These programs could be adversely affected by a significant interruption in these services or the availability of materials.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:103%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accordance with the provisions of fair value accounting, a fair value measurement assumes that the transaction to sell an asset or transfer a liability occurs in the principal market for the asset or liability or, in the absence of a principal market, the most advantageous market for the asset or liability and defines fair value based on the exit price model.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value measurement guidance establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The guidance describes three levels of inputs that may be used to measure fair value:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Level 1&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Quoted prices in active markets for identical assets or liabilities as of the reporting date. Active markets are those in which transactions for the asset or liability occur in sufficient frequency and volume to provide pricing information on an ongoing basis.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Level 2&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 2 assets and liabilities include debt securities with quoted prices that are traded less &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;frequently than exchange-traded instruments or securities or derivative contracts that are valued using a pricing model with inputs that are observable in the market or can be derived principally from or corroborated by observable market data.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Level 3&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Level 3 assets and liabilities include financial instruments whose value is determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant management judgment or estimation.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, the Company categorizes such assets and liabilities based on the lowest level input that is significant to the fair value measurement in its entirety. The Company&#x2019;s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the asset.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Assumed Contingent Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of the acquisition of Discuva Limited in December 2017, the Company assumed certain contingent liabilities as certain employees, former employees and former directors of Discuva Limited are eligible for payments from Discuva Limited based on specified development and clinical milestones related to proprietary product candidates developed under the Discuva Platform. The timing of these potential payments is uncertain. The fair value of the assumed contingent liability was estimated using the expected value of the payments. The assumed contingent liabilities are subsequently measured at amortized cost using discounted cash flow models which calculate the risk adjusted net present values of estimated potential future cash flows of the payments. The assumed contingent liabilities are remeasured when there is a specific significant event that provides evidence of a significant change in the probability of successful development and clinical milestones being achieved. The models will be updated for changes in the probability of successful development and clinical milestones being achieved and other associated assumptions with the discount factor remaining unchanged within the model. A discount factor of 13% has been used to discount the contingent liabilities back to net present value. This discount factor has been calculated using appropriate measures and rates which could have been obtained in the period that the contingent liabilities were assumed. Accretion of the discount factor is recognized as part of operating expenses in the consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Warrants issued by the Company are recognized and classified as equity when, upon exercise, the Company would issue a fixed amount of its own equity instruments (common stock) in exchange for a fixed amount of cash or another financial asset.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Consideration received, net of incremental costs directly attributable to the issue of such new warrants, is shown in equity. Such warrants are not remeasured at fair value in subsequent reporting periods.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Warrants issued in which external services are received as consideration for equity instruments of the company should be measured at the fair value of the goods or services received. Only if the fair value of the services cannot be measured reliably would the fair value of the equity instruments granted be used. The fair value for the warrants is calculated using the Black-Scholes formula and recorded in the consolidated statement of operations and comprehensive loss&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;on a straight-line basis over the period of the consulting services. If the services are terminated prior to the end of the consultancy agreement, the warrants cease vesting and any unvested portion of the warrants will lapse immediately.&lt;/span&gt;&lt;/div&gt;The warrants in issue are classified within stockholders&#x2019; equity as they are indexed to the Company's own shares of common stock and require settlement in its shares of common stocks with no provision for any cash settlement.</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMzMvZnJhZzpiZjJiYmY2YmZlMGU0MzY4YjE5YjYxN2ExNDJjYTNmMi90ZXh0cmVnaW9uOmJmMmJiZjZiZmUwZTQzNjhiMTliNjE3YTE0MmNhM2YyXzM2MTg0_6faf412c-6639-4412-9e9c-178c963f8a4b">Principles of Consolidation The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;) and pursuant to the rules and regulations of the U.S. Securities and Exchange Commission. The consolidated financial statements include the accounts of Summit Therapeutics Inc. and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMzMvZnJhZzpiZjJiYmY2YmZlMGU0MzY4YjE5YjYxN2ExNDJjYTNmMi90ZXh0cmVnaW9uOmJmMmJiZjZiZmUwZTQzNjhiMTliNjE3YTE0MmNhM2YyXzM2MTYy_c8362a5e-6e84-4873-94a2-73d69413ded0">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Foreign Currency Translation&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The financial statements of the Company&#x2019;s subsidiaries with functional currencies other than the U.S. dollar are translated into U.S. dollars using period-end exchange rates for assets and liabilities, historical exchange rates for stockholders&#x2019; equity and weighted average exchange rates for operating results. Translation gains and losses are included in accumulated other comprehensive (loss) income in shareholders&#x2019; equity. Foreign currency transaction gains and losses are included in other (expense) income, net in the results of operations. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company recorded realized and unrealized foreign currency transaction (losses) gains of $(2,135) and $54 for the years ended December 31, 2021 and 2020, respectively, which is included in other (expense) income in the statements of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMzMvZnJhZzpiZjJiYmY2YmZlMGU0MzY4YjE5YjYxN2ExNDJjYTNmMi90ZXh0cmVnaW9uOmJmMmJiZjZiZmUwZTQzNjhiMTliNjE3YTE0MmNhM2YyXzE3OTI_8b6063c6-c37c-40a1-8547-c2ea3121c5da"
      unitRef="usd">-2135000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMzMvZnJhZzpiZjJiYmY2YmZlMGU0MzY4YjE5YjYxN2ExNDJjYTNmMi90ZXh0cmVnaW9uOmJmMmJiZjZiZmUwZTQzNjhiMTliNjE3YTE0MmNhM2YyXzE3OTk_25987653-a9aa-460e-9c3b-ea982305372c"
      unitRef="usd">54000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMzMvZnJhZzpiZjJiYmY2YmZlMGU0MzY4YjE5YjYxN2ExNDJjYTNmMi90ZXh0cmVnaW9uOmJmMmJiZjZiZmUwZTQzNjhiMTliNjE3YTE0MmNhM2YyXzM2MTcw_88e22b51-892f-48a1-90a6-4bf11e86e6a2">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:103%"&gt;Revenue Recognition &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for revenue using Accounting Standards Codification ("ASC") 606 ("ASC 606"). This standard applies to all contracts with customers, except for contracts that are within the scope of other standards.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company enters into out-licensing agreements within the scope of ASC 606 under which it licenses certain rights to its product candidates to third parties. Such agreements may include the transfer of intellectual property rights in the form of licenses, transfer of technological know-how, delivery of drug substances, research and development services, and participation on certain committees with the counterparty. Payments made by the customers may include one or more of the following: non-refundable, up-front license fees; development, regulatory, and commercial milestone payments; payments for manufacturing supply services the Company provides through its contract manufacturers; and royalties on net sales of licensed products if they are successfully approved and commercialized. Each of these payments may result in license, collaboration, or other revenue, except revenue from royalties on net sales of licensed products, which would be classified as royalty revenue.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In determining the appropriate amount of revenue to be recognized as the Company fulfills its obligations under each of its out-licensing agreements, the following steps are performed: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations and assesses whether each promised good or service is distinct. Revenue is then recognized in respect of the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. As part of the accounting for these arrangements, the Company must use significant judgment to determine: (a) the performance obligations based on the determination under step (ii) above; (b) the transaction price under step (iii) above; and (c) the standalone selling price for each performance obligation identified in the contract for the allocation of transaction price in step (iv) above. The Company also uses judgment to determine whether milestone payments or other variable consideration, except for royalties and sales-based milestones, should be included in the transaction price, as described below. The transaction price is allocated to each performance obligation based on the relative standalone selling price of each performance obligation in the contract, and the Company recognizes revenue based on those amounts when, or as, the performance obligations under the contract are satisfied.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Exclusive Licenses&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If the license to the Company&#x2019;s intellectual property is determined to be distinct from the other promises or performance obligations identified in the arrangement, the Company recognizes revenue from nonrefundable, upfront fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. In assessing whether a promise or performance obligation is distinct from the other promises, the Company considers factors such as the research, development, manufacturing and commercialization capabilities of the collaboration partner and the availability of the associated expertise in the general marketplace. In addition, the Company considers whether the collaboration partner can benefit from a promise for its intended purpose without the receipt of the remaining promises, whether the value of the promise is dependent on the unsatisfied promises, whether there are other vendors that could provide the remaining promises, and whether it is separately identifiable from the remaining promises. For licenses that are combined with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of progress and related revenue recognition. The measure of progress, and the resulting periods over which revenue should be recognized, are subject to estimates by management and may change over the course of the research, development and licensing arrangement. Such a change could have a material impact on the amount of revenue the Company records in future periods. Under the Company&#x2019;s existing license and collaboration agreements, the Company has concluded that the transfer of control to the customer occurs over the time period that the research and development services are to be provided by the Company, and this output method is, in management&#x2019;s judgment, the best measure of progress towards satisfying the performance obligation.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Milestone Payments&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the inception of each arrangement that includes potential research, development or regulatory milestone payments, the Company evaluates whether the milestones are considered likely to be met and estimates the amount to be considered for inclusion in the transaction price using the most-likely-amount method. If it is probable that a significant reversal in the amount of cumulative revenue recognized would not occur, the associated milestone payment value is included in the transaction price. For milestone payments due upon events that are not within the control of the Company or the licensee, such as regulatory approvals, the Company is not able to assert that it is likely that the regulatory approval will be granted and that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur until those approvals are received. In making this assessment, the Company evaluates factors such as the scientific, clinical, regulatory, commercial and other risks that must be overcome to achieve the particular milestone. There is considerable judgment involved in determining whether it is probable that a significant reversal in the amount of cumulative revenue recognized would not occur. At the end of each subsequent reporting period, the Company reevaluates the probability of achievement of all milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price of the arrangement. Any such adjustments are recorded on a cumulative catch-up basis, which would affect the amounts of revenue and earnings in the period of adjustment.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Royalties&lt;/span&gt;&lt;/div&gt;For arrangements that include sales-based royalties, including milestone payments due upon first commercial sales or based on a level of sales, that are the result of a customer-vendor relationship and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) the occurrence of the related sales or (ii) the date upon which the performance obligation to which some or all of the royalty has been allocated has been satisfied or partially satisfied. To date, the Company has not recognized any royalty revenue from any of its licensing arrangements.</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <smmt:OtherOperatingIncomePolicyPolicyTextBlock
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMzMvZnJhZzpiZjJiYmY2YmZlMGU0MzY4YjE5YjYxN2ExNDJjYTNmMi90ZXh0cmVnaW9uOmJmMmJiZjZiZmUwZTQzNjhiMTliNjE3YTE0MmNhM2YyXzM2MTc3_ab6ca3d6-b7a6-437a-9540-2a369b20101f">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Other Operating Income&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company generates income from government contracts that reimburse the Company for certain allowable costs for funded projects. For contracts with government agencies where the funding arrangement is considered central to the Company&#x2019;s ongoing operations, the Company classifies the recognized funding received as other operating income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income from government grants is recognized as the qualifying expenses related to the contracts are incurred, provided that there is reasonable assurance of recoverability. If the government agency approves the project proposed by the Company, the government agency funds the project upon receipt of the support for the costs incurred up to the contract limit. Income recognized upon incurring qualifying expenses in advance of billing is recorded as accrued income, a component of other current assets, in the consolidated balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Grant income is not recognized as deductions of research and development costs because the Company acts as the principal in conducting the research and development activities and these contracts are central to its ongoing operations. The funds received through these means are held as deferred income in the consolidated balance sheets and are released to the consolidated statement of operations and comprehensive loss as the underlying expenditure is incurred and to the extent the conditions of the grant are met. The related costs incurred by the Company are included in research and development expense in the Company&#x2019;s consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company benefits from two U.K. research and development ("R&amp;amp;D") tax credit cash rebate regimes: Small and Medium Enterprise ("SME") Program and the Research and Development Expenditure Credit ("RDEC") Program. Each reporting period, management evaluates which tax relief programs the Company is expected to be eligible for and records as other operating income the portion of the expense that it expects to qualify under the programs, that it plans to submit a claim for, and it has reasonable assurance that the amount will ultimately be realized. Based on criteria established by HM Revenue and Customs (&#x201c;HMRC&#x201d;), management of the Company expects a proportion of expenditures being undertaken in relation to its pipeline research, clinical trials management and manufacturing development activities to be eligible for the research and development tax relief programs for the year ended December 31, 2021. Qualifying expenditures largely comprise of employment costs for research staff, consumables, a proportion of relevant, permitted sub-contract costs and certain internal overhead costs incurred as part of research projects for which the Company does not receive commercial or other funding income. Credits related to the SME and RDEC Programs are recorded as other operating income in the consolidated statements of operations and other comprehensive (loss)/income. Under both schemes, the Company receives cash rebate payments of up to 33.3% of eligible research and development expenditures and these payments are not dependent on the Company&#x2019;s pre-tax net income levels. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company has qualified under the more favorable SME regime for the year ended December 31, 2020 and expects to qualify under the SME regime for the year ending December 31, 2021.&lt;/span&gt;&lt;/div&gt;</smmt:OtherOperatingIncomePolicyPolicyTextBlock>
    <smmt:ResearchAndDevelopmentTaxCreditCashRebateMaximumPercentage
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMzMvZnJhZzpiZjJiYmY2YmZlMGU0MzY4YjE5YjYxN2ExNDJjYTNmMi90ZXh0cmVnaW9uOmJmMmJiZjZiZmUwZTQzNjhiMTliNjE3YTE0MmNhM2YyXzEyODU1_de3f0be9-693f-4e62-bee9-aa2de8f469b0"
      unitRef="number">0.333</smmt:ResearchAndDevelopmentTaxCreditCashRebateMaximumPercentage>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMzMvZnJhZzpiZjJiYmY2YmZlMGU0MzY4YjE5YjYxN2ExNDJjYTNmMi90ZXh0cmVnaW9uOmJmMmJiZjZiZmUwZTQzNjhiMTliNjE3YTE0MmNhM2YyXzM2MTc4_6243f654-30a9-488c-998b-94f8262814d1">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Net Income Per Share&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Basic net loss per share is computed by dividing the net loss by the weighted-average number of common shares outstanding for the period. Diluted net loss per share is computed by dividing the diluted net loss by the weighted-average number of common shares outstanding for the period, including potentially dilutive common shares. The dilutive effect of share options and warrants are determined under the treasury stock method using the average market price for the period.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In addition, the assumed proceeds under the treasury stock method include the average unrecognized compensation expense of stock options and warrants that are in-the-money.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:BusinessCombinationsPolicy
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMzMvZnJhZzpiZjJiYmY2YmZlMGU0MzY4YjE5YjYxN2ExNDJjYTNmMi90ZXh0cmVnaW9uOmJmMmJiZjZiZmUwZTQzNjhiMTliNjE3YTE0MmNhM2YyXzM2MTY3_62e61449-1972-4108-83dd-150ddc1e6293">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Business Combinations &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Business combinations are accounted for under the acquisition method. Acquired assets and assumed liabilities are measured at their fair values at the acquisition date. The excess of the consideration transferred over the net fair value of assets acquired and liabilities assumed is recorded as goodwill. The accounting for an acquisition involves a considerable amount of judgement and estimation. Cost, income, market or a combination of approaches may be used to establish the fair value of consideration exchanged, assets acquired, and liabilities assumed, depending on the nature of those items.  The valuation approach is &lt;/span&gt;&lt;/div&gt;determined in accordance with generally accepted valuation methods. Key areas of estimation and judgment may include the selection of valuation approaches, cost of capital, market characteristics, cost structure, impacts of synergies, and estimates of terminal value, among other factors.While the Company uses estimates and assumptions as part of the purchase price allocation process to estimate the value of assets acquired and liabilities assumed, estimates are inherently uncertain and subject to refinement. During the measurement period, which maybe up to one year from the acquisition date, the Company may record adjustments to the assets acquired and liabilities assumed, with a corresponding offset to goodwill, to the extent that adjustments are identified to the preliminary purchase price allocation. Upon conclusion of the measurement period, or final determination of the value of the assets acquired and liabilities assumed, whichever comes first, any subsequent adjustments are recorded to results of operations. Results of operations related to business combinations are included prospectively beginning with the date of acquisition and transaction costs related to business combinations are recorded within general and administrative expenses.</us-gaap:BusinessCombinationsPolicy>
    <us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMzMvZnJhZzpiZjJiYmY2YmZlMGU0MzY4YjE5YjYxN2ExNDJjYTNmMi90ZXh0cmVnaW9uOmJmMmJiZjZiZmUwZTQzNjhiMTliNjE3YTE0MmNhM2YyXzM2MTc5_80b2fc78-0736-410f-b4fb-72147d6601ef">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:102%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill represents the excess of the consideration transferred over the fair value of net assets acquired. Goodwill is assigned to reporting units at the time of acquisition or when there is a change in the reporting structure and bases that allocation on which reporting units will benefit from the acquired assets and liabilities. Reporting units are defined as operating segments or one level below an operating segment, referred to as a component. The Company assesses goodwill for impairment on an annual basis or more frequently when events and circumstances occur indicating that the recorded goodwill may be impaired.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In performing the Company&#x2019;s annual goodwill impairment test, the Company is permitted to first assess qualitative factors to determine whether it is more likely than not that the fair value of the Company&#x2019;s reporting unit is less than its carrying amount, including goodwill. In performing the qualitative assessment, the Company considers certain events and circumstances specific to the reporting unit and to the entity as a whole, such as macroeconomic conditions, industry and market considerations, overall financial performance and cost factors when evaluating whether it is more likely than not that the fair value of the reporting unit is less than its carrying amount. The Company is also permitted to bypass the qualitative assessment and proceed directly to the quantitative test. If the Company chooses to undertake the qualitative assessment and concludes that it is more likely than not that the fair value of the reporting unit is less than its carrying amount, the Company would then proceed to the quantitative impairment test. In the quantitative assessment, the Company compares the fair value of the reporting unit to its carrying amount, which includes goodwill. If the fair value exceeds the carrying value, no impairment loss exists. If the fair value is less than the carrying amount, a goodwill impairment loss is measured and recorded.&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy>
    <us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMzMvZnJhZzpiZjJiYmY2YmZlMGU0MzY4YjE5YjYxN2ExNDJjYTNmMi90ZXh0cmVnaW9uOmJmMmJiZjZiZmUwZTQzNjhiMTliNjE3YTE0MmNhM2YyXzM2MTcx_a0eee61b-bb03-4d28-8ab0-917e01c98178">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Intangible Assets &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets include patents, licenses, an option over non-financial assets and a research and development discovery platform ("Discuva Platform").&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Patents, licenses, and the option over non-financial assets are initially recorded at fair value, assigned an estimated useful life, and amortized primarily on a straight-line basis over their estimated useful lives. The Company evaluates the recoverability of its intangible and long-lived assets whenever events and changes in circumstances indicate that the carrying amount of an asset may not be fully recoverable. If events and circumstances indicate that the carrying amount may not fully be recoverable, the Company will perform a qualitative assessment, and consider certain events and circumstances specific to the intangible asset and to the entity as a whole, such as macroeconomic conditions, industry and market considerations, overall financial performance and cost factors when evaluating whether it is more likely than not that the fair value of the intangible asset is less than its carrying amount. This periodic review may result in an adjustment of estimated depreciable lives or asset impairment. When indicators of impairment are present, the carrying values of the asset are evaluated in relation to their operating performance and future undiscounted cash flows of the underlying business. If the future undiscounted cash flows are less than their carrying value, impairment exists. The impairment is measured as the difference between the carrying value and the fair &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;value of the underlying asset. Fair values are based on estimates of market prices and assumptions concerning the amount and timing of estimated future cash flows and assumed discount rates, reflecting varying degrees of perceived risk.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other intangible assets are amortized in equal installments over their estimated useful lives as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.057%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.455%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.188%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Intangible Asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortization Period&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Option over non-financial assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Over the period of the relevant agreement&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization of intangible assets is included as part of the research and development expense line shown on the face of the consolidated statement of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMzMvZnJhZzpiZjJiYmY2YmZlMGU0MzY4YjE5YjYxN2ExNDJjYTNmMi90ZXh0cmVnaW9uOmJmMmJiZjZiZmUwZTQzNjhiMTliNjE3YTE0MmNhM2YyXzM2MTcy_4f4e53ab-d9ac-482e-a57b-47729a7c94be">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other intangible assets are amortized in equal installments over their estimated useful lives as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.057%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.455%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.188%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Intangible Asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortization Period&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Option over non-financial assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Over the period of the relevant agreement&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Components of the Company's acquired intangible assets are comprised of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.836%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.293%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.587%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.587%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.587%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.650%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Accumulated amortization and impairment charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Utrophin program acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,487)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Discuva platform acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,017)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,399&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Option over non-financial asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;912&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(912)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other patents and licenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(148)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,564)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,399&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.397%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.591%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.591%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.591%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.567%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Accumulated amortization and impairment charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Utrophin program acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,534)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Discuva platform acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,565&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,050)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,515&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Option over non-financial asset&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;921&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(921)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other patents and licenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(150)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,655)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,515&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;During the year ended December 31, 2020, management identified an impairment related to the option over non-financial asset pursuant to an Evaluation and Option Agreement with a collaboration partner. The partner is no longer conducting antibiotic candidate programs over which the Company had the option, management therefore determined that the fair value of the option to acquire the assignment of the proprietary rights for antibiotic candidates is $0. Accordingly, the asset was written off in its entirety resulting in an impairment charge of $859 recognized in operating expenses.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMzMvZnJhZzpiZjJiYmY2YmZlMGU0MzY4YjE5YjYxN2ExNDJjYTNmMi90ZXh0cmVnaW9uOmJmMmJiZjZiZmUwZTQzNjhiMTliNjE3YTE0MmNhM2YyXzM2MTcz_3caaa74e-7c14-47b1-a791-840ec4254fc0">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Property and Equipment &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment are stated at cost less accumulated depreciation. Cost comprises the purchase price plus any incidental costs of acquisition and commissioning. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation is calculated based on cost, less residual value, in equal annual installments over the estimated useful lives of the assets. The residual value, if not insignificant, is reassessed annually.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.057%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.743%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Over the shorter of the asset's useful life or the remaining lease term&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2-10 years &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Office and IT equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3-5 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation is recognized as part of the general and administrative and research and development expense lines shown on the face of the consolidated statement of operations and comprehensive loss depending on the nature of the underlying assets.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expenditures for repairs and maintenance are expensed as incurred. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation are removed from the accounts and any resulting gain or loss is included in loss from operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMzMvZnJhZzpiZjJiYmY2YmZlMGU0MzY4YjE5YjYxN2ExNDJjYTNmMi90ZXh0cmVnaW9uOmJmMmJiZjZiZmUwZTQzNjhiMTliNjE3YTE0MmNhM2YyXzM2MTc0_357ea5d7-f85c-4abe-adff-7d67efb48b8b">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation is calculated based on cost, less residual value, in equal annual installments over the estimated useful lives of the assets. The residual value, if not insignificant, is reassessed annually.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.057%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.743%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Over the shorter of the asset's useful life or the remaining lease term&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2-10 years &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Office and IT equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3-5 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.421%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.367%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.774%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.582%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,626&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;759&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures, office equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,081&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;694&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="if7798276e33b48af81058807002f7542_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMzMvZnJhZzpiZjJiYmY2YmZlMGU0MzY4YjE5YjYxN2ExNDJjYTNmMi90YWJsZTozNTJkODI1NTVlNDk0Y2YxYWExMGQ4ODk4MzdlNGJhMC90YWJsZXJhbmdlOjM1MmQ4MjU1NWU0OTRjZjFhYTEwZDg4OTgzN2U0YmEwXzEtMS0xLTEtMTA5ODc2L3RleHRyZWdpb246NDRmM2NiMTUyMDBhNGU2MjkyYWM5NzJmZDI4MDM1NGRfNA_f3ccf320-8a7f-435c-93d4-631d47dad96a">P2Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="ib9e53bf038884fe1aebddae6ccd2c196_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMzMvZnJhZzpiZjJiYmY2YmZlMGU0MzY4YjE5YjYxN2ExNDJjYTNmMi90YWJsZTozNTJkODI1NTVlNDk0Y2YxYWExMGQ4ODk4MzdlNGJhMC90YWJsZXJhbmdlOjM1MmQ4MjU1NWU0OTRjZjFhYTEwZDg4OTgzN2U0YmEwXzEtMS0xLTEtMTA5ODc2L3RleHRyZWdpb246NDRmM2NiMTUyMDBhNGU2MjkyYWM5NzJmZDI4MDM1NGRfNw_8572383f-1cbf-443e-bac4-e062b4f92a22">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i942ccb9196bb4d0ab10e4c87af4250a2_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMzMvZnJhZzpiZjJiYmY2YmZlMGU0MzY4YjE5YjYxN2ExNDJjYTNmMi90YWJsZTozNTJkODI1NTVlNDk0Y2YxYWExMGQ4ODk4MzdlNGJhMC90YWJsZXJhbmdlOjM1MmQ4MjU1NWU0OTRjZjFhYTEwZDg4OTgzN2U0YmEwXzItMS0xLTEtMTA5ODc2L3RleHRyZWdpb246NWU5NWJkMTk3NDFlNDU5MGJiZjgyMWU4OGQwYTYzYzRfNA_088fc7c1-0d79-4966-9fa4-170a58a8978c">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="ia8b911ed586c4e1bbdda461a2557aff7_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMzMvZnJhZzpiZjJiYmY2YmZlMGU0MzY4YjE5YjYxN2ExNDJjYTNmMi90YWJsZTozNTJkODI1NTVlNDk0Y2YxYWExMGQ4ODk4MzdlNGJhMC90YWJsZXJhbmdlOjM1MmQ4MjU1NWU0OTRjZjFhYTEwZDg4OTgzN2U0YmEwXzItMS0xLTEtMTA5ODc2L3RleHRyZWdpb246NWU5NWJkMTk3NDFlNDU5MGJiZjgyMWU4OGQwYTYzYzRfNw_aacc7882-1794-41dc-90c0-c0a50bc6e135">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMzMvZnJhZzpiZjJiYmY2YmZlMGU0MzY4YjE5YjYxN2ExNDJjYTNmMi90ZXh0cmVnaW9uOmJmMmJiZjZiZmUwZTQzNjhiMTliNjE3YTE0MmNhM2YyXzM2MTgx_d8f51c2b-5dd9-48c0-9c7b-b648de7582b0">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has operating leases for real estate. The Company does not have any finance leases. Under Accounting Standards Codification 842, a contract is or contains a lease when the lessee has the right to control the use of an identified asset. The Company determines if an arrangement is a lease at inception of the contract, which is the date on which the terms of the contract are agreed to and the agreement creates enforceable rights and obligations. The lease term used to calculate the lease liability include options to extend or terminate the lease when it is reasonably certain that the option will be exercised.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the lease commencement date, the Company measures and recognizes a lease liability and a right-of-use asset in the financial statements. Lease liabilities are recognized based on the present value of the future lease payments over the lease term at commencement date. The right-of use asset is measured by taking the present value of future lease payments, plus any incremental direct costs incurred, less any lease incentives received. As most of the Company's leases do not provide an implicit rate, the Company uses an estimated incremental borrowing rate based on the lease term and the economic environment of the lease at the lease commencement date, which is then utilized to determine the present value of future lease payments. Lease expense for minimum lease payments are recognized on a straight-line basis over the lease term, with variable lease payments recognized in the periods in which they are incurred.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has existing lease agreements with lease and non-lease components, has elected to account for the lease and non-lease components as a single lease component, and has allocated all of the contract consideration to the lease component only. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Leases with an initial lease term of 12 months or less are not recorded on the balance sheet. The Company recognizes lease expense for its short-term leases on a straight-line basis over the lease term.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMzMvZnJhZzpiZjJiYmY2YmZlMGU0MzY4YjE5YjYxN2ExNDJjYTNmMi90ZXh0cmVnaW9uOmJmMmJiZjZiZmUwZTQzNjhiMTliNjE3YTE0MmNhM2YyXzM2MTgy_d7eb361f-c197-41ef-8101-e1b8ab951178">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Research and Development Costs&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development costs are expensed as incurred. Research and development expenses consist of costs incurred to discover, research and develop product candidates, including personnel expenses, stock-based compensation expense, allocated facility-related and depreciation expenses, third-party license fees and external costs of outside vendors engaged to conduct preclinical and clinical development activities and clinical trials as well as to manufacture clinical trial materials. Non - refundable prepayments for goods or services that will be used or rendered for future research and development activities are recorded as prepaid expenses. Such amounts are recognized as an expense as the goods are delivered or the related services are performed, or until it is no longer expected that the goods will be delivered, or the services rendered. Milestone and other payments made to third-parties with respect to in-process research and development, in accordance with the Company&#x2019;s license, acquisition and other similar agreements are expensed when determined to be probable and estimable.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has entered into various research and development contracts with other companies. These agreements are generally cancellable, and related payments are recorded as research and development expenses as incurred. The Company records accruals for estimated ongoing research and development costs or prepaid expenses where the payments made exceeds the estimated costs. When evaluating the adequacy of these balances, the Company analyzes progress of the studies, including the estimated costs to complete each study or activity, the estimation of the current stage of completion and the invoices received, as well as predetermined milestones which are not reflective of the current stage of development for prepaid expenses. Actual results could differ from the Company&#x2019;s estimates. In all cases, the full cost of each study or activity is expensed by the time the final report or where applicable, product, has been received. The Company&#x2019;s historical estimates have not been materially different from the actual costs.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMzMvZnJhZzpiZjJiYmY2YmZlMGU0MzY4YjE5YjYxN2ExNDJjYTNmMi90ZXh0cmVnaW9uOmJmMmJiZjZiZmUwZTQzNjhiMTliNjE3YTE0MmNhM2YyXzM2MTU5_1056f479-64e2-4605-95e1-ef02a9220015">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Stock-Based Compensation &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company measures and recognizes compensation expense for all stock option and restricted stock unit awards based on the estimated fair value of the award on the grant date. The Company uses the Black-Scholes option pricing model to estimate the fair value of stock option awards. The fair value is recognized as expense, over the requisite service period, which is generally the vesting period of the respective award, on a straight-line basis for each separately vesting portion of the award when the only condition to vesting is continued service.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If vesting is subject to a market or performance condition, recognition is based on the derived service period of the award. Expense for awards with performance conditions is estimated and adjusted on a quarterly basis based upon the assessment of the probability that the performance condition will be met. Use of the Black-Scholes option-pricing model requires management to apply judgment under highly subjective assumptions.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These assumptions include:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Expected term&#x2014;The expected term of stock options represents the weighted-average period the stock options are expected to be outstanding. The Company uses the simplified method for estimating the expected term as provided by the Securities and Exchange Commission. The simplified method calculates the expected term as the average of the time-to-vesting and the contractual life of the options.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Expected volatility&#x2014;The expected volatility was calculated based on historical volatility of the Company's share price.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Risk-free interest rate&#x2014;The risk-free rate assumption is based on the U.S. Treasury instruments, the terms of which were consistent with the expected term of the Company&#x2019;s stock options.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Expected dividend&#x2014;The expected dividend assumption is based on the Company&#x2019;s history and expectation of dividend payouts. The Company has not paid and does not intend to pay dividends. &lt;/span&gt;&lt;/div&gt;The Company estimates expected forfeitures at the time of grant instead of accounting for forfeitures as they occur. Stock option and restricted stock unit awards have been granted at fair value to non-employees, in connection with research and consulting services provided to the Company, to non-employees in connection with corporate activities, and to employees, in connection with Stock Purchase and Restriction Agreements. Equity awards generally vest over terms of 3 or 4 years.</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i593cfc00ba154e79a513606849b36e61_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMzMvZnJhZzpiZjJiYmY2YmZlMGU0MzY4YjE5YjYxN2ExNDJjYTNmMi90ZXh0cmVnaW9uOmJmMmJiZjZiZmUwZTQzNjhiMTliNjE3YTE0MmNhM2YyXzI3NjYx_2165f72f-5840-49d6-afb8-a1d14972d6f7">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="if0549c486ffc4be2b6a75373c950243b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMzMvZnJhZzpiZjJiYmY2YmZlMGU0MzY4YjE5YjYxN2ExNDJjYTNmMi90ZXh0cmVnaW9uOmJmMmJiZjZiZmUwZTQzNjhiMTliNjE3YTE0MmNhM2YyXzI3NjY3_cf8f38cc-3749-4c02-a869-890f098e8e91">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMzMvZnJhZzpiZjJiYmY2YmZlMGU0MzY4YjE5YjYxN2ExNDJjYTNmMi90ZXh0cmVnaW9uOmJmMmJiZjZiZmUwZTQzNjhiMTliNjE3YTE0MmNhM2YyXzM2MTUy_9fb1299b-2ef3-4164-a447-57dd97395905">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The provision for income taxes is determined using the asset and liability approach. Tax laws may require items to be included in tax filings at different times than the items are reflected in the financial statements. A current asset or liability is recognized for the estimated taxes receivable or payable for the current year. Deferred taxes represent the future tax consequences expected to occur when the reported amounts of assets and liabilities are recovered or paid. Deferred taxes are initially recognized at enacted tax rates in force at the time of initial recognition and are subsequently adjusted for any enacted changes in tax rates and tax laws. Subsequent changes to deferred taxes originally recognized in equity are recognized in income. Valuation allowances are recorded to reduce deferred tax assets when it is more likely than not that a tax benefit will not be realized. The Company has recorded a full valuation allowance against the deferred tax assets in excess of its deferred tax liabilities, as the deferred tax liability represents future reversals of existing taxable temporary differences. The Company records interest and penalties related to income tax matters as part of income tax expense.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMzMvZnJhZzpiZjJiYmY2YmZlMGU0MzY4YjE5YjYxN2ExNDJjYTNmMi90ZXh0cmVnaW9uOmJmMmJiZjZiZmUwZTQzNjhiMTliNjE3YTE0MmNhM2YyXzM2MTg2_e5e2bc7a-9f2d-4a89-a8ac-7b6178b49f9e">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Concentration of Credit Risk and of Significant Supplier&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of short-term cash deposits and accounts and other receivables. The Company's cash is comprised of short-term cash deposits at a variety of financial institutions with strong credit ratings in amounts that may exceed federally insured limits and has not experienced any losses on such accounts. Cash balances maintained during the year have been principally held with reputable U.K.-based and U.S.-based banks. The Company does not believe it is exposed to any unusual credit risk beyond the normal credit risk associated with commercial banking relationships.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company maintains deposits in accredited financial institutions in excess of federally insured limits. The Company deposits its cash in financial institutions that it believes have high credit quality and has not experienced any losses on such accounts and does not believe it is exposed to any unusual credit risk beyond the normal credit risk associated with commercial banking relationships.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The credit risk with respect to customers and funding bodies is limited as the Company has only a small number of these arrangements, including with Eurofarma, BARDA and CARB-X. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company relies, and expects to continue to rely, on a number of vendors to conduct its clinical trials and preclinical studies, manufacture drug product and supply clinical trial and preclinical study materials for its development programs. These programs could be adversely affected by a significant interruption in these services or the availability of materials.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMzMvZnJhZzpiZjJiYmY2YmZlMGU0MzY4YjE5YjYxN2ExNDJjYTNmMi90ZXh0cmVnaW9uOmJmMmJiZjZiZmUwZTQzNjhiMTliNjE3YTE0MmNhM2YyXzM2MTY4_21c1a242-f097-4be6-8c03-a4aa9069772c">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:103%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accordance with the provisions of fair value accounting, a fair value measurement assumes that the transaction to sell an asset or transfer a liability occurs in the principal market for the asset or liability or, in the absence of a principal market, the most advantageous market for the asset or liability and defines fair value based on the exit price model.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value measurement guidance establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The guidance describes three levels of inputs that may be used to measure fair value:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Level 1&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Quoted prices in active markets for identical assets or liabilities as of the reporting date. Active markets are those in which transactions for the asset or liability occur in sufficient frequency and volume to provide pricing information on an ongoing basis.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Level 2&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 2 assets and liabilities include debt securities with quoted prices that are traded less &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;frequently than exchange-traded instruments or securities or derivative contracts that are valued using a pricing model with inputs that are observable in the market or can be derived principally from or corroborated by observable market data.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Level 3&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Level 3 assets and liabilities include financial instruments whose value is determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant management judgment or estimation.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, the Company categorizes such assets and liabilities based on the lowest level input that is significant to the fair value measurement in its entirety. The Company&#x2019;s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the asset.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <smmt:AssumedContingentLiabilitiesPolicyPolicyTextBlock
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMzMvZnJhZzpiZjJiYmY2YmZlMGU0MzY4YjE5YjYxN2ExNDJjYTNmMi90ZXh0cmVnaW9uOmJmMmJiZjZiZmUwZTQzNjhiMTliNjE3YTE0MmNhM2YyXzM2MTUz_289d354c-b633-4bf3-859a-628a596a6d45">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Assumed Contingent Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of the acquisition of Discuva Limited in December 2017, the Company assumed certain contingent liabilities as certain employees, former employees and former directors of Discuva Limited are eligible for payments from Discuva Limited based on specified development and clinical milestones related to proprietary product candidates developed under the Discuva Platform. The timing of these potential payments is uncertain. The fair value of the assumed contingent liability was estimated using the expected value of the payments. The assumed contingent liabilities are subsequently measured at amortized cost using discounted cash flow models which calculate the risk adjusted net present values of estimated potential future cash flows of the payments. The assumed contingent liabilities are remeasured when there is a specific significant event that provides evidence of a significant change in the probability of successful development and clinical milestones being achieved. The models will be updated for changes in the probability of successful development and clinical milestones being achieved and other associated assumptions with the discount factor remaining unchanged within the model. A discount factor of 13% has been used to discount the contingent liabilities back to net present value. This discount factor has been calculated using appropriate measures and rates which could have been obtained in the period that the contingent liabilities were assumed. Accretion of the discount factor is recognized as part of operating expenses in the consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;</smmt:AssumedContingentLiabilitiesPolicyPolicyTextBlock>
    <smmt:BusinessCombinationAssumedContingentLiabilityMeasurementInput
      contextRef="i32242c0ff70343c9adfcc11c6595a70f_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMzMvZnJhZzpiZjJiYmY2YmZlMGU0MzY4YjE5YjYxN2ExNDJjYTNmMi90ZXh0cmVnaW9uOmJmMmJiZjZiZmUwZTQzNjhiMTliNjE3YTE0MmNhM2YyXzM0MzUz_6ebe878f-10c0-4901-af2e-03f1e5f97045"
      unitRef="number">0.13</smmt:BusinessCombinationAssumedContingentLiabilityMeasurementInput>
    <smmt:WarrantsPolicyPolicyTextBlock
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMzMvZnJhZzpiZjJiYmY2YmZlMGU0MzY4YjE5YjYxN2ExNDJjYTNmMi90ZXh0cmVnaW9uOmJmMmJiZjZiZmUwZTQzNjhiMTliNjE3YTE0MmNhM2YyXzM2MTY1_18890b22-9e06-4745-b281-38cc1f6aa4ea">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Warrants issued by the Company are recognized and classified as equity when, upon exercise, the Company would issue a fixed amount of its own equity instruments (common stock) in exchange for a fixed amount of cash or another financial asset.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Consideration received, net of incremental costs directly attributable to the issue of such new warrants, is shown in equity. Such warrants are not remeasured at fair value in subsequent reporting periods.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Warrants issued in which external services are received as consideration for equity instruments of the company should be measured at the fair value of the goods or services received. Only if the fair value of the services cannot be measured reliably would the fair value of the equity instruments granted be used. The fair value for the warrants is calculated using the Black-Scholes formula and recorded in the consolidated statement of operations and comprehensive loss&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;on a straight-line basis over the period of the consulting services. If the services are terminated prior to the end of the consultancy agreement, the warrants cease vesting and any unvested portion of the warrants will lapse immediately.&lt;/span&gt;&lt;/div&gt;The warrants in issue are classified within stockholders&#x2019; equity as they are indexed to the Company's own shares of common stock and require settlement in its shares of common stocks with no provision for any cash settlement.</smmt:WarrantsPolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMzYvZnJhZzpiYmFlYzkxMGE1OWU0MzZhYjRiOWFlM2Y3Yjg1YjQzMS90ZXh0cmVnaW9uOmJiYWVjOTEwYTU5ZTQzNmFiNGI5YWUzZjdiODViNDMxXzM4MjQ_18a7157d-a1a4-4577-bed9-f6cccb6ba026">Recently Issued or Adopted Accounting Pronouncements &lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2021, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2021-10, " Government Assistance (Topic 832)." This ASU increases the transparency of government assistance including the disclosure of (1) the types of assistance, (2) an entity's accounting for the assistance, and (3) the effect of the assistance on an entity's financial statements as diversity currently exists in the recognition, measurement, presentation and disclosure of government assistance received by business entities because of the lack of specific authoritative guidance in U.S. GAAP. This ASU is effective for annual periods, and interim periods within those fiscal years, beginning after December 15, 2021. Early application of this ASU is permitted. The Company applied the amendments of this ASU to its disclosures during the fourth quarter of 2021 and the application of this ASU did not have a material impact on its financial position, results of operations or cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2021, the FASB issued ASU No. 2021-08, "Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers." This ASU improves the accounting for acquired revenue contracts with customers in a business combination by addressing diversity in practice and inconsistency relating to: 1) recognition of an acquired contract liability and 2) payment terms and their effect on subsequent revenue recognized by the acquirer. The amendments in this ASU require acquiring entities to apply Topic 606 to recognize and measure contract assets and contract liabilities in a business combination, whereas current U.S. GAAP requires that the acquirer measure such assets and liabilities at fair value on the acquisition date. This ASU is effective for annual periods, and interim periods within those fiscal years, beginning after December 15, 2022. The Company will apply this ASU on a prospective basis for business combinations once this ASU is effective and at that time, will be able to determine the potential impact on its financial position, results of operations or cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2021, the FASB issued AS No. 2021-04, "Earnings Per Share (Topic 260), Debt - Modifications and Extinguishments (Subtopic 470-50), Compensation - Stock Compensation (Topic 718), and Derivatives and Hedging Contracts in Entity's Own Equity (Subtopic 815-40) - Issuer's Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options." This ASU provides clarification and reduces diversity in an issuer&#x2019;s accounting for modifications or exchanges of freestanding equity-classified written call options (such as warrants) that remain equity classified after modification or exchange. This ASU is effective for annual periods, and interim periods within those fiscal years, beginning after December 15, 2021. The Company will apply this ASU on a prospective basis for any modifications or exchanges once this ASU is effective and at that time, will be able to determine the potential impact on its financial position, results of operations or cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, the FASB issued ASU No. 2019-12, "Income Taxes (Topic 740)." This ASU simplifies the accounting for income taxes by removing certain exceptions to the general principles in Topic 740. The amendments also improve consistent application and simplify U.S. GAAP for other areas of Topic 740 by clarifying and amending existing guidance. This ASU is effective for annual periods, and interim periods within those fiscal years, beginning after December 15, 2020. The Company adopted this ASU during the first quarter of 2021 and the adoption of this ASU did not have a material impact on its financial position, results of operations or cash flows.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMzYvZnJhZzpiYmFlYzkxMGE1OWU0MzZhYjRiOWFlM2Y3Yjg1YjQzMS90ZXh0cmVnaW9uOmJiYWVjOTEwYTU5ZTQzNmFiNGI5YWUzZjdiODViNDMxXzM4MjQ_b911246c-cfd7-4859-8cde-d843b89f8f9f">Recently Issued or Adopted Accounting Pronouncements &lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2021, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2021-10, " Government Assistance (Topic 832)." This ASU increases the transparency of government assistance including the disclosure of (1) the types of assistance, (2) an entity's accounting for the assistance, and (3) the effect of the assistance on an entity's financial statements as diversity currently exists in the recognition, measurement, presentation and disclosure of government assistance received by business entities because of the lack of specific authoritative guidance in U.S. GAAP. This ASU is effective for annual periods, and interim periods within those fiscal years, beginning after December 15, 2021. Early application of this ASU is permitted. The Company applied the amendments of this ASU to its disclosures during the fourth quarter of 2021 and the application of this ASU did not have a material impact on its financial position, results of operations or cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2021, the FASB issued ASU No. 2021-08, "Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers." This ASU improves the accounting for acquired revenue contracts with customers in a business combination by addressing diversity in practice and inconsistency relating to: 1) recognition of an acquired contract liability and 2) payment terms and their effect on subsequent revenue recognized by the acquirer. The amendments in this ASU require acquiring entities to apply Topic 606 to recognize and measure contract assets and contract liabilities in a business combination, whereas current U.S. GAAP requires that the acquirer measure such assets and liabilities at fair value on the acquisition date. This ASU is effective for annual periods, and interim periods within those fiscal years, beginning after December 15, 2022. The Company will apply this ASU on a prospective basis for business combinations once this ASU is effective and at that time, will be able to determine the potential impact on its financial position, results of operations or cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2021, the FASB issued AS No. 2021-04, "Earnings Per Share (Topic 260), Debt - Modifications and Extinguishments (Subtopic 470-50), Compensation - Stock Compensation (Topic 718), and Derivatives and Hedging Contracts in Entity's Own Equity (Subtopic 815-40) - Issuer's Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options." This ASU provides clarification and reduces diversity in an issuer&#x2019;s accounting for modifications or exchanges of freestanding equity-classified written call options (such as warrants) that remain equity classified after modification or exchange. This ASU is effective for annual periods, and interim periods within those fiscal years, beginning after December 15, 2021. The Company will apply this ASU on a prospective basis for any modifications or exchanges once this ASU is effective and at that time, will be able to determine the potential impact on its financial position, results of operations or cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, the FASB issued ASU No. 2019-12, "Income Taxes (Topic 740)." This ASU simplifies the accounting for income taxes by removing certain exceptions to the general principles in Topic 740. The amendments also improve consistent application and simplify U.S. GAAP for other areas of Topic 740 by clarifying and amending existing guidance. This ASU is effective for annual periods, and interim periods within those fiscal years, beginning after December 15, 2020. The Company adopted this ASU during the first quarter of 2021 and the adoption of this ASU did not have a material impact on its financial position, results of operations or cash flows.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMzkvZnJhZzoyMDEzMmFlNjNjMzU0YTBmYjAzOWU4NTU2M2Q0NzkxZS90ZXh0cmVnaW9uOjIwMTMyYWU2M2MzNTRhMGZiMDM5ZTg1NTYzZDQ3OTFlXzEzNTc_bc53e38d-95f9-464c-8b6d-da8863d31767">Segment Reporting The Company's chief operating decision makers (the "CODM function"), which are the Company's Chief Executive Officer and Chief Operating Officer, utilize consolidated financial information to make decisions about allocating resources and assessing performance for the entire Company. The CODM function approves of key operating and strategic decisions, including key decisions in clinical development and clinical operating activities, entering into significant contracts, such as revenue contracts and collaboration agreements and approves the Company's consolidated operating budget. The CODM function views the Company's operations and manages its business as a single reportable operating segment. The Company's single operating segment covers the Company&#x2019;s research and development activities, primarily comprising the CDI program and antibiotic pipeline research activities. As the Company operates in one operating segment, all required financial segment information can be found in the consolidated financial statements.&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company operates in two geographic regions: the U.K. and the U.S. The following table summarizes the Company's long-lived assets, which include the Company's property and equipment, net and right-of-use assets by geography: &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.467%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United Kingdom&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,762&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;722&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,484&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For details of revenue from external customers by geography refer to Note 7.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMzkvZnJhZzoyMDEzMmFlNjNjMzU0YTBmYjAzOWU4NTU2M2Q0NzkxZS90ZXh0cmVnaW9uOjIwMTMyYWU2M2MzNTRhMGZiMDM5ZTg1NTYzZDQ3OTFlXzkyMg_1d1e2133-2dab-412d-bab5-e94f4dbae9aa"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NumberOfCountriesInWhichEntityOperates
      contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMzkvZnJhZzoyMDEzMmFlNjNjMzU0YTBmYjAzOWU4NTU2M2Q0NzkxZS90ZXh0cmVnaW9uOjIwMTMyYWU2M2MzNTRhMGZiMDM5ZTg1NTYzZDQ3OTFlXzEwNjg_dffffd85-20fe-4f27-8590-9570b1d6c626"
      unitRef="country">2</us-gaap:NumberOfCountriesInWhichEntityOperates>
    <us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMzkvZnJhZzoyMDEzMmFlNjNjMzU0YTBmYjAzOWU4NTU2M2Q0NzkxZS90ZXh0cmVnaW9uOjIwMTMyYWU2M2MzNTRhMGZiMDM5ZTg1NTYzZDQ3OTFlXzEzNTY_3c170fd5-cb25-465c-a915-f690ff40d9bf">The following table summarizes the Company's long-lived assets, which include the Company's property and equipment, net and right-of-use assets by geography: &lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.467%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United Kingdom&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,762&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;722&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,484&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock>
    <us-gaap:NoncurrentAssets
      contextRef="i435477ccebf0489e8e94db10eb60db56_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMzkvZnJhZzoyMDEzMmFlNjNjMzU0YTBmYjAzOWU4NTU2M2Q0NzkxZS90YWJsZToxNDkyNWRiNzdlNjA0NzhiYWFlNWZjMWQ5OTZhYjc4Ni90YWJsZXJhbmdlOjE0OTI1ZGI3N2U2MDQ3OGJhYWU1ZmMxZDk5NmFiNzg2XzEtMi0xLTEtMTA5ODc2_4ae45559-f76d-49d1-91dc-5825ff36a1b8"
      unitRef="usd">2762000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="if02b5108070a44ba843c22e648997315_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMzkvZnJhZzoyMDEzMmFlNjNjMzU0YTBmYjAzOWU4NTU2M2Q0NzkxZS90YWJsZToxNDkyNWRiNzdlNjA0NzhiYWFlNWZjMWQ5OTZhYjc4Ni90YWJsZXJhbmdlOjE0OTI1ZGI3N2U2MDQ3OGJhYWU1ZmMxZDk5NmFiNzg2XzEtNC0xLTEtMTA5ODc2_24aa7f83-b936-4169-b0f9-d9b6596b7ab5"
      unitRef="usd">1228000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="i4d900fb56eda43068b75b033c9bfc547_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMzkvZnJhZzoyMDEzMmFlNjNjMzU0YTBmYjAzOWU4NTU2M2Q0NzkxZS90YWJsZToxNDkyNWRiNzdlNjA0NzhiYWFlNWZjMWQ5OTZhYjc4Ni90YWJsZXJhbmdlOjE0OTI1ZGI3N2U2MDQ3OGJhYWU1ZmMxZDk5NmFiNzg2XzItMi0xLTEtMTA5ODc2_2bd5c0e7-ddd4-466a-bcd4-c655f32bb678"
      unitRef="usd">722000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="i71dfd1e7be4e496b90e176a973683625_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMzkvZnJhZzoyMDEzMmFlNjNjMzU0YTBmYjAzOWU4NTU2M2Q0NzkxZS90YWJsZToxNDkyNWRiNzdlNjA0NzhiYWFlNWZjMWQ5OTZhYjc4Ni90YWJsZXJhbmdlOjE0OTI1ZGI3N2U2MDQ3OGJhYWU1ZmMxZDk5NmFiNzg2XzItNC0xLTEtMTA5ODc2_6c4420e4-31b6-4e03-b40d-77f92f5f59cb"
      unitRef="usd">51000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMzkvZnJhZzoyMDEzMmFlNjNjMzU0YTBmYjAzOWU4NTU2M2Q0NzkxZS90YWJsZToxNDkyNWRiNzdlNjA0NzhiYWFlNWZjMWQ5OTZhYjc4Ni90YWJsZXJhbmdlOjE0OTI1ZGI3N2U2MDQ3OGJhYWU1ZmMxZDk5NmFiNzg2XzMtMi0xLTEtMTA5ODc2_7dd0b59b-27eb-4b26-81e6-e5218d515446"
      unitRef="usd">3484000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="i7372be6dc06143b5adbb4d2e83a596c5_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xMzkvZnJhZzoyMDEzMmFlNjNjMzU0YTBmYjAzOWU4NTU2M2Q0NzkxZS90YWJsZToxNDkyNWRiNzdlNjA0NzhiYWFlNWZjMWQ5OTZhYjc4Ni90YWJsZXJhbmdlOjE0OTI1ZGI3N2U2MDQ3OGJhYWU1ZmMxZDk5NmFiNzg2XzMtNC0xLTEtMTA5ODc2_e487c324-9d09-4e87-9967-13870c65f497"
      unitRef="usd">1279000</us-gaap:NoncurrentAssets>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNDIvZnJhZzphMjRjNmNhMGI0NDc0YWQ0YTZkNjYyNTU4ODdkY2M1MS90ZXh0cmVnaW9uOmEyNGM2Y2EwYjQ0NzRhZDRhNmQ2NjI1NTg4N2RjYzUxXzQzMDc_77334486-479c-48fd-8fbb-572d23ed79ff">Revenue &lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes revenue by category:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.467%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue by category:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Licensing agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,809&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue recognized during the years ended December 31, 2021 and December 31, 2020 consists of amounts received from the Company's license and commercialization agreement with Eurofarma Laborat&#xf3;rios S.A. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes revenue by geography:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.467%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue by geography:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Latin America&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,809&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,809&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The analysis of revenue by geography has been identified on the basis of the geographical location of each collaboration partner.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the deferred revenue relating to Eurofarma Laborat&#xf3;rios S.A. and deferred other income relating to BARDA (as defined in Note 8), respectively:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.836%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:82.049%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.902%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.649%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning deferred revenue and other income, January 1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,939&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,438&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amount of deferred revenue and other income recognized in the statement of operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,438)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending deferred revenue and other income, December 31&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,939&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;__________&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Beginning deferred revenue and other income included $8,370 of current deferred revenue and other income and $569 of long-term deferred revenue and other income.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Ending deferred revenue and other income is classified within current liabilities.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Refer to Note 8 below for further details regarding other income recognized under the BARDA contract. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Eurofarma Laborat&#xf3;rios S.A.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 21, 2017, Summit announced it had entered into an exclusive license and commercialization agreement with Eurofarma Laborat&#xf3;rios S.A. ("Eurofarma"), pursuant to which the Company granted Eurofarma the exclusive right to commercialize ridinilazole in specified countries in South America, Central America and the Caribbean. The Company has retained commercialization rights in the rest of the world. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the license and commercialization agreement with Eurofarma, the Company received an upfront payment of $2,500 in December 2017. In February 2020, the Company reached the first enrollment milestone and earned $1,000. In September 2021, the Company reached the second enrollment milestone and earned $1,250. The terms of the contract have been assessed under ASC 606 and currently only the upfront payment and the first two enrollment milestone payments are included in the transaction price. These payments were initially reported as deferred revenue in the balance sheet and are being recognized as revenue ratably over the performance period. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue recognized during the period ended December 31, 2021 was based on the transaction price that included the upfront payment and the first two enrollment milestones earned in accordance with the Company's revenue recognition policy. Revenue recognized during the period ended December 31, 2020 was based on the transaction price that included the upfront payment and the first enrollment milestone earned in accordance with the Company's revenue recognition policy. The revenue is being recognized ratably over the performance period to reflect the transfer of control to the customer occurring over the time period that the research and development services are provided by the Company. This output method is, in management&#x2019;s judgment, the best measure of progress towards satisfying the performance obligation. As of December 31, 2021 and 2020, the current contract liability relating to the Eurofarma contract was $756 and $759, respectively, and was recorded in current deferred revenue in the consolidated balance sheet. As of December 31, 2021 and 2020, the non-current contract liability relating to the Eurofarma contract was $0 and $569, respectively, and was recorded in non-current deferred revenue and other income in the consolidated balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, the Company will be entitled to receive an additional $1,500 for various development milestones. The Company is also eligible to receive up to $21,400 in additional development, commercial and sales milestones when cumulative net sales equal or exceed $100,000 in the Eurofarma licensed territory. Each subsequent achievement of an additional $100,000 in cumulative net sales will result in the Company receiving additional milestone payments, which, when combined with anticipated product supply transfer payments from Eurofarma paid to the Company in connection with a commercial supply agreement to be entered into between the two parties, will provide payments estimated to range from a mid-teens to high-teens percentage of cumulative net sales in the territories where we have granted Eurofarma commercialization rights. Upon achievement of these milestones, the Company will recognize the revenues in accordance with the Company's revenue policy.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNDIvZnJhZzphMjRjNmNhMGI0NDc0YWQ0YTZkNjYyNTU4ODdkY2M1MS90ZXh0cmVnaW9uOmEyNGM2Y2EwYjQ0NzRhZDRhNmQ2NjI1NTg4N2RjYzUxXzQzMDA_6c616d0f-c391-4f5b-b2e6-8b83760340b1">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes revenue by category:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.467%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue by category:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Licensing agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,809&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5429ceb33a414445be9322f8f9c293e3_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNDIvZnJhZzphMjRjNmNhMGI0NDc0YWQ0YTZkNjYyNTU4ODdkY2M1MS90YWJsZTowMzI2ZWQxODJiMzM0YjA4YjIyYzFjZDQyNjZmM2RhNi90YWJsZXJhbmdlOjAzMjZlZDE4MmIzMzRiMDhiMjJjMWNkNDI2NmYzZGE2XzItMi0xLTEtMTA5ODc2_f22cabf4-4e61-44b4-9b19-70e423d8f1a0"
      unitRef="usd">1809000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i05760767313140efb7f8f84e9096f9f3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNDIvZnJhZzphMjRjNmNhMGI0NDc0YWQ0YTZkNjYyNTU4ODdkY2M1MS90YWJsZTowMzI2ZWQxODJiMzM0YjA4YjIyYzFjZDQyNjZmM2RhNi90YWJsZXJhbmdlOjAzMjZlZDE4MmIzMzRiMDhiMjJjMWNkNDI2NmYzZGE2XzItNC0xLTEtMTA5ODc2_0087eee6-e514-4cf8-bea7-75fe427693c2"
      unitRef="usd">860000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNDIvZnJhZzphMjRjNmNhMGI0NDc0YWQ0YTZkNjYyNTU4ODdkY2M1MS90ZXh0cmVnaW9uOmEyNGM2Y2EwYjQ0NzRhZDRhNmQ2NjI1NTg4N2RjYzUxXzQzMDE_ca09d485-2ea1-444a-af2e-fe3032d85e4b">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes revenue by geography:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.467%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue by geography:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Latin America&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,809&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,809&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie0717192d4d74cfd912383af07cab29d_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNDIvZnJhZzphMjRjNmNhMGI0NDc0YWQ0YTZkNjYyNTU4ODdkY2M1MS90YWJsZTpkNDg5ZDZjZjAyYjY0NDc4OGYxMGJlZDY1NzhlOWNkZS90YWJsZXJhbmdlOmQ0ODlkNmNmMDJiNjQ0Nzg4ZjEwYmVkNjU3OGU5Y2RlXzItMi0xLTEtMTA5ODc2_e1418ccd-c79b-4961-b99b-017caff3fce5"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9367ade534d1492b81f243c12898e81d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNDIvZnJhZzphMjRjNmNhMGI0NDc0YWQ0YTZkNjYyNTU4ODdkY2M1MS90YWJsZTpkNDg5ZDZjZjAyYjY0NDc4OGYxMGJlZDY1NzhlOWNkZS90YWJsZXJhbmdlOmQ0ODlkNmNmMDJiNjQ0Nzg4ZjEwYmVkNjU3OGU5Y2RlXzItNC0xLTEtMTA5ODc2_3c407754-70e9-45f4-b51b-7833292af35d"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i04c6be661f884e9f9fcec7b8a98ba02f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNDIvZnJhZzphMjRjNmNhMGI0NDc0YWQ0YTZkNjYyNTU4ODdkY2M1MS90YWJsZTpkNDg5ZDZjZjAyYjY0NDc4OGYxMGJlZDY1NzhlOWNkZS90YWJsZXJhbmdlOmQ0ODlkNmNmMDJiNjQ0Nzg4ZjEwYmVkNjU3OGU5Y2RlXzMtMi0xLTEtMTA5ODc2_374be918-0d44-4193-8019-7946a4033172"
      unitRef="usd">1809000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie7b7d8e874e541099d3260b499ccef94_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNDIvZnJhZzphMjRjNmNhMGI0NDc0YWQ0YTZkNjYyNTU4ODdkY2M1MS90YWJsZTpkNDg5ZDZjZjAyYjY0NDc4OGYxMGJlZDY1NzhlOWNkZS90YWJsZXJhbmdlOmQ0ODlkNmNmMDJiNjQ0Nzg4ZjEwYmVkNjU3OGU5Y2RlXzMtNC0xLTEtMTA5ODc2_a7e4c357-d408-4a4f-9fc1-630e9c5eeba8"
      unitRef="usd">860000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNDIvZnJhZzphMjRjNmNhMGI0NDc0YWQ0YTZkNjYyNTU4ODdkY2M1MS90YWJsZTpkNDg5ZDZjZjAyYjY0NDc4OGYxMGJlZDY1NzhlOWNkZS90YWJsZXJhbmdlOmQ0ODlkNmNmMDJiNjQ0Nzg4ZjEwYmVkNjU3OGU5Y2RlXzQtMi0xLTEtMTA5ODc2_651dbe07-8217-4db6-b4a3-a0bc2c6bfe9e"
      unitRef="usd">1809000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNDIvZnJhZzphMjRjNmNhMGI0NDc0YWQ0YTZkNjYyNTU4ODdkY2M1MS90YWJsZTpkNDg5ZDZjZjAyYjY0NDc4OGYxMGJlZDY1NzhlOWNkZS90YWJsZXJhbmdlOmQ0ODlkNmNmMDJiNjQ0Nzg4ZjEwYmVkNjU3OGU5Y2RlXzQtNC0xLTEtMTA5ODc2_bee57716-5944-40a0-ac49-be32167e87d4"
      unitRef="usd">860000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNDIvZnJhZzphMjRjNmNhMGI0NDc0YWQ0YTZkNjYyNTU4ODdkY2M1MS90ZXh0cmVnaW9uOmEyNGM2Y2EwYjQ0NzRhZDRhNmQ2NjI1NTg4N2RjYzUxXzQzMDQ_5aac7138-af6d-42f1-ab11-0cf00c760f28">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the deferred revenue relating to Eurofarma Laborat&#xf3;rios S.A. and deferred other income relating to BARDA (as defined in Note 8), respectively:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.836%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:82.049%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.902%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.649%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning deferred revenue and other income, January 1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,939&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,438&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amount of deferred revenue and other income recognized in the statement of operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,438)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending deferred revenue and other income, December 31&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,939&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;__________&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Beginning deferred revenue and other income included $8,370 of current deferred revenue and other income and $569 of long-term deferred revenue and other income.&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Ending deferred revenue and other income is classified within current liabilities.&lt;/span&gt;</us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i7372be6dc06143b5adbb4d2e83a596c5_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNDIvZnJhZzphMjRjNmNhMGI0NDc0YWQ0YTZkNjYyNTU4ODdkY2M1MS90YWJsZTo0MWM3MWViODM2ZDM0ZTYxODRhOGI1ZmZhNzEzYmU3OC90YWJsZXJhbmdlOjQxYzcxZWI4MzZkMzRlNjE4NGE4YjVmZmE3MTNiZTc4XzEtMi0xLTEtMTA5ODc2_459435e0-7509-4279-b277-0e2ebb6fa780"
      unitRef="usd">8939000</us-gaap:ContractWithCustomerLiability>
    <smmt:ContractWithCustomerLiabilityAdditions
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNDIvZnJhZzphMjRjNmNhMGI0NDc0YWQ0YTZkNjYyNTU4ODdkY2M1MS90YWJsZTo0MWM3MWViODM2ZDM0ZTYxODRhOGI1ZmZhNzEzYmU3OC90YWJsZXJhbmdlOjQxYzcxZWI4MzZkMzRlNjE4NGE4YjVmZmE3MTNiZTc4XzItMi0xLTEtMTA5ODc2_46620ac5-d5ca-420e-ae09-9843346cb7fc"
      unitRef="usd">5438000</smmt:ContractWithCustomerLiabilityAdditions>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNDIvZnJhZzphMjRjNmNhMGI0NDc0YWQ0YTZkNjYyNTU4ODdkY2M1MS90YWJsZTo0MWM3MWViODM2ZDM0ZTYxODRhOGI1ZmZhNzEzYmU3OC90YWJsZXJhbmdlOjQxYzcxZWI4MzZkMzRlNjE4NGE4YjVmZmE3MTNiZTc4XzMtMi0xLTEtMTA5ODc2_23bea5b2-4297-499b-9aeb-c2ecfa36222c"
      unitRef="usd">6438000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNDIvZnJhZzphMjRjNmNhMGI0NDc0YWQ0YTZkNjYyNTU4ODdkY2M1MS90YWJsZTo0MWM3MWViODM2ZDM0ZTYxODRhOGI1ZmZhNzEzYmU3OC90YWJsZXJhbmdlOjQxYzcxZWI4MzZkMzRlNjE4NGE4YjVmZmE3MTNiZTc4XzQtMi0xLTEtMTA5ODc2_2eeb3f11-4b40-4fb8-a6c4-2a2695a529ac"
      unitRef="usd">7939000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i7372be6dc06143b5adbb4d2e83a596c5_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNDIvZnJhZzphMjRjNmNhMGI0NDc0YWQ0YTZkNjYyNTU4ODdkY2M1MS90ZXh0cmVnaW9uOmEyNGM2Y2EwYjQ0NzRhZDRhNmQ2NjI1NTg4N2RjYzUxXzY5NQ_e8306b19-0163-41d3-b60f-09c7f4391f34"
      unitRef="usd">8370000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i7372be6dc06143b5adbb4d2e83a596c5_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNDIvZnJhZzphMjRjNmNhMGI0NDc0YWQ0YTZkNjYyNTU4ODdkY2M1MS90ZXh0cmVnaW9uOmEyNGM2Y2EwYjQ0NzRhZDRhNmQ2NjI1NTg4N2RjYzUxXzc0Nw_c22bcd34-800b-4236-9f60-77340ea021d8"
      unitRef="usd">569000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiability
      contextRef="ib314f5dd5ac24f47a60b0925a50a5081_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNDIvZnJhZzphMjRjNmNhMGI0NDc0YWQ0YTZkNjYyNTU4ODdkY2M1MS90ZXh0cmVnaW9uOmEyNGM2Y2EwYjQ0NzRhZDRhNmQ2NjI1NTg4N2RjYzUxXzE1NTU_87902035-7aee-4b8d-af85-d7c3d619a2f3"
      unitRef="usd">2500000</us-gaap:ContractWithCustomerLiability>
    <smmt:ContractWithCustomerLiabilityEnrollmentMilestone
      contextRef="if1c80590b2284b5092629628c5efb266_I20200229"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNDIvZnJhZzphMjRjNmNhMGI0NDc0YWQ0YTZkNjYyNTU4ODdkY2M1MS90ZXh0cmVnaW9uOmEyNGM2Y2EwYjQ0NzRhZDRhNmQ2NjI1NTg4N2RjYzUxXzE2NTY_89aa892a-4412-4cf5-a2df-a50a738a9aa1"
      unitRef="usd">1000000</smmt:ContractWithCustomerLiabilityEnrollmentMilestone>
    <smmt:ContractWithCustomerLiabilityEnrollmentMilestone
      contextRef="i7d9fb711621141cd9ebefb15542db56a_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNDIvZnJhZzphMjRjNmNhMGI0NDc0YWQ0YTZkNjYyNTU4ODdkY2M1MS90ZXh0cmVnaW9uOmEyNGM2Y2EwYjQ0NzRhZDRhNmQ2NjI1NTg4N2RjYzUxXzE3NDI_c9749e43-4f57-48de-805d-71526990d3be"
      unitRef="usd">1250000</smmt:ContractWithCustomerLiabilityEnrollmentMilestone>
    <smmt:RevenueInformationUsedToDetermineTransactionPriceNumberOfEnrollmentMilestones
      contextRef="i5f7778418eab4524a04524ce76786f35_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNDIvZnJhZzphMjRjNmNhMGI0NDc0YWQ0YTZkNjYyNTU4ODdkY2M1MS90ZXh0cmVnaW9uOmEyNGM2Y2EwYjQ0NzRhZDRhNmQ2NjI1NTg4N2RjYzUxXzE4NTg_68eb3def-075a-4181-988d-a8b81b4d3a10"
      unitRef="milestone">2</smmt:RevenueInformationUsedToDetermineTransactionPriceNumberOfEnrollmentMilestones>
    <smmt:RevenueInformationUsedToDetermineTransactionPriceNumberOfEnrollmentMilestones
      contextRef="i5f7778418eab4524a04524ce76786f35_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNDIvZnJhZzphMjRjNmNhMGI0NDc0YWQ0YTZkNjYyNTU4ODdkY2M1MS90ZXh0cmVnaW9uOmEyNGM2Y2EwYjQ0NzRhZDRhNmQ2NjI1NTg4N2RjYzUxXzIyMjk_1627216c-d911-4e18-b856-f1eeaa8aeb6b"
      unitRef="milestone">2</smmt:RevenueInformationUsedToDetermineTransactionPriceNumberOfEnrollmentMilestones>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i7179bafa598f42ebb6c974d6b860624e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNDIvZnJhZzphMjRjNmNhMGI0NDc0YWQ0YTZkNjYyNTU4ODdkY2M1MS90ZXh0cmVnaW9uOmEyNGM2Y2EwYjQ0NzRhZDRhNmQ2NjI1NTg4N2RjYzUxXzMwMDY_fbc7cc1e-1905-4d0b-9b7b-88e3873a6b0d"
      unitRef="usd">756000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i75af2dac1e474913ae259011f0e40ece_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNDIvZnJhZzphMjRjNmNhMGI0NDc0YWQ0YTZkNjYyNTU4ODdkY2M1MS90ZXh0cmVnaW9uOmEyNGM2Y2EwYjQ0NzRhZDRhNmQ2NjI1NTg4N2RjYzUxXzMwMTM_8e28f2cc-5073-4098-aaf8-d46435adc34c"
      unitRef="usd">759000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i7179bafa598f42ebb6c974d6b860624e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNDIvZnJhZzphMjRjNmNhMGI0NDc0YWQ0YTZkNjYyNTU4ODdkY2M1MS90ZXh0cmVnaW9uOmEyNGM2Y2EwYjQ0NzRhZDRhNmQ2NjI1NTg4N2RjYzUxXzMyMTk_ab5208cf-f7d3-4c28-8af7-531825183e44"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i75af2dac1e474913ae259011f0e40ece_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNDIvZnJhZzphMjRjNmNhMGI0NDc0YWQ0YTZkNjYyNTU4ODdkY2M1MS90ZXh0cmVnaW9uOmEyNGM2Y2EwYjQ0NzRhZDRhNmQ2NjI1NTg4N2RjYzUxXzMyMjY_3fb207b1-07af-4b51-9dc7-8cfaf1113590"
      unitRef="usd">569000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <smmt:RevenueFromContractWithCustomerDevelopmentMilestoneRevenueEntitledToReceive
      contextRef="i5f7778418eab4524a04524ce76786f35_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNDIvZnJhZzphMjRjNmNhMGI0NDc0YWQ0YTZkNjYyNTU4ODdkY2M1MS90ZXh0cmVnaW9uOmEyNGM2Y2EwYjQ0NzRhZDRhNmQ2NjI1NTg4N2RjYzUxXzM0MTM_5a63ddb1-ab6e-4fd5-8d2f-2e2418a3f6f3"
      unitRef="usd">1500000</smmt:RevenueFromContractWithCustomerDevelopmentMilestoneRevenueEntitledToReceive>
    <smmt:RevenueFromContractWithCustomerDevelopmentCommercialAndSalesMilestoneCumulativeNetSalesTargetAchievementRevenueEntitledToReceive
      contextRef="i5f7778418eab4524a04524ce76786f35_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNDIvZnJhZzphMjRjNmNhMGI0NDc0YWQ0YTZkNjYyNTU4ODdkY2M1MS90ZXh0cmVnaW9uOmEyNGM2Y2EwYjQ0NzRhZDRhNmQ2NjI1NTg4N2RjYzUxXzM0OTg_54022898-5d86-457a-b564-d49fdad4f254"
      unitRef="usd">21400000</smmt:RevenueFromContractWithCustomerDevelopmentCommercialAndSalesMilestoneCumulativeNetSalesTargetAchievementRevenueEntitledToReceive>
    <smmt:RevenueFromContractWithCustomerDevelopmentCommercialAndSalesMilestoneCumulativeNetSalesTargetThreshold
      contextRef="i5f7778418eab4524a04524ce76786f35_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNDIvZnJhZzphMjRjNmNhMGI0NDc0YWQ0YTZkNjYyNTU4ODdkY2M1MS90ZXh0cmVnaW9uOmEyNGM2Y2EwYjQ0NzRhZDRhNmQ2NjI1NTg4N2RjYzUxXzM2MDI_bcd906b7-ddc9-4bd7-991f-ac61bf80b8d0"
      unitRef="usd">100000000</smmt:RevenueFromContractWithCustomerDevelopmentCommercialAndSalesMilestoneCumulativeNetSalesTargetThreshold>
    <smmt:RevenueFromContractWithCustomerDevelopmentCommercialAndSalesMilestoneIncrementalCumulativeNetSalesTargetThreshold
      contextRef="i5f7778418eab4524a04524ce76786f35_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNDIvZnJhZzphMjRjNmNhMGI0NDc0YWQ0YTZkNjYyNTU4ODdkY2M1MS90ZXh0cmVnaW9uOmEyNGM2Y2EwYjQ0NzRhZDRhNmQ2NjI1NTg4N2RjYzUxXzM2ODc_1cbd4309-635f-42e7-9d77-73d2a22113a6"
      unitRef="usd">100000000</smmt:RevenueFromContractWithCustomerDevelopmentCommercialAndSalesMilestoneIncrementalCumulativeNetSalesTargetThreshold>
    <us-gaap:OtherOperatingIncomeAndExpenseTextBlock
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNDUvZnJhZzpjN2YzZWYwYjFjMjA0Njk2YWVhYjdjM2FmMjBhODcwYy90ZXh0cmVnaW9uOmM3ZjNlZjBiMWMyMDQ2OTZhZWFiN2MzYWYyMGE4NzBjXzQxMzc_14fe922c-bc30-4bbc-b5e1-6a9a03e20f2f">Other Operating Income &lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the components of other operating income by category:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.467%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other operating income by category:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Funding income from BARDA (as defined below)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Research and development tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Grant income from CARB-X (as defined below)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19,312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;BARDA (as defined below)&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2017, the Company was awarded a funding contract from the Biomedical Advanced Research and Development Authority ("BARDA"), part of the Office of the Assistant Secretary for Preparedness and Response at the United States Department of Health and Human Services, in support of the Company's Ri-CoDIFy clinical trials and clinical development of of ridinilazole.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The awarded contract was originally worth up to $62,000. In June 2019 and again in January 2020, BARDA increased the value of the contract such that it is now worth up to $72,500 and brought the total amount of committed funding to $62,400. The remaining federal government funding is dependent on BARDA in its sole discretion exercising the final independent option work segment, upon the achievement by the Company of certain agreed-upon milestones for ridinilazole. As of December 31, 2021, an aggregate of $56,492 of the total committed BARDA funding had been received and the Company has recognized $50,265 of cumulative income since contract inception.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Research and development credits&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income from tax credits, consist of R&amp;amp;D tax credits received in the U.K. The Company benefits from two U.K. research and development tax credit cash rebate regimes: Small and Medium Enterprise Program ("SME, Program") and the Research and Development Expenditure Credit Program ("RDEC Program"). Qualifying expenditures largely comprise of employment costs for research staff, consumables, a proportion of relevant, permitted sub-contract costs and certain internal overhead costs incurred as part of research projects for which the Company does not receive income. Tax credits related to the SME Program and RDEC Program are recorded as other operating income in the consolidated statements of operations and other comprehensive loss. Under both schemes, the Company receives cash payments that are not dependent on the Company&#x2019;s pre-tax net income levels.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Based on criteria established by Her Majesty&#x2019;s Revenue and Customs ("HMRC"), a portion of expenditures being carried out in relation to the Company's pipeline research and development, clinical trials management and third-party manufacturing development activities are eligible for the SME regime and the Company expects such elements of expenditure will also continue to be eligible for the SME regime for future periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;As of December 31, 2021 and 2020, the current research and development tax credit receivable was $15,695 and $9,856, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;CARB-X (as defined below)&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2021, the Company announced the selection of a new preclinical candidate, SMT-738, from the DDS-04 series for development in the fight against multi-drug resistant infections, specifically Carbapenem-resistant Enterobacteriaceae ("CRE") infections. Simultaneously, the Company announced it had received an award from the Trustees of Boston University under the Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator program ("CARB-X") to progress this candidate through preclinical development and Phase Ia clinical trials. The award commits initial funding of up to $4,100, with the possibility of up to another $3,700 based on the achievement of future milestones. As of December 31, 2021, $485 of grant funding from CARB-X has been received, $96 is in accounts receivable for amounts billed, $574 is in other current assets as a contract asset and the Company has recognized $1,155 of cumulative income since contract inception.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Grant income recognized during the year ended December 31, 2021 relates to SMT-738. Grant income recognized during the year ended December, 31, 2020 consists of income from a sub-award from CARB-X for the Company's antibiotic pipeline research and development activities specifically relating to the DDS-01 series of antibiotics, targeting Neisseria gonorrhoeae, or N. gonorrhoeae, using the Discuva Platform. In the fourth quarter of 2020, the Company decided not to advance the DDS-01 series and to cease work on the gonorrhoeae program, and as such, no further grant income has been received from CARB-X under this sub-award.&lt;/span&gt;&lt;/div&gt;</us-gaap:OtherOperatingIncomeAndExpenseTextBlock>
    <smmt:ScheduleOfOtherOperatingIncomeByComponentTableTextBlock
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNDUvZnJhZzpjN2YzZWYwYjFjMjA0Njk2YWVhYjdjM2FmMjBhODcwYy90ZXh0cmVnaW9uOmM3ZjNlZjBiMWMyMDQ2OTZhZWFiN2MzYWYyMGE4NzBjXzQxNDU_68b6d17b-aa1e-433b-881b-f4748c411f61">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the components of other operating income by category:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.467%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other operating income by category:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Funding income from BARDA (as defined below)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Research and development tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Grant income from CARB-X (as defined below)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19,312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</smmt:ScheduleOfOtherOperatingIncomeByComponentTableTextBlock>
    <smmt:GrantFundingArrangementIncomeEarned
      contextRef="ia4d86426c389449ebc2c7f1874dbc3fc_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNDUvZnJhZzpjN2YzZWYwYjFjMjA0Njk2YWVhYjdjM2FmMjBhODcwYy90YWJsZTo3NzFjODJmYTg4NDg0ZDkzODc1ZmFlZGZmNmNmNmUzNy90YWJsZXJhbmdlOjc3MWM4MmZhODg0ODRkOTM4NzVmYWVkZmY2Y2Y2ZTM3XzItMi0xLTEtMTA5ODc2_75f8ccb5-6773-49cc-9669-d4ff7ef066de"
      unitRef="usd">4604000</smmt:GrantFundingArrangementIncomeEarned>
    <smmt:GrantFundingArrangementIncomeEarned
      contextRef="iab792aa058af48aba2d03719d4253bde_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNDUvZnJhZzpjN2YzZWYwYjFjMjA0Njk2YWVhYjdjM2FmMjBhODcwYy90YWJsZTo3NzFjODJmYTg4NDg0ZDkzODc1ZmFlZGZmNmNmNmUzNy90YWJsZXJhbmdlOjc3MWM4MmZhODg0ODRkOTM4NzVmYWVkZmY2Y2Y2ZTM3XzItNC0xLTEtMTA5ODc2_d280a58c-28af-498b-88f8-f562d20961bd"
      unitRef="usd">9472000</smmt:GrantFundingArrangementIncomeEarned>
    <smmt:ResearchAndDevelopmentTaxCredit
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNDUvZnJhZzpjN2YzZWYwYjFjMjA0Njk2YWVhYjdjM2FmMjBhODcwYy90YWJsZTo3NzFjODJmYTg4NDg0ZDkzODc1ZmFlZGZmNmNmNmUzNy90YWJsZXJhbmdlOjc3MWM4MmZhODg0ODRkOTM4NzVmYWVkZmY2Y2Y2ZTM3XzMtMi0xLTEtMTA5ODc2_a837e75e-ff74-4153-bc0d-a893b1740818"
      unitRef="usd">15206000</smmt:ResearchAndDevelopmentTaxCredit>
    <smmt:ResearchAndDevelopmentTaxCredit
      contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNDUvZnJhZzpjN2YzZWYwYjFjMjA0Njk2YWVhYjdjM2FmMjBhODcwYy90YWJsZTo3NzFjODJmYTg4NDg0ZDkzODc1ZmFlZGZmNmNmNmUzNy90YWJsZXJhbmdlOjc3MWM4MmZhODg0ODRkOTM4NzVmYWVkZmY2Y2Y2ZTM3XzMtNC0xLTEtMTA5ODc2_1a331733-f9fd-49d4-808e-98a1d75c6920"
      unitRef="usd">9363000</smmt:ResearchAndDevelopmentTaxCredit>
    <smmt:GrantFundingArrangementIncomeEarned
      contextRef="i4ef399140bb14718b545a1aaa04203df_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNDUvZnJhZzpjN2YzZWYwYjFjMjA0Njk2YWVhYjdjM2FmMjBhODcwYy90YWJsZTo3NzFjODJmYTg4NDg0ZDkzODc1ZmFlZGZmNmNmNmUzNy90YWJsZXJhbmdlOjc3MWM4MmZhODg0ODRkOTM4NzVmYWVkZmY2Y2Y2ZTM3XzQtMi0xLTEtMTA5ODc2_075c7e88-2f9f-467a-96de-2c092819cc4d"
      unitRef="usd">1158000</smmt:GrantFundingArrangementIncomeEarned>
    <smmt:GrantFundingArrangementIncomeEarned
      contextRef="i52c373554f2f40b4a54d0ff856b68cf6_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNDUvZnJhZzpjN2YzZWYwYjFjMjA0Njk2YWVhYjdjM2FmMjBhODcwYy90YWJsZTo3NzFjODJmYTg4NDg0ZDkzODc1ZmFlZGZmNmNmNmUzNy90YWJsZXJhbmdlOjc3MWM4MmZhODg0ODRkOTM4NzVmYWVkZmY2Y2Y2ZTM3XzQtNC0xLTEtMTA5ODc2_07fe46ff-a87c-40eb-8777-0be0ee2856b0"
      unitRef="usd">477000</smmt:GrantFundingArrangementIncomeEarned>
    <us-gaap:OtherOperatingIncome
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNDUvZnJhZzpjN2YzZWYwYjFjMjA0Njk2YWVhYjdjM2FmMjBhODcwYy90YWJsZTo3NzFjODJmYTg4NDg0ZDkzODc1ZmFlZGZmNmNmNmUzNy90YWJsZXJhbmdlOjc3MWM4MmZhODg0ODRkOTM4NzVmYWVkZmY2Y2Y2ZTM3XzUtMi0xLTEtMTA5ODc2_d41a7fa1-2918-4b33-84f0-c9e46ea1a5b2"
      unitRef="usd">20968000</us-gaap:OtherOperatingIncome>
    <us-gaap:OtherOperatingIncome
      contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNDUvZnJhZzpjN2YzZWYwYjFjMjA0Njk2YWVhYjdjM2FmMjBhODcwYy90YWJsZTo3NzFjODJmYTg4NDg0ZDkzODc1ZmFlZGZmNmNmNmUzNy90YWJsZXJhbmdlOjc3MWM4MmZhODg0ODRkOTM4NzVmYWVkZmY2Y2Y2ZTM3XzUtNC0xLTEtMTA5ODc2_a50f548d-c65e-4129-9466-d8b6829086ef"
      unitRef="usd">19312000</us-gaap:OtherOperatingIncome>
    <smmt:GrantFundingArrangementMaximumFundingValue
      contextRef="i5189024af3e3465a96e4c5c1204cfc1d_D20170901-20170930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNDUvZnJhZzpjN2YzZWYwYjFjMjA0Njk2YWVhYjdjM2FmMjBhODcwYy90ZXh0cmVnaW9uOmM3ZjNlZjBiMWMyMDQ2OTZhZWFiN2MzYWYyMGE4NzBjXzU1MA_f7620929-a1f3-4e4e-a906-ee38f4b8fe9a"
      unitRef="usd">62000000</smmt:GrantFundingArrangementMaximumFundingValue>
    <smmt:GrantFundingArrangementMaximumFundingValue
      contextRef="ia4d86426c389449ebc2c7f1874dbc3fc_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNDUvZnJhZzpjN2YzZWYwYjFjMjA0Njk2YWVhYjdjM2FmMjBhODcwYy90ZXh0cmVnaW9uOmM3ZjNlZjBiMWMyMDQ2OTZhZWFiN2MzYWYyMGE4NzBjXzY2OA_b63de970-732c-41da-8b13-a5d0a5efc121"
      unitRef="usd">72500000</smmt:GrantFundingArrangementMaximumFundingValue>
    <smmt:GrantFundingArrangementCommittedFundingTotal
      contextRef="ia4d86426c389449ebc2c7f1874dbc3fc_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNDUvZnJhZzpjN2YzZWYwYjFjMjA0Njk2YWVhYjdjM2FmMjBhODcwYy90ZXh0cmVnaW9uOmM3ZjNlZjBiMWMyMDQ2OTZhZWFiN2MzYWYyMGE4NzBjXzcyNA_bf359a12-a8a5-4e34-a3ce-9da5f85758fc"
      unitRef="usd">62400000</smmt:GrantFundingArrangementCommittedFundingTotal>
    <smmt:GrantFundingArrangementFundingReceived
      contextRef="i6080657079b74ddc92d888ef28f1a49a_D20170901-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNDUvZnJhZzpjN2YzZWYwYjFjMjA0Njk2YWVhYjdjM2FmMjBhODcwYy90ZXh0cmVnaW9uOmM3ZjNlZjBiMWMyMDQ2OTZhZWFiN2MzYWYyMGE4NzBjXzk4Mg_6cade9de-65cc-4130-9089-9346063079e3"
      unitRef="usd">56492000</smmt:GrantFundingArrangementFundingReceived>
    <smmt:GrantFundingArrangementIncomeEarned
      contextRef="i6080657079b74ddc92d888ef28f1a49a_D20170901-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNDUvZnJhZzpjN2YzZWYwYjFjMjA0Njk2YWVhYjdjM2FmMjBhODcwYy90ZXh0cmVnaW9uOmM3ZjNlZjBiMWMyMDQ2OTZhZWFiN2MzYWYyMGE4NzBjXzEwNzE_f2e85972-d1da-4ebd-933a-cc33261fb222"
      unitRef="usd">50265000</smmt:GrantFundingArrangementIncomeEarned>
    <smmt:ResearchAndDevelopmentTaxCreditReceivableCurrent
      contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNDUvZnJhZzpjN2YzZWYwYjFjMjA0Njk2YWVhYjdjM2FmMjBhODcwYy90ZXh0cmVnaW9uOmM3ZjNlZjBiMWMyMDQ2OTZhZWFiN2MzYWYyMGE4NzBjXzI1MTk_a7595fc5-eb4c-4a07-8a6e-f60d9f01de88"
      unitRef="usd">15695000</smmt:ResearchAndDevelopmentTaxCreditReceivableCurrent>
    <smmt:ResearchAndDevelopmentTaxCreditReceivableCurrent
      contextRef="i7372be6dc06143b5adbb4d2e83a596c5_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNDUvZnJhZzpjN2YzZWYwYjFjMjA0Njk2YWVhYjdjM2FmMjBhODcwYy90ZXh0cmVnaW9uOmM3ZjNlZjBiMWMyMDQ2OTZhZWFiN2MzYWYyMGE4NzBjXzI1MjY_f7c2926a-383d-4515-af59-756255b8fa6a"
      unitRef="usd">9856000</smmt:ResearchAndDevelopmentTaxCreditReceivableCurrent>
    <smmt:GrantFundingArrangementCommittedFundingBase
      contextRef="ice72e22d8b604c7a9047363b98c2c5e0_D20210501-20210531"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNDUvZnJhZzpjN2YzZWYwYjFjMjA0Njk2YWVhYjdjM2FmMjBhODcwYy90ZXh0cmVnaW9uOmM3ZjNlZjBiMWMyMDQ2OTZhZWFiN2MzYWYyMGE4NzBjXzMxNjA_0f8e3893-7756-4e44-af85-19a57122ea68"
      unitRef="usd">4100000</smmt:GrantFundingArrangementCommittedFundingBase>
    <smmt:GrantFundingArrangementMilestoneFundingIncrease
      contextRef="ice72e22d8b604c7a9047363b98c2c5e0_D20210501-20210531"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNDUvZnJhZzpjN2YzZWYwYjFjMjA0Njk2YWVhYjdjM2FmMjBhODcwYy90ZXh0cmVnaW9uOmM3ZjNlZjBiMWMyMDQ2OTZhZWFiN2MzYWYyMGE4NzBjXzMyMDI_3a1f2962-dc16-484d-945d-f9532a80ee5d"
      unitRef="usd">3700000</smmt:GrantFundingArrangementMilestoneFundingIncrease>
    <smmt:GrantFundingArrangementFundingReceived
      contextRef="i31a55aa85c704fa1b0bf71fb5d66f073_D20210501-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNDUvZnJhZzpjN2YzZWYwYjFjMjA0Njk2YWVhYjdjM2FmMjBhODcwYy90ZXh0cmVnaW9uOmM3ZjNlZjBiMWMyMDQ2OTZhZWFiN2MzYWYyMGE4NzBjXzMyNzc_906ca6d4-c9c0-42fa-b3a2-b98420ac0df6"
      unitRef="usd">485000</smmt:GrantFundingArrangementFundingReceived>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="iba2a2e6aa4554084aa69ed9ef72c2590_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNDUvZnJhZzpjN2YzZWYwYjFjMjA0Njk2YWVhYjdjM2FmMjBhODcwYy90ZXh0cmVnaW9uOmM3ZjNlZjBiMWMyMDQ2OTZhZWFiN2MzYWYyMGE4NzBjXzMzMjg_8f22224e-2a4c-4a81-8e24-f0cbae5db993"
      unitRef="usd">96000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="iba2a2e6aa4554084aa69ed9ef72c2590_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNDUvZnJhZzpjN2YzZWYwYjFjMjA0Njk2YWVhYjdjM2FmMjBhODcwYy90ZXh0cmVnaW9uOmM3ZjNlZjBiMWMyMDQ2OTZhZWFiN2MzYWYyMGE4NzBjXzMzNzc_d1edddac-a152-40df-b8df-bdb1ec5b389a"
      unitRef="usd">574000</us-gaap:ContractWithCustomerAssetNetCurrent>
    <smmt:GrantFundingArrangementIncomeEarned
      contextRef="i31a55aa85c704fa1b0bf71fb5d66f073_D20210501-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNDUvZnJhZzpjN2YzZWYwYjFjMjA0Njk2YWVhYjdjM2FmMjBhODcwYy90ZXh0cmVnaW9uOmM3ZjNlZjBiMWMyMDQ2OTZhZWFiN2MzYWYyMGE4NzBjXzM0NTg_aae98854-5e1c-43de-a6ab-e777d2205e83"
      unitRef="usd">1155000</smmt:GrantFundingArrangementIncomeEarned>
    <us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNDgvZnJhZzpjMGU3YmJjMDJjODA0NzU3OTk1MGEzODhlY2NlZTc5ZC90ZXh0cmVnaW9uOmMwZTdiYmMwMmM4MDQ3NTc5OTUwYTM4OGVjY2VlNzlkXzUwOA_848c4856-fd3a-4aa5-a62f-512f1659b72e">Other (Expense) Income&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the components of other (expense) income:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.467%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Foreign currency (loss) gain&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,135)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Remeasurement of liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(281)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(255)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,416)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;_____________&lt;/span&gt;&lt;/div&gt;(1) Remeasurement of liabilities during the year ended December 31, 2020, relates to a revaluation of assumed contingent liabilities for potential payments to certain employees, former employees and former directors of Discuva Limited, based on specified development and clinical milestones related to proprietary product candidates developed under the Discuva Platform (see Note 16 for further details).</us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock>
    <us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNDgvZnJhZzpjMGU3YmJjMDJjODA0NzU3OTk1MGEzODhlY2NlZTc5ZC90ZXh0cmVnaW9uOmMwZTdiYmMwMmM4MDQ3NTc5OTUwYTM4OGVjY2VlNzlkXzUwOQ_01b05d08-2ef8-43f5-acd3-176017b044c0">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the components of other (expense) income:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.467%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Foreign currency (loss) gain&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,135)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Remeasurement of liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(281)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(255)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,416)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;_____________&lt;/span&gt;&lt;/div&gt;(1) Remeasurement of liabilities during the year ended December 31, 2020, relates to a revaluation of assumed contingent liabilities for potential payments to certain employees, former employees and former directors of Discuva Limited, based on specified development and clinical milestones related to proprietary product candidates developed under the Discuva Platform (see Note 16 for further details).</us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNDgvZnJhZzpjMGU3YmJjMDJjODA0NzU3OTk1MGEzODhlY2NlZTc5ZC90YWJsZTo0MmRlY2U1OGUyMzI0NTJmOGJkZDg2OTczZGE3NDc2YS90YWJsZXJhbmdlOjQyZGVjZTU4ZTIzMjQ1MmY4YmRkODY5NzNkYTc0NzZhXzEtMi0xLTEtMTA5ODc2_a110f518-c035-4ba8-81bb-7708eff957b9"
      unitRef="usd">-2135000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNDgvZnJhZzpjMGU3YmJjMDJjODA0NzU3OTk1MGEzODhlY2NlZTc5ZC90YWJsZTo0MmRlY2U1OGUyMzI0NTJmOGJkZDg2OTczZGE3NDc2YS90YWJsZXJhbmdlOjQyZGVjZTU4ZTIzMjQ1MmY4YmRkODY5NzNkYTc0NzZhXzEtNC0xLTEtMTA5ODc2_6bdca8b1-ed18-4032-b690-fdd06d164410"
      unitRef="usd">54000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <smmt:GainLossOnRemeasurementOfLiabilitiesNonoperating
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNDgvZnJhZzpjMGU3YmJjMDJjODA0NzU3OTk1MGEzODhlY2NlZTc5ZC90YWJsZTo0MmRlY2U1OGUyMzI0NTJmOGJkZDg2OTczZGE3NDc2YS90YWJsZXJhbmdlOjQyZGVjZTU4ZTIzMjQ1MmY4YmRkODY5NzNkYTc0NzZhXzItMi0xLTEtMTA5ODc2_80cc77c4-a230-4180-aa0a-574228136247"
      unitRef="usd">0</smmt:GainLossOnRemeasurementOfLiabilitiesNonoperating>
    <smmt:GainLossOnRemeasurementOfLiabilitiesNonoperating
      contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNDgvZnJhZzpjMGU3YmJjMDJjODA0NzU3OTk1MGEzODhlY2NlZTc5ZC90YWJsZTo0MmRlY2U1OGUyMzI0NTJmOGJkZDg2OTczZGE3NDc2YS90YWJsZXJhbmdlOjQyZGVjZTU4ZTIzMjQ1MmY4YmRkODY5NzNkYTc0NzZhXzItNC0xLTEtMTA5ODc2_bb15ed2b-8e54-4651-8137-93008123c889"
      unitRef="usd">480000</smmt:GainLossOnRemeasurementOfLiabilitiesNonoperating>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNDgvZnJhZzpjMGU3YmJjMDJjODA0NzU3OTk1MGEzODhlY2NlZTc5ZC90YWJsZTo0MmRlY2U1OGUyMzI0NTJmOGJkZDg2OTczZGE3NDc2YS90YWJsZXJhbmdlOjQyZGVjZTU4ZTIzMjQ1MmY4YmRkODY5NzNkYTc0NzZhXzMtMi0xLTEtMTA5ODc2_28804ddf-7bfc-463b-87fd-c5f20a0650d4"
      unitRef="usd">0</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNDgvZnJhZzpjMGU3YmJjMDJjODA0NzU3OTk1MGEzODhlY2NlZTc5ZC90YWJsZTo0MmRlY2U1OGUyMzI0NTJmOGJkZDg2OTczZGE3NDc2YS90YWJsZXJhbmdlOjQyZGVjZTU4ZTIzMjQ1MmY4YmRkODY5NzNkYTc0NzZhXzMtNC0xLTEtMTA5ODc2_97fe0e26-0800-4e8a-9037-0ed1d575890e"
      unitRef="usd">4000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpense
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNDgvZnJhZzpjMGU3YmJjMDJjODA0NzU3OTk1MGEzODhlY2NlZTc5ZC90YWJsZTo0MmRlY2U1OGUyMzI0NTJmOGJkZDg2OTczZGE3NDc2YS90YWJsZXJhbmdlOjQyZGVjZTU4ZTIzMjQ1MmY4YmRkODY5NzNkYTc0NzZhXzQtMi0xLTEtMTA5ODc2_faa07b7b-54fa-48f3-9641-c51f5702db09"
      unitRef="usd">281000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNDgvZnJhZzpjMGU3YmJjMDJjODA0NzU3OTk1MGEzODhlY2NlZTc5ZC90YWJsZTo0MmRlY2U1OGUyMzI0NTJmOGJkZDg2OTczZGE3NDc2YS90YWJsZXJhbmdlOjQyZGVjZTU4ZTIzMjQ1MmY4YmRkODY5NzNkYTc0NzZhXzQtNC0xLTEtMTA5ODc2_7d23a34c-aa6f-430e-842d-7d1630aa84c3"
      unitRef="usd">255000</us-gaap:InterestExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNDgvZnJhZzpjMGU3YmJjMDJjODA0NzU3OTk1MGEzODhlY2NlZTc5ZC90YWJsZTo0MmRlY2U1OGUyMzI0NTJmOGJkZDg2OTczZGE3NDc2YS90YWJsZXJhbmdlOjQyZGVjZTU4ZTIzMjQ1MmY4YmRkODY5NzNkYTc0NzZhXzUtMi0xLTEtMTA5ODc2_ab32b29c-5198-492c-a4c6-65df1aa4ed2d"
      unitRef="usd">-2416000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNDgvZnJhZzpjMGU3YmJjMDJjODA0NzU3OTk1MGEzODhlY2NlZTc5ZC90YWJsZTo0MmRlY2U1OGUyMzI0NTJmOGJkZDg2OTczZGE3NDc2YS90YWJsZXJhbmdlOjQyZGVjZTU4ZTIzMjQ1MmY4YmRkODY5NzNkYTc0NzZhXzUtNC0xLTEtMTA5ODc2_f5e88453-4596-4bf0-8e1c-0720d52790d7"
      unitRef="usd">283000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTEvZnJhZzo2YTM0ODA1OTRlOGY0MDQ2YmU4NGM5MTBjNDUyOTkzMS90ZXh0cmVnaW9uOjZhMzQ4MDU5NGU4ZjQwNDZiZTg0YzkxMGM0NTI5OTMxXzEwMTU4_85d541ca-a2b9-405d-be0b-532419d15020">Income Tax&#160;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of the Company's loss before income taxes are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.467%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;United Kingdom&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(72,244)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(51,197)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16,358)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,713)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Loss before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(88,602)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(52,910)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Significant components of the provision for income taxes are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.198%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current income tax benefit:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Federal United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(215)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;State - United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Non-United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(213)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Federal - United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;State - United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Non-United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total deferred tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total income tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(213)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Deferred taxes are recognized for temporary differences between the basis of assets and liabilities for financial statement and income tax purposes. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The major components of deferred tax assets and liabilities are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.467%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.468%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net operating loss carryforward&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,831&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Research and development credit carryforward&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;941&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Stock based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,167&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;491&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,489&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Intangible asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,600)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,189)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(54)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(71)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,654)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,260)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net deferred tax assets before valuation allowance &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,746&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,229&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(51,746)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29,229)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Deferred tax, net&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the year ended December 31, 2021 and 2020, the Company recorded a deferred tax asset of $54.400 and $31,489 respectively. The Company has evaluated the positive and negative evidence bearing upon its ability to realize its deferred tax assets, which are comprised primarily of net operating loss carryforwards and excess tax benefits related to stock-based compensation. Management has considered the Company&#x2019;s history of cumulative net losses in the United States ("U.S.") and the United Kingdom ("U.K."), estimated future taxable income, as well as prudent and feasible tax planning strategies, and has concluded that it is more likely than not that the Company will not realize the benefits of its U.S. federal and state deferred tax assets and U.K. deferred tax assets. Accordingly, a full valuation allowance has been established against these net deferred tax assets as of December 31, 2021 and 2020, respectively. The Company reevaluates the positive and negative evidence at each &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;reporting period. The Company&#x2019;s valuation allowance increased during 2021 by $22,517 primarily due to the generation of net operating loss and stock-based compensation. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2021 and 2020, the Company had U.S. Federal net operating loss carryforwards of approximately $1,034 and $232, respectively, which may be available to offset future income tax liabilities. The 2017 Tax Cuts and Jobs Act (&#x201c; TCJA&#x201d;) will generally allow losses incurred after 2017 to be carried over indefinitely, but will generally limit the net operating loss deduction to the lesser of the net operating loss carryover or 80% of a corporation&#x2019;s taxable income (subject to Section 382 of the Internal Revenue Code of 1986, as amended). In addition, the Company has approximately $165 in U.S. State loss carryforwards which expire through various dates through 2040 and as of December 31, 2021, the Company had an estimated U.S. federal research and development tax credit carryforwards of $941 which may be available to offset future tax liabilities, and each begin to expire in 2033. The Company also had approximately $191,714 in U.K. loss carryforwards available to use against future taxable profits on a year-by-year basis (a potential deferred tax asset of $47,929). To the extent that U.K. taxable profits exceed &#xa3;5,000 in each year, the loss available to utilize against profits in excess of &#xa3;5,000 will be restricted to 50%. The U.K. loss carryforwards do not lapse and therefore, the full amount will be relieved over time provided there are sufficient profits against which the losses can be utilized. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Utilization of the U.S. net operating loss carryforwards and research and development tax credit carryforwards may be subject to a substantial annual limitation under Section 382 of the Internal Revenue Code of 1986 due to ownership changes that have occurred previously or that could occur in the future. These ownership changes may limit the amount of carryforwards that can be utilized annually to offset future taxable income. In general, an ownership change, as defined by Section 382, results from transactions increasing the ownership of certain shareholders or public groups in the stock of a corporation by more than 50% over a three-year period. The Company has not completed a study to assess whether a change of ownership has occurred, or whether there have been multiple ownership changes since its formation. Any limitation may result in the loss of a portion of the net operating loss carryforwards or research and development tax credit carryforwards before utilization.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.K. tax losses are subject to additional restrictions where there is a change in ownership in the business and certain other conditions are met. An ownership change of a UK tax resident company would occur where (directly or indirectly) a single person acquires more than half of the ordinary share capital of a company, or two or more persons each acquire a holding of at least 5% of the ordinary share capital of a company and these holdings together amount to more than half the ordinary share capital of a company. Where a change in ownership has occurred, and within three years prior to that change in ownership and five years afterwards, there is a major change in the nature and conduct of trade of that company or the trade of that business becomes small or negligible, any losses carried forward will be extinguished from the point of the change in ownership. In addition, losses accrued subsequent to April 1, 2017 will be extinguished on a change of ownership when there is a major change in the nature or conduct of a company&#x2019;s business, or where there is a major change in the scale of that business, or a company ceases to carry on a particular trade or business. The Company has not completed a study to assess whether a change of ownership has occurred since its formation, or whether there has been a major change in the Company's business that would restrict the U.K. tax losses. Any limitation may result in the loss of a portion of the net operating loss carryforwards before utilization.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2017 Tax Cuts and Jobs Act (&#x201c;2017 Act&#x201d;) created a requirement that US corporations include in income earnings of certain controlled foreign corporations (&#x201c;CFC&#x201d;) under the global intangible low taxed income (&#x201c;GILTI&#x201d;) regime. Pursuant to the FASB Staff Q&amp;amp;A, Topic 740 No.5. Accounting for Global Intangible Low-taxed Income, the Company is allowed to make an accounting policy election to either recognize deferred taxes for temporary basis differences expected to reverse as GILTI in future years or to provide for the tax expense related to GILTI in the year the tax is incurred as period expense only. The Company has elected to account for GILTI in the year the tax is incurred and include the current tax impact of GILTI in the effective tax rate. Given the Company's loss position in the U.S. and the valuation allowance recorded against its U.S. net deferred tax assets, these provisions have not had a material impact on the Company's consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 27, 2020, the United States enacted the Coronavirus Aid, Relief, and Economic Security Act (&#x201c;CARES Act&#x201d;). The Cares Act includes provisions relating to refundable payroll tax credits, deferment of the employer portion of certain payroll taxes, net operating loss carryback periods, alternative minimum tax credit refunds, modifications to the net interest deduction limitations, and technical corrections to tax depreciation methods for qualified improvement property. The CARES Act also &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;established a Paycheck Protection Program whereby certain small businesses are eligible for a loan to fund payroll expenses, rent, and related costs.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considered the provisions under the CARES Act and elected not to take advantage of the provisions of the CARES Act as the effect of such provisions was not expected to have a material impact on the Company&#x2019;s results of operations, cash flows, and consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2021, the U.K. Government announced that from April 1, 2023, the corporation tax rate would increase to 25%. This new law was enacted on June 10, 2021. The overall effect of the change was an increase in net deferred tax assets by $9,311 and an increase in valuation allowance by an equal amount.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of the Company's effective tax rate to the U.S. federal statutory rate is as follows: &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.467%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:83%"&gt;Year Ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:83%"&gt;Year Ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. federal income tax statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Non-deductible expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Refundable research and development tax credit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Effect of foreign operations taxed at various rates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the U.K., the Company is entitled to a research and development tax relief for small and medium-sized enterprises which allows the Company an enhanced deduction rate of 230% on qualifying research and development expenditure (the tax relief). If the Company incurs tax losses, it is entitled to surrender the lesser of unrelieved tax loss sustained and the tax relief. As the realization of the tax relief does not depend on generation of future taxable income or the Company's ongoing tax status or tax position, the Company does not consider the tax relief as an element of income tax accounting under ASC 740. For the year ended December 31, 2021 and 2020, the Company recognized research and development tax relief of $15,206 and $9,363 respectively, which is included in other operating income in the consolidated statements of operations and other comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;It is the intention of the Company to reinvest the earnings of its non-U.S. subsidiaries in those operations and not to repatriate the earnings to the U.S. Accordingly, the Company does not provide for deferred taxes on differences between financial reporting and tax basis in its investments in foreign subsidiaries as they are considered permanent in duration or are not expected to reverse in the foreseeable future.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company does not have any uncertain tax positions as of December 31, 2021. In the U.K., tax returns for the year ended December 31, 2020 remains subject to examination by HMRC. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the U.S., the Company files income tax returns in various states. In the U.S., tax years from 2018 remain subject to examination by the U.S. Internal Revenue Service and state tax authorities. The Company is not currently under examination by the Internal Revenue Service or any other jurisdiction for years 2018 through present. To the extent the Company has tax attribute carryforwards, the tax years in which the attribute was generated may be adjusted upon examination by the Internal Revenue Service or state tax authorities to the extent utilized in a future period. The Company&#x2019;s policy is to recognize interest and penalties related to uncertain tax positions as part of its income tax provision. As of December 31, 2021, and 2020, the Company has recorded no liability for unrecognized tax benefits, interest, or penalties related to federal, state or foreign income tax matters.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTEvZnJhZzo2YTM0ODA1OTRlOGY0MDQ2YmU4NGM5MTBjNDUyOTkzMS90ZXh0cmVnaW9uOjZhMzQ4MDU5NGU4ZjQwNDZiZTg0YzkxMGM0NTI5OTMxXzEwMTYx_c1b8dc02-107c-4019-b85d-7b4604994f9e">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of the Company's loss before income taxes are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.467%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;United Kingdom&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(72,244)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(51,197)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16,358)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,713)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Loss before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(88,602)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(52,910)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTEvZnJhZzo2YTM0ODA1OTRlOGY0MDQ2YmU4NGM5MTBjNDUyOTkzMS90YWJsZTo1MmNjMzJlZjljMDc0NjdjYWRlM2I3MmI0YjZlZDA3Ny90YWJsZXJhbmdlOjUyY2MzMmVmOWMwNzQ2N2NhZGUzYjcyYjRiNmVkMDc3XzEtMi0xLTEtMTA5ODc2_5192a60c-4fe5-4bd3-a9a2-be2273ff6321"
      unitRef="usd">-72244000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTEvZnJhZzo2YTM0ODA1OTRlOGY0MDQ2YmU4NGM5MTBjNDUyOTkzMS90YWJsZTo1MmNjMzJlZjljMDc0NjdjYWRlM2I3MmI0YjZlZDA3Ny90YWJsZXJhbmdlOjUyY2MzMmVmOWMwNzQ2N2NhZGUzYjcyYjRiNmVkMDc3XzEtNC0xLTEtMTA5ODc2_171b2c73-8d9a-4496-85b8-62b660167a87"
      unitRef="usd">-51197000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTEvZnJhZzo2YTM0ODA1OTRlOGY0MDQ2YmU4NGM5MTBjNDUyOTkzMS90YWJsZTo1MmNjMzJlZjljMDc0NjdjYWRlM2I3MmI0YjZlZDA3Ny90YWJsZXJhbmdlOjUyY2MzMmVmOWMwNzQ2N2NhZGUzYjcyYjRiNmVkMDc3XzItMi0xLTEtMTA5ODc2_080744df-9857-41e2-9237-a2753d252ed9"
      unitRef="usd">-16358000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTEvZnJhZzo2YTM0ODA1OTRlOGY0MDQ2YmU4NGM5MTBjNDUyOTkzMS90YWJsZTo1MmNjMzJlZjljMDc0NjdjYWRlM2I3MmI0YjZlZDA3Ny90YWJsZXJhbmdlOjUyY2MzMmVmOWMwNzQ2N2NhZGUzYjcyYjRiNmVkMDc3XzItNC0xLTEtMTA5ODc2_11f6c76d-83a6-4ce8-925d-9bac987dd8cb"
      unitRef="usd">-1713000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTEvZnJhZzo2YTM0ODA1OTRlOGY0MDQ2YmU4NGM5MTBjNDUyOTkzMS90YWJsZTo1MmNjMzJlZjljMDc0NjdjYWRlM2I3MmI0YjZlZDA3Ny90YWJsZXJhbmdlOjUyY2MzMmVmOWMwNzQ2N2NhZGUzYjcyYjRiNmVkMDc3XzMtMi0xLTEtMTA5ODc2_77f7af6d-a09c-413d-9704-f46c45b9e4ea"
      unitRef="usd">-88602000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTEvZnJhZzo2YTM0ODA1OTRlOGY0MDQ2YmU4NGM5MTBjNDUyOTkzMS90YWJsZTo1MmNjMzJlZjljMDc0NjdjYWRlM2I3MmI0YjZlZDA3Ny90YWJsZXJhbmdlOjUyY2MzMmVmOWMwNzQ2N2NhZGUzYjcyYjRiNmVkMDc3XzMtNC0xLTEtMTA5ODc2_1650c169-0f6e-4d32-b817-d394cbe3ee06"
      unitRef="usd">-52910000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTEvZnJhZzo2YTM0ODA1OTRlOGY0MDQ2YmU4NGM5MTBjNDUyOTkzMS90ZXh0cmVnaW9uOjZhMzQ4MDU5NGU4ZjQwNDZiZTg0YzkxMGM0NTI5OTMxXzEwMTU3_7d719edc-b2bb-40d4-901b-27aa77361dba">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Significant components of the provision for income taxes are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.198%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current income tax benefit:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Federal United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(215)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;State - United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Non-United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(213)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Federal - United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;State - United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Non-United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total deferred tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total income tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(213)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTEvZnJhZzo2YTM0ODA1OTRlOGY0MDQ2YmU4NGM5MTBjNDUyOTkzMS90YWJsZTpmNWZiZWZhMWQ5ZDY0MTM3OTA3MWM5MTIyNjg1ZDgyYi90YWJsZXJhbmdlOmY1ZmJlZmExZDlkNjQxMzc5MDcxYzkxMjI2ODVkODJiXzMtMS0xLTEtMTA5ODc2_4688d01c-21c7-4bf7-8dbc-db370fdc359b"
      unitRef="usd">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTEvZnJhZzo2YTM0ODA1OTRlOGY0MDQ2YmU4NGM5MTBjNDUyOTkzMS90YWJsZTpmNWZiZWZhMWQ5ZDY0MTM3OTA3MWM5MTIyNjg1ZDgyYi90YWJsZXJhbmdlOmY1ZmJlZmExZDlkNjQxMzc5MDcxYzkxMjI2ODVkODJiXzMtMy0xLTEtMTA5ODc2_4e52c4a7-17df-4264-85c8-41c79d7ad208"
      unitRef="usd">-215000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTEvZnJhZzo2YTM0ODA1OTRlOGY0MDQ2YmU4NGM5MTBjNDUyOTkzMS90YWJsZTpmNWZiZWZhMWQ5ZDY0MTM3OTA3MWM5MTIyNjg1ZDgyYi90YWJsZXJhbmdlOmY1ZmJlZmExZDlkNjQxMzc5MDcxYzkxMjI2ODVkODJiXzQtMS0xLTEtMTA5ODc2_c04431a7-09d7-41f8-b3ad-d6714921d813"
      unitRef="usd">0</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTEvZnJhZzo2YTM0ODA1OTRlOGY0MDQ2YmU4NGM5MTBjNDUyOTkzMS90YWJsZTpmNWZiZWZhMWQ5ZDY0MTM3OTA3MWM5MTIyNjg1ZDgyYi90YWJsZXJhbmdlOmY1ZmJlZmExZDlkNjQxMzc5MDcxYzkxMjI2ODVkODJiXzQtMy0xLTEtMTA5ODc2_b10ca8a3-8130-4b67-8f28-90158f2bac64"
      unitRef="usd">2000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTEvZnJhZzo2YTM0ODA1OTRlOGY0MDQ2YmU4NGM5MTBjNDUyOTkzMS90YWJsZTpmNWZiZWZhMWQ5ZDY0MTM3OTA3MWM5MTIyNjg1ZDgyYi90YWJsZXJhbmdlOmY1ZmJlZmExZDlkNjQxMzc5MDcxYzkxMjI2ODVkODJiXzUtMS0xLTEtMTA5ODc2_a7d29453-1054-43f6-96e3-227eb2a9b013"
      unitRef="usd">0</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTEvZnJhZzo2YTM0ODA1OTRlOGY0MDQ2YmU4NGM5MTBjNDUyOTkzMS90YWJsZTpmNWZiZWZhMWQ5ZDY0MTM3OTA3MWM5MTIyNjg1ZDgyYi90YWJsZXJhbmdlOmY1ZmJlZmExZDlkNjQxMzc5MDcxYzkxMjI2ODVkODJiXzUtMy0xLTEtMTA5ODc2_4168ea92-c790-4050-aac6-7b755aa33088"
      unitRef="usd">0</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTEvZnJhZzo2YTM0ODA1OTRlOGY0MDQ2YmU4NGM5MTBjNDUyOTkzMS90YWJsZTpmNWZiZWZhMWQ5ZDY0MTM3OTA3MWM5MTIyNjg1ZDgyYi90YWJsZXJhbmdlOmY1ZmJlZmExZDlkNjQxMzc5MDcxYzkxMjI2ODVkODJiXzYtMS0xLTEtMTA5ODc2_165108c4-53b5-4685-997b-cf5a236e1726"
      unitRef="usd">0</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTEvZnJhZzo2YTM0ODA1OTRlOGY0MDQ2YmU4NGM5MTBjNDUyOTkzMS90YWJsZTpmNWZiZWZhMWQ5ZDY0MTM3OTA3MWM5MTIyNjg1ZDgyYi90YWJsZXJhbmdlOmY1ZmJlZmExZDlkNjQxMzc5MDcxYzkxMjI2ODVkODJiXzYtMy0xLTEtMTA5ODc2_745228c5-a028-4991-9e47-d3548c2f75b9"
      unitRef="usd">-213000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTEvZnJhZzo2YTM0ODA1OTRlOGY0MDQ2YmU4NGM5MTBjNDUyOTkzMS90YWJsZTpmNWZiZWZhMWQ5ZDY0MTM3OTA3MWM5MTIyNjg1ZDgyYi90YWJsZXJhbmdlOmY1ZmJlZmExZDlkNjQxMzc5MDcxYzkxMjI2ODVkODJiXzctMS0xLTEtMTA5ODc2_f2b8a960-293e-494c-97ae-2c994ccd6b7f"
      unitRef="usd">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTEvZnJhZzo2YTM0ODA1OTRlOGY0MDQ2YmU4NGM5MTBjNDUyOTkzMS90YWJsZTpmNWZiZWZhMWQ5ZDY0MTM3OTA3MWM5MTIyNjg1ZDgyYi90YWJsZXJhbmdlOmY1ZmJlZmExZDlkNjQxMzc5MDcxYzkxMjI2ODVkODJiXzctMy0xLTEtMTA5ODc2_2196f330-423c-4044-89a3-d182e2c55536"
      unitRef="usd">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTEvZnJhZzo2YTM0ODA1OTRlOGY0MDQ2YmU4NGM5MTBjNDUyOTkzMS90YWJsZTpmNWZiZWZhMWQ5ZDY0MTM3OTA3MWM5MTIyNjg1ZDgyYi90YWJsZXJhbmdlOmY1ZmJlZmExZDlkNjQxMzc5MDcxYzkxMjI2ODVkODJiXzgtMS0xLTEtMTA5ODc2_5ae1ba15-d70f-4d3d-9906-55c14ce31c00"
      unitRef="usd">0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTEvZnJhZzo2YTM0ODA1OTRlOGY0MDQ2YmU4NGM5MTBjNDUyOTkzMS90YWJsZTpmNWZiZWZhMWQ5ZDY0MTM3OTA3MWM5MTIyNjg1ZDgyYi90YWJsZXJhbmdlOmY1ZmJlZmExZDlkNjQxMzc5MDcxYzkxMjI2ODVkODJiXzgtMy0xLTEtMTA5ODc2_b9adc3cb-582c-4a9b-aada-60902286c179"
      unitRef="usd">0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTEvZnJhZzo2YTM0ODA1OTRlOGY0MDQ2YmU4NGM5MTBjNDUyOTkzMS90YWJsZTpmNWZiZWZhMWQ5ZDY0MTM3OTA3MWM5MTIyNjg1ZDgyYi90YWJsZXJhbmdlOmY1ZmJlZmExZDlkNjQxMzc5MDcxYzkxMjI2ODVkODJiXzktMS0xLTEtMTA5ODc2_a085cb0c-9fd8-4d72-ab29-00b0e35ccb47"
      unitRef="usd">0</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTEvZnJhZzo2YTM0ODA1OTRlOGY0MDQ2YmU4NGM5MTBjNDUyOTkzMS90YWJsZTpmNWZiZWZhMWQ5ZDY0MTM3OTA3MWM5MTIyNjg1ZDgyYi90YWJsZXJhbmdlOmY1ZmJlZmExZDlkNjQxMzc5MDcxYzkxMjI2ODVkODJiXzktMy0xLTEtMTA5ODc2_dd8f9cfb-b38c-4f68-a36e-46047c071542"
      unitRef="usd">0</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTEvZnJhZzo2YTM0ODA1OTRlOGY0MDQ2YmU4NGM5MTBjNDUyOTkzMS90YWJsZTpmNWZiZWZhMWQ5ZDY0MTM3OTA3MWM5MTIyNjg1ZDgyYi90YWJsZXJhbmdlOmY1ZmJlZmExZDlkNjQxMzc5MDcxYzkxMjI2ODVkODJiXzEwLTEtMS0xLTEwOTg3Ng_fe928ab0-74e9-4b84-b73c-1b611819fd68"
      unitRef="usd">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTEvZnJhZzo2YTM0ODA1OTRlOGY0MDQ2YmU4NGM5MTBjNDUyOTkzMS90YWJsZTpmNWZiZWZhMWQ5ZDY0MTM3OTA3MWM5MTIyNjg1ZDgyYi90YWJsZXJhbmdlOmY1ZmJlZmExZDlkNjQxMzc5MDcxYzkxMjI2ODVkODJiXzEwLTMtMS0xLTEwOTg3Ng_bde62a75-e976-46d4-a9a3-7af7c723f6ed"
      unitRef="usd">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTEvZnJhZzo2YTM0ODA1OTRlOGY0MDQ2YmU4NGM5MTBjNDUyOTkzMS90YWJsZTpmNWZiZWZhMWQ5ZDY0MTM3OTA3MWM5MTIyNjg1ZDgyYi90YWJsZXJhbmdlOmY1ZmJlZmExZDlkNjQxMzc5MDcxYzkxMjI2ODVkODJiXzExLTEtMS0xLTEwOTg3Ng_af3adde1-7f14-4f61-ae5c-ef8a57297bce"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTEvZnJhZzo2YTM0ODA1OTRlOGY0MDQ2YmU4NGM5MTBjNDUyOTkzMS90YWJsZTpmNWZiZWZhMWQ5ZDY0MTM3OTA3MWM5MTIyNjg1ZDgyYi90YWJsZXJhbmdlOmY1ZmJlZmExZDlkNjQxMzc5MDcxYzkxMjI2ODVkODJiXzExLTMtMS0xLTEwOTg3Ng_f3b1175c-d324-48d8-b278-485b70cccad1"
      unitRef="usd">-213000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTEvZnJhZzo2YTM0ODA1OTRlOGY0MDQ2YmU4NGM5MTBjNDUyOTkzMS90ZXh0cmVnaW9uOjZhMzQ4MDU5NGU4ZjQwNDZiZTg0YzkxMGM0NTI5OTMxXzEwMTUy_d819ae58-9c42-4737-b89b-344a2a1afab2">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The major components of deferred tax assets and liabilities are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.467%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.468%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net operating loss carryforward&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,831&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Research and development credit carryforward&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;941&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Stock based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,167&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;491&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,489&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Intangible asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,600)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,189)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(54)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(71)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,654)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,260)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net deferred tax assets before valuation allowance &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,746&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,229&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(51,746)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29,229)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Deferred tax, net&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTEvZnJhZzo2YTM0ODA1OTRlOGY0MDQ2YmU4NGM5MTBjNDUyOTkzMS90YWJsZTphODczM2E0MzA3NDA0ZTUxYWUwMWQwNTdkNzVkMzMyZi90YWJsZXJhbmdlOmE4NzMzYTQzMDc0MDRlNTFhZTAxZDA1N2Q3NWQzMzJmXzItMS0xLTEtMTA5ODc2_70877aa0-baa3-4c84-a454-227c148be516"
      unitRef="usd">49422000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="i7372be6dc06143b5adbb4d2e83a596c5_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTEvZnJhZzo2YTM0ODA1OTRlOGY0MDQ2YmU4NGM5MTBjNDUyOTkzMS90YWJsZTphODczM2E0MzA3NDA0ZTUxYWUwMWQwNTdkNzVkMzMyZi90YWJsZXJhbmdlOmE4NzMzYTQzMDc0MDRlNTFhZTAxZDA1N2Q3NWQzMzJmXzItMy0xLTEtMTA5ODc2_94d92173-db66-4e7f-8f04-70b1324a3169"
      unitRef="usd">29831000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTEvZnJhZzo2YTM0ODA1OTRlOGY0MDQ2YmU4NGM5MTBjNDUyOTkzMS90YWJsZTphODczM2E0MzA3NDA0ZTUxYWUwMWQwNTdkNzVkMzMyZi90YWJsZXJhbmdlOmE4NzMzYTQzMDc0MDRlNTFhZTAxZDA1N2Q3NWQzMzJmXzMtMS0xLTEtMTA5ODc2_1642e2db-bea6-4100-a271-a09a4e7aad83"
      unitRef="usd">941000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="i7372be6dc06143b5adbb4d2e83a596c5_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTEvZnJhZzo2YTM0ODA1OTRlOGY0MDQ2YmU4NGM5MTBjNDUyOTkzMS90YWJsZTphODczM2E0MzA3NDA0ZTUxYWUwMWQwNTdkNzVkMzMyZi90YWJsZXJhbmdlOmE4NzMzYTQzMDc0MDRlNTFhZTAxZDA1N2Q3NWQzMzJmXzMtMy0xLTEtMTA5ODc2_9a28ee87-a54d-4208-99b5-4839d9f2602e"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTEvZnJhZzo2YTM0ODA1OTRlOGY0MDQ2YmU4NGM5MTBjNDUyOTkzMS90YWJsZTphODczM2E0MzA3NDA0ZTUxYWUwMWQwNTdkNzVkMzMyZi90YWJsZXJhbmdlOmE4NzMzYTQzMDc0MDRlNTFhZTAxZDA1N2Q3NWQzMzJmXzQtMS0xLTEtMTA5ODc2_4fcd46d8-8a64-4a7c-8bd3-26105c92e59b"
      unitRef="usd">2560000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="i7372be6dc06143b5adbb4d2e83a596c5_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTEvZnJhZzo2YTM0ODA1OTRlOGY0MDQ2YmU4NGM5MTBjNDUyOTkzMS90YWJsZTphODczM2E0MzA3NDA0ZTUxYWUwMWQwNTdkNzVkMzMyZi90YWJsZXJhbmdlOmE4NzMzYTQzMDc0MDRlNTFhZTAxZDA1N2Q3NWQzMzJmXzQtMy0xLTEtMTA5ODc2_39e806bc-e629-48db-bdd8-6e0418ff586f"
      unitRef="usd">1167000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTEvZnJhZzo2YTM0ODA1OTRlOGY0MDQ2YmU4NGM5MTBjNDUyOTkzMS90YWJsZTphODczM2E0MzA3NDA0ZTUxYWUwMWQwNTdkNzVkMzMyZi90YWJsZXJhbmdlOmE4NzMzYTQzMDc0MDRlNTFhZTAxZDA1N2Q3NWQzMzJmXzUtMS0xLTEtMTA5ODc2_e13ec877-9715-47cc-8819-79775790ca1f"
      unitRef="usd">1477000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="i7372be6dc06143b5adbb4d2e83a596c5_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTEvZnJhZzo2YTM0ODA1OTRlOGY0MDQ2YmU4NGM5MTBjNDUyOTkzMS90YWJsZTphODczM2E0MzA3NDA0ZTUxYWUwMWQwNTdkNzVkMzMyZi90YWJsZXJhbmdlOmE4NzMzYTQzMDc0MDRlNTFhZTAxZDA1N2Q3NWQzMzJmXzUtMy0xLTEtMTA5ODc2_a2966721-bb60-41a4-8213-dae2e6590f85"
      unitRef="usd">491000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTEvZnJhZzo2YTM0ODA1OTRlOGY0MDQ2YmU4NGM5MTBjNDUyOTkzMS90YWJsZTphODczM2E0MzA3NDA0ZTUxYWUwMWQwNTdkNzVkMzMyZi90YWJsZXJhbmdlOmE4NzMzYTQzMDc0MDRlNTFhZTAxZDA1N2Q3NWQzMzJmXzYtMS0xLTEtMTA5ODc2_80726099-01ce-469f-829b-c8fc8b61650b"
      unitRef="usd">54400000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="i7372be6dc06143b5adbb4d2e83a596c5_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTEvZnJhZzo2YTM0ODA1OTRlOGY0MDQ2YmU4NGM5MTBjNDUyOTkzMS90YWJsZTphODczM2E0MzA3NDA0ZTUxYWUwMWQwNTdkNzVkMzMyZi90YWJsZXJhbmdlOmE4NzMzYTQzMDc0MDRlNTFhZTAxZDA1N2Q3NWQzMzJmXzYtMy0xLTEtMTA5ODc2_47f21dc7-a2ce-4b5a-80b8-f2075d67438c"
      unitRef="usd">31489000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
      contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTEvZnJhZzo2YTM0ODA1OTRlOGY0MDQ2YmU4NGM5MTBjNDUyOTkzMS90YWJsZTphODczM2E0MzA3NDA0ZTUxYWUwMWQwNTdkNzVkMzMyZi90YWJsZXJhbmdlOmE4NzMzYTQzMDc0MDRlNTFhZTAxZDA1N2Q3NWQzMzJmXzktMS0xLTEtMTA5ODc2_f21b19a5-3d18-494d-b6f3-b380f583e8cc"
      unitRef="usd">2600000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
      contextRef="i7372be6dc06143b5adbb4d2e83a596c5_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTEvZnJhZzo2YTM0ODA1OTRlOGY0MDQ2YmU4NGM5MTBjNDUyOTkzMS90YWJsZTphODczM2E0MzA3NDA0ZTUxYWUwMWQwNTdkNzVkMzMyZi90YWJsZXJhbmdlOmE4NzMzYTQzMDc0MDRlNTFhZTAxZDA1N2Q3NWQzMzJmXzktMy0xLTEtMTA5ODc2_28ce5451-a465-4c18-aba8-2bde2fcc6821"
      unitRef="usd">2189000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTEvZnJhZzo2YTM0ODA1OTRlOGY0MDQ2YmU4NGM5MTBjNDUyOTkzMS90YWJsZTphODczM2E0MzA3NDA0ZTUxYWUwMWQwNTdkNzVkMzMyZi90YWJsZXJhbmdlOmE4NzMzYTQzMDc0MDRlNTFhZTAxZDA1N2Q3NWQzMzJmXzEwLTEtMS0xLTEwOTg3Ng_67dde2cf-64f3-411b-be0b-0bfe1f6ae094"
      unitRef="usd">54000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="i7372be6dc06143b5adbb4d2e83a596c5_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTEvZnJhZzo2YTM0ODA1OTRlOGY0MDQ2YmU4NGM5MTBjNDUyOTkzMS90YWJsZTphODczM2E0MzA3NDA0ZTUxYWUwMWQwNTdkNzVkMzMyZi90YWJsZXJhbmdlOmE4NzMzYTQzMDc0MDRlNTFhZTAxZDA1N2Q3NWQzMzJmXzEwLTMtMS0xLTEwOTg3Ng_92471dbb-1cf6-417a-afcd-7a5023ed0474"
      unitRef="usd">71000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTEvZnJhZzo2YTM0ODA1OTRlOGY0MDQ2YmU4NGM5MTBjNDUyOTkzMS90YWJsZTphODczM2E0MzA3NDA0ZTUxYWUwMWQwNTdkNzVkMzMyZi90YWJsZXJhbmdlOmE4NzMzYTQzMDc0MDRlNTFhZTAxZDA1N2Q3NWQzMzJmXzExLTEtMS0xLTEwOTg3Ng_97583218-7219-42a5-be2d-0c3cb67e76c4"
      unitRef="usd">2654000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="i7372be6dc06143b5adbb4d2e83a596c5_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTEvZnJhZzo2YTM0ODA1OTRlOGY0MDQ2YmU4NGM5MTBjNDUyOTkzMS90YWJsZTphODczM2E0MzA3NDA0ZTUxYWUwMWQwNTdkNzVkMzMyZi90YWJsZXJhbmdlOmE4NzMzYTQzMDc0MDRlNTFhZTAxZDA1N2Q3NWQzMzJmXzExLTMtMS0xLTEwOTg3Ng_d0049604-17e5-4c2c-9dfe-97aa74183f1c"
      unitRef="usd">2260000</us-gaap:DeferredIncomeTaxLiabilities>
    <smmt:DeferredTaxAssetsLiabilities
      contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTEvZnJhZzo2YTM0ODA1OTRlOGY0MDQ2YmU4NGM5MTBjNDUyOTkzMS90YWJsZTphODczM2E0MzA3NDA0ZTUxYWUwMWQwNTdkNzVkMzMyZi90YWJsZXJhbmdlOmE4NzMzYTQzMDc0MDRlNTFhZTAxZDA1N2Q3NWQzMzJmXzEzLTEtMS0xLTEwOTg3Ng_760d6dfc-ac7b-4941-917b-d36e5ef4ce23"
      unitRef="usd">51746000</smmt:DeferredTaxAssetsLiabilities>
    <smmt:DeferredTaxAssetsLiabilities
      contextRef="i7372be6dc06143b5adbb4d2e83a596c5_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTEvZnJhZzo2YTM0ODA1OTRlOGY0MDQ2YmU4NGM5MTBjNDUyOTkzMS90YWJsZTphODczM2E0MzA3NDA0ZTUxYWUwMWQwNTdkNzVkMzMyZi90YWJsZXJhbmdlOmE4NzMzYTQzMDc0MDRlNTFhZTAxZDA1N2Q3NWQzMzJmXzEzLTMtMS0xLTEwOTg3Ng_cef1fa15-c76c-46ad-bfa3-1ffc893bf7b6"
      unitRef="usd">29229000</smmt:DeferredTaxAssetsLiabilities>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTEvZnJhZzo2YTM0ODA1OTRlOGY0MDQ2YmU4NGM5MTBjNDUyOTkzMS90YWJsZTphODczM2E0MzA3NDA0ZTUxYWUwMWQwNTdkNzVkMzMyZi90YWJsZXJhbmdlOmE4NzMzYTQzMDc0MDRlNTFhZTAxZDA1N2Q3NWQzMzJmXzE0LTEtMS0xLTEwOTg3Ng_0adca284-f73a-4e1f-94db-d29dd788a729"
      unitRef="usd">51746000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i7372be6dc06143b5adbb4d2e83a596c5_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTEvZnJhZzo2YTM0ODA1OTRlOGY0MDQ2YmU4NGM5MTBjNDUyOTkzMS90YWJsZTphODczM2E0MzA3NDA0ZTUxYWUwMWQwNTdkNzVkMzMyZi90YWJsZXJhbmdlOmE4NzMzYTQzMDc0MDRlNTFhZTAxZDA1N2Q3NWQzMzJmXzE0LTMtMS0xLTEwOTg3Ng_d79379f2-d91e-43c7-b5f8-b5ae2fe5878c"
      unitRef="usd">29229000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTEvZnJhZzo2YTM0ODA1OTRlOGY0MDQ2YmU4NGM5MTBjNDUyOTkzMS90YWJsZTphODczM2E0MzA3NDA0ZTUxYWUwMWQwNTdkNzVkMzMyZi90YWJsZXJhbmdlOmE4NzMzYTQzMDc0MDRlNTFhZTAxZDA1N2Q3NWQzMzJmXzE1LTEtMS0xLTEwOTg3Ng_1625534b-701d-4d02-b3ab-19b5aac1fc43"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="i7372be6dc06143b5adbb4d2e83a596c5_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTEvZnJhZzo2YTM0ODA1OTRlOGY0MDQ2YmU4NGM5MTBjNDUyOTkzMS90YWJsZTphODczM2E0MzA3NDA0ZTUxYWUwMWQwNTdkNzVkMzMyZi90YWJsZXJhbmdlOmE4NzMzYTQzMDc0MDRlNTFhZTAxZDA1N2Q3NWQzMzJmXzE1LTMtMS0xLTEwOTg3Ng_973d0d09-10a5-454a-9370-b45cc8294687"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTEvZnJhZzo2YTM0ODA1OTRlOGY0MDQ2YmU4NGM5MTBjNDUyOTkzMS90ZXh0cmVnaW9uOjZhMzQ4MDU5NGU4ZjQwNDZiZTg0YzkxMGM0NTI5OTMxXzQ5MQ_94fbc4db-ef13-4d74-ae78-66153d55292b"
      unitRef="usd">54400000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="i7372be6dc06143b5adbb4d2e83a596c5_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTEvZnJhZzo2YTM0ODA1OTRlOGY0MDQ2YmU4NGM5MTBjNDUyOTkzMS90ZXh0cmVnaW9uOjZhMzQ4MDU5NGU4ZjQwNDZiZTg0YzkxMGM0NTI5OTMxXzQ5OA_ced0cacc-4d55-410c-8240-5b3105e763a5"
      unitRef="usd">31489000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTEvZnJhZzo2YTM0ODA1OTRlOGY0MDQ2YmU4NGM5MTBjNDUyOTkzMS90ZXh0cmVnaW9uOjZhMzQ4MDU5NGU4ZjQwNDZiZTg0YzkxMGM0NTI5OTMxXzE0NTg_8eb0ef27-eec5-45aa-bbc9-102fd9805ffe"
      unitRef="usd">22517000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i3f5f274eec6e4854a5687bcb5cfc91d9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTEvZnJhZzo2YTM0ODA1OTRlOGY0MDQ2YmU4NGM5MTBjNDUyOTkzMS90ZXh0cmVnaW9uOjZhMzQ4MDU5NGU4ZjQwNDZiZTg0YzkxMGM0NTI5OTMxXzE2NjA_9d6f746f-0de6-48f2-8887-b5a7385a76c8"
      unitRef="usd">1034000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i2ed068ac829e484093c122d76b8f373f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTEvZnJhZzo2YTM0ODA1OTRlOGY0MDQ2YmU4NGM5MTBjNDUyOTkzMS90ZXh0cmVnaW9uOjZhMzQ4MDU5NGU4ZjQwNDZiZTg0YzkxMGM0NTI5OTMxXzE2Njc_9e0f4da7-e027-4988-9dda-17b0f7aaa22f"
      unitRef="usd">232000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i0ef15edbb3914ab3807ad48ae9426591_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTEvZnJhZzo2YTM0ODA1OTRlOGY0MDQ2YmU4NGM5MTBjNDUyOTkzMS90ZXh0cmVnaW9uOjZhMzQ4MDU5NGU4ZjQwNDZiZTg0YzkxMGM0NTI5OTMxXzIxMzc_6514ba44-3fd3-4004-8d9b-a82707963ad7"
      unitRef="usd">165000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="i16643be7aeaf41edbc627f4639147976_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTEvZnJhZzo2YTM0ODA1OTRlOGY0MDQ2YmU4NGM5MTBjNDUyOTkzMS90ZXh0cmVnaW9uOjZhMzQ4MDU5NGU4ZjQwNDZiZTg0YzkxMGM0NTI5OTMxXzIzNDU_4a335bcd-ec85-487e-9817-e9ba4067d59f"
      unitRef="usd">941000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i7e1be0d5904743408b0b38cc3f4a584c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTEvZnJhZzo2YTM0ODA1OTRlOGY0MDQ2YmU4NGM5MTBjNDUyOTkzMS90ZXh0cmVnaW9uOjZhMzQ4MDU5NGU4ZjQwNDZiZTg0YzkxMGM0NTI5OTMxXzI0NzQ_999e5c9d-e976-4831-b23a-a5f4b6cb5435"
      unitRef="usd">191714000</us-gaap:OperatingLossCarryforwards>
    <smmt:PotentialDeferredTaxAssetsOperatingLossCarryforwards
      contextRef="i7e1be0d5904743408b0b38cc3f4a584c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTEvZnJhZzo2YTM0ODA1OTRlOGY0MDQ2YmU4NGM5MTBjNDUyOTkzMS90ZXh0cmVnaW9uOjZhMzQ4MDU5NGU4ZjQwNDZiZTg0YzkxMGM0NTI5OTMxXzI2MTE_b3a96956-3c27-44f3-b3c9-2e48cf3eadde"
      unitRef="usd">47929000</smmt:PotentialDeferredTaxAssetsOperatingLossCarryforwards>
    <smmt:DeferredTaxAssetsNetIncreaseDecreaseDueToChangeInEnactedTaxRateAmount
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTEvZnJhZzo2YTM0ODA1OTRlOGY0MDQ2YmU4NGM5MTBjNDUyOTkzMS90ZXh0cmVnaW9uOjZhMzQ4MDU5NGU4ZjQwNDZiZTg0YzkxMGM0NTI5OTMxXzc2MTA_b335d93d-43a6-4f49-9e92-e905f7432340"
      unitRef="usd">9311000</smmt:DeferredTaxAssetsNetIncreaseDecreaseDueToChangeInEnactedTaxRateAmount>
    <smmt:ValuationAllowanceDeferredTaxAssetIncreaseDecreaseDueToChangeInEnactedTaxRateAmount
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTEvZnJhZzo2YTM0ODA1OTRlOGY0MDQ2YmU4NGM5MTBjNDUyOTkzMS90ZXh0cmVnaW9uOjZhMzQ4MDU5NGU4ZjQwNDZiZTg0YzkxMGM0NTI5OTMxXzc2MTA_e1a86698-f828-4be8-8fab-e4d7f76f1f77"
      unitRef="usd">9311000</smmt:ValuationAllowanceDeferredTaxAssetIncreaseDecreaseDueToChangeInEnactedTaxRateAmount>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTEvZnJhZzo2YTM0ODA1OTRlOGY0MDQ2YmU4NGM5MTBjNDUyOTkzMS90ZXh0cmVnaW9uOjZhMzQ4MDU5NGU4ZjQwNDZiZTg0YzkxMGM0NTI5OTMxXzEwMTUz_0ee13b8e-ee6c-448d-a8c6-cebed369525f">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of the Company's effective tax rate to the U.S. federal statutory rate is as follows: &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.467%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:83%"&gt;Year Ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:83%"&gt;Year Ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. federal income tax statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Non-deductible expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Refundable research and development tax credit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Effect of foreign operations taxed at various rates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTEvZnJhZzo2YTM0ODA1OTRlOGY0MDQ2YmU4NGM5MTBjNDUyOTkzMS90YWJsZTo0MzIxNTIyOWE5ODI0NzYxYjQzYmM2ZDMyMTU2N2Q1OC90YWJsZXJhbmdlOjQzMjE1MjI5YTk4MjQ3NjFiNDNiYzZkMzIxNTY3ZDU4XzEtMi0xLTEtMTA5ODc2_4f515988-5eeb-48c3-b2a3-58f30d2052a2"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTEvZnJhZzo2YTM0ODA1OTRlOGY0MDQ2YmU4NGM5MTBjNDUyOTkzMS90YWJsZTo0MzIxNTIyOWE5ODI0NzYxYjQzYmM2ZDMyMTU2N2Q1OC90YWJsZXJhbmdlOjQzMjE1MjI5YTk4MjQ3NjFiNDNiYzZkMzIxNTY3ZDU4XzEtNC0xLTEtMTA5ODc2_5ce381a9-f209-42e3-a482-bad10c3269e2"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTEvZnJhZzo2YTM0ODA1OTRlOGY0MDQ2YmU4NGM5MTBjNDUyOTkzMS90YWJsZTo0MzIxNTIyOWE5ODI0NzYxYjQzYmM2ZDMyMTU2N2Q1OC90YWJsZXJhbmdlOjQzMjE1MjI5YTk4MjQ3NjFiNDNiYzZkMzIxNTY3ZDU4XzItMi0xLTEtMTA5ODc2_c4bb3886-6f90-4185-b735-570300b83b58"
      unitRef="number">-0.105</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTEvZnJhZzo2YTM0ODA1OTRlOGY0MDQ2YmU4NGM5MTBjNDUyOTkzMS90YWJsZTo0MzIxNTIyOWE5ODI0NzYxYjQzYmM2ZDMyMTU2N2Q1OC90YWJsZXJhbmdlOjQzMjE1MjI5YTk4MjQ3NjFiNDNiYzZkMzIxNTY3ZDU4XzItNC0xLTEtMTA5ODc2_0f1a8019-90ba-408d-83c9-51e455251736"
      unitRef="number">-0.121</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTEvZnJhZzo2YTM0ODA1OTRlOGY0MDQ2YmU4NGM5MTBjNDUyOTkzMS90YWJsZTo0MzIxNTIyOWE5ODI0NzYxYjQzYmM2ZDMyMTU2N2Q1OC90YWJsZXJhbmdlOjQzMjE1MjI5YTk4MjQ3NjFiNDNiYzZkMzIxNTY3ZDU4XzMtMi0xLTEtMTA5ODc2_a924daa0-181c-4fea-af49-49c83c219af0"
      unitRef="number">-0.004</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense
      contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTEvZnJhZzo2YTM0ODA1OTRlOGY0MDQ2YmU4NGM5MTBjNDUyOTkzMS90YWJsZTo0MzIxNTIyOWE5ODI0NzYxYjQzYmM2ZDMyMTU2N2Q1OC90YWJsZXJhbmdlOjQzMjE1MjI5YTk4MjQ3NjFiNDNiYzZkMzIxNTY3ZDU4XzMtNC0xLTEtMTA5ODc2_a744e56d-b79b-4bb5-a221-2cf5cea1a4e9"
      unitRef="number">-0.039</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <smmt:EffectiveIncomeTaxRateReconciliationTaxCreditRefundableResearchPercent
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTEvZnJhZzo2YTM0ODA1OTRlOGY0MDQ2YmU4NGM5MTBjNDUyOTkzMS90YWJsZTo0MzIxNTIyOWE5ODI0NzYxYjQzYmM2ZDMyMTU2N2Q1OC90YWJsZXJhbmdlOjQzMjE1MjI5YTk4MjQ3NjFiNDNiYzZkMzIxNTY3ZDU4XzQtMi0xLTEtMTA5ODc2_0d9320e0-0d89-4d33-99a9-77696076a2ab"
      unitRef="number">0.083</smmt:EffectiveIncomeTaxRateReconciliationTaxCreditRefundableResearchPercent>
    <smmt:EffectiveIncomeTaxRateReconciliationTaxCreditRefundableResearchPercent
      contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTEvZnJhZzo2YTM0ODA1OTRlOGY0MDQ2YmU4NGM5MTBjNDUyOTkzMS90YWJsZTo0MzIxNTIyOWE5ODI0NzYxYjQzYmM2ZDMyMTU2N2Q1OC90YWJsZXJhbmdlOjQzMjE1MjI5YTk4MjQ3NjFiNDNiYzZkMzIxNTY3ZDU4XzQtNC0xLTEtMTA5ODc2_f5cacc22-ddce-4e7d-b928-73e083c48dbd"
      unitRef="number">0.070</smmt:EffectiveIncomeTaxRateReconciliationTaxCreditRefundableResearchPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTEvZnJhZzo2YTM0ODA1OTRlOGY0MDQ2YmU4NGM5MTBjNDUyOTkzMS90YWJsZTo0MzIxNTIyOWE5ODI0NzYxYjQzYmM2ZDMyMTU2N2Q1OC90YWJsZXJhbmdlOjQzMjE1MjI5YTk4MjQ3NjFiNDNiYzZkMzIxNTY3ZDU4XzUtMi0xLTEtMTA5ODc2_1b1c6713-71bb-426c-891c-39e1960a4368"
      unitRef="number">0.005</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTEvZnJhZzo2YTM0ODA1OTRlOGY0MDQ2YmU4NGM5MTBjNDUyOTkzMS90YWJsZTo0MzIxNTIyOWE5ODI0NzYxYjQzYmM2ZDMyMTU2N2Q1OC90YWJsZXJhbmdlOjQzMjE1MjI5YTk4MjQ3NjFiNDNiYzZkMzIxNTY3ZDU4XzUtNC0xLTEtMTA5ODc2_754dd1a7-af9b-438b-8384-35a0ae38a2ee"
      unitRef="number">0.009</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTEvZnJhZzo2YTM0ODA1OTRlOGY0MDQ2YmU4NGM5MTBjNDUyOTkzMS90YWJsZTo0MzIxNTIyOWE5ODI0NzYxYjQzYmM2ZDMyMTU2N2Q1OC90YWJsZXJhbmdlOjQzMjE1MjI5YTk4MjQ3NjFiNDNiYzZkMzIxNTY3ZDU4XzYtMi0xLTEtMTA5ODc2_e50d523b-a30c-49c5-8eb0-923d254b5702"
      unitRef="number">-0.016</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
      contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTEvZnJhZzo2YTM0ODA1OTRlOGY0MDQ2YmU4NGM5MTBjNDUyOTkzMS90YWJsZTo0MzIxNTIyOWE5ODI0NzYxYjQzYmM2ZDMyMTU2N2Q1OC90YWJsZXJhbmdlOjQzMjE1MjI5YTk4MjQ3NjFiNDNiYzZkMzIxNTY3ZDU4XzYtNC0xLTEtMTA5ODc2_53b39403-f42e-4775-bb8c-3dad1ce6b4a5"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTEvZnJhZzo2YTM0ODA1OTRlOGY0MDQ2YmU4NGM5MTBjNDUyOTkzMS90YWJsZTo0MzIxNTIyOWE5ODI0NzYxYjQzYmM2ZDMyMTU2N2Q1OC90YWJsZXJhbmdlOjQzMjE1MjI5YTk4MjQ3NjFiNDNiYzZkMzIxNTY3ZDU4XzctMi0xLTEtMTA5ODc2_3b63ac83-c757-4b67-a48a-030276beee96"
      unitRef="number">-0.007</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTEvZnJhZzo2YTM0ODA1OTRlOGY0MDQ2YmU4NGM5MTBjNDUyOTkzMS90YWJsZTo0MzIxNTIyOWE5ODI0NzYxYjQzYmM2ZDMyMTU2N2Q1OC90YWJsZXJhbmdlOjQzMjE1MjI5YTk4MjQ3NjFiNDNiYzZkMzIxNTY3ZDU4XzctNC0xLTEtMTA5ODc2_f5468689-6c18-48bc-8855-c67725cdb2af"
      unitRef="number">0.014</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTEvZnJhZzo2YTM0ODA1OTRlOGY0MDQ2YmU4NGM5MTBjNDUyOTkzMS90YWJsZTo0MzIxNTIyOWE5ODI0NzYxYjQzYmM2ZDMyMTU2N2Q1OC90YWJsZXJhbmdlOjQzMjE1MjI5YTk4MjQ3NjFiNDNiYzZkMzIxNTY3ZDU4XzgtMi0xLTEtMTA5ODc2_4cb54cb3-b82a-40ca-a222-90da0529a9c7"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTEvZnJhZzo2YTM0ODA1OTRlOGY0MDQ2YmU4NGM5MTBjNDUyOTkzMS90YWJsZTo0MzIxNTIyOWE5ODI0NzYxYjQzYmM2ZDMyMTU2N2Q1OC90YWJsZXJhbmdlOjQzMjE1MjI5YTk4MjQ3NjFiNDNiYzZkMzIxNTY3ZDU4XzgtNC0xLTEtMTA5ODc2_8ea6caef-123b-4afa-b3d1-a9af0689e9d8"
      unitRef="number">0.0030</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <smmt:ResearchAndDevelopmentTaxCredit
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTEvZnJhZzo2YTM0ODA1OTRlOGY0MDQ2YmU4NGM5MTBjNDUyOTkzMS90ZXh0cmVnaW9uOjZhMzQ4MDU5NGU4ZjQwNDZiZTg0YzkxMGM0NTI5OTMxXzg1MDY_cfd49dc7-6ee9-4564-a78d-c730ee8f981e"
      unitRef="usd">15206000</smmt:ResearchAndDevelopmentTaxCredit>
    <smmt:ResearchAndDevelopmentTaxCredit
      contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTEvZnJhZzo2YTM0ODA1OTRlOGY0MDQ2YmU4NGM5MTBjNDUyOTkzMS90ZXh0cmVnaW9uOjZhMzQ4MDU5NGU4ZjQwNDZiZTg0YzkxMGM0NTI5OTMxXzg1MTM_f14297fb-1720-4d64-a5d9-725f7d1de2c3"
      unitRef="usd">9363000</smmt:ResearchAndDevelopmentTaxCredit>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTEvZnJhZzo2YTM0ODA1OTRlOGY0MDQ2YmU4NGM5MTBjNDUyOTkzMS90ZXh0cmVnaW9uOjZhMzQ4MDU5NGU4ZjQwNDZiZTg0YzkxMGM0NTI5OTMxXzEwMDIy_3282deaf-f2b8-4963-83df-53bcc831a7cd"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTEvZnJhZzo2YTM0ODA1OTRlOGY0MDQ2YmU4NGM5MTBjNDUyOTkzMS90ZXh0cmVnaW9uOjZhMzQ4MDU5NGU4ZjQwNDZiZTg0YzkxMGM0NTI5OTMxXzEwMDIy_5fe085eb-2c87-487f-8bd3-bb65b61c99f1"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="i7372be6dc06143b5adbb4d2e83a596c5_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTEvZnJhZzo2YTM0ODA1OTRlOGY0MDQ2YmU4NGM5MTBjNDUyOTkzMS90ZXh0cmVnaW9uOjZhMzQ4MDU5NGU4ZjQwNDZiZTg0YzkxMGM0NTI5OTMxXzEwMDIy_8d62c34b-43c2-4d8c-835e-d72ac401d555"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i7372be6dc06143b5adbb4d2e83a596c5_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTEvZnJhZzo2YTM0ODA1OTRlOGY0MDQ2YmU4NGM5MTBjNDUyOTkzMS90ZXh0cmVnaW9uOjZhMzQ4MDU5NGU4ZjQwNDZiZTg0YzkxMGM0NTI5OTMxXzEwMDIy_90da97d1-b09d-4066-b80c-120a0527da13"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTQvZnJhZzo2MmEwNjgyZGU2YzA0MWRlYjhhNGViZTQwMmJmYzcwYy90ZXh0cmVnaW9uOjYyYTA2ODJkZTZjMDQxZGViOGE0ZWJlNDAyYmZjNzBjXzEyMjg_39bd72d3-1c4a-4c03-bc43-b4c29281699a">Loss per Share &lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the computation of basic and diluted net loss per share: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.198%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(88,602)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(52,697)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic weighted average number of shares of common stock outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92,239,306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69,524,148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted weighted average number of shares of common stock outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92,239,306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69,524,148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic net loss per share&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.96)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.76)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted net loss per share&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.96)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.76)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per share is computed by dividing the net loss by the weighted-average number of common shares outstanding for the period. Diluted net loss per share is computed by dividing the diluted net loss by the weighted-average number of common shares outstanding for the period, including potentially dilutive common shares. The dilutive effect of share options and warrants are determined under the treasury stock method using the average market price for the period.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, the assumed proceeds under the treasury stock method include the average unrecognized compensation expense of stock options and warrants that are in-the-money. Since the Company was in a loss position for all periods presented, basic net loss per share is the same as diluted net loss per share for all periods, as the inclusion of all potential common share equivalents outstanding would have been anti-dilutive. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following potentially dilutive securities were excluded from the computation of the diluted net loss per share of common stock for the periods presented because their effect would have been anti-dilutive: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.198%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.523%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,923&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,797,556&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,672,968&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,821,137&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,821,137&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares expected to be purchased under employee stock purchase plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;202,045&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,820,738&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,521,028&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTQvZnJhZzo2MmEwNjgyZGU2YzA0MWRlYjhhNGViZTQwMmJmYzcwYy90ZXh0cmVnaW9uOjYyYTA2ODJkZTZjMDQxZGViOGE0ZWJlNDAyYmZjNzBjXzEyMjU_73c23543-90b5-4d06-9faf-104d9a8dbf83">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the computation of basic and diluted net loss per share: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.198%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(88,602)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(52,697)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic weighted average number of shares of common stock outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92,239,306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69,524,148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted weighted average number of shares of common stock outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92,239,306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69,524,148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic net loss per share&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.96)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.76)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted net loss per share&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.96)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.76)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTQvZnJhZzo2MmEwNjgyZGU2YzA0MWRlYjhhNGViZTQwMmJmYzcwYy90YWJsZToyYTg4Mzg1ZmNkY2E0ZjBmOWViZTJhYWM4YjhkM2IzMi90YWJsZXJhbmdlOjJhODgzODVmY2RjYTRmMGY5ZWJlMmFhYzhiOGQzYjMyXzEtMS0xLTEtMTA5ODc2_c62441af-91b8-44c7-8bc6-44d1bdcc08af"
      unitRef="usd">-88602000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTQvZnJhZzo2MmEwNjgyZGU2YzA0MWRlYjhhNGViZTQwMmJmYzcwYy90YWJsZToyYTg4Mzg1ZmNkY2E0ZjBmOWViZTJhYWM4YjhkM2IzMi90YWJsZXJhbmdlOjJhODgzODVmY2RjYTRmMGY5ZWJlMmFhYzhiOGQzYjMyXzEtMy0xLTEtMTA5ODc2_aac3188b-56f6-43e4-9122-e07018301c52"
      unitRef="usd">-52697000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTQvZnJhZzo2MmEwNjgyZGU2YzA0MWRlYjhhNGViZTQwMmJmYzcwYy90YWJsZToyYTg4Mzg1ZmNkY2E0ZjBmOWViZTJhYWM4YjhkM2IzMi90YWJsZXJhbmdlOjJhODgzODVmY2RjYTRmMGY5ZWJlMmFhYzhiOGQzYjMyXzMtMS0xLTEtMTA5ODc2_11e28f38-fc49-4035-a1da-dfe36efb13f2"
      unitRef="shares">92239306</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTQvZnJhZzo2MmEwNjgyZGU2YzA0MWRlYjhhNGViZTQwMmJmYzcwYy90YWJsZToyYTg4Mzg1ZmNkY2E0ZjBmOWViZTJhYWM4YjhkM2IzMi90YWJsZXJhbmdlOjJhODgzODVmY2RjYTRmMGY5ZWJlMmFhYzhiOGQzYjMyXzMtMy0xLTEtMTA5ODc2_712bb3df-b59f-4c79-ad61-a4c5b28abfd0"
      unitRef="shares">69524148</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTQvZnJhZzo2MmEwNjgyZGU2YzA0MWRlYjhhNGViZTQwMmJmYzcwYy90YWJsZToyYTg4Mzg1ZmNkY2E0ZjBmOWViZTJhYWM4YjhkM2IzMi90YWJsZXJhbmdlOjJhODgzODVmY2RjYTRmMGY5ZWJlMmFhYzhiOGQzYjMyXzQtMS0xLTEtMTA5ODc2_0a949783-24bf-4ba6-8e6b-4d35979d4756"
      unitRef="shares">92239306</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTQvZnJhZzo2MmEwNjgyZGU2YzA0MWRlYjhhNGViZTQwMmJmYzcwYy90YWJsZToyYTg4Mzg1ZmNkY2E0ZjBmOWViZTJhYWM4YjhkM2IzMi90YWJsZXJhbmdlOjJhODgzODVmY2RjYTRmMGY5ZWJlMmFhYzhiOGQzYjMyXzQtMy0xLTEtMTA5ODc2_1b6c7afa-f20e-479a-874d-55067b87c8a8"
      unitRef="shares">69524148</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTQvZnJhZzo2MmEwNjgyZGU2YzA0MWRlYjhhNGViZTQwMmJmYzcwYy90YWJsZToyYTg4Mzg1ZmNkY2E0ZjBmOWViZTJhYWM4YjhkM2IzMi90YWJsZXJhbmdlOjJhODgzODVmY2RjYTRmMGY5ZWJlMmFhYzhiOGQzYjMyXzUtMS0xLTEtMTA5ODc2_8887d1c6-0c6e-4e8d-9d46-a4f2dd17c668"
      unitRef="usdPerShare">-0.96</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTQvZnJhZzo2MmEwNjgyZGU2YzA0MWRlYjhhNGViZTQwMmJmYzcwYy90YWJsZToyYTg4Mzg1ZmNkY2E0ZjBmOWViZTJhYWM4YjhkM2IzMi90YWJsZXJhbmdlOjJhODgzODVmY2RjYTRmMGY5ZWJlMmFhYzhiOGQzYjMyXzUtMy0xLTEtMTA5ODc2_f29d5eea-7124-4593-9df3-5db91f66aae6"
      unitRef="usdPerShare">-0.76</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTQvZnJhZzo2MmEwNjgyZGU2YzA0MWRlYjhhNGViZTQwMmJmYzcwYy90YWJsZToyYTg4Mzg1ZmNkY2E0ZjBmOWViZTJhYWM4YjhkM2IzMi90YWJsZXJhbmdlOjJhODgzODVmY2RjYTRmMGY5ZWJlMmFhYzhiOGQzYjMyXzYtMS0xLTEtMTA5ODc2_5275471e-b2dd-41e0-9001-3d2ffd22a5e9"
      unitRef="usdPerShare">-0.96</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTQvZnJhZzo2MmEwNjgyZGU2YzA0MWRlYjhhNGViZTQwMmJmYzcwYy90YWJsZToyYTg4Mzg1ZmNkY2E0ZjBmOWViZTJhYWM4YjhkM2IzMi90YWJsZXJhbmdlOjJhODgzODVmY2RjYTRmMGY5ZWJlMmFhYzhiOGQzYjMyXzYtMy0xLTEtMTA5ODc2_920374f9-fd01-4654-8998-bab8af736629"
      unitRef="usdPerShare">-0.76</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTQvZnJhZzo2MmEwNjgyZGU2YzA0MWRlYjhhNGViZTQwMmJmYzcwYy90ZXh0cmVnaW9uOjYyYTA2ODJkZTZjMDQxZGViOGE0ZWJlNDAyYmZjNzBjXzEyMzI_ca96030d-8850-4f86-aca1-60333de58333">&lt;div style="margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following potentially dilutive securities were excluded from the computation of the diluted net loss per share of common stock for the periods presented because their effect would have been anti-dilutive: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.198%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.523%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,923&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,797,556&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,672,968&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,821,137&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,821,137&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares expected to be purchased under employee stock purchase plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;202,045&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,820,738&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,521,028&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i532f6b25e45149648f05717f44c7c477_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTQvZnJhZzo2MmEwNjgyZGU2YzA0MWRlYjhhNGViZTQwMmJmYzcwYy90YWJsZTphY2YzYjk4ZjQ3YWI0NDUxOTZmMTU4YTNjNWRmODhkMy90YWJsZXJhbmdlOmFjZjNiOThmNDdhYjQ0NTE5NmYxNThhM2M1ZGY4OGQzXzEtMi0xLTEtMTA5ODc2_2909199a-50e7-4e51-b8d3-28cf9984b7f4"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ib1c1be44b3ba438881338233be927f12_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTQvZnJhZzo2MmEwNjgyZGU2YzA0MWRlYjhhNGViZTQwMmJmYzcwYy90YWJsZTphY2YzYjk4ZjQ3YWI0NDUxOTZmMTU4YTNjNWRmODhkMy90YWJsZXJhbmdlOmFjZjNiOThmNDdhYjQ0NTE5NmYxNThhM2M1ZGY4OGQzXzEtNC0xLTEtMTA5ODc2_c098d7ef-15d3-44b9-ba22-a91eaaf1b251"
      unitRef="shares">26923</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i17a5a82d4e56446b9587e3a8aad49a1b_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTQvZnJhZzo2MmEwNjgyZGU2YzA0MWRlYjhhNGViZTQwMmJmYzcwYy90YWJsZTphY2YzYjk4ZjQ3YWI0NDUxOTZmMTU4YTNjNWRmODhkMy90YWJsZXJhbmdlOmFjZjNiOThmNDdhYjQ0NTE5NmYxNThhM2M1ZGY4OGQzXzItMi0xLTEtMTA5ODc2_6ea979e2-4b80-444b-a38f-082b0710fd12"
      unitRef="shares">13797556</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i5c71c63c2a0d454aa48a55ab0a0ec4ee_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTQvZnJhZzo2MmEwNjgyZGU2YzA0MWRlYjhhNGViZTQwMmJmYzcwYy90YWJsZTphY2YzYjk4ZjQ3YWI0NDUxOTZmMTU4YTNjNWRmODhkMy90YWJsZXJhbmdlOmFjZjNiOThmNDdhYjQ0NTE5NmYxNThhM2M1ZGY4OGQzXzItNC0xLTEtMTA5ODc2_112b5578-e4dd-4f4b-a0a0-0e47b061d587"
      unitRef="shares">3672968</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i1dba735cd51b4bd9acdace9e3eb39523_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTQvZnJhZzo2MmEwNjgyZGU2YzA0MWRlYjhhNGViZTQwMmJmYzcwYy90YWJsZTphY2YzYjk4ZjQ3YWI0NDUxOTZmMTU4YTNjNWRmODhkMy90YWJsZXJhbmdlOmFjZjNiOThmNDdhYjQ0NTE5NmYxNThhM2M1ZGY4OGQzXzMtMi0xLTEtMTA5ODc2_330b23bb-6c21-4b5d-bed0-24139903cc18"
      unitRef="shares">5821137</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i473628003f11481a823723bf532a0274_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTQvZnJhZzo2MmEwNjgyZGU2YzA0MWRlYjhhNGViZTQwMmJmYzcwYy90YWJsZTphY2YzYjk4ZjQ3YWI0NDUxOTZmMTU4YTNjNWRmODhkMy90YWJsZXJhbmdlOmFjZjNiOThmNDdhYjQ0NTE5NmYxNThhM2M1ZGY4OGQzXzMtNC0xLTEtMTA5ODc2_5ee60f5c-cb1b-4df7-8f77-7c20c017c050"
      unitRef="shares">5821137</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i5bc912ce09754534905d49a8cb511c7a_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTQvZnJhZzo2MmEwNjgyZGU2YzA0MWRlYjhhNGViZTQwMmJmYzcwYy90YWJsZTphY2YzYjk4ZjQ3YWI0NDUxOTZmMTU4YTNjNWRmODhkMy90YWJsZXJhbmdlOmFjZjNiOThmNDdhYjQ0NTE5NmYxNThhM2M1ZGY4OGQzXzQtMi0xLTEtMTA5ODc2_d901eea1-782d-4783-be38-059e6f89ebe8"
      unitRef="shares">202045</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i2fa48e55eff24bda9a7ebf8b065a3657_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTQvZnJhZzo2MmEwNjgyZGU2YzA0MWRlYjhhNGViZTQwMmJmYzcwYy90YWJsZTphY2YzYjk4ZjQ3YWI0NDUxOTZmMTU4YTNjNWRmODhkMy90YWJsZXJhbmdlOmFjZjNiOThmNDdhYjQ0NTE5NmYxNThhM2M1ZGY4OGQzXzQtNC0xLTEtMTA5ODc2_519be26f-3c00-4442-b04b-bb02f62f6ee3"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTQvZnJhZzo2MmEwNjgyZGU2YzA0MWRlYjhhNGViZTQwMmJmYzcwYy90YWJsZTphY2YzYjk4ZjQ3YWI0NDUxOTZmMTU4YTNjNWRmODhkMy90YWJsZXJhbmdlOmFjZjNiOThmNDdhYjQ0NTE5NmYxNThhM2M1ZGY4OGQzXzUtMi0xLTEtMTA5ODc2_aefe2d4f-406f-4eb4-b99d-dbd5b2fa3039"
      unitRef="shares">19820738</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTQvZnJhZzo2MmEwNjgyZGU2YzA0MWRlYjhhNGViZTQwMmJmYzcwYy90YWJsZTphY2YzYjk4ZjQ3YWI0NDUxOTZmMTU4YTNjNWRmODhkMy90YWJsZXJhbmdlOmFjZjNiOThmNDdhYjQ0NTE5NmYxNThhM2M1ZGY4OGQzXzUtNC0xLTEtMTA5ODc2_519c3fa0-6061-48be-81db-ee0607f3aefd"
      unitRef="shares">9521028</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTcvZnJhZzowZjZiOTE0MzkyZTQ0NTQ3ODFiMDExOWE2OTQwM2I4ZS90ZXh0cmVnaW9uOjBmNmI5MTQzOTJlNDQ1NDc4MWIwMTE5YTY5NDAzYjhlXzI5MTg_072fcd96-7559-42e1-8b34-29ff44fef047">Goodwill and Intangible Assets&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill is measured as the excess of the cost of the acquisition over the sum of the amounts assigned to tangible and identifiable intangible assets acquired less liabilities assumed. The Company assigns assets acquired (including goodwill) and liabilities assumed to one or more reporting units as of the date of acquisition. Typically acquisitions related to a single reporting unit do not require the allocation of goodwill to multiple reporting units. If the products obtained in an acquisition are assigned to multiple reporting units, the goodwill is distributed to the respective reporting units as part of the purchase price allocation process.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill and purchased intangible assets are reviewed for impairment annually during the fourth quarter of each fiscal year and whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. The process of evaluating the potential impairment of goodwill and intangible assets requires significant judgment. The Company regularly monitors current business conditions and other factors including, but not limited to, adverse industry or economic trends and lower projections of profitability that may impact future operating results. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s annual evaluation for impairment of goodwill consists of one reporting unit. In accordance with the Company&#x2019;s policy, the Company completed its annual evaluation for impairment in the fourth quarter of 2021 using the qualitative assessment. No impairment charge was recognized for the year ended December 31, 2021 and there have been no cumulative goodwill impairment charges recognized to date.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2021 and 2020, goodwill was $2,009 and $2,030, respectively and represents goodwill recognized from the acquisition of Discuva Limited in December of 2017. Changes year over year are the result of foreign currency movements. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Components of the Company's acquired intangible assets are comprised of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.836%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.293%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.587%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.587%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.587%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.650%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Accumulated amortization and impairment charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Utrophin program acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,487)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Discuva platform acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,017)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,399&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Option over non-financial asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;912&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(912)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other patents and licenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(148)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,564)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,399&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.397%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.591%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.591%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.591%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.567%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Accumulated amortization and impairment charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Utrophin program acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,534)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Discuva platform acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,565&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,050)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,515&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Option over non-financial asset&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;921&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(921)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other patents and licenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(150)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,655)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,515&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;During the year ended December 31, 2020, management identified an impairment related to the option over non-financial asset pursuant to an Evaluation and Option Agreement with a collaboration partner. The partner is no longer conducting antibiotic candidate programs over which the Company had the option, management therefore determined that the fair value of the option to acquire the assignment of the proprietary rights for antibiotic candidates is $0. Accordingly, the asset was written off in its entirety resulting in an impairment charge of $859 recognized in operating expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization expense was $1,017 and $1,250 for the years ended December 31, 2021 and 2020, respectively. The weighted-average remaining life at December 31, 2021 for our Discuva platform intangible asset was approximately 10.4 years. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated net amortization expense related to acquired intangible assets for future years is:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:72pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:62.134%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.194%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.430%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:NumberOfReportingUnits
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTcvZnJhZzowZjZiOTE0MzkyZTQ0NTQ3ODFiMDExOWE2OTQwM2I4ZS90ZXh0cmVnaW9uOjBmNmI5MTQzOTJlNDQ1NDc4MWIwMTE5YTY5NDAzYjhlXzEzMzI_dd141b3a-d11e-4b7e-bab3-da5f06157d5e"
      unitRef="reporting_unit">1</us-gaap:NumberOfReportingUnits>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTcvZnJhZzowZjZiOTE0MzkyZTQ0NTQ3ODFiMDExOWE2OTQwM2I4ZS90ZXh0cmVnaW9uOjBmNmI5MTQzOTJlNDQ1NDc4MWIwMTE5YTY5NDAzYjhlXzE1MTU_54e0b9a5-3dfc-4e15-ab54-154c15e3154b"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairedAccumulatedImpairmentLoss
      contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTcvZnJhZzowZjZiOTE0MzkyZTQ0NTQ3ODFiMDExOWE2OTQwM2I4ZS90ZXh0cmVnaW9uOjBmNmI5MTQzOTJlNDQ1NDc4MWIwMTE5YTY5NDAzYjhlXzE2MDg_5b57d322-8027-46a0-86d2-21db17739935"
      unitRef="usd">0</us-gaap:GoodwillImpairedAccumulatedImpairmentLoss>
    <us-gaap:Goodwill
      contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTcvZnJhZzowZjZiOTE0MzkyZTQ0NTQ3ODFiMDExOWE2OTQwM2I4ZS90ZXh0cmVnaW9uOjBmNmI5MTQzOTJlNDQ1NDc4MWIwMTE5YTY5NDAzYjhlXzE3MTg_f695310e-b76a-402c-b05d-9687665b9112"
      unitRef="usd">2009000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i7372be6dc06143b5adbb4d2e83a596c5_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTcvZnJhZzowZjZiOTE0MzkyZTQ0NTQ3ODFiMDExOWE2OTQwM2I4ZS90ZXh0cmVnaW9uOjBmNmI5MTQzOTJlNDQ1NDc4MWIwMTE5YTY5NDAzYjhlXzE3MjU_a9d7818e-a6be-4f75-95e3-5538e20f4b8c"
      unitRef="usd">2030000</us-gaap:Goodwill>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i3b2b674d2a6f48e7af3dcc03537946c3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTcvZnJhZzowZjZiOTE0MzkyZTQ0NTQ3ODFiMDExOWE2OTQwM2I4ZS90YWJsZTpkNzhjMzExOTM4OWY0NDdkYmNlMjNjZWQwNTA2MDdmYy90YWJsZXJhbmdlOmQ3OGMzMTE5Mzg5ZjQ0N2RiY2UyM2NlZDA1MDYwN2ZjXzItMi0xLTEtMTA5ODc2_b60ebda3-f66a-4028-9047-3b0e7d15b0da"
      unitRef="usd">4487000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <smmt:FiniteLivedIntangibleAssetsAccumulatedAmortizationAndImpairment
      contextRef="i3b2b674d2a6f48e7af3dcc03537946c3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTcvZnJhZzowZjZiOTE0MzkyZTQ0NTQ3ODFiMDExOWE2OTQwM2I4ZS90YWJsZTpkNzhjMzExOTM4OWY0NDdkYmNlMjNjZWQwNTA2MDdmYy90YWJsZXJhbmdlOmQ3OGMzMTE5Mzg5ZjQ0N2RiY2UyM2NlZDA1MDYwN2ZjXzItNC0xLTEtMTA5ODc2_6ce112bf-266a-4b00-900c-fd8282e60767"
      unitRef="usd">4487000</smmt:FiniteLivedIntangibleAssetsAccumulatedAmortizationAndImpairment>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i3b2b674d2a6f48e7af3dcc03537946c3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTcvZnJhZzowZjZiOTE0MzkyZTQ0NTQ3ODFiMDExOWE2OTQwM2I4ZS90YWJsZTpkNzhjMzExOTM4OWY0NDdkYmNlMjNjZWQwNTA2MDdmYy90YWJsZXJhbmdlOmQ3OGMzMTE5Mzg5ZjQ0N2RiY2UyM2NlZDA1MDYwN2ZjXzItNi0xLTEtMTA5ODc2_18395e09-bd24-4c94-8d53-f98eb7a25f1f"
      unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i2491765d7faa4157a0b9a7f08084dcb2_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTcvZnJhZzowZjZiOTE0MzkyZTQ0NTQ3ODFiMDExOWE2OTQwM2I4ZS90YWJsZTpkNzhjMzExOTM4OWY0NDdkYmNlMjNjZWQwNTA2MDdmYy90YWJsZXJhbmdlOmQ3OGMzMTE5Mzg5ZjQ0N2RiY2UyM2NlZDA1MDYwN2ZjXzMtMi0xLTEtMTA5ODc2_bc030ceb-64e6-4cae-adf7-3415aa27e968"
      unitRef="usd">14416000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <smmt:FiniteLivedIntangibleAssetsAccumulatedAmortizationAndImpairment
      contextRef="i2491765d7faa4157a0b9a7f08084dcb2_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTcvZnJhZzowZjZiOTE0MzkyZTQ0NTQ3ODFiMDExOWE2OTQwM2I4ZS90YWJsZTpkNzhjMzExOTM4OWY0NDdkYmNlMjNjZWQwNTA2MDdmYy90YWJsZXJhbmdlOmQ3OGMzMTE5Mzg5ZjQ0N2RiY2UyM2NlZDA1MDYwN2ZjXzMtNC0xLTEtMTA5ODc2_e44ac196-565e-4a25-8e1a-281af807d48c"
      unitRef="usd">4017000</smmt:FiniteLivedIntangibleAssetsAccumulatedAmortizationAndImpairment>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i2491765d7faa4157a0b9a7f08084dcb2_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTcvZnJhZzowZjZiOTE0MzkyZTQ0NTQ3ODFiMDExOWE2OTQwM2I4ZS90YWJsZTpkNzhjMzExOTM4OWY0NDdkYmNlMjNjZWQwNTA2MDdmYy90YWJsZXJhbmdlOmQ3OGMzMTE5Mzg5ZjQ0N2RiY2UyM2NlZDA1MDYwN2ZjXzMtNi0xLTEtMTA5ODc2_7fcf7a6e-ce12-4725-8196-65d2f8b207e6"
      unitRef="usd">10399000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i558da201e4864ba0a1ff4a54d2b3b599_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTcvZnJhZzowZjZiOTE0MzkyZTQ0NTQ3ODFiMDExOWE2OTQwM2I4ZS90YWJsZTpkNzhjMzExOTM4OWY0NDdkYmNlMjNjZWQwNTA2MDdmYy90YWJsZXJhbmdlOmQ3OGMzMTE5Mzg5ZjQ0N2RiY2UyM2NlZDA1MDYwN2ZjXzQtMi0xLTEtMTA5ODc2_0e9bd11f-661c-448c-9228-c0e7f2b81145"
      unitRef="usd">912000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <smmt:FiniteLivedIntangibleAssetsAccumulatedAmortizationAndImpairment
      contextRef="i558da201e4864ba0a1ff4a54d2b3b599_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTcvZnJhZzowZjZiOTE0MzkyZTQ0NTQ3ODFiMDExOWE2OTQwM2I4ZS90YWJsZTpkNzhjMzExOTM4OWY0NDdkYmNlMjNjZWQwNTA2MDdmYy90YWJsZXJhbmdlOmQ3OGMzMTE5Mzg5ZjQ0N2RiY2UyM2NlZDA1MDYwN2ZjXzQtNC0xLTEtMTA5ODc2_a4e764ad-ad70-41cb-8b1b-29f279fd8d92"
      unitRef="usd">912000</smmt:FiniteLivedIntangibleAssetsAccumulatedAmortizationAndImpairment>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i558da201e4864ba0a1ff4a54d2b3b599_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTcvZnJhZzowZjZiOTE0MzkyZTQ0NTQ3ODFiMDExOWE2OTQwM2I4ZS90YWJsZTpkNzhjMzExOTM4OWY0NDdkYmNlMjNjZWQwNTA2MDdmYy90YWJsZXJhbmdlOmQ3OGMzMTE5Mzg5ZjQ0N2RiY2UyM2NlZDA1MDYwN2ZjXzQtNi0xLTEtMTA5ODc2_61c783fb-7c12-454c-9233-94402362ead7"
      unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i93b60cd7d5744711a30a544473f93063_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTcvZnJhZzowZjZiOTE0MzkyZTQ0NTQ3ODFiMDExOWE2OTQwM2I4ZS90YWJsZTpkNzhjMzExOTM4OWY0NDdkYmNlMjNjZWQwNTA2MDdmYy90YWJsZXJhbmdlOmQ3OGMzMTE5Mzg5ZjQ0N2RiY2UyM2NlZDA1MDYwN2ZjXzUtMi0xLTEtMTA5ODc2_4a0f9a7d-a14b-48bd-b81d-ca00250a0b7c"
      unitRef="usd">148000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <smmt:FiniteLivedIntangibleAssetsAccumulatedAmortizationAndImpairment
      contextRef="i93b60cd7d5744711a30a544473f93063_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTcvZnJhZzowZjZiOTE0MzkyZTQ0NTQ3ODFiMDExOWE2OTQwM2I4ZS90YWJsZTpkNzhjMzExOTM4OWY0NDdkYmNlMjNjZWQwNTA2MDdmYy90YWJsZXJhbmdlOmQ3OGMzMTE5Mzg5ZjQ0N2RiY2UyM2NlZDA1MDYwN2ZjXzUtNC0xLTEtMTA5ODc2_f8e620cc-1c7c-4343-b0b8-c9cf5b4b695a"
      unitRef="usd">148000</smmt:FiniteLivedIntangibleAssetsAccumulatedAmortizationAndImpairment>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i93b60cd7d5744711a30a544473f93063_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTcvZnJhZzowZjZiOTE0MzkyZTQ0NTQ3ODFiMDExOWE2OTQwM2I4ZS90YWJsZTpkNzhjMzExOTM4OWY0NDdkYmNlMjNjZWQwNTA2MDdmYy90YWJsZXJhbmdlOmQ3OGMzMTE5Mzg5ZjQ0N2RiY2UyM2NlZDA1MDYwN2ZjXzUtNi0xLTEtMTA5ODc2_366fb1a7-ef05-47ab-a20f-5297bdd2d4a6"
      unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTcvZnJhZzowZjZiOTE0MzkyZTQ0NTQ3ODFiMDExOWE2OTQwM2I4ZS90YWJsZTpkNzhjMzExOTM4OWY0NDdkYmNlMjNjZWQwNTA2MDdmYy90YWJsZXJhbmdlOmQ3OGMzMTE5Mzg5ZjQ0N2RiY2UyM2NlZDA1MDYwN2ZjXzYtMi0xLTEtMTA5ODc2_73317ac4-5a30-4504-9bbc-a21bf8c9ce37"
      unitRef="usd">19963000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <smmt:FiniteLivedIntangibleAssetsAccumulatedAmortizationAndImpairment
      contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTcvZnJhZzowZjZiOTE0MzkyZTQ0NTQ3ODFiMDExOWE2OTQwM2I4ZS90YWJsZTpkNzhjMzExOTM4OWY0NDdkYmNlMjNjZWQwNTA2MDdmYy90YWJsZXJhbmdlOmQ3OGMzMTE5Mzg5ZjQ0N2RiY2UyM2NlZDA1MDYwN2ZjXzYtNC0xLTEtMTA5ODc2_6a6e1e6d-d75b-4910-a5c9-5550f19e0b87"
      unitRef="usd">9564000</smmt:FiniteLivedIntangibleAssetsAccumulatedAmortizationAndImpairment>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTcvZnJhZzowZjZiOTE0MzkyZTQ0NTQ3ODFiMDExOWE2OTQwM2I4ZS90YWJsZTpkNzhjMzExOTM4OWY0NDdkYmNlMjNjZWQwNTA2MDdmYy90YWJsZXJhbmdlOmQ3OGMzMTE5Mzg5ZjQ0N2RiY2UyM2NlZDA1MDYwN2ZjXzYtNi0xLTEtMTA5ODc2_ddc1243f-6498-4015-8904-4a2ede72ff29"
      unitRef="usd">10399000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="iaf53a1912d5743a186cd8a0986d0a4c9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTcvZnJhZzowZjZiOTE0MzkyZTQ0NTQ3ODFiMDExOWE2OTQwM2I4ZS90YWJsZTo4YjQ5MDE2MTQ2YmU0Mzg5OTY3ZjMyODE2ZGUwZTFlNC90YWJsZXJhbmdlOjhiNDkwMTYxNDZiZTQzODk5NjdmMzI4MTZkZTBlMWU0XzItMi0xLTEtMTA5ODc2_b5520808-36c7-4f3d-879e-d2577e83d2ee"
      unitRef="usd">4534000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <smmt:FiniteLivedIntangibleAssetsAccumulatedAmortizationAndImpairment
      contextRef="iaf53a1912d5743a186cd8a0986d0a4c9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTcvZnJhZzowZjZiOTE0MzkyZTQ0NTQ3ODFiMDExOWE2OTQwM2I4ZS90YWJsZTo4YjQ5MDE2MTQ2YmU0Mzg5OTY3ZjMyODE2ZGUwZTFlNC90YWJsZXJhbmdlOjhiNDkwMTYxNDZiZTQzODk5NjdmMzI4MTZkZTBlMWU0XzItNC0xLTEtMTA5ODc2_ae8a7219-bc30-424e-9dda-f3dd3626cf2b"
      unitRef="usd">4534000</smmt:FiniteLivedIntangibleAssetsAccumulatedAmortizationAndImpairment>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="iaf53a1912d5743a186cd8a0986d0a4c9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTcvZnJhZzowZjZiOTE0MzkyZTQ0NTQ3ODFiMDExOWE2OTQwM2I4ZS90YWJsZTo4YjQ5MDE2MTQ2YmU0Mzg5OTY3ZjMyODE2ZGUwZTFlNC90YWJsZXJhbmdlOjhiNDkwMTYxNDZiZTQzODk5NjdmMzI4MTZkZTBlMWU0XzItNi0xLTEtMTA5ODc2_7995522d-7048-4279-82a8-35e804b6d171"
      unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="id2256d9dc5d54775a80518270c92d9cf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTcvZnJhZzowZjZiOTE0MzkyZTQ0NTQ3ODFiMDExOWE2OTQwM2I4ZS90YWJsZTo4YjQ5MDE2MTQ2YmU0Mzg5OTY3ZjMyODE2ZGUwZTFlNC90YWJsZXJhbmdlOjhiNDkwMTYxNDZiZTQzODk5NjdmMzI4MTZkZTBlMWU0XzMtMi0xLTEtMTA5ODc2_40ca5c5f-f1a3-4392-8049-540380a62864"
      unitRef="usd">14565000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <smmt:FiniteLivedIntangibleAssetsAccumulatedAmortizationAndImpairment
      contextRef="id2256d9dc5d54775a80518270c92d9cf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTcvZnJhZzowZjZiOTE0MzkyZTQ0NTQ3ODFiMDExOWE2OTQwM2I4ZS90YWJsZTo4YjQ5MDE2MTQ2YmU0Mzg5OTY3ZjMyODE2ZGUwZTFlNC90YWJsZXJhbmdlOjhiNDkwMTYxNDZiZTQzODk5NjdmMzI4MTZkZTBlMWU0XzMtNC0xLTEtMTA5ODc2_7fb96e3a-ec3a-4bd2-b80b-ed7cb7cb531f"
      unitRef="usd">3050000</smmt:FiniteLivedIntangibleAssetsAccumulatedAmortizationAndImpairment>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="id2256d9dc5d54775a80518270c92d9cf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTcvZnJhZzowZjZiOTE0MzkyZTQ0NTQ3ODFiMDExOWE2OTQwM2I4ZS90YWJsZTo4YjQ5MDE2MTQ2YmU0Mzg5OTY3ZjMyODE2ZGUwZTFlNC90YWJsZXJhbmdlOjhiNDkwMTYxNDZiZTQzODk5NjdmMzI4MTZkZTBlMWU0XzMtNi0xLTEtMTA5ODc2_28884617-2274-4053-b9dd-53970cc7f25e"
      unitRef="usd">11515000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i74db8c4615a64aabac7a997f0967a92d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTcvZnJhZzowZjZiOTE0MzkyZTQ0NTQ3ODFiMDExOWE2OTQwM2I4ZS90YWJsZTo4YjQ5MDE2MTQ2YmU0Mzg5OTY3ZjMyODE2ZGUwZTFlNC90YWJsZXJhbmdlOjhiNDkwMTYxNDZiZTQzODk5NjdmMzI4MTZkZTBlMWU0XzQtMi0xLTEtMTA5ODc2_aa18f209-3af7-4dc9-ac4e-81358024d33e"
      unitRef="usd">921000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <smmt:FiniteLivedIntangibleAssetsAccumulatedAmortizationAndImpairment
      contextRef="i74db8c4615a64aabac7a997f0967a92d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTcvZnJhZzowZjZiOTE0MzkyZTQ0NTQ3ODFiMDExOWE2OTQwM2I4ZS90YWJsZTo4YjQ5MDE2MTQ2YmU0Mzg5OTY3ZjMyODE2ZGUwZTFlNC90YWJsZXJhbmdlOjhiNDkwMTYxNDZiZTQzODk5NjdmMzI4MTZkZTBlMWU0XzQtNC0xLTEtMTA5ODc2_3f2ccf86-bba4-4238-b070-a1ba1b62949e"
      unitRef="usd">921000</smmt:FiniteLivedIntangibleAssetsAccumulatedAmortizationAndImpairment>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i74db8c4615a64aabac7a997f0967a92d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTcvZnJhZzowZjZiOTE0MzkyZTQ0NTQ3ODFiMDExOWE2OTQwM2I4ZS90YWJsZTo4YjQ5MDE2MTQ2YmU0Mzg5OTY3ZjMyODE2ZGUwZTFlNC90YWJsZXJhbmdlOjhiNDkwMTYxNDZiZTQzODk5NjdmMzI4MTZkZTBlMWU0XzQtNi0xLTEtMTA5ODc2_caa52ee0-d146-4ad0-a547-f088281ae637"
      unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i8ae4247d97144e01bf0a9c9b8cfd0111_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTcvZnJhZzowZjZiOTE0MzkyZTQ0NTQ3ODFiMDExOWE2OTQwM2I4ZS90YWJsZTo4YjQ5MDE2MTQ2YmU0Mzg5OTY3ZjMyODE2ZGUwZTFlNC90YWJsZXJhbmdlOjhiNDkwMTYxNDZiZTQzODk5NjdmMzI4MTZkZTBlMWU0XzUtMi0xLTEtMTA5ODc2_cdf1bff6-abe4-49fc-b663-02e49bd97f53"
      unitRef="usd">150000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <smmt:FiniteLivedIntangibleAssetsAccumulatedAmortizationAndImpairment
      contextRef="i8ae4247d97144e01bf0a9c9b8cfd0111_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTcvZnJhZzowZjZiOTE0MzkyZTQ0NTQ3ODFiMDExOWE2OTQwM2I4ZS90YWJsZTo4YjQ5MDE2MTQ2YmU0Mzg5OTY3ZjMyODE2ZGUwZTFlNC90YWJsZXJhbmdlOjhiNDkwMTYxNDZiZTQzODk5NjdmMzI4MTZkZTBlMWU0XzUtNC0xLTEtMTA5ODc2_bd336abe-957f-4f66-821e-e7620be1ee1d"
      unitRef="usd">150000</smmt:FiniteLivedIntangibleAssetsAccumulatedAmortizationAndImpairment>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i8ae4247d97144e01bf0a9c9b8cfd0111_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTcvZnJhZzowZjZiOTE0MzkyZTQ0NTQ3ODFiMDExOWE2OTQwM2I4ZS90YWJsZTo4YjQ5MDE2MTQ2YmU0Mzg5OTY3ZjMyODE2ZGUwZTFlNC90YWJsZXJhbmdlOjhiNDkwMTYxNDZiZTQzODk5NjdmMzI4MTZkZTBlMWU0XzUtNi0xLTEtMTA5ODc2_507799e2-6f40-4cae-9d27-667f73abd587"
      unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i7372be6dc06143b5adbb4d2e83a596c5_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTcvZnJhZzowZjZiOTE0MzkyZTQ0NTQ3ODFiMDExOWE2OTQwM2I4ZS90YWJsZTo4YjQ5MDE2MTQ2YmU0Mzg5OTY3ZjMyODE2ZGUwZTFlNC90YWJsZXJhbmdlOjhiNDkwMTYxNDZiZTQzODk5NjdmMzI4MTZkZTBlMWU0XzYtMi0xLTEtMTA5ODc2_8acd621d-fa87-49df-8b09-bf3f325eda1f"
      unitRef="usd">20170000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <smmt:FiniteLivedIntangibleAssetsAccumulatedAmortizationAndImpairment
      contextRef="i7372be6dc06143b5adbb4d2e83a596c5_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTcvZnJhZzowZjZiOTE0MzkyZTQ0NTQ3ODFiMDExOWE2OTQwM2I4ZS90YWJsZTo4YjQ5MDE2MTQ2YmU0Mzg5OTY3ZjMyODE2ZGUwZTFlNC90YWJsZXJhbmdlOjhiNDkwMTYxNDZiZTQzODk5NjdmMzI4MTZkZTBlMWU0XzYtNC0xLTEtMTA5ODc2_23854865-e20d-4832-a82c-b118318c28b4"
      unitRef="usd">8655000</smmt:FiniteLivedIntangibleAssetsAccumulatedAmortizationAndImpairment>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i7372be6dc06143b5adbb4d2e83a596c5_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTcvZnJhZzowZjZiOTE0MzkyZTQ0NTQ3ODFiMDExOWE2OTQwM2I4ZS90YWJsZTo4YjQ5MDE2MTQ2YmU0Mzg5OTY3ZjMyODE2ZGUwZTFlNC90YWJsZXJhbmdlOjhiNDkwMTYxNDZiZTQzODk5NjdmMzI4MTZkZTBlMWU0XzYtNi0xLTEtMTA5ODc2_757960b1-a5b0-4266-9286-d81f5f5f3ebb"
      unitRef="usd">11515000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsFairValueDisclosure
      contextRef="i74db8c4615a64aabac7a997f0967a92d_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTcvZnJhZzowZjZiOTE0MzkyZTQ0NTQ3ODFiMDExOWE2OTQwM2I4ZS90ZXh0cmVnaW9uOjBmNmI5MTQzOTJlNDQ1NDc4MWIwMTE5YTY5NDAzYjhlXzI0NzY_adcf8964-e18b-438e-bcb7-76bb656ef399"
      unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsFairValueDisclosure>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="i137b9502c9084c29a43d474c1b31e151_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTcvZnJhZzowZjZiOTE0MzkyZTQ0NTQ3ODFiMDExOWE2OTQwM2I4ZS90ZXh0cmVnaW9uOjBmNmI5MTQzOTJlNDQ1NDc4MWIwMTE5YTY5NDAzYjhlXzI1NzI_7ff29c64-599d-4963-80b5-0f03612443a7"
      unitRef="usd">859000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTcvZnJhZzowZjZiOTE0MzkyZTQ0NTQ3ODFiMDExOWE2OTQwM2I4ZS90ZXh0cmVnaW9uOjBmNmI5MTQzOTJlNDQ1NDc4MWIwMTE5YTY5NDAzYjhlXzI2MzU_8859662f-94ca-4dcb-a273-3cb79382a59a"
      unitRef="usd">1017000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTcvZnJhZzowZjZiOTE0MzkyZTQ0NTQ3ODFiMDExOWE2OTQwM2I4ZS90ZXh0cmVnaW9uOjBmNmI5MTQzOTJlNDQ1NDc4MWIwMTE5YTY5NDAzYjhlXzI2NDI_a47cd5d9-b9c8-471e-879f-45e273b7fd2a"
      unitRef="usd">1250000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="ia3f12147410f43d28d06362b9dba4771_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTcvZnJhZzowZjZiOTE0MzkyZTQ0NTQ3ODFiMDExOWE2OTQwM2I4ZS90ZXh0cmVnaW9uOjBmNmI5MTQzOTJlNDQ1NDc4MWIwMTE5YTY5NDAzYjhlXzI4MDk_7cd480e3-def9-4647-ab06-ba63367beb2d">P10Y4M24D</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTcvZnJhZzowZjZiOTE0MzkyZTQ0NTQ3ODFiMDExOWE2OTQwM2I4ZS90ZXh0cmVnaW9uOjBmNmI5MTQzOTJlNDQ1NDc4MWIwMTE5YTY5NDAzYjhlXzI5MTY_73ecaeb9-d05d-4f0d-add6-38edafda05e5">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated net amortization expense related to acquired intangible assets for future years is:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:72pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:62.134%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.194%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.430%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTcvZnJhZzowZjZiOTE0MzkyZTQ0NTQ3ODFiMDExOWE2OTQwM2I4ZS90YWJsZTpiZjYyMDU4NWIwMzU0NzM2ODVhMTkwMzhmOTM0M2ZkNS90YWJsZXJhbmdlOmJmNjIwNTg1YjAzNTQ3MzY4NWExOTAzOGY5MzQzZmQ1XzEtMi0xLTEtMTA5ODc2_9ba500f5-6853-4779-9748-13844de5849b"
      unitRef="usd">999000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTcvZnJhZzowZjZiOTE0MzkyZTQ0NTQ3ODFiMDExOWE2OTQwM2I4ZS90YWJsZTpiZjYyMDU4NWIwMzU0NzM2ODVhMTkwMzhmOTM0M2ZkNS90YWJsZXJhbmdlOmJmNjIwNTg1YjAzNTQ3MzY4NWExOTAzOGY5MzQzZmQ1XzItMi0xLTEtMTA5ODc2_db06c8aa-3e8d-4b1b-a54d-7ed98a25b0d2"
      unitRef="usd">999000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTcvZnJhZzowZjZiOTE0MzkyZTQ0NTQ3ODFiMDExOWE2OTQwM2I4ZS90YWJsZTpiZjYyMDU4NWIwMzU0NzM2ODVhMTkwMzhmOTM0M2ZkNS90YWJsZXJhbmdlOmJmNjIwNTg1YjAzNTQ3MzY4NWExOTAzOGY5MzQzZmQ1XzMtMi0xLTEtMTA5ODc2_bf94a537-3722-4214-9394-97e74d3b3186"
      unitRef="usd">999000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTcvZnJhZzowZjZiOTE0MzkyZTQ0NTQ3ODFiMDExOWE2OTQwM2I4ZS90YWJsZTpiZjYyMDU4NWIwMzU0NzM2ODVhMTkwMzhmOTM0M2ZkNS90YWJsZXJhbmdlOmJmNjIwNTg1YjAzNTQ3MzY4NWExOTAzOGY5MzQzZmQ1XzQtMi0xLTEtMTA5ODc2_c890100a-ef08-46a3-b15a-6eac74f1e563"
      unitRef="usd">999000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
      contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTcvZnJhZzowZjZiOTE0MzkyZTQ0NTQ3ODFiMDExOWE2OTQwM2I4ZS90YWJsZTpiZjYyMDU4NWIwMzU0NzM2ODVhMTkwMzhmOTM0M2ZkNS90YWJsZXJhbmdlOmJmNjIwNTg1YjAzNTQ3MzY4NWExOTAzOGY5MzQzZmQ1XzUtMi0xLTEtMTA5ODc2_44574bf2-09cd-4e9b-b7fd-93279b971fa5"
      unitRef="usd">999000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
      contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNTcvZnJhZzowZjZiOTE0MzkyZTQ0NTQ3ODFiMDExOWE2OTQwM2I4ZS90YWJsZTpiZjYyMDU4NWIwMzU0NzM2ODVhMTkwMzhmOTM0M2ZkNS90YWJsZXJhbmdlOmJmNjIwNTg1YjAzNTQ3MzY4NWExOTAzOGY5MzQzZmQ1XzYtMi0xLTEtMTA5ODc2_a756fd78-c37c-4a61-972d-1626524af8b2"
      unitRef="usd">5404000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNjAvZnJhZzo4M2ZiOGEyNGZmNzQ0ZGFhYmM1ZDliYjdiZDFjODk5YS90ZXh0cmVnaW9uOjgzZmI4YTI0ZmY3NDRkYWFiYzVkOWJiN2JkMWM4OTlhXzE0OQ_a61cc376-bcd3-477e-b9a9-e66a32579ba4">Property and Equipment &lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.421%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.367%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.774%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.582%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,626&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;759&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures, office equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,081&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;694&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation expense for the years ended December 31, 2021 and 2020 was $330 and $302, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="if6f9b4ae5c0b4a59bd0bbd8975258bb6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNjAvZnJhZzo4M2ZiOGEyNGZmNzQ0ZGFhYmM1ZDliYjdiZDFjODk5YS90YWJsZTo0MTZlNTIxZDhjOGY0Yzk4YjY3MmMxZThmNTY0N2QzMC90YWJsZXJhbmdlOjQxNmU1MjFkOGM4ZjRjOThiNjcyYzFlOGY1NjQ3ZDMwXzEtMS0xLTEtMTA5ODc2_35968cb6-75d7-4873-b93a-b12c4adb3330"
      unitRef="usd">2626000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="if02dcbd0b04f40f08ccd958c30a79c08_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNjAvZnJhZzo4M2ZiOGEyNGZmNzQ0ZGFhYmM1ZDliYjdiZDFjODk5YS90YWJsZTo0MTZlNTIxZDhjOGY0Yzk4YjY3MmMxZThmNTY0N2QzMC90YWJsZXJhbmdlOjQxNmU1MjFkOGM4ZjRjOThiNjcyYzFlOGY1NjQ3ZDMwXzEtMy0xLTEtMTA5ODc2_b8567bf1-7566-4f7f-ab1f-3fb48afd836c"
      unitRef="usd">759000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ic09e2474bf014397be8c508d9cbef4b5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNjAvZnJhZzo4M2ZiOGEyNGZmNzQ0ZGFhYmM1ZDliYjdiZDFjODk5YS90YWJsZTo0MTZlNTIxZDhjOGY0Yzk4YjY3MmMxZThmNTY0N2QzMC90YWJsZXJhbmdlOjQxNmU1MjFkOGM4ZjRjOThiNjcyYzFlOGY1NjQ3ZDMwXzItMS0xLTEtMTA5ODc2_44dc6647-271c-4538-ac30-095fce0ee5b3"
      unitRef="usd">1081000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i30c79b436c2d47d98676b1f9a2231cdc_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNjAvZnJhZzo4M2ZiOGEyNGZmNzQ0ZGFhYmM1ZDliYjdiZDFjODk5YS90YWJsZTo0MTZlNTIxZDhjOGY0Yzk4YjY3MmMxZThmNTY0N2QzMC90YWJsZXJhbmdlOjQxNmU1MjFkOGM4ZjRjOThiNjcyYzFlOGY1NjQ3ZDMwXzItMy0xLTEtMTA5ODc2_1adf60f9-78f0-4f35-a997-4ef0a916595f"
      unitRef="usd">804000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ib30be684902148cdbfad1b6e48d5528d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNjAvZnJhZzo4M2ZiOGEyNGZmNzQ0ZGFhYmM1ZDliYjdiZDFjODk5YS90YWJsZTo0MTZlNTIxZDhjOGY0Yzk4YjY3MmMxZThmNTY0N2QzMC90YWJsZXJhbmdlOjQxNmU1MjFkOGM4ZjRjOThiNjcyYzFlOGY1NjQ3ZDMwXzMtMS0xLTEtMTA5ODc2_b5002bd8-7fc2-49e4-828a-ff8a8b51ca62"
      unitRef="usd">364000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i2abb02e0508e40e5b35f04d561b326de_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNjAvZnJhZzo4M2ZiOGEyNGZmNzQ0ZGFhYmM1ZDliYjdiZDFjODk5YS90YWJsZTo0MTZlNTIxZDhjOGY0Yzk4YjY3MmMxZThmNTY0N2QzMC90YWJsZXJhbmdlOjQxNmU1MjFkOGM4ZjRjOThiNjcyYzFlOGY1NjQ3ZDMwXzMtMy0xLTEtMTA5ODc2_c6db1928-eb27-4d70-82f5-fa28d06760a5"
      unitRef="usd">291000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNjAvZnJhZzo4M2ZiOGEyNGZmNzQ0ZGFhYmM1ZDliYjdiZDFjODk5YS90YWJsZTo0MTZlNTIxZDhjOGY0Yzk4YjY3MmMxZThmNTY0N2QzMC90YWJsZXJhbmdlOjQxNmU1MjFkOGM4ZjRjOThiNjcyYzFlOGY1NjQ3ZDMwXzQtMS0xLTEtMTA5ODc2_5217a9a6-61dc-4bd9-b0b6-d915634a4660"
      unitRef="usd">4071000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i7372be6dc06143b5adbb4d2e83a596c5_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNjAvZnJhZzo4M2ZiOGEyNGZmNzQ0ZGFhYmM1ZDliYjdiZDFjODk5YS90YWJsZTo0MTZlNTIxZDhjOGY0Yzk4YjY3MmMxZThmNTY0N2QzMC90YWJsZXJhbmdlOjQxNmU1MjFkOGM4ZjRjOThiNjcyYzFlOGY1NjQ3ZDMwXzQtMy0xLTEtMTA5ODc2_1b48677b-cbe2-4699-bac8-1ffb67b475fe"
      unitRef="usd">1854000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNjAvZnJhZzo4M2ZiOGEyNGZmNzQ0ZGFhYmM1ZDliYjdiZDFjODk5YS90YWJsZTo0MTZlNTIxZDhjOGY0Yzk4YjY3MmMxZThmNTY0N2QzMC90YWJsZXJhbmdlOjQxNmU1MjFkOGM4ZjRjOThiNjcyYzFlOGY1NjQ3ZDMwXzUtMS0xLTEtMTA5ODc2_ccbe8bf0-925d-44e3-a98b-c9aead351b37"
      unitRef="usd">3377000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i7372be6dc06143b5adbb4d2e83a596c5_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNjAvZnJhZzo4M2ZiOGEyNGZmNzQ0ZGFhYmM1ZDliYjdiZDFjODk5YS90YWJsZTo0MTZlNTIxZDhjOGY0Yzk4YjY3MmMxZThmNTY0N2QzMC90YWJsZXJhbmdlOjQxNmU1MjFkOGM4ZjRjOThiNjcyYzFlOGY1NjQ3ZDMwXzUtMy0xLTEtMTA5ODc2_4d964636-632c-422e-8fe1-c09108dcd67b"
      unitRef="usd">1129000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNjAvZnJhZzo4M2ZiOGEyNGZmNzQ0ZGFhYmM1ZDliYjdiZDFjODk5YS90YWJsZTo0MTZlNTIxZDhjOGY0Yzk4YjY3MmMxZThmNTY0N2QzMC90YWJsZXJhbmdlOjQxNmU1MjFkOGM4ZjRjOThiNjcyYzFlOGY1NjQ3ZDMwXzYtMS0xLTEtMTA5ODc2_ad567480-94c4-4477-af1d-fa9e3e653bbf"
      unitRef="usd">694000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i7372be6dc06143b5adbb4d2e83a596c5_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNjAvZnJhZzo4M2ZiOGEyNGZmNzQ0ZGFhYmM1ZDliYjdiZDFjODk5YS90YWJsZTo0MTZlNTIxZDhjOGY0Yzk4YjY3MmMxZThmNTY0N2QzMC90YWJsZXJhbmdlOjQxNmU1MjFkOGM4ZjRjOThiNjcyYzFlOGY1NjQ3ZDMwXzYtMy0xLTEtMTA5ODc2_a7366a60-2cdd-485f-97fc-8c5ecad4228e"
      unitRef="usd">725000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNjAvZnJhZzo4M2ZiOGEyNGZmNzQ0ZGFhYmM1ZDliYjdiZDFjODk5YS90ZXh0cmVnaW9uOjgzZmI4YTI0ZmY3NDRkYWFiYzVkOWJiN2JkMWM4OTlhXzEyNQ_2c7a2177-5974-48c4-827f-485c99bf3afa"
      unitRef="usd">330000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNjAvZnJhZzo4M2ZiOGEyNGZmNzQ0ZGFhYmM1ZDliYjdiZDFjODk5YS90ZXh0cmVnaW9uOjgzZmI4YTI0ZmY3NDRkYWFiYzVkOWJiN2JkMWM4OTlhXzEzMg_afb51573-8639-4af8-80af-e7dd717fc1b9"
      unitRef="usd">302000</us-gaap:Depreciation>
    <us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNjMvZnJhZzo4YTQyOWYzNDA1NWU0N2U3YWM3OTI4MTJkZjVlZWM4Ni90ZXh0cmVnaW9uOjhhNDI5ZjM0MDU1ZTQ3ZTdhYzc5MjgxMmRmNWVlYzg2XzEwMTc_d385a493-287a-4ed3-8042-65f7b85cb07b">Research and Development Prepaid Expenses and Accrued Liabilities Included within prepaid expenses at December 31, 2021 and 2020 is $6,138 and $8,490, respectively, of prepayments relating to research and development expenditures. Included within accrued liabilities at December 31, 2021 and 2020 is $5,226 and $1,502, respectively, relating to research and development expenditures.These amounts are determined based on the estimated costs to complete each study or activity, the estimation of the current stage of completion and the invoices received, as well as predetermined milestones which are not reflective of the current stage of development for prepaid expenses. However, prepaid expenses decrease and accrued liabilities increase as the activities progress, and if actual costs incurred exceed the prepaid expense, an accrual will be recorded for the liability. The key sensitivity is the estimated current stage of completion of each study or activity, which is based on information received from the supplier and the Company's operational knowledge of the work completed under those contracts.</us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock>
    <smmt:ResearchAndDevelopmentPrepaidExpensesCurrent
      contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNjMvZnJhZzo4YTQyOWYzNDA1NWU0N2U3YWM3OTI4MTJkZjVlZWM4Ni90ZXh0cmVnaW9uOjhhNDI5ZjM0MDU1ZTQ3ZTdhYzc5MjgxMmRmNWVlYzg2XzY1_e8d2ab82-b10d-49fc-8df8-711ad34bdde7"
      unitRef="usd">6138000</smmt:ResearchAndDevelopmentPrepaidExpensesCurrent>
    <smmt:ResearchAndDevelopmentPrepaidExpensesCurrent
      contextRef="i7372be6dc06143b5adbb4d2e83a596c5_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNjMvZnJhZzo4YTQyOWYzNDA1NWU0N2U3YWM3OTI4MTJkZjVlZWM4Ni90ZXh0cmVnaW9uOjhhNDI5ZjM0MDU1ZTQ3ZTdhYzc5MjgxMmRmNWVlYzg2Xzcy_a6241e28-858b-43d8-835c-a0181b4954dc"
      unitRef="usd">8490000</smmt:ResearchAndDevelopmentPrepaidExpensesCurrent>
    <smmt:AccruedResearchAndDevelopmentCurrent
      contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNjMvZnJhZzo4YTQyOWYzNDA1NWU0N2U3YWM3OTI4MTJkZjVlZWM4Ni90ZXh0cmVnaW9uOjhhNDI5ZjM0MDU1ZTQ3ZTdhYzc5MjgxMmRmNWVlYzg2XzIxMA_c7752680-411e-4ff3-9dc9-69ae6cd113a3"
      unitRef="usd">5226000</smmt:AccruedResearchAndDevelopmentCurrent>
    <smmt:AccruedResearchAndDevelopmentCurrent
      contextRef="i7372be6dc06143b5adbb4d2e83a596c5_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNjMvZnJhZzo4YTQyOWYzNDA1NWU0N2U3YWM3OTI4MTJkZjVlZWM4Ni90ZXh0cmVnaW9uOjhhNDI5ZjM0MDU1ZTQ3ZTdhYzc5MjgxMmRmNWVlYzg2XzIxNw_d97cbc5b-6df5-4167-817b-af53cc0b20ec"
      unitRef="usd">1502000</smmt:AccruedResearchAndDevelopmentCurrent>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNjkvZnJhZzpkOWU4MTg1NDQyMmM0OWNlYWJjNjJkZmEzY2VmYzM5My90ZXh0cmVnaW9uOmQ5ZTgxODU0NDIyYzQ5Y2VhYmM2MmRmYTNjZWZjMzkzXzEyMDQ_03cb57bd-011a-46f3-b02f-6490cbb35541">Leases &lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%"&gt;The Company has operating leases for real estate. The Company does not have any finance leases. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%"&gt;During the year ended December 31, 2021, the Company recorded $3,389 of additional right-of-use assets of which $2,359 related to two new leases that commenced during the period for its Menlo Park, California, U.S. and Sawston, U.K. locations and $1,030 which related to one lease that was extended during the period for its Oxfordshire, U.K location.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying value of the right-of-use assets as of December 31, 2021 and 2020 is $2,790 and $554, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The elements of lease expense were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.467%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Lease Cost:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Fixed lease costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Variable lease costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;164&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Short-term lease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;278&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;272&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;921&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted average discount rate and the weighted average remaining lease term were 2.5% and 3.9 years, respectively, as of December 31, 2021. The weighted average discount rate and the weighted average remaining lease term were 3.75% and 1.1 years, respectively, as of December 31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future lease payments under non-cancelable leases as of December 31, 2021 are detailed as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:67.397%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:75.255%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.318%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.941%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.886%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 5.5pt 2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year Ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 5.5pt 2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,037&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 5.5pt 2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 5.5pt 2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,782&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating lease liabilities balance sheet presentation:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 5.5pt 2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 5.5pt 2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,691&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,782&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;Amounts presented above do not include payments related to the Company's Cambridge, Massachusetts, United States office where the lease term is month to month and therefore was not capitalized on the balance sheet.</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNjkvZnJhZzpkOWU4MTg1NDQyMmM0OWNlYWJjNjJkZmEzY2VmYzM5My90ZXh0cmVnaW9uOmQ5ZTgxODU0NDIyYzQ5Y2VhYmM2MmRmYTNjZWZjMzkzXzE3NA_923c4cda-f273-41b1-b781-b029585f70d5"
      unitRef="usd">3389000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i24a6a1407c6849eda580568b0680d532_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNjkvZnJhZzpkOWU4MTg1NDQyMmM0OWNlYWJjNjJkZmEzY2VmYzM5My90ZXh0cmVnaW9uOmQ5ZTgxODU0NDIyYzQ5Y2VhYmM2MmRmYTNjZWZjMzkzXzIyMA_bc90cdf0-7aaa-4a52-b883-282763938365"
      unitRef="usd">2359000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <smmt:LesseeOperatingLeaseNumberOfContracts
      contextRef="i24a6a1407c6849eda580568b0680d532_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNjkvZnJhZzpkOWU4MTg1NDQyMmM0OWNlYWJjNjJkZmEzY2VmYzM5My90ZXh0cmVnaW9uOmQ5ZTgxODU0NDIyYzQ5Y2VhYmM2MmRmYTNjZWZjMzkzXzIzNA_a18e5802-5d44-4e46-847d-1f43a00b97c8"
      unitRef="contract">2</smmt:LesseeOperatingLeaseNumberOfContracts>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="id630c360daad499f94b27cc39c3a0633_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNjkvZnJhZzpkOWU4MTg1NDQyMmM0OWNlYWJjNjJkZmEzY2VmYzM5My90ZXh0cmVnaW9uOmQ5ZTgxODU0NDIyYzQ5Y2VhYmM2MmRmYTNjZWZjMzkzXzM1MA_77ad9b82-3886-43e2-9022-4ad4c05cacf7"
      unitRef="usd">1030000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <smmt:LesseeOperatingLeaseNumberOfContracts
      contextRef="id630c360daad499f94b27cc39c3a0633_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNjkvZnJhZzpkOWU4MTg1NDQyMmM0OWNlYWJjNjJkZmEzY2VmYzM5My90ZXh0cmVnaW9uOmQ5ZTgxODU0NDIyYzQ5Y2VhYmM2MmRmYTNjZWZjMzkzXzM3MA_c4c7dde2-3a12-499b-97c2-8af419a534c7"
      unitRef="contract">1</smmt:LesseeOperatingLeaseNumberOfContracts>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNjkvZnJhZzpkOWU4MTg1NDQyMmM0OWNlYWJjNjJkZmEzY2VmYzM5My90ZXh0cmVnaW9uOmQ5ZTgxODU0NDIyYzQ5Y2VhYmM2MmRmYTNjZWZjMzkzXzUxOA_c9210cdf-c834-4d7f-827d-17eeb5ab74c1"
      unitRef="usd">2790000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i7372be6dc06143b5adbb4d2e83a596c5_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNjkvZnJhZzpkOWU4MTg1NDQyMmM0OWNlYWJjNjJkZmEzY2VmYzM5My90ZXh0cmVnaW9uOmQ5ZTgxODU0NDIyYzQ5Y2VhYmM2MmRmYTNjZWZjMzkzXzUyNQ_42b5e1e6-2d34-4c1e-856e-87b81af24944"
      unitRef="usd">554000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNjkvZnJhZzpkOWU4MTg1NDQyMmM0OWNlYWJjNjJkZmEzY2VmYzM5My90ZXh0cmVnaW9uOmQ5ZTgxODU0NDIyYzQ5Y2VhYmM2MmRmYTNjZWZjMzkzXzEyMDI_e51a556c-23a8-4297-ada5-beadaed19c27">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The elements of lease expense were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.467%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Lease Cost:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Fixed lease costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Variable lease costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;164&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Short-term lease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;278&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;272&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;921&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNjkvZnJhZzpkOWU4MTg1NDQyMmM0OWNlYWJjNjJkZmEzY2VmYzM5My90YWJsZTo3MWZiMWJiM2FlZmM0ZTNlODQyY2RhOTRhNDFiZTU5OS90YWJsZXJhbmdlOjcxZmIxYmIzYWVmYzRlM2U4NDJjZGE5NGE0MWJlNTk5XzUtMi0xLTEtMTA5ODc2_056d72c3-bfdd-48ef-804a-11e0efdcbaab"
      unitRef="usd">785000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNjkvZnJhZzpkOWU4MTg1NDQyMmM0OWNlYWJjNjJkZmEzY2VmYzM5My90YWJsZTo3MWZiMWJiM2FlZmM0ZTNlODQyY2RhOTRhNDFiZTU5OS90YWJsZXJhbmdlOjcxZmIxYmIzYWVmYzRlM2U4NDJjZGE5NGE0MWJlNTk5XzUtNC0xLTEtMTA5ODc2_68c17c8a-d379-4625-ac40-2e60784763b4"
      unitRef="usd">478000</us-gaap:OperatingLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNjkvZnJhZzpkOWU4MTg1NDQyMmM0OWNlYWJjNjJkZmEzY2VmYzM5My90YWJsZTo3MWZiMWJiM2FlZmM0ZTNlODQyY2RhOTRhNDFiZTU5OS90YWJsZXJhbmdlOjcxZmIxYmIzYWVmYzRlM2U4NDJjZGE5NGE0MWJlNTk5XzYtMi0xLTEtMTA5ODc2_e65d3c44-1a7e-4f45-b85b-38bdea9efa0f"
      unitRef="usd">164000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNjkvZnJhZzpkOWU4MTg1NDQyMmM0OWNlYWJjNjJkZmEzY2VmYzM5My90YWJsZTo3MWZiMWJiM2FlZmM0ZTNlODQyY2RhOTRhNDFiZTU5OS90YWJsZXJhbmdlOjcxZmIxYmIzYWVmYzRlM2U4NDJjZGE5NGE0MWJlNTk5XzYtNC0xLTEtMTA5ODc2_d99859cf-45ab-485f-bdf6-379313fdb088"
      unitRef="usd">171000</us-gaap:VariableLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNjkvZnJhZzpkOWU4MTg1NDQyMmM0OWNlYWJjNjJkZmEzY2VmYzM5My90YWJsZTo3MWZiMWJiM2FlZmM0ZTNlODQyY2RhOTRhNDFiZTU5OS90YWJsZXJhbmdlOjcxZmIxYmIzYWVmYzRlM2U4NDJjZGE5NGE0MWJlNTk5XzctMi0xLTEtMTA5ODc2_9e544de5-a6e2-4635-aa57-bfe9a27d7418"
      unitRef="usd">278000</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNjkvZnJhZzpkOWU4MTg1NDQyMmM0OWNlYWJjNjJkZmEzY2VmYzM5My90YWJsZTo3MWZiMWJiM2FlZmM0ZTNlODQyY2RhOTRhNDFiZTU5OS90YWJsZXJhbmdlOjcxZmIxYmIzYWVmYzRlM2U4NDJjZGE5NGE0MWJlNTk5XzctNC0xLTEtMTA5ODc2_ae800722-ce64-472e-b005-950b2396c539"
      unitRef="usd">272000</us-gaap:ShortTermLeaseCost>
    <us-gaap:LeaseCost
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNjkvZnJhZzpkOWU4MTg1NDQyMmM0OWNlYWJjNjJkZmEzY2VmYzM5My90YWJsZTo3MWZiMWJiM2FlZmM0ZTNlODQyY2RhOTRhNDFiZTU5OS90YWJsZXJhbmdlOjcxZmIxYmIzYWVmYzRlM2U4NDJjZGE5NGE0MWJlNTk5XzgtMi0xLTEtMTA5ODc2_9434c790-8d84-45ed-ac4d-1581920a5904"
      unitRef="usd">1227000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNjkvZnJhZzpkOWU4MTg1NDQyMmM0OWNlYWJjNjJkZmEzY2VmYzM5My90YWJsZTo3MWZiMWJiM2FlZmM0ZTNlODQyY2RhOTRhNDFiZTU5OS90YWJsZXJhbmdlOjcxZmIxYmIzYWVmYzRlM2U4NDJjZGE5NGE0MWJlNTk5XzgtNC0xLTEtMTA5ODc2_3e3a8a00-4047-4123-95e3-cdad28a9adba"
      unitRef="usd">921000</us-gaap:LeaseCost>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNjkvZnJhZzpkOWU4MTg1NDQyMmM0OWNlYWJjNjJkZmEzY2VmYzM5My90ZXh0cmVnaW9uOmQ5ZTgxODU0NDIyYzQ5Y2VhYmM2MmRmYTNjZWZjMzkzXzY4Mg_c76f36ab-10fa-4fbf-a72e-b5bd2509aa4f"
      unitRef="number">0.025</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNjkvZnJhZzpkOWU4MTg1NDQyMmM0OWNlYWJjNjJkZmEzY2VmYzM5My90ZXh0cmVnaW9uOmQ5ZTgxODU0NDIyYzQ5Y2VhYmM2MmRmYTNjZWZjMzkzXzY4OQ_8afce575-bd0b-43f3-bc54-908c866ba958">P3Y10M24D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i7372be6dc06143b5adbb4d2e83a596c5_I20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNjkvZnJhZzpkOWU4MTg1NDQyMmM0OWNlYWJjNjJkZmEzY2VmYzM5My90ZXh0cmVnaW9uOmQ5ZTgxODU0NDIyYzQ5Y2VhYmM2MmRmYTNjZWZjMzkzXzgyNA_e6e18b9d-b41b-490e-b7e2-e4c2cafc3eb9"
      unitRef="number">0.0375</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i7372be6dc06143b5adbb4d2e83a596c5_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNjkvZnJhZzpkOWU4MTg1NDQyMmM0OWNlYWJjNjJkZmEzY2VmYzM5My90ZXh0cmVnaW9uOmQ5ZTgxODU0NDIyYzQ5Y2VhYmM2MmRmYTNjZWZjMzkzXzgzMQ_4ea9e2f6-b7ef-4d71-a01c-5dd5138849d6">P1Y1M6D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNjkvZnJhZzpkOWU4MTg1NDQyMmM0OWNlYWJjNjJkZmEzY2VmYzM5My90ZXh0cmVnaW9uOmQ5ZTgxODU0NDIyYzQ5Y2VhYmM2MmRmYTNjZWZjMzkzXzExOTk_adb5cb5f-43a1-4fbe-bf68-0553995354c1">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future lease payments under non-cancelable leases as of December 31, 2021 are detailed as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:67.397%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:75.255%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.318%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.941%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.886%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 5.5pt 2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year Ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 5.5pt 2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,037&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 5.5pt 2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 5.5pt 2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,782&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating lease liabilities balance sheet presentation:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 5.5pt 2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 5.5pt 2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,691&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,782&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNjkvZnJhZzpkOWU4MTg1NDQyMmM0OWNlYWJjNjJkZmEzY2VmYzM5My90YWJsZTo4OTY4MTVjMjc4MjQ0OWJmOTk4NWYxOWEzMTc5MzE1ZC90YWJsZXJhbmdlOjg5NjgxNWMyNzgyNDQ5YmY5OTg1ZjE5YTMxNzkzMTVkXzEtMi0xLTEtMTA5ODc2_a02d4e7d-9223-494f-bfa6-e22bce55db8c"
      unitRef="usd">1037000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNjkvZnJhZzpkOWU4MTg1NDQyMmM0OWNlYWJjNjJkZmEzY2VmYzM5My90YWJsZTo4OTY4MTVjMjc4MjQ0OWJmOTk4NWYxOWEzMTc5MzE1ZC90YWJsZXJhbmdlOjg5NjgxNWMyNzgyNDQ5YmY5OTg1ZjE5YTMxNzkzMTVkXzItMi0xLTEtMTA5ODc2_32f2b696-26c3-4c51-abc4-f9edf406268d"
      unitRef="usd">509000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNjkvZnJhZzpkOWU4MTg1NDQyMmM0OWNlYWJjNjJkZmEzY2VmYzM5My90YWJsZTo4OTY4MTVjMjc4MjQ0OWJmOTk4NWYxOWEzMTc5MzE1ZC90YWJsZXJhbmdlOjg5NjgxNWMyNzgyNDQ5YmY5OTg1ZjE5YTMxNzkzMTVkXzMtMi0xLTEtMTA5ODc2_933f326e-e0a5-4b2a-9da6-f98f0a0c6e98"
      unitRef="usd">508000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNjkvZnJhZzpkOWU4MTg1NDQyMmM0OWNlYWJjNjJkZmEzY2VmYzM5My90YWJsZTo4OTY4MTVjMjc4MjQ0OWJmOTk4NWYxOWEzMTc5MzE1ZC90YWJsZXJhbmdlOjg5NjgxNWMyNzgyNDQ5YmY5OTg1ZjE5YTMxNzkzMTVkXzQtMi0xLTEtMTA5ODc2_9486bbd7-dd54-415e-84cc-7f2c651ac45a"
      unitRef="usd">508000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNjkvZnJhZzpkOWU4MTg1NDQyMmM0OWNlYWJjNjJkZmEzY2VmYzM5My90YWJsZTo4OTY4MTVjMjc4MjQ0OWJmOTk4NWYxOWEzMTc5MzE1ZC90YWJsZXJhbmdlOjg5NjgxNWMyNzgyNDQ5YmY5OTg1ZjE5YTMxNzkzMTVkXzUtMi0xLTEtMTA5ODc2_0d4f46ea-6feb-4dbe-b090-b947d9da90bd"
      unitRef="usd">386000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNjkvZnJhZzpkOWU4MTg1NDQyMmM0OWNlYWJjNjJkZmEzY2VmYzM5My90YWJsZTo4OTY4MTVjMjc4MjQ0OWJmOTk4NWYxOWEzMTc5MzE1ZC90YWJsZXJhbmdlOjg5NjgxNWMyNzgyNDQ5YmY5OTg1ZjE5YTMxNzkzMTVkXzYtMi0xLTEtMTA5ODc2_4816bef0-9b12-4288-b09a-2131e8ecd76e"
      unitRef="usd">2948000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNjkvZnJhZzpkOWU4MTg1NDQyMmM0OWNlYWJjNjJkZmEzY2VmYzM5My90YWJsZTo4OTY4MTVjMjc4MjQ0OWJmOTk4NWYxOWEzMTc5MzE1ZC90YWJsZXJhbmdlOjg5NjgxNWMyNzgyNDQ5YmY5OTg1ZjE5YTMxNzkzMTVkXzctMi0xLTEtMTA5ODc2_015f357d-5dfa-4080-b24a-7b53a0b29f69"
      unitRef="usd">166000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNjkvZnJhZzpkOWU4MTg1NDQyMmM0OWNlYWJjNjJkZmEzY2VmYzM5My90YWJsZTo4OTY4MTVjMjc4MjQ0OWJmOTk4NWYxOWEzMTc5MzE1ZC90YWJsZXJhbmdlOjg5NjgxNWMyNzgyNDQ5YmY5OTg1ZjE5YTMxNzkzMTVkXzgtMi0xLTEtMTA5ODc2_847d2fe8-16fa-4a9d-a039-72b05eab4f7d"
      unitRef="usd">2782000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNjkvZnJhZzpkOWU4MTg1NDQyMmM0OWNlYWJjNjJkZmEzY2VmYzM5My90YWJsZTo4OTY4MTVjMjc4MjQ0OWJmOTk4NWYxOWEzMTc5MzE1ZC90YWJsZXJhbmdlOjg5NjgxNWMyNzgyNDQ5YmY5OTg1ZjE5YTMxNzkzMTVkXzExLTItMS0xLTEwOTg3Ng_a2f53f07-34e6-4576-a9e7-f0e8bd90e48a"
      unitRef="usd">1091000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNjkvZnJhZzpkOWU4MTg1NDQyMmM0OWNlYWJjNjJkZmEzY2VmYzM5My90YWJsZTo4OTY4MTVjMjc4MjQ0OWJmOTk4NWYxOWEzMTc5MzE1ZC90YWJsZXJhbmdlOjg5NjgxNWMyNzgyNDQ5YmY5OTg1ZjE5YTMxNzkzMTVkXzEyLTItMS0xLTEwOTg3Ng_79d67e8b-d951-4e60-a842-8acd4604099e"
      unitRef="usd">1691000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNjkvZnJhZzpkOWU4MTg1NDQyMmM0OWNlYWJjNjJkZmEzY2VmYzM5My90YWJsZTo4OTY4MTVjMjc4MjQ0OWJmOTk4NWYxOWEzMTc5MzE1ZC90YWJsZXJhbmdlOjg5NjgxNWMyNzgyNDQ5YmY5OTg1ZjE5YTMxNzkzMTVkXzEzLTItMS0xLTEwOTg3Ng_9a0d1053-f32d-4cc8-82b8-a0a53d9aca84"
      unitRef="usd">2782000</us-gaap:OperatingLeaseLiability>
    <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureNoncurrentTextBlock
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNzIvZnJhZzoyOWQxMWFmZDkwOTY0ZDY5OGQxYzdlMzVmNDllMTAwZS90ZXh0cmVnaW9uOjI5ZDExYWZkOTA5NjRkNjk4ZDFjN2UzNWY0OWUxMDBlXzExMzc_003a6c68-3107-4ae0-aafe-cde8e6e24557">Other Non-Current Liabilities&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Included within other non-current liabilities at December 31, 2021 and 2020 is $2,531 and $2,263, respectively, relating to assumed contingent liabilities. As part of the acquisition of Discuva Limited in December 2017, the Company assumed certain contingent liabilities as certain employees, former employees and former directors of Discuva Limited are eligible for payments from Discuva Limited based on specified development and clinical milestones related to proprietary product candidates developed under the Discuva Platform. The timing of these potential payments is uncertain.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The contingent liability was remeasured in the third quarter of 2020 to reflect a change in the timing of expected payments following the Company's decision not to advance the DDS-01 series of antibiotics and to cease work on the gonorrhoeae program. The gain on the remeasurement of the liability recognized during the year ended December 31, 2020 of $480 is included within other (expense) income in the consolidated statements of operations and comprehensive loss. There were no remeasurement losses or gains recognized during the year ended December 31, 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureNoncurrentTextBlock>
    <smmt:BusinessCombinationAssumedContingentLiabilityNoncurrent
      contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNzIvZnJhZzoyOWQxMWFmZDkwOTY0ZDY5OGQxYzdlMzVmNDllMTAwZS90ZXh0cmVnaW9uOjI5ZDExYWZkOTA5NjRkNjk4ZDFjN2UzNWY0OWUxMDBlXzc3_88ca9ea0-6477-4d22-b501-8a4a8cdd9158"
      unitRef="usd">2531000</smmt:BusinessCombinationAssumedContingentLiabilityNoncurrent>
    <smmt:BusinessCombinationAssumedContingentLiabilityNoncurrent
      contextRef="i7372be6dc06143b5adbb4d2e83a596c5_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNzIvZnJhZzoyOWQxMWFmZDkwOTY0ZDY5OGQxYzdlMzVmNDllMTAwZS90ZXh0cmVnaW9uOjI5ZDExYWZkOTA5NjRkNjk4ZDFjN2UzNWY0OWUxMDBlXzg0_ac0cf1a3-9165-4dc4-8ec0-02dc99ffc501"
      unitRef="usd">2263000</smmt:BusinessCombinationAssumedContingentLiabilityNoncurrent>
    <smmt:GainLossOnRemeasurementOfLiabilitiesNonoperating
      contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNzIvZnJhZzoyOWQxMWFmZDkwOTY0ZDY5OGQxYzdlMzVmNDllMTAwZS90ZXh0cmVnaW9uOjI5ZDExYWZkOTA5NjRkNjk4ZDFjN2UzNWY0OWUxMDBlXzkyOA_033b3624-2850-45e0-97ba-57635f1f8757"
      unitRef="usd">480000</smmt:GainLossOnRemeasurementOfLiabilitiesNonoperating>
    <smmt:GainLossOnRemeasurementOfLiabilitiesNonoperating
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNzIvZnJhZzoyOWQxMWFmZDkwOTY0ZDY5OGQxYzdlMzVmNDllMTAwZS90ZXh0cmVnaW9uOjI5ZDExYWZkOTA5NjRkNjk4ZDFjN2UzNWY0OWUxMDBlXzEwNTM_374d54d7-b83c-495f-aa43-428f8a366899"
      unitRef="usd">0</smmt:GainLossOnRemeasurementOfLiabilitiesNonoperating>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNzUvZnJhZzozNzYxNzMxNjEyYWM0MmY0OGUwMWRkOTgzNjdkMzgzZi90ZXh0cmVnaW9uOjM3NjE3MzE2MTJhYzQyZjQ4ZTAxZGQ5ODM2N2QzODNmXzQxMzY_cbbd47bc-7759-42ef-9ab7-7ac344abd173">Stockholders' Equity &lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Reverse Stock Split&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In conjunction with the Company&#x2019;s Redomiciliation Transaction in (as defined in Note &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;), the Company acquired all of the outstanding ordinary shares of Summit Therapeutics plc on the basis of one share of the Company&#x2019;s common stock for every 5 ordinary shares outstanding, which had the effect of a 1-for-5 reverse stock split. On the effective date of the Redomiciliation, the number of outstanding shares was reduced from 336,159,511 to 67,231,903. All share and per share amounts in these consolidated financial statements and related notes for periods prior to the Redomiciliation Transaction have been retroactively adjusted to reflect the effect of the exchange ratio.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Common Stock&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On May 12, 2021, the Company closed its rights offering, which was fully subscribed and received aggregate gross proceeds of $75,000 from the sale of 14,312,976 shares of common stock to existing investors at a price per share of $5.24. Offering costs of $159 were incurred. In connection with the closing of the rights offering, the Second Note (see Note 20) matured and became due and the Company repaid all principal and accrued interest thereunder using a portion of the proceeds from the rights offering.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November 6, 2020 the Company completed a private placement of its common stock and received gross proceeds of $50,000 from the issuance and sale of 14,970,060 shares of common stock to Mr. Robert W. Duggan and two other existing shareholders of the Company at a price of $3.34 per share. Offering costs of $48 were incurred.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 24, 2019, the Company completed a private placement of its common stock, and received aggregate gross proceeds of $50,000 from the issuance and sale of 35,075,690 shares of common stock to existing investors at a price of $1.43 per share. Offering costs of $912 were incurred. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Warrants&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of the private placement on December 24, 2019, the participating investors were granted warrants with the right to subscribe for 5,261,350 shares of common stock at an exercise price of $1.58, exercisable any time in the period commencing on the date falling six months following December 24, 2019 and ending on the tenth anniversary of admission. Each warrant entitles the warrant holder to subscribe in cash for one share. Shares of common stock allotted pursuant to the exercise of the warrant will rank in full for all dividends and other distributions with a record date after the exercise date with the shares of common stock in issue at that date. The Company has the option to require the warrant holder to exercise some or all of the outstanding warrants after the third anniversary date if the ten-day volume weighted average price of the shares of common stock as reported on Nasdaq represents a premium of at least 50 percent to the exercise price. The warrants are classified within stockholders&#x2019; equity as they are indexed to the Company's shares of common stock and require settlement in its shares of common stock with no provision for any cash settlement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Also, as part of the private placement on December 24, 2019, certain consultants were granted warrants with the right to subscribe for 3,358,732 shares of common stock in exchange for certain services. The warrants have an exercise price of $1.44 and vest quarterly over three years. If the consulting agreement terminated prior to three years after the date of the grant, all unvested warrants will be deemed cancelled. On June 30, 2020, the consulting agreement was terminated and 2,798,945 warrants cancelled immediately. The remaining 559,787 of outstanding warrants are held by Dr. Maky Zanganeh and Dr. Elaine Stracker (see Note 20).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Warrants granted over shares of common stock to consultants in exchange of certain services are similar to stock-based compensation (see Note 18). The Company had 5,821,137 total warrants outstanding as of December 31, 2021 and 2020, respectively, and an intrinsic value of $6,559 as of December 31, 2021 and $18,260 as of December 31, 2020.&lt;/span&gt;&lt;/div&gt;DividendsThe Company has never declared or paid cash dividends on its shares of common stock or on Summit Therapeutics plc's ordinary shares. The Company currently intends to retain all of its future earnings to fund the development and expansion of its business.</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i065a06364b944635a5fea7a0548c3c71_I20200917"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNzUvZnJhZzozNzYxNzMxNjEyYWM0MmY0OGUwMWRkOTgzNjdkMzgzZi90ZXh0cmVnaW9uOjM3NjE3MzE2MTJhYzQyZjQ4ZTAxZGQ5ODM2N2QzODNmXzQ2MA_46ff636b-db5a-4c83-8757-6c821ec6753b"
      unitRef="shares">336159511</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ib1b2bbd9c2ea4c81affedf30cb5ad225_I20200918"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNzUvZnJhZzozNzYxNzMxNjEyYWM0MmY0OGUwMWRkOTgzNjdkMzgzZi90ZXh0cmVnaW9uOjM3NjE3MzE2MTJhYzQyZjQ4ZTAxZGQ5ODM2N2QzODNmXzQ2Ng_77a213aa-2383-4c4c-80be-733d4a08abd0"
      unitRef="shares">67231903</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="idb475943c8884e52b4a61d6e77d4d205_D20210512-20210512"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNzUvZnJhZzozNzYxNzMxNjEyYWM0MmY0OGUwMWRkOTgzNjdkMzgzZi90ZXh0cmVnaW9uOjM3NjE3MzE2MTJhYzQyZjQ4ZTAxZGQ5ODM2N2QzODNmXzgzNA_06ce20b8-9870-4e3c-9580-ca432e47e08e"
      unitRef="usd">75000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="idb475943c8884e52b4a61d6e77d4d205_D20210512-20210512"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNzUvZnJhZzozNzYxNzMxNjEyYWM0MmY0OGUwMWRkOTgzNjdkMzgzZi90ZXh0cmVnaW9uOjM3NjE3MzE2MTJhYzQyZjQ4ZTAxZGQ5ODM2N2QzODNmXzg1NA_18067419-14aa-404e-89c1-7efdc0db8f32"
      unitRef="shares">14312976</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i28fe3cc419e94f789497abebbcb3acff_I20210512"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNzUvZnJhZzozNzYxNzMxNjEyYWM0MmY0OGUwMWRkOTgzNjdkMzgzZi90ZXh0cmVnaW9uOjM3NjE3MzE2MTJhYzQyZjQ4ZTAxZGQ5ODM2N2QzODNmXzkyNg_024ff66a-3811-4eeb-af24-2f3cdca30a68"
      unitRef="usdPerShare">5.24</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="idb475943c8884e52b4a61d6e77d4d205_D20210512-20210512"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNzUvZnJhZzozNzYxNzMxNjEyYWM0MmY0OGUwMWRkOTgzNjdkMzgzZi90ZXh0cmVnaW9uOjM3NjE3MzE2MTJhYzQyZjQ4ZTAxZGQ5ODM2N2QzODNmXzk0OA_30f895c1-78de-4826-bb90-82d418f75800"
      unitRef="usd">159000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i6a505b52efdc43a7821a6b7cc66b172e_D20201106-20201106"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNzUvZnJhZzozNzYxNzMxNjEyYWM0MmY0OGUwMWRkOTgzNjdkMzgzZi90ZXh0cmVnaW9uOjM3NjE3MzE2MTJhYzQyZjQ4ZTAxZGQ5ODM2N2QzODNmXzEzMTU_bf71a633-45e4-4a7a-9d85-f7346e8d4a48"
      unitRef="usd">50000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i6a505b52efdc43a7821a6b7cc66b172e_D20201106-20201106"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNzUvZnJhZzozNzYxNzMxNjEyYWM0MmY0OGUwMWRkOTgzNjdkMzgzZi90ZXh0cmVnaW9uOjM3NjE3MzE2MTJhYzQyZjQ4ZTAxZGQ5ODM2N2QzODNmXzEzNDg_2eb360d5-03ca-469f-b88d-42cc6b2c8b9c"
      unitRef="shares">14970060</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i1cda89fc1bbb4c82a3c7a93284736d74_I20201106"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNzUvZnJhZzozNzYxNzMxNjEyYWM0MmY0OGUwMWRkOTgzNjdkMzgzZi90ZXh0cmVnaW9uOjM3NjE3MzE2MTJhYzQyZjQ4ZTAxZGQ5ODM2N2QzODNmXzE0NjM_5954e1cb-1c15-4f55-9282-24a7e1441939"
      unitRef="usdPerShare">3.34</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="i6a505b52efdc43a7821a6b7cc66b172e_D20201106-20201106"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNzUvZnJhZzozNzYxNzMxNjEyYWM0MmY0OGUwMWRkOTgzNjdkMzgzZi90ZXh0cmVnaW9uOjM3NjE3MzE2MTJhYzQyZjQ4ZTAxZGQ5ODM2N2QzODNmXzE0OTU_5c32777c-6f40-4785-848f-08f4667aaf7f"
      unitRef="usd">48000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="ief39eb2f075b4eb78fa3e4ffac9e4610_D20191224-20191224"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNzUvZnJhZzozNzYxNzMxNjEyYWM0MmY0OGUwMWRkOTgzNjdkMzgzZi90ZXh0cmVnaW9uOjM3NjE3MzE2MTJhYzQyZjQ4ZTAxZGQ5ODM2N2QzODNmXzE2NDA_b1f9d420-c3d5-4172-9e2f-5abb35361fd5"
      unitRef="usd">50000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="ief39eb2f075b4eb78fa3e4ffac9e4610_D20191224-20191224"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNzUvZnJhZzozNzYxNzMxNjEyYWM0MmY0OGUwMWRkOTgzNjdkMzgzZi90ZXh0cmVnaW9uOjM3NjE3MzE2MTJhYzQyZjQ4ZTAxZGQ5ODM2N2QzODNmXzE2NzM_7181986f-d964-42ac-afaa-0bb970fb2a67"
      unitRef="shares">35075690</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i5b2fdb6bad994e6eb9c9380cb3807cd6_I20191224"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNzUvZnJhZzozNzYxNzMxNjEyYWM0MmY0OGUwMWRkOTgzNjdkMzgzZi90ZXh0cmVnaW9uOjM3NjE3MzE2MTJhYzQyZjQ4ZTAxZGQ5ODM2N2QzODNmXzE3MzU_8f7e67ba-5ec8-4abc-9b80-7b153dedfe78"
      unitRef="usdPerShare">1.43</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="ief39eb2f075b4eb78fa3e4ffac9e4610_D20191224-20191224"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNzUvZnJhZzozNzYxNzMxNjEyYWM0MmY0OGUwMWRkOTgzNjdkMzgzZi90ZXh0cmVnaW9uOjM3NjE3MzE2MTJhYzQyZjQ4ZTAxZGQ5ODM2N2QzODNmXzE3Njc_bacc7150-55d8-4b22-a301-870d3a833faa"
      unitRef="usd">912000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i5b2fdb6bad994e6eb9c9380cb3807cd6_I20191224"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNzUvZnJhZzozNzYxNzMxNjEyYWM0MmY0OGUwMWRkOTgzNjdkMzgzZi90ZXh0cmVnaW9uOjM3NjE3MzE2MTJhYzQyZjQ4ZTAxZGQ5ODM2N2QzODNmXzE5MzQ_cfe82858-09b0-4d05-b510-adb275b637bf"
      unitRef="shares">5261350</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i5b2fdb6bad994e6eb9c9380cb3807cd6_I20191224"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNzUvZnJhZzozNzYxNzMxNjEyYWM0MmY0OGUwMWRkOTgzNjdkMzgzZi90ZXh0cmVnaW9uOjM3NjE3MzE2MTJhYzQyZjQ4ZTAxZGQ5ODM2N2QzODNmXzE5ODQ_a5e5013a-65fb-4878-ac1e-81e9c3d9b4bd"
      unitRef="usdPerShare">1.58</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="i5b2fdb6bad994e6eb9c9380cb3807cd6_I20191224"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNzUvZnJhZzozNzYxNzMxNjEyYWM0MmY0OGUwMWRkOTgzNjdkMzgzZi90ZXh0cmVnaW9uOjM3NjE3MzE2MTJhYzQyZjQ4ZTAxZGQ5ODM2N2QzODNmXzIyMDk_f93dc0a9-ee12-445b-9d2c-94e782a88e38"
      unitRef="shares">1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <smmt:ClassOfWarrantOrRightMinimumTenDayVolumeWeightedAverageCommonStockPriceToWarrantExercisePricePremiumPercentage
      contextRef="ief39eb2f075b4eb78fa3e4ffac9e4610_D20191224-20191224"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNzUvZnJhZzozNzYxNzMxNjEyYWM0MmY0OGUwMWRkOTgzNjdkMzgzZi90ZXh0cmVnaW9uOjM3NjE3MzE2MTJhYzQyZjQ4ZTAxZGQ5ODM2N2QzODNmXzI3MjE_5196f866-b63b-443a-8eb8-8aa99058f086"
      unitRef="number">0.50</smmt:ClassOfWarrantOrRightMinimumTenDayVolumeWeightedAverageCommonStockPriceToWarrantExercisePricePremiumPercentage>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="id3dfe8aa6a324f739c2caa516220e112_I20191224"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNzUvZnJhZzozNzYxNzMxNjEyYWM0MmY0OGUwMWRkOTgzNjdkMzgzZi90ZXh0cmVnaW9uOjM3NjE3MzE2MTJhYzQyZjQ4ZTAxZGQ5ODM2N2QzODNmXzMwOTQ_a63b383b-53fb-4c55-aaf5-30da51ee4e3d"
      unitRef="shares">3358732</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="id3dfe8aa6a324f739c2caa516220e112_I20191224"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNzUvZnJhZzozNzYxNzMxNjEyYWM0MmY0OGUwMWRkOTgzNjdkMzgzZi90ZXh0cmVnaW9uOjM3NjE3MzE2MTJhYzQyZjQ4ZTAxZGQ5ODM2N2QzODNmXzMxOTM_193b6c45-fc31-4f72-a1c5-37de9008de99"
      unitRef="usdPerShare">1.44</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <smmt:ClassOfWarrantOrRightQuarterlyVestingPeriod
      contextRef="ib29a1c5799524e1987c045aee67b6831_D20191224-20191224"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNzUvZnJhZzozNzYxNzMxNjEyYWM0MmY0OGUwMWRkOTgzNjdkMzgzZi90ZXh0cmVnaW9uOjM3NjE3MzE2MTJhYzQyZjQ4ZTAxZGQ5ODM2N2QzODNmXzMyMjA_834cc01d-c325-4ba4-998f-28e457c1f22b">P3Y</smmt:ClassOfWarrantOrRightQuarterlyVestingPeriod>
    <smmt:ClassOfWarrantOrRightQuarterlyVestingPeriod
      contextRef="ib29a1c5799524e1987c045aee67b6831_D20191224-20191224"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNzUvZnJhZzozNzYxNzMxNjEyYWM0MmY0OGUwMWRkOTgzNjdkMzgzZi90ZXh0cmVnaW9uOjM3NjE3MzE2MTJhYzQyZjQ4ZTAxZGQ5ODM2N2QzODNmXzMyNzI_69813705-cc1a-4817-9fa1-62e2be553a22">P3Y</smmt:ClassOfWarrantOrRightQuarterlyVestingPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations
      contextRef="ia5f83af41ad746ffb1aa249c3a0f7238_D20200630-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNzUvZnJhZzozNzYxNzMxNjEyYWM0MmY0OGUwMWRkOTgzNjdkMzgzZi90ZXh0cmVnaW9uOjM3NjE3MzE2MTJhYzQyZjQ4ZTAxZGQ5ODM2N2QzODNmXzM0MTQ_cb95cd2e-5418-42d9-9119-e3852b1c50c1"
      unitRef="shares">2798945</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i829bd35e2a01482f995c5247b3243ee1_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNzUvZnJhZzozNzYxNzMxNjEyYWM0MmY0OGUwMWRkOTgzNjdkMzgzZi90ZXh0cmVnaW9uOjM3NjE3MzE2MTJhYzQyZjQ4ZTAxZGQ5ODM2N2QzODNmXzM0NjM_c03e0305-b61d-47f2-b26d-377106afba0c"
      unitRef="shares">559787</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i7372be6dc06143b5adbb4d2e83a596c5_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNzUvZnJhZzozNzYxNzMxNjEyYWM0MmY0OGUwMWRkOTgzNjdkMzgzZi90ZXh0cmVnaW9uOjM3NjE3MzE2MTJhYzQyZjQ4ZTAxZGQ5ODM2N2QzODNmXzM3MjI_00046ca4-b99b-4787-a915-76855e47f7e6"
      unitRef="shares">5821137</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNzUvZnJhZzozNzYxNzMxNjEyYWM0MmY0OGUwMWRkOTgzNjdkMzgzZi90ZXh0cmVnaW9uOjM3NjE3MzE2MTJhYzQyZjQ4ZTAxZGQ5ODM2N2QzODNmXzM3MjI_10eca2dd-9266-410b-b328-626b759abe19"
      unitRef="shares">5821137</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
      contextRef="if894fc66857243cf91a1a3e3a656bd4f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNzUvZnJhZzozNzYxNzMxNjEyYWM0MmY0OGUwMWRkOTgzNjdkMzgzZi90ZXh0cmVnaW9uOjM3NjE3MzE2MTJhYzQyZjQ4ZTAxZGQ5ODM2N2QzODNmXzM4MTE_4101f5ad-fe10-42c4-beca-b6cdece02476"
      unitRef="usd">6559000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
      contextRef="id2eec56c2a084d07bd27c69c542c646e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xNzUvZnJhZzozNzYxNzMxNjEyYWM0MmY0OGUwMWRkOTgzNjdkMzgzZi90ZXh0cmVnaW9uOjM3NjE3MzE2MTJhYzQyZjQ4ZTAxZGQ5ODM2N2QzODNmXzM4NDI_51a42272-2563-43f1-b145-cdc363b27971"
      unitRef="usd">18260000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODEvZnJhZzoyOTEzNTMwMjlmMjQ0ZTQ0ODgzNDE5NTEzYjBhODA3Ny90ZXh0cmVnaW9uOjI5MTM1MzAyOWYyNDRlNDQ4ODM0MTk1MTNiMGE4MDc3XzkwMzQ_e1ca2730-e181-4f8d-a7f7-ea794a131ccf">Stock-Based Compensation &lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2016 Long Term Incentive Plan&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2020, in conjunction with the Redomiciliation, the 2016 Long Term Incentive Plan, (the "2016 Plan") and the Company's outstanding restricted stock units ("RSUs") were assumed and adopted by Summit Therapeutics Inc., and all awards were exchanged with replacement awards issued. Subsequent to the Redomiciliation, no additional grants will be made under the 2016 Plan and any outstanding awards under the 2016 Plan and RSUs will continue with their original terms. The Company concluded that the adoption of the 2016 Plan and RSUs and issuance of replacement awards was a modification but with no change in the material rights and preferences and therefore, no recorded change in the fair value of each respective award is needed.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2020 Stock Award Plan&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2020, the Company&#x2019;s Board of Directors approved the 2020 Stock Incentive Plan (the &#x201c;2020 Plan&#x201d;), which became effective on September 21, 2020. The 2020 plan provides for the grant of incentive stock options, nonqualified stock options, stock appreciation rights, restricted stock, restricted stock units and other stock-based awards. Upon the effectiveness of the 2020 Plan, the Company ceased granting awards under its 2016 Plan.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A total of 8,000,000 shares of common stock were initially reserved for issuance under the 2020 Plan. Additionally, up to 5,000,000 shares of common stock, including RSUs can be added to the 2020 Plan for future issuance from options that expire, lapse unexercised or are terminated from the 2016 Plan or any other predecessor plans. The number of shares of common stock that may be issued under the 2020 Plan will automatically increase on each January 1, beginning in 2021 and continuing for each fiscal year until, and including, the fiscal year ending December 31, 2030, equal to the lesser of (i) 6,400,000 shares of common stock, (ii) 4% of the common shares outstanding on the final day of the immediately preceding calendar year and (iii) an amount as determined by the Company&#x2019;s Board of Directors. As of December 31, 2021, there are 2,293,700 shares available to be issued under the 2020 Plan.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2020 Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2020 Employee Stock Purchase Plan (the "2020 ESPP") was adopted by the Board of Directors and approved by the Company's shareholders on July 17, 2020 and approved by the predecessor company shareholders on August 19, 2020. The 2020 ESPP initially authorized the issuance of up to 1,000,000 shares of  common stock to participating employees. The number of common shares that may be issued under the 2020 ESPP automatically increases on each fiscal year commencing January 1, 2021 and continuing for each fiscal year until, and including the fiscal year commencing on, January 1, 2030 equal to the least of (i) 1,600,000 shares of common stock, (ii) 1% of the common shares outstanding on such date and  (iii) an amount as determined by the Company&#x2019;s Board of Directors. As of December 31, 2021, there were 1,825,750 shares available to be issued under the 2020 ESPP.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The first offering period of the 2020 ESPP plan consists of seven months, commenced on August 2, 2021 and will terminate on February 28, 2022. Offering periods thereafter will be six months in duration and will commence immediately proceeding the end of the previous offering period, unless otherwise determined by the Board of Directors or Compensation Committee. The next offering period commenced on March 1, 2022. Under the 2020 ESPP, eligible employees can purchase shares of common stock through payroll deductions of up to 15% of their compensation received during the plan period or such shorter period during which deductions from payroll are made, up to a defined maximum amount. The option price is determined based on the lesser of the closing price of common stock on (i) the first business day of the plan period or (ii) the exercise date, or shall be based solely on the closing price of the common stock on the exercise date; provided that such option price shall be at least 85% of the applicable closing price. In the absence of a determination by the Board of Directors or the Compensation Committee, the &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;option price is 85% of the lesser of the closing price of the common stock on (i) the first business day of the plan period or (ii) the exercise date. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The closing price is the (a) the closing price (for the primary trading session) on the Nasdaq Global Select Market or (b) the average of the closing bid and asked prices in the over-the-counter-market, whichever is applicable, as published in the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Wall Street Journal&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; or another source selected by the Board or the Committee. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Stock Option Valuation&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company estimates the fair value of stock options granted to employees and directors using the Black-Scholes valuation model. Stock options granted under the 2016 and 2020 Plans generally vest over &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODEvZnJhZzoyOTEzNTMwMjlmMjQ0ZTQ0ODgzNDE5NTEzYjBhODA3Ny90ZXh0cmVnaW9uOjI5MTM1MzAyOWYyNDRlNDQ4ODM0MTk1MTNiMGE4MDc3XzQ4MzA_52cfade8-6eaf-42ea-82a4-09b084b53c45"&gt;three&lt;/span&gt; or four years and expire after ten years. This valuation methodology utilizes several key assumptions as highlighted below.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The assumptions used in the Company's valuation are summarized as follows, presented on a weighted average basis: &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;       &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.649%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.663%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.171%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.663%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.173%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:103%"&gt;Year Ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:103%"&gt;Year Ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.05&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected annual dividends per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%"&gt;The following table summarizes the Company's stock option activity for the year ended December 31, 2021:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:103%"&gt;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.490%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.087%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number of share options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted average exercise price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted average remaining contractual term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Aggregate intrinsic value &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,672,968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.9 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,641&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,262,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,012,851)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,124,577)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December&#160;31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,797,556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.6 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December 31, 2021 - vested and expected to vest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,685,817&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.6 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,598,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.2 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted-average grant-date fair value of stock options granted during the years ended December 31, 2021 and 2020 was $3.50 and $2.20, per share, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The aggregate intrinsic value of stock options exercised during the years ended December 31, 2021 and December 31, 2020  was $3,744 and $857, respectively. The aggregate intrinsic value of stock options is calculated as the difference between the exercise price of the stock options and the fair value of the Company&#x2019;s common stock for those stock options that had exercise prices lower than the fair value of the Company&#x2019;s common stock.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2021, total unrecognized compensation cost related to unvested stock option grants was approximately $27,905. This amount is expected to be recognized over a weighted average period of approximately 2.2 years.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In September 2021, the Compensation Committee of the Board of Directors approved a modification to the Company's outstanding performance-based stock option awards for active employees which removed the performance-based vesting criteria from these awards. Following this modification, the option awards are subject only to previously existing time-based vesting conditions. The Company accounted for this change as a modification in accordance with the requirements of Accounting Standards Codification Topic 718. As a result, 9,250,000 options, related to twenty-five employees, that were previously authorized that had not achieved a grant date became granted on September 24, 2021 relating to the modification.  The Company will recognize the newly assessed measurement date fair value of the awards as compensation expense over the remaining vesting period. The incremental compensation expense related to the modification for the year ended December 31, 2021 was $4,872. The stock option activity above incorporates the modified awards. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Restricted Stock Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's outstanding restricted stock units ("RSUs") consist of nominal-cost options which were granted to non-executive directors. The following table summarizes the activity relating to RSUs for the year ended December 31, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:73.830%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.266%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.790%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.127%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.790%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.594%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number of Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Grant Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs - beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,923&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26,923)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs - end of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The aggregate intrinsic value of restricted stock units vested during the years ended December 31, 2021 and December 31, 2020 was $125, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The fair value of warrants is estimated on the date of grant using the Black-Scholes valuation methodology. Expected volatilities are based on historical share price performance, weighted to exclude periods of unusually high volatility. The Company assumed the warrants to be exercised immediately on vesting. The risk-free rate is equal to the prevailing U.K. Gilts rate at grant date that most closely matches the expected term of the grant, as the warrants were issued prior to the Redomiciliation. Expected dividend yield is zero, and consistent with the Board of Directors&#x2019; view that the Company&#x2019;s business model is to generate value through capital growth rather than the payment of dividends.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Each warrant entitles the warrant holder to subscribe in cash for one share. Shares of common stock allotted pursuant to the exercise of the warrant will rank in full for all dividends and other distributions with a record date after the exercise date with the shares of common stock in issue at that date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2021, 5,821,137 warrants were granted, of which 559,787 warrants were granted to consultants and 5,261,350 warrants were granted to investors (refer to Note 20 for further details). All warrants are considered vested at December 31, 2021, have a weighted-average exercise price of $1.56, an aggregate intrinsic value of $6,559, and a weighted average remaining contractual life of 4.0 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December 31, 2021, there was no unrecognized compensation expense related to warrants. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock&#x2011;based compensation expense related to stock options is recorded within the consolidated statements of operations and comprehensive loss as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.485%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.277%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.743%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.767%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.743%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.770%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:103%"&gt;Year Ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:103%"&gt;Year Ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%"&gt;Research and development&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,909&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;General and administrative&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,895&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%"&gt;1,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%"&gt;Total stock-based compensation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i52879ea7de8d4f93bf2933bde91a0538_I20200921"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODEvZnJhZzoyOTEzNTMwMjlmMjQ0ZTQ0ODgzNDE5NTEzYjBhODA3Ny90ZXh0cmVnaW9uOjI5MTM1MzAyOWYyNDRlNDQ4ODM0MTk1MTNiMGE4MDc3XzEyNjg_e4cdb3a2-dc62-49d5-ae00-a549652f05b6"
      unitRef="shares">8000000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <smmt:CommonStockAndRestrictedStockUnitsAdditionalCapitalSharesAllowableForForFutureIssuance
      contextRef="i52879ea7de8d4f93bf2933bde91a0538_I20200921"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODEvZnJhZzoyOTEzNTMwMjlmMjQ0ZTQ0ODgzNDE5NTEzYjBhODA3Ny90ZXh0cmVnaW9uOjI5MTM1MzAyOWYyNDRlNDQ4ODM0MTk1MTNiMGE4MDc3XzEzNzI_b94c7a3b-01ed-4c26-831b-b06322491fe2"
      unitRef="shares">5000000</smmt:CommonStockAndRestrictedStockUnitsAdditionalCapitalSharesAllowableForForFutureIssuance>
    <smmt:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan
      contextRef="i52879ea7de8d4f93bf2933bde91a0538_I20200921"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODEvZnJhZzoyOTEzNTMwMjlmMjQ0ZTQ0ODgzNDE5NTEzYjBhODA3Ny90ZXh0cmVnaW9uOjI5MTM1MzAyOWYyNDRlNDQ4ODM0MTk1MTNiMGE4MDc3XzE4NDU_6bed9d8d-3767-4ff6-9202-a92e71669114"
      unitRef="shares">6400000</smmt:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum
      contextRef="i77c56146a814495db85257a588d28851_D20200921-20200921"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODEvZnJhZzoyOTEzNTMwMjlmMjQ0ZTQ0ODgzNDE5NTEzYjBhODA3Ny90ZXh0cmVnaW9uOjI5MTM1MzAyOWYyNDRlNDQ4ODM0MTk1MTNiMGE4MDc3XzE4Nzc_6edb38ac-f227-4c11-805c-72b135945568"
      unitRef="number">0.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="ia36692a70694499e8458216f476de0aa_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODEvZnJhZzoyOTEzNTMwMjlmMjQ0ZTQ0ODgzNDE5NTEzYjBhODA3Ny90ZXh0cmVnaW9uOjI5MTM1MzAyOWYyNDRlNDQ4ODM0MTk1MTNiMGE4MDc3XzIwNzk_09987d98-6ab8-474e-99bb-c057bcef71ef"
      unitRef="shares">2293700</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i9b560a9af3b441468dab3205aa4e621c_I20200819"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODEvZnJhZzoyOTEzNTMwMjlmMjQ0ZTQ0ODgzNDE5NTEzYjBhODA3Ny90ZXh0cmVnaW9uOjI5MTM1MzAyOWYyNDRlNDQ4ODM0MTk1MTNiMGE4MDc3XzI0NTM_ad048000-4361-411b-8ff9-8656a5b6e0fc"
      unitRef="shares">1000000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <smmt:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan
      contextRef="i9b560a9af3b441468dab3205aa4e621c_I20200819"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODEvZnJhZzoyOTEzNTMwMjlmMjQ0ZTQ0ODgzNDE5NTEzYjBhODA3Ny90ZXh0cmVnaW9uOjI5MTM1MzAyOWYyNDRlNDQ4ODM0MTk1MTNiMGE4MDc3XzI3NzY_c6b4e171-c490-47f2-8845-06e6c1683b54"
      unitRef="shares">1600000</smmt:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum
      contextRef="i2e4f636d5f284aaa971b49db94dc48d6_D20200819-20200819"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODEvZnJhZzoyOTEzNTMwMjlmMjQ0ZTQ0ODgzNDE5NTEzYjBhODA3Ny90ZXh0cmVnaW9uOjI5MTM1MzAyOWYyNDRlNDQ4ODM0MTk1MTNiMGE4MDc3XzI4MDg_ff15f894-b934-493f-8ffb-a318b1df0553"
      unitRef="number">0.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i8a26223d9fc34901b9c170239c1296e3_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODEvZnJhZzoyOTEzNTMwMjlmMjQ0ZTQ0ODgzNDE5NTEzYjBhODA3Ny90ZXh0cmVnaW9uOjI5MTM1MzAyOWYyNDRlNDQ4ODM0MTk1MTNiMGE4MDc3XzI5NjU_c0dd2897-b36e-427b-83bb-942b5e149299"
      unitRef="shares">1825750</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <smmt:ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod
      contextRef="ia19b35b6945f47e0b9f50e24473f7b3f_D20210802-20210802"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODEvZnJhZzoyOTEzNTMwMjlmMjQ0ZTQ0ODgzNDE5NTEzYjBhODA3Ny90ZXh0cmVnaW9uOjI5MTM1MzAyOWYyNDRlNDQ4ODM0MTk1MTNiMGE4MDc3XzMwODA_3821a27c-8a32-4702-9918-92790f013811">P7M</smmt:ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod>
    <smmt:ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveOfferingPeriod
      contextRef="iabc12254dbae479c95e96111f5913844_D20220301-20220301"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODEvZnJhZzoyOTEzNTMwMjlmMjQ0ZTQ0ODgzNDE5NTEzYjBhODA3Ny90ZXh0cmVnaW9uOjI5MTM1MzAyOWYyNDRlNDQ4ODM0MTk1MTNiMGE4MDc3XzMxODk_3bca6773-ace9-4ef0-b737-c6f9fb8d37ec">P6M</smmt:ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveOfferingPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate
      contextRef="i9b560a9af3b441468dab3205aa4e621c_I20200819"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODEvZnJhZzoyOTEzNTMwMjlmMjQ0ZTQ0ODgzNDE5NTEzYjBhODA3Ny90ZXh0cmVnaW9uOjI5MTM1MzAyOWYyNDRlNDQ4ODM0MTk1MTNiMGE4MDc3XzM1MzI_9dcac0cc-77f2-438e-9dba-77ee7dee3883"
      unitRef="number">0.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="i75d2f909ade34437b24a7cd383ffa673_D20200819-20200819"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODEvZnJhZzoyOTEzNTMwMjlmMjQ0ZTQ0ODgzNDE5NTEzYjBhODA3Ny90ZXh0cmVnaW9uOjI5MTM1MzAyOWYyNDRlNDQ4ODM0MTk1MTNiMGE4MDc3XzM5OTM_674c9b49-2cb8-4ba1-82c6-a98cf6469f93"
      unitRef="number">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="i2e4f636d5f284aaa971b49db94dc48d6_D20200819-20200819"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODEvZnJhZzoyOTEzNTMwMjlmMjQ0ZTQ0ODgzNDE5NTEzYjBhODA3Ny90ZXh0cmVnaW9uOjI5MTM1MzAyOWYyNDRlNDQ4ODM0MTk1MTNiMGE4MDc3XzQxNDA_84b704f6-c696-46cc-83dd-1860d19046d7"
      unitRef="number">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i8083f97ada2d4b42b9fe0c6f07ec03d4_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODEvZnJhZzoyOTEzNTMwMjlmMjQ0ZTQ0ODgzNDE5NTEzYjBhODA3Ny90ZXh0cmVnaW9uOjI5MTM1MzAyOWYyNDRlNDQ4ODM0MTk1MTNiMGE4MDc3XzQ4MzY_48de70a2-2fe3-4612-ac40-3ead2b8647a0">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="i444320f038034b09878835272c70885a_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODEvZnJhZzoyOTEzNTMwMjlmMjQ0ZTQ0ODgzNDE5NTEzYjBhODA3Ny90ZXh0cmVnaW9uOjI5MTM1MzAyOWYyNDRlNDQ4ODM0MTk1MTNiMGE4MDc3XzQ4NTY_75b4a867-661d-4a1c-9309-24e414c9503d">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODEvZnJhZzoyOTEzNTMwMjlmMjQ0ZTQ0ODgzNDE5NTEzYjBhODA3Ny90ZXh0cmVnaW9uOjI5MTM1MzAyOWYyNDRlNDQ4ODM0MTk1MTNiMGE4MDc3XzkwNDY_7b23bb7b-cac7-4860-bc67-47e2918a7d3c">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The assumptions used in the Company's valuation are summarized as follows, presented on a weighted average basis: &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;       &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.649%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.663%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.171%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.663%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.173%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:103%"&gt;Year Ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:103%"&gt;Year Ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.05&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected annual dividends per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i444320f038034b09878835272c70885a_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODEvZnJhZzoyOTEzNTMwMjlmMjQ0ZTQ0ODgzNDE5NTEzYjBhODA3Ny90YWJsZTozYjY5MDQyOTQyMTY0NTQwYjU2YTQ4OWZiZTNlOWY0Yi90YWJsZXJhbmdlOjNiNjkwNDI5NDIxNjQ1NDBiNTZhNDg5ZmJlM2U5ZjRiXzEtMi0xLTEtMTA5ODc2_c4ee37f9-b215-4e4c-a3c6-8ac40d24062e"
      unitRef="number">0.0105</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i269ac82e7b7e4434933ca3c53f23e541_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODEvZnJhZzoyOTEzNTMwMjlmMjQ0ZTQ0ODgzNDE5NTEzYjBhODA3Ny90YWJsZTozYjY5MDQyOTQyMTY0NTQwYjU2YTQ4OWZiZTNlOWY0Yi90YWJsZXJhbmdlOjNiNjkwNDI5NDIxNjQ1NDBiNTZhNDg5ZmJlM2U5ZjRiXzEtNC0xLTEtMTA5ODc2_a3dde256-e67a-4c99-9c1e-d604b27777c1"
      unitRef="number">0.0029</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i444320f038034b09878835272c70885a_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODEvZnJhZzoyOTEzNTMwMjlmMjQ0ZTQ0ODgzNDE5NTEzYjBhODA3Ny90YWJsZTozYjY5MDQyOTQyMTY0NTQwYjU2YTQ4OWZiZTNlOWY0Yi90YWJsZXJhbmdlOjNiNjkwNDI5NDIxNjQ1NDBiNTZhNDg5ZmJlM2U5ZjRiXzItMi0xLTEtMTA5ODc2_723477d7-dfd7-45a5-b9f5-7dd83b2a971a">P5Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i269ac82e7b7e4434933ca3c53f23e541_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODEvZnJhZzoyOTEzNTMwMjlmMjQ0ZTQ0ODgzNDE5NTEzYjBhODA3Ny90YWJsZTozYjY5MDQyOTQyMTY0NTQwYjU2YTQ4OWZiZTNlOWY0Yi90YWJsZXJhbmdlOjNiNjkwNDI5NDIxNjQ1NDBiNTZhNDg5ZmJlM2U5ZjRiXzItNC0xLTEtMTA5ODc2_a767cfc3-45b8-4bfa-ab78-751929eda7fe">P5Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="i444320f038034b09878835272c70885a_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODEvZnJhZzoyOTEzNTMwMjlmMjQ0ZTQ0ODgzNDE5NTEzYjBhODA3Ny90YWJsZTozYjY5MDQyOTQyMTY0NTQwYjU2YTQ4OWZiZTNlOWY0Yi90YWJsZXJhbmdlOjNiNjkwNDI5NDIxNjQ1NDBiNTZhNDg5ZmJlM2U5ZjRiXzMtMi0xLTEtMTA5ODc2_f9e1c330-535f-4a77-8ea8-ee7572ddea81"
      unitRef="number">0.745</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="i269ac82e7b7e4434933ca3c53f23e541_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODEvZnJhZzoyOTEzNTMwMjlmMjQ0ZTQ0ODgzNDE5NTEzYjBhODA3Ny90YWJsZTozYjY5MDQyOTQyMTY0NTQwYjU2YTQ4OWZiZTNlOWY0Yi90YWJsZXJhbmdlOjNiNjkwNDI5NDIxNjQ1NDBiNTZhNDg5ZmJlM2U5ZjRiXzMtNC0xLTEtMTA5ODc2_10192c5d-5842-4821-8221-b5d9b251d11e"
      unitRef="number">0.719</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i444320f038034b09878835272c70885a_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODEvZnJhZzoyOTEzNTMwMjlmMjQ0ZTQ0ODgzNDE5NTEzYjBhODA3Ny90YWJsZTozYjY5MDQyOTQyMTY0NTQwYjU2YTQ4OWZiZTNlOWY0Yi90YWJsZXJhbmdlOjNiNjkwNDI5NDIxNjQ1NDBiNTZhNDg5ZmJlM2U5ZjRiXzQtMi0xLTEtMTA5ODc2_523d5bca-361e-4add-895a-2378b37d4487"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i269ac82e7b7e4434933ca3c53f23e541_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODEvZnJhZzoyOTEzNTMwMjlmMjQ0ZTQ0ODgzNDE5NTEzYjBhODA3Ny90YWJsZTozYjY5MDQyOTQyMTY0NTQwYjU2YTQ4OWZiZTNlOWY0Yi90YWJsZXJhbmdlOjNiNjkwNDI5NDIxNjQ1NDBiNTZhNDg5ZmJlM2U5ZjRiXzQtNC0xLTEtMTA5ODc2_a94cd817-f9ad-4ce1-a24a-5c6ea0b04d18"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODEvZnJhZzoyOTEzNTMwMjlmMjQ0ZTQ0ODgzNDE5NTEzYjBhODA3Ny90ZXh0cmVnaW9uOjI5MTM1MzAyOWYyNDRlNDQ4ODM0MTk1MTNiMGE4MDc3XzkwMzU_9f89bbf0-7b0b-4837-b277-34b6e1b03606">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%"&gt;The following table summarizes the Company's stock option activity for the year ended December 31, 2021:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:103%"&gt;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.490%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.087%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number of share options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted average exercise price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted average remaining contractual term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Aggregate intrinsic value &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,672,968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.9 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,641&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,262,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,012,851)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,124,577)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December&#160;31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,797,556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.6 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December 31, 2021 - vested and expected to vest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,685,817&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.6 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,598,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.2 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i7372be6dc06143b5adbb4d2e83a596c5_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODEvZnJhZzoyOTEzNTMwMjlmMjQ0ZTQ0ODgzNDE5NTEzYjBhODA3Ny90YWJsZTo4ZGEzNGJjMTYwOWY0MmI3OTk4MzgyZDZmZDg3YzA0Mi90YWJsZXJhbmdlOjhkYTM0YmMxNjA5ZjQyYjc5OTgzODJkNmZkODdjMDQyXzEtMi0xLTEtMTA5ODc2_10688f4a-e4e4-4a73-a6dd-605b466ef228"
      unitRef="shares">3672968</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i7372be6dc06143b5adbb4d2e83a596c5_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODEvZnJhZzoyOTEzNTMwMjlmMjQ0ZTQ0ODgzNDE5NTEzYjBhODA3Ny90YWJsZTo4ZGEzNGJjMTYwOWY0MmI3OTk4MzgyZDZmZDg3YzA0Mi90YWJsZXJhbmdlOjhkYTM0YmMxNjA5ZjQyYjc5OTgzODJkNmZkODdjMDQyXzEtNC0xLTEtMTA5ODc2_ee7edcd5-ce10-4a86-aa3d-1ad03f7232f0"
      unitRef="usdPerShare">2.90</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODEvZnJhZzoyOTEzNTMwMjlmMjQ0ZTQ0ODgzNDE5NTEzYjBhODA3Ny90YWJsZTo4ZGEzNGJjMTYwOWY0MmI3OTk4MzgyZDZmZDg3YzA0Mi90YWJsZXJhbmdlOjhkYTM0YmMxNjA5ZjQyYjc5OTgzODJkNmZkODdjMDQyXzEtNi0xLTEtMTA5ODc2_473d35b6-6876-4ab5-85a6-d5b242e57dff">P8Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i7372be6dc06143b5adbb4d2e83a596c5_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODEvZnJhZzoyOTEzNTMwMjlmMjQ0ZTQ0ODgzNDE5NTEzYjBhODA3Ny90YWJsZTo4ZGEzNGJjMTYwOWY0MmI3OTk4MzgyZDZmZDg3YzA0Mi90YWJsZXJhbmdlOjhkYTM0YmMxNjA5ZjQyYjc5OTgzODJkNmZkODdjMDQyXzEtOC0xLTEtMTA5ODc2_5435025c-bc07-47b4-a508-0bca9b10fd70"
      unitRef="usd">6641000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODEvZnJhZzoyOTEzNTMwMjlmMjQ0ZTQ0ODgzNDE5NTEzYjBhODA3Ny90YWJsZTo4ZGEzNGJjMTYwOWY0MmI3OTk4MzgyZDZmZDg3YzA0Mi90YWJsZXJhbmdlOjhkYTM0YmMxNjA5ZjQyYjc5OTgzODJkNmZkODdjMDQyXzItMi0xLTEtMTA5ODc2_cc4cc897-f5a8-4b32-852f-8ac01d0548c8"
      unitRef="shares">13262016</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODEvZnJhZzoyOTEzNTMwMjlmMjQ0ZTQ0ODgzNDE5NTEzYjBhODA3Ny90YWJsZTo4ZGEzNGJjMTYwOWY0MmI3OTk4MzgyZDZmZDg3YzA0Mi90YWJsZXJhbmdlOjhkYTM0YmMxNjA5ZjQyYjc5OTgzODJkNmZkODdjMDQyXzItNC0xLTEtMTA5ODc2_0853aa77-ba51-4651-af5a-4c0179457b47"
      unitRef="usdPerShare">5.76</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODEvZnJhZzoyOTEzNTMwMjlmMjQ0ZTQ0ODgzNDE5NTEzYjBhODA3Ny90YWJsZTo4ZGEzNGJjMTYwOWY0MmI3OTk4MzgyZDZmZDg3YzA0Mi90YWJsZXJhbmdlOjhkYTM0YmMxNjA5ZjQyYjc5OTgzODJkNmZkODdjMDQyXzMtMi0xLTEtMTA5ODc2_db842fa6-7e8e-4c53-8887-cfd0c7aeca86"
      unitRef="shares">2012851</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODEvZnJhZzoyOTEzNTMwMjlmMjQ0ZTQ0ODgzNDE5NTEzYjBhODA3Ny90YWJsZTo4ZGEzNGJjMTYwOWY0MmI3OTk4MzgyZDZmZDg3YzA0Mi90YWJsZXJhbmdlOjhkYTM0YmMxNjA5ZjQyYjc5OTgzODJkNmZkODdjMDQyXzMtNC0xLTEtMTA5ODc2_358047b7-7bd3-4e13-97af-18b6b5cfb2af"
      unitRef="usdPerShare">3.61</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODEvZnJhZzoyOTEzNTMwMjlmMjQ0ZTQ0ODgzNDE5NTEzYjBhODA3Ny90YWJsZTo4ZGEzNGJjMTYwOWY0MmI3OTk4MzgyZDZmZDg3YzA0Mi90YWJsZXJhbmdlOjhkYTM0YmMxNjA5ZjQyYjc5OTgzODJkNmZkODdjMDQyXzQtMi0xLTEtMTA5ODc2_0fbff85e-7d90-4694-9366-23ce0b29c450"
      unitRef="shares">1124577</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODEvZnJhZzoyOTEzNTMwMjlmMjQ0ZTQ0ODgzNDE5NTEzYjBhODA3Ny90YWJsZTo4ZGEzNGJjMTYwOWY0MmI3OTk4MzgyZDZmZDg3YzA0Mi90YWJsZXJhbmdlOjhkYTM0YmMxNjA5ZjQyYjc5OTgzODJkNmZkODdjMDQyXzQtNC0xLTEtMTA5ODc2_bd4a9156-e0ac-4857-a8ee-374989b88135"
      unitRef="usdPerShare">2.74</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODEvZnJhZzoyOTEzNTMwMjlmMjQ0ZTQ0ODgzNDE5NTEzYjBhODA3Ny90YWJsZTo4ZGEzNGJjMTYwOWY0MmI3OTk4MzgyZDZmZDg3YzA0Mi90YWJsZXJhbmdlOjhkYTM0YmMxNjA5ZjQyYjc5OTgzODJkNmZkODdjMDQyXzUtMi0xLTEtMTA5ODc2_13e6ce5e-c4ae-4ab0-a3e0-f3b436418d9e"
      unitRef="shares">13797556</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODEvZnJhZzoyOTEzNTMwMjlmMjQ0ZTQ0ODgzNDE5NTEzYjBhODA3Ny90YWJsZTo4ZGEzNGJjMTYwOWY0MmI3OTk4MzgyZDZmZDg3YzA0Mi90YWJsZXJhbmdlOjhkYTM0YmMxNjA5ZjQyYjc5OTgzODJkNmZkODdjMDQyXzUtNC0xLTEtMTA5ODc2_f78cd295-718f-4d2a-8f3f-05009a6c2c9d"
      unitRef="usdPerShare">5.55</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODEvZnJhZzoyOTEzNTMwMjlmMjQ0ZTQ0ODgzNDE5NTEzYjBhODA3Ny90YWJsZTo4ZGEzNGJjMTYwOWY0MmI3OTk4MzgyZDZmZDg3YzA0Mi90YWJsZXJhbmdlOjhkYTM0YmMxNjA5ZjQyYjc5OTgzODJkNmZkODdjMDQyXzUtNi0xLTEtMTA5ODc2_87fb1c62-8398-411d-8e2b-b73bea3045a6">P8Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODEvZnJhZzoyOTEzNTMwMjlmMjQ0ZTQ0ODgzNDE5NTEzYjBhODA3Ny90YWJsZTo4ZGEzNGJjMTYwOWY0MmI3OTk4MzgyZDZmZDg3YzA0Mi90YWJsZXJhbmdlOjhkYTM0YmMxNjA5ZjQyYjc5OTgzODJkNmZkODdjMDQyXzUtOC0xLTEtMTA5ODc2_fb8554c1-1239-4399-8b3d-27bb88bbc1c5"
      unitRef="usd">712000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODEvZnJhZzoyOTEzNTMwMjlmMjQ0ZTQ0ODgzNDE5NTEzYjBhODA3Ny90YWJsZTo4ZGEzNGJjMTYwOWY0MmI3OTk4MzgyZDZmZDg3YzA0Mi90YWJsZXJhbmdlOjhkYTM0YmMxNjA5ZjQyYjc5OTgzODJkNmZkODdjMDQyXzYtMi0xLTEtMTA5ODc2_a256f2a2-1172-4bb1-b2a5-592094822bd5"
      unitRef="shares">12685817</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODEvZnJhZzoyOTEzNTMwMjlmMjQ0ZTQ0ODgzNDE5NTEzYjBhODA3Ny90YWJsZTo4ZGEzNGJjMTYwOWY0MmI3OTk4MzgyZDZmZDg3YzA0Mi90YWJsZXJhbmdlOjhkYTM0YmMxNjA5ZjQyYjc5OTgzODJkNmZkODdjMDQyXzYtNC0xLTEtMTA5ODc2_6370ca72-edd8-4076-aa21-836685177121"
      unitRef="usdPerShare">5.51</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODEvZnJhZzoyOTEzNTMwMjlmMjQ0ZTQ0ODgzNDE5NTEzYjBhODA3Ny90YWJsZTo4ZGEzNGJjMTYwOWY0MmI3OTk4MzgyZDZmZDg3YzA0Mi90YWJsZXJhbmdlOjhkYTM0YmMxNjA5ZjQyYjc5OTgzODJkNmZkODdjMDQyXzYtNi0xLTEtMTA5ODc2_64dd6424-e4e8-4618-9c66-12ad0f13a7b1">P8Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODEvZnJhZzoyOTEzNTMwMjlmMjQ0ZTQ0ODgzNDE5NTEzYjBhODA3Ny90YWJsZTo4ZGEzNGJjMTYwOWY0MmI3OTk4MzgyZDZmZDg3YzA0Mi90YWJsZXJhbmdlOjhkYTM0YmMxNjA5ZjQyYjc5OTgzODJkNmZkODdjMDQyXzYtOC0xLTEtMTA5ODc2_506a6f23-f66e-44bd-90f0-2fd215b3ba60"
      unitRef="usd">709000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODEvZnJhZzoyOTEzNTMwMjlmMjQ0ZTQ0ODgzNDE5NTEzYjBhODA3Ny90YWJsZTo4ZGEzNGJjMTYwOWY0MmI3OTk4MzgyZDZmZDg3YzA0Mi90YWJsZXJhbmdlOjhkYTM0YmMxNjA5ZjQyYjc5OTgzODJkNmZkODdjMDQyXzctMi0xLTEtMTA5ODc2_7651fc79-9a3f-4c8f-bf57-99f2545662e4"
      unitRef="shares">1598709</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODEvZnJhZzoyOTEzNTMwMjlmMjQ0ZTQ0ODgzNDE5NTEzYjBhODA3Ny90YWJsZTo4ZGEzNGJjMTYwOWY0MmI3OTk4MzgyZDZmZDg3YzA0Mi90YWJsZXJhbmdlOjhkYTM0YmMxNjA5ZjQyYjc5OTgzODJkNmZkODdjMDQyXzctNC0xLTEtMTA5ODc2_d993f6bc-3108-4217-a49d-6f019ce6c558"
      unitRef="usdPerShare">3.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODEvZnJhZzoyOTEzNTMwMjlmMjQ0ZTQ0ODgzNDE5NTEzYjBhODA3Ny90YWJsZTo4ZGEzNGJjMTYwOWY0MmI3OTk4MzgyZDZmZDg3YzA0Mi90YWJsZXJhbmdlOjhkYTM0YmMxNjA5ZjQyYjc5OTgzODJkNmZkODdjMDQyXzctNi0xLTEtMTA5ODc2_bfe92af8-fad1-4698-bd49-1ac7708d31f0">P7Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODEvZnJhZzoyOTEzNTMwMjlmMjQ0ZTQ0ODgzNDE5NTEzYjBhODA3Ny90YWJsZTo4ZGEzNGJjMTYwOWY0MmI3OTk4MzgyZDZmZDg3YzA0Mi90YWJsZXJhbmdlOjhkYTM0YmMxNjA5ZjQyYjc5OTgzODJkNmZkODdjMDQyXzctOC0xLTEtMTA5ODc2_b586cac8-7bb3-4ab3-ae03-42aaaaa30478"
      unitRef="usd">406000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODEvZnJhZzoyOTEzNTMwMjlmMjQ0ZTQ0ODgzNDE5NTEzYjBhODA3Ny90ZXh0cmVnaW9uOjI5MTM1MzAyOWYyNDRlNDQ4ODM0MTk1MTNiMGE4MDc3XzUyODg_9e623a1c-0a76-41e4-9c89-7a8cbfedb93c"
      unitRef="usdPerShare">3.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODEvZnJhZzoyOTEzNTMwMjlmMjQ0ZTQ0ODgzNDE5NTEzYjBhODA3Ny90ZXh0cmVnaW9uOjI5MTM1MzAyOWYyNDRlNDQ4ODM0MTk1MTNiMGE4MDc3XzUyOTU_6cbd8c43-0238-49c5-b174-e4c8a6c364ff"
      unitRef="usdPerShare">2.20</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODEvZnJhZzoyOTEzNTMwMjlmMjQ0ZTQ0ODgzNDE5NTEzYjBhODA3Ny90ZXh0cmVnaW9uOjI5MTM1MzAyOWYyNDRlNDQ4ODM0MTk1MTNiMGE4MDc3XzU0NTE_3e937d94-73c0-46d3-991b-d2c313b878af"
      unitRef="usd">3744000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODEvZnJhZzoyOTEzNTMwMjlmMjQ0ZTQ0ODgzNDE5NTEzYjBhODA3Ny90ZXh0cmVnaW9uOjI5MTM1MzAyOWYyNDRlNDQ4ODM0MTk1MTNiMGE4MDc3XzU0NTg_cc84982b-91e1-4719-b744-d9bb4915da23"
      unitRef="usd">857000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODEvZnJhZzoyOTEzNTMwMjlmMjQ0ZTQ0ODgzNDE5NTEzYjBhODA3Ny90ZXh0cmVnaW9uOjI5MTM1MzAyOWYyNDRlNDQ4ODM0MTk1MTNiMGE4MDc3XzU4Nzk_45213412-05b9-4bdd-9f1a-dd3a9303ba66"
      unitRef="usd">27905000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODEvZnJhZzoyOTEzNTMwMjlmMjQ0ZTQ0ODgzNDE5NTEzYjBhODA3Ny90ZXh0cmVnaW9uOjI5MTM1MzAyOWYyNDRlNDQ4ODM0MTk1MTNiMGE4MDc3XzU5NzI_d8dfb2fe-5eb8-4305-a329-dce78482aed2">P2Y2M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="ifb5f434783cc4b4c9ef2fe9ae4041cd4_D20210924-20210924"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODEvZnJhZzoyOTEzNTMwMjlmMjQ0ZTQ0ODgzNDE5NTEzYjBhODA3Ny90ZXh0cmVnaW9uOjI5MTM1MzAyOWYyNDRlNDQ4ODM0MTk1MTNiMGE4MDc3XzY1MDQ_52e83237-1ed7-42bb-94c4-982351ff7ac9"
      unitRef="shares">9250000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected
      contextRef="ibf72cce8ac64497daeaefb6469475537_D20210924-20210924"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODEvZnJhZzoyOTEzNTMwMjlmMjQ0ZTQ0ODgzNDE5NTEzYjBhODA3Ny90ZXh0cmVnaW9uOjI5MTM1MzAyOWYyNDRlNDQ4ODM0MTk1MTNiMGE4MDc3XzY1Mjc_0997904f-8cb9-4637-acd5-d6413845fd05"
      unitRef="employee">25</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost
      contextRef="i444320f038034b09878835272c70885a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODEvZnJhZzoyOTEzNTMwMjlmMjQ0ZTQ0ODgzNDE5NTEzYjBhODA3Ny90ZXh0cmVnaW9uOjI5MTM1MzAyOWYyNDRlNDQ4ODM0MTk1MTNiMGE4MDc3XzY5Mjk_7f0a7b6f-2952-49ef-a783-a78f8a2b736b"
      unitRef="usd">4872000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODEvZnJhZzoyOTEzNTMwMjlmMjQ0ZTQ0ODgzNDE5NTEzYjBhODA3Ny90ZXh0cmVnaW9uOjI5MTM1MzAyOWYyNDRlNDQ4ODM0MTk1MTNiMGE4MDc3XzkwMzk_f4bc7aba-6f09-44b6-b19d-c36c54bab956">The following table summarizes the activity relating to RSUs for the year ended December 31, 2021:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:73.830%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.266%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.790%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.127%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.790%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.594%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number of Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Grant Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs - beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,923&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26,923)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs - end of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="ib788877f138c4513a611e7bbf11174b9_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODEvZnJhZzoyOTEzNTMwMjlmMjQ0ZTQ0ODgzNDE5NTEzYjBhODA3Ny90YWJsZTo3NWQ1ZDk3YWY5NTA0ZTI4YmFlZDgzZDFiYzgyZmEwMS90YWJsZXJhbmdlOjc1ZDVkOTdhZjk1MDRlMjhiYWVkODNkMWJjODJmYTAxXzEtMy0xLTEtMTA5ODc2_b76e1892-08c8-429a-9e1f-049e16464c1a"
      unitRef="shares">26923</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="ib788877f138c4513a611e7bbf11174b9_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODEvZnJhZzoyOTEzNTMwMjlmMjQ0ZTQ0ODgzNDE5NTEzYjBhODA3Ny90YWJsZTo3NWQ1ZDk3YWY5NTA0ZTI4YmFlZDgzZDFiYzgyZmEwMS90YWJsZXJhbmdlOjc1ZDVkOTdhZjk1MDRlMjhiYWVkODNkMWJjODJmYTAxXzEtNS0xLTEtMTA5ODc2_c0247dd9-97c3-408c-bf80-4d606cdf0585"
      unitRef="usdPerShare">1.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="ifb40b671dcdb4ef29c0a6c97d77ebb15_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODEvZnJhZzoyOTEzNTMwMjlmMjQ0ZTQ0ODgzNDE5NTEzYjBhODA3Ny90YWJsZTo3NWQ1ZDk3YWY5NTA0ZTI4YmFlZDgzZDFiYzgyZmEwMS90YWJsZXJhbmdlOjc1ZDVkOTdhZjk1MDRlMjhiYWVkODNkMWJjODJmYTAxXzMtMy0xLTEtMTA5ODc2_67d27a98-ce91-42c3-b40a-e862eb65349d"
      unitRef="shares">26923</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="ifb40b671dcdb4ef29c0a6c97d77ebb15_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODEvZnJhZzoyOTEzNTMwMjlmMjQ0ZTQ0ODgzNDE5NTEzYjBhODA3Ny90YWJsZTo3NWQ1ZDk3YWY5NTA0ZTI4YmFlZDgzZDFiYzgyZmEwMS90YWJsZXJhbmdlOjc1ZDVkOTdhZjk1MDRlMjhiYWVkODNkMWJjODJmYTAxXzMtNS0xLTEtMTA5ODc2_76847b97-dabe-43a0-9ef5-6e0bacfd00f3"
      unitRef="usdPerShare">1.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i151cdfd1b29442d4840888fb00f8949d_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODEvZnJhZzoyOTEzNTMwMjlmMjQ0ZTQ0ODgzNDE5NTEzYjBhODA3Ny90YWJsZTo3NWQ1ZDk3YWY5NTA0ZTI4YmFlZDgzZDFiYzgyZmEwMS90YWJsZXJhbmdlOjc1ZDVkOTdhZjk1MDRlMjhiYWVkODNkMWJjODJmYTAxXzQtMy0xLTEtMTA5ODc2_79ed6b7e-85b2-4867-a933-0dbe81087190"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i151cdfd1b29442d4840888fb00f8949d_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODEvZnJhZzoyOTEzNTMwMjlmMjQ0ZTQ0ODgzNDE5NTEzYjBhODA3Ny90YWJsZTo3NWQ1ZDk3YWY5NTA0ZTI4YmFlZDgzZDFiYzgyZmEwMS90YWJsZXJhbmdlOjc1ZDVkOTdhZjk1MDRlMjhiYWVkODNkMWJjODJmYTAxXzQtNS0xLTEtMTA5ODc2_11de9290-7e33-4196-b150-5b11c59b62f4"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested
      contextRef="i4d5f6c2289bf42c8a42f632397ea769e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODEvZnJhZzoyOTEzNTMwMjlmMjQ0ZTQ0ODgzNDE5NTEzYjBhODA3Ny90ZXh0cmVnaW9uOjI5MTM1MzAyOWYyNDRlNDQ4ODM0MTk1MTNiMGE4MDc3XzczNzg_7289d800-7785-45af-8482-42da29e5a8e4"
      unitRef="usd">125000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested
      contextRef="ifb40b671dcdb4ef29c0a6c97d77ebb15_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODEvZnJhZzoyOTEzNTMwMjlmMjQ0ZTQ0ODgzNDE5NTEzYjBhODA3Ny90ZXh0cmVnaW9uOjI5MTM1MzAyOWYyNDRlNDQ4ODM0MTk1MTNiMGE4MDc3XzczNzg_c6e2731d-1ea2-41c7-a63e-88186953e349"
      unitRef="usd">125000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i395ac2e436db41e1b784ce9a6a63fdfd_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODEvZnJhZzoyOTEzNTMwMjlmMjQ0ZTQ0ODgzNDE5NTEzYjBhODA3Ny90ZXh0cmVnaW9uOjI5MTM1MzAyOWYyNDRlNDQ4ODM0MTk1MTNiMGE4MDc3Xzc5MzY_f6d842d2-d4f7-419a-8b41-0f51ed01f0e9"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODEvZnJhZzoyOTEzNTMwMjlmMjQ0ZTQ0ODgzNDE5NTEzYjBhODA3Ny90ZXh0cmVnaW9uOjI5MTM1MzAyOWYyNDRlNDQ4ODM0MTk1MTNiMGE4MDc3XzgxNzI_fef33167-a59d-4070-915e-44ae3223c2ea"
      unitRef="shares">1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <smmt:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedOutstandingNumber
      contextRef="if894fc66857243cf91a1a3e3a656bd4f_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODEvZnJhZzoyOTEzNTMwMjlmMjQ0ZTQ0ODgzNDE5NTEzYjBhODA3Ny90ZXh0cmVnaW9uOjI5MTM1MzAyOWYyNDRlNDQ4ODM0MTk1MTNiMGE4MDc3Xzg0MjI_439aec4b-3b2e-4e6e-907e-ad1f67996ff5"
      unitRef="shares">5821137</smmt:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedOutstandingNumber>
    <smmt:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedOutstandingNumber
      contextRef="i1b7a43e1795f40b497c444b01b9f6b53_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODEvZnJhZzoyOTEzNTMwMjlmMjQ0ZTQ0ODgzNDE5NTEzYjBhODA3Ny90ZXh0cmVnaW9uOjI5MTM1MzAyOWYyNDRlNDQ4ODM0MTk1MTNiMGE4MDc3Xzg0NTc_f182ee6a-5e70-40ce-a17e-8a5f86e3be5b"
      unitRef="shares">559787</smmt:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedOutstandingNumber>
    <smmt:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedOutstandingNumber
      contextRef="ia09aa906eefb458f9f484f59eac63b0f_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODEvZnJhZzoyOTEzNTMwMjlmMjQ0ZTQ0ODgzNDE5NTEzYjBhODA3Ny90ZXh0cmVnaW9uOjI5MTM1MzAyOWYyNDRlNDQ4ODM0MTk1MTNiMGE4MDc3Xzg1MDE_f4251425-f205-4e14-b119-869f4df6545d"
      unitRef="shares">5261350</smmt:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedOutstandingNumber>
    <smmt:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice
      contextRef="if894fc66857243cf91a1a3e3a656bd4f_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODEvZnJhZzoyOTEzNTMwMjlmMjQ0ZTQ0ODgzNDE5NTEzYjBhODA3Ny90ZXh0cmVnaW9uOjI5MTM1MzAyOWYyNDRlNDQ4ODM0MTk1MTNiMGE4MDc3Xzg2Nzg_0cd2028f-72d9-440a-9c6a-c869fe58ff1c"
      unitRef="usdPerShare">1.56</smmt:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested
      contextRef="i395ac2e436db41e1b784ce9a6a63fdfd_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODEvZnJhZzoyOTEzNTMwMjlmMjQ0ZTQ0ODgzNDE5NTEzYjBhODA3Ny90ZXh0cmVnaW9uOjI5MTM1MzAyOWYyNDRlNDQ4ODM0MTk1MTNiMGE4MDc3Xzg3MTQ_3a69fc6d-c76f-4897-a1ae-20955e6a1ec6"
      unitRef="usd">6559000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="i395ac2e436db41e1b784ce9a6a63fdfd_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODEvZnJhZzoyOTEzNTMwMjlmMjQ0ZTQ0ODgzNDE5NTEzYjBhODA3Ny90ZXh0cmVnaW9uOjI5MTM1MzAyOWYyNDRlNDQ4ODM0MTk1MTNiMGE4MDc3Xzg3NzE_9c471d75-4638-4424-b8e3-530e3480cd03">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="if894fc66857243cf91a1a3e3a656bd4f_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODEvZnJhZzoyOTEzNTMwMjlmMjQ0ZTQ0ODgzNDE5NTEzYjBhODA3Ny90ZXh0cmVnaW9uOjI5MTM1MzAyOWYyNDRlNDQ4ODM0MTk1MTNiMGE4MDc3Xzg3OTI_7be580cc-dd08-40b9-a6f3-c552b02598a5"
      unitRef="usd">0</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODEvZnJhZzoyOTEzNTMwMjlmMjQ0ZTQ0ODgzNDE5NTEzYjBhODA3Ny90ZXh0cmVnaW9uOjI5MTM1MzAyOWYyNDRlNDQ4ODM0MTk1MTNiMGE4MDc3XzkwNDM_545e38a6-629c-47cb-9682-58e43be0d0f9">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock&#x2011;based compensation expense related to stock options is recorded within the consolidated statements of operations and comprehensive loss as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.485%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.277%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.743%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.767%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.743%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.770%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:103%"&gt;Year Ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:103%"&gt;Year Ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%"&gt;Research and development&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,909&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;General and administrative&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,895&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%"&gt;1,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%"&gt;Total stock-based compensation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ie40533d6881a4b8e84e00ba2095c6a46_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODEvZnJhZzoyOTEzNTMwMjlmMjQ0ZTQ0ODgzNDE5NTEzYjBhODA3Ny90YWJsZToyMGIxZDY4YjNkNDg0OGNlYTI4ZjdkM2I4MzRiNDhlNC90YWJsZXJhbmdlOjIwYjFkNjhiM2Q0ODQ4Y2VhMjhmN2QzYjgzNGI0OGU0XzEtMi0xLTEtMTA5ODc2_c5408058-41bb-4b43-85e3-e126c6029df1"
      unitRef="usd">5909000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i9692194cdd1947979995cb545a07d30f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODEvZnJhZzoyOTEzNTMwMjlmMjQ0ZTQ0ODgzNDE5NTEzYjBhODA3Ny90YWJsZToyMGIxZDY4YjNkNDg0OGNlYTI4ZjdkM2I4MzRiNDhlNC90YWJsZXJhbmdlOjIwYjFkNjhiM2Q0ODQ4Y2VhMjhmN2QzYjgzNGI0OGU0XzEtNC0xLTEtMTA5ODc2_295bb603-a230-4e2a-a9b8-a87b35461e8b"
      unitRef="usd">749000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i1b50b0a3bb8f405dafa9635ba05d5e1a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODEvZnJhZzoyOTEzNTMwMjlmMjQ0ZTQ0ODgzNDE5NTEzYjBhODA3Ny90YWJsZToyMGIxZDY4YjNkNDg0OGNlYTI4ZjdkM2I4MzRiNDhlNC90YWJsZXJhbmdlOjIwYjFkNjhiM2Q0ODQ4Y2VhMjhmN2QzYjgzNGI0OGU0XzItMi0xLTEtMTA5ODc2_a338e36c-8aa0-4fe0-8ed1-79cd454eaad1"
      unitRef="usd">6895000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="id19f5fb0cc5346e48e222529f4a6e420_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODEvZnJhZzoyOTEzNTMwMjlmMjQ0ZTQ0ODgzNDE5NTEzYjBhODA3Ny90YWJsZToyMGIxZDY4YjNkNDg0OGNlYTI4ZjdkM2I4MzRiNDhlNC90YWJsZXJhbmdlOjIwYjFkNjhiM2Q0ODQ4Y2VhMjhmN2QzYjgzNGI0OGU0XzItNC0xLTEtMTA5ODc2_4c2111fc-262e-4c0d-805f-68b2280a2e39"
      unitRef="usd">1017000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODEvZnJhZzoyOTEzNTMwMjlmMjQ0ZTQ0ODgzNDE5NTEzYjBhODA3Ny90YWJsZToyMGIxZDY4YjNkNDg0OGNlYTI4ZjdkM2I4MzRiNDhlNC90YWJsZXJhbmdlOjIwYjFkNjhiM2Q0ODQ4Y2VhMjhmN2QzYjgzNGI0OGU0XzMtMi0xLTEtMTA5ODc2_ead88647-66e8-4f58-8482-e79df5e990cb"
      unitRef="usd">12804000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ide29fa0246b242de921f4a3c66ca4c8b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODEvZnJhZzoyOTEzNTMwMjlmMjQ0ZTQ0ODgzNDE5NTEzYjBhODA3Ny90YWJsZToyMGIxZDY4YjNkNDg0OGNlYTI4ZjdkM2I4MzRiNDhlNC90YWJsZXJhbmdlOjIwYjFkNjhiM2Q0ODQ4Y2VhMjhmN2QzYjgzNGI0OGU0XzMtNC0xLTEtMTA5ODc2_1effc9fb-32e9-4b7f-b3ed-a3b431c5a01b"
      unitRef="usd">1766000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODQvZnJhZzoxZmY5MTNiMmRmMjQ0NDQzYTQ4ZjMxMjhjZGFjNWM2OS90ZXh0cmVnaW9uOjFmZjkxM2IyZGYyNDQ0NDNhNDhmMzEyOGNkYWM1YzY5XzE0OTU_89c31c4d-7c0e-408b-9e36-670cfdf74aaf">Commitments and Contingencies &lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fixed asset purchase commitments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December 31, 2021 and 2020, the Company had no capital commitments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other commitments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company enters into contracts in the normal course of business with various third parties for clinical trials, preclinical research studies and testing, manufacturing and other services and products for operating purposes. Most contracts provide for termination upon notice, and therefore are cancellable contracts. As of December 31, 2021, total contractual commitments are estimated to be approximately $17,046 and the majority of these commitments are due within one year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Indemnifications&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's certificate of incorporation provides that it will indemnify the directors and officers to the fullest extent permitted by Delaware law. In addition, the Company has entered into indemnification agreements with all of the directors and executive officers. These indemnification agreements may require the Company, among other things, to indemnify each such director or executive officer for some expenses, including attorneys&#x2019; fees, judgments, fines, and settlement amounts incurred by him or her in any action or proceeding arising out of his or her service as one of the Company's directors or executive officers. The Company believes the fair value for these indemnification obligations is minimal. Accordingly, the Company has not recognized any liabilities relating to these obligations as of December 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Legal Proceedings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is not currently subject to any material legal proceedings.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:PurchaseObligation
      contextRef="i7372be6dc06143b5adbb4d2e83a596c5_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODQvZnJhZzoxZmY5MTNiMmRmMjQ0NDQzYTQ4ZjMxMjhjZGFjNWM2OS90ZXh0cmVnaW9uOjFmZjkxM2IyZGYyNDQ0NDNhNDhmMzEyOGNkYWM1YzY5Xzc2_14a61985-532a-457a-97a9-13cfb7ecfcc1"
      unitRef="usd">0</us-gaap:PurchaseObligation>
    <us-gaap:PurchaseObligation
      contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODQvZnJhZzoxZmY5MTNiMmRmMjQ0NDQzYTQ4ZjMxMjhjZGFjNWM2OS90ZXh0cmVnaW9uOjFmZjkxM2IyZGYyNDQ0NDNhNDhmMzEyOGNkYWM1YzY5Xzc2_a687a99e-7137-4208-ab5e-185084424144"
      unitRef="usd">0</us-gaap:PurchaseObligation>
    <us-gaap:OtherCommitment
      contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODQvZnJhZzoxZmY5MTNiMmRmMjQ0NDQzYTQ4ZjMxMjhjZGFjNWM2OS90ZXh0cmVnaW9uOjFmZjkxM2IyZGYyNDQ0NDNhNDhmMzEyOGNkYWM1YzY5XzUxMg_a350bf70-8b44-4442-ad04-0fd89bdb69a1"
      unitRef="usd">17046000</us-gaap:OtherCommitment>
    <smmt:OtherCommitmentPeriodForWhichTheMajorityOfCommitmentsAreToBePaid
      contextRef="i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODQvZnJhZzoxZmY5MTNiMmRmMjQ0NDQzYTQ4ZjMxMjhjZGFjNWM2OS90ZXh0cmVnaW9uOjFmZjkxM2IyZGYyNDQ0NDNhNDhmMzEyOGNkYWM1YzY5XzU2OA_da5f345a-e896-4e7f-8cd4-d0220ea22d98">P1Y</smmt:OtherCommitmentPeriodForWhichTheMajorityOfCommitmentsAreToBePaid>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODcvZnJhZzplOWNhNGFmYWViZmI0NTMxYjI5ZWU4YTEwNjk3MDdjMS90ZXh0cmVnaW9uOmU5Y2E0YWZhZWJmYjQ1MzFiMjllZThhMTA2OTcwN2MxXzczNDk_4fd6702a-b0f6-41b9-ab63-3f8c15374123">Related Party Transactions &lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December&#160;6, 2019, the Company entered into a deed of termination of the relationship agreement with Mr. Robert W. Duggan and Cairn Financial Advisers LLP, a limited liability partnership incorporated in England and Wales with the Registrar of Companies of England and Wales, as the Company's nominated adviser. The relationship agreement regulated the Company&#x2019;s relationship with Mr. Robert W. Duggan and limited Mr. Robert W. Duggan&#x2019;s influence over the Company&#x2019;s corporate actions and activities and the outcome of general matters pertaining to the Company. The deed of termination became effective on February 24, 2020, upon the cancellation of the admission of the ordinary shares on the Alternative Investment Market, a sub-market of the London Stock Exchanges.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;December 24, 2019 Private Placement&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 24, 2019, the Company completed a private placement of its common stock and received aggregate gross proceeds of $50,000 from the issuance and sale of 35,075,690 shares of common stock at a price of $1.43 per share, of which 33,231,410 shares of common stock were subscribed by Mr.&#160;Robert&#160;W. Duggan. Also, as part of the private placement, &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;participating investors were granted warrants with the right to subscribe for 5,261,350 shares of common stock at an exercise price of $1.58, of which 4,984,711 were granted to Mr. Robert W. Duggan at an exercise price of $1.43 per share for a subscription share plus a subscription warrant, pursuant to a securities purchase agreement he entered into with the Company.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In conjunction with the December 24, 2019 private placement, 90,495 shares of common stock were subscribed by Mr.&#160;Glyn Edwards, the Company's former Chief Executive Officer. Also as part of this private placement, Mr. Glyn Edwards was granted warrants with the right to subscribe for 13,574 shares of common stock at an exercise price of $1.43 per share for a subscription share plus a subscription warrant, pursuant to a securities purchase agreement he entered into with the Company. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;November 6, 2020 Private Placement&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November 6, 2020 the Company completed a private placement of its common stock and received gross proceeds of $50,000 from the issuance and sale of 14,970,060 shares of common stock at a price of $3.34 per share, of which 14,071,856 shares of common stock were subscribed by Mr. Robert W. Duggan.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In conjunction with the November 6, 2020 private placement, 149,701 shares of common stock were subscribed by the Mahkam Zanganeh Revocable Trust. Dr. Maky Zanganeh was appointed to the Board of Directors on November 11, 2020 and became the Company's Chief Operations Officer on November 22, 2020. As trustee of the Mahkam Zanganeh Revocable Trust, Dr. Maky Zanganeh is deemed to beneficially own the securities of the Company held by the Mahkam Zanganeh Revocable Trust.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Consultancy Agreements&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2020, the Company had in place a consultancy agreement with Dr. Maky Zanganeh and Associates, Inc. (&#x201c;MZA&#x201d;) to provide support for clinical operation activities related to the global Phase III clinical program. Dr. Maky Zanganeh is the sole owner of MZA, and Dr. Elaine Stracker, who served for a period during fiscal year 2020 as a director of the Company and as the Company&#x2019;s Interim Chief Operations Officer, was at the time the General Counsel and Senior Vice President for Corporate Development at MZA. The fees for such services under the consultancy agreement with MZA were $75 per month. In addition to such monthly fee, MZA was granted warrants over 3,358,732 shares of common stock with an exercise price of $1.44 per share, vesting on a quarterly basis over three years from the date of grant, subject to MZA&#x2019;s provision of consultancy services to the Company during such period. During the period of MZA's engagement, $470 of consultancy fees were incurred by the Company and a warrant expense of $512 was recognized. The consultancy agreement with MZA was terminated by mutual agreement on June 30, 2020. The warrants granted to MZA were subsequently assigned to Dr. Maky Zanganeh and Dr. Elaine Stracker. Dr. Maky Zanganeh and Dr. Elaine Stracker have vested warrants to purchase 489,815 and 69,972 shares of common stock, respectively, which can be exercised through June 30, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;March 24, 2021 Note Purchase Agreement&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 24, 2021, Mr. Robert W. Duggan, entered into a Note Purchase Agreement (the &#x201c;Initial Purchase Agreement&#x201d;) pursuant to which he has loaned the Company $55,000 in exchange for the issuance by the Company of an unsecured promissory note (the &#x201c;Initial Note&#x201d;) in the amount of $55,000. The Initial Note was to accrue interest at a rate per annum equal to 150% of the applicable 10 Year U.S. Treasury rate, as adjusted monthly. The rate is initially estimated to be approximately 2.4%. The terms of the Initial Note were that it would mature and become due upon the earlier of (i) the consummation of a registered public offering with net proceeds of no less than $55,000, or (ii) 13 months from the date of issuance of the Initial Note. On April 20, 2021, the Company determined, with Mr. Duggan&#x2019;s agreement, to rescind both the Initial Purchase Agreement and the Initial Note issued thereunder, and repaid the principal amount of the Initial Note in full, without interest or penalty, as such for the year ended December 31, 2021, the Company recognized imputed interest of $103 within additional paid in capital. For the year ended December 31, 2021, debt issuance costs recognized related to the Initial Note were immaterial.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;March 26, 2021 Sublease Agreement with Dr. Maky Zanganeh and Associates, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 26, 2021, the Company entered into a sublease with Dr. Maky Zanganeh and Associates, Inc. ("MZA") consisting of 4,500 square feet of office space at 2882 Sand Hill Road, Menlo Park, CA (the &#x201c;Sublease&#x201d;). Dr. Maky Zanganeh is the sole owner of MZA. The sublease runs until September 2022. The rent payable under the terms of the sublease is equivalent to the proportionate share of the rent payable by MZA to the third-party landlord, based on the square footage of office space sublet by the Company, and no mark-up has been applied. During the year ended December 31, 2021, payments of $556, were made pursuant to the sublease.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;April 20, 2021 Note Purchase Agreement&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 20, 2021, subsequent to the repayment of the Initial Note, Mr. Robert W. Duggan entered into a second Note Purchase Agreement (the &#x201c;Second Purchase Agreement&#x201d;) pursuant to which he loaned the Company $55,000 in exchange for the issuance by the Company of an unsecured promissory note (the &#x201c;Second Note&#x201d;) in the amount of $55,000. The Second Note accrued interest at a rate per annum equal to 150% of the applicable 10 Year US Treasury rate, as adjusted monthly (initially estimated to be approximately 2.4%). The Company was permitted to prepay any portion of the second note at its option without penalty.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;May 12, 2021 Rights Offering&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 12, 2021, the Company closed its rights offering, which was fully subscribed. Aggregate gross proceeds from the rights offering of $75,000 from the sale of&#x202f;14,312,976&#x202f;shares of the Company's common stock, of which 11,365,921 shares were purchased by Mr. Robert W. Duggan and 389,977 shares were purchased by Dr. Maky Zanganeh, at price of $5.24 per share. In connection with the closing of the rights offering, the Second Note, issued by the Company in favor of Mr. Robert W. Duggan, matured and became due and was repaid using a portion of the proceeds from the rights offering.&lt;/span&gt;&lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="ief39eb2f075b4eb78fa3e4ffac9e4610_D20191224-20191224"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODcvZnJhZzplOWNhNGFmYWViZmI0NTMxYjI5ZWU4YTEwNjk3MDdjMS90ZXh0cmVnaW9uOmU5Y2E0YWZhZWJmYjQ1MzFiMjllZThhMTA2OTcwN2MxXzk0Nw_02850f29-4c01-4230-99e7-c4d93f510759"
      unitRef="usd">50000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="ief39eb2f075b4eb78fa3e4ffac9e4610_D20191224-20191224"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODcvZnJhZzplOWNhNGFmYWViZmI0NTMxYjI5ZWU4YTEwNjk3MDdjMS90ZXh0cmVnaW9uOmU5Y2E0YWZhZWJmYjQ1MzFiMjllZThhMTA2OTcwN2MxXzk4MA_63473d1e-5fbd-49dd-9735-b4d39eff70e5"
      unitRef="shares">35075690</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i5b2fdb6bad994e6eb9c9380cb3807cd6_I20191224"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODcvZnJhZzplOWNhNGFmYWViZmI0NTMxYjI5ZWU4YTEwNjk3MDdjMS90ZXh0cmVnaW9uOmU5Y2E0YWZhZWJmYjQ1MzFiMjllZThhMTA2OTcwN2MxXzEwMjA_d8f220c7-969c-4091-939e-98d4338e7a68"
      unitRef="usdPerShare">1.43</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:CommonStockSharesSubscribedButUnissued
      contextRef="i7be0acfd60d747fbba039b448bffe68f_I20191224"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODcvZnJhZzplOWNhNGFmYWViZmI0NTMxYjI5ZWU4YTEwNjk3MDdjMS90ZXh0cmVnaW9uOmU5Y2E0YWZhZWJmYjQ1MzFiMjllZThhMTA2OTcwN2MxXzEwNDM_867df915-aacb-4d28-98c5-8f8077deb7c2"
      unitRef="shares">33231410</us-gaap:CommonStockSharesSubscribedButUnissued>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i5b2fdb6bad994e6eb9c9380cb3807cd6_I20191224"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODcvZnJhZzplOWNhNGFmYWViZmI0NTMxYjI5ZWU4YTEwNjk3MDdjMS90ZXh0cmVnaW9uOmU5Y2E0YWZhZWJmYjQ1MzFiMjllZThhMTA2OTcwN2MxXzEyMjg_cfe82858-09b0-4d05-b510-adb275b637bf"
      unitRef="shares">5261350</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i5b2fdb6bad994e6eb9c9380cb3807cd6_I20191224"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODcvZnJhZzplOWNhNGFmYWViZmI0NTMxYjI5ZWU4YTEwNjk3MDdjMS90ZXh0cmVnaW9uOmU5Y2E0YWZhZWJmYjQ1MzFiMjllZThhMTA2OTcwN2MxXzEyNzg_a5e5013a-65fb-4878-ac1e-81e9c3d9b4bd"
      unitRef="usdPerShare">1.58</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i7be0acfd60d747fbba039b448bffe68f_I20191224"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODcvZnJhZzplOWNhNGFmYWViZmI0NTMxYjI5ZWU4YTEwNjk3MDdjMS90ZXh0cmVnaW9uOmU5Y2E0YWZhZWJmYjQ1MzFiMjllZThhMTA2OTcwN2MxXzEyOTE_7836cc6c-6dad-4cb8-ac52-eb85689908d7"
      unitRef="shares">4984711</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i7be0acfd60d747fbba039b448bffe68f_I20191224"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODcvZnJhZzplOWNhNGFmYWViZmI0NTMxYjI5ZWU4YTEwNjk3MDdjMS90ZXh0cmVnaW9uOmU5Y2E0YWZhZWJmYjQ1MzFiMjllZThhMTA2OTcwN2MxXzEzNTU_0dcb4a3a-10db-4774-ac25-1ab29ed117d4"
      unitRef="usdPerShare">1.43</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:CommonStockSharesSubscribedButUnissued
      contextRef="i4f6915c5f2074c63ae73f25be0258821_I20191224"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODcvZnJhZzplOWNhNGFmYWViZmI0NTMxYjI5ZWU4YTEwNjk3MDdjMS90ZXh0cmVnaW9uOmU5Y2E0YWZhZWJmYjQ1MzFiMjllZThhMTA2OTcwN2MxXzE1NjI_05eb13fa-4423-40f3-a2f4-59270e722a22"
      unitRef="shares">90495</us-gaap:CommonStockSharesSubscribedButUnissued>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i4f6915c5f2074c63ae73f25be0258821_I20191224"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODcvZnJhZzplOWNhNGFmYWViZmI0NTMxYjI5ZWU4YTEwNjk3MDdjMS90ZXh0cmVnaW9uOmU5Y2E0YWZhZWJmYjQ1MzFiMjllZThhMTA2OTcwN2MxXzE3ODE_9e63bbc1-385b-4b17-aa0f-bb28be12d240"
      unitRef="shares">13574</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i4f6915c5f2074c63ae73f25be0258821_I20191224"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODcvZnJhZzplOWNhNGFmYWViZmI0NTMxYjI5ZWU4YTEwNjk3MDdjMS90ZXh0cmVnaW9uOmU5Y2E0YWZhZWJmYjQ1MzFiMjllZThhMTA2OTcwN2MxXzE4MzE_355f75cd-6726-46cd-9fde-00993d1b957a"
      unitRef="usdPerShare">1.43</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i6a505b52efdc43a7821a6b7cc66b172e_D20201106-20201106"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODcvZnJhZzplOWNhNGFmYWViZmI0NTMxYjI5ZWU4YTEwNjk3MDdjMS90ZXh0cmVnaW9uOmU5Y2E0YWZhZWJmYjQ1MzFiMjllZThhMTA2OTcwN2MxXzIxMjc_bf71a633-45e4-4a7a-9d85-f7346e8d4a48"
      unitRef="usd">50000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i6a505b52efdc43a7821a6b7cc66b172e_D20201106-20201106"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODcvZnJhZzplOWNhNGFmYWViZmI0NTMxYjI5ZWU4YTEwNjk3MDdjMS90ZXh0cmVnaW9uOmU5Y2E0YWZhZWJmYjQ1MzFiMjllZThhMTA2OTcwN2MxXzIxNjA_2eb360d5-03ca-469f-b88d-42cc6b2c8b9c"
      unitRef="shares">14970060</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i1cda89fc1bbb4c82a3c7a93284736d74_I20201106"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODcvZnJhZzplOWNhNGFmYWViZmI0NTMxYjI5ZWU4YTEwNjk3MDdjMS90ZXh0cmVnaW9uOmU5Y2E0YWZhZWJmYjQ1MzFiMjllZThhMTA2OTcwN2MxXzIyMDA_dfa93078-b64b-4dec-afb0-202ed3f3532d"
      unitRef="usdPerShare">3.34</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:CommonStockSharesSubscribedButUnissued
      contextRef="i7f56091566944d9bb672ff557a22aff4_I20201106"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODcvZnJhZzplOWNhNGFmYWViZmI0NTMxYjI5ZWU4YTEwNjk3MDdjMS90ZXh0cmVnaW9uOmU5Y2E0YWZhZWJmYjQ1MzFiMjllZThhMTA2OTcwN2MxXzIyMjM_d2271d13-4ac6-4837-8322-9f3c2338e767"
      unitRef="shares">14071856</us-gaap:CommonStockSharesSubscribedButUnissued>
    <us-gaap:CommonStockSharesSubscribedButUnissued
      contextRef="ibc0f44cee68945c1910a87557a1bdd5d_I20201106"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODcvZnJhZzplOWNhNGFmYWViZmI0NTMxYjI5ZWU4YTEwNjk3MDdjMS90ZXh0cmVnaW9uOmU5Y2E0YWZhZWJmYjQ1MzFiMjllZThhMTA2OTcwN2MxXzIzNTE_ff65e520-b38d-4aa7-ad1b-4b910d95d5b3"
      unitRef="shares">149701</us-gaap:CommonStockSharesSubscribedButUnissued>
    <smmt:RelatedPartyTransactionMonthlyExpensesFromTransactionsWithRelatedParty
      contextRef="ib29a1c5799524e1987c045aee67b6831_D20191224-20191224"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODcvZnJhZzplOWNhNGFmYWViZmI0NTMxYjI5ZWU4YTEwNjk3MDdjMS90ZXh0cmVnaW9uOmU5Y2E0YWZhZWJmYjQ1MzFiMjllZThhMTA2OTcwN2MxXzMzNjY_b28e09b8-e297-4d65-822d-bf5f25b689fc"
      unitRef="usd">75000</smmt:RelatedPartyTransactionMonthlyExpensesFromTransactionsWithRelatedParty>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="id3dfe8aa6a324f739c2caa516220e112_I20191224"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODcvZnJhZzplOWNhNGFmYWViZmI0NTMxYjI5ZWU4YTEwNjk3MDdjMS90ZXh0cmVnaW9uOmU5Y2E0YWZhZWJmYjQ1MzFiMjllZThhMTA2OTcwN2MxXzM0NDM_241bfaea-6ee6-4d97-8153-fb893d96ba48"
      unitRef="shares">3358732</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="id3dfe8aa6a324f739c2caa516220e112_I20191224"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODcvZnJhZzplOWNhNGFmYWViZmI0NTMxYjI5ZWU4YTEwNjk3MDdjMS90ZXh0cmVnaW9uOmU5Y2E0YWZhZWJmYjQ1MzFiMjllZThhMTA2OTcwN2MxXzM0OTU_005d473f-73ce-412e-92bf-eb638c34376a"
      unitRef="usdPerShare">1.44</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <smmt:ClassOfWarrantOrRightQuarterlyVestingPeriod
      contextRef="ib29a1c5799524e1987c045aee67b6831_D20191224-20191224"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODcvZnJhZzplOWNhNGFmYWViZmI0NTMxYjI5ZWU4YTEwNjk3MDdjMS90ZXh0cmVnaW9uOmU5Y2E0YWZhZWJmYjQ1MzFiMjllZThhMTA2OTcwN2MxXzM1NDM_5d6efe75-8a04-4a7a-9afe-c225620b66b1">P3Y</smmt:ClassOfWarrantOrRightQuarterlyVestingPeriod>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="i2a2d5cacc14249f0a5bbe8fcc0619c62_D20191224-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODcvZnJhZzplOWNhNGFmYWViZmI0NTMxYjI5ZWU4YTEwNjk3MDdjMS90ZXh0cmVnaW9uOmU5Y2E0YWZhZWJmYjQ1MzFiMjllZThhMTA2OTcwN2MxXzM2OTU_dc50d7a4-c847-46f6-8820-19d1db1148b4"
      unitRef="usd">470000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="ib8d80178d3e743bd88db3e643c215cb4_D20191224-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODcvZnJhZzplOWNhNGFmYWViZmI0NTMxYjI5ZWU4YTEwNjk3MDdjMS90ZXh0cmVnaW9uOmU5Y2E0YWZhZWJmYjQ1MzFiMjllZThhMTA2OTcwN2MxXzM3NzI_a6fd3a70-6d00-42ab-a4cb-90dcc5339ed6"
      unitRef="usd">512000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <smmt:ClassOfWarrantOrRightVested
      contextRef="i0346f51cbc1549bc97088b050e2cd48e_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODcvZnJhZzplOWNhNGFmYWViZmI0NTMxYjI5ZWU4YTEwNjk3MDdjMS90ZXh0cmVnaW9uOmU5Y2E0YWZhZWJmYjQ1MzFiMjllZThhMTA2OTcwN2MxXzQwNTU_109f83d6-9052-4a56-ab26-b05ade1ce473"
      unitRef="shares">489815</smmt:ClassOfWarrantOrRightVested>
    <smmt:ClassOfWarrantOrRightVested
      contextRef="i093a476c99524d7c821d17ca295cc4d5_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODcvZnJhZzplOWNhNGFmYWViZmI0NTMxYjI5ZWU4YTEwNjk3MDdjMS90ZXh0cmVnaW9uOmU5Y2E0YWZhZWJmYjQ1MzFiMjllZThhMTA2OTcwN2MxXzQwNjI_052dfce1-4258-4317-ae05-e5647341339a"
      unitRef="shares">69972</smmt:ClassOfWarrantOrRightVested>
    <us-gaap:ProceedsFromRelatedPartyDebt
      contextRef="i4a8e4bc29f1645008a3ae3a8a5bb7985_D20210324-20210324"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODcvZnJhZzplOWNhNGFmYWViZmI0NTMxYjI5ZWU4YTEwNjk3MDdjMS90ZXh0cmVnaW9uOmU5Y2E0YWZhZWJmYjQ1MzFiMjllZThhMTA2OTcwN2MxXzQzNDk_95bd9772-e3c9-4023-89c7-8f357d314041"
      unitRef="usd">55000000</us-gaap:ProceedsFromRelatedPartyDebt>
    <us-gaap:NotesPayableRelatedPartiesCurrentAndNoncurrent
      contextRef="i0ad778717801435f8f8ca0b3e18b51e9_I20210324"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODcvZnJhZzplOWNhNGFmYWViZmI0NTMxYjI5ZWU4YTEwNjk3MDdjMS90ZXh0cmVnaW9uOmU5Y2E0YWZhZWJmYjQ1MzFiMjllZThhMTA2OTcwN2MxXzQ0NjY_b169f710-79ce-4bbe-9705-0a1191fec903"
      unitRef="usd">55000000</us-gaap:NotesPayableRelatedPartiesCurrentAndNoncurrent>
    <smmt:RelatedPartyTransactionRateBasisSpreadOnVariableRate
      contextRef="i325d85a3830d40bba514256f5133edfa_D20210324-20210324"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODcvZnJhZzplOWNhNGFmYWViZmI0NTMxYjI5ZWU4YTEwNjk3MDdjMS90ZXh0cmVnaW9uOmU5Y2E0YWZhZWJmYjQ1MzFiMjllZThhMTA2OTcwN2MxXzQ1Mzk_fbe2f727-4e7a-47a2-83b0-8714a8ac6771"
      unitRef="number">1.50</smmt:RelatedPartyTransactionRateBasisSpreadOnVariableRate>
    <smmt:RelatedPartyTransactionExpectedRate
      contextRef="i4a8e4bc29f1645008a3ae3a8a5bb7985_D20210324-20210324"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODcvZnJhZzplOWNhNGFmYWViZmI0NTMxYjI5ZWU4YTEwNjk3MDdjMS90ZXh0cmVnaW9uOmU5Y2E0YWZhZWJmYjQ1MzFiMjllZThhMTA2OTcwN2MxXzQ2NjE_e9e8a075-5478-46f1-9694-895e9747ba1e"
      unitRef="number">0.024</smmt:RelatedPartyTransactionExpectedRate>
    <smmt:NotesPayableRelatedPartiesMaturityTriggeringEventPublicOfferingProceedsThreshold
      contextRef="i4a8e4bc29f1645008a3ae3a8a5bb7985_D20210324-20210324"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODcvZnJhZzplOWNhNGFmYWViZmI0NTMxYjI5ZWU4YTEwNjk3MDdjMS90ZXh0cmVnaW9uOmU5Y2E0YWZhZWJmYjQ1MzFiMjllZThhMTA2OTcwN2MxXzQ4NDM_83fbd8fe-7f0e-4534-8051-6e9facca3f8b"
      unitRef="usd">55000000</smmt:NotesPayableRelatedPartiesMaturityTriggeringEventPublicOfferingProceedsThreshold>
    <smmt:NotesPayableRelatedPartiesMaximumTerm
      contextRef="i4a8e4bc29f1645008a3ae3a8a5bb7985_D20210324-20210324"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODcvZnJhZzplOWNhNGFmYWViZmI0NTMxYjI5ZWU4YTEwNjk3MDdjMS90ZXh0cmVnaW9uOmU5Y2E0YWZhZWJmYjQ1MzFiMjllZThhMTA2OTcwN2MxXzQ4NTU_ab4d03dd-78e1-452f-9efe-8434313b886c">P13M</smmt:NotesPayableRelatedPartiesMaximumTerm>
    <smmt:AdjustmentsToAdditionalPaidInCapitalImputedInterestExpenseRelatedParty
      contextRef="i09dcbb2d540d490da156db0310d0ba16_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODcvZnJhZzplOWNhNGFmYWViZmI0NTMxYjI5ZWU4YTEwNjk3MDdjMS90ZXh0cmVnaW9uOmU5Y2E0YWZhZWJmYjQ1MzFiMjllZThhMTA2OTcwN2MxXzUyNTA_b8e390f9-e5d5-4013-818e-20e812e322cf"
      unitRef="usd">103000</smmt:AdjustmentsToAdditionalPaidInCapitalImputedInterestExpenseRelatedParty>
    <smmt:AreaOfPremisesSubleased
      contextRef="idb48cdbb6adf4bcf9f8d62840ec9c140_I20210326"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODcvZnJhZzplOWNhNGFmYWViZmI0NTMxYjI5ZWU4YTEwNjk3MDdjMS90ZXh0cmVnaW9uOmU5Y2E0YWZhZWJmYjQ1MzFiMjllZThhMTA2OTcwN2MxXzU2MDQ_fdbe6c97-d7b8-414a-b32e-721af856336b"
      unitRef="sqft">4500</smmt:AreaOfPremisesSubleased>
    <smmt:RelatedPartyTransactionPaymentsToRelatedParty
      contextRef="i581d5e9999fd48be88afa99a5a463cea_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODcvZnJhZzplOWNhNGFmYWViZmI0NTMxYjI5ZWU4YTEwNjk3MDdjMS90ZXh0cmVnaW9uOmU5Y2E0YWZhZWJmYjQ1MzFiMjllZThhMTA2OTcwN2MxXzYwNzU_243cddf0-8e36-4d6f-98ec-30575153ad6c"
      unitRef="usd">556000</smmt:RelatedPartyTransactionPaymentsToRelatedParty>
    <us-gaap:ProceedsFromRelatedPartyDebt
      contextRef="i5c623b14e066454399e945948de2ad12_D20210420-20210420"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODcvZnJhZzplOWNhNGFmYWViZmI0NTMxYjI5ZWU4YTEwNjk3MDdjMS90ZXh0cmVnaW9uOmU5Y2E0YWZhZWJmYjQ1MzFiMjllZThhMTA2OTcwN2MxXzYzNjU_f83d8385-8cf8-4366-b5c9-5d8795703904"
      unitRef="usd">55000000</us-gaap:ProceedsFromRelatedPartyDebt>
    <us-gaap:NotesPayableRelatedPartiesCurrentAndNoncurrent
      contextRef="i9d8f0174c08f45cab10ea87b88a0b06d_I20210420"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODcvZnJhZzplOWNhNGFmYWViZmI0NTMxYjI5ZWU4YTEwNjk3MDdjMS90ZXh0cmVnaW9uOmU5Y2E0YWZhZWJmYjQ1MzFiMjllZThhMTA2OTcwN2MxXzY0ODE_6491d4aa-a5be-47e0-aba6-c72d0176797f"
      unitRef="usd">55000000</us-gaap:NotesPayableRelatedPartiesCurrentAndNoncurrent>
    <smmt:RelatedPartyTransactionRateBasisSpreadOnVariableRate
      contextRef="i6f7965621e7641dba292d1568adf65f8_D20210420-20210420"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODcvZnJhZzplOWNhNGFmYWViZmI0NTMxYjI5ZWU4YTEwNjk3MDdjMS90ZXh0cmVnaW9uOmU5Y2E0YWZhZWJmYjQ1MzFiMjllZThhMTA2OTcwN2MxXzY1NDc_fc925bac-61be-4911-8635-4e100322ba3f"
      unitRef="number">1.50</smmt:RelatedPartyTransactionRateBasisSpreadOnVariableRate>
    <smmt:RelatedPartyTransactionExpectedRate
      contextRef="i5c623b14e066454399e945948de2ad12_D20210420-20210420"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODcvZnJhZzplOWNhNGFmYWViZmI0NTMxYjI5ZWU4YTEwNjk3MDdjMS90ZXh0cmVnaW9uOmU5Y2E0YWZhZWJmYjQ1MzFiMjllZThhMTA2OTcwN2MxXzY2NTU_ccc9e01a-b2b7-4447-92c2-51058b35f3bf"
      unitRef="number">0.024</smmt:RelatedPartyTransactionExpectedRate>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="idb475943c8884e52b4a61d6e77d4d205_D20210512-20210512"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODcvZnJhZzplOWNhNGFmYWViZmI0NTMxYjI5ZWU4YTEwNjk3MDdjMS90ZXh0cmVnaW9uOmU5Y2E0YWZhZWJmYjQ1MzFiMjllZThhMTA2OTcwN2MxXzY5Mjc_6f4da8ac-53e3-4606-99d8-77c7b6eed8c6"
      unitRef="usd">75000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="idb475943c8884e52b4a61d6e77d4d205_D20210512-20210512"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODcvZnJhZzplOWNhNGFmYWViZmI0NTMxYjI5ZWU4YTEwNjk3MDdjMS90ZXh0cmVnaW9uOmU5Y2E0YWZhZWJmYjQ1MzFiMjllZThhMTA2OTcwN2MxXzY5NDc_ba3ff3b8-bb39-4505-98fd-74ffb2417155"
      unitRef="shares">14312976</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="ie3fb42912674490dbad67b4354fdb2ee_D20210512-20210512"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODcvZnJhZzplOWNhNGFmYWViZmI0NTMxYjI5ZWU4YTEwNjk3MDdjMS90ZXh0cmVnaW9uOmU5Y2E0YWZhZWJmYjQ1MzFiMjllZThhMTA2OTcwN2MxXzY5OTc_415be3b8-63cc-4951-b7f3-706e24ede78c"
      unitRef="shares">11365921</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i2c16f78153794bfc9c3b372a28a98377_D20210512-20210512"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODcvZnJhZzplOWNhNGFmYWViZmI0NTMxYjI5ZWU4YTEwNjk3MDdjMS90ZXh0cmVnaW9uOmU5Y2E0YWZhZWJmYjQ1MzFiMjllZThhMTA2OTcwN2MxXzcwNTA_50829544-31e4-4cd1-9a21-ef6480021656"
      unitRef="shares">389977</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i8148167fc4184c02abb40835e22beac6_I20210512"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODcvZnJhZzplOWNhNGFmYWViZmI0NTMxYjI5ZWU4YTEwNjk3MDdjMS90ZXh0cmVnaW9uOmU5Y2E0YWZhZWJmYjQ1MzFiMjllZThhMTA2OTcwN2MxXzcxMDk_31dcb4cb-91c3-4042-a240-adc0a0e1ffe3"
      unitRef="usdPerShare">5.24</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i11be25b5a09d46a5851abb451892b99c_I20210512"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xODcvZnJhZzplOWNhNGFmYWViZmI0NTMxYjI5ZWU4YTEwNjk3MDdjMS90ZXh0cmVnaW9uOmU5Y2E0YWZhZWJmYjQ1MzFiMjllZThhMTA2OTcwN2MxXzcxMDk_9e263e41-279b-44c4-a6b7-f7f77aff4e36"
      unitRef="usdPerShare">5.24</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="i0f6242234d28477e9478c049c2986ce6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xOTAvZnJhZzoyMzA5NDBmZjdjYTU0ZjlmYWMyYmZlZTQxNmM2N2E0Yy90ZXh0cmVnaW9uOjIzMDk0MGZmN2NhNTRmOWZhYzJiZmVlNDE2YzY3YTRjXzYwNA_6bb86354-8650-4430-9cc3-12dee5213ef1">Subsequent Event&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;On March 10, 2022, Mr. Robert W. Duggan, entered into a Note Purchase Agreement (the &#x201c;2022 Note&#x201d;), pursuant to which he has loaned the Company $25,000 in exchange for the issuance by the Company of an unsecured promissory note in the amount of $25,000. The 2022 Note is to accrue interest at a rate per annum equal to the prime rate as reported in the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%"&gt;Wall Street Journal&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;, which is 3.25% as of the effective date. The 2022 Note becomes due upon the earlier of (i) the consummation of a registered public offering with net proceeds of no less than $25,000 or (ii) 18 months from the date of issuance of the 2022 Note.&lt;/span&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:ProceedsFromRelatedPartyDebt
      contextRef="idf7a081c7b9c4705a95c5f2ab53d19bb_D20220310-20220310"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xOTAvZnJhZzoyMzA5NDBmZjdjYTU0ZjlmYWMyYmZlZTQxNmM2N2E0Yy90ZXh0cmVnaW9uOjIzMDk0MGZmN2NhNTRmOWZhYzJiZmVlNDE2YzY3YTRjXzE1Nw_69138b23-a984-44ed-9f22-fd824b580d4b"
      unitRef="usd">25000000</us-gaap:ProceedsFromRelatedPartyDebt>
    <us-gaap:NotesPayableRelatedPartiesCurrentAndNoncurrent
      contextRef="id74d06c0cec74c7fa7641c591943da88_I20220310"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xOTAvZnJhZzoyMzA5NDBmZjdjYTU0ZjlmYWMyYmZlZTQxNmM2N2E0Yy90ZXh0cmVnaW9uOjIzMDk0MGZmN2NhNTRmOWZhYzJiZmVlNDE2YzY3YTRjXzI1Mw_8d5360bb-1df5-46b7-85b8-71efccc7c96f"
      unitRef="usd">25000000</us-gaap:NotesPayableRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:RelatedPartyTransactionRate
      contextRef="idf7a081c7b9c4705a95c5f2ab53d19bb_D20220310-20220310"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xOTAvZnJhZzoyMzA5NDBmZjdjYTU0ZjlmYWMyYmZlZTQxNmM2N2E0Yy90ZXh0cmVnaW9uOjIzMDk0MGZmN2NhNTRmOWZhYzJiZmVlNDE2YzY3YTRjXzM4Ng_2d605ab6-a553-4e44-8921-654e4bceff98"
      unitRef="number">0.0325</us-gaap:RelatedPartyTransactionRate>
    <smmt:NotesPayableRelatedPartiesMaturityTriggeringEventPublicOfferingProceedsThreshold
      contextRef="idf7a081c7b9c4705a95c5f2ab53d19bb_D20220310-20220310"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xOTAvZnJhZzoyMzA5NDBmZjdjYTU0ZjlmYWMyYmZlZTQxNmM2N2E0Yy90ZXh0cmVnaW9uOjIzMDk0MGZmN2NhNTRmOWZhYzJiZmVlNDE2YzY3YTRjXzU0OA_9c9d674c-41f3-44fd-b07b-fa148e8b1101"
      unitRef="usd">25000000</smmt:NotesPayableRelatedPartiesMaturityTriggeringEventPublicOfferingProceedsThreshold>
    <smmt:NotesPayableRelatedPartiesMaximumTerm
      contextRef="idf7a081c7b9c4705a95c5f2ab53d19bb_D20220310-20220310"
      id="id3VybDovL2RvY3MudjEvZG9jOjJlZWNkZWJlZGVjNjQwOTE5OTRkZjViN2E5NmJhYWI3L3NlYzoyZWVjZGViZWRlYzY0MDkxOTk0ZGY1YjdhOTZiYWFiN18xOTAvZnJhZzoyMzA5NDBmZjdjYTU0ZjlmYWMyYmZlZTQxNmM2N2E0Yy90ZXh0cmVnaW9uOjIzMDk0MGZmN2NhNTRmOWZhYzJiZmVlNDE2YzY3YTRjXzU1OQ_65a644fe-f3b7-4ee6-9ad6-9675b5620b7a">P18M</smmt:NotesPayableRelatedPartiesMaximumTerm>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>94
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( (*"E54'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    " ""@I55^*&N(>X    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9+!
M2@,Q$(9?17+?G4TJ0L,VEXHG!<&"XBTDTS:XV81D9+=O;W9MMX@^@,?,_/GF
M&YC61&E"PN<4(B9RF&]&W_59FKAA1Z(H ;(YHM>Y+HF^-/<A>4WEF0X0M?G0
M!P31-'?@D;35I&$"5G$A,M5:(TU"32&=\=8L^/B9NAEF#6"''GO*P&L.3$T3
MXVGL6K@")AAA\OF[@'8ASM4_L7,'V#DY9K>DAF&HA]6<*SMP>'MZ?)G7K5R?
M2?<&RZ_L))TB;MAE\NMJ>[][8$HT0E1<5(+O!)=\+6_7[Y/K#[^KL _6[=T_
M-KX(JA9^W87Z E!+ P04    " ""@I55F5R<(Q &  "<)P  $P   'AL+W1H
M96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03<VEVV[29A.U.
M'X416(UL>621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X
M8-DOV]:[MR_>X%<R)!%!,!FGK_# "J5,7K5::0##.'W)$Q+#W(*+"$MX%,O6
M7.!;&B\CUNJTV]U6A&ELH1A'9&!]7BQH0-!445IO7R"TY1\S^!7+5(UEHP$3
M5T$FN8BT\OELQ?S:WCYES^DZ'3*!;C ;6"!_SF^GY$Y:B.%4PL3 :F<_5FO'
MT=)(@(+)?90%NDGVH],5"#(-.SJ=6,YV?/;$[9^,RMIT-&T:X./Q>#BVR]*+
M<!P$X%&[GL*=]&R_I$$)M*-IT&38]MJND::JC5-/T_=]W^N;:)P*C5M/TVMW
MW=..B<:MT'@-OO%/A\.NB<:KT'3K:28G_:YKI.D6:$)&X^MZ$A6UY4#3( !8
M<';6S-(#EEXI^G64&MD=N]U!7/!8[CF)$?[&Q036:=(9EC1&<IV0!0X -\31
M3%!\KT&VBN#"DM)<D-;/*;50&@B:R('U1X(AQ=RO_?67N\FD,WJ=?3K.:Y1_
M::L!I^V[F\^3_'/HY)^GD]=-0LYPO"P)\?LC6V&')VX[$W(Z'&="?,_V]I&E
M)3+/[_D*ZTX\9Q]6EK!=S\_DGHQR([O=]EA]]D]';B/7J<"S(M>41B1%G\@M
MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7
MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V<
M/!T3$LV4"P9!AI<D)A*I.7Y-2!/^*Z7:_IS30/"4+R3Z2I&/:;,CIW0FS>@S
M&L%&KQMUAVC2/'K^!?F<-0H<D1L= F<;LT8AA&F[\!ZO)(Z:K<(1*T(^8ADV
M&G*U%H&V<:F$8%H2QM%X3M*T$?Q9K#63/F#([,V1=<[6D0X1DEXW0CYBSHN0
M$;\>ACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0'
MHYI9";V$5FJ?JH<T/J@>,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y
M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RS<C'5*^3*=@Y
MG\#L_6@^GO'M^MDDA*^:62TC%I!+@;-!)+C\B\KP*L0)Z&1;)0G+5--E-XH2
MGD(;;NE3]4J5U^6ON2BX/%ODZ:^A=#XLS_D\7^>TS0LS0[=R2^JVE+ZU)CA*
M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D*
MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-#
MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B
M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P
MOFH]M!5.S_Y9K<B?#!%.%@L22&.4%Z9*HO,94[[G*TG$53B_13.V$I<8O./F
MQW%.4[@2=K8/ C*YNSFI>F4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W
MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2
MD 83 <V4R43P H)DIAR F/H+O?(,N2D5SJT^.7]%+(.&3E[2)1(4BK ,!2$7
M<N/O[Y-J=XS7^BR!;814,F35%\I#B<$],W)#V%0E\Z[:)@N%V^)4S;L:OB9@
M2\-Z;ITM)__;7M0]M!<]1O.CF> >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F
M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+
M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5
M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0    (
M (*"E573I*:?P@<  &TO   8    >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL
MM9IK<^JV%H;_BH;NZ;0S(?A"N.PFF2&P<PZG3<H):3N[G7X0M@#-MBV.)(?P
M[\^2#1AG9&%WQ)<$7]9KZ[$DKU=>MUO&OXDU(1*]QU$B[EIK*3>?.QT1K$F,
MQ37;D 2.+!F/L81-ONJ(#2<XS(+BJ.,Y3J\38YJT[F^S?3-^?\M2&=&$S#@2
M:1QCOGL@$=O>M=S68<<+7:VEVM&YO]W@%9D3^=MFQF&K<U0):4P205F".%G>
MM4;NYXG?5P'9&;]3LA4GOY%JRH*Q;VIC&MZU''5')"*!5!(8_KV1,8DBI03W
M\;^]:.MX315X^ON@_I@U'AJSP(*,6?0'#>7ZKC5HH9 L<1K)%[;]-]DWZ$;I
M!2P2V5^TS<^]Z;50D K)XGTPW$%,D_P_?M^#. D8.!4!WC[ ^Q#@=BL"_'V
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M;Q:4 (Q;0/-KK7'7<0_HCM7T+U!+ P04    " ""@I55BM\_#'4&  ##'
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M ?W[@FN&VCV8]UC=>\OYOU!+ P04    " ""@I55.^<609\"  !E!P  &
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M4>9LW5!#TXF26Z)L-++9@<N-0Z,;)NPI+HS"MPQQ)IU)H25G.360DVO*J<B
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MG4W"\C8^**'_3;2?6BPYDSQ-8JH@1@]*?^D>*8GX&MWN0-"\UA)1%J,ES_1
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M%"UWA=8?!'M- 3Z/J/"U8Y"]&:.'AZDRP,"'*(V-V>@R;N84+7>%UJ=^KUQ
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M5$A%[:8%M5W0-H#.<Z5PN[ 7](T\^0U02P,$%     @ @H*550[#+ ($"
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M3I-!V0$BSDA>]#=,(;NLP'AHX3EXDC/P]$L9O-W"Z>05)V'RKN!\K]Y.'>'
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M_,.)!L=7T",K 6)7BU:WBJ+#1EF3=YF'&4U.B";E'!SB=-% OYWV)7NK,&2
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MJQOOHK>FU%DD2,)MH$@NY05?J;?&:5<8I.4C%@F*3%']=K6,*4!3OS^5HNS
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MR;B.^'E%CA- .XG@S"$):,\2(O[#1Q+LJDM=H(GZ! "[EX "T0]8L8.4-?:
MU8"8V%9VMS9X56WP%2A?&@L-["=R;:P%?\@?G O:1)PLD014#L"*7BKX5G4
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M<C12(5_R\TORK5RLES[AFBZ/-7X74> -^%YY-*3^A0T,O[0N_P902P,$%
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M?F<YMG1C5Y8D[RA*NQ9D7!4_S>[%_ 2P8HQ1E3I:?LDP2+_0JQG7)6P]G[Q
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M\/VV ^J7/W"#VZ[_1."]_$]02P,$%     @ @H*55:+_G5$>!P  !!0  !D
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MX'Q\=):0B5D-$5B[7Y@>')R<7I"4,GKUC1>VW"\W"<:_U&T&'&>*.Q?Q35R
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M_&03H=FG0FAN9;YE=WFH,G$^M)!-.X9A)6?EY4Q>D3.>L'N5V\2PFSP2T:&
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M&Z^:>)>S1U%8'XG):+P(7-BO$':>[]D.)_B.:PH89W'E?(A*([QZBVC_2L+
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M&N="M$>!QL) -\BZQ( =$4?=PKQ[_C-66WEK',Y+/U->N8G= )*W]^LKZJL
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M%K,>[D[N<Z5_L*IPGP@Q>6%\<3]I*!6:-N!]K)2M'TA!\\WX\O]02P,$%
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MZ.PR50,J W#NA1_0%9#'GG*&\FRQ>\:9BN36QQH 6$$I=C#E8XW,+T972(?
MNQBQ^5JQ%BG,,'_[BU%,!Q4JL6<OSD83)# 0A?5"2\L>"HCUQ*@L1Z<@2B!'
M<R5+ #==HNR*"ZHK$#!M[%.&L\E34?,AW24%!\-4;YP)D;WDS%$XXXBELZ+.
MJ\X2J84%>52 N?GJ5.*QH=( _[MZB6+6DG8"\T$8,:D@N"&><B+LA48\^<QW
M#>1SND'F_*@TZL_;NK?N#FQH^H%8+,: 5*3&A?%-F*J!#^6?!I<0U(HM(-.M
M[4;%2%16[/.:<C=$VR+V8+PI$7B!"I1 EC(@+NHTD1$A21,;YTW&#MXG3**U
MN.QWDC*_G@*$>G\7O-3I;M#7.WC+*.FC +G]/2X84SEV@"J"?4=M'!OK%,:Q
M+)%$(M=#V.:W+B0+M-/$>TN5V#=E!6-2;@U;6Q<I=L.1FC8ULJ=8K8"@FR:1
MY=3@7O0@3CAGY&3QC.(+V;,F_#5&@&$@OV'D)Y^A)",U%5<LKJH3UA,AA2.4
M-US5::\!6KSEGRB$;1X1UV&X> ^; 6>#2,XKBT4&]A5JB:4@D<ZV9#KYKFND
MM/>BWJ )]AA6!&=PK7=].\DI_Q]^Y6O0NO7F<8.2P?<%*UK'\]%68A9#&1O#
MEE4C"@)6-XJU77/S4BYJ:,?XO#!82L$:1N4@]&7AS%2DM7OZ%1U]_ID9!1^6
MBY0XU! =-Q2^CA,$MK@25T6>Y'^=D&E0]F_(DAQW\?^H\=)U+&^MTV78!BX6
MJ O$=@UM;BPU [SI\NIL,-6VH L3$<I.8HJGC^'D%+27-!< #T>JU-G3/[%0
M" > %4\+.%&LO&$+D&##]@1Y)/&Q^J=$BL%][#L(\;&UU9IW%Z[)@9-*1TN:
M*#QX#9#AHI(J&)G V2T;YJAK2+X'ULQG=]",<VP_L!@DKJRX4@N6>S 6-?F6
M1_]E8X(+0Q )?\T I306955JN1]$DNW:$"B9=NA<A6"+! .:KZ4B%(SD0LT*
MC-./ ='W$M?@:G%<UB!#H<W\41O9P&LH,E6<4R+O'UR7,Z8A)(/UYX_495%V
M5=D80I/#!XT%0.Q[^Q!A%^OTOL9Y?FO$,96;9+@"32+*1@/\XCH%POMM*YOY
M?R78#Z'V8 #PW8!AN=N#D,;*6 ,"2P$U?=+4 ]N_-$(,@?TC2U4>@@=-M4J!
M7Y1=&@:TK,VR;[M!G+,$:@41_[[\@[/GC%:=/ &F5Y5%FHJ'&;O*^U0")S?O
M;AHF),?C!D1:++C7W[1RJ7JF9G[36P\$?GC_RV_O&Q(E2A]*D#[6I:NU^!L1
M?'=]^X9JQ.52_>=W.MN\N!ZAHM@@<[E S?=K,3Z3WA$PEK1-O?T?A(=.._F7
M8OM,>'CO&VO=>I#<AHI\*00R_87@C" @$-T4R)1VJCE@I@+-LA4V9Q.]*LB?
M,;0G%5(U=<\K4."94'H@>X4'\#$!ZX0VR*>/ L<"WKYR$-)K*2.)3.Y,M_?9
MD&BZRV&P[?8OG,_8&A)%/M@83ALVO4)$Q8];1 Y4V.@8?OVA&8_#&@)P/5H&
M*N+VC^03$&JL?L#/?7]FKY(F'#6A\[;P"4W7H:9:VSGW]573PCS0,QSYL-Z<
M*3K).0GHN 175'V75/D$@?8YI18S[">1-N_]8R= S=]S]8'3Q>ABU.FS];O*
M)M=Q:-#?%"7ROCM;UD 'B\#_B0K-I20 WV/%(H.#H'BH2^K+=P'DYOK3][==
M!/%[KBG5HH%^PUQ79C8OKB[(6I=P=ZG<]8Z0HI/50F&L108A#X?P@K38P5DZ
M,!G ID.!&B&'D'.A496(O5*[).7"D:TDL[G-ZJR;6 N#&)<5"9\2"VYY/*$E
M+%6> /].IZU%>M^/J4R\SC$Y)?0K3=P2P4J)0<F);93(@( $OM@O_D 9B#4)
M[#+2GZ Q[L!\%=PK[(!T<GI];/51[^*U@;0?RZ+R<(/;5:DS"?6+75O1<:(4
M(ILO$(Q/F9@=#1UJQBM22:-M[_*.2LJ\&OE6@"!(7+AJ+[+O'9)T[*+%_8Y0
MU,SRJ,'G"J0R@M3D#K"N5^;>.7W[W4)+Q'70@%Z[&N[1F;'UV4871]DSO^61
M3185JFE*03:^:0Z-Q-JMU9+.:D<AJ?V6^[YM&_2C-I?X@6KDW!\LYT#..!S"
M<&[:R26CF4SK5MP!_7RJ$DX#2,SHC#M5 -K<;%6JMZR,  ^8^U.=&S6=2.M3
MMI)X(6-I%=I)AVFZSMLU8%J'CE#H_.%J-)O*D<#>I"'$7>RXU4I^X2LAA&O&
M8>@QM;V^58N9]Z- <-]>JY8VH>8#.AYBW;_KDY;N(IVSA;WUH-R)>AHN-TWF
M.:2'X^ED?':"8<?3:#RE&_JRPN,/N6OP274\&<]YX&Q\1==/+=X^IJUP?#F>
M\?2+\82NWS<['K*YUMI]7@:3#&WUDD,-6,7,R?@*_]X>."R"(.-S6B <:#\-
MQ_.3\04]GX[GO;>3\8S4]#YO7.1>%D8-Y2KUV<;#TG)GE67R,$B#,FB@SIXY
M[LD9 GD^8 Y'";P;KK<HV6:^UNR;;3#@W87&HAFUNG*/ZCMR\H-,\?YA RAK
M.P[)D'!)AR/+OJR4(;E.N3'R)[-=#3C.E@+ MF= ==ZTE0,!C'44$GS.U5^>
MC_7HD9SC]ERNH\JD, *I"&Y8EN3NGR8.=C1#3=_Z;I&O"DX5@L-(_DH'U3Y=
MZ^][LVX(,_N,"3HAI(2DHN.1G21=8M'U[0T5!N-_]?L*_\'18VR0#CNF9Z-H
M<B[GF,#'\]G@0:9M:K!$-7VV-M_Q<OEDMA=XVG#3CU>\8NC7(>,P:_J*]DZ*
M4Y@=&Q51HY0G'P!;R>AL?F?D^+Q7$E)VG-,'8(2'U JQB050A.\>"JH:^JSX
M@%^:C49IS;C=I=D%\=Z!_Z!!= N>O?(*<@Q]_=7&Y_;@G1V"OA/A&LS*%RLB
ML"C4Y@TT]F24'&3GOU5I4B (G.E<OOVCLWGO'R6/VT])0FD7CB *,BC#_M,Y
MCK@ONJ0R>$)I@V1[70\Z^"W#> ]?V4JQ3NZ:LO$!AYA@,'W>[;IM9O-5(\EN
MS@%^_/#IIK/*[1Z*+VTJQ^3!0\/R'!<ER+ QNWTB&"O5+J='T61ZZ;EY@)G&
MF.Z=)=V:\L[&IO-)"L-%#:LM.Q\'=((/0Y 4J.G.H\G <@=7(@N@'B<[X^](
M"5TB'7G6O(C&4H5#:_ZJF/*A_0/2?@7.?%?PID5=F7XC:=1 I9"'KMH#PW8.
MY7<>RK'IX7PZ^1TQ [_Y*ZX_*>B@1H-W>SF:PS&;\_<\'#P>^@K&=UFL$\<)
MC96F6*.M1&1"]4>+=3H>#_@(M2\#DG4_[0R%Q,%/7D8'OWEQ;1<A+YIS_!WO
M,H7F)G9T/TX;-6)P$W-0#)]PCKQVZ2-5#TL=SE'<@(X;#WV"?MKYXX#,E"O^
M$PAJ0"!"RM\)-$^;O[*XEC\N:(?+GVA\T.6*<" U2TQ%1G=VI$KYLP?Y414;
M_E.#15%51<:W:Z,A  W ^V6!\M7_H 6:OSUY_7]02P,$%     @ @H*55>A4
MI4V!!   F L  !D   !X;"]W;W)K<VAE971S+W-H965T,3DN>&ULM5;;;N,V
M$/V5@;98= '%UL77K&T@ERVZ0+<-DK:+HN@#+8TM(A*I):DX[M=W2$I:)W'<
M%FA?;%+#.3-G;N1B)]6]+A -/%:ET,N@,*8^'PYU5F#%]$#6*$BRD:IBAK9J
M.]2U0I8[I:H<)E$T&5:,BV"U<-]NU&HA&U-R@3<*=%-53.TOL92[91 'W8=;
MOBV,_3!<+6JVQ3LTO]0WBG;#'B7G%0K-I0"%FV5P$9]?CNQY=^!7CCM]L ;+
M9"WEO=U\S)=!9!W"$C-C$1C]/> 5EJ4%(C>^M)A!;](J'JX[].\<=^*R9AJO
M9/F9YZ98!K, <MRPIC2W<O<]MGS&%B^3I7:_L/-GTRB K-%&5JTR>5!QX?_9
M8QN' X79:PI)JY XO[TAY^4U,VRU4'('RIXF-+MP5)TV.<>%3<J=423EI&=6
M/TBMH48%=P53N!@:PK228=;J7WK]Y!7].(%/4IA"PP>18_X48$C.]!XEG4>7
MR4G$:\P&D,8A)%$2G\!+>X:IPTM?P?O E.!BJ^&F8PF_7ZRU4500?QPC[.%&
MQ^%LDYSKFF6X#*@+-*H'#%9OW\23Z/T)9T>]LZ-3Z/\@'?]&'WXN$#:RI,ZC
M"(!AZQ)!H]'T49D"#(DS6=6-8:Y%Y,96.,^ B1QR7C8&<Q T&<H.5EO8<_@-
MF?()!TH75FL2=2D[)8S@QP[M&_AV-@LG4?+.+L=).)E/W\&E,[]SO43Z[ $5
MC080C4,A_YP#VJ[(\8I\I@[)[H'&C3;DM:4Y3\(DG8=I-(')/!PGHS >S>"Z
MI?-_8'NO7P;*,HL&\\D[OYC2XOK5J!XY_"HNUVW>"&F]IU0]<.>>36A_G 1V
MWQ$^>TFXH]GR/N!)]>&4R227^>"4VZ=\>5%#_YU/(7"1E8V3U-*@,)R5Y=Z;
MI$'_%&C@6J&7X69#MT*?<Y"UK7_MZG['E&*">L0*<C2H:.P2AX8JVCM@Z/;3
MC=JW]5&A*23)=<>Z(T6WW#T1KQ7/\$5$/]*-E.?<V@V]EJ:+D>S42F:(N?Y;
M@YX_/C'9"(69W K^)R'9M-#UZ7L;'^T:'6=?UL<XFX(91YR+,\(]HPCB?@!W
M9,L;NB),)O:DH>D,L+8:I'9,'$M*0\N2!'9$"LITV$Z6XP5DD36K;!!.S)WG
MZ*$];E5=)'0[P=R!KB">5 '@EX8_L!(MT\/*VLFFS*&@(,(:D5B1[EE7+(-G
M4_1HL6G,&D4AH)+=H;7TZ'*3PT;)ZMB</=H=7YD^GT%/J^<@KN1PQAKMDL-5
M5]@G"9W[,>W&\2W21<@S"^0--8)3<-Z^F25Q\AZ223A/4OBI+14CH6Y45M K
MZ*E[<1I.Y]-P/)Y &DZF23B?S.!S5U3CD-#".)T>K.Y\?]NJ=-8)>HT]>M=M
M6-6EW".V9GKC=<F$)1!&HW'O;#PG]"B<IC.PHSD.HV1V[$H>'KR6*E1;]R:T
M0ZP1QC^<^J_]L_/"O[:^'O=OUD],;3D%IL0-J=+0'@>@_#O0;XRLW=MK+0V]
MY-RRH*<S*GN Y!M)U=1NK('^,;[Z"U!+ P04    " ""@I55V5$J_XT'   >
M$P  &0   'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6RU6&UOXS82_BN$&_02
MP+4EOR1Q-@F0W>WU%KBVB[[<?3C<!UJB;+84J26I..ZOOV=(6I(3;[8H<%]L
M2B)GGIEYYD6ZW1G[N]L*X=E3K;2[&VV];VZF4U=L1<W=Q#1"XTEE;,T]+NUF
MZAHK>!D.U6HZR[++:<VE'MW?AGL?[?VM:;V26GRTS+5US>W^K5!F=S?*1X<;
M/\G-UM.-Z?UMPS?B9^%_;3Y:7$T[*:6LA7;2:&9%=3=ZR&_>+FA_V/ O*79N
ML&9DR=J8W^GB0WDWR@B04*+P)('C[U&\$TJ1(,#XE&2..I5T<+@^2/][L!VV
MK+D3[XSZMRS]]FYT/6*EJ'BK_$]F]P^1[%F2O,(H%W[9+NY=SD>L:)TW=3H,
M!+74\9\_)3\,#EQGGSDP2P=F 7=4%%"^YY[?WUJS8Y9V0QHM@JGA-,!)34'Y
MV5L\E3CG[[\SIMQ)I1C7)?N@/=<;N5:"/3@GO+N=>NB@G=,BR7L;Y<T^(R^?
ML>^-]EO'OM6E*(\%3 &N0S@[('P[>U7B>U%,V#P?LUDVRU^1-^\LG@=Y\[]D
M,7LO7:&,:ZU@_WE8.V_!F_^>\D/4LCBMA7+IQC6\$'<C)(L3]E&,[K_^*K_,
MWKQBPZ*S8?&:]+\0M5?EG4;[!4=UC[N%=*P6G%Q7,NZ8WPHFG@KA'#-5N"J,
M\X<U+SZUTLF0FN91V' 3I:%[7IM60PUW3FXT)'K#.@B$2)9">UE)3C=D#X]'
M>$$^(5$$0&&;5- F@L2V%N6$_0(U[TS=<+U/:MR+T^=2%ZHMI=ZP3;+S(J@_
M(9$@&BV8L:PVX(\5C;&>CK9:!E,.QI7<"UH/G  X^T867*G]\+:#%(7=03AG
M#M+4<\FL-$P;C[L!='2?4J;@T;M5!YV$U*A7LGDAQ$W8APBNL:9L"^ U:X^J
M#M42U5,?18Q;<129SPD=!XF; 4-*B9R2ZS:91(_!N$:$ZGS*90VW'6F:UA9;
MU&!@E,61D0!-3)NP(]8>]I>G"!(B](@RC\?H;DR""=*BX7B<U6V(1-E: D.Z
M*]-:OV6?6N !78%(\&++*M0+KMA><!M4[K9""^(S?HB_$ P(>@.:P(V%M$5;
M.V IPHT2$?<4,>YCAG!K]Z3QD:LV4D1'P"CZ^Q#E-<$N*&6(^9'%R?H BDYR
M?T#=&$]I H0#\X:,"*GTPCF)2HY1B)%D!<>QW]IR0^>/,\>*3:NXA;-J@Y@9
MZ]"WK"4]ZQ9\)5R%@:61SJ3/ )EE%2HK[>XR;(P#/MBH9"TC0<:,ES#548J7
M:(=V3QZ%_=K4LF >>LHH%.,%A,(3O\6&'[R!RTKZF*G[Z&;R(_FB\*QJ/=5Y
M3#@V>@P6@\CNR,"OO[J>Y5=O7")%YV"0[AEKAFX%0 >F!Q!4$XZ)C5RC?"J,
M+8D)Z/E@EC^ALS%*%OOQ\!E$U\@T<D_(D"^A NM.TY?Z*:,(1:;@"9S$0QH2
M"YR+L?[!#*6!RW8#P-P%%H(<?Z3T(1DA"P0U?H:V+>HU-!U:=P@2!5ZP+8>.
MM1 :P0994#RBVKY./%=XI UE@PKH!)V([#BM"8MLW$LDP&>S<9:MPE-:SO&\
M+SU4=O$ <:(&2)G;G1T::DW]LGU586IH'SG[9R(NG-[!"J[.KR;L7:H#P4NA
MY\6JD4IV)!]MASLQ3>J41P5EUJ,@;U"1?M&(B1>@F/9=>TE,^=N@CYVN?T0E
M*ZD^II.504G=@1(W)]SZG37(Y8<B18RZ?$VD_B/R+E22EX'[ ;7K5V]-LY6A
M3&\LKWM<9VPQ7EQ?X?\\+"ZP"NR?O>F<VD 9O7[TIW+LS2_I"!Q[P?)L/%^M
MV(]-/TUHH[^II$9V4>V+%72%X?0</Q>=AA]#(6JX#]Z+;;W &P=@YXMK=HZ?
M?O,9RU?CU>6<L*[&R\L%84VJGSLK^[\Y:SE?1&=A\:>=M;Q<LO/Y.%MF<%8^
M7N;++SKK/+]@*P3]'#]_SF'+#(=(0^\PI&!^E1'>Z_'E<AD<%M63^/=]<WVE
M<"!+:Z[Q@ABK69KZR)]ZZ,'!F$0"S1?,PV3@6FIJ-%9I]FU?/LFHY)R'C151
M;2C0'/FB%%\;FV8.E%(M;&K!\8)&'!0U99#I-O0]C%)D)73)M30>30O-M)1A
M!$P1=A'G;BN+HS: 0ED.K#ER1*BD5"CP#HJ"7H=!K9LC*KBEGR$&#B%SB\&8
M&&:X0_=*TQ]*@O!X0V>67FE=J.ZGX#LR]BR;$,O1R6@T3:TJ^IAJ[LY*#[)
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M4*WKA9CBZJPQH.=FPN"DH]7 [9$+&9""YD;'&Y44OKBH7-L9%@=4[(="7^_
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M;/KF-!&NO[+[3;!MO"8W-N#2C<L:?SGD6 #?MQ9%/VS8P/C?M/H$4$L#!!0
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M).L_? )I9UA&E/@Q (,UI;003;J4A(S**W$O=+N^^'C$DJB'@]6%:&V'%#*
M[(U"M(+X3\7M7MBV>&"]U>%S.=B-7>FJ)G3C:/R4T(V?%KJN!N$SB-+_:RQ2
MLHJC:3**)J-O#$:T)GO$0EM2"]1:N)L2_IBLDW[)\E1<@,V<=A6)Y11D:JCO
ML"V,&D-@E@G^GK2L35 ?,@\N>JOFEHR53&E=TA>_=85PO$^Y@/="U>STG6>*
M62"K+1<E@4<CR YRFE2IX$&J"!N$\+W5IG:["H 47N14AZ ,&\B?!VQX %[
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M9@1X"HZ#LVW?,'!ATLH6T39Q8I-Z1R?G85J)0[2B=C6UD"M8U^J==H#<?ZF
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MIPJ(D,,AI TQZTZ60  $3#*_ \=M S=8.F(;@C(-X2K*CFF.M8A%W>@MDLR
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MU5\O^5&A(Y?O<.#5ILFYO1I%U9N?0MNA*11=QBAZY-:AE/H?^R82G%R^!43
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M7G[\!(_^I5[1-,OSLT5RDOP8;F8!>Z?@WD3)@Y_K/>AG3Q]=G*Y.6)C#V\P
M4\W6(R<B=EFK."'?7O(2AHH3[5&Z A)+8?^#<[E(^[!WFK,B[RV2!Q>GP?_[
MQW;BBO#H<<2S!X]XO-"@.7Y*_)!^R*E<(+IN!$MB6F03DK9#,?*"J[[$Y>HS
M6A;6,%ZH(I3Z9)=XR]- \KP7A*RV\.%EDIXE=[EH-2JJ72A65(U.^VY;-]J0
MRGNM8:F4BO?CY>7[E3G$5N!#S2])'%*3#9$;<ND#!HJ*G2_W]*HD^I8VL"-X
M@9I/+&!UUT5%FF>ZP388WLP]?ZSW$+Q.,?M6DO@#\8<%^:Z)@Z:EE,8@Y>P
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MC[_8(PQZQU,<--**C?K6":3*.4,:BFH!$.M49+\:;2V53U,UI>> [WK&%<S
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MH,Q,^T'2;IRN_4? 0CM\4OAE@6\X8>@ _L^U=NL-&=A\%<[_ U!+ P04
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M>_L5=ME.[GMXN__NF"ZY-""PH-3H]'P2@&YW2GNPJO%SO%*6MH(W*UK#J%T
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MABL)&LMY<)-,;S/G[QT^<]R:(QN<DI52W]S@?3$/8D<(!>;6(3#Z;? -"N&
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M.S.E"V'I5<\[9JE19$ZIR#NA[\>=0LBR-1ZZM6L]'JJ5S66)UQK,JBB$?KK
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M68#V9TK9W0L;J#]UQO\"4$L#!!0    ( (*"E57KQ5[W@P<  )U(   9
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MH%P9PAEMA#.R%T#+A,V)]YW%:]TI)9_F\R1F19M&K*!#-8*$N4B8AX3Y2%B
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M!BC-@])\*"V TD(4S9Q5V[@3U.Y./-'B]R1;9T25=UF;M)ZA.6.2E?-^V_H
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MDY&H=,XX+"1155%0N;^%7.S&7N@]3-RS3:;-A#\9E70#2]!?RX7$D=^@I*P
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M+DV5CM(N,/.I$'K=L1O4=?_X+U!+ P04    " ""@I55;@;(GE8"  !A!0
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M)E6C8H:)ZB6!ZP#U?,68W$[T!G5W&OP%4$L#!!0    ( (*"E56ZX;(S&P,
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M&;[=0)H ')\)H3<-4Z!Z#49_ %!+ P04    " ""@I55HHP,A_,$  "N'P
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ML:+S*@:"9JH7N:-"7DCU&,EN%5AN(-<7E(JG0;Y!U?]._@-02P,$%     @
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M#^B>".@4 1V3:$YFTIICB?TQ9UO$M5JYZ8:9&Q.MLB%4+^-"<O64J#CIW].
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MIUH_;NS'!"AG8-^OI#3/ ]>N=I\G^3]02P,$%     @ @H*557KZ H)V!
M<Q8  !D   !X;"]W;W)K<VAE971S+W-H965T-3@N>&ULM5A=<^(V%/TK&K?3
MV9UIL26#@128V23=:::[W4S8M ^=/@C[ IJU)2H)2/KK*W_$QK'1!&KR$&QQ
M[]$Y5U\'3?9"?E-K (V>DIBKJ;/6>G/ENBI<0T)53VR FV^60B94FU>Y<M5&
M HVRI"1VB><%;D(9=V:3K.U>SB9BJV/&X5XBM4T2*I^O(1;[J8.=EX8'MEKK
MM,&=339T!7/0CYM[:=[<$B5B"7#%!$<2EE/G [ZZ(7Z:D$7\P6"O#IY1*F4A
MQ+?TY2Z:.E[*"&((=0I!S<<.;B".4R3#XY\"U"G[3!,/GU_0/V;BC9@%57 C
MXC]9I-=39^2@")9T&^L'L?\5"D&#%"\4L<K^HWT>._0<%&Z5%DF1;!@DC.>?
M]*DHQ$$"#HXDD"*!O$[H'TGPBX2L<F[.+)-U2S6=3:38(YE&&[3T(:M-EFW4
M,)X.XUQ+\RTS>7IVQT.1 /I*G]!/Z'<J)4W+BM[=@J8L5N]-Z^/\%KW[_OW$
MU::_-,L-"^SK')L<P<8$?19<KQ7ZA4<0U0%<0[1D2U[87A,KXBV$/>3C'Q'Q
M"&XA=//V=,]"QR^+YV=X_A&\N5E4T38&]&6)#@KYUR<3A^XT).KOMJKEH/UV
MT'3=7JD-#6'JF(6I0.[ F?WP'0Z\G]L4=P16T]\O]?=MZ*:>2Y 2(J2-:JH4
MZ#:Y.<8@PTAWE=ULT.][Z=_$W1U*:0;ZN#\:'P;6: Y*F@,K33,T9H=3@!A'
M.QIO:;Z!Q&8+HSR$-LXY8'! A9 !'C8Y6WL^L_Q!J2MXLRYN=ORH,1P*15M
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M'/M:D&8#?L^$T,>).:#KE./_ %!+ P04    " ""@I55;EKN]0P#   7"0
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MU /??B"UG[[FBWDFS2_:UEC'0G$I%<_K8%"04U;]X^=Z'UH!;G @P*L#O/V
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MBRY_E8"@)7SH>?[0=X(]AZ^!P;#O]=Q>V.TQ:#P&1SW.:%9J<__597"JR]?
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MU4+P/1"%M8Y67)2Y*;TU&\J*U_B@A/Z6:C^U>L]YO*=) C"+P1U3F&WH4T+
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M+,S' )3=8-:74NKMQ#:H[O.2_@902P,$%     @ @H*55?$R+)-C P  J0X
M !D   !X;"]W;W)K<VAE971S+W-H965T-C4N>&ULM5=M3]LP$/XK5H8FD!AY
M:Y.6M95&&1H2DRH8VX=I'TQZ:2V2.-A."_]^YS2D21LRF,*7UD[NGCSW^&S?
MC=9<W,LE@"*/<93(L;%4*CTU31DL(:;RA*>0X)N0BY@JG(J%*5,!=)X[Q9'I
M6)9GQI0EQF24/YN)R8AG*F()S 2161Q3\70&$5^/#=MX?G#-%DNE'YB344H7
M< /J-IT)G)DERIS%D$C&$R(@'!M?[-.IW=,.N<5/!FM9&1,=RAWG]WIR.1\;
MEF8$$01*0U#\6\$4HD@C(8^' M0HOZD=J^-G](L\> SFCDJ8\N@7FZOEV!@8
M9 XAS2)US=??H BHK_$"'LG\EZP+6\L@0285CPMG9!"S9/-/'PLA*@X8:+.#
M4S@XKW5P"P<W#W3#+ _KG"HZ&0F^)D);(YH>Y-KDWA@-2_0RWBB!;QGZJ<E,
M8$8(]41H,B=?'S*6XAHI\HE,>9SR!,>2\)"D53,HS0[/05$6R2-TN+TY)X<'
M1^2 L(3\6/),HJT<F0I9ZF^90<'H;,/(>8'1.00GQ+6/B6,Y=H/[]/7N5MW=
M1&U*@9Q2("?'<_\AT#&9111#KNOT^PK-R:6"6/YI"G6#W6O&UEOT5*8T@+&!
M>U""6($Q^?C!]JS/38%W!%:3P2UE<-O0ZWE2)L Q60@N&Q=Y ]?/X?19LIKT
M+!_7<U6-:-_('O1[I5&-::]DVFME>@52GN+Q$&1Q%E$%<]S5*$C J#XWFJAN
M\+P*"]?U_1VJ^T:V[0R;J?9+JOW_$C4!U<2SOT?!&_9V:.[;^$Z_F:57LO3:
M!:5W7%#%Q=.68Q.]5I2WYGI'8+6 _3)@_QVWO-^E#!V!U608E#(,NMWR@[W<
M<SS'VTG0?2.__\(V&I9$AZU$+S*1,)4)R)F&[%&/Y3'>6R$+H')=Z=>2AVI-
M!30%T/J9MRY=1V U16QK>ZU;[YC#!7A'2G2%5I>B4N'8W>9Q@5<[ZZW![MW5
M8#6P7KB[[&VU8;?>XGA[84VZY-&<L!B+KA5HKLTL.ZTMND*KA[VM+FSW/=.U
MM79YLQ0=H=6EV)8O=GO]\O9T[>U54:ZW6Q<T&#E#>R=;S4H?H9NX[U0L6"))
M!"%Z62<^NHM-7[29*)[FK<4=5]BHY,,E]I(@M &^#SE7SQ/=K93=Z>0O4$L#
M!!0    ( (*"E57I-U8N80(  +L%   9    >&PO=V]R:W-H965T<R]S:&5E
M=#8V+GAM;*U436_;, S]*X)7#"W0Q5]I.F2)@7QTZ X=@F;=#L,.BLW$0F7)
ME>0D_?>C9,=+BB3;81=;I/B>^"B1@XU4SSH',&1;<*&'7FY,V?=]G>904-V1
M)0C<64I54(.F6OFZ5$ S!RJX'P5!SR\H$UXR<+Z92@:R,IP)F"FBJZ*@ZG4,
M7&Z&7NCM'(]LE1OK\)-!25<P!_-4SA1:?LN2L0*$9E(0!<NA-PK[DZZ-=P'?
M&6STWII8)0LIGZWQ)1MZ@4T(.*3&,E#\K6$"G%LB3..EX?3:(RUP?[UC_^RT
MHY8%U3"1_ ?+3#[T/GHD@R6MN'F4FWMH]-Q8OE1R[;YD4\?>!AY)*VUDT8 Q
M@X*)^D^W31WV &'O!"!J -%;0/<$(&X L1-:9^9D3:FAR4#)#5$V&MGLPM7&
MH5$-$_86YT;A+D.<268*'X0RKX2*C-R]5*S$*S+D _E*E:*VQ.1R"H8RKJ_0
M^S2?DLN+*W)!F"#?<EEIQ.F!;S 52^BGS;'C^MCHQ+%A1!ZD,+DF=R*#[)#
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M\7I0# 1-\PY[1H7LU_/+E7RE0DQ-D,\7E(JW@6K:JY>T\!]02P,$%     @
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M8'U@8"&649+5Y[TXEQ=K45RMHY14HNB,;\WTWJ9!0PDHC4)I#$KC)XZQ(91
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M^WF>5Z\OZ@J>\N)+L]O3_P%02P,$%     @ @H*556GI)_8# P  4P@  !D
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MXX.R&W!]+J79#JR#YC]$]@=02P,$%     @ @H*551+X#J4C P  G L  !D
M  !X;"]W;W)K<VAE971S+W-H965T-S<N>&ULQ59=;]HP%/TK5E9-K=0V'T"
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M)<?.48Y?( 5!8W-8-,0O#I-*4/VMK6)Y%.NM1U,3V([L;BF[^\Y5W*W3JIK
M=JQRG9>>P:FMC@NH[8O6[W1;>X5<$>4Z;GNOE.VM/B<!L3#MGT0*Z'_>!92K
M98LY-(W5WOI(MYZF?WJ!R?O6.RH6+)4DACE".I=MI"3R5C"?*)Z9;FK&%?9F
M9AAA^PQ"!^#[.>=J,]$;E WYX!]02P,$%     @ @H*556=74 ]O @  YP8
M !D   !X;"]W;W)K<VAE971S+W-H965T-S@N>&ULK57?;],P$/Y73@&A38+F
M1]L5C3;2E@K! U*U:?" >'"3:V/FQ,%VF^V_Y^RDH8,LC(F7Q&??]]U]9_L\
MKZ6ZU3FB@;M"E'KAY<94Y[ZOTQP+ID>RPI)6-E(5S)"IMKZN%++,@0KA1T%P
MYA>,EUX\=W,K%<_ES@A>XDJ!WA4%4_>7*&2]\$+O,''%M[FQ$WX\K]@6K]'<
M5"M%EM^Q9+S 4G-9@L+-PKL(SY.I]7<.GSG6^F@,5LE:REMK?,P67F 30H&I
ML0R,?GM,4 A+1&G\:#F]+J0%'H\/[.^==M*R9AH3*;[PS.0+[ZT'&6[83I@K
M67_ 5H]+,)5"NR_4C>\L\B#=:2.+%DP9%+QL_NRNK<,1()P\ HA:0/14P+@%
MC)W0)C,G:\D,B^=*UJ"L-['9@:N-0Y,:7MI=O#:*5CGA3)S(HN"&ML5H8&4&
MB2P-+[=8IAPUG"S1,"[T*;R!F^LEG+P\G?N&PEJPG[8A+IL0T2,AEIB.8!R^
MABB(PAYX\G1X\!#ND]A.<=0ICAS?^%F*EURG0NJ=0OAZL=9&T3G[UJ>Y"3+I
M#V+OWKFN6(H+CRZ71K5'+W[U(CP+WO55X#^1/:C'N*O'>(@]3EC%#1.0_JI+
MG]Z&9.I(;&O8Q[09^V,10QX/,IMTF4V&,Z.=L?7?_3V[R1^QPUDP.0N"WY,<
MC/C,2D\[/=-!/2M47&9 K1?JG*<YF!SI+G^7BIM[D!L2V2L8&)U&(V&-4#&>
M]>D?#AS"/3+5=_ &<?]:#O^H#=DGX!-36UYJ$+@A^F THVBJ::N-863E.M-:
M&NIS;IC32X3*.M#Z1DIS,&RSZ]ZV^"=02P,$%     @ @H*558>Z6W,G$0
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MU^773KQ?K*XXU_<5P_-?4$L#!!0    ( (*"E54L 6<[&P(   XN   3
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M_>Z+X^=G/;AN?,EG\]_ K_X 4$L! A0#%     @ @H*550=!36*!    L0
M !               ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4
M" ""@I55^*&N(>X    K @  $0              @ &O    9&]C4')O<',O
M8V]R92YX;6Q02P$"% ,4    " ""@I55F5R<(Q &  "<)P  $P
M    @ ', 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( (*"E573
MI*:?P@<  &TO   8              " @0T(  !X;"]W;W)K<VAE971S+W-H
M965T,2YX;6Q02P$"% ,4    " ""@I55T0H-YWH"  !B!P  &
M    @($%$   >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @
M@H*558K?/PQU!@  PQP  !@              ("!M1(  'AL+W=O<FMS:&5E
M=',O<VAE970S+GAM;%!+ 0(4 Q0    ( (*"E54[YQ9!GP(  &4'   8
M          " @6 9  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4
M    " ""@I55?^E_H!8%  !@%   &               @($U'   >&PO=V]R
M:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%     @ @H*557=[[)C-!@  6BP
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M965T,3 N>&UL4$L! A0#%     @ @H*556,#];K/!0  =0T  !D
M     ("!MD4  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4
M" ""@I55)/'7'?4G  !LA0  &0              @(&\2P  >&PO=V]R:W-H
M965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    ( (*"E56B_YU1'@<   04   9
M              " @>AS  !X;"]W;W)K<VAE971S+W-H965T,3,N>&UL4$L!
M A0#%     @ @H*558;C&2)S!   6 H  !D              ("!/7L  'AL
M+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4    " ""@I55;5A5D"\(
M  "'%P  &0              @('G?P  >&PO=V]R:W-H965T<R]S:&5E=#$U
M+GAM;%!+ 0(4 Q0    ( (*"E545=^N7+@D  #\6   9              "
M@4V(  !X;"]W;W)K<VAE971S+W-H965T,38N>&UL4$L! A0#%     @ @H*5
M5:$'YC>< @  Y@4  !D              ("!LI$  'AL+W=O<FMS:&5E=',O
M<VAE970Q-RYX;6Q02P$"% ,4    " ""@I556/YWG%$1  "',@  &0
M        @(&%E   >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0
M   ( (*"E57H5*5-@00  )@+   9              " @0VF  !X;"]W;W)K
M<VAE971S+W-H965T,3DN>&UL4$L! A0#%     @ @H*55=E1*O^-!P  'A,
M !D              ("!Q:H  'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q0
M2P$"% ,4    " ""@I5527CG>=0"  !T!@  &0              @(&)L@
M>&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    ( (*"E56TY9PN
MW ,  &\)   9              " @92U  !X;"]W;W)K<VAE971S+W-H965T
M,C(N>&UL4$L! A0#%     @ @H*55?/F96%&!   9 H  !D
M ("!I[D  'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"% ,4    " ""
M@I55LMM#O@D$  !#"0  &0              @($DO@  >&PO=V]R:W-H965T
M<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    ( (*"E56QRC5TYP<  %84   9
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M970R.2YX;6Q02P$"% ,4    " ""@I55I^/DYX@N  "*I@  &0
M    @(&+[@  >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    (
M (*"E54F0[M*O 4  "$.   9              " @4H= 0!X;"]W;W)K<VAE
M971S+W-H965T,S$N>&UL4$L! A0#%     @ @H*551 GGOB@ @  WP4  !D
M             ("!/2,! 'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q02P$"
M% ,4    " ""@I55WQIM :@#   O"@  &0              @($4)@$ >&PO
M=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    ( (*"E56^A><8P@(
M #X&   9              " @?,I 0!X;"]W;W)K<VAE971S+W-H965T,S0N
M>&UL4$L! A0#%     @ @H*55:.GRTZI @  Y 4  !D              ("!
M["P! 'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q02P$"% ,4    " ""@I55
M"TVF@N0$  #O#0  &0              @(',+P$ >&PO=V]R:W-H965T<R]S
M:&5E=#,V+GAM;%!+ 0(4 Q0    ( (*"E56PM\YHH@,  .H(   9
M      " @><T 0!X;"]W;W)K<VAE971S+W-H965T,S<N>&UL4$L! A0#%
M  @ @H*557Y(DG;C!   /PP  !D              ("!P#@! 'AL+W=O<FMS
M:&5E=',O<VAE970S."YX;6Q02P$"% ,4    " ""@I55I^[4J%X#  "1!P
M&0              @(':/0$ >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+
M 0(4 Q0    ( (*"E54..&L')P,  - '   9              " @6]! 0!X
M;"]W;W)K<VAE971S+W-H965T-# N>&UL4$L! A0#%     @ @H*55<=!SQO\
M!   ]@P  !D              ("!S40! 'AL+W=O<FMS:&5E=',O<VAE970T
M,2YX;6Q02P$"% ,4    " ""@I55Z\5>]X,'  "=2   &0
M@($ 2@$ >&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+ 0(4 Q0    ( (*"
ME54RP96*4P0  !X2   9              " @;I1 0!X;"]W;W)K<VAE971S
M+W-H965T-#,N>&UL4$L! A0#%     @ @H*55:8->_^^ P  W \  !D
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M=#0X+GAM;%!+ 0(4 Q0    ( (*"E56,=;'^U@(  *D*   9
M  " @;]E 0!X;"]W;W)K<VAE971S+W-H965T-#DN>&UL4$L! A0#%     @
M@H*55;KALC,; P  &0H  !D              ("!S&@! 'AL+W=O<FMS:&5E
M=',O<VAE970U,"YX;6Q02P$"% ,4    " ""@I55HHP,A_,$  "N'P  &0
M            @($>; $ >&PO=V]R:W-H965T<R]S:&5E=#4Q+GAM;%!+ 0(4
M Q0    ( (*"E54@@R_/>0,   L/   9              " @4AQ 0!X;"]W
M;W)K<VAE971S+W-H965T-3(N>&UL4$L! A0#%     @ @H*555N6OZ&/!0
M:B@  !D              ("!^'0! 'AL+W=O<FMS:&5E=',O<VAE970U,RYX
M;6Q02P$"% ,4    " ""@I551L6HI]P"   ]"   &0              @(&^
M>@$ >&PO=V]R:W-H965T<R]S:&5E=#4T+GAM;%!+ 0(4 Q0    ( (*"E57C
M"CL7J@(   @'   9              " @=%] 0!X;"]W;W)K<VAE971S+W-H
M965T-34N>&UL4$L! A0#%     @ @H*55=PF!A8- P  K@H  !D
M     ("!LH ! 'AL+W=O<FMS:&5E=',O<VAE970U-BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( (*"E57"XY."S ,  - 2   9              "
M@6J3 0!X;"]W;W)K<VAE971S+W-H965T-C$N>&UL4$L! A0#%     @ @H*5
M5=,<M#1X P   @P  !D              ("!;9<! 'AL+W=O<FMS:&5E=',O
M<VAE970V,BYX;6Q02P$"% ,4    " ""@I550.QDW:P$  #&&   &0
M        @($<FP$ >&PO=V]R:W-H965T<R]S:&5E=#8S+GAM;%!+ 0(4 Q0
M   ( (*"E56"PO8$9P(  &H&   9              " @?^? 0!X;"]W;W)K
M<VAE971S+W-H965T-C0N>&UL4$L! A0#%     @ @H*55?$R+)-C P  J0X
M !D              ("!G:(! 'AL+W=O<FMS:&5E=',O<VAE970V-2YX;6Q0
M2P$"% ,4    " ""@I55Z3=6+F$"  "[!0  &0              @($WI@$
M>&PO=V]R:W-H965T<R]S:&5E=#8V+GAM;%!+ 0(4 Q0    ( (*"E56V)T64
MA@(  "T&   9              " @<^H 0!X;"]W;W)K<VAE971S+W-H965T
M-C<N>&UL4$L! A0#%     @ @H*55;*L1SO& P  ? \  !D
M ("!C*L! 'AL+W=O<FMS:&5E=',O<VAE970V."YX;6Q02P$"% ,4    " ""
M@I55$M>?#J "  !E!P  &0              @(&)KP$ >&PO=V]R:W-H965T
M<R]S:&5E=#8Y+GAM;%!+ 0(4 Q0    ( (*"E56@%H7M/@,  + -   9
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M970W-"YX;6Q02P$"% ,4    " ""@I55;&I8.($%  !;(   &0
M    @($!TP$ >&PO=V]R:W-H965T<R]S:&5E=#<U+GAM;%!+ 0(4 Q0    (
M (*"E57U R-RRP(  $\(   9              " @;G8 0!X;"]W;W)K<VAE
M971S+W-H965T-S8N>&UL4$L! A0#%     @ @H*551+X#J4C P  G L  !D
M             ("!N]L! 'AL+W=O<FMS:&5E=',O<VAE970W-RYX;6Q02P$"
M% ,4    " ""@I559U=0#V\"  #G!@  &0              @($5WP$ >&PO
M=V]R:W-H965T<R]S:&5E=#<X+GAM;%!+ 0(4 Q0    ( (*"E56'NEMS)Q$
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M<F5L<R\N<F5L<U!+ 0(4 Q0    ( (*"E54*";U$/@8  +4T   /
M      "  1S[ 0!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " ""@I55M,4*
MKF@"  !'+P  &@              @ &' 0( >&PO7W)E;',O=V]R:V)O;VLN
M>&UL+G)E;'-02P$"% ,4    " ""@I55+ %G.QL"   .+@  $P
M    @ $G! ( 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     6 !8 !\8  !S
%!@(    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>155</ContextCount>
  <ElementCount>368</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>61</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>11</UnitCount>
  <MyReports>
    <Report instance="smmt-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.summitplc.com/role/DocumentandEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="smmt-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.summitplc.com/role/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="smmt-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.summitplc.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="smmt-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.summitplc.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="smmt-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.summitplc.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="smmt-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - Consolidated Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.summitplc.com/role/ConsolidatedStatementsofStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="smmt-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Statement - Consolidated Statements of Stockholders' Equity (Deficit) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.summitplc.com/role/ConsolidatedStatementsofStockholdersEquityDeficitParenthetical</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity (Deficit) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="smmt-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="smmt-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Disclosure - Nature of Business and Operations and Recent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.summitplc.com/role/NatureofBusinessandOperationsandRecentEvents</Role>
      <ShortName>Nature of Business and Operations and Recent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="smmt-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - Basis of Presentation and Use of Estimates</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.summitplc.com/role/BasisofPresentationandUseofEstimates</Role>
      <ShortName>Basis of Presentation and Use of Estimates</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="smmt-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - Liquidity and Capital Resources</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.summitplc.com/role/LiquidityandCapitalResources</Role>
      <ShortName>Liquidity and Capital Resources</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="smmt-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.summitplc.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="smmt-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - Recently Issued or Adopted Accounting Pronouncements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.summitplc.com/role/RecentlyIssuedorAdoptedAccountingPronouncements</Role>
      <ShortName>Recently Issued or Adopted Accounting Pronouncements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="smmt-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - Segment Reporting</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.summitplc.com/role/SegmentReporting</Role>
      <ShortName>Segment Reporting</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="smmt-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - Revenue</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.summitplc.com/role/Revenue</Role>
      <ShortName>Revenue</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="smmt-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - Other Operating Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.summitplc.com/role/OtherOperatingIncome</Role>
      <ShortName>Other Operating Income</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="smmt-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - Other (Expense) Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.summitplc.com/role/OtherExpenseIncome</Role>
      <ShortName>Other (Expense) Income</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="smmt-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - Income Tax</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.summitplc.com/role/IncomeTax</Role>
      <ShortName>Income Tax</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="smmt-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - Loss per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.summitplc.com/role/LossperShare</Role>
      <ShortName>Loss per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="smmt-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - Goodwill and Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.summitplc.com/role/GoodwillandIntangibleAssets</Role>
      <ShortName>Goodwill and Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="smmt-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0000021 - Disclosure - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.summitplc.com/role/PropertyandEquipment</Role>
      <ShortName>Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="smmt-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0000022 - Disclosure - Research and Development Prepaid Expenses and Accrued Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.summitplc.com/role/ResearchandDevelopmentPrepaidExpensesandAccruedLiabilities</Role>
      <ShortName>Research and Development Prepaid Expenses and Accrued Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="smmt-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0000023 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.summitplc.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="smmt-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0000024 - Disclosure - Other Non-Current Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.summitplc.com/role/OtherNonCurrentLiabilities</Role>
      <ShortName>Other Non-Current Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="smmt-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0000025 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.summitplc.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="smmt-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0000026 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.summitplc.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="smmt-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0000027 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.summitplc.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="smmt-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>0000028 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.summitplc.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="smmt-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>0000029 - Disclosure - Subsequent Event</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.summitplc.com/role/SubsequentEvent</Role>
      <ShortName>Subsequent Event</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="smmt-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>0000030 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.summitplc.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.summitplc.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="smmt-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>0000031 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.summitplc.com/role/SummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.summitplc.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="smmt-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>0000032 - Disclosure - Segment Reporting (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.summitplc.com/role/SegmentReportingTables</Role>
      <ShortName>Segment Reporting (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.summitplc.com/role/SegmentReporting</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="smmt-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>0000033 - Disclosure - Revenue (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.summitplc.com/role/RevenueTables</Role>
      <ShortName>Revenue (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.summitplc.com/role/Revenue</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="smmt-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>0000034 - Disclosure - Other Operating Income (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.summitplc.com/role/OtherOperatingIncomeTables</Role>
      <ShortName>Other Operating Income (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.summitplc.com/role/OtherOperatingIncome</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="smmt-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>0000035 - Disclosure - Other (Expense) Income (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.summitplc.com/role/OtherExpenseIncomeTables</Role>
      <ShortName>Other (Expense) Income (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.summitplc.com/role/OtherOperatingIncome</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="smmt-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>0000036 - Disclosure - Income Tax (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.summitplc.com/role/IncomeTaxTables</Role>
      <ShortName>Income Tax (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.summitplc.com/role/IncomeTax</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="smmt-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>0000037 - Disclosure - Loss per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.summitplc.com/role/LossperShareTables</Role>
      <ShortName>Loss per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.summitplc.com/role/LossperShare</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="smmt-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>0000038 - Disclosure - Goodwill and Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.summitplc.com/role/GoodwillandIntangibleAssetsTables</Role>
      <ShortName>Goodwill and Intangible Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.summitplc.com/role/GoodwillandIntangibleAssets</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="smmt-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>0000039 - Disclosure - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.summitplc.com/role/PropertyandEquipmentTables</Role>
      <ShortName>Property and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.summitplc.com/role/PropertyandEquipment</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="smmt-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>0000040 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.summitplc.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.summitplc.com/role/Leases</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="smmt-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>0000041 - Disclosure - Stock Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.summitplc.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="smmt-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>0000042 - Disclosure - Nature of Business and Operations and Recent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.summitplc.com/role/NatureofBusinessandOperationsandRecentEventsDetails</Role>
      <ShortName>Nature of Business and Operations and Recent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.summitplc.com/role/NatureofBusinessandOperationsandRecentEvents</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="smmt-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>0000043 - Disclosure - Liquidity and Capital Resources (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.summitplc.com/role/LiquidityandCapitalResourcesDetails</Role>
      <ShortName>Liquidity and Capital Resources (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.summitplc.com/role/LiquidityandCapitalResources</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="smmt-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>0000044 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.summitplc.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="smmt-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>0000045 - Disclosure - Summary of Significant Accounting Policies - Property and equipment useful lives (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.summitplc.com/role/SummaryofSignificantAccountingPoliciesPropertyandequipmentusefullivesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Property and equipment useful lives (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="smmt-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>0000046 - Disclosure - Segment Reporting - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.summitplc.com/role/SegmentReportingNarrativeDetails</Role>
      <ShortName>Segment Reporting - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="smmt-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>0000047 - Disclosure - Segment Reporting - Long-lived assets by geography (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.summitplc.com/role/SegmentReportingLonglivedassetsbygeographyDetails</Role>
      <ShortName>Segment Reporting - Long-lived assets by geography (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="smmt-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>0000048 - Disclosure - Revenue - Revenue by category (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.summitplc.com/role/RevenueRevenuebycategoryDetails</Role>
      <ShortName>Revenue - Revenue by category (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="smmt-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>0000049 - Disclosure - Revenue - Revenue by geography (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.summitplc.com/role/RevenueRevenuebygeographyDetails</Role>
      <ShortName>Revenue - Revenue by geography (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="smmt-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>0000050 - Disclosure - Revenue - Deferred revenue and other income (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.summitplc.com/role/RevenueDeferredrevenueandotherincomeDetails</Role>
      <ShortName>Revenue - Deferred revenue and other income (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="smmt-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>0000051 - Disclosure - Revenue - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.summitplc.com/role/RevenueNarrativeDetails</Role>
      <ShortName>Revenue - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="smmt-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>0000052 - Disclosure - Other Operating Income - Other operating income by category (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.summitplc.com/role/OtherOperatingIncomeOtheroperatingincomebycategoryDetails</Role>
      <ShortName>Other Operating Income - Other operating income by category (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="smmt-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>0000053 - Disclosure - Other Operating Income - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.summitplc.com/role/OtherOperatingIncomeNarrativeDetails</Role>
      <ShortName>Other Operating Income - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="smmt-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>0000054 - Disclosure - Other (Expense) Income (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.summitplc.com/role/OtherExpenseIncomeDetails</Role>
      <ShortName>Other (Expense) Income (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.summitplc.com/role/OtherOperatingIncomeTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="smmt-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>0000055 - Disclosure - Income Tax - Components of loss before income taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.summitplc.com/role/IncomeTaxComponentsoflossbeforeincometaxesDetails</Role>
      <ShortName>Income Tax - Components of loss before income taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="smmt-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>0000056 - Disclosure - Income Tax - Significant components of the provision for income taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.summitplc.com/role/IncomeTaxSignificantcomponentsoftheprovisionforincometaxesDetails</Role>
      <ShortName>Income Tax - Significant components of the provision for income taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="smmt-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>0000057 - Disclosure - Income Tax - Major components of deferred tax assets and liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.summitplc.com/role/IncomeTaxMajorcomponentsofdeferredtaxassetsandliabilitiesDetails</Role>
      <ShortName>Income Tax - Major components of deferred tax assets and liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="smmt-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>0000058 - Disclosure - Income Tax - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.summitplc.com/role/IncomeTaxNarrativeDetails</Role>
      <ShortName>Income Tax - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="smmt-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>0000059 - Disclosure - Income Tax - Reconciliation of the effective income tax rate to statutory rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.summitplc.com/role/IncomeTaxReconciliationoftheeffectiveincometaxratetostatutoryrateDetails</Role>
      <ShortName>Income Tax - Reconciliation of the effective income tax rate to statutory rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="smmt-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>0000060 - Disclosure - Loss per Share - Computation of net loss per share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.summitplc.com/role/LossperShareComputationofnetlosspershareDetails</Role>
      <ShortName>Loss per Share - Computation of net loss per share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="smmt-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>0000061 - Disclosure - Loss per Share - Potentially dilutive securities excluded from the computation of loss per share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.summitplc.com/role/LossperSharePotentiallydilutivesecuritiesexcludedfromthecomputationoflosspershareDetails</Role>
      <ShortName>Loss per Share - Potentially dilutive securities excluded from the computation of loss per share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="smmt-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>0000062 - Disclosure - Goodwill and Intangible Assets - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.summitplc.com/role/GoodwillandIntangibleAssetsNarrativeDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="smmt-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>0000063 - Disclosure - Goodwill and Intangible Assets - Schedule of acquired intangible assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.summitplc.com/role/GoodwillandIntangibleAssetsScheduleofacquiredintangibleassetsDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Schedule of acquired intangible assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="smmt-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>0000064 - Disclosure - Goodwill and Intangible Assets - Estimated amortization expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.summitplc.com/role/GoodwillandIntangibleAssetsEstimatedamortizationexpenseDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Estimated amortization expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="smmt-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>0000065 - Disclosure - Property and Equipment - Components of property and equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.summitplc.com/role/PropertyandEquipmentComponentsofpropertyandequipmentDetails</Role>
      <ShortName>Property and Equipment - Components of property and equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="smmt-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>0000066 - Disclosure - Property and Equipment - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.summitplc.com/role/PropertyandEquipmentNarrativeDetails</Role>
      <ShortName>Property and Equipment - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="smmt-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>0000067 - Disclosure - Research and Development Prepaid Expenses and Accrued Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.summitplc.com/role/ResearchandDevelopmentPrepaidExpensesandAccruedLiabilitiesDetails</Role>
      <ShortName>Research and Development Prepaid Expenses and Accrued Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.summitplc.com/role/ResearchandDevelopmentPrepaidExpensesandAccruedLiabilities</ParentRole>
      <Position>67</Position>
    </Report>
    <Report instance="smmt-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>0000068 - Disclosure - Leases - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.summitplc.com/role/LeasesNarrativeDetails</Role>
      <ShortName>Leases - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="smmt-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>0000069 - Disclosure - Leases - Lease expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.summitplc.com/role/LeasesLeaseexpenseDetails</Role>
      <ShortName>Leases - Lease expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="smmt-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>0000070 - Disclosure - Leases - Future lease payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.summitplc.com/role/LeasesFutureleasepaymentsDetails</Role>
      <ShortName>Leases - Future lease payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="smmt-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>0000071 - Disclosure - Other Non-Current Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.summitplc.com/role/OtherNonCurrentLiabilitiesDetails</Role>
      <ShortName>Other Non-Current Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.summitplc.com/role/OtherNonCurrentLiabilities</ParentRole>
      <Position>71</Position>
    </Report>
    <Report instance="smmt-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>0000072 - Disclosure - Stockholders' Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.summitplc.com/role/StockholdersEquityDetails</Role>
      <ShortName>Stockholders' Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.summitplc.com/role/StockholdersEquity</ParentRole>
      <Position>72</Position>
    </Report>
    <Report instance="smmt-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>0000073 - Disclosure - Stock Based Compensation - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.summitplc.com/role/StockBasedCompensationNarrativeDetails</Role>
      <ShortName>Stock Based Compensation - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="smmt-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>0000074 - Disclosure - Stock Based Compensation - Weighted-average assumptions used for stock option awards (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.summitplc.com/role/StockBasedCompensationWeightedaverageassumptionsusedforstockoptionawardsDetails</Role>
      <ShortName>Stock Based Compensation - Weighted-average assumptions used for stock option awards (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="smmt-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>0000075 - Disclosure - Stock Based Compensation - Stock option activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.summitplc.com/role/StockBasedCompensationStockoptionactivityDetails</Role>
      <ShortName>Stock Based Compensation - Stock option activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="smmt-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>0000076 - Disclosure - Stock-Based Compensation - RSU activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.summitplc.com/role/StockBasedCompensationRSUactivityDetails</Role>
      <ShortName>Stock-Based Compensation - RSU activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="smmt-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>0000077 - Disclosure - Stock-Based Compensation - Summary of stock-based compensation expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.summitplc.com/role/StockBasedCompensationSummaryofstockbasedcompensationexpenseDetails</Role>
      <ShortName>Stock-Based Compensation - Summary of stock-based compensation expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="smmt-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>0000078 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.summitplc.com/role/CommitmentsandContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.summitplc.com/role/CommitmentsandContingencies</ParentRole>
      <Position>78</Position>
    </Report>
    <Report instance="smmt-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>0000079 - Disclosure - Related Party Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.summitplc.com/role/RelatedPartyTransactionsDetails</Role>
      <ShortName>Related Party Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.summitplc.com/role/RelatedPartyTransactions</ParentRole>
      <Position>79</Position>
    </Report>
    <Report instance="smmt-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>0000080 - Disclosure - Subsequent Event (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.summitplc.com/role/SubsequentEventDetails</Role>
      <ShortName>Subsequent Event (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.summitplc.com/role/SubsequentEvent</ParentRole>
      <Position>80</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 3 fact(s) appearing in ix:hidden were eligible for transformation: us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1, us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 -  smmt-20211231.htm 4</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-K/A" original="smmt-20211231.htm">smmt-20211231.htm</File>
    <File>smmt-20211231.xsd</File>
    <File>smmt-20211231_cal.xml</File>
    <File>smmt-20211231_def.xml</File>
    <File>smmt-20211231_lab.xml</File>
    <File>smmt-20211231_pre.xml</File>
    <File>sum-ex231_20211231x10xkaxu.htm</File>
    <File>sum-ex232_20211231x10xkaxu.htm</File>
    <File>sum-ex311_20211231x10xka.htm</File>
    <File>sum-ex312_20211231x10xka.htm</File>
    <File>sum-ex313_20211231x10xka.htm</File>
    <File>sum-ex321_20211231x10xka.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="630">http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="40">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>100
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "smmt-20211231.htm": {
   "axisCustom": 0,
   "axisStandard": 21,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2021-01-31": 630,
    "http://xbrl.sec.gov/dei/2021q4": 40
   },
   "contextCount": 155,
   "dts": {
    "calculationLink": {
     "local": [
      "smmt-20211231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "smmt-20211231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "smmt-20211231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "smmt-20211231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "smmt-20211231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "smmt-20211231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"
     ]
    }
   },
   "elementCount": 550,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2021-01-31": 3,
    "http://xbrl.sec.gov/dei/2021q4": 4,
    "total": 7
   },
   "keyCustom": 59,
   "keyStandard": 309,
   "memberCustom": 24,
   "memberStandard": 33,
   "nsprefix": "smmt",
   "nsuri": "http://www.summitplc.com/20211231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "smmt-20211231.htm",
      "contextRef": "i0f6242234d28477e9478c049c2986ce6_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Document and Entity Information",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.summitplc.com/role/DocumentandEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "smmt-20211231.htm",
      "contextRef": "i0f6242234d28477e9478c049c2986ce6_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "smmt-20211231.htm",
      "contextRef": "i0f6242234d28477e9478c049c2986ce6_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccounting",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000010 - Disclosure - Basis of Presentation and Use of Estimates",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://www.summitplc.com/role/BasisofPresentationandUseofEstimates",
     "shortName": "Basis of Presentation and Use of Estimates",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "smmt-20211231.htm",
      "contextRef": "i0f6242234d28477e9478c049c2986ce6_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccounting",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "smmt-20211231.htm",
      "contextRef": "i0f6242234d28477e9478c049c2986ce6_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "smmt:LiquidityAndCapitalResourcesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000011 - Disclosure - Liquidity and Capital Resources",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://www.summitplc.com/role/LiquidityandCapitalResources",
     "shortName": "Liquidity and Capital Resources",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "smmt-20211231.htm",
      "contextRef": "i0f6242234d28477e9478c049c2986ce6_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "smmt:LiquidityAndCapitalResourcesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "smmt-20211231.htm",
      "contextRef": "i0f6242234d28477e9478c049c2986ce6_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000012 - Disclosure - Summary of Significant Accounting Policies",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://www.summitplc.com/role/SummaryofSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "smmt-20211231.htm",
      "contextRef": "i0f6242234d28477e9478c049c2986ce6_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "smmt-20211231.htm",
      "contextRef": "i0f6242234d28477e9478c049c2986ce6_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000013 - Disclosure - Recently Issued or Adopted Accounting Pronouncements",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://www.summitplc.com/role/RecentlyIssuedorAdoptedAccountingPronouncements",
     "shortName": "Recently Issued or Adopted Accounting Pronouncements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "smmt-20211231.htm",
      "contextRef": "i0f6242234d28477e9478c049c2986ce6_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "smmt-20211231.htm",
      "contextRef": "i0f6242234d28477e9478c049c2986ce6_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000014 - Disclosure - Segment Reporting",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://www.summitplc.com/role/SegmentReporting",
     "shortName": "Segment Reporting",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "smmt-20211231.htm",
      "contextRef": "i0f6242234d28477e9478c049c2986ce6_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "smmt-20211231.htm",
      "contextRef": "i0f6242234d28477e9478c049c2986ce6_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000015 - Disclosure - Revenue",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://www.summitplc.com/role/Revenue",
     "shortName": "Revenue",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "smmt-20211231.htm",
      "contextRef": "i0f6242234d28477e9478c049c2986ce6_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "smmt-20211231.htm",
      "contextRef": "i0f6242234d28477e9478c049c2986ce6_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherOperatingIncomeAndExpenseTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000016 - Disclosure - Other Operating Income",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://www.summitplc.com/role/OtherOperatingIncome",
     "shortName": "Other Operating Income",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "smmt-20211231.htm",
      "contextRef": "i0f6242234d28477e9478c049c2986ce6_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherOperatingIncomeAndExpenseTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "smmt-20211231.htm",
      "contextRef": "i0f6242234d28477e9478c049c2986ce6_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000017 - Disclosure - Other (Expense) Income",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://www.summitplc.com/role/OtherExpenseIncome",
     "shortName": "Other (Expense) Income",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "smmt-20211231.htm",
      "contextRef": "i0f6242234d28477e9478c049c2986ce6_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "smmt-20211231.htm",
      "contextRef": "i0f6242234d28477e9478c049c2986ce6_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000018 - Disclosure - Income Tax",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://www.summitplc.com/role/IncomeTax",
     "shortName": "Income Tax",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "smmt-20211231.htm",
      "contextRef": "i0f6242234d28477e9478c049c2986ce6_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "smmt-20211231.htm",
      "contextRef": "i0f6242234d28477e9478c049c2986ce6_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000019 - Disclosure - Loss per Share",
     "menuCat": "Notes",
     "order": "19",
     "role": "http://www.summitplc.com/role/LossperShare",
     "shortName": "Loss per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "smmt-20211231.htm",
      "contextRef": "i0f6242234d28477e9478c049c2986ce6_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "smmt-20211231.htm",
      "contextRef": "i0f6242234d28477e9478c049c2986ce6_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorFirmId",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "false",
     "longName": "0000002 - Document - Audit Information",
     "menuCat": "Cover",
     "order": "2",
     "role": "http://www.summitplc.com/role/AuditInformation",
     "shortName": "Audit Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "smmt-20211231.htm",
      "contextRef": "i0f6242234d28477e9478c049c2986ce6_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorFirmId",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "smmt-20211231.htm",
      "contextRef": "i0f6242234d28477e9478c049c2986ce6_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000020 - Disclosure - Goodwill and Intangible Assets",
     "menuCat": "Notes",
     "order": "20",
     "role": "http://www.summitplc.com/role/GoodwillandIntangibleAssets",
     "shortName": "Goodwill and Intangible Assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "smmt-20211231.htm",
      "contextRef": "i0f6242234d28477e9478c049c2986ce6_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "smmt-20211231.htm",
      "contextRef": "i0f6242234d28477e9478c049c2986ce6_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000021 - Disclosure - Property and Equipment",
     "menuCat": "Notes",
     "order": "21",
     "role": "http://www.summitplc.com/role/PropertyandEquipment",
     "shortName": "Property and Equipment",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "smmt-20211231.htm",
      "contextRef": "i0f6242234d28477e9478c049c2986ce6_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "smmt-20211231.htm",
      "contextRef": "i0f6242234d28477e9478c049c2986ce6_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000022 - Disclosure - Research and Development Prepaid Expenses and Accrued Liabilities",
     "menuCat": "Notes",
     "order": "22",
     "role": "http://www.summitplc.com/role/ResearchandDevelopmentPrepaidExpensesandAccruedLiabilities",
     "shortName": "Research and Development Prepaid Expenses and Accrued Liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "smmt-20211231.htm",
      "contextRef": "i0f6242234d28477e9478c049c2986ce6_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "smmt-20211231.htm",
      "contextRef": "i0f6242234d28477e9478c049c2986ce6_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000023 - Disclosure - Leases",
     "menuCat": "Notes",
     "order": "23",
     "role": "http://www.summitplc.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "smmt-20211231.htm",
      "contextRef": "i0f6242234d28477e9478c049c2986ce6_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "smmt-20211231.htm",
      "contextRef": "i0f6242234d28477e9478c049c2986ce6_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureNoncurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000024 - Disclosure - Other Non-Current Liabilities",
     "menuCat": "Notes",
     "order": "24",
     "role": "http://www.summitplc.com/role/OtherNonCurrentLiabilities",
     "shortName": "Other Non-Current Liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "smmt-20211231.htm",
      "contextRef": "i0f6242234d28477e9478c049c2986ce6_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureNoncurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "smmt-20211231.htm",
      "contextRef": "i0f6242234d28477e9478c049c2986ce6_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000025 - Disclosure - Stockholders' Equity",
     "menuCat": "Notes",
     "order": "25",
     "role": "http://www.summitplc.com/role/StockholdersEquity",
     "shortName": "Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "smmt-20211231.htm",
      "contextRef": "i0f6242234d28477e9478c049c2986ce6_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "smmt-20211231.htm",
      "contextRef": "i0f6242234d28477e9478c049c2986ce6_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000026 - Disclosure - Stock-Based Compensation",
     "menuCat": "Notes",
     "order": "26",
     "role": "http://www.summitplc.com/role/StockBasedCompensation",
     "shortName": "Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "smmt-20211231.htm",
      "contextRef": "i0f6242234d28477e9478c049c2986ce6_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "smmt-20211231.htm",
      "contextRef": "i0f6242234d28477e9478c049c2986ce6_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000027 - Disclosure - Commitments and Contingencies",
     "menuCat": "Notes",
     "order": "27",
     "role": "http://www.summitplc.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "smmt-20211231.htm",
      "contextRef": "i0f6242234d28477e9478c049c2986ce6_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "smmt-20211231.htm",
      "contextRef": "i0f6242234d28477e9478c049c2986ce6_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000028 - Disclosure - Related Party Transactions",
     "menuCat": "Notes",
     "order": "28",
     "role": "http://www.summitplc.com/role/RelatedPartyTransactions",
     "shortName": "Related Party Transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "smmt-20211231.htm",
      "contextRef": "i0f6242234d28477e9478c049c2986ce6_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "smmt-20211231.htm",
      "contextRef": "i0f6242234d28477e9478c049c2986ce6_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000029 - Disclosure - Subsequent Event",
     "menuCat": "Notes",
     "order": "29",
     "role": "http://www.summitplc.com/role/SubsequentEvent",
     "shortName": "Subsequent Event",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "smmt-20211231.htm",
      "contextRef": "i0f6242234d28477e9478c049c2986ce6_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "smmt-20211231.htm",
      "contextRef": "i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Cash",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000003 - Statement - Consolidated Balance Sheets",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://www.summitplc.com/role/ConsolidatedBalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "smmt-20211231.htm",
      "contextRef": "i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:PrepaidExpenseCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "smmt-20211231.htm",
      "contextRef": "i0f6242234d28477e9478c049c2986ce6_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000030 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "menuCat": "Policies",
     "order": "30",
     "role": "http://www.summitplc.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "smmt-20211231.htm",
      "contextRef": "i0f6242234d28477e9478c049c2986ce6_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "smmt-20211231.htm",
      "contextRef": "i0f6242234d28477e9478c049c2986ce6_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000031 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "menuCat": "Tables",
     "order": "31",
     "role": "http://www.summitplc.com/role/SummaryofSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": null
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "smmt-20211231.htm",
      "contextRef": "i0f6242234d28477e9478c049c2986ce6_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000032 - Disclosure - Segment Reporting (Tables)",
     "menuCat": "Tables",
     "order": "32",
     "role": "http://www.summitplc.com/role/SegmentReportingTables",
     "shortName": "Segment Reporting (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "smmt-20211231.htm",
      "contextRef": "i0f6242234d28477e9478c049c2986ce6_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "smmt-20211231.htm",
      "contextRef": "i0f6242234d28477e9478c049c2986ce6_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000033 - Disclosure - Revenue (Tables)",
     "menuCat": "Tables",
     "order": "33",
     "role": "http://www.summitplc.com/role/RevenueTables",
     "shortName": "Revenue (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "smmt-20211231.htm",
      "contextRef": "i0f6242234d28477e9478c049c2986ce6_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "smmt-20211231.htm",
      "contextRef": "i0f6242234d28477e9478c049c2986ce6_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "smmt:ScheduleOfOtherOperatingIncomeByComponentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000034 - Disclosure - Other Operating Income (Tables)",
     "menuCat": "Tables",
     "order": "34",
     "role": "http://www.summitplc.com/role/OtherOperatingIncomeTables",
     "shortName": "Other Operating Income (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "smmt-20211231.htm",
      "contextRef": "i0f6242234d28477e9478c049c2986ce6_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "smmt:ScheduleOfOtherOperatingIncomeByComponentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "smmt-20211231.htm",
      "contextRef": "i0f6242234d28477e9478c049c2986ce6_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000035 - Disclosure - Other (Expense) Income (Tables)",
     "menuCat": "Tables",
     "order": "35",
     "role": "http://www.summitplc.com/role/OtherExpenseIncomeTables",
     "shortName": "Other (Expense) Income (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "smmt-20211231.htm",
      "contextRef": "i0f6242234d28477e9478c049c2986ce6_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "smmt-20211231.htm",
      "contextRef": "i0f6242234d28477e9478c049c2986ce6_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000036 - Disclosure - Income Tax (Tables)",
     "menuCat": "Tables",
     "order": "36",
     "role": "http://www.summitplc.com/role/IncomeTaxTables",
     "shortName": "Income Tax (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "smmt-20211231.htm",
      "contextRef": "i0f6242234d28477e9478c049c2986ce6_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "smmt-20211231.htm",
      "contextRef": "i0f6242234d28477e9478c049c2986ce6_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000037 - Disclosure - Loss per Share (Tables)",
     "menuCat": "Tables",
     "order": "37",
     "role": "http://www.summitplc.com/role/LossperShareTables",
     "shortName": "Loss per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "smmt-20211231.htm",
      "contextRef": "i0f6242234d28477e9478c049c2986ce6_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "smmt-20211231.htm",
      "contextRef": "i0f6242234d28477e9478c049c2986ce6_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000038 - Disclosure - Goodwill and Intangible Assets (Tables)",
     "menuCat": "Tables",
     "order": "38",
     "role": "http://www.summitplc.com/role/GoodwillandIntangibleAssetsTables",
     "shortName": "Goodwill and Intangible Assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "smmt-20211231.htm",
      "contextRef": "i0f6242234d28477e9478c049c2986ce6_D20210101-20211231",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "smmt-20211231.htm",
      "contextRef": "i0f6242234d28477e9478c049c2986ce6_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000039 - Disclosure - Property and Equipment (Tables)",
     "menuCat": "Tables",
     "order": "39",
     "role": "http://www.summitplc.com/role/PropertyandEquipmentTables",
     "shortName": "Property and Equipment (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": null
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "smmt-20211231.htm",
      "contextRef": "i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000004 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://www.summitplc.com/role/ConsolidatedBalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "smmt-20211231.htm",
      "contextRef": "i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "smmt-20211231.htm",
      "contextRef": "i0f6242234d28477e9478c049c2986ce6_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000040 - Disclosure - Leases (Tables)",
     "menuCat": "Tables",
     "order": "40",
     "role": "http://www.summitplc.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "smmt-20211231.htm",
      "contextRef": "i0f6242234d28477e9478c049c2986ce6_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "smmt-20211231.htm",
      "contextRef": "i0f6242234d28477e9478c049c2986ce6_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000041 - Disclosure - Stock Based Compensation (Tables)",
     "menuCat": "Tables",
     "order": "41",
     "role": "http://www.summitplc.com/role/StockBasedCompensationTables",
     "shortName": "Stock Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "smmt-20211231.htm",
      "contextRef": "i0f6242234d28477e9478c049c2986ce6_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "smmt-20211231.htm",
      "contextRef": "i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000042 - Disclosure - Nature of Business and Operations and Recent Events (Details)",
     "menuCat": "Details",
     "order": "42",
     "role": "http://www.summitplc.com/role/NatureofBusinessandOperationsandRecentEventsDetails",
     "shortName": "Nature of Business and Operations and Recent Events (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "smmt-20211231.htm",
      "contextRef": "i9e4481b351c140ec829740b8f3c87fca_I20210511",
      "decimals": "2",
      "lang": "en-US",
      "name": "smmt:RelatedPartyTransactionBeneficialOwnershipPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "smmt-20211231.htm",
      "contextRef": "i0f6242234d28477e9478c049c2986ce6_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000043 - Disclosure - Liquidity and Capital Resources (Details)",
     "menuCat": "Details",
     "order": "43",
     "role": "http://www.summitplc.com/role/LiquidityandCapitalResourcesDetails",
     "shortName": "Liquidity and Capital Resources (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "smmt-20211231.htm",
      "contextRef": "i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "smmt:ResearchAndDevelopmentTaxCreditReceivable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "smmt-20211231.htm",
      "contextRef": "i0f6242234d28477e9478c049c2986ce6_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ForeignCurrencyTransactionGainLossBeforeTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000044 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)",
     "menuCat": "Details",
     "order": "44",
     "role": "http://www.summitplc.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
     "shortName": "Summary of Significant Accounting Policies - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "smmt:OtherOperatingIncomePolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "smmt-20211231.htm",
      "contextRef": "i0f6242234d28477e9478c049c2986ce6_D20210101-20211231",
      "decimals": "3",
      "lang": "en-US",
      "name": "smmt:ResearchAndDevelopmentTaxCreditCashRebateMaximumPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "smmt-20211231.htm",
      "contextRef": "if7798276e33b48af81058807002f7542_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000045 - Disclosure - Summary of Significant Accounting Policies - Property and equipment useful lives (Details)",
     "menuCat": "Details",
     "order": "45",
     "role": "http://www.summitplc.com/role/SummaryofSignificantAccountingPoliciesPropertyandequipmentusefullivesDetails",
     "shortName": "Summary of Significant Accounting Policies - Property and equipment useful lives (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "smmt-20211231.htm",
      "contextRef": "if7798276e33b48af81058807002f7542_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "smmt-20211231.htm",
      "contextRef": "i0f6242234d28477e9478c049c2986ce6_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000046 - Disclosure - Segment Reporting - Narrative (Details)",
     "menuCat": "Details",
     "order": "46",
     "role": "http://www.summitplc.com/role/SegmentReportingNarrativeDetails",
     "shortName": "Segment Reporting - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "smmt-20211231.htm",
      "contextRef": "i0f6242234d28477e9478c049c2986ce6_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "smmt-20211231.htm",
      "contextRef": "i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NoncurrentAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000047 - Disclosure - Segment Reporting - Long-lived assets by geography (Details)",
     "menuCat": "Details",
     "order": "47",
     "role": "http://www.summitplc.com/role/SegmentReportingLonglivedassetsbygeographyDetails",
     "shortName": "Segment Reporting - Long-lived assets by geography (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "smmt-20211231.htm",
      "contextRef": "i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NoncurrentAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "smmt-20211231.htm",
      "contextRef": "i0f6242234d28477e9478c049c2986ce6_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000048 - Disclosure - Revenue - Revenue by category (Details)",
     "menuCat": "Details",
     "order": "48",
     "role": "http://www.summitplc.com/role/RevenueRevenuebycategoryDetails",
     "shortName": "Revenue - Revenue by category (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "smmt-20211231.htm",
      "contextRef": "i5429ceb33a414445be9322f8f9c293e3_D20210101-20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "smmt-20211231.htm",
      "contextRef": "i0f6242234d28477e9478c049c2986ce6_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000049 - Disclosure - Revenue - Revenue by geography (Details)",
     "menuCat": "Details",
     "order": "49",
     "role": "http://www.summitplc.com/role/RevenueRevenuebygeographyDetails",
     "shortName": "Revenue - Revenue by geography (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "smmt-20211231.htm",
      "contextRef": "ie0717192d4d74cfd912383af07cab29d_D20210101-20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "smmt-20211231.htm",
      "contextRef": "i0f6242234d28477e9478c049c2986ce6_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000005 - Statement - Consolidated Statements of Operations and Comprehensive Loss",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://www.summitplc.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
     "shortName": "Consolidated Statements of Operations and Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "smmt-20211231.htm",
      "contextRef": "i0f6242234d28477e9478c049c2986ce6_D20210101-20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "smmt-20211231.htm",
      "contextRef": "i7372be6dc06143b5adbb4d2e83a596c5_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerLiability",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000050 - Disclosure - Revenue - Deferred revenue and other income (Details)",
     "menuCat": "Details",
     "order": "50",
     "role": "http://www.summitplc.com/role/RevenueDeferredrevenueandotherincomeDetails",
     "shortName": "Revenue - Deferred revenue and other income (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "smmt-20211231.htm",
      "contextRef": "i0f6242234d28477e9478c049c2986ce6_D20210101-20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "smmt:ContractWithCustomerLiabilityAdditions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "smmt-20211231.htm",
      "contextRef": "i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerLiability",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000051 - Disclosure - Revenue - Narrative (Details)",
     "menuCat": "Details",
     "order": "51",
     "role": "http://www.summitplc.com/role/RevenueNarrativeDetails",
     "shortName": "Revenue - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "smmt-20211231.htm",
      "contextRef": "ib314f5dd5ac24f47a60b0925a50a5081_I20171231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "smmt-20211231.htm",
      "contextRef": "i0f6242234d28477e9478c049c2986ce6_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "smmt:ResearchAndDevelopmentTaxCredit",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000052 - Disclosure - Other Operating Income - Other operating income by category (Details)",
     "menuCat": "Details",
     "order": "52",
     "role": "http://www.summitplc.com/role/OtherOperatingIncomeOtheroperatingincomebycategoryDetails",
     "shortName": "Other Operating Income - Other operating income by category (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "smmt:ScheduleOfOtherOperatingIncomeByComponentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "smmt-20211231.htm",
      "contextRef": "i4ef399140bb14718b545a1aaa04203df_D20210101-20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "smmt:GrantFundingArrangementIncomeEarned",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "smmt-20211231.htm",
      "contextRef": "i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "smmt:ResearchAndDevelopmentTaxCreditReceivableCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000053 - Disclosure - Other Operating Income - Narrative (Details)",
     "menuCat": "Details",
     "order": "53",
     "role": "http://www.summitplc.com/role/OtherOperatingIncomeNarrativeDetails",
     "shortName": "Other Operating Income - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "smmt-20211231.htm",
      "contextRef": "i5189024af3e3465a96e4c5c1204cfc1d_D20170901-20170930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "smmt:GrantFundingArrangementMaximumFundingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "smmt-20211231.htm",
      "contextRef": "i0f6242234d28477e9478c049c2986ce6_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ForeignCurrencyTransactionGainLossBeforeTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000054 - Disclosure - Other (Expense) Income (Details)",
     "menuCat": "Details",
     "order": "54",
     "role": "http://www.summitplc.com/role/OtherExpenseIncomeDetails",
     "shortName": "Other (Expense) Income (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "smmt-20211231.htm",
      "contextRef": "i0f6242234d28477e9478c049c2986ce6_D20210101-20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:InvestmentIncomeInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "smmt-20211231.htm",
      "contextRef": "i0f6242234d28477e9478c049c2986ce6_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000055 - Disclosure - Income Tax - Components of loss before income taxes (Details)",
     "menuCat": "Details",
     "order": "55",
     "role": "http://www.summitplc.com/role/IncomeTaxComponentsoflossbeforeincometaxesDetails",
     "shortName": "Income Tax - Components of loss before income taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "smmt-20211231.htm",
      "contextRef": "i0f6242234d28477e9478c049c2986ce6_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "smmt-20211231.htm",
      "contextRef": "i0f6242234d28477e9478c049c2986ce6_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000056 - Disclosure - Income Tax - Significant components of the provision for income taxes (Details)",
     "menuCat": "Details",
     "order": "56",
     "role": "http://www.summitplc.com/role/IncomeTaxSignificantcomponentsoftheprovisionforincometaxesDetails",
     "shortName": "Income Tax - Significant components of the provision for income taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "smmt-20211231.htm",
      "contextRef": "i0f6242234d28477e9478c049c2986ce6_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "smmt-20211231.htm",
      "contextRef": "i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000057 - Disclosure - Income Tax - Major components of deferred tax assets and liabilities (Details)",
     "menuCat": "Details",
     "order": "57",
     "role": "http://www.summitplc.com/role/IncomeTaxMajorcomponentsofdeferredtaxassetsandliabilitiesDetails",
     "shortName": "Income Tax - Major components of deferred tax assets and liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "smmt-20211231.htm",
      "contextRef": "i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "smmt-20211231.htm",
      "contextRef": "i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsGross",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000058 - Disclosure - Income Tax - Narrative (Details)",
     "menuCat": "Details",
     "order": "58",
     "role": "http://www.summitplc.com/role/IncomeTaxNarrativeDetails",
     "shortName": "Income Tax - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "smmt-20211231.htm",
      "contextRef": "i0f6242234d28477e9478c049c2986ce6_D20210101-20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "smmt-20211231.htm",
      "contextRef": "i0f6242234d28477e9478c049c2986ce6_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000059 - Disclosure - Income Tax - Reconciliation of the effective income tax rate to statutory rate (Details)",
     "menuCat": "Details",
     "order": "59",
     "role": "http://www.summitplc.com/role/IncomeTaxReconciliationoftheeffectiveincometaxratetostatutoryrateDetails",
     "shortName": "Income Tax - Reconciliation of the effective income tax rate to statutory rate (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "smmt-20211231.htm",
      "contextRef": "i0f6242234d28477e9478c049c2986ce6_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "smmt-20211231.htm",
      "contextRef": "iadaf16e26a374273b81a7480b2aef461_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000006 - Statement - Consolidated Statements of Stockholders' Equity",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://www.summitplc.com/role/ConsolidatedStatementsofStockholdersEquity",
     "shortName": "Consolidated Statements of Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "smmt-20211231.htm",
      "contextRef": "iadaf16e26a374273b81a7480b2aef461_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "smmt-20211231.htm",
      "contextRef": "i0f6242234d28477e9478c049c2986ce6_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000060 - Disclosure - Loss per Share - Computation of net loss per share (Details)",
     "menuCat": "Details",
     "order": "60",
     "role": "http://www.summitplc.com/role/LossperShareComputationofnetlosspershareDetails",
     "shortName": "Loss per Share - Computation of net loss per share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "smmt-20211231.htm",
      "contextRef": "i0f6242234d28477e9478c049c2986ce6_D20210101-20211231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000061 - Disclosure - Loss per Share - Potentially dilutive securities excluded from the computation of loss per share (Details)",
     "menuCat": "Details",
     "order": "61",
     "role": "http://www.summitplc.com/role/LossperSharePotentiallydilutivesecuritiesexcludedfromthecomputationoflosspershareDetails",
     "shortName": "Loss per Share - Potentially dilutive securities excluded from the computation of loss per share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "smmt-20211231.htm",
      "contextRef": "i0f6242234d28477e9478c049c2986ce6_D20210101-20211231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "smmt-20211231.htm",
      "contextRef": "i0f6242234d28477e9478c049c2986ce6_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfReportingUnits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "reporting_unit",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000062 - Disclosure - Goodwill and Intangible Assets - Narrative (Details)",
     "menuCat": "Details",
     "order": "62",
     "role": "http://www.summitplc.com/role/GoodwillandIntangibleAssetsNarrativeDetails",
     "shortName": "Goodwill and Intangible Assets - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "smmt-20211231.htm",
      "contextRef": "i0f6242234d28477e9478c049c2986ce6_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfReportingUnits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "reporting_unit",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "smmt-20211231.htm",
      "contextRef": "i7372be6dc06143b5adbb4d2e83a596c5_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000063 - Disclosure - Goodwill and Intangible Assets - Schedule of acquired intangible assets (Details)",
     "menuCat": "Details",
     "order": "63",
     "role": "http://www.summitplc.com/role/GoodwillandIntangibleAssetsScheduleofacquiredintangibleassetsDetails",
     "shortName": "Goodwill and Intangible Assets - Schedule of acquired intangible assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "smmt-20211231.htm",
      "contextRef": "i7372be6dc06143b5adbb4d2e83a596c5_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "smmt-20211231.htm",
      "contextRef": "i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000064 - Disclosure - Goodwill and Intangible Assets - Estimated amortization expense (Details)",
     "menuCat": "Details",
     "order": "64",
     "role": "http://www.summitplc.com/role/GoodwillandIntangibleAssetsEstimatedamortizationexpenseDetails",
     "shortName": "Goodwill and Intangible Assets - Estimated amortization expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "smmt-20211231.htm",
      "contextRef": "i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "smmt-20211231.htm",
      "contextRef": "i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000065 - Disclosure - Property and Equipment - Components of property and equipment (Details)",
     "menuCat": "Details",
     "order": "65",
     "role": "http://www.summitplc.com/role/PropertyandEquipmentComponentsofpropertyandequipmentDetails",
     "shortName": "Property and Equipment - Components of property and equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "smmt-20211231.htm",
      "contextRef": "i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "smmt-20211231.htm",
      "contextRef": "i0f6242234d28477e9478c049c2986ce6_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000066 - Disclosure - Property and Equipment - Narrative (Details)",
     "menuCat": "Details",
     "order": "66",
     "role": "http://www.summitplc.com/role/PropertyandEquipmentNarrativeDetails",
     "shortName": "Property and Equipment - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "smmt-20211231.htm",
      "contextRef": "i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "smmt:ResearchAndDevelopmentPrepaidExpensesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000067 - Disclosure - Research and Development Prepaid Expenses and Accrued Liabilities (Details)",
     "menuCat": "Details",
     "order": "67",
     "role": "http://www.summitplc.com/role/ResearchandDevelopmentPrepaidExpensesandAccruedLiabilitiesDetails",
     "shortName": "Research and Development Prepaid Expenses and Accrued Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "smmt-20211231.htm",
      "contextRef": "i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "smmt:ResearchAndDevelopmentPrepaidExpensesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "smmt-20211231.htm",
      "contextRef": "i0f6242234d28477e9478c049c2986ce6_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000068 - Disclosure - Leases - Narrative (Details)",
     "menuCat": "Details",
     "order": "68",
     "role": "http://www.summitplc.com/role/LeasesNarrativeDetails",
     "shortName": "Leases - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "smmt-20211231.htm",
      "contextRef": "i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231",
      "decimals": "3",
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "smmt-20211231.htm",
      "contextRef": "i0f6242234d28477e9478c049c2986ce6_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000069 - Disclosure - Leases - Lease expense (Details)",
     "menuCat": "Details",
     "order": "69",
     "role": "http://www.summitplc.com/role/LeasesLeaseexpenseDetails",
     "shortName": "Leases - Lease expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "smmt-20211231.htm",
      "contextRef": "i0f6242234d28477e9478c049c2986ce6_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "smmt-20211231.htm",
      "contextRef": "i0f6242234d28477e9478c049c2986ce6_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000007 - Statement - Consolidated Statements of Stockholders' Equity (Deficit) (Parenthetical)",
     "menuCat": "Statements",
     "order": "7",
     "role": "http://www.summitplc.com/role/ConsolidatedStatementsofStockholdersEquityDeficitParenthetical",
     "shortName": "Consolidated Statements of Stockholders' Equity (Deficit) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "smmt-20211231.htm",
      "contextRef": "i0f6242234d28477e9478c049c2986ce6_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "smmt-20211231.htm",
      "contextRef": "i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000070 - Disclosure - Leases - Future lease payments (Details)",
     "menuCat": "Details",
     "order": "70",
     "role": "http://www.summitplc.com/role/LeasesFutureleasepaymentsDetails",
     "shortName": "Leases - Future lease payments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "smmt-20211231.htm",
      "contextRef": "i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "smmt-20211231.htm",
      "contextRef": "i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "smmt:BusinessCombinationAssumedContingentLiabilityNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000071 - Disclosure - Other Non-Current Liabilities (Details)",
     "menuCat": "Details",
     "order": "71",
     "role": "http://www.summitplc.com/role/OtherNonCurrentLiabilitiesDetails",
     "shortName": "Other Non-Current Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "smmt-20211231.htm",
      "contextRef": "i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "smmt:BusinessCombinationAssumedContingentLiabilityNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "smmt-20211231.htm",
      "contextRef": "ib1b2bbd9c2ea4c81affedf30cb5ad225_I20200918",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000072 - Disclosure - Stockholders' Equity (Details)",
     "menuCat": "Details",
     "order": "72",
     "role": "http://www.summitplc.com/role/StockholdersEquityDetails",
     "shortName": "Stockholders' Equity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "smmt-20211231.htm",
      "contextRef": "ib1b2bbd9c2ea4c81affedf30cb5ad225_I20200918",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "smmt-20211231.htm",
      "contextRef": "i0f6242234d28477e9478c049c2986ce6_D20210101-20211231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000073 - Disclosure - Stock Based Compensation - Narrative (Details)",
     "menuCat": "Details",
     "order": "73",
     "role": "http://www.summitplc.com/role/StockBasedCompensationNarrativeDetails",
     "shortName": "Stock Based Compensation - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "smmt-20211231.htm",
      "contextRef": "i0f6242234d28477e9478c049c2986ce6_D20210101-20211231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R74": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "smmt-20211231.htm",
      "contextRef": "i444320f038034b09878835272c70885a_D20210101-20211231",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000074 - Disclosure - Stock Based Compensation - Weighted-average assumptions used for stock option awards (Details)",
     "menuCat": "Details",
     "order": "74",
     "role": "http://www.summitplc.com/role/StockBasedCompensationWeightedaverageassumptionsusedforstockoptionawardsDetails",
     "shortName": "Stock Based Compensation - Weighted-average assumptions used for stock option awards (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "smmt-20211231.htm",
      "contextRef": "i444320f038034b09878835272c70885a_D20210101-20211231",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R75": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "smmt-20211231.htm",
      "contextRef": "i7372be6dc06143b5adbb4d2e83a596c5_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000075 - Disclosure - Stock Based Compensation - Stock option activity (Details)",
     "menuCat": "Details",
     "order": "75",
     "role": "http://www.summitplc.com/role/StockBasedCompensationStockoptionactivityDetails",
     "shortName": "Stock Based Compensation - Stock option activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "smmt-20211231.htm",
      "contextRef": "i0f6242234d28477e9478c049c2986ce6_D20210101-20211231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R76": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "smmt-20211231.htm",
      "contextRef": "ib788877f138c4513a611e7bbf11174b9_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000076 - Disclosure - Stock-Based Compensation - RSU activity (Details)",
     "menuCat": "Details",
     "order": "76",
     "role": "http://www.summitplc.com/role/StockBasedCompensationRSUactivityDetails",
     "shortName": "Stock-Based Compensation - RSU activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "smmt-20211231.htm",
      "contextRef": "ib788877f138c4513a611e7bbf11174b9_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R77": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "smmt-20211231.htm",
      "contextRef": "i0f6242234d28477e9478c049c2986ce6_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000077 - Disclosure - Stock-Based Compensation - Summary of stock-based compensation expense (Details)",
     "menuCat": "Details",
     "order": "77",
     "role": "http://www.summitplc.com/role/StockBasedCompensationSummaryofstockbasedcompensationexpenseDetails",
     "shortName": "Stock-Based Compensation - Summary of stock-based compensation expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "smmt-20211231.htm",
      "contextRef": "i0f6242234d28477e9478c049c2986ce6_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R78": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PurchaseObligation",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "smmt-20211231.htm",
      "contextRef": "i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PurchaseObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000078 - Disclosure - Commitments and Contingencies (Details)",
     "menuCat": "Details",
     "order": "78",
     "role": "http://www.summitplc.com/role/CommitmentsandContingenciesDetails",
     "shortName": "Commitments and Contingencies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PurchaseObligation",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "smmt-20211231.htm",
      "contextRef": "i2ecb9792ec164bb8ab38ef8adeb2b902_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PurchaseObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R79": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "smmt-20211231.htm",
      "contextRef": "i0f6242234d28477e9478c049c2986ce6_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromRelatedPartyDebt",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000079 - Disclosure - Related Party Transactions (Details)",
     "menuCat": "Details",
     "order": "79",
     "role": "http://www.summitplc.com/role/RelatedPartyTransactionsDetails",
     "shortName": "Related Party Transactions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "smmt-20211231.htm",
      "contextRef": "i4a8e4bc29f1645008a3ae3a8a5bb7985_D20210324-20210324",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromRelatedPartyDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "smmt-20211231.htm",
      "contextRef": "i0f6242234d28477e9478c049c2986ce6_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000008 - Statement - Consolidated Statements of Cash Flows",
     "menuCat": "Statements",
     "order": "8",
     "role": "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "smmt-20211231.htm",
      "contextRef": "i0f6242234d28477e9478c049c2986ce6_D20210101-20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "smmt:GainLossOnRemeasurementOfLiabilitiesOperatingAndNonoperating",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R80": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "smmt-20211231.htm",
      "contextRef": "i0f6242234d28477e9478c049c2986ce6_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromRelatedPartyDebt",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000080 - Disclosure - Subsequent Event (Details)",
     "menuCat": "Details",
     "order": "80",
     "role": "http://www.summitplc.com/role/SubsequentEventDetails",
     "shortName": "Subsequent Event (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "smmt-20211231.htm",
      "contextRef": "i0f6242234d28477e9478c049c2986ce6_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000009 - Disclosure - Nature of Business and Operations and Recent Events",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://www.summitplc.com/role/NatureofBusinessandOperationsandRecentEvents",
     "shortName": "Nature of Business and Operations and Recent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "smmt-20211231.htm",
      "contextRef": "i0f6242234d28477e9478c049c2986ce6_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 61,
   "tag": {
    "country_GB": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED KINGDOM",
        "terseLabel": "United Kingdom"
       }
      }
     },
     "localname": "GB",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.summitplc.com/role/SegmentReportingLonglivedassetsbygeographyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "United States"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.summitplc.com/role/RevenueRevenuebygeographyDetails",
      "http://www.summitplc.com/role/SegmentReportingLonglivedassetsbygeographyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.summitplc.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r536",
      "r537",
      "r538"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID",
        "terseLabel": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.summitplc.com/role/AuditInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r536",
      "r537",
      "r538"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location",
        "terseLabel": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.summitplc.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r536",
      "r537",
      "r538"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name",
        "terseLabel": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.summitplc.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.summitplc.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.summitplc.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r536",
      "r537",
      "r538"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.summitplc.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.summitplc.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.summitplc.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.summitplc.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r539"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.summitplc.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.summitplc.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r534"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.summitplc.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.summitplc.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.summitplc.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.summitplc.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.summitplc.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r533"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.summitplc.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.summitplc.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.summitplc.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r533"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.summitplc.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.summitplc.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r533"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.summitplc.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.summitplc.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r540"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.summitplc.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.summitplc.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r533"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.summitplc.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r533"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.summitplc.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r533"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.summitplc.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r533"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.summitplc.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.summitplc.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r541"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.summitplc.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r536",
      "r537",
      "r538"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.summitplc.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.summitplc.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r532"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.summitplc.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.summitplc.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.summitplc.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "smmt_A2020StockIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2020 Stock Incentive Plan",
        "label": "2020 Stock Incentive Plan [Member]",
        "terseLabel": "2020 Plan"
       }
      }
     },
     "localname": "A2020StockIncentivePlanMember",
     "nsuri": "http://www.summitplc.com/20211231",
     "presentation": [
      "http://www.summitplc.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "smmt_A2022NoteMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2022 Note",
        "label": "2022 Note [Member]",
        "terseLabel": "2022 Note"
       }
      }
     },
     "localname": "A2022NoteMember",
     "nsuri": "http://www.summitplc.com/20211231",
     "presentation": [
      "http://www.summitplc.com/role/LiquidityandCapitalResourcesDetails",
      "http://www.summitplc.com/role/NatureofBusinessandOperationsandRecentEventsDetails",
      "http://www.summitplc.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "smmt_AccruedResearchAndDevelopmentCurrent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Research And Development, Current",
        "label": "Accrued Research And Development, Current",
        "terseLabel": "Accrued research and development expenditure"
       }
      }
     },
     "localname": "AccruedResearchAndDevelopmentCurrent",
     "nsuri": "http://www.summitplc.com/20211231",
     "presentation": [
      "http://www.summitplc.com/role/ResearchandDevelopmentPrepaidExpensesandAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "smmt_AdjustmentsToAdditionalPaidInCapitalImputedInterestExpenseRelatedParty": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments to Additional Paid in Capital, Imputed Interest Expense, Related Party",
        "label": "Adjustments to Additional Paid in Capital, Imputed Interest Expense, Related Party",
        "terseLabel": "Imputed interest expense on promissory note payable to a related party"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalImputedInterestExpenseRelatedParty",
     "nsuri": "http://www.summitplc.com/20211231",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.summitplc.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "smmt_AreaOfPremisesSubleased": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area Of Premises Subleased",
        "label": "Area Of Premises Subleased",
        "terseLabel": "Area of premises subleased"
       }
      }
     },
     "localname": "AreaOfPremisesSubleased",
     "nsuri": "http://www.summitplc.com/20211231",
     "presentation": [
      "http://www.summitplc.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "smmt_AssignmentAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assignment Agreement",
        "label": "Assignment Agreement [Member]",
        "terseLabel": "Assignment Agreement"
       }
      }
     },
     "localname": "AssignmentAgreementMember",
     "nsuri": "http://www.summitplc.com/20211231",
     "presentation": [
      "http://www.summitplc.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "smmt_AssumedContingentLiabilitiesPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assumed Contingent Liabilities, Policy",
        "label": "Assumed Contingent Liabilities, Policy [Policy Text Block]",
        "terseLabel": "Assumed Contingent Liabilities"
       }
      }
     },
     "localname": "AssumedContingentLiabilitiesPolicyPolicyTextBlock",
     "nsuri": "http://www.summitplc.com/20211231",
     "presentation": [
      "http://www.summitplc.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "smmt_AuditInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Audit Information [Abstract]",
        "label": "Audit Information [Abstract]"
       }
      }
     },
     "localname": "AuditInformationAbstract",
     "nsuri": "http://www.summitplc.com/20211231",
     "xbrltype": "stringItemType"
    },
    "smmt_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Biomedical Advanced Research And Development Authority",
        "label": "Biomedical Advanced Research And Development Authority [Member]",
        "terseLabel": "BARDA"
       }
      }
     },
     "localname": "BiomedicalAdvancedResearchAndDevelopmentAuthorityMember",
     "nsuri": "http://www.summitplc.com/20211231",
     "presentation": [
      "http://www.summitplc.com/role/OtherOperatingIncomeNarrativeDetails",
      "http://www.summitplc.com/role/OtherOperatingIncomeOtheroperatingincomebycategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "smmt_BusinessCombinationAssumedContingentLiabilityMeasurementInput": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Assumed Contingent Liability, Measurement Input",
        "label": "Business Combination, Assumed Contingent Liability, Measurement Input",
        "terseLabel": "Assumed contingent liability, measurement input"
       }
      }
     },
     "localname": "BusinessCombinationAssumedContingentLiabilityMeasurementInput",
     "nsuri": "http://www.summitplc.com/20211231",
     "presentation": [
      "http://www.summitplc.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "smmt_BusinessCombinationAssumedContingentLiabilityNoncurrent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Assumed Contingent Liability, Noncurrent",
        "label": "Business Combination, Assumed Contingent Liability, Noncurrent",
        "terseLabel": "Assumed contingent liabilities, non-current"
       }
      }
     },
     "localname": "BusinessCombinationAssumedContingentLiabilityNoncurrent",
     "nsuri": "http://www.summitplc.com/20211231",
     "presentation": [
      "http://www.summitplc.com/role/OtherNonCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "smmt_ChangeInContractWithCustomerAssetAndLiabilityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in Contract with Customer, Asset and Liability",
        "label": "Change in Contract with Customer, Asset and Liability [Roll Forward]",
        "terseLabel": "Change in Contract with Customer, Asset and Liability [Roll Forward]"
       }
      }
     },
     "localname": "ChangeInContractWithCustomerAssetAndLiabilityRollForward",
     "nsuri": "http://www.summitplc.com/20211231",
     "presentation": [
      "http://www.summitplc.com/role/RevenueDeferredrevenueandotherincomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "smmt_ClassOfWarrantOrRightMinimumTenDayVolumeWeightedAverageCommonStockPriceToWarrantExercisePricePremiumPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class Of Warrant Or Right, Minimum Ten Day Volume Weighted Average Common Stock Price to Warrant Exercise Price, Premium, Percentage",
        "label": "Class Of Warrant Or Right, Minimum Ten Day Volume Weighted Average Common Stock Price to Warrant Exercise Price, Premium, Percentage",
        "terseLabel": "Minimum volume weighted average common stock price to warrant exercise price, premium, percentage"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightMinimumTenDayVolumeWeightedAverageCommonStockPriceToWarrantExercisePricePremiumPercentage",
     "nsuri": "http://www.summitplc.com/20211231",
     "presentation": [
      "http://www.summitplc.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "smmt_ClassOfWarrantOrRightQuarterlyVestingPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of Warrant or Right, Quarterly Vesting Period",
        "label": "Class of Warrant or Right, Quarterly Vesting Period",
        "terseLabel": "Warrants quarterly vesting period"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightQuarterlyVestingPeriod",
     "nsuri": "http://www.summitplc.com/20211231",
     "presentation": [
      "http://www.summitplc.com/role/RelatedPartyTransactionsDetails",
      "http://www.summitplc.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "smmt_ClassOfWarrantOrRightVested": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of Warrant or Right, Vested",
        "label": "Class of Warrant or Right, Vested",
        "terseLabel": "Warrants vested (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightVested",
     "nsuri": "http://www.summitplc.com/20211231",
     "presentation": [
      "http://www.summitplc.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "smmt_CombatingAntibioticResistantBacteriaBiopharmaceuticalAcceleratorProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator Program",
        "label": "Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator Program [Member]",
        "terseLabel": "CARB-X"
       }
      }
     },
     "localname": "CombatingAntibioticResistantBacteriaBiopharmaceuticalAcceleratorProgramMember",
     "nsuri": "http://www.summitplc.com/20211231",
     "presentation": [
      "http://www.summitplc.com/role/OtherOperatingIncomeNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "smmt_CommonStockAndRestrictedStockUnitsAdditionalCapitalSharesAllowableForForFutureIssuance": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock and Restricted Stock Units, Additional Capital Shares Allowable For For Future Issuance",
        "label": "Common Stock and Restricted Stock Units, Additional Capital Shares Allowable For For Future Issuance",
        "terseLabel": "Number of shares that can be added to the plan (in shares)"
       }
      }
     },
     "localname": "CommonStockAndRestrictedStockUnitsAdditionalCapitalSharesAllowableForForFutureIssuance",
     "nsuri": "http://www.summitplc.com/20211231",
     "presentation": [
      "http://www.summitplc.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "smmt_ConsultancyAgreementWarrantVestingExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Consultancy Agreement, Warrant Vesting Expense",
        "label": "Consultancy Agreement, Warrant Vesting Expense [Member]",
        "terseLabel": "Warrant vesting expense"
       }
      }
     },
     "localname": "ConsultancyAgreementWarrantVestingExpenseMember",
     "nsuri": "http://www.summitplc.com/20211231",
     "presentation": [
      "http://www.summitplc.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "smmt_ConsultantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Consultants",
        "label": "Consultants [Member]",
        "terseLabel": "Consultants"
       }
      }
     },
     "localname": "ConsultantsMember",
     "nsuri": "http://www.summitplc.com/20211231",
     "presentation": [
      "http://www.summitplc.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "smmt_ConsultingAgreementConsultancyFeesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Consulting Agreement, Consultancy Fees",
        "label": "Consulting Agreement, Consultancy Fees [Member]",
        "terseLabel": "Consultancy fees"
       }
      }
     },
     "localname": "ConsultingAgreementConsultancyFeesMember",
     "nsuri": "http://www.summitplc.com/20211231",
     "presentation": [
      "http://www.summitplc.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "smmt_ConsultingAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Consulting Agreement",
        "label": "Consulting Agreement [Member]",
        "terseLabel": "Consulting Agreement"
       }
      }
     },
     "localname": "ConsultingAgreementMember",
     "nsuri": "http://www.summitplc.com/20211231",
     "presentation": [
      "http://www.summitplc.com/role/RelatedPartyTransactionsDetails",
      "http://www.summitplc.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "smmt_ContractWithCustomerLiabilityAdditions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract with Customer, Liability, Additions",
        "label": "Contract with Customer, Liability, Additions",
        "terseLabel": "Additions"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityAdditions",
     "nsuri": "http://www.summitplc.com/20211231",
     "presentation": [
      "http://www.summitplc.com/role/RevenueDeferredrevenueandotherincomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "smmt_ContractWithCustomerLiabilityEnrollmentMilestone": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract With Customer, Liability, Enrollment Milestone",
        "label": "Contract With Customer, Liability, Enrollment Milestone",
        "terseLabel": "Deferred revenue, enrollment milestone"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityEnrollmentMilestone",
     "nsuri": "http://www.summitplc.com/20211231",
     "presentation": [
      "http://www.summitplc.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "smmt_DeferredTaxAssetsLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.summitplc.com/role/IncomeTaxMajorcomponentsofdeferredtaxassetsandliabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets (Liabilities)",
        "label": "Deferred Tax Assets (Liabilities)",
        "totalLabel": "Net deferred tax assets before valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilities",
     "nsuri": "http://www.summitplc.com/20211231",
     "presentation": [
      "http://www.summitplc.com/role/IncomeTaxMajorcomponentsofdeferredtaxassetsandliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "smmt_DeferredTaxAssetsNetIncreaseDecreaseDueToChangeInEnactedTaxRateAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets, Net, Increase (Decrease) Due To Change In Enacted Tax Rate, Amount",
        "label": "Deferred Tax Assets, Net, Increase (Decrease) Due To Change In Enacted Tax Rate, Amount",
        "terseLabel": "Increase in net deferred tax assets due to change in enacted tax rate"
       }
      }
     },
     "localname": "DeferredTaxAssetsNetIncreaseDecreaseDueToChangeInEnactedTaxRateAmount",
     "nsuri": "http://www.summitplc.com/20211231",
     "presentation": [
      "http://www.summitplc.com/role/IncomeTaxNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "smmt_DiscuvaPlatformMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discuva Platform",
        "label": "Discuva Platform [Member]",
        "terseLabel": "Discuva platform"
       }
      }
     },
     "localname": "DiscuvaPlatformMember",
     "nsuri": "http://www.summitplc.com/20211231",
     "presentation": [
      "http://www.summitplc.com/role/GoodwillandIntangibleAssetsNarrativeDetails",
      "http://www.summitplc.com/role/GoodwillandIntangibleAssetsScheduleofacquiredintangibleassetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "smmt_EffectiveIncomeTaxRateReconciliationTaxCreditRefundableResearchPercent": {
     "auth_ref": [],
     "calculation": {
      "http://www.summitplc.com/role/IncomeTaxReconciliationoftheeffectiveincometaxratetostatutoryrateDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Tax Credit Refundable, Research, Percent",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit Refundable, Research, Percent",
        "negatedLabel": "Refundable research and development tax credit"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditRefundableResearchPercent",
     "nsuri": "http://www.summitplc.com/20211231",
     "presentation": [
      "http://www.summitplc.com/role/IncomeTaxReconciliationoftheeffectiveincometaxratetostatutoryrateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "smmt_EuroFarmaLaboratoriosSAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "EuroFarma Laboratorios S.A.",
        "label": "EuroFarma Laboratorios S.A. [Member]",
        "terseLabel": "EuroFarma"
       }
      }
     },
     "localname": "EuroFarmaLaboratoriosSAMember",
     "nsuri": "http://www.summitplc.com/20211231",
     "presentation": [
      "http://www.summitplc.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "smmt_FiniteLivedIntangibleAssetsAccumulatedAmortizationAndImpairment": {
     "auth_ref": [],
     "calculation": {
      "http://www.summitplc.com/role/GoodwillandIntangibleAssetsScheduleofacquiredintangibleassetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finite-Lived Intangible Assets, Accumulated Amortization And Impairment",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization And Impairment",
        "negatedTerseLabel": "Accumulated amortization and impairment charges"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortizationAndImpairment",
     "nsuri": "http://www.summitplc.com/20211231",
     "presentation": [
      "http://www.summitplc.com/role/GoodwillandIntangibleAssetsScheduleofacquiredintangibleassetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "smmt_FormerChiefExecutiveOfficerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Former Chief Executive Officer",
        "label": "Former Chief Executive Officer [Member]",
        "terseLabel": "Former Chief Executive Officer"
       }
      }
     },
     "localname": "FormerChiefExecutiveOfficerMember",
     "nsuri": "http://www.summitplc.com/20211231",
     "presentation": [
      "http://www.summitplc.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "smmt_FractionalStockIssuedDuringPeriodSharesReverseStockSplit": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fractional Stock Issued During Period, Shares, Reverse Stock Split",
        "label": "Fractional Stock Issued During Period, Shares, Reverse Stock Split",
        "terseLabel": "Fractional shares issued from reverse stock split"
       }
      }
     },
     "localname": "FractionalStockIssuedDuringPeriodSharesReverseStockSplit",
     "nsuri": "http://www.summitplc.com/20211231",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "smmt_FurnitureAndFixturesOfficeEquipmentAndSoftwareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Furniture and Fixtures, Office Equipment and Software",
        "label": "Furniture and Fixtures, Office Equipment and Software [Member]",
        "terseLabel": "Furniture and fixtures, office equipment and software"
       }
      }
     },
     "localname": "FurnitureAndFixturesOfficeEquipmentAndSoftwareMember",
     "nsuri": "http://www.summitplc.com/20211231",
     "presentation": [
      "http://www.summitplc.com/role/PropertyandEquipmentComponentsofpropertyandequipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "smmt_GainLossOnRemeasurementOfLiabilitiesNonoperating": {
     "auth_ref": [],
     "calculation": {
      "http://www.summitplc.com/role/OtherExpenseIncomeDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain (Loss) On Remeasurement Of Liabilities, Nonoperating",
        "label": "Gain (Loss) On Remeasurement Of Liabilities, Nonoperating",
        "terseLabel": "Remeasurement of liabilities",
        "verboseLabel": "Gain on remeasurement of contingent liability"
       }
      }
     },
     "localname": "GainLossOnRemeasurementOfLiabilitiesNonoperating",
     "nsuri": "http://www.summitplc.com/20211231",
     "presentation": [
      "http://www.summitplc.com/role/OtherExpenseIncomeDetails",
      "http://www.summitplc.com/role/OtherNonCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "smmt_GainLossOnRemeasurementOfLiabilitiesOperatingAndNonoperating": {
     "auth_ref": [],
     "calculation": {
      "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain (Loss) On Remeasurement Of Liabilities, Operating And Nonoperating",
        "label": "Gain (Loss) On Remeasurement Of Liabilities, Operating And Nonoperating",
        "negatedTerseLabel": "Gain on remeasurement of liabilities"
       }
      }
     },
     "localname": "GainLossOnRemeasurementOfLiabilitiesOperatingAndNonoperating",
     "nsuri": "http://www.summitplc.com/20211231",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "smmt_GrantFundingArrangementCommittedFundingBase": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Grant Funding Arrangement, Committed Funding, Base",
        "label": "Grant Funding Arrangement, Committed Funding, Base",
        "terseLabel": "Committed funding base"
       }
      }
     },
     "localname": "GrantFundingArrangementCommittedFundingBase",
     "nsuri": "http://www.summitplc.com/20211231",
     "presentation": [
      "http://www.summitplc.com/role/OtherOperatingIncomeNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "smmt_GrantFundingArrangementCommittedFundingTotal": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Grant Funding Arrangement, Committed Funding, Total",
        "label": "Grant Funding Arrangement, Committed Funding, Total",
        "terseLabel": "Total committed funding"
       }
      }
     },
     "localname": "GrantFundingArrangementCommittedFundingTotal",
     "nsuri": "http://www.summitplc.com/20211231",
     "presentation": [
      "http://www.summitplc.com/role/OtherOperatingIncomeNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "smmt_GrantFundingArrangementFundingReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Grant Funding Arrangement, Funding Received",
        "label": "Grant Funding Arrangement, Funding Received",
        "terseLabel": "Funding received"
       }
      }
     },
     "localname": "GrantFundingArrangementFundingReceived",
     "nsuri": "http://www.summitplc.com/20211231",
     "presentation": [
      "http://www.summitplc.com/role/OtherOperatingIncomeNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "smmt_GrantFundingArrangementIncomeEarned": {
     "auth_ref": [],
     "calculation": {
      "http://www.summitplc.com/role/OtherOperatingIncomeOtheroperatingincomebycategoryDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherOperatingIncome",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Grant Funding Arrangement, Income Earned",
        "label": "Grant Funding Arrangement, Income Earned",
        "terseLabel": "Funding/Grant income"
       }
      }
     },
     "localname": "GrantFundingArrangementIncomeEarned",
     "nsuri": "http://www.summitplc.com/20211231",
     "presentation": [
      "http://www.summitplc.com/role/OtherOperatingIncomeNarrativeDetails",
      "http://www.summitplc.com/role/OtherOperatingIncomeOtheroperatingincomebycategoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "smmt_GrantFundingArrangementMaximumFundingValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Grant Funding Arrangement, Maximum Funding Value",
        "label": "Grant Funding Arrangement, Maximum Funding Value",
        "terseLabel": "Maximum funding value"
       }
      }
     },
     "localname": "GrantFundingArrangementMaximumFundingValue",
     "nsuri": "http://www.summitplc.com/20211231",
     "presentation": [
      "http://www.summitplc.com/role/OtherOperatingIncomeNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "smmt_GrantFundingArrangementMilestoneFundingIncrease": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Grant Funding Arrangement, Milestone, Funding Increase",
        "label": "Grant Funding Arrangement, Milestone, Funding Increase",
        "terseLabel": "Funding increase based on achievement of future milestones"
       }
      }
     },
     "localname": "GrantFundingArrangementMilestoneFundingIncrease",
     "nsuri": "http://www.summitplc.com/20211231",
     "presentation": [
      "http://www.summitplc.com/role/OtherOperatingIncomeNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "smmt_IncomeStatementAndStatementOfComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income Statement And Statement Of Comprehensive Income",
        "label": "Income Statement And Statement Of Comprehensive Income [Abstract]",
        "terseLabel": "Income Statement And Statement Of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAndStatementOfComprehensiveIncomeAbstract",
     "nsuri": "http://www.summitplc.com/20211231",
     "xbrltype": "stringItemType"
    },
    "smmt_IncreaseDecreaseInAccruedLiabilitiesAndEmployeeRelatedLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 18.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) in Accrued Liabilities and Employee-related Liabilities",
        "label": "Increase (Decrease) in Accrued Liabilities and Employee-related Liabilities",
        "terseLabel": "Accrued liabilities and accrued compensation"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndEmployeeRelatedLiabilities",
     "nsuri": "http://www.summitplc.com/20211231",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "smmt_IncreaseDecreaseInResearchAndDevelopmentTaxCreditReceivable": {
     "auth_ref": [],
     "calculation": {
      "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Research And Development Tax Credit Receivable",
        "label": "Increase (Decrease) In Research And Development Tax Credit Receivable",
        "negatedTerseLabel": "Research and development tax credit receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInResearchAndDevelopmentTaxCreditReceivable",
     "nsuri": "http://www.summitplc.com/20211231",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "smmt_InitialPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Initial Purchase Agreement",
        "label": "Initial Purchase Agreement [Member]",
        "terseLabel": "Initial Purchase Agreement"
       }
      }
     },
     "localname": "InitialPurchaseAgreementMember",
     "nsuri": "http://www.summitplc.com/20211231",
     "presentation": [
      "http://www.summitplc.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "smmt_InterestExpenseIncomeNoncash": {
     "auth_ref": [],
     "calculation": {
      "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest Expense (Income), Noncash",
        "label": "Interest Expense (Income), Noncash",
        "terseLabel": "Non-cash interest expense"
       }
      }
     },
     "localname": "InterestExpenseIncomeNoncash",
     "nsuri": "http://www.summitplc.com/20211231",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "smmt_LaboratoryEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Laboratory Equipment",
        "label": "Laboratory Equipment [Member]",
        "terseLabel": "Laboratory equipment"
       }
      }
     },
     "localname": "LaboratoryEquipmentMember",
     "nsuri": "http://www.summitplc.com/20211231",
     "presentation": [
      "http://www.summitplc.com/role/PropertyandEquipmentComponentsofpropertyandequipmentDetails",
      "http://www.summitplc.com/role/SummaryofSignificantAccountingPoliciesPropertyandequipmentusefullivesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "smmt_LesseeOperatingLeaseNumberOfContracts": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Number Of Contracts",
        "label": "Lessee, Operating Lease, Number Of Contracts",
        "terseLabel": "Number of leases"
       }
      }
     },
     "localname": "LesseeOperatingLeaseNumberOfContracts",
     "nsuri": "http://www.summitplc.com/20211231",
     "presentation": [
      "http://www.summitplc.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "smmt_LiquidityAndCapitalResourcesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liquidity and Capital Resources",
        "label": "Liquidity and Capital Resources [Text Block]",
        "terseLabel": "Liquidity and Capital Resources"
       }
      }
     },
     "localname": "LiquidityAndCapitalResourcesTextBlock",
     "nsuri": "http://www.summitplc.com/20211231",
     "presentation": [
      "http://www.summitplc.com/role/LiquidityandCapitalResources"
     ],
     "xbrltype": "textBlockItemType"
    },
    "smmt_MenloParkCaliforniaUSAndSawstonUKMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Menlo Park, California, US and Sawston, UK",
        "label": "Menlo Park, California, US and Sawston, UK [Member]",
        "terseLabel": "Menlo Park, California, U.S. and Sawston, UK"
       }
      }
     },
     "localname": "MenloParkCaliforniaUSAndSawstonUKMember",
     "nsuri": "http://www.summitplc.com/20211231",
     "presentation": [
      "http://www.summitplc.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "smmt_NotesPayableRelatedPartiesMaturityTriggeringEventPublicOfferingProceedsThreshold": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Notes Payable, Related Parties, Maturity Triggering Event, Public Offering Proceeds Threshold",
        "label": "Notes Payable, Related Parties, Maturity Triggering Event, Public Offering Proceeds Threshold",
        "terseLabel": "Notes payable, maturity triggering event, public offering proceeds threshold"
       }
      }
     },
     "localname": "NotesPayableRelatedPartiesMaturityTriggeringEventPublicOfferingProceedsThreshold",
     "nsuri": "http://www.summitplc.com/20211231",
     "presentation": [
      "http://www.summitplc.com/role/NatureofBusinessandOperationsandRecentEventsDetails",
      "http://www.summitplc.com/role/RelatedPartyTransactionsDetails",
      "http://www.summitplc.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "smmt_NotesPayableRelatedPartiesMaximumTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Notes Payable, Related Parties, Maximum Term",
        "label": "Notes Payable, Related Parties, Maximum Term",
        "terseLabel": "Notes payable, maximum term"
       }
      }
     },
     "localname": "NotesPayableRelatedPartiesMaximumTerm",
     "nsuri": "http://www.summitplc.com/20211231",
     "presentation": [
      "http://www.summitplc.com/role/NatureofBusinessandOperationsandRecentEventsDetails",
      "http://www.summitplc.com/role/RelatedPartyTransactionsDetails",
      "http://www.summitplc.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "smmt_OfficeAndTechnologyEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Office And Technology Equipment",
        "label": "Office And Technology Equipment [Member]",
        "terseLabel": "Office and IT equipment"
       }
      }
     },
     "localname": "OfficeAndTechnologyEquipmentMember",
     "nsuri": "http://www.summitplc.com/20211231",
     "presentation": [
      "http://www.summitplc.com/role/SummaryofSignificantAccountingPoliciesPropertyandequipmentusefullivesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "smmt_OptionOverNonFinancialAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Option Over Non-Financial Assets",
        "label": "Option Over Non-Financial Assets [Member]",
        "terseLabel": "Option over non-financial asset"
       }
      }
     },
     "localname": "OptionOverNonFinancialAssetsMember",
     "nsuri": "http://www.summitplc.com/20211231",
     "presentation": [
      "http://www.summitplc.com/role/GoodwillandIntangibleAssetsScheduleofacquiredintangibleassetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "smmt_OtherCommitmentPeriodForWhichTheMajorityOfCommitmentsAreToBePaid": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Commitment, Period for Which the Majority of Commitments are To Be Paid",
        "label": "Other Commitment, Period for Which the Majority of Commitments are To Be Paid",
        "terseLabel": "Period for which the majority of contractual commitments are to be paid"
       }
      }
     },
     "localname": "OtherCommitmentPeriodForWhichTheMajorityOfCommitmentsAreToBePaid",
     "nsuri": "http://www.summitplc.com/20211231",
     "presentation": [
      "http://www.summitplc.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "smmt_OtherGrantFundingCounterpartiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Grant Funding Counterparties",
        "label": "Other Grant Funding Counterparties [Member]",
        "terseLabel": "Other grant funding counterparties"
       }
      }
     },
     "localname": "OtherGrantFundingCounterpartiesMember",
     "nsuri": "http://www.summitplc.com/20211231",
     "presentation": [
      "http://www.summitplc.com/role/OtherOperatingIncomeOtheroperatingincomebycategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "smmt_OtherOperatingIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Operating Income, Policy",
        "label": "Other Operating Income, Policy [Policy Text Block]",
        "terseLabel": "Other Operating Income"
       }
      }
     },
     "localname": "OtherOperatingIncomePolicyPolicyTextBlock",
     "nsuri": "http://www.summitplc.com/20211231",
     "presentation": [
      "http://www.summitplc.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "smmt_OtherPatentsAndLicensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Patents and Licenses",
        "label": "Other Patents and Licenses [Member]",
        "terseLabel": "Other patents and licenses"
       }
      }
     },
     "localname": "OtherPatentsAndLicensesMember",
     "nsuri": "http://www.summitplc.com/20211231",
     "presentation": [
      "http://www.summitplc.com/role/GoodwillandIntangibleAssetsScheduleofacquiredintangibleassetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "smmt_OxfordshireUKMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Oxfordshire, UK",
        "label": "Oxfordshire, UK [Member]",
        "terseLabel": "Oxfordshire, UK"
       }
      }
     },
     "localname": "OxfordshireUKMember",
     "nsuri": "http://www.summitplc.com/20211231",
     "presentation": [
      "http://www.summitplc.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "smmt_PotentialDeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential Deferred Tax Assets, Operating Loss Carryforwards",
        "label": "Potential Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Potential deferred tax asset"
       }
      }
     },
     "localname": "PotentialDeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://www.summitplc.com/20211231",
     "presentation": [
      "http://www.summitplc.com/role/IncomeTaxNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "smmt_RelatedPartyTransactionBeneficialOwnershipPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related Party Transaction, Ownership Percentage",
        "label": "Related Party Transaction, Beneficial Ownership Percentage",
        "terseLabel": "Beneficial ownership percentage"
       }
      }
     },
     "localname": "RelatedPartyTransactionBeneficialOwnershipPercentage",
     "nsuri": "http://www.summitplc.com/20211231",
     "presentation": [
      "http://www.summitplc.com/role/NatureofBusinessandOperationsandRecentEventsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "smmt_RelatedPartyTransactionExpectedRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related Party Transaction, Expected Rate",
        "label": "Related Party Transaction, Expected Rate",
        "terseLabel": "Notes payable, estimated interest rate"
       }
      }
     },
     "localname": "RelatedPartyTransactionExpectedRate",
     "nsuri": "http://www.summitplc.com/20211231",
     "presentation": [
      "http://www.summitplc.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "smmt_RelatedPartyTransactionMonthlyExpensesFromTransactionsWithRelatedParty": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related Party Transaction, Monthly Expenses From Transactions With Related Party",
        "label": "Related Party Transaction, Monthly Expenses From Transactions With Related Party",
        "terseLabel": "Monthly expense from related party"
       }
      }
     },
     "localname": "RelatedPartyTransactionMonthlyExpensesFromTransactionsWithRelatedParty",
     "nsuri": "http://www.summitplc.com/20211231",
     "presentation": [
      "http://www.summitplc.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "smmt_RelatedPartyTransactionPaymentsToRelatedParty": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related Party Transaction, Payments To Related Party",
        "label": "Related Party Transaction, Payments To Related Party",
        "terseLabel": "Payments to related party"
       }
      }
     },
     "localname": "RelatedPartyTransactionPaymentsToRelatedParty",
     "nsuri": "http://www.summitplc.com/20211231",
     "presentation": [
      "http://www.summitplc.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "smmt_RelatedPartyTransactionRateBasisSpreadOnVariableRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related Party Transaction, Rate, Basis Spread On Variable Rate",
        "label": "Related Party Transaction, Rate, Basis Spread On Variable Rate",
        "terseLabel": "Notes payable, basis spread on variable rate"
       }
      }
     },
     "localname": "RelatedPartyTransactionRateBasisSpreadOnVariableRate",
     "nsuri": "http://www.summitplc.com/20211231",
     "presentation": [
      "http://www.summitplc.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "smmt_ResearchAndDevelopmentPrepaidExpensesCurrent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and Development Prepaid Expenses, Current",
        "label": "Research and Development Prepaid Expenses, Current",
        "terseLabel": "Prepaid research and development expenditures"
       }
      }
     },
     "localname": "ResearchAndDevelopmentPrepaidExpensesCurrent",
     "nsuri": "http://www.summitplc.com/20211231",
     "presentation": [
      "http://www.summitplc.com/role/ResearchandDevelopmentPrepaidExpensesandAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "smmt_ResearchAndDevelopmentTaxCredit": {
     "auth_ref": [],
     "calculation": {
      "http://www.summitplc.com/role/OtherOperatingIncomeOtheroperatingincomebycategoryDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherOperatingIncome",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research And Development, Tax Credit",
        "label": "Research And Development, Tax Credit",
        "terseLabel": "Research and development tax credits",
        "verboseLabel": "Research and development tax relief"
       }
      }
     },
     "localname": "ResearchAndDevelopmentTaxCredit",
     "nsuri": "http://www.summitplc.com/20211231",
     "presentation": [
      "http://www.summitplc.com/role/IncomeTaxNarrativeDetails",
      "http://www.summitplc.com/role/OtherOperatingIncomeOtheroperatingincomebycategoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "smmt_ResearchAndDevelopmentTaxCreditCashRebateMaximumPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research And Development Tax Credit, Cash Rebate Maximum, Percentage",
        "label": "Research And Development Tax Credit, Cash Rebate Maximum, Percentage",
        "terseLabel": "Research and development maximum cash rebate percentage"
       }
      }
     },
     "localname": "ResearchAndDevelopmentTaxCreditCashRebateMaximumPercentage",
     "nsuri": "http://www.summitplc.com/20211231",
     "presentation": [
      "http://www.summitplc.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "smmt_ResearchAndDevelopmentTaxCreditReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research And Development Tax Credit Receivable",
        "label": "Research And Development Tax Credit Receivable",
        "terseLabel": "Research and development tax credit receivable"
       }
      }
     },
     "localname": "ResearchAndDevelopmentTaxCreditReceivable",
     "nsuri": "http://www.summitplc.com/20211231",
     "presentation": [
      "http://www.summitplc.com/role/LiquidityandCapitalResourcesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "smmt_ResearchAndDevelopmentTaxCreditReceivableCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.summitplc.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research And Development Tax Credit Receivable, Current",
        "label": "Research And Development Tax Credit Receivable, Current",
        "terseLabel": "Research and development tax credit receivable",
        "verboseLabel": "Current research and development tax credit receivable"
       }
      }
     },
     "localname": "ResearchAndDevelopmentTaxCreditReceivableCurrent",
     "nsuri": "http://www.summitplc.com/20211231",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedBalanceSheets",
      "http://www.summitplc.com/role/OtherOperatingIncomeNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "smmt_RevenueFromContractWithCustomerDevelopmentCommercialAndSalesMilestoneCumulativeNetSalesTargetAchievementRevenueEntitledToReceive": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue From Contract With Customer, Development, Commercial And Sales Milestone, Cumulative Net Sales Target Achievement, Revenue Entitled To Receive",
        "label": "Revenue From Contract With Customer, Development, Commercial And Sales Milestone, Cumulative Net Sales Target Achievement, Revenue Entitled To Receive",
        "terseLabel": "Revenue entitled to receive upon achieving cumulative net sales targets"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerDevelopmentCommercialAndSalesMilestoneCumulativeNetSalesTargetAchievementRevenueEntitledToReceive",
     "nsuri": "http://www.summitplc.com/20211231",
     "presentation": [
      "http://www.summitplc.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "smmt_RevenueFromContractWithCustomerDevelopmentCommercialAndSalesMilestoneCumulativeNetSalesTargetThreshold": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue From Contract With Customer, Development, Commercial And Sales Milestone, Cumulative Net Sales Target Threshold",
        "label": "Revenue From Contract With Customer, Development, Commercial And Sales Milestone, Cumulative Net Sales Target Threshold",
        "terseLabel": "Cumulative net sales target threshold"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerDevelopmentCommercialAndSalesMilestoneCumulativeNetSalesTargetThreshold",
     "nsuri": "http://www.summitplc.com/20211231",
     "presentation": [
      "http://www.summitplc.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "smmt_RevenueFromContractWithCustomerDevelopmentCommercialAndSalesMilestoneIncrementalCumulativeNetSalesTargetThreshold": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue From Contract With Customer, Development, Commercial And Sales Milestone, Incremental Cumulative Net Sales Target Threshold",
        "label": "Revenue From Contract With Customer, Development, Commercial And Sales Milestone, Incremental Cumulative Net Sales Target Threshold",
        "terseLabel": "Incremental cumulative net sales target threshold"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerDevelopmentCommercialAndSalesMilestoneIncrementalCumulativeNetSalesTargetThreshold",
     "nsuri": "http://www.summitplc.com/20211231",
     "presentation": [
      "http://www.summitplc.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "smmt_RevenueFromContractWithCustomerDevelopmentMilestoneRevenueEntitledToReceive": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue From Contract With Customer, Development Milestone, Revenue Entitled To Receive",
        "label": "Revenue From Contract With Customer, Development Milestone, Revenue Entitled To Receive",
        "terseLabel": "Revenue entitled to receive upon various development milestones"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerDevelopmentMilestoneRevenueEntitledToReceive",
     "nsuri": "http://www.summitplc.com/20211231",
     "presentation": [
      "http://www.summitplc.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "smmt_RevenueInformationUsedToDetermineTransactionPriceNumberOfEnrollmentMilestones": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue, Information Used to Determine Transaction Price, Number of Enrollment Milestones",
        "label": "Revenue, Information Used to Determine Transaction Price, Number of Enrollment Milestones",
        "terseLabel": "Number of enrollment milestones included in transaction price"
       }
      }
     },
     "localname": "RevenueInformationUsedToDetermineTransactionPriceNumberOfEnrollmentMilestones",
     "nsuri": "http://www.summitplc.com/20211231",
     "presentation": [
      "http://www.summitplc.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "smmt_RightsOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights Offering",
        "label": "Rights Offering [Member]",
        "terseLabel": "Rights Offering"
       }
      }
     },
     "localname": "RightsOfferingMember",
     "nsuri": "http://www.summitplc.com/20211231",
     "presentation": [
      "http://www.summitplc.com/role/NatureofBusinessandOperationsandRecentEventsDetails",
      "http://www.summitplc.com/role/RelatedPartyTransactionsDetails",
      "http://www.summitplc.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "smmt_ScheduleOfOtherOperatingIncomeByComponentTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Other Operating Income, by Component",
        "label": "Schedule of Other Operating Income, by Component [Table Text Block]",
        "terseLabel": "Summary of other operating income by category"
       }
      }
     },
     "localname": "ScheduleOfOtherOperatingIncomeByComponentTableTextBlock",
     "nsuri": "http://www.summitplc.com/20211231",
     "presentation": [
      "http://www.summitplc.com/role/OtherOperatingIncomeTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "smmt_SecondPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Second Purchase Agreement",
        "label": "Second Purchase Agreement [Member]",
        "terseLabel": "Second Purchase Agreement"
       }
      }
     },
     "localname": "SecondPurchaseAgreementMember",
     "nsuri": "http://www.summitplc.com/20211231",
     "presentation": [
      "http://www.summitplc.com/role/NatureofBusinessandOperationsandRecentEventsDetails",
      "http://www.summitplc.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "smmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveOfferingPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-based Payment Award, Consecutive Offering Period",
        "label": "Share-Based Compensation Arrangement By Share-based Payment Award, Consecutive Offering Period",
        "terseLabel": "Consecutive offering period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveOfferingPeriod",
     "nsuri": "http://www.summitplc.com/20211231",
     "presentation": [
      "http://www.summitplc.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "smmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedOutstandingNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested, Outstanding, Number",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested, Outstanding, Number",
        "terseLabel": "Outstanding vested awards (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedOutstandingNumber",
     "nsuri": "http://www.summitplc.com/20211231",
     "presentation": [
      "http://www.summitplc.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "smmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement By Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Weighted Average Exercise Price",
        "label": "Share-based Compensation Arrangement By Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Weighted Average Exercise Price",
        "verboseLabel": "Weighted average exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://www.summitplc.com/20211231",
     "presentation": [
      "http://www.summitplc.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "smmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Allowable Under The Plan",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Allowable Under The Plan",
        "terseLabel": "Number of additional shares that can be added to the plan for future issuance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan",
     "nsuri": "http://www.summitplc.com/20211231",
     "presentation": [
      "http://www.summitplc.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "smmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-based Payment Award, Offering Period",
        "label": "Share-Based Compensation Arrangement By Share-based Payment Award, Offering Period",
        "terseLabel": "Offering period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod",
     "nsuri": "http://www.summitplc.com/20211231",
     "presentation": [
      "http://www.summitplc.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "smmt_StockIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issuance Costs Incurred During Noncash or Partial Noncash Transaction",
        "label": "Stock Issuance Costs Incurred During Noncash or Partial Noncash Transaction",
        "terseLabel": "Transaction costs included in accrued expenses"
       }
      }
     },
     "localname": "StockIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction",
     "nsuri": "http://www.summitplc.com/20211231",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "smmt_UtrophinProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Utrophin Program",
        "label": "Utrophin Program [Member]",
        "terseLabel": "Utrophin program"
       }
      }
     },
     "localname": "UtrophinProgramMember",
     "nsuri": "http://www.summitplc.com/20211231",
     "presentation": [
      "http://www.summitplc.com/role/GoodwillandIntangibleAssetsScheduleofacquiredintangibleassetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "smmt_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseDueToChangeInEnactedTaxRateAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease) Due To Change In Enacted Tax Rate, Amount",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease) Due To Change In Enacted Tax Rate, Amount",
        "terseLabel": "Increase in valuation allowance due to change in enacted tax rate"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetIncreaseDecreaseDueToChangeInEnactedTaxRateAmount",
     "nsuri": "http://www.summitplc.com/20211231",
     "presentation": [
      "http://www.summitplc.com/role/IncomeTaxNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "smmt_WarrantsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants, Policy",
        "label": "Warrants, Policy [Policy Text Block]",
        "terseLabel": "Warrants"
       }
      }
     },
     "localname": "WarrantsPolicyPolicyTextBlock",
     "nsuri": "http://www.summitplc.com/20211231",
     "presentation": [
      "http://www.summitplc.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "srt_AffiliatedEntityMember": {
     "auth_ref": [
      "r503",
      "r569",
      "r588",
      "r589",
      "r591"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Affiliated Entity [Member]",
        "terseLabel": "Affiliated entity"
       }
      }
     },
     "localname": "AffiliatedEntityMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/RelatedPartyTransactionsDetails",
      "http://www.summitplc.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ChiefExecutiveOfficerMember": {
     "auth_ref": [
      "r558"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chief Executive Officer [Member]",
        "terseLabel": "Chief Executive Officer"
       }
      }
     },
     "localname": "ChiefExecutiveOfficerMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/LiquidityandCapitalResourcesDetails",
      "http://www.summitplc.com/role/NatureofBusinessandOperationsandRecentEventsDetails",
      "http://www.summitplc.com/role/RelatedPartyTransactionsDetails",
      "http://www.summitplc.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ChiefOperatingOfficerMember": {
     "auth_ref": [
      "r558",
      "r590"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chief Operating Officer [Member]",
        "terseLabel": "Chief Operations Officer"
       }
      }
     },
     "localname": "ChiefOperatingOfficerMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r210",
      "r211",
      "r308",
      "r310",
      "r509",
      "r511"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/OtherOperatingIncomeNarrativeDetails",
      "http://www.summitplc.com/role/OtherOperatingIncomeOtheroperatingincomebycategoryDetails",
      "http://www.summitplc.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_DirectorMember": {
     "auth_ref": [
      "r558"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Director [Member]",
        "terseLabel": "Director"
       }
      }
     },
     "localname": "DirectorMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_LatinAmericaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Latin America [Member]",
        "terseLabel": "Latin America"
       }
      }
     },
     "localname": "LatinAmericaMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/RevenueRevenuebygeographyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r355",
      "r449",
      "r478",
      "r504",
      "r505",
      "r517",
      "r525",
      "r531",
      "r565",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.summitplc.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.summitplc.com/role/SummaryofSignificantAccountingPoliciesPropertyandequipmentusefullivesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r355",
      "r449",
      "r478",
      "r504",
      "r505",
      "r517",
      "r525",
      "r531",
      "r565",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.summitplc.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.summitplc.com/role/SummaryofSignificantAccountingPoliciesPropertyandequipmentusefullivesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r273",
      "r451",
      "r518",
      "r529",
      "r567",
      "r601"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/GoodwillandIntangibleAssetsNarrativeDetails",
      "http://www.summitplc.com/role/GoodwillandIntangibleAssetsScheduleofacquiredintangibleassetsDetails",
      "http://www.summitplc.com/role/RevenueNarrativeDetails",
      "http://www.summitplc.com/role/RevenueRevenuebycategoryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r273",
      "r451",
      "r518",
      "r529",
      "r567",
      "r601"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/GoodwillandIntangibleAssetsNarrativeDetails",
      "http://www.summitplc.com/role/GoodwillandIntangibleAssetsScheduleofacquiredintangibleassetsDetails",
      "http://www.summitplc.com/role/RevenueNarrativeDetails",
      "http://www.summitplc.com/role/RevenueRevenuebycategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r353",
      "r355",
      "r448",
      "r449",
      "r478",
      "r504",
      "r505",
      "r517",
      "r525",
      "r531",
      "r565",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.summitplc.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.summitplc.com/role/SummaryofSignificantAccountingPoliciesPropertyandequipmentusefullivesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r353",
      "r355",
      "r448",
      "r449",
      "r478",
      "r504",
      "r505",
      "r517",
      "r525",
      "r531",
      "r565",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.summitplc.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.summitplc.com/role/SummaryofSignificantAccountingPoliciesPropertyandequipmentusefullivesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r210",
      "r211",
      "r308",
      "r310",
      "r510",
      "r511"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/OtherOperatingIncomeNarrativeDetails",
      "http://www.summitplc.com/role/OtherOperatingIncomeOtheroperatingincomebycategoryDetails",
      "http://www.summitplc.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioForecastMember": {
     "auth_ref": [
      "r356",
      "r555"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forecast [Member]",
        "terseLabel": "Forecast"
       }
      }
     },
     "localname": "ScenarioForecastMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r229",
      "r356",
      "r555"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]",
        "terseLabel": "Scenario [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r274",
      "r275",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r519",
      "r530",
      "r567"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/LeasesNarrativeDetails",
      "http://www.summitplc.com/role/RevenueRevenuebygeographyDetails",
      "http://www.summitplc.com/role/SegmentReportingLonglivedassetsbygeographyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r274",
      "r275",
      "r489",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r519",
      "r530",
      "r567"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/LeasesNarrativeDetails",
      "http://www.summitplc.com/role/RevenueRevenuebygeographyDetails",
      "http://www.summitplc.com/role/SegmentReportingLonglivedassetsbygeographyDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r229",
      "r356",
      "r542",
      "r543",
      "r555"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]",
        "terseLabel": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r558",
      "r590"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]",
        "terseLabel": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]",
        "terseLabel": "Title of Individual [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingChangesAndErrorCorrectionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Changes and Error Corrections [Abstract]"
       }
      }
     },
     "localname": "AccountingChangesAndErrorCorrectionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureNoncurrentTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as noncurrent at the end of the reporting period.",
        "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Noncurrent [Text Block]",
        "terseLabel": "Other Non-Current Liabilities"
       }
      }
     },
     "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureNoncurrentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/OtherNonCurrentLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r22",
      "r528"
     ],
     "calculation": {
      "http://www.summitplc.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r185",
      "r279",
      "r280",
      "r508"
     ],
     "calculation": {
      "http://www.summitplc.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedBalanceSheets",
      "http://www.summitplc.com/role/LiquidityandCapitalResourcesDetails",
      "http://www.summitplc.com/role/OtherOperatingIncomeNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r24"
     ],
     "calculation": {
      "http://www.summitplc.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r20",
      "r88"
     ],
     "calculation": {
      "http://www.summitplc.com/role/PropertyandEquipmentComponentsofpropertyandequipmentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "terseLabel": "Less: accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/PropertyandEquipmentComponentsofpropertyandequipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r33",
      "r34",
      "r35",
      "r186",
      "r474",
      "r483",
      "r486"
     ],
     "calculation": {
      "http://www.summitplc.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r32",
      "r35",
      "r153",
      "r479",
      "r480",
      "r506",
      "r544",
      "r545",
      "r546",
      "r552",
      "r553",
      "r554"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": {
     "auth_ref": [
      "r78"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Acquired Finite-lived Intangible Assets, Weighted Average Useful Life",
        "terseLabel": "Weighted-average remaining useful life"
       }
      }
     },
     "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/GoodwillandIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r12",
      "r361",
      "r528"
     ],
     "calculation": {
      "http://www.summitplc.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r357",
      "r358",
      "r359",
      "r552",
      "r553",
      "r554",
      "r579"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.summitplc.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r98",
      "r100",
      "r134",
      "r135"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {
     "auth_ref": [
      "r94",
      "r95"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.",
        "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs",
        "terseLabel": "Offering cots"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r100",
      "r126",
      "r133"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/StockBasedCompensationSummaryofstockbasedcompensationexpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r54",
      "r76",
      "r82"
     ],
     "calculation": {
      "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Amortization of intangible assets",
        "verboseLabel": "Amortization expense"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.summitplc.com/role/GoodwillandIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Potentially dilutive securities excluded from the computation of diluted loss per share"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/LossperSharePotentiallydilutivesecuritiesexcludedfromthecomputationoflosspershareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r60"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/LossperSharePotentiallydilutivesecuritiesexcludedfromthecomputationoflosspershareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/LossperSharePotentiallydilutivesecuritiesexcludedfromthecomputationoflosspershareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r60"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/LossperSharePotentiallydilutivesecuritiesexcludedfromthecomputationoflosspershareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r163",
      "r172",
      "r206",
      "r260",
      "r264",
      "r269",
      "r283",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r398",
      "r400",
      "r407",
      "r528",
      "r563",
      "r564",
      "r592"
     ],
     "calculation": {
      "http://www.summitplc.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r1",
      "r3",
      "r31",
      "r206",
      "r283",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r398",
      "r400",
      "r407",
      "r528",
      "r563",
      "r564",
      "r592"
     ],
     "calculation": {
      "http://www.summitplc.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Noncurrent [Abstract]",
        "terseLabel": "Non-current assets:"
       }
      }
     },
     "localname": "AssetsNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r101",
      "r130"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.summitplc.com/role/StockBasedCompensationRSUactivityDetails",
      "http://www.summitplc.com/role/StockBasedCompensationWeightedaverageassumptionsusedforstockoptionawardsDetails",
      "http://www.summitplc.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccounting": {
     "auth_ref": [
      "r59"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting [Text Block]",
        "terseLabel": "Basis of Presentation and Use of Estimates"
       }
      }
     },
     "localname": "BasisOfAccounting",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/BasisofPresentationandUseofEstimates"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BeneficialOwnerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Any person who, directly or indirectly, through any contract, arrangement, understanding, relationship, or otherwise has shares of the entity with 1) voting power which includes the power to vote, or to direct the voting of, such security, and/or 2) investment power which includes the power to dispose, or to direct the disposition of, such security.",
        "label": "Beneficial Owner [Member]",
        "terseLabel": "Beneficial owner"
       }
      }
     },
     "localname": "BeneficialOwnerMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": {
     "auth_ref": [
      "r397",
      "r547"
     ],
     "calculation": {
      "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.",
        "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability",
        "verboseLabel": "Gain on recognition of contingent consideration payable"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationsPolicy": {
     "auth_ref": [
      "r148"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.",
        "label": "Business Combinations Policy [Policy Text Block]",
        "terseLabel": "Business Combinations"
       }
      }
     },
     "localname": "BusinessCombinationsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Cash": {
     "auth_ref": [
      "r17",
      "r487",
      "r488",
      "r528"
     ],
     "calculation": {
      "http://www.summitplc.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash",
        "terseLabel": "Cash"
       }
      }
     },
     "localname": "Cash",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedBalanceSheets",
      "http://www.summitplc.com/role/LiquidityandCapitalResourcesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r51",
      "r56",
      "r58"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash at end of period",
        "periodStartLabel": "Cash at beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r51",
      "r156"
     ],
     "calculation": {
      "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Increase in cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Exercise price of warrants (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/RelatedPartyTransactionsDetails",
      "http://www.summitplc.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Each Warrant or Right",
        "terseLabel": "Number of common stock shares into which each warrant converts (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.summitplc.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "terseLabel": "Number of common stock shares into which warrants may be converted (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/RelatedPartyTransactionsDetails",
      "http://www.summitplc.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Outstanding",
        "terseLabel": "Warrants outstanding (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r27",
      "r92",
      "r166",
      "r176"
     ],
     "calculation": {
      "http://www.summitplc.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 19)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r91",
      "r93",
      "r297",
      "r298",
      "r490"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r28"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Number of shares initially reserve for future issuance (in shares)"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r552",
      "r553",
      "r579"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.summitplc.com/role/NatureofBusinessandOperationsandRecentEventsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r11",
      "r94"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.summitplc.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.summitplc.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesSubscribedButUnissued": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of common stock allocated to investors to buy shares of a new issue of common stock before they are offered to the public. When stock is sold on a subscription basis, the issuer does not initially receive the total proceeds. In general, the issuer does not issue the shares to the investor until it receives the entire proceeds.",
        "label": "Common Stock, Shares Subscribed but Unissued",
        "terseLabel": "Number of shares of common stock subscribed (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesSubscribedButUnissued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r11",
      "r528"
     ],
     "calculation": {
      "http://www.summitplc.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.01 par value: 250,000,000 shares authorized; 98,039,540 and 82,575,064 shares issued and outstanding at December 31, 2021 and 2020, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Assets [Abstract]",
        "terseLabel": "Deferred tax assets:"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxAssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/IncomeTaxMajorcomponentsofdeferredtaxassetsandliabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Liabilities [Abstract]",
        "terseLabel": "Deferred tax liabilities:"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/IncomeTaxMajorcomponentsofdeferredtaxassetsandliabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r36",
      "r188",
      "r190",
      "r196",
      "r470",
      "r475"
     ],
     "calculation": {
      "http://www.summitplc.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComputerSoftwareIntangibleAssetMember": {
     "auth_ref": [
      "r526",
      "r560",
      "r561"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collection of computer programs and related data that provide instructions to a computer, for example, but not limited to, application program, control module or operating system, that perform one or more particular functions or tasks.",
        "label": "Computer Software, Intangible Asset [Member]",
        "terseLabel": "Software"
       }
      }
     },
     "localname": "ComputerSoftwareIntangibleAssetMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/GoodwillandIntangibleAssetsNarrativeDetails",
      "http://www.summitplc.com/role/GoodwillandIntangibleAssetsScheduleofacquiredintangibleassetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r170",
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration of Credit Risk and of Significant Supplier"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r151",
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Principles of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": {
     "auth_ref": [
      "r566"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.",
        "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]",
        "terseLabel": "Summary of deferred revenue and other income"
       }
      }
     },
     "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/RevenueTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerAssetNetCurrent": {
     "auth_ref": [
      "r324",
      "r326",
      "r345"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.",
        "label": "Contract with Customer, Asset, after Allowance for Credit Loss, Current",
        "terseLabel": "Current contract asset"
       }
      }
     },
     "localname": "ContractWithCustomerAssetNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/OtherOperatingIncomeNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r324",
      "r325",
      "r345"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability",
        "periodEndLabel": "Ending deferred revenue and other income",
        "periodStartLabel": "Beginning deferred revenue and other income",
        "terseLabel": "Deferred revenue, upfront payment"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/RevenueDeferredrevenueandotherincomeDetails",
      "http://www.summitplc.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r324",
      "r325",
      "r345"
     ],
     "calculation": {
      "http://www.summitplc.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "netLabel": "Current deferred revenue and other income",
        "terseLabel": "Deferred revenue and other income",
        "verboseLabel": "Current contract liability"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedBalanceSheets",
      "http://www.summitplc.com/role/RevenueDeferredrevenueandotherincomeDetails",
      "http://www.summitplc.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r324",
      "r325",
      "r345"
     ],
     "calculation": {
      "http://www.summitplc.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract with Customer, Liability, Noncurrent",
        "netLabel": "Long-term deferred revenue and other income",
        "terseLabel": "Deferred revenue and other income, net of current portion",
        "verboseLabel": "Non-current contract liability"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedBalanceSheets",
      "http://www.summitplc.com/role/RevenueDeferredrevenueandotherincomeDetails",
      "http://www.summitplc.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "auth_ref": [
      "r346"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "negatedTerseLabel": "Amount of deferred revenue and other income recognized in the statement of operations"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/RevenueDeferredrevenueandotherincomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "auth_ref": [
      "r147",
      "r550",
      "r575"
     ],
     "calculation": {
      "http://www.summitplc.com/role/IncomeTaxSignificantcomponentsoftheprovisionforincometaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Federal Tax Expense (Benefit)",
        "terseLabel": "Federal United States"
       }
      }
     },
     "localname": "CurrentFederalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/IncomeTaxSignificantcomponentsoftheprovisionforincometaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentForeignTaxExpenseBenefit": {
     "auth_ref": [
      "r550",
      "r575"
     ],
     "calculation": {
      "http://www.summitplc.com/role/IncomeTaxSignificantcomponentsoftheprovisionforincometaxesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Foreign Tax Expense (Benefit)",
        "terseLabel": "Non-United States"
       }
      }
     },
     "localname": "CurrentForeignTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/IncomeTaxSignificantcomponentsoftheprovisionforincometaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r147",
      "r378",
      "r389",
      "r550"
     ],
     "calculation": {
      "http://www.summitplc.com/role/IncomeTaxSignificantcomponentsoftheprovisionforincometaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.",
        "label": "Current Income Tax Expense (Benefit)",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/IncomeTaxSignificantcomponentsoftheprovisionforincometaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Current income tax benefit:"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/IncomeTaxSignificantcomponentsoftheprovisionforincometaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [
      "r147",
      "r550",
      "r575"
     ],
     "calculation": {
      "http://www.summitplc.com/role/IncomeTaxSignificantcomponentsoftheprovisionforincometaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current State and Local Tax Expense (Benefit)",
        "terseLabel": "State - United States"
       }
      }
     },
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/IncomeTaxSignificantcomponentsoftheprovisionforincometaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r147",
      "r550",
      "r576"
     ],
     "calculation": {
      "http://www.summitplc.com/role/IncomeTaxSignificantcomponentsoftheprovisionforincometaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "terseLabel": "Federal - United States"
       }
      }
     },
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/IncomeTaxSignificantcomponentsoftheprovisionforincometaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r147",
      "r550",
      "r576"
     ],
     "calculation": {
      "http://www.summitplc.com/role/IncomeTaxSignificantcomponentsoftheprovisionforincometaxesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Foreign Income Tax Expense (Benefit)",
        "terseLabel": "Non-United States"
       }
      }
     },
     "localname": "DeferredForeignIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/IncomeTaxSignificantcomponentsoftheprovisionforincometaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r54",
      "r147",
      "r379",
      "r388",
      "r389",
      "r550"
     ],
     "calculation": {
      "http://www.summitplc.com/role/IncomeTaxSignificantcomponentsoftheprovisionforincometaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "totalLabel": "Total deferred tax"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/IncomeTaxSignificantcomponentsoftheprovisionforincometaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "auth_ref": [
      "r8",
      "r9",
      "r164",
      "r171",
      "r372"
     ],
     "calculation": {
      "http://www.summitplc.com/role/IncomeTaxMajorcomponentsofdeferredtaxassetsandliabilitiesDetails": {
       "order": 2.0,
       "parentTag": "smmt_DeferredTaxAssetsLiabilities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Tax Liabilities, Gross",
        "negatedTotalLabel": "Total deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/IncomeTaxMajorcomponentsofdeferredtaxassetsandliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r147",
      "r550",
      "r576"
     ],
     "calculation": {
      "http://www.summitplc.com/role/IncomeTaxSignificantcomponentsoftheprovisionforincometaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "terseLabel": "State - United States"
       }
      }
     },
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/IncomeTaxSignificantcomponentsoftheprovisionforincometaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r373"
     ],
     "calculation": {
      "http://www.summitplc.com/role/IncomeTaxMajorcomponentsofdeferredtaxassetsandliabilitiesDetails": {
       "order": 1.0,
       "parentTag": "smmt_DeferredTaxAssetsLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "terseLabel": "Deferred tax asset",
        "totalLabel": "Total deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/IncomeTaxMajorcomponentsofdeferredtaxassetsandliabilitiesDetails",
      "http://www.summitplc.com/role/IncomeTaxNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r573"
     ],
     "calculation": {
      "http://www.summitplc.com/role/IncomeTaxMajorcomponentsofdeferredtaxassetsandliabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets, Net",
        "negatedTotalLabel": "Deferred tax, net"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/IncomeTaxMajorcomponentsofdeferredtaxassetsandliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r145",
      "r574"
     ],
     "calculation": {
      "http://www.summitplc.com/role/IncomeTaxMajorcomponentsofdeferredtaxassetsandliabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforward"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/IncomeTaxMajorcomponentsofdeferredtaxassetsandliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r145",
      "r574"
     ],
     "calculation": {
      "http://www.summitplc.com/role/IncomeTaxMajorcomponentsofdeferredtaxassetsandliabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/IncomeTaxMajorcomponentsofdeferredtaxassetsandliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "auth_ref": [
      "r143",
      "r145",
      "r574"
     ],
     "calculation": {
      "http://www.summitplc.com/role/IncomeTaxMajorcomponentsofdeferredtaxassetsandliabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "terseLabel": "Research and development credit carryforward"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/IncomeTaxMajorcomponentsofdeferredtaxassetsandliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r145",
      "r574"
     ],
     "calculation": {
      "http://www.summitplc.com/role/IncomeTaxMajorcomponentsofdeferredtaxassetsandliabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost",
        "terseLabel": "Stock based compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/IncomeTaxMajorcomponentsofdeferredtaxassetsandliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r374"
     ],
     "calculation": {
      "http://www.summitplc.com/role/IncomeTaxMajorcomponentsofdeferredtaxassetsandliabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedTerseLabel": "Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/IncomeTaxMajorcomponentsofdeferredtaxassetsandliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets": {
     "auth_ref": [
      "r145",
      "r574"
     ],
     "calculation": {
      "http://www.summitplc.com/role/IncomeTaxMajorcomponentsofdeferredtaxassetsandliabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.",
        "label": "Deferred Tax Liabilities, Intangible Assets",
        "negatedTerseLabel": "Intangible asset"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/IncomeTaxMajorcomponentsofdeferredtaxassetsandliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesOther": {
     "auth_ref": [
      "r145",
      "r574"
     ],
     "calculation": {
      "http://www.summitplc.com/role/IncomeTaxMajorcomponentsofdeferredtaxassetsandliabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other.",
        "label": "Deferred Tax Liabilities, Other",
        "negatedTerseLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/IncomeTaxMajorcomponentsofdeferredtaxassetsandliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r54",
      "r86"
     ],
     "calculation": {
      "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation",
        "verboseLabel": "Depreciation expense"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.summitplc.com/role/PropertyandEquipmentNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/RevenueNarrativeDetails",
      "http://www.summitplc.com/role/RevenueRevenuebygeographyDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r344",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/RevenueNarrativeDetails",
      "http://www.summitplc.com/role/RevenueRevenuebygeographyDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r136"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/StockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Tax Authority [Member]",
        "terseLabel": "U.S. Federal"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/IncomeTaxNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r197",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r232",
      "r234",
      "r236",
      "r237",
      "r238",
      "r242",
      "r404",
      "r405",
      "r471",
      "r476",
      "r514"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Basic (in dollars per share)",
        "verboseLabel": "Basic net loss per share (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.summitplc.com/role/LossperShareComputationofnetlosspershareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDilutedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic and Diluted [Abstract]",
        "terseLabel": "Net loss per share:"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDilutedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r197",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r234",
      "r236",
      "r237",
      "r238",
      "r242",
      "r404",
      "r405",
      "r471",
      "r476",
      "r514"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Diluted (in dollars per share)",
        "verboseLabel": "Diluted net loss per share (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.summitplc.com/role/LossperShareComputationofnetlosspershareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r60",
      "r61"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Income Per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r239",
      "r240",
      "r241",
      "r243"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Loss per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/LossperShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r415"
     ],
     "calculation": {
      "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "terseLabel": "Effect of exchange rates on cash"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r366"
     ],
     "calculation": {
      "http://www.summitplc.com/role/IncomeTaxReconciliationoftheeffectiveincometaxratetostatutoryrateDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Effective tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/IncomeTaxReconciliationoftheeffectiveincometaxratetostatutoryrateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r208",
      "r366",
      "r391"
     ],
     "calculation": {
      "http://www.summitplc.com/role/IncomeTaxReconciliationoftheeffectiveincometaxratetostatutoryrateDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "U.S. federal income tax statutory rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/IncomeTaxReconciliationoftheeffectiveincometaxratetostatutoryrateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r572",
      "r577"
     ],
     "calculation": {
      "http://www.summitplc.com/role/IncomeTaxReconciliationoftheeffectiveincometaxratetostatutoryrateDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "terseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/IncomeTaxReconciliationoftheeffectiveincometaxratetostatutoryrateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": {
     "auth_ref": [
      "r572",
      "r577"
     ],
     "calculation": {
      "http://www.summitplc.com/role/IncomeTaxReconciliationoftheeffectiveincometaxratetostatutoryrateDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent",
        "terseLabel": "Effect of foreign operations taxed at various rates"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/IncomeTaxReconciliationoftheeffectiveincometaxratetostatutoryrateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense": {
     "auth_ref": [
      "r572",
      "r577"
     ],
     "calculation": {
      "http://www.summitplc.com/role/IncomeTaxReconciliationoftheeffectiveincometaxratetostatutoryrateDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent",
        "terseLabel": "Non-deductible expenses"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/IncomeTaxReconciliationoftheeffectiveincometaxratetostatutoryrateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "auth_ref": [
      "r572",
      "r577"
     ],
     "calculation": {
      "http://www.summitplc.com/role/IncomeTaxReconciliationoftheeffectiveincometaxratetostatutoryrateDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/IncomeTaxReconciliationoftheeffectiveincometaxratetostatutoryrateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent": {
     "auth_ref": [
      "r571",
      "r572"
     ],
     "calculation": {
      "http://www.summitplc.com/role/IncomeTaxReconciliationoftheeffectiveincometaxratetostatutoryrateDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Percent",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/IncomeTaxReconciliationoftheeffectiveincometaxratetostatutoryrateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r24"
     ],
     "calculation": {
      "http://www.summitplc.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Accrued compensation"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/StockBasedCompensationSummaryofstockbasedcompensationexpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r129"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Unrecognized compensation expense for options, period of recognition"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "auth_ref": [
      "r129"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r129"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation expense for options"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Employee Stock [Member]",
        "terseLabel": "ESPP",
        "verboseLabel": "Shares expected to be purchased under employee stock purchase plan"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/LossperSharePotentiallydilutivesecuritiesexcludedfromthecomputationoflosspershareDetails",
      "http://www.summitplc.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r570"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock options",
        "verboseLabel": "Options to purchase common stock"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/LossperSharePotentiallydilutivesecuritiesexcludedfromthecomputationoflosspershareDetails",
      "http://www.summitplc.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.summitplc.com/role/StockBasedCompensationWeightedaverageassumptionsusedforstockoptionawardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenue from External Customer [Line Items]",
        "terseLabel": "Revenue from External Customer [Line Items]"
       }
      }
     },
     "localname": "EntityWideInformationRevenueFromExternalCustomerLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/OtherOperatingIncomeOtheroperatingincomebycategoryDetails",
      "http://www.summitplc.com/role/RevenueRevenuebycategoryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r94",
      "r182",
      "r192",
      "r193",
      "r194",
      "r212",
      "r213",
      "r214",
      "r218",
      "r226",
      "r228",
      "r244",
      "r284",
      "r323",
      "r357",
      "r358",
      "r359",
      "r381",
      "r382",
      "r403",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r479",
      "r480",
      "r481",
      "r506"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.summitplc.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r154",
      "r155"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Financial Value Measurements"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/GoodwillandIntangibleAssetsEstimatedamortizationexpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r83"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/GoodwillandIntangibleAssetsEstimatedamortizationexpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "auth_ref": [
      "r83"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/GoodwillandIntangibleAssetsEstimatedamortizationexpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r83"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/GoodwillandIntangibleAssetsEstimatedamortizationexpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r83"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/GoodwillandIntangibleAssetsEstimatedamortizationexpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r83"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/GoodwillandIntangibleAssetsEstimatedamortizationexpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r291",
      "r292",
      "r293",
      "r294",
      "r452",
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/GoodwillandIntangibleAssetsNarrativeDetails",
      "http://www.summitplc.com/role/GoodwillandIntangibleAssetsScheduleofacquiredintangibleassetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure": {
     "auth_ref": [
      "r580"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of assets, excluding financial assets, that lack physical substance, having a limited useful life.",
        "label": "Finite-lived Intangible Assets, Fair Value Disclosure",
        "terseLabel": "Fair value of option over non-financial asset"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/GoodwillandIntangibleAssetsScheduleofacquiredintangibleassetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r81",
      "r456"
     ],
     "calculation": {
      "http://www.summitplc.com/role/GoodwillandIntangibleAssetsScheduleofacquiredintangibleassetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "terseLabel": "Gross"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/GoodwillandIntangibleAssetsScheduleofacquiredintangibleassetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/GoodwillandIntangibleAssetsNarrativeDetails",
      "http://www.summitplc.com/role/GoodwillandIntangibleAssetsScheduleofacquiredintangibleassetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r77",
      "r80"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/GoodwillandIntangibleAssetsNarrativeDetails",
      "http://www.summitplc.com/role/GoodwillandIntangibleAssetsScheduleofacquiredintangibleassetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r81",
      "r452"
     ],
     "calculation": {
      "http://www.summitplc.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.summitplc.com/role/GoodwillandIntangibleAssetsScheduleofacquiredintangibleassetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "totalLabel": "Net",
        "verboseLabel": "Intangible assets, net"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedBalanceSheets",
      "http://www.summitplc.com/role/GoodwillandIntangibleAssetsScheduleofacquiredintangibleassetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile.",
        "label": "Foreign Tax Authority [Member]",
        "terseLabel": "U.K."
       }
      }
     },
     "localname": "ForeignCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/IncomeTaxNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "auth_ref": [
      "r411",
      "r412",
      "r413",
      "r414"
     ],
     "calculation": {
      "http://www.summitplc.com/role/OtherExpenseIncomeDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.",
        "label": "Foreign Currency Transaction Gain (Loss), before Tax",
        "terseLabel": "Foreign currency (loss) gain",
        "verboseLabel": "Foreign currency transaction (losses) gains"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/OtherExpenseIncomeDetails",
      "http://www.summitplc.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyTransactionGainLossUnrealized": {
     "auth_ref": [
      "r55",
      "r583",
      "r584"
     ],
     "calculation": {
      "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction unrealized gain (loss) recognized in the income statement.",
        "label": "Foreign Currency Transaction Gain (Loss), Unrealized",
        "negatedTerseLabel": "Unrealized foreign exchange loss (gain)"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLossUnrealized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "terseLabel": "Foreign Currency Translation"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://www.summitplc.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r40"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/StockBasedCompensationSummaryofstockbasedcompensationexpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r70",
      "r72",
      "r469",
      "r528"
     ],
     "calculation": {
      "http://www.summitplc.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedBalanceSheets",
      "http://www.summitplc.com/role/GoodwillandIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r85"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "terseLabel": "Goodwill and Intangible Assets"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/GoodwillandIntangibleAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": {
     "auth_ref": [
      "r74"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.",
        "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy": {
     "auth_ref": [
      "r79"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined.",
        "label": "Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]",
        "terseLabel": "Intangible Assets"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsIntangibleAssetsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillImpairedAccumulatedImpairmentLoss": {
     "auth_ref": [
      "r289",
      "r290"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impaired, Accumulated Impairment Loss",
        "terseLabel": "Cumulative goodwill impairment charges"
       }
      }
     },
     "localname": "GoodwillImpairedAccumulatedImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/GoodwillandIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "auth_ref": [
      "r54",
      "r71",
      "r73",
      "r75"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impairment Loss",
        "terseLabel": "Goodwill impairment charge"
       }
      }
     },
     "localname": "GoodwillImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/GoodwillandIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r54",
      "r84"
     ],
     "calculation": {
      "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.summitplc.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.",
        "label": "Impairment of Intangible Assets (Excluding Goodwill)",
        "terseLabel": "Impairment of intangible assets"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.summitplc.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsFinitelived": {
     "auth_ref": [
      "r548",
      "r562"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.",
        "label": "Impairment of Intangible Assets, Finite-lived",
        "terseLabel": "Impairment of Intangible Assets, Finite-lived"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsFinitelived",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/GoodwillandIntangibleAssetsScheduleofacquiredintangibleassetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "auth_ref": [
      "r207",
      "r390"
     ],
     "calculation": {
      "http://www.summitplc.com/role/IncomeTaxComponentsoflossbeforeincometaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "terseLabel": "United States"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/IncomeTaxComponentsoflossbeforeincometaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r38",
      "r162",
      "r167",
      "r179",
      "r260",
      "r263",
      "r268",
      "r271",
      "r472",
      "r516"
     ],
     "calculation": {
      "http://www.summitplc.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      },
      "http://www.summitplc.com/role/IncomeTaxComponentsoflossbeforeincometaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss before income tax"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.summitplc.com/role/IncomeTaxComponentsoflossbeforeincometaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "auth_ref": [
      "r207",
      "r390"
     ],
     "calculation": {
      "http://www.summitplc.com/role/IncomeTaxComponentsoflossbeforeincometaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "terseLabel": "United Kingdom"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/IncomeTaxComponentsoflossbeforeincometaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r295",
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/StockBasedCompensationSummaryofstockbasedcompensationexpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/StockBasedCompensationSummaryofstockbasedcompensationexpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r141"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/IncomeTaxNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/IncomeTaxNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r208",
      "r367",
      "r370",
      "r377",
      "r386",
      "r392",
      "r394",
      "r395",
      "r396"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Tax"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/IncomeTax"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r209",
      "r227",
      "r228",
      "r259",
      "r365",
      "r387",
      "r393",
      "r477"
     ],
     "calculation": {
      "http://www.summitplc.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      },
      "http://www.summitplc.com/role/IncomeTaxSignificantcomponentsoftheprovisionforincometaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedTerseLabel": "Income tax benefit",
        "totalLabel": "Total income tax benefit"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.summitplc.com/role/IncomeTaxSignificantcomponentsoftheprovisionforincometaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r191",
      "r363",
      "r364",
      "r370",
      "r371",
      "r376",
      "r380"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "auth_ref": [
      "r57"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.",
        "label": "Income Taxes Paid, Net",
        "terseLabel": "Cash paid (received) for income taxes"
       }
      }
     },
     "localname": "IncomeTaxesPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r53"
     ],
     "calculation": {
      "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r53"
     ],
     "calculation": {
      "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedTerseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r450",
      "r547"
     ],
     "calculation": {
      "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Deferred revenue and other income"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "auth_ref": [
      "r547",
      "r585"
     ],
     "calculation": {
      "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 19.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation for operating lease.",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r53"
     ],
     "calculation": {
      "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedTerseLabel": "Other current and long-term assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpense": {
     "auth_ref": [
      "r53"
     ],
     "calculation": {
      "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.",
        "label": "Increase (Decrease) in Prepaid Expense",
        "negatedTerseLabel": "Prepaid expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r157",
      "r169",
      "r195",
      "r258",
      "r424"
     ],
     "calculation": {
      "http://www.summitplc.com/role/OtherExpenseIncomeDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedTerseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/OtherExpenseIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r200",
      "r202",
      "r203"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Cash paid for interest on related party promissory note"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r43",
      "r257"
     ],
     "calculation": {
      "http://www.summitplc.com/role/OtherExpenseIncomeDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/OtherExpenseIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestorMember": {
     "auth_ref": [
      "r588",
      "r589"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business entity or individual that puts money, by purchase or expenditure, in something offering potential profitable returns, such as interest income or appreciation in value.",
        "label": "Investor [Member]",
        "terseLabel": "Investor"
       }
      }
     },
     "localname": "InvestorMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r435",
      "r527"
     ],
     "calculation": {
      "http://www.summitplc.com/role/LeasesLeaseexpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "totalLabel": "Total lease cost"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/LeasesLeaseexpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost [Abstract]",
        "terseLabel": "Lease Cost:"
       }
      }
     },
     "localname": "LeaseCostAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/LeasesLeaseexpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r586"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Schedule of lease expense"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r87"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/PropertyandEquipmentComponentsofpropertyandequipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r587"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of future lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r436"
     ],
     "calculation": {
      "http://www.summitplc.com/role/LeasesFutureleasepaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.summitplc.com/role/LeasesFutureleasepaymentsDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/LeasesFutureleasepaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r436"
     ],
     "calculation": {
      "http://www.summitplc.com/role/LeasesFutureleasepaymentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/LeasesFutureleasepaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r436"
     ],
     "calculation": {
      "http://www.summitplc.com/role/LeasesFutureleasepaymentsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/LeasesFutureleasepaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r436"
     ],
     "calculation": {
      "http://www.summitplc.com/role/LeasesFutureleasepaymentsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/LeasesFutureleasepaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r436"
     ],
     "calculation": {
      "http://www.summitplc.com/role/LeasesFutureleasepaymentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/LeasesFutureleasepaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r436"
     ],
     "calculation": {
      "http://www.summitplc.com/role/LeasesFutureleasepaymentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/LeasesFutureleasepaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r436"
     ],
     "calculation": {
      "http://www.summitplc.com/role/LeasesFutureleasepaymentsDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "terseLabel": "Less: imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/LeasesFutureleasepaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r437"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r23",
      "r206",
      "r283",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r399",
      "r400",
      "r401",
      "r407",
      "r515",
      "r563",
      "r592",
      "r593"
     ],
     "calculation": {
      "http://www.summitplc.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r16",
      "r165",
      "r174",
      "r528",
      "r549",
      "r559",
      "r582"
     ],
     "calculation": {
      "http://www.summitplc.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r25",
      "r206",
      "r283",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r399",
      "r400",
      "r401",
      "r407",
      "r528",
      "r563",
      "r592",
      "r593"
     ],
     "calculation": {
      "http://www.summitplc.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Noncurrent [Abstract]",
        "terseLabel": "Non-current liabilities"
       }
      }
     },
     "localname": "LiabilitiesNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LicenseAndServiceMember": {
     "auth_ref": [
      "r568"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right to use intangible asset and performance of related service. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.",
        "label": "License and Service [Member]",
        "terseLabel": "Licensing agreements"
       }
      }
     },
     "localname": "LicenseAndServiceMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/RevenueNarrativeDetails",
      "http://www.summitplc.com/role/RevenueRevenuebycategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock": {
     "auth_ref": [
      "r67"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of long-lived assets, excluding financial instruments, long-term customer relationships of a financial institution, mortgage rights, deferred policy acquisition costs, and deferred tax assets, by geographic areas located in the entity's country of domicile and foreign countries in which the entity holds assets.",
        "label": "Long-lived Assets by Geographic Areas [Table Text Block]",
        "terseLabel": "Summary of long-lived assets by geography"
       }
      }
     },
     "localname": "LongLivedAssetsByGeographicAreasTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/SegmentReportingTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MeasurementInputDiscountRateMember": {
     "auth_ref": [
      "r581"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using interest rate to determine present value of future cash flows.",
        "label": "Measurement Input, Discount Rate [Member]",
        "terseLabel": "Discount rate"
       }
      }
     },
     "localname": "MeasurementInputDiscountRateMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r406"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]",
        "terseLabel": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]",
        "terseLabel": "Measurement Input Type [Domain]"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NatureOfOperations": {
     "auth_ref": [
      "r245",
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.",
        "label": "Nature of Operations [Text Block]",
        "terseLabel": "Nature of Business and Operations and Recent Events"
       }
      }
     },
     "localname": "NatureOfOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/NatureofBusinessandOperationsandRecentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r201"
     ],
     "calculation": {
      "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows provided by financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r201"
     ],
     "calculation": {
      "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows used in investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r51",
      "r52",
      "r55"
     ],
     "calculation": {
      "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "negatedLabel": "Net cash used in operating activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.summitplc.com/role/LiquidityandCapitalResourcesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows used in operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r39",
      "r55",
      "r168",
      "r178",
      "r184",
      "r187",
      "r189",
      "r194",
      "r206",
      "r217",
      "r221",
      "r222",
      "r223",
      "r224",
      "r227",
      "r228",
      "r235",
      "r260",
      "r263",
      "r268",
      "r271",
      "r283",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r405",
      "r407",
      "r516",
      "r563"
     ],
     "calculation": {
      "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.summitplc.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "negatedLabel": "Net loss",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.summitplc.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.summitplc.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.summitplc.com/role/LiquidityandCapitalResourcesDetails",
      "http://www.summitplc.com/role/LossperShareComputationofnetlosspershareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": {
     "auth_ref": [
      "r183",
      "r215",
      "r216",
      "r219",
      "r220",
      "r229",
      "r230",
      "r231",
      "r281",
      "r282",
      "r285",
      "r286",
      "r348",
      "r349",
      "r350",
      "r351",
      "r360",
      "r383",
      "r384",
      "r385",
      "r402",
      "r408",
      "r409",
      "r410",
      "r438",
      "r453",
      "r454",
      "r455",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.",
        "label": "Accounting Standards Update and Change in Accounting Principle [Text Block]",
        "terseLabel": "Recently Issued or Adopted Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/RecentlyIssuedorAdoptedAccountingPronouncements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Issued or Adopted Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncurrentAssets": {
     "auth_ref": [
      "r275"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets.",
        "label": "Long-Lived Assets",
        "terseLabel": "Long-lived assets"
       }
      }
     },
     "localname": "NoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/SegmentReportingLonglivedassetsbygeographyDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://www.summitplc.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      },
      "http://www.summitplc.com/role/OtherExpenseIncomeDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "terseLabel": "Other (expense) income, net",
        "totalLabel": "Other (expense) income, net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.summitplc.com/role/OtherExpenseIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent": {
     "auth_ref": [
      "r159",
      "r177",
      "r551"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount for notes payable (written promise to pay), due to related parties.",
        "label": "Notes Payable, Related Parties",
        "terseLabel": "Notes payable"
       }
      }
     },
     "localname": "NotesPayableRelatedPartiesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/NatureofBusinessandOperationsandRecentEventsDetails",
      "http://www.summitplc.com/role/RelatedPartyTransactionsDetails",
      "http://www.summitplc.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NumberOfCountriesInWhichEntityOperates": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of countries in which the entity operates as of balance sheet date.",
        "label": "Number of Countries in which Entity Operates",
        "terseLabel": "Number of geographic regions in which the Company operates"
       }
      }
     },
     "localname": "NumberOfCountriesInWhichEntityOperates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/SegmentReportingNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r557"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/SegmentReportingNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_NumberOfReportingUnits": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of reporting units tested for impairment of goodwill. A reporting unit is an operating segment or one level below an operating segment.",
        "label": "Number of Reporting Units",
        "terseLabel": "Number of reporting units"
       }
      }
     },
     "localname": "NumberOfReportingUnits",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/GoodwillandIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.summitplc.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r260",
      "r263",
      "r268",
      "r271",
      "r516"
     ],
     "calculation": {
      "http://www.summitplc.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Operating loss"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r429",
      "r527"
     ],
     "calculation": {
      "http://www.summitplc.com/role/LeasesLeaseexpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Fixed lease costs"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/LeasesLeaseexpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r426"
     ],
     "calculation": {
      "http://www.summitplc.com/role/LeasesFutureleasepaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.summitplc.com/role/LeasesFutureleasepaymentsDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "totalLabel": "Total operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/LeasesFutureleasepaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability [Abstract]",
        "terseLabel": "Total operating lease liabilities balance sheet presentation:"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/LeasesFutureleasepaymentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r426"
     ],
     "calculation": {
      "http://www.summitplc.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.summitplc.com/role/LeasesFutureleasepaymentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Lease liabilities",
        "verboseLabel": "Current lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedBalanceSheets",
      "http://www.summitplc.com/role/LeasesFutureleasepaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r426"
     ],
     "calculation": {
      "http://www.summitplc.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://www.summitplc.com/role/LeasesFutureleasepaymentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Lease liabilities, net of current portion",
        "verboseLabel": "Non-current lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedBalanceSheets",
      "http://www.summitplc.com/role/LeasesFutureleasepaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r425"
     ],
     "calculation": {
      "http://www.summitplc.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedBalanceSheets",
      "http://www.summitplc.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "auth_ref": [
      "r548"
     ],
     "calculation": {
      "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for right-of-use asset from operating lease.",
        "label": "Operating Lease, Right-of-Use Asset, Amortization Expense",
        "terseLabel": "Amortization of operating right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r434",
      "r527"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r433",
      "r527"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted average remaining lease term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r143"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Operating loss carryforwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/IncomeTaxNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Operating Loss Carryforwards [Line Items]",
        "terseLabel": "Schedule Of Income Tax [Line Items]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/IncomeTaxNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "auth_ref": [
      "r144"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.",
        "label": "Operating Loss Carryforwards [Table]",
        "terseLabel": "Schedule Of Income Tax [Table]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/IncomeTaxNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r30",
      "r528"
     ],
     "calculation": {
      "http://www.summitplc.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "terseLabel": "Other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r21"
     ],
     "calculation": {
      "http://www.summitplc.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCommitment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.",
        "label": "Other Commitment",
        "terseLabel": "Contractual commitments"
       }
      }
     },
     "localname": "OtherCommitment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r149",
      "r150",
      "r152"
     ],
     "calculation": {
      "http://www.summitplc.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Foreign currency translation adjustments",
        "verboseLabel": "Foreign currency translation adjustment"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.summitplc.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "terseLabel": "Other comprehensive (loss) income:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherIncomeAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Income and Expenses [Abstract]"
       }
      }
     },
     "localname": "OtherIncomeAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r4",
      "r5",
      "r24",
      "r528"
     ],
     "calculation": {
      "http://www.summitplc.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "terseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r26"
     ],
     "calculation": {
      "http://www.summitplc.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other non-current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r55"
     ],
     "calculation": {
      "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "Other Noncash Income (Expense)",
        "negatedTerseLabel": "Other adjustments"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock": {
     "auth_ref": [
      "r198",
      "r199"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the components of non-operating income or non-operating expense, including, but not limited to, amounts earned from dividends, interest on securities, gain (loss) on securities sold, equity earnings of unconsolidated affiliates, gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.",
        "label": "Other Nonoperating Income and Expense [Text Block]",
        "terseLabel": "Other (Expense) Income"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeAndExpenseTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/OtherExpenseIncome"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherOperatingIncome": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://www.summitplc.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      },
      "http://www.summitplc.com/role/OtherOperatingIncomeOtheroperatingincomebycategoryDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of other operating income, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operation.",
        "label": "Other Operating Income",
        "terseLabel": "Other operating income",
        "totalLabel": "Other operating income"
       }
      }
     },
     "localname": "OtherOperatingIncome",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.summitplc.com/role/OtherOperatingIncomeOtheroperatingincomebycategoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherOperatingIncomeAndExpenseTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for other operating income and other operating expense items.",
        "label": "Other Operating Income and Expense [Text Block]",
        "terseLabel": "Other Operating Income"
       }
      }
     },
     "localname": "OtherOperatingIncomeAndExpenseTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/OtherOperatingIncome"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsOfDebtIssuanceCosts": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.",
        "label": "Payments of Debt Issuance Costs",
        "negatedTerseLabel": "Payments of related party promissory notes issuance costs"
       }
      }
     },
     "localname": "PaymentsOfDebtIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "negatedTerseLabel": "Transaction costs from the issuance of common stock",
        "terseLabel": "Offering costs"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.summitplc.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedTerseLabel": "Purchase of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r101",
      "r130"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "auth_ref": [
      "r0",
      "r2",
      "r287",
      "r288"
     ],
     "calculation": {
      "http://www.summitplc.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense, Current",
        "terseLabel": "Prepaid expenses"
       }
      }
     },
     "localname": "PrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrivatePlacementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts.",
        "label": "Private Placement [Member]",
        "terseLabel": "Private placement"
       }
      }
     },
     "localname": "PrivatePlacementMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/RelatedPartyTransactionsDetails",
      "http://www.summitplc.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from the issuance of common stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromRelatedPartyDebt": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.",
        "label": "Proceeds from Related Party Debt",
        "terseLabel": "Proceeds from related party promissory notes"
       }
      }
     },
     "localname": "ProceedsFromRelatedPartyDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.summitplc.com/role/LiquidityandCapitalResourcesDetails",
      "http://www.summitplc.com/role/NatureofBusinessandOperationsandRecentEventsDetails",
      "http://www.summitplc.com/role/RelatedPartyTransactionsDetails",
      "http://www.summitplc.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r46",
      "r131"
     ],
     "calculation": {
      "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from exercise of share options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r20",
      "r89"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/PropertyandEquipmentComponentsofpropertyandequipmentDetails",
      "http://www.summitplc.com/role/SummaryofSignificantAccountingPoliciesPropertyandequipmentusefullivesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r90",
      "r491",
      "r492",
      "r493"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/PropertyandEquipment"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r19",
      "r87"
     ],
     "calculation": {
      "http://www.summitplc.com/role/PropertyandEquipmentComponentsofpropertyandequipmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/PropertyandEquipmentComponentsofpropertyandequipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/PropertyandEquipmentComponentsofpropertyandequipmentDetails",
      "http://www.summitplc.com/role/SummaryofSignificantAccountingPoliciesPropertyandequipmentusefullivesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r6",
      "r7",
      "r89",
      "r175",
      "r473",
      "r528"
     ],
     "calculation": {
      "http://www.summitplc.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.summitplc.com/role/PropertyandEquipmentComponentsofpropertyandequipmentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedBalanceSheets",
      "http://www.summitplc.com/role/PropertyandEquipmentComponentsofpropertyandequipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r18",
      "r89",
      "r491",
      "r492"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r6",
      "r89"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of property and equipment useful lives",
        "verboseLabel": "Schedule of property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/PropertyandEquipmentTables",
      "http://www.summitplc.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r6",
      "r87"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Long-Lived Tangible Asset [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/PropertyandEquipmentComponentsofpropertyandequipmentDetails",
      "http://www.summitplc.com/role/SummaryofSignificantAccountingPoliciesPropertyandequipmentusefullivesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Property and equipment, estimated useful Lives"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/SummaryofSignificantAccountingPoliciesPropertyandequipmentusefullivesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_PurchaseObligation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier.",
        "label": "Purchase Obligation",
        "terseLabel": "Capital commitments"
       }
      }
     },
     "localname": "PurchaseObligation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r354",
      "r441",
      "r442"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/LiquidityandCapitalResourcesDetails",
      "http://www.summitplc.com/role/NatureofBusinessandOperationsandRecentEventsDetails",
      "http://www.summitplc.com/role/RelatedPartyTransactionsDetails",
      "http://www.summitplc.com/role/StockholdersEquityDetails",
      "http://www.summitplc.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "auth_ref": [
      "r354",
      "r441",
      "r442",
      "r591"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party transaction.",
        "label": "Related Party Transaction [Axis]",
        "terseLabel": "Related Party Transaction [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/LiquidityandCapitalResourcesDetails",
      "http://www.summitplc.com/role/NatureofBusinessandOperationsandRecentEventsDetails",
      "http://www.summitplc.com/role/RelatedPartyTransactionsDetails",
      "http://www.summitplc.com/role/StockholdersEquityDetails",
      "http://www.summitplc.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "auth_ref": [
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction between related party.",
        "label": "Related Party Transaction [Domain]",
        "terseLabel": "Related Party Transaction [Domain]"
       }
      }
     },
     "localname": "RelatedPartyTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/LiquidityandCapitalResourcesDetails",
      "http://www.summitplc.com/role/NatureofBusinessandOperationsandRecentEventsDetails",
      "http://www.summitplc.com/role/RelatedPartyTransactionsDetails",
      "http://www.summitplc.com/role/StockholdersEquityDetails",
      "http://www.summitplc.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty": {
     "auth_ref": [
      "r158"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.",
        "label": "Related Party Transaction, Expenses from Transactions with Related Party",
        "terseLabel": "Expenses from related party transactions"
       }
      }
     },
     "localname": "RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/LiquidityandCapitalResourcesDetails",
      "http://www.summitplc.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identify the stated interest rate per the agreement, for example, leasing and debt arrangements between related parties.",
        "label": "Related Party Transaction, Rate",
        "terseLabel": "Interest rate"
       }
      }
     },
     "localname": "RelatedPartyTransactionRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/NatureofBusinessandOperationsandRecentEventsDetails",
      "http://www.summitplc.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r354",
      "r441",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r591"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]",
        "terseLabel": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/LiquidityandCapitalResourcesDetails",
      "http://www.summitplc.com/role/NatureofBusinessandOperationsandRecentEventsDetails",
      "http://www.summitplc.com/role/RelatedPartyTransactionsDetails",
      "http://www.summitplc.com/role/StockholdersEquityDetails",
      "http://www.summitplc.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r439",
      "r440",
      "r442",
      "r443",
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "Related Party Transactions"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/RelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RepaymentsOfRelatedPartyDebt": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates.",
        "label": "Repayments of Related Party Debt",
        "negatedTerseLabel": "Re-payment of related party promissory notes"
       }
      }
     },
     "localname": "RepaymentsOfRelatedPartyDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Research and Development Arrangement, Contract to Perform for Others [Line Items]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others [Line Items]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/OtherOperatingIncomeNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r137",
      "r180",
      "r600"
     ],
     "calculation": {
      "http://www.summitplc.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/StockBasedCompensationSummaryofstockbasedcompensationexpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r137"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Costs"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock": {
     "auth_ref": [
      "r181"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period.",
        "label": "Research, Development, and Computer Software Disclosure [Text Block]",
        "terseLabel": "Research and Development Prepaid Expenses and Accrued Liabilities"
       }
      }
     },
     "localname": "ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/ResearchandDevelopmentPrepaidExpensesandAccruedLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchMember": {
     "auth_ref": [
      "r144"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes.",
        "label": "Research Tax Credit Carryforward [Member]",
        "terseLabel": "Research and development tax credit carryforwards"
       }
      }
     },
     "localname": "ResearchMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/IncomeTaxNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "RSUs",
        "verboseLabel": "Restricted stock units"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/LossperSharePotentiallydilutivesecuritiesexcludedfromthecomputationoflosspershareDetails",
      "http://www.summitplc.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.summitplc.com/role/StockBasedCompensationRSUactivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r13",
      "r95",
      "r173",
      "r361",
      "r482",
      "r486",
      "r528"
     ],
     "calculation": {
      "http://www.summitplc.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "negatedTerseLabel": "Accumulated deficit",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedBalanceSheets",
      "http://www.summitplc.com/role/LiquidityandCapitalResourcesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r182",
      "r212",
      "r213",
      "r214",
      "r218",
      "r226",
      "r228",
      "r284",
      "r357",
      "r358",
      "r359",
      "r381",
      "r382",
      "r403",
      "r479",
      "r481"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Total Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r255",
      "r256",
      "r262",
      "r266",
      "r267",
      "r273",
      "r274",
      "r277",
      "r343",
      "r344",
      "r451"
     ],
     "calculation": {
      "http://www.summitplc.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.summitplc.com/role/RevenueRevenuebycategoryDetails",
      "http://www.summitplc.com/role/RevenueRevenuebygeographyDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r352",
      "r513"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r347",
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/Revenue"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock": {
     "auth_ref": [
      "r66"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.",
        "label": "Revenue from External Customers by Geographic Areas [Table Text Block]",
        "terseLabel": "Summary of revenue by geography"
       }
      }
     },
     "localname": "RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/RevenueTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenues from External Customers and Long-Lived Assets [Line Items]",
        "terseLabel": "Revenues from External Customers and Long-Lived Assets [Line Items]"
       }
      }
     },
     "localname": "RevenuesFromExternalCustomersAndLongLivedAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/SegmentReportingLonglivedassetsbygeographyDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r432",
      "r527"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Leased assets obtained in exchange for operating lease liabilities",
        "verboseLabel": "Additional right-of-use assets recorded"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.summitplc.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Consideration received on sale of stock"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/NatureofBusinessandOperationsandRecentEventsDetails",
      "http://www.summitplc.com/role/RelatedPartyTransactionsDetails",
      "http://www.summitplc.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/NatureofBusinessandOperationsandRecentEventsDetails",
      "http://www.summitplc.com/role/RelatedPartyTransactionsDetails",
      "http://www.summitplc.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Shares issued (in shares)"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/NatureofBusinessandOperationsandRecentEventsDetails",
      "http://www.summitplc.com/role/RelatedPartyTransactionsDetails",
      "http://www.summitplc.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Sale of stock price (in dollars per share)"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/NatureofBusinessandOperationsandRecentEventsDetails",
      "http://www.summitplc.com/role/RelatedPartyTransactionsDetails",
      "http://www.summitplc.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r60"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/LossperSharePotentiallydilutivesecuritiesexcludedfromthecomputationoflosspershareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r60"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of potentially dilutive securities excluded from the computation of loss per share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/LossperShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r146"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Significant components of the provision for income taxes"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/IncomeTaxTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r142"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Major components of deferred tax assets and liabilities"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/IncomeTaxTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r556"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of net loss per share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/LossperShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r140"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Reconciliation of the effective income tax rate to the statutory rate"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/IncomeTaxTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r100",
      "r125",
      "r133"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/StockBasedCompensationSummaryofstockbasedcompensationexpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r100",
      "r125",
      "r133"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Schedule of stock-based compensation expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable": {
     "auth_ref": [
      "r65"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular presentation of the description and amount of revenues from a product or service, or a group of similar products or similar services, reported from external customers during the period, if the information is not provided as part of the reportable operating segment information.",
        "label": "Revenue from External Customers by Products and Services [Table]",
        "terseLabel": "Revenue from External Customers by Products and Services [Table]"
       }
      }
     },
     "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/OtherOperatingIncomeOtheroperatingincomebycategoryDetails",
      "http://www.summitplc.com/role/RevenueRevenuebycategoryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock": {
     "auth_ref": [
      "r65"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.",
        "label": "Revenue from External Customers by Products and Services [Table Text Block]",
        "terseLabel": "Summary of revenue by category"
       }
      }
     },
     "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/RevenueTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r77",
      "r80",
      "r452"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/GoodwillandIntangibleAssetsNarrativeDetails",
      "http://www.summitplc.com/role/GoodwillandIntangibleAssetsScheduleofacquiredintangibleassetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r77",
      "r80"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Schedule of acquired intangible assets"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/GoodwillandIntangibleAssetsTables",
      "http://www.summitplc.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "auth_ref": [
      "r550"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions.",
        "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]",
        "terseLabel": "Components of loss before income taxes"
       }
      }
     },
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/IncomeTaxTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.",
        "label": "Schedule of Other Nonoperating Income (Expense) [Table Text Block]",
        "terseLabel": "Schedule of other (expense) income"
       }
      }
     },
     "localname": "ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/OtherExpenseIncomeTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r20",
      "r89"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/PropertyandEquipmentComponentsofpropertyandequipmentDetails",
      "http://www.summitplc.com/role/SummaryofSignificantAccountingPoliciesPropertyandequipmentusefullivesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r160",
      "r161"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/LiquidityandCapitalResourcesDetails",
      "http://www.summitplc.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable": {
     "auth_ref": [
      "r138",
      "r139"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A schedule reflecting the terms of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others (including royalty arrangements, purchase provisions, license agreements, and commitments to provide additional funding), aggregated by similar arrangements or individually if necessary to understand the effects on the financial statements.",
        "label": "Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]",
        "terseLabel": "Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]"
       }
      }
     },
     "localname": "ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/OtherOperatingIncomeNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable": {
     "auth_ref": [
      "r37",
      "r68"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material.  An entity may also provide subtotals of geographic information about groups of countries.",
        "label": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]",
        "terseLabel": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/SegmentReportingLonglivedassetsbygeographyDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r101",
      "r130"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.summitplc.com/role/StockBasedCompensationRSUactivityDetails",
      "http://www.summitplc.com/role/StockBasedCompensationWeightedaverageassumptionsusedforstockoptionawardsDetails",
      "http://www.summitplc.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "auth_ref": [
      "r106"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Schedule of RSU activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r106",
      "r115",
      "r118"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule of stock option activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r120"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of weighted-average assumptions used for stock option awards"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "auth_ref": [
      "r80"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.",
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "terseLabel": "Schedule estimated future amortization expense related to acquired intangible assets"
       }
      }
     },
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/GoodwillandIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "localname": "SegmentReportingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "auth_ref": [
      "r252",
      "r253",
      "r254",
      "r260",
      "r261",
      "r265",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r276",
      "r277",
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.",
        "label": "Segment Reporting Disclosure [Text Block]",
        "terseLabel": "Segment Reporting"
       }
      }
     },
     "localname": "SegmentReportingDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/SegmentReporting"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r53"
     ],
     "calculation": {
      "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r102"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.summitplc.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r113"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/StockBasedCompensationRSUactivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Number of Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/StockBasedCompensationRSUactivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r113"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Ending balance (in dollars per share)",
        "periodStartLabel": "Beginning balance (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/StockBasedCompensationRSUactivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted Average Grant Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/StockBasedCompensationRSUactivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": {
     "auth_ref": [
      "r119"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms",
        "terseLabel": "Weighted average remaining contractual term"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r114"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedTerseLabel": "Vested (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/StockBasedCompensationRSUactivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r114"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/StockBasedCompensationRSUactivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r123"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected annual dividends per share",
        "verboseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.summitplc.com/role/StockBasedCompensationWeightedaverageassumptionsusedforstockoptionawardsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r124"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/StockBasedCompensationWeightedaverageassumptionsusedforstockoptionawardsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate": {
     "auth_ref": [
      "r122"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rate of weighted-average expected volatility for award under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/StockBasedCompensationWeightedaverageassumptionsusedforstockoptionawardsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.summitplc.com/role/StockBasedCompensationRSUactivityDetails",
      "http://www.summitplc.com/role/StockBasedCompensationWeightedaverageassumptionsusedforstockoptionawardsDetails",
      "http://www.summitplc.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate": {
     "auth_ref": [
      "r130"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Rate",
        "terseLabel": "Maximum common stock purchase allowable as a percentage of compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations": {
     "auth_ref": [
      "r112"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares under non-option equity instrument agreements that were either cancelled or expired.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures and Expirations",
        "terseLabel": "Warrants cancelled (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r130"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Number of shares available for grant (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Stock option activity, additional disclosures"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/StockBasedCompensationStockoptionactivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r109"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Number of share options, exercisable (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/StockBasedCompensationStockoptionactivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r109"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, exercisable (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/StockBasedCompensationStockoptionactivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r117"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value, options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r111"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedTerseLabel": "Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/StockBasedCompensationStockoptionactivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (in shares)",
        "verboseLabel": "Stock options granted previously subject to performance-based vesting (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.summitplc.com/role/StockBasedCompensationStockoptionactivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r116"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average grant date fair value of stock options granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r130"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value, options outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/StockBasedCompensationStockoptionactivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r108",
      "r130"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/StockBasedCompensationStockoptionactivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number of share options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/StockBasedCompensationStockoptionactivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r107"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Ending balance (in dollars per share)",
        "periodStartLabel": "Beginning balance (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/StockBasedCompensationStockoptionactivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted average exercise price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/StockBasedCompensationStockoptionactivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r118"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value, vested and expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/StockBasedCompensationStockoptionactivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r119"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Number of share options, vested and expected to vest (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/StockBasedCompensationStockoptionactivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r119"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, vested and expected to vest (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/StockBasedCompensationStockoptionactivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum",
        "terseLabel": "Maximum percentage of outstanding shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost": {
     "auth_ref": [
      "r128"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An excess of the fair value of the modified award over the fair value of the award immediately before the modification.",
        "label": "Share-based Payment Arrangement, Plan Modification, Incremental Cost",
        "terseLabel": "Incremental costs related to the modification"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected": {
     "auth_ref": [
      "r127"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of grantees affected by modification of award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Plan Modification, Number of Grantees Affected",
        "terseLabel": "Number of employees affected by modification"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r99",
      "r104"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.summitplc.com/role/StockBasedCompensationRSUactivityDetails",
      "http://www.summitplc.com/role/StockBasedCompensationWeightedaverageassumptionsusedforstockoptionawardsDetails",
      "http://www.summitplc.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/StockBasedCompensationStockoptionactivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/StockBasedCompensationStockoptionactivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/StockBasedCompensationStockoptionactivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r101",
      "r105"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding",
        "terseLabel": "Aggregate intrinsic value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intrinsic value of vested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested",
        "terseLabel": "Aggregate intrinsic value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r103"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period",
        "terseLabel": "Expiration period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r121",
      "r132"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/StockBasedCompensationWeightedaverageassumptionsusedforstockoptionawardsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r130"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value, exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/StockBasedCompensationStockoptionactivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r130"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted average remaining contractual term, exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/StockBasedCompensationStockoptionactivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r119"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted average remaining contractual term, options outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/StockBasedCompensationStockoptionactivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r119"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted average remaining contractual term, vested and expected to vest"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/StockBasedCompensationStockoptionactivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent",
        "terseLabel": "Purchase price of common stock as a percentage of closing price"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShortTermLeaseCost": {
     "auth_ref": [
      "r430",
      "r527"
     ],
     "calculation": {
      "http://www.summitplc.com/role/LeasesLeaseexpenseDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less.",
        "label": "Short-term Lease, Cost",
        "terseLabel": "Short-term lease"
       }
      }
     },
     "localname": "ShortTermLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/LeasesLeaseexpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r59",
      "r204"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "U.S. State"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/IncomeTaxNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r29",
      "r94",
      "r182",
      "r192",
      "r193",
      "r194",
      "r212",
      "r213",
      "r214",
      "r218",
      "r226",
      "r228",
      "r244",
      "r284",
      "r323",
      "r357",
      "r358",
      "r359",
      "r381",
      "r382",
      "r403",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r479",
      "r480",
      "r481",
      "r506"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.summitplc.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r212",
      "r213",
      "r214",
      "r244",
      "r451"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r10",
      "r11",
      "r94",
      "r95"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Private placement/Rights offering of common stock, net of offering costs (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r10",
      "r11",
      "r94",
      "r95",
      "r110"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedNetLabel": "Exercised (in shares)",
        "terseLabel": "Issuance on common stock from exercise of share options (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.summitplc.com/role/StockBasedCompensationStockoptionactivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r10",
      "r11",
      "r94",
      "r95"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Private placement/Rights offering of common stock, net of offering costs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r29",
      "r94",
      "r95"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Issuance on common stock from exercise of share options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r11",
      "r14",
      "r15",
      "r69",
      "r528",
      "r549",
      "r559",
      "r582"
     ],
     "calculation": {
      "http://www.summitplc.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedBalanceSheets",
      "http://www.summitplc.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r97",
      "r205",
      "r309",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r323"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/StockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": {
     "auth_ref": [
      "r96"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.",
        "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio",
        "terseLabel": "Reverse stock split ratio"
       }
      }
     },
     "localname": "StockholdersEquityNoteStockSplitConversionRatio1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/NatureofBusinessandOperationsandRecentEventsDetails",
      "http://www.summitplc.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r422",
      "r446"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/LiquidityandCapitalResourcesDetails",
      "http://www.summitplc.com/role/NatureofBusinessandOperationsandRecentEventsDetails",
      "http://www.summitplc.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r422",
      "r446"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r422",
      "r446"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/LiquidityandCapitalResourcesDetails",
      "http://www.summitplc.com/role/NatureofBusinessandOperationsandRecentEventsDetails",
      "http://www.summitplc.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r422",
      "r446"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/LiquidityandCapitalResourcesDetails",
      "http://www.summitplc.com/role/NatureofBusinessandOperationsandRecentEventsDetails",
      "http://www.summitplc.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r445",
      "r447"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/SubsequentEvent"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Different names of stock transactions and the different attributes of each transaction.",
        "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]",
        "terseLabel": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]"
       }
      }
     },
     "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/NatureofBusinessandOperationsandRecentEventsDetails",
      "http://www.summitplc.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/NatureofBusinessandOperationsandRecentEventsDetails",
      "http://www.summitplc.com/role/RelatedPartyTransactionsDetails",
      "http://www.summitplc.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Subsidiary, Sale of Stock [Line Items]",
        "terseLabel": "Subsidiary, Sale of Stock [Line Items]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/NatureofBusinessandOperationsandRecentEventsDetails",
      "http://www.summitplc.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental Disclosure of Cash Flow Information"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "auth_ref": [
      "r143"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Tax Credit Carryforward, Amount",
        "terseLabel": "Tax credit carryforward"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/IncomeTaxNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "auth_ref": [
      "r144"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by specific tax credit related to an unused tax credit.",
        "label": "Tax Credit Carryforward [Axis]",
        "terseLabel": "Tax Credit Carryforward [Axis]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/IncomeTaxNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "auth_ref": [
      "r144"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name of the tax credit carryforward.",
        "label": "Tax Credit Carryforward, Name [Domain]",
        "terseLabel": "Tax Credit Carryforward, Name [Domain]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/IncomeTaxNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r362",
      "r369"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "terseLabel": "Liability for unrecognized tax benefits"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/IncomeTaxNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": {
     "auth_ref": [
      "r368"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued",
        "terseLabel": "Liability for interest and penalties"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/IncomeTaxNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UsTreasuryUstInterestRateMember": {
     "auth_ref": [
      "r578"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate on direct treasury obligation of U.S. government (UST).",
        "label": "US Treasury (UST) Interest Rate [Member]",
        "terseLabel": "10 year US Treasury rate"
       }
      }
     },
     "localname": "UsTreasuryUstInterestRateMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r62",
      "r63",
      "r64",
      "r246",
      "r247",
      "r249",
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r375"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "terseLabel": "Increase in valuation allowance"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/IncomeTaxNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VariableLeaseCost": {
     "auth_ref": [
      "r431",
      "r527"
     ],
     "calculation": {
      "http://www.summitplc.com/role/LeasesLeaseexpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.",
        "label": "Variable Lease, Cost",
        "terseLabel": "Variable lease costs"
       }
      }
     },
     "localname": "VariableLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/LeasesLeaseexpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]",
        "terseLabel": "Variable Rate [Axis]"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate [Domain]",
        "terseLabel": "Variable Rate [Domain]"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]",
        "terseLabel": "Warrants"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/LossperSharePotentiallydilutivesecuritiesexcludedfromthecomputationoflosspershareDetails",
      "http://www.summitplc.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.summitplc.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r233",
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Diluted (in shares)",
        "verboseLabel": "Diluted weighted average number of shares of common stock outstanding (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.summitplc.com/role/LossperShareComputationofnetlosspershareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r232",
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Basic weighted average number of shares of common stock outstanding (in shares)",
        "verboseLabel": "Basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.summitplc.com/role/LossperShareComputationofnetlosspershareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]",
        "terseLabel": "Weighted average common shares outstanding:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 11
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)-(4)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6909625&loc=d3e227-128457",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569643-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123345438&loc=d3e61044-112788",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(15)(b)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.17)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "730",
   "Topic": "985",
   "URI": "http://asc.fasb.org/subtopic&trid=2197926",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(7))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(9))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6787-107765",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=SL108384541-122693",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "250",
   "URI": "http://asc.fasb.org/topic&trid=2122394",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8657-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "26",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8844-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "34",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8981-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "280",
   "URI": "http://asc.fasb.org/topic&trid=2134510",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)(1)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)(2)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=123349782&loc=d3e5879-108316",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130532-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130533-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130558-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130561-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130564-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130550-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(i)(2)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(j)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e7008-128479",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=120253306&loc=d3e28228-110885",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123602790&loc=d3e30226-110892",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=125521441&loc=d3e30690-110894",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=124440516&loc=d3e30840-110895",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "830",
   "URI": "http://asc.fasb.org/topic&trid=2175825",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918666-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "848",
   "URI": "http://asc.fasb.org/extlink&oid=122150657&loc=SL122150809-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "http://asc.fasb.org/topic&trid=2122745",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=123371682&loc=d3e55415-109406",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(1)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(2)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(3)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 4))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "848",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "38",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r532": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r533": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r534": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r535": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r536": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r537": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r538": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r539": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r540": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r541": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "740",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120384911&loc=d3e23163-113944",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=124256753&loc=SL5864739-113975",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=125521441&loc=d3e30690-110894",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=124440516&loc=d3e30840-110895",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "a",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "b",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "http://asc.fasb.org/topic&trid=2144416",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 4.C)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>101
<FILENAME>0001599298-22-000147-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001599298-22-000147-xbrl.zip
M4$L#!!0    ( (*"E56,8]3L1.8! #R!$@ 1    <VUM="TR,#(Q,3(S,2YH
M=&WLO7E;V\JR-_K_^12Z[/>>G=PW@AZE[JRU<A["D,TZL4G 23;\DZ<G88%M
ML66;(9_^5DLVHPD&#![0VN<0VYI:756_&KJZZL__.6NW@A.7=].L\]<27D9+
MP?]\^//_"<-_?]SY'*QGIM]VG5ZPECO5<S8X37O-X(=UW:,@R;-V\"/+C](3
M%8;%-6O9\7F>'C1[ 4&$W#B8OV=",ZPH#:TB.F1*F%#%DH4Q28P3$L68JG<'
M[QV-%++2A-)(%#)*;"B(3D*62!;'V$B2)._L>^*<L4X[ZTS$D,12,IMP'2L9
M::5T[!_;[,';P1MVNN^[>>^OI6:O=_Q^92517;V<Y0<K\.,*#!6'"(<4+PU.
M/=-YRZ879_NOQ=D$H6BE/'AQ:BOM'%V<>7IZNGQ*BW-A.'*E.#H\M=_+KYUX
M];9R!8Y>W+.;CKHCG(97_EW[O&N:KJW"M-/MJ8YQ%[?OA@=*'=]^Q\&!$>^9
MGO5&CRCMP,"=YX"57JXZW23+VZH''.)O@D)$0DR&-S%9O]/+SZ_/5M>9Y8/L
M9&5PL'CV\ +KTM$GPX'BQ/^P*P,,X>BU00[/_MT8,0^1N$'0],[)IRLWYS+M
M9HS@^'=7E&=<#O2N<S&],M+AZ=UV^_K,=_OM=MH[;IEED[6+2<#D8OAWLY=G
M[^$];S'B]0'[PUIURU=\WU*=@[^67"?\MKL$4N*4_?!GV_54X*\/W7_ZZ<E?
M2VM9IP>R'S;.C^$R4W[[:ZGGSGHKQ9-7/OS7?_W7G[VTUW(?_"N%PX'_N5+^
M^.=*>6N=V?,/?]KT).CVSEONKR6;=H];ZOQ])^LX&$!Z]MZ?Z/+R8VJMZQ0?
MX7@= "A/3?G\L]Z.2_Y:2E$2$48(998(P 0'P" ,8M(0*2+CHI_K?B@(_A=>
M3F9'M?VC7?I^%3#->ES;;*F#I:!D';CM6>]]DIXY&R:JY:<JM?"CI=_/]7IV
M\IGLG.S16M\>;ISL?Y*'VX=_M_9_U(_V?\"_G[X?U@^_GFXW-OAV8^=H__![
M6B<;O-[^N[GW8XM^IO76WJ_L?/_']T,X-]W_L0/?]U!M_>ALNW&$]C_MX;U#
MV]QN[*=[/S;3.A;H,]D_W_MAHKW&QFGMUS>VW_Z*:W!-?7V5['_:;,%O?*^Q
M16OK.X?;G[;.]S]MG-A/FZG^]"VJ-W;:>S_J;1C?8>W3_F%]?1.^_PWW_I[6
M#FNT3FJX_ND;V6\/K_D.S^*=_48&O^\W]\A^:X_43O?;-53[ =_A/?9_;)W7
M?AFZ]^L;VF_LM_>^B[//C8U>;1?Y?^'=#VC]X"=%$8J1P&',.0D98R84DB:A
MD1[^D906)TL?-E<_[V[\N7*-Q,])\8T.<.3Y&I \5ZVMCG5G_^O.*P+?1^#S
M$00VC@E/QQ!QQT"+,QY*9W!H:!3SB)+84KOT 8&VXE("=5Z0RD-S93/M&M7:
M<RK?A%^Z%9WOH_.O$72."#8QM38T6,F0Z<2%0B$4BIAR:V)C1:*7/G@R3(W"
M7^#^F:UH/!:-T0@:JSCA5O($3'#C+7(6AU([&2H7*;"O(X$5R/+FWAT4WLR5
M\297T.^D)7T[_;9V^=)UFDL3)U+%491(S!S0G'-E8R<4)S8Q<5S0'(Q@+,+A
MAZ4 S/JT#6KXKZ6M^N:0!0:V[/O=7F:.FED+3(;N!E@KO?-ZUG/%K[O'K;0'
MILO I]GQ-B&PD&<7N &:+I^<U0Z_GNQW@#Z_,J#+$=!Q!YZS1>L_@';M;V1[
M_6-SO_WM5_W7*JG]V$#;ZQMD?U>B_7\WD6E_[Z@?LK]]N-/:;L ]/GT_VCLT
M>._7U_/]QAZK?=IL[S=JP&-[9WN-KZS6V&_]^U<-_W01DQ@Y$<9& V+',,]"
M<Q$Z9:*$"RT3#9*,ELF0S$.Z5G1^+)WKOPZ&=";U'UNHWMY)@9X4Y!YM-YIP
M[AX\S_RJ-0Y8_5<SW6O7VWOG-^GL[_L5\&,+Z&F/@*9\^Q.,ZW"5UW_5SK;7
M#^CV)\ )LG]8T%G&AO,HCL)(80R([50H:8Q"*[5AB4:&:_I;.H]$;/"PP5]W
MD4/$,". I(3K*+&*6L<2ZGZ#V!=D;*K<?03OPZYE[6/7Z1:.VFH.?MN!\W#^
M\?SRE"_JW/^T>JIR6_SY[KJ]M'-0@CV>,F%!((>$/8?[_JHW:J>UPU8;!!L$
M^BL([,&O^CH\ X[M'7YL;J^OTOHMPF[Q6J,&"F+U?/O'WGE]?:=57__*MM<!
M!!I'N-:HI[5/&ZRV;NB_?X$@_UK]R8E)P$,28>14$C("M!5$L1!)C033G!K&
MESY\H;>A>N6Z2Y6[Q.4.G-WN"$_0>XGONT6  8@?%/&+]SWP__Y:ZJ;MXY9W
M'XO?FKGGC6M.W_)9%W3%GRO7[U$^__*A@S%TLWY>?"M<\_<#ABM)^Q@387@C
M5]CYPV^I]=^3U.5!,2 W,I*PMO6_U^W5FQ=_&/YT_>['!4,.OW5[*N^MJY[[
M, RT(#R\[O+8Q3#MY:F8A!1?/J(\,OP^?,C*M8D:.6^*2ZX21I $7TL!WC-M
M##9")BZAL8Q^;A7S%E$T ]-5AEQZ@\F*0HHN;C0X,MX,>(U4O'Z_X+[RQ[93
MW7[N/@RB-.^_[:X/+Q\>&G[WUX^<3:L3(SE8N409\&*IUM)0+.,H)IB"+!:S
M21#%,S:;)$0TQ$^=S:Z'X^ZM"1VP<W'PX3/JB$P4(BS2(-_628(3IJB)(J-
ML>B!>3"0:S2+<HW&EVLT,;DFSF@92_@'1TQKH305+A&@#331$I%2KF=DNJ[)
M];49>!@G7IN!F,9$N\@:%&&01#!!M ;MX 0%S(L,+V9@5ACFR@R@I\S 560#
MVZ<PD"Y>SZ8G,*RKIQ;Z7O6R_)$@>.MZ_^.ZZV3MM#/JMN-"P;5;K%P?_7V(
MH:Q*<.1(I&C,2$PU^*,Q$T@3Y1(684]W+%^"[H.W=0?>-"V_6GC8&3@A)NW5
MG/>& IO"T7(A[=*! :'WUY3>BS=_LPY\[:Z>I0"OP]/@]W;6*?R:\EY_KHQ\
MQ,6478SD00R)Y<1$DE #NB8A'"O%5 RP!"X!>!]$QR:)(K4PI%FU-O7>BFI]
M4:G=ZJRIX[2G6G-")BPDCQ(:Q5@2)B771H !8PAX;C*.F5T<,AG3;_=;?I%Z
MN]=TN3\O=TU_MQ.WU3%9V\T+R5",F,)&@Q4//GPD*==$2HD3+6(=ZX4AV8[K
MJ;3C[(;*.^#?=^>$/AQI*81D$<%@RH++930F6G!F$Q-A)U^./M.: ;#<.1B<
M$<>8,F,0N$F8.F4QXTI*$4_!D)]G_3Q]#\-A0Q(J$B8Q9D(Z!=RB941L% LP
MM^WB$?3%M/KTB6MC&44.)1;L-688 T- ,&4,@)CFSBR@M$[%%I@^H9%!*#8@
MR\AI!II)Q9@BXYR,J8VU2A:/T,]O04R?JF"V8V$1C0@RS!FE$G"&$R4<,4IB
M+5XN]C'/.G9209GKEJ!!F"4DTHXD+$Z(Q(HJ($J$N&:$Q@M#FBGXP!,DDXM1
M9+BSG$K+7$*U!:0DABFF5<1+@WTQR#1='WB")(LC+I1RU#L6C"@E%+,L0A8T
M&6<1>\& []QKL&>ACXFTC!-C(ZM /VDE-#@/RH%\)4S3V$YAB7:>M=/TUXZ)
M(S9)(D,H5<Q8K9%$2H")P6(7)XE9/().QP.<"G&%%;% 7!CA+&,ZT=11PV,#
MGB"*M6,+2-RI>X!3(3270I'8>'V)F*%6("IY'%G$*!*,B<4C] M[@-/!9F8
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M9I8GD2%$2)TP8H1B)(DHH3)V*H[D7/65F"49FXIM2"57ACA&(P!,[##H-6;
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M'4J=352%2C/&.&./X+O*4Z5;;@?&<=VT^]9MY$7.\?FW;F\+F"$'&]Z?MI"
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M?N&71,MXS*74!XTV6F9BO-$^/DXS>P9#T=C3LZ)3IAF8ENIVG^;3S^ KYJI
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MJ!%V@+<E6FE1^W:0!N4SVHJ<QC*3T9L216WI$1?[<@/@?=RG))[+18?7GYE
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M#7S%(<:M99UNO]7S&ZQ^J+SH%O18;*M<Q=<-,JP"F0ID2I#!UT%FJP,W\<7
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M\YS@,N6@2GU9-!896]_<6?_^@46(7R#S96&JPA!>E8.I]-*\@ [8U0)Q#SH
M,72E2"'O9>((3.XH@A]_ E=Q+[X/6!T=;MPC0_TS1@ROB,U--K'\G]U@K9_G
M7J'<L*_%'?;UXV!N^+I\WC/\%@F$HPJ$YPV$7VV( TF"A2Q F @L;X%P_!/C
M!X-P/3NYXO0_%(6_9"V5!VOJ&'R/5K );UFLLH3>CN\YT^S ;!^<EP=F'J!O
M3L6KL43C"@0K$)QC$"33!<&::AZI]N6*\HX[R4R1/5\6E'CT M%K +YI89[X
MQRN-K;Y:Y!BL$ &#,Q$CLF+C*"+QU=W0P^H,6_"T=N<RAGI9>F$L/'#*-(>5
M_2Z+/&PG<#^_$E26TBHK/HQ;\>]W^Z$?"!&/7!RZC .7Q;5?!TK("B46#272
ML_^QF?GK06%V*E>Z[78O]&P/!HCT</&/E"<R1EIKFFC#I(R%<$A1A0T1" EM
M?U)"Y-('$'R0&L"#C?9Q*SN_:G?4U-7EEP?9'"E(J6L%ZUE'M6PW>T#\ZU8O
M\(>;&4_&D+(+QPT,F8:0!XL-8!15 %8!V!, C,9%(FZY?GPWALG'8-AWN,NO
MM-M2)\%NSR6JDYT\ ,5NKEE6*+:X*(8K%%LT%'N\LS;(__6"-ZB2=UF<_4OK
M(2N!=R;D5B[5\\DRJ61YT63Y!2T2^#>^#-1L'Y?QF5.5VZ 8:C )6+C9)V96
M3(L%101:(4*%"$] !$PN$6%T!=W+ .[D0.)F!Y8*))X5)-AT0>*B-E"%$[/A
M!= K7D 9E'!N(-(7Z[P/D^@[=]W,I#=0E=G[;9D]=F/>JC)[59F]JLQ>56:O
M*K,WPS8>KTR\UV'B7;I^5[U C J3;U#,&4P\_M.;07Y/&WP[NJ@*\YO%J(M,
M-O*H324W,_G&MQU'K*F/;K*"T63-QEJQ,Y*6203X-7B"TVVP5*'$K*%$- (E
M=OM@((],]2WEA929KOAV]\O?UH:Z1(I1, (/?4CMJ(*7*]AX*=B8;ONCZ<)&
M/.NP\=L!/@DVAOL%L/^5W-ZY2G\B3H07@D'GR;.K\>)K22[B#LQXKD2]*0>D
MKK[S:]D*146U%:H"N+D"N*%=5"RB$>+M(D"CL)/UW/$@$*Y*."L!K@X'?K,5
MJC0,<%F,@\SPGOSE21I"N#2$R&LPA*;;S*#"B=G"B>,\\]*0Y><>,9B(XK-!
ML?"+ X&'C+OP(>T4PM91;5>LOS\: AZQ^;&"@,= 0+0\W6+;%0+,@"O$)/.N
M4'2]B ^X0OS2%?KL>CV7!PD 0?#E=&THG_<+U36O:1!I&1<(HFEO=+PZZ(?5
MZ.&+6Z-G&D %;%AU!9A5E'JNA)^K1@HE@R OP=C'>'$1XSWK]G4WM0.(2KME
M_4N@5[%?&^!AMSB>JAP$?39*0<[*; 5OJOFX.A]C:20/0W=II)>,U9?5VWTK
MA(J$ER1<=&N=T&7\_U5:<(ZUX("#Z14.QNCL2)WU+]O<#,HB?\E3XTX!C?)F
MUN^ZM2P['I2.?Q>H8-VUU*G*7= :%%ANI4JGK;1W'OC:RATXM9D>5Q;K5(65
M5,*Z",)*GBJL?ML)B.C_ NTLN,]^BTGOO)+-Z<DFQ94B7039I/BF(AU(II_L
MJUT/YLA.ON?-FFIAWB7-VX-&.0OS2FO-U"6WZKPMS.OE[Q:'5.7BU,*\SN4J
MV[O%>:?C?M[M^S!>+[L:'KD(C:R:7K#3;\%/F*H0LS?J;8$GF-OAMVZ@;';L
MS:^K-_/;7^(_*")>.13!%Y5KU7'=</NLY<Z+&\,1@A"I*O-/U4Z;L@]597A/
M3,9ONE%WF&J7RG-8%_5=L):%HS4K'"LJS^>NF]JRAWF^?#UO^UV%(A6*T I%
M%@1%Z'@H\B5/.R8]]GTH+MIO#B!C#LVCT2_]+ECM'/7S8+T)K)BK>;3[1K]8
MA=BO';%)%9];"+@F8\3GY@^V[GBKLKWJ799JN:I?'EP G737'%Q%6RR*?J]K
MRP/<Q92C=[^'9HFB"IIG&9I]?XRM^NZ,H//P^MO5;P:_^#U3Y>+9-"9KJZC0
M$_S[X\[G8*O3[?D6QL%Z9OI%^;FP8/-T^+L=_FXS&$$GZP7J^-BI?)A5O^7K
MIP B%*ZQZJF@2"K2SJA^UQ7]18KG]-0!"%CN E_[P-I!AM'%/2X'-'Q>)4G3
MDZ3=M7]5DO1026JHLZR3M<]!Q_9<ITB,VS5-UU87HE6Q]/18>FWU<\72$V#I
M-=4R_589T/B<=H[\'M^*P6> P=<W-BL&GP"#K[LD[:05?\\:?W]>_5CQ]P3X
M^[/2KE6Q]BRQ]I>=C>FR=CNUMN46@;O]DBMP\U/MDRJQ=<),SF:$P:?Q]FL9
MC";XH@[N"I:\2;*\K7H^]*BZUX(A/C9KX $*?K$^XG)9C.!*19UY >N9'MQ=
MUXQ5[G;F)7 <\7MX8=_YE\W-8K-CT^7.AR.71XG4W*.OWPI*V!^O&8 [29&'
MY9>V>KE3O2*@W02PU;Y@U$&N.@/P[66!@9$#W@9^ORQ8$=WAPL]@Q6LYN':[
MMM]= Q_@M'9:0CA@=KF'MNN.E=^XVSI_R';:Q63"_SL#OMM4>&\D-Z7=(3L!
M%YZXD@V'##1<.P%V.2^63/RBRY#/"JXYS?HMO[?RR+-6>;+)VL>NEQ:615/E
M[>%V\-P=I-V>9_ @30*;=DTKZSJ['-SFLJI=QV_;=? ;WD/5KJ-JUU&UZZC:
M=53M.F94];ZYX2*_*INW ;J_:YK.%OFHWF@8&!S=VQ;'<K *KWM\[FT3U3F_
M,$2&UP=9?F&NG*:M%EP<)/V\DW;A^/@EUX+^,?S)W7_ZKML;98 L ,]-MP/@
M5#ENJV-]ZB3<$&X%9E#A8_G@5=D*)2]-U$Y7]7R]SF/?]PY^5'GNV<2?/,+Q
MJ4S2WYJDT;R8I'>=,OK&U^;TKLM2^]=22IPSUFD'5DK$D,12,IMP'2L9::5T
M_%/BI0D\ZY[+GH_LMTR.@NR[6Y_JJXUO.QN[$YO-JY>E'1_<>$^CJ2SR4'C!
M+U<2<$LG]C_]-"] HG"@0=<4"SR8>@C!_(U]>Y&>>\>^##B,)65EGB_<R#K[
MKKA@Y])!]@$AT'<#E]J6?GI>%DZ#D8#6Z\*$P@%XM%>DVC55*_%5V?R-"O-X
M<$+/1Q3[';BHN)_J]YI9#A-@EQ\Z]>.S9"&.?XRXS<OZ@Q%?9C)^C#^(Q7(<
M11-WW>@R9I-W"&.V'$OZ>(=0SK)M,]K3V?U6JVTU@L:_-G96OVQ\:VRM[09;
M];61\<H;>AH_:4$U>JY5TE)D9L9X_'C^_@'FXU0#"&,O/?@ P>1?:GHT6NFN
M7-_?."$W9L98L0XZ\GVA>AIIK^5>+5].<O5WJF]\G6<]8>_:\^6/O?G-1N41
M>0=WNFE74H;B:5B3A;F\#D[I^V#=F4';3?PN&%2IG8SQ_"SNS=,N>S'W>%8\
MX?AN3_@!SB*[<!9GR7U^#K9\::] \&6!Q:-6B<2R8&+R"SK+DI.%6<\9UX*_
MHS/6T[3[[*W)^%R[<;R2>#*K,=->8GFAL._HN=[J6'<V#-1<&@N[/="Z1<#F
ML1'Q9Y*[%RB>\-#5U,LM]E,?RV W_3_N5Y9PHZ4/PZX"2>#9X-@5<:=!2,WE
MS@9?^KJ5FF#5F*S?Z0&]@$7R]M6=\M/@V>#-E[75[8_!UGKP9WKVOI-UZOTV
MW,H4ZQ4P.3M^$E*41(010IDE@L6QDRP6!C%IB!21<='/=5]K ,'_PF'1@:6B
MR]A?2]:E[U?[-NUEN7_A+;M4VB"6?C_7Z]G)9[)SLD=K?7NX<;+_21YN'_[=
MVO]1/]K_ ?]^^GY8/_QZNMW8X-N-G:/]P^]IG6SP>OOOYMZ/+?J9UEM[O[+S
M_1_?#^'<=/_'#GS?0[7UH[/MQA':_[2']PYM<[NQG^[]V$SK6/#ZFFR;]F9G
M^_#@O-9HIO5?K79M_2O;/]Q)Z^M'O$Z^I[5?JW3OU]%I[<?FT5Y[@W^F.\V]
M]EEK^_#C47W]8[/>./JU[^_9^'I6/_S&ZC\V</VP=EX_]/_;;-=_U=/A-?"L
M_C[Y%M4^?46U3QMXNU%O^?'7US=(O7& ]QK?2.W7%JGY__V F2!_)[5S=/JY
ML=&K[:(S>!=6_[5W8C]]9_9?,">D=:(/CX]J/[98O?&Q56O4F[7V!JHW-M.]
M]E=<_[0)[_.-[?W:.-TCFX?U[X+65G\ZS&04)3I44L8ATXJ%0#H=.B4=Q8I:
MCJVOB2[^7+G&!Q\>WJ[T$3ATCU'X?*#P^.HN4Q_+ P%*ODCOC4JY3)QV=-&5
MBW5$)@H1%FE0,M9)@A.FJ(DBHY@1NE N:*A<4*5<GJ9<ZFOW*9>,UM?W#_?7
MMTYKZP;7VENH#O^_#9_K/_9PC7Q#]<-55FM_.X=W]LJ%<:LY,R3$RO&0$2E#
M;5@<)MBIR% BG $N%G%4*9<%5"Y 6HPK[3*?VB4JVZ1X1[UHK/91M8IB1[M-
MYWK=.ZA:B>@,C.6!5,;W5&6K1'16153>$-'+@)*W"+>/77GW0?W"K'V<NZ;?
M!'[B@L]9MY+A!9%A8 -,*QF>2QG&Y+<RO-O+S%$S:_FTN7\&&__I___L?6M3
M&TG6YE]1L!/[]D0H/7F_N'>)<-ON?IEMP';C<<,71UZ-;%UX=;$-OWXS2Q((
M2M@2*J&22,>,&I!4E94GSY//.7DN][<?RVI;@[$L*7E$L]INI]JR'ZKM2STX
M;_S>[GW+>^R.*&N4-V)96;=36>7>_E$O9=U<]_^>T=SYY[%9:W=!:Z/@$5^J
MYOAJ4=B+'-=O/E^K+@%ILHJ M.((:TT1:4L$GLU$<2+\@,R4325+H92P_^!3
MI.7"Z7[ZYB,N0)0"VT[&V\%O/=UWZ>FG;<O&#I-9VZNPQ7X6&;;9)RVN^+PU
MC.O)_D3FZ=F/+UK=HN-2]^=12346X0<_SM76Z:QOG%76T#:ET>KN95JH=G:O
M-Q,?]B#YL'\DTV(!I/RUP<@,6JZE^RE;[I=T]:)4%/SUY?@6Q6_HUZ)M45I!
MTPAJ@IHI@!J-N]R-$_3:Q1AN#6APRVSHW?;8V5L>NW9O,&BF3PUFUF6Z/1*_
M-GSA&2B^%3]AD_D1DOG1"+U^<??+U(X@_M!M3/+Z6EW;'J4MZM;@N@5-^B7%
MMOJB!%_[,KX7?+\_SF)/Y9]NYN#6HX3K%73S4-/9>18GM=$;]>,3%JMNG%;X
MTZ\W+L:E*AM!M_KMRS3HAF[?%)2*0QM<Q'$.QM>[N<1T+YQF/$Z$=9^09F0T
M&+7'LDC"OR./]*>?3VT:9'RR5*\PB:2H:J5O@/-BG#60*@Y\\MUX_79*?K36
M%VU5)LT>)FWG"U4L1O.B.!756XHUO^E!:SQ?$]2IR6/\>',X]X-%UFBJ/C59
M.Q?QPRW3:B>YWUYY$SV=S?M_UCB."G'G6ZW"1O'?T\)/BVZJ,%.8OGNYGP\O
M%7<MLG&3^A4H^:P103.-6C<NQOOZS/(,<5^?%,0J=O[KHFP3"C#5I!DJ</RU
MR.D]'TXVTE]NK=Y_3F(]QFW>TFTGF<INDB_<FJ$<Q=TF2GUCK(WOF'0_WK3O
M"@2_'E=J4]0(D1_VTW/?9#:W];?!M5[KBXLX^"*:OW]=[",^Y:1*_V!.9O1]
M!3JFERP>JB[Z^+,M,BX3-[))*->K8/+("RWQ>Z8^=;]Q4>+7TS>>D[B;]@:S
M[TX$'C^BHXC]N*Y%FL<(KPDFQR(J!A5EWC-%,;C(W0>];B$R/1B,^L6MM>F-
MXB7.?4H>7W /24LN]+U/@[S>.)(TIQ]I7E_0C7RA?OU^A*KXO]"/HTK/,[,*
MQ_U]9M=PXA_-^-=^?+9XK_B OOLI*GGQYN01$PVXF?=6,:=Q*-TXE*+\1Z_=
M*"K@WCS!.*<^ZM>SQHNX$>HQ/[\1WS=?4J;)S,4[C?/LDP"2@J8[+GJWAHD3
MG)YPNKM=C/H729SQ(A-82I\J(Y,/8<P8N@FY[D&_91ZZ6'#QQ[3OISF=8&*W
M%SF9/9_>?BLT\/A::F/6Y:^7_I@1]*QWH_[8/Q47>WK,8D=I#;X,[EVVTSG^
MJ0;\9'TW9U7Q[GB2QHZWJ$D1H[04BG$]B]PYBF'FP]?/YK_'2>S&2S73XM"-
MN L,TS[4BD/Q7U-94%L47=3]:_ZI.VDW&:/NI #CY)J+/>-X,QW/L6X/>C.#
M^:K;(SV\OM%<)E:4LDCW3K4IBO:&<7[CJ%N=2;$>YU,)BYO-NZB1\<U'+AK_
M>^<6:4TGEGHQ6V=]46$5F[/Q[9;_.@',&Y6/<YUF+\[2+#J::W(U0[#KHA9+
M$L77G8OSXG'B=!VF:M_]FCS'#]4[XG-:LZ/!8,S@DZ^Y0:;\90']G*4Y1?&P
MZ8Z9G(AI^<3/3[Z9UEBO$483<Z37_=0K(/[:4DD]U*>K]!IWIROT9B'&Y375
MMT0.6C=63J?\];1A%^ 4+9K6ISCN<=F7HAY[/VV)A<JYHLJ?F9V#+5V&+Q,'
MM''2BPCBR4JLNSL$BDE).SL=_1@U)E*RD<*.ND7UL50^-UJPA>"F;^L(Z@7_
M[_?&?"P2X7[:9>+":O7<+<ZX .D:4ST]N'W;7O\N^;_U]D1AQK=*[Z02>W["
MN./U?FG]<^*H&.^48R@?I,O.[AG%9Q,WNMXV%]7$XE:_M.)M6MVOO?;7"5\N
M[)%68:A'>Z#=CO2NV-P&(_-YS'F:T]IM;?^]\7GD/DVPO!#']2-.U&^N? 8S
MO2/;A59UBSJ#W_3E+*Y/V=8BH**_^&Y1RBGN_[VV'^_S$]H8[]-,.]K,X":[
MU_S54RR8YF0'*@C@=>7NTM#F7B!M3]W9';@LMEX<9RM2BM9P*N7:P\=\)8S4
MM3^:$(HWD=+JEFN\BUQ ]^/3I3^^BNC;[ET4+.YE;U![3^OXJ09EA!\TZ+A[
M.UUBM[NF9I/NIA>3*8H,WW<'B=[<XZ6+>/4/_@S%7:C=GNA2\=W+L?*.C\K&
M&V1_=KK=S'07-XGK,BVYY)6\/10]D5R[I0N'3.LGHV'/\/5H'G#[6Y9E/QUV
M1FNY&$,JEI\HW92#NNN=_MY+V[20DE*5YO-;JK0V-N:F<U4P6O_=^HG+_.8^
MQ66N%6_.0@MAC<E!::$U?G#SQ]A !S/F2)PWYR-^=8KF,K=,@!O/VIP)+)HD
M%/M!!$BOH[@&PY&[+*IYIAVC-;QLSGYOUD28;+Q193X59O?D.K/.I[0]M:Q/
M:][ZN/^X6_9(7  S@XZ3%&_2ZQ8+(>'KM%Q^WX>)D__>6\^NKS!G:3UK_'?O
M6_Q,OUE>=<[;9*5,]IUYFA6!H/C$]%1A,C/IK;C1?$KF_OC+K9#>&Q5^@T'A
M.RE&ZF97\)W[CQTN8U6Z+L@[5K$$3!/GQG0TE^.M^HN_C-M:-YT=?)UZ8V_+
M]@>R20Z2>P0]V==FG+&M[KB?T1@XQC*\X5Z#4?)7)E8VGX]?L_WX;%^ZO6]M
M[SY="_%;K__E>NVYL2MH8KA/*\W.V5B?;!"">KSZL*N6@=V<27%Q7>HJ[>\M
M=WTL-G4[3/%FO*(+!C[?HS2[2^H9GC15WY]L;X7),I]A3L]A9ETX4RI^![F_
MI<.ZZ9"GQ/=&RW\\AFMUCL\YZG<;[;'E,GM;/4X\O;[]C*E0X$%1:CR$%'.1
M^,_<B2H^<^-8&C_JC/>L/3695D2GF2+C-5Z$+YR;NIZ3K*:>AZF5]I I'!_3
M=B=E<HM#C>DU"H-KXL5;UO J=I*!G^<8;29>D2Z?G+%Q'25[=F9\\QPOZ2+)
MG9[<J .=I#GC[[N[@A\D_U_'!F_$MJE=-[Y-_,(/]&"RCQ1?OOT4XZ/0J7=R
M>A@PW<_C@OU6G G-#"T]RD*WG>$'UP=[@T$O"F!\=#XA!4E+9W?:,55J1F9P
M<_B0CCFG1W_]L4 6W)-_G3@)OOZS\&M?S_UDP^V.SVT+PC.*<W1]$#P.8"Q"
M4ESJ:C@3?]$;SC*;6P;)]4Q/KEF0H$A9$NA,2>K=^?O!+E\OS2Y\;:E8Z/H+
MS*1:G9NM /#]\-6+KV?=?Y^?7?6NCD[.VH>=]_2L<P#//I_"T\^OOQ^_>DU/
M\>MO1Z\.T>'5Z=79B85G+07/_CZ'MO.?KOZ@1L>?#]%1Y_WEV<EYY_3SN\[1
MYW>MPY/7]/#D_//IR0MX>/7^ZNCS4?OHZEWG[ZM3='3U^J.G3-.(HL!(K '5
M&@/-E0=.*JP-,SPHN+?_)DZ\_Y8<9N>]T<"_["6..6C\^>>;NYGY==\OBE6U
M_A7U9V_LT7N2J^KPHY>(Q:G!0"+A "7> XT# DP%+XW!VE.UM_];+UF>S<9A
MQ.FX^\2%-4S.KML+JB9+YK#8<Y!HSB]\6L-%/HU]C%__.FG-..?,?4I&(WF*
MK">MZ ?M"_G-![[Y9"UK!+?'M%XXV8#,ZY52:?#_3[XV22P!*;7H.4JU/J=_
MZ8_G7LZK/+K.:]_JIP&P?$;8(]2QGG]R^RB9#'.G*S42V<Q,K#.W84FR5Y>9
M>7@NQ$)Y$ ]ZS&6F3&ULV<S+I]AL"@4LIU"L4O2D>5]9A6GRQ$WN]NT(_W%P
M?VET.9'B'E$]-)/B_GE>7UI%(_Y[?"VO/S"6$C>JV \V!VZ5IG3\5RV2.08Y
MFZ.Z;(XY(+!-RSLG>JR6Z+'5PL\Y!CG'X)%S#):%R\=7C%3<(%*[GYTQ55-G
MNA9G3(?7IP&'G?C^U?GYX=7!Y?&' WCTX9"<?GA_=12O??0Y_GQR2([_>/OM
M[&7I-. RCN7S\1^OKPX_'[#3SV_C==SYV<EAO)_%A_'GPRM+SU[]]N7OJP-T
M]/G%1\F((9H9H(SV@ 8;@/;0 :*(TU@RJ=E29TS;Z75X\(E4->NO-B=2FUB#
M!Q^#IQQB2X#5"@$*M062&@=D(,C[(+VV.CD(BSB'YM06_'_Q%]?K_'0!;L4:
M&Q]A32.4ZP[.> S.'^XYP/JOFZ.K(@@CKOLBIVK^"=;3/65!]Y^R+'.PP:NH
MHB3P:E64:E 0"2_4!*ZN _]!Q?;['5QU&?PO!1./U""RY")>*WGO&H/SPKLQ
MMA\FOZ4(JG]6?;(V[VN/VP%2J6>123VD R13SS!>K%?C4NWFGRE!'W35'[_'
MR!K&RI]1KK9HL&*Q 2U87?2A-0DK^^B&NUXNV'FHE,?UT-:+NS@9\-9D_&3A
M&6V_?.KW1ET')N.U-O+LL&S+[\TU<'\Q&/B%>F_^]%$7:8"ZSFO<VUUU6T>X
M]-H+Q;_M67LO)['ZNEB#SQ^T".\\\X/$\U2NL?-@]K__%^+PU_M>4U!#78%N
M&1' 1KUZB,^7Q3_N3O52CSC[:$7<7:V>;>+'_#UEF*1#AU&W-?9BC@9N[[9;
M$WMKE%#Q/XA38Z0V1/H@M?,&&P7QQX.;^'KG;:NCVX/_NP?(U+<Y&H!/6E\\
M3XMWKS%.SHF7_3Y\WAUU@.L5!<+3M^+:B[/CBU6X8=_GZ=3WB4Y/W)?#5_]I
MGYT<?3G"!_"P\Q;&[]&CSBDYZZ2.BP?HZ.H%.OY+P=,/_QZ<G5RT#O]X^_WP
M\PM\_,<!.TN=&U\=?3X]^>W+Z97K')W$OYW$WS^\I]??^?O?YZ;CVL>=@V]G
MKUY?QOO3T\_M+V>OWGX[Q$?GAW^\^WR$3]'AYW8[_7YV\HG]?74X/+R$WXM.
MCR<OV/$KBS]ZHBABU@,,E0(4:PV4\!)(PQB7GE%EQ=Z^0$VAT-17.ET"$^A9
M9<TG2K#DVL\(E!'HIP@DB,#&<V<A1Y08IITQU&$OB6:*6U8@$,P(]/@(=/37
M703"S"B-+9!20T 9YD ;98&2P1 1+/4*[>USWJ1(U B!=MY0^3&O?#$MYC1.
MF$V.S]J;,G@YZ<P%_*U&Q:IXV53X[ZYE?^2'$\,VHV5U:/FVS->0L 9S3P%5
M"2T5-< P0H%WT'E&A'4N=:QJ4DY7!<OY@+56NI8U^9'YS8\U.2OK4LI:HC;"
MBBA9IZ,UA1&@4?N =-P"8;363AJKN=G;)V1ERZI"57WB_K(W=ZJ9U=5WMA 4
M+FK%;C445D5J)I)_/19\9C.5 ^3[,IL1G&A)L0%>(!79#!) *6( PA *S*"W
MT.[MBR;B.^A\RBI<-9O)*KQV%2YQ' R)H%H00"6-+X1Q(*'5 %/DA7!,2D3V
M]E63T>R]J0W+.2XR=NRMH^CLOJD[3%;%= KICV-@,D96CI&G99J#J2'$<@4(
M1S+2G&@1JBA(P+C4,BA'L<#):1/WN!I9@EE_:TISLOZN5W]+'(<3J2W$'NB(
MM( ZHH#B6@.A T9>12V.(HOZRS"ID?X^<4_.N_NJR0[U]X;M>U>T&UGI\"K[
M>;:(_0PZG>'SZ:)XT74SO5A.]/>7Q8*X<8-G8*T<6.V\TRQ)"-,4."0C,3*!
M DTBQ'H3;4@>8=?8$(&5-;EB-;(>LV[7C!EEW=ZX;I<=0]HX1A4&F 4"J+<4
MF" Y8)19Q$@((A4*5DW)>(U4>^<=0R?CHO/;Y?I9X!H_SS/9-="L+)HG6Y+K
M <5/9<)#O0H6*0,X5A105(0]>@ZTQ=1%:S)(%PF/$DV"< D5-ZVF3T_%*@NS
MR2JV+A4K\8[@A1 $!X!2;P)J* 1*& LT$YX10YD,:&]?BB87Y1"Y>7FP=RJ,
M3 I]U]%'D*_Q! C<4:\+;$XBS4FDCQD4EPJV32IEIU*?%^,RA5T_S'[3NG.8
MZN+CQHO@35MWAR^Z[O5T'1SY'"J\'&MY'1G+X?!PS%SB\W\B1Y\^0B,TMA(#
MZ1Q.O$4#";T#7#ACA7/.>[ZWS]7*<?W9$5I?9:TN$BXK:X7*^OZNLF)&!7;,
M .<8 M0C C2/+_'O6F'*23!X;U_@.IU:[#PS_LEY</HDZ 4P*AJ/;X7?\\F'
MS%06\C9N0]+]]&?J.U\LA>/P?N +QTQVR%2(EI=SJ(U5&$'K K"24$"="$!B
MX0 2WL<]S@AJT=X^;@H%:Q0_DY6YIN3F)\J<]75)?2VQ&X($U@Y1$!R-^NJ9
M %I:!Q@U3C$(@X!N;Y^Q.J48/W$7S1^]GOO6:K>S/Z;N*%@5I9E*/+.7"M'P
M:@Y["0*3$+P!VB=;CV )-*(>".,(\U@'R5AB+Q"J&EE[66]KREZRWJY';\L^
M&BDA9Y(!85-Z(DQ=:KAGP 9JL6:48DH*O24K6QW92U,5CSGH#G7W4VO2%,ZG
M!F,//67*CIHM9#6_MU)[GC];7[V[60KC\)FC[*FI%#/A'*ZC'4."X@B2Q&E
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M/=G;9[Q.,;Y/W!\TC@?L5NB,S#Z@+20^=V.-LO-G+: YK]H7AP(1J3&@'#E
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M&QO)CX9 62,!TA!J::DE7!9G8@3M6IS?SCN,;B+O']P?]3%,Q&U$R64Z_E1
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MU?2O_REV90^QVX$_VQW:LT1DS\/ KAQZ/TN+QZ2X/A$Z6P)BI2:T/%!,@^
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M!B-+;8B&15FEMM;CFETU<U_?^8'7?7M>L!+GO_IV[Z)(.ASJ[XVHA:XU7/6
M*YMYFVK9<A=-I\)^T76O;D1]HK^_+ 2=#[W6@K]T7A4'3H@5$$<F@TS$7RA2
M=RP!+%&:*TNYY61OGS<A*CMVMM8ZS,J^SG8O6=EKHNPELD4A=MA9"["7'$1F
M18'$(@ 1C.4*62EX-&!HD\AR6.G6*GMV!=U3R3/X?E3 2*J^^N[(%[RK5_B'
M6D5@:+99ZTZQ%G8(I2ZC:4@?6L/SEZ-!G"#?OVXQFH%U.6!E<UB4\!$_E8P$
M"@F40H<04)Y[H!WA'L6ME""\MR\1V1TS=O>UN5X.J)_H<&9.52IXB3GQ:/]
M;B%P*L45I;! 0R4#B'J/+$U1_V9OGS6)R)%%3\)==1UT?:$OLT-JI]C25+1O
MQI+-V%H=MA[,*R2*:)"$(P*(1Q!0A20P1 >@M9:0.:R)#$6&.-HAJW3WU;M>
M]"DK]5J5NAR(S:(0D=' &YYR(;D!DD8=-UIZ2#5V3J9&XDU.5R9,-=/L[&^Z
MCS#U1_Y6QF3A<M*3OZ]<*2L;JS4YW)M(^L\;0;_HNM>=BW;OTOMWOJV'M][,
M4%PA%,^K-.HHLX(;!KPUJ8TQ"\!(YX"S7B@??T52[NW+)L:[5J!P]]7^D<_Y
M[MA0&0#J" !E+A;-*$:I!"P$ JC0'FBI4YD**S#Q-&@Q+NFN<FF*7:=AUR&,
MC792UEDZEEU8.^/"NMTG-1\3K -IYQ4O589XC; $0@H!J/$8&"88(#@PI!72
M0A4E!"!?I81 S0S>K.:;JB%PKYIG35Y2DTN<R1DK=+25@/<B<B9JH]$4Y0EP
M"!I3Q)(P4]_CLLFTM7J\\XZK(S]LI,)WC5$JS7Z[I%>4W=>'LZ *C5#3ZSO?
M!W&6GJ?%,.BU6ZZ1YF;7@7-]_"C*_644^YM^[VN$9_?;Y?LH_QGT?'$M_$R0
M*H35>65-H4!8,1)%&+R*L$H"T()!0%T@.@CFC29[^P(WF5PE&WDI7=HB#]63
M!8?UL:H,#IL"AS+G8DA0Y@B( ,$!51(!':4)D/ 0.:RX$BAR+ME$*T4"; TX
M3 C9],M3Y<'%)^I2E'/):_Q\UI_@"'>>>2>$;81V[]O@FGNWNE_]X [W?E@)
MW354G]C9:V2O^/PZ<:.^/4_N\%YH7/2363B\+*(3_/^,6D6Z6G:.U]WXNTWK
MWNC+HKG(2>^%C3+L^S<3L;YIZ^XPG4=.)9N9VW+,;5YY.,=DE%5(,9LIA)-A
M!:2U'!AAF=)0"\A@ZE:QROEBS;QE67_7&L&9]7>-^ENNPB*4HX(+8)CR@,K4
M="_5SO4D(&2<XM@F;S?>H0#LG>?<)6_W/,:=O=W;2WB6<V@=3*4_Z]#*R+D,
M<LZM"8>=TT03P)R6$3F]!#)(!Y017'K*HES5JLQG:QQ66?EKZLW.RE^%\I=I
MD];622*!A3;2)B%3KR\+H]!T@,XS3B%:E39MC?)G;_43&>'.,^<9;_7%!$@;
MYK(16EW=M=ECG3W6=?!8]WMQTMR@$?J]3F-X[ANMP6 4UV?AP[:]3J>7GJ1G
MOV3/]58DTUT[OB:"_3W*]6 BTN/PLA#H7TF>.0RA.E9W.*\>@6 >4R4E<,2Y
MR.JH IKP^&*UD<@Z[+G>VQ>L&1?ACN4N9]5>JT\[J_;CJG:Y ":EG <O@,#)
M8 N21]4. F!+"+>86BOXWCZ#.ZC:.\_:'\:C3OKQEA,LL+W!<%V$*J<I;SP4
MX#@4(#M%WI=)VAE4EP/5>?4%M*'$>LJ B/ 9054AH'C\E2*BN;%(J"*]&.6N
MN3NJL6L[_,\:6XG&EFB0I(YY%!D0<CRD0&L-C',"0,BIT\99S60*M-X=A<U>
MI 6\2/UQ:8[&A4[ACQ?Q3Y$"]?J7C6YOF,L#;+$?:5)SY4V2ZRMOAMG.K!!@
MY]4!P%1:;TT !.E(A+SGP&@D@%+>".D,]2A5OT.[:&AFM7XL']*/U3JTOGL'
MKGR_ES5Z:8TN]]!5AB/F L J14@2%("$ 0..O*2(6N0(2;NPQ C_NF,:G5U'
M]W2L Q=C0R5YB-9 GK(%NC'V],Y?7-N@F3VM$6OG%0F03C&*4[TZ2B2@5JF4
M!RP ,1 1PCRADMS/GK;61MU]E=XD<5I<HS-Q6D&9R\4G103AX VPRE! N8Q6
M$$\ADPQR1)W!!+O*B%/--#I[G>9[G2:*^'/:=',&5YS-91?4=K&H&S]^0MGL
MQE\!6N$<GN2M,RC( "!/N2=**V 4Q0!2RI&FRD0BM;?/5NF=7C-+=/?UM1['
M;G/4-3.DBM2XQ)"\5M1"98$5$@$:"1/0'L+(D#@6DGFOB<JNI2?E6KI]+N>_
M^[YMC:N3#,YU/_YPD62?O4K;>R17!#8<C\7X>B)?ESU+%4(MFL.8K-=2B("
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M9^Z&V& ?S 8)HE0A@)YSG50PH(H&V1_/^]YZQ2G^GE\SC_S<#C,[XUGD9Z
M1Z'O9$'B)+Z7LS@FO^8M"&GKU_PJI+5"]WF<!UYHIZGEY$5@^6$:67&0QE;D
M\"++LBA+PF(C:0E=0O,D2@FOI)>R=5)27)'T&;2>P)983C$W3M3**#V BR<8
M)D>B9!#J$?[U82F@[RG#%40]*%]_5,L:A/9]ZJ*&SG.W@-47<O>!6/^&\-4;
M^.6O'*6B^9RZ>0A[G(86"[ 4E/N^%2>N8X4!_#O->%$D\<XS;]==[_KSWR.F
M=4)XCE/B($5-^]=/U)TU%%-8SF4)'V?UI!0!SD?E8PWGL)Q.==$>DVG-7"2$
M4TI]&_E%-6\&U*XC"? &*,@3U!3)0+D7I8(BIIL%P0%&6DHDQ/+LC!9""6>O
M:7%'<FU*(3D^!SZ%.=Q;4;&!AIW#JQ>G29;D(0AN"^M^00LI<BNUHQ08F^/'
M/$X=QW8V:R&@>#PJ@0"O*T/_6]1Q2WKX7$Z7TV->3SN'#'PW>Y(OL;9G<?X+
MGNO1_JO3,& AG":W"@^DO\]Y:"4LA_\)HR -0M=.([;SS(G[%>0CVC0CLH@\
MB<)J2KF47$MSJ-TO#9M\'3R&Z/[Q&-QOCL?P&R;S'Q5[.B__WJD[D]0]_WCB
M?CC_<#R9'+CO_)/W+^R3Z5_^R?&!<WA\YA[M9_[!])T'%!P<O.U1]_3PXX?I
MR\G1^W=7'X[/ST^.WY0?]L_/#Z[> 26?^(=79ZL/QYE]>/7I\[^O8+Y7!Z=V
M'+ \"B,K<UEN^7G*K-3A#F9*P?ZEOF\[>1^K('=L.W)2)\J*S/=LQH*(^QF/
M KN WW*_#\?PFRJ<>"TBL$*RH@OFG? WO6@6E%>$$9"O"\-PXU3OT6/RO2G\
M=07"?27^]QB^]-NDRC[]DF3_UREW@03<%$1TB&2?><QB$4^MS [\((_=Q(ZC
M/ME';FR[G#E9%L<^2_(D+A(G]0L_86[N%V&?[(]O PVFW)[";R#.ZOJ2'%4\
M=PDJV61%^7EYIY).5.V0?:EJV?3 E$O36A_-Z)Q=<%&OQ+$ ;L:D:=E.'![;
M_8)K>:_7:YTAW'B(MSRV=M_FF(]4Z_X>59V3<"?#P"S[$JE*6#5XQF=PJ'AX
M\'?,$M'&_% .RNCWO;W7.Z)HTG1F4K+2LJU"/%M.)+B-U"OH9:,V%A_39:]8
MCU12L>ONNJ+QK84OL/VC0C/]7Y(%O3N-/=>)"M^S'*=($?XHM^(\YE9<1&Z4
M1Y'GV6LLB 5VD*8L#.(P]GD<LX3Q,$\*%GBAZ\;N$ L2],F,K+=F0_E=C269
MF/X.=X_)2DX@M"G[!':R%M&4:8>EE*J.E' !R/*6)932026\H*)B<KAB4V7V
MY9W&]&+)9_CUSL.+CA:]L8A0#3HTCYJ#F;N47U9->$:Y2-AJ7Z+[2H6-!,\"
MO*N:63('#J7JV-PA&0M"U!OX2'>?/B[S,YJ5&?%9G%<-UTW-,30D9H5!M>IL
M)HN$53(CJDP45\'Q#.P'/?VQ2,>U1+X?<GSXM80. "$ M[W$!O7B",:CLZK*
M+\O)9#RJ"/]A4LW.K(DHL&I/R>Q_N3LZ:%>+7[EVI9AQ:)2?XBP1W"<3,;<*
M [8";4A\O@!!5-4&ND0*<HA?Z'I/A(>H9FBQ&@7965EGRREF)6=<YARJC LX
M9.'R0RM6Y++KTG@@9-S_=JHLK9:"JC)6UX3V286BU]&LGB@&F6%V>8E\?(XB
M */):.R)E375LLY(&F>+I0BPT@RG;$5!>ER\- T;\WZ)98HG<$CSKA&\R4R$
M-9L?4BH+CE2=U0II058I'/WKU;[E)"/$+>%3*7-*NJN(9W)!0%5*]>$S>65+
M4&\0Z&'6*W5(%1I9S:>LG.&F2L")+C$+6A/A]LT<3I1G$GG@UX>Y3MVA59%D
M24%<^EDGXU)T:29<+&0%7;!R(EXAJM.I1IY.Y,5$B0L,D=(L/R^X&<P<WCRQ
M+TUO5]J)*UI,^0K!=M8^.D(. =QFSL6=E0%N@_T8%P'3,B:K=HL%_!DF12UD
MQ79>4@4W<7 ,@@!!?;&OX[;N#,^^?W>&]\W<&>37^[,$N0U,8;4WRY^S.09K
MWG#)?AZ,H7>UI[QWWLG57Y\/KT!C.G[A'GY\99]<3>#9ORX/KC+G</H.M:-+
M&./SA[Z6]3'_>+C_PCMP#R<'QP@G^>;CT7N8U_[>%;SC?CC^Y!T>_P;S?3GY
M]]4K^.;!J5LP.PL#UPIBV#X_C'R+.7%@<3#RPM2SW:18PV)T\\#V4B]-(K 1
M'+M(/?08Y&["_3A)W34M2^\_4;X\@9$^@J_MT[AY>MWEI(E7A'8,I!.@.R=-
MDC0KPB)UO"AC49'>IP]DOU6]5J#FC 2DX0 3[):X270>1I&72262<NX2:/D*
MG48V-$L]Y O1+_5/F-8/$C'Y[G<SLT_C.'; QO$ME]G,\G/'!_.'.DD5?E $
MA>>R;.=9'(]#VUT/EP@1TX":-ZDN04(WPH9N&Q$1@(C0V+!6\L'0!G:<?UU7
M%R70^6\K,(3S5S/=OF%/3WI+.,.$\V)U^-=IGF1I6MB9%3MV8OE> )9S$'M6
M$>1.%!=>FGK)SK/('0?Q>@=OT,<W*5HFCR$T'W+H+*=+8:GE5&=ZY[2>OP<@
M<PT5O>$B__L%J['RIMEKY[@OIKBEG@W4$QR>G1:1Q[@;,RLN8A>#M=Q*,YY8
M2<@]WTUS$);!SC,W2<:!'Z_7*@JV\]UHH(<B!-_>'NX&?>_R:.\T\6(X7SC2
M+,.&A*#O66GD%%8<!H4=^B%W/!]8@S..DG40H?%F9\N"?1YE:,@L9.T>F6S?
MF0ID&;R8(NCZ^^T$C]GGYS2]-WIV6SK90"?NP=FIG^1YG-LY!CM=;#Z66'',
MP#9(<E9XB1>$A8O-2L9ALIYRI(J-A5OQ_NA!<049XFO:LT=%XX=*[_S^5!
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M.> WJ]NXI1;Z70J,4C:A9.PO*C#JU:!\H9"]L5;B'MEUO^[Q1[B[P[4DMR)
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M)10\()?0&^5NO*E":1MA[D28DVV$>1MAWD:8V\CO31'C7N0W<^W(S=S0]I/
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M"Z%^S"IU'!HP1Y2&JM<,-YZL1QC L[A.W?!N4C>*P8#A)6GL&IQB+<VH0\'
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MK$<O4QG\/(^+/@&FF> Y(\7AHJ)!":(\DS(/T4D+]HI$3CLF[BPVS6:.^:<
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M. K<O8)Z(K4UN1%:Y3RUY\>8TF=609A'>5A*)\7[-[]Y5+^L[QR=Y-9)YTA
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M"^ORZ2H^S_'A5WY\N'==/_]$ZJTC?M3Z_.U@YTCL7^]_.SIT,(;CL_^[WET
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MC^1\'^UZZ_!KKV_NQ2)UZ U[+RJ2Q'6(<8;I[%[[.RS=N%EON)A5.+,4,[B
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M^.P8('(66*+V2R^$6@2(K9&LA)LO8!T\7+?1[/VZ=1<!G<>-70HP@R O#\Q
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MUL#:E>%THFGK+2,5HPMGX:4[:U][8#@LGU9V<'EV< %L 598<NYSI)60B)-
M42S$(T.E8)X*&KS>>$>R32;4G>W@TQFU2EE7,F:IE/4IE'4^:"%YYF3FD6(F
M0]P%!<HJ/-+@Z[62WBMG(_^&)/-]22NBJZ^]F/?O&_:#7K"LM\Y]J4]<]%O+
MQM37'OGM_NAW#:Q HVVZ5WO]T(H(-XDBJ--LIE;71> /E;-YC+-9@  A92Y-
M#L[&8.T@,F3@9R3F*.>9X\+JP(/9>*?49H9I=4R@,L>5.7Z=L7UECE_"',_'
M_IG CF0:@:\.B/L(,JN(1)YI[FQ@(>!LXYV@FYK,0Y.].7.\X#S"/=K[?WIB
MX2%O#A^BM B2@LF8[^D?=63]8V/J6^4JX/%7C(4Y'_1O_LI<D\CS6[W4/L?P
MS!F+B7_/NN-,\30@VPWF&S(Y#/:?IGEIKGH;_S/=*==HH\D)7)UG7]P+_640
M">]KAV=@6B_"(#(=1@JSK?GV[U4;>>QP3RW\X""2<J<>^@_@ =HN=OFGVGK1
MY[_RS_)+([(T=@9P#=_;K(4?D6&TUCM+_9EM7P/'5_X%3VEF$9!O;E>^M?UX
MIETY>$.RX(EFS$7N/"-TYDT>3&9Y9AQ_QG;E]Z-^UF'K,CCZ\NC@[Z$=\D:_
M:E4^_,I.I)=$!^^0I=9&SF2.-"8646F,E"PCWIK5:57^ KJ6^%?;_04MRQ?=
MSO=&+XIO/+=RKU;E=>I)5EM$JW5JR%VK[F'^0MW#Z][[6K4$OW!+\,- _UZR
MC:&@;NE/6.J:+7SS/Q^TEU#.P.VIVX.PB.X*7[::([Q%G(9^#8*S\//;KMXG
MGVF_[24UY4, >8&LY*>-/_=YWM?9U+D*M=+51QHOS6XI4W-YT>H#CC^JOGG1
MVO\;<J*_(5?Z^Y,XWH'O'-;9P>$VJ_\=O[-WM7]^2HYW3J^.&C/US=81.6[!
M,[5V?QSO-+_!<_VH7SM1WW$_4GYUOD</=O[Z=K#S1R-M-WV9J6_R#/)G3!RB
MQ,F(N"*1\M8A;YG$N7=,:/N* <?7R#X]U2;0*ABHM=K,N=5653;I?C;I:M8F
M!4$=-Q(1Z7/$:<:1$DXA#B9*>VD\Q6KC'25+8"Q=%5/T!C*K%"#6T,_CQ04-
MI:\(<'D%(JPT[=MM_^^.J^*LI[)IG^;C+%@[S@C8- P6#"Q9KI!EQB.?2<+!
M-WE%6,53MW)Z?<? Y"7A*.^HV)4"WT^!9X,22[ SRK!(2X<A4<H@4<JIBCM3
M GX!:<XX!"6O3'7?0!UKO]-&CX])W@(IU9-5?88X754T\A3&[.M\-&*DISKB
M[!(<V399GB&=!88HE<%2HRU>8C2R8JG6&FOT^D0CE4H_M4K/%4U(IH+1%#FI
M<<2BC$38+D/22B&,80PK]5I5^@U43PX[?=-\3+7D$0<=JIAEWL#=T,!7V;>E
MV+>C^9"%9()@Y3@2S K$,R60UM(BEPM#61:(I-FR"RBKT7"_Q-+*:S("*[49
M=*,YJ-3^?FH_&]9(+BA53B!8O4B:I G2@<?S-X(K1W,I;.2=O,?)^S76]C=0
MC1EV%2UCG^A-9'!+#W!V0A[ IOER):I YRDMGIL/=')JE=$91E2S !:/.Z2E
M"8@Z#;\[GUF9O]9$KM+LIZS-5)K]O)H]&\M0HK.<Q=TCRB(% ^=(:<.0)XK&
M0VU"L.6E,"NFV6^@1/.J&US6*'"9V@FOC-Q3&KG3^?!%F$"L(0)YB?,(F."1
MUCA#0CC"76#$85PUNKP!_7ZR\*72[^?4[[D^&&V\8\XBH2@$,49;9(PW*,,:
M4PJ6FTC]6O7[#=1?7FTWS!H%,.7F>67:GM*T?5O0%8.5<!8[I'.O('21%!E+
M-<+8XL"$<Y;+UYJ?59K]+)672K.?1;-G@Q;O5:Y=;I%E*K+Q9 H9%O'<,LRE
MPY((3E^K9K^!RDMJC@$%+)0L@C:\_DZ9-8IG*G/WE.9N]S*9NB*8@><_9?NG
M)SGX+&4L1I('C;A5'%G)'"(V(T01"'"RY74#KLW^>64(7C;\J0S!4QN"^JPA
ML#YDU$B!@I89Q#N>1PI"AJ3)I9.4Y5GP;\\0O(%"3A$3S<-8O0A&^*M$]EEG
M]/35[[.N?,63^HH?"X)&DS,0S4"0S F/63)!)@B'0JZ,D%1+Z\*RL^1U1SQ_
M&Q:T(J!8<\RBJC]]659S+L+.F25$@IGTC(+55%XA2Z6"WX25V#EG/'ELA_HK
M,99WH(>8@+(O+X&BF?LGR])EBOGZ"1/$,ZHWH:#>.Q-%QQ+3NQM<Y[0-U_ )
M\[L?6A>=KNE>U7PCAP^'M@N1JZY_&4([881;TVLDP'#3ZX5^+^'C-QO&-IJ-
M?B/TTE7R$0M ;\@"D#XW$>!?#+H7G5[H+6 ZN'GBG@O\?CA/8(*VTU/&!H[Q
M,U; ]X=?KTZ\(AHB+H6TXQ1QR22R2EO$.#?4$),;2U<'^/X01+=ESD$XIV'O
M)^OP-XGT:\*^QUN2T^7#R<LMGLDG@)-7E#W-8.^&__]&4>HK:/J;YV(:C_Z.
M K(&%:6=>4-X)Q#Y92"QWP>T_7[W>P.UT_W0KW4*:K[V::T9N86=Z7:O(!"[
M-%V_QB#G%8CP?8J:-#BKI88?)./6*F.9BL4P'RRU&M.3O?MMA(^"WX.A<$5*
MR/<3HM5["W2.%V<'.^ZZ3G=Q_7J;[>]LX^/#KS^._OYZ">G[Y?ZA_[9__=>W
M^G7]ZG@N7=_E^]?UZZ/#3]>1!K*^\[FY?_CA[/AP&]+W;;)//[']O^&]ZS]:
MD<I]KL5/8B6E,1A98QCB3G%DN. 1^,H1KFP0)-MXQ_4F)#ZOK ^H,E2OUU!!
MIDAMR+S#&>',"N.MA;0]*!;Y[IQ(ANH>&_65H7IN0S7;L:BYUY1(AKS-,L2#
MS)'*,4<26\(H-XQD$?=";RI&5LA0O9[@_7/H!=-U9ZETX</WT.Q<I*J; _UH
M]'\:$"YH,GK='4-/%BC!+^_3?$_9GN':5&;F7F9F ?T++!<-U%MD@P$S PN/
M#)4$&:P-&!UCO&(;[S2_IXUYNICG'GU]KUOEGLSEWZ9RK[O_XOE4<<[C&ZI"
M4!(9P3WB%"ND=82Z4TQ[G=,,TX=V7SR#9W\-99\O_8[[%G?C@D];&J'=2\S3
MU1'(E_#[P]?*CH7W$PNRW?9E T/O2^00_STNV>0'WG=Z_2I!69ZY6D!HPG/G
M>>854B;CB!OID+*>(9H1+!R(1"*.HYLBPRN4GRS[J.3C#.!:Z_Y3!B"5[J^4
M[L^&*DP'A3/K4,BHCBU/D#]X, 59P)RH/!<JRS?>D4V2R3G=?Z5[?0?]L]"M
MZ@!/MF$2I[?2ZN5I]0)2D$!8<$I*I"6!M$,Z\.B*:"2UE$)J[ Q)6LWEO%:O
M:C7@3K9DK57NZ4K_A<I56G4_K9KUE8;J+).4(&LSC#@Q'$$&SY W@89,:)PK
M$7<<YRML]_&4KR']GC_%7S;-/";_?JMG>)_,$W_L=GK5YM\2;<8"K@N%)<VP
MU@@3%T%*= XV0UOD5.Z4S4@F,.36@F^"F"SW'-8*'QZXYS7N_$"O1N6?+!*H
M5'[Y*C]'WR5S2KR3R-"H\K!Z2&&K4$ZQ%#Z3G"FW\8Y!]*WTG2*%H: .I4DD
M37KN9M&J.?5INXHGSE3<J;7X.0J=2[_&ZZD2[;7[IGW:B"=;4FA[CT, :^&M
M[G/8]0DBU(D#91\['7_9:#:WVWX\Z84[F_V[\FS+\VP+4#7!KUFBC4#,D\C@
MQ#VR6<XB%!_.A6)!.1<WBK(%L>S<"=DW5 .ZCRX]0>A7Z=(*Z-(<@XAR07!!
MD.&90-R!0AEK%*+6!YH[ERD:SYIOD@5!XJ]OK9[T\RV9U[9SNSJNMRH<WU_7
M%X(X9M*#6KL<91S\)2<DMFEBB[#- \DS$[#FL0ST(+=9]3RLGJ.M-.=AFC.'
MR:(IEP26!A&7Q[9F:9#)G4?2"$Q9\)A+T!PYO^=R+R>Y1KYPP=[*1.E@*8>2
M7YVN+]M+CC"8)C2^BI>7: D68=II"2DFA3A94J(1IY"'VD ]PI'#)I-!9HZG
M[/.!;G2II<Q7IT++=I>5"CV]"LTY4X\QUQGFB,@0DT[JD/9YB*RT1G*B6$Y2
M 8<NZ/1=Z$_OLS7QPGN$+UT/7^[VQQH%+!&"8Q&0E V@[:'VW30'J=NW9B*"
ME&F[4'MMQ?1G#%5ZK59_?M^W,K)/8V2O%\0I,L,^\[E#QDD;J^0$:0*_>98%
M$7+N F60ZY--R;.?[_^^K2KY,P8CE9(\LY+,12(NY"2/W+(.PG;$,^.1S0U#
M),^=TLSFTF8)%('2NS5)O.;R]U_S+K(JAC]GI^1H ;:'\U\9B"4:"+S BV+C
MG:&*HUPR@W@@.=+<@Q>EVGNIE)%4W^A%JZKYNI0!*A5[-A6;KP9(S:3.*?*:
M!,29D\B*7,$_)M \""5CH^(-/OBUEM<G>_(V:^WYQJ[I$N!;IH)X_8P/JQ![
M3&0E^^'5D^8\ESTD"T(.DE$A&+=(8N(1]Y@BRXQ%1(-%-([DCK.'DN:L'-W#
M;<"2E7FKS-MSQ'V5>7LB\S;?22&9QQYK1+ 1B MN$,1_&%DNG%-4\TS)-31O
M=V.B^2G?S/ Q)FY\/NCU&_G5\RMFXN/X$,EFSD+M*IAN+;0]A*-SK ,)S3(J
MW6;Z:,1-,>VK1%G3C5\P"S9=(J?'?ZU"4%.>0RN5.EM3I7XX2\PG4?]THGEN
M7:QIA)PPB#<D1R9(A;*,".:%H)JFLZ%;B\Z&IN6_SUI69PI?9J$/MD]<\-@9
MYV"-A8C0G XIRC$2EA$L@LQ@"6X\$0@:W;L(\/OWT+S:JAU.Z/J9Z=5"L7\:
MM1S>N>CT&O&323K:X=2D/\+WAH]<534+]B3R( PN0%8:D<PG^=ZK6K\#MP'+
M=QW2RPNV:S=KEV>-B*';#0E1K]N(V'KPHP67;%Y%R]+^.=="01T4?K@ ;TS0
MV/;@ULWB"3I@:#ON&YH'[MNJU4W;G!9L6?&Y0;9[\%3=\L'+*4G>2_[6JYTU
MX$K=-"PW: V:Q43$$<9Q@:5N%(1=7T%AX!)?(A-7K_;+QM>M+UL;OZ:13KS]
M+W@@WVFE]_\%[V_6 KB'5AIT/N@/NHFV*]$<%2Q>FY$2Z3(TF_'G17?@AR1?
M>3"]=&@LT7PU3;L=YZK7ATD+IQ #;:9/E0_HF@.?GL_T85EJC5ZM%7?,FXUO
M( KQY7:MW>D7[T_Z@'C"([TS7--$33:<;9B2^",^*0P'IM TTTT3&]F-E$_Q
MP1>]N57;=M'CP&,TKV#T,!]P\T6;^O&A;"1*@[F#J6KTSJ*7.C6-=B\-OU>L
MS\(!I%'_S 7>K"3=,%21WEU4!*8R&)#SZ2 A*F6TIHUV\5A384/INB4%WUY<
MO0.12RAD;LQ*]8^-J6^5P1(>?\58"(T&_9N_,D<%]$+A"2,SLS/Q[UEWG&&>
M!F1!!+\AD\-@_VF:E^:JM_$_4\_4:K31Y 2NSK//,1ZE9_\R:+5 %T'"NN8B
M#" N[=7VVFX!4]^JC7R_DU2@ YK13C%X,E\?1FR$7X9LA+W5?Y9?DOGN#. :
M'FQF="HQLSA+9'2@U^"%RK_@*<VOB\1U1J.+P"1X0[+@B6;,<>5X#(V\ :.=
M69X9QXN8"KX3_':,=8B7&6$!9SE67 MI)5',$<="$,K0<*,,OVQ^T0T7G6[R
MTC!1C8Z?LI@C'[K(B(-[ XV.WMD/4BB1[+"]NE<HNG2&\?G-H]DH]3TXR].P
MU]YN=0;M5PXJ^0CR2OC]]$0%BT-.)0K!Q4*!,<A:%^L&-/=:89'G(-B4;@HR
M#Q\W$1+Z08CF)CK=4P@^NH4L+0X4BP#DIMCO'BRHJZANV[>&+_VIJ-X7P=F'
M,CB[-:Z.?+,7%]W.CQ22-N^GC"P7L-8<UCH+7 DP>9F2UEGA<J>)UW?-\=\J
MO\PCM(WNGV^?:)_EDF<YPCYDB*N<(J54W(HUDBGX)W,J8C5B-G^LX=Y%  J9
M:*9,+/?!8G.LP5E1"D[,JIQ)EM^U"/"SQ7[3Z^E.=, Y]P:L)P83RK522'MO
M$)$6Y](80VD.UI/-DY)-9S'#A+MEKB!MJIGOIM%,&2:8U$Z>QVI>F7I.$$=/
MG 0K?#HLIJR!$ZR]'Y2)W!\=VX.<K5_[)3IZBG^K';[_8SO]3G[[M<@="W/=
M!$N2//\X9W:#E)JE>+ZX-HP&1A?M$01/M<YW>+W1AARN$3/G^!1VT)^]:+,1
M0^AH\Q:8-LAX!X4<E[ZC&>#FW6CD;OA&,H;ISIUN3>%_)'L(<M^-9-WQ2J.(
M9CI)K_W2&]ASF.]XIR^AN"E3='BKO1C@ML$ ?P[? X1\8*%]B&\2"%-2A@\Z
M$8NSOV[!9VNQEATO,6O->X\PSN"'B0C>6J8)C]57+(WGRD#(1#.AR3*,\YO5
MU[T?]6MWD@G"K>$<L=PS! Z<(^6U1491B:7.F/$2[&\FYJTO)"')4:?,:9%C
M+C0X_+AHQ K16;<S.#V#L!I"[D$O9B:I)%&\2C''23]OJ'7,QPBF/5&%FJKF
M=&\BO(HF8@'I5>^^^P(DRSBS09I@<DY /EU&9<ZS**52R^RN8KF0H&88HK]=
MN;R&ZYQPPYBPSJ/@5*2.D0%I1<"M:)!6G$DO=+Z8S^G.CF/&8Q2UQU3]LN&T
MD0QP*;OP!\6,35?68%$[A20^V+[)0&S \"CQ&#?C6%D,1LXYED,<JKBK@L\G
M$S*\?_WI1&L=A-,@9*"UD9^(($N904;DW&:0!' FP/AILBG)@O S&<!_;2VL
M]4^*W: 71I7>F7HY2$Y1E08'FO8[D;U":=\3$L%&K_:+J5UT^F"\&@L1A>]K
MN1XK<.GDR)_# 54DFX^70UH_W#VQS.A,BPPQ%X-FGD#%G$84LA27LP"Q5=AX
MQ^6F7M2*"F:I"!5AF9.;BQLB23!GI2P6"D%\8C,#^TUL0MH?93B9O"ASA9,M
M"A)3\MMOI'V4H0P/+Q>_6^QG@1A.7C0%O&!\P1/WNPU7;FX)_(_"@MZD-+Z3
MMFV:YJ(7AGM0W71,LAA9VELQR3].W*+9 !=?QMX0#Z2GC=L9Y=?3EEUOD.<-
MUXBS,QS\\&$*;S%\\!#'U(X7+A_:KWWYY6MZD%'U*>WKQ7#I3ON5]X^E2K\[
MD5N8^$>O;PHC9MKM ?Q(29 I[17$;??.0(;UM<XEY%6]L\9%S:4B9Z^0_S/S
M'3[JRHSMHAN^QZ@S[M1VBP^XSJ#IBT\,=T,+VYQD% 1P_L+QT<;)6RF(<8MU
M:@**JT\+4?G4S:N%4<A$4I92J3)5C ')W"A2XI423+BJO9J<MI1 #YH@VWFW
MTZKUNR TA8WH#0O7<:7CV,=7C<,/W3[H0K%C<-9IPFKTXC1=#&RSX6KQA,?%
M:,<X52GG4LPXDK0YFW9E14Q"HSJ:&-^'4#BT!;7VE!Y&E8_USF;HI[Z=7G_@
MTSQ%#]>+642(BAQOF&8@WGP\_GB%X3)OQE$//UXH?Q*#M.W:@IEIP$T6K"M,
MBRMV_@LGE8JNV^VK22&-:U],[W FDL:DB4B["6/MNKU@V7V 7I7GQ0=C;=ZZ
MO^U9&YM5>J^A32YL^-BBE+6&(ME++B9)^65:\V+E(7@:24QC4H_*Y;,#6/90
MUMZ'*M!)H@,A4W']XL:MT(_B,"<XQ>)__5<:*(RCD=H<W+ +8<*^%./ZQ4,N
MX?J%#6JTAW_]&F4^]@^$J"*]& FZ_PS@S=Z$2IV99CZ4K]1N8+I7Y1:?,Q>-
MB(E4ZF2Z>]*$_F4G_D@7*:[<*WQ]>7WX>-3V**3QN^!XP4+T:^(?][C1T$V#
MO2RO%?=83TN-+2PD+-C,@]SQXENUOPL/OG =IS4_CN.RT3]+JPLV)P4TL?FD
M$6>B4UKE!9=);2FQ!Z+X0JKM)8W;G!2DECF'ZXR_G_3<) .>Y <D9N"2,P"S
M6SBITLL4TU1V-$Z_.1)!&Z+M!T,$P7 S?K8=3D$+8Z=,?+*K<6A2U!E+HS *
M@D!M8>8'14])8?Q3JT>C\$_QCP6//E.V&ZJ:<]T!7";Z[/"?02@6<!LFLEE+
MQ1@B%]\WI3"+3#1(?_N.<]GI3D[E2!!&%<SAC TM_;2V+[IPRBSF9CQ]?RS$
M+N[IIN: 9'.+1[DPL>UVT 3752Y;=_3]I_1BB]S10L]6]A,M?NYR;/_O>,Z*
M&2C,TM!JEM'@E+%]4M?WIKS8'7<@TD?@A=$F1 S5"BGJAF2I6^.T[LMDV)7B
MNM@E%Q>FK.J#%6LG,SP1V<4:0+?3;!:F X;8GK[*<"3O/[P?#:*(RM/N=;-C
MP3(WQI#O<5,$! 8N-]Q**"_P<>_?AWNC2W3#:2.&M'\.NKV!*0Q)O."'[2^_
MQZIQGM<^_;=I7?RVO0DI[ 7$FI+CVGYG2Q1M=8-V$B,8<NUC,88)V/E_=RY1
M,8:]LN=PLD(<[4'<NRDRSY;Y%NUTM&W#BUYT(+:]JH5F&.VVA$92K]A"?MJ.
M^>YDO24D;:SU0RM.&]B(HC[C&SE\)K;.Q>PZ[EX5=X1\ U0[@N/7TIS$!2H#
M_L+/%%ZI3%6+2Y\5)<E04(5.MH6.+C'JBA]^N#&Y+=4K8^S1)3KMA3VSS=$P
MRPDIIOAN-VG[D= EOQ)?+N/6!MRCL-Q3UPHP16E7KPB4X*&V:A_ASUE#E<S%
ML!UPU*$:4]5A/^JBEIQQQW^9T(^Z.V]HI]PLXY4T][TD_RE+B!8\E7-KL9+;
MC;GJ\(%F1^HF6\CR40M9;]1"-F_4ULMR';1K]92>4+DYT:,QW2X<VL8-.Z_?
M=[H0CG]O= =@VQH0CWV.=9F\B,MV8;XZ+5!O2%8'W=AP/6G^WF]_WOTR:?]*
MB34Q HX?+,6M-[EB17]IS&:CKN5@K(I"E[F*=FXBBX+E3C*03&CII4"'FYTK
M4/4)[S4TE1-7B%L"-SFT"'U0:EO<.&BF0D62\5:CW6@-6I.)7#% ^%RK _:B
MX4JK6UK#>(M&K'2 3Y[8_AT[X')GHA_<63N> XJVNQO<^")P)Q\NX*5&Z; A
M3H!Q):W^SP#D*8]!(P@SS%_A2^ W&'Q_:!R&*U#L:52]OS_I_:55[V_5^_L:
M>W_7M)=WZC1%[4]SY<X"F.8_N[#DA2&%7T^[IE6DB_9J7.Y,R?8P.RJ+3*%,
MNY/M-&#P30H-H_T>N88RNNK%>FN[OUG6R8M@S75ZZ^_])P/&F8-&$RYXG"!,
M^(^X@UZ&E^EL3O1.,?;VWR'^-Z=AZ((GKE.^,G&1WD38&-_N#2 2F?C&99EO
M3P;<*82[+70;U1&&A?*8A%^4K;FPGL[TSFHY1):ERWWU<=[.N(M]<UP+^!B+
M]^U6<6BK#0F"&Q[#2K6EB5H09<77)K<"AD%^66H8MLS'1:(B[0!"/M&&\3?-
M95K*81P)W_UCT XU@HN>GR(XB6.)BCH6AXER5ORZ:8_O 6I]TR&JEVK27PRV
MN!_Z>^6@=T+Y<Q ..\-&_=UB3N#SGV$JJ[;]G^VA.UH_W#ZQC FOF4><F0SQ
MG&ND@Z8H:"QRR1DL);X7YL-R)>#V,QJ5/"Q5'@(Q*LNT0KFB"G$;%%*YL2AP
M+W.9Y227<N.=WF1D$6'YHD[S&4.SJ!AAKU)?8DRZRMV/^WB(*=R&)0CC=)/8
M%XB,_* 9#O+=84%FA$(?A>ISB&=N&\TBB3R,^?0AW/_W9L=]>W,RM'M9/_QZ
M?8)#(,RJ@$*(.*U<>624RY +-GB6:4%%OE$+H&H7T:UW!V68_$(';5(Q;+R&
MH]!J5+B:+\4-JQ!3';0QP!FD ^3I(XUT!#GO1#'O_?.>_3#O_K\$3C*#E0)3
MDMI\_CG\Y3??Z%TTS=4_&^WT8.E+O[5,]Q2RY+)@("[FP%!2)%6\/<Z?MW"1
M0Y>(?.6=R[>WTELS""[%>YG<XIF\\6V\11[XGF WW_1GW_S98 G;$D17@Q5W
M^N8=$1J?A/*YE-Z[4Z44]867@86<+3HH!G-X%'<#=A<#\3P)M<RKGC+\T"E[
M)JSO5L/[9G@9_-$I-S1QLFO:(STIOC%=!IG)C0" "R&]GF;&'PN#!QF%C2Q^
MR\R*]O8_S,:E=XE&M_OE:> O0SF8^O HV4%T32/5 B"O@^O7>W"-O:N#OV%,
M._&4PM&/H_-/UT>M.CW>J5]!5$KWZ2=R\'X&( \^4S_?)?7S/7%T^(W7SS^Q
M_7,8T\Y^X^CZ^%MQW2-VO/.50W3;KS=F"'EY+HB(IS5%"!9QY1BRU# D5,ZP
MIUA00S?>47#R]\3&>YP.W1T6[T5UZ!^OS2*M)C#G0HOD ]6YP91G%BR3#YJ2
MG!OFLLP9[I1-%@D/+=+<Z>[*(JV&1=I_/V.1A M,$:-13G$D/ P,&:XHLL83
M[!C-=%AMB_2B.K1\BW3OZ#-/_ZU3]/E^U$*YH+CWH F=F8,'F?@%\[@FAOQF
M:HVGB"WC.L C@\U]B$$?5MKO1,U1&??[&/>]^7#3<6N94AG*<HT1)TH@*YE
M0F*&L57,B@C[@K?F<0?FV&WN:8!>K_6NC,WSA8V5L5E98S,72>*<&(6)1AI;
M@SA6'JEXO%J0P(6@@DB6@;&A6_,[@96Q>8BQ>0.%ROU.&Y7-NG%W:]@3]M)U
M@-=OMU\T2(15'R_Z;K'FE8&^GX&NST>#1E/NC<&(*.(0SX-!)C;PP*J"H:9$
MFQQOO,-;\Q@L=[?/BTW,Z[7/E5%9EV"P,BK+,"IS49^1G >1>4@LM460;PID
M*(4%=+EPP1##@]YXQ[9N(W>LC$I5'RPG[?/XI-D= #S6,X=_T7VT9X\%)SIT
M[]8562(VCB7A<RD(?X9N;$*I#/?]#/>G^6@0>\TH#AAAKR &](PAK8U&4F8Z
MPS(SU-B-=VJ+O52VOH9;S2]N5MY6-%B9E1<W*W/Q($1]QCE*D?<N(!XD1(::
M*B19P"KRG7CK-][)!=O)51&P*@(NG+3=T9FT(:S*^#1A"9!B^B/$Z]BYN*8%
MPK?3H#B'K7P7^_VA6/VI3^R4R# 1]+*RWO>SWE_G@T)BB<LD84@2"]D\S1Q2
MFCC$=" 0%1K.,A5+A//[Q0]K!GHSD>&+VY:WTVI8V9:5L"USD:$4W'MB)#)Y
MK!0R99%BBB,F##:!1?2+$&W+?*7P.6W+&H:';[Q<^.4&1K<J@U_]PN C]G.^
M1/2=W^.JOY]8]-V$E ]?^+U@(JX2^P>9[Z/YT# ([ 5E%AF&7=PS%BAR.")-
MF:>"6R$QW7A'MK(JL:^LS2N)"N]I8R:!0O+&C^#1=>AV*MMS7]LS?TB%6:8Y
M9BCG-"!P-0)9JR M]<83<#26&['Q+N%.T=\>&SY61NA-51</(ASQ>N;T;VL3
M^1&Q8EKC;1]1X!*@7&62[V>2W7PXR&S&C%,,.2DDXC:3\=R@09AA*C,;0M!9
MS.;GR;N?J>^G*A)6X>"2P\'*C#S6C"S8+N:9RI1&F2,*<64=4DH(Y#(IJ7#>
M4I/'K'*^)[DJ"KY84? N"$-/F>M.PQ<Q6$;?&<1VP72,_ V#-#PRR.)W,XKO
M.PG5&F;R8+0/7R6_RS&1IPLP8R)#KK,,647CN3IG8H<U11I[@P751CNY[.1W
M&1KVJLUK9<U6/L1[E#6KK-;]K-9<8*>"@64*.2)QSX";W"#+/$$FGC*#@"]H
MGSI)V*-Q92J3M:0ZW_\D--A)1IHQ3O(:HN[OM4=8^W.L9;&IH]\LV;E^?LHD
M45^GUL.2RR)^J!5\8]!*P_&U!(IYT6U$=HN"YSJAV?2F;AH!J]MG)H'\C^F'
M$O!O)Z]1%LE\VR6/T%5D"[AQ4.D0M&\DEK-?AN1AQ2A_W:KMY=//&AG%>A.\
M@YNU1G]V!GJ)76S(,]&,/!W=.*I!>\3[/;P ?+87>3U*CK+IVV_5MHN'[@8S
M2X8],96^$PIF"1_BD\3G+KB8AY]?R-D\)/<<PRQWVJ>=1$XU1*XL^-[@KR'C
MT?2ZC^X[9-N8'5A!<Q":84AC-0&-.4%J5U!R;']Y'XGTMFH?RH$E,K>P&+XU
M3=:8X6LXHA$)WBT4X.7X8$0O1ZXP;)7?;ON=\?!&/?453/YBB/-34M\Y.G&Y
MY]H[B;(0-.(BX\A(!:99,AR"RK4B8>,=$9L4S^^?)Y&XS\(_,G"J%GY)"W]8
M/\D)IUKF%A%),>(^+KSP&DDJ<ND)K)1CB1\AFS]G%6W"11&Q-J\V2]?2&+&1
M^MJ(2GO,G5=:K)+6<8I99\RG,TW(D\1K2,G=NNB&LP#F\7O!/_N*>6/WDA^,
MTQ1Y =L+H/P+VL-&^WOD#$QD21.LKY$ $U8+)2SE2./<\ W3;81>,?F=2 PZ
M/<<E55,W7)A^MY%8 2:O.4D1$'E9(W/W:5SXA3YLDM-TAD$5GF.2,-6&_F5D
M,!XS*\$((B4CB$ORX>!@"IK52&_;CS_B Q>2$@E5RT,74\]8L$==)3:O"?(J
M>&!8E^BVX(M^,'3IW?2Y63*I(7MK*:SQ/KT0DLLO(H!UYWTZ7+1P!846O!()
MGPJ.M,F0)4TMB-=<")%XQ"<"VA06P"RU>R->VY]$(!@^W(K,K7$9S^-QFDC%
M^P.>NEVLD;VJ_6_]\_L%-(/K->=[8T+;:<W)&\VDFZ.(;CA["8>R.#N43&1O
M8J:_E#-=L DG7B[PEZJ<S)_,Y4B3]]J)M+19^PS2WAZ$VI?0_=YP!8M@NE\1
M7@[ 9'1! L(,ZWFC#%D+ N#F51E]+KC=C7>*Z@=7*DS\^0 2%=\H8H@H.,6C
MI:?JGT'">!I)X$ 1VWT82&&28&T+:NQIAN,T[CZ8,CN IYAB(-\<A=;%Y6&N
M"O<57QY_)Q*+E:$_R&QD0+>1Q2Y*$/P]N( AWO-!%\[HT+26SU'0HA?^TPR3
MC8)E=FKN1SQV)8MUHU=8K2%Q]8A.MB"$A!&EFTTP2O]$Q2/O_="-3 CEB'\O
MY5*+[,#F#;E$7)$12_,]@D4:G-52PP^2<6N5L4R%7!D?++4:TY.].R+,?VV/
MTYEQ<]SM.P/XS86&NY?UG;VK$T85!.<F1SFU"G&=,:28SY%@UCG%B)'.WXM+
M[:F7<E0W_7,H[) 3[)5: "%+=Q!\M=PW+;?( U8B6$2=DH@KF2-E/4/69L)F
MQ&F=DWLMMV22VI!YAS/"F17&6PNY?E#,")TYD9;[+DCLU7(_P7(KGT%NQ^-)
M)T<A\U,.M%L$Y"4UCF/BA1 KM=S54MZTE'&G54.VCBS6'G&<9<@J[!!$G'$'
M5GI#((EO=VYG.+P#!V*S82S$)_VK%)T-)M:JR-3*U=H<A1^;,>Y9&'Z4##^;
M950$'QOF<A,1!ZPX7&<VT:_XZ*?XZ%G%1U_QT:\Y'_UC:G?)[M,0G(^4G,%E
M'&NB-?>YL-+HS!ICY0D1?&.N</#<,T7(5NV).5YWRY+=GZ&;3@BM#H'KIY&#
MK+=V+_?/3Z^./WZE1]?;N!Z_?WYVMA^O=?CILM[ZHW5T[2Z/KF8=Y-'5T>$V
M/=CYX]OQX?$Y.-8?\?X''W=Q'/?^SO;54>OX?/_Z]W-PD%?U\],3IBU$-1#*
M$L<-X@Y#4.LX_,-A4JDBF=:F"&; G02_'4,,(8.7.5,ZDX[3W"A#G<7*B=PP
MIR(@^S3?Z[_CYF.4\C3CM;GMZ7OQ_TYZMF+);AW.,_(&STC7[Z;7<''SI1%]
MI5\QRN"7D+BO)Q)B:B9 Q#2V H)KG"&=0R9-,/?:*&]SQ5:',?@P5;=C3T"Q
M79V(>D,_%6[[9^5.3>MBT!_M@,=ZO"NV@HM5K[5#O]B 'UGZ!13!HQBC(/1-
MW2Y%E\?ZL .K+:+5.E'CKA6/+W\A'M\5)Y,MPN_G(^!]+=/R-DEV[]BFMU^:
M[*=AR%O8\KMR<_!?3_3PJWW\[^:SL4_2I77#R5B0OZ*$&V/G=6G3>5@\6;8[
M0QQYRNO7I^2XM?_MB$+\>/Y[Z^#O^/DXICJ'[W^KT[WK>F.VW?F/LX.=T^N#
MG;]:1_3S^='AYU;]XY&(SUEO?3@[NCZ#>/33]=%Y_2H1^WZ995J#1>0$(E!-
MXEX.=Q(IZS+XS1/KG<,JGF-3:C/#]/$G8I^,U7>9QU4K,U>9N:7V)%9F[MG-
MW-4LVX=QC"AED<AR,&XL<#!XE** )2:*8>($W7@GZ&:FEW#P?_7-7!G&SFR,
M$%[DW"MXNG;=K_$6\H94\*L5'XGG+&!LYC34BC-RL3J4RC^I.PC,7JL3!]AQ
MWVJ=0;_7-^WXG#>F9:\3B^9&/U3,U'(C;CSK@/XN5VJ[6*C]M$X'>2K>]@[&
MBY+6]6X.ZN6WVM?!0=7GXW!" E4Y4RAWD=D.,X$,\0;Y/+ LY):P'!R4IIN4
MZ4VVX+#%B^!8KQ=*S!JI^B.CSDK55TC59V-12:BUL5_2"ITCR+@U,CXC"!96
M6*J,S3W>>)?I34'Y)N'JE:GZ6B,[WU'9RRW/%XB%UI?<;25CH7(AY^QD92*7
M9R(_S4=#V&BNI6*(<@LFTIH,J9#9R/8FM-2>2Y$M,QI:#M_;>D$HKY&R/U,T
M5"G[LRC[;#Q$;.9DQ%G)*8X@R=H@);E'0N!,6B6=,FJ9\="**?N2*D-I_&)+
M+(B,TM^-M@_M_C\1WUK0";,"9:/Y/J$7WGY^4:2<%]N765$:CT'/#]L*EQL(
MTIOQF1>U,U;6_E[6_NM\:*>4DIZX#&&719Y-Y1'$<QEDOSGUGDAPZ@E?2S^&
MC^.)]F%&RK'&V\V565L+L_;(D+<R:T]LUF:#V)QJ+T(P2!+*$1>:@5G+&1+>
M:I)GF3&A@)5_$V9M236^]8UI=V[L?G\</.3,>K]-W[#$F7E]CN/9XN%2Q"O7
M<2_7<30?$0LJ!9<D( L!,.(D8*3!LR/F:9Y[2HT(^M$1\?)TYJG]RBV%T<I>
M5O9R+0/MREX^T%[.AMJ:8B9YKE'N85%X)CA26BMDC54FERS+J'YTJ/TZ[.7=
MX+$7G;Y,U[@#?M["[SSW.=6;*L@1^:PXH JAN+VJP;@;/AUE/0OCCY?H;,.]
M>C2_5S_<H2^W[,<[0R,$PR$*V\UQ_T_',G=8=GECVBQA5^,[%YU^P0K?O"IN
M&=%2IRY4X,B-W@N)>6#4KE#K7(Q102]-MVLB!D4";PC]T&TE>.W!")"[WPVF
M-^A>E:T-K= _Z\#[O>%3#Q\*9.A;B,B@$0MO9D:'@O<2B RUY[GYC7B04:/'
M:."FUP.=]1%I#S)OW[MUHDNXW:FIGH+EF20=+]#9>PG4O>Q$6;36_3/33PL>
M=?XL()"<<+55^P+W"E.H?A$A,<$4%EI0(N>DU8U8],7J]H:(C0'$U/Y$B>.5
M>^!=(P#AS0?+9Z^^6:*]%C/1*X^HIP\,%6%*^FOA/X/&=W#."6IX0J,N.X.F
M+P!0;42DA:EHH*&2_ 10YLX&];D@&K9AX,-Q?PEN4,!,[OXH<)D_=#NM]^/S
M_/.(#F\:O>%Z[\09G6&&?:1ZPXCG*D/&&8+@1<9\$ I^+$)O6"EG.0WJL- E
M]$:B 1XHZD4I( 60[ +8AX4^;*R7LTUNTS9^P@J >CDSZ"53TN@.W<]/U>^.
M:!(/CF?> @#%JT**>)K!4O9" !3K \IP>U25!/O5@E+<_?FGT2>>Z6C8BU9F
M/H=>'T*;@LXANH!8F9D#F%CJ,9([7./."?QJE[WNUTPI&,TS2T7@@G"=<95C
M(8G,X]E_!Q'F?3NG'QE3;K<B/=$:8+@^IEIV<78$GSPZ_Q9Q6QF, >_O?(5[
M';?JAU_YT>'^^?[?GUL'.V??ZE<SU;+6AW,(0AL'AV>M_1U_=G3^">\?QF<Y
M@C&=G=5IG<!X>:R8I9//LRR<5"?$0X,$#A+Q( BRRC-$E<NU5MS"RM_,PEEI
MZ MHJ"6.V,"Y9=9PII0BC"G*F V:RIS0^[8[/X&&OLXFZ.=3TSG:28>U\O\_
M>V_:U%:2K8W^%07O.6]719!TSH/[AB.HPJY+W98HV[C<\(7(:8.PD&@-QO#K
M[\K<6T)(8A8@[%VG#P9ICYDKG_6LE6M0J>VD@,4)<V^0LY0B:TBTMB  V 2X
M@UPW=+[ATN/HQ,/RJUYT/>U4OJEAKW$ZZOLC.XA7+,PG;8W[N+%\[>!$E!56
MTP":1'(NG1%:16:UM8$;2]P*T(<:G!X#3MOS'$)&:Y2)%'&G,8 3=\@R72"L
MJ<.*X"(0NO:6L'5EU+H0\_MN]7I\.CKO%?&2>6IQX();R[45PCIL<?0\QIHL
MO/KU.$<6 %6=$$JCR%/$4)'6(\PWPI$KAR4)@,EK;]FZ5'3=R/F$J9_._?"E
MVK]Z:7/F!\8A$IQ53/@@B.,N&.N#]=%$%ATS@K*:%[QR'&K.\P+&L*/,.20]
M)4 .1$ N!HPH)\P8S+PG>NVM6->4K!,V7UBM7HY/MARY8I)JC%E!"-<$&#M3
M,%6%8$ 4J.(U+7CURW&.%H@8)2Z$1]Z15"NA4$@72B'E*?:8*(\%OO-R_!G<
M"&6F_Y7>OBY./ KC4*9X<MKIG<=8[5Q,' ZG'=NM#9NG,VR<-X3ZB(T27#!N
ML$@>!NV=(,0K6Q.*5XY@'^8)13"8Q&@)4IJ"89,JP+C(-,+"1%EH$UW4>0=U
M'7-1>QF>;S'2PG(=A0#61('=6V-5=(4&8U-8)H5: 3I1;QH^>!W.,PEB7*2R
M0,SC[/"CR&'ND'.8%A+^%R.[XZ;A8]T+R^#W2]B!K(*XV.FP$7JC%!)VOQ2
M'PD,EEU[K=;,*X8(G^<ULXU%I($7J8LL_(B.(V=,0,$%X4 [,,S,VEMBP+C
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MB-8?-8IVLD4;YZG]<,Z>/XK=F+0U_,BIY?T&/$+W,.84>=_N^]%)RC7W^8,
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MEVW-/':]UI4(7F MSQDLK*#>%UHBYRRP)LHT<EAA9(F#_TEJN+EF+=>UPWX
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MP-)"L (KQ'B4B LED351H0)'[8+!D6N;P[O-HRN8/,K<KH.X'[>R6RF?<ZG
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MC.NW5?.<0"+M-J>&[H.?6#-\Q3N;!PP7VHBTY'6(B&LJD7,&(TT#)[I0H"6
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MBPG7M #D\X!]R@'U83&2Q>5:[TJSZPS=.\A(BAOTF$7,TFZ&!&7(54&1HS(
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MKW2SO'*.3N9J_;N M27='&R.0W^WQV_Z=WK1>POQSQ<LU>3-W7<'(+:D .6
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M]GI9X.N\$]BT2.<N7,C+0'9%9.:'!-E;\KR[K'V_S 6==,2KT'56_2>UO\6
MOL=!?X.ZZZ'N7\O$3U 6A/,6,4DB$+\0D#;"(LJ4=DP%SK7:VBER5/27VP+O
MZN#G\P/>#?H\%L7;H,]S1I_EB)CA/FBB4#(V=\R(!%G*+1)>1HL=YH'H#?JL
MHGW_7?)*9Y4'9N.%CY=6^]C)[+,8,)O,OIM;7H&S]N(3V%O?WQ^:I(US"2/E
ML -7BRF4=\,1\$$9B<-,8ODD$MA+.F21\2LIZ*6JKDK"GB2H#Q?%OF<JZAJV
M'O1ID[9)$Y=5&:<_WT^-*+W6,\Y#V6.\Y>H.EO^\*D.^I#H\1GX\0.,VKAC(
MN@GRG&US<Q\)\N*&:?>7YIR3;27%2[]9IOD+OUFVC;7:E![</L6^R-S,]R:;
ME&"_U*J#HIJP6,TUU=\HBA&;5S/S:@:Q:]NEQUSFM-D?&=?-DU_R:]H].AK$
MHRR*VX:7TNX-@?-7(@J/D<  Q.21W+4WLVVY5VJUX\?>2KPP3_6'BD"MU+I7
M3%$79?!8$LZ<L,$Y<$*C9E88Z44E^7J?@:?:)9TQD_TZ5/8CB]S7P2;^Z0_X
MSA__/&D=?/R:@TJM[AZ#:_'6]Z.S3Z\^=3^].F(?O^_BUE*PZ?CSQX,6_MAM
M?=L_V16?3OXZ^WCBX;F.OK]Y]<_/^]U/G]^\"B<YD+6R@(5@J77B%D4>><YQ
M8,C*$)#$PG$I8Z)4;^VPIE2T::2^[XSPVP:B;@(=5]_,(JC<(Y \N4W(_[B?
ML7WBP<4+T7,\S$UD"H3="832>P30A>2,US5U+6* &^1<$SF7PO0QJAA\$,A'
M@E'65D'6LH"(#9@E11E->&N';IOEUB(_ &C>JMYCW0=Z%EBQ,J ?(C7)8LJE
MHYR&:"B!Q99Y*;WE7KO[S&6_$A#>3ARVW\[]M9SD3G_0)/>'PXI%EL45"[DY
M#I):2< *)Y 65J(@LEE$H4)*6SMZ.<E](L9T]X[1AL.\9 YS)]P%W5UNZ3)6
M[4VB)24;X7I>(-O@T[7PZ<TBEQ&<"4R%1\[C+-GE.+(":X2=M\81G(("+B.;
MDB^W_7N*9.9NDT ?+VAVT?YC]><?E33JW69A_?"AKAOE6-QKS*N,XW"OUJ[\
M8] ?#C=1K[O#NQ4EN]YS[W-OR"1L+CID%/@835FV!9. !==>;^T0UJ22-C&1
MZX'>_;EC5Y"Y'X>9_2 TZX)0T2TA:/V8T7 M!-K$C>X0>Y;B1E@+9G,MH;."
M("[A#PLPA#A CS)< /E212[@R:/.XQ[ZP^^87D[^?N\/4FQ?C_YM"C#GW^Q/
MSYTQUH,_AGO=6R5YOF&,MT+M%;7@P6E.DY5(11T!JP5#6FN%? K8*QN]U7)K
M)Y-%VM1BV4M>TE"ZYT+,APP5_CBT\WJ/^+3![4?@HROP;4-*[Q#>ED@I$QIS
MY112+C#$(V'(*)L0T4XZX9.C-FWML&UY5_&_)P1O/\PY7D;4<S+S-W'/QZ>Q
MN:YH;S@<Q_"J- *OH+I ^W"VT&PZ9AN6>G<POJ)P'2>7DA81J6 PXM)P9)B4
MB#(?L:/&<X&W=DB34-X42EV;I6XBFIN(YO-BD!/$V?#'^P">)?[H K>&9$UI
M;#WB6BAD=8R(*6ZT<5H3)G(RG.*;H.83"&H^*KQ<7 E2F<(:W6XVY2#WLT=.
MHW=&&?B+2.Z<MH[IF+0-T5%G,"WY0 \1Z-R4@]PCCK]?40["(BS70" ]MUGY
MR&%D6<0H,<>9Y$0'$\O&N#*J*<2:6U3/.[5Y$P;]P<.@-T.]307',P&[)=*:
MP$<)U BDB$X(7!>+=&()88&QL=)3;T+>B1=/1-_WL8.-SXGHW)N\TJ8:X]G-
M^T62HU5RQ$N*-#,:<4("TI$ZY!1ST3+,A96Y&D,^G6J,#;=X2L^V1F7%S3C%
M@U96;(HGUH*3I>*)Y+00W!,$HV@09\8@[5A 5,%X:^<\\2)K=-,GQ")^()7L
MJX5%2 ,UOL1AI:0=&G':Y:Q?/KYC%=M-U.C1HT9_E\'>[85IZZ9^_F@33+I'
M8/RX'$RR5,A$+46$*(K (@ARU HD#,6&:TI= & DM"FU:&JRO!UY.3X^0LQH
MLUOYC##JR0=ZKH:I3?SG#O%I*?XCF<+> C3%$, /Q"HK>.0.*TP"(A$%E(V4
M^,^:26]/:M/R.?&,IQJT67NB7A3+^5';1S[<'%[D&)*'(#GE6;\,YK D&ADO
M)?AB-N!$F%6.W"Z6LUGSGRQ>/*< S-48,E4*W01H;H41R^H66%IP1!A*4D;$
MN0O(X(0138$2X9BS$F_M*+QF#[4'B,/\$/D^-6LM.OAVM!R=V>3Y;"(V,S:R
M"<W<-23Z%3WKI2#)*X.,90EQKQ-R22AD3**""REIY#E17!C=7!L8-VD^3PL3
M7NI6W-.._LQ WB;,<X=8MQ3F"<:P))U'C&!P$2E1R'(3D$R8&!^E%T*7VL:[
M$FI]0F"V2?-YG(C1Q9-[$QJZKWF_R'%<BH;:I,$ 0Q;:,1JYP TBUBN%=6 D
M"S2K;;I)\]EPBZ<49;H;W)F/(I%-&&E-/%D*(SD!JX?U&BGG6*Z-8,A&##]1
MF_]C&):9K1V.[ZHHX@'B2Y.V@W"S\7+6L#GRID=NAN#1C]P,P:,?N1F"1S]R
M,P2/?N1F"![]R.LUBI^<889MG8R'HW8ZJWV1G?_C!O^]L]0'^G$:S.=FX%_K
M, .:M.,\RIJ^*.3.D\FV!W73R=S<=:8;^+ Z+(9&* (^TX;@PXLZ@I<4ZMP-
MHO'5#AO_\1RT0FXC?EQ^^0I>XN_P#N?WXY]K0/;3_QQCW_V[9S^8\9N3/=$Z
M:)'6]]TS<*;.]E^][>R_^HN_>=7"K8//I'6PWV[]\9JW7GGV/]_?G\$Y#TV4
ME%GB$;:YF0V)'!FO#5)6>Y=B<(;Y'$\5R_'48CPWL9D;]5':V,S3L)F#]X?2
MNZ ]9PA3IA',=8$<43EKRVLK/9,\-T"BVW399IJ-4X"?LGW=; SB,&?/M+_$
MSMEVXP+X?7+8;"_L ;P$QY/^TFL"\E(OW<;5\'RWL'SW&5-+$DX'_9'MO*2^
M0+>8=1C.=<BB82H8CA3S60XN,&0,<2A0SPAS6NFBZME4?%F6Z6JHOEN(?BS[
M>=$F<G3HO>9&4X<,B01Q10QR8 XH&.>X(2)8RK9VM%@NSED$XS6!KCULP)OW
MXXXM=7G# G2AG5(<Q)Z/#1='7V/LE8\GH-@XS3OB^5SYT_GS97/-G\YSW?Q)
MMA[;._O?_TM3HGZ!R_:[W7ZO_CK !QS4'RZ>;G1L1XUC&Q:N/6QT^E]C_HKM
MW>!RV\]AQ=I=7439;(SR_ $(&$3?/^K!&;/3=3XSX1_#$1A%-:*C/AQ95UW.
MOMK*X1B6Y<F>G@[ZWP  1F!!:X'-7>VWO.Z>=OIG,;Z+@R\PO*LA9[]?/TA!
MEV&!D=G?_P;/O=\??8QP<Y,W,ZM^NEFD+D @OO_]\R$7E#!.*,+"&<1=",@D
M8E$(S!J&<W9N5M9738.7=5@R[ "2V&Y_W!ME3)DM[G6Q,6.J?2#G#3OUDQL3
M/_FTK W9Y.?-\9XS#.[-\JJU[O?^H/XH'_?#)1?<PNC$_O>]PZ!#<C1%)*(#
M?X1A@2RC!@4?E>::VAAH\4=6YP8LX'@^)MM'NS<NPW(ULD\PO09>10&93_O#
M,E@_%PB%5?67K^TP.IYL1L]\J]KC^QF??\6Z8;\S'EW\E9E E@>>% </OZ=>
M%A>.%U[=S)_'@_/4^J.(W"#:S\@FN-F?;>>K/1MN_??<,W7;/33[ I_.LZN5
MS_YNW.VV1YDH#>QI'(_:?MC8Z_D5?NQ3NW/ &#@90.IOL)SEK-VRQ/_>[MF>
M;P,G>#>"#XHL[]-_EI_:F;GUQW".,&S"@N%CSD7.^%M(Y#3:T("GM/]89:X+
MT[V"4*FB](DQ9GC@05'-A--2^>B8P9BEBL' =P#-,PYKDX*()L#3)JYQM%I[
MP6 U85@21OC6XU! 0N$=[?4:[^"M5 2P)G\UM9VR/?@'6/,H3HGOKWU8HPIU
M;,.R.^H/:H+W)2^VC6X?R'W;5]\%2YJARO\%A'-&Q ,&H"Q6X 6@DN<RSQ]M
M60H+<;?%^6C$>BD%4GG<]L>PZ'?+1?,EED^6%]1\&3]H@Q&V;2,-^MU\+'#\
MZMS;C=_['>#Y5?@%2,7LO5=O8OY>LK$,Q^X$GKK1[P%W@.<['<0O;; R^%?\
MUJXN.8(Q6KR+/CQT88F5!U6_$G@TGRD-'%EY*-E=.LZ.;W:5%MXF&'0^?!#R
M4S:^MD?'Y1X'\=]C&(EJ6L*P[%:GS%=]E]]UN?7?9D]TT#\%IJ.(WF[LYJN
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M5[\7X-M%NZ'Q^IL_SD)S3[XK ,S=:F<Y9,&(\JY^'@-;'.2CMG:FA*UZO\0
M]6E_R4/_9\?ZN%Q;_!0?< Z<ID\R#TPY[[,3RY3,NJOE$4\GCUC\N=%P0=H>
MC!SH< 03"3-RFT>#K)91DZ?ANFJ;,3$3'4U8"<>C4SI9%GE*UIO()2EIWL00
M2CF:_'"%VJ;-VC+%*'^K=6G+(+^M[_Q-;V:%>RXANH<F'Y_Q_M=#3+7 B9J<
MIDT0S^5BQD2%/ ^&)4%@R,S6CL!-,.7E$%T:]+O%X');@0Q,E9L)+W1&"_.:
MDM:W-))5'7+.K63:4Z-<>:^T_ME;WT@>7]7OP8V$MW8/)>.*!1*12"X@;D)
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MP3HH((I-HWE3$;*BX]1"HZG54?H[!)*;V=7&W[^&17S?/WA_B(-WW )6$!P
M*Y3B8!%4(&(=-3$0H@*_TM^ONIM.J$>1;YYT*>^,AXN_J<E+<ZZ;*APSG=OG
MU1?GVT>Y]^GLKMN4^$PV7)Y# '^OEXW[9-RKS'_Z#,O[$ZM<V[7PF"<)KKL7
MB6+%O60V*I:H@-E$A=:4;"(I#S/)R/[)WB$6T1&6;.X1Q!#'*0NU)8Z$H0I'
M1:FE=&O'X"9?H61TDRC*'YVS7N-U**ULF@O;MGF@P-1^.V['U'@]3<IZ4R5E
M5:&6^4A+>[C*'C/TSUZG- 6Z9P?E[JQZPS+NQ=S9FU>O#TV4S#E/$-,B2ZT2
MA:S%"3E'M8N$!LHQK"FL*=2R\,-#>"<W,Z,-J;B& ?#6]]>'3(BDA ](*BH1
ME_"322$BC(UA@3@CE'T6I&(YI/;D6,5E>0_[_2\5KY!56LFS37M8>I [3'JX
M7:J#M (+)VA,P7-F%:"'E4Z!DR4!]VBL5#8(P1)-?MBD.MP[#.U]:YWX0Y<4
M# 8#QB4B1]SF.MJ@!4HJBP_JP"W7#Y/K<$LKV>0ZW).5[)_L'M+HF,1!(,P\
M,'1I@*AH'1"G,#R.>NU,[E',FT:!I<B'3'8@/EAMDB?..>XUM<PK:UA.S68R
M*%Y7WB]8RX:G7&/HSUJO=@]#@K>)E49.\KS#'3VRR>$\!V-@B0E&P]8.VV8K
M:.H=)#LD(3'P4"D-Y\$X!VPI)0'<"!S"E"X8W8V+?O>F<-(Z#)0J$@BL%=8#
M9=5,(<TH!=[*/"V)+U(5%,"*-/6*?N7KN>E+0=-G';]:HF>W#E\YCQ/GP,BD
M-EQX<,:PU2K/#>)"$&$S-QYF;GS?/WA]F)(445",',OKHK7@SX,7!YX]#$LP
M(@C'\MPP3857[!E<?V)D6VK9X\^VV_AD>S KXG'C;?S2]T5AX& P'HY@OL#L
M:=G/9^>'Y,"3/3WMMR>[$OD\O_;MH"3?OSHO0IQQ)$C=7:N0NCHG?SY.5@7(
MWIRW%*PC9'.GH;0Z31$]&.4;C-,ZR"N>I+GB2=K#7#/0G<@?]")<L6T[G;-&
M_VN5TC_CT,Z76X(SV[GV2WSZ8'.96YO]HG%G!)S\K+$[K<Q]^L]4 '2U'%.[
M5V$E,$8_\W0+%4/+!I.M=W<X[(.5C'*13LEI^BG7N%#\2^O3;OF)_/*/;$\3
MD8_A&.8*K#US0B33UIFS%3 SK3GS#1]U^BZ7C98HRM[>WOFWX=1' ]M=-3G;
M5=G0L)_]IJ^]6&J-X,ZJ"N5\_.N.A1?5>)=%03['01/(5+^4%L.5JQC0:9%@
M:(1*\R2U,QX7J8!Z"N=HT'E-]?RT*$4]<Z5+TPJ@O1S[:7<OG.G-"EE&Y<NC
M=HT0DX8>O_7'O6&L&GN\B[TV7/KOS/7_!+"#U]RK7O!OTRJC5^>-[/(YX154
M14*Y@+NJ^<ZEX5,9EV+OTX:G%Q@$G*3"T75"%HX:2[Q0Q@C*(S%:><R%A;56
M.:D9N79U1E'+N*#<LP57/.Z<U:*@P]_!F9XM0OP =S_[S1<<JVA]WS_Y>.BH
MCCBW[(G4*'!%I$ P<P-R2>3(M,QNX-:.6K$]E!V1;G[;<YH)U4X+&%2W&HAL
M9LW*7E9MTY0JN?4H6F A16VMM(SRI)CQU%LKB,R:'H30S5[,(]L5SDG<E!.7
M;+1(POP&NP+CTD0PE)PV+.22]1P#8TTF=%,Q>GWV5I0U[FI#YF:VM$D7N[6)
M9,51C$7@BB6DF(^($QJ1H2ZAZ"33GG&F9+5;<WD4Y$NE4);IL6W\>PRH#GSM
MK.'LL#V/+RN%!VZT*,TL0RN'_J_)7?Q=W5LEY?2D]9D>W 1(Z3<?9$Q1P9IC
M\212;E-$GE(A*78Y3+VU,SH&\E%XUW!10^ \6AYJY:"C:CMN1IVCIJ.%>A4N
M.JE@GB4X4_XS7T\]X7YE2:OH8(Z<E,]**4C%$"MJ^5]9(.C('M61A[54XRP-
MPEOO":?<)&R%<U$GG[5/C9=TS@PIQI+AR[=S+J!'&UYTM672#$[!"QR4Y<AK
M#KQ()HFTIA@1$TAPA'#M^-8.5RO"\@N657AV(<NS&DA+KL*$$TW4E];=$'0Z
M:$R4#BPJSES0.C@6)6>>$N$=WUC0PUD0V_^^=VAE"LPJC&3 &'%J';+<.V1P
MR&W(F(E!;NT(LH+[9*I\KA55N6M7>6/9UZSE'BH+ZXZ+TN7YL6 __QR#P\OP
M)':4SSNEXK/9M1/W+H?)XK_'E> 1+'3MHUYUQ.J(P JO>I5K?L&AC6/[)9;E
M?-9#R &$20;%>HX"9C!M!?'.$\&-\T9AK1T6.%(?N(Y5+'=Q(LPX"A<O\'^7
MF]QX *OM_Z^O.<.78),T"Q(,7E!8VX5$UE&)8 1LB,1'X'Z H-HTP3%8K<JY
MYG@;9KF2OE"YH#PL^8$H;ZD1WO,@-N-]?^-=DDUI2#YF<8?<[9SE[+N(!8I"
MPDAS H@'=%Z:IE'7=O>:693XM!*LR:)ZU7:GMUG.9NH"9K6<07]\=#P';^*9
M!YM;18JY%N8AC5R.V9C(H)]'GY_^,Y8\JOF'::[<B6PNREM=\,B-GS)WJD/-
M>X (N1IU^;!I!'HV,:^R'_AZ5F3L]&UO7A9J+<+%K8[<>6H2D5Q@K"VSD5F=
MJ;LR6M22=:PB7.6'RPE7+8M8F-4LDWH5W;.1?WYPZ"G"=D:X8)2B*#)O$,>4
M(6V\0CHQH0(C''-P(X58G7#5SM&D2G!J(OIYGGNU0-4!GVRVBK(=%HO@>9;$
MZ@_.LCID7&F;V8ZGUE@KN%>RJ.MR?&R#4EH!R\>$,Y%TTMYBH/E$.T&BJ82E
MK[:T4MO]ISW+.W,SEI:#G96\Y6XO[/=[M=;EQO8NL#U< NA$FJ0(SMVA(^+@
MMB,@F@)A2\#=2M$;S"ZTO8J"SQI*1>0!_KP?C+/+F"%Q.*J2NLI^3@Y]V1X,
M0P.8>9;R[U_,DWHEFKU@18R*H(5EFN' L7-6$%BR,U5F+(9DKP"N1<)T@9_X
M%C[\-<?@WIT.H@UO>G_;0;L8'/QB:C6(OCRS@=]]/DPNTJ2HRJKD%G%E*=+,
M802S&Q86ZZ526;)^11GU?T[5^$Y/.^UJ=YW@QL>\+?E^^QV8%+SOX1@0*9M+
M$2^Q(7<3 [BJ-V5JP<1L3>VL65C,#SR\R[L@K&=EMUP>K[79EV,1'CY_\29%
M]T]>'T83M<5*H*R%FD-6)(LI<5@*132**V<)\$JZO1Q._\_*('+\8)K>,0]*
ML:B.U^+K_7$G9"G*<2V?X6+1J<S=$:;RD6"-G7:UZ?Y3^Q_G^\G=[E11TF9M
MSO:PXGRG8P?&G"6Z8PFNEL!&+W?$FDF0[_4;G=SE!.ZD]SA<K5CCQ<MG*[^4
M=K;1]M%1>9#77W(KA_)P;^IGF_"\@V- ]N-^YYI^Y0M<8'F1@V+)!9TB4BDW
MIA.,YR[O!,EH$JR2EJ4LG'+! MO,"O _M<$"+]L$NI%Y7-,@ #['W0.862NW
M?PH@O\2!/7A_:!T/F(6 E,Y1 T$3,A'&67/&&6%.:YD3X-G2GD]Y:</EK9\I
M:5\!8=L-<$-W3P?M3H/B:5^@V8V>6(5/8VB>"P$OJ/M.8ZFEPP+,7M_.\->O
MTU$O=D:GFKYSJ%KE@%:]C8KGWZPKA$YM.TR4QGI9DZ<SXS LGZ97VEM4MYV;
M)4Q)8^ZG$'NV,SHK-*!L8DT\G)+&%.&J867'I)DW,].UH-T]'5?RSI,KK.G
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MUT6,&E1KVGB7+>;_YK9S;_L67(16['7ZN<O-YV;CM]VYN/]DR"8Q_W6J$ZI
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M*Q./YOQR-/GAA]]!?? )^YKL?SV4AC#M*$/@S@"'!I\+F40I2D%3[H3&@3L
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M%Q4 _K?KAS/XZWC4[>S\?U!+ P04    " ""@I551#N[J\\5  #&\   $0
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M!]%\QE1Q&WB\CX^1S\'@X'!P!)QH%$D^CB-V+61PR3P:^]#%./P>4Y][G+F
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MLAW!IE$FSFPXN0E!B/4%7=C8*O7?UJ6NR9 %'6((]0V$J]<9"Q5K \%J4RL
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M$.%!:$-RAUOQHJT\#K/UX@JX$@S/-=,0LW?56GO2R\F#XMXSKI+3ND_69TN
M0_*:6U&FAVRZ;;ZX@@=3"*A)P46G55VU+^ %)C 4\R>7 R^=5DPV8QJ25]U,
MH[21P U&_/'YS2EZ1Z^;-!+X94E_KI+;L[)6A_1IJ(GN*\6PM0SV.K;'=QEX
MQ)V:MR#8=92-^A-<V)G+HN)1R=:*(@,H%B4H72*0_\S!,^-R$DS%TB>[>0>8
M_6N4/^/T!-_08W67?GS]-4U.:N>2&K;0?[D64Z.T&A,SD T:"B7H ?/H)7"/
M,A<4J$V?DLX=P [))]Z72[?+F/O*KKWSO,Y7T; ]R[4;#4C$2,Z9\C1L42#S
M2%%J(*T:.A<#GD-YI',,WQ1#]IOXML[-C;&-(L9@6$Z0DB<F)C+8P6@+6M12
M1!EM*7VTR%UHAN3O-B?!OK/?C =_P^65,0GM@RTJ W*;0&6GP1G&P#AFO$7D
MRJ4N!+@&8]\Q75[I7 ^/IR<TSY>^RL]89O/UIB12P;AX_95T-9%J/ WST[?$
MA96O637X;#)9B6B)<UPL1]H5GZT)M2B!'M92E_N$$1"%UM):EISMHR4[#FI(
M!GEW/MY\QH;"@F:/Z@70M>7X&:=8QA0<&V8=1<C R5Q02.P,!(<>:DVAM2C)
MM^A)R5N !F6^6_-IO^EO6=]V<W/EQ<9*H9F1D2%X%PA0$A*"K=OPI Z%8F.M
M>*\V(AM!M353/GN%2B60M:F#LAF!YMZ"UR4XFV72G?8RW6.FGE9MMN+#3=+O
M/N]M/=4[QO>&=/?X]^G9$D0Z_74>I@L*M^K\3_/JU5H:^9\4?:UW8:UFY,-L
MOOI@N9R/X\FR+LG].OL0SEI(<0K"A*R/;TU7Q=52/09P%JW(K/"2.A;%'VJ8
M0UI^Z$7=X?*FL4?0Q\6Q$BU/9,>X$XS"FTAFS5@+1B3FBJP[]_OL%CJ8H]LF
M\X@V(C<A@5&6!,^\A.BX ([6&LXL=YU:HSZ8>7Q:BS04;F[,O^PHPW:1]VPZ
MNXYE[5B.G,/HK+<@K"<O53H%'ID#SQ6C]S,ZU8=2&R$-R5X,E5AMY-DQP4N6
M5$F,%F)<Y9FY(V/J+,CB%>-6J"S[-"U](,&[RPK)7956%]/-BW)>21#%U6TD
M)H(/KM2?E,_9*N[[)+'NA34DW;P?-VZO>;221KL-[A2;S\.$$+W(1^/I>+&L
MX_U\\40RQ;EQ*8 AW4Y^I0GD8=;<K3;99:EBPD[[WN\'-B0]VY8D+272SG\^
M.@[C>67K^W)SL_;%4MW%GOXDA'42):#B 51(&9R3"C*I=2V]%"'TZ0'T*)B#
M7#9I0J%^TGJ: I&Z?>C-9/:E:2W(Y46[EGULP-ZHPJ-NHJ$;?)C//H_I:C^?
M_K:HW10NZ/2"PO7/9^5%%D7P)1.AI.&@C/#@@M8@D@_2&TPQ=5NQVA)CV]PG
M.F]DX1%"SF1%-?,0B@[ ;(B>%V99IYKMP>8^.['E_E3H8\309F_'7\)X6F_]
M?OJ1GL*P.)GCF2Z\4B!W.>9IOAJ/C%B(G$):BCZ$(_.JC 7OLP9F*/#5F4EN
MV4,J9V\40UL8ZLF:PXJLF4?T\\EB/,7%XN7L*%*T7.?Q8H_^LAH#FJOY6F9S
MLL!G]N#EI_KCV^F+H[H;\GW9\"L7E;U\5/ME2TDQ<&(UT ZE)G95@HQ<F2*8
MDPZ[:+$##7!(7MB!].,0J=-&\YZGA]9>['J-8C9-=?^WD"B4S@)*79U0UC#P
MZ.I"L,A1D9,9L]Q*L]YWER$5=Q]"<3:;\7:]U3:N&ITK^=^F<PR3\;\QCVR*
M419&NKJ&.@KK%C_.&009=>VBW6U?W6-0/G('YC=MC;M+\3 -.TE)SI?C?Z\F
M]#QQPKT+WI%?$*(E1U0$#A3<.B ]F((TZ&VG:H_'(AU2@[<#T:VK,)M1[A4>
MSS&-5T!&V@K-B\O 63!UNPZ'&+0"1"'(']44W?2I?[B*8ANJV.^+*CL+H5U/
MF2M\O)U@&V$4='<*0IP)]?PC5L]6\P4B,IZD$ QUGT3+_;BVH8K[OJC24%!/
ME$E76FD6O2>CJHC?B!H<V5<0GF?+"]G=3EMMFV?2_?=%K7YB;->O[U.8X\]D
M3E>[#<EJGJG,X%0LZ#R% H6P>*\@JHBUXTZNQ[/QS#KU[+L3SU;Y4?9]D:>!
M9-H6C:X#QNO%&$P*QDU!<K$",5?7'@2%&:B+10Q3BDYWVBFZ"=)67.'?6236
M1D M*RGGU4=_A6=_OYW>;NTV,JCI16(TU-JA/]=='XH$'9*, ;-U!3N9K2W0
M;<6B[R6[WDUL'0EUO3_<R'&4):,$)6L6BS&BN>7D\BONDF1.J$X'SC^$;"LB
MR>^>2'N(JR.)KF\<77O\/,J,9$JAI"#(#S,2?"3!)UYB,"$*U6GG]G;XMB*4
M^NX)M;?H6BUFW 2V==^ZD4LF"Y=$W=6@R8%3-"&B'GP;6)"8F<[\QIZ C6L=
M.X/8BDW?2][ZH!+KJ+;N[?,T"CESF4C#:,[K;MK:!S%K26$"]Q$35[Y78=WC
M@&Y%O>\LA=U3E@?PWC^$T]5SH%C@C-@.CM=\A:#XT]EDH68J2F(I>=7G](\'
MH6U%JN\LV=U67KWL(F&:GV"^?NS!ZZ/CR>P4\2.NSB:]VNG,)>U8+!J2J+J6
MH8 @E -2O]JATLS=+"K?VCH^$LI6G/I.LN)/(+R>_OW=/31'A$X7&S18&W(]
M(ME"8!F!9>G0<B9*I]67K2%NQ;GO+5W>17XM>_O<-0MOIY]Q<6,6"(5ASB"(
M4(]N4<'65M0!-"MH8LQ<B3XAY/88]SX9(9RN*LY^G;U(_W,RGN/&TUI'/$74
MW@7(ID9EC)/A*;&>WDON"S?%1]/G!(WM,3ZR /M)HJ!]B7;KA(4^$NS]O+T9
M3\,T79\&K;D6QC (.@:*R[B!@-'5=)(*I']8$'W*++;'V. TZH285[MTWRX6
M)W1]K/6=1T>SZ>JT)U*]UI+L R3)2"E*ZR'XBCIR] %3-K9/>^X'H7T#VQOV
M9=4=9U<W%%>[\VS6S_S[L@)QCNSE;+%<C(*-PHE20%M#B+(-$**/*[4B-7J;
M3)]MG/>A^A9V.30G3RLI-3P'Z9+.:W?_0R!3\0KC<E2B<5A\AL@#KQ7$&GPJ
M!H2/B7FGLDY]L@'WH?H&M@STU#E[":D9;3[B\065;R%"AAZ]\34R]* *K^<;
MTDN7D^:6G KLU!OJ/E2/W!KP7:B;9E+J8*8JANOZ+R;%4M+$W)!HI+8D"$I%
M$%%IFS/%?[F3MMD,ZELH_N]GI/:341<;M;*;[X]7_6M>?\5Y&M,<C+"V(;))
M 0:5:BT,!Q<=&5$O4[9<L^@Z!:(/0?L&JOE[6JO]Q=6N%2@-O?Y?@]_/88*K
MXI?%<CY.I!;K!Q087W_CRC<_X'P\R[?S6.M2S]=?TVI_WD=2L:]+P;0<6>68
M]2* -[6D)DA6MRB4VF;!2^YR#KE/%Z'#CK-3+N"N#*37KDC+)?A0"R0E(C@M
M+!DL(F-!:3%VV]&_4PN#)VYU.ER^W]$RH <)GB)!S%*T*+('+J*N15"BMG!A
M@$F71'.4D^G4DV['!/$3-S7]YDFZ+PF>(JM:A&(Y<0TYDDTG@Z[ B^*A)&5$
M9AHC]K%-NV95GS;*__9)NB\)FI'T;(COR]5AOY_N-<$CQ7A,#HEO;M4VDJP!
MV0(+%A./04FG?1\V=QC,D!H8?$.T?VI:]6V,=M<I.*OW+IK@C%?OQ5-Z_/#W
MV?ST%2[#>+)3P[3=;]:DD5JCL;8Z0N^N\X<"0X,H(C&S;KR))D&(20(/Y'PR
MAJ&H/F68#Y_^],A:KK_,PW3YYF2Z.FGMLMG,>I]1F$\I5D^.88R<@=6A/@8Q
MUU:_&GPT2A;#<F;N(4YM>[,AA4][B_YZAZO&,]VFEN^!^NA1DH*3BQ#!E)3K
ML0(>G-<6I')2,NZXNUGMLMNI]T.*2-K*O>4,'\#(7.LCM*\1N?-B[8S$PUA;
M==G<V+"<,6-4T@&*SKD>:<3!>\M 2Z%UX4R[7DTUMVM __BQ/MSXYZQI?#UT
MQ!J7BJ*(0:9$^DH5!L&E"-PKX4+4J%.?;9Z/ #DDB]*&1X]OU;2;Q [7C/-Z
M-T>1#"=X@,77DP5T(H48))CH4G:A%*ZWVSKUV#L/R0:U94I_030L]*[)M$O/
MZ.+ ";*]4;L<P*1Z]JO*"KR2&HP,W#!NE<(^N?]-B(:4G^JC6)K(HB$SKG4Z
M'"'RR+SG8%6RH*PM$"PY:)'3>&TJ(>0^)6TW@ RKK*03$7:?^KX^Z\71-;61
MRFQZUG)]0EHNKDS>6:9@64^VV<.7??Q-FOBX>XZMD>_;\Q ACB6JE#RP*!RH
MVH7+FU1 :YF3EN@U[[;7<*@GI^T ;>T CDP,B7O)P/A5#P\K(<9@Z:6/5DD6
M3:<:F-TQ#\D['PK3&QS/O LCGO*LQ5?TPV(Y3B->E,^N[C'+>G4X9(901 8M
MO-0QB"+D8"A\#GI(<<-WQ.&=.'$@;^,7>KC&99S"=)FN&.?E)SRNZZX+NA&-
MIK'WL?--VWHC;<;>U#NY?=1X%LBLS)P<W5C[G5,4ZR36\Y=%[;3 I<\]SV1]
MX*3W'4H75\F=Y:;AHHU62R_ E%JL&1A"4#9"8AF#\(Q[WJG4\%Y<P[/N^S'E
MIE9K*)6&/:H+$JJ\<;R1%^%" H84#)(V#>!<3*"SX\I[EBF0[T*5!X -SXJV
MY4I+N;2KB+Z?P$6JR*4DRYN,HO'Z ,'XVAW)L)0DUUGU\<8>HU9V'O4;K&>F
M3&X/FXMHD!4'G)<(2O $/BL%3$GR0(01$OL<N?, L"&ITX;,V:!5FXBG]9.R
M.MGOQ32_HU^X"YHK(2A>>V*0GZR\+5"Q@G(>51:F]&J9NQ6\(:G8_OQI**K6
M+%J'Y[=!T4 UW=> 3M)7CR$3M8,!6[0+7(5$QJ>KYMD ;$AK'0?0/"W$<S"'
M+J22$^<&T'A5#]\IX'UDD)W-&%%G9 -PZ'8?]]H.;!R^L/4@,T;/L6:U'56B
MYY@FP@FO;72%IT[GXVV';T@VNR63-KFW#:75_ FZ9A$V^N%&^B#)NXB,UQ[&
MD< QRR%PRZ3$[!GVZ>_T&)1#LN2'8%5SR37GUMIF;,+F10IU9RL-G5P.Y50&
M\C[(Y5"F1*F%*Z[/8O5V^(9DWP^BI=I)ZT 9Y[^&?\[F5_.M>3V49?@:5AVR
MPS1/+BMY6B2<=[UGVWQSDY$W2C>?\X=@G;4E_\N\'G$M:TLGX@:@Y A*U=[1
M!0-1LK@4T3LE^N1)[L;32J==7/6R5R-=_668ST_+;/XES/-B%#4YQ9Z&[JWD
M9- 3@T ^,42G3$I)9<?ZE&4] N00?; ]&+1)J;465W,;>0&0?CA_;ZUYKYZ#
M1'9^K8@7=Q^45!N1C)SC+'&*Q4J)JR.U:@=:G2#9[ NC,?).?3A[C&:(_EQ/
MAAZ: /VHO-J(,.).LR19 2E]/4DP% @B!C"8+:=0QV1]*"U8\0S1G>NJ\!XM
MA*ZZ[6QGSS7%>[X+:*13,%B" Z\3>:^9U:I)65NW.2:R\$AQR\'4UCU A[0-
M^4 :J978VNR;N(7P:@_V)+(U*A6@.(C@&);.AJZ+,=[7*,5MMT?BOKLT?S3.
MQ$:!E(@R*\A9U^4;J2C,TAY$[2=ODG"]CGS?QEE^&N>PK< ?Y/KCY= OF7UU
MD"('9;EWD+@AB\ZU!2<(&U<VD7<J<\2^NO$N5(-H4GL8@NPME,/01.=08HD"
M4JB[I&-M &5D 6,)HA5>*M]GD6Q[FNRE+*]<]?P 8?*(;QXR?.LT:Q>$%S0W
MD) S4%Z0^V.XA\ \FJ*3=*)OBG%GZ$-0P<V9=X\6/H" >_BW5V"?.=PZ*[JG
M1&"AGE*<' ///!D4K4Q4K&0C^VQ^O@?4$"/I W'I\4+I%P5=W5.*RU%FF'A6
MA@3* JBB.5&W1)"H2T@RR%Y'N#X K)^';C-CA@PE 0N21IP"1,$LI'K&8(S%
M6KE=XXSM/?1A*,X6%+BV;[G9-/=C^]_#Y.1LWB>3V9?:*WEDZW8(RRUHGN@Q
M-#[6WMH:N+#6DL.=?>A;E7$/N$&XM#UYTTM0!UKK^XAI-DTT!ZMKKK96X*J]
MV?CSY:[/>5CB<K98AN4)L?6TOFRQYK?OO=NN_36=B49K@*_/ 5RBI#O>M:5I
M%$ORBJG:0[N0=L*8P5GG('INBU+)2-_GV)[M,;9IYWCS3M?E]N*\EO>7<QE=
M^_)(^<P$HQDRR&H!9O0T38J#T98+YATB]FDCTP#\D$QP)V;>W6KQ<")OW'KT
M?N O5]TCWTZW,1U"1YF8$R!TK43)IE:(: 2AA%>!:1\[=:!H/) AQ4P#XG O
M*AR4SW^;59-W0E^+DXM>()H;1%Z?OJSK29[2TAR2BR69TK%(8[CODVC=%?&0
M%C0'Q-"]A=MFJ6H;J!?K:^00GTQS/;KZ?''M \Y3/8DR"*F*=06L<O[,)D06
M%10EK3*B<&>VZS/:!L^@^OIT)MU3B?&@JO!FT6?]QJLQ_6+=\S$.DY&04F65
M.-A24V>U=J!V\0<FHQ)9:\UYGU/+6J!_Y#E5WS);GTSH!Z7K*IW[(O_SY*P%
MVV+DE7*J$($\LD1351PXQQ,$HX6)12=1^G1+V@7MD$Z]&A =]Q+J0>EW=^7=
MZZ\)%[589EV@=Z[TO3*61D"N!@VH%N,A1&.0QE*X\#P+'I\N%'K44+8AKOV_
M1]Q^=.B;5#U?8 VW%UA_29_(>9[@K(2S0]+S^.(;9QL+]DBH-KEODV1J^QEH
ME$A],YX2_=\1[VX!JXG_Z!/99<N@R.SKJ;:6&$T*0)LHHA>L^-AG!>5^7'OW
MU]Y\];.ZK(1666L(&?,9ZJ9B\(8L D5SS.5H@I)]DL8/(1M2JK,A=VZUTVXI
MH#8!]CV07J1T<G2R.MCWQ=%LOAS_^[R$_NW1<1C/JY<QLC&)H)&!98:<C.(L
M1!==[9CA<I'(<]$/*;060 :U\-B!0@<75E_;^6%UY,[RE"Q'/19I=7#%RRL;
M\8XO/\?SS_<PF?O<KHFE;#;>1@;R',\'LMW+%U= 57X*TC1"UX-":ALJE8*&
M6*($&6).0B3';F;+VAUXO!%5@W.>[[[VNN)?\<A,=F S!>PJ1@.121JSD"(J
MKFGH??9\W8]K2(:Q&6?N.-.YE6B:Q;%7].DK/)YC.HM5Z.<)KA7K53V[<0BC
M+"+W2-9<ZQQ)V3,#(09#XY Z&D^/<NC3/['5" 9E6;MQ\$GDW=?&OJN'(BY6
M?^+9 LX>%G3SQ9K8QRVQ-K)^J_N<[?3,G">9,@3/25I9UE)9M(!2%)F<%B+T
MV3%T 6%?176Y(_MB4,D6FX4KM=]C7:8C ,[Y $9SS8(T,O<Z0_ 6EB'9K]VD
M?E-1[#G?S0S4W\-\7-?(+F%DG5Q5,&!\+7Q)]>@4AP*$8-9([]'J/C7SMZ ,
MJ>JCC=3WF^UF0O_E$YF@7W%^=(E#V^Q=;5)CE!"@O')G:Z*V9$GVSFC1J4G9
M;2Q#*J5H(_8]Y_L0]OW-R?)DCC6IBL?A=+7RL[>9O^>:#:W]MLB;&?T%.1?7
MU?=Y0?CIAW, )SB2F=F08X$2?/7;1.T"Y6NB1O*()4D1^FP"W!;AOEIDV_O\
MC6;^UR\X^8Q_G4V7GQ8C[[-UI@30B'4^BJA'_&5@R03RKH4NML]2W*Z(A^5^
M=.#?385U$-$V,V?;HOUO#/-?O\Q&V04*GTHB91L**,<<*76FH6B>8E*<S&Z?
M9EB/!#HL_V= M-M%D$_#-J(/CJ)@KEC+ 16K#7]5 )^S!^18!"K#N.]3%O-H
MJ,-RO8;&N$<+\TDX]V9V,A]Q@0*94_4474(I'(? G 13LJWI+6;,TSH?YTB'
MU,5G<(Q[M"B?AG#CSSBRDEDO?8 8;$59''@;/'"CH[+&>QO[5*8^%NF0JE"'
M1[C'BK(9X3;@&WE>]ZU8"4J;>J2;TA U@3&60N00>2BF3ZW)!D"=QKGNZS]*
MT@8I=:A-%@3-O180(T9PRG'C##/^9MNLOL-=XQI2 -2"*?=G8_>22N\GHAY]
MN(;EC="R'IN95H=<9Z\@F$2B-=%S4?NHQH.2Y1+:D"*7 _)E1]D\;7YO=,-[
M:)/AHZL>),=W$_VALWRH Y-":,B*BWKJ&JF&0B&HY-S6(VUSSKU6_@Z3Y=OT
M^&@K:V\U"GPR@5-><G#:U9)#1U.!VD35I])E*\/\C>3H'L.>+770HP1SF'CA
MMVD>+]+L9+JLS91K/?Z+H_IJI"3+)7%=B_ MV57#(0I>(#/#"M>%]$V?%>:=
MX [)J!V$8?V%NJ7E6[]?_XB$X<]_^%]02P,$%     @ @H*559&(&IQF6@
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M2S.1'BD9$A<D*,4@.):<[!2D. XU;HCE]Z_%;<36L_;^0$FA$[D&$J3@&K]
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MTH#ZT.(V8JN:!B2T4M)32H")<H]$9N*XLD1X13WGAC+57[F/8TD#VD;X&].
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MS]&);@TC=GG[Z7!C& 7TG7UT"^=K6%RD)OP&Z_\NX</L8G-\,2T.8OG^.[^
M->=]\)IK]/E,2J6D:4C$^X0+8K):6VF%=;03A7J!<V*<&EY%?:<J/6QZ;3\>
M87T("C+Q.I0^SFBG.1">&"59R$S[>+/[]0;*50!W8@0\M/KZ[T=S?VF?%'-.
M8 7NX 8%Q1B:=Y1+DJP$Q&VYC \&C8ZSCE)5FO0IU@IY2A^G#<39I^GXOULN
M_@I3%/@"=U_ILRWG.M8)@^.5BGA' ^$\2\]ILM;6:6FQ =#IL*)/R5=(,=H
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M:O7&+;RYN<F-F$0N0=\^L#40=!8V,YB>C?JBS4*(,K-9+U8OOK;4MO*2VZ?
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M(2_+WU:%:&I#+#Q)(H\(!N,@J0^HII!$JL<("T,>"Q0CY@_8C+/!,-/]N2U
M(!MK@/C&[O3"::,7_^I6F6(I1&35-V9>T3G5$^7.MYQVN$$/.-#(P2N-_8<K
ML(7O4"-P &EN10%M $RK CB FCW9OR'W&)"/]7I)RO*3;/,8/A5?LMN[ZM=L
ME=VO[V_$Z@VIIX;WXG>A/Q#\^E$4Y%;HHL/YJM[T^EQD3-SD[1W>?A,%RTI1
M__9S(>ZS]7V[;*TN6P@J8A2P (813R *(PE30@CTB4QC(6F($3=.\)H6^]Q"
MS]90\%C;"/YLC02DL5+O0BHSVV-+#]HDK?O^9V.J<L2-K<TG5^JOVMPK7:VC
M-=@BI6KBI^BT6Y_YLS'RJ% ;#CY)T ('GPI0&W\%NB=&V0\4 :!A '04@)8#
MT)#0'N3YW#TYW?TZ)II/ZC+6S9/S^3MX<BRR^^;[!$V4+CCK)\DN1?%E^O)D
MSN/$D*9+HGP9KG>R,E\(PK#)YB]YSO_,ELOW]P\D*_1[K:.[12)H&I,XA#Z+
M*40^)Y#Z0@7"411++TE8FEB=D#O<S-R"F@XER#8P@9HQ%J9CRAE2S>:#EU,U
M\AC? ;P"6XA 8W0WO3O-@=.)W)&F)IVRG3;W^>3LS+>'GI!MLX.VA<8M5W=/
MW&%&#V\O"V^+<Y2%6@,^'!\2/=[>Q"=&SQJ^?WST_"4#EA>NUSRKWJ]D7MPW
M8BIF3_3):V?T+-<000^CR7-LP9+%=,4%6Q--+ :Q9A?PGV/C9&A^].+I@NAS
M^'?"W;-?'IJ0]?6>+)<_K\ML)53P%$<Q0BQ D"4Q@DC2!!)$$B@#S*3GBR"-
MD%TZUL[]YQ:*MCE'-4;0@;1-Q=IE\+33<\#+R.[.CI(!25@'#;\P!6OWGA,G
M8!TT:#_]ZO#7AJ9W+_4&WV=25/UM YUSOA#81QA[%(8,)1"E(H8I%X&:66*M
MP8)9Q(W.5QNT-;?7>:,U8"_4<(I1L\C<$4\CO]XM2E##[.\F7M7G95PF9)^E
MPW$B]O'V)D[ /FOX?N+U^4N<UTK\H!S1^TK<ZV4H@F+L*6>!PQ B#V%(,/(A
MED&2LI@Q(:2CHHB;1N?F.DY6YRO!'QHXJ)%;)GP:]8!A#H-C7L?.77! J<NR
MAGL<356_<-OP7 H5[E%A49%P_]IAKJDK7ZU3NE:\7I&_RY?J^K*16EU@(=)
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MT3G3^B6.SGYW6/CX+B]$=KMJ8E3VU-LG_(5DJP]Y6?XLE#O268$+X0DI_(!
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MN[S0R?G_"^#TR@OQ582\>NJ9!E=1$EUY,>J^G#5;DOK#7D(J(!5X(YBXIZ(
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M9WA?-L_/\T*M?#/=+H/OYAP'@G3H)>0 32O<W3Z@=]'#<EX(LV@T?PY"2>@
M5>"DN,O]C9P8=U7QT^2XZZ_<FFU_0$^X5VPTUT(F4#!@?C!;;HPTX+EB@&=$
M952P1!$OJW.UQZG9GDK.HZ*[9@4W%J<1.'JV!9N6CB%%[LA3D>*$LA103#5
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M5U?;01UK%J=:9D"P5)EE %% ;"%6DN8J(RA)%1%NCGIHL$?STR_#O5+S0NF
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M01)+SB4":6+6')08%Y?S- >"9Q3J.!5,<5?']EP'4ULH&AFK^.Q&3"]^H8M
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M@=? 0RP_[.&X3QL<E&S,#9O05&-7>AV;:,P-A#,T8XXO]C,^-6O0C,J<\TQ
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M(!8[)]%U]S4U ])(&[7B1EMY/;*DKL![Q:,("]K@1_27\+H>/.@-G$>^6#@
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MF$&09HNLL0(\3Q'@D.4PYE 1Z57']$(_4UL#]LLPS*W(_6HN7$+5S;4,@-7
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MBONB%]2$>0LQJFGK"]&QR>O=3M]:A,VEL"K;4GE0*R0I2@&V6>A()1KP# E
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M9!C2V*$QA@PG!,::9"E."8Z5ETN_IQQ3XU#SDB&_'5/?"7#;4HT Z\"<6VD
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M;VK._O3)K ?_N /-.]!@ %H@E M\"P:PQZ%,]++VA,'"=@)>5[]OP6$# "I
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MYE>BT7'<J2U?MA+L8E6TPDD]TRM<\7:SB0= <>A]\DFWGSM02EVZ&FJY1VD
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M7]PSP8A9G]=G_7GG,YE1C3A*,P5S43:Q9!HR'$DH9,:(R!*JJ%\*T<D04_O
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MM#'7.Y$^B?;]K/*?J #ZS.IN&."_S.:XLJ>K+NOA^O/<31?(7E']-';?359
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M O=6<NNZKENQ2:>Y"%P#<UZOBRR<X$"159,E>LZJCI>Y/XT#W\%H#JV5M-N
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MGXVPC)P5G#MH'=;9//<^WI?26MC'Y[.04ES\@D*]Z=-4+EW>=ET<$:JU\BR
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MWSOW2WXYTL10XV-&NTU+@7C68)P+8 ASD>KDC:QSQ6,757L!S?R 0.M-%0W
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MD]NO8=?A":L'E S=9O<<^G^8NCI%&<TFJ=:B7/_EKQ&2Z6(V/R4E]=PC^TE
M'41X3^FF]<L*[,H=N)(+^'V\_'(#O;L!G"D[EJT%'E4 884"%V0"+TE&C(E(
M3)W#BCT)["\9M<K;_CZ.Z>TTS^:7G28WJ'BT.E]>?YC/XE58EG7Z*<V_C4-:
M[PB2XZ*4*#6C)2Y)78(3YBR@CZ$5]YI[6Z<!615VFK"0O2)U>R9K*!0,G(98
M\_!^ON9@U5#42L$%01]9"/1KJ*7@6&GXSB0G) :2U%YML_?*0#Q%02MIK<%
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MVM;CVBF\Z/VV"G_A\H!X;_>7#!,''LC<0/'A%15OILM$;R='Z0J9BCQJ=+$
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M_&7VZFL-.R8\*IV122@ZTK(< D)444/F,5H4IM!_33"V*Z6].N_#H*^IWCK
MY1.W0KTK6G+C(;KBZI"@#-X+!DGH')TNHC2J.#[PTNX(F^<P6!M(%QV@ZN&X
MY\) LDA2UHQG;>A?"W%H">=,0-(>(W=9%7_$2'&'-:S=W+?&N!I*&V,/./TP
M7Y$TI^%LE[OM*+3!3$MQ/?BKQW;D)\A0F]@$F8,HR<OMAISN\_:1A\ UPM5Q
ME#$VVN[Q]1O6UJ8+#$OR 3;_/\?/\TL'X.TLI-7Z^Q]K"N+"OD(,1IB8P.9,
M\O5Q/0Z/%N[LC''*27<W_[QMT? ^Y(S;9JHI'H^OKK$!^KQKNCO_TH48-18(
MIE;)%O)C/<H 5BL>"S<AH=T*K@V(VPJ\]B3!.[8JQX;RY9'DJUE^@]_Q;/ZM
MSCB^\ELF.962L3:A$Y8$RSFYOTPHR$XA\>F$2L_6H&[SHJT@YDX28D.*>&^X
M?,=%G \48_P^6V":_S&;_FN-_,M.&A-4H;C:_M1Y:4E"2D/P+((0107!LG.N
M3;>?1PC:"E/^U# UI!8Z"%@?8>.JNN #SL+9^MK<^B;O>BS<JY06YY@G"M$Q
M[S+0@JO(<K*E$"H9T P%8DKD/[3)IQ] ]'9'QNR%H7)P=0Z&W&:W-SZ2'&9I
M>C9=/W,]Z Y+P53O2%Q-N2-=X&J^I/>>DYG\J'\=XK+'H>\>^&[(H*(XPE62
MA$4Z6R(X)-BK3%&)-]+7-(<B82=M9)N620VODKR]%/BU5DC"MS7SZG**UZ=+
M+=SZ\L24Q"/*"++V+U(Q"(@I>]#*!,URY$:UR>X.0'PG!;P'HNWN<GMLK7;@
M,&S#\F5XMLWU5!E+RKDVPF;U')8"M#HD'$$)Q8HL FUI,T9F8$8ZJ2@> >"M
MM'TB8/]M7K?#<_I:/,--L\-)<;5W82@@ZM@=%:P&G[,"9,JCXI)IV2:%N"_%
MG10SCP#?@_4W]AG2-DQ>'7>0*WT^R[7DZ?)<Y ,N$JEH(KPQ)=;F2]YH4)9B
MUA"X!73!U92^,TD_YP$/2$^_#1OV >18BCKTLOW15M&[HWWJ-]Y,Z1\N+I)M
M$\N,).X8R%2CXJP+A%KV%'Q6!EU,F,9S?I^COM^N$*U7UT'U>B(>P<,]C=_^
ME7"YO#Z4N31GX[P3=3"D$);15D.B",CK3!@5K=:E.-^FJ>O@K/0[RZ<URMMI
M_$0@OVZQ]RK_U_ER5;,KRPES7'N;+21!;I-"G2$:7R=09AX2NFQ2FV3$/M2.
MFV =$[@'Z:U;;#XTZ'?BK0\,A;_(R9#;9,$K*^BG@*X$9I)O,Q!H>QK'S<(>
M%X<'ZZC;^6@UM4,LK?>$NAV<KS;G[C-<G5U\MJR?'9!IV/45PR04#F)LH+S!
MV["8$6:6'S9T7,_O)A0ZX25@1-I4>4K@K"E@->/69&&$;I.,?(RB0Y>VBS(N
M,I@J]HFRGIN<$3*KE["%D61[PH M5DJN2I"R#7NWR!CW%'\0W=]=G?87<P?;
MWW]2;/6%PO17WVD)_0-_.Z\7&]^7M726[\]7RU6891(9N:;3-'&,0JQL,G!4
MN1Z^,O!26BC,9@JW6/:-0NB=R!SW(+T)QMJIJ5\,OIF>G=-O[_$XR=E[&6J8
M3\9$.[M&VN-9!A&Y+"$EKUF;^UT[$CKNB?@Q<3B(JKHHC;LKM0N#\O5BA^,%
MBF(%5#("8I8&<C .K4.66*-DS$/DC'NPW017AXN]2_1L[&*2E3(VH@6GR )4
MKE%)]A&\IY\58]$W&KOT"$'CGB8?!4'[B'Y #+4,":_N#YW]R)5+"HR7F,X7
MZV;*^%<Z.Z<HJ8I]]073S2BK0>PX*"W#!YGM1-4Z&C6*%CW!%*2L#2B'"ER]
M8BAR#*0*PJYMX^2TBD8_I2^8S\_P?7E%&KG4QJ<K;;S=:.,=:>/&V<#[<I>@
MBW8;AK8 0_L "&=8;>-">X.+DN(L5C!@+!+;;,G#\M%I/+P+^NZU$1Q/T1T$
M,P?R_-./AQ^P[GR58E$E: M!Y01*9@E!Z !6,1V8QR)4FXZ\#9D:UP#&Q.J\
M3^!T:T,W>WB)P(@5"BLEUDE<BH%S,4)@VF<FR-/3;7*#SU$V+IJ[@=!6T-Y3
MGQW@\R/2-CFM]T8_K>;IOW^?35?+CY]^WW2%JU78B"I"1$Z2TEQ#5$9#,(49
M69-@J4T]\I-D]8C,?1%PORO?0.KHXQ"!8K#Y#\0U,^^_W6C [+R64B0-)6EB
MQ0H#(2@*DIGS'J,(D;79_Q\E:=RC]J:H&D8-72#J/^MHG]GJDOPBO VZCEIR
MF59R4P=[%0:9?)0L/1,IMRECN$7&N(?C39&SO[@[V-MNP7[# B\,I4D1N*_E
M9B5;<)87X%IG'KA GAN58MTG9MS#[^.M.'N(OHNUYD ?]->K2\P^"F64YV!4
MG0CG]?K@-H&@+9NV=&]\:', -A0'X^Z-+R>RW0\2'2RE!_*]:49C2PEU( -H
MQ4GR7@2H#97 R5B,5]Q34-:C'>S0>:C7@'A/Y T+_SU@T&UOA9_G\_SG].PL
MK'M'A-D?]<;<IN?8 +,R=WG\,+FFO1D:*'UT^?Y7]]__0 VN-3'9>E/&*2GJ
M39D /JG:&55*4US,P;3QXW8B\^"RQTU1RD?\-E_43BGK X&)LM(J1;&:*YP\
M,^-(#"'13RQ;5*+>T&P3]CQ,S[@+8SO<W*N./%P;'6SEE_+ZY>NW,%W4BP[K
M8D]CA"R,&; )ZT3D;"!Z5EO&:1L#^4>R44+F87K&]3B/AZD!M-$=IC"_2NG\
MZ_E9O31[A[&H$B>I1-"R<% H$&(@[Z/8H#%%921OT\YF:Q+'/<T9"WE#Z:PC
M,$XREIRMBA!2[3.L9*&?9(+@,0OC2LB-IG!?4C#N <_QH;23Q#M "L4CM(__
M:Q.MW!721*#(6=:B/2OJ?&[:TR-M]&#)3X\,C5*\S;S.I^D:M^+Q>*@:4#M=
M'"=>'V.]FY+C2"'Y=[PGPXLCJL2#*DPC,%W'DV8T$"(MP"P9DU00L<@VHX6V
MIW'<^^W'0V$CK8W9)V>QFGQ8S&N7G_>+3[CX/DVXKHL0/FJ3&8-23V.4#K1Z
MV\3!2_J?T?2)W2JFIA?<0!S][2[:'J.@EP*J834]'U#L?<"F-DS=<+#<)(L*
M%L-+O9VL$J/0ETEP6CD0:+5Q-GK)M[H6L MV[I,Q#H"&T>Q]F!PHYK%;<=6%
M^/Q[^$ A19DOOFZR@-%P0^LM!TRNRD1A[:F@( AA4:(,SFW7Q/W!QX\.@$-U
M-A]4@!WXV$^LI3_]^$?XK_GB]5E87A3F.=J/ ^8"S,?:Y\ &B"Q:X(E'%9)F
MC+<YU-V!R%Y2H4WVJ-9*ZQN/UXS=J(((GH):%2(4I7V]R*7 !?I)!Q88=]::
MTJ;7P(Z$CNL[-0/,]L \6'L=@/,B>XJ+3_.R^I,$?X?'RQW !A>431 CUW6F
M"P?R,P(D+IFSS/"45!-(;D5>MT \'"#SUMKJ ()/"/"ZAL!R49AR$LCA2* 2
M_>0=1Q#.69E2]*;@L1?%7_N8K3W^#KV?FCJ WJOT/^<U$_$$;W>:-OR^Q')^
M]NNTX,0X(3TG0T:;:%<1OA:5Z  EA6QM+-YCH\/: ZCN=JW<$T-W3W"/I=!3
MK!*Z7"CF)6S$-+WZ1K@XR6Q2/K3]>YO7%>TI@E$*CD+BRC(AP/@L:A1?KQ&C
M J-5*"805&.;]>6H!4<[[%ZY!"Y22>!X'4:=1 0?$_WDD^-92^M"FV+.@7,4
MG10F[8*O W(4NVBM Y=@E[B2,>]+#21S\.3**Z$AN'I]@:%"3\Z\;]1+:^C3
MHQXR'#OAY(#3HUV4UC<>'PPOE4 >2BB0=# 4_+D WM:V3ZRHQ)0PR-HD<E_L
MZ=%.@#GP]&@7[74 SNW.(XJ4S IM(=62"56, B]R@B!US)*<^FS:5."]P-.C
MG0"RU^G1+MH:.^%W<;/X/45RO\UG),HP2]-PMA'?!3M(VTHR25$45VR-)FE;
M8=Y"I" S"E^BD>ZYV&;+=XV;J#D&DEH(?70,U1[\'T)M=593J;].4QU!=<F)
M9=P$IS-@"+:>UGH(6I&4>'))26N2S]O!YZG7C'N >#SD#";J/JI2;M=>L& M
M+9R^WO*4Y+;6V\O1N3I9IT@FLLUQJ[Q=VV*F'A+%^[CZ@XB]#]@\4+$A:%%,
M%@U(&S7%XH%#L$6#K4-(M8T%Q5:]P5]4,=-.FMVJF&D7,8^]+_V^6LR_?9G.
MB)L_%N&R%L=QZ77D&9QV2!PD)-/A9#\J*N=Y]#:JK?:C!Q\_.@ .U=E\4 &.
M#8&'R[&*R3G83"8M4J#M5] ZFAR#K /MG,IX9[:#P/[U;(-O(HT@<+@ .PBR
MMTJ:)>VS49:6R5 ;Y0C.(#I?0)2$.8H<]5T_]>_\^-'.(/=34]_0^WE1+^HQ
M>]'/"P3W"90S)# 4M$\C10$D3:/5T<LRUI1U>ZJS)Q:V!]ONBAE[FWN"F1M7
M1&]>SJH)KJL;HY,<I5%!*="Z\AKJEEXGMBCM+$N\7HC?;G3R@81T>_YS&.:.
MKJ-#IR9_/L;Z]QNN)IX;83TOP,AOH.W"1G"".]!1(T/F3-9M.A@\35>WITG-
MU[Y=E3+8$,,F$'M'QO//<':.U\G[24FU"6)$B*HF[5/09$?1@O$L.8W6\73T
M]-X#=(Y[#WU,"!ZJM Z\ONME^_XEZ O.SRKGDR1U0E8*!(J82(PA@[<D1E9"
MB5XC]]AF^=N2P'&OK3<'80LUG6)9X]OE:OJU[OOAAO>!?]4YX(WZH6WSQN:E
MC#NS/4H1(S?,2A$,%%^/VQ)MQ*XX#9IC$ 5E<=BF9N^H18Q/><<WM//V0CN_
MD28^_XEGW_$?\]GJRW)BLLL13:+HK(YJTYY!R,$#YYYYI[V/JDV!Q&%TGU*Q
MXRXXW&&W'UJ['>S^NW'[?S L/O\YGP2*ZT0."+1A<5!&"(@R1H@ZHM,L:GU\
MO_1Q<D^IU]OQD+N/+D\3L(1 G-AU[V6=:UU? L4I4(Q1U['3-EH5K%*Z&\A6
M@D^I3=R10;NS/D\2MN_FYXM)<%Y:%>MXZE@E2\;I#$65'J7)Q@2%\NB)GB?H
M/:6&=,<%[<[:/$W,TG<G09"?PS6[N,>GD$)=LM-$<A8A\!QSJ^9B^]%[2NWN
MCHS97;5Y<IA]5>C-5ZQJYUD@%QU0DSND/(_@F$3RY U3EJ'GK$WT>@#1I]0F
M[WCHW5^OW1Z)?5C,O^%B]2/,\MO_.9]^JR>!M<1_/JOUM?/R[?ISO/S\@/.P
M0UXWS&'88 P/=!)V2<^'LS!;O;I!U!6^L]%,YJP@11=JHW:$4-MQ9)UMX2F%
MI-NT\GF6M.&N[3[ZJHN2&E0N9TPU"2<,J"SKU(UD(!?+;4!.'GJ;.Y+;4CCN
M*=:P&'K\FNZ 6NI@3W^4FY]^?*9'K*N'@Q*%9X_ K8B@HB66.*MM)&PTPFET
MMLTDT2V(Z^52[I"HF+=54<^HJPQM2E49N<,&B1O!ZJ1?7SRX3#")UF-"1&-T
MFZ/\+8CK=*7;%Q#; FY/[8Q=%4=/F"_J%WY<<;*I7S9&2K(_3F:)M7Y9.?"A
M]K0S68BDG?)INX:FC[ZB4Z3LJ\GYX&(=&QSOSA<4_=10:I;?3?^J/RW?ES)-
M>.U S/+E1=\-@XI[F]=%49Q6<I6Y@<#)G1"I2!.=XEC,5KC9Y^WCIER:0JJY
M,CK8^W[%L,0O\[-:T[F8?\?*U.7%39V3$R0J$A<2*UQI\$Q*2,8+:9Q)+FQU
M>6WG/>\)HL9-EK2"V]#:Z !8CXKJUZLBJ2 5L:0X%$P:5&*9UF3+R"O0KN@0
M##^V3_5K;V-JQW#D]U-0SY"[N#J1<^$^Y0@9A0 E54U_NP)2DTN@LM!HVMQI
M>9JN3GVR/5&P+<AV5TD' +MQ(^(-$A%INM83_7R&FZL1-X^H'V5^HKS3VO@"
M:3TYEQD),9)<!6KE?))DUVW.,(;BH%.O;QC0CJ+F#N#]*"/KZQ>)PBB5)+B4
M,VTU%,)[42B*XHD,&"G =VWJ$YZBJE-OL/':N:LZ!KL-<XQ,UQ CK[=Z;KO<
MU5&&7#^?8% VT!I3;Z>X*&GU<8I^RA2(J.*]12-#:#/;N7F2ZN:J/(FF"%XO
M'Z)THLZ ]Q"2S2"%<"S&VFNDS:B7FU1TZL3MA86[Z]#>TAYP5N+0*\]'>@X1
M]H7,]@U^Q[/Y6EP?%O@M3/.FM&!)'Y(KL#@GJJ<A3L^FJRD>TDK[\)<.LV8-
MS/Q "]J;#4)>SY>KY>OP;4I[S_1?F#=T$:S7;<8>K3G)1CMAI $F3!UTS0M$
M@0($;8[H0B@!VYQ6'4CX0>?%EZI\]90J7Y\O%FMWE(F8A V0(DN@A,C@@K$U
M*2.""46BW^Z<>)>WCKLR'A-4M\Z.FREF[ S%9E%XF+]+AFR)T7KA  M%/RI[
M#D%+!)XB$IR$,7F[5D;;O&W<6'0TA VNB&X+XM:GXLLA H-'GC3,MKH-F0/M
ME1>ONIY*G#WI-SG@PM:<4Z%@$+4&$ZUA195@[T["'#)1LQS*K?\5R4AP_<PW
MN$R+Z;HA[<5)MU6<G%1M@?S72$LD.HB8!<6["IEE6"1KDRMX@JAQM[8#,' _
M[32,X$=NP_F)A+].F?V,M3/@MR_3%,[6]2?&&8^A3NPNDC;8[!!\2K3F&IT<
M<X%QN56]]U9M.!\E8VR\#*3D^= 2'QLV^,==%BX;(KO(HL^&_#+:.)5UEFRJ
MD%@45\9KM%$/-\;\43+&:]XYD'KG0\MZ;!_X'S@[FW\(B_]^3;Y>F2]FT_#[
MIUH*$OY<KN:SW__?3<J>*>NUEK7S=>T"$A/QY#""P)BUXLFZG+9R@[=\X8A(
M&4:O\\9"'ALX[_\B1O+RRW2!5_3;+(/Q7 -:=3FN26NLNW<,S B#<;NJOP<>
M/E[3UP: .%1X'638'MZ#K]-%2KG@ V'9Y=J!/YH P2D.O* KR#R%<FTN53Q#
MV+@A]M">2PMM= "NCW7^Y?OR^_+BMMS[2/'GK%ZB>_M7/>O] ]_-%^^_88U.
M9W^LN;X\V?TQX=IKYH0"Y4V=A91K], YA$3K9]&\Y@^: .\ HGMTI_<$SWP<
M30Z8H-FW&'XMQ=N\_'9>E_;WY?5\M@YMEQ-IZ^16;2"GVB?<8[VC' )D36*L
M&WS>\CAQJ]?UN-@=AJM&HNY@S;O-SAV[F=@0L\N2@\[D$ZCHZZ )HZ'6R@KN
M-6=)-%G5GB1KW**5ENO6<-KH#EIWIDO7@_SY^6SUD0+D#[A(]:P=N4;DS(%!
M\D?6K;FC9 *2-HXQ(6@QDD= V_.4CMN[Y7@ '%AGO6/R(];XZO+#S[CXRB<I
M"A*72R"]*:!0%(JS:'6/WA47<I"6MRDTW972<7NSC(;)0W76><YN_>?A+5L?
M?]B0F;MGB6V3O,/:=$<63XARM33+%P@B*M)^B!:]0JO:F.C0R3MZ6DV"7V>V
M16 V</(=8Z'0'(,"YW3E+COFI(V9-<Q*WB1E[$AQ;WT_>#]L;R%WMX%53B84
MKPKF5($D0JP!:X2 @0,JPZVQR7%LTT3L/BT=X&1_Y3ZY[>PLZ0ZP\L^PF-8S
MOFL&.).Q2)O(6Y,403B*):+7 <B:HD_.:KU=/FYGJ-PC9>PS@B&1<IB<.P#*
MIR_SQ:KZ3M<<"!.C"X9#"M83!TE"4"D0\JL3E7BVL4WD?Y^6L</](:%RH*0[
MP,HUX8:+S%S.('6=0FJSAAA\[=B97"[(O>-MCKQW0T;#.'Q(9.PGUVYO)EWX
M;._.:\^'L_KSM_!C?1G_X"CFB6<.&<QL2WJ;F"9K&S 2]$NN9:<\(WA;QR]F
M)927%,+>G=S6:4QS_\C\*M/RX5*LY_=' WA.NZ?B%?D%:Z/J#%Y)VD!-= 6=
M0M7HV&5?BCOP?/=#S\,YW<8JZV(?VX[/R][_VJ"JV3_:H:.EM9W1LAX"TB+M
M"N,"<VG4-6]'0CMPK(\+Q'T4=&KX6[?QSURR*%/MAB-5'=!=KR(P"YK+8(*/
MKM4DXYU)[<!C'P&#.ROIQ%"X[LMO5'&>&7)Q/9*+2\R"8\&!I[BEUI+)PEN=
M2>Y&:0>QP?$QN+.*3@V"M4<YSX6G6#3X4FK)8C;@O6.0C#%5SK+5>>>NE(Z=
MDAL'@KNJZ(0@..%.QI2E 1%9#?"3@B!] J\-"X$CWJNC.C+TQIUQ, +D=E))
M!U.-G^3K]UG>E%A@?OM7HJ^^^EK_-DG<6F-Y!BLU>159%8BU8E_;G US,4L<
MP?5[C-RM0&A/'82#**N#Q>^Q.EBO5#',&N#5G54F(01%07TLCGLG+5E6&T_O
MD&IE=P*H&D+@':QDC[!Q)2(OF8HZ"+ FU859&PA"%]#.4AA$\N&\S56,9PC;
M"D?^='&TEP+Z78<N&S%XDUC %&AW3Q:4C0IBG0K'HY7",.83;W-__6FZQCWW
M'10"V\%K'WV,>DWB&7Y^F\_2AB5R%='X6K7/ZT5([SG$6EC$I/"A")3QN!"[
M)FW<0]T14+:G5GH&VB0G+8(5"-$B^85Q/3C8:I!1.Q,4BVB/<9EB-X>JV2GM
M"*#:20,GFUF?W#E9&2:W/N%'RJ[?)?\JO_X?>TMLW3^*5I3-UC5,+\+G'SJ,
MO'8D?JCFJ.%'K6A;OMHT,0QGUSZKDBK[7"*4Q,B*UB$*A;2 S$?.HD,IVA01
M/D'407<H?SI?3F<4O[^>?XW3V<4*N"15U)YDL[J,W)#[S9TI!B,=^>Q 01LY
M[]%Y<($9L)'1)RPQVIV>@]$A!(S<,W4@B-RZ8WD,58S=P^+G,)W].E\NW\\^
MXE=: 6DAK O@^W+#MHFU^>4F-LDA6E>B "V2 "58!*^R 8D^*)&9T-)OA;-=
MWSQRD_H6 &LJ_([[]7Y:S=-_U\$XA.':W7CUXX"][_&'#;/G;4GL0'O=Q1NN
MH96]3[+V8]*\WA[C$KR3I']?C,9DDV1M2N]NTW%P3?=Y7$[S-"Q^O%]<//D?
MN/HRS[_,ON-RA?@IU/$X:TG_]./^ER^_=M$D1&7E4RP%D-/*JI)'<$9XL#*C
M5=F2$]UFW/>07(R[71Z LGM%Y&.IMH-3PFMV;G"Y[JB&.HM<FR%Q7]NJ<94H
MN N^MD6*4G@E?&K3OOI1DD8>9CL:2AZ%ZR$JZP%[U^3_%K[2CY\78;8D:ZZS
M;2YZ<T4>F+92@PU!@C*J]E4BR"3FG,)$+FIHT\+@>=IZ0>-!(+@+K6$U,G9D
ML&[X42=DXH)<STV'MJ2=Y5XQX#KQVE#& 1DB0K91YA1X$*ILY?T_]/2103&P
M^N9#RK*#!>?#8OJ]]MHX"PEOSN-UJ!W%.% B\NH[6 B(F@1C<W4B,DNIR2+S
M,#TCCWIL@Z$!5= !D%[]&1;Y>IBXC@G14;1<ZH!5HS6$3$81BF(2-2/EMZEB
MNT7&R+#IQ3O:7S4=X.K3%Q+V3V%9C^>^UKX?&_TM:H^]]:D^">_J.YNRO37'
MUVS/<IVZ5&WWTEQ1Z90CF6L,2#*(M$@[0W](;U20*)AL4]_;@IMQ-]@#P'7O
MXO+(FNX [?]9)U-<;0'"99>PUM7;6N.L:N?<*&@?\#%I907CN<V9R"TR1G;@
M1D?%?"@5=8"OC[@>F?HA+%8_;G@Q:]M5B=EHM(5$P@%E:U&I%PQ\09:T5#J7
M-M5T3Q U;@%!-SOX4&KK%X&7AEE8B2S50TH*UU5&0TYORF2=S$E=@M&\S8KW
M)%GCKH"#*7\[4.VAB;$/-5[/9\OSLYI+>_7' F\&45*S4#1'"([^4+K>'8^:
M_AI,=J)XS_2=$]M'3C8>?467V-A'A_/!!=KO:D,^P\U/UJ;$C9?!R@1,B]JE
M7GL(@G;RA"H(G6+RMDU2;GL:Q[UPVOMN>*A2.X/KQH:YJUV]I8;D6.W=Y,F&
M&</U' U:\X/%TB;G=)^6+I>Z@[7^!+CV4,'(<[)>E3(]FU8&WLY6:PN].)1.
M7NA,*[^1I&CE:I3"Z2=K%)82Z7_;E9UO-23K81KZ <\^6IT/*N(.5IH'DV6_
M7C53CH)V=5?#6L-M+7[R$&T4$$E"@0PJ>=7F_/9INL:][M[-!CB@\GJ XKU2
MK-_F*US_]M.WL^F*G-'O]!$I^6-5-9]@T($>(T!%$:JIE5HO5SGEB9>@N$]M
M+M'L2FF'^? ]47(7@"U5U@$D7\^_?IW/+OBI9XO+]^>KY2K,<BW7=-ZA1D,
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M'0(DL^9M;JWUU(-B?WT^ HP]A#OV6>LKTA.[J+>8U;-B<H8J-Y=M"@H:JW0
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M01\"'1L4>Z1#1_-V;[R NY12<1$D)&;6?:TR>)=K*T[KHI/"&MWM]CMJV6X
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MI@L3L9,5]'\W$_0H_7:<"7J,L!LX>';.Z.^O.)IQ7Z*4H%7DH$0BCU([3P8
M!INY<"E?))CX\U']FH;KS3MP-/$TP3< H(-9[K9V&/"93N&<:OV$R^"LS2"-
MTP)3]#QW&@(Y0LW!A8!THMZ/*34X1@D- .K(Q'4KHU".A*6"U:!8". 2*R 4
MCS9X09Q?3:G!I2)(_8!N0$4U ,,#F>T3K[RSTD<0 4V=$.2 Z(]@E2 'MQ3#
M![H;#Q#5E*O7#\#Z4L'8\:3>\XB1Q6 ,F1QD:-")'IF X.A;RS*KV53,[,X?
M;"D5_%(VVGD@'%]S+</V>U*RJ =W]9SLNE.CU,219P%B2E$[Z:+PW3)T^\L
M'ZY[^44!=IJ,AT]UV_Z@?HEAB7__V_\ 4$L#!!0    ( (*"E55D[WFPW (
M ($(   >    <W5M+65X,C,Q7S(P,C$Q,C,Q>#$P>&MA>'4N:'1MS5913]LP
M$'[?K[@5;0RI:9(FI;242M &5@U*U0:A/4U.<FTL$CNR74+WZ^?$[38-;1-(
M(/)@Y7+?G>\[VY\S>#^^'H5?9P&D*L]@=G-V.1E!P[+M6V]DV^-P#)_#JTOP
M6XX+H2!,4D4Y(YEM!],&-%*EBKYMEV79*KT6%RL[G-M5*M_..)?82E32& ZJ
M+WI$D@S?#=Y;%HQYO,Z1*8@%$H4)K"5E*[A-4-Z!96U1(UYL!%VE"MI.NPVW
M7-S1>V+\BJH,A[L\ ]O8 [N>9!#Q9#,<)/0>:'+2H,2)T,,DZI##V'>B;A2W
M>]V>'[N^YQ[V,/GFZB)M#3<Q4FTR/&GDE%DI5O/W_4ZACDN:J+3O.LZ'1HT;
M#I:<*3V9T,'FU>3XF>FOB/_X=A4H?% 6R>B*]>L^-$S0SAWSC(O^GE,_QY7'
M6I*<9IO^?DASE##%$N8\)VR_*?7:61(%71J@I-]1<]&T:K,T/+LZ3T89[GB[
M[8IL\)#2B.I5\%KN4VM]%L&7#8KUAD'QXKWT_^REV]&]'%U/%\$TA.MSF$S'
MP2S0@S;GP<5D$0;S8+P[A*>CT?7--)Q,+^!\,K]Z,K'GM>-?>_6U6W6+D*+
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M<-*018HX":.*N225/)J23RZ3]Z12R:5Z(EXD?.HKTJ@W&N232.[YC&;]BJN
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MVN>R5[-JZ0M/EO9&E=:RMY7M>].7_P-02P,$%     @ @H*55;0IKDO@"
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M:LNT;,/L%12HB[)PG"36>5XK@MF0[U!8A53HH8\E,81TT/_W!*43(QYM6GJ
M)ZCHD5'F([8US&ST]1F .?=)O3A.?9A1N1('FL0,G)EKV-V$GC'O$MOY.^9G
MN_Y']L6_MAK/X_>P=TN-_>'./[];,L>*;OY,%!](2'/B.D8?^$C#[14Z8E-]
MKORB4*!*Q')5M\T-C*</)A5CSW']1$ 6Z$:7PS,SPA' #&J5FKKQ7RO@_'EC
MOR<<CIN'+ D=<QQP_/\=T3<KUAT?N@HZCP-3%#[IO:O#&4"0U=S5SF3!Z)TN
MHJG.,F74*$1S))D?U;P*6MD^(MWO/\%CU$5'R58T]C0,,U$)>\ )VJ^8EG&)
M&BZ3(,!.Z ]F(LG*Q),G6H=:HO=SR])!)?9B\$$1*6:&OP 2<UJ<H:F85C<>
MSH4_9[K$A72:'7K'&>6Q(/+%DJ%U,1,IS]$-K );?[W4EP_@![P>5LUP'NF!
MRX,)(JG:Q?1]BF_Y]RSX'[U @=V6.:YMI2<4<[;U2D7><2*4$D'+>NA")U+X
MB=KN\L);&.GG+'YX'J>L- %OW)6HAURWJ+^@2UGX'B]_*+.U78448S]<0NY]
M&DG6RK^T480CGRY;/#09-)W:X)\IG,C6 4]'>ZXK.81@]K.V89&T.?/MK%FV
MZW7MGH)/RLTGSCPO&\\KRMUNJUMERZX_VVR5[6?;OC9LHWQ:;7[[4:WR:>-L
MIV$K9B'B1VBTZX9RE=Z/^1)/__O"6>$17;<L8ANKUXU3^_HXW\<T\^ZE/M7H
MGF!=48&(^9I7HK77B[8P)J(?7YO,$_9AN:G5'B_)R=/AY;&9,-?#TV5F?Z(S
M/\=+\[GYAL5&O#OF=0?89-2#@%MZB<RI+\G#/,0%'-* ?1T@/W'P/P(QA[@N
M8_T2Z*ZH.,0 NS/.//)QI46OT@V]EB!'U^F)-.YNM1^3IT"RS\6L8C30*\^+
M]D9K5M+WC\V;T!?_ U!+ P04    " ""@I55V5UC00L&  "P*@  '    '-U
M;2UE>#,R,5\R,#(Q,3(S,7@Q,'AK82YH=&WM6FMSVC@4_;Z_XI9,VV0&/R'A
MV<RX0*;,IL" LVGWRXZP!=;$V%Y9A+"_?J]D'-*0]S9IMB63\=A<Z>KJW*.K
MXT?S3;O?<K\..A"(60B#DX_'W184-,,X+;4,H^VVX9/[^1C*NFF!RTF4,L'B
MB(2&T>D5H! (D=0-8[%8Z(N2'O.IX0X-Z:ILA'&<4MT7?N&P*7_!(R7^X6_-
M-YH&[=B;SV@DP..4".K#/&71%$Y]FIZ!IJU:M>)DR=DT$&";M@VG,3]CYR2S
M"R9">IC[:1K9==-0@S3'L;\\;/KL')C_H<"(61F7#DKEL6^.RY.Q5[5+EE^E
M-;]FURQJ^W]9&*2!S;,^J5B&]$-AQB(MH'+\>GE?+QTDHK%@O@CJEFF^+:BF
MA\U)' D<CV/_[#1SL^%,T NAD9!-H[J:4N'6KG>YO<=VSV"YV8O#F-=W3/77
MD!9M0F8L7-;?NVQ&4^C1!0SC&8G>%U/,N992SB99PY3]0Q$ Q$)=+C)\*N@G
M9!'-\;)*)42H<Q&P,1-0LG7K(;%ZF$G*[T3FOEXO/<569^AVC[HMQ^WV>] _
MR@-^WEC*-\8"+S/XS4 ,AMU>JSMPCJ'SI=,Z<;M_=! .1*8S!*?7AK7]J-MS
M\!3/<OO@9#@Z<7HNN'VPJG"BC_26#J-.2X%JE?;-(C@C<-K]@=MI?],\;U0S
M#] =N)\Z,'*&'YU>9Z3UOQQWOH+3<J7%-DW[Z6N)13ZRK&Z7D^=?2YO)K2&^
MW0B\.(JH)^LO+)@(P,'*YZLJVHMU"T0,(J#@1-&<A#"D2<P%8-NCF,_ ,K7?
MW^V4*PT'X@F,YK,9KDLWH)PD="Z8ET(W\G38E1[>[51MVVRTXEE"HJ6ZLAI[
M,(FY&F!)"0<<&:MVFWIT-J8<2E91UF@\DA0F+$2;"E&VE^F$$?7F'/<.!(1$
M/G0NO(!$4XHE'B-)4SDG_)?-?=P/  .C&.?5<+()Y=$4@1(OD'.13>88#4^Q
M&."X\63"/+Q2/L9+P'/!)CAP$9(Y3^<$\4*HKO!LA6G&,XR?^'$B]Z2KS?-&
MDF>K04>$CTE$4ZU_$=(E.)Z0%LFS(MJ)R!,RIJFR!"P%A!##@K,H7B!&4_IN
M9[_:@"?Q,B&^CWNF%M*)J*O-Z2I3-:OZ&*HZG)'POQ'4TG]4[:N];7P#1DT_
MJ,C)([WS93"9AR%2 1D=2@I><I/3O^>,4[F(4K4P+KFP2_9DMJS]77_O,N-K
M$E\2>)5VJU8J8S)K#47OGR*A]JM,*(NP#LV(RA(61$&87/0LJQUYM@GCF.Z$
MTU0FMBC-) P!NU&)"Z8]33#3:5'UFK"(1)[\'1WZ2N"J+&*K>9CQ(DZP4DI#
MFG-A51WUQ^7ZL"G(.*0YF..88^'2$-.0)"FMYR<-GZ5)2)9U%BED5*?&C/ I
M2M)Q+$0\J^\CC.>RMGDD7"DAQ9?,O%:JNIFI58'A"#\?>676E<D0_J:M7-%K
MU>JM9E.W;K7=Y=:JZ;52Y;N[M:MZI;+_(+>&0B)# P%/,8T?"J7"M658MY,+
ML/)%F.$KR7@=\PSNEQ<%*JEM)'2VA5SNQ':V$Z^US@J..V9JRGD6'M_T,4#J
MIIW@;=PFINK^9(/(<?*#$/VX5'C>BM[!0WB2W9&\GDDIX9>J([I#E@@XU:$]
MGTY)],U,'YC1!Q!F5=EPSG5L"VD<,A_RF5Z##M8,N6^U_3@,>V1&[Z;&3S'Y
MC9L[-?D7(LWKAN9F7KCRN=-#B?&Z)WAS[EL!JBGTHB11*V!T@N(7A;!@YQ3Z
MV<W6,_/A?T^=FY'='7"&NC-!X;F!Z-Y-D.8!YEZ4*'XJ=IL[V9,W]ZU*VJJD
MGTLE?29G2_@3;_!)1(.M1-I*I'N+>9OK+\*:UXW-+ZJ1UMMWFW'JB9@7H15K
MMZBEHI)2 TY3YJMWEUOQ] +B::MDMDKF%U0R3G0VY] .,'1.MDIFJV3NK:PO
MP9C7C<LOJF(RN7)T^39L^W#G^^B3#42?_^'.=]_TM]']G-$9ZM7R#5\C7/OP
M,8FS+S_KG(9$:NV-3R'7^Z%Z/6VNNY Q;HISL=GEGJ\G5\?L6T[U5>GAOU!+
M 0(4 Q0    ( (*"E56,8]3L1.8! #R!$@ 1              "  0    !S
M;6UT+3(P,C$Q,C,Q+FAT;5!+ 0(4 Q0    ( (*"E55$.[NKSQ4  ,;P   1
M              "  7/F 0!S;6UT+3(P,C$Q,C,Q+GAS9%!+ 0(4 Q0    (
M (*"E55'EQZ6@2    5$ 0 5              "  7'\ 0!S;6UT+3(P,C$Q
M,C,Q7V-A;"YX;6Q02P$"% ,4    " ""@I55D8@:G&9:  !H[0, %0
M        @ $E'0( <VUM="TR,#(Q,3(S,5]D968N>&UL4$L! A0#%     @
M@H*55<0.T&W.! $ ? P+ !4              ( !OG<" '-M;70M,C R,3$R
M,S%?;&%B+GAM;%!+ 0(4 Q0    ( (*"E55RCQA>H*H  &B]!P 5
M      "  ;]\ P!S;6UT+3(P,C$Q,C,Q7W!R92YX;6Q02P$"% ,4    " ""
M@I559.]YL-P"  "!"   '@              @ &2)P0 <W5M+65X,C,Q7S(P
M,C$Q,C,Q>#$P>&MA>'4N:'1M4$L! A0#%     @ @H*558"7\9'H @  LP@
M !X              ( !JBH$ '-U;2UE>#(S,E\R,#(Q,3(S,7@Q,'AK87AU
M+FAT;5!+ 0(4 Q0    ( (*"E56WIP'0[0@  'DM   <              "
M <XM! !S=6TM97@S,3%?,C R,3$R,S%X,3!X:V$N:'1M4$L! A0#%     @
M@H*55?/AD ?^"   DBT  !P              ( !]38$ '-U;2UE>#,Q,E\R
M,#(Q,3(S,7@Q,'AK82YH=&U02P$"% ,4    " ""@I55M"FN2^ (  !D+0
M'               @ $M0 0 <W5M+65X,S$S7S(P,C$Q,C,Q>#$P>&MA+FAT
M;5!+ 0(4 Q0    ( (*"E57976-!"P8  + J   <              "  4=)
M! !S=6TM97@S,C%?,C R,3$R,S%X,3!X:V$N:'1M4$L%!@     ,  P 2@,
' (Q/!     $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
